<SEC-DOCUMENT>0001178913-24-000818.txt : 20240305
<SEC-HEADER>0001178913-24-000818.hdr.sgml : 20240305
<ACCEPTANCE-DATETIME>20240305160621
ACCESSION NUMBER:		0001178913-24-000818
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240305
DATE AS OF CHANGE:		20240305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		24720300

	BUSINESS ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>zk2431047.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:cgen="http://cgen.com/20231231" xmlns:ecd="http://xbrl.sec.gov/ecd/2023"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>COMPUGEN LTD - 1119774 - 2024</title></head><body><div style="font-size: 10pt;"><div style="font-size: 10pt;">
        <div style="display:none">
        <ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20230101to20231231" id="FFact_0000000000684">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20230101to20231231" id="FFact_0000000000685">0001119774</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="C_20230101to20231231" id="FFact_0000000000686">FY</ix:nonNumeric><ix:nonFraction name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20230214013608017" unitRef="usd" xsi:nil="true"></ix:nonFraction><ix:footnote id="FN20240228010307168" xml:lang="en-US">Representing amount lower than $ 1.</ix:footnote>
</ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="cgen-20231231.xsd"/>
        </ix:references><ix:resources><xbrli:context id="C_20230101to20231231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:AntibodiesDiscoveryCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:AntibodiesDiscoveryCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:AntibodiesDiscoveryCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221101to20221111"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-11</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210901to20210929"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-09-01</xbrli:startDate>
        <xbrli:endDate>2021-09-29</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231201to20231227"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-12-01</xbrli:startDate>
        <xbrli:endDate>2023-12-27</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231210to20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:LicenseAgreementWithGileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-12-10</xbrli:startDate>
        <xbrli:endDate>2023-12-18</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:LicenseAgreementWithGileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-18</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201201to20201218"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-18</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240131_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgen:OrdinarySharesIssuedAndSoldThroughAtmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-10-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-10-10</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-11-02</xbrli:startDate>
        <xbrli:endDate>2021-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:TwoThousandTenShareOptionsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:TwoThousandTenShareOptionsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180601to20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:JmpSecuritiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-14</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:JmpSecuritiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-06-14</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230131_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:LeerinkPartnersLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:LeerinkPartnersLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_cgenSegmentReportingGeographicAreaAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_cgenSegmentReportingGeographicAreaAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_cgenSegmentReportingGeographicAreaAxis_countryUS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_cgenSegmentReportingGeographicAreaAxis_countryUS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_cgenSegmentReportingGeographicAreaAxis_countryUS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_countryUS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_cgenSegmentReportingGeographicAreaAxis_countryUS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapSubsidiaryOfCommonParentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:SubsidiaryOfCommonParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20130801to20130805"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2013-08-01</xbrli:startDate>
        <xbrli:endDate>2013-08-05</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20130805"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2013-08-05</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211130"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231218"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-18</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231218"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-18</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240131"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:unit id="Item"><xbrli:measure>cgen:Item</xbrli:measure></xbrli:unit>
<xbrli:unit id="NIS_Per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<ix:relationship fromRefs="Fxbrl_20230214013608017" toRefs="FN20240228010307168"></ix:relationship></ix:resources></ix:header></div><div><div style="">
  <div>
    <div>
      <div>
        <div>
          <div>
            <div>
              <hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center"/>
            </div>
            <div style="font-weight:bold">&#160;</div>
            <div style="text-align:center">
              <div style="line-height:1.25"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">UNITED STATES</span><span style="font-weight:bold">&#160;</span></span></span></span></span></div>
              <div style="line-height:1.25"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">SECURITIES AND EXCHANGE COMMISSION </span></span></span></span></span></div>
              <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>WASHINGTON, D.C. 20549</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-size:14pt;font-weight:bold"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif"><span><span>FORM <ix:nonNumeric id="F20240228054805245_0" name="dei:DocumentType" contextRef="C_20230101to20231231">20-F</ix:nonNumeric></span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:36pt;vertical-align:top;color:#000000;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="F20240228054805246_1" name="dei:DocumentRegistrationStatement" contextRef="C_20230101to20231231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></span></span></td>
                    <td style="width:auto;vertical-align:top">
                      <div style="color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>OR</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:36pt;vertical-align:top;color:#000000;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="F20240228054805246_2" name="dei:DocumentAnnualReport" contextRef="C_20230101to20231231" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span></span></span></span></td>
                    <td style="width:auto;vertical-align:top">
                      <div style="color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>For the fiscal year ended <ix:nonNumeric id="F20240228054805246_3" name="dei:DocumentPeriodEndDate" contextRef="C_20230101to20231231" format="ixt:date-monthname-day-year-en"><ix:nonNumeric id="F20240228054805247_4" name="dei:CurrentFiscalYearEndDate" contextRef="C_20230101to20231231" format="ixt:date-monthname-day-en">December 31</ix:nonNumeric>, <ix:nonNumeric id="F20240228054805247_5" name="dei:DocumentFiscalYearFocus" contextRef="C_20230101to20231231">2023</ix:nonNumeric></ix:nonNumeric></span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>OR</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:36pt;vertical-align:top;color:#000000;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="F20240228054805247_6" name="dei:DocumentTransitionReport" contextRef="C_20230101to20231231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></span></span></td>
                    <td style="width:auto;vertical-align:top">
                      <div style="color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>OR</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:36pt;vertical-align:top;color:#000000;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="F20240228054805247_7" name="dei:DocumentShellCompanyReport" contextRef="C_20230101to20231231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></span></span></td>
                    <td style="width:auto;vertical-align:top">
                      <div style="color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:left;margin-left:36pt;line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal">Date of event requiring this shell company report</span>&#160;<span style="font-weight:bold">-----------------------------</span></span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">For the transition period from </span>____________ <span style="font-weight:bold">to </span>____________</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal">Commission file number:</span>&#160;<span style="font-weight:bold"><ix:nonNumeric id="F20240228054805248_8" name="dei:EntityFileNumber" contextRef="C_20230101to20231231">000-30902</ix:nonNumeric></span>&#160;</span></span></span></span></div>
              <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>____________________________________________________</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25"><span style="font-size:16pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonNumeric id="F20240228054805248_9" name="dei:EntityRegistrantName" contextRef="C_20230101to20231231">Compugen Ltd</ix:nonNumeric>. </span></span></span></span></span></div>
              <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(Exact name of Registrant as specified in its charter)</span></span></span></span></div>
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>____________________________________ </span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal">(Translation of Registrant&#8217;s name into English) </span></span></span></span></span></div>
              <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>___________________________________________________________________</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonNumeric id="F20240228054805254_38" name="dei:EntityIncorporationStateCountryCode" contextRef="C_20230101to20231231" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric>&#160;</span></span></span></span></span></div>
              <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(Jurisdiction of incorporation or organization)</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonNumeric id="F20240228054805248_10" name="dei:EntityAddressAddressLine1" contextRef="C_20230101to20231231">Azrieli Center</ix:nonNumeric>, <ix:nonNumeric id="F20240228054805248_11" name="dei:EntityAddressAddressLine2" contextRef="C_20230101to20231231">26 Harokmim Street</ix:nonNumeric>, <ix:nonNumeric id="F20240228054805248_12" name="dei:EntityAddressAddressLine3" contextRef="C_20230101to20231231">Building D</ix:nonNumeric>, <ix:nonNumeric id="F20240228054805249_13" name="dei:EntityAddressCityOrTown" contextRef="C_20230101to20231231">Holon</ix:nonNumeric>&#160;<ix:nonNumeric id="F20240228054805249_14" name="dei:EntityAddressPostalZipCode" contextRef="C_20230101to20231231">5885849</ix:nonNumeric>&#160;<ix:nonNumeric id="F20240228054805249_15" name="dei:EntityAddressCountry" contextRef="C_20230101to20231231" format="ixt-sec:countrynameen">Israel</ix:nonNumeric>&#160;</span></span></span></span></span></div>
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal">(Address of principal executive offices) </span></span></span></span></span></div>
              <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>________________________________________________</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonNumeric id="F20240228054805249_16" name="dei:ContactPersonnelName" contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Alberto Sessa</ix:nonNumeric>, Chief Financial Officer&#160;</span></span></span></span></span></div>
              <div style="line-height:1.25;margin-top:0px;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Phone: +<ix:nonNumeric id="F20240228054805250_17" name="dei:CityAreaCode" contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">972</ix:nonNumeric>-<ix:nonNumeric id="Fxbrl_20240228131713468" name="dei:LocalPhoneNumber" contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">3-765-8585</ix:nonNumeric>, Fax: +<ix:nonNumeric id="F20240228054805250_19" name="dei:ContactPersonnelFaxNumber" contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">972-3-765-8555</ix:nonNumeric>&#160;&#160;</span></span></span></span></span></div>
              <div style="line-height:1.25;margin-top:0px;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold"><ix:nonNumeric id="F20240228054805250_20" name="dei:EntityAddressAddressLine1" contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Azrieli Center</ix:nonNumeric>, <ix:nonNumeric id="F20240228054805250_21" name="dei:EntityAddressAddressLine2" contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">26 Harokmim Str</ix:nonNumeric><span>eet</span>, <ix:nonNumeric id="F20240228054805251_22" name="dei:EntityAddressAddressLine3" contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Building D</ix:nonNumeric>, <ix:nonNumeric id="F20240228054805251_23" name="dei:EntityAddressCityOrTown" contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Holon</ix:nonNumeric>&#160;<ix:nonNumeric id="F20240228054805251_24" name="dei:EntityAddressPostalZipCode" contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">5885849</ix:nonNumeric>&#160;<ix:nonNumeric id="F20240228054805251_25" name="dei:EntityAddressCountry" contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember" format="ixt-sec:countrynameen">Israel</ix:nonNumeric>&#160;</span></span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>________________________________________________</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25">
                <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Securities registered or to be registered pursuant to Section 12(b) of the Act.</span></span></span></span></div>
                <div style="line-height:1.25">&#160;</div>
              </div>
              <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:33%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Title of each class</span></span></span></span></div>
                    </td>
                    <td style="width:33%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Trading Symbol(s)</span></span></span></span></div>
                    </td>
                    <td style="width:33%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Name of each exchange on which registered</span></span></span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width:33%;vertical-align:top">&#160;</td>
                    <td rowspan="1" style="width:33%;vertical-align:top">&#160;</td>
                    <td rowspan="1" style="width:33%;vertical-align:top">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:33%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="F20240228054805251_26" name="dei:Security12bTitle" contextRef="C_20230101to20231231">Ordinary shares, par value NIS 0.01 per share</ix:nonNumeric></span></span></span></span></div>
                    </td>
                    <td style="width:33%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="F20240228054805252_27" name="dei:TradingSymbol" contextRef="C_20230101to20231231">CGEN</ix:nonNumeric></span></span></span></span></div>
                    </td>
                    <td style="width:33%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The <ix:nonNumeric id="F20240228054805252_28" name="dei:SecurityExchangeName" contextRef="C_20230101to20231231" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Stock Market LLC&#160;</span></span></span></span></div>
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(The Nasdaq Global Market)</span></span></span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">
                <div style="line-height:1.25">&#160;</div>
              </div>
              <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Securities registered or to be registered pursuant to Section 12(g) of the Act.</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>None </span></span></span></span></div>
              <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(Title of Class)</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.</span></span></span></span></div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>None</span></span></span></span></div>
              <div style="line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(Title of Class)</span></span></span></span></div>
              <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
                <div style="page-break-after:always">
                  <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
                </div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report: <span style="font-weight:bold"><ix:nonFraction id="F20240228054805252_29" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,237,465</ix:nonFraction></span><span style="font-weight:bold">&#160;</span><span style="font-weight:bold">Ordinary Shares</span></span></span></span></span></div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></span></span></span></div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal;color:rgb(0, 0, 0)">&#9744;</span><span style="font-weight:normal;color:rgb(0, 0, 0)">&#160;Yes</span><span style="font-weight:normal">&#160; &#160; &#160; &#160; &#160;&#160;<span style="color:rgb(0, 0, 0)">&#9746; <span><ix:nonNumeric id="F20240228054805252_30" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_20230101to20231231">No</ix:nonNumeric></span></span></span></span></span></span></span></div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="text-align:justify;line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to</span><span style="font-weight:normal"> Section 13 or 15(d) of the Securities Exchange Act of 1934</span></span></span></span></span></div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal;color:rgb(0, 0, 0)">&#9744;</span><span style="font-weight:normal;color:rgb(0, 0, 0)">&#160;Yes</span><span style="font-weight:normal">&#160; &#160; &#160; &#160; &#160;&#160;<span style="color:rgb(0, 0, 0)">&#9746; <span><ix:nonNumeric id="F20240228054805252_31" name="dei:EntityVoluntaryFilers" contextRef="C_20230101to20231231">No</ix:nonNumeric></span></span></span></span></span></span></span></div>
              </div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="text-align:justify;line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act</span><span style="font-weight:normal"> of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></span></span></span></span></div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal">&#9746;</span><span style="font-weight:normal;color:rgb(0, 0, 0)">&#160;<ix:nonNumeric id="F20240228054805253_32" name="dei:EntityCurrentReportingStatus" contextRef="C_20230101to20231231">Yes</ix:nonNumeric></span><span style="font-weight:normal">&#160; &#160; &#160; &#160; &#160;&#160;<span style="color:rgb(0, 0, 0)">&#9744; <span>No</span></span></span></span></span></span></span></div>
              </div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:rgb(0, 0, 0);font-weight:normal">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (</span><span style="color:rgb(34, 30, 31);font-weight:normal">&#167;</span><span style="color:rgb(0, 0, 0);font-weight:normal">232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></span></span></span></span></div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="line-height:1.25">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal">&#9746;</span><span style="font-weight:normal;color:rgb(0, 0, 0)">&#160;<ix:nonNumeric id="F20240228054805253_33" name="dei:EntityInteractiveDataCurrent" contextRef="C_20230101to20231231">Yes</ix:nonNumeric></span><span style="font-weight:normal">&#160; &#160; &#160; &#160; &#160;&#160;<span style="color:rgb(0, 0, 0)">&#9744; <span>No</span></span></span></span></span></span></span></div>
                </div>
              </div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal;color:rgb(0, 0, 0)">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer </span><span style="font-weight:normal">or an emerging growth company<span style="color:rgb(0, 0, 0)">. See definition of &#8220;accelerated filer&#8221; &#8220;large accelerated filer&#8221; </span>and &#8220;emerging growth company&#8221; <span style="color:rgb(0, 0, 0)">in Rule 12b-2 of the Exchange Act.</span></span></span></span></span></span><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal;color:rgb(0, 0, 0)">&#160;</span></span></span></span></span></div>
              <div style="line-height:1.25;font-weight:normal">
                <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;color:#000000;width:100%">

                    <tr>
                      <td style="width:25.00%">
                        <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal;color:rgb(0, 0, 0)">Large accelerated filer </span><span style="font-weight:normal">&#9744;</span></span></span></span></span></div>
                      </td>
                      <td style="width:25.00%">
                        <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;<ix:nonNumeric id="Fxbrl_20240305013307112" name="dei:EntityFilerCategory" contextRef="C_20230101to20231231" format="ixt-sec:entityfilercategoryen">Accelerated filer</ix:nonNumeric>&#160;<span style="font-weight:normal;color:rgb(0, 0, 0)">&#9746;</span></span></span></span></span></div>
                      </td>
                      <td style="width:25.00%">
                        <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal;color:rgb(0, 0, 0)">Non-accelerated filer <span style="font-weight:normal;color:rgb(0, 0, 0)">&#9744;</span>&#160;</span></span></span></span></span></div>
                      </td>
                      <td style="width:25.00%">
                        <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal;color:rgb(0, 0, 0)">Emerging growth company </span><span style="font-weight:normal;color:rgb(0, 0, 0)"><ix:nonNumeric id="F20240228054805254_39" name="dei:EntityEmergingGrowthCompany" contextRef="C_20230101to20231231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></span></span></span></div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:rgb(0, 0, 0);font-weight:normal">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards</span><span style="font-weight:normal">&#8224;<span style="color:#000000"> provided pursuant to Section 13(a) of the Exchange Act&#160;</span></span></span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:normal;color:rgb(0, 0, 0)">&#9744;</span></div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="text-align:left;line-height:1.25;font-family:'Times New Roman',serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#8224; The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</span></span></span></span></div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="text-align:left;line-height:1.25;font-family:'Times New Roman',serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <span style="font-weight:normal;color:rgb(0, 0, 0)"><ix:nonNumeric id="F20240228054805253_35" name="dei:IcfrAuditorAttestationFlag" contextRef="C_20230101to20231231" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span></span></span></span></span></div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="text-align:left;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>If securities are registered pursuant to Section 12(b) of the Act indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statement. <span style="font-weight:normal;color:rgb(0, 0, 0)"><ix:nonNumeric id="F20240228054805254_40" name="dei:DocumentFinStmtErrorCorrectionFlag" contextRef="C_20230101to20231231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></span></span></span></div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="text-align:left;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-weight:normal;color:rgb(0, 0, 0)">&#9744;</span></span></span></span></span></div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="text-align:left;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></span></span></span></div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:18.87%;vertical-align:top;font-weight:normal">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonNumeric id="F20240228054805253_36" name="dei:DocumentAccountingStandard" contextRef="C_20230101to20231231">U.S. GAAP</ix:nonNumeric>&#160;<span style="font-weight:normal;color:rgb(0, 0, 0)">&#9746;</span></span></span></span></span></div>
                    </td>
                    <td style="width:57.73%;vertical-align:top;font-weight:normal">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>International Financial Reporting Standards as issued</span></span></span></span></div>
                    </td>
                    <td style="width:23.39%;vertical-align:top;font-weight:normal">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other <span style="font-weight:normal;color:rgb(0, 0, 0)">&#9744;</span></span></span></span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:18.87%;vertical-align:top;font-weight:normal">&#160;</td>
                    <td style="width:57.73%;vertical-align:top;font-weight:normal">
                      <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>by the International Accounting Standards Board <span style="font-weight:normal;color:rgb(0, 0, 0)">&#9744;</span></span></span></span></span></div>
                    </td>
                    <td style="width:23.39%;vertical-align:top;font-weight:normal">&#160;</td>
                  </tr>

              </table>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="text-align:left;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</span></span></span></span></div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:rgb(0, 0, 0);font-weight:normal">Item 17 </span><span style="color:rgb(0, 0, 0);font-weight:normal">&#9744;</span><span style="font-weight:normal">&#160; &#160; &#160; &#160; &#160;&#160;<span style="color:rgb(0, 0, 0)">Item 18 <span>&#9744;</span></span></span></span></span></span></span></div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="text-align:left;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></span></span></span></div>
              <div style="line-height:1.25;font-weight:normal">&#160;</div>
              <div style="line-height:1.25">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:normal;color:rgb(0, 0, 0)">&#9744;</span><span style="font-weight:normal;color:rgb(0, 0, 0)">&#160;Yes&#160; &#160; &#160; &#160; &#160;</span><span style="font-weight:normal">&#160;<span style="color:rgb(0, 0, 0)"><ix:nonNumeric id="F20240228054805254_37" name="dei:EntityShellCompany" contextRef="C_20230101to20231231" format="ixt:fixed-false">&#9746;</ix:nonNumeric>&#160;<span>No</span></span></span></span></span></span></span></div>
                </div>
              </div>
            </div>
            <div>&#160;</div>
            <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
              <div style="page-break-after:always">
                <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left"></p>

<!-- Field: Include-Text; File: PF\body.htm; Date: 2024%2D03%2D04T21:43:25; Size: 0x0010FF3B; Options: XMLPreprocess -->


<div>&#160;

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span style="text-decoration: underline">TABLE OF CONTENTS</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: -72pt; margin-left: 72pt; line-height: 1.25"><a href="#CAUTIONARYSTATEMENTREGARD">CAUTIONARY STATEMENT REGARDING
FORWARD-LOOKING STATEMENTS</a></div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" border="0" id="z4c310bd024f54a1283496f710fdc46af" style="font: 10pt Times New Roman,Times,serif; width: 100%; text-align: left; color: rgb(0, 0, 0)">
  <tr>
    <td rowspan="1" style="width: 10%; vertical-align: top">
        <div style="text-indent: -72pt; margin-left: 72pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#PARTI.">PART
        I.</a></div> </td>
    <td rowspan="1" style="width: 87%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 3%; vertical-align: top; text-align: center">&#160;</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM1.">ITEM
        1.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM1.">IDENTITY
        OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</a></div> </td>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: center; margin-right: 4.2pt; line-height: 1.25; font-variant: small-caps">1</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM2.">ITEM
        2.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM2.">OFFER
        STATISTICS AND EXPECTED TIMETABLE</a></div> </td>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: center; margin-right: 4.2pt; line-height: 1.25; font-variant: small-caps">1</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM3.">ITEM
        3.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM3.">KEY
        INFORMATION</a></div> </td>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: center; margin-right: 4.2pt; line-height: 1.25; font-variant: small-caps">1</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM4.">ITEM
        4.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM4.">INFORMATION
        ON THE COMPANY</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">49<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM4A.">ITEM
        4A.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM4A.">UNRESOLVED
        STAFF COMMENTS</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">67<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM5.">ITEM
        5.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM5.">OPERATING
        AND FINANCIAL REVIEW AND PROSPECTS</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">68<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM6.">ITEM
        6.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM6.">DIRECTORS,
        SENIOR MANAGEMENT AND EMPLOYEES</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">80<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM7.">ITEM
        7.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM7.">MAJOR
        SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">102<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM8.">ITEM
        8.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM8.">FINANCIAL
        INFORMATION</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">103<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM9.">ITEM
        9.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM9.">THE
        OFFER AND LISTING</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">104<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM10.">ITEM
        10.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM10.">ADDITIONAL
        INFORMATION</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">104<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM11.">ITEM
        11.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM11.">QUANTITATIVE
        AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">112<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM12.">ITEM
        12.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM12.">DESCRIPTION
        OF SECURITIES OTHER THAN EQUITY SECURITIES</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">113<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#PARTII">PART
        II.</a></div> </td>
    <td style="width: 87%; vertical-align: top">&#160;</td>
    <td style="width: 3%; vertical-align: top; text-align: center"><br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM13.">ITEM
        13.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM13.">DEFAULTS,
        DIVIDEND ARREARAGES AND DELINQUENCIES</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">113<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM14.">ITEM
        14.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM14.">MATERIAL
        MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">113<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM15.">ITEM
        15.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM15.">CONTROLS
        AND PROCEDURES</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">113<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16.">ITEM
        16.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16.">RESERVED</a></div>
        </td>
    <td style="width: 3%; vertical-align: top; text-align: center">114<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16A.">ITEM
        16A.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16A.">AUDIT
        COMMITTEE FINANCIAL EXPERT</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">114<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16B.">ITEM
        16B</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16B.">CODE
        OF ETHICS</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">114<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16C.">ITEM
        16C.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16C.">PRINCIPAL
        ACCOUNTANT FEES AND SERVICES</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">115<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16D.">ITEM
        16D.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16D.">EXEMPTIONS
        FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">115 </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16E.">ITEM
        16E.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16E.">PURCHASES
        OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">115 </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16F.">ITEM
        16F.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16F.">CHANGES
        IN REGISTRANT'S CERTIFYING ACCOUNTANT</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">115 </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16G.">ITEM
        16G.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16G.">CORPORATE
        GOVERNANCE</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">115 </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16H.">ITEM
        16H.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16H.">MINE
        SAFETY DISCLOSURE</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">116<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16I."><span style="text-decoration: underline">ITEM
        16I.</span></a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM16I."><span style="text-decoration: underline">DISCLOSURE
        REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">116<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM16J.">ITEM 16J</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM16J.">INSIDER TRADING POLICIES</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">116<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM16K.">ITEM 16K.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM16K.">CYBERSECURITY</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">116<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#PARTIII">PART
        III</a></div> </td>
    <td style="width: 87%; vertical-align: top">&#160;</td>
    <td style="width: 3%; vertical-align: top; text-align: center"><br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM17.">ITEM
        17.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM17.">FINANCIAL
        STATEMENTS</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">117<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM18.">ITEM
        18.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM18.">FINANCIAL
        STATEMENTS</a></div> </td>
    <td style="width: 3%; vertical-align: top; text-align: center">117<br/> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM19.EXHIBITS">ITEM
        19.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="margin-right: 4.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-variant: small-caps"><a href="#ITEM19.EXHIBITS">EXHIBITS</a></div>
        </td>
    <td style="width: 3%; vertical-align: top; text-align: center">118</td> </tr>
  </table> </div> &#160;

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">(i)</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">CERTAIN DEFINED TERMS</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">All references in this Annual Report on Form 20-F to &#8220;Compugen,&#8221; the &#8220;Company,&#8221;
&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or similar references refer to Compugen Ltd. and our wholly owned subsidiary Compugen
USA, Inc., except where the context otherwise requires or as otherwise indicated.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: center; line-height: 1.25">&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">We have prepared our consolidated financial statements in United States dollars and
in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. All references herein to &#8220;dollars&#8221;
or &#8220;$&#8221; are to United States dollars, and all references to &#8220;Shekels&#8221; or &#8220;NIS&#8221; are to New Israeli Shekels.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">(ii)</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div>

<div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span style="line-height: 1.25; font-weight: bold">CAUTIONARY </span>STATEMENT
REGARDING</div> </div> </div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">FORWARD-LOOKING STATEMENTS</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">This Annual Report on Form 20-F, or the Annual Report, includes &#8220;forward-looking
statements&#8221; within the meaning of the Securities Act of 1933, as amended, or the Securities Act, the Securities Exchange Act of
1934, as amended, or the Exchange Act, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements are based on our current beliefs, expectations and assumptions. Forward-looking statements can be identified by the use of
terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;assume,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221;
&#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;believe,&#8221; &#8220;suggest,&#8221;
and &#8220;intend,&#8221; and similar expressions that are intended to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. These forward-looking statements involve known and unknown risks and uncertainties that may
cause our actual results, performance or achievements to be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Factors that could cause our actual results to differ materially from those projected
in the forward-looking statements include, without limitation, the risk factors set forth under &#8220;Item 3. Key Information - D. Risk
Factors,&#8221; the information about us set forth under &#8220;Item 4. Information on the Company&#8221; and information related to our
financial condition under &#8220;Item 5. Operating and Financial Review and Prospects.&#8221; Any forward-looking statements represent
our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We do not assume
any obligation to update any forward-looking statements unless required by law.</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">(iii)</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>
<!--PROfilePageNumberReset%Num%1%%%-->

<div><br/>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="PARTI."><!--Anchor--></span>PART I.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25"><span style="font-weight: bold">ITEM 1.</span> <span id="ITEM1."><!--Anchor--></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span style="font-weight: bold">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25"><span style="font-weight: bold">ITEM 2.</span><span id="ITEM2."><!--Anchor--></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span style="font-weight: bold">OFFER STATISTICS AND EXPECTED TIMETABLE</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25"><span style="font-weight: bold">ITEM 3.<span id="ITEM3."><!--Anchor--></span></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span style="font-weight: bold">KEY INFORMATION</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">A. [RESERVED]</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">B. CAPITALIZATION AND INDEBTEDNESS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. REASONS FOR THE OFFER AND USE OF PROCEEDS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">D. RISK FACTORS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">An investment in our ordinary shares involves a high
degree of risk and many factors could affect our results, financial condition, cash flows and results of operations. You should carefully
consider the following risk factors, as well as the other information in this Annual Report. If we do not, or cannot, successfully address
the risks to which we are subject, we could experience a material adverse effect on our business, results of operations and financial
condition, which could include the need to limit or even discontinue our business operations, and accordingly our share price may decline,
and you could lose all or part of your investment. We can give no assurance that we will successfully address any of these risks. The
principal risks we face are described below</span>.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Summary Risk Factors </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Our business is subject to a number of risks of which you should
be aware of before making an investment decision. These risks are discussed more fully under the caption &#8220;Item 3. Key Information
- D. Risk Factors&#8221; section of this Annual Report. These risks include, but are not limited to, the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9fa0d7055d6848ab8e35e10357618d19" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We have a history of losses and we expect to incur future losses and may never achieve or sustain profitability. </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4bfe07399b514035b2087d698e4fb587" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We may need to raise additional funds in the future, and if we are unable to raise such additional funds, we may need to limit, curtail
        or cease operations. To the extent any such funding is based on the sale of equity, our existing shareholders would experience dilution
        of their shareholdings.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z99dd03de3100419da1f976959be586a3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We cannot provide assurance that our business model will succeed in generating substantial revenues. </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z246e7a39f5b44b12aa4b49dc4d063df2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>In the near term, we are highly dependent on the success of COM701, COM902 and COM503. We may not be able to advance our internal
        clinical stage programs through clinical development or manufacturing or successfully partner or commercialize them, or obtain marketing
        approval, either alone or with a collaborator, or may experience significant delays in doing so.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1d866dcf27ba48a6a66a8133817bb8c8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Clinical trials of any product candidates that we, or any current or future collaborators may conduct, may fail to satisfactorily
        demonstrate safety and/or efficacy, and we, or any collaborator, may incur additional costs or experience delays in completing, or ultimately
        be unable to complete the development and commercialization of these product candidates.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z822a0623418c49838d1085e375733e00" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Clinical development involves a lengthy and expensive process, with an uncertain outcome. We may encounter substantial delays or
        even an inability to begin clinical trials for any specific product or may not be able to conduct or complete our trials on the timelines
        we expect.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z918c87ab405a4d72a01f5e3303c997d4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>From time to time we publicly disclose preliminary data from our ongoing clinical trials. As more patient data become available the
        data and the interpretation of the data may change.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb3ebd35d01b94d36b1fc524d055c98b3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We rely and expect to continue to rely on third parties to conduct our clinical trials. These third parties may not successfully
        or professionally carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, and we may experience
        significant delays in the conduct of our clinical trials as well as significant increased expenditures.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">1</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" id="z479842501c3c4e6cb195836e28dfec8d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Serious adverse events or undesirable side effects or lack of efficacy, may emerge in clinical trials conducted by other companies
        running clinical trials investigating the same target as us, which could adversely affect our development programs or our capability to
        enroll patients or partner the program for further development and commercialization.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1642ce416989403abc9caf34347142ad" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We are subject to certain manufacturing risks, any of which could either result in additional costs or delays in completing, or ultimately
        make us unable to complete, the development and commercialization of our product candidates.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z25e40182f35545319101f4e4746d95c5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>From time to time, we may also publish preliminary biomarker data from our ongoing clinical trials. As more patient data become available
        the data and the interpretation of the data may change.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5e19301d397b4b7aa00c59a16083793e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our current and future relationships, and/or the relationships of our collaborators through which we may market, sell, and distribute
        our products, with healthcare professionals, physicians and other parties in the United States and elsewhere may be subject, directly
        or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health information and general
        privacy and security and other healthcare laws and regulations, which could expose us to adverse consequences.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5cc5b575dc8e4465af5cce6a7494ce0f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>There are risks that are inherent in the development and commercialization of new therapeutic products.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z918d0d7cd75f49db8f7fc40a9df8f4f2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We have limited experience in the development of therapeutic product candidates, and we may be unable to implement our business strategy.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2878beb6e96a4d5ba081a3a4016a0afd" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our approach to the discovery of therapeutic products is based on our predictive computational discovery capabilities that are not
        yet fully proven clinically, and we do not know whether we will be able to discover and develop additional potential product candidates
        or products of commercial value.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zaa964af2d4ad4be09a4ec3e7aa216c51" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We are focusing our discovery and therapeutic development activities on therapeutic product candidates for uses in immuno-oncology.
        Our current candidates may fail, and we may fail to continue to discover and develop therapeutic product candidates of industry interest
        in this field.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3edbc95fbaca4d27943fa8cfc86661d3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We depend significantly on third parties to carry out the research, development and commercialization of our therapeutic product
        candidates. If we are unable to maintain our existing agreements or to enter into additional agreements with such third parties, mainly
        collaborators, in the future, our business will likely be materially harmed.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za7290db8056f41d888102f619f751e85" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our dependence on collaboration agreements with third parties presents number of risks.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8c4b3e58ad72437490c94963dd2999eb" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our existing partnership agreement with Gilead is subject to many risks. </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z39a7c9f1fa7a458f814ced7a39897358" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We operate in a highly competitive and rapidly changing industry which may result in others discovering, developing or commercializing
        competing products ahead of us or more successfully than we do.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3b1f8d4dd4504c1c8152460bdf50565c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Given our level of managerial, operational, financial and other resources, our current activities and future growth may be limited.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z17267287e8554c109bfa47e4f58873b8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our information technology systems, or those of the third parties upon whom we rely, including our cloud providers, CROs or other
        contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our pipeline and our
        business, as well as to regulatory investigations or actions; litigation; fines and penalties; reputational harm; loss of revenue and
        other adverse consequences.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za53deb07c0ee4397b0311373da287015" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We are subject to stringent and changing obligations related to data privacy and security. Failure or perceived failure to comply
        with current or future obligations could lead to government enforcement actions (which could include civil or criminal penalties), private
        litigation, and/or adverse publicity and could negatively affect our operating results and business.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf2615a66773d4c9fb53bc979421fe08e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability
        to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">2</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" id="zc0be4d8afcfe4b2e979d7c1a7bb4d2ec" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We may need to obtain additional licenses of third-party technology or other rights that may not be available to us or are available
        only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that
        was not anticipated.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z09d8c7fbcdcd485c846f47f6dcb9c833" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We, or potential collaborators and licensees, may infringe third-party rights and may become involved in litigation, which may materially
        harm our business.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z642609a278bf4b148727ccb5b5de9795" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time
        consuming and unsuccessful. </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb57621a523e34c92a26d83a562cced10" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Conditions in Israel and in the Middle East may adversely affect our operations.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5e51b3ff6e924df3bc29f44ba5dd6ece" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our results of operations may be adversely affected by the exchange rate fluctuations between the dollar and the New Israeli Shekel.
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8f7c2cf21bae40399653331893ed5cff" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We may not be able to meet the continued listing standards of Nasdaq, which require a minimum closing bid price of $1.00 per share,
        which could result in our delisting and negatively impact the price of our ordinary shares and our ability to access the capital markets.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zac3eac5d06634283be4b4b723a0bcd90" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Future sales of our ordinary shares or securities convertible or exchangeable for our ordinary shares may depress our share price.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z920ea7c6b49a401790fdb177f51c0e5d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>If we sell ordinary shares in future financings, shareholders may experience immediate dilution and, as a result, our share price
        may decline. </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z585475f125464279a102725dc8fecda6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our share price and trading volume have been volatile and may be volatile in the future and that could limit investors&#8217; ability
        to sell our shares at a profit and could limit our ability to successfully raise funds.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z859dbd18c0394fba99268d5465ad1fb1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>If we are a passive foreign investment company, or PFIC, our U.S. shareholders may be subject to adverse U.S. federal income tax
        consequences.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="line-height: 1.25; font-weight: bold">Risks Related to our Business, Financial Results and Financing Needs</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We have a history of losses and we expect to
incur future losses and may never achieve or sustain profitability.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2023, we had an accumulated deficit of approximately $474.5 million
and had incurred net losses of approximately $18.8 million in 2023, $33.7 million in 2022 and approximately $34.2 million in 2021, in
large part due to the expenditures associated with our ongoing research and development and limited revenues received to date. In addition,
we expect to continue to incur net losses in the future due to our anticipated costs and expenses, primarily associated with our preclinical
and clinical activities. We previously entered into three therapeutic pipeline program-based partnership agreements, one with Bayer Pharma
AG, or Bayer, the other with AstraZeneca plc, or&#160;AstraZeneca, and the third with Bristol Myers Squibb Company, or Bristol Myers Squibb,
under which, through the end of 2022, we received an aggregate amount of $90.7 million, including a $32.0 million equity investment from
Bristol Myers Squibb. Currently, following the termination of the Bristol Myers Squibb and the Bayer collaborations in August 2022 and
in February 2023, respectively, and after entering into an exclusive license agreement, or the License Agreement, with Gilead Sciences,
Inc., or Gilead, on December 18, 2023, we have two therapeutic pipeline program-based partnership agreements in effect, one with AstraZeneca
and the second with Gilead. In the first quarter of 2024, we received $51 million as an upfront payment from Gilead (after $9 million
tax withheld at source) and $10 million as a milestone payment from AstraZeneca. We cannot be certain that we will receive additional
revenues under any of these partnership agreements or that we will enter into additional arrangements for any of our therapeutic pipeline
programs or with respect to our predictive computational discovery capabilities, or that such additional arrangements, if any, will provide
sufficient revenues to achieve profitability. </div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">3</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"><br/> We may need to raise additional funds
in the future, and if we are unable to raise such additional funds, we may need to limit, curtail or cease operations. To the extent any
such funding is based on the sale of equity, our existing shareholders would experience dilution of their shareholdings.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Based on our current plans and our expectation that IND clearance for COM503 will
take place in the second half of 2024, we believe that our current existing cash and cash equivalents, short-term bank deposits, investment
in marketable securities together with the COM503 IND clearance milestone payment from Gilead will be sufficient to fund operations into
2027, without considering the possible receipt of any additional funds, such as proceeds from existing or additional licensing and/or
collaborative agreements, or from financings. However, if our plans change, our cash balances may only be sufficient for a shorter period
of time. We cannot predict with any degree of certainty when, or even if, we will generate significant revenues or achieve profitability,
and therefore we may need additional funds to continue financing our operations. We may seek additional capital for various reasons, including
for our ongoing operations or strategic considerations, even if we believe we have sufficient funds for our current and future operating
plans. Additional funds, including proceeds from license or collaborative agreements, or from other financings, may not be available to
us on acceptable terms, or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our existing
shareholders. For example, if we raise additional funds by issuing equity securities, our existing shareholders will experience dilution
of their shareholdings. Debt financing, if available, may involve restrictive covenants that could limit our flexibility in conducting
future business activities. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any failure to raise funds as and when needed would materially harm our business,
financial condition and results of operations, and result in us having to significantly curtail one or more of our research or development
programs or otherwise reduce our operations and thereby not having the ability to have some or all of such therapeutic product candidates
developed and have a negative impact on our ability to pursue our business strategy. We also could be required to seek funds through arrangements
with partners or other investors that may require us to enter into arrangements on terms that would otherwise not be acceptable to us
which could materially harm our business, financial condition and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We cannot provide assurance that our business
model will succeed in generating substantial revenues.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our business model is primarily based on expected future revenues in various forms,
including upfront fees, research funding, in-kind funding, milestone payments, license fees, royalties on product sales and other revenue
sharing payments from development and commercialization of products by third parties, pursuant to various forms of collaborations for
our novel targets and related drug product candidates at various stages of research and development. Our primary focus in immuno-oncology
utilizes our predictive computational discovery capabilities to identify novel drug targets and develop potentially first-in-class therapeutics
in the field of cancer immunotherapy. Drug target candidates discovered by our predictive computational discovery capabilities undergo
initial target validation studies and, in selected cases, are advanced to the discovery and development of the therapeutic product candidate.
Such drug target candidates and their related therapeutic product candidates may serve as the basis for licensing and other forms of third-party
collaborations. Following the termination of the Bristol Myers Squibb and the Bayer collaborations in August 2022 and in February 2023,
respectively, and after entering into the License Agreement with Gilead on December 18, 2023, we currently have two collaborations in
effect, one with AstraZeneca and the second with Gilead. The termination of our existing or any future collaboration agreements may have
varying impacts on our financial position and, specifically, our ability to generate revenue. For example, while the termination of our
agreement with Bristol Myers Squibb has different effects on our operations, this termination caused us to lose free access to PD-1 immune
checkpoint inhibitor, which has an adverse impact on our expenditure thereby requiring us to purchase PD-1 inhibitor for our clinical
studies. The main effect of the termination of the collaboration agreement with Bayer was extinguishing our potential to achieve future
revenues from such collaboration.&#160;The inability to derive adequate revenues, or at all, from our business model would materially
harm our business, financial condition and results of operations and could result in the need to limit or even discontinue our business
operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We have a limited operating
history with respect to the partnering and commercialization aspects of our business model upon which investors can base an investment
decision or upon which to predict future revenues.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our ability to generate revenues from partnerships for our novel drug targets and
related therapeutic product candidates at various stages of research and development has been limited. To date, we have entered into four
partnership agreements with respect to our therapeutic pipeline programs under which we have received a total amount of $151.7 million
(after $9 million withholding taxes), of which $32 million was the form of an equity investment. We recognized revenue of $33.5 million
in 2023, $7.5 million in 2022 and $6.0 million in 2021 from our partnerships. There can be no guarantee that we will achieve the same
level of revenue in the future.&#160; </div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">4</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">We cannot be certain that our focus on discovery, research and drug development in
the field of immuno-oncology, along with advancing selected programs to preclinical and clinical development partially or fully at our
own expense, will generate a stable or significant revenue stream. Additionally, financial terms for agreements by other companies, to
the degree disclosed, vary greatly and therefore financial terms that may be available for our candidates at the various R&amp;D stages
may vary greatly. The inability to derive adequate revenues within our field of focus and for our specific drug targets or product candidates
would materially harm our business, financial condition and results of operations and could result in the need to limit or even discontinue
our business operations. Moreover, our operating history with respect to the partnering and commercialization aspects of our model provides
a limited basis to assess our ability to generate significant fees, research revenues, milestone payments, royalties or other revenue
sharing payments from the licensing, development and anticipated future commercialization of our programs based on our existing and future
novel drug targets and related therapeutic products and any future product candidates. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Our failure to establish
and maintain effective internal control over financial reporting could result in material misstatements in our financial statements or
a failure to meet our reporting obligations. This may cause investors to lose confidence in our reported financial information, which
could result in the trading price of our shares to decline.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our management is responsible for establishing and maintaining adequate internal control
over financial reporting, as such term is defined in Rule&#160;13a-15(f) of the Exchange Act. Under the supervision and with the participation
of our management, including the Chief Executive Officer and the Chief Financial Officer, we carried out an evaluation of the effectiveness
of our internal control over financial reporting as of December&#160;31, 2023, using the criteria established in &#8220;Internal Control
- Integrated Framework&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO
criteria). Based on our assessment under that framework and the criteria established therein, our management concluded that the Company&#8217;s
internal control over financial reporting was effective as of December 31, 2023, in providing reasonable assurance regarding the reliability
of the Company&#8217;s financial reporting.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">However, if we conclude in the future that our internal controls over financial reporting
are not effective, we may fail to meet our future reporting obligations on a timely basis, our financial statements may contain material
misstatements, our operating results may be negatively impacted, and we may be subject to litigation and regulatory actions, causing investor
perceptions to be adversely affected and potentially resulting in a decline in the market price of our shares. Even if we conclude that
our internal controls over financial reporting are adequate, any internal control or procedure, no matter how well designed and operated,
can only provide reasonable assurance of achieving desired control objectives and cannot prevent all mistakes or intentional misconduct
or fraud.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Risks Related to Development, Manufacturing, Clinical Trials and Government Regulation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">In the near term, we are
highly dependent on the success of COM701, COM902 and COM503. We may not be able to advance our internal clinical stage programs through
clinical development or manufacturing or successfully partner or commercialize them, or obtain marketing approval, either alone or with
a collaborator, or may experience significant delays in doing so.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We currently have no products approved for sale and are investing a significant portion
of our efforts and financial resources in the clinical development of COM701 and of COM902 and preclinical development of COM503. Our
prospects are substantially dependent on our ability, or that of any existing and future partners, to manufacture, develop, obtain marketing
approval for and successfully commercialize COM701, COM902 and COM503 as a stand alone or in combination with other drugs. We have reported
favorable safety and toxicity profile and preliminary signals of antitumor activity in our ongoing Phase 1 trial with COM701 monotherapy,
COM701 combination with nivolumab, and in the triplet combination of COM701, nivolumab and BMS-986207 (anti-TIGIT antibody). We have reported
preliminary signals of antitumor activity from our Phase 1 dose escalation monotherapy trial of COM902 with a best response of stable
disease. These preliminary clinical results may not predict the final results of the on-going clinical trials or future clinical trials
or otherwise be sufficient to attract a partner or support a future drug approval. Many companies in the pharmaceutical, biopharmaceutical
and biotechnology industries have suffered significant setbacks or failures in clinical trials after achieving positive results, and we
cannot be certain that we will not face similar setbacks or failures.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our pipeline currently consists of three clinical stage programs, which are at early
stage of clinical development. Two, COM701 and COM902 are being developed internally and the third, rilvegostomig, is being developed
by our collaborator, AstraZeneca. Our pipeline also consists of additional programs in early stage, the most advanced of which is COM503,
which is in IND enabling studies and is licensed to Gilead and requires substantial development and investment.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">5</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">If we are able to advance our programs throughout the different clinical development
phases, we will need to expand our personnel and operational capabilities to support these activities. We may also need to raise additional
capital in such event. In part because of our limited infrastructure, limited experience in conducting clinical trials and limited experience
in interacting with&#160; regulatory authorities, we cannot be certain that our clinical trials will be completed on time, that our planned
clinical trials will be initiated on time, if at all, that our planned development programs and development path forward will be designed
well or would be acceptable to the U.S. Food and Drug Administration, or FDA, or other comparable foreign regulatory authorities, or that,
even if approval is obtained, such investigational products can be successfully commercialized.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The success of COM701, COM902 and COM503 is dependent upon several factors, including
the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8bbd8d2bad32411082b2fd44dd7dd8c1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the successful clearance of IND for COM503; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5e68abdc635d4f5ba900ce93223ce8d0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the successful clinical trial design (and implementation thereof) and results;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1e30cd3d070443a8a35e8fe836c81488" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="margin: 0px 0px 0px 13pt; line-height: 1.25; text-align: justify; text-indent: -13pt">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div>our ability to fund clinical trials designed to obtain regulatory approval and to become commercially successful;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc95d6a917d894703b18b595c0a59e3a8" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">our ability to design trials required to allow for a path for registration or obtain
        regulatory approval;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2556b1c5c1e446ad9f82ffab6feb3858" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">the success of trials designed to allow for a path for registration/approval by regulatory
        authorities;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z08182f8298f849be9fded404bb33894f" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">our selected regulatory strategy;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1024e193093e47a39012a3b96794fe19" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">our timely initiation, enrollment and completion of clinical trials;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zcb9f0a3f721d43ab85263b1af2c68075" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">the enrolled patient population&#8217;s demographics, prior therapy/ies and other
        patients characteristics, even if they meet the inclusion/exclusion enrollment criteria;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zded7c2d929ea4653a9e5a114af86b25e" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">a safety, tolerability and efficacy profile, alone or in combination with other approved
        or investigational products, that is satisfactory to the FDA or comparable foreign regulatory authorities;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb54f980267a441a98836a303d62b2a18" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">a safety, tolerability and efficacy profile, alone or in combination with other approved
        or investigational products, that fits the competitive treatment landscape/ unmet patients&#8217; need;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z85a5c477bbeb469bb4442315203f7651" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">selection of drug dosing;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za14fe8ce7af64c00a42f1288276ec1eb" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">selection of indications;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z489fd8a6fec14ae19e9c59f7f5120fa8" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">selection of patient populations;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z23ada5f4d0e449a8a07aaeca5f00852a" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">selection of comparator study arm</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z474173fdef694877b51ff214d4558bc0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">selection of drug(s) for combinations;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z660a36e07fd24bbfb10fb8d38ffeeffc" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">access to drugs required for combination studies or approval;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc2b102b3d6a141e2ba3074a583e971a8" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">successful identification of biomarkers, including for patient selection;</div> </td>
        </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8d1c4124e8e949058f22139d60448ce0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">timely receipt of marketing approvals from applicable regulatory authorities;</div>
        </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zeabe3cf6b5cf4c2eabcbba638793e747" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">the performance of our current and future collaborators, if any;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; text-align: center">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zca60fb13a38d48d48465fa15a6777642" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">the extent of any required post-marketing approval commitments to applicable regulatory
        authorities;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3e9ce7f5528d4154956fa981b1fa4db6" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">establishment, management and monitoring of CRO arrangements and processes with third-party
        service providers for conducting the clinical trial;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zbad99c63f5614a07b495b72139ff95cd" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">ability to convince clinical investigators in the potential of our clinical drug candidates
        and their interest in enrolling patients to our studies;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf19f5ccef2434682bbb9052b1c80b52a" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">establishment and monitoring of manufacturing arrangements and processes with third-party
        service providers and clinical manufacturing organizations for manufacturing drug substance and drug product;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z735fa4498832411ba9f7ca0d2f440279" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">establishment and monitoring of arrangements with third-party suppliers of raw materials
        and service for fill-finish, packaging and labeling;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">6</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25"> <br/> </div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0f6efe8b0755444cb2c2615feb420f17" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">stability of our drug substance and drug products;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z81bb9316ef974e3ca66aaff14cfaca97" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">supply of our drugs in sufficient quantities and quality for our clinical trials;</div>
        </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb4caf46239d549deb5b3490425fefa8b" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">establishment of arrangements with third-party manufacturers and processes monitoring
        to obtain commercial quality drug product that is appropriately packaged for sale;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd92a6aad3b4948c1944a804ceb772ace" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">adequate ongoing availability of raw materials and drug product for clinical development
        and any commercial sales;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3bb3cdfea7ea42a9ac9a3f42737bb7e4" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">protection of our rights in our intellectual property portfolio;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7d094402f12e4df5a40d4a447d785918" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">successful launch of commercial sales following any marketing approval;</div> </td>
        </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zadf0838869354a69a5d44a83fb6e78cb" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">a continued acceptable safety profile following any marketing approval; and</div>
        </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za3a5e13de0c84a5690460858c595c3df" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 13pt">
        <div style="width: 13pt; text-align: left">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">commercial acceptance by patients, the medical community and third-party payors.</div>
        </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Many of these factors are beyond our control, including clinical development by us
and our competitors, the regulatory submission and review process, potential threats to our intellectual property rights and the manufacturing,
marketing and sales efforts of any current and future third party. If we are unable to develop, receive marketing approval for and successfully
commercialize COM701, COM902 and COM503, on our own or with any collaborator, or experience delays as a result of any of these factors
or otherwise, our business could be substantially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We depend on enrollment
of patients in our clinical trials in order to continue development of our product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are currently conducting two Phase 1 clinical trials one in metastatic microsatellite
stable colorectal cancer and one in platinum resistant ovarian cancer, in which we test the combination of COM701 with COM902 and pembrolizumab.
We completed our enrollment of 20 patients in the metastatic microsatellite stable colorectal cancer trial and expect to complete enrollment
of at least 20 patients with platinum resistant ovarian cancer in the first quarter of 2024, later than we initially projected due to
various reasons, including competing studies, trying to identify suitable enrolling sites and the general treatment landscape in this
indication. Our anticipated time to data in these trials is subject to our ability to enroll a sufficient number of eligible patients
that will need to be enrolled for observing clinical activity, if at all. There can be no assurance that we will complete enrollment or
have data from the trials when we anticipate or at all or that our data will support the further development of our proposed combination.
The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient
number of patients that are in line with our inclusions and exclusion criteria and our ability to monitor these patients as required.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We may experience difficulties in patient enrollment in our clinical trials for a
variety of reasons. Patient enrollment is affected by many factors including the size and nature of the patient population, the eligibility
criteria for the trial, the design of the clinical trial, the size of the patient population required for analysis of the trial&#8217;s
primary endpoints, the proximity of patients to clinical trial sites, our ability to recruit clinical trial investigators with the appropriate
competencies and experience, the number of enrolling clinical sites, our ability to obtain and maintain patient consents, the risk that
patients enrolled in clinical trials will drop out of the trials before completion or even before any/sufficient imaging assessment, the
willingness of patients to attend clinic visits given epidemic and pandemic concerns, and competing clinical trials (including other clinical
trials that we are conducting or will conduct in the future) and clinicians&#8217; and patients&#8217; perceptions as to the potential
advantages of the drug being studied in relation to other available therapies, or competing drugs against the same target as well as a
changing treatment landscape, including any new drugs that may be approved for the indications we are investigating. For example, the
platinum resistant ovarian cancer landscape is continually evolving and becoming more competitive, with the approval of mirvetuximab and
other competing studies, which may have an impact on our enrollment rate and may raise the bar for success in our clinical trial results.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Many pharmaceutical companies are conducting clinical trials in
patients with the disease indications that COM701, COM902, COM503 and our future potential drug products may target. Additionally, other
pharmaceutical companies are already clinically investigating their own therapeutic candidates against PVRIG, the target of COM701, or
against TIGIT, the target of COM902, and the IL-18 pathway, which COM503 is targeting, which may hamper the enrollment of patients in
our trials for COM701, COM902, or COM503.&#160; For example, in the case of COM701, there are currently several PVRIG antibodies in Phase
1 studies, such as GSK&#8217;s GSK4381562 (formerly SRF813), Hengrui&#8217;s PVRIG/TIGIT bi-specific, SHR-2002, Simcere&#8217;s TIGIT/PVRIG
bispecific antibody, SIM0348, Biotheus&#8217;s PVRIG/TIGIT bi-specific, PM-1009, and Hefei TG ImmunoPharma&#8217;s NM1F.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">7</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">In the case of COM902, the landscape includes a significant number of anti-TIGIT antibodies
at various stages of development, with the leading ones currently in Phase 3 clinical trials, such as tiragolumab by Roche, vibostolumab
by Merck, rilvegostomigby AstraZeneca, ociperlimab by Beigene, domvanalimab by Arcus, as well as others at earlier stages in development.
In the IL-18 pathway field, the programs that are more advanced than COM503 and are in clinical stage are ST-067, a mutated IL-18 fusion
protein at Phase 1/2 and two IL-18 CART therapies in Phase 1. As a result, we must compete with these competitors for clinical sites,
clinicians&#8217; interest and the limited number of patients who fulfill the stringent requirements for participation in clinical trials
in general. Also, patient enrollment may be limited due to changes in the regulatory landscape in the indications of interest to us. Our
clinical trials may be delayed or terminated due to the inability to enroll enough patients or lack of successful drug performance. The
delay or inability to meet planned patient enrollment or successful results may result in increased costs and delay or termination of
our trials, which could have a harmful effect on our ability to develop products. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Clinical trials of any product
candidates that we, or any current or future collaborators may conduct, may fail to satisfactorily demonstrate safety and/or efficacy,
and we, or any collaborator, may incur additional costs or experience delays in completing, or ultimately be unable to complete the development
and commercialization of these product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We, and any current or future collaborators, are not permitted to commercialize, market,
promote or sell any therapeutic product candidate in any jurisdiction without obtaining marketing approval from the relevant regulatory
authority, such as the FDA in case of the United States. We, and any collaborators, must complete clinical trials to demonstrate the safety
and efficacy of our therapeutic product candidates in humans before we will be able to obtain these approvals.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Clinical testing is expensive, is difficult to design and implement, can take many
years to complete and is inherently uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned
or completed on schedule, if at all. The clinical development of our therapeutic product candidates is susceptible to the risk of failure
inherent at any stage of product development, including failure to demonstrate efficacy in a clinical trial or across population of patients,
choosing the incorrect patient population or indication, the occurrence of adverse events that are severe or medically or commercially
unacceptable, failure to comply with protocols or applicable regulatory requirements and determination by the FDA that a therapeutic product
candidate may not continue development or is not approvable. The outcome of preclinical studies and early clinical trials may not predict
the success of later clinical trials and interim results of a clinical trial do not necessarily predict final results. A number of companies
in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of efficacy
or unacceptable safety profiles, notwithstanding promising results in earlier trials. Despite the preliminary safety and anti-tumor activity
results reported to date from our ongoing Phase 1 trial for COM701 and COM902, we do not know whether the clinical trials we or our partners
may conduct will demonstrate adequate efficacy and safety to result in the further advancement of clinical development or regulatory approval
to market of COM701 and/or COM902, or any other of our product candidates when they reach the clinic, in any particular jurisdiction or
jurisdictions. The same applies to COM503 which has not yet entered the clinic. It is also possible that, even if one or more of our therapeutic
product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of
a variety of factors, including the size, patient population, duration, design, measurements, conduct or analysis of our clinical trials,
patient monitoring, the dosing we choose and other factors.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">8</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">Any inability to successfully complete preclinical and clinical development could
result in additional costs to us, or any collaborators, and impair our ability to generate revenues from product sales, development, regulatory
and commercialization milestones and royalties. Moreover, if we, or any collaborators, are required to conduct additional clinical trials
or repeat clinical trials or other testing of our product candidates beyond the trials and testing that we or they contemplate, if we,
or they, are unable to successfully complete clinical trials of our product candidates or other testing, or the results of these trials
or tests are unfavorable, uncertain or are only modestly favorable, or there are unacceptable safety concerns associated with our product
candidates, we, or any collaborators, may, among others:</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;cease
the development of the product candidates; </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;incur
additional unplanned costs;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;terminate
or amend the respective collaboration, if applicable; </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;not
obtain approval to proceed to next development phase; </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;be
delayed in obtaining marketing approval for our product candidates;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;not
obtain marketing approval at all;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;obtain
approval for indications or patient populations that are not as broad as intended or desired;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;obtain
approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;be
subject to additional post-marketing testing or other requirements; or</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;be
required to remove the product from the market after obtaining marketing approval.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our failure to successfully initiate and complete clinical trials of our product candidates
and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market any of our product candidates would significantly
harm our business, could further result in significant harm to our financial position and results of operations and could result in the
need to limit or even discontinue our business operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Clinical development involves a lengthy and
expensive process, with an uncertain outcome. We may encounter substantial delays or even an inability to begin clinical trials for any
specific product or may not be able to conduct or complete our trials on the timelines we expect.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Obtaining marketing approval from regulatory authorities for the
sale of any therapeutic product requires substantial preclinical development and then extensive human clinical trials to demonstrate the
safety and efficacy of such product candidates. It is impossible to predict when or if any of our programs or those of our collaborators
based on our target discoveries will yield products that will be approved for human testing, or, if such testing is proven sufficiently
safe and effective for further development or to receive regulatory approval for marketing. Preclinical and clinical testing is expensive,
time consuming, and subject to uncertainty and will require significant additional financial and management resources. As a company, we
have limited experience in conducting clinical trials and have never progressed a product candidate through to regulatory approval. In
part because of this lack of experience, our clinical trials may require more time and incur greater costs than we anticipate. We cannot
guarantee that any of our therapeutic drug candidates from our pipeline will be advanced into clinical trials or that our clinical trials
will be conducted as planned or completed on schedule, if at all. The outcome of preclinical testing and early clinical trials may not
be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results.
Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed
their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to continue to achieve
such successes at later stages of the clinical studies or to obtain marketing approval for such products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We submitted to the FDA an Investigational New Drug application,
or IND, for COM701, which was cleared by the FDA in June 2018 and an IND for COM902, which was cleared by the FDA in October 2019 and
we plan to submit IND to the FDA for COM503 in 2024. However, there can be no assurance that we will submit additional INDs, including
for COM503, nor if submitted, the actual timing for such submission (including amendments), nor that such submissions will be accepted
by the FDA at all or within anticipated timeframe, allowing clinical trials to begin or continue. There can be no assurance that clinical
trials will begin at any predicted date or will be completed on schedule, if at all. Moreover, even if these clinical trials begin, issues
may arise that could result in the suspension of or termination of such clinical trials. A failure of one or more clinical trials can
occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za253ffb6556949de8c4127cc18d0cef8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>inability to generate sufficient preclinical, toxicology, or other data to support the initiation of clinical trials;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z39267e0a04c54981ae6a6fefd85169e9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>lack of authorization from regulators or institutional review boards, or IRBs, or ethics committees to allow us or our investigators
        to amend a clinical trial or commence a clinical trial or conduct a clinical trial at a prospective trial site or continue such clinical
        trial;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcfe1349af5924e40aaf39eed39ca8fe7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>delays in sufficiently developing, characterizing, or controlling a manufacturing process suitable for clinical trials;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">9</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" id="z579a912bd9e546e6894d731ea739e093" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>inability to generate sufficient quantities or quality of our drug substance or drug product to support the initiation or continuation
        of clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z84e5ca0551e8449796c45750a87c1f26" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>delays in reaching a consensus with collaborators or regulatory agencies on trial design or trial amendment;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2b795f297379482abfeeef75de5cd059" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>delays in reaching agreement on acceptable terms with prospective CROs, and clinical trial sites, the terms of which can be subject
        to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5a2584fa13364ce38599ff3430e0ba16" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>imposition of a temporary or permanent clinical hold by the FDA, or a similar delay imposed by foreign regulatory agencies for a
        number of reasons, including after review of an IND, other application or amendment; (i) as a result of a new safety finding that presents
        unreasonable risk to clinical trial participants; (ii) a negative finding from an inspection of our clinical trial operations or trial
        sites; (iii) developments on trials conducted by competitors for related technology that raises FDA concerns about risk to patients of
        the technology broadly; or (iv) if FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z92be93d1c89b4d8e9ed78b28ddb848af" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results and we may
        decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product
        development programs;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbe88143bc90c458fbed1e998fcbe84ad" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>difficulty collaborating with patient groups and investigators;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z348654b103bc4088bf07cba96094d263" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>failure by our CROs, other third parties, or us to adhere to clinical trial and related regulatory requirements;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfff19c1ba14041679e6af08443c72f27" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>failure to perform in accordance with the FDA&#8217;s Good Clinical Practice, or GCP, requirements, or similar applicable regulatory
        guidelines in other countries;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5fed33dd17cd422fad6bae743978686f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>failure to perform in accordance with the FDA&#8217;s Good Manufacturing Practice, or GMP, requirements, or similar applicable regulatory
        guidelines in other countries;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zacb6bd75c3bf4e0fb61401a77164bb12" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the number of patients required for clinical trials of any product candidates may be larger than we anticipate or can financially
        support, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials or
        fail to return for post-treatment follow-up at a higher rate than we anticipate;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z184580436c9047669611a71dc91ca5a5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>delays in having patients complete their participation in a trial or return for post-treatment follow-up;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6f2d9e640675485cba3c438bc5fbe5fd" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z24ac5301cfbe4430aff10452b5df3c7d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z09000bc418874875bef6272a9828df6c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes in the standard of care or in the regulatory landscape on which a clinical development plan was based, which may require
        new or additional trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd423c6a5a4194092aea725862c04526c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the cost of clinical trials of our product candidates being greater than we anticipate;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7de00a91b0464266b4179a14f70f1fdd" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>clinical trials of our product candidates producing negative or inconclusive results, or early results that will not be repeated
        in larger or future cohorts or randomized studies, which may result in our deciding, or regulators requiring us, to conduct additional
        clinical trials or abandon product development programs;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2a4e21ef647d4ea487f678faa36a08fc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>choosing the wrong dosing regimen and/or the wrong drug combination;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8238f7fc92e5486f819e5d364fbc29c4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>delays or failure to secure supply agreements with suitable reagent suppliers, or any failures by suppliers to meet our quantity
        or quality requirements for necessary reagents; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4968ed12d2834b1298f904ca280b7006" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates
        for use in clinical trials or the inability to do any of the foregoing.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our product development and other costs will increase if we experience delays in clinical
trials (including termination thereof) or in obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical
trials will begin as planned, and once begun whether will need to be restructured or will be completed on schedule, or at all. Significant
preclinical or clinical trial delays also may allow our competitors to bring products to market before we do, potentially impairing our
ability to be first-in-class or successfully commercialize our product candidates and harming our potential market share and business
and results of operations. Any delays in our preclinical or clinical development programs may harm our business, financial condition and
prospects significantly.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">10</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">From time to time, we publicly disclose preliminary
data from our ongoing clinical trials. As more patient data become available the data and the interpretation of the data may change.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">From time to time, we publish preliminary or interim investigator assessed data from
our ongoing clinical trials. Preliminary data remain subject to audit confirmation and verification procedures that may result in the
final data being materially different from the preliminary data we previously published. Preliminary data are also subject to the risk
that one or more of the clinical outcomes may materially change as time goes by and cutoff date changes, patient enrollment continues
and with further patient monitoring where more patient data become available. As a result, preliminary data should be viewed with caution
until clinical trial completion where the final data are available. Also, data may also change upon the further assessment in additional
studies. Material adverse changes in the data along the clinical development process could significantly harm our business prospects,
financial condition and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We rely and expect to continue to rely on third
parties to conduct our clinical trials. These third parties may not successfully or professionally carry out their contractual duties,
comply with regulatory requirements or meet expected deadlines, and we may experience significant delays in the conduct of our clinical
trials as well as significant increased expenditures.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We do not have the ability to independently conduct clinical trials. We rely and will
continue to rely on medical institutions, clinical investigators, contract manufacturing research organizations, contract laboratories,
outsourced preclinical and clinical service providers and other third parties, such as CROs and advisors, to conduct or otherwise support
our clinical trials. We rely heavily and will continue to rely heavily on these parties for execution of clinical trials for COM701 and
COM902 and any other future product candidates we may take to the clinic, including COM503 (to the extent we take it to the clinic), and
we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our internal clinical
trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance
on these third parties, including our CROs, will not relieve us of our regulatory responsibilities. For any violations of laws and regulations
during the conduct of our clinical trials, we could be subject to untitled and warning letters or enforcement action that may include
civil penalties up to and including criminal prosecution.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We believe that our financial results and the commercial prospects for COM701, COM902,
and any other future therapeutic product candidates we may take to the clinic, including COM503 (to the extent we take it to the clinic),
would be harmed, our costs could materially increase and our ability to generate revenue could be significantly adversely impacted, if
our clinical investigators, CROs or other third parties providing us services fail to successfully carry out their contractual duties
or obligations diligently and in a professional manner or fail to meet their expected deadlines.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Serious adverse events or undesirable side
effects or lack of efficacy, may emerge in clinical trials conducted by other companies running clinical trials investigating the same
drug target as us, which could adversely affect our development programs or our capability to enroll patients or partner the program for
further development and commercialization.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">We initiated a Phase 1 clinical trial for COM902, which targets TIGIT, in March 2020.
There are additional companies that have a program targeting TIGIT in advanced clinical trials, such as Merck, Roche, Gilead/Arcus, AstraZeneca,
and BeiGene. We have no control over their clinical trials or development programs, and lack of or insufficient efficacy such as recently
reported for Roche&#8217;s TIGIT targeting antibody tiragolumab in SCLC and NSCLC, adverse events or undesirable side effects experienced
by subjects in their clinical trials could affect our development and regulatory path of COM902 or the enthusiasm of clinicians recruiting
patients for our clinical trials for COM902 or any other service provider or harm its potential to be partnered for further development
and commercialization and generate revenues for the Company.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Furthermore, any negative results that may be reported in clinical
trials of other programs targeting TIGIT may make it difficult or impossible to recruit and retain subjects in our clinical trials of
COM902. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials,
which could prevent completion of these trials and adversely affect our ability to advance the development of COM902. Failures in planned
subject enrollment or retention may result in increased costs or program delays and could render further development impossible.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">11</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">The same risk applies to COM701 since other anti-PVRIG antibodies
such as GSK&#8217;s GSK4381562 (formerly SRF813), Hengrui&#8217;s PVRIG/TIGIT bi-specific, SHR-2002, Simcere&#8217;s TIGIT/PVRIG bispecific
antibody, SIM0348, Biotheus&#8217;s PVRIG/TIGIT bi-specific, PM-1009, and Hefei TG ImmunoPharma&#8217;s NM1F&#160;which entered the clinic.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">The same risk applies to COM503 as Simcha Therapeutics Inc. entered
its Phase I/II with ST-067, with results expected by June 2024. There are three IL-18 related CAR-T therapies CMN-008 by Co-Immune, huCART19-IL18
by University of Pennsylvania and EU-307 by Eutilex that have entered Phase 1 studies.&#160; </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We are subject to certain manufacturing risks,
any of which could either result in additional costs or delays in completing, or ultimately make us unable to complete, the development
and commercialization of our product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The process of manufacturing biologics, in addition to the shipment and storage thereof,
is susceptible to product loss or unavailability due to contamination, degradation, instability, equipment failure, lack of critical reagents
or disposables, improper installation or operation of equipment, vendor or operator error leading to process deviations or any other factor.
Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply
disruptions up to supply termination. If microbial, viral or other contaminations are discovered in our products or in the manufacturing
facilities in which our products are made, the products may need to be manufactured again and/or such manufacturing facilities may need
to be closed for an extended time to investigate and remediate the contamination. In addition, the product manufactured may be determined
at later stage to be insufficiently stable or qualified as a therapeutic agent, even following treatment.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have not contracted with alternate suppliers to support us in the event we experience
any problems with our current manufacturers. If we are unable to arrange for alternative third-party manufacturing sources or are unable
to reserve another manufacturing slot with our current manufacturers or are unable to do so on commercially reasonable terms or in a timely
manner, or are unable to provide backup drug, we may incur additional costs or be delayed in the development or delivery of our current
and future product candidates, and even fail to supply drug to patients on study treatment on time or at all, or meet other obligations,
each event of which can cause us material harm.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">It may be difficult to manufacture therapeutic products addressing
our drug target candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Our therapeutic pipeline is focused mainly on monoclonal antibodies,
or mAbs, generated against our discovered targets. These types of therapeutics can be difficult to manufacture in the quantity and quality
needed for preclinical, clinical and commercial use. The production of mAbs must be conducted pursuant to a well-controlled and reproducible
process and the resulting product testing must conform to defined quality standards. Should it prove to be difficult to manufacture or
repeat manufacturing, of any therapeutics addressing our drug candidates in sufficient quantities or commercial scale, meeting the required
quality standards or in an economical manner to conduct clinical trials and to commercialize any approved therapeutic candidate, our business,
financial condition and results of operations would be materially harmed. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We or any of our collaborators, or third-party
manufacturers, may fail to comply with regulatory and legal requirements, and we or they could be subject to enforcement or other regulatory
actions.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">If we or any of our collaborators or third-party manufacturers
with whom we work or with whom we may enter into agreements in the future fail to comply with applicable federal, state or foreign laws
or regulations, or other legal obligations we or they could be subject to enforcement or other regulatory actions. These actions may include:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zef539db6078b4a94990ce3316539d234" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>warning letters; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div>clinical trial holds;</div> </div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25"> <br/> </div>

<table cellspacing="0" cellpadding="0" id="z0060c599f4ae4c27bf405db97c65d312" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>recalls, product seizures or medical product safety alerts; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6a5edf39957f498ebd361c8c608d8446" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>data lock or order to destroy or not use personal data;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7abe7efab0cd447db6528826889dc8e0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>restrictions on, or prohibitions against, marketing such products; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z41cedebd10164b9b96c7520a3d48ed91" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>restrictions on importation of such products; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">12</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" id="z8e771bbd481d448f972c195b584aa779" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>suspension of review or refusal to accept or approve new or pending applications; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zec1963069db04582a401bdfc17ac614f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>withdrawal of product approvals; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb13fb76f34484609964db69ba4f8ab45" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>injunctions; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z87fe8d1725184b86bfea48b72cb78685" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>civil and criminal penalties and fines; or </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z38d36a66a88342d7b85e95b1ca812b17" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>debarment or other exclusions from government programs. </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we or our collaborators become subject to such enforcement actions, these enforcement
actions could affect the ability to successfully develop, market and sell therapeutic products based on our discoveries and could significantly
harm our financial status and/or reputation and lead to reduced acceptance of such products by the market.&#160;In addition, we may be
subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement or imprisonment.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may require companion or complementary diagnostics
and/or biomarkers for our clinical trials, or a portion of our clinical trials, and may be required to have such in order to obtain marketing
approval or commercialization of our therapeutic programs. Failure to successfully discover, develop, validate and obtain regulatory clearance
or approval for such tests could harm our patients&#8217; selection strategy and may harm our clinical outcome.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Companion or complementary diagnostics are subject to regulation by the FDA and comparable
foreign regulatory authorities and may require separate regulatory authorization prior to commercialization. We may require for our clinical
trials or for certain portions of our clinical programs, companion diagnostics and/or biomarkers to correctly identify the right patients
for the appropriate indications. We rely on access to patient tumor and blood samples for analysis of protein, DNA, and RNA biomarkers.
We may rely on third parties for the tumor and blood samples&#8217; handling, processing, and analysis, discovery, development, and validation
of these potential biomarker candidates, biomarkers and/or companion diagnostics, as well as the application for and receipt of any required
regulatory authorization. If we, or the third parties we engage for this purpose, are unable to successfully discover, validate and/or
develop the required companion diagnostics and/or biomarkers for our clinical programs, or develop with altered specifications, or experience
delays in doing so, the development of our clinical candidates may be adversely affected and this can harm our patient selection and our
clinical outcome, as well as obtaining marketing authorization for these product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">From time to time, we may also publish preliminary
biomarker data from our ongoing clinical trials. As more patient data become available the data and the interpretation of the data may
change.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Preliminary biomarker data are subject to the risk that it may materially change as
patient enrollment continues, as assay or reagents conditions change, as selected signal cutoff changes and it remains subject to audit
confirmation and verification procedures that may result in the final data being materially different from the preliminary data we previously
published. As a result, preliminary data should be viewed with caution. Material adverse changes in the biomarker data along the clinical
development process could harm our patient selection, the success of our studies and could cause other damages and could eventually significantly
harm our business prospects, financial condition and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our current and future relationships, and/or
the relationships of our collaborators through which we may market, sell, and distribute our products, with healthcare professionals,
physicians and other parties in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud
and abuse, false claims, physician payment transparency, health information and general privacy and security and other healthcare laws
and regulations, which could expose us to adverse consequences.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our current and future business operations, and our or our collaborators&#8217; business
and financial arrangements and relationships with healthcare providers, physicians and other parties through which we or our collaborators
may market, sell and distribute our products, once approved, may be subject to extensive U.S. federal, U.S. state and foreign healthcare
fraud and abuse, transparency, health information and general data privacy and security laws. For example, U.S. federal civil and criminal
laws and regulations prohibit, among other things: knowingly and willfully soliciting, receiving, offering or providing remuneration,
directly or indirectly, to induce or reward either the referral of an individual, or the furnishing, recommending or arranging for a good
or service, for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs; knowingly presenting
or causing to be presented, a false or fraudulent claim for payment by a federal healthcare program; and knowingly and willfully executing,
or attempting to execute, a scheme to defraud any healthcare benefit program (including a private payor), or knowingly and willfully falsifying,
concealing or covering up a material fact or making any materially false statement in connection with the delivery of, or payment for,
healthcare benefits, items or services. Many U.S. states and foreign countries have analogous prohibitions that may be broader in scope
and apply regardless of payor. In addition, we may be subject to U.S. federal, U.S. state and foreign laws that require us to report information
related to certain payments and other transfers of value to certain health care professionals, as well as ownership and investment interests
in our company held by those health care professionals and their immediate family members, and health information and general security
and privacy laws that restrict our practices with respect to the use and storage of certain health information and other data.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">13</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">If we or our collaborators are found to be in violation of any of these laws, we or
our collaborators could be subject to significant civil, criminal and administrative penalties, including damages, fines, disgorgement,
imprisonment, exclusion from participation in government healthcare programs, additional integrity oversight and reporting obligations,
contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which, whether enforced against
us or our collaborators, could significantly harm our business and our royalties from any of our products, once approved, that we license
to such collaborators.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to our Discovery and Development Activities </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">There are risks that are inherent in the development
and commercialization of new therapeutic products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We and our collaborators face a number of risks of failure that are inherent in the
lengthy and costly process of developing and commercializing new therapeutic products. These risks, which typically result in very high
failure rates even for successful biopharmaceutical companies, include, among others, the possibility that:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbf0c48282cb44b66a8c2c95c5e8f36eb" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we will not be able to discover additional drug targets;&#160; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb9305d3ef9954eb7807df1e522402256" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our new target candidates will prove to be inappropriate for treatment of cancer;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1b9ffc9fad674c55a6c0bdd1adeb4e9b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our new target candidates will prove to be inappropriate targets for therapeutic product candidates; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z578062f2bf7b4741b758b2611feae3ee" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our new target candidates will prove to be inappropriate targets for immunotherapy;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we will not succeed in selecting the appropriate tumor type, indication or patient population for the therapeutic product candidate;</div>
        </td> </tr>
  </table> </div>

<div style="line-height: 1.25"> <br/>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we will not succeed in developing or choosing the appropriate mAb for these targets, or the appropriate mAb lead or the appropriate
        mAb isotype; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we will not succeed in identifying or developing a biomarker or companion diagnostic for our therapeutic product candidates; </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div> </div>

<table cellspacing="0" cellpadding="0" id="z546e3758e70b42f0862a9e0e20daa26f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we will not succeed in choosing the appropriate drug modality for these targets; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z58781c97a8c34a60ae2d677df5ad8f80" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our therapeutic product candidates will fail to progress to preclinical studies or clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z20b6ca710ef441a986110c3e6b0f5859" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our therapeutic product candidates will be found to be therapeutically ineffective;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div style="line-height: 1.25">we will not choose or have access to the right drug combination for our therapeutic product candidates;
        </div> </div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25"> <br/>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we will not select or find the appropriate dosing regimen; </div> </td> </tr>
  </table> <br/> </div>

<table cellspacing="0" cellpadding="0" id="zc2e2426f2aff429d82fe09647a23e345" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our therapeutic product candidates will be found to be toxic or to have other unacceptable side effects or negative consequences;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z83492faf5d6f4779ac6b5b9861873d5f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our therapeutic product candidates will be inferior, or not show added value, compared to competing products or the standard of care;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z10df3e2e5c884c07a92c6c8775683aa3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our early-stage development efforts may provoke competition by others or may face competition by others; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z76c98fab7e1140019f27e20c9ef0e132" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our early-stage development efforts will bear significant delays in the development of additional preclinical stage programs;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8558faea1457465da765df33ac18c995" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our products covered by our collaborations may face internal competition from our partners&#8217; internal pipeline;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">14</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" id="z9e478ae0024e4ba3a10e40f5ed811ec0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we or our collaborators will fail to receive required regulatory approvals; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9c6ee099f55843fb9de55c30857df06a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we or our collaborators will fail to manufacture our therapeutic product candidates in the quantity or quality needed for preclinical
        studies or clinical trials on a large or commercial scale, on time or in a cost-effective manner or with the drug stability required;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3d6b9abda03e498eb94662ad9b408d40" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the discovery of drug targets and the discovery, development or commercialization of our therapeutic product candidates will infringe
        third-party intellectual property rights; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z129f01020db24163b11ccf2effdb9025" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the development, marketing or sale of our therapeutic product candidates will fail because of our inability or failure to protect
        or maintain our own intellectual property rights; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1d4c181c940e4595afa395f3127e1142" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>once a product is commercially available, there will be little or no demand for it for a number of possible reasons, including lack
        of acceptance by the medical community or by patients, lack of or insufficient coverage and payment by third-party payors, inefficient
        or insufficient marketing and sales activities or as a result of there being more attractive, less risky or less expensive, products available
        for the same use; and </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div><br/> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div>the product will be withdrawn from the market, or sales limited due to side effects observed in clinical practice.</div> </div> </td>
        </tr>
  </table> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">If one or more of these risks or any similar risks should materialize, our business,
financial condition and results of operations may be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We have limited experience in the development
of therapeutic product candidates, and we may be unable to implement our business strategy.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our experience in the development of therapeutic product candidates is limited. Therefore,
we may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business
objectives. To successfully develop and commercialize therapeutic products, we must either access such expertise via collaborations, consultants
or service providers, and/or enhance and improve our internal expertise and capabilities. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we are not able to attract, retain and motivate necessary personnel or third party
service providers or collaborators to accomplish our business objectives or fail to have available, at the appropriate times, the required
experience and expertise for the further development and commercialization of our therapeutic product candidates, we may be unsuccessful
in these activities, or these activities may be significantly delayed and as a result we may be unable to implement our business strategy
and our business would be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our computational target discovery activities
are primarily focused on the discovery of new drug target candidates and our therapeutic pipeline is based on our discovered targets.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">While we believe that our drug target programs represent a compelling and unique opportunity
to generate potentially first-in-class therapeutics in the field of cancer immunotherapy, they require significant investment in the research
and validation of the drug target candidate and in the discovery and development of the respective therapeutic product candidate and bear
high risk. Our predictive computational discovery capabilities are a source for the development of potential first-in-class therapeutics
in the field of cancer immunotherapy, but the inherent lack of sufficient published scientific and clinical data to support the potential
of these new drug targets candidates to serve as therapeutic opportunities, increases the risk of failure. Although we have built the
target identification, validation and drug discovery infrastructure and capabilities that we believe are required to scientifically validate
our new drug targets and to later translate them into therapeutic antibody development programs, we cannot be assured that our investment
in such new discoveries will result in validated drug targets that will enable the development of effective cancer immunotherapies, nor
that we will realize success in product development or our ability to partner and commercialize such opportunities and generate revenues.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our approach to the discovery of therapeutic
products is based on our predictive computational discovery capabilities that are not yet fully proven clinically, and we do not know
whether we will be able to discover and develop additional potential product candidates or products of commercial value.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our method of identifying novel drug targets is based on our predictive computational
discovery capabilities and involves first identifying unmet needs in the field of cancer immunotherapy, where we believe our predictive
computational discovery capabilities would be relevant or could be modified to be relevant. We focus on the discovery of drug targets
that could serve as the basis for the development of possible treatments for patients non-responsive, refractory or relapsing to existing
cancer immunotherapies. In this field, we apply our predictive computational target discovery capabilities, or develop new capabilities,
to identify novel drug targets for addressing such unmet patient need. </div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">15</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"><br/> While we believe that applying our predictive computational discovery capabilities
to identify new drug targets may potentially enable the development of potentially first-in-class therapeutics in the field of cancer
immunotherapy, our capabilities are yet not fully proven clinically and our efforts may not result in the discovery and development of
therapeutic products, or commercially viable or successful therapeutic products. Although our approach has resulted in the discovery of
several new drug targets and their related potential first-in-class or best-in-class therapeutic product candidates in the field of cancer
immunotherapy, they are in early stages of research and development or in clinical stage, with COM701 having entered the clinic in 2018,
COM902 which entered the clinic in March 2020 and rilvegostomigwhich entered the clinic in the fourth quarter of 2021. Our approach may
not result in time savings, higher success rates or reduced costs, or clinically meaningful programs and if not, we may not attract collaborators
or develop new drugs as quickly or cost effectively or at all and therefore we may not be able to partner and commercialize our products
as expected. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We are focusing our discovery and therapeutic
development activities on therapeutic product candidates for uses in immuno-oncology. Our current candidates may fail, and we may fail
to continue to discover and develop therapeutic product candidates of industry interest in this field.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The focus of our discovery and therapeutic development activities is on mAb therapeutics
in the field of immuno-oncology for treatment of cancer. As a result, we are not undertaking internal discovery and development activities
in other therapeutic areas, and presently we only pursue activities in our area of focus. If our current candidates fail, or if we fail
to continue to discover and develop therapeutic product candidates of clinical value and medical interest in this field, or if we are
unable to discover drug targets for mAb therapeutics, or if other modalities would be more successful in treating cancer patients, our
business will likely be materially harmed. With respect to cancer immunotherapies, although there have been positive clinical results
reported by others resulting in some products gaining approval by the FDA, there can be no assurance that our therapeutic product candidates
or our earlier stage immuno-oncology target candidates in our pipeline, will provide similar clinical advantages or interest, that no
long term adverse effects will be seen, or that other classes of targets or other products will not be discovered and developed with comparable
or superior attributes or clinical activity. In the event of any of these occurrences, the actual and/or perceived value of a substantial
portion of our pipeline would likely be reduced in which case our business may be materially harmed. To date, we have signed four partnership
agreements involving our therapeutic product candidates, two of which, one with AstraZeneca and one with Gilead, are in effect. There
is no assurance that we will be able to enter into additional collaborations or agreements on reasonable terms, if at all. In addition,
if we fail to continue to discover and validate drug targets or develop product candidates of industry interest in our field of focus,
our business will likely be materially harmed. There are many risks associated with our decision to focus on immuno-oncology that include,
among others:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8b3f72e05729483e96c7586e4dada279" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>not being able to discover new drug targets in this field; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our full scope of target discovery capabilities may not be adequate; </div> </td> </tr>
  </table> </div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zb00be1baaf934688970bf1bb27a78f88" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>not having chosen the right therapeutic area; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z950fb68d77fb4d229816debfc2673a91" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>having chosen a therapeutic area with a very high degree of competition;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3cc8f732c71f417fa2916cf55e501e2a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>industry interest in this area or in specific classes/families of drug targets within this area of focus would decrease over time;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2169141bab3e496c9329a636ad9131f4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the checkpoint inhibitors field is facing fatigue; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z47ccbc6c929244fbadc51f7dc5b2cbf7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>having chosen a therapeutic area of great biological complexity and with very high failure rates in product development; </div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6345af49a742491982ebff5617a4531c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>not choosing the appropriate drug modality; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z462452ff3b194db9b1e553e65ca62360" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>having insufficient knowledge, expertise, personnel or capabilities in our chosen therapeutic area to identify the right unmet medical
        needs, or drug targets, or to timely, properly and efficiently validate the targets and/or select the appropriate mAb for further development
        as therapeutic product candidates, or to timely, properly or efficiently further them in development; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z06ea579e33af4d57adf83e97b414d3c5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the inherent risk of high program failure rate throughout therapeutic development. </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In each case, our failure could be due to lack of experience and expertise, delays
in our internal research programs or applying the wrong criteria or experimental systems and procedures, or selecting an inappropriate
drug modality, or unanticipated scientific, safety, activity or efficacy issues with our selected drug targets or product candidates,
with the possible result that none of our product candidates result in licensed or marketable products. If any of these risks should materialize,
our business, financial condition and results of operations would be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">16</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold"> <br/> </div>

<div style="line-height: 1.25; font-weight: bold">Risks Related to Our Dependence on Third Parties</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We depend significantly on third parties to
carry out the research, development and commercialization of our therapeutic product candidates. If we are unable to maintain our existing
agreements or to enter into additional agreements with such third parties, mainly collaborators, in the future, our business will likely
be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Our primary strategy for the development and commercialization
of products based on our drug targets and therapeutic product candidates depends on third parties to carry out and/or finance, the research,
development and commercialization of such products, principally by pharmaceutical and biotechnology companies and other healthcare related
organizations and CROs, either on their own or in collaboration with us. To date, we have entered into four partnership agreements with
respect to our drug target candidates, two of which (one with AstraZeneca and one with Gilead) are in effect. We cannot be sure that the
partnership agreements with AstraZeneca or Gilead will result in the successful development or commercialization of any product. Further,
we cannot provide assurance that we will succeed in identifying additional suitable parties or entering into any other additional agreements
on satisfactory terms or at all for the discovery, research, development and/or commercialization of our drug target or therapeutic product
candidates. If we are unable to identify such additional suitable parties or enter into new agreements on satisfactory terms, or at all,
our business will likely be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We rely and expect to continue to rely completely
on third parties to manufacture and supply our preclinical and clinical drug supplies. Our business could be harmed if those third parties
fail to provide us with sufficient quantities of drug product or fail to do so at acceptable quality and quantity levels, prices or timelines.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We do not currently have, nor do we plan to acquire, the infrastructure or capability
internally to manufacture our preclinical and clinical drug supplies for use in the conduct of preclinical testing and our clinical trials,
and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. In order
to develop products, apply for regulatory approvals and commercialize our products, we need to develop, contract for, or otherwise arrange
for access to the necessary manufacturing capabilities. We rely and expect to continue to rely on contract manufacturing organizations,
or CMOs, and other third-party contractors to manufacture formulations and produce larger scale amounts and/or commercial-scale of drug
substance and drug products required for any clinical trials that we initiate and other related services. Such third parties may not be
able to deliver in a timely manner, or at all, or may fail to comply with the FDA&#8217;s current Good Manufacturing Practice, or cGMP,
to manufacture our drugs in the required quality or quantity. We have entered into manufacturing and supply agreements with third parties
for the manufacturing and respective analytics of each of COM701, COM902 and COM503.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The manufacturing process for any products based on our technologies that we or our
partners may develop is subject to the FDA regulation and foreign regulatory authority approval process, and we will need to contract
with manufacturers who can meet cGMP requirements and foreign regulatory authority requirements on an ongoing basis. In addition, if we
receive the necessary regulatory approval for any therapeutic drug candidate, we also expect to rely on third parties, to produce materials
required for late-stage pivotal clinical trial(s) and commercial supply. We may experience difficulty in obtaining adequate manufacturing
capacity for our needs, adequate and sufficient material as well as difficulties and challenges in technology transfer from one manufacturer
to the other, as needed. If we are unable to obtain or maintain adequate manufacturing sources for these product candidates, or to do
so on commercially reasonable terms and adequate timeline, quality and quantity, we may not be able to successfully develop and commercialize
our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">17</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">We are also dependent upon these third parties with respect to critical reagents supply,
supplies required for our manufacturing and quality control, packaging, labelling, storage and others. The failure of a third-party manufacturer
or supplier to perform its obligations as expected could adversely affect our business in a number of ways, including:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8ebf0b55e2234dfd8582fcdb7b8ad118" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we may not be able to initiate or continue preclinical and clinical trials of products that are under development;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc49cd36e7d674c80bd28ff7e8be72a57" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we may experience significant disruption and delay to our clinical supply chain;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z01ff5f8c62b44f3eacbaf71b92fa1f7d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we may experience significant adverse effect if we are unable to transfer the manufacturing process to a different third-party manufacturer
        in a timely and efficient manner;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z36f4b0da96cc478e9c393982f467519c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we may need to repeat clinical trials or stop our clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6312a55ec09a467096db4dd28d614c59" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we may be delayed in submitting regulatory applications, or receiving regulatory approvals, for our product candidates;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z20e4c5c251194df1b1149c2c77bfe370" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we may lose the cooperation of our collaborators;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7ff5b9a111b848349c9b2ec9f32474e8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we may be required to cease distribution or recall some or all batches of our products; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1da31ce7d3644ccb8c282d898bdbc5f6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>ultimately, we may not be able to meet commercial demands for our products, if approved.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If a third-party manufacturer or supplier with whom we contract fails to perform its
obligations, we may be forced to manufacture or otherwise obtain the materials ourselves, for which we do not currently and may not in
the future have the capabilities or resources, or identify and qualify a different third-party manufacturer, which we may not be able
to do timely or on reasonable terms, if at all. In some cases, the technical skills or processes required to manufacture our product may
be unique to the original manufacturer and we may have difficulty transferring such skills or processes to a back-up or alternate manufacturer
or supplier, or we may be unable to transfer such skills or processes at all. In addition, if we are required to change manufacturers
for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards
and with all applicable regulations and guidelines. We will also be required to demonstrate that the newly manufactured material is similar
to the previously manufactured material, or we may need to repeat clinical trials with the newly manufactured material. The delays associated
with the verification of a new manufacturer could negatively affect our ability to develop product candidates or commercialize approved
products in a timely manner or within budget. Furthermore, a manufacturer may possess technology related to the manufacture of our product
candidate that such manufacturer owns independently, which would increase our reliance on such manufacturer or require us to obtain a
license from such manufacturer in order to have another third-party manufacture our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our dependence on collaboration agreements
with third parties presents number of risks.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">The risks that we face in connection with our existing collaborations
and other business alliances as well as those that we may enter into in the future include, among others, the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4d18cffca8ae44dba912805f6023105b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we may be unable to reach mutually agreeable terms and conditions with respect to potential new collaborations; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze9ca950ca6a04f0d91d557a0d9adef6f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we or our current and/or future collaborators may be unable to comply or fully comply with the obligations under collaboration agreements
        to which we are (or will become) a party, and as a result, we may not generate milestone payments or royalties from such agreements, and
        our ability to enter into additional agreements may be harmed; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z06e756371754490c8a47ac5303bbfce3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our obligations under existing or future collaboration agreements may harm our ability to enter into additional collaboration agreements;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze01c194c6ae34239ada54b7ce792c9d5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>collaborators generally have significant discretion in electing whether to pursue any of the planned activities and the manner in
        which it will be done, including the amount and nature of the resources to be devoted to the development and commercialization of our
        product candidates; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcb54c75c719641b9a07a5c67bd5113c9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>collaborators generally have significant discretion in terminating the collaborations for scientific, clinical, business or other
        reasons; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3420357f859744e588abb5c9cdf6a2e1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>if our current and/or future collaborators breach or terminate an agreement with us, the development and commercialization of our
        therapeutic product candidates could be adversely affected because at such time we may not have sufficient financial or other resources
        or capabilities or access to the other partner&#8217;s data and drug(s) to successfully develop and commercialize these therapeutics on
        our own or find other partners or enforce our rights under breached or terminated agreement; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9312045670444502a0e3d803fdd26c5d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our current and/or future collaborators may require us changing or adopting the trial design to fit their business priorities, standards
        and other objectives; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">18</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"> <br/> </div>

<table cellspacing="0" cellpadding="0" id="z7b5ccc8034e84ab68653b2acd3a896a5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes in a collaborator&#8217;s business strategy may negatively affect its willingness or ability to complete its obligations
        under its arrangement or to continue with its collaboration with us; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8ac148ffa3f34a509f9cd0a1eaa4f0cd" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our current and/or future collaborators may terminate the program or the agreement and then compete against us in the development
        or commercialization of similar therapeutics;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbef5e32a52394d00b5d801361663a5b1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>disagreements between us and our current and/or future collaborators may lead to delays in, or termination of, the collaboration;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8e8e325b7ae746dea04cb7b25989f6cb" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 14.2pt"><br/> </td>
    <td style="width: 14.15pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our current and/or future collaborations may face internal competition by their internal pipelines;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9c9f895b308f4690a7dbbc614df30a9f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 14.2pt"><br/> </td>
    <td style="width: 14.15pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>prospective collaborators may hesitate to pursue collaborations on novel target candidates that lack robust validation to serve as
        a basis for the development of therapeutics; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za9d595cfb47a425da2c0b4cd57b29aa8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our current and/or future collaborators may be acquired by, acquire, or merge with, another company, and the resulting entity may
        have different priorities or competitive products to the collaboration product being developed previously by these collaborators. </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">If any of these risks should materialize, our business, financial condition and results of operations may
be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our existing partnership agreement with AstraZeneca
is subject to many risks. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In March 2018, we entered into an exclusive license agreement with MedImmune Limited,
the global biologics research and development arm of AstraZeneca, which is currently part of AstraZeneca. Under the terms of the license
agreement, we provided an exclusive license to AstraZeneca to use our monospecific antibodies that bind to TIGIT, including COM902, for
the development of bi-specific and multi-specific antibody products, excluding such bi-specific and multi-specific antibodies that also
bind to PVRIG, PVRL2 and/or TIGIT. In connection with such license agreement, AstraZeneca developed rilvegostomig, a novel TIGIT/PD-1
bi-specific antibody with a TIGIT component that is derived from our COM902. Subject to termination rights for material breach, bankruptcy
or by us for patent challenge by AstraZeneca, the term of the license agreement continues until the expiration of the last royalty term
in the territory as further specified in the license agreement. In addition, AstraZeneca may terminate the agreement for convenience upon
prior written notice.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If significant adverse unforeseen events occur in this collaboration or it is terminated,
particularly prior to our signing additional collaboration agreements, our business and financial condition may be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our existing partnership agreement with Gilead
is subject to many risks. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In December 2023, we entered into the License Agreement with Gilead. Under the terms
of the License Agreement, we granted Gilead an exclusive license under our preclinical antibody program against IL-18 binding protein
and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products, including
COM503, and additional products that may be so developed by Gilead, together with COM503, or the Licensed Products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the License Agreement, we will be responsible for conducting a Phase 1
clinical trial for COM503, including handling the regulatory matters in connection therewith, and will bear the costs of such trial (including
the COM503 drug supply), with Gilead providing at no cost an anti-PD-1/PD-L1 antibody for such trial. Nevertheless, in certain circumstances,
Gilead may require us to transfer to them the role of conducting the Phase 1 clinical trial, before the Phase 1 clinical trial is initiated
or completed. In such case,our business and financial condition may be harmed. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, Gilead may terminate the agreement for material breach, bankruptcy and
even for convenience and therefore, if this agreement is terminated, particularly prior to our signing additional collaboration agreement
at that scale, our business and financial condition may be materially harmed. If significant adverse unforeseen events occur in this collaboration
or it is terminated, our business and financial condition may be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">19</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our reliance on third parties for the performance
of key activities heightens the risks faced by our business. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We outsource many of our activities and many key functions to third parties, including
major preclinical activities, drug development activities, manufacturing operations, research, validation, discovery and others. We do
not control the third parties to whom we outsourced these functions and have limited internal expertise to appropriately manage their
activities. However, we are dependent on them to undertake activities and provide services, results, our product candidates or materials,
including the production of certain biological reagents, which may be significant to us. If these third parties fail to properly or timely
perform these activities or provide us with incorrect or incomplete services or results or fail to produce and/or provide certain materials,
tests or analysis, this could lead to significant delays in the program or even program failure, along with significant additional costs
and damage. In addition, should any of these third parties fail to comply with the applicable laws and regulations and/or research and
development or manufacturing accepted standards in the course of their performance of services for us, there is a risk that we could be
held responsible for such violations of law as well. Any such failures by third parties could have a material adverse effect on our business,
financial condition or results of operations. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Moreover, we do not always independently verify the results obtained by such third
parties and in some cases, primarily with respect to clinical data, we have to rely upon the data provided by the third-party. If we fail
to identify and obtain accurate and quality data, services and/or technologies from such third parties, or if the contractual demands
of such third parties become unreasonable and we are not able to reach satisfactory agreements with such third parties, we may lose our
investment in these services, fail to receive the expected benefits from our discoveries, and our validation and development capabilities,
clinical trials or other activities or our final products, may be significantly harmed, delayed or terminated.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may need to obtain third-party drugs for
combination with our clinical programs that may not be available to us or are available only on commercially unreasonable terms or may
not serve us as well as other drugs. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We&#160;may&#160;need to obtain certain drugs from third&#160;parties&#160;or to acquire
marketed drugs to&#160;further&#160;develop&#160;our drug candidates to work in combinations with other drugs for selected indications.
If we fail to obtain these drugs or license thereof, our drug candidates may not be sufficiently efficient, and we may not be able to
pursue them through development. We will also need to obtain certain drugs from third&#160;parties&#160;in order to register and commercialize&#160;our&#160;drug
candidates. If we fail to enter into collaboration with the marketing authorization holder, we may not be able to pursue our combination
drugs through registration and commercialization. Furthermore, if we pursue clinical trials with third parties to&#160;further&#160;develop&#160;our
drug candidates to work in combinations with such other drugs for selected indications and those third parties&#8217; drugs have not received
regulatory approval for an indication of interest to us, such clinical trials may not provide us a path for registration and therefore
may not serve us best as other drug(s) in the relevant indication. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-weight: bold">Risks Related to Competition and Commercialization</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our business model is challenging to implement
and to date has not yielded significant revenues.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our discovery and development capabilities are designed to identify and develop novel
products addressing a specific unmet need and enter into collaborations with partners with respect to such novel products. Our objective
is that under these collaborations, we will have the right to receive various forms of revenues from such products or product candidates.
To date, we have entered into four partnership agreements with respect to our pipeline programs, only two of which are in effect. There
can be no assurance that our current or any future agreements for novel targets based on our discoveries and associated product candidates
will be successful and thus provide significant revenues to us, nor can there be any assurance that we will be able to enter into additional
future agreements. If we are unable to succeed in securing additional license agreements or other collaboration arrangements related to
our discoveries and product candidates, our business may be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Currently we have an ongoing collaboration with AstraZeneca, pursuant to which rilvegostomig,
a novel PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from our COM902 program, entered into a Phase 3 clinical
trial in the fourth quarter of 2023 and a collaboration with Gilead, pursuant to which we granted Gilead an exclusive license under our
preclinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research,
develop, manufacture and commercialize products, including our COM503 product candidate,&#160; which is in IND enabling studies, and additional
products that may be so developed by Gilead. In addition, we have two clinical programs fully owned by us, COM701 and COM902, that are
available for partnering arrangements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">There can be no assurance that we will be able to establish collaborations for COM701
or COM902 or any collaboration for our early-stage programs. Failure to enter into collaborations, may materially harm our business. The
research and validation data generated to date for our early-stage pipeline and the clinical data generated to date for COM701 and COM902
may not be sufficient to attract interest from prospective collaborators and we may fail to generate data suitable to draw interest with
potential partners. Furthermore, our drug target candidates or therapeutic product candidates may not fit their corporate or clinical
strategy or will present a sufficient market competitive edge, or not at all. These companies may require more data, including their independent
testing of our early-stage therapeutic product candidate, before considering a collaboration. We are therefore dependent on the potential
fit of our programs with individual pharmaceutical company strategies and there can be no assurance that we will be able to identify additional
partners interested in our programs at their current stages. This may adversely affect our ability to enter into additional agreements
for the research, development, license or other form of collaborative arrangements of our therapeutic product candidates, and as a result
may harm our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">20</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">Additionally, we may not be able to demonstrate efficacy or safety, prove our scientific
or preclinical hypothesis or obtain approval for and commercialize our products as monotherapy treatments. We may be required to combine
our product candidates with other products to provide sufficient data for approval by FDA and other regulatory authorities, in all or
in specific indications (which may require our dependency on third-party drugs). As part of our business strategy, we are looking to establish
clinical collaborations with pharmaceutical and biotechnology companies to specifically test the hypothesis that there may be greater
effects when combining our products with other products. There can be no assurance that we will be able to establish clinical collaborations
or to maintain our existing collaborations. Failure to enter into clinical collaborations to pursue drug combinations may materially harm
our business. These potential combination products may include both marketed as well as investigational products, and as such, adverse
events resulting from combining the products or investigational agents are unknown and could be severe, including resulting in death of
the patient due to these unknown toxicities. Furthermore, using our therapeutic product candidates as part of combinations therapy may
result in a situation under which our therapeutic product candidates will be entitled to only a fraction of the anticipated product revenues.
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We operate in a highly competitive and rapidly
changing industry which may result in others discovering, developing or commercializing competing products ahead of us or more successfully
than we do.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The biotechnology and biopharmaceutical industries are highly competitive, characterized
by rapid and significant technological advancements, and have a strong emphasis on proprietary products. Our success is highly dependent
upon our ability to identify, develop and obtain regulatory approvals for therapeutic products based on our discovered novel drug targets.
In doing so, we face and will continue to face intense competition from a variety of businesses, including large, fully integrated, well-established
pharmaceutical companies, specialty pharmaceutical and biopharmaceutical companies, academic institutions, government agencies and other
private and public companies and research institutions.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Many of the companies against which we are competing or against which we may compete
in the future have significantly greater resources and expertise in research and development, manufacturing, preclinical testing, conducting
clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. These competitors and others may develop competing
products targeting the same mechanisms, the same drug targets and pathways as our products, or the same therapeutic indications and they
can leverage their resources or use different approaches than we do to receive marketing approval before our products. For example, in
case of COM701, there are currently several PVRIG antibodies in Phase 1 studies, such as GSK&#8217;s GSK4381562 (formerly SRF813), Hengrui&#8217;s
PVRIG/TIGIT bi-specific, SHR-2002, Simcere&#8217;s TIGIT/PVRIG bispecific antibody, SIM0348, Biotheus&#8217;s TIGIT/PVRIG bispecific,
PM-1009, and Hefei TG ImmunoPharma&#8217;s NM1F. In the IL-18 pathway field, Simcha therapeutics is leading with its ST-067, a mutated
IL-18 fusion protein at Ph 1/2. There are three IL-18 related CAR-T therapies CMN-008 by Co-Immune, huCART19-IL18 by University of Pennsylvania
and EU-307 by Eutilex that have entered Phase 1 studies. BrightPeak Therapeutics, Sonnet Biotherapeutics, and Xencor are examples of companies
who are developing recombinant IL-18 and are in the preclinical phase or IND enabling stages. Antibodies for IL-18BP are also being developed
in Lassen Therapeutics (LASN-500) in the discovery stage. Additionally, these third parties compete with us in recruiting and retaining
qualified scientific, drug development and management personnel and advisors, establishing clinical trial sites and patient enrollment
for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in
the biopharmaceutical industry could result in even more resources being concentrated among a small number of our competitors or a change
in potential acquirers&#8217; preferences. In addition, increased industry interest and deals in the anti-TIGIT and anti-PVRIG field may
further enhance the competition for our clinical stage assets COM902 and COM701 and may include companies with significantly greater resources
and capabilities than we have. For example, in January 2022 Coherus exercised its option to Junshi Biosciences&#8217; TIGIT-targeted antibody
JS006 and initiated phase 1 clinical trials, in May 2021 Bristol Myers Squibb licensed Agenus&#8217;s anti TIGIT bi specific program,
in November 2021 Gilead and Taiho each exercised its option to Arcus&#8217; anti-TIGIT antibodies domvanalimab and AB308 each pursuant
to its respective territorial rights, in June 2021 GSK and iTeos Therapeutics entered into an agreement to co-develop and co-commercialize
iTeos&#8217; anti-TIGIT antibody EOS-448, and in December 2020 GSK licensed worldwide development and commercial rights to Surface Oncology&#8217;s
preclinical program SRF813 (now GSK4381562), an antibody targeting PVRIG which has received FDA IND clearance in December 2021 and initiated
phase I studies.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">21</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">In addition to the competition we face in the drug target space, we also face competition
in the drug modality field. Technological breakthroughs in new modalities will be a key driver of growth for the&#160;biopharma industry
over the next decade. Drug discovery and development has undergone an impressive transformation over recent years driven by the emergence
of new drug modalities. This expansion in innovative drug modalities has provided an impressive drug modality toolbox to enhance the drug
effectiveness and also allow to enhance the potential from such targets that the efficacy of a naked antibody targeting these drug targets
has been limited. Such drug modalities include among others, bi-specifics, T cell engagers (TCE), cell therapies, antibody drug conjugates
(ADC), protein degraders, molecular glues, and mRNA therapeutics. An example of a drug modality gaining a lot of interest and attention
are the ADC, with eleven (11) FDA approvals as of June 2023 and the significant investment as exemplified by the Pfizer&#8217;s $43 billion
acquisition Seagen for its ADC.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Competition may further increase as a result of advances in the commercial applicability
of technologies similar to our predictive computational discovery capabilities and greater availability of capital for investment in these
industries. Over the last several years, there has been an increase in the interest of pharmaceutical companies, the healthcare community
and the investment community in applying computational methodologies, mostly Artificial Intelligence (AI) and Machine Learning (ML) algorithms,
to the field of data-driven drug discovery/healthcare. This interest may be seen in the increase in the number of companies within the
pharmaceutical and biotech industries which focus on this area, including by way of establishing internal AI and/or ML capabilities or
receiving investments or entering into partnerships or acquisitions in furtherance thereof. Several companies that utilize AI/ML for target
discovery in the field of immuno-oncology/cancer include Exscientia, Recursion, Benevolent, and InSilico Medicine. Our competitors may
succeed in discovering targets and therefore also develop products that are competitive to ours.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, there is a trend towards mergers and acquisitions in the pharmaceutical,
diagnostic and biotechnology industry, which may result in the remaining companies having greater financial resources and discovery and
technological capabilities, thus intensifying competition in our industry. Several top mergers and acquisitions in 2023 include Pfizer&#8217;s
acquisition of Seattle Genetics for $43 billion, Amgen&#8217;s acquisition of Horizon Therapeutics for approximately $27.8 billion, and
Merck&#8217;s acquisition of Promethus for approximately $10.8 billion. In January 2024, several planned mergers and acquisitions were
announced, such as J&amp;J/Ambrx, Merck/Harpoon Therapeutics, and Novartis/ Calypso Biotech. In addition, it is possible that because
of adverse or volatile capital market conditions, companies may be willing to enter into mergers and acquisition transactions or other
sale of asset transactions on terms more favorable to acquirer and thereby further intensify competition. This trend may also result in
fewer potential collaborators or licensees for our therapeutic product candidates. Also, if a consolidating company is already doing business
with our competitors, we may lose existing or potential licensees or collaborators as a result of such consolidation. In addition, if
a consolidating company is already doing business with us, we may lose the interest of the consolidating parties in our discovery capabilities
or individual discoveries or product candidates as a result of a modified strategy, new priorities, competition and revised capabilities
or portfolio of such consolidated entity. This trend may adversely affect our ability to enter into agreements for the development and
commercialization of our therapeutic product candidates or to keep current collaboration in place or on-track and as a result may harm
our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Established biopharmaceutical companies may invest heavily to accelerate discovery
and development of novel drug targets or therapeutic products or to in-license novel drug targets or therapeutic products that could make
our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling
advantages in efficacy, compliance regimen, tolerability and safety in order to overcome price competition and to be commercially successful.
Accordingly, our competitors may succeed in obtaining patent protection, discovering, developing, receiving FDA approval for or commercializing
drugs before we do, which would have an adverse impact on our business and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">22</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Potential collaborators, including major pharmaceutical
companies, might be hesitant to pursue target validation and preclinical and clinical development programs based on novel targets lacking
robust experimental scientific support particularly those discovered through a computational discovery approach.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">There is a need for new drug targets generating new treatment options for patients
who are non-responsive or refractory to current immunotherapies. Our business model includes selectively entering into collaborations
for novel targets and related therapeutic product candidates at various stages of research and development under various revenue-sharing
arrangements. Entering into collaborations with product candidates and targets at an early validation stage or drug discovery stage is
significantly more challenging than identifying partnerships for later-stage products that would have a more complete data package to
support its clinical, business and commercial potential. In addition, although we have demonstrated success in validating our predictive
computational discovery capabilities with product candidates in human clinical trials, major pharmaceutical companies may be hesitant
to enter into early-stage collaborations based on newly discovered targets, more so if discovered by computer prediction and has no or
limited published scientific support, as opposed to drug targets backed with human clinical trial data, or product candidates with significant
published experimental validation and scientific support. Therefore, we cannot assure that our business model to enter into partnering
arrangements for our early-stage novel targets and product candidates will be successful.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic"><span style="font-weight: bold">The agreement cycle for potential
collaborations is complex and long to implement and, if we are not able to establish collaborations on commercially reasonable terms,
we may expend substantial funds and management resources with no assurance of success</span>.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In general, each potential license agreement or other form of collaboration we may
enter into will require negotiating with our potential collaborator, a large number of scientific, legal and business terms and conditions
that can vary significantly in each instance due to the specific drug target or therapeutic product candidate or candidates involved,
the potential market opportunity, the potential collaborator&#8217;s licensing, development and business operations and strategy, and
competition in the partnering and business development space. The accommodation of these requirements mandates a thorough consideration
of both the scientific and business aspects of each transaction. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Whether we reach a definitive agreement for new collaborations will depend, among
other things, upon our assessment of the collaborator&#8217;s resources, capabilities and expertise, the terms and conditions of the proposed
collaboration, the proposed collaborator&#8217;s evaluation of our business, drug targets and therapeutic product candidates, and the
competition in the business development space. We may not be successful in our efforts to establish a collaboration or other alternative
arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort
and third parties may not view them as having the requisite potential to demonstrate safety and efficacy or may find any other development
hurdles and challenges as a limiting factor. If we are unable to do so, we will need to expend substantial funds and substantial key personnel
time and effort into these business development activities with no assurance of successfully entering into agreements with potential collaborators
and this could harm our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We rely on our predictive computational discovery
capabilities to identify drug targets. Our competitive position could be materially harmed if our competitors develop capabilities similar
to ours and identify and develop rival drug targets and product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We rely on know-how and other proprietary computational processes and tools to maintain
our competitive computational discovery position. We consider know-how to be our primary intellectual property with respect to our predictive
computational discovery capabilities. Know-how can be difficult to protect and enforce. In particular, we anticipate that with respect
to our capabilities, this know-how may over time be disseminated within the industry through independent development and the movement
of skilled personnel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We cannot rule out that our competitors may have or obtain the knowledge necessary
to identify and develop therapeutic products based on novel drug targets that could compete with the drug targets we identify. Our competitors
may have significantly greater experience in artificial intelligence, computer sciences, algorithmic tool development and alike to identify
targets and greater experience in using translational science to develop product candidates and may also have significantly greater financial,
product development, scientific, technical and human resources than we do to discover novel drug targets and develop product candidates.
</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">23</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">We may not be able to prohibit our competitors from using methods to identify and
develop product candidates, including such methods that are the same as or similar to our own. Since our competitors develop products
that compete with COM701, COM902 or COM503 or any future product candidates we develop, our ability to develop and commercialize these
product candidates may diminish substantially, which could have a material adverse effect on our business prospects, financial condition,
and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The biotechnology and pharmaceutical industries
are highly competitive, and we may be unable to compete effectively.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The biotechnology and pharmaceutical industries in general, and the immuno-oncology
field in particular, are highly competitive. Numerous entities in the United States, Europe and elsewhere compete with our efforts to
discover, validate, develop and partner with licensees and/or collaborators to commercialize drug target and therapeutic products candidates.
Clinical trial failures of novel agents in the immuno-oncology field may adversely impact our ability to sign early-stage collaborations,
and as a result we may be required to advance our programs into clinical development and show clinical proof of concept before we may
attract potential collaborators. Our competitors include pharmaceutical and biotechnology companies, academic and research institutions
and governmental and other publicly funded agencies. We face, for COM701, COM902, and COM503, and expect to continue to face for our future
therapeutic product candidates, competition from these entities to the extent they develop products that have a function similar or identical
to or competing with the function of our therapeutic product candidates in the field of immuno-oncology that may attract our potential
collaborators or that may reach the market sooner. We also face, and expect to continue to face, competition from entities that seek to
develop technologies that enable the discovery of novel targets and therapeutic agents in the field of immuno-oncology. These competitors
include traditional pharmaceutical and biotechnology companies and additionally, an increasing number of new entities looking to apply
computer science, bioinformatics, AI or ML technologies to the field of target discovery. Many of our competitors have one or more of
the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zaa591295452a4eba800974a029008d44" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>much greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and
        commercialization process; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze04ee34ae6be43b691225a40e763557c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>more extensive experience in computational discovery, preclinical testing, conducting clinical trials, obtaining regulatory approvals,
        and in manufacturing and marketing therapeutics; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze1412f7e70e94cddbd720c057aebbbe9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>more extensive experience in oncology and immuno-oncology and in the fields of mAb therapeutics; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" id="zfd9eb5c1cc8b4c57b263606bfcd8f279" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>accessibility to enhanced technologies that may result in better products; </div> </td> </tr>
  </table> &#160; <br/> </div>

<table cellspacing="0" cellpadding="0" id="zfd9eb5c1cc8b4c56b263606bfcd8f279" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>access to and experience in the development of therapeutic modalities that are competitive to mAb therapeutics;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za1293d0cae3548ab9cca8d59b7d1ec92" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>more extensive experience in oncology and immuno-oncology and in the field of target discovery;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z306a929a451f41ab9bd2ee41461c4d53" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>more extensive experience in the research and development of biological or genetic markers to determine response of or responders
        to therapeutic agents or for patient selection;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z29787d8e300d4db4ba7cba679d5efd3a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>greater accessibility to data and proprietary data from patients;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z529acfe2f6a1430a97d45c44f9c78075" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>access to internally developed, proprietary technologies for the discovery, research, development, or manufacturing of therapeutic
        agents; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6835ef9b32a14175aaea84777920ab69" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>greater resources and means to compete with us on target discovery and as well as in acquiring or generating technologies complementary
        to, or necessary for, our programs as well as in recruiting and retaining qualified scientific and management personnel and establishing
        clinical trial sites;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdd5efd0a63d749b6bcacaa908219edc2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>products that have been approved or are in late stages of development and in many cases, PD-1 or PDL-1 inhibitors that are serving
        or will be serving as the backbone of cancer immunotherapy; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z801767b2aeb047b19077a536bc8d58e2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>reduced reliance on collaborations or partnerships with third parties in order to further develop and commercialize competitive therapeutic
        products; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6070f889422d4f0ba19a63ae10aa8b68" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>collaborative arrangements in our target markets with leading companies and research institutions. </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">24</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">Since we are a small company with limited human and financial resources, we are not
able to work with a large number of collaborators in parallel and/or advance a large number of drug target or therapeutic product candidates
in parallel. Our competitors may develop or commercialize products with significant advantages over any therapeutic products we, our collaborators
or third-party licensees may develop. They may also obtain patents and other intellectual property rights before us, or broader than ours,
and thereby prevent us from pursuing the development and commercialization of our discoveries. They may also develop products faster than
us and therefore limit our market share. Our competitors may therefore be more successful in developing and/or commercializing products
than we, our collaborators, or third-party licensees are, which could adversely affect our competitive position and business. If we are
unable to compete successfully against existing or potential competitors, our financial results and business may be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Healthcare policy is volatile and changes in
healthcare policy could increase our expenses, decrease our revenues and impact sales of, and reimbursement for, our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our ability to commercialize our future therapeutic product candidates successfully,
alone or with collaborators, will depend in part on the extent to which coverage and reimbursement for these product candidates will be
available from government health programs, such as Medicare and Medicaid in the United States, private health insurers and other third-party
payors. At present, significant changes in healthcare policy, in particular the continuing efforts of the U.S. and other governments,
insurance companies, managed care organizations and other payors to contain or reduce health care costs are being discussed, considered
and proposed.&#160;Drug prices in particular are under significant scrutiny and continue to be subject to intense political and societal
pressures, which we anticipate will continue and escalate on a global basis.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For example, in the United States, there have been several initiatives implemented
to achieve these aims. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation
Act, and collectively, the ACA, represents the biggest regulatory overhaul to the health care system in decades and substantially changes
the way health care is financed by both governmental and private insurers. Since its enactment, there have been&#160; congressional, judicial,
and executive&#160; challenges to the ACA, which have resulted in delays in the implementation of, and action taken to repeal or replace,
certain aspects of the ACA For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued
the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. In addition, there
have been a number of health reform initiatives by the Biden administration that have impacted the ACA. On August 16, 2022, President
Biden signed the Inflation Reduction Act of 2022, or the IRA, into law, which among other things, extends enhanced subsidies for individuals
purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221;
under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly
established manufacturer discount program. It is possible that the ACA will be subject to judicial or congressional challenges or additional
health reform measures of the Biden administration will impact the ACA and our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, the IRA, among other things, (i) directs the Secretary of HHS to negotiate
the price of certain high-expenditure, single-source drugs and biologics covered under Medicare Part B and Medicare Part D, and subjects
drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated
&#8220;maximum fair price&#8221; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases
that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the
initial years. These provisions take effect progressively starting in fiscal year 2023. On August 29, 2023, HHS announced the list of
the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject
to legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical
industry. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement constraints, discounts, and restrictions on certain product access.
In some cases, such legislation and regulations have been designed to encourage importation from other countries and bulk purchasing.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We expect that the ACA, the IRA, and any other healthcare reform measures that may
be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria,
new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement
from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost
containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize
our product candidates, if approved.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">25</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The commercial success of our products depends
on the availability and sufficiency of third-party payor coverage and reimbursement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Market acceptance of drug products is dependent on the extent to which coverage and
reimbursement is available from third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any
products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost
therapeutic alternatives are already available. Even if we obtain coverage for a given product, the associated reimbursement rate may
not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution expenses,
or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate
to cover all or a significant portion of the cost of our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Coverage and reimbursement policies for products can differ significantly from payor
to payor as there is no uniform policy of coverage and reimbursement for products among third-party payors in the United States. There
may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time
consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately,
with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities
and third-party payors will decide with respect to coverage and reimbursement for our drug products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Additionally, we or our collaborators may develop companion diagnostic tests for use
with our product candidates. We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate
and apart from the coverage and reimbursement we seek for our product candidates, once approved. While we have not yet developed any companion
diagnostic test for our product candidates, if we or our collaborators do, there is significant uncertainty regarding our ability to obtain
coverage and adequate reimbursement for the same reasons applicable to our product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-weight: bold">Risks Related to our Operations and Other Risks
Related to our Business</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Given our level of managerial, operational,
financial and other resources, our current activities and future growth may be limited.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We manage our operations, including clinical trials and preclinical development activities
of our therapeutic candidates with a limited workforce, which is spread globally, and by using third parties to provide us services that
we do not possess in-house. Our personnel, systems and facilities currently in place may not be adequate to support our current activities
or future growth.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we are unable to maintain or expand our managerial, operational, financial and
other resources to the extent required to manage our development and commercialization activities, our business may be materially adversely
affected.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may be unable to hire or retain key personnel
or sufficiently qualified management, clinical and scientific personnel. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our business is highly dependent upon the continued services of our senior management
and key scientific and clinical personnel. While members of our senior management and other key personnel have entered into employment
or consulting agreements and non-competition and non-disclosure agreements, they can terminate their employment agreements with us at
any time without cause. We cannot be sure that these key personnel and others will not leave us or compete with us, which could harm our
business activities and operations. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">It can also be difficult for us to find employees with appropriate experience for
our business, which difficulty is further heightened when seeking experienced personnel in Israel, and specifically considering the ongoing
war situation in Israel. We require a multidisciplinary approach and some of our researchers require an understanding in both exact and
biological sciences. In addition, we require experience in drug and clinical development and immuno-oncology, for which there is significant
competition for highly qualified personnel in these fields. As a result and taking into consideration the ongoing war in Israel and the
effect thereof outside of Israel, we may face higher than average employee turnover or challenges in hiring due to such competition. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The competition for qualified personnel in the pharmaceutical and biotech industry
is intense. The loss of service of any of our key personnel could harm our business. Due to our limited resources, we may not be able
to effectively retain our existing key personnel or attract and recruit additional qualified key personnel.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">26</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our information technology systems, or those
of the third parties upon whom we rely, including our cloud providers, CROs or other contractors or consultants, may fail or suffer security
breaches, which could result in a material disruption of our pipeline and our business, as well as to regulatory investigations or actions;
litigation; fines and penalties; reputational harm; loss of revenue and other adverse consequences.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We, and the third parties upon whom we rely, process, collect,
receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively,
process) proprietary, confidential, and sensitive data, including personal data (such as health-related data and clinical trial data),
intellectual property, trade secrets and other sensitive data (collectively, sensitive information). Our business is increasingly dependent
on critical, complex and interdependent information technology systems to support business processes as well as internal and external
communications. Despite the implementation of security measures, our information technology systems, cloud-based computers and those of
the third parties upon whom we rely, including without limitation our CROs and other contractors and consultants, are vulnerable to damage.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Cyber-attacks, malicious internet-based activity, online and offline fraud, and other
similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems,
and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect,
and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized
criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some
actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical
reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, including the
current situation in Israel, we or the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including
retaliatory cyber-attacks, that could materially disrupt our systems and operations. For example, we have operations in Israel, where
businesses have experienced an increase in cyberattacks in relation to the Israel/Hamas conflict.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our information technology systems, and those of the third parties upon which we rely,
are vulnerable to a variety of evolving threats including, but are not limited to, social-engineering attacks (including through deep
fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses), malware,
denial-of-service attacks, credential stuffing attacks, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain
attacks, server malfunctions, software or hardware failures, attacks enhanced or facilitated by artificial intelligence, or other disruptive
events including but not limited to natural disasters such as fire, storm, flood, power loss, earthquakes, telecommunications failures,
physical or software break-ins or similar events.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In particular, severe ransomware attacks are becoming increasingly prevalent and can
lead to significant interruptions in our operations, loss of sensitive data, reputational harm, and diversion of funds. Extortion payments
may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example,
applicable laws or regulations prohibiting such payments. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Remote work has become more common and has increased risks to our information technology
systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including
working at home, while in transit and in public locations. Future business transactions (such as acquisitions or integrations) could expose
us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired
or integrated entities&#8217; systems and technologies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We rely on certain third parties, including service providers, vendors, and partners,
and their technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without
limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email and other communication
functions, and other functions, and to provide other services necessary to operate our business, including our CROs and to keep financial
and corporate records. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties
may not have adequate information security measures in place. If the third parties upon which we rely experience a security incident or
other interruption, we could experience adverse consequences. While we may be entitled to damages if the third parties upon which we rely
fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be
unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that
third parties&#8217; infrastructure in our supply chain or the third parties&#8217; upon whom we rely supply chains have not been or will
not be compromised.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">27</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">If we or the third parties upon whom we rely were to suffer a security breach or other
interruption, we could experience unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption,
disclosure of, or access to our data or data held by us or our vendors and partners (including personally identifiable information or
personal data and other confidential information). Although we have implemented security measures designed to protect against security
breaches and other incidents and maintain offsite back-ups of our data, such measures may fail. We may not detect and remediate all vulnerabilities,
including on a timely basis.&#160; Further, we may experience delays in developing and deploying remedial measures and patches designed
to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We may expend significant resources or modify our activities to try to protect against
security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures
or industry-standard or reasonable security measures to protect our information technology systems and sensitive information. Applicable
data privacy and security obligations may require us to notify relevant stakeholders, including affected individuals, customers, regulators,
and investors, of security incidents.&#160; Such disclosures are costly, and the disclosure or the failure to comply with such requirements
could lead to adverse consequences.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we or the third parties upon whom we rely experience (or are perceived to have
experienced) a security breach or other incident or disruption, we may experience adverse consequences, including but not limited to,
government enforcement actions (e.g., investigations, fines, penalties, audits, and inspections), federal, state and/or foreign data breach
notification obligations, additional reporting requirements and/or oversight, restrictions on processing data (including clinical trial
data and other personal data), litigation, indemnification obligations, loss of data (including clinical trial data and other sensitive
information) or damage to the integrity of that data, negative publicity, reputational harm, monetary fund diversions, interruptions in
our operations, financial loss, and other similar harms. Such attendant consequences may interrupt our clinical trials, reduce demand
for our product candidates, and delay or negatively impact the development and commercialization of our product candidates and ability
to grow and operate our business. For example, the loss of clinical trial data from the clinical trials of our therapeutic product candidate
could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore,
our contracts may not contain limitations of liability, and even where they do, there can be no assurances that limitations of liability
in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.
We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out
of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or
that such coverage will pay future claims. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We are subject to stringent and changing obligations
related to data privacy and security. Failure or perceived failure to comply with current or future obligations could lead to government
enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively
affect our operating results and business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We and the third parties upon whom we rely process sensitive information. We and the
third parties upon whom we rely may be subject to numerous data privacy and security obligations, such as various federal, state, local
and foreign data laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and
other obligations that govern the processing of personal data by us and on our behalf.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the United States, numerous federal, state, and local laws and regulations, including
federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state
consumer protection laws, that govern the collection, use, disclosure and protection of health-related and other personal data may apply
to our operations or the operations of our collaborators. For example, the federal Health Insurance Portability and Accountability Act
of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, imposes specific requirements
relating to the privacy, security, and transmission of individually identifiable health information. As another example, the Controlling
the Assault of Non-Solicited Pornography and Marketing Act of 2003 (&#8220;CAN-SPAM&#8221;) imposes specific requirements on our correspondence
with subscribers for email communication. Additionally, laws in all 50 states require businesses to provide notice to parties whose personally
identifiable information has been disclosed as a result of a data breach. The laws are not consistent, and compliance in the event of
a widespread data breach is costly.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">28</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">Furthermore, California enacted the California Consumer Privacy Act, or the CCPA,
which provides for civil penalties for violations, as well as a private right of action for data breaches. The CCPA, as amended requires
businesses to provide specific disclosures in privacy notices and honor requests of California residents (including consumers, business
representatives, and employees) to exercise certain privacy rights. The CCPA provides for fines of up to $7,500 per intentional violation
and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some
data processed in the context of clinical trials, the CCPA increases compliance costs and potential liability with respect to other personal
data we maintain about California residents. Other states, such as Virginia and Colorado, have also passed comprehensive privacy laws,
and similar laws are being considered in several other states, as well as at the federal and local levels. While these states, like the
CCPA, also exempt some data processed in the context of clinical trials, these developments further complicate compliance efforts, and
increase legal risk and compliance costs for us and the third parties upon whom we rely.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Additionally, an increasing number of foreign data protection laws may also apply
to health-related and other personal data obtained from individuals outside of the United States. For example, the European Union&#8217;s
General Data Protection Regulation, or EU GDPR introduced new data protection requirements in the EU, as well as potential fines for noncompliant
companies of up to the greater of &#8364;20 million or 4% of annual global revenue, temporary or definitive bans on data processing, and
other corrective actions. Additionally, private litigation related to processing of personal data can be brought under the EU GDPR by
classes of data subjects or consumer protection organizations authorized at law to represent their interests. In addition, we are also
subject to the Israeli Privacy Protection Law&#160;5741-1981&#160;and the regulations promulgated thereunder, or the PPL, including the
Israeli Privacy Protection Regulations (Data Security) 2017, imposing obligations with respect to the manner personal data is processed,
maintained, transferred, disclosed, accessed and secured, as well as the guidelines of the Israeli Privacy Protection Authority. In this
respect, the PPL may require us to adjust certain data protection and data security practices, information security measures, certain
organizational procedures, applicable positions and other technical and organizational security measures. Failure to comply with the PPL
and with guidelines issued by the Israeli Privacy Protection Authority, may expose us to administrative fines, civil claims (including
class&#160;actions) and in certain cases criminal liability.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, Europe and other jurisdictions have enacted data localization laws and
cross-border personal data transfer laws, which could make it more difficult to transfer information across jurisdictions (such as transferring
or receiving personal data that originates in the European Economic Area). In particular, the European Economic Area (EEA) and the United
Kingdom (UK) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it
generally believes are inadequate. Although there are currently various mechanisms that may be used to transfer personal data from the
EEA and UK to the United States in compliance with law, such as the EEA standard contractual clauses, the UK&#8217;s International Data
Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant
U.S.-based organizations who self-certify compliance and participate in the Framework), existing mechanisms that may facilitate cross-border
personal data transfers may change, be challenged or be invalidated, and there is no assurance that we can satisfy or rely on these measures
to lawfully transfer personal data to the United States. If we cannot implement a valid compliance mechanism for cross-border data transfers,
we could experience material adverse effects.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We publish privacy policies and other statements regarding data privacy and security.&#160;
If these policies or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices,
we may be subject to investigation, enforcement actions by regulators or other adverse consequences.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our obligations related to privacy and security are quickly changing in an increasingly
stringent fashion, creating some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject
to differing applications and interpretations, which may be inconsistent or in conflict among jurisdictions. Preparing for and complying
with these obligations requires us to devote significant resources (including, without limitation, financial and time-related resources).
These obligations may necessitate changes to our practices and to those of any third parties that process personal data on our behalf.
In addition, these obligations may require us to change our business model. Compliance with privacy and security obligations could require
us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact
our ability to operate in certain jurisdictions. Failure or perceived failure by us or the third parties upon whom we rely to comply with
U.S. and foreign data privacy or security obligations could result in government enforcement actions (which could include civil or criminal
penalties), private litigation or mass arbitration demands, bans on processing personal data, additional reporting requirements or oversight,
orders to destroy or not use personal data, and/or adverse publicity and could negatively affect our operating results and business. Claims
that we have violated individuals&#8217; privacy rights or failed to comply with privacy or security obligations, even if we are not found
liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on
our business, financial condition, results of operations and prospects.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">29</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If a successful liability claim or other claim
for damages or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, we could be forced
to pay substantial damage awards. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The use of any of our therapeutic product candidates in clinical trials might expose
us to liability. We have obtained clinical trial insurance coverage in amounts that we believe are reasonable and customary in our industry
based on the size and design of our clinical trials. However, there can be no assurance that such insurance coverage will fully protect
us against some or all of the claims to which we might become subject. We might not be able to maintain adequate insurance coverage at
a reasonable cost or in sufficient amounts or scope to protect us against potential losses. In the event a claim is brought against us,
we might be required to pay legal and other expenses to defend the claim, as well as uncovered damages awards resulting from a claim brought
successfully against us. Furthermore, whether or not we are ultimately successful in defending any such claims, we might be required to
direct financial and managerial resources to such defense and adverse publicity could result, all of which could harm our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If we fail to comply with laws regulating the
protection of the environment and health and human safety, our business could be adversely affected.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our research and development activities involve the use of hazardous materials and
chemicals, and we maintain quantities of microbial agents, various flammable and toxic chemicals in our facilities. Although we believe
our safety and other procedures for storing, handling and disposing these materials in our facilities comply with applicable governmental
and local regulations and guidelines, the risk to our employees or others of accidental contamination or injury from these materials cannot
be eliminated. If an accident occurs, we could be held liable for resulting damages, which may exceed our financial resources and may
seriously harm our business. We are also subject to numerous environmental, health and workplace safety laws and regulations, including
those governing laboratory procedures, exposure to blood-borne pathogens and the handling of biohazardous materials. We may be subject
to liability and may be required to comply with new or existing laws and regulations regulating pharmaceuticals or be subject to substantial
fines or penalties if we violate any of these laws or regulations. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to Intellectual Property. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If the scope of any patent protection we obtain
is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar
or identical product candidates would be adversely affected.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have applied for patents covering proteins, therapeutic and diagnostic product
candidates and their method of use, and the success of our business depends, to a large extent, on our ability to obtain and maintain
such patents and any additional patents covering our future product candidates. We design our patent strategy to fit the business competitive
landscape and continual legislative changes. In addition, we periodically analyze and examine our patent portfolio to align it with our
pipeline strategy and business needs. We have issued patents and pending patent applications that are related to our product candidates
in the U.S., Europe, and other territories. We plan to continue to apply for patent protection for our therapeutic and diagnostic inventions,
but we cannot be sure that any of our patent applications will be accepted, or that they will be accepted to the extent that we seek or
that they will not be challenged. Additionally, we file for patent protection in selected countries and not in all countries of the world.
Therefore, we are exposed to competition in those countries in which we have no patent protection. Also, due to our early-stage pipeline
and various business considerations, we may be required to seek patent protection at a very early-stage. This may cause us to file with
insufficient supportive data, possibly making it difficult to obtain patents in jurisdictions that do not accept post filing evidence
to support the claims, and thus enabling others to compete with us. This may also cause issuance of a patent at an earlier stage creating
a shorter commercialization period under patent protection, possibly enabling others to compete with us. Delays in filing patents may
preclude us from obtaining protection on some or all of our product candidates due to others filing ahead of us. Patent applications filed
before us, but yet unpublished, may cause us to spend significant resources in areas that due to these previously filed patents or applications
we will not be able to obtain patent protection, practice the claimed invention without infringing upon such earlier patents (if granted),
or will only be able to obtain a narrower scope of protection than contemplated.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">30</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">Because the patent position of biopharmaceutical companies involves complex legal
and factual questions, we cannot predict the validity, scope or enforceability of patents with certainty. The issuance of a patent is
not conclusive as to its inventorship, scope, validity or enforceability and our patents may be subject to a third party pre issuance
submission of prior art to the patent authorities or become involved in opposition, derivation, revocation, reexamination, post-grant
and <span style="font-style: italic">inter partes</span> review, or other similar proceedings challenging our patent rights in the United
States and other jurisdictions which may result in such patents being narrowed, invalidated, or held unenforceable, and thus could limit
our ability to stop competitors from marketing related products or limit the length of the term of patent protection that we may have
for our product candidates. Such proceedings also may result in substantial cost and require our pending patent applications, and those
we may file in the future may not result in patents being issued. Furthermore, even if our patents do issue, and even if they are unchallenged,
our patents may not adequately protect all our intellectual property or prevent others from designing their products in a way to avoid
being covered by our claims. If the breadth or strength of protection provided by the patents we hold is threatened, this could dissuade
companies from collaborating with us to develop and could threaten our ability to commercialize product candidates and expose us to unexpected
competition that could have a material adverse impact on our business. For example, in October 2020, two parties, one being GSK (following
an assignment), filed oppositions in the European Patent Office, or EPO, requesting revocation of our granted European patent relating
to anti-PVRIG antibodies and following different proceedings, on July 11, 2023 in an oral proceedings hearing, the opposition division
of the&#160;European Patent Office ruled in favor of maintaining the broad claims in the patent as granted to us. The opposition division&#8217;s
written decision was received on January 18, 2024. The opponents have until March 18, 2024 to file an appeal. If an appeal is not filed
by that time, the decision will become final and unappealable. In January 2023, another opposition was filed by GSK, requesting revocation
of our granted European patent relating to method of screening for inhibitors of the binding association of PVRIG polypeptide with PVRL2
and we already responded to this opposition. In May 2023, two other European oppositions were filed by GSK and another party, with respect
to anti-PVRIG antibodies competing with COM701 and we already provided our response.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, changes in either the patent laws or interpretation of the patent laws
in the United States or other jurisdictions could weaken our ability to obtain new patents or to enforce our existing patents and patents
that we might obtain in the future and increase the uncertainties and costs surrounding the prosecution of patent applications, and the
enforcement or defense of our issued patents. Such changes could diminish the value of our patents and applications, thereby impairing
our ability to protect our product candidates, and could have a material adverse effect on our business, financial condition, results
of operations and prospects. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the
scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In October
2017, in <span style="font-style: italic">Amgen v. Sanofi</span>, the Federal Circuit overturned the &#8220;newly characterized antigen&#8221;
test, which permitted patentees to claim a genus of antibodies by describing the structure of a corresponding antigen, on the grounds
that it failed to satisfy the requirements found in Section 112 of the Patent Act, 35 U.S.C. &#167; 112. In doing so, the Federal Circuit
called into question the validity of numerous existing patents. On May 18, 2023, the Supreme Court affirmed the Federal Circuit&#8217;s
judgement in <span style="font-style: italic">Amgen v. Sanofi</span>. Thus, in the current IP environment in the U.S., we may not be able
to obtain or defend broad patent protection on our antibody inventions. In addition, recent U.S. court decisions raise questions regarding
the award of patent term adjustment (PTA) for patens in families where related patents have issued without PTA. Thus, it cannot be said
without certainty how PTA will/will not be viewed in the future and whether patent expiration dates may be impacted.&#160; Similarly,
changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes
in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce
patents. For example, the complexity and uncertainty of European patent laws have increased in recent years. In Europe, a new unitary
patent system took effect June 1, 2023, which will significantly impact European patents, including those granted before introduction
of the system. Under the unitary patent system, European applications have the option, upon receipt of a patent, of becoming a Unitary
Patent subject to the jurisdictions of the Unitary Patent Court (UPC). As the UPC is a new court system, there is no precedent for the
court, increasing the uncertainty of any litigation. Patents granted before implementation of the UPC have the option of opting out of
the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under jurisdiction of the UPC
will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries
who are signatories to the UPC. All our patents and patent applications for which a request for opt out was available in the sunrise period
were opted out. We cannot predict with certainty the long-term effects of any potential changes.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">31</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">Moreover, because of the extensive time required for development, testing and regulatory
review of a potential product, it is possible that, before any particular product candidate can be commercialized, any related patent
may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the patent protection.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The process of obtaining patents for inventions that cover our products is uncertain
for a number of reasons, including but not limited to:</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5ba5ea63a46f41c7b059fc98d5e704fa" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the patenting of inventions involves complex legal issues relating to intellectual property laws, prosecution and enforcement of
        patent claims across a number or patent jurisdictions, many of which have not yet been settled;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4e30ffbb836f4c31ab7ba37184e40a22" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>legislative and judicial changes, or changes in the examination guidelines of governmental patent offices may negatively affect our
        ability to obtain patent claims to certain biological molecules- and/or use of certain therapeutic targets;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4c30b579ff834f17bf0c021d7c507d10" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>if we are not the first to file a patent application on one of our inventions, we may not be able to obtain a patent on our invention,
        and may not be able to protect one or more of our therapeutic product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc25aa1cafc534e07b86e4ee6e993eb29" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>competition from other biotechnology and pharmaceutical companies who have already sought patent protection relating to proteins
        and protein based products, as well as therapeutic antibodies or other modulators specifically binding these proteins, and their utility
        based discoveries that we may intend to develop and commercialize; such prior patents may negatively affect our ability to obtain patent
        claims on antibodies or certain proteins or other biologic modulators, or may hinder our ability to obtain sufficiently broad patent claims
        for our inventions, and/or may limit our freedom to operate;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2ca3e93109144098a1a5fb7d4dbf650c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>publication of data on gene products or proteins by non-commercial and commercial entities may hinder our ability to obtain sufficiently
        broad patent claims for our inventions;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z029ccb5e41d147f9ad5972fa12434517" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>even if we succeed in obtaining patent protection, such protection may not be sufficient to prevent third parties from circumventing
        our patent claims;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9e320cd4ed8047da98651f3877a52f81" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>even if we succeed in obtaining patent protection, we may face freedom to operate issues;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1dc6dcc85e564e4799c774a430ce1e77" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>even if we succeed in obtaining patent claims protecting our inventions and product candidates, our patents could be subject to challenge
        and litigation by our competitors, and may be partially or wholly invalidated as a result of such legal/judicial challenges and in connection
        with such challenges;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z25b4cb69c2c44339a294b7555d48efee" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>significant costs that may need to be incurred in registering and filing patents;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z52009df0b97c4f9e8f4da7abd8a019c9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>insufficient data to support our claims and/or may support others in strengthening their patents;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z91ce2817c8fd4c41aec4214ba2da62ff" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>seeking patent protection at an early stage may prevent us from providing comprehensive data supporting the patent claims and may
        prevent allowance of certain patent claims or limit the scope of patent claim coverage;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf1f905b9ee0c412a91e43ee115126fcb" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we may not be able to supply sufficient data to support our claims, within the legally prescribed time following our initial filing
        in order to support our patent claims and this may harm our ability to get appropriate patent protection or protection at all;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcb070f7e131e4ba1a9026186087b6862" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our claims may be too broad and not have sufficient enablement, in which case such claims might be rejected by patent offices or
        invalidated in court; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z26ee7722e3b04a51b37a2896659258bf" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we might fail to demonstrate a unique technical feature for our antibodies as compared to existing prior art, in which case our claims
        might be rejected by the respective patent office, requiring superiority over prior art.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we do not succeed in obtaining patent protection for our inventions (should it
be discoveries, drug targets candidates and product candidates) to the fullest extent for which we seek protection, or if we fail to select
the best inventions to seek such protection, our business and financial results could be materially harmed.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">32</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We may not be able to protect
our intellectual property rights throughout the world.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Patents are of national or regional effect, and filing, prosecuting and defending
patents on all of our investigational products throughout the world would be extremely expensive. Thus, we may not be able to prevent
third parties from practicing or from selling or importing products made using our inventions in all countries. Further, the legal systems
of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property
protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation
of our proprietary rights generally. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled
to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if
we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This
could limit our potential revenues. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate
to obtain a significant commercial advantage from the intellectual property that we develop or license.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">The existence of third-party
intellectual property rights may prevent us from developing our discoveries and/or discoveries we licensed to partners, or require us
to expend financial and other resources to be able to continue to do so.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In selecting a drug target or a therapeutic product candidate for
development, we take into account, among other considerations, the existence of third-party intellectual property rights that may hinder
our right to develop and commercialize that product candidate. To our knowledge, third parties, including our competitors, have been filing
patent applications covering an increasing portion of the human proteome or antibodies directed thereto. As a result of the existence
of third-party intellectual property rights, we may be further required to:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7352133e02c04fd0a33b2ea90444a2dc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>forgo the research, development and commercialization of certain drug target candidates and product candidates that we discover,
        notwithstanding their promising scientific and commercial merits; or </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9e50e0a7e5e84082b86b4e521d8454f9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>invest substantial management and financial resources to either challenge or in-license such third-party intellectual property, and
        we cannot be sure that we will succeed in doing so on commercially reasonable terms, if at all. </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We do not always have available to us, in a timely manner, information
of the existence of third-party intellectual property rights related to our own discoveries. The content of U.S. and other patent applications
remains unavailable to the public for a period of approximately 18 months from the filing date and therefore we cannot be certain that
we were the first to file any patent application related to our product candidate. In some instances, the content of U.S. patent applications
remains unavailable to the public until the patents are issued. Moreover, when patents ultimately are issued, the claims may be substantially
different from those that were originally published and may vary from country to country. Furthermore, there may be issued patents or
pending patent applications that we are aware of, but that we believe are irrelevant to our therapeutic product candidates, but which
may ultimately be found to be infringed by the manufacture, sale, or use of such product candidates. As a result, we can never be certain
that programs that we commence will be free of third-party intellectual property rights. If we become aware of the existence of third-party
intellectual property rights only after we have commenced a particular program, we may have to forgo such project after having invested
substantial resources in it or, to the extent such third-party right has not expired, obtain a license which may involve substantial financial
resources.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">33</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We may need to obtain additional
licenses of third-party technology or other rights that may not be available to us or are available only on commercially unreasonable
terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We may be required to license technology or other rights from third
parties to further develop or commercialize our investigational products. Should we be required to obtain licenses to any third-party
technology, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party
license required to develop or commercialize any of our products could cause us to abandon any related efforts, which could seriously
harm our business and operations.<span style="font-weight: bold; font-style: italic">&#160;</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We, or potential collaborators
and licensees, may infringe third-party rights and may become involved in litigation, which may materially harm our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">If a third-party accuses us, our collaborators or a potential collaborator
and licensee of infringing its intellectual property rights or if a third-party commences litigation against us, our collaborators or
a potential collaborator and licensee for the infringement of patent or other intellectual property rights, we may incur significant costs
in obtaining a license or defending such action, whether or not we ultimately prevail. We are aware of U.S. and foreign issued patents
and pending patent applications controlled by third parties that may relate to the areas in which we are developing therapeutic products.
Because all issued patents are entitled to a presumption of validity in many countries, including the United States and many European
countries, issued patents held by others with claims related to products, may limit our freedom to operate unless and until these patents
expire or are declared invalid or unenforceable in a court of applicable jurisdiction, if we do not obtain a license or other right to
practice the claimed inventions. Typically, patent litigation in the pharmaceutical and biotechnology industry is expensive and prolonged.
Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property
litigation to a greater degree and for longer periods of time than we could. Costs that we may incur in defending third-party infringement
actions would also result in the diversion of management&#8217;s and technical personnel&#8217;s time. In addition, parties making claims
against us may be able to obtain injunctive or other equitable relief that could prevent us or our collaborators and licensees from further
developing our discoveries or commercializing our products. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In the event of a successful claim of infringement against us or
a potential collaborator and licensee, we may be required to pay damages, including treble damages and attorney&#8217;s fees if we are
found to be willfully infringing a third-party&#8217;s patent, or obtain one or more licenses from the prevailing third-party (if not
obtained prior to such litigation), which may not be available to us on commercially reasonable terms, if at all. Even if we were able
to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property. If we
are not able to obtain such a license or not able to obtain such a license at a reasonable cost, we could be prevented from commercializing
a product until the relevant patents expired, or we could be forced to redesign our products, or to cease some aspect of our business
operations, and we could encounter delays in product introductions and loss of substantial resources while we attempt to develop alternative
products. Defense of any lawsuit or failure to obtain any such license could prevent us or our partners from commercializing available
products and could cause us to incur substantial expenditures and would divert management&#8217;s attention from our core business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We may become involved in
lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Competitors may infringe, misappropriate or otherwise violate our
patents, trademarks, copyrights or other intellectual property, or those of our licensors. To counter infringement, misappropriation,
unauthorized use or other violations, we may be required to file legal claims, which can be expensive and time consuming and divert the
time and attention of our management and scientific personnel. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Additionally, after a patent is granted, it can be annulled, or
its scope of protection restricted through an appeal, revocation or invalidation procedure. Such procedures are lengthy, expensive and
time consuming, and may have an adverse effect on us.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We may not be able to prevent, alone or with our licensees or any
future licensees, infringement, misappropriation or other violations of our intellectual property rights, particularly in countries where
the laws may not protect those rights as fully as in the United States. Any claims we assert against perceived infringers could provoke
these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement or opposition
proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that
we do not have the right to stop the other party from using the invention at issue. In this respect, as stated above, we are currently
facing two outstanding European oppositions and one opposition in which we prevailed but remains subject to appeal. There is also a risk
that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do
not have the right to stop the other party from using the invention at issue on the grounds that our patents do not cover the invention.
An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties
or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products.
Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly,
if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that
the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately
be forced to cease use of such trademarks.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">34</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In any infringement, misappropriation or other intellectual property
litigation, any award of monetary damages we receive may not be commercially valuable. Even if we establish infringement, the court may
decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be
an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation,
there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public
announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive
these results to be negative, it could have an adverse effect on our share price. Moreover, there can be no assurance that we will have
sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded.
Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management
and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Increased progress in our scientific and technological
environment may reduce our chances of obtaining a patent.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In order to obtain a patent to protect one of our therapeutic product candidates,
we must show that the underlying invention (that is, the product candidate itself or its use) is inventive. As an increasing amount of
scientific knowledge is becoming available regarding genes, proteins, biological mechanisms, and the relevance of the genes and proteins
to various clinical indications, the bar is increasingly raised to show sufficient inventiveness, as inventiveness is judged against all
publicly available information available prior to filing of the patent application (the exact date may vary by country or due to other
circumstances). As an increasing amount of scientific knowledge is becoming available for various proteins and their potential use as
drug targets, with time we may be limited or may not be able to obtain patents for our product candidates due to the increased information
published in this area. Our own published patent applications and other publications also serve as prior art against our new inventions
and patent applications and may prevent us from obtaining new patents.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">We may become subject to claims for remuneration or royalties for
assigned service invention rights by our employees, which could result in litigation and adversely affect our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We enter into assignment of invention agreements with our employees pursuant to which
such individuals agree to assign to us all rights to any inventions created in the scope of their employment or engagement with us. A
significant portion of our intellectual property has been developed by our employees in the course of their employment for us. Under the
Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee due to and during his or her employment with a company
are regarded as &#8220;service inventions&#8221;, which belong to the employer, unless the employee and employer have entered into a specific
agreement stating otherwise, except if the employer waived the service invention within six months of receipt of a notice by the employee
regarding the creation of the service invention (in accordance with provisions of the Patent Law). The Patent Law also provides that if
there is no agreement with respect to whether the employee is entitled to remuneration for his or her service invention, to what extent
and under what conditions, such entitlement and terms shall be determined by the Israeli Compensation and Royalties Committee, or the
Committee, a body constituted under the Patent Law. Decisions by the Committee and Israeli courts have created some uncertainty in this
area. Although our employees have agreed to assign to us service invention rights and have waived any rights for additional compensation
for such service inventions, we may still face claims demanding remuneration in consideration for assigned service inventions. As a consequence
of such claims, we could be required to pay additional remuneration or royalties to our current and/or former employees, or be forced
to litigate such claims, which could negatively affect our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">35</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The USPTO and various foreign patent agencies require compliance with a number of
procedural, documentary, fee payment and other provisions to maintain patent applications and issued patents. Noncompliance with these
requirements can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights
in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the
case.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may be subject to claims that we or our
employees or consultants have infringed, misappropriated or otherwise violated the intellectual property of a third-party, or claiming
ownership of what we regard as our own intellectual property.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We may be subject to claims that we or our employees or consultants have inadvertently
or otherwise used or disclosed confidential information of former employers, competitors or other third-parties. We may be further subject
to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing
our product candidates, resulting, among others, in disputes regarding ownership interest in our patents or other intellectual property.
Although we have implemented reasonable measures to ensure that our employees and consultants do not use the intellectual property of
others in their work for us, we may become subject to claims that we caused an employee or consultant to breach, among others, the terms
of his or her non-competition, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged proprietary
information of a former employer, competitor or other third-party.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">While we may litigate to defend ourselves against these claims, even if we are successful,
litigation could result in substantial costs and could distract the attention of our management. If our defenses to these claims fail,
in addition to requiring us to pay monetary damages, a court could deprive our rights in such technologies or features that are essential
to our investigational products, if such technologies or features are found to incorporate or be derived from the proprietary information
of third-parties and prohibit us from using them. Moreover, any such litigation may adversely affect our ability to form strategic alliances,
engage with scientific advisors or hire employees or consultants.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, while we typically require our employees, consultants and contractors
who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may
be unsuccessful in executing such an agreement with each party who in fact develops intellectual property. To the extent that we fail
to obtain such assignments, or such assignments do not contain a self-executing assignment of intellectual property rights, or such assignments
are breached, we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership
of what we regard as our intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary
damages, we may lose valuable intellectual property rights. Such intellectual property rights could be awarded to a third-party, and we
could be required to obtain a license from such third-party to commercialize our technology or products. Such a license may not be available
on commercially reasonable terms or at all. Even if we are successful in prosecuting or defending against such claims, litigation could
result in substantial costs and be a distraction to our management and scientific personnel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may become subject to claims challenging
the inventorship or ownership of our patents.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We may be subject to claims that former employees, collaborators or other third parties
have an interest in our patents as co-inventor. The failure to name the proper inventors on a patent application can result in the patents
issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals,
the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations
of third parties involved or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary
to resolve claims challenging inventorship and/or ownership. If we fail in defending any such claims, in addition to paying monetary damages,
we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such
an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation
could result in substantial costs and be a distraction to management and other employees.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">36</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Patent terms may be inadequate to protect our
competitive position on our product candidates for an adequate amount of time.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Patents have a limited lifespan. In the United States, if all maintenance fees are
timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions
may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates
are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars.
Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such
candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio
may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Intellectual property rights do not necessarily
address all potential threats to our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Once granted, patents may remain open to opposition (as specified above generally
and with respect to us specifically), interference, re-examination, post-grant review, <span style="font-style: italic">inter partes</span>
review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance
or grant, during which time third parties can raise objections against such grant. In the course of such proceedings, which may continue
for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked or
may lose the allowed or granted claims altogether. In addition, the degree of future protection afforded by our intellectual property
rights is uncertain because even granted intellectual property rights have limitations and may not adequately protect our business. The
following examples are illustrative:</div>

<div style="line-height: 1.25">&#160;</div>

<div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0d408d0108f34b48993d7d5e286af349" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 9pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 9pt">
        <div style="text-align: left; line-height: 1.25">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">issued patents that we may own or that we license may be held invalid or unenforceable,
        as a result of legal challenges;</div> </td> </tr>
  </table> </div>

<div style="text-align: justify"> </div> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4ecf349ac8ec44819c7075d8ee6cf42a" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 9pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 9pt">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">others may be able to make products that are similar to our products but that are
        not covered by the claims of our patent rights&#894;</div> </td> </tr>
  </table> </div>

<div style="text-align: justify"> </div> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7784678925c54c4184ddd7ec2b6c4971" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 9pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 9pt">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">we or our licensors or any future strategic partners might not have been the first
        to file patent applications on the inventions covered by the issued patent or pending patent application that we own or have exclusively
        licensed&#894;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z25460991fb12483a8ae0f496135784af" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 9pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 9pt">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">others may independently develop similar or alternative technologies without infringing
        our intellectual property rights&#894;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf9daedd1084846be9e890dff3f9751fc" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 9pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 9pt">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">it is possible that our pending patent applications will not lead to issued patents&#894;</div>
        </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8f6c95dfd3384d418e470b4beb474101" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 9pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 9pt">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">issued patents that we may own or that we license may not provide us with any competitive
        advantage;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z438f6fa71b3f415c9e413d4faae0c25b" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 9pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 9pt">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">our competitors might conduct research and development activities in countries where
        we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our
        major commercial markets&#894;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zcc5c8734a07544c4b6e33f5355929aac" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 9pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 9pt">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">third parties performing manufacturing or testing for us using our product candidates
        or technologies could use the intellectual property of others without obtaining a proper license;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z50f47a8004c84b4b8d84b2852aef311f" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 9pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 9pt">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">we may not develop additional proprietary technologies that are patentable&#894; and</div>
        </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8163c802dd224c669784fd997c36fd1c" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 9pt">&#160;</td>
    <td style="text-align: right; vertical-align: top; width: 9pt">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25">the patents of others may have an adverse effect on our business.</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Should any of these events occur, they could have a material adverse effect on our
business, financial condition, results of operations and prospects.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may rely on trade secret and proprietary
know-how which can be difficult to trace and enforce.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to seeking patent protection for some of our technology and investigational
products, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our
competitive position. Trade secrets and know-how can be difficult to protect. Any disclosure, either intentional or unintentional, by
our employees or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities,
or misappropriation by third parties (such as through a security breach) of our trade secrets or proprietary information could enable
competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We require our employees to enter into written employment agreements containing provisions
of confidentiality and obligations to assign to us any inventions generated in the course of their employment. We further seek to protect
our potential trade secrets and proprietary know-how by entering into non-disclosure and confidentiality agreements with any third parties
who are given access to them, including our collaborators, contract manufacturers, consultants, advisors and other third parties. With
our consultants, contractors, and collaborators, these agreements typically include invention assignment obligations. Despite these efforts,
any of these parties may breach the agreements and disclose our proprietary information or assign our inventions to third parties, which
may be difficult to trace, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally
disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">37</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">If we are unable to adequately protect our proprietary know-how and trade secrets,
competitors may be able to develop technologies and resulting discoveries and inventions that are identical, similar to or better than
our own discoveries and inventions, which could materially harm our business, financial condition and results of operations. Costly and
time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade
secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop
our trade secrets and proprietary information, and the existence of&#160;our own trade secrets affords no protection against such independent
discovery.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to Operations in Israel </div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Conditions in Israel and in the Middle East may adversely affect
our operations. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our headquarters and research and development facilities are located in Israel. Accordingly,
we are directly influenced by the political, economic and military conditions affecting Israel. Specifically, we could be adversely affected
by:</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;hostilities
involving Israel;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a
full or partial mobilization of the reserve forces of the Israeli army;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the
interruption or curtailment of trade between Israel and its present trading partners; and </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a
downturn in the economic, political, social or financial condition in Israel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Since its establishment in 1948, Israel has been subject to a number of armed conflicts
that have taken place between it and its Middle Eastern neighbors. While Israel has entered into peace agreements with both Egypt and
Jordan and has entered into several normalization agreements in 2020 with the United Arab Emirates, Bahrain, Sudan and Morocco, Israel
has no peace or arrangements with any other neighboring or Arab country. Further, all efforts to improve Israel&#8217;s relationship with
the Palestinians have failed to result in a permanent peaceful solution, and there have been numerous periods of hostility as well as
civil insurrection of Palestinians in the West Bank and the Gaza Strip in recent years. In general, Israel is engaged, from time to time
(and more recently during the ongoing &#8220;Swards of Iron&#8221; war), in armed conflicts with Hamas (a militia group and political
party controlling the Gaza Strip), which in some occasions resulted in missiles being fired from the Gaza Strip against civilian targets
in various parts of Israel, including areas in which our employees are located, and negatively affected business conditions in Israel.
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On October 7, 2023, the &#8220;Swords of Iron&#8221; war broke between Israel and
the terrorist organizations in the Gaza Strip, following a surprise attack on Israel led by certain armed groups in the Gaza Strip that
included massacres, terrorism and crimes against humanity. As of the date hereof, the majority of the fighting is concentrated in the
southern region of the State of Israel, whereas the Hezbollah (a&#160;Shia&#160;Islamist&#160;political party and&#160;militant&#160;group
based in&#160;Lebanon) also joined the war with low intensity. In addition, the Houthi movement in Yemen, aligned with&#160;Hamas, launched
attacks targeting Israel and ships claimed to be destined for Israel, and in response to such attacks, the U.S. announced the creation
of a multilateral naval task force of protective escorts for commercial vessels in the region, and has launched &#8220;Operation Prosperity
Guardian&#8221; in December 2023. Israel responds to the attacks against it with airstrikes and extensive mobilization of armed forces,
including reserves, in the Gaza Strip and in the north of Israel. Our headquarters and research and development facilities are located
in Holon, which is about 50 kilometers from the Gaza Strip. Our facilities did not sustain any damage and in accordance with the instructions
of the Israeli National Emergency Management Authority, there is currently no limitation or denial of access or activity limitation in
our facilities. None of our employees were directly harmed as a result of the war. As of the date hereof, we operate continuously, and
so far, the situation in Israel does not have a material effect on our operations and business. We monitor closely the directives of the
Israeli National Emergency Management Authority and where needed, make required adjustments to our operations in accordance with such
directives, including by instructing our workforce to work remotely.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">38</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">Also, relations between Israel and Iran continue to be hostile, due to the fact that
Iran is perceived by Israel as sponsor of Hamas and Hezbollah, while maintaining a military presence in Syria and Lebanon and has threatened
to attack Israel in the course of the &#8220;Swords of Iron&#8221;, and with regard to Iran&#8217;s nuclear program. In addition, the
normalization agreements that Israel has entered into with some Arab countries in the Middle East may affect the geo-political condition
in the Middle East in general, and the relations between Israel and Iran in particular. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">All of the above raise a concern as to the stability in the region which may affect
the security, social, economic and political landscape in Israel and therefore could adversely affect our business, financial condition
and results of operations. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, certain countries, primarily in the Middle East but also in Malaysia
and Indonesia, as well as certain companies and organizations in different parts of the world, continue to participate in a boycott of
Israeli brands and others doing business with Israel and Israeli companies. The boycott, restrictive laws, policies or practices directed
towards Israel or Israeli businesses could, individually or in the aggregate, have a material adverse effect on our business in the future.
In addition, should the BDS Movement, the movement for boycotting, divesting and sanctioning Israel and Israeli institutions (including
universities) and products become increasingly influential in the United States and Europe, this may also adversely affect our business
and financial condition. Further deterioration of Israel&#8217;s relationship with the Palestinians or countries in the Middle East could
expand the disruption of international trading activities in Israel, may materially and negatively affect our business conditions, could
harm our results of operation and adversely affect the share price of our Company. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our business may also be disturbed by the obligation of personnel to perform military
service. Our employees who are Israeli citizens are generally subject to a periodic obligation to perform reserve military service, until
they reach the age of 40 (or older, for reservists with certain occupations), but during military conflicts, these employees may be called
to active duty for longer periods of time, as occurred, and may continue to occur, during the &#8220;Swords of Iron&#8221; war. In response
to the increase in violence and terrorist activity in the past years, and especially during the &#8220;Swords of Iron&#8221; war, there
have been, and may continue to be, periods of significant call-ups for military reservists. In case of further regional instability such
employees, who may include one or more of our key employees, may be absent for extended periods of time which may materially adversely
affect our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, recent political and civil actions in Israel which began in early 2023,
resulting from, among other things, proposed changes to certain Israeli constitutional legislation, may have an adverse effect on the
Israeli social, economic and political landscape and in turn, on us. However, it is difficult to predict at this time what the effect
of such actions will be, if any.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We can give no assurance that the political, economic and security situation in Israel
will not have a material adverse impact on our business in the future.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, our Company&#8217;s insurance does not cover any loss arising of events
related to the security situation in the Middle East. While the Israeli government generally covers the reinstatement value of direct
damages caused by acts of war or terror attacks, we cannot be certain that such coverage will be maintained or that it will sufficiently
cover our damages.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our results of operations may be adversely
affected by the exchange rate fluctuations between the dollar and the New Israeli Shekel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We hold most of our cash, cash equivalents and short-term and long-term bank deposits
in dollars but incur a significant portion of our expenses, principally salaries and related personnel expenses and administrative expenses
for our Israeli based operations, in NIS. As a result, we are exposed to exchange rate fluctuations between the dollar and the NIS, which
may have a material adverse effect on our financial condition. For example, if the dollar significantly devaluates against the NIS, then
the dollar cost of our operations in Israel would increase and our results of operations would be adversely affected.&#160;In 2023 and
2022 the dollar appreciated against the NIS by 3.1% and 13.2%, respectively, while in 2021 the dollar depreciated against the NIS by 3.3%.
As a result of these fluctuations, our NIS denominated expenses were affected.&#160; &#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">39</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The dollar cost of our operations in Israel
will increase to the extent increases in the rate of inflation in Israel are not offset by a devaluation of the NIS in relation to the
dollar, which would harm our results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Inflation in Israel, was 3.0% and 5.3% in 2023 and 2022, respectively,
has affected us by increasing the costs of materials and labor needed to operate our business and could continue to adversely affect us
in future periods. Additionally, since a considerable portion of our expenses such as employees&#8217; salaries are linked to an extent
to the rate of inflation in Israel, the dollar cost of our operations is influenced by the extent to which any increase in the rate of
inflation in Israel is or is not offset by the devaluation of the NIS in relation to the dollar. As a result, we are exposed to the risk
that the NIS, after adjustment for inflation in Israel, will appreciate in relation to the dollar. In that event, the dollar cost of our
operations in Israel will increase and our dollar-measured results of operations will be adversely affected. We cannot predict whether
the NIS will appreciate against the dollar or vice versa in the future. Any increase in the rate of inflation in Israel, unless the increase
is offset on a timely basis by a devaluation of the NIS in relation to the dollar, will increase labor and other costs, which will increase
the dollar cost of our operations in Israel and harm our results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may not be entitled to certain Israeli tax
benefits.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the future, we may be entitled to benefit from certain Israeli government programs
and enjoy certain tax benefits, particularly tax exemptions, resulting from the &#8216;Benefiting Enterprise&#8217; status, or Benefiting
Enterprise, granted to us under the Israel Law for Encouragement of Capital Investments, 1959, or the Investment Law. The availability
of these tax benefits, however, is subject to us meeting certain conditions under the Investment Law, including making specified investments
in fixed assets and equipment. The tax benefits that we anticipate receiving under the &#8220;Benefiting Enterprise&#8221; program may
not be continued in the future at their current levels or at all. To date, we have not actually received any such tax benefits because
we have not yet generated any taxable income.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">It may be difficult to enforce certain U.S.
judgments against us, or our officers and directors or to assert U.S. Securities law claims in Israel. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are incorporated under the laws of the State of Israel. Service of process upon
our directors and officers, the majority of whom reside outside the United States, may be difficult to obtain within the United States.
Furthermore, because the majority of our assets and investments, and a majority of our directors and officers are located outside the
United States, any judgment obtained in the United States against us or any of them may not be collectible within the United States. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, it may be difficult for an investor, or any other person or entity, to
assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged
violation of U.S. securities laws reasoning that Israel is not the most appropriate forum to bring such a claim. In addition, even if
an Israeli court agrees to hear such a claim, it is not certain whether Israeli law or U.S. law will be applicable to the claim. If U.S.
law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time consuming
and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel that
addresses the matters described above. Under certain circumstances, Israeli courts might not enforce judgments rendered outside Israel,
which may make it difficult to collect on judgments rendered against us or our non-U.S.&#160;officers and directors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Moreover, an Israeli court will not enforce a non-Israeli judgment if it was given
in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases), if its enforcement
is likely to prejudice the sovereignty or security of the State of Israel, if it was obtained by fraud or in the absence of due process,
if it is at variance with another valid judgment that was given in the same matter between the same parties, or if a suit in the same
matter between the same parties was pending before a court or tribunal in Israel at the time the foreign action was brought.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our amended and restated Articles of Association
provide that unless we consent to an alternative forum, the federal district courts of the United States of America shall be the exclusive
forum of resolution of any claims arising under the Securities Act which may impose additional litigation costs on our shareholders&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our amended and restated Articles of Association, or Articles, provide that the federal
district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause or causes of action,
or a claim or claims arising under the Securities Act, including all causes of action or claims asserted against any defendant to such
complaint. Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities
Act actions. Accordingly, both U.S.&#160;state and federal courts have jurisdiction to entertain such claims. This choice of forum provision
may limit a shareholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors,
officers or other employees and may increase the costs associated with such lawsuits, which may discourage such lawsuits against us and
our directors, officers and employees. Alternatively, if a court were to find these provisions of our Articles inapplicable to, or unenforceable
in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such
matters in other jurisdictions, which could adversely affect our business and financial condition. Any person or entity purchasing or
otherwise acquiring any interest in our share capital shall be deemed to have notice of and to have consented to the choice of forum provisions
of our Articles described above. This provision does not apply to causes of action arising under the Exchange Act.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">40</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our Articles of Association provide that unless
the Company consents otherwise, the competent courts of Tel Aviv, Israel shall be the sole and exclusive forum for substantially all disputes
between the Company and its shareholders under the Companies Law and the Israeli Securities Law, which could limit its shareholders ability
to bring claims and proceedings against, as well as obtain favorable judicial forum for disputes with the Company, its directors, officers
and other employees.</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="text-align: justify; line-height: 1.25">The competent courts of Tel Aviv, Israel shall be the exclusive forum for (i) any
derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of fiduciary duty owed by
any director, officer or other employee of the Company to the Company or the Company&#8217;s shareholders, or (iii) any action asserting
a claim arising pursuant to any provision of the Companies Law, 5759-1999, as amended together with all regulations promulgated thereunder,
or the Companies Law, or the Securities Law, 5728-1968, as amended and the regulations promulgated thereunder, or the Israeli Securities
Law. This exclusive forum provision is intended to apply to claims arising under Israeli Law and would not apply to claims brought pursuant
to the Securities Act or the Exchange Act or any other claim for which federal courts would have exclusive jurisdiction. Such exclusive
forum provision in our Articles will not relieve the Company of its duties to comply with federal securities laws and the rules and regulations
thereunder, and shareholders of the Company will not be deemed to have waived the Company&#8217;s compliance with these laws, rules and
regulations. This exclusive forum provision may limit a shareholder&#8217;s ability to bring a claim in a judicial forum of its choosing
for disputes with the Company or its directors or other employees which may discourage lawsuits against the Company, its directors, officers
and employees.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Provisions of Israeli law may delay, prevent
or make undesirable an acquisition of all or a significant portion of our shares or assets. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Israeli corporate law regulates mergers and acquisitions and requires that a tender
offer be affected when certain thresholds of percentage ownership of voting power in a company are exceeded (subject to certain conditions),
which may have the effect of delaying, preventing or making more difficult a merger with, or acquisition of, us. See &#8220;Item 10. Additional
Information &#8211; B. Memorandum and Articles of Association.&#8221; Further, Israeli tax considerations may make potential transactions
undesirable to us or to some of our shareholders whose country of residence does not have a tax treaty with Israel granting tax relief
to such shareholders from Israeli tax. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes
the deferral contingent on the fulfillment of numerous conditions, including a holding period of two years from the date of the transaction
during which certain sales and dispositions of shares of the participating companies are restricted. Moreover, with respect to certain
share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no actual disposition
of the shares has occurred. See &#8220;Item 10. Additional Information &#8211; E. Taxation &#8211; Israeli Taxation.&#8221; </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, in accordance with the Restrictive Trade Practices Law, 1988 and under
the Israeli Law for the Encouragement of Industrial Research and Development of 1984 and regulations promulgated thereunder, together,
the R&amp;D Law, approvals regarding a change in control (such as a merger or similar transaction) may be required in certain circumstances.
For more information regarding such required approvals please see &#8220;Item 5. Operating and Financial Review and Prospects - C. Research
and Development, Patents and Licenses &#8211; The Israel Innovation Authority.&#8221; In addition, as a corporation incorporated under
the laws of the State of Israel, we are subject to the Israeli Economic Competition Law, 1988 and the regulations promulgated thereunder
(formerly known as the Israeli Antitrust Law, 1988), under which we may be required in certain circumstances to obtain the approval of
the Israel Competition Authority (formerly known as the Israel Antitrust Authority) in order to consummate a merger or a sale of all or
substantially all of our assets. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">These provisions of Israeli law could have the effect of delaying
or preventing a change in control and may make it more difficult for a third-party to acquire us, even if doing so would be beneficial
to our shareholders and may limit the price that investors may be willing to pay in the future for our ordinary shares. </div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">41</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We received grants from the IIA that may require
us to payment of royalties and restrict the transfer of know-how that we develop. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We have received governmental grants from the Israeli Innovation
Authority, or the IIA, for the financing of a portion of our research and development expenditures. Accordingly, we are obligated to repay
the grants by way of royalty payments from revenues generated by the sale of products and/or services developed in the framework of the
approved R&amp;D program using financing from such grants, or Financed Know-How. Such royalties are payable until 100% of the amount of
the grant (as adjusted for fluctuation in the USD/NIS exchange rate) is repaid with applicable interest. Even following full repayment
of any IIA grants (together with the applicable interest), and unless agreed otherwise by the applicable authority of the IIA, we must
nevertheless continue to comply with the requirements of the R&amp;D Law with respect to the Financed Know-How. In addition to the obligation
to pay royalties to the IIA, the R&amp;D Law requires that products which incorporate Financed Know-How be manufactured in Israel and
prohibits the transfer of the Financed Know-How and any right derived therefrom to third parties, unless otherwise approved in advance
by the IIA; Such prior approval may be given by the IIA subject to payment of increased royalties. Failure to comply with the requirements
under the R&amp;D Law may subject us to financial sanctions, to mandatory repayment of grants received by us (together with interest and
penalties), as well as expose us to criminal proceedings. Although such restrictions do not apply to the export from Israel of Company&#8217;s
products developed with such Financed Know-How, they may prevent us from engaging in transactions involving the sale, outsource or transfer
of such Financed Know-How or of manufacturing activities with respect to any product or technology based on Financed Know-How, outside
of Israel, which might otherwise be beneficial to us. Furthermore, the consideration available to our shareholders in a transaction involving
the transfer outside of Israel of Financed Know-How (such as a merger or similar transaction) may be reduced by any amounts that we are
required to pay to the IIA. Moreover, the government of Israel may from time to time audit sales of products which it claims incorporate
Financed Know-How and this may lead to royalties being payable on additional products, and may subject such products to the restrictions
and obligations specified hereunder.&#160;For more information regarding such restrictions please see &#8220;Item 5. Operating and Financial
Review and Prospects- C. Research and Development, Patents and Licenses &#8211; The Israel Innovation Authority.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Being a foreign private issuer exempts us from
certain SEC requirements and Nasdaq rules, which may result in less protection that is afforded to investors under rules applicable to
domestic issuers. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are a &#8220;foreign private issuer&#8221; within the meaning of rules promulgated
by the SEC. As such, we are exempt from certain provisions under the Exchange Act,<span style="font-weight: bold">&#160;</span>applicable
to U.S. public companies, including:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5e5fcf70da16454fb24a4168309b3fa1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q and current reports on Form
        8-K; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze7184f5effc14a1b856efd4329efa19c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered
        under the Exchange Act, including extensive disclosure of compensation paid or payable to certain of our highly compensated executives
        as well as disclosure of the compensation determination process; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd7e334fbfc254a82bc8ea2061a86066d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the provisions of Regulation FD aimed at preventing issuers from making selective disclosures of material information; and </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdd84ab6bb18d4d399604737940c93c0c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and establishing
        insider liability for profits realized from any &#8220;short-swing&#8221; trading transaction (a purchase and sale, or sale and purchase,
        of the issuer&#8217;s equity securities within less than six months). </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In addition, we may follow home country corporate governance practices
and law instead of those rules and practices otherwise required by Nasdaq for domestic issuers. For instance, we have relied on the foreign
private issuer exemption with respect to shareholder approval requirements for equity-based incentive plans for our employees. For the
list of specific exemptions that we chose to adopt, please see &#8220;Item 16G &#8211; Corporate Governance.&#8221; </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Following our home country corporate governance practices as opposed
to the requirements that would otherwise apply to a U.S. company listed on Nasdaq may provide less protection to investors than is afforded
to investors under the Nasdaq Listing Rules applicable to domestic issuers. </div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">42</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We may lose our status as
a foreign private issuer, which would increase our compliance costs and could negatively impact our operations results.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We may lose our foreign private issuer status if (a) a majority
of our outstanding voting securities are either directly or indirectly owned of record by residents of the United States and (b)(i) a
majority of our executive officers or directors are U.S. citizens or residents, (ii) more than 50% of our assets are located in the United
States or (iii) our business is administered principally in the United States. If we will not be a foreign private issuer, we will be
required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more extensive than
the forms available to a foreign private issuer. We would also be required to follow U.S. proxy disclosure requirements, including the
requirement to disclose, under U.S. law, more detailed information about the compensation of our senior executive officers on an individual
basis. We may also be required to modify certain of our policies to comply with accepted governance practices associated with U.S. domestic
issuers. Such conversion and modifications will involve increased costs. In addition, we would lose our ability to rely upon exemptions
from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers, as described in
the previous risk factor above.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Our shareholders rights
and responsibilities are governed by Israeli law which differs in some material respects from the rights and responsibilities of shareholders
of U.S. companies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Because we are incorporated under Israeli law, the rights and responsibilities of
our shareholders are governed by our Articles and Israeli law. These rights and responsibilities differ in some respects from the rights
and responsibilities of shareholders in U.S.-based corporations. In particular, a shareholder of an Israeli company has a duty to act
in good faith and in a customary manner in exercising its rights and performing its obligations towards the company and other shareholders
and to refrain from abusing its power in the company, including, among other things, in voting at the general meeting of shareholders
on certain matters, such as an amendment to a company&#8217;s articles of association, an increase of a company&#8217;s authorized share
capital, a merger of a company and approval of interested party transactions that require shareholder approval. A shareholder also has
a general duty to refrain from discriminating against other shareholders. In addition, a controlling shareholder or a shareholder who
knows that it possesses the power to determine the outcome of a shareholders&#8217; vote or to appoint or prevent the appointment of an
office holder in a company or has another power with respect to a company, has a duty to act in fairness towards such company. Israeli
law does not define the substance of this duty of fairness and there is limited case law available to assist us in understanding the nature
of this duty or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities
on our shareholders that are not typically imposed on shareholders of U.S. corporations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to our Ordinary Shares </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We may not be able to meet
the continued listing standards of Nasdaq, which require a minimum closing bid price of $1.00 per share, which could result in our delisting
and negatively impact the price of our ordinary shares and our ability to access the capital markets.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Our ordinary shares are listed on The Nasdaq Capital Market.&#160;The
Nasdaq Stock Market LLC, or the Nasdaq, provides various continued listing requirements that a company must meet in order for its shares
to continue trading on the exchange. Among these requirements is the requirement that our shares trade at a minimum bid price of $1.00
per share.&#160;On October 31, 2022, we received a written notice from the Listing Qualifications Department of Nasdaq, notifying us that
our ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the
applicable Nasdaq minimum bid price rules and on June 12, 2023 (after the transfer of the listing of our ordinary shares from the Nasdaq
Global Market to the Nasdaq Capital Market), we received a notification letter from the Listing Qualifications Department of Nasdaq notifying
us that we had regained compliance with the applicable minimum bid price rules. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Thereafter, on November 3, 2023, we received a notification letter
from the Listing Qualifications Department of Nasdaq notifying us that our ordinary shares failed to maintain a minimum bid price of $1.00
over the previous 30 consecutive business days as required by the applicable minimum bid price rules and on January 4, 2024, we received
a notification letter from the Listing Qualifications Department of Nasdaq notifying us that we had regained compliance with the applicable
minimum bid price requirement.&#160; </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">While currently we are in compliance with the applicable Nasdaq minimum bid price
rules, there is no assurance that our share price will trade&#160;at or above a minimum bid price of $1.00 per share and if we fail to
meet minimum listing requirements,&#160;there can be no assurance that we will be able to regain compliance with the applicable minimum
bid price rules or will otherwise be in compliance with other Nasdaq listing criteria. Any such delisting could adversely affect our ability
to obtain financing for the continuation of our operations and could result in the loss of confidence by investors, collaborators and
employees.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">43</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Future sales of our ordinary
shares or securities convertible or exchangeable for our ordinary shares may depress our share price.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If our existing shareholders or holders of our options sell, or indicate an intention
to sell, substantial amounts of our ordinary shares in the public market, the trading price of our ordinary shares could decline. The
perception in the market that these sales may occur could also cause the trading price of our ordinary shares to decline. As of December
31, 2023, we had a total of 89,237,465 ordinary shares outstanding.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Based on the number of shares subject to awards under our 2010 Share Incentive Plan,
as amended, or 2010 Plan, and our 2021 Employee Share Purchase Plan, or ESPP, as of December 31, 2023, 9,690,192 ordinary shares that
are either subject to outstanding options or reserved for future issuance under our 2010 Plan and ESPP were eligible for sale in the public
market, subject to, in the case of shares issued to directors, executive officers and other affiliates, the volume limitations under Rule
144 under the Securities Act. If these additional ordinary shares are sold, or if it is perceived that they will be sold, in the public
market, the trading price of our ordinary shares could decline.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, our directors, executive officers and other affiliates may establish,
and certain executive officers and directors have established, programmed selling plans under Rule 10b5-1 of the Exchange Act, for the
purpose of effecting sales of our ordinary shares. Any sales of securities by these shareholders, or the perception that those sales may
occur, including the entry into such programmed selling plans, could have a material adverse effect on the trading price of our ordinary
shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">If we sell ordinary shares
in future financings, shareholders may experience immediate dilution and, as a result, our share price may decline. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In order to raise additional capital, we may at any time offer additional ordinary
shares or other securities convertible into or exchangeable for our ordinary shares, through our &#8220;at-the-market offering&#8221;
(ATM) facility pursuant to a sales agreement entered with Leerink Partners on January 31, 2023 or other manners, at prices that may not
be the same as the price paid for our ordinary shares by our shareholders. The price per share at which we sell additional ordinary shares,
or securities convertible or exchangeable into ordinary shares, in future transactions may be higher or lower than the price per share
paid by our existing shareholders. If we issue ordinary shares or securities convertible into ordinary shares, our shareholders will experience
additional dilution and, as a result, our share price may decline.<span style="font-weight: bold; font-style: italic">&#160;</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, as opportunities present themselves, we may enter into financing or similar
arrangements in the future, including the issuance of debt securities or ordinary shares with or without additional securities convertible
or exchangeable into ordinary shares. Whether or not we issue additional shares at a discount, any issuance of ordinary shares will, and
any issuance of other equity securities or of options, warrants or other rights to purchase ordinary shares may, result in additional
dilution of the percentage ownership of our shareholders and could cause our share price to decline. New investors could also gain rights,
preference and privileges senior to those of our shareholders, which could cause the price of our ordinary shares to decline. Debt securities
may also contain covenants that restrict our operational flexibility or impose liens or other restrictions on our assets, which could
also cause the price of our ordinary shares to decline.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Our share price and trading
volume have been volatile and may be volatile in the future and that could limit investors&#8217; ability to sell our shares at a profit
and could limit our ability to successfully raise funds. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">During the 2023 calendar year, our closing share price on Nasdaq ranged from a low
of $0.53 to a high of $2.00 and trading volume was volatile. The volatile price of our shares and periodic volatile trading volume may
make it difficult for investors to predict the value of their investment, to sell shares at a profit at any given time, or to plan purchases
and sales in advance. A variety of factors may affect the market price of our ordinary shares including:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z44caf3dc0eda4a51b92032e3c8acb1a4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>global or regional macroeconomic developments; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2b575a59f71741caba7b5a938cc605a5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>general market, political and economic conditions in the countries in which Compugen operates, including Israel and the effect of
        the evolving nature of the recent &#8220;Swords of Iron&#8221; war in Israel;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5aeb802202154206b420888a7463a766" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the spread, and resulting actions, of COVID-19 or other global or regional health pandemics or epidemics; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">44</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"> <br/> </div>

<table cellspacing="0" cellpadding="0" id="z250cd36b4c554d7ca1f7e3888ce70d6e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>clinical data disclosed by us or our competitors; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z297bbb390ff74e4f9cefc2e55ab2aad0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>massive sell of our shares by a large shareholder; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3f56056e36464e23b868a7342e83e439" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our success (or lack thereof) in entering into collaboration agreements and achieving certain research and developmental milestones
        thereunder; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9242d2e3de2b4e6e919efb7bd992e77e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our need to raise additional capital and our success or failure in doing so; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6011a6f429e84d6faf644076e8b670c1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability (or lack thereof) to disclose key discoveries or developments due to competitive concerns or need to secure our intellectual
        property position;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za78f204c190547589a2e29138165a988" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>achievement or denial of regulatory approvals by us or our competitors; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf1434a34f70745e190274f7f07c759d4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>announcements of technological innovations or new commercial products by our competitors; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>trends in share price of companies in our field or industry; </div> </td> </tr>
  </table>

<div><br/> </div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>announcement of corporate transactions, merger and acquisition activities or other similar events by companies in our field or industry;</div>
        </td> </tr>
  </table> </div>

<div><br/> </div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>
        <div style="line-height: 1.25">changes and developments effecting our field or industry; </div> </div> </td> </tr>
  </table> </div> </div> &#160; <br/>

<table cellspacing="0" cellpadding="0" id="z1280dee0017641faba9f836fb766ed6c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>developments concerning material proprietary rights, including material patents; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5e624ac31bee4cf4b7f0db0564011a91" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>developments concerning our existing or new collaborations; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z678461da7f034e3eb06c02cb3f5511aa" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>regulatory developments in the United States, Israel and other countries; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8d2ac782c0624d08844e9989885f44df" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes in the structure of healthcare payment systems;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z66fe4de317614334bb5b4db0a158bc91" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>delay or failure by us or our partners in initiating, completing or analyzing preclinical or clinical trials or the unsatisfactory
        design or results of such trials; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6aea5ae332f44328b420de442af1f94f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>period to period fluctuations in our results of operations; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc8e7bcfaad5a49a3918d52097e02c0cd" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes in estimates by securities analysts; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5c060591423843a8a9509930b764674e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes in senior management or the board of directors or changes in the size or structure of the company; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze9dd6cd3e482494586c428d22c143b60" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability (or lack thereof) to disclose the commercial terms of, or progress under, our collaborations; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z691691ae9e2d4bfe892e11216527dea8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability (or lack thereof) to show and accurately predict revenues; and </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z214675e182c642799353f58308e4e5ad" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>transactions with respect to our ordinary shares by insiders or institutional investors. </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are not able to control many of these factors, and we believe that period-to-period
comparisons of our financial results will not necessarily be indicative of our future performance.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In addition, the stock market in general, and the market for biotechnology
companies in particular, have experienced extreme price and volume fluctuations that may be unrelated or disproportionate to the operating
performance of individual companies. These broad market and industry factors may seriously harm the market price of our ordinary shares,
regardless of our operating performance.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Furthermore, the market prices of equity securities of companies
that have a significant presence in Israel may also be affected by the current and changing security situation in the Middle East and
particularly in Israel and the effect of the evolving nature of the recent &#8220;Swords of Iron&#8221; war. As a result, these companies
may experience volatility in their stock prices and/or difficulties in raising additional financing required to effectively operate and
grow their businesses. Thus, market and industry-wide fluctuations and political, economic and military conditions in the Middle East,
but also in the United States and worldwide may adversely affect the trading price of our ordinary shares, regardless of our actual operating
performance.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">As a result of the volatility of our share price, we could be subject
to securities litigation, which could result in substantial costs and divert management&#8217;s attention and company resources from our
business.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">45</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Because we do not intend to declare cash dividends
on our ordinary shares in the foreseeable future, shareholders must rely on appreciation of the value of our ordinary shares for any return
on their investment and may not receive any funds without selling their ordinary shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We have never declared or paid cash dividends on our ordinary shares
and do not anticipate declaring or paying any cash dividends in the foreseeable future. In addition, the terms of any future debt agreements
may preclude us from paying dividends. As a result, we expect that only appreciation of the price of our ordinary shares, if any, could
provide a return to investors for the foreseeable future. In addition, because we do not intend to declare cash dividends on our ordinary
shares in the foreseeable future, if our shareholders want to receive funds in respect of our ordinary shares, they must sell their ordinary
shares to do so.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Our ordinary shares are traded on more than one market and this
may result in price variations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to being traded on The Nasdaq Capital Market, our ordinary shares are
also traded on the Tel Aviv Stock Exchange, or TASE. Trading in our ordinary shares on these markets take place in different currencies
(dollars on Nasdaq and NIS on the TASE), and at different times (resulting from different time zones, trading days and public holidays
in the United States and Israel). The trading prices of our ordinary shares on these two markets may differ due to these and other factors.
Any decrease in the price of our ordinary shares on one market could cause a decrease in the trading price of our ordinary shares on the
other market.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If we are a passive foreign investment company,
or PFIC, our U.S. shareholders may be subject to adverse U.S. federal income tax consequences. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">For U.S. federal income tax purposes, we generally will be classified
as a PFIC for any taxable year in which, after the application of certain look-through rules with respect to our subsidiaries, either:
(i) 75% or more of our gross income is passive income or (ii) at least 50% of the average value (determined on the basis of a weighted
quarterly average) of our total assets for the taxable year produce or are held for the production of passive income. For purposes of
these tests, passive income includes, among other things, dividends, interest, and gains from the sale or exchange of investment property
and certain rents or royalties (excluding rents and royalties that are received from unrelated parties in connection with the active conduct
of a trade or business). Assets that produce or are held for the production of passive income may include cash, (unless held in a non-interest
bearing account for short term working capital needs), marketable securities, and other assets that may produce passive income. Generally,
in determining whether a non-U.S. corporation is a PFIC, a non-U.S. corporation that directly or indirectly owns at least 25% by value
of the shares of another corporation is treated as holding and receiving directly its proportionate share of assets and income of such
corporation.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Based on our analysis of our estimated income, estimated assets,
activities and market capitalization, we believe that we were a PFIC for the taxable year ended December 31, 2023. However, the determination
of whether or not we are a PFIC is a fact-intensive determination made on an annual basis and because the applicable law is subject to
varying interpretations, we cannot provide any assurance regarding our PFIC status and our U.S. counsel expresses no opinion with respect
to our PFIC status for any taxable year. If we are classified as a PFIC for any taxable year during which a U.S. shareholder holds our
ordinary shares, U.S. investors could be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including
the treatment of gains realized on the sale of our ordinary shares as ordinary income, rather than as capital gain, the loss of the preferential
rate applicable to dividends received on our ordinary shares by individuals who are U.S. holders (as defined in &#8220;Item 10. Additional
Information &#8211; E. Taxation &#8211; Certain Material U.S. Federal Income Tax Considerations to U.S. Holders&#8221;), the addition
of interest charges on certain taxes treated as deferred taxes, and additional reporting requirements. A U.S. shareholder of a PFIC generally
may mitigate these adverse U.S. federal income tax consequences by making a &#8220;qualified electing fund&#8221; election, or QEF election,
or, in some circumstances, a &#8220;mark to market&#8221; election. We may provide the information necessary for U.S. holders to make
QEF elections if we were treated as a PFIC for any taxable year. There is no assurance that we will have timely knowledge of our status
as a PFIC in the future. Accordingly, U.S. holders may be unable to make a timely QEF election with respect to our ordinary shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">For further discussion of the PFIC rules and the adverse U.S. federal
income tax consequences in the event we are classified as a PFIC, as well as certain elections that may be available to U.S. holders,
see &#8220;Item 10. Additional Information &#8211; E. Taxation &#8211; Certain Material U.S. Federal Income Tax Considerations to U.S.
Holders &#8211; Passive Foreign Investment Company Rules&#8221;.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">46</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If we are a controlled foreign corporation,
there could be materially adverse U.S. federal income tax consequences to certain U.S. Holders of our ordinary shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Each &#8220;Ten Percent Shareholder&#8221; (as defined below) in
a non-U.S. corporation that is classified as a controlled foreign corporation, or a &#8220;CFC&#8221;, for U.S. federal income tax purposes
generally is required to include in income for U.S. federal tax purposes such Ten Percent Shareholder&#8217;s pro rata share of the CFC&#8217;s
&#8220;Subpart F income&#8221; (as defined below), &#8220;global intangible low taxed income,&#8221; and investment of earnings in U.S.
property, regardless of whether we make any distributions. Subpart F income generally includes dividends, interest, rents, royalties,
gains from the sale of securities and income from certain transactions with related parties. In addition, a Ten Percent Shareholder that
realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather
than capital gain. An individual that is a Ten Percent Shareholder with respect to a CFC generally would not be allowed certain tax deductions
or foreign tax credits that would be allowed to a Ten Percent Shareholder that is a U.S. corporation. We cannot provide any assurance
that we will assist investors in determining whether we or any of our future non-U.S. subsidiaries are treated as a CFC or furnish to
any U.S. holder the information required to comply with the reporting and tax-paying obligations discussed above. Failure to comply with
these reporting obligations may subject a Ten Percent Shareholder to significant monetary penalties and may prevent the statute of limitations
with respect to such Ten Percent Shareholder&#8217;s U.S. federal income tax return for the year for which reporting was due from starting.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">A non-U.S. corporation generally will be classified as a CFC for
U.S. federal income tax purposes if Ten Percent Shareholders own, directly or indirectly, more than 50% of either the total combined voting
power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A &#8220;Ten
Percent Shareholder&#8221; is a United States person (as defined by the Internal Revenue Code of 1986, as amended, or, the Code) who owns
(directly or indirectly) 10% or more of the total combined voting power of all classes of stock entitled to vote or 10% or more of the
total value of all classes of stock of such corporation.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">The determination of CFC status is complex and includes attribution
rules, the application of which is not entirely certain. In addition, changes to the attribution rules relating to the determination of
CFC status may make it difficult to determine our CFC status for any taxable year. Because our group includes at least one U.S. subsidiary
(Compugen USA, Inc.), those changes to the attribution rules may cause any non-U.S. subsidiaries that we form or acquire in the future
to be treated as controlled foreign corporations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Each U.S. holder (as defined in Item 10. Additional Information
&#8211; E. Taxation &#8211; Certain Material U.S. Federal Income Tax Considerations to U.S. Holders&#8221;) should consult its own tax
advisors with respect to the potential adverse U.S. tax consequences of becoming a Ten Percent Shareholder in a CFC. If we are classified
as both a CFC and a PFIC (as defined above), we generally will not be treated as a PFIC with respect to those U.S. holders that meet the
definition of a Ten Percent Shareholder during the period in which we are a CFC.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Shareholder activism can negatively affect our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In recent years, shareholder activists have become involved in
numerous public companies. Shareholder activists could propose to involve themselves in the governance, strategic direction and operations
of a company. We encountered such activism prior to our 2017 annual general shareholders&#8217; meeting, when we received a formal request
from an individual private shareholder, holding approximately 1.3% of the Company&#8217;s voting rights at that time, to add to the agenda
of the meeting the proposed appointment of two new director candidates, both of whom were not recommended by management. This proposal
was rejected by the shareholders at the meeting.&#160;Shareholder activism, including potential proxy contests, divert our management&#8217;s
and board of directors&#8217; attention and resources from our business, could give rise to perceived uncertainties as to our future direction
and could result in the loss of potential business opportunities and make it more difficult to attract and retain qualified personnel
for positions in both management and on the board level and to raise funds. If nominees advanced by activist shareholders are elected
or appointed to our board of directors with a specific agenda, it may adversely affect our ability to effectively and timely implement
our strategic plans or to realize long-term value from our assets. Also, we may be required to incur significant expenses including legal
fees related to activist shareholder matters. Further, our share price could be subject to significant fluctuations or otherwise be adversely
affected by the events, risks and uncertainties of any shareholder activism.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-weight: bold">General Risks </div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Unfavorable global or domestic political or economic conditions
could adversely affect our business, financial condition or results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">The global economy continues to experience significant volatility,
and the economic environment may continue to be, or become, less favorable than that of past years. Higher costs for goods and services,
inflation, deflation, the imposition of tariffs or other measures that create barriers to or increase the costs associated with international
trade, overall economic slowdown or recession and other economic factors in Israel, the U.S. or in any other markets in which we operate
could adversely affect our operations and operating results. Among other matters, the continued risk of a debt default by one or more
European countries, related financial restructuring efforts in Europe, and/or evolving deficit and spending reduction programs instituted
by the U.S. and other governments could negatively impact the global economy and/or pharmaceutical industry.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">47</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In addition, recent political and civil actions in Israel which
commenced in the beginning of 2023, resulting from, among other things, proposed changes to certain Israeli constitutional legislation,
may have an adverse effect on the Israeli social, economic and political landscape and in turn, on us. However, it is difficult to predict
at this time what the effect of such actions will be, if any. Furthermore, although to date we have not been directly impacted by the
current military conflict between Russia and Ukraine, this conflict, or any expansion thereof, could disrupt or otherwise adversely impact
our operations and those of third parties upon which we rely. Related sanctions, export controls or other actions have been or may in
the future be initiated by nations including the United States, the European Union or Russia (e.g., potential cyberattacks, disruption
of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with
whom we conduct business. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic
climate and financial market conditions could adversely impact our business.&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Environmental, social and governance matters may impact our business
and reputation.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In addition to the importance of their financial performance, companies
are being increasingly judged by their performance on a variety of environmental, social and governance, or ESG, matters, which are considered
to contribute to the long-term sustainability of companies&#8217; performance.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">A variety of organizations measure the performance of companies
on such ESG topics, and the results of these assessments are widely publicized. In addition, investment in funds that specialize in companies
that perform well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance
of such ESG measures to their investment decisions. Topics taken into account in such assessments include, among others, the company&#8217;s
efforts and impacts on&#160;climate&#160;change&#160;and human rights, ethics and compliance with the law, and the role of the company&#8217;s
board of directors in supervising various sustainability issues. In addition to the topics typically considered in such assessments, in
the healthcare industry, issues of the public&#8217;s ability to access a company&#8217;s medicines are of particular importance.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In light of investors&#8217; increased focus on ESG matters, there
can be no certainty that we will manage such issues successfully, or that we will successfully meet society&#8217;s expectations as to
our proper role.&#160; Our actual or perceived failure to meet investors, partners or employees&#8217; expectations on ESG matters could
adversely affect our brand and reputation, our employees&#8217; engagement and reputation, and the willingness of our partners to do business
with us.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Climate&#160;change, or
legal or regulatory measures to address&#160;climate&#160;change, may negatively affect us.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Climate&#160;change resulting from increased concentrations of
carbon dioxide and other greenhouse gases in the atmosphere could present risks to our operations. For example, we have operations in
California, where serious drought has made water less available and more costly and has increased the risk of wildfires. Changes in&#160;climate&#160;patterns
leading to extreme heat waves or unusual cold weather at some of our locations can lead to increased energy usage and costs, or otherwise
adversely impact our facilities and operations and disrupt our supply chains and distribution systems. Concern over&#160;climate&#160;change
can also result in new or additional legal or regulatory requirements designed to reduce greenhouse gas emissions or mitigate the effects
of&#160;climate&#160;change on the environment. Any such new or additional legal or regulatory requirements may increase the costs associated
with, or disrupt, sourcing, manufacturing and distribution of our products, which may adversely affect our business and financial results.
In addition, any failure to adequately address stakeholder expectations with respect to ESG matters may result in the loss of business,
adverse reputational impacts, diluted market valuations and challenges in attracting and retaining customers and talented employees. In
addition, our adoption of certain standards or mandated compliance to certain requirements could necessitate additional investments that
could impact our cash position and expected cash runway.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">48</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">ITEM 4. <span id="ITEM4."><!--Anchor--></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
INFORMATION ON THE COMPANY</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">A. HISTORY AND DEVELOPMENT OF THE COMPANY</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">History</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our legal and commercial name is Compugen Ltd. We were incorporated on February 10,
1993, as an Israeli corporation and operate under the Companies Law. Our principal offices are located at 26 Harokmim Street, Holon 5885849,
Israel, and our telephone number is +972-3-765-8585. Our web address is <span style="font-style: italic">www.cgen.com</span>. Information
contained on our website does not constitute a part of this Annual Report. The SEC maintains an internet site, http://www.sec.gov that
contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Neither
such internet addresses are a part of this Annual Report.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our agent for service of process in the United States is Compugen USA, Inc., our wholly
owned U.S. subsidiary located at 225 Bush Street, Suite 348, San Francisco, CA 94104, which was incorporated in Delaware in March 1997
and is qualified to do business in California. This subsidiary did not have any significant operations from 2008 to March 2012.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-weight: bold">Principal Capital Expenditures </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the years ended December 31, 2023, 2022 and 2021, our capital expenditures were
$0.2 million, $0.4 million and $0.4 million, respectively. As of December 31, 2023, we had no significant commitments for capital expenditures.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">B. BUSINESS OVERVIEW</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Summary</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are a clinical-stage therapeutic discovery and development company utilizing our
broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop
therapeutics in the field of cancer immunotherapy. Our innovative immuno-oncology pipeline consists of three clinical stage programs,
COM701, COM902 and rilvegostomig, targeting immune checkpoints we discovered computationally. Two programs that we are pursuing internally,
COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody, are in
Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of dual (PVRIG/PD-1,
PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. Based on the data from the Phase 1 trials and as part of our focus on two specific
tumor types for the further clinical evaluation of COM701 and COM902, we initiated in 2023 two clinical trials evaluating the triple combination
treatment of COM701, COM902 and pembrolizumab, one in metastatic microsatellite stable colorectal cancer patients and one in platinum
resistant ovarian cancer patients. We plan to report data from our metastatic microsatellite stable colorectal clinical trial in the first
half of 2024 and from our platinum resistance ovarian cancer in the fourth quarter of 2024. Rilvegostomig,&#160;a novel anti PD-1/TIGIT
bispecific antibody with a TIGIT-specific component that is derived from our COM902 antibody, is being developed by AstraZeneca pursuant
to an exclusive license agreement between us and AstraZeneca and is being evaluated in multiple clinical trials, including in Phase 3
clinical trial in patients with biliary tract cancer who will be randomized to receive rilvegostomig or placebo with investigator choice
chemotherapy as adjuvant treatment after resection with curative intent. Our therapeutic pipeline of early-stage immuno-oncology programs
consists of programs aiming to address various mechanisms of immune resistance. Our most advanced early-stage program, COM503, is in IND
enabling studies and was licensed to Gilead in December 2023. COM503 is a potential first-in-class high affinity antibody, which blocks
the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer
growth. Our business model is to selectively enter into collaborations for our novel targets and drug product candidates at various stages
of research and development under various revenue-sharing arrangements. Integrating cutting edge computational capabilities with ground-breaking
immuno-oncology research and drug development expertise is our differentiator and has enabled the advancement of drug targets from computer
prediction through successful preclinical studies to the clinic and as a result, we believe that we are uniquely positioned to discover
and develop potential new, first-in-class treatment options for cancer patients.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">49</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our Strategy</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We aim to transform patient lives by developing first-in-class therapeutics in the
field of cancer immunotherapy based on our computational target discovery capabilities. Our pipeline strategy for the development of potentially
first-in-class cancer immunotherapies is differentiated in the competitive landscape of immuno-oncology in the following manner:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z8d728f2379294e6f81037f8226825cc2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We integrate our cutting-edge computational capabilities with our ground-breaking immuno-oncology research and drug development expertise
        to discover novel drug targets and biological pathways with the potential to address the unmet need of patients non-responsive to current
        cancer immunotherapies</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z335a404a3099400c8f2187f9a858006f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We harness these capabilities to inform our drug development process; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z303c136c672148db98363c4c35a9cef4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We identify drug combinations and design biomarker strategy for potential future patient selection.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25">We believe this uniquely positions us in the discovery and the development of first-in-class
drugs for cancer immunotherapy.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">In our clinical therapeutic pipeline, our most advanced programs are:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z982b72c19f3e4139a5543100f7881e2a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">COM701 </span>is our internal lead immuno-oncology pipeline program. COM701 is a humanized antibody
        that binds with high affinity to PVRIG, a novel immune checkpoint target candidate discovered by us that blocks the interaction with its
        ligand, PVRL2. Our data suggests that the PVRIG pathway is parallel and complementary to TIGIT, an immune checkpoint discovered computationally
        by us in 2009. These two pathways intersect with DNAM-1, a costimulatory receptor on T cells and NK cells. The PD-1 pathway also intersects
        with DNAM-1. In certain tumors, and in certain patient populations, the simultaneous blockade of these pathways may be required to stimulate
        an antitumor immune response. Phase 1 trials for COM701 were initiated in September 2018.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z678534db4f1b44f9bcf857fe885162f0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">COM902</span> is a high affinity, fully human antibody developed by us, targeting TIGIT, an immune
        checkpoint. COM902 blocks the interaction of TIGIT with PVR, its ligand. As part of the DNAM-1 axis signaling, in certain tumors, and
        in certain patient populations, the simultaneous blockade of TIGIT, PVRIG and PD-1 may be required to stimulate an antitumor immune response.
        Phase 1 trials for COM902 were initiated in March 2020.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z767c4507af1240d2a26fd96b7707f9c1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">Rilvegostomig</span>&#160;is a novel PD-1/TIGIT bispecific antibody with a TIGIT component that is
        derived from COM902 and is being developed by AstraZeneca pursuant to an exclusive license agreement with AstraZeneca. AstraZeneca initiated
        its Phase 3 ARTEMIDE-Bil01 trial as adjuvant therapy for biliary tract cancer after resection in combination with chemotherapy at the
        end of 2023 dosing its first patient in such trial in December 2023. In addition, AstraZeneca is also running several Phase 1 and 2 trials
        with rilvegostomig in additional indications.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25">In addition to our clinical therapeutic pipeline, bapotulimab, an antibody targeting
ILDR2, a drug target discovered by us, which was licensed for further research and development to Bayer, under a research and discovery
collaboration and license agreement, the RDCLA. Bapotulimab has been evaluated in Phase 1 clinical trials in na&#239;ve head and neck
squamous cell carcinoma patients. As of February 27, 2023, the license granted to Bayer was terminated, and the rights previously licensed
to Bayer reverted us, at which time, we also exercised our right to get a license to certain intellectual property rights developed by
Bayer under such license agreement. We have the right to continue the development and commercialization of bapotulimab, should we choose
to do so.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">In our preclinical therapeutic pipeline, our most advanced program is:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z28d531722e684fd0bb8bb6c4c1252977" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">COM503 </span>is a potential first-in-class high affinity antibody, which blocks the interaction
        between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. &#8220;interleukin-18
        binding protein and interleukin-18 complex&#8221; is a potential dominant immunosuppressive mechanism which is used by tumors to escape
        the immune system. The inflammasome-induced pro-inflammatory cytokine, interleukin-18, is present at high levels in the tumor microenvironment,
        where it is expected to naturally activate anti-tumor effector cells, such as T and NK cells. But IL-18 is one of the rare cytokines that
        is naturally blocked by an endogenous high affinity inhibitor, called IL-18 binding protein.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">50</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Research Focus - Immuno-Oncology</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our research and development efforts focus on identifying novel drug targets and developing
first-in-class therapeutics in the field of cancer immunotherapy.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Cancer immunotherapies represents a significant commercial market. Sales of therapies
targeting immune checkpoints registered approximately $37.12 billion worldwide in 2022 and $43 billion in 2023 and are predicted to reach
approximately $169 billion by 2032 with a registered&#160;CAGR of 16.4% during the forecast period 2023 to 2032, as reported by Precedence
Research.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The immune system is naturally programmed to seek out and destroy abnormal cells.
Cancer is believed to thrive, in part, because of a number of cellular mechanisms that aid in the evasion of immune response. Such mechanisms
of immune system evasion include masking or reducing the expression of tumor antigens to avoid detection, recruiting T-cell suppressor
cells or expressing inhibitory molecules that suppress immune activation, inducing conditions in the tumor microenvironment that promote
tumor cell proliferation and survival, and a number of other factors. Immuno-oncology therapies that overcome immune suppression by stimulating
responses directed to cancer cells are emerging as a powerful means of counteracting the cellular mechanisms that enable the growth and
spread of tumors. Immuno-oncology agents are expanding as a potential path to durable and long-lasting responses in certain patients.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our discovery strategy is focused on the discovery of new drug targets involved in
mechanisms of immune resistance and which may consequently provide new cancer immunotherapies for enhancing anti-tumor immune responses
in cancer patients.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">While immunotherapy revolutionized the landscape for oncology treatments by providing
a new treatment option leading to lasting benefits for some patients; the response rates to immunotherapy vary greatly across different
cancer indications. However, a large proportion of patients do not respond to these therapies, averaging approximately between 15% to
30% overall, thereby leaving a significant unmet medical need for many patients that may be addressed by the discovery of new biological
pathways that could serve for the development of new cancer immunotherapies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Therapeutic Pipeline</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z21ef39d78db54763ac983eebcf79d080" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-style: italic; font-weight: bold">COM701 - a therapeutic antibody targeting PVRIG</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="margin-left: 36pt; line-height: 1.25; font-style: italic">Pathway expression and preclinical data</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">COM701 is a potentially first-in-class humanized antibody that
binds with high affinity to PVRIG, a novel immune checkpoint target candidate discovered by Compugen, blocking the interaction with its
ligand, PVRL2. Blockade of PVRIG by COM701 has demonstrated potent, reproducible enhancement of T cell activation, consistent with the
desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor immune responses.&#160; In addition,
COM701 combined with anti-PD-1 antibodies has demonstrated synergistic effects in enhancing human T cell stimulation and inhibiting tumor
growth in murine models, supporting the suggested intersection of the PVRIG and PD-1 inhibitory pathways and the potential of these combinations
to further enhance immune response against tumors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">PVRIG and TIGIT constitute parallel immune checkpoint pathways
that interact with DNAM-1, a costimulatory molecule on T cells and NK cells. While PVRIG and TIGIT are complementary and part of the same
biological axis,&#160;our research&#160;shows that they are in fact distinct. PVRIG and TIGIT bind to different ligands (PVRL2 and PVR,
respectively), they are expressed on different immune cell types and their ligands have different expression patterns.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2123c4c2b7f342f5bb486bb2e3ac7e82" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top"><br/> </td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Furthermore, our data show that, PVRIG is expressed in stem-like memory T cells (TSCM) and PVRL2 is expressed in both dendritic cells
        and tertiary lymphoid structures, as well as in PD-L1 low&#160;less inflamed tumors. TSCM&#160;cells, dendritic cells and tertiary lymphoid
        structures have all been shown to be important in clinical response to checkpoint inhibitors and this unique expression pattern might
        enable PVRIG blockade to be active in patients with less inflamed tumors. In addition, expression studies showed that PVRIG, TIGIT, and
        their respective ligands, are expressed in a broad variety of tumor types, such as breast endometrial and ovarian. These two pathways
        intersect with DNAM-1, a costimulatory receptor on T cells and NK cells. The PD-1 pathway also intersects with DNAM-1. In certain tumors,
        and in certain patient populations, the simultaneous blockade of these pathways may be required to stimulate an antitumor immune response.
        COM701 is in a Phase 1 clinical trial in patients with advanced solid tumors, to evaluate in combination therapy with PD-1 inhibitor +
        TIGIT inhibitor.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">51</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-style: italic"> <br/> </div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-style: italic">Clinical Development - Bristol Myers Squibb
Collaboration</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In October 2018, we entered into a master clinical trial collaboration
agreement, or the MCTC, with Bristol Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol Myers
Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>
(nivolumab). In February 2020, the MCTC was amended to include a Phase 1/2 clinical trial, sponsored by Compugen, to evaluate the safety,
tolerability and antitumor activity of COM701 in combination with Opdivo&#174; (nivolumab), and Bristol Myers Squibb&#8217;s investigational
antibody targeting TIGIT known as BMS-986207, in patients with advanced solid tumors. In February 2021, the MCTC was further amended to
include an expansion of the Phase 1 combination trial designed to evaluate the dual combination of COM701 and Opdivo&#174; in patients
with advanced solid tumors and in November 2021 the MCTC was amended again to, among other things, establish a joint steering committee
(alongside the existing joint development committee which acts at an operational level) to facilitate strategic oversight and guidance
for the programs run under the collaboration.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">On August 3, 2022, in efforts to adapt to challenging market conditions,
we took a strategic decision to focus on prioritized indications and to wind down our broad Phase 1 cohort expansion program and therefore
entered into a letter agreement with Bristol Myers Squibb pursuant to which the MCTC between the parties was terminated as of such date.
In connection with such termination, the parties agreed to use reasonable efforts to wind down activities under the CTCA with respect
to the dual combination study of COM701 with Opdivo&#174; and the triple combination study of COM701 with Opdivo&#174; and Bristol Myers
Squibb&#8217;s investigational anti-TIGIT antibody BMS- 986207 and to create a sub-team of the parties to oversee such wind-down activities.
See &#8220;Business Strategy and Partnerships - Bristol Myers Squibb Collaboration&#8221; below. Until the conclusion of the wind down
of the combination studies with Bristol Myers Squibb, Bristol Myers Squibb continues to supply at no cost Opdivo&#174; and its investigational
antibody targeting TIGIT known as BMS-986207 for the triple combination trial. As of January 1, 2024, we had two patients receiving study
treatment on the triplet study of COM701 with Opdivo&#174; BMS- 986207. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-weight: bold">COM701 Clinical Programs</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In September 2018, we dosed our first patient in the Phase 1 clinical
trial of COM701.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="font-weight: bold">Phase 1 Arm A</span> of the trial
evaluated the safety and tolerability and preliminary antitumor activity of COM701 monotherapy. We completed the enrollment to both the
dose escalation and expansion cohorts.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">The patient population enrolled in the dose escalation was all
comers and included patients who have failed prior therapies including other checkpoint inhibitors and have no other available approved
therapies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="font-weight: bold">Phase 1 Arm B</span> of the trial
evaluated the safety and tolerability and preliminary antitumor activity of COM701 in combination with a PD-1 inhibitor (nivolumab). A
patient population with similar eligibility criteria as enrolled for the dose escalation cohorts in Arm A was enrolled for this part of
the trial and enrollment was completed during 2020.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In June 2021, we announced that the first patient in the combination
expansion cohort of this Phase 1 Arm B clinical has been dosed.&#160;The indications for the combination therapy expansion cohort, ovarian,
breast, endometrial and colorectal cancers were selected based on preclinical biomarker assessments and based on emerging clinical data
from the dose-escalation cohorts of the trial.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Following the completion of enrollment of few cohorts in the study
and data disclosure from completed cohorts, we are currently winding down this study and do not plan to further enroll additional patients.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">52</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="text-decoration: underline"> <br/> </span></div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="text-decoration: underline">Data disclosed from this
arm in 2022:</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In November 2022, at the 37<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup>
Annual Meeting of the Society for Immunotherapy of Cancer (SITC), we presented preliminary data in a poster titled &#8220;PVRIG, a novel
T cell checkpoint, is preferentially expressed in TLS on stem-like memory T cells, potentially inhibiting their expansion&#8221;. Key
findings from the poster included:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9a42df68f04042d1a004e7e4d04e8f42" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>COM701 in combination with nivolumab induced preliminary anti-tumor activity and TME immune-modulation in patients with MSS-CRC typically
        not responsive to approved checkpoint inhibitors</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z7374d71c762e45d187f93aa244a01c51" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>PVRIG has a unique dominant expression on early differentiated T like stem cells (Tscm) and its ligand, PVRL2, is expressed on dendritic
        cells (DCs)</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="ze3df520cc49d460fb5f203570cbc8e40" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Spatial transcriptomic analysis showed that Tscm and DCs preferentially localize to Tertiary Lymphoid Structures (TLS) regions while
        exhausted T cells localize to the tumor</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z863446c5911d44358c8174bd8595b54b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>PVRIG is dominantly expressed on CD8+ T cells in TLS region</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zdd34a3be5540481382ebf5c410c6121b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>PVRIG blockade may enhance Tscm activation by DCs in lymph-nodes and TLS, a mechanism which potentially could lead to increased T
        cell expansion and infiltration into cold tumors</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In November 2022, at the 37<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup>
Annual Meeting of the Society for Immunotherapy of Cancer (SITC), we presented preliminary data in a poster titled &#8220;COM701 plus
nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC
and liver metastases&#8221;. Key findings from the poster, with a data cut-off date of June 17, 2022, included:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za8607d325d5b47638059038f645a0916" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>COM701+ nivolumab combination is well tolerated with a favorable safety profile</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z7c9d58256f8b4822a94945c9477fa2c3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>ORR 2/22 (9%) higher than ORR (1-2%) reported for standard of care - regorafenib or TAS-102</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z211a788e452c4a6492575041b9ec16f1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Encouraging preliminary antitumor activity in the subset of MSS-CRC patients with liver metastases, ORR 2/17 (12%), compared to 0%
        ORR historically for other immunotherapies in a U.S. patient population&#160;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z876be902a3ac4fb88f9128bf9974aa49" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Translational data demonstrated potent TME immune activation, in the majority of patients based on 13 paired biopsies, most notable
        in responders and consistent with COM701 mechanism of action. Such modulation is not typical of checkpoint inhibitors in cold indications</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25">In December 2022, at the European Society of Medical Oncology
Immuno-Oncology (ESMO-IO), we presented preliminary data from poster&#160;&#8220;COM701 in combination with nivolumab demonstrates preliminary
antitumor activity in patients with platinum resistant epithelial ovarian cancer&#8221;. Key findings from the poster, with a data cut-off
date of November 23, 2022,&#160;included:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2903b358866c450fb52a821e50a5e977" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>In 20 patients who had exhausted all standard therapies, with a median number of 6 prior therapies, the dual combination demonstrated:</div>
        </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zb988b6741cec4f119e2c15bb9ade03cc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Encouraging overall response rate of 10%, with 2 partial responses and 1 ongoing at the data cut-off date</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z2bf3511afd69484e8271cf24fc65c938" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Disease control rate of 45% (2 confirmed partial responses, 7 stable disease)</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z4bc0df66358241c4bc195422bfc52943" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Translational assessment of peripheral blood, showed a pharmacodynamic activation of the immune system</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z2660965b72624c75a7fa9d5eecebd44b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>One patient with a partial response supported by increased infiltration of CD8 cells into the tumor microenvironment, had high grade
        serous adenocarcinoma, 7 prior lines of treatment including best response of progressive disease on the combination of nivolumab and lucitanib
        (an investigational agent)</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z17ca8ef658334c5492e0fd30b04a15ac" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Most frequent treatment related adverse events grade 1/2, no grade 4/5 adverse events</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z9e7b14e367b347e8abc694362bdb5622" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>65% of the patients had high-grade serous adenocarcinoma, including the two responders</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">53</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25">In December 2022, at the European Society of Medical Oncology
Immuno-Oncology (ESMO-IO), we presented preliminary data from poster&#160;&#8220;COM701 &#177; Nivolumab &#8211; preliminary results of
antitumor activity from a phase 1 trial in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor&#8221;. Key findings
from the poster, with a data cut-off date of November 23, 2022,&#160;showed that COM701 &#177; nivolumab demonstrates preliminary encouraging
signal of antitumor activity in a heavily pretreated population of patients with NSCLC with prior ICI treatment. Most of the patients
4/7 [57%] received &#8805;2 prior lines of immune checkpoint inhibitors, all 4 patients with SD, with 2/4 [50%] with SD &#8805;6 months
median overall survival (median of 4 prior lines of therapy including multiple ICI in 57% of patients): COM701 + nivolumab (10 months),
COM701 monotherapy (9.5 months). Historical data with LungMAP2: post ICI NSCLC data - 1 prior line of ICI in metastatic setting, median
overall survival 14.5 months (80% CI: 13.9 to 16.1) for ramucirumab + pembrolizumab vs standard of care of 11.6 months (80% CI 9.9 to
13.0).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="text-decoration: underline">Data disclosed from this
arm in 2023:</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In November 2023, at the Annual Meeting of the Society for Immunotherapy
of Cancer (SITC) we presented data from poster: &#8220;The combination of COM701 + nivolumab demonstrates preliminary antitumor activity
in patients with metastatic breast cancer.&#8221; Key findings from the poster, with a data cut-off date of September 5, 2023,&#160;included:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z24cb56c032ee4740aa91bd8de891070a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Metastatic breast cancer adds to previous indications in which COM701 combinations show clinical benefit in tumors typically not
        responding to immunotherapy</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zf0a5084b60cd4eb6ae3b11c04dd6af57" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Presentation of new data from the metastatic breast cancer cohort expansion study of patients treated with COM701 and nivolumab,
        another indication showing clinical benefit in patients typically not responding to immunotherapy with initial data showing that baseline
        PVRL2 levels are higher in patients with clinical benefit supporting the findings in platinum resistant ovarian cancer patients (see below
        finding in platinum resistant ovarian cancer patients)</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="font-weight: bold">Phase 1/2 </span>trial was designed
to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo&#174;&#160;and BMS-986207. The trial
was designed to evaluate a safe and tolerable dose of the combination during dose escalation and antitumor activity in selected tumor
types in the expansion cohorts (ovarian cancer, endometrial cancer, head and neck and a biomarker-driven arm of tumor types with high
expression of PVRL2).&#160;Dose levels for Opdivo&#174;&#160;and BMS-986207 combinations have already been determined through prior testing
by Bristol Myers Squibb, allowing for dose escalation of COM701 with fixed doses of Opdivo&#174;&#160;and BMS&#8209;986207.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In July 2021 we dosed the first patient in this trial. Following
the completion of enrollment of the ovarian cohort in the study and its respective data disclosure we are currently winding down this
study and do not plan to further enroll additional patients.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="text-decoration: underline">Data disclosed from this
trial in 2022:</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In December 2022, at the European Society of Medical Oncology Immuno-Oncology
(ESMO-IO), we presented data from poster:&#160;&#8220;Triple blockade of the DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates
preliminary antitumor activity in patients with platinum resistant OVCA.&#8221; Key findings from the poster, with a data cut-off date
of November 23, 2022,&#160;included:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3935ba2c6b294f66a18ab5d83fd4a0bd" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>In 20 patients who had exhausted all standard therapies, with a median number of 4 prior therapies, the triple combination demonstrated:</div>
        </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z3ee4d006ebdf4f86b1f3ddcb29c86257" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Encouraging overall response rate of 20%, with 4 confirmed partial responses, out of which 3 are responding for at least 9 months.
        All 4 responders are still on study treatment at the data cut-off date, therefore median duration of response has not been reached</div>
        </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zec9eaf3c61164bdb9616c7ec84dc3d51" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Disease control rate of 45% (4 confirmed partial responses, 5 stable disease)</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zf6fe18fb64314e048eefb0df0136e484" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt"><br/> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Low pre-treatment PD-L1 expression in 2 of the responders (CPS &lt;1 and 3), analysis of the other responders is still ongoing</div>
        </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zdceff134254d47808a5848c652934677" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Translational assessment of peripheral blood, including profiling of cytokines and circulating immune cells, showed a pharmacodynamic
        activation of the immune system</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z284f18ea18174559a2d0cb4743802e58" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Most frequent treatment related adverse events grade 1/2, no grade 4/5 treatment related adverse events</div> </td> </tr>
  </table>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">55% of the patients had high-grade serous adenocarcinoma, including
three of the responders</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">54</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="text-decoration: underline"> <br/> </span></div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="text-decoration: underline">Data disclosed from this
arm in 2023:</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In June 2023, at the American Society of Clinical Oncology (ASCO)
Annual Meeting we presented data from poster: &#8220;Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab
in patients with recurrent, metastatic MSS endometrial cancer.&#8221;&#160;Key findings from the poster, with a data cut-off date of April
10, 2023,&#160;included:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z423ac396f0174fdd96648d6230b041b4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>COM701 in combination with nivolumab and BMS-986207 (anti-TIGIT) resulted in encouraging confirmed durable partial responses (overall
        response rate 22% (2/9) and disease control rate 44%) with a favorable safety profile</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z3dcbe8b6b2724e6da0646322b8f67963" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Partial response reported in a patient on study treatment for almost 7 months who was previously refractory to standard of care lenvatinib
        and pembrolizumab</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z8d4492234ef54f33a5e5c354a20f473b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Greater peripheral immune activation seen in patients experiencing clinical benefit</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zb19000268bd848398efaa81fdd05c282" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Data further support potential of COM701 in hard-to-treat tumors including those refractory to immune checkpoint inhibitors</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In November 2023, at the Annual Meeting of the Society for Immunotherapy
of Cancer (SITC) we presented several posters. Key findings from the posters,&#160;included:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zecfb24fe383c4fa484ce3c3b5f0af5d3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>COM701 +&#160;nivolumab + BMS-986207 (anti-TIGIT) resulted in clinically meaningful durable partial responses &gt; 16 months in platinum
        resistant ovarian cancer patients</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zc13a535d754548c9805b96b48837ebc7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>COM701 dual and triple combinations mediated clinical benefit in platinum resistant ovarian cancer patients, independent of baseline
        inflammatory status and was associated with an increase in&#160;T cell infiltration to the tumor</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z013e1be3a07445c49a57c94b7c73119b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>PVRL2, the PVRIG ligand, identified as potential predictive biomarker to help enrich for patients who may derive benefit from COM701
        combinations for certain indications</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="font-weight: bold">Phase 1 Combination of COM902 with
COM701 </span>&#8211; For details please see information below under the header &#8220;COM902 - a therapeutic antibody targeting TIGIT<span style="font-style: italic">&#8221;.</span></div>

<div style="line-height: 1.25">&#160; <br/> </div>

<table cellspacing="0" cellpadding="0" id="zfb24a49ade51464c8ec1d673a7274e4f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-style: italic; font-weight: bold">COM902 - a therapeutic antibody targeting TIGIT</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-style: italic">Pathway expression and preclinical data</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">COM902, a high affinity, fully human and a potentially best-in-class
antibody targeting TIGIT, an immune checkpoint is developed by us. COM902 was shown to have superior binding affinity to T cells with
similar and or greater in vitro function compared to several clinical anti-TIGIT antibodies. COM902 is a mouse-cross reactive Ab and inhibited
tumor growth and increased survival when combined with anti-PVRIG or anti-PD-L1 antibodies in in-vivo studies. Preclinical data demonstrated
that TIGIT inhibition, either alone or in combination with other checkpoint inhibitors, can enhance T&#160;cell activation and increase
anti-tumor immune responses. In preclinical studies, parallel inhibition of TIGIT and PVRIG, two coinhibitory arms of the DNAM-1 axis,
resulted in synergistic effects on effector T&#160;cell function and tumor growth inhibition in various model systems that can be further
increased with the addition of PD-1 blockade. Based on preclinical data these combinations may be clinically important for enhancing anti-tumor
immune response and expanding the patient population responsive to checkpoint inhibition.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">We discovered TIGIT in 2009 with our immune checkpoint computational
discovery capabilities through which PVRIG was also discovered. The TIGIT discovery was published by us in October 2009 in the Proceedings
of the National Academy of Sciences (PNAS).</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">55</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Expression studies show that PVRIG and TIGIT, and their respective
ligands, are expressed in a broad variety of tumor types, such as breast, endometrial, ovarian, lung, kidney, and head &amp; neck cancers.
These results indicate that within the same tumor indications there are variations with respect to the possible dominance of the two pathways,
and that in patient populations where the two pathways are operative, the blockade of both TIGIT and PVRIG may be required to sufficiently
stimulate an anti-tumor immune response.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-style: italic">Clinical Development</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In March 2020, we dosed our first patient in the Phase 1 clinical
trial of COM902.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-weight: bold">COM902 Clinical Programs</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="font-weight: bold">Phase 1 Monotherapy </span>trial
evaluated the safety and tolerability of COM902 in patients with advanced malignancies through sequential dose escalations. The patient
population enrolled to the dose escalation cohort is all comers and included patients who have failed prior therapies including other
checkpoint inhibitors and have no other available approved therapies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">We completed the monotherapy dose escalation trial, and enrolled
patients to the expansion cohort.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="font-weight: bold">Phase 1 Combination of COM902 with
COM701 </span>was designed to assess the safety, tolerability and preliminary antitumor activity of COM902 in combination with COM701
in patients with advanced malignancies during dose escalation and in selected tumor types in the expansion cohorts (colorectal cancer,
non-small cell lung cancer and head and neck). Enrollment to these cohorts was terminated in conjunction with the winding down of the
studies under collaboration with Bristol Myers Squibb and the decision to focus on two tumor types for further studies. We amended the
study protocol to include patients with metastatic CRC (MSS) and platinum resistant ovarian cancer. These patients with MSS-CRC and platinum
resistant ovarian cancer receive study treatment with COM902 + COM701 + pembrolizumab.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="font-weight: bold">Phase 1 Combination of COM902 with
COM701 and Pembrolizumab</span> small proof-of-concept trials were designed to evaluate this triplet combination in patients with microsatellite
stable colorectal cancer and platinum resistant ovarian cancer. In March 2023 we announced the dosing of the first patient in themicrosatellite
stable colorectal cancer cohort in this Phase 1 triple immunotherapy combination proof-of-concept trial and in November 2023 we announced
the enrollment completion of all patients in such cohort (n=20). In June 2023 we announced the dosing of the first patient in platinum
resistant ovarian cancer cohort in this trial. </div>

<div style="line-height: 1.25">&#160; <br/> </div>

<table cellspacing="0" cellpadding="0" id="z55b06e85f10946c2bf2d174ad12f6617" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div><span style="font-weight: bold; font-style: italic">Rilvegostomig - a therapeutic PD-1/TIGIT bi-specific antibody with a TIGIT component
        that is derived from our COM902</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Rilvegostomig is a novel PD-1/TIGIT bi-specific antibody with a
TIGIT component that is derived from our COM902 being developed by AstraZeneca pursuant to an exclusive license between us and AstraZeneca.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In March 2018, we entered into an exclusive license agreement with
AstraZeneca, pursuant to which, we granted to AstraZeneca an exclusive license to use our monospecific antibodies that bind to TIGIT,
including COM902, for the development of bi-specific and multi-specific antibody products, excluding such bi-specific and multi-specific
antibodies that also bind to PVRIG, PVRL2 and/or TIGIT.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Rilvegostomig is currently being evaluated by AstraZeneca in a
Phase 3 ARTEMIDE-Bil01 trial as adjuvant therapy for biliary tract cancer after resection in combination with chemotherapy with the first
patient dosed in December 2023. In addition, AstraZeneca is also running several Phase 1 and 2 trials with rilvegostomig in additional
indications.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze4aa2a87c2704f32bb78bea6fa5c2f19" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-style: italic; font-weight: bold">Bapotulimab (formerly known as BAY1905254) &#8211; a therapeutic antibody targeting
        CGEN-15001T/ILDR2</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Bapotulimab (formerly known as BAY1905254, an antibody to ILDR2
(formerly CGEN-15001T), a novel immune checkpoint target discovered by Compugen, was developed with Bayer pursuant to a research and discovery
collaboration and license agreement signed in August 2013. See &#8220;Business Strategy and Partnerships - Bayer Collaboration&#8221;
below. Studies testing the immune function of ILDR2 demonstrated inhibitory effects on T cells consistent with it being an immune checkpoint
ligand. ILDR2 appears to have a unique mechanism of action relative to other immune checkpoints currently being targeted in clinical testing.
ILDR2 is expressed in lymph nodes, suggesting that bapotulimab&#160;exerts its effects on immune cell priming rather than on directly
enhancing immune cell killing effects in the tumor microenvironment.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">56</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In April 2018, Bayer disclosed bapotulimab&#160;a human/monkey/mouse
cross-reactive antibody blocking the immunosuppressive activity of ILDR2. Bapotulimab has exhibited anti-tumor activity as a monotherapy
in various mouse models and was also shown to have additive anti-tumor effects in combination with other cancer therapy approaches, indicating
the possibility for multiple combination uses in cancer immunotherapy.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Under the collaboration agreement, bapotulimab&#160;was previously
evaluated by Bayer in a Phase 1 expansion trial in combination with Keytruda, in head and neck cancer that has returned or is discovered
to be metastatic and is expressing PDL1 to evaluate the combination treatment.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">On November 29, 2022, Bayer notified us that it has resolved to
terminate, effective as of February 27, 2023, our 2013 research and development collaboration and license agreement.&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In accordance with the terms of said agreement, we obtained from
Bayer such rights necessary to allow us to continue the development and commercialization of bapotulimab, should we choose to do so.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Biomarker Driven Strategy</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We recognize that one of the major limitations of current immunotherapy approaches
is the lack of tools to help predict patient responses. Through the use of informed biomarker driven strategies, based on the new biological
pathways we discover, we aim to identify biomarkers that can help us predict which patients are most likely to respond to our novel therapies.
This long-term approach also seeks to improve the probability of success of our clinical studies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are using three approaches in our biomarker strategy. We are computationally analyzing
omics data to identify tumor indications in which the pathway of our target is elevated. This analysis is thereafter being validated experimentally,
and the validated data is used for indication selection for our clinical trials. We used this approach for COM701 to select the tumor
types for inclusion in our cohort expansion studies. Such antitumor activity further supports our biomarker-informed approach and predictive
discovery capabilities.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The second part of our biomarker strategy is the identification of potential biomarkers
for future patient selection. In this approach, being used for our COM701 program as a stand-alone and in combination, we are using various
cutting-edge technologies and methodologies on both biopsies, liquid biopsies, and blood samples. The different technologies include immunohistochemistry,
transcriptomic, genomic and proteomic analysis. Data generated by these technologies also inform us on the suggested mechanism of action
of COM701. In the immunohistochemistry analysis, we are currently evaluating the correlation between the expression of PDL-1 and the PVRIG
pathway with clinical response.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Thirdly, we have a pharmacodynamic biomarker approach where we measure immune modulation
induced by COM701 and combinations in peripheral and tumor patient samples obtained before and during treatment. In this analysis we measure
both protein and sequence analytics, such as cytokine analysis, immune phenotyping, proteomic changes, transcriptomics analysis, and TCR
clonality. This again serves for the identification of potential biomarkers and also inform us on the suggested mechanism of action of
COM701.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">At SITC 2023, we presented new translational data and initial biomarker data from
platinum resistant ovarian cancer studies evaluating COM701 + nivolumab &#177; BMS anti-TIGIT and in a small breast cancer cohort treated
with COM701 +/- nivolumab, both supporting a COM701 mediated clinical benefit and initial data to suggest PVRL2 as a potential biomarker
for patients who may derive benefit from COM701 combinations.</div> <br/>

<div style="line-height: 1.25; font-weight: bold">Early-Stage Pipeline</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Immuno-oncology represents a paradigm shift in the treatment of cancer, and biological
drugs blocking immune checkpoint targets have already resulted in long-term patient survival in certain cancer types. Despite their potential,
current checkpoint inhibitors are limited to a few targets and are only effective in certain patients and in certain cancers. We believe
that the identification of new drug targets and new biological pathways has the potential to broaden the reach of cancer immunotherapies
to more types of cancers and many more patients.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">57</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">Our early-stage programs were discovered using our discovery capabilities and consists
of drug targets with the potential to address various mechanisms of immune resistance and consequently may provide new cancer immunotherapies
for patients non-responsive to current cancer therapies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our most advanced early-stage program, COM503, was licensed to Gilead in December
2023 and is currently being advanced by us towards IND clearance, which we expect to take place in 2024.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Our Predictive Computational Discovery Approach</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our target discovery is a predictive, proprietary computational process that we initiate
based on a clinical need. The unmet clinical need and the therapeutic strategy dictate the target discovery approach, the appropriate
tools and most relevant data to be employed. We have developed predictive drug target discovery capabilities that leverage the power of
computational modeling, guided by our scientific expertise and extensive public and proprietary datasets, to identify novel drug targets
and new biological pathways towards the development of new cancer immunotherapy treatments. Our multi-omics data analysis is designed
to identify first-in-class drug target candidates, which are generally difficult to identify using traditional experimental approaches.&#160;We
believe that our cutting-edge computational capabilities integrated with our ground-breaking immuno-oncology research and drug development
expertise is a key differentiator from others employing computational discovery approaches.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our broadly applicable predictive drug target discovery capabilities employ a suite
of cloud-based computational solutions and purpose-built algorithms to sort through both public and proprietary datasets encompassing
genomics, single cell and spatial transcriptomics, proteomics and machine learning based analysis of IHC images. From these massive datasets,
our platforms analyze characteristics, such as gene structure, protein domains, predicted cellular localization, expression pattern, as
well as other characteristics to identify potential druggable targets and predict their biological functions. Over the past decade, we
have continued to refine our analysis by incorporating new public and in-house experimental data.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; text-align: justify">We have demonstrated the applicability of our discovery approach in computationally
identifying multiple in-silico targets, including&#160;PVRIG,&#160;TIGIT&#160;and&#160;ILDR2, the first two now serve as the targets for
therapeutic antibodies currently being evaluated in the clinic by us and others. The antibodies designed to block these targets have all
been evaluated in Phase 1 clinical trials by us (COM701 and COM902) or by our partners (bapotulimab and rilvegostomig). In addition, more
recently we have identified IL-18BP as a dominant tumor-associated-macrophages immune resistance mechanism and based on this biological
understanding, developed COM503, a potential first-in-class antibody that is licensed to Gilead in accordance with our license agreement
dated December 18, 2023, and is currently being advanced by us towards IND clearance.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Business Strategy and Partnerships </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our business strategy includes entering into various forms of revenue-sharing collaborations
with pharmaceutical or biotechnology partners for our novel drug targets and product candidates at various stages of research and development.
Such collaborations or other types of partnering arrangements might include one or more of our therapeutic pipeline programs. Through
these collaborations we seek to create, further develop and commercialize our therapeutic product candidates. Additionally, our discovery
capabilities designed to feed our internal pipeline may allow for future research and discovery collaborations aimed at harnessing our
capabilities towards a potential partner&#8217;s pipeline needs. Potential revenue sources in line with this business strategy could include
upfront fees, research funding, in-kind funding, milestones payments, license fees, royalties and other revenue sharing payments. We may
also seek co-development arrangements pursuant to which we would further advance partnered programs under any such partnership in order
to potentially retain a higher share of proceeds from future collaborations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Gilead License</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On December 18, 2023, we entered into the License Agreement, pursuant to which we
granted Gilead an exclusive license under our preclinical antibody program against IL-18 binding protein and all intellectual property
rights subsisting therein, to use, research, develop, manufacture and commercialize products, including COM503, and additional products
that may be so developed by Gilead, together with COM503, referred to herein as the Licensed Products.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">58</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the License Agreement, Gilead paid us a $60 million upfront license payment
and we are also eligible to receive from Gilead $30 million in the form of a milestone payment upon clearance of the IND application for
COM503. We are also eligible to receive up to approximately $758 million in additional milestone payments upon the achievement of certain
development, regulatory and commercial milestones. We are further eligible to receive single-digit to low double-digit tiered royalties
on worldwide net sales of Licensed Products. We are required to make certain upstream payments to certain service providers with respect
to the Licensed Products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We will be responsible for conducting a Phase 1 clinical trial for COM503, including
handling the regulatory matters in connection therewith, and will bear the costs of such trial (including the COM503 drug supply), with
Gilead providing at no cost an anti-PD-1/PD-L1 antibody for such trial. In certain circumstances, Gilead may assume the role of conducting
the Phase 1 clinical trial.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Upon completion of the Phase 1 clinical trial for COM503, we will initiate the transfer
of development activities related to COM503 to Gilead, following which, Gilead will have sole responsibility to develop and commercialize
the Licensed Products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">During the term of the License Agreement, we are prohibited from researching, developing,
making and commercializing any compounds, molecules, products or treatment methods that are directed to IL-18 or any companion diagnostics
for an IL-18 product.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Unless terminated early by a party pursuant to its terms, the License Agreement will
continue in effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the last royalty term
in such country.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Gilead withheld at source 15% from the upfront payment amount paid to us in January
2024, and is expected to continue to withhold at source all taxes required by law from all payments payable to us under the License Agreement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The License Agreement contains customary representations, warranties, covenants, and
terms governing the prosecution and enforcement of certain intellectual property and issues related to technology transfer, manufacturing
transfer, provisions with respect to establishment of joint steering committee and its governance covenants with respect change of control
and others.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">AstraZeneca License</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In March 2018, we entered into an exclusive license agreement with AstraZeneca, to
enable the development of bi-specific and multi-specific immuno-oncology antibody products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the terms of the license agreement, we granted an exclusive license to AstraZeneca
to use our monospecific antibodies that bind to TIGIT, including COM902, for the development of bi-specific and multi-specific antibody
products, excluding such bi-specific and multi-specific antibodies that also bind to PVRIG, PVRL2 and/or TIGIT. AstraZeneca has the right
to create multiple products under this license and will be solely responsible for all research, development and commercial activities
under the agreement. In connection with such license agreement, AstraZeneca developed rilvegostomig, a novel PD-/TIGIT bi-specific antibody
with a TIGIT component that is derived from our COM902 and entered the clinic in September 2021 and initiated Phase 3 with first patient
dosing in Phase 3 in December 2023.</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25"> We received a $10&#160;million upfront payment and are eligible to receive up to
$200 million in development, regulatory and commercial milestones for the first product as well as tiered royalties on future product
sales, out of which we accrued $2 million in 2020 as a preclinical milestone, $6 million in 2021 as a clinical milestone (triggered by
the dosing of the first patient in a Phase 1/2 trial evaluating rilvegostomig), additional $7.5 million in 2022 as a clinical milestone
(triggered by the dosing of the first patient in its ARTEMIDE Phase 2 trial evaluating rilvegostomig) and an additional $10 million in
2023 as a clinical milestone (triggered by the dosing of the first patient in its ARTEMIDE-Bil01&#160;Phase 3 trial evaluating rilvegostomig).
If additional products are developed, additional milestones and royalties would be due to us for each product. We retained all other rights
to our entire pipeline of programs as monotherapies and in combination with other products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Subject to termination rights for material breach, bankruptcy or by us for patent
challenge by AstraZeneca, the term of the license agreement continues until the expiration of the last Royalty Term in the Territory,
each as defined in the license agreement. In addition, AstraZeneca may terminate the agreement for convenience upon prior written notice.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Bayer Collaboration</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On August 5, 2013, we entered into a collaboration with Bayer, or the Bayer Collaboration,
for the research, development, and commercialization of antibody-based therapeutics against two novel Compugen-discovered immune checkpoint
regulators, CGEN 15001T/ILDR2 and CGEN 15022.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">59</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">Under the terms of the Bayer Collaboration, we received an upfront payment of $10
million, and, following the return of the CGEN 15022 program to us, we were eligible to receive an aggregate of over $250 million in potential
milestone payments for bapotulimab&#160;(formerly known as BAY1905254) (an antibody against CGEN 15001T/ILDR2), not including aggregate
milestone payments of approximately $23 million received to date. Additionally, we were eligible to receive mid-to-high single digit royalties
on global net sales of any approved products under the collaboration. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In 2014, we achieved the first and second preclinical milestones and in 2015 we achieved
the third preclinical milestone with respect to bapotulimab. Pursuant to the terms of the Bayer Collaboration, this program was transferred
to Bayer&#8217;s full control for further preclinical and clinical development activities, and worldwide commercialization under milestone
and royalty bearing licenses from us. In September 2018, the program achieved the fourth milestone, following the dosing of the first
patient in the Phase 1 clinical trial of bapotulimab.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On November 29, 2022, Bayer notified us that it has resolved to terminate, effective
as of February 27, 2023, our 2013 research and development collaboration and license agreement.&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In accordance with the terms of said agreement, we obtained from Bayer such rights
necessary to allow us to continue the development and commercialization of bapotulimab, should we choose to do so.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Bristol Myers Squibb Collaboration</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On October 10, 2018, we entered into the MCTC with Bristol Myers Squibb to evaluate
the safety and tolerability of COM701 in combination with Bristol Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab),
in patients with advanced solid tumors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The collaboration was also designed to address potential future combinations, including
trials to investigate combined inhibition of checkpoint mechanisms. The parties agreed that Bristol Myers Squibb and Compugen will each
supply the other company with its own compound for the other party&#8217;s study, and otherwise each party will be responsible for all
costs associated with the study that it is conducting. Any combination trial performed under this agreement is referred to as a Combined
Therapy Study.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the terms of MCTC, as amended from time to time, we conducted triple combination
clinical trials to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo&#174; (nivolumab), and
Bristol Myers Squibb&#8217;s investigational antibody targeting TIGIT known as BMS-986207, in patients with advanced solid tumors, and
dual combination clinical trials to evaluate the dual combination of COM701 and Opdivo&#174; in patients with advanced solid tumors. In
all these clinical trials we were responsible for and sponsored all the clinical trials and Bristol Myers Squibb provided us with Opdivo&#174;
and BMS-986207 at no cost to us.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The MCTC provided Bristol Myers Squibb a right to negotiate a license for commercialization
and further provided Bristol Myers Squibb with certain exclusivity rights.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In conjunction with the signing of the MCTC in October 2018, Bristol Myers Squibb
made a $12&#160;million investment in us and in conjunction with the signing one of the amendments to the MCTC in November 2021, Bristol
Myers Squibb made additional $20 million investment in us. In both investments, the share price paid by Bristol Myers Squibb represented
a 33% premium over the closing price of our ordinary shares on the last trading day immediately prior to the execution of the applicable
securities purchase agreement. In these two investments, we issued to Bristol Myers Squibb 4,757,058 ordinary shares aggregately.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On August 3, 2022, in an effort to adapt to challenging market conditions, we took
a strategic decision to focus on prioritized indications and to wind down our broad Phase 1 cohort expansion program and therefore entered
into a letter agreement with Bristol Myers Squibb pursuant to which the MCTC between the parties was terminated as of such date and all
ongoing clinical trials at the time of the termination entered into a winding down process. Please see &#8220;Item 5. Operating and Financial
Review and Prospects Finance - B. Liquidity and Capital Resources.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Competition</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The biotechnology and pharmaceutical industries are highly competitive and characterized
by the rapid evolution of new technologies and the adoption of new therapies. Additionally, the oncology therapeutic space, and in particular
the immuno-oncology or cancer immunotherapy subsector, represents the therapeutic area with what we believe to be one of the highest industry
focus and investment. In addition, in recent years, computational approaches and systems are being integrated into multiple life science
aspects, including the formation of new companies focusing on computational drug target discovery. Our competitors include biotechnology
and pharmaceutical companies both small and large, the research and discovery groups within pharmaceutical companies, computational discovery
and development companies, academic and research institutions, newly founded companies and governmental and other publicly funded agencies.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">60</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">Any product candidates that we successfully develop will compete with currently approved
therapies and new therapies that may become available in the future. We face, and expect to continue to face, ongoing competition from
entities that discover novel targets and develop novel products, and that have therapeutic product candidates or products that address
the same drug targets or act by similar, or possibly identical, mechanism of action (MOA) as well as by different mechanisms but address
the same drug target or patient population or unmet clinical need. Our potential competitors are also comprised of companies that discover
and develop monoclonal antibody therapies and/or therapeutic proteins to novel targets, and/or other modalities, including cell therapies
for oncology diseases. Specifically, in the field of immune checkpoints for cancer immunotherapy, there are several leading pharmaceutical
and biotechnology companies as well as smaller biotechnology companies and academic institutions that are developing cancer immunotherapies
to enhance immune response towards tumors, some of which may be based on the same targets we pursue. For example, there are a significant
number of anti-TIGIT antibodies that are currently in advanced Phase 3 clinical studies, such as tiragolumab by Roche, vibostolumab by
Merck, rilvegostomig by AstraZeneca, ociperlimab by Beigene, domvanalimab by Gilead/Arcus, and others at earlier clinical stages of development.
There are a number of anti-PVRIG antibodies in Phase 1 clinical development, for example, GSK4381562 (formerly SRF813) by GSK, SHR-2002,
a PVRIG/TIGIT bi specific by Hengrui, SIM-0348, a PVRIG/TIGIT bi specific by Simcere Pharmaceutical, PM-1009, a PVRIG/TIGIT bi specific
by Biotheus and NM1F&#160;by Hefei TG ImmunoPharma. In the IL-18 pathway field, Simcha therapeutics is leading with its ST-067, a mutated
IL-18 fusion protein at Ph 1/2. There are three IL-18 related CAR-T therapies CMN-008 by Co-Immune, huCART19-IL18 by Univ of Pennsylvania
and EU-307 by Eutilex that have entered Phase 1 studies. BrightPeak Therapeutics, Sonnet Biotherapeutics, and Xencor are examples of companies
who are developing recombinant IL-18 and are in the preclinical phase or IND enabling stages. Antibodies for IL-18BP are also being developed
in Lassen Therapeutics (LASN-500) in the discovery stage.If advanced or approved, such cancer immunotherapy products would compete with
our product candidates for commercialization or approved products in the respective fields. If in development stage, such cancer immunotherapy
products would compete with our product candidates for entering into strategic partnerships with pharmaceutical and biotechnology companies
which form the basis of our business model. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our discovery program depends, in large part, on our computational discovery capabilities
in integration with our immune-oncology experimental capabilities and drug development capabilities as well as our proprietary data to
make inventions and establish intellectual property rights in our drug target candidates and product candidates. There are additional
companies exploring computational approaches and systems for drug target discovery and number of other means by which such inventions
and intellectual property can be generated. We believe that our computational capabilities, and specifically our IO predictive computational
discovery capabilities, provide us with a competitive advantage in predicting new protein functions and linking proteins to specific mechanisms
and diseases, and as a result, predicting new immune-oncology drug targets. We believe that this advantage is made possible by building
an integrated immune-oncology platform for predictive discovery based on the integration of scientific understanding and predictive models
as well as our unique team of multidisciplinary research scientists, who have vast experience in computational discovery, including developing
and handling advance data science approaches, and who over time discovered three drug targets that entered clinical studies and have generated&#160;
peer reviewed publications&#160; in scientific journals.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Many of our potential competitors, either alone or with their collaborative partners,
have substantially greater financial, technical and human resources than we do and significantly greater experience in computational approaches
and the discovery, development and manufacturing of therapeutics, obtaining FDA and other regulatory approvals, and commercialization
of products. Accordingly, our competitors may be more successful than we may be in identifying new drug targets and product candidates,
protecting them with patent applications, developing them, accelerating their development process, obtaining FDA and other regulatory&#160;approvals
and achieving widespread market acceptance. We anticipate that we will face intense and increasing competition as advanced technologies
or new therapy modalities become available.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">61</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold"> <br/> </div>

<div style="line-height: 1.25; font-weight: bold">Intellectual Property Rights </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our intellectual property assets are our principal assets. These assets include the
intellectual property rights subsisting in our proprietary know-how and trade secrets underlying our predictive biology capabilities and
discovery capabilities, our patents and patent applications, particularly with respect to our discovered proteins, therapeutic and diagnostic
product candidates. We seek to vigorously protect our rights and interests in our intellectual property. We expect that our commercial
success will depend on, among other things, our ability to obtain commercially valuable patents, especially for our therapeutic and diagnostic
product candidates, maintain the confidentiality of our proprietary know-how and trade secrets, and otherwise protect our intellectual
property. We design our patent strategy to fit the business competitive landscape and continual legislative changes. In addition, we periodically
analyze and examine our patent portfolio to align it with our pipeline strategy and business needs. We seek patent protection for certain
promising inventions that relate to our therapeutic and diagnostic product candidates. As of February 1, 2024, we had a total of 61 issued
and allowed patents, of which 17 are U.S. patents, 8 are European patents and additional 36 patents in other territories. Our issued and
allowed patents expire between 2028 and 2038. As of February 1, 2024, we had over 138 pending patent applications that have been filed
in the United States, Europe and in other territories as well as pending patent applications that have been filed under the Patent Cooperation
Treaty for which we have not yet designated the countries of filing. The patents issued in the U.S. and Europe for COM701 and COM902 were
issued between 2017 and 2023 and should expire no earlier than 2036. These patents include issued claims directed to, among others, the
composition of these product candidates and/or methods of using the same to treat cancer by activating T cells and/or NK cells, and/or
combinations of our product candidates with other checkpoint inhibitors. Our general policy is to continue patent filings and maintenance
for our therapeutic and diagnostic product candidates, only with respect to candidates or programs that are being actively pursued internally
or with partners, or that we believe to have future commercial value. We routinely abandon patent applications and may choose to abandon
maintenance of patents supporting candidates or programs that do not meet these criteria.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We also seek protection for our proprietary know-how and trade secrets that are not
protectable or protected by patents, by way of safeguarding them against unauthorized disclosure. This is done through the extensive use
of confidentiality agreements and assignment agreements with our employees, consultants and third parties as well as by technological
means. We use license agreements both to access third-party technologies and to grant licenses to third parties to exploit our intellectual
property rights.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In October 2020, two parties, one being GSK (following an assignment), filed oppositions
in the European Patent Office, or EPO, requesting revocation of our granted European patent relating to anti-PVRIG antibodies, that expires
in 2036. Following different proceedings, on July 11, 2023, in an oral proceedings hearing, the opposition division of the&#160;European
Patent Office ruled in favor of maintaining the broad claims in the patent as granted to us.&#160;The opponents can still appeal this
decision.&#160;In January 2023, another opposition was filed by GSK, requesting revocation of our granted European patent relating to
method of screening for inhibitors of the binding association of PVRIG polypeptide with PVRL2 and we already responded to this opposition.
In May 2023, two other oppositions were filed by GSK and another party requesting revocation of our granted European patent relating to
anti PVRIG antibodies competing with COM701, and we already provided our response.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Manufacturing </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We currently rely on contract manufacturers or our collaborative partners to produce
and control materials, drug substances and drug products required for the research and development activities. We do not currently own
or operate manufacturing facilities for the production of clinical or commercial quantities of our therapeutic drug candidates. We do
not have, and we do not currently plan to acquire or develop the facilities or capabilities to manufacture bulk drug substance or filled
drug product for use in human clinical trials. We rely on CMOs, advisors and third-party contractors to generate formulations and produce
small scale and larger scale amounts of GLP, cGMP clinical and commercial drug substance and the drug product required for our clinical
trials for the foreseeable future. We also contract with CMOs and third-party contractors for the labeling, packaging, storage and distribution
of investigational drug products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We entered into agreements with certain CMOs for the manufacturing and respective
analytics of COM701, COM902 and COM503. Our manufacturing strategy is currently structured to support the current clinical development
of COM701 and COM902 and to support the current preclinical development and future clinical development of COM503. Although we believe
the general manufacturing strategy developed for the United States will be applicable in other geographies, specific strategies for other
geographies will be developed as part of our clinical and commercial plans for such other geographies. See &#8220;Item 3. Key Information
- D. Risk Factors - Risks Related to Our Dependence on Third Parties - We rely and expect to continue to rely completely on third parties
to manufacture and supply our preclinical and clinical drug supplies. Our business could be harmed if those third parties fail to provide
us with sufficient quantities of drug product or fail to do so at acceptable quality and quantity levels, prices or timelines.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">62</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold"> <br/> </div>

<div style="line-height: 1.25; font-weight: bold">Government Regulation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Regulation of Therapeutic Product Candidates </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the United States, the FDA regulates pharmaceutical and biologic products under
the Federal Food, Drug, and Cosmetic Act, or FDCA, the&#160;Public Health Service Act, other statutes and regulations and implementing
regulations. We anticipate that our product candidates will be regulated as biologics. The process of obtaining regulatory approvals and
the subsequent compliance with applicable federal, state and local statutes and regulations require the expenditure of substantial time
and financial resources. Failure to comply with the applicable United States requirements at any time during the product development process,
approval process or after approval, may subject an applicant to administrative or judicial sanctions. The process required by the FDA
before a biologic may be marketed in the United States generally involves the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z64378cee73f84db4a199bd32fa79821a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>completion of preclinical laboratory tests and animal studies in compliance with the FDA&#8217;s GLP or other applicable regulations;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3bdc9d8669fa42cc8eaff52528810c58" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>submission to the FDA of an IND, which must become effective before human clinical trials may begin; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zed25e12faa584d3f8f7753b2c1b1b1dc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>performance of adequate and well-controlled human clinical trials in accordance with GCPs to establish the safety and efficacy of
        the product for its intended use; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc24f2ed297a545478276208d28a62bed" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>submission of annual reports to regulatory authorities; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8b35bb44c17a46efa668cbecb75d067b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>submission to the FDA of a biologics license application, or BLA; </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z87902261e0c643dda5d7ccdd84850738" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug or biologic is produced
        to assess compliance with current Good Manufacturing Practice, or cGMP, to assure that the facilities, methods and controls are adequate
        to preserve the product&#8217;s identity, strength, quality and purity; and </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbfc550811a95454eaa76434d6d921e6f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>FDA review and approval of the BLA. </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Once a pharmaceutical candidate is identified for development it enters the preclinical
testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies.
An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, among other
information, to the FDA as part of the IND. The sponsor will also include a clinical protocol detailing, among other things, the objectives
of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated,
if the first phase lends itself to an efficacy evaluation. The IND automatically becomes effective 30 days after receipt by the FDA, unless
the FDA, within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must
resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before
or during a clinical trial due to, among other things, safety concerns or non-compliance with applicable requirements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">All clinical trials must be conducted under the supervision of one or more qualified
investigators in accordance with GCPs. An IRB at each institution participating in the clinical trial must review and approve the study
plan for any clinical trial before it commences at that institution. An IRB considers, among other things, whether the risks to individuals
participating in the trials are minimized and are reasonable in relation to anticipated benefits. The IRB also reviews the information
regarding the trial, participant recruiting materials and the informed consent form that must be provided to each trial subject or his
or her legal representative before participating in the trial. In addition, the IRB will monitor the trial until completed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Each new clinical protocol must be submitted to the FDA, and to the IRBs. Protocols
detail, among other things, the objectives of the study, dosing procedures, subject selection and exclusion criteria, and the parameters
to be used to monitor subject safety and determine efficacy.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">63</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">Human clinical trials are typically conducted in three sequential phases that may
overlap or be combined:</div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z10874f4fa61e4c1490e3a3471352854f" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 9pt">&#160;&#8226;</td>
    <td style="text-align: right; vertical-align: top; width: 9pt">
        <div style="text-align: left; line-height: 1.25"><br/> </div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Phase 1: </span>The product candidate is initially
        introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In
        the case of<span style="font-style: italic">&#160;</span>some products, usually for severe or life-threatening diseases, especially when
        the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing may be conducted in patients.</div>
        </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z71a1fb61f25b4daf9ed4aca877e3ef36" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 9pt">&#160;&#8226;</td>
    <td style="text-align: right; vertical-align: top; width: 9pt"><br/> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Phase 2: </span>Involves studies in a limited patient
        population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific<span style="font-style: italic">&#160;</span>targeted
        diseases and to determine dosage tolerance and optimal dosage.</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zdeb5728276d3465698e5c62ec509839b" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 9pt">&#160;&#8226;</td>
    <td style="text-align: right; vertical-align: top; width: 9pt">
        <div style="text-align: left; line-height: 1.25"><br/> </div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Phase 3: </span>Involves studies undertaken to further
        evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites.<span style="font-style: italic">&#160;</span>These
        studies are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for product labeling and
        approval.</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Progress reports detailing the results of the clinical trials must be submitted at
least annually to the FDA and safety reports for serious and unexpected adverse events must be submitted to the FDA and the investigators
more frequently. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding
that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval
of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the applicable regulations or IRB
requirements or if the drug has been associated with unexpected serious harm to patients.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Concurrent with clinical trials, companies usually complete additional nonclinical
studies and must also finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements.
The manufacturing process must be capable of consistently producing quality batches of the product within required specifications and,
among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the product. Additionally,
appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product does not undergo
unacceptable deterioration over its shelf life.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic">United States Review and Approval Processes</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The results of product development, nonclinical studies and clinical trials, along
with descriptions of the manufacturing process, analytical tests, proposed labeling, and other relevant information are submitted to the
FDA as part of a BLA requesting approval to market the product for one or more indications. The FDA initially reviews all BLAs submitted
to ensure that they are sufficiently complete for substantive review before it accepts them for filing. The FDA may request additional
information rather than accept a BLA for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review.
The FDA may refer the BLA to an advisory committee for review, evaluation and recommendation as to whether the application should be approved
and under what conditions. The FDA is not bound by the recommendation of an advisory committee.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The review process is lengthy, and the FDA may issue a complete response letter rather
than approve a BLA if the applicable regulatory criteria are not satisfied or may require the submission of additional clinical or other
data and information. Even if such data and information are submitted, the FDA may ultimately decide that the BLA does not satisfy the
criteria for approval.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If a product receives regulatory approval, the approval will be limited to specific
diseases and dosages or the approved indications for use may otherwise be limited, which could restrict the commercial value of the product.
In addition, the FDA may require a company to conduct post-approval testing and clinical trials, to further assess a product&#8217;s safety
and effectiveness after BLA approval and may require testing and surveillance programs to monitor the safety of approved products which
have been commercialized including Risk Evaluation and Mitigation Strategy (REMS) programs to ensure that the benefits of a product outweigh
its risks.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic">Post-approval Requirements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Approved biologics are subject to extensive and continuing regulation by the FDA,
including, among other things, cGMP compliance, record-keeping requirements, reporting of adverse experiences, providing the FDA with
updated safety and efficacy information, and complying with FDA promotion and advertising requirements. After an approval is granted,
the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if serious problems occur after the
product reaches the market. Biologics may be promoted for use only for the approved indication or indications and in accordance with the
provisions of the approved label. The FDA and other federal and state agencies actively enforce the laws and regulations prohibiting the
promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to criminal and civil
penalties.<span style="font-style: italic">&#160;</span>However, physicians may, in their independent medical judgment, prescribe legally
available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments, but the FDA
does restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">64</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic"> <br/> </div>

<div style="line-height: 1.25; font-style: italic">Other Healthcare Laws </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our current and future business operations, including, among other things, our clinical
research activities and our business and financial arrangements and relationships with healthcare providers, physicians and other parties
through which we may market, sell and distribute our products, once approved, may be subject to extensive U.S. federal, U.S. state and
foreign healthcare fraud and abuse, transparency, and data privacy and security laws. For example, U.S. federal civil and criminal laws
and regulations prohibit, among other things: knowingly and willfully soliciting, receiving, offering or providing remuneration, directly
or indirectly, to induce or reward either the referral of an individual, or the furnishing, recommending or arranging for a good or service,
for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs; knowingly presenting or
causing to be presented, a false or fraudulent claim for payment by a federal healthcare program; and knowingly and willfully executing,
or attempting to execute, a scheme to defraud any healthcare benefit program (including a private payor), or knowingly and willfully falsifying,
concealing or covering up a material fact or making any materially false statement in connection with the delivery of, or payment for,
healthcare benefits, items or services. Many U.S. states and foreign countries have analogous prohibitions that may be broader in scope
and apply regardless of payor. In addition, we may be subject to U.S. federal, U.S. state and foreign laws that require us to report information
related to certain payments and other transfers of value to certain health care professionals, as well as ownership and investment interests
in our company held by those health care professionals and their immediate family members, and data security and privacy laws that restrict
our practices with respect to the use and storage of certain data.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Efforts to ensure that our current and future business arrangements with third parties
comply with applicable healthcare laws and regulations may involve substantial costs. If we are found to be in violation of any of these
laws, we could be subject to significant civil, criminal and administrative penalties, including damages, fines, disgorgement, imprisonment,
exclusion from participation in government healthcare programs, additional integrity oversight and reporting obligations, contractual
damages, reputational harm and the curtailment or restructuring of our operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic">Healthcare Policy and Reform</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our ability to commercialize our future therapeutic product candidates successfully,
alone or with collaborators, will depend in part on the extent to which coverage and reimbursement for these product candidates will be
available from government health programs, such as Medicare and Medicaid in the United States, private health insurers and other third-party
payors. At present, significant changes in healthcare policy, in particular the continuing efforts of the U.S. and other governments,
insurance companies, managed care organizations and other payors to contain or reduce health care costs are being discussed, considered
and proposed.&#160;Drug prices in particular are under significant scrutiny and continue to be subject to intense political and societal
pressures, which we anticipate will continue and escalate on a global basis.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For example, in the United States, there have been several initiatives implemented
to achieve these aims. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation
Act, collectively, the ACA, substantially changed the way healthcare is financed by both governmental and private insurers and significantly
affects the pharmaceutical industry. With regard to biopharmaceutical products, the ACA has, among other things, expanded and increased
industry rebates for products covered under Medicaid programs and changed the coverage requirements under the Medicare Part D program.
There have been congressional, judicial, and executive branch challenges to the ACA, which has resulted in delays in the implementation
of, and action taken to repeal or replace, certain aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed
a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual
mandate&#8221; was repealed by Congress. In addition, there have been a number of health reform initiatives by the Biden administration
that have impacted the ACA. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or the IRA, into law, which
among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year
2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering
the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the ACA will
be subject to judicial or congressional challenges in the future. It is unclear how other such challenges and any additional healthcare
reform measures of the Biden administration will impact the ACA and the pharmaceutical industry.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">65</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">In addition, other legislative changes have been proposed and adopted since the ACA
was enacted. The Budget Control Act of 2011, triggered automatic reduction to several government programs, including reductions to Medicare
payments to providers, which went into effect in April 2013 and will remain in effect until 2032, unless additional congressional action
is taken.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Additionally, there has been increasing legislative and enforcement interest in the
United States with respect to drug pricing practices. Specifically, there have been several recent U.S. congressional inquiries, presidential
executive orders and legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription
drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement
methodologies for drugs. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition
in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on
September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform
and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, the IRA,
among other things, (i) directs the Secretary of HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics
covered under Medicare Part B and Medicare Part D, and subjects drug manufacturers to civil monetary penalties and a potential excise
tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) imposes
rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement
many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions take effect progressively
starting in fiscal year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations,
although the Medicare drug price negotiation program is currently subject to legal challenges. It is currently unclear how the IRA will
be implemented but is likely to have a significant impact on the pharmaceutical industry.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We cannot predict what healthcare reform initiatives may be adopted in the future.
However, we anticipate that Congress, state legislatures, and third-party payors may continue to review and assess alternative healthcare
delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations effecting additional
fundamental changes in the healthcare delivery system. We also expect ongoing legislative and regulatory initiatives to increase pressure
on drug pricing.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Coverage and Reimbursement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Market acceptance of products is dependent on the extent to which coverage and reimbursement
is available from third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any products for which
we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives
are already available. Even if we obtain coverage for a given product, the associated reimbursement rate may not be adequate to cover
our costs, including research, development, intellectual property, manufacture, sale and distribution expenses, or may require co-payments
that patients find unacceptably high. Coverage and reimbursement policies for products can differ significantly from payor to payor as
there is no uniform policy of coverage and reimbursement for products among third party payors in the United States. Additionally, we,
or our collaborators, may develop companion diagnostic tests for use with our product candidates, once approved. We, or our collaborators,
will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for
our product candidates, once approved.&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Non-U.S. Regulations</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to regulations in the United States, biologics are subject to a variety
of foreign laws and regulations governing clinical trials and commercial sales and distribution before they may be sold outside the United
States. Whether or not we obtain FDA approval for a product, we must obtain the necessary approvals from comparable regulatory authorities
of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies
from country to country and the time may be longer or shorter than that required for FDA approval. In some countries, we will also have
to get pricing approval.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">66</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Environmental Regulation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Some of our research and development activities involve the controlled use of biologic
and chemical materials, a small amount of which could be considered to be hazardous. We are subject to laws and regulations in the U.S.,
European Union and Israel governing the use, storage, handling and disposal of all these materials and resulting waste products. We store
relatively small amounts of biologic and chemical materials. To our knowledge, we substantially comply with these laws and regulations.
However, the risk of accidental contamination or injury from these materials cannot be entirely eliminated. In the event of an accident,
we could be held liable for any resulting damages, and any liability could exceed our resources.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Regulation of Use of Human Tissue</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We need to access and use various human or non-human tissue samples for the purpose
of research, development and or validation of some of our product candidates. Our access and use of these samples are subject to government
regulation, in the United States, Israel and elsewhere and may become subject to further regulation. The use of clinical data associated
with human tissue samples is also heavily regulated in the United States, Israel and elsewhere. United States and other governmental agencies
may also impose restrictions on the use of data derived from human or other tissue samples.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Regulations Concerning the Use of Animals in Research</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We also are subject to various laws and regulations regarding laboratory practices
and the use of animals in our research. In the United States, the FDA regulations describe good laboratory practices, or GLPs, for various
types of nonclinical laboratory studies that support or are intended to support applications for research or marketing permits for products
regulated by the FDA, including INDs. Nonclinical animal studies conducted by us or third parties on our behalf may be subject to the
U.S. Animal Welfare Act, the U.S. Public Health Service Policy on Humane Animal Care and Use, U.S. Department of Agriculture regulations
for certain animal species or applicable laws and regulations of other countries where we or third parties on our behalf conduct these
studies. In Israel, the Council on Animal Experimentation has regulatory and enforcement powers, including the ability to suspend, change
or withdraw approvals, among other powers. To our knowledge, we and the third-party service providers we work with, as applicable, substantially
comply with these regulatory requirements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Regulation of Products Developed with the Support of Research and
Development Grants</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For a discussion of regulations governing products developed with research and development
grants from the Government of Israel, see &#8220;Item 5. Operating and Financial Review and Prospects - C. - Research and Development,
Patents and Licenses - The Israel Innovation Authority.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. ORGANIZATIONAL STRUCTURE</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We were incorporated under the laws of the State of Israel on February 10, 1993, as
Compugen Ltd., which is both our legal and commercial name. Compugen USA, Inc., our wholly owned subsidiary, was incorporated in Delaware
in March 1997 and is qualified to do business in California.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">D. PROPERTY, PLANTS AND EQUIPMENT</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In December 2015, we moved to new facilities in Holon, Israel where we leased an aggregate
of approximately 35,250 square feet of office, biology laboratory facilities and warehouse. Following the exercise of our first option,
we lease 30,140 square feet under that lease that expires on March 14, 2026 (with an option to extend the lease for additional five-year
period). In addition, Compugen USA, Inc. currently leases approximately 400 square feet of office space in San Francisco, California,
under a lease that expires on October 31, 2025.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">To our knowledge, there are no environmental issues that affect our use of the properties
that we lease.</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25"><span style="font-weight: bold">ITEM 4A.</span> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <span style="font-weight: bold">UNRESOLVED
STAFF COMMENTS</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">None</div> </div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">67</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;&#160; </div>

<div style="line-height: 1.25"><span style="font-weight: bold"><span id="ITEM5."><!--Anchor--></span>ITEM 5.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight: bold">OPERATING
AND FINANCIAL REVIEW AND PROSPECTS</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">The following discussion of our operating and financial
review and prospects should be read in conjunction with our consolidated financial statements and related notes, prepared in accordance
with U.S. GAAP as of December 31, 2023, and with any other financial data included elsewhere in this Annual Report</span>.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Background</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are a clinical-stage therapeutic discovery and development company utilizing our
broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop
therapeutics in the field of cancer immunotherapy. Our innovative immuno-oncology pipeline consists of three clinical stage programs,
COM701, COM902 and rilvegostomig, targeting immune checkpoints we discovered computationally. Two programs that we are pursuing internally,
COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody, are in
Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of dual (PVRIG/PD-1,
PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. Based on the data from the Phase 1 trials and as part of our focus on two specific
tumor types for the further clinical evaluation of COM701 and COM902, we initiated in 2023 two clinical trials evaluating the triple combination
treatment of COM701, COM902 and pembrolizumab, one in metastatic microsatellite stable colorectal cancer patients and one in platinum
resistant ovarian cancer patients. Rilvegostomig,&#160;a novel anti PD-1/TIGIT bispecific antibody with a TIGIT-specific component that
is derived from our COM902 antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between us and AstraZeneca
and is being evaluated in multiple clinical trials, including in Phase 3 clinical trial in patients with biliary tract cancer who will
be randomized to receive rilvegostomig or placebo with investigator choice chemotherapy as adjuvant treatment after resection with curative
intent. Our therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of
immune resistance. Our most advanced early-stage program, COM503, is in IND enabling studies and was licensed to Gilead in December 2023.
COM503 is a potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, thereby
freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Our business model is to selectively enter into collaborations
for our novel targets and drug product candidates at various stages of research and development under various revenue-sharing arrangements.
Integrating cutting edge computational capabilities with ground-breaking immuno-oncology research and drug development expertise is our
differentiator and has enabled the advancement of drug targets from computer prediction through successful preclinical studies to the
clinic and as a result, we believe that we are uniquely positioned to discover and develop potential new, first-in-class treatment options
for cancer patients.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">A. OPERATING RESULTS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Overview</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Since our inception, we have incurred significant losses and, as of December 31, 2023,
we had an accumulated deficit of $474.5 million. We expect to continue to incur net losses for the foreseeable future.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">While our predictive computational discovery capabilities have potentially broad applicability
and is not limited to a certain indication or therapeutic field, we focus our predictive computational discovery efforts on the discovery
of novel drug targets and new biological pathways towards the development of new therapeutic antibodies for cancer, a significant unmet
medical need for cancer patients. We have discovered new targets through computational prediction with three different product candidates
currently being clinically evaluated, supporting the power and validity of our computational capabilities.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are currently pursuing clinical development of COM701 and COM902 independently
and have two partnerships in place, one with AstraZeneca, who is developing rilvegostomig,&#160;a novel anti PD-1/TIGIT bispecific antibody
with a TIGIT-specific component that is derived from our COM902 antibody and is in Phase 3 clinical trials, and the second, with Gilead,&#160;
pursuant to the License Agreement for our preclinical COM503 program, which is expected to receive IND clearance in 2024.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We incurred net losses of approximately $34.2 million in 2021, approximately $33.7
million in 2022 and approximately $18.8 million in 2023. We expect to continue to incur net losses for the foreseeable future due in part
to the costs and expenses associated with our research, discovery and development activities. While we currently have two collaborations,
our business model primarily involves establishing collaborations for our novel targets and therapeutic product candidates at various
stages of research and development providing us with potential milestone payments and royalties on product sales or other forms of revenue
sharing payments.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">68</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">Our research and development expenses are expected to continue to be our major operating
expense in 2024, expected to account for approximately 80% of our expected total 2024 operating expenses. Our research and development
expenditures have always comprised a significant portion of our total cash expenditures, and they are expected to remain in 2024 at a
similar level compared to 2023.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We believe that we have sufficient cash and cash equivalents, short-term bank deposits
and investment in marketable securities in order to sustain our operations into 2027, based on our current plans and our expectation that
we will receive IND clearance for COM503 in the second half of 2024, resulting in the receipt from Gilead of the respective milestone
payment without considering the possible receipt of any additional funds, such as proceeds from existing or additional licensing and/or
collaborative agreements, or from financings.&#160;However, if our plans change, our cash balances may only be sufficient for a shorter
period of time. For a detailed description of our cash and cash equivalents position, see &#8220;Item 5. Operating and Financial Review
and Prospects - B. Liquidity and Capital Resources.&#8221;</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Years Ended December 31, 2023 and 2022</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Revenues.</span> Revenues for the year ended December
31, 2023, were approximately $33.5 million, compared with $7.5 million in the comparable period of 2022. The revenues for 2023 include
the portion of the upfront payment from the license agreement with Gilead allocated to the license and the clinical milestone from the
license agreement with AstraZeneca in the amount of $10 million, while the revenues for 2022 reflect the previous clinical milestones
from the license agreement with AstraZeneca.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Cost of Revenues. </span>During the year ended December
31, 2023, the Company had approximately $2.0 million in cost of revenues compared with approximately $1.0 million cost of revenues in
the comparable period of 2022. Cost of revenues for the years ended December 31, 2023 and 2022, represent milestone and royalty payments
in connection with our revenues.</div> <br/>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Research and Development Expenses. </span>Research
and development expenses during 2023 increased by 12% and totaled approximately $34.5 million compared with approximately $30.6 million
in the comparable period of 2022. The increase is mainly due to lower amortization of the deferred participation in R&amp;D expenses following
the termination of the agreement with Bristol Myers Squibb offset by decrease in headcount related expenses. Research and development
expenses, as a percentage of total operating expenses, were 78% in 2023 compared to 73% in 2022.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Marketing and Business Development Expenses</span>.
Marketing and business development expenses decreased by 74% and totaled in approximately $0.2 million in 2023 compared with approximately
$0.9 million in the comparable period of 2022. The decrease is mainly due to headcount reduction. Marketing and business development expenses,
as a percentage of total operating expenses, were 1% in 2023 compared to 2% in 2022.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">General and Administrative Expenses. </span>General
and administrative expenses during 2023 decreased by 6% and totaled approximately $9.7 million in 2023 compared with approximately $10.3
million in the comparable period of 2022. The decrease during 2023 was attributed mostly to decrease in D&amp;O insurance premium costs
and in non-cash stock option related expenses. General and administrative expenses, as a percentage of total operating expenses, were
22% in 2023 compared to 25% in 2022.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Financial and Other Income, Net. </span>Financial
and other income increased by 85% to approximately $3.2 million in 2023 up from approximately $1.7 million in the comparable period of
2022. The increase is attributed mainly to increased interest income due to higher interest rates in the market offset by a lower level
of cash and deposits balances.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Taxes on Income. </span>Taxes on income were approximately
$9.0 in 2023 compared with $0.1 million in 2022. The taxes on income in 2022 represent state income taxes of our U.S. subsidiary, and
in 2023, taxes withheld by Gilead on the upfront payment, offset by a negligible U.S. state income tax benefit.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Years Ended December 31, 2022 and 2021</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Revenues.</span> Revenues for the year ended December
31, 2022, were $7.5 million, compared with $6.0 million in the comparable period of 2021. The revenues for 2022 and 2021 reflect clinical
milestones from the license agreement with AstraZeneca.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Cost of Revenues. </span>During the year ended December
31, 2022, the Company had approximately $1.0 million in cost of revenues compared with approximately $0.7 million cost of revenues in
the comparable period of 2021. Cost of revenues for the years ended December 31, 2022 and 2021, represent milestone and royalty payments
in connection with our revenues.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">69</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic"> <br/> </span></div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Research and Development Expenses. </span>Research
and development expenses during 2022 increased by 7% and totaled approximately $30.6 million compared with approximately $28.7 million
in the comparable period of 2021. The increase is mainly due to higher expenses associated with our preclinical and CMC activities, offset
by higher Bristol Myers Squibb participation in R&amp;D expenses. Research and development expenses, as a percentage of total operating
expenses, were 73% in 2022 compared to 71% in 2021.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Marketing and Business Development Expenses</span>.
Marketing and business development expenses increased by 11% and totaled approximately $0.9 million in 2022 compared with approximately
$0.8 million in the comparable period of 2021. Marketing and business development expenses, as a percentage of total operating expenses,
were 2% in 2022 and 2021.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">General and Administrative Expenses. </span>General
and administrative expenses during 2022 decreased by 5% and totaled approximately $10.3 million in 2022 compared with approximately $10.9
million in the comparable period of 2021. The decrease during 2022 was attributed mostly to decrease in D&amp;O insurance premium costs
(that effected our industry) and in non-cash stock option related expenses. General and administrative expenses, as a percentage of total
operating expenses, were 25% in 2022 compared to 27% in 2021.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Financial and Other Income, Net. </span>Financial
and other income increased to approximately $1.7 million in 2022 from approximately $0.9 million in the comparable period of 2021. The
increase is attributed mainly to increased interest income due to higher interest rates in the market offset by lower level of cash and
deposits balances.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Taxes on Income. </span>Taxes on income were approximately
$0.1 million in 2022. The taxes on income represent state income taxes of our U.S. subsidiary.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Governmental Policies that Materially Affected
or Could Materially Affect Our Operations</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">Our income tax obligations consist of those of Compugen Ltd. in Israel and of Compugen
USA, Inc. in its taxing jurisdictions.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">The corporate tax rate in Israel was 23% in 2023, 2022 and 2021.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the future, if and when we generate taxable income, our effective tax rate may
be influenced by, among others: (a) the split of taxable income between the various tax jurisdictions; (b) the availability of tax loss
carry forwards and the extent to which valuation allowance has been recorded against deferred tax assets; (c) the portion of our income
which is entitled to tax benefits pursuant to the Investment Law; (d) the changes in the exchange rate of the dollar to the NIS and (e)
the Company&#8217;s election to submit its tax returns for 2014 and onwards on a dollar basis, which may not be accepted by the Israeli
Tax Authority. We may benefit from certain government programs and tax legislation, particularly as a result of the Benefiting Enterprise
status that resulted from our eligibility for tax benefits under the Investment Law. To be eligible for these benefits, we need to meet
certain conditions. Should we fail to meet such conditions, these benefits could be cancelled, and we might be required to refund the
amount of the benefits previously received, if any, in whole or in part, together with interest and linkage differences to the Israeli
CPI, or other monetary penalty. We also benefit from a Government of Israel program under which we received grants from the IIA. For more
information, please see &#8220;Item 5 Operating and Financial Review and Prospects - C. Research and Development, Patents and Licenses
- The Israel Innovation Authority.&#8221; There can be no assurance that these programs and tax legislation will continue in the future
or that the available benefits will not be reduced.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The termination or curtailment of these programs or the loss or reduction of benefits
under the Investment Law could have a material adverse effect on our business, financial condition and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">Currently we have one Benefiting Enterprise program under the Investment Law. The
tax benefits period with respect to this program has not yet begun as we have not yet generated any taxable income. These benefits should
result in income recognized by us being tax exempt or taxed at a lower rate for a specified period of time after we begin to report taxable
income and exhaust any net operating loss carry-forward. However, these benefits may not be applied to reduce the U.S. federal tax rate
for any income that our U.S. subsidiary may generate.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">70</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">In April 2005, substantive amendments to the Investment Law came into effect. Under
these amendments, eligible investment programs of the type in which we participated prior to the amendment were eligible to qualify for
substantially similar benefits as a &#8216;Benefiting Enterprise&#8217;, subject to meeting certain criteria. This replaced the previous
terminology of &#8216;Approved Enterprise&#8217;, which required pre-approval from the Investment Center of the Ministry of the Economy
of the State of Israel. As a result of these amendments, tax-exempt income generated from Benefiting Enterprises under the provisions
of the amended law will, if distributed upon liquidation or if paid to a shareholder for the purchase of his or her shares, be deemed
distributed as a dividend and will subject the Company to the applicable corporate tax that would otherwise have been payable on such
income. Therefore, a company may be required to record deferred tax liability with respect to such tax-exempt income, which would have
an adverse effect on its results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Additional amendments to the Investment Law became effective in January 2011, or the
2011 Amendment. Under the 2011 Amendment, income derived by &#8216;Preferred Companies&#8217; from &#8216;Preferred Enterprises&#8217;
(both as defined in the 2011 Amendment) would be subject to a uniform rate of corporate tax for an unlimited period as opposed to the
incentives prior to the 2011 Amendment that were limited to income from Approved or Benefiting Enterprises during their benefits period.
According to the 2011 Amendment, the uniform tax rate on such income, referred to as &#8216;Preferred Income&#8217;, would be 10% in areas
in Israel that are designated as Development Zone A and 15% elsewhere in Israel during 2011-2012, 7% and 12.5%, respectively, in 2013,
and 9% and 16%, respectively, thereafter. Income derived by a Preferred Company from a &#8216;Special Preferred Enterprise&#8217; (as
defined in the Investment Law) would enjoy further reduced tax rates for a period of ten years of 5% in Development Zone A and 8% elsewhere.
As of January 1, 2014, dividends distributed from Preferred Income would subject the recipient to a 20% tax (or lower, if so provided
under an applicable tax treaty, subject to the receipt in advance of a valid tax certificate from the Israel Tax Authority allowing for
a reduced tax rate), which would generally be withheld by the distributing company, provided however that dividends distributed from &#8216;Preferred
Income&#8217; from one Israeli corporation to another, would not be subject to tax. Under the transitional provisions of the 2011 Amendment,
companies may elect to irrevocably implement the 2011 Amendment with respect to their existing Approved and Benefiting Enterprises while
waiving benefits provided under the legislation prior to the 2011 Amendment or keep implementing the legislation prior to the 2011 Amendment.
Should a company elect to implement the 2011 Amendment with respect to its existing Benefiting Enterprises prior to June 30, 2015 dividends
distributed from taxable income derived from Benefiting Enterprises to another Israeli company would not be subject to tax. While a company
may incur additional tax liability in the event of distribution of dividends from tax exempt income generated from its Benefiting Enterprise,
as previously described, no additional tax liability will be incurred by a company in the event of distribution of dividends from Preferred
Income. We have not elected to implement the 2011 Amendment and we do not currently have any Preferred Enterprises.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying
the Economic Policy for the 2017 and 2018 Budget Years), 2016 which includes Amendment 73 to the Law, or Amendment 73, was published.
According to Amendment 73, a Preferred Enterprise located in development area A will be subject, under certain conditions, to a tax rate
of 7.5% instead of 9% effective from January 1, 2017, and thereafter (the tax rate applicable to preferred enterprises located in other
areas remains at 16%). Amendment 73 also prescribes special tax tracks for Technological Enterprises, which are subject to regulations
issued by the Minister of Finance on May 16, 2017.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The new tax tracks under the Amendment are as follows:</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Technological Preferred Enterprise - an enterprise for which total consolidated revenues
of its parent company and all subsidiaries are less than NIS 10 billion. A Technological Preferred Enterprise, as defined in the Law,
which is located in the center of Israel will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development
area A - a tax rate of 7.5%).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Special Technological Preferred Enterprise - an enterprise for which total consolidated
revenues of its parent company and all subsidiaries exceed NIS 10 billion. Such enterprise will be subject to tax at a rate of 6% on profits
deriving from intellectual property, regardless of the enterprise&#8217;s geographical location.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any dividends distributed to &#8220;foreign companies&#8221;, as defined in the Law,
deriving from income from the Technological Enterprises will be subject, under certain conditions, including holding at least 90% of the
share capital, to tax at a rate of 4%.</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2023, our net operating loss carry-forward for Israeli tax purposes
amounted to approximately $401.1 million. Under Israeli law, these net operating losses may generally be carried forward indefinitely
and offset against certain future taxable income.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">As of December 31, 2023, the net operating loss carry-forward of our U.S. subsidiary for federal income
tax purposes amounted to approximately $3.0 million. Approximately $1.9 million of these losses are available to offset any future U.S.
taxable income of our U.S. subsidiary and will expire between 2024 and 2032.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">71</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">Use of our U.S. net operating losses may be subject to substantial annual limitation
due to the &#8220;change in ownership&#8221; provisions of the Code and similar state provisions. The annual limitation may result in
the expiration of net operating losses before utilization.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For a description of Israel government policies that affect our research and development
expenses, and the financing of our research and development, see &#8220;Item 5. Operating and Financial Review and Prospects - C. Research
and Development, Patents and Licenses - The Israel Innovation Authority.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. LIQUIDITY AND CAPITAL RESOURCES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Public Offering of Ordinary Shares</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-style: italic">Registered Direct Offering</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On June 14, 2018, we entered into a definitive securities purchase agreement with
certain institutional investors and a placement agency agreement with JMP Securities LLC, in connection with a registered direct offering
which resulted in the issuance of 5,316,457 of our ordinary shares at a purchase price of $3.95 per share. In connection with the issuance
of the ordinary shares, we also issued warrants to purchase up to approximately 4.3 million additional ordinary shares. The warrants had
an exercise price of $4.74 per share and had a term of five years from the date of issuance and therefore already expired. Gross proceeds
from the sale of the ordinary shares were approximately $21 million, before deducting placement agent discounts and commissions and offering
expenses paid by us.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">During 2020, the Company issued and sold 3,866,139 ordinary shares underlying 3,866,139
warrants (with proceeds of approximately $18.3 million). During 2021, the Company issued and sold 89,557 ordinary shares underlying 89,557
warrants (with proceeds of approximately $0.4 million). As of December 31, 2023, no warrants remained outstanding.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Public Offering</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On March 11, 2020, we entered into an underwriting agreement with Leerink Partners
LLC, or Leerink, and Stifel,&#160;Nicolaus &amp; Company, Incorporated, as representatives of the several underwriters named therein,
for the issuance and sale in a public offering of 8,333,334 of our ordinary shares at a price to the public of $9.00 per share. In addition,
we granted the underwriters a 30-day option to purchase up to 1,250,000 additional ordinary shares at the public offering price, less
the underwriting discounts and commissions.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In this underwritten public offering we issued a total of 8,816,339 ordinary shares
(including the shares issued upon exercise of the underwriters&#8217; option) at said $9.00 price per share. Gross proceeds from the sale
of the ordinary shares were approximately $79 million, before deducting underwriting discounts and commissions and offering expenses paid
by us.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Sales Agreement with Leerink Partners LLC</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On January 31, 2023, we entered into a Sales Agreement, or the Sales Agreement with
Leerink, as sales agent, pursuant to which we may offer and sell, from time to time through Leerink, our ordinary shares. The offer and
sale of our ordinary shares, if any, will be made pursuant to our shelf registration statement on Form F-3, as supplemented by the prospectus
supplement filed on January 31, 2023. Pursuant to the said prospectus supplement, we may offer and sell up to $50 million of our ordinary
shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are not obligated to make any sales under the Sales Agreement and no assurance
can be given that we will sell any ordinary shares under the Sales Agreement, or, if we do, as to the price or number of ordinary shares
that we will sell, or the dates on which any such sales will take place.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Since the date the Company entered into the Sales Agreement and through December 31,
2023, and for the period between January 1, 2024, and February 20, 2024, the Company sold 2,612,822 ordinary shares and 292,728 ordinary
shares, respectively, through the Sales Agreement, for gross proceeds of approximately $ 3.6 million and $0.6 million, respectively, and
net proceeds (after deducting commission paid) of approximately $3.5 million and $0.6 million, respectively.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">72</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Shelf Registration Statement</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="text-align: justify; line-height: 1.25">On March 30, 2023, we filed a shelf registration statement on Form F-3 with the SEC
under which we may offer and sell from time to time in one or more offerings, our ordinary shares, debt securities, rights, warrants and
units having an aggregate offering price of up to $350 million, $50 million of which may be offered, issued and sold under the above mentioned
Sales Agreement with Leerink. This registration statement was declared effective by the SEC on June 27, 2023.&#160;Although we believe
that we have sufficient cash, cash equivalents, short-term bank deposits and investment in marketable securities in order to sustain our
operations at least into 2027, based on our different expectations and assumptions as specified above, nevertheless, we may seek additional
capital or various reasons, including for our ongoing operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Securities Purchase Agreement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Bristol Myers Squibb Securities Purchase Agreement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">On November 10, 2021, the Company and Bristol Myers Squibb entered into a securities
purchase agreement pursuant to which Bristol Myers Squibb made a $20 million investment in Compugen comprised of the purchase of 2,332,815
ordinary shares of Compugen at $8.57333 per share, which represented a 33% premium over the closing price of our ordinary shares on the
last trading day immediately prior to the execution of this agreement. This investment is in addition to Bristol Myers Squibb&#8217;s
$12 million investment (at $4.95 per share, which represented a 33% premium over the average closing price on the last 20 Nasdaq trading
days prior to signing) that took place in October 2018.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">License Agreement</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">AstraZeneca License Agreement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">On March 30, 2018, we and AstraZeneca, entered into an exclusive license agreement
to enable the development of bi-specific and multi-specific immuno-oncology antibody products&#160;based on the Company&#8217;s monospecific
antibodies that bind to TIGIT, including COM902, pursuant to which the Company received an upfront payment of $10 million and is eligible
to receive up to $200 million in development, regulatory and commercial milestones for the first product as well as tiered royalties on
future product sales, out of which we accrued $2 million in 2020 as a preclinical milestone, $6 million in 2021 as a clinical milestone
(triggered by the dosing of the first patient in a Phase 1/2 trial evaluating rilvegostomig), $7.5 million in 2022 as a clinical milestone
(triggered by the dosing of the first patient in its ARTEMIDE Phase 2 trial evaluating rilvegostomig) and $10 million in 2023 as a clinical
milestone (triggered by the dosing of the first patient in its ARTEMIDE-Bil01 Phase 3 trial evaluating rilvegostomig). If additional products
are developed, additional milestones and royalties would be due to us for each product. </div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Gilead License Agreement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">On December 18, 2023, we and Gilead, entered into an exclusive license agreement,
or the License Agreement, pursuant to which we granted Gilead an exclusive license under our preclinical antibody program against IL-18
binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products,
including our COM503 product candidate, or together, the&#160; COM503,<span style="font-weight: bold">&#160;</span>and additional products
that may be developed by Gilead, together with COM503, the Licensed Products.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the License Agreement, Gilead paid us a gross amount of $60 million upfront
license payment (with a net amount of $51, after withholding taxes of $9 million at source). We are eligible to receive from Gilead $30
million in the form of a milestone payment upon clearance of the IND application for COM503. We are also eligible to receive up to approximately
$758 million in additional milestone payments upon the achievement of certain development, regulatory and commercial milestones. We are
further eligible to receive single-digit to low double-digit tiered royalties on worldwide net sales of Licensed Products.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">Unless terminated early by a party pursuant to its terms, the License Agreement will
continue in effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the last royalty term
in such country.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">Gilead will withhold at source all taxes required by law from all payments payable
to us under the License Agreement.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">If additional products are developed, additional milestones and royalties would be
due to us. </div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">73</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Capital Resources</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">In 2023, our primary sources of cash were:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1dec3937b1cc4a59b28c2534e82a5d74" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>cash at hand and yield on investment of such cash balances; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z96f56c6b04a047b5a694461b86c0f0b7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>proceeds from ordinary shares sold through the Sales Agreement with Leerink.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -34pt; margin-left: 34pt; line-height: 1.25">We used these funds primarily to finance our
business operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We expect that our sources of cash for 2024 will include cash at hand at the end of
2023, proceeds received from AstraZeneca in connection with its Phase 3 milestone payment and proceeds received from Gilead in connection
with its upfront payment (both took place in 2024) and expected milestone payment upon clearance of the IND application for COM503. Additional
sources of cash may include proceeds generated from agreements with collaborators and other third parties with respect to our novel targets
and therapeutic drug candidates and proceeds from issuance of ordinary shares as a result of exercise of options, issuance of ordinary
shares pursuant to our employee share purchase plan and/or from financing transactions. In addition, if we choose to do so, we may generate
additional proceeds from sales of our ordinary shares pursuant to the Sales Agreement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Net Cash Used in Operating Activities</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Net cash used in operating activities was approximately $22.7 million in 2021, approximately
$34.1 million in 2022 and approximately $35.9 million in 2023. Increase in net cash used in 2023 compared to 2022 is mainly due to $7
million clinical milestones from the license agreement with AstraZeneca collected, net of milestone payment paid in 2022, offset by higher
interest and yield collected on our cash deposits and marketable securities and a decrease in cash operating expenses, mainly expenses
associated with our CMC and research and drug development activities and headcount related expenses in 2023.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Net Cash Provided by Investing Activities</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Net cash provided by investing activities was approximately $6.6 million in 2021,
$37.1 million in 2022 and $35.5 million in 2023. Changes in net cash during the years are affected by the level of cash in the Company
over the years which are deposited or withdrawn from bank deposits, or invested or received from maturity of marketable securities based
on the cash needs to fund our operating activities. During 2023 cash provided by investing activities was lower than 2022 as a result
of ordinary shares sold through the Sales Agreement with Leerink in 2023 compared to much lower proceeds from exercise of stock based
awards in 2022, offset by higher cash used in operating activities in 2023.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic"><span style="font-weight: bold">Net Cash Provided by Financing
Activitie</span>s</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Net cash provided by financing activities was approximately $16.8 million in 2021,
approximately $0.4 million in 2022 and approximately $3.1 million in 2023. The principal source of cash provided by financing activities
in 2023 was proceeds received sale of ordinary shares through the Sales Agreement with Leerink. The principal source of cash provided
by financing activities in 2022 was proceeds received from stock-based awards exercises.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Net Liquidity</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Liquidity refers to the liquid financial assets available to fund our business operations
and pay for near-term obligations. These liquid financial assets mostly consist of cash and cash equivalents as well as short-term bank
deposits and investment in marketable securities. As of December 31, 2023, we had cash and cash equivalents, short-term bank deposits
and investment in marketable securities of approximately $50.7 million compared to approximately $83.3 million on December 31, 2022. We
believe that our existing cash, cash equivalents, short-term bank deposits and investment in marketable securities will be sufficient
to fund our operations over the next 12 months. We believe we will meet longer-term expected future cash requirements into 2027 based
on our current plans and different expectations and assumptions specified above. We believe that our working capital is sufficient for
our present requirements.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">74</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">The table below summarizes our contractual obligations as of December 31, 2023, and
should be read together with the accompanying comments that follow.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z0cf1668750a5451aa9b3561febe714f1" class="cfttable" style="font: 10pt Times New Roman,Times,serif; text-align: left; color: rgb(0, 0, 0); width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="18" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Payments due by period</div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">(US$ in thousands)</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Total</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Less than 1 year</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">1-3 years</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">3-5 years</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">More than 5 years</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 40%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Operating Lease Obligations<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">1,436</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">690</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">746</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 40%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Accrued Severance Pay, net<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">421</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">421</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 40%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Total</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">1,857</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">690</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">746</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">421</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: -14.15pt; margin-left: 28.35pt; line-height: 1.25"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup>&#160;
Consists of operating leases for our facilities and for motor vehicles. Includes the first five-year option period of the lease of the
Israeli facility. The first option was exercised during 2020.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; text-indent: -14.15pt; margin-left: 28.35pt; line-height: 1.25"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup>&#160;
Severance pay obligations to our Israeli employees. For more information, see &#8220;Item 6. Directors, Senior Management and Employees
&#8211; D. Employees.&#8221;</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The above table does not include royalties that we may be required to pay to the IIA.
For more information, see &#8220;Item 5. Operating and Financial Review and Prospects - C. Research and Development, Patents and Licenses.&#8221;</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The above table also does not include contingent contractual obligations or commitments
that may enter into effect in the future, such as contractual undertakings to pay royalties subject to certain conditions occurring.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Although we have sufficient cash, cash equivalents, short-term bank deposits and investment
in marketable securities that we believe will enable us to fund our operations into 2027 based on our different expectations and assumptions
specified above, our ability to fund our capital needs depends on our ongoing ability to generate cash from existing and future collaborations
and from our ability to raise additional funds.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We invest heavily in research and development. Research and development expenses were
our major operating expenses representing approximately 74% of total operating expenses in 2023, 2022 and 2021. Our research and development
expenses, net, were approximately $34.5 million in 2023, approximately $30.6 million in 2022 and approximately $28.7 million in 2021.
As of December 31, 2023, 46 of our employees were engaged in research and development on a full-time basis. This represents approximately
70% of our entire work force at that time.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We focus our efforts on the development of our discovery capabilities and related
technologies, and the discovery and validation of our drug targets and the preclinical and clinical development of the respective therapeutic
product. Our pipeline programs are continuously evolving and we are working to advance selected drug target programs through research
into preclinical and clinical development of therapeutic products. We expect that in 2024 our research and development expenses will continue
to be our major operating expense.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We believe that our future success will depend, in large part, on our ability to discover
promising drug target candidates and therapeutic product candidates and to successfully advance the research and development of certain
of our product candidates in our internal pipeline towards preclinical and clinical studies and to successfully enter into revenue-sharing
partnering agreements with pharmaceutical companies with respect to our product candidates at the various development stages. In addition,
we expect to continue to expand our discovery infrastructure and capabilities which provide us with the underlying engine for the discovery
of promising drug targets for our therapeutic pipeline.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Research and Development Grants</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have participated in programs offered by the IIA that support research and development
activities. See Note 7b to our 2023 consolidated financial statement. We have not applied for additional grants from the IIA for research
and technological development since 2012.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The Israel Innovation Authority</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The government of Israel encourages research and development projects in Israel through
the IIA, pursuant to and subject to the provisions of the R&amp;D Law. Under the R&amp;D Law, research and development projects which
are approved by the Research Committee of the IIA are eligible for grants, in exchange for payment of royalties from revenues generated
by the products and/or services developed within the framework of such approved project and subject to compliance with certain requirements
and restrictions under the R&amp;D Law as detailed below, which must generally continue to be complied with even following full repayment
of all IIA grants (as adjusted for fluctuation in the USD/NIS exchange rate), with applicable interest.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">75</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">We received grants from the IIA for several projects and may receive additional grants
in the future. Under the terms of the grants received, we are required to pay royalties ranging between 3% to 5% of the revenues we generate
from our products and/or services which incorporate Financed Know-How, or IIA Products, until 100% of the dollar value of the grant is
repaid, plus, as follows: (i) with respect to grants received on or after January 1, 1999 and until December 31, 2023, the applicable
interest is (a) LIBOR interest until December 31, 2023, and (b) from January 1, 2024, the 12 months Term SOFR interest as published on
the first trading day of each year by CME Group, or by any other party authorized by the Federal Reserve, or in alternative publication
by the Bank of Israel, together with an additional 0.71513% to the applicable interest rate, and (ii) with respect to grants received
on or after January 1, 2024, the applicable interest shall be the 12 months Term SOFR interest as detailed in section (b) above.&#160;
As of December 31, 2023, we received grants from the IIA in the principal amount of approximately $7.3 million. Therefore, our contingent
obligation for royalties, net of royalties already paid or accrued in the sum of approximately $3.0 million, along with the accumulated
LIBOR interest to date of approximately $4.7 million, totaled to approximately $9.0 million as of December 31, 2023.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, the Company participated in four MAGNET Consortium programs - Drugs and
Diagnostic Kits, or DAAT Consortium, Tevel Biotechnology Consortium, Pharmalogica Consortium and Rimonim Consortium &#8211; for which
it received from the IIA a total amount of approximately $2.1 million, and in two MAGNETON programs, for which it received from the IIA
approximately $0.5 million. These grants do not bear any royalty obligations, but as the R&amp;D Law applies to these programs, the restrictions
on transfer of know-how or manufacturing outside of Israel, as detailed below, do apply. The R&amp;D Law requires that the manufacture
of products which incorporate Financed Know-How will be carried out in Israel, unless the IIA provides its approval to the contrary. This
approval may be subject to various conditions, including the repayment of increased royalties equal to up to 300% of the total grant amount
plus applicable interest and an increase of 1% in the royalty rate, depending on the extent of the manufacturing that is to be conducted
outside of Israel. The R&amp;D Law also provides that Financed Know-How and any right derived therefrom may not be transferred to third
parties, unless such transfer was approved in accordance with the R&amp;D Law. The Research Committee operating under the IIA may approve
the transfer of Financed Know-How between Israeli entities, provided that the transferee undertakes all the obligations in connection
with the grant as prescribed under the R&amp;D Law. In certain cases, the research committee may also approve a transfer of the Financed
Know-How outside of Israel, in both cases, subject to the receipt of certain payments calculated according to a formula set forth in the
R&amp;D Law. In the case of transfer outside of Israel, a payment of up to 600% of the total amount of grants plus applicable interest;
and in the case the R&amp;D activity related to the know-how remains in Israel, a payment of up to 300% of such total amount. These approvals
are not required for the sale or export of any products resulting from such R&amp;D activity or based on such Financed Know-How. In addition,
the government of Israel may from time to time audit sales of products which it claims incorporate Financed Know-How and this may lead
to royalties being payable on additional products, and may subject such products to the restrictions and obligations specified hereunder.
Failure to comply with the requirements under the R&amp;D Law may subject us to financial sanctions, to mandatory repayment of grants
received by us (together with interest and penalties), as well as expose us to criminal proceedings.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For a discussion regarding the effects of the grants we received from the IIA on our
business, see &#8220;Item 3. Key Information &#8211; D. Risk Factors - Risks Related to Operations in Israel -<span style="font-weight: bold">&#160;</span>We
received grants from the IIA that may require us to payment of royalties and restrict the transfer of know-how that we develop.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">D. TREND INFORMATION</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are unable to predict with a reasonable degree of accuracy the outcome of our research
and development efforts. As such, it is not possible for us to predict with a reasonable degree of accuracy any material trends, uncertainties,
or other events that are reasonably likely to have a material effect on our net loss, liquidity or capital resources, or that would cause
financial information to not necessarily be indicative of our future operating results or our financial condition. However, subject to
such limitation, we did identify certain trends that may have an effect on us, some of which are as specified below, and as covered in
the risk factors set forth under &#8220;Item 3. Key Information - D. Risk Factors.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">76</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Access to Additional Funds</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Should we need to secure additional sources of liquidity, we believe that we could
finance our needs through the issuance of equity securities, including through our Sales Agreement with Leerink, debt securities or other
arrangements. However, we cannot guarantee that we will be able to obtain financing through the issuance of any of the above arrangements
on reasonable terms. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Unfavorable Global or Domestic Political or Economic Conditions
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">The global economy continues to experience significant volatility,
and the economic environment may continue to be, or become, less favorable than that of past years. Higher costs for goods and services,
inflation, deflation, the imposition of tariffs or other measures that create barriers to or increase the costs associated with international
trade, overall economic slowdown or recession and other economic factors in Israel, the U.S. or in any other markets in which we operate
could adversely affect our operations and operating results and can result in increased operations costs. On February 9, 2024, Moody&#8217;s
Investors Service, or Moody&#8217;s, downgraded the Government of Israel&#8217;s foreign-currency and local-currency issuer ratings to
A2 from A1 and assigned it a &#8220;negative&#8221; credit outlook. In addition, on February 13, 2024, Moody&#8217;s downgraded the deposit
ratings of Israel&#8217;s five largest banks to A3 from A2. While these downgrades do not have an immediate nor direct impact on us, an
extended period of economic disruption, including a continued market downfall, in Israel, the United States or any other major market
in which we or our partners operate, could materially affect our ability to secure additional funds and could further materially affect
our business, strategy, results of operations and financial condition.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">To date, our operations and business have not been materially impacted
by the &#8220;Swards of Iron&#8221; war and the Russia and Ukraine conflict. However, the &#8220;Swards of Iron&#8221; war in Gaza and
the hostility around Israel and the ongoing Russia and Ukraine conflict and other global economic factors, have caused a negative impact
on the outlook for the global economy and created significant volatility and disruption of financial markets. In addition, the &#8220;Swards
of Iron&#8221; war in particular has a potential to have a greater effect for companies that have a significant presence in Israel. For
instance, the &#8220;Sward of Iron&#8221; war, may have an adverse effect on the Israeli social, economic and political landscape and
in turn, on us, and may cause, among other things, major devaluation in the NIS.Should any of these conflicts still persist or expand
to include additional countries or regions, we could be impacted. We will continue to assess global and regional conflicts and the situation
in the financial markets and any impact they may have on our ability to access additional funds.&#160; </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Exchange Rate</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A significant portion of our expenses is denominated in currencies other than the
dollar. The Company is therefore subject to non-U.S. currency risks and non-U.S. exchange exposure, especially the NIS. Exchange rates
can be volatile and a substantial change of foreign currencies against the dollar could increase or reduce the Company&#8217;s expenses
and net loss and impact the comparability of results from period to period. The appreciation (devaluation) of the dollar against the NIS
was 3.1%, 13.2% and (3.3%) in 2023, 2022 and 2021, respectively. For example, for the year ended December 31, 2023, assuming a 10% devaluation
of the dollar against the NIS, we would have experienced an increase in our net loss of approximately $1.4 million, while assuming a 10%
appreciation of the dollar against the NIS, we would experience a decrease in our net loss of approximately $1.1 million. Should Moody&#8217;s
or other financial rating firms further downgrade the Government of Israel&#8217;s foreign-currency and local-currency issuer ratings,
this could have a negative impact on the value of our NIS denominated holdings. For more information regarding exchange rate risk please
see &#8220;Item 11. Quantitative And Qualitative Disclosures About Market Risk &#8211; Interest Rate Risk.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Interest rate</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A significant portion of our cash and cash equivalents is invested in bank deposits
or in marketable securities and bear interest or yield that depend on the interest rate. The Company&#8217;s financial income is therefore
subject to interest rate risk. Interest rates can be volatile, and a substantial change in interest rates could increase or reduce the
Company&#8217;s financial income and net loss. In addition to the impact on our cash and cash equivalents, rising interest rates, or the
perception thereof, may have wide economic impacts, including an adverse impact on capital markets, the price of our shares and on supplies
that we require to conduct our different operations. For more information regarding interest rate risk please see &#8220;Item 11. Quantitative
And Qualitative Disclosures About Market Risk &#8211; Interest Rate Risk.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">77</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Trend Towards Biologics</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Biologics (monoclonal and bispecific antibodies, ADCs, enzymes and pegylated proteins)
represent one of the fastest growing segments in the drug industry, making up 31% of FDA approved drugs in 2023. The growth of this class
has driven a large number of companies to invest in new technologies (e.g., bi-specific monoclonal antibodies, multi-specific antibodies,
antibody fragments, T cell engagers) and new approaches to fully exploit the potential of this class. In addition, the striking efficacy
and recent approval ofcell therapies for the treatment of cancer, such as CAR-T therapies, has also captured much attention in the pharma
industry. The availability of such new technologies and approaches to address drug targets may increase the differentiation and attractiveness
of our novel therapeutic candidates. </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">E. CRITICAL ACCOUNTING ESTIMATES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The preparation of our consolidated financial statements and other financial information
appearing in this Annual Report requires our management to make estimates and judgments that affect the reported amounts of assets, liabilities,
revenues and expenses, and related disclosure of contingent assets and liabilities. We evaluate on an on-going basis these estimates,
mainly related to share-based payments, deferred participation in research and development expenses, revenue recognition, and research
and development expenses.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We base our estimates on our experience and on various assumptions that we believe
are reasonable under the circumstances. The results of our estimates form the basis for our management&#8217;s judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under
different assumptions or conditions.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Share Based Payments</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We account for stock-based compensation in accordance with ASC 718, &#8220;Compensation
- Stock Compensation&#8221;, or ASC 718, which requires companies to estimate the fair value of equity-based payment awards on the date
of grant using an option-pricing model. We account for forfeitures as they occur. The value of the pro-rata portion of the award, assuming
no forfeiture, is recognized in our consolidated statement of comprehensive loss as an expense over the requisite service periods. Upon
forfeiture the expense is adjusted so that expense is recognized for the portion of the award that actually vested.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We selected the Black-Scholes-Merthon option pricing model as the most appropriate
method for estimating the fair value of our share-based awards. The resulting cost of an equity incentive award is recognized as an expense
over the requisite service period of the award, which is usually the vesting period. We recognize compensation expense over the vesting
period using the straight-line method and classify these amounts in the consolidated financial statements based on the department to which
the related employee reports.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">This model evaluates the options as if there is a single exercise point, and thus
considers expected option life (expected term). The input factored in this model is constant for the entire expected life of the option.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The determination of the grant date fair value is affected by estimates and assumptions
regarding a number of complex and subjective variables, including the expected term of the options, the expected volatility of our share
price over the expected term, risk-free interest rates and expected dividends. The computation of expected volatility is based on historical
volatility of our shares. The risk-free interest rate assumption is the implied yield currently available on United States treasury zero-coupon
issues with a remaining term equal to the expected life term of the options. We determined the expected life of the options based on historical
experience, representing the period of time that options granted are expected to be outstanding.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Share-based compensation expense recognized under ASC 718 was approximately $3.6 million,
$4.3 million and $4.3 million for the years ended December 31, 2023, 2022 and 2021, respectively.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Revenue Recognition</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our revenues are generated mainly from collaborative and license agreements. In the
agreements, revenues are typically derived mainly from upfront payment and contingent payments related to milestone achievements.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The Company recognizes revenue in accordance with ASC 606 - &#8220;Revenue from Contracts
with Customers.&#8221;</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">As such, the Company analyzes its collaborative and license agreements to assess whether
they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations
under each of its agreements, the Company performs the following five steps: (i) identification of the contract, or contracts, with a
customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation
of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when, or as, we satisfy a performance
obligation.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">78</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The consideration promised in a contract with a customer may include fixed amounts,
variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained.
We use assumptions to determine the standalone selling price of each performance obligation identified in the contract. We then allocate
the total transaction price to each performance obligation based on the estimated standalone selling prices of each performance obligation.
We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance
obligation is satisfied.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">After contract inception, the transaction price is reassessed at every period end
and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations
on the same basis as at contract inception.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">In December 2020 the program under the exclusive license agreement with AstraZeneca
achieved a preclinical milestone and in September 2021, November 2022 and December 2023 such program achieved clinical milestones and
in connection with such milestones, we recognized revenues in an amount of $2 million, $6 million, $7.5 million and $10 million, in the
years 2020, 2021, 2022, and 2023, respectively, in accordance with the criteria prescribed under ASC 606. See Note 2k to our 2023 consolidated
financial statements.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">In December 2023, following entrance into license agreement with Gilead, we assessed
the promises under the license agreement and concluded that its promise to deliver the COM503 License, the promise to perform IND research
and development activities and Phase 1 research and development activities represented separate performance obligations in the license
agreement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We also evaluated as a possible variable consideration all milestones and royalties.
With respect to clinical development and regulatory milestones, we concluded that all such amounts should be fully constrained and are
not included in the initial transaction price. Accordingly, we did not include any potential clinical development, regulatory and sales
milestones and royalties in the initial transaction price.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We allocated the transaction price to each performance obligation on a relative estimated
standalone selling price basis. We developed the estimated standalone selling price for the license. In developing such an estimate, we
applied judgement in determining the timing needed to develop the licensed product, the probability of success, and the discount rate.
We developed the estimated standalone selling price for the IND research and development activities using a &#8220;cost plus&#8221; reasonable
margin approach. To determine the estimated standalone selling price of the Phase 1 research and development activities obligation, we
estimated the standalone selling price of the underlying performance obligations and estimated the probability of our performance of such
obligations.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">We determined that the license granted was a functional license since the underlying
intellectual property has significant standalone functionality and recognized the entirety of the initial transaction price allocated
to the license performance obligation during the year ended December 31, 2023, in the amount of $23.5.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The IND research and development activities and Phase 1 research and development activities
performance obligations are recognized over time when, or as, we perform the required services. We determined that the input method under
ASC 606 is the best measure of progress towards satisfying the performance obligation and reflects a faithful depiction of the transfer
of goods and services. The method of measuring progress towards delivery of the services incorporates actual internal and external costs
incurred, relative to total internal and external costs expected to be incurred to satisfy the performance obligation. The period over
which total costs were estimated reflected our best estimate of the period over which it would perform the activities to achieve clearance
of an IND application and completion of the phase 1 clinical trial.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Research and Development Expenses</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Research and development costs are charged to the statement of comprehensive loss
as incurred.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The Company accrues costs for preclinical and clinical trial activities based upon
estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or
other preclinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable
advance payments to vendors for goods or services that will be received in the future for use in research and development activities.
In such circumstances, the nonrefundable advance payments are deferred and capitalized, even when there is no alternative future use for
the research and development, until related goods or services are provided.&#160;Payments made in advance of the performance of the related
services are recorded as prepaid expenses until the services are rendered.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">79</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The portion of the Bristol Myers Squibb $12.0 million investment in 2018 over the
fair market value of the shares issued in the amount of approximately $4.1 million and the portion of the Bristol Myers Squibb $20.0 million
investment in 2021 over the fair market value of the shares issued in the amount of $5.0 million were considered as deferred participation
of Bristol Myers Squibb in research and development expenses which was amortized over the period of the clinical trial based on the progress
in the research and development, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;, see Note 1f and Note 8b to our 2023
consolidated financial statements.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Amortization of participation in research and development expenses for the years ended
December 31, 2023, 2022 and 2021 were approximately $0.3 million, $6.0 million and $1.3 million, respectively.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Recent Accounting Pronouncements</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">See Note 2t to our 2023 consolidated financial statement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25"><span style="font-weight: bold">ITEM 6.</span><span id="ITEM6."><!--Anchor--></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span style="font-weight: bold">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. DIRECTORS AND SENIOR MANAGEMENT</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The following table sets forth information with respect to Compugen&#8217;s directors
and senior management as of February 20, 2024:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="3" border="0" id="z0bb930f09e23494a882fadc60cc85b3f" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 34%">
        <div style="line-height: 1.25">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Name</div> </div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 9%">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Age</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 55%">
        <div style="line-height: 1.25">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Positions</div> </div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: middle; width: 34%; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Paul Sekhri<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; text-align: center">65</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: middle; width: 55%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Chairman of the Board of Directors (Chairman of the Nomination and Corporate Governance Committee)</div>
        </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: middle; width: 34%">
        <div style="text-align: justify; line-height: 1.25">Anat Cohen-Dayag, Ph.D.</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; text-align: center">57</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: middle; width: 55%">
        <div style="margin-right: 2.55pt; line-height: 1.25">President and Chief Executive Officer, Director</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: middle; width: 34%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Mathias Hukkelhoven, Ph.D.</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; text-align: center">70</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: middle; width: 55%; background-color: rgb(204, 238, 255)">
        <div style="margin-right: 2.55pt; line-height: 1.25">Director</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: middle; width: 34%">
        <div style="text-align: justify; line-height: 1.25">Gilead Halevy<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; text-align: center">57</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: middle; width: 55%">
        <div style="margin-right: 2.55pt; line-height: 1.25">Director (Chairman of the Audit Committee)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: middle; width: 34%; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Kinneret Livnat Savitzky, Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)(3)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; text-align: center">56</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: middle; width: 55%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Director</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 34%">
        <div style="text-align: justify; line-height: 1.25">Eran Perry<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)(2)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; text-align: center">53</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 55%">
        <div style="line-height: 1.25">Director</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 34%; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Sanford (Sandy) Zweifach<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)(2)(3)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; text-align: center">67</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 55%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Director (Chairman of the Compensation Committee)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 34%">
        <div style="text-align: justify; line-height: 1.25">Alberto Sessa</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; text-align: center">61</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 55%">
        <div style="line-height: 1.25">Chief Financial Officer</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 34%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Henry Adewoye, MD<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(4)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; text-align: center">59</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 55%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Senior Vice President and Chief Medical Officer</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 34%">
        <div style="text-align: justify; line-height: 1.25">Zurit Levine, Ph.D.</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; text-align: center">56</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 55%">
        <div style="line-height: 1.25">Senior Vice President, Technology Innovation</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 34%; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Yaron Turpaz, Ph.D.</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; text-align: center">53</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 55%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Senior Vice President and Senior Advisor, Data and Informatics Solutions</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 34%">
        <div style="text-align: justify; line-height: 1.25">Eran Ophir, Ph.D.</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; text-align: center">46</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 55%">
        <div style="line-height: 1.25">Chief Scientific Officer</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 34%; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Pierre Ferre, Ph.D.</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; text-align: center">47</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 55%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Vice President, Preclinical Development</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br/> <hr style="border-style: none; height: 1px; width: 30%; color: #000000; background-color: #000000; text-align: left; margin-left: 0px; margin-right: auto"/></div>

<div style="text-align: justify; margin-left: 18pt; line-height: 1.25">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Member
of our Compensation Committee</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Member
of our Audit Committee</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Member
of our Nomination and Corporate Governance Committee</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Dr. Henry
Adewoye retired from his position on February 29, 2024. </div>

<div style="line-height: 1.25">&#160;&#160; </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">80</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Paul Sekhri </span>joined Compugen&#8217;s Board of
Directors as its Chairman in October 2017. Mr. Sekhri serves as the President and Chief Executive Officer of vTv Therapeutics Inc. Prior
to joining vTv Therapeutics Inc., from January 2019 until April 2022, Mr. Sekhri served as the President and CEO of eGenesis, Inc. since
January 2019. Prior to joining eGenesis, Inc., Mr. Sekhri served as President and CEO of Lycera Corp. from February 2015 through December
2018. From April 2014 through January 2015, Mr. Sekhri served as Senior Vice President, Integrated Care for Sanofi. From May 2013 through
March 2014, Mr. Sekhri served as Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical
Industries Ltd. Prior to joining Teva, Mr. Sekhri spent five years as Operating Partner and Head of the Biotechnology Operating Group
at TPG Biotech, the life sciences venture capital arm of TPG Capital. From 2004 to 2009, Mr. Sekhri was Founder, President, and Chief
Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD
Pharmaceuticals, Inc. Previously, Mr. Sekhri spent four years at Novartis, as Senior Vice President, and Head of Global Search and Evaluation,
Business Development and Licensing for Novartis Pharma AG. Mr. Sekhri also developed the Disease Area Strategy for Novartis, identifying
those specific therapeutic areas upon which the company would focus. Mr. Sekhri&#8217;s first role at Novartis was as Global Head, Early
Commercial Development. Mr. Sekhri completed graduate work in Neuroscience at the University of Maryland School of Medicine, where he
also received his BS in Zoology. Mr. Sekhri is currently a member of the Board of Directors of vTv Therapeutics Inc., eGenesis, Inc.,
Veeva Systems Inc., and Spring Discovery&#160;and Chairman of the Board of Directors of Longboard Pharmaceuticals, Inc. Additionally,
Mr. Sekhri is the Chairman of the Board of the Young Concert Artists (YCA), and a member of Boards of The Metropolitan Opera. Mr. Sekhri
is also an active member of the Patrons Council of Carnegie Hall, where he established the Life Sciences Council of Carnegie Hall.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Anat Cohen-Dayag, Ph.D. </span>joined Compugen&#8217;s
Board of Directors in February 2014. Dr. Anat Cohen-Dayag has over 25 years of experience in the biotech industry, both in R&amp;D and
executive leadership roles. Anat joined Compugen in 2002, and has held various senior managerial positions, including VP R&amp;D, before
being appointed President and CEO in 2010. Under her leadership, Compugen transformed from a service provider in the field of computational
biology to a therapeutic discovery and development company advancing an innovative immuno-oncology pipeline originating from the company&#8217;s
computational discovery platforms. Anat is also a member of the Board of Directors of Pyxis Ltd. Prior to Compugen, Anat was the Head
of R&amp;D and was a member of the executive management team of Mindsense Biosystems Ltd. Anat holds a B.Sc. in Biology from Ben-Gurion
University, and an M.Sc. in Chemical Immunology and a Ph.D. in Cellular Biology, both from the Weizmann Institute of Science.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Dr. Mathias (Math) Hukkelhoven </span>joined Compugen&#8217;s
Board of Directors in March 2022. Dr. Hukkelhoven has a wealth of experience in global regulatory affairs and drug development, evidenced
by his contribution to more than 50 NCEs and hundreds of new indications and line extensions over his career to date. Dr. Hukkelhoven
has participated in activities that have shaped health authority interactions for the industry, including serving as chairperson of the
Regulatory Affairs Coordinating Committee at PhRMA, and recently as a PhRMA negotiator for the PDUFA VII negotiations with the FDA. Since
his retirement from Bristol Myers Squibb in July 2021, Math has been a consultant for several biotech companies, R&amp;D Strategy Advisor
for LianBio and Senior Advisor for McKinsey and on July 1, 2022 he joined the Board of Directors of Centessa Pharmaceuticals plc. Math
joined Bristol Myers Squibb in March 2010 as the Senior Vice President, Global Regulatory, Safety &amp; Biometrics and was also responsible
for the R&amp;D group in BMS China and the Clinical Pharmacology and Pharmacometrics group. As such, he had responsibility for a large
part of the global Bristol Myers Squibb development organization. Since the acquisition of Celgene by Bristol Myers Squibb, he was responsible
for Global Regulatory and Safety Sciences at Bristol Myers Squibb. He was accountable for setting regulatory strategy and driving execution
of global regulatory and pharmacovigilance plans for Bristol Myers Squibb. He led the regulatory and development efforts across the product
development and commercialization process to ensure optimal regulatory strategy and interactions at each step of the process &#8211; research
and development, manufacturing, and commercialization. Prior to joining Bristol Myers Squibb, Math held the role of Chairman Portfolio
Stewardship Board at Novartis Pharmaceuticals. From 2001 to 2009, he was the Senior Vice President, Global Head Drug Regulatory Affairs
at Novartis. Math received&#160;his B.S. and Ph.D. honors degrees in Biology and Biochemistry from the University of Nijmegen, the Netherlands.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">81</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Gilead Halevy </span>joined Compugen&#8217;s Board
of Directors in June 2018. Mr. Halevy serves as a general partner of Kedma Capital Partners, a leading Israeli private equity fund, of
which he is also a founding member, since 2006. Prior to establishing Kedma, Mr. Halevy served as a Director at Giza Venture Capital from
2001 to 2006, where he led investments in communication and information technology companies and directed Giza&#8217;s European business
activities. From 1998 to 2001, Mr. Halevy practiced law at White &amp; Case LLP. Mr. Halevy was also a founding member of the White &amp;
Case Israel practice group during that time. Mr. Halevy currently serves as chairman of board of directors of Carmel Wineries; Continuity
Software Ltd., Zriha Hlavin Industries Ltd. and a director of S. AL Holdings Ltd., Plas-Fit Ltd. and A.A. Politiv Ltd. Mr. Halevy holds
a B.A. in Humanities (multidisciplinary program for exceptional students) and an LL.B. (Magna Cum Laude) both from the Hebrew University
of Jerusalem.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Dr. Kinneret Livnat Savitzky </span>joined Compugen&#8217;s
Board of Directors in June 2018. Dr. Livnat Savitzky currently serves as an entrepreneur in residence at Team8 Dr. Livnat Savitzky also
serves on the boards of the following biotechnology or healthcare companies: Ramot (TTO of Tel-Aviv University), DreaMed Diabetes Ltd.,
and Biomica Ltd. Between 2017 and 2021 she served as the CEO of FutuRx Ltd., an Israeli biotechnology accelerator established by OrbiMed
Israel Partners, Johnson &amp; Johnson Innovation, Takeda Ventures Inc., and LEAPS, the venture arm of Bayer. From 2010 to 2016, Dr. Livnat
Savitzky served as CEO of BioLineRX Ltd., a Nasdaq-listed drug development company focused on oncology and immunology. During her tenure,
BioLineRX signed a strategic collaboration with Novartis as well as licensing agreements with Merck (MSD), Genentech and others. Prior
to being appointed CEO of BioLineRX, Dr. Livnat Savitzky held various R&amp;D management positions at BioLineRX and Compugen. Dr. Livnat
Savitzky holds a B.Sc. in Biology from The Hebrew University of Jerusalem, and an M.S.c and Ph.D. with distinction in Human Genetics from
Tel Aviv University.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Eran Perry </span>joined Compugen&#8217;s Board of
Directors in July 2019. Eran Perry brings to Compugen over 20 years of diverse experience across various segments of the healthcare industry
as an entrepreneur and venture capital investor as well as in general management and strategy. In 2018, Mr.&#160;Perry co-founded MII
Fund &amp; Labs, a dermatology-focused venture capital fund where he also serves as Managing Director and Chairman of the Investment Committee.
Mr. Perry is also the co-founder and board member of several pharmaceutical companies including ICD Pharma, Seanergy Dermatology, Follicle
Pharma and Upstream Bio. Mr. Perry also serves on the board of directors of MyBiotics Pharma and Noon Aesthetics. From 2006 to 2016, he
served as Managing Director and Partner of Israel Healthcare Ventures (IHCV) and represented IHCV in numerous portfolio companies. Prior
to IHCV, Mr. Perry was a consultant in McKinsey &amp; Company, serving clients worldwide in the pharmaceutical industry, among others.
Prior to that, he was a member of the Global Marketing group at Novartis Oncology.&#160;Before moving to the private sector, Mr.&#160;Perry
served in the Israeli Ministry of Justice. Mr. Perry holds an MBA from Columbia University, and an LL.B. in Law and a B.Sc. in Mathematics
and Computer Science, both from Tel Aviv University.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Sanford (Sandy) Zweifach </span>joined Compugen&#8217;s
Board of Directors in June 2018. Mr. Zweifach is the Founder of Nuvelution Pharma, Inc. and since 2015 through 2019 was the Chief Executive
Officer of Nuvelution Pharma, Inc. From 2010 to 2015, Mr. Zweifach served as CEO of Ascendancy Healthcare, Inc., which he also founded.
He has also been a Partner at Reedland Capital Partners, a boutique investment bank, from 2005 to 2010, where he headed its life sciences
M&amp;A and advisory efforts. From 2003 to 2005, he was CEO of Pathways Diagnostics, a biomarker development company. Mr. Zweifach was
a Managing Director/CFO of Bay City Capital, a venture capital/merchant banking firm, specializing in the biotech and the life science
industry, where he was responsible for oversight of the firm&#8217;s finance department, as well as President of the firm&#8217;s M&amp;A
and financing division. Prior to this, he was President and CFO of Epoch Biosciences, which was acquired by Nanogen in 2004. Currently
Mr. Zweifach serves as an Executive Chairman of the Board of Directors of Kaerus Bioscience, Chairman of the Board of Directors of Carisma
Therapeutics, Inc., President, CBO and Chair of the Business Advisory Board of IMIDomics, S.L. and as a member of the Board of Directors
of Essa Pharma, Inc. Earlier in his career, Mr. Zweifach was a Certified Public Accountant (US) for Coopers &amp; Lybrand and held various
investment banking positions focusing on biotech. He received his B.A. in Biology from UC San Diego and an M.S. in Human Physiology from
UC Davis.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">82</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold"> <br/> </span></div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Alberto Sessa</span> joined Compugen in November 2022
as Chief Financial Officer. Alberto brings more than 30 years of industry experience to Compugen by serving in public and private companies.
Throughout his career he has gained vast experience in leading financing, investor relations, M&amp;A, and business development transactions.
He most recently served as acting CFO at several startup companies in the high-tech industry. Prior to this, as CFO at Nasdaq and TASE
listed Allot, he was instrumental in helping turn around the company to reach a path of sustained growth. Previously, Alberto spent seven
years as Worldwide Group CFO at Nasdaq listed Amdocs with responsibility for the global financial business activities. Alberto holds a
Master of Business Administration and bachelor&#8217;s in economics and statistics from the Hebrew University of Jerusalem.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Dr. Henry Adewoye </span>joined Compugen in March
2018 as Chief Medical Officer, bringing to Compugen over 20 years of extensive experience in leading multiple clinical trials in Oncology
and Hematology in both the biopharmaceutical industry and academia. Before Compugen, Dr. Adewoye was with Gilead Sciences Inc., as Clinical
Director in Oncology Clinical Research and was on the Oncology Leadership Team. He most recently served as Project Team and Clinical Lead
for Idelalisib (first-in-class PI3K delta inhibitor approved for the treatment of relapsed CLL, FL/SLL) and Andecaliximab (MMP9 mAb inhibitor).
Previously, he was Clinical Research Medical Director in Oncology at Amgen Inc. Dr. Adewoye was the Global Medical Monitor for the initial
registrational trial of the bi-specific antibody blinatumomab (Blincyto&#174;) and several Phase 2 and 3 studies evaluating VEGF inhibitors
(Motesanib, Trebananib) in patients with solid tumors. Dr. Adewoye completed his fellowship in Hematology/Oncology at Boston Medical Center
and completed his residency in Internal Medicine at Meharry Medical College. Dr. Adewoye received his medical degree at the University
of Jos, Nigeria and Fellowship training in Hematology and Laboratory medicine at the University College Hospital Ibadan, Nigeria. Dr.
Adewoye has initial board certifications by the American Board of Internal Medicine in Medical Oncology, Hematology and Internal Medicine.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Zurit Levine, Ph.D. </span>was appointed as Senior
Vice President, Technology Innovation in 2018, responsible for leading and advancing the Company&#8217;s computational innovation towards
new discovery fields and areas. In this capacity, Dr. Levine is also responsible for the Company&#8217;s IP strategy and portfolio. Dr.
Levine joined Compugen in 1999 and has held several positions in Compugen&#8217;s Research &amp; Development department. In 2004, she
was appointed Director of Therapeutic Selection &amp; Validation, which position she held until 2007 when she was appointed Director of
Therapeutic Discovery. In 2009, she was appointed Executive Director of Research &amp; Development. From January 2010 to August 2011,
she held the position of Vice President, Research and Development. In August 2011 she was appointed Vice President, Research and Discovery.
Dr. Levine holds a B.Sc. in Biology, a M.Sc. in Biochemistry and a Ph.D. in Biochemistry, all from the Tel Aviv University, Israel.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Yaron Turpaz, Ph.D.</span> was appointed as Senior
Vice President and Senior Advisor, Data and Informatics Solutions in May 2023. In his role, Dr. Turpaz is responsible for the overall
data flow inside and outside the organization. Dr. Turpaz supports the Computational Discovery unit in the ongoing development of the
computational platforms, and also oversees the establishment of systems for data analytics across the organization. Dr. Turpaz joined
Compugen in November 2019 as Senior Vice President and Senior Advisor, Computational Discovery. Dr. Turpaz has over 15 years of experience
in the fields of research and development informatics, data sciences and technology in the biotech and pharma space with hands-on experience
using cloud-based high throughput computational, machine learning and genomics platforms for drug discovery and development applications
in precision medicine. In his extensive pharma and biotech career, he held senior R&amp;D Informatics roles at Human Longevity, AstraZeneca,
Eli Lilly, Global Gene Corp. and Affymetrix. Dr. Turpaz continues to serve as Chief Information Officer and Senior Advisor at Engine Biosciences.
Dr. Turpaz received a B.Sc. in Biology from Tel Aviv University, a Ph.D. in Bioengineering from the University of Illinois and an MBA
from the University of Chicago, Booth School of Business. He also held an Adjunct Assistant Professor position at the Centre for Quantitative
Medicine of Duke-National University of Singapore, Graduate Medical School.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Eran Ophir, Ph.D.</span> joined Compugen in 2015 and
was appointed Vice President of Research and Drug Discovery in March 2020 and became a Senior Vice President, Research and Drug Discovery
in March 2022 and Chief Scientific Officer in May 2023. In his role, Dr. Ophir is overseeing the Company&#8217;s computational discovery
and the research and drug discovery activities and is responsible for the scientific, translational medicine and biomarker strategy of
the Company&#8217;s innovative portfolio of product candidates. Dr. Ophir brings significant expertise in immunology and immuno-oncology
from his research work at the Weizmann Institute of Science and the Ludwig Institute for Cancer Research in Lausanne, Switzerland. Dr.
Ophir joined Compugen as a senior scientist and has since held various positions in the Research and Development department, with increasing
responsibilities, including appointment to the management team in March 2020. Dr. Ophir received a B.Sc. in Bioinformatics from Tel Aviv
University and a Ph.D. in Biology from the Weizmann Institute of Science.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">83</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Pierre Ferre, Ph.D.</span> joined Compugen in April
2021 as Vice President Preclinical Development. In his role, Dr. Ferre leads the preclinical development, CMC and drug supply management,
clinical biomarker operations, and project management team and activities across the Company. Dr. Ferre has two decades of experience
in all aspects of clinical and non-clinical drug development in oncology and immuno-oncology. Dr. Ferre joined Compugen from Pierre Fabre
Pharmaceuticals, France, where he spent most of his career in multiple positions, lastly as Director of Oncology Programs in which he
led the development strategy of a portfolio of R&amp;D programs in oncology from initiation and discovery, through preclinical and clinical
development. Previously, at Pierre Fabre Oncology R&amp;D, he acted as Director, Pharmacokinetics/Pharmacodynamics, overseeing also translational,
biomarker-related activities. Before that Dr. Ferre was in charge of oncology preclinical pharmacokinetics. Dr. Ferre is a Doctor in Veterinary
Medicine, holds a PhD in biology from Toulouse INP (Institut National Polytechnique), and a MSc from Aix-Marseille University and Paris
INA-PG (Institut National Agronomique) for his research work conducted in experimental pathophysiology and toxicology.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Arrangements Involving Directors and Senior Management</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">There are no arrangements or understandings of which we are aware relating to the
election of our directors or the appointment of executive officers in our Company. In addition, there are no family relationships among
any of the individuals listed in this Item 6.A.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. COMPENSATION</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Aggregate Executive Compensation</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">During 2023, the aggregate compensation paid or accrued by us to all persons listed
in Item 6.A above (Directors and Senior Management) and one member of senior management (Dr. Oliver Froescheis) who ceased to serve before
the end of 2023, was approximately $5.4 million. This amount includes approximately $0.6 million set aside or accrued to provide pension,
severance, retirement or similar benefits, but excludes expenses (including business travel, professional and business association dues
and expenses) reimbursed to our executives and other fringe benefits commonly reimbursed or paid by companies in Israel.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">During 2023, we granted to our Directors and Senior Management listed in Item 6.A
a total of 690,000 options to purchase ordinary shares. These options are exercisable at an average exercise price of $1.30 per share,
and generally expire ten years after their respective dates of grant. As of December 31, 2023, there were a total of 4,506,624 outstanding
options to purchase ordinary shares that were held by our Directors and Senior Management listed in Item 6.A.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">84</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Individual Compensation of Covered Office Holders</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">The table below outlines the compensation granted to our five most highly compensated
Office Holders (as such term is defined in the Companies Law - see below under &#8220;Approvals Required for Office Holders Terms of Employment&#8221;)
with respect to the year ended December&#160;31, 2023. All amounts reported in the table reflect the cost to the Company, as recognized
in our financial statements for the year ended December&#160;31, 2023. We refer to the five individuals for whom disclosure is provided
herein as our &#8220;Covered Office Holders&#8221;.</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div> </div>

<table cellspacing="0" cellpadding="0" border="0" id="za19c3c267dfa4afe9af4c6ed62656ad6" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px; width: 48%">
        <div style="line-height: 1.25; font-weight: bold">Information Regarding the Covered Office Holders</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="14" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Compensation for Services<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 48%">
        <div style="line-height: 1.25; font-weight: bold">Name and Principal Position<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Base Salary ($)</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; width: 1%">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Benefits and</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold"> Perquisites ($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div>
        </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; width: 1%">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Stock-Based Compensation ($) <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(4)</sup></div>
        </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; width: 1%">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Total ($)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 48%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Dr. Anat Cohen-Dayag</div>
        <div style="line-height: 1.25">President &amp; Chief Executive Officer</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">479,234</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">461,150</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">524,064</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,464,448</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 48%">
        <div style="line-height: 1.25">Dr. Henry Adewoye</div>
        <div style="line-height: 1.25">Senior Vice President and Chief Medical Officer</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">425,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">131,067</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">271,502</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">827,569</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 48%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Dr. Pierre Ferre</div>
        <div style="line-height: 1.25">Vice President, Preclinical Development</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">211,521</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">238,439</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">120,440</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">570,400</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 48%">
        <div style="line-height: 1.25">Dr. Eran Ophir</div>
        <div style="line-height: 1.25">Senior Vice President, Research and Drug Discovery</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">195,677</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">161,131</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">183,835</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">540,643</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 48%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Dr. Zurit Levine</div>
        <div style="line-height: 1.25">Senior VP, Technology Innovations</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">188,631</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">167,207</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">176,426</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">532,264</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zad0f3407c99b4f81857693808abd6bc9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>All Covered Office Holders listed in the table were full-time officers of the Company during their term of service in 2023.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160; <br/> </div>

<table cellspacing="0" cellpadding="0" id="zea446168652d4e7e8f3155ddbc3c9279" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Cash compensation amounts denominated in currencies other than the dollar were converted into dollars at an exchange rate of NIS
        3.6897= $1.00, which reflects the average conversion rate for 2023, or the Representative Rate.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160; <br/> </div>

<table cellspacing="0" cellpadding="0" id="z6f98095d2575468d9fbb9857e97e7b62" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Amounts reported in this column include benefits and perquisites, including those mandated by applicable law. Such benefits and perquisites
        may include, to the extent applicable to the respective Covered Office Holder, bonuses, payments, contributions and/or allocations for
        savings funds, pension, severance, vacation, car or car allowance, medical insurances and benefits, risk insurance (e.g., life, disability,
        accident), phone, convalescence pay, payments for social security, tax gross-up payments and other benefits and perquisites consistent
        with the Company&#8217;s policies.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160; <br/> </div>

<table cellspacing="0" cellpadding="0" id="z416ea7d0e432483fb9963943b1f422d3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">4)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Amounts reported in this column represent the expense recorded in our financial statements for the year ended December 31, 2023,
        with respect to options to purchase our ordinary shares granted to our Covered Office Holders. Assumptions and key variables used in the
        calculation of such amounts are discussed in Note 2o to our 2023 consolidated financial statements set forth elsewhere in this report.</div>
        </td> </tr>
  </table> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Compensation Policy</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law we are required to adopt a compensation policy, which sets
forth company&#8217;s policy regarding the terms of office and employment of office holders, including compensation, equity awards, severance
and other benefits, exemption from liability and indemnification. Such compensation policy should take into account, among other things,
the provision of proper incentives to directors and officers, management of risks by the company, the officer&#8217;s contribution to
achieving corporate objectives and increasing profits, and the function of the officer or director.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Our compensation policy, or the Compensation Policy, is designed to balance between
the importance of incentivizing office holders to reach personal targets and the need to assure that the overall compensation meets our
Company&#8217;s long-term strategic performance and financial objectives. The Compensation Policy provides our compensation committee
and our board of directors with adequate measures and flexibility to tailor each of our office holder&#8217;s compensation package based,
among other matters, on geography, tasks, role, seniority and capability. Moreover, the Compensation Policy is intended to motivate our
office holders to achieve ongoing targeted results in addition to high-level business performance in the long term, without encouraging
excessive risk taking. The Company draws upon a pool of talent that is highly sought after by large and established global pharmaceutical
and biotechnology companies, as well as by other development-stage life science companies which operate both within and outside of the
Company&#8217;s geographic areas. The Company believes that it therefore must offer compensation terms, both to its executives and to
its directors that are competitive with the compensation standards that exist in the companies with whom it competes for such talents.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">85</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">In accordance with the Companies Law, an Israeli public company&#8217;s compensation
policy and any amendments thereto must be approved by the board of directors, after considering the recommendations of the compensation
committee, and by a special majority of our shareholders, or a Special Majority, which should include (i) at least a majority of the shareholders
who are not controlling shareholders and who do not have a personal interest in the matter, present and voting (abstentions are disregarded),
or (ii) the non-controlling shareholders and shareholders who do not have a personal interest in the matter who were present and voted
against the matter hold two percent or less of the voting power of the company. The compensation policy must be reviewed from time to
time by the board and must be re-approved or amended by the board of directors and the shareholders no less than every three years. If
the compensation policy is not approved by the shareholders, the compensation committee and the board of directors may nonetheless approve
the policy, following further discussion of the matter and for detailed reasons.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Our Compensation Policy for office holders was originally approved by our shareholders
in September 2013, with the most recent amendment adopted at the 2023 Annual General Meeting of Shareholders held on September 20, 2023,
or the 2023 AGM.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Approvals Required for Office Holders Terms of Employment</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The term &#8220;Office Holder&#8221; as defined in the Companies Law includes a director,
the chief executive officer, chief business manager, deputy chief executive officer, vice chief executive officer, any other person fulfilling
or assuming any of the foregoing positions without regard to such person&#8217;s title, and any manager who is directly subordinated to
the chief executive officer. In addition to each person listed in the table under &#8220;Item 6. Directors, Senior Management and Employees
- A. Directors and Senior Management&#8221;, two other individuals have been Office Holders as of December 31, 2023.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">&#8220;Terms of Office and Employment&#8221; means the terms of office and employment
of our Office Holders, including exemption and release of the Office Holder from liability for breach of his or her duty of care to the
Company, an undertaking to indemnify the Office Holder, post factum indemnification or insurance; any grant, payment, remuneration, compensation,
or other benefit provided in connection with termination of service and any benefit, other payment or undertaking to provide any payment
as aforesaid.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Compensation for Office Holders subordinated to the
Chief Executive Officer.</span> The terms of office and employment of Office Holders (other than directors and the chief executive officer)
require the approval of the compensation committee and the board of directors, provided such terms are in accordance with the company&#8217;s
compensation policy. Shareholder approval is also required if the compensation of such officer is not in accordance with such policy.
However, in special circumstances the compensation committee and then the board of directors may nonetheless approve such compensation
even if such compensation was not approved by the shareholders, following a further discussion and for detailed reasoning.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Compensation for Office Holders who are Directors
or Chief Executive Officers.</span> The Terms of Office and Employment of directors, other than directors who serve as chief executive
officers and/or who possess a controlling interest in a company or who are external directors (to the extent applicable), require the
approval of the compensation committee, board of directors and shareholders by a simple majority, as long as it complies with the compensation
policy. With respect to our president and chief executive officer, who is also a director, or with respect to any chief executive officer
who is not a director (to the extent applicable in the future), further approval of the shareholders by the Special Majority is required.
However: (A) under certain circumstances, and to the extent that the proposed Terms of Office and Employment are in compliance with the
compensation policy, a company may be exempt from receiving shareholder approval with respect to the Terms of Office and Employment of
a candidate for the position of chief executive officer (provided that the candidate is not a director) (i) provided that the company&#8217;s
compensation committee and board of directors approved such terms and that such terms: (a) are not more beneficial than the terms of the
former chief executive officer, or are essentially the same in their effect; (b) are in line with the compensation policy; and (c) are
brought for shareholder approval at the next general meeting of shareholders; and (B) a company&#8217;s compensation committee and board
of directors are permitted to approve Terms of Office and Employment of a director, without convening a general meeting of shareholders,
provided that such terms are only beneficial to the Company or that such terms are in compliance with the terms set forth in the Israeli
Companies Regulations (Rules Regarding Compensation and Expenses of External Directors), 2000, or the Compensation Regulations. To the
extent applicable, external directors are entitled to Terms of Office and Employment as set forth in the Compensation Regulations, as
supplemented by the Israeli Companies Regulations (Alleviation for Public Companies whose shares are Traded on the Stock Exchange Outside
of Israel), 2000, or the Alleviation Regulations. In addition, the Israel Securities Authority may issue from time to time bulletins or
staff position statements relating to, among other things, compensation payable to external directors. Since our board of directors determined
to opt out of the requirement to elect and have external directors and composition criteria of the audit committee and compensation committee
under the Companies Law pursuant to the relief available under the Alleviation Regulations, as further detailed in this Item below under
&#8220;Board Practices - External Directors and Independent Directors Under the Companies Law&#8221;, we are not subject to such bulletins
or staff position statements.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">86</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Variable Compensation and Annual Cash Bonuses of
Office Holders</span>. The Companies Law requires that all variable compensation of directors and chief executive officers be based on
measurable criteria, with the exception of a non-substantial portion of up to 3 monthly salaries, which should take into consideration
the applicable Office Holder&#8217;s contribution to the company. With respect to Office Holders who are not directors or chief executive
officers, the Companies Law allows that 100% of the variable compensation be based on non-measurable criteria. Our Compensation Policy
allows for a non-substantial portion of up to 20% of the bonus objectives for each year to be based on non-measurable criteria, provided,
however, that with respect to (i) our Office Holders who are not directors nor our chief executive officer, our compensation committee
and board of directors may increase the portion of targets based on non-measurable criteria above the rate of 20%, up to 50% and with
respect to our chief executive officer, our compensation committee and board of directors may increase the portion of targets based on
non-measurable criteria for up to three (3) monthly base salaries. Further, the annual cash bonus of each of our Office Holders who is
not a director is determined according to a formula that is consistent with the Compensation Policy and that links the bonus payment score
to measurable and qualitative objectives relating to both the Company&#8217;s performance and to the performance by each such Office Holder
of his responsibilities. In the case of our Office Holders, other than the chief executive officer, assuming that the bonus terms conform
to the Compensation Policy, the annual bonus objectives and subsequent payment scores are determined by the compensation committee and
board of directors, while the bonus terms for our chief executive officer generally require the additional approval by our shareholders.
For each fiscal year, our board of directors determines the maximum target bonus for each of our Office Holders, including our chief executive
officer.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Compensation Paid to our Non-Executive Directors (other than Mr.
Paul Sekhri)</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">On August 6, 2018, our shareholders approved, following previous resolutions made
by our audit committee (then sitting as a compensation committee) and the board of directors, and consistent with our Compensation Policy,
to compensate each of our non-executive directors whether currently in office or appointed in the future, excluding the Chairman of the
Board (each a &#8220;non-executive director&#8221;) as follows:</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic"><span style="text-decoration: underline">Cash Fee</span></div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-left: 7.1pt; line-height: 1.25">(i) an annual fee of $45,000; and</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; margin-left: 9pt; line-height: 1.25">(ii) an additional annual amount to be paid to non-executive directors
for service as members on each of the Company&#8217;s committees, as follows:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z31df3358d891479bb42d77cb6d0617f0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">(a)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Audit Committee - $2,500 for a member, or $5,000 for the chairperson;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zc8f8e4e8c6bd47929a3c12d8e1198d76" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">(b)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Compensation Committee - $2,000 for a member, or $4,000 for the chairperson; and</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zdf68038df7c04866bdfe21218e349e3e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">(c)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Nomination and Governance Committee - $1,000 for a member, or $3,000 for the chairperson.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25">No additional compensation shall be paid for attendance at a board or committee meeting.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">VAT is added to the above compensation in accordance with applicable law.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic"><span style="text-decoration: underline">Equity</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to the cash compensation detailed above, each non-executive director is
entitled to a yearly grant of options to purchase the Company&#8217;s ordinary shares, so that in the first year of service as a director,
each non-executive director shall be entitled to a one-time grant of 35,000 options, or Initial Option Grant, and, in addition, to a yearly
grant of 10,000 options in each of the following years of service, or the Annual Option Grant, as detailed below.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">87</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The grant date of each Initial Option Grant is the date of appointment for service
as director, whether initially appointed by the Board or by the general meeting of shareholders, with an exercise price equal to the closing
price of the Company&#8217;s ordinary shares on the Nasdaq on the last trading day prior to the date of their initial appointment to serve
on the Board. The grant date of each Annual Option Grant shall be such date in each year on which the Board approves the annual option
grants to other management Office Holders (provided that the service as director continues at the time of each grant), with an exercise
price equal to the closing price of the Company&#8217;s ordinary shares on the Nasdaq on the last trading day prior to such Board approval.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Both the Initial and the Annual Option Grants are subject (other than as described
herein) to the terms and conditions of the 2010 Plan, or any other equity-based incentive plan the Company may adopt in the future and
pursuant to which these equity awards would be granted. All such grants vest over a four-year period as follows: twenty five percent (25%)
of the options granted vest on the first day of the quarter one calendar year immediately following the quarter in which the options were
granted; and an additional 6.25% of the options granted vest each quarter thereafter, for the next 36 months.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Notwithstanding the terms of the relevant plan, all options granted to non-executive
directors become fully vested immediately upon the completion of one or more of the following events, whether by way of a consolidation,
merger or reorganization of the Company or otherwise: (a) a sale of all or substantially all of Company&#8217;s issued share capital or
assets to any other company, entity, person or a group of persons, or (b) the acquisition of more than 50% of the Company&#8217;s equity
or voting power by any shareholder or group of shareholders. Further, notwithstanding the terms of the relevant plan, all options granted
which shall be vested as of the date of final termination of office as a non-executive director of the Company may be exercised within
one year following such termination of office. To the extent legally available and applicable, such options will be granted to the non-executive
directors through a trustee under Section 102 of the Israel Income Tax Ordinance [New Version], 5721-1961, or the Tax Ordinance, under
the capital gains route.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">At the Company&#8217;s Annual General Meeting of Shareholders for 2020, held on September
16, 2020, or the 2020 AGM, our shareholders approved, following previous resolutions made by our compensation committee and the board
of directors, and consistent with our Compensation Policy, that instead of an Annual Option Grant, the compensation committee and the
board may issue to all non-executive directors RSUs or other equity awards which are not options, or Other Equity,&#160;in which case
the Annual Option Grant of 10,000 options shall be&#160;adjusted to 5,000 units of Other Equity awards, provided, that with respect to
an annual equity grant that combines both types of equity awards (<span style="font-style: italic">i.e.</span>, options and Other Equity),
such grant shall be adjusted, on a&#160;pro rata&#160;basis, to give effect to the relative portion of each type of equity awarded (for
illustration purposes, if the compensation committee and board approve the grant of 4,000 RSUs to the non-executive directors, the relevant&#160;annual
equity grant will be comprised of a total of 6,000 units, out of which 4,000 will be RSUs and 2,000 will be options).</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The provisions relating to vesting, acceleration and exercise period applicable to
options, as specified above, shall apply to Other Equity that may be granted,&#160;<span style="font-style: italic">mutatis mutandis</span>.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Compensation to the Company&#8217;s Chairman of the Board of Directors,
a Non-Executive Director</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">On October 19, 2017, our shareholders approved, following previous resolutions made
by our audit committee (then sitting as a compensation committee) and the board of directors, and consistent with our Compensation Policy,
the following compensation for our non-executive Chairman of the Board, Mr. Paul Sekhri:</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Cash Fees: </span>An annual cash fee in the amount
of $150,000. No meeting fees will be paid in addition to such annual cash fee.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Grant of Options to Purchase Ordinary Shares:</span>
In connection with his appointment as the Chairman of the Board, we issued to Mr. Sekhri an initial grant of options to purchase 500,000
ordinary shares. These options were issued pursuant to the terms and conditions applicable to options granted under the Company&#8217;s
2010 Option Plan. Such grant vested over a four-year period as follows: twenty five percent (25%) vested on the first day of the quarter
one calendar year immediately following the quarter in which the options were granted; and an additional 6.25% vested each quarter thereafter
for the next 36 months. These options will expire ten years after the grant date, unless they expire earlier in accordance with the terms
of the Company&#8217;s 2010 Option Plan. The acceleration provisions applicable to options granted to other non-executive directors also
apply to the options granted to Mr. Sekhri and all options granted which shall be vested as of the date of final termination of office
as a director of the Company may be exercised within one year following such termination date.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">88</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">At the 2020 AGM, our shareholders approved, following previous resolutions made by
our compensation committee and the board of directors, and consistent with our Compensation Policy, that Mr. Sekhri, in his role as the
non-executive chairman of the Board, shall be entitled to an annual option grant of 10,000 options to purchase Ordinary Shares each year,
or Chairman&#8217;s Annual Option Grant, starting from 2020 and for each of the following years of service, similar to the terms of the
Annual Option Grant to the other non-executive directors as specified above.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As approved for the other non-executive directors, instead of Chairman&#8217;s Annual
Option Grant, the compensation committee and the board may issue to Mr. Sekhri Other Equity,&#160;in which case the Chairman&#8217;s Annual
Option Grant of 10,000 options shall be&#160;adjusted to 5,000 units of Other Equity awards, provided, that with respect to an annual
equity grant that combines both types of equity awards, such grant shall be adjusted, on a&#160;pro rata&#160;basis, to give effect to
the relative portion of each type of equity awarded as specified above with respect to other non-executive directors.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25">The provisions relating to vesting, acceleration and exercise period applicable to
the options, as specified above, shall apply to Other Equity that may be granted as set forth above,&#160;<span style="font-style: italic">mutatis
mutandis</span>.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Compensation to our President and Chief Executive Officer</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">&#160;Pursuant to Dr. Anat Cohen-Dayag&#8217;s employment agreement (and in accordance
with the approval of her updated compensation terms at the 2023 AGM), as the chief executive officer of the Company she is entitled to
a gross monthly salary of NIS 150,000 (approximately $40,650 according to the Representative Rate). Dr. Cohen-Dayag is also entitled to
certain benefits and perquisites customary in Israel, including those mandated by applicable law. In addition, Dr. Anat Cohen-Dayag is
eligible for an annual grant of equity-based compensation and to an annual cash bonus based upon achievement of objectives determined
by the Company, both subject to receipt of all approvals required by applicable law and to the terms of our Compensation Policy.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">At the 2020 AGM, our shareholders approved that Dr. Cohen-Dayag shall be eligible
to receive an annual cash bonus of up to nine monthly salaries for each of the calendar years 2021, 2022 and 2023, without the need for
further shareholder approval, subject to meeting the specific performance criteria determined by the compensation committee and board
with respect to each such year, in accordance with the objectives and terms thereof and the continuous employment of Dr. Cohen-Dayag as
the Company&#8217;s chief executive officer through the last day of the calendar year with respect to which the annual cash bonus is proposed
to be paid. The same terms were approved at the 2023 AGM with respect to the calendar years 2024, 2025 and 2026.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Additionally, at the 2023 AGM, our shareholders approved an annual equity grant plan
for Dr. Cohen-Dayag for each of the calendar years 2024, 2025 and 2026, according to which Dr. Cohen-Dayag shall be granted options to
purchase up to 300,000 Ordinary Shares, or Equity Framework, in each of these years, as shall be determined by the compensation committee
and board of directors with respect to each such year. In order to align such grants (including the exercise price and vesting period)
with the annual grant of options to other executive Office Holders (for whom shareholder approval is not required), our shareholders resolved
that the annual grant to Dr. Cohen-Dayag will be made on such date in 2024, 2025 and 2026 on which the board of directors approves the
respective year&#8217;s annual option grants to management Office Holders in such year.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The compensation committee and the board of directors may nevertheless determine that
as part of an annual equity grant, they wish to issue&#160;Dr. Cohen-Dayag Other Equity. For the purpose of demining the applicability
of the Equity Framework to Other Equity, Other Equity shall be given a &#8220;double weight&#8221; relative to options, so that each unit
of Other Equity will be equal to two (2) option units. For illustration purposes, if the compensation committee and board of directors
approve an annual equity grant to Dr. Cohen-Dayag of 40,000 options and 30,000 RSUs, then for the purpose of determining whether such
grant is within the Equity Framework, the 30,000 RSUs will be given a weight of 60,000 units and the 40,000 options will be counted as
40,000 units, comprising an aggregate of 100,000 units which is within the Equity Framework. In any event, at least 30% of the value of
any annual equity grant to Dr. Cohen-Dayag shall be based on either (i) options granted with fair market value exercise price; or (ii)
Other Equity which vesting is based on both time and performance criteria, as shall be determined by the compensation committee and board
of directors.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">89</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">The options granted in each respective year shall be subject to the terms and conditions
applicable to options granted under the 2010 Plan (or any other option plan adopted by the Company). Each annual option grant will vest
over a four-year period as follows: twenty five percent (25%) will vest on the last day of the quarter one calendar year from the date
of grant; and an additional 6.25% will vest each quarter thereafter for the next 36 months. These options will have an exercise price
equal to the closing price of the Company&#8217;s ordinary shares on Nasdaq on the last trading day prior to the approval of each year&#8217;s
grant by the board of directors. These options will expire ten years after the grant date, unless they expire earlier in accordance with
the terms of the 2010 Plan or the terms of the option agreement to be entered into between the Company and Dr. Cohen-Dayag. If applicable,
the options will be granted through a trustee under Section 102 of the Tax Ordinance and, in accordance with the Company&#8217;s previous
election in this regard, be subject to the capital gains route for tax purposes.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">All vested options and Other Equity (to the extent applicable) granted to Dr. Cohen-Dayag
under the Equity Framework shall have a one-year exercise period following the termination of her employment as the Company&#8217;s chief
executive officer, other than in the event of termination for &#8220;cause&#8221; (as defined in her employment agreement as shall be
in effect from time to time). In addition to the foregoing, and not as part of the Equity Framework, Dr. Anat Cohen-Dayag will be entitled
to participate in the ESPP or any other employee share purchase plan(s) that may be adopted by the Company from time to time until the
end of 2026, as long as the fair market value of the benefit provided to her under such employee share purchase plan(s) (determined by
the Company at the beginning of the respective offering period) in any given twelve (12) month period does not exceed ten percent (10%)
of her annual base salary.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">In addition to the foregoing annual equity grant plan for 2024 through 2026 and the
annual grant for 2023 already approved by our shareholders at the 2020 AGM, at the 2023 AGM, our shareholders approved a special option
grant of additional options to purchase 150,000 ordinary shares with an exercise price equal to the closing price of the Company&#8217;s
ordinary shares on the Nasdaq on the last trading day prior to the 2023 AGM, or the 2023 Special Option Award. All the terms of the 2023
Special Option Award are the same as those set forth above with respect to the options underlying the annual equity grant plan.</div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In 2023 Dr. Cohen-Dayag was granted with 300,000 options (including the 2023 Special
Option Award), 150,000 of which with an exercise price of $1.15 (pursuant to the terms of the CEO&#8217;s three-year equity framework
approved by our shareholders in 2020 AGM) and 150,000 of which with an exercise price of $1.02 (pursuant to the terms of the 2023 Special
Option Award). As of December 31, 2023, Dr. Cohen-Dayag held options to purchase a total of 1,420,000 ordinary shares. Out of these outstanding
options: (i) options to purchase 932,500 ordinary shares, with a weighted average exercise price of $6.35 per share, were exercisable
as of December 31, 2023; and (ii) options to purchase 487,500 ordinary shares, with a weighted average exercise price of $3.20 per share,
had not vested as of December 31, 2023. Of the unvested options on December 31, 2023, options to purchase 206,250 ordinary shares are
expected to vest during 2024, options to purchase 140,625 ordinary shares are expected to vest during 2025 and options to purchase the
remaining 140,625 ordinary shares are expected to vest during the period between March 31, 2026, and September 30, 2027. These unvested
options were granted under the Company&#8217;s 2010 Plan. For additional information on Dr. Cohen-Dayag&#8217;s holdings see &#8220;Item
6. Directors, Senior Management and Employee - E. Share Ownership - Share Ownership by Directors and Other Executive Officers.&#8221;</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">Dr. Cohen-Dayag&#8217;s employment agreement may generally be terminated by either
party by providing six (6) months advance written notice, provided that in the event of termination by the Company for &#8220;justifiable
cause&#8221; (as such term is defined in her employment agreement as shall be in effect from time to time) the Company may terminate Dr.
Cohen-Dayag&#8217;s employment without advance notice and that Dr. Cohen-Dayag may resign with advance notice of only two (2) months in
the event of resignation for &#8220;good reason&#8221; (as such term is defined in her employment agreement as shall be in effect from
time to time). Upon termination, Dr. Anat Cohen-Dayag will be entitled to receive certain payments associated with termination.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the event that Dr. Cohen-Dayag&#8217;s employment is: (a) terminated by the Company,
other than for &#8220;justifiable cause&#8221;; or (b) terminated by Dr. Cohen-Dayag for &#8220;good reason&#8221; (hereinafter, (a) and
(b) shall be referred to together as &#8220;Dismissal&#8221;), Dr. Cohen-Dayag will also be entitled to an additional one-time payment
equal to six (6) monthly salaries, or the Termination Payment, and upon Dismissal within one year following certain &#8220;change of control&#8221;
events (as defined in her employment agreement as shall be in effect from time to time), Dr. Cohen-Dayag will be entitled to a special
termination payment (in addition to the Termination Payment) in an amount equal to six (6) monthly salaries.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">90</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">In addition, upon Dismissal, or in the event of a &#8220;change of control&#8221;,
all outstanding unvested options granted to Dr. Cohen-Dayag as of such time will be accelerated and become immediately exercisable as
of the effective date of such Dismissal or change of control. Upon Dismissal, Dr. Cohen-Dayag will also be entitled to exercise all outstanding
vested options (including those options vested as a result of such accelerated vesting) for a period of one (1) year from the date of
such Dismissal, provided that such period does not extend beyond ten (10) years from the date of grant. Upon an event of change of control,
following which Dr. Cohen-Dayag&#8217;s employment is, within 12 months of the closing of such an event: (a) terminated by the Company,
other than for &#8220;justifiable cause&#8221;; or (b) terminated by Dr. Cohen-Dayag for any reason, Dr. Cohen-Dayag will be entitled
to exercise all outstanding vested options (including those vested as a result of such accelerated vesting) for a period of one (1) year
from the date of termination of her employment, provided that such period does not extend beyond ten (10) years from the date of grant.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Dr. Cohen-Dayag is not entitled to any compensation (including in connection with
her role as a director) in addition to that being paid to her as the chief executive officer of the Company. However, in the event of
termination of Dr. Cohen-Dayag employment agreement, she will be entitled to receive such compensation to the extent and for as long as
she will serve as a non-executive director of the Company.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Insurance, Indemnification and Exemption</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Our Office Holder&#8217;s Insurance</span>. Our Articles
provide that, subject to the provisions of the Companies Law, we may enter into contracts to insure the liabilities of our Office Holders
for any liabilities or expenses incurred by or imposed upon them as a result of any act (or omission) carried out by them as our Office
Holders, including with respect to any of the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z12056a5c99274b42ab6001d1888ed1ac" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>a breach of duty of care to us or to another person;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z552012ba4b854a50b44317a8087b8bd4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>a breach of duty of loyalty to us, provided that the Office Holder acted in good faith and had reasonable grounds to assume that
        such act would not prejudice our interests;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd8dd80c884134424958ab5d469c13d06" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>monetary liabilities or obligations imposed upon him or her in favor of another person;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb948bd76a9464e5a8d5ede145eb7cc09" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>A payment which the Office Holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Securities
        Law, and expenses that the Office Holder incurred in connection with a proceeding under Chapters H&#8217;3, H&#8217;4 or I&#8217;1 of
        the Securities Law, including reasonable litigation expenses, including attorney&#8217;s fees, or in connection with Article D of Chapter
        Four of Part Nine of the Companies Law; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z214efd53e16f49f38113aaee922c9796" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Expenses incurred by the Office Holder in connection with a proceeding under Chapter G&#8217;1, of the Israel Restrictive Trade Practices
        Law, 5748-1988, or Restrictive Trade Law, including reasonable litigation expenses, including attorney&#8217;s fees.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law, exemption and indemnification of, and procurement of insurance
coverage for, our Office Holders, must be approved by our compensation committee and our board of directors and, with respect to an Office
Holder who is the CEO or a director, also by our shareholders. However, according to regulations promulgated under the Companies Law,
shareholders and board of directors approvals for the procurement of such insurance are not required if the insurance policy is approved
by our compensation committee and: (i) the terms of such policy are within the framework for insurance coverage as approved by our shareholders
and set forth in our Compensation Policy; (ii) the premium paid under the insurance policy is at fair market value; and (iii) the insurance
policy does not and may not have a substantial effect on the Company&#8217;s profitability, assets or obligations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In accordance with our Compensation Policy, approved by our shareholders at the 2023
AGM,&#160;we are currently entitled to hold directors&#8217; and officers&#8217; liability insurance policy for the benefit of our Office
Holders with insurance coverage of up to $100 million and with such annual premium reflecting market&#160;terms&#160;and not having a
substantial effect on our profitability, assets or obligations.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">91</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic"> <br/> </span></div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Our Office Holders&#8217; Indemnification.&#160;</span>Our
Articles provide that, subject to the provisions of the Companies Law, we may indemnify any of our Office Holders for all liabilities
and expenses incurred by them arising from or as a result of any act (or omission) carried out by them as Office Holders of the Company,
including as follows:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zffd63e4c291d4ac88b40297b126b0448" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>For any monetary liabilities or obligations imposed on our Office Holder in favor of another person pursuant to a court judgment,
        including a compromise judgment or an arbitrator&#8217;s decision approved by a court;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3d59a51334a24ac0bdab735c1aedb62b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>For any payments which our Office Holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the
        Israeli Securities Law and expenses the Office Holder incurred in connection with a proceeding under Chapters H&#8217;3, H&#8217;4 or
        I&#8217;1 of the Israeli Securities Law, including reasonable litigation expenses, including attorney&#8217;s fees, or in connection with
        Article D of Chapter Four of Part Nine of the Companies Law;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4f5676272b33459197cc792f55b52790" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>For reasonable litigation expenses, including attorney&#8217;s fees, incurred by the Office Holder in consequence of an investigation
        or proceeding instituted against the Office Holder by an authority that is authorized to conduct such investigation or proceeding, and
        which was concluded without filing of an indictment against the Office Holder and without imposing on the Office Holder a financial obligation
        in lieu of criminal proceedings, or which was concluded without filing of an indictment against the Office Holder but with imposing on
        such Office Holder a financial obligation in lieu of criminal proceedings in respect of an offense that does not require proof of criminal
        intent or in connection with a financial sanction; For the purposes hereof: (i) &#8220;a proceeding that concluded without filing an indictment
        in a matter in respect of which an investigation was conducted&#8221;; and (ii) &#8220;financial obligation in lieu of a criminal proceeding&#8221;,
        shall have the meanings specified in Section 260(a)(1A) of the Companies Law;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2f0e8d7b3bce4b67885012841db3e3d9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>For reasonable litigation expenses, including attorney&#8217;s fees, incurred by the Office Holder or which the Office Holder is
        ordered to pay by a court, in a proceeding filed against the Office Holder by the Company or on its behalf or by another person, or in
        a criminal action of which the Office Holder is acquitted, or in a criminal action in which the Office Holder is convicted of an offense
        that does not require proof of criminal intent;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z379ba0b1386d44ce8aff2ca24d535f1a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>For expenses incurred by our Office Holder in connection with a proceeding under Chapter G&#8217;1, of the Restrictive Trade Law,
        including reasonable litigation expenses, including attorney&#8217;s fees; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8ea53dc51c1a49a29dd5a295fbd0c65f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>For any other liability, obligation or expense indemnifiable or which our Officer Holders may from time to time be indemnifiable
        by law.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Company may undertake to indemnify an office holder as mentioned above: (a) prospectively,
provided that with respect of the first act (financial liability) the undertaking is limited to events which in the opinion of the board
of directors are foreseeable in light of the Company&#8217;s actual operations when the undertaking to indemnify is given, and to an amount
or criteria set by the board of directors as reasonable under the circumstances, and further provided that such events and amount or criteria
are set forth in the undertaking to indemnify, and (b) retroactively.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Indemnification letters, covering indemnification of those liabilities discussed above,
were granted to each of our present Office Holders and were amended at the Company&#8217;s Annual General Meeting of Shareholders for
2021, held on September 2, 2021, or the 2021 AGM. The indemnification letters, as amended, seek to indemnify our Office Holders to the
fullest extent permitted under the Companies Law, subject to the specific limitations specified therein.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Our Office Holder&#8217;s Exemption. </span>Our Articles
provide that, subject to the provisions of the Companies Law, we may exempt and release our Office Holders, including in advance, from
all or part of such Office Holder&#8217;s liability for monetary or other damages due to a breach of their duty of care to the Company.
Our directors are released and exempt from all liability as aforesaid to the fullest extent permitted by law with respect to any such
breach, which has been or may be committed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Limitations on Insurance, Indemnification and Exemption.</span>&#160;The
Companies Law provides that a company may not insure, exempt or indemnify an Office Holder for any breach of his or her liability arising
from any of the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z671eee55abe04b8796325bb20547f335" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>a breach by the Office Holder of his or her duty of loyalty, except that the company may enter into an insurance contract or indemnify
        an Office Holder if the Office Holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8b950a98f86b4862b665872c9abcb25a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>a breach by the Office Holder of his or her duty of care if such breach was intentional or reckless, but unless such breach was solely
        negligent;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z327c10b81dd347458733b60db9e9d4e8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>any act or omission done with the intent to derive an illegal personal benefit; or</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd6096c5e97f94bd98ebb9275b4b3ab26" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>any fine, civil fine, financial sanction or monetary settlement in lieu of criminal proceedings imposed on such Office Holder.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">92</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Administrative Enforcement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Israeli Securities Law includes an administrative enforcement procedure that may
be used by the Israeli Securities Authority, to enhance the efficacy of enforcement in the securities market in Israel. Pursuant to the
Companies Law and the Israeli Securities Law, the Israeli Securities Authority is authorized to impose administrative sanctions, including
monetary fines, against companies like ours and their officers and directors for certain violations of the Israeli Securities Law or the
Companies Law. Furthermore, the Israeli Securities Law requires that the CEO of a company supervise and take all reasonable measures to
prevent the company or any of its employees from breaching the Israeli Securities Law. The CEO is presumed to have fulfilled such supervisory
duty if the company adopts internal enforcement procedures designed to prevent such breaches, appoints a representative to supervise the
implementation of such procedures and takes measures to correct the breach and prevent its reoccurrence.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Israeli Securities Law, a company cannot obtain insurance against or indemnify
a third-party (including its officers and/or employees) for any administrative procedure and/or monetary fine (other than for payment
of damages to an injured party). The Israeli Securities Law permits insurance and/or indemnification for expenses related to an administrative
procedure, such as reasonable legal fees, provided that it is permitted under the company&#8217;s articles of association.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have adopted and implemented an internal enforcement plan to reduce our exposure
to potential breaches of sections in the Companies Law and the Israeli Securities Law, applicable to us. Our Articles and letters of indemnification
permit, among others, insurance and/or indemnification as contemplated under the Israeli Securities Law (see &#8220;<span style="font-style: italic">Insurance,
Indemnification and Exemption&#8221;</span> above).</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. BOARD PRACTICES</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">We are incorporated in Israel, and, therefore, are generally subject to various corporate
governance practices under Israeli law such as with respect to external directors, independent directors, audit committee, compensation
committee, an internal auditor and approvals of interested party transactions. These matters are in addition to the requirements of The
Nasdaq Capital Market and other relevant provisions of U.S. securities laws applicable to us. Under the Nasdaq Listing Rules, a foreign
private issuer may generally follow its home country practices for corporate governance in lieu of the comparable Nasdaq Capital Market
requirements, except for certain matters such as composition and responsibilities of the audit committee and the SEC-mandated standards
for the independence of its members. We currently comply with all the above-mentioned requirements. See &#8220;Item 3. Key Information
- D. Risk Factors - Risks related to operations in Israel - Being a foreign private issuer exempts us from certain SEC requirements and
Nasdaq rules, which may result in less protection that is afforded to investors under rules applicable to domestic issuers&#8221;. For
information regarding home country practices followed by us see &#8220;Item 16G - Corporate Governance&#8221;.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Board of Directors</div> &#160;

<div style="text-align: justify; line-height: 1.25">Our Articles provide that we may have no less than five nor more than fourteen directors.
Currently our board of directors consists of seven members. Our directors are elected at the annual general meeting for a term of approximately
one year, ending at the annual general meeting immediately following the annual general meeting at which they were elected or upon earlier
termination in circumstanced referred to under the Companies Law or our Articles. Our directors may further be appointed by the board
of director and in this case shall hold office until the end of the immediately following annual general meeting or upon earlier termination
in circumstanced referred to under the Companies Law or our Articles.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">None of our directors is party to a service contract with us that provides for any
severance or similar benefits upon termination of his or her service, other than our president and chief executive officer, Dr. Anat Cohen-Dayag,
with whom we entered into an employment agreement. For additional information on the employment agreement entered into with Dr. Cohen-Dayag,
please see &#8220;Item 6 - Directors, Senior Management and Employees - B. Compensation - Compensation to our President and Chief Executive
Officer.&#8221;</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">93</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Board of Directors Diversity</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">The table below provides certain information regarding the diversity of our board of directors.</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" border="0" id="z343e569f025f4950b17b1552291cfcae" style="font: 10pt Times New Roman,Times,serif; width: 100%; text-align: left; color: rgb(0, 0, 0)">
  <tr>
    <td colspan="5" style="border-top: rgb(0, 0, 0) 1px solid; width: 100%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">Board Diversity Matrix as of February 20,
        2024</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Total Number of Directors</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 1px solid; width: 64.18%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">7</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid; background-color: rgb(182, 182, 182)">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid; background-color: rgb(182, 182, 182)">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">Female</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid; background-color: rgb(182, 182, 182)">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">Male</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid; background-color: rgb(182, 182, 182)">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">Non-Binary</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid; background-color: rgb(182, 182, 182)">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">Did Not Disclose Gender</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid; background-color: rgb(182, 182, 182)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Part I: Gender Identity</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 1px solid; width: 64.18%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid; background-color: rgb(182, 182, 182)">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Directors</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">2</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">4</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">1</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid; background-color: rgb(182, 182, 182)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Part II: Demographic Background</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 1px solid; width: 64.18%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid; background-color: rgb(182, 182, 182)">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">African American or Black</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Alaskan Native or Native American</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Asian</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Hispanic or Latinx</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Native Hawaiian or Pacific Islander</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">White</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">2</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">3</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Two or More Races or Ethnicities</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">1</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">LGBTQ+</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 1px solid; width: 64.18%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">1</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 35.82%; vertical-align: top; border-bottom: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Did Not Disclose Demographic Background</div> </td>
    <td colspan="4" style="border: rgb(0, 0, 0) 1px solid; width: 64.18%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">1</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Directors Under the Companies Law - General</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">A nominee for service as a director in a public company may not be elected without
submitting a declaration to the company, prior to his or her election, specifying that he or she has the requisite qualifications to serve
as a director, an external director or an independent director, as applicable, and the ability to devote the appropriate time to performing
his or her duties as such.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">A director, including an external director or an independent director, who ceases
to meet the statutory requirements to serve as a director, external director or independent director, as applicable, must notify the company
to that effect immediately and his or her service as a director will expire upon submission of such notice.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">External Directors and Independent Directors Under the Companies
Law</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law, Israeli public companies are generally required to have on
their board of directors at least two external directors meeting certain independence criteria, provided under Israeli law. In accordance
with the Alleviation Regulations, we, as an Israeli public company with no controlling shareholder (within the meaning of the Companies
Law), whose shares are listed on The Nasdaq Capital Market, may opt out from the requirement of electing and having external directors
on our board of directors and related requirements concerning the composition of the audit and compensation committees of the board of
directors, provided that we do not have a controlling shareholder, we continue to comply with the U.S. securities laws and Nasdaq Listing
Rules applicable to U.S. domestic issuers regarding the independence of the board of directors and the composition of the audit and compensation
committee, or the Opt Out Criteria. On June 7, 2018, our board of directors determined to opt out of the requirement to elect and have
external directors and of the rules governing composition of the audit committee and compensation committee under the Companies Law pursuant
to the relief available under the Alleviation Regulations, since at that time (and since that time) we have complied and continue to comply
with the Opt Out Criteria. In accordance with this decision, we currently have no external directors on our board of directors and we
are subject to the U.S. securities laws and Nasdaq Listing Rules applicable to U.S. domestic issuers regarding the independence of our
board of directors and the composition of our audit and compensation committees.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The term controlling shareholder, as used in the Companies Law for purposes of all
matters related to external directors and for certain other purposes, means a shareholder that has the ability to direct the activities
of the company, other than by virtue of being an Office Holder. For purposes of all matters related to external directors, a shareholder
is presumed to be a controlling shareholder if the shareholder holds 50% or more of the voting rights in the company or has the right
to appoint the majority of the directors of the company or its chief executive officer.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law, an &#8216;independent director&#8217; is either an external
director or a director appointed or classified as such who meets the same non-affiliation criteria as an external director, as determined
by the company&#8217;s audit committee, and who has not served as a director of the company for more than nine consecutive years. For
these purposes, ceasing to serve as a director for a period of two years or less would not be deemed to sever the consecutive nature of
such director&#8217;s service. However, as our shares are listed on The Nasdaq Capital Market, pursuant to the Alleviation Regulations,
we may also classify directors who qualify as independent directors under the relevant non-Israeli rules, as &#8216;independent directors&#8217;
under the Companies Law. In addition, the Alleviation Regulations provide that &#8216;independent directors&#8217; may be elected for
additional terms that do not exceed three years each, beyond the 9 consecutive years, provided that, if the director is being re-elected
for an additional term or terms beyond the 9 consecutive years, the audit committee and board of directors must determine that, in light
of the director&#8217;s expertise and special contribution to the board of directors and its committees, the re-election for an additional
term is to the company&#8217;s benefit and the director must be re-elected by the required majority of shareholders and subject to the
terms specified in the Companies Law. Each of our directors, other than Dr. Anat Cohen-Dayag, who also serves as our chief executive officer,
meets the &#8216;independent directors&#8217; criteria under the Companies Law.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">94</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Independent Directors Under the Nasdaq Listing
Rules</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">In addition to the requirements of the Companies Law as described above, since our
shares are listed on The Nasdaq Capital Market, pursuant to the Nasdaq Listing Rules, a majority of our directors must be independent
(as defined under the Nasdaq Listing Rules). We comply with such Nasdaq independence requirement, as each of our directors, other than
Dr. Anat Cohen-Dayag, who also serves as our president and chief executive officer, has been determined by our board of directors to meet
the Nasdaq independence requirements.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Financial and Accounting Expertise Under the
Companies Law</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the Companies Law, the board of directors of a publicly traded company
is required to make a determination as to the minimum number of directors who must have financial and accounting expertise according to
criteria set forth under the Companies Law and regulations promulgated there under and based, among other things, on the type of company,
its size, the volume and complexity of the company&#8217;s activities and the number of directors. Our board of directors has determined
that the minimum number of directors with financial and accounting expertise is one. Currently, each of Mr. Gilead Halevy, Mr. Eran Perry
and Mr. Sanford (Sandy) Zweifach qualifies as such.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Board Committees</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Audit Committee</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Companies Law requires public companies such as ours to appoint an audit committee,
the responsibilities of which include, among other things: (i) identifying flaws in the management of the company&#8217;s business, among
other things, in consultation with the company&#8217;s internal auditor or external auditor, and making recommendations to the board of
directors as to how to correct them, (ii) reviewing and considering certain related party transactions and certain actions involving conflicts
of interest (as well as deciding whether certain actions specified in the Companies Law are considered material or non-material and whether
certain transactions are considered exceptional or ordinary), (iii) establishing procedures to be followed with respect to related party
transactions with a &#8220;controlling shareholder&#8221; (where such are not extraordinary transactions), which may include, where applicable,
the establishment of a competitive process for such transaction, under the supervision of the audit committee, or individual, or other
committee or body selected by the audit committee, in accordance with criteria determined by the audit committee, (iv) determining procedures
for approving certain related party transactions with a &#8220;controlling shareholder&#8221;, which were determined by the audit committee
not to be extraordinary transactions, but which were also determined by the audit committee not to be negligible transactions, (v) reviewing
the internal auditor&#8217;s work program performance, examining the company&#8217;s internal control structure and processes and determining
whether the internal auditor has the requisite tools and resources required to perform his or her role, (vi) examining the external auditor&#8217;s
scope of work as well as the external auditor&#8217;s fees and providing its recommendations to the appropriate corporate organ, (vii)
overseeing the accounting and financial reporting processes of the Company, and (viii) providing arrangements regarding employee complaints
with respect to flaws in the management of the Company&#8217;s business and the protection to be provided to such employees.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Nasdaq Listing Rules, we are required to maintain an audit committee that
operates under a formal written charter and has certain responsibilities and authority, including being directly responsible for the appointment,
compensation, retention and oversight of the work of our external auditor. However, under Israeli law and our Articles, the appointment
of external auditor requires the approval of the shareholders and their compensation requires the approval of our board of directors.
In addition, as described above, pursuant to the Companies Law, the audit committee is required to examine the external auditor&#8217;s
scope of work as well as the external auditor&#8217;s fees and to provide its recommendations with respect thereto to the appropriate
corporate organ. Accordingly, the appointment of our external auditor is approved by our shareholders at the audit committee&#8217;s recommendation
and its compensation for audit and non-audit services is approved by the board of directors following the audit committee&#8217;s recommendation.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">95</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have adopted a charter for the audit committee, which sets forth the purpose and
responsibilities of such committee.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In carrying out its duties, the audit committee meets with management at least once
in each fiscal quarter at which time, among other things, it reviews, and either approves or disapproves, the financial results of the
Company for the immediately preceding fiscal quarter and conveys its conclusions in this regard to the board of directors. The audit committee
also generally monitors the services provided by the Company&#8217;s external auditor to ensure their independence and reviews all audit
and non-audit services provided by them. The Company&#8217;s external and internal auditors also report regularly to the audit committee
and the audit committee discusses with our external auditor the quality, not just the acceptability, of the accounting principles, the
reasonableness of significant judgments and the clarity of disclosures in our financial statements, as and when it deems it appropriate
to do so.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Nasdaq Listing Rules, the audit committee is required to consist of at least
three independent directors, each of whom is financially literate and at least one of whom has accounting or related financial management
expertise.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have an audit committee consisting of three directors, Mr. Gilead Halevy,<span style="font-weight: bold">&#160;</span>who<span style="font-weight: bold">&#160;</span>serves
as the chairman of our audit committee, Mr. Eran Perry and Mr. Sanford (Sandy) Zweifach, all of whom are financially literate under the
applicable rules and regulations of the SEC and Nasdaq Listing Rules and each of whom is an audit committee financial expert, as defined
by the SEC rules, and has the requisite financial experience required under the Nasdaq Listing Rules. Additionally, each of the members
of the audit committee is &#8220;independent&#8221; as such term is defined in Rule 10A-3(b)(1) under the Exchange Act, which is different
from the general test for independence of board and committee members under the Nasdaq Listing Rules.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The audit committee composition requirements referred to under Section 115 of the
Companies Law are not applicable to the Company as our board of directors, as part of its decision to opt out of the requirement to elect
external directors pursuant to the relief available under the Alleviation Regulations, also opted out of such composition requirements
on the basis that the Company complies, and will continue to comply, with the U.S. Securities Law and Nasdaq Listing Rules concerning
the composition of the audit committee, as described above.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Compensation Committee</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The Companies Law generally provides that public companies such as the Company must
appoint a compensation committee, the responsibilities of which include, among others: (i) reviewing and making recommendations to the
board of directors with respect to our Compensation Policy and with respect to any updates which may be required thereto from time to
time, (ii) reviewing the implementation of the Compensation Policy by the Company, (iii) reviewing and considering arrangements with respect
to the Terms of Office and Employment of Office Holders, (iv) exempting, under certain circumstances, a transaction relating to the Terms
of Office and Employment of Office Holders from the requirement of approval of the shareholders, and (v) overseeing, subject to applicable
law, the administration of the Company&#8217;s various compensation plans and arrangements, including, incentive compensation and equity
based plans. Under the Companies Law, the compensation committee may need to seek the approval of the board of directors and the shareholders
for certain compensation-related decisions, (see &#8220;Item 6 - Directors, Senior Management and Employees - B. Compensation - Approvals
Required for Office Holders Terms of Employment&#8221;).</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">We have adopted a charter for the compensation committee, which sets forth the purpose
and responsibilities of such committee.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Under the Nasdaq Listing Rules, we are required to maintain a compensation committee
consisting of at least two independent directors (as defined under the Nasdaq Listing Rules). Each compensation committee member must
also be deemed by our board of directors to meet the enhanced independence requirements for members of the compensation committee under
the Nasdaq Listing Rules, which requires, among other things, that our board of directors considers the source of each such committee
member&#8217;s compensation in considering whether he or she is independent.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">96</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The compensation committee composition requirements referred to under Section 118A
of the Companies Law are not applicable to the Company as our board of directors, as part of its decision to opt out of the requirement
to elect external directors pursuant to the relief available under the Alleviation Regulations, also opted out of such composition requirements
on the basis that the Company complies, and will continue to comply, with the Nasdaq majority board independence requirement and with
US Securities Law and Nasdaq Listing Rules concerning the composition of the compensation committee, as described above.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">We have a compensation committee consisting of three directors, Mr. Sanford (Sandy)
Zweifach, who serves as the chairman of our compensation committee, Dr. Kinneret Livnat Savitzky and Eran Perry.&#160;Each member of our
compensation committee is an &#8216;independent director&#8217; in accordance with the Nasdaq listing standards.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Nomination and Corporate Governance Committee</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The Nasdaq Listing Rules require that director nominees be selected or recommended
for the board&#8217;s selection either by a nomination committee composed solely of independent directors, or by a majority of independent
directors, in a vote in which only independent directors participate, subject to certain exceptions. Mr. Paul Sekhri, who serves as the
chairman of our nomination and corporate governance committee, Dr. Kinneret Livnat Savitzky and Mr. Sanford (Sandy) Zweifach, each an
independent director, are the members of our nomination and corporate governance committee, which, among other responsibilities, recommends
director nominees for our board&#8217;s approval.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Internal Auditor</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law, the board of directors must appoint an internal auditor,
recommended by the audit committee. The role of the internal auditor is to examine, among other matters, whether the company&#8217;s actions
comply with the law and orderly business procedures. Under the Companies Law, an interested party or an Office Holder of a company, or
a relative of an interested party or of an Office Holder of a company, as well as the company&#8217;s external auditor or any one on behalf
of the external auditor may not serve as a company&#8217;s internal auditor. The internal auditor&#8217;s tenure cannot be terminated
without his or her consent, nor can he or she be suspended from such position unless the board of directors has so resolved after hearing
the opinion of the audit committee and after providing the internal auditor with the opportunity to present his or her position to the
board of directors and to the audit committee. An interested party is defined in the Companies Law as a holder of 5% or more of the company&#8217;s
outstanding shares or voting rights, any person or entity who has the right to designate one or more directors or the chief executive
officer of the company or any person who serves as a director or as a chief executive officer of the company.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Ms. Tali Yaron of Brightman, Almagor, Zohar &amp; Co., a member firm of Deloitte Touche
Tohmatsu, has served as our internal auditor since 2023 (replacing a different partner at Brightman Almagor Zohar &amp; Co., a member
firm of Deloitte Touche Tohmatsu during 2023). Ms. Tali Yaron is not an employee, affiliate or Office Holder of the Company, or affiliated
with the Company&#8217;s external auditor.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Fiduciary Duties and Approval of Related Party Transactions Under
Israeli Law</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Fiduciary Duties of Office Holders</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The Companies Law codifies the fiduciary duties that Office Holders owe to a company.
All persons listed in the table under &#8220;Item 6. Directors, Senior Management and Employees - A. Directors and Senior Management&#8221;
are Office Holders. In addition to those persons listed in the table under Item 6.A, there were two additional individuals who were Office
Holders of the Company as of December 31, 2023.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">An Office Holder&#8217;s fiduciary duties consist of a duty of care and a duty of
loyalty. The duty of care requires an Office Holder to act with the standard of skills with which a reasonable Office Holder in the same
position would have acted under the same circumstances. The duty of care includes a duty to use reasonable means to obtain:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc355f83a5f2a4aa5b320aeb41d5b9054" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>information regarding the business advisability of a given action brought for the Office Holder&#8217;s approval or performed by
        the Office Holder by virtue of his or her position; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z233ad48b56a447cbaf1764ec545387ff" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>all other information of importance pertaining to the aforesaid actions.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">97</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The duty of loyalty requires an Office Holder to act in good faith and for the benefit
of the company and includes the duty to:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z236c0164a3ed4231aaa3446d7f8dd8d0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>refrain from any act involving a conflict of interest between the fulfillment of his or her position in the company and the fulfillment
        of any other position or his or her personal affairs;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbb5c8108c13945038bf1530b7a2bed90" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>refrain from any act that is competitive with the business of the company;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc3af1aee6778482e92c91fc41a3e640e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>refrain from exploiting any business opportunity of the company with the aim of obtaining a personal gain for himself or herself
        or for others; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z54f571600150499da01a8162fd304e1d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt"><br/> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>disclose to the company all relevant information and provide it with all documents relating to the company&#8217;s affairs which
        the Office Holder obtained due to his or her position in the company.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Disclosure of Personal Interests of Office
Holders and Approval of Certain Transactions</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The Companies Law requires that an Office Holder promptly discloses to the company
any personal interest that the Office Holder may have, and all related material information known to him or her, in connection with any
existing or proposed transaction by the company. In addition, if the transaction is an extraordinary transaction, as defined under Israeli
law, the Office Holder must also disclose any personal interest held by the Office Holder&#8217;s spouse, siblings, parents, grandparents,
descendants, spouse&#8217;s descendants and the spouses of any of the foregoing, or a Relative. In addition, the Office Holder must also
disclose any interest held by any corporation in which the Office Holder: (i) holds at least 5% of the company&#8217;s outstanding share
capital or voting rights; (ii) is a director or general manager; or (iii) has the right to appoint at least one director or the general
manager. An extraordinary transaction is defined as a transaction which is either not in the ordinary course of business, not on market
terms, or likely to have a material impact on the company&#8217;s profitability, assets or liabilities.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law, unless the articles of association of a company provide otherwise,
a transaction in which an Office Holder has a personal interest and which is not an extraordinary transaction, requires board approval,
after the Office Holder complies with the above disclosure requirement and provided the transaction is not adverse to the company&#8217;s
interest. Our Articles do not provide for a different method of approval. Furthermore, if the transaction is an extraordinary transaction,
then, in addition to any approval stipulated by the articles of association, it also must be approved by the company&#8217;s audit committee
and then by the board of directors, and, under certain circumstances, by the shareholders of the company.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">A person with a personal interest in any matter may not generally be present at any
audit committee, compensation committee or board of directors meeting where such matter is being considered, and if he or she is a member
of the committee or a director, he or she may not generally vote on such matter at the applicable meeting.</div>

<div style="line-height: 1.25">&#160; <br/> </div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Disclosure of Personal Interest of Controlling Shareholders and
Approval of certain Transactions</div>

<div style="line-height: 1.25">&#160; <br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">The Companies Law extends the disclosure requirements applicable to an Office Holder
to a &#8216;controlling shareholder&#8217; in a public company. For this purpose, a &#8216;controlling shareholder&#8217; is a shareholder
who has the ability to direct the activities of a company, including a shareholder or a group of shareholders who together own 25% or
more of the voting rights if no other shareholder holds more than 50% of the voting rights.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Extraordinary transactions of a public company with a controlling shareholder or in
which a controlling shareholder has a personal interest, as well as any engagement by a public company of a controlling shareholder or
of such controlling shareholder&#8217;s Relative, directly or indirectly, with respect to the provision of services to the company, and,
if such person is also an Office Holder of such company, with respect to such person&#8217;s Terms of Office and Employment as an Office
Holder, and if such person is an employee of the company but not an Office Holder, with respect to such person&#8217;s employment by the
company, generally require the approval of each of the audit committee (or with respect to Terms of Office and Employment, the compensation
committee), the board of directors and the shareholders of the company, in that order. The shareholder approval must fulfill one of the
following requirements: (i) it received the positive vote of at least a majority of the voting rights in the company who are present and
voting in the meeting and held by shareholders who do not have a personal interest in the transaction; (abstentions are disregarded) or
(ii) the voting rights held by shareholders who have no personal interest in the transaction and who have voted against the transaction,
do not exceed two percent of the voting rights in the company.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Any extraordinary transactions with a controlling shareholder or in which a controlling
shareholder has a personal interest with a term of more than three years generally need to be brought for re-approval in accordance with
the above procedure every three years, unless the audit committee determines that the duration of the transaction is reasonable given
the circumstances related thereto and has been approved by the shareholders for such longer duration.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">98</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Pursuant to regulations promulgated under the Companies Law, certain transactions
with a controlling shareholder or his or her Relative, or with directors, that would otherwise require approval of a company&#8217;s shareholders
may be exempt from shareholder approval upon certain determinations of the audit committee or the compensation committee and board of
directors.</div>

<div style="line-height: 1.25">&#160; <br/> </div> </div>

<div style="text-align: justify; line-height: 1.25">For information concerning the direct and indirect personal interests of certain of
our Office Holders and principal shareholders in certain transactions with us, see &#8220;Item 7. Major Shareholders and Related Party
Transactions - B. Related Party Transactions.&#8221;</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Shareholders Duties</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the Companies Law, a shareholder has a duty to: (i) act in good faith
in fulfilling his obligations towards the company and the other shareholders; and (ii) refrain from abusing his or her power with respect
to the company, including, when voting at a general meeting with respect to the following matters: (a) an amendment to the company&#8217;s
articles of association; (b) an increase of the company&#8217;s authorized share capital; (c) a merger; or (d) approval of interested
party transactions that require shareholders&#8217; approval.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">In addition, any controlling shareholder, any shareholder who knows that it possesses
power to determine the outcome of a shareholder vote and any shareholder who, pursuant to the provisions of a company&#8217;s articles
of association has the power to appoint or prevent the appointment of an office holder in the company, is under a duty of fairness towards
the company. The Companies Law does not describe the substance of such duty of fairness but states that the remedies generally available
upon a breach of contract will also apply in the event of a breach of the duty of fairness, taking into account such shareholder&#8217;s
position.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Approval of Significant Private Placement</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law, a significant private placement of securities requires approval
by the board of directors and the shareholders by a simple majority. A private placement is considered a significant private placement
if it results in a person becoming a controlling shareholder, or if all of the following conditions are met: the securities issued amount
to 20% or more of the company&#8217;s outstanding voting rights before the issuance; some or all of the consideration is other than cash
or listed securities or the transaction is not on market terms; and the transaction will increase the relative holdings of a shareholder
who holds 5% or more of the company&#8217;s outstanding share capital or voting rights or will cause any person to become, as a result
of the issuance, a holder of more than 5% of the company&#8217;s outstanding share capital or voting rights.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">D. EMPLOYEES</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The following table sets out the number of our full-time employees engaged in specified
activities, at the end of the fiscal years 2023, 2022 and 2021 (the numbers include employees of our wholly owned U.S. subsidiary Compugen
USA, Inc.):</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<table cellspacing="0" cellpadding="0" border="0" id="z3e43309e24cb44aeac299b0451e3d128" style="font: 10pt Times New Roman,Times,serif; width: 100%; text-align: left; color: rgb(0, 0, 0)">
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 33.01%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 15.63%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">December 31, 2023</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 17.51%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">December 31, 2022</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 33.92%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">December 31, 2021</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 33.01%; vertical-align: top; background-color: rgb(204, 238, 255); border-left: rgb(0, 0, 0) 2px solid">
        <div style="margin-right: 28.4pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Research &amp; Development</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 15.63%; vertical-align: bottom; background-color: rgb(204, 238, 255); border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif">46</div>
        </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 17.51%; vertical-align: bottom; background-color: rgb(204, 238, 255); border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif">46</div>
        </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 33.92%; vertical-align: bottom; background-color: rgb(204, 238, 255); border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif">51</div>
        </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 33.01%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Administration, Accounting and Operations</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 15.63%; vertical-align: bottom; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif">21</div>
        </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 17.51%; vertical-align: bottom; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif">21</div>
        </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 33.92%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif">21</div>
        </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 33.01%; vertical-align: top; background-color: rgb(204, 238, 255); border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Marketing and Business Development</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 15.63%; vertical-align: bottom; background-color: rgb(204, 238, 255); border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif">1</div>
        </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 17.51%; vertical-align: bottom; background-color: rgb(204, 238, 255); border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif">2</div>
        </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 33.92%; vertical-align: bottom; background-color: rgb(204, 238, 255); border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif">1</div>
        </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 33.01%; vertical-align: top; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Total</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 15.63%; vertical-align: top; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif">68</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 17.51%; vertical-align: top; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif">69</div> </td>
    <td style="border: rgb(0, 0, 0) 2px solid; width: 33.92%; vertical-align: top">
        <div style="text-align: right; margin-right: 2.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif">73</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">99</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to the headquarters in Holon, Israel, we maintain a subsidiary in San
Francisco, California. On December 31, 2021, 58 of our employees were located in Israel, 12 were located in the United States and 3 employees
were located in Europe; on December 31, 2022, 57 of our employees were located in Israel, 8 were located in the United States and 4 employees
were located in Europe; and on December 31, 2023, 58 of our employees were located in Israel, 7 were located in the United States and
3 employees were located in Europe.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We consider our relations with our employees to be satisfactory and we have not experienced
a significant labor dispute or strike. We are not a party to any collective bargaining agreement with respect to our Israeli employees.
However, we are subject to certain labor related statutes and to certain provisions of expansion orders the Israeli Minister of the Economy
has given to collective bargaining agreements between the Histadrut (General Federation of Labor in Israel) and the Coordinating Bureau
of Economic Organizations and/or the Industrialists&#8217; Association, which are applicable to the employment of our Israeli employees.
These statutes and provisions and additional mandatory Israeli labor law provisions cover a wide range of subjects and provide certain
minimum employment standards, including the length of the workday and work week, minimum wages, travel expenses, contributions to a pension
fund, insurance for work-related accidents, determination of severance pay, annual and other vacations, sick pay and other conditions
of employment. We generally provide our employees with benefits and working conditions beyond the required minimum.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our severance pay liability to our Israeli employees, based upon the number of years
of service and the latest monthly salary, is in the large part covered by regular deposits with recognized pension funds, deposits with
severance pay funds and purchases of insurance policies. Pursuant to Section 14 of the Israeli Severance Pay Law 5723-1963, certain of
our liabilities for employee severance rights upon termination are covered by regular contributions to defined contribution plans, so
that upon termination of employment of the relevant employees, we are only required to release the payments made by us to such funds on
account of severance and by doing so are deemed to have complied with all of our severance payment obligations relating to the service
of applicable employees with respect to the period during which the provisions of such section apply. For information concerning our liability
for severance pay, see Note 2n to our 2023 consolidated financial statements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our employees are not represented by a labor union. We have written employment contracts
(including signed offers of employment) with each of our employees.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">E. SHARE OWNERSHIP</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Share Ownership by Directors and Other Executive Officers</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">All of the persons listed above under the caption &#8220;Directors and Senior Management&#8221;
own ordinary shares of the Company and/or options to purchase ordinary shares of the Company. Except as set forth in the table below,
none of the directors or executive officers beneficially owns ordinary shares and/or ordinary shares underlying options amounting to 1%
or more of the outstanding ordinary shares. The following table sets forth certain information as of February 20, 2024, regarding the
beneficial ownership by our directors and senior management. All numbers quoted in the table are inclusive of options to purchase shares
that are exercisable within 60 days after February 20, 2024. The shares that may be issued under these options are deemed to be outstanding
for the purpose of computing the percentage of ownership of such individual or group but are not deemed to be outstanding for the purpose
of computing the percentage of ownership of the other individual or group shown in the table. The information in this table is based on
89,530,193 ordinary shares outstanding as of February 20, 2024.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">100</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"> <br/> </div>

<table cellspacing="0" cellpadding="0" id="z58b236a2e38f4034a9320292891e7a08" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Beneficial Owner</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Amount Owned</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Percent of Class</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Anat Cohen-Dayag<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,026,122</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1.1</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="text-align: justify; line-height: 1.25">All directors and executive officers as a group (13 persons)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3,143,964</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3.4</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25"> <hr style="border-style: none; height: 1px; width: 30%; color: #000000; background-color: #000000; margin-left: 0px; margin-right: auto"/>&#160;</div>

<table cellspacing="0" cellpadding="0" id="z514b8cb7d1dc4c0198e922aaf92bda88" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt"><br/> </td>
    <td style="width: 22.5pt; vertical-align: top">&#160;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Includes (i) 56,122 shares held by Dr. Cohen-Dayag, and (ii) 970,000 shares subject to options that are exercisable within 60 days
        after February 20, 2024, with a weighted average exercise price of $6.47 per share, and which expire between March 2024 and March 2032.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb34b15c272aa4b81ae243aa0a56ee51b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt"><br/> </td>
    <td style="width: 22.5pt; vertical-align: top"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;(2)</sup></td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Includes (i) a total of 76,259 ordinary shares held by directors and executive officers, and (ii) a total of 3,067,705 shares subject
        to options that are beneficially owned by directors and executive officers that are exercisable within 60 days after February 20, 2024,
        with a weighted average exercise price of $5.48 per share and which expire between February 2024 and November 2032.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Share Incentive Plan and Employee Share Purchase Plan</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">We currently maintain one active share incentive plan, which is our 2010 Share Incentive
Plan, or the 2010 Plan. In addition to the discussion below, see Note 8 to our 2023 consolidated financial statements.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Compugen 2010 Share Incentive Plan</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">On July 25, 2010, our board of directors adopted the 2010 Plan which was also approved
by our shareholders on May 12, 2011. In addition, the board of directors and shareholders resolved that the options available for grants
under the 2000 Option Plan, at such time, as well as any options that may return to such pool in connection with terminated options, will
be made available for future grants under the 2010 Plan. In May 2020 the board of directors extended the term of the 2010 Plan by additional
ten (10) years. Subject to applicable law, our board of directors may amend the 2010 Plan, provided that any action by our board of directors
which will alter or impair the rights or obligations of an option holder requires the prior consent of that option holder. In August 2023,
our board of directors decreased the number of shares available under the 2010 Plan by 500,000.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The compensation committee administers the 2010 Plan and has the authority to designate
the terms of the options granted thereunder, including the identity of the grantees, exercise prices, grant dates, vesting schedules and
expiration dates, which may be no more than ten years after the grant date. According to the 2010 Plan, options may not be granted with
an exercise price of less than the fair market value of our ordinary shares on the date of grant, unless otherwise determined by our board
of directors. The administration of the 2010 Plan by our compensation committee is subject to applicable law, including with respect to
the approval procedure of compensation to Office Holders required under the Companies Law (for additional information on the approval
procedure of compensation to Office Holders, see &#8220;Item 6. Directors, Senior Management and Employees - B. Approvals Required for
Office Holders Terms of Employment&#8221;).</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">If a grantee leaves his or her employment or other relationship with us, or if his
or her relationship with us is terminated without cause (and other than by reason of death or disability, as defined in the 2010 Plan),
the term of his or her unexercised options will generally expire in 90 days, unless determined otherwise by our board of directors.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2023, options to purchase 8,373,745 ordinary shares at a weighted
average exercise price of approximately $4.65 per share were outstanding (i.e., were granted but not canceled, expired nor exercised)
under the 2010 Plan and 1,202,301 ordinary shares remained available for future grant under the 2010 Plan. Options to purchase 4,319,106
ordinary shares under the 2010 Plan have previously been exercised through December 31, 2023, at a weighted average exercise price of
approximately $4.92. As of December 31, 2023, outstanding options granted by the Company pursuant to the 2010 Plan expire between February
2024 and October 2033 (subject to terms of the plan).</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Compugen 2021 Employee Share Purchase Plan</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">In November 2020, we adopted the Compugen Ltd. 2021 Employee Share Purchase Plan,
or ESPP.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The ESPP currently applies to our employees and officers.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the ESPP, in each twelve (12) months period, there are two offering periods,
comprised of six (6) months each (except for the first offering period under the ESPP which was for five (5) months only). Each eligible
participant, has the right to contribute up to 15% of his or her monthly Compensation (as defined in the ESPP), in order to buy ordinary
shares from us at a price per share equal with respect to each offering period, to 85% of the Fair Market Value of a share on the Entry
Date or the Purchase Date (as such terms are defined in the ESPP), whichever is lower, until changed by the committee of the board administering
the ESPP prior to the commencement of the enrollment process for such offering period. The maximum number of ordinary shares a Participant
may purchase during any calendar year shall be that whole number of ordinary shares determined by dividing $40,000 by the Purchase Price.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">101</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The maximum number of shares that were available for issuance under the ESPP upon
its approval was 600,000.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2023, following issuance of shares in connection with offering
periods already ended and decreasing the number of shares available for issuance under the ESPP by 210,000 as approved by our board of
directors in August 2023, there were 114,146 ordinary shares available for issuance under the ESPP. Currently our ESPP is suspended, and
we reserve the right to resume it at any time.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Taxation of Equity Granted under our 2010 Plan
and ESPP to Israeli Grantees</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Our board of directors elected the &#8220;Capital Gains Track&#8221; (as defined in
Section 102(b) (2) of the Tax Ordinance) for the grant of equity under the 2010 Plan and ESPP to Israeli grantees who are eligible for
grant under said Section 102 of the Tax Ordinance.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Pursuant to such election, and provided such eligible grantees comply with all the
requirements of the &#8220;Capital Gains Track&#8221;, gains derived by them, arising from the sale of shares acquired pursuant to the
ESPP or the exercise of options granted to them, will generally be subject to a flat capital gains tax rate of 25%, although these gains,
or part of them, will also be considered part of a grantee&#8217;s regular salary and subject to such grantee&#8217;s regular tax rate
applicable to such salary. As a result of the Company&#8217;s election in the &#8220;Capital Gains Track&#8221; under Section 102, the
Company is not allowed to claim as an expense for tax purposes in Israel the amounts credited to the grantee as capital gains, although
it is generally entitled to do so in respect of the salary income component (if any) of such grant, if any, when the related tax is paid
by the grantee as long as the grantee complies with all the requirements of the &#8220;Capital Gains Track&#8221;.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">F. DISCLOSURE OF A REGISTRANT&#8217;S ACTION
TO RECOVER ERRONEOUSLY AWARDED COMPENSATION.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">On October 30, 2023 we adopted a Policy for Recovery of Erroneously Awarded Compensation,
or the Clawback Policy, providing for recovery of certain incentive-based compensation from current and former executive officers of the
Company in the event we are required to restate any of our financial statements filed with the SEC under the Exchange Act in order to
correct an error that is material to the previously-issued financial statements, or that would result in a material misstatement if the
error were corrected in the current period or left uncorrected in the current period. Adoption of the Clawback Policy was mandated by
Nasdaq listing standards introduced pursuant to Exchange Act Rule 10D-1. The Clawback Policy is in addition to Section 304 of the Sarbanes-Oxley
Act of 2002 which permits the SEC to order disgorgement of bonuses and incentive-based compensation earned by a registrant issuer&#8217;s
chief executive officer and chief financial officer in the year following the filing of any financial statement that the issuer is required
to restate because of misconduct, and the reimbursement of those funds to the issuer. A copy of the Clawback Policy has been filed herewith
as Exhibit 97.1.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 7.<span id="ITEM7."><!--Anchor--></span> MAJOR SHAREHOLDERS
AND RELATED PARTY TRANSACTIONS</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. MAJOR SHAREHOLDERS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">The following table sets forth share ownership information as of February 20, 2024
(unless otherwise noted below) with respect to each person who is known by us to be the beneficial owner of more than 5% of our outstanding
ordinary shares. The information contained in the table below has been obtained from the Company&#8217;s records or from information furnished
by an individual or entity to the Company or disclosed in public filings with the SEC. Except where otherwise indicated, and except pursuant
to community property laws, we believe, based on information furnished by such owners, that the beneficial owners of the ordinary shares
listed below have sole investment and voting power with respect to such shares. As of February 20, 2024, there were a total of 36 holders
of record of our ordinary shares, of which 23 were registered with addresses in the United States. Such United States holders were, as
of such date, the holders of record of more than 99.0 % of our outstanding ordinary shares.<span style="font-weight: bold">&#160;</span>Our
ordinary shares are traded on the Nasdaq Capital Market in the United States and on the TASE in Israel. A significant portion of our shares
are held in &#8220;street name&#8221;, therefore we cannot determine who our shareholders are, their geographical location or how many
shares a particular shareholder owns.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25">Total &#8220;Number of Ordinary Shares Beneficially Owned&#8221; in the table below
include shares that may be acquired by any of the below entities upon the exercise of options or warrants known to us, that are either
currently exercisable or will become exercisable within 60&#160;days of February 20, 2024.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">102</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"> <br/> </div>

<div style="line-height: 1.25">The shareholders listed below do not have any different voting rights from any of our other shareholders.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" border="0" id="z9e6fcbb84fe7474384753fa4e3ea2b2d" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 68%; text-align: center">
        <div style="margin-right: 4.5pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Reporting Beneficial
        Owner</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; width: 1%; text-align: center; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Number of Ordinary Shares Beneficially Owned</div>
        </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; width: 1%; text-align: center; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Percent of Ordinary Shares Beneficially Owned<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 68%">
        <div style="line-height: 1.25">Bristol-Myers Squibb Company<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup>&#160;</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 13%">
        <div style="line-height: 1.25">4,757,058</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 13%">
        <div style="line-height: 1.25">5.3</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z4bb3483ca8754d279d1e1e58f84ba822" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Based upon 89,530,193 ordinary shares issued and outstanding as of February 20, 2024.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z74f0864d13b04e27aadce17170f1fc36" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Based upon information provided by the shareholder in its Form 13G filed with the SEC on November 19, 2021. With respect to the ordinary
        shares reported in its Schedule 13G, Bristol-Myers Squibb Company, indicated as having (i) sole voting power and dispositive power with
        respect to 4,757,058 ordinary shares, and (ii) no shared voting power nor shared dispositive power with respect to ordinary shares. Furthermore,
        in such filing BMS indicated aggregate beneficial ownership of 4,757,058 ordinary shares. The address of the principal business office
        of BMS is 430 East 29th&#160;Street, New York, NY 10016.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. RELATED PARTY TRANSACTIONS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">Other than as set forth below and transactions related to compensation of our executive
officers and directors as described under &#8220;Item 6. Directors, Senior Management and Employees - B. Compensation,&#8221; since January
1, 2023, we have not entered into any material related party transaction.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Indemnification and Exemption Agreements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">Our Articles permit us to exculpate, indemnify and insure our Office Holders to the
fullest extent permitted by the Companies Law. Accordingly, we release our Office Holders from liability and indemnify them to the fullest
extent permitted by law and provide them with letters of indemnification and exemption and release for this purpose, in the form most
recently approved at our 2021 AGM. Under the letters of indemnification and exemption and release (i) our undertaking to indemnify each
Office Holder for monetary liabilities or obligations imposed by a court judgment (including a settlement or an arbitrator&#8217;s award
approved by a court) is limited to matters that result from or are connected to those events or circumstances set forth therein, and (ii)
the indemnification that we undertake towards all persons whom it resolved to indemnify for the matters and circumstances described therein,
jointly and in the aggregate, do not exceed the higher of the: (i) an amount equal to 25% of the Company&#8217;s shareholders&#8217; equity,
per the most recent financial statements (audited or reviewed) after the time that notice is provided to the Company; or (y) $20 million.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">Our Office Holders are also covered by directors&#8217; and officers&#8217; liability
insurance. For more information see &#8220;Item 6. Directors, Senior Management and Employees - B. Compensation - Insurance, Indemnification
and Exemption.&#8221;</div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. INTERESTS OF EXPERTS AND COUNSEL</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 8.<span id="ITEM8."><!--Anchor--></span> FINANCIAL INFORMATION</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. CONSOLIDATED STATEMENTS AND OTHER FINANCIAL
INFORMATION</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Consolidated Financial Statements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our consolidated financial statements are included beginning on page F-1 of this Annual
Report. See also &#8220;Item 18. Financial Statements.&#8221;</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Legal Proceedings</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Currently, we are not a party to any legal or arbitration proceedings, including governmental
proceedings, that are pending or known to be contemplated, that our management believes, individually or in the aggregate, may have, or
have had in the recent past, a significant effect on our financial position or profitability, nor are we party to any material proceeding
in which any director, member of our senior management or affiliate is a party adverse to us or our subsidiary or has a material interest
adverse to us or our subsidiary.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">103</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Dividend Distribution Policy</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have never paid any cash dividends on our ordinary shares, and we do not intend
to pay cash dividends on our ordinary shares in the foreseeable future. Our current policy is to retain any earnings we have (if any)
for use in our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the event that we decide to pay a cash dividend from income that is tax exempt
under our Benefiting Enterprises program, we would be required to pay the applicable corporate tax that would otherwise have been payable
on such income which would be in addition to the tax payable by the dividend payee. See &#8220;Item 10. Additional Information - E. Taxation.&#8221;</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">B. <span style="font-style: italic">SIGNIFICANT CHANGES</span></div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 9.<span id="ITEM9."><!--Anchor--></span> THE OFFER AND LISTING</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. OFFER AND LISTING DETAILS</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Our ordinary shares were listed on The Nasdaq Global Market through June 16, 2009.
On June 17, 2009, the listing of our ordinary shares was transferred from The Nasdaq Global Market to The Nasdaq Capital Market, and on
January 27, 2014, the listing of our ordinary shares transferred back from The Nasdaq Capital Market to The Nasdaq Global Market. On May
4, 2023, our ordinary shares transferred back from The Nasdaq Global Market to The Nasdaq Capital Market. Our trading symbol on Nasdaq
is CGEN. Our ordinary shares have been dually listed on the Tel Aviv Stock Exchange since January 2002. Our trading symbol on each of
The Nasdaq Capital Market and the Tel Aviv Stock Exchange is CGEN.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. PLAN OF DISTRIBUTION</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Not applicable</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. MARKETS</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Our ordinary shares are traded in the United States on The Nasdaq Capital Market and
in Israel on the Tel Aviv Stock Exchange (TASE).</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">D. SELLING SHAREHOLDERS</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Not applicable</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">E. DILUTION</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Not applicable</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">F. EXPENSES OF THE ISSUE</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Not applicable</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 10.<span id="ITEM10."><!--Anchor--></span> ADDITIONAL INFORMATION</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. SHARE CAPITAL</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Not applicable</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. MEMORANDUM AND ARTICLES OF ASSOCIATION</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Copies of our Amended and Restated Articles and our Amended and Restated Memorandum
of Association, as in effect as of the date of this Annual Report, are attached as Exhibits 1.1 and 1.2, respectively, to this Annual
Report. The information called for by this Item is set forth in Exhibit 2.1 to this Annual Report and is incorporated by reference into
this Annual Report.&#160;</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. MATERIAL CONTRACTS</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Please see &#8220;Item 4. Information on the Company - B. Business Overview - Business
Strategy and Partnerships &#8211; Gilead License&#8221;, and &#8220;Item 4. Information on the Company - B. Business Overview - Business
Strategy and Partnerships - AstraZeneca License&#8221; and &#8220;Item 5. Operating and Financial Review and Prospects Finance - B. Liquidity
and Capital Resources&#8221; for a discussion of our material contracts.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">D. EXCHANGE CONTROLS</div>

<div style="line-height: 1.25">&#160;<br/> </div>

<div style="text-align: justify; line-height: 1.25">There are currently no exchange controls in effect in Israel that restrict the repatriation
by non-residents of Israel in non-Israeli currency of any dividends, if any are declared and paid, and liquidation distributions or the
Company&#8217;s ability to import and export capital, except that such restrictions may exist with respect to citizens of countries which
are in a state of war with Israel.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">104</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">E. TAXATION</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The following is a brief summary of certain material Israeli and U.S. federal tax
consequences concerning the ownership and disposition of our ordinary shares by purchasers or holders of our ordinary shares. Because
parts of this discussion are based on new or existing tax or other legislation that has not been subject to judicial or administrative
interpretation, there can be no assurance that the views expressed herein will be accepted by the tax or other authorities in question.
The summary below does not address all of the tax consequences that may be relevant to all purchasers or holders of our ordinary shares
in light of each purchaser&#8217;s or holder&#8217;s particular circumstances and specific tax treatment. For example, the summary below
does not address the tax treatment of residents of Israel and traders in securities who are subject to specific tax regimes. As individual
circumstances may differ, holders of our ordinary shares should consult their own tax advisors as to U.S., Israeli or other tax consequences
of the purchase, ownership and disposition of our ordinary shares. This discussion is not intended, nor should it be construed, as legal
or professional tax advice and it is not exhaustive of all possible tax considerations. Each person should consult his, her or its own
tax or legal advisor.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Israeli Taxation</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Taxation of Capital Gains Applicable to Non-Israeli
Shareholders</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Israeli law generally imposes a capital gains tax on the sale of securities of an
Israeli resident company traded on the TASE, on an authorized stock exchange outside Israel or on a regulated market (which includes a
system through which securities are traded pursuant to rules prescribed by the competent authority in the relevant jurisdiction), which
includes Nasdaq, in or outside Israel, or a &#8220;Recognized Exchange&#8221;. Pursuant to the Tax Ordinance, the capital gains tax rate
applicable to individuals upon the sale of such securities is such individual&#8217;s marginal tax rate but not more than 25%, or 30%
with respect to an individual who meets the definition of a &#8216;Substantial Shareholder&#8217; on the date of the sale of the securities
or at any time during the 12 months preceding such date. A &#8216;Substantial Shareholder&#8217; is defined as a person who, either alone
or together with any other person, holds, directly or indirectly, at least 10% of any of the means of control of a company (which includes,
among other things, the right to receive profits of the company, voting rights, the right to receive the company&#8217;s liquidation proceeds
and the right to appoint a director).</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">With respect to corporate investors, capital gain tax equal to the corporate tax rate
(23% in 2023 and thereafter) will be imposed on the sale of our traded shares.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">However, if our ordinary shares are traded on a Recognized Exchange gains on the sale
of our ordinary shares held by non-Israeli tax resident investors will generally be, subject to certain conditions, exempt from Israeli
capital gains tax so long as the gains were not derived from a permanent establishment that the non-Israeli tax resident investor maintains
in Israel. Furthermore, non-Israeli &#8220;Body of Persons&#8221; (as defined in the Ordinance, and includes corporate entities, partnerships,
and other entities) will not be entitled to such exemption if Israeli residents, whether directly or indirectly, (i) holds more than 25%
of the means of control in such non-Israeli corporation or (ii) are the beneficiaries of or are entitled to 25% or more of the revenues
or profits of such corporation.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Notwithstanding the foregoing, dealers in securities in Israel are taxed at regular
tax rates applicable to business income.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">In addition, persons paying consideration for shares, including purchasers of shares,
Israeli securities dealers effecting a transaction, or a financial institution through which securities being sold are held, are required,
subject to any applicable exemptions and the demonstration by the selling shareholder of its non-Israeli residency and other requirements,
to withhold tax upon the sale of publicly traded securities at a rate of 25% for individuals and at the corporate tax rate (23% in 2023
and thereafter) for corporations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The sale of shares may also be exempt from Israeli capital gain tax under the provisions
of an applicable tax treaty. For example, the Convention Between the Government of the United States and the Government of the State of
Israel With Respect to Taxes of Income, as amended, or the U.S.-Israel Tax Treaty), exempts U.S. residents for the purposes of the treaty
(who are entitled to claim the benefits of the U.S.-Israel Tax Treaty) from Israeli capital gain tax in connection with such sale, provided
(i) the U.S. resident owned, directly or indirectly, less than 10% of the Israeli resident company&#8217;s voting power at any time within
the 12-month period preceding such sale; (ii) the seller, being an individual, is present in Israel for a period or periods of less than
183 days during the taxable year; and (iii) the capital gain from the sale was not derived through a permanent establishment of the U.S.
resident in Israel. Under the U.S.-Israel Tax Treaty, U.S. residents for the purposes of the treaty may be permitted to claim a credit
for such taxes against U.S. federal income tax imposed on the sale, under the circumstances and subject to the limitations specified in
the U.S.-Israel Tax Treaty and U.S. tax legislation, as discussed below under &#8220;<span style="font-style: italic">Certain Material
U.S. Federal Income Tax Considerations to U.S. Holders &#8211; Distributions</span>.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">105</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Income Taxes on Dividend Distribution to Non-Israeli
Shareholders</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In principle, non-Israeli residents (whether individuals or corporations) are generally
subject to Israeli income tax on the receipt of dividends paid by Israeli publicly traded companies at the rate of 25% if the shares are
registered with a nominee company (as such term is used in the Israeli Securities Law). If the shares are not registered with a nominee
company, the rate of 25% will apply to non-Israeli residents shareholders who are not considered Substantial Shareholders, as defined
above, and who were not considered Substantial Shareholders at any time during the 12 months preceding the date of the distribution, and
the rate of 30% will apply to dividends paid to Substantial Shareholders and to persons who were Substantial Shareholders at any time
during the 12 months preceding the date of the distribution. Notwithstanding the above, a lower tax rate may be provided under an applicable
tax treaty between Israel and the shareholder&#8217;s country of residence (subject to the receipt in advance of a valid tax certificate
from the Israel Tax Authority allowing for a reduced tax rate). The distribution of dividends to non-Israeli residents (either individuals
or corporations) from income derived from a company&#8217;s Approved Enterprises or Benefiting Enterprises during the applicable benefits
period or from Preferred Enterprises is subject to withholding tax at a rate of 20%, unless a lower tax rate is provided under an applicable
tax treaty (subject to the receipt in advance of a valid tax certificate from the Israel Tax Authority allowing for a 20% withholding
tax rate or a lower tax rate, provided by an applicable tax treaty).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A non-resident of Israel who has received dividend income derived from or accrued
in Israel, from which the full amount of tax was withheld, is generally exempt from the duty to file tax returns in Israel with respect
to such income, provided that: (i) such income was not derived from a business conducted in Israel by the taxpayer; (ii) the taxpayer
has no other taxable sources of income in Israel with respect to which a tax return is required to be filed; and (iii) the taxpayer is
not liable for Excess Tax (as described below).</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Residents of the United States generally will have withholding tax in Israel deducted
at source. They may be entitled to a credit or deduction for U.S. federal income tax purposes for all or part of the amount of the taxes
withheld, subject to detailed rules contained in U.S. tax legislation, as discussed below under &#8220;<span style="font-style: italic">Certain
Material U.S. Federal Income Tax Considerations to U.S. Holders &#8211; Distributions</span>.&#8221;</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">U.S. Israel Tax Treaty</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Under the U.S.-Israel Tax Treaty, the maximum Israeli withholding tax rate on dividends
paid to a holder of our ordinary shares who is a U.S. resident for the purposes of the U.S.-Israel Tax Treaty, is generally 25%. The U.S.-Israel
Tax Treaty provides that a 15% or a 12.5% Israeli dividend withholding tax will apply to dividends paid to a U.S. corporation owning 10%
or more of an Israeli company&#8217;s voting shares during, in general, the current and preceding tax year of the Israeli company. The
15% rate applies to dividends distributed from income derived from an Approved Enterprise, or a Benefiting Enterprise, in each case within
the applicable period or, from a Preferred Enterprise, and the lower 12.5% rate applies to dividends distributed from income derived from
other sources. However, these provisions do not apply if the company has certain amounts of passive income. The aforementioned rates under
the U.S.-Israel Treaty will not apply if the dividend income was derived through a permanent establishment of the U.S. resident in Israel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Excess Tax</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, an additional tax liability at the rate of 3% is applicable on the annual
taxable income, including, but not limited to, income derived from dividends, interest and capital gains, of individuals who are subject
to tax in Israel (whether such individual is an Israeli resident or non-Israeli resident) exceeding a certain threshold (NIS 698,280 in
2023), which amount is linked to the Israeli consumer price index.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Estate and Gift Tax</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Israeli law currently does not impose estate or gift taxes.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">106</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Certain Material U.S. Federal Income Tax Considerations to U.S.
Holders</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">General</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The following is a summary of certain material U.S. federal income tax considerations
generally applicable to the acquisition, ownership and disposition of our ordinary shares by U.S. holders (as defined below) that hold
our ordinary shares as &#8220;capital assets&#8221; (generally, property held for investment) under the Code. For this purpose, a U.S.
holder is, a holder, who, for U.S. federal income tax purposes, is a beneficial owner of ordinary shares and who is: (a) a citizen or
individual resident of the United States; (b) a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes)
created or organized in or under the laws of the United States, any state thereof or the District of Columbia; (c) an estate the income
of which is subject to U.S. federal income tax regardless of its source; or (d) a trust that is subject to the primary supervision of
a court over its administration and one or more U.S. persons control all substantial decisions, or a trust that has validly elected to
be treated as a domestic trust under applicable Treasury Regulations. This summary does not address any tax consequences to persons other
than U.S. holders.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The statements in this summary are based on the current U.S. federal income tax laws
as contained in the Code, Treasury Regulations, and relevant judicial decisions and administrative guidance, all as of the date hereof,
and such authorities may be replaced, revoked or modified, possibly with retroactive effect, so as to result in U.S. federal income tax
consequences different from those discussed below. No ruling has been sought from the U.S. Internal Revenue Service, or IRS, with respect
to any U.S. federal income tax consequences described below, and there can be no assurance that the IRS will not take a contrary position
or that a court will not sustain such a position in the event of a challenge.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The following summary does not address all aspects of U.S. federal income tax consequences
that may apply to certain types of U.S. holders that are subject to special treatment, such as banks, insurance companies, tax-exempt
or governmental organizations, financial institutions, broker-dealers, dealers in securities or currencies, traders in securities that
elect to use the mark-to-market method of accounting for their securities, S corporations, partnerships or other pass-through entities
(or arrangements treated as a partnership) for U.S. federal tax purposes, regulated investment companies, real estate investment trusts,
&#8220;controlled foreign corporations&#8221; within the meaning of Section 957(a) of the Code, &#8220;passive foreign investment companies&#8221;
within the meaning of Section 1297(a) of the Code, certain expatriates, persons owning, directly, constructively or by attribution, 5%
or more, by voting power or value, of our ordinary shares, persons whose &#8220;functional currency&#8221; is not the U.S. dollar, persons
who hold ordinary shares as part of a hedging, constructive sale or conversion, straddle, or other risk-reducing transaction, former U.S.
citizens or long term residents of the United States, corporations that accumulate earnings to avoid U.S. federal income tax, persons
who hold our ordinary shares in connection with a trade or business, permanent establishment or fixed base outside the United States,
or persons that received an interest in our ordinary shares through the exercise of an option or otherwise in exchange for services.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">This summary is a general summary and does not address all aspects of U.S. federal
income taxation that may be relevant to particular U.S. holders based on their particular investment or tax circumstances.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">This summary relates only to U.S. federal income taxes and does not address any other
taxes, including but not limited to, U.S. state or local, or non-U.S., taxes and does not describe all of the U.S. federal income tax
consequences that may be relevant, including the special tax accounting rules under Section 451(b) of the Code, the U.S. federal non-income
tax considerations, including estate or gift tax considerations, the Medicare contribution tax on net investment income and the alternative
minimum tax.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">If a partnership (including an entity or arrangement classified as a partnership for
U.S. federal income tax purposes) holds our ordinary shares, the tax treatment of a partner (including a person classified as a partner
for U.S. federal income tax purposes) will generally depend upon the status of the partner and the activities of the partnership. A partner
of a partnership holding our ordinary shares should consult its tax advisors.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">107</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">This summary is not a substitute for careful tax planning. Investors
are urged to consult their own tax advisors regarding the specific U.S. federal, state, foreign and other tax consequences to them, in
light of their own particular circumstances, of the purchase, ownership and disposition of our ordinary shares and the effect of potential
changes in applicable tax laws.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Passive Foreign Investment Company Rules</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">In general, a corporation organized outside the United States will be classified as
a passive foreign investment company, or PFIC, for U.S. federal income tax purposes for any taxable year in which, after the application
of certain look-through rules with respect to income and assets of its subsidiaries, either:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd78d8de1e619432385e1f3d7a0b68836" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>at least 75% of its gross income is passive income, or</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z91ccb92ba6e046e8ac3e126ef3583251" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br/> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>at least 50% of the value (determined on the basis of a quarterly weighted average) of its total assets for the taxable year is attributable
        to assets that produce or are held for the production of passive income.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For this purpose, passive income generally includes, among other things, dividends,
interest, royalties and rents (other than royalties and rents derived in the active conduct of a trade or business and not derived from
a related person). Assets that produce or are held for the production of passive income may include cash (unless held in a non-interest
bearing account for short term working capital needs), marketable securities and other assets that may produce passive income. The 50%
passive asset test described above is generally based on the fair market value of each asset, with the value of goodwill and going concern
value determined in large part by reference to the market value of our ordinary shares, which may be volatile. Generally, in determining
whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly
or indirectly, at least a 25% interest (by value) is taken into account. Whether we are a PFIC for any taxable year will depend on the
composition of our income and the composition and value of our assets (which, may be determined in large part by reference to the market
price of the ordinary shares, which is likely to continue to fluctuate) in each year, and because this is a factual determination made
annually after the end of each taxable year, there can be no assurance that we will not be considered a PFIC in any taxable year.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Based on the composition of our income, and the composition and value of our assets,
in 2023, we believe that we were a PFIC for the taxable year ended December 31, 2023. However, the determination of whether or not we
are a PFIC is a fact-intensive determination made on an annual basis and because the applicable law is subject to varying interpretations
we cannot provide any assurance regarding our PFIC status and our U.S. counsel expresses no opinion with respect to our PFIC status for
any taxable year. In particular, our status as a PFIC in current or any future tax year is uncertain because, among other things, (i)
we currently own a substantial amount of passive assets, including cash, (ii) we may not receive milestone payments under any of our collaboration
agreements, in which case, our income may be exclusively passive and (iii) the valuation of our assets that generate non-passive income
for PFIC purposes, including our intangible assets, is uncertain and may be determined in substantial part by our market capitalization,
which may vary substantially over time. Furthermore, there can be no assurance that the IRS will agree with our conclusion or that the
IRS would not successfully challenge our position. No ruling from the IRS concerning our status as a PFIC has been obtained or is currently
planned to be requested. Accordingly, we cannot provide any assurances regarding our PFIC status for the current or future taxable years.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">If we are classified as a PFIC in any taxable year during a U.S. holder&#8217;s holding
period of our ordinary shares, such U.S. holder could be liable for additional taxes and interest charges upon (1) a distribution paid
during a taxable year that is greater than 125% of the average annual distributions paid in the three preceding taxable years, or, if
shorter, the U.S. holder&#8217;s holding period for the ordinary shares, and (2) any gain recognized on a sale, exchange or other taxable
disposition, including a pledge, of the ordinary shares, whether or not we continue to be a PFIC. In these circumstances, the tax will
be determined by allocating such distribution or gain ratably over the U.S. holder&#8217;s holding period for the ordinary shares. The
amount allocated to the current taxable year (i.e., the year in which the distribution occurs, or the gain is recognized) and any year
prior to the first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year. The amount
allocated to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations, as applicable,
to ordinary income for each such taxable year, and an interest charge, generally applicable to underpayments of tax, will be added to
the tax. In addition, non-corporate U.S. Holders will not be eligible for reduced rates of taxation on any dividends received from us,
if we are a PFIC in the taxable year in which such dividends are paid or in the preceding taxable year.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">If we are a PFIC for any year during which a U.S. holder holds the ordinary shares,
we must generally continue to be treated as a PFIC by that holder for all succeeding years during which the U.S. holder holds the ordinary
shares, unless we cease to meet the requirements for PFIC status and the U.S. holder makes a &#8220;deemed sale&#8221; election with respect
to the ordinary shares. If such election is made, the U.S. holder will be deemed to have sold the ordinary shares it holds at their fair
market value on the last day of the last taxable year in which we qualified as a PFIC, and any gain from such deemed sale would be subject
to the consequences described above. After the deemed sale election, the U.S. holder&#8217;s ordinary shares with respect to which the
deemed sale election was made will not be treated as shares in a PFIC unless we subsequently again become a PFIC.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">108</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">If a U.S. holder has made a qualified electing fund, or QEF election covering all
taxable years during which the holder holds ordinary shares and in which we are a PFIC, distributions and gains will not be taxed as described
above. Instead, a U.S. holder that makes a QEF election is required for each taxable year to include in income (i) the holder&#8217;s
pro rata share of the PFIC&#8217;s ordinary earnings as ordinary income or (ii) the holder&#8217;s pro rata share of the QEF net capital
gain as capital gain, regardless of whether such earnings or gain have in fact been distributed, for each taxable year that the entity
is classified as a PFIC. If a U.S. holder makes a QEF election with respect to us, any distributions paid by us out of our earnings and
profits that were previously included in the U.S. holder&#8217;s income under the QEF election would not be taxable to the holder. A U.S.
holder will increase its tax basis in its ordinary shares by an amount equal to any income included under the QEF election and will decrease
its tax basis by any amount distributed on the ordinary shares that is not included in the holder&#8217;s income. If a U.S. holder has
made a QEF election with respect to its ordinary shares, any gain or loss recognized by the U.S. holder on a sale or other disposition
of such ordinary shares will constitute capital gain or loss. In addition, if a U.S. holder makes a timely QEF election, our ordinary
shares will not be considered shares in a PFIC in years in which we are not a PFIC, even if the U.S. holder had held ordinary shares in
prior years in which we were a PFIC.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">U.S. holders should consult their tax advisors regarding making QEF elections in their
particular circumstances. If a U.S. holder does not make and maintain a QEF election for the U.S. holder&#8217;s entire holding period
for our ordinary shares by making the election for the first year in which the U.S. holder owns our ordinary shares, the U.S. holder will
be subject to the adverse PFIC rules discussed above unless the U.S. holder can properly make a &#8220;purging election&#8221; with respect
to our ordinary shares in connection with the U.S. holder&#8217;s QEF election. A purging election may require the U.S. holder to recognize
taxable gain on the U.S. holder&#8217;s ordinary shares.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">In order to comply with the requirements of a QEF election, a U.S. holder must receive
certain information from us. The QEF election is made on a shareholder-by-shareholder basis and can be revoked only with the consent of
the IRS. A shareholder makes a QEF election by attaching a completed IRS Form 8621, including the information provided in the PFIC annual
information statement, to a timely filed U.S. federal income tax return and by filing a copy of the form with the IRS. We may provide
the information necessary for U.S. holders to make QEF elections if we were treated as a PFIC for any taxable year. There is no assurance
that we will have timely knowledge of our status as a PFIC in the future. Accordingly, U.S. holders may be unable to make a timely QEF
election with respect to our ordinary shares.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">U.S. holders should consult their tax advisors to determine whether any of these above
elections would be available and if so, what the consequences of the alternative treatments would be in their particular circumstances.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The tax consequences that would apply if we are a PFIC would also be different from
those described above if a timely and valid &#8220;mark-to-market&#8221; election is made by a U.S. holder for the ordinary shares held
by such U.S. holder. An electing U.S. holder would generally take into account as ordinary income or loss each year an amount equal to
the difference between the U.S. holder&#8217;s adjusted tax basis in such ordinary shares and their fair market value; however, losses
would be allowed only to the extent of the excess of amounts previously included in income over ordinary losses deducted in prior years
as a result of the mark-to-market election. Any gain from a sale, exchange or other taxable disposition of the ordinary shares in any
taxable year in which we are a PFIC would be treated as ordinary income and any loss from such sale, exchange or other taxable disposition
would be treated first as ordinary loss (to the extent of any net mark-to-market gains previously included in income) and thereafter as
capital loss. The adjusted tax basis of a U.S. holder&#8217;s ordinary shares is increased by the amount included in gross income under
the mark-to-market regime, or is decreased by the amount of the deduction allowed under the regime. If a U.S. holder makes a mark-to-market
election it will be effective for the taxable year for which the election is made and all subsequent taxable years unless the shares are
no longer regularly traded on a qualified exchange or the IRS consents to the revocation of the election.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">A mark-to-market election is available to a U.S. holder only for &#8220;marketable
stock.&#8221; Generally, stock will be considered marketable stock if it is &#8220;regularly traded&#8221; on a &#8220;qualified exchange&#8221;
within the meaning of applicable Treasury Regulations. A class of stock is regularly traded during any calendar year during which such
class of stock is traded, other than in <span style="font-style: italic">de minimis</span> quantities, on at least 15 days during each
calendar quarter. The ordinary shares will be marketable stock as long as they remain listed on a qualified exchange, such as Nasdaq,
and are regularly traded. However, we can provide no assurances that our ordinary shares will continue to be listed on a qualified exchange
or will be regularly traded. A mark-to-market election will not apply to the ordinary shares for any taxable year during which we are
not a PFIC but will remain in effect with respect to any subsequent taxable year in which we become a PFIC. U.S. holders are urged to
consult their tax advisor about the availability of the mark-to-market election, and whether making the election would be advisable in
such holder&#8217;s particular circumstances.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">109</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we are a PFIC and, at any time, have a non-U.S. subsidiary that is classified as
a PFIC (a &#8220;lower-tier&#8221; PFIC), U.S. holders of our ordinary shares generally would be deemed to own, and also would be subject
to the PFIC rules with respect to, their indirect ownership interests in that lower-tier PFIC. If we are a PFIC and a U.S. holder of our
ordinary shares does not make a QEF election in respect of a lower-tier PFIC, the U.S. holder could incur liability for the deferred tax
and interest charge described above if either (1) we receive a distribution from, or dispose of all or part of our interest in, the lower-tier
PFIC or (2) the U.S. holder disposes of all or part of its ordinary shares. We may provide the information necessary for U.S. holders
to make QEF elections with respect to any lower-tier PFIC. A mark-to-market election under the PFIC rules with respect to our ordinary
shares would not apply to a lower-tier PFIC, and a U.S. holder would not be able to make such a mark-to-market election in respect of
its indirect ownership interest in that lower-tier PFIC. Consequently, U.S. holders of our ordinary shares could be subject to the PFIC
rules with respect to income of the lower-tier PFIC the value of which already had been taken into account indirectly via mark-to-market
adjustments. U.S. holders are urged to consult their own tax advisors regarding the issues raised by lower-tier PFICs.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Each U.S. holder who is a shareholder of a PFIC must file an annual information report
on IRS Form 8621 containing such information as the U.S. Treasury Department may require (whether or not a QEF election or a mark-to-market
election is made). The failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the statute of limitations
with respect to U.S. federal income tax.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">THE RULES DEALING WITH PFICS AND WITH THE QEF AND MARK-TO-MARKET
ELECTIONS ARE VERY COMPLEX AND ARE AFFECTED BY VARIOUS FACTORS IN ADDITION TO THOSE DESCRIBED ABOVE, INCLUDING OUR OWNERSHIP OF ANY NON-U.S.
SUBSIDIARIES. AS A RESULT, U.S. HOLDERS OF ORDINARY SHARES ARE STRONGLY ENCOURAGED TO CONSULT THEIR TAX ADVISORS ABOUT THE PFIC RULES
IN CONNECTION WITH THEIR PURCHASING, HOLDING OR DISPOSING OF ORDINARY SHARES.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold; font-style: italic">U.S. Federal Income Tax Consequences
If We Are Not a PFIC</span>.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The description of the U.S. federal income tax consequences of the receipt of distributions
and the sale or other taxable exchange of our ordinary shares, described in the following two sections &#8220;- <span style="font-style: italic">Distributions</span>&#8221;
and &#8220;<span style="font-style: italic">- Disposition of Ordinary Shares</span>,&#8221; apply only if we are not a PFIC in the relevant
year and our ordinary shares are not subject to the rules described above under &#8220;-<span style="font-style: italic">Passive Foreign
Investment Company Rules</span>&#8221;.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Distributions</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Subject to the discussion under &#8220;<span style="font-style: italic">- Passive
Foreign Investment Company Rules</span>&#8221; above, the gross amount of any distributions with respect to our ordinary shares (including
any amounts withheld to reflect Israeli withholding taxes) will be taxable as dividends, to the extent paid out of our current or accumulated
earnings and profits, as determined under U.S. federal income tax principles. Such income (including any withheld taxes) will be includable
in a U.S. holder&#8217;s gross income as ordinary income on the day actually or constructively received. Distributions in excess of earnings
and profits will be non-taxable to the U.S. holder to the extent of, and will be applied against and reduce (but not below zero), the
U.S. holder&#8217;s adjusted tax basis in the ordinary shares. Distributions in excess of earnings and profits and such adjusted tax basis
will generally be taxable to the U.S. holder as described below under &#8220;<span style="font-style: italic">- Disposition of Ordinary
Shares</span>.&#8221; However, since we do not calculate our earnings and profits under U.S. federal income tax principles, it is expected
that any distribution will be reported as a dividend, even if that distribution would otherwise be treated as a non-taxable return of
capital or as capital gain under the rules described above. The amount of any dividend paid by us will be treated as foreign-source dividend
income to U.S. holders, and the dividends received deduction will not be available to a U.S. holder that is taxed as a corporation as
a result.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">With respect to non-corporate U.S. holders, certain dividends received from a &#8220;qualified
foreign corporation&#8221; that is not a PFIC may be subject to reduced rates of taxation. A qualified foreign corporation includes a
foreign corporation that is eligible for the benefits of a comprehensive income tax treaty with the United States which the United States
Treasury Department determines to be satisfactory for these purposes and which includes an exchange of information provision. The United
States Treasury Department has determined that the US-Israel Tax Treaty meets these requirements. A foreign corporation is also treated
as a qualified foreign corporation with respect to dividends paid by that corporation on shares that are readily tradable on an established
securities market in the United States. As discussed under &#8220;- <span style="font-style: italic">Passive Foreign Investment Company
Rules</span>&#8221; above, there can be no assurance that our ordinary shares will be considered readily tradable on an established securities
market in any year. If we are a qualified foreign corporation, and we are not classified as a PFIC for the taxable year in which a dividend
is paid or in the preceding taxable year (as discussed above under &#8220;<span style="font-style: italic">- Passive Foreign Investment
Company Rules</span>&#8221;), dividend income will generally qualify as &#8220;qualified dividend income&#8221; in the hands of individual
U.S. holders, which is generally taxed at the lower applicable long term capital gains rates, provided certain holding period and other
requirements for treatment of such dividends as &#8220;qualified dividend income&#8221; are satisfied. U.S. holders should consult their
own tax advisors regarding the availability of the lower rate for dividends paid with respect to our ordinary shares.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">110</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">Although, to the extent we pay dividends in the future, we intend to pay dividends
to U.S. holders in dollars, the amount of any dividend paid in Israeli currency will equal its dollar value for U.S. federal income tax
purposes, calculated by reference to the exchange rate in effect on the date the dividend is received by the U.S. holder, regardless of
whether the Israeli currency is converted into dollars. If the Israeli currency received as a dividend are converted into United States
dollars on the date they are received, the U.S. holder generally will not be required to recognize foreign currency gain or loss in respect
of the dividend income. If the Israeli currency is not converted into dollars on the date of receipt, the U.S. holder will have a basis
in the Israeli currency equal to its dollar value on the date of receipt. Any subsequent gain or loss upon the conversion or other disposition
of the Israeli currency will be treated as ordinary income or loss, and generally will, for U.S. federal income tax purposes, be treated
as income or loss from U.S. sources.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Certain U.S. holders generally may be eligible, subject to a number of complex limitations,
to claim Israeli taxes withheld from distributions and paid over to the Israeli taxing authorities either as a deduction from gross income
or as a credit against U.S. federal income tax liability. To the extent a refund of the tax withheld is available to a U.S. holder under
Israeli law or under the US-Israel Tax Treaty, the amount of tax withheld that is refundable will not be eligible for credit against a
U.S. holder&#8217;s United States federal income tax liability. The foreign tax credit is subject to numerous complex limitations that
must be determined and applied on an individual basis. U.S. holders should consult their own tax advisors regarding the foreign tax credit
rules.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Disposition of Ordinary Shares</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In general, subject to the discussion under &#8220;- <span style="font-style: italic">Passive
Foreign Investment Company Rules</span>&#8221;, above, a U.S. holder will recognize U.S.-source capital gain or loss upon a taxable disposition
of an ordinary share equal to the difference between the sum of the fair market value of any property and the amount of cash received
in such disposition (including the amount of any foreign taxes withheld therefrom) and the U.S. holder&#8217;s adjusted tax basis in such
share. A U.S. holder&#8217;s adjusted tax basis generally will equal the U.S. holder&#8217;s acquisition cost less any distributions treated
as a return of capital as described under &#8220;- <span style="font-style: italic">Distributions</span>&#8221; above. Such capital gain
or loss will be long-term capital gain or loss if a U.S. holder&#8217;s holding period in the ordinary share is more than one year at
the time of the taxable disposition. Under current law, subject to certain exceptions (including but not limited to those described under
&#8220;<span style="font-style: italic">- Passive Foreign Investment Company Rules</span> &#8221; above), long-term capital gain realized
by a non-corporate U.S. holder generally will be eligible for reduced rates of tax. The deduction of capital losses may be subject to
limitation. Because gain from the sale or other taxable disposition of an ordinary share will generally be treated as U.S.-source income
and, subject to certain exceptions, Treasury Regulations generally preclude U.S. taxpayers from claiming a foreign tax credit with respect
to any non-U.S. tax imposed on gains from dispositions of shares held as capital assets unless the tax is creditable under an applicable
income tax treaty, your ability to claim a foreign tax credit with respect to Israeli tax imposed on any such sale or other taxable disposition,
if any, may be significantly limited. U.S. holders should consult their own tax advisors regarding the foreign tax credit rules with respect
to any foreign taxes withheld from a taxable disposition of ordinary shares, as well as regarding any foreign currency gain or loss in
connection with such a disposition.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">111</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Backup Withholding and Information Reporting</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In general, information reporting will apply to dividends in respect of our ordinary
shares and the proceeds from the sale or exchange of our ordinary shares that are paid to a U.S. holder within the United States (and
in certain cases, outside the United States), unless such holder is an exempt recipient. A backup withholding tax generally applies to
such payments if the U.S. holder fails to provide a taxpayer identification number and a duly executed IRS Form W-9 or other certification
of exempt status unless the U.S. holder otherwise establishes that it is exempt from such rules.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Any amounts withheld under the backup withholding rules will be allowed as a refund
or a credit against a U.S. holder&#8217;s U.S. federal income tax liability provided the required information is furnished to the IRS
in a timely manner.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Individuals who own &#8220;specified foreign financial assets&#8221; with an aggregate
value in excess of $50,000 may be required to file an information report on IRS Form 8938, &#8220;Statement of Specified Foreign Financial
Assets,&#8221; with respect to such assets with their tax returns. &#8220;Specified foreign financial assets&#8221; include any financial
accounts maintained by foreign financial institutions, as well as any of the following, but only if they are not held in accounts maintained
by financial institutions: (i) stocks and securities issued by non-U.S. persons; (ii) financial instruments and contracts held for investment
that have non-U.S. issuers or counterparties; and (iii) interests in foreign entities. U.S. holders that are individuals are urged to
consult their tax advisors regarding the application of these rules to their ownership of our ordinary shares.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">F. DIVIDENDS AND PAYING AGENTS</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">G. STATEMENT BY EXPERTS</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">H. DOCUMENTS ON DISPLAY</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">We are required to file reports and other information with the SEC under the Exchange
Act, and the regulations thereunder applicable to foreign private issuers. As a &#8220;foreign private issuer&#8221; we are exempt from
the rules and regulations under the Securities Exchange Act prescribing the furnishing and content of proxy statements, and our officers,
directors and principal shareholders are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions contained
in Section 16 of the Securities Exchange Act, with respect to their purchase and sale of our shares. In addition, we are not required
to file reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under
the Securities Exchange Act. Furthermore, as a foreign private issuer, we are also not subject to the requirements of Regulation FD (Fair
Disclosure) promulgated under the Exchange Act. Nasdaq rules generally require that companies send an annual report to shareholders prior
to the annual general meeting, however we rely upon an exception under the Nasdaq Listing Rules and follow the generally accepted business
practice for companies in Israel. Specifically, we file annual reports on Form 20-F, which contain financial statements audited by an
independent accounting firm, electronically with the SEC and post a copy on our website. We also furnish to the SEC reports on Form 6-K
containing unaudited financial information after the end of each of the first three quarters.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">You may review a copy of our filings with the SEC, including any exhibits and schedules,
at the offices of the Israel Securities Authority at 22 Kanfei Nesharim St., Jerusalem, Israel. As a foreign private issuer, we were only
required to file through the SEC&#8217;s EDGAR system as of November 2002. Our periodic filings are therefore available on the SEC&#8217;s
Website <span style="font-style: italic">www.sec.gov</span> from that date. You may read and copy any reports, statements or other information
that we file with the SEC, through the SEC&#8217;s EDGAR system available on the SEC&#8217;s website. These SEC filings are also available
to the public on the Israel Securities Authority&#8217;s website at <span style="font-style: italic">www.isa.gov.il</span> and from commercial
document retrieval services.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Any statement in this Annual Report about any of our contracts or other documents
is not necessarily complete. If the contract or document is filed as an exhibit to this Annual Report, the contract or document is deemed
to modify the description contained in this Annual Report. We urge you to review the exhibits themselves for a complete description of
the contract or document.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">I. SUBSIDIARY INFORMATION</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM11."><!--Anchor--></span>ITEM 11. QUANTITATIVE AND
QUALITATIVE DISCLOSURES ABOUT MARKET RISK</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">We are exposed to a variety of risks, including changes in interest rates and foreign
currency exchange risk and inflation.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Interest Rate Risk</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2023, we had approximately $51.1 million in cash, cash equivalents,
restricted cash, short-term bank deposits and investment in marketable securities. We mostly invest our cash surplus in bank deposits
and U.S. government securities. Since these investments typically carry fixed interest rate or yields, financial income over the holding
period is not sensitive to changes in interest rates. For more information, see Note 2 to our 2023 consolidated financial statements.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">112</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Foreign Currency Exchange Risk and Inflation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The cost of our Israel operations, as expressed in dollars, is influenced by the extent
to which any increase in the rate of inflation in Israel is not offset (or is offset on a lagging basis) by a devaluation of the NIS in
relation to the dollar. The inflation rate in Israel was 3.0%, 5.3% and 2.8% in 2023, 2022, and 2021, respectively. The appreciation (devaluation)
of the dollar against the NIS was 3.1%, 13.2% and (3.3%) in 2023, 2022 and 2021, respectively. For 2023, assuming a 10% devaluation of
the dollar against the NIS, we would experience an increase in our net loss of approximately $1.4 million, while assuming a 10% appreciation
of the dollar against the NIS, we would experience a decrease in our net loss of approximately $1.1 million. A significant portion of
our expenditures is employee compensation related. Salaries for Israel-based employees are paid in NIS and may be adjusted for changes
in the Israeli consumer price index, or CPI, through salary increases or adjustments. These upward adjustments increase salary expenses
in dollar terms. The devaluation/appreciation of the NIS against the dollar decreases/increases employee compensation expenditures as
expressed in dollars proportionally. Some of our other NIS based expenses are either currently adjusted to dollars or are adjusted to
the CPI. We currently have no foreign currency derivative contracts to hedge against currency exchange risk fluctuation but may consider
entering into such contracts in the future.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 12.<span id="ITEM12."><!--Anchor--></span> DESCRIPTION OF
SECURITIES OTHER THAN EQUITY SECURITIES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">PART II<span id="PARTII"><!--Anchor--></span></div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 13.<span id="ITEM13."><!--Anchor--></span> DEFAULTS, DIVIDEND
ARREARAGES AND DELINQUENCIES</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">None.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; text-indent: -45pt; margin-left: 45pt; line-height: 1.25; font-weight: bold">ITEM 14.<span id="ITEM14."><!--Anchor--></span>
MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 15.<span id="ITEM15."><!--Anchor--></span> CONTROLS AND PROCEDURES</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. DISCLOSURE CONTROLS AND PROCEDURES</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Our disclosure controls and procedures are designed to ensure that information required
to be disclosed in the reports we are required to file is recorded, processed, summarized and reported on a timely basis. Under the supervision
of our chief executive officer (principal executive officer) and chief financial officer (principal financial officer), we conducted an
evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rule 13a-15(f) and 15d-15(f)
promulgated under the Exchange Act. Based on this evaluation, our chief executive officer and chief financial officer concluded that our
disclosure controls and procedures were effective as of the end of the period covered by this Annual Report.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. MANAGEMENT&#8217;S ANNUAL REPORT ON INTERNAL
CONTROL OVER FINANCIAL REPORTING</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Our management, with the involvement of our board of directors and audit committee,
is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial
reporting (as defined in Rules 13a-15(e) and 15(d) - 15(e) of the Exchange Act) has been designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of our consolidated financial statements for external purposes in accordance
with generally accepted accounting principles.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Under the supervision of our chief executive officer (principal executive officer)
and chief financial officer (principal financial officer), our management conducted an evaluation of the effectiveness of our internal
control over financial reporting, as such term is defined under Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act. In making
this assessment, our management used the criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO). Based on this evaluation, our chief executive officer and chief financial officer have
concluded that our internal control over financial reporting was effective as of the end of the period covered by this Annual Report.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">113</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25">Notwithstanding the foregoing, all internal control systems no matter how well designed
have inherent limitations. Therefore, even those systems determined to be effective may not prevent or detect misstatements and can provide
only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Kost Forer Gabbay &amp; Kasierer, a member firm of Ernst &amp; Young Global, an independent
registered public accounting firm in Israel,&#160;which has audited our financial statements for the year ended December 31, 2023, that
are included in this Annual Report, has issued an attestation report on our internal control over financial reporting as of December&#160;31,
2023.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. ATTESTATION REPORT OF THE REGISTERED PUBLIC
ACCOUNTING FIRM</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The attestation report of Kost Forer Gabbay &amp; Kasierer, a member firm of Ernst
&amp; Young Global, an independent registered public accounting firm in Israel, on our internal control over financial reporting as of
December 31, 2023, is provided on page F-4, as included under Item 18 of this Annual Report and is incorporated herein by reference.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">&#160;D. CHANGES IN INTERNAL CONTROL OVER FINANCIAL
REPORTING</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Based on the evaluation conducted by our management, with the participation of our
chief executive officer and chief financial officer, pursuant to Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act, our
management (including such officers) have concluded that, there were no changes in our internal control over financial reporting that
occurred during the period covered by this Annual Report that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM16."><!--Anchor--></span>ITEM 16. RESERVED</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16A.<span id="ITEM16A."><!--Anchor--></span> AUDIT COMMITTEE
FINANCIAL EXPERT</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Our board of directors has determined that each of Mr. Gilead Halevy, Mr. Eran Perry
and Mr. Sanford (Sandy) Zweifach, each of whom serves on our audit committee and who meets the &#8220;independence&#8221; definition under
the Nasdaq Listing Rules, qualifies as an &#8220;audit committee financial expert&#8221; as defined in the instructions to this Item 16A
of Form 20-F. See<span style="font-style: italic">&#160;</span>&#8220;Item 6.A &#8211; Directors, Senior Management and Employees &#8211;
Directors and Senior Management&#8221; for a summary of Mr. Gilead Halevy, Mr. Eran Perry and Mr. Sanford (Sandy) Zweifach&#8217;s relevant
professional experience.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16B.<span id="ITEM16B."><!--Anchor--></span> CODE OF ETHICS</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">We have adopted a code of business conduct that applies to all of our employees, officers
and directors as well as a code of ethics for senior financial officers that applies to our chief executive officer, chief financial officer,
director of finance, controller, assistant controller and persons performing similar functions at our subsidiary.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The code of ethics for senior financial officers is available on our website, <span style="font-style: italic"><span style="text-decoration: underline">www.cgen.com</span></span>.
However, information contained on our website does not constitute a part of this Annual Report.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">We intend to post on our website all disclosures that are required by the rules and
regulations of the SEC or by the Nasdaq Listing Rules concerning any amendments to, or waivers from, any provision of the code of business
conduct or the code of ethics.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">114</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16C.<span id="ITEM16C."><!--Anchor--></span> PRINCIPAL ACCOUNTANT
FEES AND SERVICES</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The following table presents the fees billed or accrued to us by our principal accountant
for professional services rendered in the years ended December 31, 2023, and 2022:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z92a9a149f1674bba9dab83a2039b2bb9" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2023</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2022</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Audit Fees</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">163,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">163,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25">Audit Related Fees</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">65,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">10,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Tax Fees</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">4,500</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">4,500</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25">All Other Fees</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2,500</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2,500</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
        <div style="margin-right: 2.85pt; line-height: 1.25; font-weight: bold">Total</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold">235,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold">180,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">&#8220;Audit Fees&#8221; are fees for professional services rendered by our principal
accountant in connection with the integrated audit (including review of internal control over financial reporting) of our consolidated
annual financial statements and review of our unaudited interim financial statements;</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">&#8220;Audit Related Fees&#8221; are fees for professional services rendered by our
principal accountant in connection with the audit and other assignments, including consultancy, comfort letters and consents with respect
to registration statements filed with the SEC;</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">&#8220;Tax Fees&#8221; are fees for services rendered by our principal accountant
in connection with tax compliance, tax advice and tax planning which in years 2021 and 2020 were consultancy relating to withholding tax
on payments to foreign suppliers and annual Israeli tax reports; and</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">&#8220;All Other Fees&#8221; are fees for other consulting services rendered by our
principal accountant to us.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Pre-Approval Policies for Non-Audit Services</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Our audit committee is in charge of a policy and procedures for approval of audit
and non-audit services rendered by our external auditor. This policy generally provides that we will not engage our independent registered
public accounting firm to render audit or non-audit services unless the service is specifically approved in advance by our audit committee
or the engagement is entered into pursuant to the pre-approval procedure described below. Annually, our audit committee pre-approves specified
types of services that are expected to be provided to us by our independent registered public accounting firm during the next 12 months.
Any such pre-approval is detailed as to the particular service or type of services to be provided and is also generally subject to a maximum
dollar amount. All of the fees listed in the table above were approved by our audit committee.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; text-indent: -81pt; margin-left: 81pt; line-height: 1.25; font-weight: bold">ITEM 16D.<span id="ITEM16D."><!--Anchor--></span>
EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Not Applicable.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; text-indent: -54pt; margin-left: 54pt; line-height: 1.25; font-weight: bold">ITEM 16E.<span id="ITEM16E."><!--Anchor--></span>
PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16F.<span id="ITEM16F."><!--Anchor--></span> CHANGE IN REGISTRANT&#8217;S
CERTIFYING ACCOUNTANT</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16G. <span id="ITEM16G."><!--Anchor--></span>CORPORATE GOVERNANCE</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The Nasdaq Listing Rules require companies with securities listed thereon to comply
with its corporate governance standards. As a foreign private issuer whose shares are listed on Nasdaq, we are permitted to follow certain
home country corporate governance practices instead of those followed by U.S. companies under the Nasdaq Listing Rules, including:</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Shareholder Approval.</span> Pursuant to Israeli
law, we seek shareholder approval for all corporate actions requiring such approval under the requirements of the Companies Law, which
are different from the requirements for seeking shareholder approval under Nasdaq Listing Rule 5635. We seek shareholder approval in specified
situations, including upon issuance of options to directors in their capacity as directors, as required by Israeli law.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Quorum at an Adjourned General Meeting of Shareholders.</span>
Consistent with Israeli law, generally, a quorum for an adjourned general meeting of shareholders of the Company is any two shareholders
present in person, by proxy, by proxy card or by electronic vote at such meeting. As such, the Israeli quorum requirements for an adjourned
meeting are different from the Nasdaq requirement that an issuer listed on Nasdaq have a quorum requirement that in no case be less than
33 1/3% of the outstanding shares of the company&#8217;s common voting stock.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Distribution of Annual Reports</span>. We have chosen
to follow our home country practice in lieu of the requirements of Nasdaq Rule 5250(d)(1), relating to an issuer&#8217;s furnishing of
its annual report to shareholders. Specifically, we file annual reports on Form 20-F, which contain financial statements audited by an
independent accounting firm, electronically with the SEC and post a copy on our website.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">115</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16H.<span id="ITEM16H."><!--Anchor--></span> MINE SAFETY DISCLOSURE</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16I.<span id="ITEM16I."><!--Anchor--></span> DISCLOSURE REGARDING
FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16J. <span id="ITEM16J."><!--Anchor--></span>INSIDER TRADING
POLICIES</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">We have adopted an insider trading policy governing the purchase, sale, and other
dispositions of our securities by directors, senior management, and employees that are reasonably designed to promote compliance with
applicable insider trading laws, rules and regulations, and any listing standards applicable to us.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16K.<span id="ITEM16K."><!--Anchor--></span> CYBERSECURITY</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have implemented and maintain various information security processes designed to
identify, assess and manage material risks from cybersecurity threats to our critical computer networks, certain third party hosted services,
communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is
proprietary, strategic or competitive in nature, and employees&#8217; information, or the Information Systems and Data.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our Senior Vice President/Senior Advisor, Data and Informatics Solutions help identify,
assess and manage the Company&#8217;s cybersecurity threats and risks by monitoring and evaluating our threat environment using various
methods including, for example, by engaging third parties to conduct penetration tests on our behalf.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Depending on the environment and system, we implement and maintain various technical,
physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity
threats to our Information Systems and Data, including, for example, incident response policy, business continuity plan, cybersecurity
insurance, firewalls and access controls for certain environments and systems, physical security measures, and employee cybersecurity
trainings.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our overall risk assessment and management processes covers material risks from cybersecurity
threats.&#160; For example, cybersecurity risk is a component in our internal auditor&#8217;s risk assessment report. Our Senior Vice
President/Senior Advisor, Data and Informatic Solutions works with relevant management members to prioritize and mitigate cybersecurity
threats that are more likely to lead to a material impact to our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We use third-party service providers to assist us from time to time to identify, assess,
and manage material risks from cybersecurity threats, including, for example, professional services firms, including legal counsel, cybersecurity
and cloud consultants, and a penetration testing firm.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We use third-party service providers to perform a variety of functions throughout
our business, including in connection with our clinical data management, antibody development, financial information management, payments
and others. We review and require certain security measures of certain of these third parties, such as encryption at rest and in transit
and access controls, and in relevant cases, we seek to confirm their compliance with different industry standards and certifications,
such as SOC1, SOC2, SOC3, ISO 27001, ISO 27017.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For a description of the risks from cybersecurity threats that may materially affect
the Company and how they may do so, see our risk factors under Part 1. Item 3D. Risk Factors in this Annual Report on Form 20-F, including
the applicable risk factors under &#8220;Risk Factors - Risks Related to our Operations and Other Risks Related to our Business.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">116</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Governance</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our board of directors addresses the Company&#8217;s cybersecurity risk management
as part of its general oversight function through its audit committee.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our cybersecurity risk assessment and management processes are under the responsibility
of our Senior Vice President/Senior Advisor, Data and Informatics Solutions, who has over 15 years of experience in the data science,
technology, and machine learning spaces.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our Senior Vice President/Senior Advisor, Data and Informatics Solutions, is responsible
for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management
strategy, communicating key priorities to relevant personnel (such as the Chief Executive Officer), helping prepare for cybersecurity
incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our cybersecurity incident response policy is designed to escalate certain cybersecurity
incidents to certain members of management, our Senior Vice President/Senior Advisor, Data and Informatics Solutions, our Chief Financial
Officer and our General Counsel. Under our cybersecurity incident response policy, those members of management will work with the Company&#8217;s
incident response team member(s) to help the Company mitigate and remediate cybersecurity incidents of which they are notified.&#160;
In addition, the Company&#8217;s cybersecurity incident response policy includes reporting to the audit committee of the board of directors
for certain cybersecurity incidents.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The audit committee receives periodic reports at least annually from our Senior Vice
President/Senior Advisor, Data and Informatics Solutions concerning the Company&#8217;s significant cybersecurity threats and risk and
the processes the Company has implemented to address them. The audit committee also receives various reports, summaries or presentations
related to cybersecurity threats, risk and mitigation.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold"><span id="PARTIII"><!--Anchor--></span>PART III</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 17.<span id="ITEM17."><!--Anchor--></span> FINANCIAL STATEMENTS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">See Item 18.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 18.<span id="ITEM18."><!--Anchor--></span> FINANCIAL STATEMENTS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our consolidated financial statements and related notes are included in this Annual
Report beginning on page F-1.</div>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">117</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: -72pt; margin-left: 72pt; line-height: 1.25; font-weight: bold"> <br/> </div>

<div style="text-align: justify; text-indent: -72pt; margin-left: 72pt; line-height: 1.25; font-weight: bold"><span id="ITEM19.EXHIBITS"><!--Anchor--></span>ITEM
19. EXHIBITS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">Index to Exhibits</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze54cb4dc2ee341758fabe441873d995e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Exhibit Number</div> </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Description</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891323002714/exhibit_99-1.htm">1.1</a></div>
        </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891323002714/exhibit_99-1.htm">Amended
        and Restated Articles of Association of Compugen, as amended (incorporated by reference to Exhibit B to Exhibit 99.1 to Compugen&#8217;s
        report on Form 6-K filed with the SEC on August 7, 2023 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891319002031/exhibit_99-4.htm">1.2</a></div>
        </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891319002031/exhibit_99-4.htm">Memorandum
        of Association of Compugen, as amended (incorporated by reference to Annex A2 of Exhibit 99.4 to Compugen&#8217;s report on Form 6-K filed
        with the SEC on August 5, 2019 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_2-1.htm">2.1*</a></div> </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_2-1.htm">Description of Securities.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891320003355/exhibit_10-1.htm">4.1</a></div>
        </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891320003355/exhibit_10-1.htm">Compugen
        Ltd. 2021 Employee Share Purchase Plan (incorporated by reference to Exhibit 10.1 to Compugen&#8217;s Registration Statement on Form S-8
        filed with the SEC on December 12, 2020 (File No. 333-251263)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891320002176/exhibit_4-1.htm">4.2</a></div>
        </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891320002176/exhibit_4-1.htm">Compugen
        Ltd. 2010 Share Incentive Plan, as amended (incorporated by reference to Exhibit 4.1 to Compugen&#8217;s Registration Statement on Form
        S-8, filed with the SEC on July 30, 2020 (File No.333-240182)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-8.htm">4.3</a></div>
        </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-8.htm">Amended
        and Restated Form of Indemnification Undertaking and Exemption and Release between Compugen Ltd. and its directors and office holders
        (incorporated by reference to Exhibit 4.8 to Compugen&#8217;s Annual Report on Form 20-F/A for the year ended December 31, 2021, filed
        with the SEC on February 28, 2022 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891315001448/exhibit_99-2.htm">4.4</a></div>
        </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891315001448/exhibit_99-2.htm">Office
        Lease Agreement (&#8220;Holon Lease&#8221;), dated March 2015, by and between Kanit Hashalom Investments Ltd. and Compugen Ltd. (incorporated
        by reference to Exhibit 99.2 to Compugen&#8217;s Form 6-K filed with the SEC on May 5, 2015 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891316004622/exhibit_4-10.htm">4.5</a></div>
        </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891316004622/exhibit_4-10.htm">Amendment
        to Holon Lease made and entered into on November 26, 2015, by and between Kanit Hashalom Investments Ltd. and Compugen Ltd. (incorporated
        by reference to Exhibit 4.10 to Compugen&#8217;s Annual Report on Form 20-F for the year ended December 31, 2015, filed with the SEC on
        March 7, 2016 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891321000791/exhibit_4-11.htm">4.6</a></div>
        </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891321000791/exhibit_4-11.htm">Addendum
        to Holon Lease made and entered into on October 14, 2020 by and between Kanit Hashalom Investments Ltd. and Compugen Ltd. (incorporated
        by reference to Exhibit 4.11 to Compugen&#8217;s Annual Report on Form 20-F for the year ended December 31, 2020, filed with the SEC on
        February 25, 2021 (File No. 000-30902))</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318001533/exhibit_10-1.htm">4.7@</a></div>
        </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318001533/exhibit_10-1.htm">License
        Agreement, between the Company and MedImmune Limited (&#8220;MedImmune&#8221;), entered into as of March 30, 2018 (incorporated by reference
        to Exhibit 10.1 to Compugen&#8217;s Form 6-K, filed with the SEC on May 9, 2018 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318002228/exhibit_10-1.htm">4.8@</a></div>
        </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318002228/exhibit_10-1.htm">Amendment
        No. 1 to the License Agreement, between the Company and MedImmune, dated May 9, 2018 (incorporated by reference to Exhibit 10.1 to Compugen&#8217;s
        Form 6-K, filed with the SEC on August 1, 2018 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891321000791/exhibit_4-14.htm">4.9</a></div>
        </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891321000791/exhibit_4-14.htm">Amendment
        No. 2 to the License Agreement, between the Company and MedImmune, dated September 16, 2020 (incorporated by reference to Exhibit 4.14
        to Compugen&#8217;s Annual Report on Form 20-F for the year ended December 31, 2020, filed with the SEC on February 25, 2021 (File No.
        000-30902)).</a></div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">118</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-15.htm">4.10#</a></div>
        </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-15.htm">Amendment
        No. 3 to the License Agreement, between the Company and MedImmune, dated August 4, 2021 (incorporated by reference to Exhibit 4.15 to
        Compugen&#8217;s Annual Report on Form 20-F/A for the year ended December 31, 2021, filed with the SEC on February 28, 2022 (File No.
        000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-11.htm">4.11*#</a></div> </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-11.htm">License Agreement, between Compugen Ltd. and Gilead Sciences,
        Inc., dated December 18, 2023.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top"><a href="exhibit_8-1.htm">8.1* <br/> </a></td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_8-1.htm">Subsidiaries.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_12-1.htm">12.1*</a></div> </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_12-1.htm">Certification by Principal Executive Officer pursuant to
        Rule 13a-14(a)/Rule 15d-14(a) under the Exchange Act and Section 302 of the Sarbanes-Oxley Act of 2002.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_12-2.htm">12.2*</a></div> </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_12-2.htm">Certification by Principal Financial Officer pursuant to
        Rule 13a-14(a)/Rule 15d-14(a) under the Exchange Act and Section 302 of the Sarbanes-Oxley Act of 2002.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_13-1.htm">13.1*</a></div> </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_13-1.htm">Certification by Principal Executive Officer and Principal
        Financial Officer pursuant to Rule 13a-14(b)/Rule 15d-14(b) under the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to
        Section 906 of the Sarbanes-Oxley Act of 2002.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_15-1.htm">15.1*</a></div> </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_15-1.htm">Consent of Kost Forer Gabbay &amp; Kasierer, a member firm
        of Ernst &amp; Young Global.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_97-1.htm">97.1*</a></div> </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_97-1.htm">Compugen&#8217;s Policy for Recovery of Erroneously Awarded
        Compensation.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 85.71%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="line-height: 1.25">101*</div> </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">The following financial information from Compugen Ltd.&#8217;s Annual Report on Form
        20-F for the year ended December 31, 2023, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Statements
        of Operations for the years ended December 31, 2023, 2022 and 2021; (ii) Consolidated Balance Sheets as of December 31, 2023 and 2022;
        (iii) Consolidated Statements of Changes in Shareholders&#8217; Equity for the years ended December 31, 2023, 2022 and 2021; (iv) Consolidated
        Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021; and (v) Notes to Consolidated Financial Statements.</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 85.71%; vertical-align: top">&#160;</td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z66e6b0c9e50c4a6795f5d4f8197ede20" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="line-height: 1.25">101.INS</div> </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="line-height: 1.25">Inline XBRL Instance Document</div> </td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="line-height: 1.25">101.SCH</div> </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="line-height: 1.25">Inline XBRL Taxonomy Extension Schema Document</div> </td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="line-height: 1.25">101.PRE</div> </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="line-height: 1.25">Inline XBRL Taxonomy Extension Presentation Linkbase Document</div> </td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="line-height: 1.25">101.CAL</div> </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="line-height: 1.25">Inline XBRL Taxonomy Calculation Linkbase Document</div> </td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="line-height: 1.25">101.LAB</div> </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="line-height: 1.25">Inline XBRL Taxonomy Label Linkbase Document</div> </td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="line-height: 1.25">101.DEF</div> </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="line-height: 1.25">Inline XBRL Taxonomy Extension Definition Linkbase Document</div> </td> </tr>
  <tr>
    <td style="width: 14.29%; vertical-align: top">
        <div style="line-height: 1.25">104</div> </td>
    <td style="width: 85.71%; vertical-align: top">
        <div style="line-height: 1.25">Cover Page Interactive Data File&#160;(Formatted as Inline XBRL and contained in Exhibit 101).</div> </td>
        </tr>
  <tr>
    <td rowspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 14.29%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 85.71%; vertical-align: top">&#160;</td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zb44feb3fe3b8470fafb939679197b211" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">*</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Filed herewith.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160; <br/> </div>

<table cellspacing="0" cellpadding="0" id="z71d929a057304a15814f4f1ee116eb51" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">@</td>
    <td style="width: auto; vertical-align: top">
        <div>Confidential treatment has been granted by the Securities and Exchange Commission as to certain portions.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160; <br/> </div>

<table cellspacing="0" cellpadding="0" id="z3fd9006dfd3241d6946b131535564225" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">#</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Portions of this exhibit (indicated by asterisks therein) have been omitted as these portions are both not material and private or
        confidential.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160; <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">119</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; margin-right: 28.4pt; margin-left: 18pt; line-height: 1.25; font-weight: bold"> <br/> </div>

<div style="text-align: center; margin-right: 28.4pt; margin-left: 18pt; line-height: 1.25; font-weight: bold"><span id="SIGNATURES"><!--Anchor--></span>SIGNATURES</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25">The registrant hereby certifies that it meets all of the requirements for filing on
Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</div>

<div style="line-height: 1.25">&#160; <br/> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" border="0" id="z8e47fcf959354fb48fef6c1db177c3ec" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td style="width: 50%">
        <div>&#160;</div> </td>
    <td style="width: 50%">
        <div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">COMPUGEN LTD.</div> </div>
        </td> </tr>
  <tr>
    <td style="width: 50%">
        <div>&#160;</div> </td>
    <td style="width: 50%">
        <div>&#160;</div> </td> </tr>
  <tr>
    <td style="width: 50%">
        <div>&#160;</div> </td>
    <td style="width: 50%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="text-decoration: underline">Signature:
        /s/ Dr. Anat Cohen-Dayag</span></div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Name: Dr. Anat Cohen-Dayag</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman,Times,serif">Title: President and Chief Executive Officer,
        Director</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Date: March 5, 2024</div> </td> </tr>
  </table> </div>

<div><br/> </div> </div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">120</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div> <br/> </div>
<!-- Field: /Include-Text -->

<p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman,Times,serif; text-align: left">&#160;</p>
</div><div style="">
  <div>
    <div>
      <div>
        <div>
          <div>
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED FINANCIAL STATEMENTS</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">AS OF DECEMBER 31, 2023</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. DOLLARS IN THOUSANDS</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INDEX</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:85.36%;vertical-align:bottom">&#160;</td>
                  <td style="width:14.64%;vertical-align:bottom;border-bottom:2px solid #000000">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Page</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="width:85.36%;vertical-align:bottom">&#160;</td>
                  <td style="width:14.64%;vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="width:85.36%;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><a href="#REPORTOFINDEPENDENTREGIST_integixAnchor">Report of Independent Registered Public Accounting Firm</a> (</span><span style="font-style:italic">PCAOB ID: <ix:nonNumeric id="FFact_0000000000042" name="dei:AuditorFirmId" contextRef="C_20230101to20231231">1281</ix:nonNumeric></span><span style="font-weight:bold">)</span></span></span></div>
                  </td>
                  <td style="width:14.64%;vertical-align:bottom">
                    <div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-2 - F-4</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:85.36%;vertical-align:bottom">&#160;</td>
                  <td style="width:14.64%;vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="width:85.36%;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#BALANCESHEETS_integixAnchor">Consolidated Balance Sheets</a></span></span></div>
                  </td>
                  <td style="width:14.64%;vertical-align:bottom">
                    <div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-5 - F-6</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:85.36%;vertical-align:bottom">&#160;</td>
                  <td style="width:14.64%;vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="width:85.36%;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#COMPREHENSIVELOSS_integixAnchor">Consolidated Statements of Comprehensive Loss</a></span></span></div>
                  </td>
                  <td style="width:14.64%;vertical-align:bottom">
                    <div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-7</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:85.36%;vertical-align:bottom">&#160;</td>
                  <td style="width:14.64%;vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="width:85.36%;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CHANGESINSHAREHOLDERSEQUI_integixAnchor"><span style="font-weight:bold">Statements of Changes in Shareholders</span>&#8217;<span style="font-weight:bold"> Equity</span></a></span></span></div>
                  </td>
                  <td style="width:14.64%;vertical-align:bottom">
                    <div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-8</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:85.36%;vertical-align:bottom">&#160;</td>
                  <td style="width:14.64%;vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="width:85.36%;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CASHFLOWS_integixAnchor">Consolidated Statements of Cash Flows</a></span></span></div>
                  </td>
                  <td style="width:14.64%;vertical-align:bottom">
                    <div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-9 - F-10</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:85.36%;vertical-align:bottom">&#160;</td>
                  <td style="width:14.64%;vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="width:85.36%;vertical-align:bottom">
                    <div style="margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#NOTESTOCONSOLIDATEDFINANC_integixAnchor">Notes to Consolidated Financial Statements</a></span></span></div>
                  </td>
                  <td style="width:14.64%;vertical-align:bottom">
                    <div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-11 - F-43</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="line-height:1.25">&#160;</div>
            <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
              <div style="page-break-after:always">
                <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
              </div>
            </div>&#160;<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:20%;vertical-align:top">
                    <div style="line-height:1.25"><img alt="image0.jpg" src="image0.jpg" style="width:99px;height:114px"/></div>
                  </td>
                  <td rowspan="1" style="width:30%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Kost Forer Gabbay &amp; Kasierer</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">144 Menachem Begin Road, Building A,</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel-Aviv 6492102, Israel</span></span></div>
                  </td>
                  <td style="width:50%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel: +972-3-6232525</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fax: +972-3-5622555</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ey.com</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="REPORTOFINDEPENDENTREGIST_integixAnchor"></span>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To the Shareholders and Board of Directors of</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Opinion on the Financial Statements</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<span>&#160;</span></span></span>
            <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have audited the accompanying consolidated balance sheets of Compugen Ltd. and its subsidiary (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, the related consolidated statements of comprehensive loss, changes in shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2023, and related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></span><span style="font-size:10pt;text-align:left;color:rgba(0, 0, 0, 0.87)">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></div>
            </div> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<span>&#160;</span></span></span>
            <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March 5, 2024, expressed an unqualified opinion thereon.</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></div>
            </div> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<span>&#160;</span></span></span>
            <div style="text-align:justify;line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basis for Opinion</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></div> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<span>&#160;</span></span></span>
            <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></span><span style="font-size:10pt;text-align:left">&#160;</span><span style="font-size:10pt;text-align:left">&#160;<span style="font-size:10pt">&#160;</span></span></div> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<span>&#160;</span></span></span>
            <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></div> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<span>&#160;</span></span></span>
            <div style="line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Critical Audit Matters</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></div> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<span>&#160;</span></span></span>
            <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></span></div>
            </div>
            <div>&#160;</div>
            <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
              <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F - 2</span></span></span></div>
              <div style="page-break-after:always">
                <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
              </div>
            </div>
            <div style="line-height:1.25"><img alt="image0.jpg" src="image0.jpg" style="width:99px;height:114px"/>
              <div>
                <div style="line-height:1.25;font-weight:bold"><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued Pre-Clinical and Clinical Trial Expenses</span></span></div>
              </div>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:13.36%;vertical-align:top">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description of the matter</span></span></div>
                  </td>
                  <td style="width:2.03%;vertical-align:top">&#160;</td>
                  <td style="width:84.6%;vertical-align:top">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As discussed in Note 2(m) to the consolidated financial statements, the Company records costs for pre-clinical and clinical trial activities based upon estimates of costs incurred through the balance sheet date that have yet to be invoiced by the contract research organizations and other vendors.</span></span></div>
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Auditing the Company&#8217;s accruals for pre-clinical and clinical trial activities is challenging due to the fact that information necessary to estimate the accruals for the services that have been received during the reporting period is accumulated from multiple sources such as Company&#8217;s personnel that oversee the pre-clinical and clinical trial activities, information from service providers and terms and conditions included in the contracts with the service providers. In addition, in certain circumstances, the determination of the nature and level of services that have been received during the reporting period requires judgment because the timing and pattern of vendor invoicing does not correspond to the level of services provided and there may be delays in invoicing from pre-clinical and clinical study sites and other vendors.</span></span></div>
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25">&#160;</span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:13.36%;vertical-align:top">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">How we addressed the matter in our audit</span></span></div>
                  </td>
                  <td style="width:2.03%;vertical-align:top">&#160;</td>
                  <td style="width:84.6%;vertical-align:top">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We obtained an understanding of, evaluated the design and tested the operating effectiveness of internal controls that addressed the identified risks related to the Company&#8217;s process for recording accrued pre-clinical and clinical trial expenses.</span></span></div>
                    <div style="text-align:justify;line-height:1.25">&#160;</div>
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To test the pre-clinical and clinical trial accruals, our audit procedures included, among others, reviewing a sample of agreements with the service providers to corroborate key terms and conditions and testing the accuracy and completeness of the underlying data used in the accrual computations. We also evaluated management&#8217;s estimates of the progress of a sample of pre-clinical and clinical trial activities by making direct inquiries of the Company&#8217;s personnel that oversee the pre-clinical and clinical trial activities and obtaining information directly from certain service providers which indicated the progress of pre-clinical and clinical trial completed through the balance sheet date and compared that to the Company&#8217;s accrual computations. To evaluate the completeness of the accruals, we also examined subsequent invoices from the service providers and cash disbursements to the service providers, to the extent such invoices were received, or payments were made prior to the date that the consolidated financial statements were issued.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">License Agreement with Gilead</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></div>
            <div style="line-height:1.25">
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:13.36%;vertical-align:top;font-family:'Times New Roman'">
                      <div style="line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description of the matter</span></span></div>
                    </td>
                    <td style="width:2.03%;vertical-align:top;font-family:'Times New Roman'">&#160;</td>
                    <td style="width:84.6%;vertical-align:top">
                      <div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As described in Note 2(k) to the consolidated financial statements, the Company entered into a license agreement with Gilead Sciences, Inc. The Company&#8217;s obligations under the license agreement include: (i) delivery of exclusive license; (ii) certain research transition activities through the clearance of an IND; (iii) contingent promise to additional research and development activities for Phase 1 clinical trial. Under this agreement amounts received include upfront payment, milestone and other contingent payments for the achievement of defined collaboration objectives and certain preclinical, clinical, regulatory and sales-based events, as well as royalties on sales of commercialized products. The initial transaction price of $60 million was allocated to the obligations based on the relative estimated standalone selling prices of each obligation, over which management has applied significant judgment.</span></span><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></div>
                      <div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Auditing the Company&#8217;s evaluation of the standalone selling price of the license performance obligation was challenging and complex due to the assumptions used by management and high degree of auditor judgment required to evaluate the standalone selling price of the license. The Company developed the estimated standalone selling price of the license based on the present value of expected future cash flows associated with the license and related clinical development and regulatory milestones. In developing such estimate, the Company applied judgement in determining the timing needed to develop the Licensed Product, the probability of success, the expected future cash flows and the discount rate. In addition, the audit effort involved the use of professionals with specialized skill and knowledge to assist in evaluating the audit evidence obtained.</span></span></div>
                      <div style="line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25">&#160;</span></span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:13.36%;vertical-align:top;font-family:'Times New Roman'">
                      <div style="line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">How we addressed the matter in our audit</span></span></div>
                    </td>
                    <td style="width:2.03%;vertical-align:top;font-family:'Times New Roman'">&#160;</td>
                    <td style="width:84.6%;vertical-align:top">
                      <div style="line-height:1.25">
                        <div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company&#8217;s evaluation of the standalone selling price of the license performance obligation process, including controls over management&#8217;s process to determine the methods used to develop standalone selling price of the license, and controls over development of the assumptions related to the methods, including expected future cash flows, discount rates, probability of success and costs estimates for manufacturing and supply costs.</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25">&#160;</span></span></span></div>
                        <div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To&#160;audit the Company&#8217;s evaluation of the standalone selling price of the license performance obligation related to the Gilead license agreement, we performed audit procedures that included, among others, reading the contractual terms of the license agreement, understanding and testing management&#8217;s process for developing the standalone selling price, including evaluating the appropriateness of the method and the reasonableness of management&#8217;s assumptions relating to the indications that will be pursued, forecasted future revenues, probability of success, estimates for manufacturing and supply costs and testing the completeness, accuracy and relevance of underlying data used. Evaluating management&#8217;s assumptions related to the future revenue included in the expected future cash flows, probability of success, and cost estimates for manufacturing and supply costs involved evaluating whether the assumptions used by management were reasonable considering the consistency with data from internal and external sources including market and industry data. We involved valuation professionals to assist in the assessment of the estimation methodology and the significant assumptions used in determining the estimated standalone selling price of the license.</span></span></div>
                      </div>
                    </td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">KOST FORER GABBAY &amp; KASIERER</span></span></div>
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A Member of EY Global</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have served as the Company&#8217;s auditor since 2002</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:100%;vertical-align:top">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel-Aviv, Israel</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:100%;vertical-align:top">
                    <div style="text-align:justify;line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March 5, 2024</span></span></div>
                    </div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
              <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F - 3</span></span></span></div>
              <div style="page-break-after:always">
                <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
              </div>
            </div> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;</span></span>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:20%;vertical-align:top">
                    <div style="line-height:1.25"><img alt="image0.jpg" src="image0.jpg" style="width:99px;height:114px"/></div>
                  </td>
                  <td style="width:30%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Kost Forer Gabbay &amp; Kasierer</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">144 Menachem Begin Road, Building A,</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel-Aviv 6492102, Israel</span></span></div>
                  </td>
                  <td style="width:50%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel: +972-3-6232525</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fax: +972-3-5622555</span></span></div>
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ey.com</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To the Shareholders and Board of Directors of</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Opinion on Internal Control over Financial Reporting</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have audited Compugen Ltd. and its subsidiary&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Compugen Ltd. and its subsidiary (the &#8220;Company&#8221;) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25">
              <div style="line-height:1.25;font-family:'Times New Roman', serif;font-size:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(46, 46, 56)">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2023 and 2022 and the related consolidated statements of comprehensive loss, changes in shareholders</span><span style="color:rgb(0, 0, 0)">&#8217;</span><span style="color:rgb(46, 46, 56)"> equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes and our report dated March 5, 2024, expressed an unqualified opinion thereon. </span></span></span></div>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basis for Opinion</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures, as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Definition and Limitations of Internal Control Over Financial Reporting</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000043" name="dei:AuditorName" contextRef="C_20230101to20231231">KOST FORER GABBAY &amp; KASIERER</ix:nonNumeric></span></span></div>
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A Member of EY Global</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:100%;vertical-align:top">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000044" name="dei:AuditorLocation" contextRef="C_20230101to20231231">Tel-Aviv, Israel</ix:nonNumeric></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:100%;vertical-align:top">
                    <div style="text-align:justify;line-height:1.25">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March 5, 2024</span></span></div>
                      </div>
                    </div>
                  </td>
                </tr>

            </table>
            <div>
              <div style="text-align:center;line-height:1.25">&#160;</div>
              <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
                <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F - 4</span></span></span></div>
                <div style="page-break-after:always">
                  <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
</div><div style="">
  <div>
    <div>
      <div>
        <div>
          <div>
            <div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
          </div>
          <div style="line-height:1.25">
            <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED <span id="BALANCESHEETS_integixAnchor"></span>BALANCE SHEETS</span></span>
              <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;margin-top:5pt;margin-bottom:5pt"/>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ASSETS</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CURRENT ASSETS:</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000045" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,890</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000046" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,059</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000047" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">365</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000048" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">362</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposits</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000049" name="us-gaap:OtherShortTermInvestments" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,053</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000050" name="us-gaap:OtherShortTermInvestments" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,287</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investment in marketable securities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240227231100990_Fact_0000000000049" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,742</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240227231100990_Fact_0000000000050" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade receivables</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-family:'Times New Roman',serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240227231059015_Fact_0000000000049" name="us-gaap:ReceivablesNetCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,000</ix:nonFraction></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240227231059015_Fact_0000000000050" name="us-gaap:ReceivablesNetCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other accounts receivable and prepaid expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000053" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,529</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000054" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,417</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span> current assets</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-family:'Times New Roman',serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000055" name="us-gaap:AssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,579</ix:nonFraction></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000056" name="us-gaap:AssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,125</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NON-CURRENT ASSETS:</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term prepaid expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000057" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,233</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000058" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,899</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Severance pay fund</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000059" name="cgen:SeverancePayFundNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,977</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000060" name="cgen:SeverancePayFundNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,794</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease right of use asset</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000061" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,329</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000062" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,826</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment, net</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000063" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,216</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000064" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,532</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span> non- current assets</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000065" name="us-gaap:AssetsNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,755</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000066" name="us-gaap:AssetsNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,051</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span> assets</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-family:'Times New Roman',serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000067" name="us-gaap:Assets" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,334</ix:nonFraction></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000068" name="us-gaap:Assets" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,176</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span>
            <p style="margin:0pt">&#160;</p>
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 5</span></span></span></span></p><div style="text-align:center"><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt;margin-bottom:10pt"/></div>
          </div>
          <div style="line-height:1.25">
            <div style="text-align:justify;line-height:1.25;font-weight:bold">
              <div>
                <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
              </div>
            </div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED BALANCE SHEETS</span></span>
              <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;margin-top:5pt;margin-bottom:5pt"/>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share and per share data)</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:17pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CURRENT LIABILITIES:</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000069" name="us-gaap:AccountsPayableCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,502</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000070" name="us-gaap:AccountsPayableCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,773</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term deferred participation in R&amp;D expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000071" name="cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000072" name="cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">325</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term deferred revenues</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240227231820447_Fact_0000000000071" name="us-gaap:DeferredRevenueCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,149</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240227231820447_Fact_0000000000072" name="us-gaap:DeferredRevenueCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current maturity of operating lease liability</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000073" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">632</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000074" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">613</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other accounts payable and accrued expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000075" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,983</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000076" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,208</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span> current liabilities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000077" name="us-gaap:LiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,266</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000078" name="us-gaap:LiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,919</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NON- CURRENT LIABILITIES:</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term deferred revenues</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240227232504678_Fact_0000000000081" name="us-gaap:DeferredRevenueNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,392</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240227232504678_Fact_0000000000082" name="us-gaap:DeferredRevenueNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term operating lease liability</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000081" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">719</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000082" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,312</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued severance pay</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000083" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,398</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000084" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,265</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span> non-current liabilities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000085" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,509</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000086" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,577</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMMITMENTS AND CONTINGENT LIABILITIES</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"><ix:nonFraction id="Fxbrl_20240301101027819" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20231231" unitRef="usd" xsi:nil="true"></ix:nonFraction></td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"><ix:nonFraction id="Fxbrl_20240301101033339" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20221231" unitRef="usd" xsi:nil="true"></ix:nonFraction></td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:center;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SHAREHOLDERS&#8217; EQUITY:</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share capital:</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:28.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary shares of NIS <ix:nonFraction id="Fxbrl_20230214011115128" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20221231" unitRef="NIS_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230214011053357" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231" unitRef="NIS_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction id="Fxbrl_s_20230214011030882" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230214011030883" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2023 and 2022; <ix:nonFraction id="Fxbrl_20230214101530012" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000092" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,237,465</ix:nonFraction></ix:nonFraction> and <ix:nonFraction id="Fxbrl_20230214011437479" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000094" name="us-gaap:CommonStockSharesIssued" contextRef="C_20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,624,643</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2023 and 2022, respectively</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000095" name="us-gaap:CommonStockValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">247</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000096" name="us-gaap:CommonStockValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional paid-in capital</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000097" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">539,837</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000098" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">533,213</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated other comprehensive income</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240227232850023_Fact_0000000000097" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240227232850023_Fact_0000000000098" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated deficit</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-family:'Times New Roman',serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000099" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">474,527</ix:nonFraction></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000100" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">455,773</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                  <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span> shareholders&#8217; equity</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000101" name="us-gaap:StockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,559</ix:nonFraction></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000102" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,680</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                  <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span> liabilities and shareholders&#8217; equity</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000103" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,334</ix:nonFraction></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000104" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,176</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
        </div>
      </div>
      <div style="text-align:justify;line-height:1.25">
        <p style="margin:0pt">&#160;</p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 6</span></span></span></span></p><div style="text-align:center"><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt;margin-bottom:10pt"/></div>
      </div>
    </div>
  </div>
</div><div style="">
  <div>
    <div>
      <div>
        <div>
          <div style="line-height:1.25">
            <div style="text-align:justify;line-height:1.25;font-weight:bold">
              <div style="line-height:1.25;font-weight:bold">
                <div>
                  <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
                </div>
              </div>
            </div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS<span id="COMPREHENSIVELOSS_integixAnchor"></span></span></span>
              <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;margin-top:5pt;margin-bottom:5pt"/>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share and per share data)</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000105" name="us-gaap:Revenues" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,459</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000106" name="us-gaap:Revenues" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214012425376" name="us-gaap:Revenues" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost of revenue</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000108" name="us-gaap:CostOfRevenue" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,004</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000109" name="us-gaap:CostOfRevenue" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">975</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214012430928" name="us-gaap:CostOfRevenue" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">680</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross profit</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000111" name="us-gaap:GrossProfit" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,455</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000112" name="us-gaap:GrossProfit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,525</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214012436309" name="us-gaap:GrossProfit" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,320</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating expenses:</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses, net</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115443735_Fact_0000000000117" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,472</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115443735_Fact_0000000000118" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,648</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115443735_Fact_0000000000119" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,694</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing and business development expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000117" name="us-gaap:BusinessDevelopment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000118" name="us-gaap:BusinessDevelopment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">932</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000119" name="us-gaap:BusinessDevelopment" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">842</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115622478_Fact_0000000000117" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,731</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115622478_Fact_0000000000118" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,319</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115622478_Fact_0000000000119" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,858</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total operating expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115529913" name="us-gaap:OperatingExpenses" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,447</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000124" name="us-gaap:OperatingExpenses" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,899</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000125" name="us-gaap:OperatingExpenses" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,394</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating loss</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000126" name="us-gaap:OperatingIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,992</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000127" name="us-gaap:OperatingIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">35,374</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000128" name="us-gaap:OperatingIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">35,074</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr style="text-align:center">
                <td style="vertical-align:bottom;width:45.91%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:10.25%;padding-bottom:2px;vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:10.25%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000129" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,208</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;text-align:right;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;text-align:right;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:10.25%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000130" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,738</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;text-align:right;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;text-align:right;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;text-align:right;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:10.25%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000131" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">871</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:45.91%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:45.91%;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before taxes on income</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000132" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,784</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000133" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,636</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000134" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,203</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:45.91%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxes on income, net</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214012403897" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,970</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25">&#160;</div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214012406780" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000137" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:45.91%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:45.91%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-family:'Times New Roman',serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000138" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,754</ix:nonFraction></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000139" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000140" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,203</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:45.91%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:45.91%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted net loss per share</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000141" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.21</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000142" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.39</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000143" name="us-gaap:EarningsPerShareBasic" contextRef="C_20210101to20211231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.41</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:45.91%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:45.91%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other comprehensive loss:</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:45.91%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:45.91%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unrealized gain arising during the period from marketable securities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228001617126_Fact_0000000000129" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228001617126_Fact_0000000000130" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228001617126_Fact_0000000000131" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:45.91%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:45.91%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total comprehensive loss</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000147" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,752</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000148" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000149" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,203</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:45.91%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:45.91%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228001903510" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230101to20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000153" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">87,633,298</ix:nonFraction></ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228001918048" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000154" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,555,628</ix:nonFraction></ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.25%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228001929235" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20210101to20211231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000155" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20210101to20211231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">84,203,971</ix:nonFraction></ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1.17%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
        </div>
      </div>
      <div style="line-height:1.25">
        <p style="margin:0pt">&#160;</p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 7</span></span></span></span></p><div style="text-align:center"><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt;margin-bottom:10pt"/></div>
      </div>
    </div>
  </div>
</div><div style="">
  <div>
    <div>
      <div>
        <div>
          <div>
            <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">&#160;</span></span></span></div>
          </div>
          <div style="line-height:1.25">
            <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">STATEMENTS OF CHANGES IN SHAREHOLDERS</span>&#8217;<span style="font-weight:bold"> EQUITY<span id="CHANGESINSHAREHOLDERSEQUI_integixAnchor"></span></span></span></span>
              <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;margin-top:5pt;margin-bottom:5pt"/>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share data)</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

              <tr>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary shares</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional</span></span></div>
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">paid-in</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated other comprehensive</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">shareholders&#8217;</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amount</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">capital</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">income</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">deficit</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">equity</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of January 1, 2021</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000156" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">83,675,856</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000157" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">231</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000158" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">507,427</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228010706277" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000159" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">387,876</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000160" name="us-gaap:StockholdersEquity" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,782</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise of options and ESPP shares</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214013709298" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">335,204</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214013718917" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214013728837" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,454</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214013739149" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,455</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants exercised</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214013524660" name="cgen:NumberOfWarrantsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,557</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<span style="-sec-ix-hidden:Fxbrl_20230214013608017">*</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214013559422" name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">425</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214013636006" name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">425</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares, net</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000165" name="cgen:IssuanceOfSharesAndWarrantsNetShares" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,332,815</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000166" name="cgen:IssuanceOfSharesAndWarrantsNetValue" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000167" name="cgen:IssuanceOfSharesAndWarrantsNetValue" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,951</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000168" name="cgen:IssuanceOfSharesAndWarrantsNetValue" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,958</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation issued to employees, directors and non-employees</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000190" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,276</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000191" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,276</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;padding-left:9pt;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000171" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,203</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000172" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,203</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;padding-left:9pt;width:28%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2021</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000173" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,433,432</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000174" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000175" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">528,533</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228010711681" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000176" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">422,079</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000177" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,693</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise of options and ESPP shares</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000199" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">191,211</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000200" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000201" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">352</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000202" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation issued to employees, directors and non-employees</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000211" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,328</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000212" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,328</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;padding-left:9pt;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000213" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000214" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;padding-left:9pt;width:28%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2022</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000215" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,624,643</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000216" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000217" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">533,213</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228010718949" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000218" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">455,773</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000219" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,680</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares, net</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228004702895_Fact_0000000000165" name="cgen:IssuanceOfSharesAndWarrantsNetShares" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,612,822</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228004702895_Fact_0000000000166" name="cgen:IssuanceOfSharesAndWarrantsNetValue" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228004702895_Fact_0000000000167" name="cgen:IssuanceOfSharesAndWarrantsNetValue" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,074</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228004702895_Fact_0000000000168" name="cgen:IssuanceOfSharesAndWarrantsNetValue" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,081</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation issued to employees, directors and non-employees</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228004651156_Fact_0000000000211" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,550</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228004651156_Fact_0000000000212" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,550</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in other comprehensive income from marketable securities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228005606782" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228005611158" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;padding-left:9pt;width:28%;padding-bottom:2px;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240228004710783_Fact_0000000000213" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,754</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240228004710783_Fact_0000000000214" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,754</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;padding-left:9pt;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="vertical-align:bottom;padding-left:9pt;width:28%;padding-bottom:4px;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2023</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228003430903_Fact_0000000000215" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,237,465</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228003430903_Fact_0000000000216" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">247</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228003430903_Fact_0000000000217" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">539,837</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228010218091" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240228003430903_Fact_0000000000218" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">474,527</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228005626619" name="us-gaap:StockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,559</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(*)&#160; &#160; &#160; &#160; &#160; Representing amount lower than $ 1.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
        </div>
      </div>
      <div style="text-align:justify;line-height:1.25">
        <p style="margin:0pt">&#160;</p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 8</span></span></span></span></p><div style="text-align:center"><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt;margin-bottom:10pt"/></div>
      </div>
    </div>
  </div>
</div><div style="">
  <div>
    <div>
      <div>
        <div>
          <div>
            <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
          </div>
          <div style="line-height:1.25">
            <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED STATEMENTS OF CASH FLOWS<span id="CASHFLOWS_integixAnchor"></span></span></span>
              <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;margin-top:5pt;margin-bottom:5pt"/>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Cash flows from operating activities:</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000220" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,754</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000221" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000222" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,203</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustments required to reconcile net loss to net cash used in operating activities:</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000223" name="us-gaap:ShareBasedCompensation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,550</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000224" name="us-gaap:ShareBasedCompensation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,328</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000225" name="us-gaap:ShareBasedCompensation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,276</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000226" name="us-gaap:Depreciation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">476</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000227" name="us-gaap:Depreciation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">482</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000228" name="us-gaap:Depreciation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">461</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in severance pay, net</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000229" name="cgen:SeverancePayNet" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">50</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214015430934" name="cgen:SeverancePayNet" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">81</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000231" name="cgen:SeverancePayNet" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">101</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss (gain) from property and equipment sales and disposals</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000232" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000233" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000234" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',serif;margin-left:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange rate differences loss (gain) on cash balances</span></span></div>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240301111210380" name="cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">129</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240301111218731" name="cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">393</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240301111232004" name="cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">59</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in interest receivables from short-term bank deposits</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214015508662" name="cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">92</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000236" name="cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">584</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214015458380" name="cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">469</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of discount and accrued interest on marketable securities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240228013916179_xbrl_20230214015610319" name="cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">280</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013916179_Fact_0000000000251" name="cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013916179_Fact_0000000000252" name="cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in trade receivables</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-family:'Times New Roman',serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000238" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,000</ix:nonFraction></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000239" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214015520285" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,000</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in other accounts receivable and prepaid expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000241" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000242" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,043</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000243" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,802</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in long-term prepaid expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000244" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">666</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000245" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214015551570" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in operating lease right of use asset</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000247" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">568</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000248" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">658</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000249" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">525</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase (decrease) in trade payables and other accounts payable and accrued expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214015610319" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,509</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000251" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,601</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000252" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,367</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase (decrease) in deferred participation in R&amp;D expenses</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214015629815" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">325</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000254" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,019</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000255" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,708</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase in deferred revenues</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013913681_xbrl_20230214015610319" name="cgen:IncreaseDecreaseInDeferredRevenues" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">36,541</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013913681_Fact_0000000000251" name="cgen:IncreaseDecreaseInDeferredRevenues" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013913681_Fact_0000000000252" name="cgen:IncreaseDecreaseInDeferredRevenues" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in operating lease liability</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000256" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">645</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000257" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,062</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000258" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">416</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash used in operating activities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000259" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">35,886</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000260" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,113</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000261" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">22,691</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Cash flows from investing activities:</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from maturity of short-term bank deposits</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000262" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,242</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000263" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,445</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000264" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">136,850</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investment in short-term bank deposits</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000265" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,100</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000266" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,900</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000267" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,945</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from maturity of marketable securities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013918979_xbrl_20230214015610319" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,145</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013918979_Fact_0000000000251" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013918979_Fact_0000000000252" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investment in marketable securities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240228013920658_xbrl_20230214015610319" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,605</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013920658_Fact_0000000000251" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228013920658_Fact_0000000000252" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase of property and equipment</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000268" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">172</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000269" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">477</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000270" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">292</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Costs of disposal of property and equipment</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115924752_Fact_0000000000268" name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230222115924752_Fact_0000000000269" name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115924752_Fact_0000000000270" name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from sale of property and equipment</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222112447073" name="cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000272" name="cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000273" name="cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by investing activities</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000274" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,510</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000275" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,060</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214015724492" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,616</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span>
            <p style="margin:0pt">&#160;</p>
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 9</span></span></span></span></p><div style="text-align:center"><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt;margin-bottom:10pt"/></div>
          </div>
          <div style="line-height:1.25">
            <div style="text-align:justify;line-height:1.25;font-weight:bold">
              <div>
                <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
              </div>
            </div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></span>
              <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Cash flows from financing activities:</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:64%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from issuance of ordinary shares, net</span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000277" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,081</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000278" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000279" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,958</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from exercise of warrants</span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000280" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000281" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214015741861" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">425</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:64%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from exercise of stock-based awards</span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000283" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000284" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000285" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,455</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:64%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by financing activities</span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000286" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,081</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000287" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000288" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,838</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td rowspan="1" style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td rowspan="1" style="width:64%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effect of exchange rate changes on cash</span></span></div>
                </td>
                <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;border-bottom:1.5pt solid black;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;border-bottom:1.5pt solid black;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240301111348803" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">129</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" rowspan="1" style="width:1%;font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="width:1%;font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="width:1%;font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:1.5pt solid black;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;border-bottom:1.5pt solid black;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240301111408147" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">393</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" rowspan="1" style="width:1%;font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                <td colspan="1" rowspan="1" style="width:1%;font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="width:1%;font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:1.5pt solid black;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;border-bottom:1.5pt solid black;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240301111411299" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">59</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" rowspan="1" style="width:1%;font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:64%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase in cash, cash equivalents and restricted cash</span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000289" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,834</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000290" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,907</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214015801453" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">704</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:64%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash, cash equivalents and restricted cash at the beginning of the year</span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000292" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,421</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000293" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,514</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000294" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,810</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents and restricted cash at the end of the year</span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000295" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,255</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000296" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,421</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000297" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,514</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:64%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Supplemental disclosure of non-cash investing and financing activities:</span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase of property and equipment</span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000298" name="cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000299" name="cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000300" name="cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right-of-use asset obtained in exchange for operating lease liability</span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214015821971" name="cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">71</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000305" name="cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214015838501" name="cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:64%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Cash received during the year for:</span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:64%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest payments received from short-term bank deposits and cash equivalents</span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000307" name="cgen:InterestPaidReceivedNet" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,052</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000308" name="cgen:InterestPaidReceivedNet" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">852</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000309" name="cgen:InterestPaidReceivedNet" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,364</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:64%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Reconciliation of cash, cash equivalents and restricted cash:</span></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:64%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000310" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,890</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000311" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,059</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000312" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,801</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:64%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash</span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000313" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">365</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000314" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">362</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000315" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">713</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total cash, cash equivalents and restricted cash</span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000316" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,255</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000317" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,421</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </td>
                <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000318" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,514</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
        </div>
      </div>
      <div style="text-align:justify;line-height:1.25">
        <p style="margin:0pt">&#160;</p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 10</span></span></span></span></p><div style="text-align:center"><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt;margin-bottom:10pt"/></div>
      </div>
    </div>
  </div>
</div><div style="">
  <div>
    <div>
      <div>
        <div>
          <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
          <div style="line-height:1.25">
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span id="NOTESTOCONSOLIDATEDFINANC_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></span></span>
              <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;margin-top:5pt;margin-bottom:5pt"/>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share and per share data)</span></span></div>
        </div>
        <div style="text-align:justify;line-height:1.25">&#160;</div>
      </div>
      <ix:nonNumeric id="Fxbrl_20240228025141975" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">
        <div>
          <div>
            <div style="text-align:justify;line-height:1.25">
              <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">

                  <tr>
                    <td style="font-size:10pt;vertical-align:top;width:56.7pt">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">NOTE 1:-</span></p>
                    </td>
                    <td style="font-size:10pt;width:auto"><span style="fonfamily:Times New Roman,Times,serif"><span style="font-weight:bold">GENERAL</span></span></td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compugen Ltd. (the &#8220;Company&#8221;) is a clinical-stage therapeutic discovery and development company utilizing our broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. The Company&#8217;s innovative immuno-oncology pipeline consists of three clinical stage programs, COM701, COM902 and rilvegostomig, targeting immune checkpoints the Company discovered computationally. Two programs that are pursued internally, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. Based on the data from the Phase 1 trials and as part of our focus on two specific tumor types for the further clinical evaluation of COM701 and COM902, the Company initiated in 2023 two clinical trials evaluating the triple combination treatment of COM701, COM902 and pembrolizumab, one in metastatic microsatellite stable colorectal cancer patients and one in platinum resistant ovarian cancer patients. Rilvegostomig, a novel anti PD-1/TIGIT bispecific antibody with a TIGIT-specific component that is derived from the Company&#8217;s COM902 antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between the Company and AstraZeneca and is being evaluated in multiple clinical trials, including in Phase 3 clinical trial in patients with biliary tract cancer who will be randomized to receive rilvegostomig or placebo with investigator choice chemotherapy as adjuvant treatment after resection with curative intent. The Company&#8217;s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. The Company&#8217;s most advanced early-stage program, COM503, is in IND enabling studies and was licensed to Gilead in December 2023. COM503 is a potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. The Company&#8217;s business model is to selectively enter into collaborations for our novel targets and drug product candidates at various stages of research and development under various revenue-sharing arrangements.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is headquartered in Holon, Israel. Its clinical development activities are headed from its United States subsidiary, Compugen USA, Inc, located in San Francisco, CA.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has incurred losses in the amount of $ <ix:nonFraction id="FFact_0000000000319" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,754</ix:nonFraction> during the year ended December 31, 2023, has an accumulated deficit of $ <ix:nonFraction id="FFact_0000000000320" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">474,527</ix:nonFraction> as of December 31, 2023 and has an accumulated negative cash flow from operating activities in the amount of $ <ix:nonFraction id="FFact_0000000000321" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">35,886</ix:nonFraction> for the year ended December 31, 2023. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures at least twelve months from the reporting date.</span></span></div>
                  </td>
                </tr>

            </table>
            <div>
              <p style="margin:0pt">&#160;</p>
              <div><ix:exclude>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 11</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;border:0px">

                    <tr>
                      <td style="font-size:10pt;vertical-align:top;width:56.7pt">
                        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE 1:-</span></p>
                      </td>
                      <td style="font-size:10pt;width:auto"><span style="font-weight:bold">GENERAL (Cont.)</span></td>
                    </tr>
                    <tr>
                      <td style="font-size:10pt;vertical-align:top;width:56.7pt">&#160;</td>
                      <td style="font-size:10pt;width:auto">&#160;</td>
                    </tr>

                </table>
              </ix:exclude></div>
            </div>
          </div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (&#8220;Bayer Agreement&#8221;) with Bayer Pharma AG (&#8220;Bayer&#8221;) for the research, development, and commercialization of antibody-based therapeutics against two novel, Compugen-discovered immune checkpoint regulators.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the terms of the Bayer Agreement, the Company received an upfront payment of $ <ix:nonFraction id="FFact_0000000000323" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="C_20130801to20130805" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction>, and, following the return of the CGEN 15022 program in 2017, the Company was eligible to receive an aggregate amount of over $ <ix:nonFraction id="FFact_0000000000324" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivable" contextRef="C_20130805" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">250,000</ix:nonFraction> in potential milestone payments for Bapotulimab (formerly known as BAY1905254), not including aggregate milestone payments of $ <ix:nonFraction id="FFact_0000000000325" name="cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" contextRef="C_20130805" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,200</ix:nonFraction> received to date. Additionally, the Company was eligible to receive mid to high single digit royalties on global net sales of any approved products under the collaboration.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the terms of Bayer Agreement, Bapotulimab program was transferred to Bayer&#8217;s full control for further preclinical and clinical development activities, and worldwide commercialization under milestone and royalty bearing license from Compugen.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 29, 2022, Bayer notified the Company that it has resolved to terminate,&#160;</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">effective as of February 27, 2023, the Bayer Agreement.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#8220;AstraZeneca&#8221;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and will be solely responsible for all research, development, and commercial activities under the agreement. In connection with such license agreement, AstraZeneca developed rilvegostomig, a novel PD-/TIGIT bi-specific antibody with a TIGIT component that is derived from our COM902 and entered the clinic in September 2021 and initiated Phase 3 with first patient dosing in Phase 3 in December 2023. Compugen received a $<ix:nonFraction id="FFact_0000000000326" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction> upfront payment, and received or accrued $ <ix:nonFraction id="FFact_0000000000327" name="cgen:AccruedMilestonePayment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,500</ix:nonFraction> milestone payments out of up to $<ix:nonFraction id="Fxbrl_20240228095106065" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivable" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal"> 200,000</ix:nonFraction> it is eligible to receive in development, regulatory and commercial milestones for the first product in addition to tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Agreement&#8221;) with Bristol-Myers Squibb Company (&#8220;Bristol-Myers Squibb&#8221;) to evaluate the safety and tolerability of Compugen&#8217;s COM701 in combination with Bristol-Myers Squibbs&#8217; PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors.</span></span></div>
                    <div>&#160;</div>
                  </td>
                </tr>

            </table>
            <div><ix:exclude>
              <div>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 12</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
              </div>
              <div style="text-align:justify;line-height:1.25">
                <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;border:0px">

                    <tr>
                      <td style="font-size:10pt;vertical-align:top;width:56.7pt">
                        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE 1:-</span></p>
                      </td>
                      <td style="font-size:10pt;width:auto"><span style="font-weight:bold">GENERAL (Cont.)</span></td>
                    </tr>
                    <tr>
                      <td style="font-size:10pt;vertical-align:top;width:56.7pt">&#160;</td>
                      <td style="font-size:10pt;width:auto">&#160;</td>
                    </tr>

                </table>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:56.7pt">&#160;</td>
                      <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify">
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Cont.)</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width:56.7pt">&#160;</td>
                      <td style="width:28.35pt;vertical-align:top">&#160;</td>
                      <td style="width:auto;vertical-align:top;text-align:justify">&#160;</td>
                    </tr>

                </table>
              </div>
            </ix:exclude></div>
            <div style="text-align:justify;margin-left:85.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the Agreement, Compugen was responsible for and sponsored the ongoing two-part Phase 1 trial, which included the evaluation of the combination of COM701 and Opdivo&#174;. The collaboration was also designed to address potential future combinations, including trials sponsored by Bristol-Myers Squibb to investigate combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT. Bristol-Myers Squibb and Compugen each supplied the other company with its own compound for the other party&#8217;s study, and otherwise each party was responsible for all costs associated with the study that it is conducting.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In conjunction with the signing of the Agreement in October 2018, Bristol-Myers Squibb made a $ <ix:nonFraction id="FFact_0000000000329" name="us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction> investment in Compugen, see Note 8b.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On February 14, 2020, the Agreement was amended to include a triple combination clinical trial to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo&#174; (nivolumab), and Bristol-Myers Squibb&#8217;s investigational antibody targeting TIGIT known as BMS-986207, in patients with advanced solid tumors, instead of the planned expansion of the combined therapy study designed to evaluate the dual combination of COM701 and Opdivo&#174;.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the Agreement, as amended, the Company sponsored the two-part Phase 1/2 trial, which evaluates the triple combination of COM701, Opdivo&#174; and BMS-986207, in patients with advanced solid tumors where Bristol-Myers Squibb provided Opdivo&#174; and BMS-986207 at no cost to the Company.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As part of the amended Agreement, it was agreed that the Company will complete the dose escalation arm of the dual combination of COM701 with Opdivo<sup style="vertical-align:text-top;line-height:1;font-size:smaller">&#174;</sup> under the ongoing Phase 1 study and will not continue the expansion cohorts of the dual combination. However, on February 19, 2021, the Agreement was further amended to include an expansion of the Phase 1 combination study designed to evaluate the dual combination of COM701 and Opdivo&#174; in patients with advanced solid tumors, where the Company is responsible for and sponsored the expansion cohort and Bristol Myers Squibb provided Opdivo&#174; at no cost to the Company for this study.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 10, 2021, the Agreement was further amended to establish a joint steering committee (alongside the existing joint development committee which acts at an operational level) to facilitate strategic oversight and guidance for the programs run under the collaboration.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In conjunction with the signing of the amendment to the Agreement in November 2021, Bristol-Myers Squibb made a $ <ix:nonFraction id="FFact_0000000000330" name="us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue" contextRef="C_20211130" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction> investment in Compugen, see Note 8b.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 3, 2022, the Company and Bristol-Myers Squibb entered into a letter agreement pursuant to which the Agreement, as amended thereafter, was terminated as of such date.</span></span></div>
            <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25">&#160;</div>
            <div><ix:exclude>
              <div style="line-height:1.25">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 13</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
              </div>
              <div style="text-align:justify;line-height:1.25">
                <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;border:0px">

                    <tr>
                      <td style="font-size:10pt;vertical-align:top;width:56.7pt">
                        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE 1:-</span></p>
                      </td>
                      <td style="font-size:10pt;width:auto"><span style="font-weight:bold">GENERAL (Cont.)</span></td>
                    </tr>
                    <tr>
                      <td style="font-size:10pt;vertical-align:top;width:56.7pt">&#160;</td>
                      <td style="font-size:10pt;width:auto">&#160;</td>
                    </tr>

                </table>
              </div>
            </ix:exclude></div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 18, 2023, the Company entered into an exclusive license agreement (the &#160;&#8220;License Agreement&#8221;) with Gilead Sciences, Inc. (&#8220;Gilead&#8221;), pursuant to which the Company granted Gilead an exclusive license under the Company&#8217;s pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products, including the Company&#8217;s COM503 product candidate (&#8220;COM503 License&#8221;), and additional products that may be so developed by Gilead (together with COM503, the &#8220;Licensed Products&#8221;).</span></span></div>
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<br/>Pursuant to the License Agreement, Gilead paid the Company a one-time, upfront payment of $<ix:nonFraction id="Fxbrl_20240228025953345" name="cgen:NonRefundableUpfrontPayment" contextRef="C_20230101to20231218" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">60</ix:nonFraction> million in January 2024. The Company has continued to develop COM503 during the initial development term, which included conducting activities defined within the agreement to advance COM503 through the clearance of an investigational new drug application (&#8220;IND&#8221;). The Company is eligible to receive from Gilead $<ix:nonFraction id="Fxbrl_20240228031257594" name="cgen:MilestonePaymentReceivable" contextRef="C_20230101to20231218" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">30</ix:nonFraction> million in the form of a milestone payment upon clearance of the IND for COM503. The Company is also eligible to receive up to approximately $<ix:nonFraction id="Fxbrl_20240228030428945" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" contextRef="C_20231218" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">758</ix:nonFraction> million in additional milestone payments upon the achievement of certain development, regulatory and commercial milestones. The Company is further eligible to receive single-digit to low double-digit tiered royalties on worldwide net sales of Licensed Products.<br/>&#160;<br/>The Company will be responsible for conducting a Phase 1 clinical trial for COM503, including handling the regulatory matters in connection therewith, and will bear the costs of such trial (including the COM503 drug supply), with Gilead providing at no cost an anti-PD-1/PD-L1 antibody for such trial. In certain circumstances, Gilead may assume the role of conducting the Phase 1 clinical trial.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="text-align:justify;margin-left:84.3pt;line-height:1.25">
              <p style="margin:0pt">&#160;</p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Upon completion of the Phase 1 clinical trial for COM503, the Company will initiate the transfer of development activities related to COM503 to Gilead, following which, Gilead will have sole responsibility to develop and commercialize the Licensed Products.<br/>&#160;<br/>During the term of the License Agreement, the Company is prohibited from researching, developing, making, and commercializing any compounds, molecules, products or treatment methods that are directed to IL-18 or any companion diagnostics for an IL-18 product.<br/>&#160;<br/>Unless terminated early by a party pursuant to its terms, the License Agreement will continue in effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the last royalty term in such country.<br/>&#160;<br/>Gilead withheld at source <ix:nonFraction id="Fxbrl_20240228030716817" name="cgen:PercentageOfExpectedFromUpfrontPaymentAmountPaid" contextRef="C_20240101to20240131" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction>% from the upfront payment amount paid to the Company in January 2024 and is expected to continue and withhold at source all taxes required by law from all payments payable to the Company under the License Agreement.<br/>&#160;<br/>The License Agreement contains customary representations, warranties, covenants, and terms governing the prosecution and enforcement of certain intellectual property and issues related to technology transfer, manufacturing transfer, provisions with respect to establishment of joint steering committee and its governance covenants with respect change of control and others.</span></span></span></span>
            </div>
          </div>
        </div>
      </ix:nonNumeric>
      <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
      <div>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 14</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
        </div>
      </div>
    </div>
  </div>
</div><div style="">
  <ix:nonNumeric id="Fxbrl_20240228140455566" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20230101to20231231" escape="true">
    <div>
      <div style="margin-top:0pt;margin-bottom:0pt">
        <div style="margin-top:0pt;margin-bottom:0pt">
          <div style="margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
              <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">

                  <tr>
                    <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:56.7pt">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">NOTE 2:-</span></span></span></p>
                    </td>
                    <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="fonfamily:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">SIGNIFICANT ACCOUNTING POLICIES</span></span></span></span></td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
            <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</span></span></span></span></div>
            <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
          </div>
        </div>
        <ix:nonNumeric id="F20240228054857421_1" name="us-gaap:UseOfEstimates" contextRef="C_20230101to20231231" escape="true">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">a.<span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt">Use of estimates:</span></span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company&#8217;s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></span></span></span></p>
        </ix:nonNumeric>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
        <ix:nonNumeric id="F20240228054857421_2" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">b.<span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt">Financial statements in U.S. dollars:</span></span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The reporting and functional currency of the Company is the U.S. dollar, as the Company&#8217;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.</span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No. 830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate.</span></span></span></span></p>
        </ix:nonNumeric>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
        <ix:nonNumeric id="F20240228054857422_3" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">c.<span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt">Basis of consolidation:</span></span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation.</span></span></span></span></p>
        </ix:nonNumeric>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
        <ix:nonNumeric id="F20240228054857422_4" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">d.<span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt">Cash equivalents:</span></span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.</span></span></span></span></p>
        </ix:nonNumeric>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
        <ix:nonNumeric id="F20240228054857423_5" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_20230101to20231231" escape="true">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">e.<span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt">Restricted cash:</span></span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Restricted cash is held in interest bearing saving accounts which are used as a security for the Company&#8217;s Israeli facility leasehold&#160;and leased cars fueling bank guarantees and credit card security for Compugen USA, Inc.</span></span></span></span></p>
        </ix:nonNumeric>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
        <div style="margin-top:0pt;margin-bottom:0pt"><ix:exclude>
          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 15</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
          <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;border:0px">

              <tr>
                <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:56.7pt">
                  <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">NOTE 2:-</span></span></span></p>
                </td>
                <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></span></td>
              </tr>

          </table>
          <p style="margin:0pt">&#160;</p>
        </ix:exclude></div>
      </div>
      <ix:nonNumeric id="F20240228054857423_6" name="cgen:ShortTermBankDepositsPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">f.<span style="padding-left:22.17pt;margin-top:0pt;margin-bottom:0pt">Short-term bank deposits:</span></span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values.</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The short-term bank deposits as of December 31, 2023&#160;and 2022&#160;are in U.S. dollars and bear an annual weighted average interest rate of <ix:nonFraction id="F20240228054857424_7" name="cgen:ShortTermBankDepositsWeightedAverageRateForeign" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">6.20</ix:nonFraction>% and <ix:nonFraction id="F20240228054857424_8" name="cgen:ShortTermBankDepositsWeightedAverageRateForeign" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.84</ix:nonFraction>%, respectively.</span></span></span></span></p>
      </ix:nonNumeric>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
      <div style="margin-top:0pt;margin-bottom:0pt">
        <div style="margin-top:0pt;margin-bottom:0pt">
          <ix:nonNumeric id="F20240228054857466_78" name="us-gaap:MarketableSecuritiesPolicy" contextRef="C_20230101to20231231" escape="true">
            <div style="margin-top:0pt;margin-bottom:0pt">
              <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">g.&#160; &#160; &#160; &#160; &#160;Investments in marketable securities:</span></span></span></span></div>
              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company accounts for investments in marketable securities in accordance with ASC No. 320, &#8220;Investments - Debt Securities&#8221;.</span></span></span></span></div>
              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation at each balance sheet date. The Company classifies all of its debt securities as available-for-sale (&#8220;AFS&#8221;). The Company classifies its marketable securities as either short-term or long-term based on each instrument&#8217;s underlying contractual maturity date. Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders&#8217; equity. Realized gains and losses on sale of investments are included in financial income, net.</span></span></span></span></div>
              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.</span></span></span></span></div>
              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">At each reporting period, the Company evaluates whether declines in fair value below amortized cost are due to expected credit losses, as well as the Company&#8217;s ability and intent to hold the investment until a forecasted recovery occurs in accordance with ASC 326, Financial Instrument- Credit losses. Allowance for credit losses on AFS debt securities are recognized in the Company&#8217;s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in shareholders&#8217; equity. No credit loss impairment was identified in the year ended December 31, 2023.</span></span></span></span></div>
            </div>
          </ix:nonNumeric>
        </div>
      </div>
      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
      <ix:nonNumeric id="F20240228054857425_9" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">h.<span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt">Property and equipment, net:</span></span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:</span></span></span></span></p>
        <div style="margin-top:0pt;margin-bottom:0pt">
          <ix:nonNumeric id="F20240228054857451_53" name="cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" contextRef="C_20230101to20231231" escape="true">
            <div style="margin-top:0pt;margin-bottom:0pt">
              <div style="margin-top:0pt;margin-bottom:0pt">
                <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                <div style="margin-left:90pt;margin-top:0pt;margin-bottom:0pt">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">

                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="padding-bottom:2px;width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td colspan="1" style="padding-bottom:2px;width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="border-bottom:2px solid rgb(0, 0, 0);width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">%</span></span></span></div>
                        </td>
                        <td colspan="1" style="padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>
                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>
                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="width:80%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Computers, software and related equipment</span></span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td rowspan="1" style="width:18%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="line-height:1.25;font-family:Times New Roman, Times, serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857425_10" name="cgen:AnnualDepreciationRate" contextRef="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction></span></span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>
                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Laboratory equipment and office furniture</span></span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:center;line-height:1.25;text-indent:2pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857426_11" name="cgen:AnnualDepreciationRate" contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">6</ix:nonFraction> - <ix:nonFraction id="F20240228054857426_12" name="cgen:AnnualDepreciationRate" contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction> (mainly <ix:nonFraction id="F20240228054857431_13" name="cgen:AnnualDepreciationRate" contextRef="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction>)</span></span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>
                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="background-color:rgb(204, 238, 255);width:80%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Leasehold improvements</span></span></span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="background-color:rgb(204, 238, 255);width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:center;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20240228113754899" name="cgen:AnnualDepreciationRateDescription" contextRef="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">Shorter of the term of the lease or useful life</ix:nonNumeric></p>
                          </div>
                        </td>
                        <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>
          </ix:nonNumeric>
        </div>
      </ix:nonNumeric>
      <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
      <ix:nonNumeric id="F20240228054857432_15" name="us-gaap:PropertyPlantAndEquipmentImpairment" contextRef="C_20230101to20231231" escape="true">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">i.<span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt">Impairment of long-lived assets:</span></span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The long-lived assets of the Company. are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant, and Equipment&#8221; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset (assets group) with the future undiscounted cash flows expected to be generated by the asset (assets group). If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets group exceeds the fair value of the assets group. During the years 2023, 2022 and 2021, no impairment losses have been identified.</span></span></span></span></p>
      </ix:nonNumeric>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
      <div style="margin-top:0pt;margin-bottom:0pt">
        <div style="margin-top:0pt;margin-bottom:0pt">
          <div style="margin-top:0pt;margin-bottom:0pt">
            <ix:nonNumeric id="F20240228054857465_76" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
              <div style="margin-top:0pt;margin-bottom:0pt">
                <div style="margin-top:0pt;margin-bottom:0pt">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">j.<span style="padding-left:22.72pt;margin-top:0pt;margin-bottom:0pt">Leases:</span></span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company accounts for its leases according to ASC 842 - Leases (&#8220;ASC 842&#8221;). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#8220;ROU&#8221;) asset for leases with a term of twelve months or less. The Company elected to combine its lease and non-lease components.</span></span></span></span></p>
                  <p style="margin:0pt">&#160;</p>
                  <div style="margin-top:0pt;margin-bottom:0pt"><ix:exclude>
                    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 16</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                    <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;border:0px">

                        <tr>
                          <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:56.7pt">
                            <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">NOTE 2:-</span></span></span></p>
                          </td>
                          <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></span></td>
                        </tr>
                        <tr>
                          <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:56.7pt">&#160;</td>
                          <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;width:auto">&#160;</td>
                        </tr>

                    </table>
                    <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;margin-left:76pt;text-indent:-20pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">j.<span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt">Leases&#160;</span>&#160;(Cont.):&#160;</span></span></span></span></p>
                    <p style="margin:0pt">&#160;</p>
                  </ix:exclude></div>
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured based on the discounted present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The implicit rate within the operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (&#8220;IBR&#8221;) based on the information available at commencement date in determining the present value of lease payments. The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located.</span></span></p>
                  <p style="margin:0pt">&#160;</p>
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate the lease is considered unless it is reasonably certain that the Company will not exercise the option.</span></span></p>
                </div>
              </div>
            </ix:nonNumeric>
          </div>
        </div>
      </div>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify">&#160;</p>
      <div style="margin-top:0pt;margin-bottom:0pt">
        <div style="margin-top:0pt;margin-bottom:0pt">
          <div style="margin-top:0pt;margin-bottom:0pt">
            <div style="margin-top:0pt;margin-bottom:0pt">
              <ix:nonNumeric id="F20240228054857465_77" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
                <div style="margin-top:0pt;margin-bottom:0pt">
                  <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:76pt;text-indent:-20pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">k.<span style="padding-left:23.06pt;margin-top:0pt;margin-bottom:0pt">Revenue recognition:</span></span></span></p>
                  <p style="margin:0pt">&#160;</p>
                  <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:85.05pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements.</span></span></p>
                  <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:85.05pt;text-align:justify">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company recognizes revenue in accordance with ASC 606 &#8211; &#8220;Revenue from Contracts with Customers&#8221;.</span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">As such, the Company analyzes its contracts to assess whether they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:</span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
                  <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">

                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">&#8226;</span></span></span></p>
                        </td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-style:italic">Identification of the contract, or contracts, with a customer</span></span></span></p>
                        </td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">&#160;</td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">&#8226;</span></span></span></p>
                        </td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt;font-style:italic">Identification of the performance obligations in the contract</span>&#160;</span></span></span></p>
                        </td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">&#160;</td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">&#8226;</span></span></span></p>
                        </td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt;font-style:italic">Determination of the transaction price</span>&#160;</span></span></span></p>
                        </td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">&#160;</td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">&#8226;</span></span></span></p>
                        </td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt;font-style:italic">Allocation of the transaction price to the performance obligations in the contract</span>&#160;</span></span></span></p>
                        </td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">&#160;</td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">&#8226;</span></span></span></p>
                        </td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt;font-style:italic">Recognition of revenue when, or as, the Company satisfies a performance obligation</span>&#160;</span></span></span></p>
                        </td>
                      </tr>

                  </table>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt">&#160;</p>
                  <div style="margin-top:0pt;margin-bottom:0pt"><ix:exclude>
                    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 17</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                    <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;border:0px">

                        <tr>
                          <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:56.7pt">
                            <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">NOTE 2:-</span></span></span></p>
                          </td>
                          <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></span></td>
                        </tr>
                        <tr>
                          <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:56.7pt">&#160;</td>
                          <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;width:auto">&#160;</td>
                        </tr>

                    </table>
                    <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;margin-left:76pt;text-indent:-20pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">k.<span style="padding-left:23.06pt;margin-top:0pt;margin-bottom:0pt">Revenue recognition (Cont.):</span></span></span></span></span></p>
                    <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;margin-left:76pt;text-indent:-20pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
                  </ix:exclude></div>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:85pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">At the contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></span></span></span></p>
                  <p style="margin:0pt">&#160;</p>
                  <div style="margin-top:0pt;margin-bottom:0pt">
                    <div style="margin-left:85.05pt;text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property (</span></span></span></span>&#8220;<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">IP&#8221;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $&#160;<ix:nonFraction id="F20240228054857433_16" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction> upfront payment and is eligible to receive up to $&#160;<ix:nonFraction id="F20240228054857433_17" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivable" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,000</ix:nonFraction> for development, regulatory and commercial milestones for the first product, of which $&#160;<ix:nonFraction id="F20240228054857434_18" name="cgen:AccruedMilestonePayments" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,500</ix:nonFraction> was received or accrued&#160;as well as tiered royalties on future product sales.</span></span></span></span></div>
                    <div style="margin-left:85.05pt;text-align:justify;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                  </div>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer.</span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#8220;probable&#8221; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone.</span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Sales&#160;or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales&#160;or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties.</span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">On December 18, 2020 the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ <ix:nonFraction id="Fxbrl_20240301103700585" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="C_20201201to20201218" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,000</ix:nonFraction> in accordance with the criteria prescribed under ASC 606.</span></span></span></span></p>
                  <p style="margin:0pt">&#160;</p>
                  <div style="margin-top:0pt;margin-bottom:0pt"><ix:exclude>
                    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 18</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                    <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;border:0px">

                        <tr>
                          <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:56.7pt">
                            <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">NOTE 2:-</span></span></span></p>
                          </td>
                          <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></span></td>
                        </tr>

                    </table>
                    <p style="margin:0pt">&#160;</p>
                    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:76pt;text-indent:-20pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">k.<span style="padding-left:23.06pt;margin-top:0pt;margin-bottom:0pt">Revenue recognition (Cont.):</span></span></span></span></p>
                    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:76pt;text-indent:-20pt">&#160;</p>
                  </ix:exclude></div>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On&#160;September 29, 2021 the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ <ix:nonFraction id="F20240228054857467_79" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="C_20210901to20210929" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,000</ix:nonFraction> in accordance with the criteria prescribed under ASC 606.</span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">On November 11, 2022, the third milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ <ix:nonFraction id="F20240228054857446_43" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="C_20221101to20221111" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction> in accordance with the criteria prescribed under ASC 606.</span></span></span></span><br/>&#160;</p>
                  <div style="margin-top:0pt;margin-bottom:0pt">
                    <div style="margin-top:0pt;margin-bottom:0pt">
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">On December 27, 2023, the fourth milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ <ix:nonFraction id="Fxbrl_20240228115609016" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="C_20231201to20231227" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction> in accordance with the criteria prescribed under ASC 606.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">On December 18, 2023, the Company entered into an exclusive License Agreement with Gilead. Under the terms of the agreement, the Company granted Gilead an exclusive license under the Company&#8217;s pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products derived from a Compugen pipeline program. Compugen received an upfront payment of $<ix:nonFraction id="Fxbrl_20240228120200198" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="C_20231210to20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,000</ix:nonFraction> and is also eligible to receive up to approximately $ <ix:nonFraction id="Fxbrl_20240228120212438" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivable" contextRef="C_20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">788,000</ix:nonFraction> additional milestone payments subject to and upon the achievement of certain development, regulatory and commercial milestones and as detailed in the agreement.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Gilead may terminate the Gilead Collaboration Agreement for convenience by giving a certain prior written notice to the Company at any time after the effective date of the agreement.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company concluded that Gilead is a customer and therefore revenue recognition should be accounted for in accordance with ASC 606, because the Company granted to Gilead licenses to its intellectual property and will provide research and development services, all of which are outputs of the Company&#8217;s ongoing activities, in exchange for consideration.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company assessed the promises under the License Agreement and concluded that (i) the delivery of the COM503 License; (ii) the preclinical research and development activities towards IND approval of COM503 (the &#8220;IND research and development activities&#8221;) and (iii) the contingent promise to additional research and development activities for Phase 1 clinical (the &#8220;Phase 1 research and development activities&#8221;), are capable of being distinct and are distinct within the context of the License Agreement. The Company considered that the license has standalone functionality, considered to be functional intellectual property, and is capable of being distinct. The Company also determined that the IND research and development activities and Phase 1 research and development activities could be provided by resources otherwise available to Gilead and thus are capable of being distinct. Also, the Company concluded that the Company&#8217;s contingent promise to additional research and development activities for Phase 1 clinical represents a material right.</span></span></span></span></div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">As a result, the Company concluded that its promise to deliver the COM503 License, the promise to perform IND research and development activities and Phase 1 research and development activities represented separate performance obligations in the License Agreement.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="margin-top:0pt;margin-bottom:0pt"><ix:exclude>
                        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                          <div style="margin-top:0pt;margin-bottom:0pt">
                            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 19</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                          </div>
                        </div>
                        <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">
                          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">NOTE 2:-</span></span></span></span></td>
                                <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                                  <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></span></span></div>
                                </td>
                              </tr>

                          </table>
                          <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                          <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                            <div style="margin:0pt 0px 0pt 58pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">k.</span>&#160; &#160; &#160; &#160;<span style="margin-top:0pt;margin-bottom:0pt">Revenue recognition (Cont.):</span></span></span></span></span></div>
                            <div style="margin-left:56.7pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                          </div>
                        </div>
                      </ix:exclude></div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company also evaluated as a possible variable consideration all milestones and royalties. With respect to clinical development and regulatory milestones, based upon the high degree of uncertainty and risk associated with these potential payments, the Company concluded that all such amounts should be fully constrained and are not included in the initial transaction price as the Company cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Accordingly, the Company did not include any potential clinical development, regulatory and sales milestones and royalties in the initial transaction price.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company allocated the transaction price to each performance obligation on a relative estimated standalone selling price basis. The Company developed the estimated standalone selling price for the COM503 License based on the present value of expected future cash flows associated with the license and related clinical development and regulatory milestones. In developing such estimate, the Company applied judgement in determining the timing needed to develop the Licensed Product, the probability of success, and the discount rate. The Company developed the estimated standalone selling price for the IND research and development activities using a &#8220;cost plus&#8221; reasonable margin approach. To determine the estimated standalone selling price of the material right for the Phase 1 research and development activities obligation, the Company estimated the standalone selling price of the underlying performance obligations included in the material right and estimated the probability of the Company&#8217;s performance of such obligations.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company determined that the COM503 License was a functional license since the underlying intellectual property (the &#8220;IP&#8221;) has significant standalone functionality. In addition, the Company determined that December 18, 2023 represents (i) the date at which the Company made available the IP to Gilead and (ii) the beginning of the period during which Gilead is able to use and benefit from its right to use the IP. Based upon these considerations, the Company recognized the entirety of the initial transaction price allocated to the COM503 License performance obligation during the year ended December 31, 2023.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Further, the IND research and development activities and Phase 1 research and development activities performance obligations are recognized over time when, or as, the Company performs the required services to Gilead. The Company determined that the input method under ASC 606 is the best measure of progress towards satisfying the performance obligation and reflects a faithful depiction of the transfer of goods and services. The method of measuring progress towards delivery of the services incorporates actual internal and external costs incurred, relative to total internal and external costs expected to be incurred to satisfy the performance obligation. The period over which total costs were estimated reflected the Company&#8217;s best estimate of the period over which it would perform the activities to achieve clearance of an IND application for COM503 and the phase 1 clinical trial.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">During the year ended December 31, 2023, the Company recognized $ <ix:nonFraction id="Fxbrl_20240228121336624" name="cgen:LicenseRevenue" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,459</ix:nonFraction> of license revenue. The Company included deferred revenues of $ <ix:nonFraction id="Fxbrl_20240228121352406" name="cgen:DeferredRevenuesIncludedInCurrentLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,149</ix:nonFraction> in current liabilities and $ <ix:nonFraction id="Fxbrl_20240228121407737" name="cgen:DeferredRevenuesIncludedInNonCurrentLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,392</ix:nonFraction> in non-current liabilities.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">For additional information regarding revenues, please refer to Note 10 below.</span></span></span></span></div>
                      <p style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                      <div style="margin-top:0pt;margin-bottom:0pt"><ix:exclude>
                        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                          <div style="margin-top:0pt;margin-bottom:0pt">
                            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 20</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                          </div>
                        </div>
                        <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:56.7pt">
                                  <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">NOTE 2:-</span></span></span></p>
                                </td>
                                <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></span></td>
                              </tr>
                              <tr>
                                <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:56.7pt">&#160;</td>
                                <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;width:auto">&#160;</td>
                              </tr>

                          </table>
                        </div>
                      </ix:exclude></div>
                    </div>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <ix:nonNumeric id="F20240228054857434_19" name="cgen:CostOfSalesContractWithCustomerPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">l.<span style="padding-left:22.72pt;margin-top:0pt;margin-bottom:0pt">Cost of revenues:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Cost of revenues consist of certain royalties and milestones paid or accrued.</span></span></span></span></p>
            </ix:nonNumeric>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt">&#160;</p>
            <ix:nonNumeric id="F20240228054857434_20" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_20230101to20231231" escape="true">
              <div style="margin-top:0pt;margin-bottom:0pt">
                <div style="margin-top:0pt;margin-bottom:0pt">
                  <div style="margin:0pt 0px 0pt 58pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">m.&#160; &#160; &#160; &#160;Research and development expenses, net:</span></span></span></span></div>
                  <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                  <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received.</span></span></span></span></div>
                  <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                  <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span></span></span></span></div>
                  <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                  <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The portion of the Bristol-Myers Squibb $ <ix:nonFraction id="F20240228054857451_54" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20231231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction> investment in 2018 over the fair market value of the shares issued in the amount of $ <ix:nonFraction id="F20240228054857452_55" name="cgen:DeferredParticipationOfBMSInRAndDExpenses" contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,121</ix:nonFraction> and the portion of the $ <ix:nonFraction id="F20240228054857453_56" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20231231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction> investment in 2021 over the fair market value of the shares issued in the amount of $ <ix:nonFraction id="F20240228054857453_57" name="cgen:DeferredParticipationOfBMSInRAndDExpenses" contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction> were considered as deferred participation of Bristol-Myers Squibb in R&amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;D, see Note 1f and Note 8b.</span></span></span></span></div>
                  <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                  <div style="text-align:justify;margin-left:85.5pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Amortization of participation in R&amp;D expenses for the years ended December 31, 2023, 2022 and 2021 were $ <ix:nonFraction id="F20240228054857435_21" name="us-gaap:AdjustmentForAmortization" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">325</ix:nonFraction>, $ <ix:nonFraction id="F20240228054857435_22" name="us-gaap:AdjustmentForAmortization" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,019</ix:nonFraction> and $ <ix:nonFraction id="F20240228054857436_23" name="us-gaap:AdjustmentForAmortization" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,291</ix:nonFraction>, respectively.</span></span></span></span></div>
                </div>
              </div>
            </ix:nonNumeric>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
            <div style="margin-top:0pt;margin-bottom:0pt"><ix:exclude>
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 21</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong style="margin-top:0pt;margin-bottom:0pt">NOTE 2:-&#160; &#160; SIGNIFICANT ACCOUNTING POLICIES (Cont.)</strong></span></span></p>
              <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
            </ix:exclude></div>
            <ix:nonNumeric id="F20240228054857436_24" name="cgen:ServerancePayPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">n.<span style="padding-left:22.72pt;margin-top:0pt;margin-bottom:0pt">Severance pay:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company&#8217;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date, and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset on the Company&#8217;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#8217;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#8217;s monthly salary for each year of service, no additional calculations are conducted between the parties regarding the matter of severance pay and no additional payments are made by the Company to the employee.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Severance expenses for the years ended December 31, 2023, 2022 and 2021 amounted to approximately $&#160;<ix:nonFraction id="F20240228054857437_25" name="us-gaap:SeveranceCosts1" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">432</ix:nonFraction>, $&#160;<ix:nonFraction id="F20240228054857437_26" name="us-gaap:SeveranceCosts1" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">468</ix:nonFraction> and $&#160;<ix:nonFraction id="F20240228054857438_27" name="us-gaap:SeveranceCosts1" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">383</ix:nonFraction>, respectively.</span></span></span></span></p>
            </ix:nonNumeric>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
            <ix:nonNumeric id="F20240228054857438_28" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_20230101to20231231" escape="true">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">o.<span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt">Stock-based compensation:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company accounts for stock-based compensation to employees and non-employees in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company selected the Black-Scholes-Merton (&#8220;Black-Scholes&#8221;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></span></span></span></p>
              <p style="margin:0pt">&#160;</p>
              <div style="margin-top:0pt;margin-bottom:0pt"><ix:exclude>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 22</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;border:0px">

                    <tr>
                      <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:56.7pt">
                        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">NOTE 2:-</span></span></span></p>
                      </td>
                      <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></span></td>
                    </tr>

                </table>
                <p style="margin:0pt">&#160;</p>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:76pt;text-indent:-20pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">o.<span style="padding-left:20.72pt;margin-top:0pt;margin-bottom:0pt">Stock-based compensation (Cont.):</span></span></span></span></p>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </ix:exclude></div>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company used the following assumptions for options granted to employees, directors and non-employees and ESPP:</span></span></span></span></p>
              <p style="margin:0pt">&#160;</p>
              <div style="margin-left:90pt;margin-top:0pt;margin-bottom:0pt">
                <ix:nonNumeric id="F20240228054857450_52" name="cgen:ScheduleOfWeightedAverageAssumptionsForGrantedOptions" contextRef="C_20230101to20231231" continuedAt="F20230214151604936" escape="true">
                  <div style="margin-top:0pt;margin-bottom:0pt">
                    <div style="margin-top:0pt;margin-bottom:0pt">
                      <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">

                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="5" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Year ended December 31,</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2023</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2022</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2021</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="background-color:rgb(204, 238, 255);width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Employee stock options</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Volatility</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857454_58" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">75.93</ix:nonFraction>%-<ix:nonFraction id="F20240228054857454_59" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">80.95</ix:nonFraction>%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                            </td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857455_60" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">69.44</ix:nonFraction>%-<ix:nonFraction id="F20240228054857455_61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">74.61</ix:nonFraction>%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857456_62" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">66.02</ix:nonFraction>%-<ix:nonFraction id="F20240228054857456_63" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">69.05</ix:nonFraction>%</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Risk-free interest rate</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857457_64" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.37</ix:nonFraction>%-<ix:nonFraction id="F20240228054857458_65" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.81</ix:nonFraction>%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                            </td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857459_66" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.54</ix:nonFraction>%-<ix:nonFraction id="F20240228054857460_67" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.39</ix:nonFraction>%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857460_68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.51</ix:nonFraction>%-<ix:nonFraction id="F20240228054857461_69" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.14</ix:nonFraction>%</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Dividend yield</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857439_29" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                            </td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857439_30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20240228114441654" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20210101to20211231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Expected life (years)</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="F20240228054857461_70" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">4.02</ix:nonNumeric>-<ix:nonNumeric id="F20240228054857462_71" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">5.06</ix:nonNumeric></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="F20240228054857463_72" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">5.05</ix:nonNumeric>-<ix:nonNumeric id="F20240228054857463_73" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">5.4</ix:nonNumeric></span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="F20240228054857464_74" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">5.04</ix:nonNumeric>-<ix:nonNumeric id="F20240228054857464_75" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">5.31</ix:nonNumeric></span></span></span></span></div>
                            </td>
                          </tr>

                      </table>
                      <p style="margin:0pt">&#160;</p>
                    </div>
                  </div>
                </ix:nonNumeric>
              </div>
              <div style="margin-left:90pt;margin-top:0pt;margin-bottom:0pt">
                <div style="margin-top:0pt;margin-bottom:0pt">
                  <ix:continuation id="F20230214151604936">
                    <div style="margin-top:0pt;margin-bottom:0pt">
                      <div style="margin-top:0pt;margin-bottom:0pt">
                        <div style="margin-top:0pt;margin-bottom:0pt">
                          <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">

                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="5" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Year ended December 31,</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2023</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2022</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2021</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="background-color:rgb(204, 238, 255);width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">ESPP</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Volatility</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857440_31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857447_44" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">69.74</ix:nonFraction>%</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                                </td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857467_80" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">64.68</ix:nonFraction>%-<ix:nonFraction id="F20240228054857447_45" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">69.68</ix:nonFraction>%</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Risk-free interest rate</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857440_32" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857448_46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.63</ix:nonFraction>%</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                                </td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857468_81" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.04</ix:nonFraction>%-<ix:nonFraction id="F20240228054857448_47" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.10</ix:nonFraction>%</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Dividend yield</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857440_33" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857449_48" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                                </td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20240228054857450_51" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20210101to20211231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Expected life (years)</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt">-</div>
                                </td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="F20240228054857449_49" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" format="ixt-sec:duryear">0.50</ix:nonNumeric></span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="F20240228054857468_82" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" format="ixt-sec:duryear">0.42</ix:nonNumeric>-<ix:nonNumeric id="F20240228054857449_50" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" format="ixt-sec:duryear">0.50</ix:nonNumeric></span></span></span></span></div>
                                </td>
                              </tr>

                          </table>
                        </div>
                      </div>
                    </div>
                  </ix:continuation>
                </div>
              </div>
            </ix:nonNumeric>
            <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
            <ix:nonNumeric id="F20240228054857441_35" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_20230101to20231231" escape="true">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">p.<span style="padding-left:21.5pt;margin-top:0pt;margin-bottom:0pt">Concentration of credit risks:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits and investment in marketable securities.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Cash, cash equivalents, restricted cash and short-term bank deposits are invested in major banks in Israel and in the United States. Generally, these deposits may be redeemed upon demand and bear minimal risk.</span></span></span></span></p>
            </ix:nonNumeric>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
            <ix:nonNumeric id="F20240228054857442_36" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">q.<span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt">Basic and diluted loss per share:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#8220;Earnings per Share</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#8221;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">All outstanding share options and warrants for the years ended December 31, 2023, 2022 and 2021 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2023, 2022 and 2021 the average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were <ix:nonFraction id="F20240228054857442_37" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">7,921,020</ix:nonFraction>, <ix:nonFraction id="F20240228054857443_38" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,405,615</ix:nonFraction> and <ix:nonFraction id="F20240228054857445_39" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">6,758,300</ix:nonFraction>, respectively.</span></span></span></span></p>
            </ix:nonNumeric>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
            <div style="margin-top:0pt;margin-bottom:0pt"><ix:exclude>
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 23</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
              <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;border:0px">

                  <tr>
                    <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:56.7pt">
                      <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">NOTE 2:-</span></span></span></p>
                    </td>
                    <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></span></td>
                  </tr>

              </table>
              <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
            </ix:exclude></div>
            <ix:nonNumeric id="F20240228054857445_40" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">r.<span style="padding-left:24.5pt;margin-top:0pt;margin-bottom:0pt">Income taxes:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company accounts for income taxes in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2023 and 2022, a full valuation allowance was provided by the Company.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10.</span></span></span></span></p>
            </ix:nonNumeric>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
            <ix:nonNumeric id="F20240228054857446_41" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_20230101to20231231" escape="true">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">s.<span style="padding-left:23.5pt;margin-top:0pt;margin-bottom:0pt">Fair value of financial instruments:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company applies ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.</span></span></span></span></p>
              <p style="margin:0pt">&#160;</p>
              <div style="margin-top:0pt;margin-bottom:0pt"><ix:exclude>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 24</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;border:0px">

                    <tr>
                      <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:56.7pt">
                        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">NOTE 2:-</span></span></span></p>
                      </td>
                      <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></span></td>
                    </tr>
                    <tr>
                      <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:56.7pt">&#160;</td>
                      <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;width:auto">&#160;</td>
                    </tr>

                </table>
                <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;margin-left:76pt;text-indent:-20pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">s.<span style="padding-left:23.5pt;margin-top:0pt;margin-bottom:0pt">Fair value of financial instruments (Cont.):</span></span></span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;margin-left:76pt;text-indent:-20pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
              </ix:exclude></div>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The hierarchy is broken down into three levels based on the inputs as follows:</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;margin-top:0pt;margin-bottom:0pt">

                  <tr style="margin-top:0pt;margin-bottom:0pt">
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Level 1&#160;</span><span style="margin-top:0pt;margin-bottom:0pt">-</span></span></span></p>
                    </td>
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can </span>access at the measurement date.</span></span></span></td>
                  </tr>
                  <tr>
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                  </tr>

              </table>
              <div style="margin-top:0pt;margin-bottom:0pt">
                <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;margin-top:0pt;margin-bottom:0pt">

                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt">
                        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Level 2&#160;-</span></span></span></p>
                      </td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Valuations based on one or more quoted prices in markets that are not active or for which all </span>significant inputs are observable, either directly or indirectly.</span></span></span></td>
                    </tr>
                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="width:85.5pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      <td style="width:56.7pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      <td style="text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                    </tr>
                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt">
                        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Level 3&#160;-</span></span></span></p>
                      </td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></span></span></span></td>
                    </tr>

                </table>
              </div>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, other accounts receivable and prepaid expenses, trade payable and other accounts payable and accrued expenses approximate their fair values due to the short-term maturities of such instruments.</span></span></span></span></p>
            </ix:nonNumeric>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
            <ix:nonNumeric id="F20240228054857446_42" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">t.<span style="padding-left:23.06pt;margin-top:0pt;margin-bottom:0pt">Recently issued accounting pronouncement not yet adopted by the Company:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">In&#160;December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.</span></span></span></span></p>
            </ix:nonNumeric>
          </div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <div style="margin-top:0pt;margin-bottom:0pt">
    <div style="margin-top:0pt;margin-bottom:0pt">
      <div style="margin-top:0pt;margin-bottom:0pt">
        <p style="margin:0pt">&#160;</p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 25</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
      </div>
    </div>
  </div>
</div><div style="">
  <ix:nonNumeric id="Fxbrl_20230222132226340" name="cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock" contextRef="C_20230101to20231231" escape="true">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;color:rgb(0, 0, 0)">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span>NOTE 3:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</span></span></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <div>
          <div style="line-height:1.25">&#160;</div>
          <div style="margin-left:63pt">
            <ix:nonNumeric id="Fxbrl_20240228020440395" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" contextRef="C_20230101to20231231" escape="true">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid expenses</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000406" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,211</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000407" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,100</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Government authorities</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000408" name="cgen:GovernmentAuthorities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000409" name="cgen:GovernmentAuthorities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">85</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-indent:-4.25pt;margin-left:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000410" name="us-gaap:OtherAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">226</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000411" name="us-gaap:OtherAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">232</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="width:76%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000412" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,529</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000413" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,417</ix:nonFraction></span></span></div>
                    </td>
                  </tr>

              </table>
            </ix:nonNumeric>
          </div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 26</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000441" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_20230101to20231231" escape="true">
    <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;color:rgb(0, 0, 0)">

        <tr>
          <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span>NOTE 4:-</span></span></td>
          <td style="width:auto;vertical-align:top;text-align:justify">
            <div style="font-weight:bold"><span style="font-size:10pt"><span>LEASES</span></span></div>
          </td>
        </tr>

    </table>
    <div>
      <div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company leases all its real estate, storage area and cars under various operating lease agreements that expire on various dates.</span></span></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s operating leases have original lease periods expiring between 2021 and 2026. The offices in Israel lease include two options to renew, one of which was exercised in 2020. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably certain.</span></span></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease payments included in the measurement of the lease liability comprise the following: the fixed non-cancelable lease payments and payments for optional renewal periods where it is reasonably certain the renewal period will be exercised.</span></span></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under ASC 842, all leases, including non-cancelable operating leases, are now recognized on the balance sheet. The aggregated present value of lease payments is recorded as a long-term asset titled Operating lease right of use asset. The corresponding lease liabilities are split between current maturity of operating lease liability within current liabilities and long-term operating lease liability within long-term liabilities. The Company&#8217;s leases do not provide an implicit rate, therefore the Company uses its incremental borrowing rate based on information available on the commencement date to determine the present value of lease payments.</span></span></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table represents the weighted-average remaining lease term and discount rate:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">
          <ix:nonNumeric id="Fxbrl_20230222013426728" name="cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" contextRef="C_20230101to20231231" escape="true">
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;width:89.79%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.03%;vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:top;width:9.18%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;width:89.79%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1.03%;vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);width:9.18%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:89.79%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.03%;vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:top;width:9.18%;vertical-align:bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:89.79%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining lease term</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.03%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td rowspan="1" style="vertical-align:bottom;width:9.18%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-align:center"><ix:nonNumeric id="FFact_0000000000421" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_20231231" format="ixt-sec:duryear">2.19</ix:nonNumeric></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:89.79%;vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average discount (annual) rate</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.03%;vertical-align:bottom">&#160;</td>
                    <td rowspan="1" style="vertical-align:bottom;width:9.18%;vertical-align:bottom">
                      <div style="text-align:center"><ix:nonFraction id="FFact_0000000000422" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_20231231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.32</ix:nonFraction>%</div>
                    </td>
                  </tr>

              </table>
            </div>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease expenses were approximately $ <ix:nonFraction id="FFact_0000000000424" name="us-gaap:OperatingLeasePayments" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">800</ix:nonFraction>, $ <ix:nonFraction id="FFact_0000000000425" name="us-gaap:OperatingLeasePayments" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">884</ix:nonFraction> and $ <ix:nonFraction id="FFact_0000000000426" name="us-gaap:OperatingLeasePayments" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">956</ix:nonFraction> in the years ended December 31, 2023, 2022 and 2021, respectively.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Variable payments as CPI, included in the lease expenses, were approximately $ <ix:nonFraction id="Fxbrl_20240301102821130" name="us-gaap:VariableLeasePayment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61</ix:nonFraction>, $ <ix:nonFraction id="Fxbrl_20240301102854023" name="us-gaap:VariableLeasePayment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction> and $ <ix:nonFraction id="Fxbrl_20240301102901175" name="us-gaap:VariableLeasePayment" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction> in the years ended December 31, 2023, 2022 and 2021, respectively.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash paid for amounts included in the measurement of lease liabilities was approximately $ <ix:nonFraction id="FFact_0000000000427" name="cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">852</ix:nonFraction>, $ <ix:nonFraction id="FFact_0000000000428" name="cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">959</ix:nonFraction> and $ <ix:nonFraction id="FFact_0000000000429" name="cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">914</ix:nonFraction> in the years ended December 31, 2023, 2022 and 2021, respectively.</span></span></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 27</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
          </div>
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

              <tr style="margin-top:0pt;margin-bottom:0pt">
                <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 4:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                  <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">LEASES (Cont.)</span></span></div>
                </td>
              </tr>

          </table>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </ix:exclude></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Maturities of operating lease liabilities were as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20230222013609784" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,&#160;2023</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000431" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">690</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000432" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">631</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000433" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">115</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total operating lease payments</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000435" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,436</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less: imputed interest</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000436" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">85</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000437" name="us-gaap:OperatingLeaseLiability" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,351</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, current</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000438" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">632</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, non- current</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000439" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">719</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom">
                      <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214024012785" name="us-gaap:OperatingLeaseLiability" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,351</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The above annual minimum future rental commitments include the period covered by the first exercised option with respect to the leased facility of Compugen Ltd. through March 2026 and exclude the second option to extend the lease of the Company facility for additional five-year period following expiration of the current lease period.</span></span></div>
      </div>
    </div>
  </ix:nonNumeric>
  <div style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</div>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 28</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000468" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">
    <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;color:rgb(0, 0, 0)">

        <tr>
          <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span>NOTE 5:-</span></span></td>
          <td style="width:auto;vertical-align:top;text-align:justify">
            <div style="font-weight:bold"><span style="font-size:10pt"><span>PROPERTY AND EQUIPMENT, NET</span></span></div>
          </td>
        </tr>

    </table>
    <div>
      <div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">
          <ix:nonNumeric id="FFact_0000000000460" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_20230101to20231231" escape="true">
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers, software and related equipment</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000442" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">739</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000443" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,617</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment and office furniture</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000444" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,519</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000445" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,831</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000446" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,314</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000447" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,314</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000448" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,572</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000449" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,762</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated depreciation:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers, software and related equipment</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000450" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">609</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000451" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,435</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment and office furniture</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000452" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,909</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000453" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,190</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000454" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,838</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000455" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,605</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000456" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,356</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000457" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,230</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciated cost</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000458" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,216</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000459" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,532</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During 2023 and 2022 total cost of $ <ix:nonFraction id="FFact_0000000000461" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,357</ix:nonFraction> and $ <ix:nonFraction id="FFact_0000000000462" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">99</ix:nonFraction>, respectively and total accumulated depreciation of $ <ix:nonFraction id="FFact_0000000000463" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,350</ix:nonFraction> and $ <ix:nonFraction id="FFact_0000000000464" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">95</ix:nonFraction>, respectively were disposed from the consolidated balance sheets.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the years ended December 31, 2023, 2022 and 2021, depreciation expenses were approximately $ <ix:nonFraction id="FFact_0000000000465" name="us-gaap:Depreciation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">476</ix:nonFraction>, $ <ix:nonFraction id="FFact_0000000000466" name="us-gaap:Depreciation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">482</ix:nonFraction> and $ <ix:nonFraction id="FFact_0000000000467" name="us-gaap:Depreciation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">461</ix:nonFraction>, respectively.</span></span></div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000476" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="C_20230101to20231231" escape="true">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NOTE 6:-</span></span></span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></span></span></span></div>
              </td>
            </tr>

        </table>
        <ix:nonNumeric id="Fxbrl_20230222132609363" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December 31,</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Employees and related accruals</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000469" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,125</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000470" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,812</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued expenses</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000471" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,858</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000472" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,396</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000473" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,983</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000474" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,208</ix:nonFraction></span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 29</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000498" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 7:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMMITMENTS AND CONTINGENCIES</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company provided bank guarantees in the amount of $ <ix:nonFraction id="FFact_0000000000477" name="us-gaap:GuaranteeObligationsMaximumExposure" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">296</ix:nonFraction> related to its offices in Israel, leased cars fueling in Israel and credit card security for its U.S. subsidiary.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the Office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly known as the Office of the Chief Scientist (the &#8220;IIA&#8221;), the Company is not obligated to repay any amounts received from the IIA if it does not generate any income from the results of the funded research program(s). If income is generated from a funded research program, the Company is committed to pay royalties at a rate of between <ix:nonFraction id="FFact_0000000000478" name="cgen:RoyaltyPercentageBasedOnFutureRevenues" contextRef="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMinimumMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction>% to <ix:nonFraction id="FFact_0000000000479" name="cgen:RoyaltyPercentageBasedOnFutureRevenues" contextRef="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMaximumMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of future revenue arising from such research program(s), and up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum to be repaid is <ix:nonFraction id="FFact_0000000000480" name="cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived" contextRef="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction>% plus interest at LIBOR until December 31, 2023, and from January 1, 2024, the 12 months Term SOFR interest). For the years ended December 31, 2023, 2022 and 2021, the Company had an aggregate of paid or accrued royalties to the IIA, recorded as cost of revenue in the consolidated statements of comprehensive loss in the amount of $ <ix:nonFraction id="FFact_0000000000481" name="us-gaap:RoyaltyExpense" contextRef="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,004</ix:nonFraction>, $ <ix:nonFraction id="FFact_0000000000482" name="us-gaap:RoyaltyExpense" contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction> and $ <ix:nonFraction id="FFact_0000000000483" name="us-gaap:RoyaltyExpense" contextRef="C_20210101to20211231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">180</ix:nonFraction>, respectively.</span></span></div>
                <div>&#160;</div>
                <div style="font-family:'Times New Roman',Times,serif">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, the Company&#8217;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled approximately to $ <ix:nonFraction id="FFact_0000000000484" name="cgen:RoyaltyContingentObligations" contextRef="C_20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,970</ix:nonFraction>.</span></span></div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 25, 2012 the Company entered into an Antibodies Discovery Collaboration Agreement (the &#8220;Antibodies Discovery Agreement&#8221;) with a U.S. antibody technology company (&#8220;mAb Technology Company&#8221;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company will be entitled to certain royalties that could be eliminated, upon payment of certain one-time fees (all payments referred together as &#8220;Contingent Fees&#8221;). For the years ended December 31, 2023, 2022 and 2021, the Company incurred such Contingent Fees in the amounts of $ <ix:nonFraction id="FFact_0000000000485" name="cgen:ContingentFees" contextRef="C_20231231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction>, $ <ix:nonFraction id="FFact_0000000000486" name="cgen:ContingentFees" contextRef="C_20221231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">750</ix:nonFraction> and $ <ix:nonFraction id="FFact_0000000000487" name="cgen:ContingentFees" contextRef="C_20211231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction>.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On <ix:nonNumeric id="FFact_0000000000488" name="cgen:AgreementStartDate" contextRef="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember" format="ixt:date-monthname-day-year-en">May 9, 2012</ix:nonNumeric>, the Company entered into agreement (the &#8220;May 2012 Agreement&#8221;) with a U.S. Business Development Strategic Advisor (&#8220;Advisor&#8221;) for the purpose of entering into transactions with Pharma companies related to selected Pipeline Program Candidates.</span></span></div>
                <div>&#160;</div>
                <div style="font-family:'Times New Roman',Times,serif">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the agreement the Advisor was entitled to <ix:nonFraction id="FFact_0000000000489" name="cgen:ParticipationRights" contextRef="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember_srtRangeAxis_srtMinimumMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction>% of the cash considerations that may be received under such transactions. <ix:nonNumeric id="FFact_0000000000490" name="cgen:AgreementTerminationDescription" contextRef="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember">In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.</ix:nonNumeric></span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Bayer Agreement was terminated effective February 27, 2023 and no further payments are expected under the May 2012 Agreement.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the years ended December 31, 2023, 2022 and 2021, the Company has not paid and did not accrue payments under this agreement.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                </div>
              </td>
            </tr>

        </table>
        <div><ix:exclude>
          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 30</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

              <tr style="margin-top:0pt;margin-bottom:0pt">
                <td style="width:56.7pt;vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 7:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                  <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">COMMITMENTS AND CONTINGENCIES (Cont.)</span></span></div>
                </td>
              </tr>

          </table>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </ix:exclude></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (CLA) with a European cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and <ix:nonFraction id="FFact_0000000000491" name="cgen:RoyaltyPercentage" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction>% royalties on annual net sales with respect to each commercialized product manufactured using the company&#8217;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the years ended December 31, 2023, 2022 and 2021, the Company did not incur any amount in the research and development expenses in connection with such milestone payment.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the years ended December 31, 2023, 2022 and 2021, the Company incurred in the research and development expenses such milestone payment in the amounts of $ <ix:nonFraction id="FFact_0000000000495" name="cgen:ResearchAndDevelopmentExpensesMilestonePayment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction>, $ <ix:nonFraction id="FFact_0000000000496" name="cgen:ResearchAndDevelopmentExpensesMilestonePayment" contextRef="C_20220101to20221231" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">0</ix:nonFraction> and $ <ix:nonFraction id="FFact_0000000000497" name="cgen:ResearchAndDevelopmentExpensesMilestonePayment" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">250</ix:nonFraction>.</span></span></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
</div><div style="">
  <div>
    <ix:nonNumeric id="Fxbrl_20240228135111319" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" contextRef="C_20230101to20231231" escape="true">
      <div>
        <div style="text-align:justify;line-height:1.25">
          <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">

              <tr>
                <td style="font-size:10pt;vertical-align:top;width:56.7pt">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">NOTE 8:-</span></p>
                </td>
                <td style="font-size:10pt;width:auto"><span style="fonfamily:Times New Roman,Times,serif"><span style="font-weight:bold">SHAREHOLDERS</span>&#8217;<span style="font-weight:bold"> EQUITY</span></span></td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary shares:</span></span></div>
                <div>&#160;</div>
                <div style="font-family:'Times New Roman',Times,serif">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The ordinary shares confer upon their holders the right to attend and vote at general meetings of the shareholders. Subject to the rights of holders of shares with limited or preferred rights which may be issued in the future, the ordinary shares of the Company confer upon the holders thereof equal rights to receive dividends, and to participate in the distribution of the assets of the Company upon its winding-up, in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the nominal value, if any.</span></span></div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25">
          <div><ix:exclude>
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 31</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
            <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;border:0px">

                <tr>
                  <td style="font-size:10pt;vertical-align:top;width:56.7pt">
                    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE 8:-</span></p>
                  </td>
                  <td style="font-size:10pt;width:auto"><span style="font-weight:bold">SHAREHOLDERS</span>&#8217;<span style="font-weight:bold"> EQUITY (Cont.)</span></td>
                </tr>
                <tr>
                  <td style="font-size:10pt;vertical-align:top;width:56.7pt">&#160;</td>
                  <td style="font-size:10pt;width:auto">&#160;</td>
                </tr>

            </table>
          </ix:exclude></div>
        </div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares:</span></span></div>
                <div>&#160;</div>
                <div style="font-family:'Times New Roman',Times,serif">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 14, 2018, the Company entered into securities purchase agreement with certain institutional investors and a placement agency agreement with JMP Securities LLC in connection with a registered direct offering (the &#8220;Offering&#8221;) of an aggregate of <ix:nonFraction id="Fxbrl_20240227235014159" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20180601to20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">5,316,457</ix:nonFraction> ordinary shares (the &#8220;RD Shares&#8221;) of the Company at a purchase price of $ <ix:nonFraction id="Fxbrl_20240227235028063" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">3.95</ix:nonFraction> per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to <ix:nonFraction id="Fxbrl_20240227235036671" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">4,253,165</ix:nonFraction> additional ordinary shares. The Warrants were exercisable at a price of $ <ix:nonFraction id="Fxbrl_20240227235043689" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember" unitRef="USD_per_share" scale="0" decimals="2" format="ixt:num-dot-decimal">4.74</ix:nonFraction> per ordinary share and had a term of <ix:nonNumeric id="Fxbrl_20240227235050367" name="cgen:ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" contextRef="C_20180601to20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric> from the date of issuance. The Offering was made pursuant to the Company&#8217;s Registration Statement. Proceeds from the Offering were $ <ix:nonFraction id="Fxbrl_20240227235102743" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_20180601to20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,767</ix:nonFraction> (net of $ <ix:nonFraction id="Fxbrl_20240227235108404" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20180601to20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,233</ix:nonFraction> issuance expenses).</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the years ended December 31, 2021 and 2020, warrants to purchase an aggregate of <ix:nonFraction id="Fxbrl_20240228112711109" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20201231_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230214032847386" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20211231_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">3,955,696</ix:nonFraction></ix:nonFraction> ordinary shares were exercised with proceeds of approximately $ <ix:nonFraction id="Fxbrl_20230214033059280" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230214032855904" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20210101to20211231_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,750</ix:nonFraction></ix:nonFraction> and as of December 31, 2023 and 2022, warrants to purchase <ix:nonFraction id="Fxbrl_s_20240228112751966" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20221231_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20240228112751966" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20231231_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction> and up to <ix:nonFraction id="Fxbrl_20240228112829453" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20221231_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230214032904124" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20231231_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">297,469</ix:nonFraction></ix:nonFraction> ordinary shares, respectively, remain outstanding. The warrants expired in June 2023.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Master Clinical Agreement&#8221;) with Bristol-Myers Squibb to evaluate the safety and tolerability of the Company&#8217;s COM701 in combination with Bristol-Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol-Myers Squibb made a $ <ix:nonFraction id="FFact_0000000000516" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction> equity investment in the Company.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the terms of the securities purchase agreement, Bristol-Myers Squibb purchased <ix:nonFraction id="FFact_0000000000517" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" contextRef="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,424,243</ix:nonFraction> ordinary shares of the Company at a purchase price of $ <ix:nonFraction id="FFact_0000000000518" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">4.95</ix:nonFraction> per share. The share price represented a <ix:nonFraction id="FFact_0000000000519" name="cgen:PercentageOfClosingPrice" contextRef="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction>% premium over the average closing price of Compugen&#8217;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The premium over the fair market value in the amount of $ <ix:nonFraction id="Fxbrl_20230221120705140" name="cgen:DeferredParticipationOfBMSInRAndDExpenses" contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,121</ix:nonFraction> represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D) and $ <ix:nonFraction id="Fxbrl_20230221120728895" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,788</ix:nonFraction> (net of $ <ix:nonFraction id="Fxbrl_20230221120826639" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction> issuance expenses) were considered equity investment.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $ <ix:nonFraction id="FFact_0000000000523" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction> investment in the Company, purchasing <ix:nonFraction id="FFact_0000000000524" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" contextRef="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,332,815</ix:nonFraction> ordinary shares of the Company at a purchase price of $ <ix:nonFraction id="FFact_0000000000525" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">8.57333</ix:nonFraction> per share. The share price represented a <ix:nonFraction id="FFact_0000000000526" name="cgen:PercentageOfClosingPrice" contextRef="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction>% premium over the closing price of Company&#8217;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The premium over the fair market value in the amount of $ <ix:nonFraction id="Fxbrl_20230221122449076" name="cgen:DeferredParticipationOfBMSInRAndDExpenses" contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction> represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D) and $ <ix:nonFraction id="Fxbrl_20230221122456788" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,958</ix:nonFraction> (net of $ <ix:nonFraction id="Fxbrl_20230221122504540" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction> issuance expenses) were considered equity investment.</span></span></div>
                </div>
              </td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 32</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
          </div>
          <div style="text-align:justify;line-height:1.25">
            <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;border:0px">

                <tr>
                  <td style="font-size:10pt;vertical-align:top;width:56.7pt">
                    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE 8:-</span></p>
                  </td>
                  <td style="font-size:10pt;width:auto"><span style="font-weight:bold">SHAREHOLDERS</span>&#8217;<span style="font-weight:bold"> EQUITY (Cont.)</span></td>
                </tr>

            </table>
          </div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares: (Cont.)</span></span></div>
                </td>
              </tr>

          </table>
          <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
        </ix:exclude></div>
        <div style="margin-left:85.05pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On January 31, 2023, the Company entered into a Sales Agreement with Leerink Partners LLC (previously known as SVB Securities LLC) (&#8220;Leerink Partners&#8221;), as sales agent, pursuant to which the Company may offer and sell, from time to time through Leerink Partners, its ordinary shares through an &#8220;at the market offering&#8221; (ATM). The offer and sale of our ordinary shares, if any, will be made pursuant to the Company&#8217;s shelf registration statement on Form F-3, as supplemented by a prospectus supplement filed on January 31, 2023. Pursuant to the applicable prospectus supplement, the Company may offer and sell up to $<ix:nonFraction id="Fxbrl_20240228000020266" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_20230101to20230131_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,000</ix:nonFraction> of its ordinary shares. As of December 31, 2023, <ix:nonFraction id="Fxbrl_20240228001142902" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,612,822</ix:nonFraction> ordinary shares were issued and sold through the ATM, with proceeds of approximately $<ix:nonFraction id="Fxbrl_20240228000338462" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,081</ix:nonFraction> (net of $<ix:nonFraction id="Fxbrl_20240228000400555" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">513</ix:nonFraction> issuance expenses).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share option plan:</span></span></div>
                <div>&#160;</div>
                <div style="font-family:'Times New Roman',Times,serif">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the Company&#8217;s 2010 Share Option Plan, as amended (the &#8220;Plan&#8221;), options may be granted to employees, directors and non-employees of the Company and Compugen USA, Inc.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the 2010 Share Option Plan the Company reserved for issuance up to an aggregate of <ix:nonFraction id="FFact_0000000000537" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_20231231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">13,895,152</ix:nonFraction> ordinary shares. The Company&#8217;s Board of Directors last amended the Plan in August 2023, to decrease the number of shares available under the 2010 Plan. As of December 31, 2023, an aggregate of <ix:nonFraction id="FFact_0000000000538" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_20231231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">1,202,301</ix:nonFraction> options under the 2010 Share Option Plan of the Company were still available for future grants.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In general, options granted under the Plan vest over a <ix:nonNumeric id="FFact_0000000000539" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> period and expire <ix:nonNumeric id="FFact_0000000000540" name="cgen:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember" format="ixt-sec:duryear">10</ix:nonNumeric> years from the date of grant and are granted at an exercise price of not less than the fair market value of the Company&#8217;s ordinary shares on the date of grant, unless otherwise determined by the Company&#8217;s board of directors. The exercise price of the options granted under the Plan may not be less than the nominal value of the shares into which such options are exercisable, and the expiration date may not be later than 10 years from the date of grant. If a grantee leaves his or her employment or other relationship with the Company, or if his or her relationship with the Company is terminated without cause (and other than by reason of death or disability, as defined in the Plan), the term of his or her unexercised options will generally expire in 90 days, unless determined otherwise by the Company.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Any options that are cancelled, forfeited or expired become available for future grants.</span></span></div>
                </div>
              </td>
            </tr>

        </table>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <div style="width:100%">&#160;</div>
        </div>
        <div><ix:exclude>
          <div style="text-align:justify;line-height:1.25">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 33</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
            <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;border:0px">

                <tr>
                  <td style="font-size:10pt;vertical-align:top;width:56.7pt">
                    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE 8:-</span></p>
                  </td>
                  <td style="font-size:10pt;width:auto"><span style="font-weight:bold">SHAREHOLDERS</span>&#8217;<span style="font-weight:bold"> EQUITY (Cont.)</span></td>
                </tr>

            </table>
          </div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Share option plan (Cont.):</p>
                </td>
              </tr>

          </table>
          <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
        </ix:exclude></div>
        <div style="font-family:'Times New Roman',Times,serif">
          <div style="line-height:1.25;margin-left:85.05pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Transactions related to the grant of options to employees, directors and non-employees under the above Plan during the year ended December 31, 2023, were as follows:</span></span></div>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:90pt">
          <ix:nonNumeric id="Fxbrl_20240228135136508" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="C_20230101to20231231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of options</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">price</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining contractual</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">life</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Aggregate</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">intrinsic</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">value</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Years</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options outstanding at beginning of year</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000541" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,157,749</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000542" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">5.43</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000543" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" format="ixt-sec:duryear">6.32</ix:nonNumeric></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options granted</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000545" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">1,576,500</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000546" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">1.20</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options forfeited</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000549" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">1,086,404</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000550" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">5.49</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="width:52%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options expired</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">274,100</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000552" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">4.92</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options outstanding at end of year</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000553" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,373,745</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000554" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">4.65</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000555" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" format="ixt-sec:duryear">6.61</ix:nonNumeric></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000556" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,912</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercisable at end of year</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000557" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">5,017,329</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000558" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">5.71</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000559" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" format="ixt-sec:duryear">5.15</ix:nonNumeric></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000560" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average fair value of options granted to employees, directors and non-employees during the years 2023, 2022 and 2021 was $ <ix:nonFraction id="FFact_0000000000562" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">0.70</ix:nonFraction>, $ <ix:nonFraction id="FFact_0000000000563" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">1.51</ix:nonFraction> and $ <ix:nonFraction id="FFact_0000000000564" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20210101to20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">3.81</ix:nonFraction> per share, respectively.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Aggregate intrinsic value of exercised options by employees, directors and non-employees during the years 2023, 2022 and 2021 was $ <ix:nonFraction id="FFact_0000000000565" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction>, $ <ix:nonFraction id="FFact_0000000000566" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction> and $ <ix:nonFraction id="FFact_0000000000567" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">759</ix:nonFraction>, respectively. The aggregate intrinsic value of the exercised options represents the total intrinsic value (the difference between the sale price of the Company&#8217;s share at the date of exercise, and the exercise price) multiplied by the number of options exercised.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company&#8217;s closing share price on the last trading day of calendar 2023 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2023. This amount is impacted by the changes in the fair market value of the Company&#8217;s shares.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, the total unrecognized estimated compensation cost related to non-vested share options granted prior to that date was $ <ix:nonFraction id="FFact_0000000000568" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_20231231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,370</ix:nonFraction> which is expected to be recognized over a weighted average period of approximately <ix:nonNumeric id="FFact_0000000000569" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember" format="ixt-sec:duryear">2.06</ix:nonNumeric> years.</span></span></div>
        <div style="text-align:justify;margin-left:85.5pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25">
          <div><ix:exclude>
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 34</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
            <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;border:0px">

                <tr>
                  <td style="font-size:10pt;vertical-align:top;width:56.7pt">
                    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE 8:-</span></p>
                  </td>
                  <td style="font-size:10pt;width:auto"><span style="font-weight:bold">SHAREHOLDERS</span>&#8217;<span style="font-weight:bold"> EQUITY (Cont.)</span></td>
                </tr>
                <tr>
                  <td style="font-size:10pt;vertical-align:top;width:56.7pt">&#160;</td>
                  <td style="font-size:10pt;width:auto">&#160;</td>
                </tr>

            </table>
          </ix:exclude></div>
        </div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:58.5pt">&#160;</td>
              <td style="width:26.5pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee Stock Purchase Plan:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company adopted an ESPP in November 2020, with the first offering period starting on January 1, 2021. In connection with its adoption, a total of <ix:nonFraction id="Fxbrl_20240228002524767" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">600,000</ix:nonFraction> ordinary shares were reserved for issuance under this plan.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:0.5pt;margin-left:85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The ESPP is implemented through six-month offering periods (except for the first offering period that was <ix:nonNumeric id="FFact_0000000000571" name="us-gaap:InitialOfferingPeriod" contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">five months</ix:nonNumeric>). According to the ESPP, eligible employees and non-employees may use up to <ix:nonFraction id="FFact_0000000000572" name="cgen:PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction>% of their base salaries to purchase ordinary shares up to an aggregate limit of $ <ix:nonFraction id="FFact_0000000000573" name="cgen:AggregateLimitOfOrdinarySharesPerCalendarYear" contextRef="C_20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">40</ix:nonFraction> per participant for every calendar year. The price of an ordinary share purchased under the ESPP is equal to <ix:nonFraction id="FFact_0000000000574" name="cgen:PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction>% of the lower of the fair market value of the ordinary share on the first day of each offering period or on the last day of such period.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:0.5pt;margin-left:85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In the years ended December 31, 2023, 2022 and 2021, <ix:nonFraction id="Fxbrl_20240301101934967" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction>, <ix:nonFraction id="Fxbrl_20240301101942293" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">158,025</ix:nonFraction> and <ix:nonFraction id="Fxbrl_20240301101953685" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="C_20210101to20211231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">117,829</ix:nonFraction> ordinary shares, respectively, had been purchased under the ESPP and as of December 31, 2023, <ix:nonFraction id="Fxbrl_20240301102135569" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">114,146</ix:nonFraction> ordinary shares were available for issuance under the ESPP.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.3pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The stock-based compensation expenses related to stock options and ESPP are included as follows in the expense categories:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:90pt">
          <ix:nonNumeric id="Fxbrl_20240228135148323" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_20230101to20231231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000577" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,933</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000578" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,158</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000579" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,971</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing and business development expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000580" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">41</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000581" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">269</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000582" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">215</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000583" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,658</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000584" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,901</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000585" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,090</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000586" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,550</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000587" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,328</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000588" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,276</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
      </div>
    </ix:nonNumeric>
    <div style="line-height:1.25">
      <p style="margin:0pt">&#160;</p>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 35</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
    </div>
  </div>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000629" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">
    <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

        <tr>
          <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 9:-</span></td>
          <td style="width:auto;vertical-align:top;text-align:justify">
            <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">TAXES ON INCOME, NET</span></div>
          </td>
        </tr>

    </table>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Israeli taxation:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax rates applicable to the income of the Company.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxable income of the Company is subject to a corporate tax rate of <ix:nonFraction id="Fxbrl_20230214114856319" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20210101to20211231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230214114847978" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230214114839776" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>% in 2021, 2022 and 2023.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Measurement of taxable income in U.S. dollars:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has elected to measure its taxable income and file its tax return under the Israeli Income Tax Regulations (Principles Regarding the Management of Books of Account of Foreign Invested Companies and Certain Partnerships and the Determination of Their Taxable Income), 1986. Accordingly, results for tax purposes are measured in terms of earnings in dollars.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax benefits under the Israeli Law for the Encouragement of Capital Investments, 1959 (the &#8220;Investment Law&#8221;):</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 1, 2005, an amendment to the Investment Law came into effect (the &#8220;Amendment 60&#8221;) that significantly changed the provisions of the Investment Law. The Amendment 60 limits the scope of enterprises that may be approved by the Investment Center by setting criteria for the approval of a facility as a &#8220;Beneficiary Enterprise&#8221; including a provision generally requiring that at least <ix:nonFraction id="FFact_0000000000594" name="cgen:ReducedTaxRate" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction>% of the Beneficiary Enterprise&#8217;s income will be derived from export.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Another condition for receiving the benefits under the alternative track in respect of expansion programs pursuant to Amendment 60 is a minimum qualifying investment. The Company was eligible under the terms of minimum qualifying investment and elected 2012 as its &#8220;year of election&#8221;.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additionally, Amendment 60 enacted major changes in the manner in which tax benefits are awarded under the Investment Law so that companies no longer require Investment Center approval in order to qualify for tax benefits. However, the Investment Law provides that terms and benefits included in any certificate of approval already granted will remain subject to the provisions of the Investment Law as they were on the date of such approval.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, there was no taxable income attributable to the Beneficiary Enterprise.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In January 2011, another amendment to the Investment Law came into effect (the &#8220;2011 Amendment&#8221;). According to the 2011 Amendment, the benefit tracks in the Investment Law were modified and a flat tax rate applies to the Company&#8217;s entire income subject to this amendment (the &#8220;Preferred Income&#8221;).</span></span></div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <div style="width:100%;margin-top:0pt;margin-bottom:0pt">
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 36</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
            <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px;margin-top:0pt;margin-bottom:0pt">

                <tr style="margin-top:0pt;margin-bottom:0pt">
                  <td style="width:56.7pt;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">NOTE 9:-</span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                    <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-weight:bold;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">TAXES ON INCOME, NET&#160;</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt">(Cont.)</span></div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Israeli taxation (Cont.):</span></span></div>
                </td>
              </tr>

          </table>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </ix:exclude></div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Once an election is made, the Company&#8217;s income will be subject to the amended tax rate of 16% from 2015 and thereafter (or 9% for a preferred enterprise located in development area A).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commencing 2011 tax year, the Company can elect (without possibility of reversal) to apply the Amendment in a certain tax year and from that year and thereafter, it will be subject to the amended tax rates.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company does not currently intend to adopt the 2011 Amendment and intends to continue to comply with the Investment Law as in effect prior to enactment of the 2011 Amendment. Accordingly, the Company did not adjust its deferred tax balances as of December 31, 2023. The Company&#8217;s position may change in the future.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2016 and 2017 Budget Years), 2016, which includes Amendment 73 to the Law (the &#8220;Amendment 73&#8221;) was published. According to Amendment 73, a preferred enterprise located in development area A will be subject to a tax rate of 7.5% instead of 9% effective from January 1, 2016 and thereafter (the tax rate applicable to preferred enterprises located in other areas remains at 16%).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amendment 73 also prescribes special tax tracks for technological enterprises, which are subject to rules that were issued by the Minister of Finance in May 2017. The new tax tracks under the Amendment are as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preferred Technological Enterprise (&#8220;PTE&#8221;) - an enterprise for which total consolidated revenues of its parent company and all subsidiaries are less than NIS 10 billion in a tax year. A PTE, as defined in the Law, which is located in the center of Israel will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development area A - a tax rate of 7.5%).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The above changes in the tax rates relating to PTE tax track were not taken into account in the computation of deferred taxes as of December 31, 2023 and 2022, since the Company estimates that it will not implement the PTE tax track.</span></span></div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <div style="width:100%;margin-top:0pt;margin-bottom:0pt">
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 37</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
            <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px;margin-top:0pt;margin-bottom:0pt">

                <tr style="margin-top:0pt;margin-bottom:0pt">
                  <td style="width:56.7pt;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 9:-</span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                    <div style="margin-top:0pt;margin-bottom:0pt;font-weight:bold"><span style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-weight:bold;font-family:Times New Roman, Times, serif">TAXES ON INCOME, NET&#160;</span><span style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-weight:bold;font-family:Times New Roman, Times, serif">(Cont.)</span></div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt">&#160;</td>
                <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Israeli taxation (Cont.):</span></span></div>
                </td>
              </tr>

          </table>
          <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </ix:exclude></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax benefits under the law for the Encouragement of Industry (Taxes), 1969 (the &#8220;Encouragement Law&#8221;):</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Encouragement Law provides several tax benefits for industrial companies. An industrial company is defined as a company resident in Israel, at least 90% of the income of which in a given tax year exclusive of income from specified Government loans, capital gains, interest and dividends, is derived from an industrial enterprise owned by it. An industrial enterprise is defined as an enterprise whose major activity in a given tax year is industrial production activity.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Management believes that the Company is currently qualified as an &#8220;industrial company&#8220; under the Encouragement Law and, as such, is entitled to tax benefits, including: (1) deduction of purchase of know-how and patents and/or right to use a patent over an eight-year period; (2) the right to elect, under specified conditions, to file a consolidated tax return with additional related Israeli industrial companies and an industrial holding company; (3) accelerated depreciation rates on equipment and buildings; and (4) expenses related to a public offering on the Tel-Aviv Stock exchange and on recognized stock markets outside of Israel, are deductible in equal amounts over three years.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Eligibility for benefits under the Encouragement Law is not subject to receipt of prior approval from any Governmental authority. No assurance can be given that the Israeli tax authorities will agree that the Company qualifies, or, that the Company will continue to qualify as an industrial company or that the benefits described above will be available to the Company in the future.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net operating losses carryforward and capital loss:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, Compugen Ltd. &#8217;s net operating losses carryforward for tax purposes in Israel amounted to approximately $ <ix:nonFraction id="FFact_0000000000595" name="us-gaap:OperatingLossCarryforwards" contextRef="C_20231231_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">401,100</ix:nonFraction>. These net operating losses may be carried forward indefinitely and may be offset against future taxable income.</span></span></div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 38</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
          </div>
          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
            <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px;margin-top:0pt;margin-bottom:0pt">

                <tr style="margin-top:0pt;margin-bottom:0pt">
                  <td style="width:56.7pt;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 9:-</span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                    <div style="margin-top:0pt;margin-bottom:0pt;font-weight:bold"><span style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-weight:bold;font-family:Times New Roman, Times, serif">TAXES ON INCOME, NET&#160;</span><span style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-weight:bold;font-family:Times New Roman, Times, serif">(Cont.)</span></div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
        </ix:exclude></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-Israeli subsidiary, Compugen USA, Inc.:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the &#8220;U.S. Tax Reform&#8221; or &#8220;TCJA&#8221;); a comprehensive tax legislation that includes significant changes to the taxation of business entities. These changes include several key tax provisions that might impact the Company, among others: (i) a permanent reduction to the statutory federal corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017; (ii) a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain new rules designed to prevent erosion of the U.S. income tax base - &#8220;BEAT&#8221;); (iii) establishing immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits; and (iv) providing a permanent deduction to corporations generating revenues from non-US markets (known as a deduction for foreign derived intangible income - &#8220;FDII&#8221;) .</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, Compugen USA, Inc. has net operating loss carryforwards for federal income tax purposes of approximately $ <ix:nonFraction id="FFact_0000000000597" name="cgen:NetOperatingLossCarryforwardExpired" contextRef="C_20211231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,050</ix:nonFraction>. Approximately $<ix:nonFraction id="Fxbrl_20240228003646758" name="cgen:NetOperatingLossCarryforwardExpired" contextRef="C_20211231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapSubsidiaryOfCommonParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,950</ix:nonFraction> of these losses are available to offset any future U.S. taxable income of our U.S. subsidiary and will expire in the years 2024 to 2032. Utilization of the U.S. net operating losses may be subject to substantial annual limitation due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Neither Israeli income taxes, foreign withholding taxes nor deferred income taxes were provided in relation to undistributed earnings of the Company&#8217;s foreign subsidiary. This is because the Company has the intent and ability to reinvest these earnings indefinitely in the foreign subsidiary and therefore those earnings are continually redeployed in those jurisdictions.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss (income) before taxes is comprised as follows:</span></span></div>
              </td>
            </tr>

        </table>
        <ix:nonNumeric id="Fxbrl_20230214044607742" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:90pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Domestic (Israel)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000600" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">10,164</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000601" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,096</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000602" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,619</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:64%;padding-bottom:2px;vertical-align:baseline">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000603" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">380</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000604" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">460</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000605" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">416</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000606" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,784</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000607" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,636</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000608" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,203</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxes on income for the years ended December 31, 2023 and 2022, represent state income taxes in the United States.</span></span></div>
              </td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        <div><ix:exclude>
          <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 39</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
          </div>
          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
            <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px;margin-top:0pt;margin-bottom:0pt">

                <tr style="margin-top:0pt;margin-bottom:0pt">
                  <td style="width:56.7pt;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 9:-</span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;margin-top:0pt;margin-bottom:0pt">
                    <div style="margin-top:0pt;margin-bottom:0pt;font-weight:bold"><span style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-weight:bold;font-family:Times New Roman, Times, serif">TAXES ON INCOME, NET&#160;</span><span style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-weight:bold;font-family:Times New Roman, Times, serif">(Cont.)</span></div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
        </ix:exclude></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred taxes:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company and Compugen USA, Inc.&#8217;s deferred tax assets are comprised of operating loss carryforward and other temporary differences. Significant components of the Company and Compugen USA, Inc. deferred tax assets are as follows:</span></span></div>
        <ix:nonNumeric id="Fxbrl_20230214044633836" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:90pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax assets:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating loss carryforward</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000610" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,885</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000611" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,704</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000612" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,109</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000613" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,083</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued social benefits and other</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000614" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,072</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000615" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,123</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000618" name="cgen:DeferredIncomeTaxLeaseLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">312</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000619" name="cgen:DeferredIncomeTaxLeaseLiabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">444</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000620" name="cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000621" name="cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax asset before valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000622" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,380</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000623" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,356</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000624" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,073</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000625" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,941</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax asset after valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228010347732_Fact_0000000000622" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">307</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228010347732_Fact_0000000000623" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">415</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax liabilities:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:76%;padding-bottom:2px;vertical-align:baseline">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right of use assets</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000616" name="cgen:DeferredIncomeTaxRightOfUseAssets" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">307</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000617" name="cgen:DeferredIncomeTaxRightOfUseAssets" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">415</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:76%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:76%;padding-bottom:2px;vertical-align:baseline">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240228010350775_Fact_0000000000622" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">307</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240228010350775_Fact_0000000000623" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">415</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax assets</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228010353797_Fact_0000000000622" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228010353797_Fact_0000000000623" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has provided full valuation allowances in respect of deferred tax assets resulting from operating loss carryforward and other temporary differences. Management currently believes that since the Company has a history of losses, it is more likely than not that the deferred tax regarding the operating loss carryforward and other temporary differences will not be realized in the foreseeable future.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Reconciliation of the theoretical tax expense (benefit) to the actual tax expense (benefit):</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits from accumulated net operating loss carryforward among the Company and<span style="font-weight:bold">&#160;</span>Compugen USA, Inc. due to the uncertainty of the realization of such tax benefits&#160;and withholding taxes on the upfront payment pursuant to the Gilead license agreement.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax assessments:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has tax assessments through 2018 that are deemed to be final.</span></span></div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 40</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
</div><div style="">
  <ix:nonNumeric id="Fxbrl_20230222123726446" name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">
    <div>
      <div>
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 10:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s business is currently comprised of <ix:nonFraction id="FFact_0000000000630" name="us-gaap:NumberOfOperatingSegments" contextRef="C_20230101to20231231" unitRef="Item" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> operating segment, the research, development and commercialization of therapeutic and product candidates. The nature of the products and services provided by the Company and the type of customers for these products and services are similar. Operations in Israel and the United States include research and development, clinical operations, marketing and business development. The Company follows ASC 280, &#8220;Segment Reporting&#8221;. Total revenues are attributed to geographic areas based on the location of the end customer.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div>
            <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following represents the total revenue for the years ended December 31, 2023, 2022 and 2021 and long-lived assets as of December 31, 2023 and 2022:</span></span></div>
            <ix:nonNumeric id="Fxbrl_20240228125735648" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" contextRef="C_20230101to20231231" escape="true">
              <div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
                <div style="margin-left:63pt">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue from sales to customers:</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Europe</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000631" name="us-gaap:Revenues" contextRef="C_20230101to20231231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000632" name="us-gaap:Revenues" contextRef="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214023238881" name="us-gaap:Revenues" contextRef="C_20210101to20211231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">United States</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228002914108_Fact_0000000000631" name="us-gaap:Revenues" contextRef="C_20230101to20231231_cgenSegmentReportingGeographicAreaAxis_countryUS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,459</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228002914108_Fact_0000000000632" name="us-gaap:Revenues" contextRef="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_countryUS" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228002914108_xbrl_20230214023238881" name="us-gaap:Revenues" contextRef="C_20210101to20211231_cgenSegmentReportingGeographicAreaAxis_countryUS" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total revenue</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000634" name="us-gaap:Revenues" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,459</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000635" name="us-gaap:Revenues" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214023305010" name="us-gaap:Revenues" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
                <div style="line-height:1.25">&#160;</div>
                <div style="margin-left:63pt">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-lived assets:</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Israel</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000637" name="us-gaap:NoncurrentAssets" contextRef="C_20231231_cgenSegmentReportingGeographicAreaAxis_countryIL" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,468</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000638" name="us-gaap:NoncurrentAssets" contextRef="C_20221231_cgenSegmentReportingGeographicAreaAxis_countryIL" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,239</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                          <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">United States</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000639" name="us-gaap:NoncurrentAssets" contextRef="C_20231231_cgenSegmentReportingGeographicAreaAxis_countryUS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000640" name="us-gaap:NoncurrentAssets" contextRef="C_20221231_cgenSegmentReportingGeographicAreaAxis_countryUS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">119</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                          <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total long-lived assets</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000641" name="us-gaap:NoncurrentAssets" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,545</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000642" name="us-gaap:NoncurrentAssets" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,358</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
              </div>
            </ix:nonNumeric>
            <div style="margin-left:63pt">&#160;</div>
          </div>
          <div style="margin-left:63pt">
            <ix:nonNumeric id="FFact_0000000000647" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" contextRef="C_20230101to20231231" escape="true">
              <div>
                <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sales to a single customer exceeding 10%:</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer A</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000644" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20230101to20231231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">30</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000645" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214023433284" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20210101to20211231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                        <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer B</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228002946105_Fact_0000000000644" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20230101to20231231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">70</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228002946105_Fact_0000000000645" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228002946105_xbrl_20230214023433284" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20210101to20211231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>

                </table>
              </div>
            </ix:nonNumeric>
          </div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 41</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000665" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">
    <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

        <tr>
          <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 11:-</span></td>
          <td style="width:auto;vertical-align:top;text-align:justify">
            <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">FINANCIAL AND OTHER INCOME, NET</span></div>
          </td>
        </tr>

    </table>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
    <div>
      <div>
        <div style="margin-left:63pt">
          <ix:nonNumeric id="FFact_0000000000664" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" contextRef="C_20230101to20231231" escape="true">
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000649" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,960</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000650" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,437</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000651" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">894</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of discount on marketable securities, net</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228002028020_Fact_0000000000649" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">281</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228002028020_Fact_0000000000650" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240228002028020_Fact_0000000000651" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank fees and other finance expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000652" name="us-gaap:InterestAndDebtExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000653" name="us-gaap:InterestAndDebtExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000654" name="us-gaap:InterestAndDebtExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign currency transaction adjustments</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000655" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214022140608" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">340</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000657" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gain (loss) from sales and disposals of fixed assets</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214022153855" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:1.5px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000659" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:1.5px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000660" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000661" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,208</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000662" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,738</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000663" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">871</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </ix:nonNumeric>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000672" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">
    <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

        <tr>
          <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 12:-</span></td>
          <td style="width:auto;vertical-align:top;text-align:justify">
            <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">RELATED PARTY BALANCES AND TRANSACTIONS</span></div>
          </td>
        </tr>

    </table>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
    <div>
      <div>
        <ix:nonNumeric id="FFact_0000000000671" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables and accrued expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000666" name="us-gaap:OtherLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">53</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000667" name="us-gaap:OtherLiabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts charged to:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000668" name="us-gaap:CostsAndExpensesRelatedParty" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">147</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000669" name="us-gaap:CostsAndExpensesRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">194</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000670" name="us-gaap:CostsAndExpensesRelatedParty" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the years ended December 31, 2023, 2022 and 2021 the Company received research and development services related with cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies. The transaction was at arm&#8217;s length.</span></span></div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
  <div style="margin-bottom:0pt">
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 42</span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;page-break-after:always;margin-top:0pt"/><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:12pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:5pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/><p style="margin-top:5pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
  </div>
</div><div style="">
  <ix:nonNumeric id="Fxbrl_20230222124735774" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20230101to20231231" escape="true">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 13:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">LOSSES PER SHARE</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin:0px 0px 0px 85.5pt;line-height:1.25;text-align:justify;text-indent:-28.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the computation of basic and diluted losses per share:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">
          <ix:nonNumeric id="Fxbrl_20230222124750140" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_20230101to20231231" escape="true">
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Numerator:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:64%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for basic and diluted loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000673" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,754</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000674" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000675" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,203</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Denominator:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares</span></span></div>
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">used in computing basic and diluted net loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000676" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">87,633,298</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000677" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,555,628</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000678" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20210101to20211231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">84,203,971</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted loss per ordinary share</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214135651704" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20231231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="FFact_0000000000679" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.21</ix:nonFraction></ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:3px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214135713278" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20221231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="FFact_0000000000680" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.39</ix:nonFraction></ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:3px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214135731057" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20210101to20211231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="FFact_0000000000681" name="us-gaap:EarningsPerShareBasic" contextRef="C_20210101to20211231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.41</ix:nonFraction></ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:3px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
          </ix:nonNumeric>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
</div><div style="">
  <ix:nonNumeric id="Fxbrl_20230214053733944" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20230101to20231231" escape="true">
    <div>
      <div>
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 14:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SUBSEQUENT EVENTS</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="margin:0px 0px 0px 85.5pt;line-height:1.25;text-align:justify;text-indent:-28.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In January 2024, <ix:nonFraction id="Fxbrl_20240228000412030" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20240101to20240131_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">292,728</ix:nonFraction> ordinary shares were issued and sold through the ATM, with proceeds of approximately $<ix:nonFraction id="Fxbrl_20240228000432241" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" contextRef="C_20240101to20240131_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">562</ix:nonFraction> (net of $<ix:nonFraction id="Fxbrl_20240228000436548" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20240101to20240131_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction> issuance expenses).</span></span></div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
  <div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F&#8201;-&#8201;43</span></span></p>
    <div style="width:100%;clear:both;margin-top:0pt">
      <hr style="border-top:0.75pt solid #000000;width:100%;margin-left:0pt;text-align:left;margin-top:0pt"/>
      <hr style="border-top:3pt solid #000000;width:100%;margin-left:0pt;text-align:left"/>
    </div>
  </div>
</div></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>exhibit_2-1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Exhibit 2.1</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;DESCRIPTION OF SECURITIES</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The descriptions of the securities contained herein summarize the material terms and provisions of the ordinary shares of Compugen Ltd. (the &#8220;Company&#8221;), registered under Section 12 of the Securities
      Exchange Act of 1934.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">ORDINARY SHARES</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Our authorized share capital is NIS 2,000,000 divided into 200,000,000 ordinary shares, nominal (par) value NIS 0.01 per share. Subject to our amended and restated articles of association, or our
      Articles, fully paid ordinary shares of the Company confer on the holders thereof rights to attend and to vote at general meetings of the shareholders. Subject to the rights of holders of shares with limited or preferred rights which may be issued in
      the future, the ordinary shares of the Company confer upon the holders thereof equal rights to vote, to receive dividends and to participate in the distribution of the assets of the Company upon its winding-up, in proportion to the amount paid up or
      credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the nominal value,
      if any. All outstanding ordinary shares are validly issued and fully paid.</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">The Nasdaq Capital Market and the Tel Aviv Stock Exchange</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="line-height: 1.25;">Our ordinary shares are listed on each of The Nasdaq Capital Market and the Tel Aviv Stock Exchange&#160;under the symbol &#8220;CGEN&#8221;.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Rights Attached to Our Shares</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Subject to our Articles, fully paid ordinary shares confer on the holders thereof rights to attend and to vote at general meetings of the shareholders. Subject to the rights of holders of shares with
      limited or preferred rights which may be issued in the future, our ordinary shares confer upon the holders thereof equal rights to receive dividends and to participate in the distribution of our assets upon our winding-up, in proportion to the amount
      paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the
      nominal value, if any. No preferred shares are currently authorized. All outstanding ordinary shares are validly issued and fully paid.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Voting Rights</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Subject to the provisions of our Articles, holders of ordinary shares have one vote for each ordinary share held by such shareholder of record, on all matters submitted to a vote of shareholders.
      Shareholders may vote in person, by proxy or by proxy card. Alternatively, shareholders who hold shares through members of the Tel Aviv Stock Exchange may vote electronically via the electronic voting system of the Israel Securities Authority, or
      Electronic Vote. These voting rights may be affected by the grant of any special voting rights to the holders of a class of shares with preferential rights that may be authorized in the future. As our ordinary shares do not have cumulative voting
      rights in the election of directors, the holders of the majority of the shares present and voting at a shareholders meeting have the power to elect all of our directors. In the event that we cease meeting the Opt Out Criteria (as defined in the
      annual report on Form 20-F to which this Exhibit 2.1 is attached), or if our board of directors shall decide to opt in the requirement to elect and have external directors and comply with the composition criteria of the audit committee and
      compensation committee under the Companies Law, the external directors will be elected by a special majority vote, as set forth under the Companies Law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Transfer of Shares</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our ordinary shares which have been fully paid-up are transferable by submission of a proper instrument of transfer together with the certificate of the shares to be transferred and such other
      evidence of title, as our board of directors may require, unless such transfer is prohibited by another instrument or by applicable securities laws.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;"> <br>
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Dividends</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Under the Companies Law, dividends may be distributed only out of profits available for dividends as determined by the Companies Law, provided that there is no reasonable concern that the
      distribution will prevent the Company from being able to meet its existing and anticipated obligations when they become due. If the company does not meet the profit requirement, a court may nevertheless allow the company to distribute a dividend, as
      long as the court is convinced that there is no reasonable concern that such distribution will prevent the company from being able to meet its existing and anticipated obligations when they become due. Pursuant to our Articles, no dividend shall be
      paid other than out of the profits of the Company. Generally, under the Companies Law, the decision to distribute dividends and the amount to be distributed is made by a company&#8217;s board of directors.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our Articles provide that our board of directors, may, subject to the Companies Law, from time to time, declare and cause the Company to pay such dividends as may appear to the board of directors to
      be justified by the profits of our Company. Subject to the rights of the holders of shares with preferential, special or deferred rights that may be authorized in the future, our profits which shall be declared as dividends shall be distributed
      according to the proportion of the nominal (par) value paid up or credited as paid up on account of the shares held at the date so appointed by the Company and in respect of which such dividend is being paid, without regard to the premium paid in
      excess of the nominal (par) value, if any. The declaration of dividends does not require shareholders&#8217; approval.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">To date, we have not declared or distributed any dividend and we do not intend to pay cash dividends on our ordinary shares in the foreseeable future.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Liquidation Rights</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">In the event of our winding up on liquidation or dissolution, subject to applicable law and after satisfaction of liabilities to creditors, our assets available for distribution among the
      shareholders shall be distributed to the holders of ordinary shares in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such distribution is being
      made, without regard to any premium paid in excess of the nominal value, if any. This liquidation right may be affected by the grant of limited or preferential rights as to liquidation to the holders of a class of shares that may be authorized in the
      future.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Redemption Provisions</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">We may, subject to applicable law and to our Articles, issue redeemable shares and redeem the same upon such terms and conditions as determined by our board of directors.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Limitation of Liability</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Under our Articles, the liability of each shareholder for the Company&#8217;s obligations is limited to the unpaid sum, if any, owing to the Company in consideration for the issuance of the shares held by
      such shareholder.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Modification of Class Rights</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our amended and restated Memorandum of Association, or Memorandum, provides that we may amend the Memorandum in order to increase, consolidate or divide or otherwise amend our share capital by a
      simple majority of the voting power present at a shareholders meeting as currently provided in our Articles or by such other majority as shall be set forth in our Articles from time to time.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to our Articles, if at any time our share capital is divided into different classes of shares, the rights attached to any class, unless otherwise provided by our Articles, may be modified or
      abrogated by the Company, subject to the consent in writing of, or sanction of a resolution passed by, the holders of a majority of the issued shares of such class at a separate general meeting of the holders of the shares of such class.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Limitations on the Rights to Own Securities</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our Articles and Israeli law do not restrict the ownership or voting of ordinary shares by non-residents or persons who are not citizens of Israel, though such ownership is prohibited under
      applicable law with respect to subjects of nations which are in a state of war with Israel.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Changes in Authorized Share Capital</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our Articles enable us, among others, to increase or reduce our authorized share capital. Any such changes are subject to the provisions of the Companies Law and our Articles and must be approved by
      a resolution duly passed by a simple majority of our shareholders at a general meeting by voting on such change in capital.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Shareholders&#8217; Meetings and Resolutions</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our Articles and the Companies Law provide that our annual general meeting shall be held once in every calendar year at such time (within a period of not more than fifteen months after the last
      preceding annual general meeting), and place determined by our board of directors. Our board of directors may, in its discretion, convene additional special shareholders meetings and, pursuant to the Companies Law, must convene a meeting upon the
      demand of: (a) two directors or one quarter of the directors in office; or (b) the holder or holders of (i) 5% or more of our issued share capital and one percent or more of our voting rights; or (ii) 5% or more of our voting rights. All demands for
      shareholders meetings must set forth the items to be considered at that meeting. If the board of directors does not convene a meeting upon a valid demand of any of the above, then the persons who made the demand, and in the case of shareholders, part
      of such demanding shareholders holding at least half of the voting rights of such demanding shareholders, may convene a meeting of the shareholders to be held within three months of the demand. Alternatively, upon petition by the individuals making
      the demand, a court may order that a meeting be convened.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The chairman of the board of directors, or any other director or office holder of the Company which may be designated for this purpose by the board of directors, shall preside as chairman at each of
      our general meetings. If there is no such chairman, or if the appointed chairman is unwilling to take the chair, or if he shall have indicated in advance that he will not be attending, or if at any meeting such chairman is not present within thirty
      (30) minutes after the time fixed for holding the meeting, then those present at the meeting shall choose someone present to be chairman of the meeting. The office of chairman shall not, by itself, entitle the holder thereof to vote at any general
      meeting nor shall it entitle a second or casting vote.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">According to regulations promulgated pursuant to the Companies Law and governing the terms of notice and publication of shareholder meetings of public companies, or the General Meeting Regulations,
      holder(s) of one percent or more of the Company&#8217;s voting rights may propose any matter appropriate for deliberation at a shareholder meeting to be included on the agenda of a shareholder meeting, generally by submitting a proposal within seven days
      of publicizing the convening of a shareholder meeting, or within fourteen days, if the Company publishes at least 21 days prior to publicizing the proxy materials for a shareholder meeting, a preliminary notice stating its intention to convene such
      meeting, the agenda thereof, shareholder&#8217;s right to propose a matter to be included on the agenda of such meeting and company&#8217;s right not to examine such proposals received upon termination of 14 day period from the publication of such notice. Any
      such proposal must further comply with the information requirements under applicable law and our Articles, and in the event that such shareholders propose to appoint directors for service on the Company&#8217;s board of directors, the proposal must include
      information regarding the director candidates as well as certain declarations of the director candidates, as required pursuant to the General Meeting Regulations. The agenda for a shareholder meeting is determined by the board of directors and must
      include matters in respect of which the convening of a shareholder meeting was demanded and any matter requested to be included by holder(s) of one percent of the Company&#8217;s voting rights, as detailed above.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to the Companies Law and the General Meeting Regulations shareholder meetings generally require prior notice of not less than 21 days, and not less than 35 days in certain cases. Pursuant to
      our Articles, we are not required to deliver or serve notice of a general meeting or of any adjournments thereof to any shareholder. However, subject to applicable law and stock exchange rules and regulations, we will publicize the convening of a
      general meeting in any manner reasonably determined by us, and any such publication shall be deemed duly made, given and delivered to all shareholders on the date on which it is first made, posted, filed or published in the manner so determined by us
      in our sole discretion.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">The function of the general meeting is to elect directors, receive and consider the profit and loss account, the balance sheet and the ordinary reports and accounts of the directors and auditors,
      appoint external auditor, approve certain interested party transactions requiring general meeting approval as provided in the Companies Law, approve the Company&#8217;s merger, exercise of the powers of the board of directors if the board of directors is
      unable to exercise its powers and the exercise of any of its powers is vital for our proper management, approve amendments of the Articles and transact any other business which under our Articles or applicable law may be transacted by the
      shareholders of the Company in a general meeting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to our Articles, the quorum required for a meeting of shareholders consists of at least two shareholders, present in person, by proxy, by proxy card or by Electronic Vote and holding shares
      conferring in the aggregate twenty-five percent (25%) or more of the voting power of the Company. If within half an hour from the time appointed for the meeting a quorum is not present, the meeting shall stand adjourned to the same day in the
      following week at the same time and place or to such other later day, time and place as the board of directors may determine and specify in the publication with respect to the Meeting. At the adjourned meeting, any number of participants will
      constitute a quorum present, in person, by proxy, by proxy card or by Electronic Vote; provided, however, that special general meeting which was convened by the Board upon the demand of shareholders or directors then in office, as detailed above, or
      directly by such shareholders or directors, in accordance the terms of the Companies Law, shall be cancelled.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Generally, under the Companies Law and our Articles, shareholder resolutions are deemed adopted if approved by the holders of a simple majority of the voting rights represented at the meeting, in
      person, by proxy, by proxy card or by Electronic Vote, and voting on the matter, unless a different majority is required by law or pursuant to our Articles such as a resolution for the voluntary winding up of our Company which requires the approval
      of holders of 75% of the voting power presented and voting at the meeting, or resolutions concerning certain related party transactions as set forth in Sections 267 and 270-275 of the Companies Law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Change of Control</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Merger</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Under the Companies Law, a merger is generally required to be approved by the shareholders and board of directors of each of the merging companies. If the share capital of the company that will not
      be the surviving company is divided into different classes of shares, the approval of each class is also required, unless determined otherwise by the court. Similarly, unless an Israeli court determines otherwise, a merger will not be approved if it
      is objected to by shareholders holding a majority of the voting rights participating and voting at the meeting (abstentions are disregarded), after excluding the shares held by the other party to the merger, by any person who holds 25% or more of the
      other party to the merger or by anyone on their behalf, including by the relatives of, or corporations controlled by, these persons. In approving a merger, the board of directors of both merging companies must determine that there is no reasonable
      concern that, as a result of the merger, the surviving company will not be able to satisfy its obligations to its creditors. Similarly, upon the request of a creditor of either party to the proposed merger, an Israeli court may prevent or delay the
      merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will not be able to satisfy the obligations of the merging parties. A court may also issue other instructions for the protection of
      the creditors&#8217; rights in connection with a merger. Further, a merger may not be completed unless at least (i) 50 days have passed from the time that the requisite proposals for the approval of the merger were filed with the Israeli registrar of
      companies; and (ii) 30 days have passed since the merger was approved by the shareholders of each party.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;"> <br>
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Special Tender Offer</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a
      holder of 25% or more of the voting rights in the company. This rule does not apply if there is already another holder of 25% or more of the voting rights in the company. Similarly, the Companies Law provides that an acquisition of shares in a public
      company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company who holds more than
      45% of the voting rights in the company. These requirements do not apply if the acquisition (i) occurs in the context of a private placement by the company that received shareholder approval for the purpose of allowing the purchaser to hold more than
      25% of the voting rights in the company if there is no other holder of 25% or more of the voting rights in the company, or 45% of the voting rights in the company if there is no other holder of 45% or more of the voting rights in the company, as the
      case may be, (ii) was from a shareholder holding 25% or more of the voting rights in the company and resulted in the acquirer becoming a holder of 25% or more of the voting rights in the company, or (iii) was from a holder of more than 45% of the
      voting rights in the company and resulted in the acquirer becoming a holder of more than 45% of the voting rights in the company. A special tender offer may be consummated only if (i) at least 5% of the voting power attached to the company&#8217;s
      outstanding shares will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding controlling shareholders, holders of 25% or more of the voting rights
      in the company and any person having a personal interest in the acceptance of the special tender offer).</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">In the event that a special tender offer is made, a company&#8217;s board of directors is required to express its opinion on the advisability of the offer, or shall abstain from expressing any opinion if
      it is unable to do so, provided that it gives the reasons for its abstention. An office holder in a target company who, in his or her capacity as an office holder, performs an action the purpose of which is to cause the failure of an existing or
      foreseeable special tender offer or is to impair the chances of its acceptance, is liable to the potential purchaser and shareholders for damages, unless such office holder acted in good faith and had reasonable grounds to believe he or she was
      acting for the benefit of the company. However, office holders of the target company may negotiate with the potential purchaser in order to improve the terms of the special tender offer and may further negotiate with third parties in order to obtain
      a competing offer. Shares purchased in contradiction to the tender offer rules under the Companies Law will have no rights and will become dormant shares.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">If a special tender offer is accepted, then shareholders who did not respond to or that had objected the offer may accept the offer within four days of the last day set for the acceptance of the
      offer. In the event that a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the
      purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the
      initial special tender offer.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Full Tender Offer</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Under the Companies Law, a person may not acquire shares in a public company if, after the acquisition, the acquirer will hold more than 90% of the shares or more than 90% of any class of shares of
      that company, unless a tender offer is made to purchase all of the shares or all of the shares of the particular class. The Companies Law also generally provides that as long as a shareholder in a public company holds more than 90% of the company&#8217;s
      shares or of a class of shares, that shareholder shall be precluded from purchasing any additional shares. In order for all of the shares that the purchaser offered to purchase be transferred to him by operation of law, one of the following needs to
      have occurred: (i) the shareholders who declined or do not respond to the tender offer hold less than 5% of the company&#8217;s outstanding share capital or of the relevant class of shares and the majority of offerees who do not have a personal interest in
      accepting the tender offer accepted the offer, or (ii) the shareholders who declined or do not respond to the tender offer hold less than 2% of the company&#8217;s outstanding share capital or of the relevant class of shares.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">A shareholder that had his or her shares so transferred, whether he or she accepted the tender offer or not, has the right, within six months from the date of acceptance of the tender offer, to
      petition the court to determine that the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, the purchaser may provide in its offer that shareholders who accept the tender offer will
      not be entitled to such rights.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">If the conditions set forth above are not met, the purchaser may not acquire additional shares of the company from shareholders who accepted the tender offer to the extent that following such
      acquisition, the purchaser would own more than 90% of the company&#8217;s issued and outstanding share capital. The above restrictions apply, in addition to the acquisition of shares, to the acquisition of voting power.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Forum for Adjudication of Disputes</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our Articles provide that unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for
      the resolution of any complaint asserting a claim, cause of action, claims, or causes of action arising under the United States Securities Act of 1933, as amended, including all claims and causes of action asserted against any defendant to such
      complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by the Company, its officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional or entity whose
      profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our Articles further provide that unless the Company consents in writing to the selection of an alternative forum, the competent courts in Tel Aviv, Israel shall be the exclusive forum for (i)&#160;any
      derivative action or proceeding brought on behalf of the Company; (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company&#8217;s shareholders; or
      (iii)&#160;any action asserting a claim arising pursuant to any provision of the Companies Law or the Securities Law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Any person or entity purchasing or otherwise acquiring&#160;or holding&#160;any interest in&#160;shares of the Company shall be deemed to have notice of and consented to the provisions set forth under the heading
      &#8220;Forum for Adjudication of Disputes&#8221;.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.11
<SEQUENCE>3
<FILENAME>exhibit_4-11.htm
<DESCRIPTION>EXHIBIT 4.11
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div class="BRPFPageHeader">
        <div style="text-align: justify; margin-left: 108pt; line-height: 1.25;"><br>
          <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 4.11</u><br>
          </div>
        </div>
        <div style="text-align: justify; margin-left: 108pt; line-height: 1.25;"><font style="background-color: rgb(255, 255, 255); font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br>
          </font></div>
        <div style="line-height: 1.25;">
          <table cellspacing="0" cellpadding="0" border="0" id="z1393464a65e54650bba8d33c50e7b3d7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 25%;">
                  <div>&#160;</div>
                </td>
                <td style="width: 50%;">
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">[**] = CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT COMPUGEN TREATS AS PRIVATE OR
                      CONFIDENTIAL.</font></div>
                </td>
                <td style="width: 25%;">
                  <div>&#160;</div>
                </td>
              </tr>

          </table>
        </div>
        <div style="text-align: right; line-height: 1.25; font-weight: bold;"> <br>
        </div>
        <div style="text-align: right; line-height: 1.25; font-weight: bold;">Confidential</div>
        <div style="text-align: right; line-height: 1.25; font-weight: bold;">Execution Copy</div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">LICENSE AGREEMENT</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">between</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><font style="font-variant: small-caps;">Compugen Ltd</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">and</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><font style="font-variant: small-caps;">Gilead Sciences, Inc</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">dated December 18, 2023</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%LCR%1%- % -%-->
      <div class="BRPFPageHeader">
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">TABLE OF CONTENTS</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: right; line-height: 1.25; font-weight: bold;">Page</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="3" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zacb6872d092545098c70cfb7b0afe541">

          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A1">1.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A1">DEFINITIONS</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">1</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A2">2.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A2">DEVELOPMENT PROGRAM</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">22</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2.1.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Development Plan; Protocol</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">22</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2.2.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">License to CGEN</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">22</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2.3.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Gilead-Provided PD-1/PD-L1</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">22</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2.4.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Performance Standards</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">22</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2.5.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Development Program Costs</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">22</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2.6.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Records; Updates</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">22</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2.7.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Data Ownership</div>
            </td>
            <td style="width: 8%; vertical-align: top; text-align: right;">23</td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2.8.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Reports and Data Package; Development Program Transfer</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">23</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2.9.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">COM503 Study Budget</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">25</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A3">3.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A3">LICENSE; EXCLUSIVITY</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">26</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">3.1.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">License to Gilead</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">26</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">3.2.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Sublicensees</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">26</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">3.3.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Subcontractors</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">26</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">3.4.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Retained Rights; No Implied License</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">26</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">3.5.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Technology Transfer</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">27</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">3.6.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Exclusivity</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">27</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A4">4.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A4">GOVERNANCE</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">28</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">4.1.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Joint Steering Committee</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">28</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">4.2.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Additional Subcommittees and Working Groups</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">30</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">4.3.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Alliance Managers</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">30</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A5">5.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A5">GILEAD DEVELOPMENT</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">31</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">5.1.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">IL-18 Molecules and IL-18 Products</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">31</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">5.2.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Performance Standards</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">31</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">5.3.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Records</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">31</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">5.4.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Development Reporting</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">31</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">5.5.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Data Ownership</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">31</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A6">6.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A6">REGULATORY</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">31</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">6.1.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">IL-18 Molecules and IL-18 Products</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">31</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">6.2.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Transfer of Regulatory Materials</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">32</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">6.3.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Conflict</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">33</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A7">7.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A7">COMMERCIALIZATION</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">33</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">7.1.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Responsibility; Diligence</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">33</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- i -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%LCR%1%- % -%-->
      <div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">TABLE OF CONTENTS</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">(continued)</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: right; line-height: 1.25; font-weight: bold;">Page</div>
      </div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="3" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A8">8.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A8">MANUFACTURE AND SUPPLY</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">34</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">8.1.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">COM503</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">34</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">8.2.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Observation by Gilead</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">35</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">8.3.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Manufacturing Technology Transfer</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">35</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">8.4.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Exercise of Rights under CGEN CMO Manufacturing Agreement</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">35</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A9">9.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A9">PAYMENTS</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">35</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">9.1.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Upfront Payment</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">35</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">9.2.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Research Milestone Payment</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">36</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">9.3.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Development Milestone Payments</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">36</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">9.4.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Regulatory Milestone Payments</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">37</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">9.5.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Commercial Milestone Payments</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">38</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">9.6.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Additional Milestone Payment Terms</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">39</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">9.7.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Royalties on Net Sales</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">39</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">9.8.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">CGEN Third Party Payments</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">41</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A10">10.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A10">PAYMENTS; REPORTS; RECORDS; AUDITS</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">41</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">10.1.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Reimbursable Costs</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">41</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">10.2.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Manufacturing Costs</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">42</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">10.3.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">[**]</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">42</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">10.4.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Royalty Payments</div>
            </td>
            <td style="width: 8%; vertical-align: top; text-align: right;">43</td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">10.5.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Distinguishing Financial Products</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">43</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">10.6.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Payment Exchange Rate</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">43</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">10.7.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Taxes</div>
            </td>
            <td style="width: 8%; vertical-align: top; text-align: right;">44</td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">10.8.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Records</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">44</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">10.9.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Audit Rights</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">45</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">10.10.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Confidentiality</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">45</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A11">11.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A11">CONFIDENTIALITY; PUBLICATION</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">45</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">11.1.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Nondisclosure Obligation</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">45</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">11.2.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Publication</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">48</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">11.3.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Publicity; Use of Names</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">48</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A12">12.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A12">COMPLIANCE</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">49</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">12.1.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">General</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">49</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">12.2.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Covenants, Representations and Warranties for Compliance with Laws</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">49</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">- ii -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">TABLE OF CONTENTS</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">(continued)</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: right; line-height: 1.25; font-weight: bold;">Page</div>
        <div style="text-align: right; line-height: 1.25; font-weight: bold;"> <br>
        </div>
      </div>
      <table cellspacing="0" cellpadding="3" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A13">13.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A13">REPRESENTATIONS AND WARRANTIES</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">52</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">13.1.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Mutual Representations and Warranties</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">52</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">13.2.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Representations and Warranties of CGEN</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">53</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">13.3.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Covenants</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">55</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">13.4.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">No Other Representations or Warranties</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">57</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A14">14.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A14">INDEMNIFICATION</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">57</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">14.1.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">By Gilead</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">57</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">14.2.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">By CGEN</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">57</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">14.3.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Indemnification Procedure</div>
            </td>
            <td style="width: 8%; vertical-align: top; text-align: right;">58</td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">14.4.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Settlement</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">58</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">14.5.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Insurance</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">58</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">14.6.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Limitation of Liability</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">59</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A15">15.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A15">INTELLECTUAL PROPERTY</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">59</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">15.1.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Ownership of Intellectual Property</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">59</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">15.2.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Patent Filing, Prosecution and Maintenance</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">59</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">15.3.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Patent Prosecution Cooperation</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">60</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">15.4.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Enforcement</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">61</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">15.5.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Defense</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">62</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">15.6.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Patent Listing</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">63</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">15.7.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Patent Term Extensions</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">63</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A16">16.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A16">DISPUTE RESOLUTION</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">63</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">16.1.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Exclusive Dispute Resolution Mechanism</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">63</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">16.2.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Resolution by Executive Officers</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">63</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">16.3.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Jurisdiction; Venue; Service of Process</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">63</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">16.4.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Governing Law</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">63</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">16.5.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Waiver of Jury Trial</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">64</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">16.6.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Patent Disputes</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">64</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">16.7.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Equitable Relief</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">64</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A17">17.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A17">TERM AND TERMINATION</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">64</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">17.1.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Term</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">64</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">17.2.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Termination for Material Breach</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">64</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">17.3.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Termination for Convenience</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">65</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">17.4.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Termination for Force Majeure</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">65</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">17.5.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Termination for Bankruptcy</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">65</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">- iii -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">TABLE OF CONTENTS</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">(continued)</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: right; line-height: 1.25; font-weight: bold;">Page</div>
        <div style="text-align: right; line-height: 1.25; font-weight: bold;"> <br>
        </div>
      </div>
      <table cellspacing="0" cellpadding="3" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">17.6.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Termination by Gilead for Safety Reasons</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">65</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">17.7.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">[**]</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">65</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">17.8.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Effects of Termination</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">66</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">17.9.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Surviving Provisions</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">67</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A18">18.</a></div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="#A18">MISCELLANEOUS</a></div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">67</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">18.1.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Force Majeure</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">67</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">18.2.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Section&#160;365(n) of the Bankruptcy Code</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">68</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">18.3.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Assignment; Change of Control</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">68</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">18.4.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Severability</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">69</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">18.5.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Notices</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">69</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">18.6.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Entire Agreement; Amendments</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">70</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">18.7.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Headings</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">70</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">18.8.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Independent Contractors</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">70</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">18.9.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">No Third Party Beneficiary Rights</div>
            </td>
            <td style="width: 8%; vertical-align: top; text-align: right;">71</td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">18.10.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Performance by Affiliates</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">71</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">18.11.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Waiver</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">71</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">18.12.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Cumulative Remedies</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">71</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">18.13.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Waiver of Rule of Construction</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">71</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">18.14.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Counterparts</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">71</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">18.15.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Further Assurances</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">71</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">18.16.</div>
            </td>
            <td style="width: 84%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Construction</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">71</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Schedules</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zb1197e94edcb4338acfdc13aaf9a1f09">

          <tr>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Schedule 1.36</div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CGEN Development and Manufacturing Agreements</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Schedule 1.51</font></div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">COM503</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Schedule 1.134</font></div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">IL-18 Patents</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Schedule 1.137</font></div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">IL-18 Trial Data Package</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Schedule 1.156</font></div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Knowledge Parties</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Schedule 1.242</font></div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Existing Upstream License Agreements</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Schedule 2.1</font></div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Development Plan</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Schedule 2.9</font></div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">COM503 Study Budget</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Schedule 11.3(a)</font></div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Press Release</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">- iv -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">LICENSE AGREEMENT</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">This License Agreement (&#8220;<font style="font-weight: bold;">Agreement</font>&#8221;), effective as of December 18, 2023 (the &#8220;<font style="font-weight: bold;">Effective Date</font>&#8221;), is entered into by and between Compugen
        Ltd., a limited liability company organized under the laws of Israel with a place of business at Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849, Israel (&#8220;<font style="font-weight: bold;">CGEN</font>&#8221;), and Gilead Sciences, Inc., a
        Delaware corporation with a place of business at 333 Lakeside Drive, Foster City, CA 94404 (&#8220;<font style="font-weight: bold;">Gilead</font>&#8221;). CGEN and Gilead may be referred to herein individually as a &#8220;<font style="font-weight: bold;">Party</font>&#8221;
        or collectively as the &#8220;<font style="font-weight: bold;">Parties</font>&#8221;.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">RECITALS</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-indent: 36pt;"><font style="font-weight: bold; font-variant: small-caps;">Whereas,</font> CGEN has expertise in, and platforms for, the discovery, development and
        commercialization of products for the treatment of patients with cancer;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-indent: 36pt;"><font style="font-weight: bold; font-variant: small-caps;">Whereas,</font> CGEN has discovered and is developing COM503, an antibody that binds to and
        moderates IL-18BP (as defined below);</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-indent: 36pt;"><font style="font-weight: bold; font-variant: small-caps;">Whereas,</font> Gilead has expertise in the research, development and commercialization of
        pharmaceutical products; and</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-indent: 36pt;"><font style="font-weight: bold; font-variant: small-caps;">Whereas,</font> CGEN desires to grant, and Gilead desires to receive, an exclusive license under
        the IL-18 IP for the development, commercialization and other exploitation of IL-18 Molecules and IL-18 Products, including COM503, in the Field in the Territory (with each capitalized term as defined below), pursuant to the terms and conditions
        set forth in this Agreement.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-indent: 36pt;"><font style="font-weight: bold; font-variant: small-caps;">Now, Therefore,</font> in consideration of the foregoing premises and the mutual covenants
        herein contained, the Parties hereby agree as follows:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">AGREEMENT</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A1"><!--Anchor--></a>1.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold;">DEFINITIONS</font>. Unless specifically set forth to the contrary herein, the following capitalized terms, whether used
        in the singular or plural, shall have the respective meanings set forth below:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.1.&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#8220;<font style="font-weight: bold;">Accounting Standards</font>&#8221; means, with respect to a Person, the International Financial Reporting Standards or GAAP, as
        applicable, as generally and consistently applied throughout such Person&#8217;s organization.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#8220;<font style="font-weight: bold;">Acquired Affiliate</font>&#8221; is defined in Section 3.6(b)(iii) (Acquisition of an Existing Competitive Program).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.3.&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#8220;<font style="font-weight: bold;">Acquirer</font>&#8221; means any Third Party that acquires a Party through a Change of Control transaction and, as of immediately
        before such Change of Control transaction, any of such Third Party&#8217;s Affiliates.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#8220;<font style="font-weight: bold;">Acquisition</font>&#8221; is defined in Section 3.6(b)(iii) (Acquisition of an Existing Competitive Program).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.5.&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#160; &#8220;<font style="font-weight: bold;">Acting Improperly</font>&#8221; is defined in Section 12.2(a)(i) (Anti-Corruption Laws).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.6.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#8220;<font style="font-weight: bold;">Action</font>&#8221; means any claim, action, suit, arbitration, inquiry, audit, proceeding or investigation by or before, or
        otherwise involving, any governmental authority.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.7.&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#160; &#8220;[**]&#8221; is defined in Section&#160;8.1(a)(i) (During Development Term).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.8.&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#8220;[**]&#8221; means [**]. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.9.&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#8220;[**]&#8221; means the [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.10.&#160;&#160;&#160; &#160;&#160; &#160;&#160; &#8220;[**]&#8221; means the [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.11.&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; &#8220;[**]&#8221; means the [**].&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Affiliate</font>&#8221; means with respect to any Party, any person or entity controlling, controlled by or under common control with
        such Party, for as long as such control exists. For purposes of this Section&#160;1.12 (&#8220;Affiliate&#8221;), &#8220;control&#8221; means (a) in the case of a corporate entity, direct or indirect ownership of at least fifty percent (50%) or more of the stock or shares
        having the right to vote for the election of directors of such corporate entity and (b) in the case of an entity that is not a corporate entity, the possession, directly or indirectly, of the power to direct, or cause the direction of, the
        management or policies of such entity, whether through the ownership of voting securities, by contract or otherwise.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Agreement</font>&#8221; is defined in Preamble.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Alliance Manager</font>&#8221; means the individual appointed by each Party from within their respective organization to coordinate and
        facilitate the communication, interaction and cooperation of the Parties pursuant to this Agreement. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Annual Net Sales</font>&#8221; means, on a Financial Product-by-Financial Product basis, total Net Sales in the Territory of such
        Financial Product in a particular Calendar Year, calculated in accordance with Accounting Standards.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Antibody</font>&#8221; means a molecule that comprises or contains: (a) one or more immunoglobulin variable domains; (b) fragments,
        variants, modifications or derivatives of such immunoglobulin variable domains irrespective of origin or source, including antigen binding portions including Fab, Fab&#8217;, F(ab&#8217;)2, Fv, dAb, and CDR fragments, single chain antibodies (scFv), chimeric
        antibodies, diabodies and polypeptides (including humanized versions thereof), in each case that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding; or (c) the nucleic acid consisting of a sequence
        of nucleotides encoding (or complementary to a nucleic acid encoding) any of the foregoing molecules in (a) or (b).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.17.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Anti-Corruption Laws</font>&#8221; means the U.S. Foreign Corrupt Practices Act, the U.S. Anti-Kickback Statute, and any other laws
        that prohibit the corrupt payment, offer, promise or authorization of the payment or transfer of anything of value (including gifts or entertainment), directly or indirectly, to any Government Official, commercial entity, or any other Person to
        obtain an improper business advantage, in each case, as amended.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.18.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Antitrust Laws</font>&#8221; means any Applicable Laws and Regulations that are designed to prohibit, restrict or regulate actions
        having the purpose or effect of monopolization, lessening of competition or restraint of trade, including the HSR Act.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.19.&#160; &#160; &#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Applicable Laws and Regulations</font>&#8221; means all international, national, federal, state, regional, provincial, municipal and
        local government laws, rules, treaties (including tax treaties), and regulations that apply to either Party in the conduct of any Development, Manufacturing or Commercialization activities or Regulatory Activities, in each case, under this
        Agreement, including GLP, cGMP, cGCP, GBPS, and the guidelines of the ICH, each as may be then in effect, as applicable and amended from time to time.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.20.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Approved Auditor</font>&#8221; means one of the internationally recognized accounting firms known as KPMG, Deloitte,
        PricewaterhouseCoopers or Ernst &amp; Young (i.e., the &#8220;Big 4&#8221; global accounting firms).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.21.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Assigned Regulatory Materials</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 6.2(a) (Regulatory Transfer).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.22.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Audited Party</font>&#8221; is defined in Section 10.9 (Audit Rights).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.23.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Background IP</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 15.1(a) (Background IP).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.24.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Bankruptcy Events</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 17.5 (Termination for Bankruptcy). </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.25.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Bankrupt Party</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 17.5 (Termination for Bankruptcy).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.26.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Biosimilar Product</font>&#8221; means, with respect to an IL-18 Product sold in a country, a product that: (a) is marketed by a Third
        Party that has not obtained the rights to such product as a Sublicensee or distributor of, or through any other contractual relationship with, Gilead or any of its Affiliates or Sublicensees; and (b) has been granted Regulatory Approval as a
        biosimilar or interchangeable biological product by the applicable Regulatory Authority with such IL-18 Product as the reference product, including any product authorized for sale in (i) the U.S. pursuant to an application under Section&#160;351(k) of
        the US Public Health Service Act (42&#160;U.S.C.&#160;&#167;&#160;262(k)), as may be amended, or any subsequent or superseding law, statute or regulation and (ii) in any other country or jurisdiction pursuant to the equivalent of such provision. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.27.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">BLA</font>&#8221; means a Biologics License Application filed with the FDA for marketing approval of an IL-18 Product, as more fully
        defined in the United States FDCA, 21 U.S.C. &#167; 301 et seq., as amended from time to time, or under Section 351 of the Public Health Service Act (&#8220;<font style="font-weight: bold;">PHS Act</font>&#8221;), which is codified at 42 U.S.C. &#167;262, or any
        successor applications or procedures, and all supplements and amendments that may be filed with respect to the foregoing, or similar filings with applicable Regulatory Authorities outside of the U.S., for approval to commercially market, import and
        sell an IL-18 Product. The term BLA shall exclude Pricing and Reimbursement Approvals.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.28.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Breaching Party</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 17.2(a) (Material Breach).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.29.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Business Day</font>&#8221; means a day on which banking institutions in Tel-Aviv, Israel and Foster City, California are open for
        business, excluding (a) any Saturday or Sunday, (b) December 26 through December 31 and (c) the seven (7) day period that begins on a Sunday and ends on a Saturday during which period July 4th occurs.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.30.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Calendar Quarter</font>&#8221; means the respective periods of three (3) consecutive calendar months ending on March 31, June 30,
        September 30 and December 31, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date,
        and the last Calendar Quarter shall end on the last day of the Term.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.31.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Calendar Year</font>&#8221; means the respective periods of twelve (12) months commencing on January 1 and ending on December 31, except
        that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term
        ends and end on the last day of the Term.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.32.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">CDR</font>&#8221; means, with respect to an Antibody, the complementarity-determining region of such Antibody as determined by the
        Kabat numbering scheme.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.33.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">cGCP</font>&#8221; means current Good Clinical Practices as set forth in the Applicable Laws and Regulations, including the FDCA and the
        PHS Act and regulations set forth at 21 C.F.R. Parts 50, 54, 56 and 312, the requirements set forth in Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 and Commission Directive 2005/28/EC of 8 April 2005, in each
        case, to the extent applicable to a Clinical Trial regarding any IL-18 Product, as such obligations are interpreted and enforced by the applicable Regulatory Authority, and as interpreted under prevailing industry standards, including standards of
        medical ethics, applicable guidance documents issued by the FDA and any other Regulatory Authority, including guidelines adopted by the ICH with respect to cGCP, and all equivalent legal requirements in other applicable jurisdictions, as the same
        may be amended from time to time.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.34.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">CGEN</font>&#8221; is defined in Preamble.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.35.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">CGEN CMO Manufacturing Agreement(s)</font>&#8221; means each agreement CGEN has entered into with any CMO under which CGEN has the
        right to be supplied with IL-18 Product, including the [**] Services Agreement.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.36.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">CGEN Development and Manufacturing Agreements</font>&#8221; means any contract or agreement, between CGEN (or any of its Affiliates, as
        applicable) and any Third Party that is in effect as of the Effective Date and under which CGEN and such Third Party are actively Developing or Manufacturing (as of the Effective Date) any IL-18 Molecule or IL-18 Product, including such agreements
        related solely to any IL-18 Molecule or IL-18 Product, including master services agreements for which all statements of work are related solely to IL-18 Molecules or IL-18 Products or agreements under which such IL-18 Molecule or IL-18 Product
        itself, or its Manufacturing process, was conceived of, reduced to practice, invented, made, generated or created (the &#8220;<font style="font-weight: bold;">IL-18-Only Development and Manufacturing Agreements</font>&#8221;). The IL-18-Only Development and
        Manufacturing Agreements that exist as of the Effective Date are listed in <font style="font-weight: bold;">Schedule 1.36(a)</font> (IL-18-Only Development and Manufacturing Agreements) attached hereto; <font style="font-style: italic;">provided</font>,
        that any failure of an agreement to be on <font style="font-weight: bold;">Schedule 1.36 </font>(CGEN Development and Manufacturing Agreements) either as of the Effective Date or during the Term shall not, in itself, indicate that such agreement
        is not a CGEN Development and Manufacturing Agreement hereunder.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.37.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">CGEN Foreground Know-How</font>&#8221; means all Foreground Know-How that are solely owned by CGEN.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.38.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">CGEN Foreground Patent</font>&#8221; means all Foreground Patents that are solely owned by CGEN.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.39.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">CGEN Indemnitee(s)</font>&#8221; is defined in Section 14.1 (By Gilead).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.40.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">CGEN Manufacturing Facilities</font>&#8221; means the facilities used by [**] under the [**] Agreement to Manufacture IL-18 Product.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.41.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">cGMP</font>&#8221; means current Good Manufacturing Practices as set forth in the Applicable Laws and Regulations, including the FDCA
        and the PHS Act, and in applicable regulations, including 21 C.F.R. Parts 210, 211, 600 and 610, as in effect at the time when any IL-18 Product is being manufactured for clinical development or commercial use, as such regulations are interpreted
        and enforced by the FDA, including as set forth in applicable guidance documents issued by the FDA, and in accordance with applicable, generally accepted industry standards, and the equivalent legal requirements in other applicable jurisdictions,
        all as the same may be amended from time to time. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.42.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Change of Control</font>&#8221; means, with respect to a Party, that: (a) any Third Party acquires directly or indirectly the
        beneficial ownership of any voting security of such Party, or if the percentage ownership of such Third Party in the voting securities of such Party is increased through stock redemption, cancellation or other recapitalization, and immediately
        after such acquisition or increase such Third Party is, directly or indirectly, the beneficial owner of voting securities representing more than fifty percent (50%) of the total voting power of all of the then outstanding voting securities of such
        Party; (b) a merger, consolidation, recapitalization, or reorganization of such Party is consummated unless such merger, consolidation, recapitalization, or reorganization would result in stockholders or equity holders of such Party immediately
        prior to such transaction owning more than fifty percent (50%) of the outstanding securities of the surviving entity (or its parent entity) immediately following such transaction; or (c) the sale or transfer to a Third Party of (i) all or
        substantially all of such Party&#8217;s assets taken as a whole or (ii) a majority of such Party&#8217;s assets which relate to this Agreement, is effected. Notwithstanding the foregoing, the following will not constitute a Change of Control: (i) a sale of
        capital stock to underwriters in an underwritten public offering of a Party&#8217;s capital stock solely for the purpose of financing, or (ii) the acquisition of securities of a Party by any Person or group of Persons that acquires such Party&#8217;s
        securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for such Party through the issuance of equity securities.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.43.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"> </sup>&#8220;<font style="font-weight: bold;">Clinical Study Report</font>&#8221; means, with respect to a Clinical Trial, a report containing the results of such
        Clinical Trial that is consistent in content and format with Applicable Laws and Regulations and with the guidelines of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
        on Structure and Content of Clinical Study Reports.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.44.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Clinical Subcommittee</font>&#8221; is defined in Section 4.2 (Additional Subcommittees and Working Groups).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.45.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Clinical Supply Agreement</font>&#8221; is defined in Section 8.1(a)(iv) (Clinical Supply Agreement).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.46.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Clinical Supply Batches</font>&#8221; is defined in Section&#160;8.1(a)(i) (During Development Term)</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.47.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Clinical Supply Term</font>&#8221; is defined in Section 8.1(a)(ii) (During the Clinical Supply Term).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.48.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Clinical Trial</font>&#8221; means an experiment that has been approved by a Regulatory Authority in which a drug is administered to
        human subjects and includes Phase 1 Clinical Trials, Phase 2 Clinical Trials, Phase 3 Clinical Trials, Pivotal Trials or Phase 4 Clinical Trials, as applicable.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.49.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">CMC</font>&#8221; means chemistry, manufacturing and controls.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.50.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">CMO</font>&#8221; means a Third Party contract manufacturer.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.51.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">COM503</font>&#8221; means the Antibody with the heavy chain and light chain protein sequences described in <font style="font-weight: bold;">Schedule 1.51</font> (COM503) and with the internal CGEN identifier COM503. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.52.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">COM503 Financial Product</font>&#8221; means the IL-18 Product that contains COM503 and is the subject of the COM503 Phase 1 Trial.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.53.&#160;&#160;&#160;&#160; &#160; &#160; &#8220;<font style="font-weight: bold;">COM503 Phase 1 Trial</font>&#8221; means the Phase 1 Clinical Trial of COM503 conducted under this Agreement, as further described in
        the Development Plan and in the COM503 Phase 1 Trial Protocol. The COM503 Phase 1 Trial includes the COM503 Phase 1a Trial and COM503 Phase 1b Trial. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.54.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">COM503 Phase 1 Trial</font>&#160;<font style="font-weight: bold;">Completion</font>&#8221;<font style="font-weight: bold;">&#160;</font>means
        [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.55.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">COM503 Phase 1 Trial Protocol</font>&#8221; is defined in Section 2.1 (Development Plan; Protocol). </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.56.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">COM503</font>&#160;<font style="font-weight: bold;">Phase 1a Trial</font>&#8221; means, in connection with the conduct of the COM503 Phase 1
        Trial, the activities to be undertaken to identify the maximum tolerated dose (MTD) or maximum administered dose (MAD) for COM503, independently and in combination with any Gilead-Provided PD-1/PD-L1 in accordance with the Development Plan.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.57.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">COM503</font>&#160;<font style="font-weight: bold;">Phase 1b Trial</font>&#8221; means, in connection with the conduct of the COM503 Phase 1
        Trial, the investigation of COM503 at a defined dose and schedule in accordance with the Development Plan.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.58.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">COM503 Study Budget</font>&#8221; is defined in Section 2.9 (COM503 Study Budget).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.59.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">COM503 Transfer Price</font>&#8221; is a fixed batch cost that represents [**] of the Fully Burdened Manufacturing Costs incurred by
        CGEN to Manufacture a batch of COM503 for clinical supply purposes (including the cost to manufacture COM503 drug product).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.60.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Combination Product</font>&#8221; means (a) any single product comprising both (i) a Financial Product and (ii) one or more other
        therapies or pharmaceutically active compounds or substances that is not a Financial Product (but excluding, for clarity, formulation and drug delivery technologies); (b) any Financial Product sold together with one or more other therapies or
        products that are not Financial Products for a single invoice price; or (c) any Financial Product sold as part of a bundle with one or more other therapies, products or services that are not Financial Products, where the sale of the Financial
        Product is only available from the seller with the purchase of such other therapies, products or services, for a single invoice price, to the extent not described in clause (a) or (b). The Financial Product portion of any Combination Product, as
        applicable, shall be the &#8220;<font style="font-weight: bold;">Financial Component</font>&#8221; and the other portion of such Combination Product shall be the &#8220;<font style="font-weight: bold;">Other Component</font>&#8221;, and each Combination Product shall be a
        Financial Product hereunder. For clarity, the co-administration of separate products comprising a Financial Product containing no Other Component, on the one hand, with another therapy or pharmaceutically active compound or substance on the other
        hand shall either be (i) a Combination Product, if sold together as reflected in clause (b) or (c) or (ii) two separate products, one a Financial Product and the other, a product that does not generate Net Sales under this Agreement. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.61.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Commercialize</font>&#8221; means activities taken before or after obtaining Regulatory Approval relating specifically to the
        pre-launch, launch, promotion, marketing, sales force recruitment and training, sale and distribution of a pharmaceutical or biologic product and post-launch activities, including: (a)&#160;distribution for commercial sale; (b) coverage, reimbursement,
        pricing, and market access activities; (c)&#160;strategic marketing, sales force, detailing, advertising and promotion, and market and product support; (d) medical education and medical science liaison strategy and any Phase&#160;4 Clinical Trials unless
        required as a condition for Regulatory Approval, to the extent permitted by this Agreement; (e) all customer support, invoicing and sales activities; and (f) all post-approval regulatory activities, including those necessary to maintain Regulatory
        Approvals. Cognates of the word &#8220;Commercialize&#8221; shall have correlative meanings. For clarity, &#8220;Commercialization&#8221; does not include Development or Manufacturing activities.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.62.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Commercially Reasonable Efforts</font>&#8221; means, with respect to the efforts to be expended by a Party with respect to any
        objective or activity under this Agreement, that measure of efforts and resources that is consistent with the efforts and resources used by pharmaceutical or biopharmaceutical companies, as applicable, of comparable size and resources to such Party
        for a similar biological or pharmaceutical product owned by it or to which it has exclusive rights, which product is at a similar stage in its development or product life and is of similar market potential taking into account all relevant factors,
        including [**]. Commercially Reasonable Efforts will be determined on a country-by-country and Indication-by-Indication basis for the applicable IL-18 Molecule or IL-18 Product, and it is anticipated that the level of effort will change over time,
        reflecting changes in the status of such IL-18 Molecule or IL-18 Product (as applicable) and the market or country involved.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.63.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Commercial Milestone Event</font>&#8221; is defined in Section 9.5 (Commercial Milestone Payments).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.64.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Commercial Milestone Payment</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 9.5 (Commercial Milestone
        Payments).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.65.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;[**]&#8221; means, with respect to an IL-18 Product [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.66.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;[**]&#8221; means a [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.67.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Confidential Information</font>&#8221; means, with respect to a Party, all information (including chemical or biological materials,
        chemical structures correspondence, customer lists, data, formulae, improvements, Inventions, Know-How, processes, Regulatory Approvals, Regulatory Submissions and other regulatory filings, reports, strategies, techniques or other information) that
        is disclosed by or on behalf of such Party or any of its Affiliates to the other Party or any of its Affiliates pursuant to this Agreement or the Existing CDA, regardless of whether any of the foregoing are marked &#8220;confidential&#8221; or &#8220;proprietary&#8221; or
        communicated to the other Party by or on behalf of the Disclosing Party in oral, written, visual, graphic or electronic form. Without limiting the generality of the foregoing, and subject to the terms of Article 11 (Confidentiality; Publication):
        (a) the existence and terms of this Agreement are the Confidential Information of both Parties (and both Parties will be deemed to be the Disclosing Party and the Receiving Party with respect thereto) and (b) the existence and terms of each
        Development Report provided by Gilead to CGEN pursuant to Section 5.4 (Development Reporting) will be the Confidential Information of Gilead (and Gilead will be considered the Disclosing Party with respect thereto). </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.68.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Control</font>&#8221; means with respect to (a) a product or component (including a molecule) thereof, the legal authority or right to
        grant a license, sublicense, access, or right to use (as applicable) such product or component to the other Party under Patents that Cover such product or component or proprietary Know-How that is incorporated in or embodies such product or
        component on the terms set forth herein or (b) any Patent, Know-How or other Intellectual Property Right, the ability of a Party or its Affiliates, as applicable (whether through ownership or license, other than pursuant to this Agreement) to grant
        to the other Party or its Affiliates access to, or a license or sublicense of, such Patent, Know-How or other Intellectual Property Right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party;
        <font style="font-style: italic;">provided</font>, that, in each case, a Party or any of its Affiliates shall be deemed not to &#8220;Control&#8221; any product, component, Patent, Know-How or other Intellectual Property Right if such product, component,
        Patent, Know-How or other Intellectual Property Right is owned or in-licensed by an Acquirer of a Party that becomes an Affiliate of such Party (or that merges or consolidates with such Party) on or after the Effective Date as a result of a Change
        of Control of such Party, except to the extent, and only to the extent that, such product, component, Patent, Know-How or other Intellectual Property Right is (i) actually used by such Party or its Affiliates, or the Acquirer, to Develop,
        Manufacture, Commercialize or otherwise Exploit the IL-18 Molecules or IL-18 Products following the consummation of such Change of Control, (ii) made, conceived or reduced to practice by the Acquirer or its Affiliates through the use of, or
        reference to, any Patent, Know-How or other Intellectual Property Right of such acquired Party or the other Party, or (iii) was Controlled by such acquired Party or its Affiliates prior to the applicable Change of Control. Cognates of the word
        &#8220;Control&#8221; shall have correlative meanings. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.69.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Cover</font>&#8221; means, with reference to a Patent and a product or method, that the manufacture, use, offer for sale, sale or
        importation of such product, or practice of such method, would infringe a Valid Claim of such Patent in the country in which such activity occurs without a license thereto (or ownership thereof). Cognates of &#8220;Cover&#8221; shall have correlative meanings.
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.70.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">CPI</font>&#8221; means the Consumer Price Index-Urban Wage Earners and Clerical Workers, U.S. City Average, All Items, 1982-1984=100,
        published by the U.S. Department of Labor, Bureau of Labor Statistics (or its successor equivalent index) in the U.S. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.71.&#160;&#160;&#160; &#160; &#160;&#160; &#8220;<font style="font-weight: bold;">Data Protection Laws</font>&#8221; means all Applicable Laws and Regulations relating to privacy, information security, cybersecurity,
        or data protection, including (a) the General Data Protection Regulation ((EU) 2016/679) and any national implementing law relating to the Processing of personal data or the privacy or security of electronic communications, including the Privacy
        and Electronic Communications Directive (2002/58/EC) and the Privacy and Electronic Communications (EC Directive) Regulations 2003 (SI 2003/2426), (b) the Health Insurance Portability and Accountability Act of 1996, as amended by the Health
        Information Technology for Economic and Clinical Health Act adopted as part of the American Recovery and Reinvestment Act of 2009, and any regulations promulgated thereunder, and (c) FDA&#8217;s regulatory guidance pertaining to informed consent or
        cybersecurity requirements.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.72.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Deadlock</font>&#8221; is defined in Section&#160;4.1(d) (Decision-Making).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.73.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Deficiency Notice</font>&#8221; is defined in Section 2.8(b) (IL-18 Trial Data Package).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.74.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Develop</font>&#8221; means research, discovery, and preclinical and clinical drug or biological development activities, including
        toxicology, statistical analysis, preclinical studies and Clinical Trials (but excluding Phase 4 Clinical Trials unless required as a condition for Regulatory Approval) and pre-approval regulatory activities, including those in support of other
        Development activities. Cognates of the word &#8220;Develop&#8221; shall have correlative meanings. For clarity, &#8220;Development&#8221; does not include Manufacturing or Commercialization activities.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.75.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Development Milestone Event</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 9.3 (Development Milestone
        Payments).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.76.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Development Milestone Payment</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 9.3 (Development Milestone
        Payments).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.77.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Development Plan</font>&#8221; is defined in Section 2.1 (Development Plan; Protocol).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.78.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Development Program</font>&#8221; is defined in Section 2.1 (Development Plan; Protocol).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.79.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Development</font>&#160;<font style="font-weight: bold;">Program Transfer</font>&#8221; is defined in Section 2.8(d) (Development Program
        Transfer Plan).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.80.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Development</font>&#160;<font style="font-weight: bold;">Program Transfer Date</font>&#8221; means the earlier of (a) delivery of the Gilead
        Transfer Notice, and (b) the Early Development Transfer Date.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.81.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Development</font>&#160;<font style="font-weight: bold;">Program Transfer Notice</font>&#8221; is defined in Section 2.8(c)(i) (Early
        Transfer).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.82.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Development Program</font>&#160;<font style="font-weight: bold;">Transfer Plan</font>&#8221; is defined in Section 2.8(d) (Development
        Program Transfer Plan).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.83.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Development Report</font>&#8221; is defined in Section 5.4 (Development Reporting). </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.84.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Development Term</font>&#8221; means the period of time beginning on the Effective Date and ending on the first to occur of (a) the
        Development Program Transfer Date, or (b) the No-Transfer Date.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.85.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Directed To</font>&#8221; means, with respect to a particular compound, molecule or product and a biological target, that [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.86.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Disclosing Party</font>&#8221;<font style="font-weight: bold;">&#160;</font>is defined in<font style="font-weight: bold;">&#160;</font>Section
        11.1(a) (Definition and Restrictions).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.87.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Dispute</font>&#8221; means any dispute, claim or controversy arising from or related to this Agreement or to the interpretation,
        application, breach, termination or validity of this Agreement, including any claim of inducement of this Agreement by fraud or otherwise.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.88.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Early Development Transfer Date</font>&#8221; is defined in Section 2.8(c)(i) (Early Transfer).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.89.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Effective Date</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Preamble.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.90.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Enforcement Effort</font>&#8221; is defined in Section 15.4(b) (Enforcement of Patent Rights). </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.91.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Executive Officer</font>&#8221; means, with respect to either Party, a senior executive designated by such Party for purposes of
        resolving Deadlocks at the JSC pursuant to Section&#160;4.1(d) (Decision-Making) and Disputes pursuant to Section 16.2 (Resolution by Executive Officers).<font style="font-weight: bold; font-style: italic;">&#160;</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.92.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Existing CDA</font>&#8221; means that certain Mutual Confidential Disclosure Agreement between the Parties, effective as of [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.93.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Existing Competitive Program</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 3.6(b)(i) (As of Closing of
        CGEN Change of Control).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.94.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Existing Upstream License Agreement</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 1.242 (&#8220;<font style="font-weight: bold;">Upstream License Agreement</font>&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.95.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Exploit</font>&#8221; means to research, Develop, use, have used, sell, have sold, offer for sale, make, have made, Manufacture,
        Commercialize, distribute, import or export. Cognates of the word &#8220;Exploit&#8221; shall have correlative meanings.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.96.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Export Control Laws</font>&#8221; is defined in Section 12.2(d) (Export Control Laws).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.97.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;[**]&#8221; is defined in Section 15.4(d)(ii).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.98.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">FDA</font>&#8221; means the United States Food and Drug Administration, or any successor agency thereto.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.99.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">FDCA</font>&#8221; means the Federal Food, Drug and Cosmetic Act, as amended.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.100.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Field</font>&#8221; means therapeutic or prophylactic uses, including treatment, palliation, mitigation, cure, control or prevention of
        a human disease, or medical or aesthetic conditions in humans, and companion diagnostic use in conjunction therewith.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.101.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Financial Component</font>&#8221; is defined in Section 1.60 (&#8220;Combination Product&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.102.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Financial Patent</font>&#8221; means, on a country-by-country basis, any IL-18 Patent in such country that Covers the composition of
        matter or method of use of any IL-18 Molecule or IL-18 Product. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.103.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Financial Product</font>&#8221; means any IL-18 Product that (a) contains or comprises COM503; (b) contains or comprises an IL-18
        Molecule (other than COM503) (i) that [**], or (ii)&#160;that contains [**] (as defined in <font style="font-weight: bold;">Schedule&#160;1.51</font>) and [**] (as defined in <font style="font-weight: bold;">Schedule&#160;1.51</font>) as [**] (as defined in <font style="font-weight: bold;">Schedule 1.51</font>) in COM503; or (c)&#160;is Covered by a Financial Patent.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.104.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;[**]&#8221; means the [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.105.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">First Commercial Sale</font>&#8221; means, with respect to any IL-18 Product, the first sale of such IL-18 Product by Gilead or any
        Related Parties to a Third Party for end use or consumption of such IL-18 Product in a country after Regulatory Approval has been granted by the Regulatory Authority for such IL-18 Product in such country. First Commercial Sale excludes transfers
        of IL-18 Product to Third Parties as <font style="font-style: italic;">bona fide</font> samples, as donations, for the performance of Clinical Trials or for similar purposes in accordance with Applicable Laws and Regulations pertaining to any
        expanded access program, any compassionate sales or use program (including named patient program or single patient program) or any indigent program.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.106.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;[**]&#8221; is defined in Section&#160;9.6(a).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.107.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Force Majeure</font>&#8221; is defined in Section 18.1 (Force Majeure).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.108.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Foreground IP</font>&#8221; means any Inventions made, created, conceived or reduced to practice in the performance of a Party&#8217;s
        obligations or exercise of its rights under this Agreement and all Intellectual Property Rights therein, including Patents (such Patents, &#8220;<font style="font-weight: bold;">Foreground Patents</font>&#8221;) and Know-How (such Know-How, &#8220;<font style="font-weight: bold;">Foreground Know-How</font>&#8221;). </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.109.&#160;&#160;&#160;&#160;&#160; &#160; &#8220;<font style="font-weight: bold;">Foreground Know-How</font>&#8221; is defined in Section 1.108 (&#8220;Foreground IP&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.110.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Foreground Patent</font>&#8221; is defined in Section 1.108 (&#8220;Foreground IP&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.111.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">FTE</font>&#8221; means [**] hours of work devoted to or in direct support of specified Development or Manufacturing activities,
        conducted by one or more qualified employees or full-time contractors of a Party or its Affiliate. For clarity, any individual contributing less than [**] hours per Calendar Year (or equivalent pro-rata portion thereof for the period beginning on
        the Effective Date and ending on the last day of the first Calendar Year) shall be calculated as a fraction of an FTE on a pro-rata basis. Overtime and work on weekends, holidays and the like will not be counted with any multiplier (for example,
        time-and-a-half or double time) toward the number of hours that are used to calculate the FTE contribution. For the avoidance of doubt, no individual will count as more than one FTE for any year.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.112.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">FTE Cost</font>&#8221; means, with respect to any period, activity and a Party or its Affiliate, the FTE Rate multiplied by the number
        of FTEs expended by such Party or its Affiliate in the conduct of such activity during such period; <font style="font-style: italic;">provided</font>, that the other Party shall not be charged more than once for any FTE Cost if such FTE Cost is
        already included as a component of other expenses payable under this Agreement.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">10</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.113.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">FTE Rate</font>&#8221; means a rate of [**] per FTE per Calendar Year, pro-rated for the period beginning on the Effective Date and
        ending on the last day of the first Calendar Year. Beginning on January 1, 2023, and on January 1 of each subsequent Calendar Year during the Term, the FTE Rate is subject to annual adjustment by the percentage increase in the applicable CPI
        comparing the levels of the applicable CPI as of December 31 of the most recently completed Calendar Years. The FTE Rate includes all wages and salaries, employee benefits, bonus, travel and entertainment, and other direct expenses expended in
        connection with an FTE&#8217;s performance of activities under this Agreement and excludes indirect allocations, including all general and administrative expenses, human resources, finance, occupancy and depreciation expended in connection with such
        FTE&#8217;s performance of activities under this Agreement. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.114.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Fully Burdened Manufacturing Cost</font>&#8221; means, with respect to COM503, whether as active pharmaceutical ingredient or finished
        form, supplied by CGEN to Gilead pursuant to Section 8.1 (COM503): [**] of: (a) if Manufactured by a Permitted Subcontractors, the Out-of-Pocket Costs paid by CGEN or its Affiliate to such Permitted Subcontractors in connection with the supply of
        COM503, on a pass-through basis, without mark-up; or (b) if Manufactured by (and not on behalf of) CGEN or its Affiliates, means: (i) the direct cost of raw materials (including reagents and associated warehousing costs), packaging and labeling
        materials (including vials), labor (as measured by FTE Costs and Out-of-Pocket Costs for consultants, contractors and other personnel performing Manufacturing or supply activities), (ii) the direct cost of any quality assurance and control
        activities (including required stability monitoring) for COM503, (iii) operating costs of equipment and facilities and (iv) shipping costs (including all duties and import fees, as applicable), in each case (i) through (iv), as reasonably incurred
        by CGEN in connection with and reasonably allocated to the Manufacture of COM503. In no case shall Fully Burdened Manufacturing Costs include any amounts incurred due to the gross negligence or willful misconduct of CGEN, its Affiliates or any
        Third Party. All components of Fully Burdened Manufacturing Costs shall be allocated on a basis consistent with GAAP and consistent with the cost accounting policy applied by CGEN to other similar products that it produces. For clarity, Fully
        Burdened Manufacturing Costs will not include the cost of the [**] and [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.115.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">GAAP</font>&#8221; means U.S. generally accepted accounting principles.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.116.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">GBPS</font>&#8221; means the General Biological Products Standards as set forth in 21 C.F.R. Part 610, to the extent applicable.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.117.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Gilead</font>&#8221; is defined in Preamble.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.118.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Gilead Indemnitee(s)</font>&#8221; is defined in Section 14.2 (By CGEN).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.119.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Gilead PD-1/PD-L1 Foreground IP</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 15.1(b)(i) (Gilead
        PD-1/PD-L1 Foreground IP).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.120.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Gilead-Provided PD-1/PD-L1</font>&#8221; means any Antibody that is Directed To PD-1/PD-L1 [**] to be provided by Gilead under Section
        2.3 (Gilead-Provided PD-1/PD-L1) in accordance with the COM503 Phase 1 Trial Protocol.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.121.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Gilead Transfer Notice</font>&#8221; is defined in Section 2.8(c)(ii) (Gilead Transfer).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.122.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">GLP</font>&#8221; or &#8220;<font style="font-weight: bold;">Good Laboratory Practices</font>&#8221; means the Good Laboratory Practices, set forth
        in the Applicable Laws and Regulations that govern the conduct of non-clinical laboratory studies, including those set forth in 21 C.F.R. Part 58 and the equivalent legal requirements in other applicable jurisdictions, as the same may be amended
        from time to time.<font style="font-style: italic;">&#160;</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">11</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.123.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Government Official</font>&#8221; means (a) any official, officer, employee, or representative of, or any individual acting in an
        official capacity for or on behalf of, any regional, federal, state, provincial, county, or municipal government or government department, agency, or other division, or any other Governmental Entity; (b) any officer, employee, or representative of
        any enterprise that is owned or controlled by a government; (c) any officer, employee, or representative of any Governmental Entity; (d) any political party or party official or candidate for political office; or (e) any person acting in an
        official capacity for any government or Governmental Entity, or other government entity, enterprise, or organization identified above.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.124.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Governmental Entity</font>&#8221; means any: (a) national, federal, state, county, local, municipal, foreign, or other government; (b)
        governmental or quasigovernmental authority of any nature (including any agency, board, body, branch, bureau, commission, council, department, entity, governmental division, instrumentality, office, officer, official, organization, representative,
        subdivision, unit, or political subdivision of any government, entity, or organization described in the foregoing clauses (a) or (b), and any court or other tribunal); (c) public international or multinational governmental organization or body; (d)
        entity or body exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military, or taxing authority or power of any nature (including any arbiter) or administrative functions of or pertaining
        to government; (e) any company, business, enterprise, or other entity owned, in whole or in part, or controlled by any government, entity, organization, or other Person described in the foregoing clauses (a), (b), (c), or (d) of this definition; or
        (f) any political party.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.125.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">HSR Act</font>&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (15&#160;U.S.C. &#167;&#160;18a).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.126.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">ICH</font>&#8221; means the International Conference on Harmonisation.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.127.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">IL-18-Only Development and Manufacturing Agreements</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 1.36
        (&#8220;CGEN Development and Manufacturing Agreements&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.128.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">IL-18</font>&#8221; means the protein encoded by the human IL-18 gene, identified by the following UniProt number: Q14116. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.129.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">IL-18BP</font>&#8221; means the protein encoded by the human IL-18BP gene, identified by the following UniProt number: O95998.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.130.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">IL-18 IP</font>&#8221; means the IL-18 Patents and the IL-18 Know-How.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.131.&#160;&#160;&#160;&#160;&#160; &#160; &#8220;<font style="font-weight: bold;">IL-18 Know-How</font>&#8221; means any Know-How (excluding any Jointly Owned Foreground Know-How) that is Controlled by CGEN or any of
        its Affiliates as of the Effective Date or at any time during the Term that is necessary or reasonably useful to Exploit IL-18 Molecules or IL-18 Products in the Field in the Territory (including all CGEN Foreground Know-How). </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.132.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">IL-18 License</font>&#8221; is defined in Section 3.1 (License to Gilead). </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.133.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">IL-18 Molecule</font>&#8221; means (a) any Antibodies or Antibody-based molecules that are: (i) owned or Controlled by CGEN or any of
        its Affiliates as of the Effective Date, or during the Term, and (ii)&#160;Directed To IL-18BP, including COM503 [**], and (b) any improvements or modifications to the foregoing (a) [**].&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">12</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.134.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">IL-18 Patents</font>&#8221; means any Patents (excluding any Jointly Owned Foreground Patents) that are Controlled by CGEN or any of its
        Affiliates as of the Effective Date or at any time during the Term that are necessary or reasonably useful to Exploit IL-18 Molecules or IL-18 Products in the Field in the Territory (including all CGEN Foreground Patents). The IL-18 Patents
        Controlled by CGEN or any of its Affiliates as of the Effective Date are listed in <font style="font-weight: bold;">Schedule 1.134</font> (IL-18 Patents) attached hereto; <font style="font-style: italic;">provided</font>, that any failure of a
        Patent to be listed on <font style="font-weight: bold;">Schedule</font>&#160;<font style="font-weight: bold;">1.134</font> (IL-18 Patents) either as of the Effective Date or during the Term shall not, in itself, indicate that such Patent is not an
        IL-18 Patent hereunder. CGEN will use reasonable efforts to update <font style="font-weight: bold;">Schedule 1.134</font> (IL-18 Patents) [**] during the Term, and to take reasonable steps to ensure the accuracy thereof. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.135.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">IL-18 Product</font>&#8221; means any product, in any and all forms, formulations, dosages, and delivery modes, that comprises, contains
        or incorporates an IL-18 Molecule, alone or in combination with one (1) or more other therapeutically active ingredients.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.136.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">IL-18R</font>&#8221; means the protein encoded by the human IL-18R gene, identified by the following UniProt protein accession number:
        Q13478.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.137.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">IL-18 Trial Data Package</font>&#8221; means a written report containing all of the information described on <font style="font-weight: bold;">Schedule 1.137 </font>(IL-18 Trial Data Package).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.138.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">IND</font>&#8221; means an Investigational New Drug application, or similar application or submission for approval to conduct human
        clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.139.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">IND Clearance</font>&#8221; means, with respect to an IND, the earlier of: (a) receipt by a Party, its Affiliate or a Sublicensee of
        written confirmation from a Regulatory Authority or other applicable Person that Clinical Trials may proceed under such IND and (b) expiration of the applicable waiting period under Applicable Laws and Regulations after which Clinical Trials may
        proceed under such IND.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.140.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Indemnified Party</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 14.3 (Indemnification Procedure).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.141.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Indemnifying Party</font>&#8221; is defined in Section 14.3 (Indemnification Procedure).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.142.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Indication</font>&#8221; means [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.143.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">&#8220;Infringement&#8221; </font>is defined in<font style="font-weight: bold;">&#160;</font>Section 15.4(a) (Notice).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.144.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"> </sup>&#8220;<font style="font-weight: bold;">Initiation</font>&#8221; means, with respect to a Clinical Trial of an IL-18 Product, [**] in such Clinical Trial.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.145.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Intellectual Property Rights</font>&#8221; means the following subsisting throughout the world: (a) Patents; (b) copyrights, designs,
        data and database rights and registrations and applications for registration thereof; (c) Inventions, invention disclosures, statutory invention registrations, whether patentable or nonpatentable, whether copyrightable or noncopyrightable and
        whether or not reduced to practice; (d) Know-How; and (e) other proprietary rights relating to any of the foregoing (including remedies against infringement thereof and rights of protection of interest therein under Applicable Laws and Regulations
        of all jurisdictions).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.146.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Invention</font>&#8221; means any process, invention, method, composition of matter, article of manufacture, discovery, or finding that
        is conceived or reduced to practice.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.147.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Involved Party</font>&#8221; is defined in Section 18.2 (Section 365(n) of the Bankruptcy Code).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">13</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.148.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Jointly Owned Foreground IP</font>&#8221;<font style="font-weight: bold;">&#160;</font>is defined in Section 15.1(b)(ii) (Other Foreground
        IP).<font style="font-weight: bold;">&#160;</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.149.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Jointly Owned Foreground Know-How</font>&#8221; means any Know-How in the Jointly Owned Foreground IP. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.150.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Jointly Owned Foreground Patent</font>&#8221; means any Patent in the Jointly Owned Foreground IP. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.151.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Joint Steering Committee</font> or <font style="font-weight: bold;">JSC</font>&#8221; is defined in Section 4.1(a) (Membership).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.152.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">JSC Co-Chairperson</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 4.1(a) (Membership).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.153.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;[**]&#8221; means [**], having a place of business at [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.154.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;[**] <font style="font-weight: bold;">Services Agreement</font>&#8221; means the Master Services Agreement, by and between CGEN and [**], dated [**], as amended from
        time to time (subject to Section 13.3(f)).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.155.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Know-How</font>&#8221; means any proprietary scientific or technical information, results and data of any type whatsoever, in any
        tangible or intangible form whatsoever, including databases, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data (including pharmacological, medicinal chemistry, biological,
        chemical, biochemical, toxicological and clinical test data), analytical and quality control data, stability data, studies and procedures, and manufacturing process and development information, results and data.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.156.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Knowledge</font>&#8221; means, with respect to a Party, the actual knowledge of those Persons listed for such Party on <font style="font-weight: bold;">Schedule 1.156</font> (Knowledge Parties). </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.157.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Losses</font>&#8221; is defined in Section 14.1 (By Gilead).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.158.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">MAA</font>&#8221; means a marketing authorization application such as an NDA, BLA or other similar application seeking marketing approval
        or licensure of a drug or biologic, in each case, filed with the applicable Regulatory Authority in a country or other regulatory jurisdiction, which application is required to be approved to commercially market or sell such product in such country
        or jurisdiction (and any amendments thereto).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.159.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Major European Country</font>&#8221; means [**] and [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.160.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Major Market Country</font>&#8221; means [**], or any Major European Country.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.161.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Manufacture</font>&#8221; means all operations involved in the manufacturing (including process development activities, formulation
        activities, quality assurance and quality control testing (including test method development and in-process, release and stability testing, if applicable)), fill-finish, storage, releasing, packaging and importation to supply molecules and products
        for Development and Commercialization. Cognates of the word &#8220;Manufacture&#8221; shall have correlative meanings. For clarity, &#8220;<font style="font-weight: bold;">Manufacturing</font>&#8221; includes Packaging and Labeling and does not include Development or
        Commercialization activities.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.162.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Manufacturing Process</font>&#8221; means the process for the Manufacture of the IL-18 Molecules or the IL-18 Products at the time of
        the Manufacturing Technology Transfer, including any associated Know-How owned or Controlled by CGEN that is necessary or reasonably useful for such Manufacturing, as more fully described in Section 8.3 (Manufacturing Technology Transfer) and as
        further developed under this Agreement. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">14</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.163.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Manufacturing Technology Transfer</font>&#8221; is defined in Section 8.3 (Manufacturing Technology Transfer).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.164.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Manufacturing Transition Plan</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 8.3 (Manufacturing Technology
        Transfer).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.165.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Milestone Event</font>&#8221; means a Research Milestone Event, Development Milestone Event, Regulatory Milestone Event, or Commercial
        Milestone Event. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.166.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Milestone Payments</font>&#8221; means the Research Milestone Payments, Development Milestone Payments, Regulatory Milestone Payments
        and the Commercial Milestone Payments. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.167.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">NDA</font>&#8221; means a New Drug Application filed with the FDA for marketing approval of an IL-18 Product or any successor
        applications or procedures, and all supplements and amendments that may be filed with respect to the foregoing, or similar filings with applicable Regulatory Authorities outside of the U.S., for approval to commercially market, import and sell an
        IL-18 Product. The term NDA shall exclude Pricing and Reimbursement Approvals.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.168.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;[**]&#8221; means [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.169.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Net Sales</font>&#8221; means, with respect to each Financial Product, the gross amount invoiced by Gilead or its Related Parties for the
        sale or other disposition of a Financial Product in an arm&#8217;s length transaction to a Third Party (other than a Related Party) after deducting, if not previously deducted from the amount invoiced, the following: </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">[**] with respect to [**];</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">[**], including [**];</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">[**], and any other [**] (including
          through [**]);</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">[**], including [**], including [**];</font></div>
      <div style="line-height: 1.25; text-indent: 18pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">[**] related to the [**];</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">[**] (including [**]) [**] (other than
          [**]); and</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">[**] that are [**]; <font style="font-style: italic;">provided</font>, that [**].</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In no event will any particular amount identified above be deducted more than once in calculating Net Sales.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Such amounts shall be determined from the books and records of Gilead or its Related Party, maintained in accordance with such Person&#8217;s applicable Accounting Standards. Gilead
        further agrees, in determining such amounts, it shall use Gilead&#8217;s then-current standard procedures and methodology, including Gilead&#8217;s then-current standard exchange rate methodology for the translation of foreign currency sales into US Dollars
        or, in the case of Sublicensees, such similar methodology, consistently applied. Without limiting the generality of the foregoing, [**] for [**] shall be excluded from Net Sales, as will [**], unless [**]; <font style="font-style: italic;">provided</font>,
        that any [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">15</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">[**]</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If Gilead or any of its Related Parties sells a Financial Product as a Financial Component of a Combination Product in a country in the Territory in any Calendar Quarter, then
        Net Sales shall be calculated by [**], (i) where [**] and (ii) [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the event that, on a country-by-country basis, no separate sales of the Financial Component or any Other Component(s) included in a Combination Product are made by Gilead or
        its Related Parties during a Calendar Quarter in which such Combination Product is sold, the average Net Sales per unit sold shall be determined [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Notwithstanding anything to the contrary in this Agreement, Net Sales will exclude amounts invoiced for Financial Products by any [**] pursuant to a [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.170.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">New</font>&#160;<font style="font-weight: bold;">Competitive Program</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section

        3.6(b)(ii) (After Closing of CGEN Change of Control).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.171.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Non-Bankrupt Party</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 17.5 (Termination for Bankruptcy).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.172.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Non-Breaching Party</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 17.2(a) (Material Breach).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.173.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Noninvolved Party</font>&#8221; is defined in Section 18.2 (Section 365(n) of the Bankruptcy Code).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.174.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">No-Transfer Date</font>&#8221; is defined in Section 2.8(c)(ii) (Gilead Transfer).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.175.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Obligants</font>&#8221; is defined in Section 12.2 (Covenants, Representations and Warranties for Compliance with Laws).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.176.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">OFAC</font>&#8221; is defined in Section 12.2(d) (Export Control Laws).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.177.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Other Component</font>&#8221; is defined in Section 1.60 (&#8220;Combination Product&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.178.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Out-of-Pocket Costs</font>&#8221; means, with respect to certain activities hereunder, direct expenses actually paid by a Party or its
        Affiliates to Third Parties and specifically identifiable and incurred to conduct such activities, but excluding (a) any costs included in the FTE Rate, (b) any costs attributable to CGEN&#8217;s breach or default under agreements with such Third Parties
        (to the extent not attributable to any requests or instructions provided to CGEN by Gilead), (c) the COM503 Transfer Price amounts paid by Gilead to CGEN, or (d) any CGEN&#8217;s costs required to be approved by Gilead in accordance with Section
        2.8(f)(iii) (Coordination and Costs) that are not so approved.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.179.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Packaging and Labeling</font>&#8221; means primary, secondary or tertiary packaging and labeling of a product (in its clinical or
        commercial packaging presentation) for testing, sale or use and all release thereof.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.180.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Party</font>&#8221; or &#8220;<font style="font-weight: bold;">Parties</font>&#8221; is defined in Preamble.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.181.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Patent Prosecution</font>&#8221; means with respect to a Patent, the responsibility for (a)<font style="font-weight: bold;">&#160;</font>preparing,
        filing, prosecuting, and pursuing registration of, applications (of all types) for such Patents, (b) maintaining such Patent, and (c)<font style="font-weight: bold;">&#160;</font>managing any initiation or defense of administrative proceedings relating
        to the foregoing in relevant patent authorities, including inter partes reviews, derivations, re-examinations, post-grant reviews, re-issues, oppositions, and other similar proceedings (or other defense proceedings with respect to such Patent, but
        excluding the defense of challenges to such Patent as a counterclaim in an infringement proceeding).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">16</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.182.&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Patents</font>&#8221; means (a) all patents and patent applications in any country, region or supranational jurisdiction and (b) any
        provisionals, substitutions, divisions, continuations, continuations in part, reissues, renewals, registrations, confirmations, reexaminations, extensions, supplementary protection certificates and the like, of any such patents or patent
        applications.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.183.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Patent Term Extensions</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 15.7 (Patent Term Extensions).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.184.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">PD-1</font>&#8221; means the protein encoded by the human PD-1 gene, identified by the following UniProt number: Q15116.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.185.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">PD-L1</font>&#8221; means the protein encoded by the human PD-L1 gene, identified by the following UniProt number: Q9NZQ7.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.186.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Permitted Subcontractor</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 3.3 (Subcontractors).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.187.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Person</font>&#8221; means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership,
        corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a
        government.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.188.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Phase&#160;1 Clinical Trial</font>&#8221; means a human clinical trial, or the relevant portion of such trial, of an IL-18 Product conducted
        in any country in the Territory in accordance with cGCP that generally provides for the first introduction into humans of an IL-18 Product and intended to determine safety, metabolism and pharmacokinetic properties and clinical pharmacology of such
        IL-18 Product in patients or healthy volunteers, or that would otherwise satisfy the requirements of Applicable Laws and Regulations for such country in which such human clinical trial is conducted, such as 21 C.F.R. &#167;&#160;312.21(a), relating to human
        clinical trials conducted in the United States, or any successor regulation thereto or foreign equivalents.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.189.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Phase&#160;2 Clinical Trial</font>&#8221; means a human clinical trial, or the relevant portion of such trial, of an IL-18 Product, conducted
        in patients in any country in the Territory in accordance with cGCP to evaluate the effectiveness of the IL-18 Product for a particular Indication or Indications in patients with the disease or condition under study and to determine the common
        short-term side effects and risks associated with the IL-18 Product, as well as to obtain a preliminary Indication of the unit or daily dosage regimen required, or that would otherwise satisfy the requirements of Applicable Laws and Regulations of
        the country in which such human clinical trial is conducted, such as 21 C.F.R. &#167;&#160;312.21(b), relating to human clinical trials conducted in the United States, or any successor regulation thereto or foreign equivalents. For clarity, a Phase 1
        Clinical Trial with an expansion cohort of patients that meets the descriptions or otherwise satisfies the requirements in the foregoing shall be deemed a Phase 2 Clinical Trial.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.190.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Phase&#160;3 Clinical Trial</font>&#8221;<font style="font-weight: bold;">&#160;</font>means a human clinical trial, or the relevant portion of
        such trial, of an IL-18 Product, conducted in patients in any country in the Territory in accordance with cGCP and the results of which are intended to gather additional information about effectiveness and safety that is needed to evaluate the
        overall benefit-risk relationship of the IL-18 Product and to provide an adequate basis for physician labeling. The Phase 3 Clinical Trial will be used as a pivotal study to establish both safety and efficacy of such IL-18 Product as a basis for a
        BLA or NDA submitted to the FDA or the appropriate Regulatory Authority of such country, or that would otherwise satisfy the requirements of 21 C.F.R. &#167;&#160;312.21(c), relating to human clinical trials conducted in the United States or any successor
        regulation thereto or foreign equivalents.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">17</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.191.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Phase&#160;4 Clinical Trial</font>&#8221;<font style="font-weight: bold;">&#160;</font>means a human clinical trial conducted after the Regulatory
        Approval of an IL-18 Product in a country, which trial is conducted (a) voluntarily to provide additional information about such IL-18 Product (including for expansion of product labeling or dose optimization); or (b) in response to a request or
        requirement of a Regulatory Authority of such country.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.192.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">PHS Act</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 1.27 (&#8220;BLA&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.193.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Pivotal Trial</font>&#8221; means an expanded Clinical Trial of a pharmaceutical or biological product that: (a) is designed to
        demonstrate or that actually demonstrates that a product is safe and effective for use in a particular Indication in a manner sufficient to evaluate the overall risk-benefit relationship of the product and to provide an adequate basis for physician
        labeling; (b) is intended to provide or that actually provides sufficient efficacy data to support the filing of a MAA for such product without the need for any additional Clinical Trials; and (c) which, at the time of Initiation of such Clinical
        Trial, is expected to be, or thereafter actually becomes, the basis for European Union Regulatory Approval of such product or Regulatory Approval by the FDA of such product, in each case, based on discussions with the relevant Regulatory Authority.
        For clarity, (x) a Phase 3 Clinical Trial (as defined herein) is always a &#8220;Pivotal Trial,&#8221; and (y) a Phase 2 Clinical Trial, Phase 1 Clinical Trial, or other Clinical Trial (as such terms are defined herein) are only a &#8220;Pivotal Trial&#8221; if all
        conditions of this definition are met.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.194.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Pricing and Reimbursement Approval</font>&#8221; means, in a country in which Regulatory Authorities authorize coverage or reimbursement
        for, or approve, negotiate or determine pricing for, pharmaceutical or biologic products to be marketed and sold or reimbursed in such country or for certain patients in such country, receipt (or, if required to make such authorization, approval or
        determination effective, publication) of such authorization, approval or determination (as the case may be).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.195.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Processing</font>&#8221; means any operation or set of operations performed upon personal data or sets of personal data, whether or not
        by automated means, such as collection, recording, organization, structuring, storage, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available, alignment or combination,
        restriction, erasure or destruction. Cognates of &#8220;Processing&#8221; shall have correlative meanings. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.196.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Protected Personal Information</font>&#8221; is defined in Section 12.2(b)(i) (Data Protection Laws).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.197.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Receiving Party</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 11.1(a) (Definition and Restrictions).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.198.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Recovery</font>&#8221; is defined in Section 15.4(d)(i) (Recovery Allocations).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.199.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Reduced Payment Amount</font>&#8221; is defined in Section 17.7(a).&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.200.&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Regulatory Activities</font>&#8221; means, with respect to a given IL-18 Product, all regulatory activities necessary to obtain or
        maintain Regulatory Approval of such IL-18 Product in the Field in the Territory, including: (a) preparing, obtaining and maintaining all Regulatory Submissions and Regulatory Approvals for such IL-18 Product; and (b) communicating and interacting
        with the relevant Regulatory Authorities for such IL-18 Product. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">18</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.201.&#160;&#160;&#160;&#160;&#160; &#160; &#8220;<font style="font-weight: bold;">Regulatory Approval</font>&#8221; means, with respect to a particular country or other regulatory jurisdiction, any approval of a BLA,
        NDA or other MAA from the applicable Regulatory Authority necessary for the commercial marketing or sale of a pharmaceutical or biologic product in such country or other regulatory jurisdiction, including Pricing and Reimbursement Approval in those
        countries and jurisdictions where required.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.202.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Regulatory Authority</font>&#8221; means any applicable government regulatory authority with the legal authority to regulate the conduct
        of clinical trials or the Manufacturing, marketing, Commercialization, reimbursement or pricing, as applicable, of an IL-18 Product, including the FDA and any successor governmental authority having substantially the same function.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.203.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Regulatory</font>&#160;<font style="font-weight: bold;">Exclusivity Period</font>&#8221; means, with respect to an IL-18 Product in any
        country in the Territory, the period, if any, during which the applicable Regulatory Authority grants an additional market protection, other than Patent protection, that confer an exclusive Commercialization period during which a Party or its
        Affiliates or Sublicensees have the exclusive right to market and sell such IL-18 Product in such country through a regulatory exclusivity right (e.g., new use or indication exclusivity, formulation exclusivity, orphan drug exclusivity, pediatric
        exclusivity, or any applicable data exclusivity).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.204.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Regulatory Milestone Event</font>&#8221; is defined in Section 9.4 (Regulatory Milestone Payments). </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.205.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Regulatory Milestone Payment</font>&#8221; is defined in Section 9.4 (Regulatory Milestone Payments). </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.206.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Regulatory Submission</font>&#8221; means any filing, application, or submission with or to any Regulatory Authority including,
        authorizations, approvals or clearances arising from the foregoing, including INDs, BLAs, NDAs, and Regulatory Approvals, and all correspondence or communication with or from the relevant Regulatory Authority, as well as minutes of any meetings,
        telephone conferences or discussions with the relevant Regulatory Authority, in each case, with respect to an IL-18 Product.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.207.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Related Party</font>&#8221; means, with respect to a Party, its Affiliates and their respective Sublicensees.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.208.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Representatives</font>&#8221; is defined in Section 11.1(c)(iii) (Permitted Disclosures).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.209.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Requesting Party</font>&#8221; is defined in Section 10.9 (Audit Rights).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.210.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Research Milestone Event</font>&#8221; is defined Section 9.2 (Research Milestone Payments).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.211.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Research Milestone Payment</font>&#8221; is defined in Section 9.2 (Research Milestone Payments).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.212.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Reverted Products</font>&#8221; is defined in Section 17.8(b)(i) (Additional Effects of Certain Termination). </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.213.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Royalty Term</font>&#8221; means, on a Financial Product-by-Financial Product and country-by-country basis, the time period beginning on
        the First Commercial Sale of a Financial Product in a country and expiring on the latest of the following dates: (a) the tenth (10<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) anniversary of the date of First Commercial Sale of such Financial Product in such country, (b) the
        expiration of the last-to-expire Financial Patent Covering such Financial Product in the applicable country, and (c) the expiration of the last-to-expire Regulatory Exclusivity Period for such Financial Product in such country.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">19</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.214.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Safety/AE Matters</font>&#8221; is defined in Section 6.2(d) (Adverse Event Reporting; Global Safety Database).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.215.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Second Financial Product</font>&#8221; means the first Financial Product that is distinct (as determined in accordance with Section 10.5
        (Distinguishing Financial Products)) from the COM503 Financial Product.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.216.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;[**]&#8221; is defined in Section&#160;9.6(a).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.217.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Secured Information</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 12.2(c)(i).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.218.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Securities Regulator</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 11.1(c)(ii).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.219.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Security Incident</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 12.2(c)(iv).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.220.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Segregate</font>&#8221; means, with respect to an Existing Competitive Program or New Competitive Program, to segregate the Exploitation
        activities relating to such Existing Competitive Program or New Competitive Program, as applicable, from the Exploitation activities relating to IL-18 Molecules and IL-18 Products in a manner such that no data, information, Inventions, or
        Intellectual Property Rights related to IL-18 Molecules and IL-18 Products are accessible for use in the Exploitation of such Existing Competitive Program or New Competitive Program, as applicable, and that there is no overlap in such Exploitation
        activities, including ensuring that: (a) [**]; and (b) [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.221.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;[**]&#8221; means [**].&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.222.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;[**]&#8221; means [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.223.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;[**]&#8221; means the [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.224.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;[**]&#8221; means the [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.225.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Solely Owned Foreground IP</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 15.1(b)(ii) (Other Foreground
        IP).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.226.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Subject Party</font>&#8221; is defined in Section 12.1 (General).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.227.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Subject Party Audit</font>&#8221; is defined in Section 12.2(a)(iii)(6).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.228.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Sublicensee</font>&#8221; means a Third Party to whom a Party or any of its Affiliates grants a sublicense under the licenses granted to
        such Party under this Agreement, as permitted herein, excluding all Third Parties that are solely Permitted Subcontractors.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.229.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;[**]&#8221; means [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.230.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Technology Transfer Plan</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section&#160;3.5 (Technology Transfer).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.231.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Term</font>&#8221; is defined in Section 17.1 (Term).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.232.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Terminated Product</font>&#8221; means (a) any IL-18 Product with respect to which this Agreement is terminated pursuant to Section 17.3
        (Termination for Convenience) or Section 17.6 (Termination by Gilead for Safety Reasons), and (b) in the event of termination of this Agreement in its entirety, all IL-18 Products.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">20</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.233.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Territory</font>&#8221; means all countries and regions of the world.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.234.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;[**] <font style="font-weight: bold;">Review Period</font>&#8221; is defined in Section 2.8(c)(ii) (Gilead Transfer).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.235.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">&#8220;Third Party</font>&#8221; means an entity other than (a) Gilead and its Affiliates and (b) CGEN and its Affiliates.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.236.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Third Party Allegation</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 15.5(a) (Notice of Allegations).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.237.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Third Party Claims</font>&#8221;<font style="font-weight: bold;">&#160;</font>means collectively, any and all Third Party demands, claims,
        actions, suits, and proceedings (whether criminal or civil or in contract, tort, or otherwise).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.238.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Third Party Distributor</font>&#8221; means any Third Party that purchases IL-18 Product from Gilead or its Affiliates or Sublicensees,
        takes title to such IL-18 Product, and distributes such IL-18 Product directly to customers, but does not Develop, Manufacture or otherwise Commercialize any IL-18 Product and does not make any upfront, milestone, royalty, profit-share or other
        payment to Gilead or its Affiliates or Sublicensees, other than payment for the purchase of IL-18 Products for resale.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.239.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Third Party Suit</font>&#8221; is defined in<font style="font-weight: bold;">&#160;</font>Section 15.5(b) (Notice of Suit).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.240.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Trademark</font>&#8221; means all trade names, logos, common law trademarks and service marks, trademark and service mark registrations
        and applications throughout the world.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.241.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">United States</font>&#8221; or &#8220;<font style="font-weight: bold;">U.S.</font>&#8221; means the United States of America and its territories and
        possessions, including the Commonwealth of Puerto Rico and the U.S. Virgin Islands.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.242.&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Upstream License Agreement</font>&#8221; means any contract or agreement with a Third Party pursuant to which CGEN in-licenses Patents,
        Know-How or other Intellectual Property Rights that constitute IL-18 IP for purposes of this Agreement, including such Upstream License Agreements set forth on<font style="font-weight: bold;"> Schedule 1.242</font> (Existing Upstream License
        Agreements) existing as of the Effective Date (each, an &#8220;<font style="font-weight: bold;">Existing Upstream License Agreement</font>&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.243.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">US Dollars</font>&#8221; means United States Dollars, the lawful currency of the US.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.244.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Valid Claim</font>&#8221; means a claim of: (a) an issued and unexpired Patent in a country in which said Patent has not been revoked or
        held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and has not been abandoned, disclaimed or admitted to be invalid or
        unenforceable through reissue, disclaimer or otherwise; or (b) a pending patent application that has been filed in good faith and that has not been cancelled, withdrawn, finally rejected or abandoned and has not been pending for more than [**] from
        the earliest priority date; <font style="font-style: italic;">provided</font>, that, if a claim ceases to be a Valid Claim by reason of the foregoing subclause (b), then such claim shall again be a Valid Claim in the event and at the time such
        claim subsequently issues.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.245.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;[**]&#8221; means [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">21</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A2"><!--Anchor--></a>2.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-weight: bold; font-variant: small-caps;">Development Program</font>.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">2.1.&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-weight: bold;">Development Plan; Protocol</font>. During the Development Term, the Parties shall conduct all Development and Manufacturing
        activities for the IL-18 Molecules and IL-18 Products under this Agreement pursuant to a written development plan (the &#8220;<font style="font-weight: bold;">Development Plan</font>&#8221; and such activities the &#8220;<font style="font-weight: bold;">Development
          Program</font>&#8221;). The initial Development Plan is set forth on <font style="font-weight: bold;">Schedule 2.1 </font>(Development Plan) and includes the material Development and Manufacturing activities anticipated to be required to achieve
        COM503 Phase 1 Trial Completion, including the conduct of the COM503 Phase 1a Trial and COM503 Phase 1b Trial. Reasonably in advance of the IND filing for COM503, the Parties shall discuss and agree to the initial Clinical Trial protocol for the
        COM503 Phase 1 Trial (the &#8220;<font style="font-weight: bold;">COM503 Phase 1 Trial Protocol</font>&#8221;). Subject to Section 2.8(c) (Early Development Program Transfer), CGEN shall serve as the sponsor of the COM503 Phase 1 Trial. The JSC shall review,
        discuss, and determine whether to approve any updates or amendments to the Development Plan or the COM503 Phase 1 Trial Protocol in accordance with Section 4.1(b) (Responsibilities). Subject to Section 4.1(b) (Responsibilities) and Section&#160;4.1(d)
        (Decision-Making), each Party shall have the right to propose additional amendments to the Development Plan or the COM503 Phase 1 Trial Protocol in connection with the progress of the Development Program for the JSC to review, discuss and determine
        whether to approve. Any proposed amendments to the Development Plan or the COM503 Phase 1 Trial Protocol will become effective only upon [**] and [**], including under Section&#160;4.1(d) (Decision-Making) to the extent applicable. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">2.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">License to CGEN</font>. Subject to the terms and conditions of this Agreement and any clinical supply, pharmacovigilance and
        quality agreements entered into pursuant to Section 2.3 (Gilead-Provided PD-1/PD-L1), Gilead hereby grants to CGEN a worldwide, royalty-free, non-transferable, non-exclusive license under Gilead&#8217;s Background IP, the Gilead PD-1/PD-L1 Foreground IP
        and Gilead&#8217;s interest in the Jointly Owned Foreground IP solely to perform the Development Program activities pursuant to the Development Plan.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">2.3.&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold;">Gilead-Provided PD-1/PD-L1</font>. To the extent required under the Development Plan, Gilead shall supply Gilead-Provided
        PD-1/PD-L1 to CGEN for use in combination with COM503. Such Gilead-Provided PD-1/PD-L1 shall be selected by Gilead in its sole and reasonable discretion. The Parties shall enter into clinical supply, pharmacovigilance and quality agreements
        governing the provision of the Gilead-Provided PD-1/PD-L1 by or on behalf of Gilead to CGEN promptly after Gilead&#8217;s selection of the Gilead-Provided PD-1/PD-L1 under this Section 2.3 (Gilead-Provided PD-1/PD-L1).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">2.4.&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold;">Performance Standards</font>. Each Party shall conduct its assigned activities pursuant to the Development Plan. Each Party shall
        perform such activities in accordance with the Development Plan and in compliance with all Applicable Laws and Regulations. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">2.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Development Program Costs</font>. CGEN shall be responsible for all costs incurred by or on behalf of CGEN in connection with
        activities conducted under the Development Program. Gilead shall be solely responsible for the costs incurred by Gilead of supplying the Gilead-Provided PD-1/PD-L1 to the extent that coverage and reimbursement are not otherwise available for such
        Gilead-Provided PD-1/PD-L1.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">2.6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Records; Updates</font>. During the Term and for a period of [**] after expiration or termination of this Agreement, each Party
        shall maintain complete, current and accurate records of all activities conducted under the Development Program, and all data and other information resulting from the performance of such activities. Such records shall fully and properly reflect all
        work performed and results achieved in the performance of any Development Program activities in good scientific manner appropriate for regulatory and patent purposes. Additionally, during each JSC meeting, each Party shall provide the JSC with an
        update on the results and progress of any Development Program activities conducted by or on behalf of such Party since the prior JSC meeting.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">22</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">2.7.&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-weight: bold;">Data Ownership</font>. All data or information generated by or on behalf of either Party or jointly by the Parties in the conduct
        of any Development Program activities that is related to any Gilead-Provided PD-1/PD-L1 (including any Gilead-Provided PD-1/PD-L1 in combination with any IL-18 Molecule) shall be considered Gilead PD-1/PD-L1 Foreground IP, ownership of which will
        be governed by Section 15.1(b)(i) (Gilead PD-1/PD-L1 Foreground IP). Subject to the foregoing, each Party shall solely own all data or information generated by or on behalf of such Party in the conduct of any Development Program activities (which
        data or information shall be included in such Party&#8217;s Solely Owned Foreground IP), and the Parties shall jointly own any such data or information that is jointly generated by or on behalf of the Parties (which data or information shall be included
        in Jointly Owned Foreground Know-How).&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">2.8.&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold;">Reports and Data Package; Development Program Transfer</font>.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Annual
            Reports</font>. During the Development Term and without limiting the generality of the updates provided by CGEN at each JSC meeting as set forth in Section&#160;2.6 (Records; Updates) or Section 4.1(c) (Quarterly Reports), CGEN shall deliver to
          Gilead a copy of each annual report that CGEN submits to the FDA with respect to the COM503 Phase 1 Trial within [**] after CGEN submits each such annual report to the FDA.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">IL-18
            Trial Data Package</font>. Within [**] after the COM503 Phase 1 Trial Completion, CGEN shall deliver to Gilead [**] from the COM503 Phase 1 Trial. Within [**] after the COM503 Phase 1 Trial Completion, CGEN will deliver to Gilead [**] from the
          COM503 Phase 1 Trial (&#8220;[**]&#8221;). CGEN shall deliver the IL-18 Trial Data Package to Gilead within [**] after the COM503 Phase 1 Trial Completion. Within [**] following Gilead&#8217;s receipt of the IL-18 Trial Data Package, Gilead may provide CGEN with
          written notice if Gilead believes in good faith that the purported IL-18 Trial Data Package provided by CGEN does not contain all of the information set forth in <font style="font-weight: bold;">Schedule 1.137</font> (IL-18 Trial Data Package)
          (a &#8220;<font style="font-weight: bold;">Deficiency Notice</font>&#8221;), which Deficiency Notice will reasonably specify the missing item(s). CGEN will provide an updated IL-18 Trial Data Package that includes the missing information within [**]&#160; after
          receipt of the Deficiency Notice, <font style="font-style: italic;">provided</font>, that CGEN will not be required to perform any work to generate any information identified in the Deficiency Notice other than activities described in the
          Development Plan that generate the information described in <font style="font-weight: bold;">Schedule 1.137</font> (IL-18 Trial Data Package) that have not been performed by CGEN with respect to the IL-18 Trial Data Package. Within [**] after
          Gilead&#8217;s receipt of the IL-18 Trial Data Package, Gilead may, itself or through the JSC, provide CGEN with written notice requesting assistance and cooperation from CGEN in analyzing the IL-18 Trial Data Package, including a request for a
          discussion with CGEN representative(s) who have relevant knowledge and information regarding the IL-18 Trial Data Package, and CGEN will use good faith efforts to promptly provide any such assistance and cooperation reasonably requested by
          Gilead. Gilead shall reimburse CGEN for such assistance and cooperation (for clarity, excluding work in connection with a Deficiency Notice) as FTE Costs pursuant to Section&#160;10.1 (Reimbursable Costs).</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Development
            Program Transfer</font>.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Early
            Transfer</font>. If Gilead determines in its reasonable, good faith judgment that [**], then Gilead shall provide written notice thereof to CGEN, including [**]. Within [**] following delivery of such notice by Gilead, CGEN may request a
          meeting with Gilead, and within [**] following such request by CGEN, the Parties shall promptly discuss [**] and [**]. If [**], then Gilead shall have the right to transition the COM503 Phase 1 Trial from CGEN to Gilead in accordance with Section
          2.8(d) (Development Program Transfer Plan) by providing written notice to CGEN demanding that CGEN transfer the Development Program to Gilead (a &#8220;<font style="font-weight: bold;">Development Program Transfer Notice</font>&#8221;, and the date of such
          written notice, the &#8220;<font style="font-weight: bold;">Early Development Transfer Date</font>&#8221;).</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">23</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Gilead
            Transfer</font>. If Gilead wishes to have the Development Program transferred from CGEN to Gilead after the occurrence of COM503 Phase 1 Trial Completion, Gilead shall have the right to do so upon delivery of written notice to CGEN within [**]
          (such time period the &#8220;[**] <font style="font-weight: bold;">Review Period</font>&#8221;) after Gilead&#8217;s receipt of the complete [**] (as described in Section 2.8(b) (IL-18 Trial Data Package)) (such notice &#8220;<font style="font-weight: bold;">Gilead
            Transfer Notice</font>&#8221;). If Gilead does not deliver a Gilead Transfer Notice prior to the expiration of the [**] Review Period (the day that occurs after the expiration of such [**] Review Period without Gilead delivering such Gilead Transfer
          Notice, the &#8220;<font style="font-weight: bold;">No-Transfer Date</font>&#8221;), then, notwithstanding any remaining obligations of CGEN under the Development Plan, CGEN shall have the right to wind down the Development Program in its reasonable
          discretion, subject to complying with the terms and conditions of this Agreement, including Section 2.8(f) (CGEN Development and Manufacturing Agreements), Section 3.5 (Technology Transfer), and Section 8.3 (Manufacturing Technology Transfer).
          For clarity, if the No-Transfer Date occurs in accordance with this Section 2.8(c)(ii) (Gilead Transfer), then the Development Program Transfer Date will be deemed to not occur.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Development
            Program Transfer Plan</font>. Upon the occurrence of the Development Program Transfer Date but not upon the occurrence of the No-Transfer Date, CGEN shall initiate the transfer of any Development activities related to all IL-18 Products
          (including any Clinical Trials that are ongoing) (such transfer, the &#8220;<font style="font-weight: bold;">Development Program Transfer</font>&#8221;) in accordance with this Section 2.8(d) (Development Program Transfer Plan).&#160;To facilitate the Development
          Program Transfer, upon Gilead&#8217;s request the Parties shall promptly agree upon a written transfer plan setting forth a process for the Development Program Transfer, and an overall timeline for its progress and completion; <font style="font-style: italic;">provided</font>, that such timeline shall specify that CGEN shall use Commercially Reasonable Efforts to complete the Development Program Transfer within [**] of the Development Program Transfer Date, provided Gilead&#8217;s performance of
          its obligations necessary for such completion within such time period have also occurred (such plan, the &#8220;<font style="font-weight: bold;">Development Program</font>&#160;<font style="font-weight: bold;">Transfer Plan</font>&#8221;). In the event of a
          Development Program Transfer pursuant to Section 2.8(c)(i) (Early Transfer), the Development Program Transfer Plan shall include CGEN&#8217;s obligations to continue and/or wind-down its Development activities in accordance with Gilead&#8217;s reasonable
          instructions until the completion of the Development Program Transfer. After the Development Program Transfer Date, each of the Parties shall perform its respective obligations under the Development Program Transfer Plan in accordance with the
          timelines set forth therein.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">CGEN
            Support</font>. In addition to any assistance CGEN agrees to provide Gilead pursuant to the Technology Transfer Plan (as described in Section 3.5 (Technology Transfer)) or the Development Program Transfer Plan (as described in Section 2.8(d)
          (Development Program Transfer Plan)), CGEN hereby agrees to provide Gilead with reasonable access to CGEN&#8217;s personnel (by teleconference or in person at CGEN&#8217;s facilities) involved in the research, Manufacture and Development of IL-18 Molecules
          and IL-18 Products, and such personnel shall provide reasonable guidance and assistance to Gilead, as requested by Gilead, with respect to any CMC, clinical operation, medical affairs, regulatory, and toxicology activities for the IL-18 Molecules
          and IL-18 Products in the Territory under the transition services agreement further described in this Section 2.8(e) (CGEN Support). Upon Gilead&#8217;s delivery of written notice, but in any event within [**] after the Development Program Transfer
          Date, the Parties shall negotiate in good faith to enter into a transition services agreement pursuant to which CGEN shall provide Gilead with the foregoing services. The term of the transition services agreement shall be [**]. Gilead shall
          reimburse CGEN for such transition services as FTE Costs pursuant to Section&#160;10.1 (Reimbursable Costs).</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">CGEN
            Development and Manufacturing Agreements</font>.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">CGEN
            Development and Manufacturing Agreements</font>. Within [**] after the Development Program Transfer Date or the No-Transfer Date, as applicable, CGEN shall update <font style="font-weight: bold;">Schedule 1.36</font> (CGEN Development and
          Manufacturing Agreements) with the CGEN Development and Manufacturing Agreements in effect as of the Development Program Transfer Date.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">24</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Assignment
            or Assistance</font>. Promptly following the Development Program Transfer Date or the No-Transfer Date, as applicable, CGEN shall, or shall cause its Affiliates to, as applicable, to the extent permissible under Applicable Laws and Regulations
          and the terms of the applicable CGEN Development and Manufacturing Agreements: (1) assign to Gilead or its designee any or all (as designated by Gilead) IL-18-Only Development and Manufacturing Agreements; and (2) reasonably assist Gilead or its
          Affiliate in entering into new agreements directly with the counterparties to any or all CGEN Development and Manufacturing Agreements other than IL-18-Only Development and Manufacturing Agreements to cover the subject matter related to IL-18
          Molecules or IL-18 Products of such CGEN Development and Manufacturing Agreements, as applicable, in each case ((1) and (2)), to the extent requested by Gilead in writing. If any IL-18-Only Development and Manufacturing Agreement cannot be
          assigned to Gilead without consent from the relevant counterparty, then CGEN shall, or shall cause its Affiliates to, as applicable, use reasonable efforts to obtain such consent, to the extent requested by Gilead in writing. If any IL-18-Only
          Development and Manufacturing Agreement is assigned to Gilead, CGEN shall be responsible (subject to any qualifying reimbursement under Section&#160;10.1 (Reimbursable Costs)) for any payments that accrued prior to the date of such assignment but
          which do not become payable until after the date of such assignment.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Coordination
            and Costs</font>. Promptly following the Development Program Transfer Date or the No-Transfer Date, as applicable, the Parties shall in good faith coordinate activities under the CGEN Development and Manufacturing Agreements that are not
          assigned to Gilead, or until assigned to Gilead, with the goal of maintaining continuity of operations. At Gilead&#8217;s written request, for no more than [**] after the Development Program Transfer Date or the No-Transfer Date, as applicable (for
          clarity, without derogating from CGEN&#8217;s obligations pursuant to Article 8 (Manufacture and Supply)), CGEN shall exercise its rights under such CGEN Development and Manufacturing Agreements to conduct activities reasonably required for the
          continued Development and Manufacture of the IL-18 Molecule or IL-18 Products, including, as applicable, entering into new statements of work under master services agreements; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that Gilead: (1) approves in writing in advance any such actions, including the costs thereof; and (2) reimburses CGEN for all Out-of-Pocket Costs so approved that CGEN incurs under such CGEN
          Development and Manufacturing Agreements as a direct result of conducting such activities (and for clarity, such Out-of-Pocket Costs are not subject to and do not contribute to the initial Out-of-Pocket Costs threshold set forth in
          Section&#160;10.1(d) (All Other Out-of-Pocket Costs)). Gilead shall reimburse CGEN for the conduct of such activities as FTE Costs pursuant to Section&#160;10.1 (Reimbursable Costs).</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Termination</font>.
          In the event that a given IL-18-Only Development and Manufacturing Agreement is not assigned to Gilead pursuant to Section 2.8(f)(ii) (Assignment or Assistance), then, upon the written request of Gilead and solely to the extent permitted under
          the terms of such IL-18-Only Development and Manufacturing Agreement, CGEN shall, or shall cause its Affiliates to, terminate the applicable IL-18-Only Development and Manufacturing Agreement.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2.9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">COM503 Study Budget</font>. Within [**] after the Effective Date, the Parties (via the
        JSC) shall negotiate in good faith to mutually approve a budget for the performance of the COM503 Phase 1 Trial in accordance with this Section 2.9 (COM503 Study Budget) (upon such approval the &#8220;<font style="font-weight: bold;">COM503 Study Budget</font>&#8221;
        and automatically attached as <font style="font-weight: bold;">Schedule 2.9</font>). The COM503 Study Budget shall only include costs to be paid to Third Parties (other than any amounts to be paid by CGEN to Manufacture and supply COM503 for use
        in the COM503 Phase 1 Trial) that are anticipated to be incurred by CGEN for the performance of the COM503 Phase 1 Trial in accordance with the COM503 Phase 1 Trial Protocol, and for clarity shall exclude any FTEs incurred by CGEN to conduct the
        COM503 Phase 1 Trial.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">25</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A3"><!--Anchor--></a>3.&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">License; Exclusivity</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">3.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">License to Gilead</font>.&#160;Subject to the terms and conditions of this Agreement, CGEN hereby grants to Gilead an exclusive (subject
        to Section 3.4 (Retained Rights)), royalty-bearing, non-transferable (except in accordance with Section 18.3 (Assignment; Change of Control)) license under the IL-18 IP and CGEN&#8217;s right, title and interest in the Jointly Owned Foreground IP, with
        the right to grant sublicenses through multiple tiers to its Affiliates and Third Parties (each subject to Section 3.2(a) (Sublicensing by Gilead)), to Exploit IL-18 Molecules and IL-18 Products in the Field in the Territory (the &#8220;<font style="font-weight: bold;">IL-18 License</font>&#8221;). </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">3.2.&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; <font style="font-weight: bold;">Sublicensees</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Sublicensing
            by Gilead</font>. Gilead shall have the right to grant sublicenses through multiple tiers of the IL-18 License, including sublicenses to a subset of the rights granted thereunder, to any of its Affiliates or any Third Parties, in each case,
          without CGEN&#8217;s consent. Each sublicense granted by Gilead to a Third Party under this Agreement shall be consistent with this Agreement, and Gilead shall remain responsible to CGEN for the compliance of each such Sublicensee with the terms and
          conditions of this Agreement. Without derogating from the generality of the foregoing, each such Sublicensee must agree in writing to be bound by terms regarding maintaining the confidentiality of proprietary information that are no less
          stringent than those contained in this Agreement and regarding ownership of Intellectual Property Rights that are consistent with those contained in this Agreement. Gilead shall promptly notify CGEN in writing of its entry into any agreement
          granting a sublicense to any Third Party and provide to CGEN a copy of such sublicense; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">that </font>Gilead may redact such sublicense agreement to the extent
          the redacted information is not necessary for CGEN to confirm compliance with this Agreement.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Survival
            of Gilead Sublicenses</font>. Upon termination of this Agreement for any reason, upon the written request of any Sublicensee of Gilead who is not then in breach of its sublicense agreement or the terms of this Agreement applicable to such
          Sublicensee, CGEN will enter into a direct license with such Sublicensee on the same terms as this Agreement, subject to any necessary revisions to account for any difference in license scope between this Agreement and Gilead&#8217;s sublicense
          agreement with such Sublicensee.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">3.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Subcontractors</font>. Each Party shall have the right to engage Third Party contractors to perform any portion of its obligations
        or exercise certain rights of such Party under this Agreement on a fee-for-service basis (including Third Party Distributors, contract research organizations and CMOs); <font style="font-style: italic;">provided</font>, that CGEN may engage Third
        Party contractors not otherwise set forth on <font style="font-weight: bold;">Schedule 3.3</font> (Subcontractors) only with Gilead&#8217;s prior written consent (each such subcontractor, a &#8220;<font style="font-weight: bold;">Permitted Subcontractor</font>&#8221;).

        Any such Permitted Subcontractor to be engaged by a Party hereunder shall meet the qualifications typically required by such Party for the performance of work similar in scope and complexity to the subcontracted activity. Each Party that engages a
        Permitted Subcontractor shall require such Permitted Subcontractor, in writing, to be bound by terms regarding maintaining the confidentiality of proprietary information that are no less stringent than those contained in this Agreement and
        regarding ownership of Intellectual Property Rights that are consistent with those contained in this Agreement. A Party&#8217;s use of Permitted Subcontractors shall not relieve it of any of its obligations pursuant to this Agreement. Any Party engaging
        a Permitted Subcontractor to perform any of its obligations hereunder shall remain liable and obligated to the other Party for the performance of such activities. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">3.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Retained Rights; No Implied License</font>. Notwithstanding the IL-18 License, CGEN reserves for itself and its Affiliates: (a) the
        right to conduct any Development or other activities allocated to CGEN with respect to IL-18 Molecules or IL-18 Products pursuant to the Development Plan, (b) the right to Manufacture or have Manufactured IL-18 Molecules and IL-18 Products for
        Gilead during the Clinical Supply Term in accordance with this Agreement and the Clinical Supply Agreement, and (c) the right to conduct Regulatory Activities requested by Gilead for IL-18 Products, as further described in Section 6.1(b) (After the
        Development Term). Except as explicitly set forth in this Agreement, no license or other right is or shall be created or granted by either Party under this Agreement by implication, estoppel, or otherwise. Each Party shall retain all rights not
        otherwise granted to the other Party. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">26</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">3.5.&#160;&#160; &#160; &#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Technology Transfer</font>.&#160;Within [**] after the earlier<font style="font-weight: bold;">&#160;</font>of (a) Gilead&#8217;s written
        request, (b) the Development Program Transfer Date, and (c) the No-Transfer Date, CGEN shall disclose and transfer to Gilead copies of the IL-18 Know-How (other than IL-18 Know-How relating to the Manufacture of IL-18 Molecule and IL-18 Products,
        the initial transfer of which will be performed in accordance with Section 8.3 (Manufacturing Technology Transfer)), including sequences of IL-18 Molecules then in existence. Thereafter, (x) to the extent Gilead delivered such written request prior
        to the Development Program Transfer Date or the No-Transfer Date, as applicable, then upon the Development Program Transfer Date or the No-Transfer Date, as applicable, and (y)&#160;no more than [**] every [**] during the [**] following the Development
        Program Transfer Date or the No-Transfer Date, as applicable, as Gilead may reasonably request, in each case (or (x) and (y)), CGEN will provide to Gilead copies of IL-18 Know-How that (i) is created, developed, invented or otherwise made since
        such previous transfer of IL-18 Know-How, and (ii) has not previously been transferred to Gilead. To facilitate the transfer of IL-18 Know-How described above, upon Gilead&#8217;s written request, the Parties shall promptly agree upon a written
        technology transfer plan to transfer to Gilead such IL-18 Know-How (&#8220;<font style="font-weight: bold;">Technology</font>&#160;<font style="font-weight: bold;">Transfer Plan</font>&#8221;), which will set forth a process for the transfer of such IL-18 Know-How,
        and an overall timeline for its progress and completion. Each of the Parties shall perform its respective obligations under the Technology Transfer Plan and shall use Commercially Reasonable Efforts to do so in accordance with the timelines set
        forth therein. Each Party shall be responsible for all Out-of-Pocket Costs incurred by such Party to conduct the transfer of the IL-18 Know-How in accordance with this Section 3.5 (Technology Transfer). Gilead shall reimburse CGEN for its
        performance of activities set forth in the Technology Transfer Plan as FTE Costs as well as for Out-of-Pocket Costs, in each case, pursuant to Section&#160;10.1 (Reimbursable Costs).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">3.6.&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160; <font style="font-weight: bold;">Exclusivity</font>.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">IL -18
            Exclusivity</font>. During [**], except as permitted under this Agreement in connection with the exercise of CGEN&#8217;s retained rights set forth in Section 3.4 (Retained Rights; No Implied License), CGEN shall not, itself, or with or through any
          of its Affiliates or any Third Party, research, Develop, make, or Commercialize (1) any compounds, molecules, products or treatment methods that are Directed To IL-18, IL-18R or IL-18BP or (2) [**] for an IL-18 Product. Notwithstanding the
          foregoing, (x) CGEN may research, Develop, make, have made, and Commercialize [**] without the use of [**], solely if (1) [**], and (2) [**], and (y) CGEN would not [**], in such case [**].</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Business
            Combinations</font>.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">As of
            Closing of CGEN Change of Control</font>. If CGEN undergoes a Change of Control and, at the closing of such Change of Control transaction, the Acquirer in such Change of Control transaction is (either directly or through an Affiliate, or in
          collaboration with any other Third Party) conducting any Exploitation activities of a compound or product that would be in breach of Section&#160;3.6(a) (IL-18 Exclusivity) if performed by CGEN itself, (such Exploitation activities, an &#8220;<font style="font-weight: bold;">Existing Competitive Program</font>&#8221;), then CGEN will not be in breach of the restrictions set forth in Section&#160;3.6(a) (IL-18 Exclusivity) if: (1)(A) CGEN provides Gilead with written notice of such Change of Control
          [**], but [**] following the earlier of (x) the [**] and (y) the [**], and if so, no later than [**]), (B) CGEN and its Affiliates [**], (2) [**], and (3) such Acquirer Segregates such Existing Competitive Program.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">27</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">After
            Closing of CGEN Change of Control</font>. If CGEN undergoes a Change of Control and, after the closing of such Change of Control transaction, the Acquirer in such Change of Control transaction commences (either directly or through an Affiliate,
          or in collaboration with any other Third Party) any Exploitation activities of a compound or product that would be in breach of Section 3.6(a) (IL-18 Exclusivity) if performed by CGEN itself (such Exploitation activities, a &#8220;<font style="font-weight: bold;">New</font>&#160;<font style="font-weight: bold;">Competitive Program</font>&#8221;), then CGEN will not be in breach of the restrictions set forth in Section 3.6(a) (IL-18 Exclusivity) if: (1) [**], and (2) such Acquirer
          Segregates such New Competitive Program.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Acquisition
            of an Existing Competitive Program</font>. If any Third Party becomes an Affiliate of CGEN<font style="font-weight: bold;">&#160;</font>that CGEN<font style="font-weight: bold;">&#160;</font>controls (as such term is defined in the definition of
          &#8220;Affiliate&#8221;) as a result of a merger, acquisition, consolidation, asset sale, or other similar transaction (whether in a single transaction or series of related transactions), and, as of the closing date of such transaction, such Third Party has
          an Existing Competitive Program (such transaction an &#8220;<font style="font-weight: bold;">Acquisition</font>&#8221; and such Third Party, an &#8220;<font style="font-weight: bold;">Acquired Affiliate</font>&#8221;), then continuation of Exploitation activities with
          respect to such Existing Competitive Program shall not be a breach of Section 3.6(a) (IL-18 Exclusivity) if (1) CGEN and the Acquired Affiliate Segregate such Existing Competitive Program [**], (2) CGEN provides Gilead with written notice of the
          Acquisition [**], but no later than [**] following the earlier of [**] and [**] ([**], and if so, no later than [**]), and (3) CGEN does (or causes the Acquired Affiliate to), within [**] after the closing of the Acquisition, either (x) [**] or
          (y) [**]. For clarity, in no event shall the Acquired Affiliate commence (either directly or through an Affiliate, or in collaboration with any other Third Party) any New Competitive Program.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A4"><!--Anchor--></a>4.&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">Governance</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">4.1.&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; <font style="font-weight: bold;">Joint Steering Committee</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Membership</font>.
          Promptly after the Effective Date, the Parties will establish a joint steering committee (the &#8220;<font style="font-weight: bold;">Joint Steering Committee</font>&#8221; or &#8220;<font style="font-weight: bold;">JSC</font>&#8221;), to coordinate, oversee and, as
          applicable, approve the Parties&#8217; activities related to the IL-18 Molecules and IL-18 Products in accordance with this Article 4 (Governance). The JSC shall consist of [**] representatives from each Party (or such other number as the Parties may
          agree). Each Party shall designate one (1) of its representatives of the JSC as a co-chairperson of the JSC (each, a &#8220;<font style="font-weight: bold;">JSC Co-Chairperson</font>&#8221;). Each Party may replace its appointed JSC representatives at any
          time upon reasonable written notice to the other Party. The JSC Co-Chairpersons, in consultation with the Alliance Managers, will have the following roles and responsibilities: (i) to call meetings, send notice of each such meeting and designate
          the time, date and place of each such meeting; (ii) to convene or poll the representatives by other permitted means; and (iii) to approve (including via email) the final minutes of any meeting of the JSC. The JSC Co-Chairpersons shall have no
          other authority or special voting power.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Responsibilities</font>.
          The responsibilities of the JSC shall be:</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">to provide a forum by which the
          Parties may share information regarding the overall strategy for the conduct of the Development Program and to discuss, monitor and coordinate all activities under the Development Program;</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">to facilitate the exchange of
          information between the Parties with respect to the activities hereunder and to establish procedures for the efficient sharing of information necessary for the Parties to fulfill their respective responsibilities with respect to conduct of the
          Development Program;</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">to [**], and to [**];</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">28</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">to discuss the progress of activities
          being conducted under the Development Program or the COM503 Phase 1 Trial Protocol no less than [**] per [**];</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">to review and discuss safety and dose
          escalation data generated as part of the Development Program;</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(vi)</font>&#160;&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">to review, discuss and determine whether
          to approve each Manufacturing Transition Plan and updates or amendments thereto and coordinate the activities under each such Manufacturing Transition Plan, as described in Section 8.3 (Manufacturing Technology Transfer);</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(vii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">review the COM503 Study Budget;</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(viii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">to perform such other functions as
          expressly set forth in this Agreement or as appropriate to further the purposes of this Agreement, as determined jointly by the Parties; and</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ix)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">to [**].</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Quarterly
            Reports</font>. Within [**] following the end of each Calendar Quarter, CGEN shall provide to JSC with a quarterly written report for such Calendar Quarter describing pre-IND activities, safety and efficacy data, standard study conduct metrics,
          including patient enrollment data, list of participating sites&#160;and corresponding investigators,&#160;and any data collection and cleaning metrics.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Decision-Making</font>.
          The JSC shall make decisions unanimously, with each Party&#8217;s representatives collectively having one (1) vote irrespective of the number of representatives of such Party in attendance, or by a written resolution signed by at least one
          representative appointed by each Party. In the event the JSC cannot reach agreement regarding any matter within the JSC&#8217;s authority as described in Section 4.1 (Joint Steering Committee) for a period of [**] (a &#8220;<font style="font-weight: bold;">Deadlock</font>&#8221;),
          then either Party may elect to submit such issue to the Parties&#8217; Executive Officers, and if a Party makes an election to refer a matter to the Executive Officers, then the Executive Officers shall use good faith efforts to promptly resolve such
          matter, which good faith efforts shall include at least one (1) in-person, video or telephonic meeting between such Executive Officers within [**] after the submission of such matter to them. If the Executive Officers are unable to reach
          consensus on any such matter within [**] after its submission to them, then the Deadlock shall be resolved in accordance with the provisions of this Section 4.1(d) (Decision-Making):</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Except for those Deadlocks [**] as set
          forth in Section&#160;4.1(d)(ii) (Decision-Making), and subject to Section 4.1(g) (Limitations), [**] shall have the final decision-making authority with respect to (1) [**], (2) the [**], (3)&#160;[**], (4) [**], (5) [**], and (6) [**].</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">[**] will have final decision-making
          authority over [**], and such matters must be decided by [**].</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Any Deadlock [**].</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">29</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">JSC
            Meetings</font>. No later than [**] after the Effective Date, the JSC will hold a meeting to establish the JSC&#8217;s operating procedures, and the JSC shall meet at least [**] every [**] thereafter, unless the Parties mutually agree in writing to a
          different frequency. Additional meetings of the JSC may be held with the consent of each Party (such consent not to be unreasonably withheld, delayed or conditioned), as required under this Agreement or to resolve any matter or dispute referred
          to the JSC in accordance with this Agreement. In the case of any matter or dispute referred to the JSC, such meeting shall be held within [**] following referral to the JSC. Employees or consultants of either Party that are not representatives of
          the Parties on the JSC may attend JSC meetings with prior notice and with respect to any consultants, prior consent, of the other Party; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that
          such attendees: (i) will not vote; (ii) will not be counted when determining whether a quorum exists at any such meeting; and (iii) will be bound by obligations of confidentiality and non-disclosure equivalent to those set forth in Article 11
          (Confidentiality; Publication). A JSC meeting may be held either in person or by audio, video or internet teleconference with the consent of each Party. Meetings of the JSC shall be effective only if at least one (1) representative of each Party
          is present or participating. Each Party shall be responsible for all of its own expenses of participating in the JSC meetings.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Duration
            and Scope of JSC</font>. The JSC shall continue to exist with respect to the IL-18 Molecules and IL-18 Products until the Development Program Transfer Date or the No-Transfer Date, as applicable, or, if Gilead provides written notice to CGEN
          before the Development Program Transfer Date or the No-Transfer Date, as applicable, requiring the JSC to continue to exist until completion of the Manufacturing Technology Transfer, then until the completion of the Manufacturing Technology
          Transfer. Notwithstanding the foregoing, the JSC shall be disbanded upon (i)&#160;the Parties mutually agreeing in writing to disband the JSC earlier, (ii) Gilead providing the written notice described in Section 18.3(b)(iii) (Assignment; Change of
          Control<font style="font-weight: bold;">)</font>, or (iii) termination of this Agreement in accordance with the terms hereof.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Limitations</font>.
          The JSC shall have no authority other than that expressly set forth in this Section&#160;4.1 (Joint Steering Committee) and, specifically, shall have no authority (i) to amend or interpret this Agreement, (ii) to determine whether or not a breach of
          this Agreement has occurred, (iii) to make a determination as to whether a particular milestone or other criteria has been achieved or that any of the obligations under this Agreement have been fulfilled, (iv) to amend or add to a<font style="font-weight: bold;">&#160;</font>Party&#8217;s consent or approval rights, (v) to impose any requirements that a<font style="font-weight: bold;">&#160;</font>Party take or decline to take any action that would result in a violation of Applicable Laws
          and Regulations or any agreement with any Third Party that exists as of the Effective Date or is otherwise entered into after the Effective Date in accordance with this Agreement or the infringement of Intellectual Property Rights of any Third
          Party, (vi)&#160;to make a decision that is expressly stated to require the consent or approval of the other Party, (vii) to change<font style="font-weight: bold;">&#160;</font>a<font style="font-weight: bold;">&#160;</font>Party&#8217;s obligations (including
          payment obligations) or rights under this Agreement, (viii) [**]; or (ix) to amend the Development Plan in a manner that would cause the COM503 Study Budget to increase [**].</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">4.2.&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; <font style="font-weight: bold;">Additional Subcommittees and Working Groups</font>. The JSC may establish other subcommittees or working groups as needed to
        further the purposes of this Agreement, including any responsibilities assigned to the JSC under this Agreement; <font style="font-style: italic;">provided</font>,<font style="font-style: italic;"> however</font>, that the JSC shall not delegate
        its dispute resolution authority. The purpose, scope and procedures of any such subcommittee or working group shall be mutually agreed in writing by the JSC. The Parties shall, within [**] after the Effective Date, establish a clinical subcommittee
        to review and discuss activities or matters related to the Development Program, including the Development Plan (&#8220;<font style="font-weight: bold;">Clinical Subcommittee</font>&#8221;). Neither the Clinical Subcommittee nor any other subcommittee or
        working group shall have any decision-making authority.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">4.3.&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-weight: bold;">Alliance Managers</font>. Promptly following the Effective Date, each Party shall designate in writing an Alliance Manager to
        serve as the primary point of contact for the Parties regarding all activities contemplated under this Agreement. Each Alliance Manager shall, among other things: (a) facilitate communication and coordination of the Parties&#8217; activities under this
        Agreement relating to the IL-18 Molecules and the IL-18 Products; (b) coordinate meetings between members of each Party&#8217;s Development Program teams; and (c) attempt to resolve conflicts with respect to the Development Program. The Alliance Managers
        shall be non-voting members of the JSC. The Alliance Managers shall be allowed to attend meetings of the JSC, as well as any subcommittee or working group established by the JSC of which the Alliance Manager is not a member. From time to time, each
        Party may substitute its Alliance Manager at any time upon written notice to the other Party.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">30</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A5"><!--Anchor--></a>5.&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">Gilead Development</font>.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">5.1.&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-weight: bold;">IL-18 Molecules and IL-18 Products</font>. Effective upon the first to occur of the Development Program Transfer Date and the
        No-Transfer Date, Gilead shall have the sole right and sole control, at its sole cost and expense, for the Development of the IL-18 Molecules and IL-18 Products. Gilead shall use Commercially Reasonable Efforts to Develop [**] IL-18 Product in the
        Field in [**]. Gilead will have no other diligence obligations with respect to the Development of any IL-18 Molecules or IL-18 Products other than as set forth in this Section 5.1 (IL-18 Molecules and IL-18 Products).<font style="font-weight: bold; font-style: italic;">&#160;</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">5.2.&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160; <font style="font-weight: bold;">Performance Standards</font>. Gilead shall conduct all Development activities with respect to the IL-18 Molecules and IL-18
        Products in compliance with all Applicable Laws and Regulations.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">5.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Records</font>. During the Term and for a period of [**] after expiration or termination of this Agreement or such shorter period
        permitted under Applicable Laws and Regulations, Gilead shall maintain complete, current and accurate records of all activities conducted by or on behalf of Gilead in the Development of the IL-18 Molecules and IL-18 Products. Such records shall
        fully and properly reflect all work performed and results achieved in the performance of such Development activities in good scientific manner appropriate for regulatory and patent purposes.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">5.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Development Reporting</font>. Beginning [**], as applicable and continuing every [**] thereafter [**], Gilead shall provide CGEN
        with a high-level written Development report (&#8220;<font style="font-weight: bold;">Development Report</font>&#8221;) in accordance with this Section 5.4 (Development Reporting). Each Development Report shall detail Gilead&#8217;s material efforts and progress
        with respect to the Development of IL-18 Molecules and IL-18 Products that occurred during the immediately preceding [**] period for the first such Development Report, and for each subsequent Development Report the activities that occurred since
        the prior Development Report was delivered. Each Development Report shall include a description of: (a)&#160;[**]; (b) [**]; (c) [**]; and (d) [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">5.5.&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; <font style="font-weight: bold;">Data Ownership</font>. Gilead shall solely own all data or information generated by or on behalf of Gilead in the performance of
        any Development activities with respect to the IL-18 Molecules or IL-18 Products. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A6"><!--Anchor--></a>6.&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">Regulatory</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">6.1.&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-weight: bold;">IL-18 Molecules and IL-18 Products</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Development
            Term</font>. During the Development Term and subject to Section 4.1(d) (Decision-Making), CGEN shall be solely responsible, at its sole cost and expense, for conducting all Regulatory Activities related to the IL-18 Molecules and IL-18 Products
          in the Field in the Territory, and shall own all Regulatory Submissions (including Regulatory Approvals) generated (or received) with respect to IL-18 Molecules or IL-18 Products. CGEN shall submit the final Clinical Study Report for the COM503
          Phase 1 Trial in accordance with the COM503 Phase 1 Trial Protocol, including with respect to the date by which the final Clinical Study Report for the COM503 Phase 1 Trial is to be submitted to the applicable Regulatory Authorities. CGEN shall
          provide Gilead with a reasonable opportunity, at least [**] in advance of any relevant deadline, to review and comment on all Regulatory Submissions for IL-18 Molecules and IL-18 Products. Further, CGEN shall provide Gilead with a copy of all
          material communications from any Regulatory Authorities regarding such IL-18 Molecule or IL-18 Product, and provide any drafts of any such Regulatory Submissions to be made to such Regulatory Authorities reasonably in advance (to the extent
          possible) of submitting such Regulatory Submissions filings or responses. CGEN shall incorporate Gilead&#8217;s reasonable comments regarding such Regulatory Submissions and drafts in good faith. Gilead (or its designee) shall have a right to
          participate in all meetings and interactions with the Regulatory Authorities that solely relate to any IL-18 Molecule or IL-18 Product or any combination thereof, including with the Gilead-Provided PD-1/PD-L1, and CGEN shall provide Gilead with
          no less than [**] written notice in advance of scheduled<font style="font-weight: bold;">&#160;</font>meetings and interactions or provide Gilead with immediate written notice with respect to meetings and interactions scheduled less than [**] in
          advance. Gilead shall assist CGEN, as reasonably requested by CGEN, in connection with the preparation and filing of Regulatory Submissions related to the combination of the Gilead-Provided PD-1/PD-L1 with the IL-18 Product, including by
          providing CGEN with all necessary data or other information in Gilead&#8217;s Control related to the Gilead-Provided PD-1/PD-L1 if such Gilead-Provided PD-1/PD-L1 is owned or otherwise Controlled by Gilead. In the event of any Regulatory Authority
          inspection in connection with the Development Program, CGEN will notify Gilead of such inspection within [**] of becoming aware of such inspection. CGEN will provide Gilead with reasonable opportunity to review and comment on any correspondence
          to be submitted to the Regulatory Authority in connection with such inspection. Notwithstanding the foregoing, CGEN shall (i) promptly, but in any event within [**], inform Gilead of any action by, or notification it receives from, any Regulatory
          Authority that (1)&#8239;raises any material concerns regarding the safety or efficacy of an IL-18 Product; (2)&#8239;indicates or suggests a potential material liability of either Party to Third Parties in connection with an IL-18 Product; or (3)&#8239;is
          reasonably likely to lead to a clinical hold with respect to an IL-18 Product; and (ii) (1) provide Gilead with any response or feedback from a Regulatory Authority in response to an IND filing for an IL-18 Product within [**] or receipt of such
          response or feedback, and (2) implement any reasonable feedback provided by Gilead in any CGEN response to any such Regulatory Authority unless CGEN is required under Applicable Law and Regulations to provide such a response prior to Gilead&#8217;s
          provision of such feedback. CGEN shall also promptly, but in any event within [**] after receipt of any correspondence from a Regulatory Authority regarding the matters referred to above, provide Gilead with a copy of such correspondence. Gilead
          shall have the right to provide to CGEN input with respect to any responses to be provided by or on behalf of CGEN in response to such matters, which CGEN shall consider in good faith.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">31</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">After the
            Development Term</font>. After the Development Term, Gilead shall have the sole right and sole control over, at its sole cost and expense, all Regulatory Activities related to the IL-18 Molecules and IL-18 Products (except for any Regulatory
          Activities relating to the CGEN Manufacturing Facilities, including any Regulatory Authority inspections with respect thereto (for which matters CGEN shall have responsibility for in accordance with the Clinical Supply Agreement)). CGEN will
          support Gilead as may be reasonably requested by Gilead from time to time in connection with Gilead&#8217;s preparation, submission to Regulatory Authorities and maintenance of Regulatory Submissions for IL-18 Products, including, upon Gilead&#8217;s
          reasonable request, attending meetings with Regulatory Authorities regarding any IL-18 Product. Gilead shall be solely responsible for all costs incurred by or on behalf Gilead in connection with the conduct of any Regulatory Activities conducted
          after the Development Term related to the IL-18 Molecules or IL-18 Products. Gilead shall reimburse CGEN for the conduct of any Regulatory Activities requested by Gilead after the Development Term as FTE Costs pursuant to Section&#160;10.1
          (Reimbursable Costs).</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">6.2.&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; <font style="font-weight: bold;">Transfer of Regulatory Materials</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Regulatory
            Transfer</font>. Within [**] after the Development Program Transfer Date or the No-Transfer Date, as applicable, CGEN will, or will cause its designee to, transfer and assign (and hereby does assign and transfer) to Gilead all rights, title and
          interests in and to all INDs and all other Regulatory Submissions for COM503 (the &#8220;<font style="font-weight: bold;">Assigned Regulatory Materials</font>&#8221;), including copies of all such Assigned Regulatory Materials in electronic format, to the
          extent the same are available in electronic format, and have not been previously made available to Gilead. Until the date that such transfer of the Assigned Regulatory Materials becomes effective, CGEN shall continue to conduct all matters
          applicable to the IND at Gilead&#8217;s direction, including interactions with the Regulatory Authorities in the Territory related thereto, and shall keep Gilead fully informed of all such matters and interactions relating to the IL-18 Molecules and
          IL-18 Products in the Field in the Territory of which it is aware, including providing Gilead with reasonable advance notice of, and the opportunity to participate as an observer in (to the extent permitted under Applicable Laws and Regulations),
          all scheduled meetings and teleconferences with Regulatory Authorities in the Territory pertaining to the IL-18 Molecules and IL-18 Products in the Field in the Territory.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">32</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Cooperation</font>.
          Upon a Party&#8217;s written request, the other Party will execute and deliver, or will cause to be executed and delivered, to the requesting Party such endorsements, assignments, commitments, acknowledgements, letters and other documents as may be
          necessary (i) to assign, convey, transfer and deliver to Gilead all of CGEN&#8217;s or its applicable Affiliate&#8217;s or designee&#8217;s rights, title and interests in and to the applicable Assigned Regulatory Materials, or (ii) to notify each applicable
          Regulatory Authority or other governmental authority in the Territory of, or otherwise giving effect to, the transfer of ownership to Gilead of the Assigned Regulatory Materials in the Field in the Territory as provided in Section 6.2(a)
          (Regulatory Transfer).</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Right of
            Reference or Use</font>. CGEN hereby grants to Gilead a &#8220;Right of Reference or Use,&#8221; as that term is defined in 21 C.F.R. &#167; 314.3(b) (or any successor regulation or analogous Applicable Laws and Regulations recognized outside of the United
          States), to all Regulatory Submissions (other than Assigned Regulatory Materials that have been assigned to Gilead) pertaining to the IL-18 Products in the Field submitted by or on behalf of CGEN or its Affiliates. Gilead and its Sublicensees may
          use such right of reference solely for the purpose of seeking, obtaining, supporting and maintaining Regulatory Approval and any Pricing and Reimbursement Approvals, as applicable, for any IL-18 Products in the Field in the Territory. CGEN will
          take such actions as may be reasonably requested by Gilead to give effect to the intent of this Section 6.2(c) (Right of Reference or Use), including, if requested by Gilead, (i) providing a signed statement that Gilead may rely on, and that the
          applicable Regulatory Authority may access, CGEN&#8217;s Regulatory Submissions in support of Gilead&#8217;s application for Regulatory Approval for any IL-18 Product, and (ii) providing Gilead with any underlying raw data or information submitted by CGEN to
          the Regulatory Authority with respect to any Regulatory Submissions Controlled by CGEN or any of its Affiliates that relates to any IL-18 Product.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Safety
            Reporting; Global Safety Database</font>. During the Development Term, CGEN shall establish and maintain a drug safety database for COM503, and shall be responsible for monitoring and reviewing all information relevant to the safety of COM503
          and the filing of all required safety reports and serious or other adverse event information to all Regulatory Authorities in connection therewith (collectively, &#8220;<font style="font-weight: bold;">Safety/AE Matters</font>&#8221;) as required under
          Applicable Laws and Regulations. CGEN will complete the transfer to Gilead of such drug safety database for COM503 promptly following the Development Program Transfer Date or the No-Transfer Date, as applicable and, following such transfer,
          Gilead will have the sole right and responsibility for holding and maintaining such drug safety database. Promptly upon Gilead&#8217;s request or sooner if required by Applicable Laws and Regulations, the Parties shall in good faith negotiate and enter
          into a pharmacovigilance agreement governing Safety/AE Matters.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">6.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-weight: bold;">Conflict</font>. If the Parties rights and obligations in this Article 6 (Regulatory) conflict with the Parties rights and
        obligations with respect to Development or Commercialization activities under this Agreement, then this Article 6 (Regulatory) will control solely with respect to any such conflict. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A7"><!--Anchor--></a>7.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">Commercialization</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">7.1.&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; <font style="font-weight: bold;">Responsibility; Diligence</font>. Gilead shall have the sole right and sole control, at its sole cost and expense, for the
        Commercialization of the IL-18 Molecules and IL-18 Products. Gilead shall use Commercially Reasonable Efforts to Commercialize [**] IL-18 Product in the Field in [**] where [**]. Gilead will have no other diligence obligations with respect to the
        Commercialization of any IL-18 Products other than as set forth in this Section 7.1 (Responsibility; Diligence).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">33</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A8"><!--Anchor--></a>8.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">Manufacture and Supply</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">8.1.&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-weight: bold;">COM503</font>.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Clinical
            Supply</font>.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">During</font>&#160;<font style="font-weight: bold;">Development Term</font>. During the Development Term, CGEN is responsible, at its sole cost and expense (subject to Section&#160;10.1(e) (Early Development Program Transfer Costs)), for the Manufacture, either by itself or
          through its Permitted Subcontractors, of, and shall provide, all amounts of IL-18 Product necessary to undertake the Development activities conducted by or on behalf of the Parties under the Development Plan (including, for clarity, the COM503
          Phase 1 Trial), including [**]. If [**], CGEN shall, at its sole cost and expense (subject to Section&#160;10.1(e) (Early Development Program Transfer Costs)), [**] (the &#8220;[**]&#8221;). Upon Gilead&#8217;s reasonable written request during the Development Term,
          subject to the terms of the CGEN CMO Manufacturing Agreement(s) existing as of the Effective Date, CGEN shall use Commercially Reasonable Efforts to Manufacture, either by itself or through its Permitted Subcontractors, one or more additional
          batches of COM503 as necessary to meet Gilead&#8217;s forecasted demand for COM503, during the Clinical Supply Term (&#8220;<font style="font-weight: bold;">Clinical Supply Batches</font>&#8221;), and Gilead shall compensate CGEN for such Clinical Supply Batches
          (for clarity, but neither the [**] nor [**], subject to Section&#160;10.1(e) (Early Development Program Transfer Costs)) at a price equal to the COM503 Transfer Price within [**] after receipt from CGEN of an invoice therefor, which CGEN may issue on
          a quarterly basis.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">During
            the Clinical Supply Term</font>. Commencing on the Development Program Transfer Date or the No-Transfer Date, as applicable and continuing for [**] thereafter or such other period mutually agreed upon by the Parties in writing (the &#8220;<font style="font-weight: bold;">Clinical Supply Term</font>&#8221;), CGEN shall exercise its rights under the CGEN CMO Manufacturing Agreement(s) existing as of the Effective Date to supply Gilead with Clinical Supply Batches of COM503 pursuant to the
          terms of the Clinical Supply Agreement. Gilead shall compensate CGEN for such Clinical Supply Batches of COM503 pursuant to Section 10.2 (Manufacturing Costs).</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">After
            the Clinical Supply Term</font>. Following the expiration of the Clinical Supply Term, Gilead shall have the sole right and control over the Manufacture, either by itself or through one or more Third Parties, of any IL-18 Products for
          Development activities conducted by or on behalf of Gilead in the Field in the Territory.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Clinical
            Supply Agreement</font>. At Gilead&#8217;s written request, the Parties shall initiate negotiations for a clinical supply agreement (the &#8220;<font style="font-weight: bold;">Clinical Supply Agreement</font>&#8221;) that will set forth customary terms and
          conditions (subject to Section 8.1(a)(ii)) for CGEN&#8217;s provision of COM503 to Gilead during the Clinical Supply Term, including with respect to ordering, lead times and nonconforming product, provided that under the Clinical Supply Agreement, CGEN
          shall provide Clinical Supply Batches of COM503 at the COM503 Transfer Price.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Packaging
            and Labelling</font>. For clarity, during the Clinical Supply Term and for the remainder of the Term after expiration of the Clinical Supply Term, Gilead will have the sole right and control over the Packaging and Labeling, either by itself or
          through one or more Third Parties, of COM503 for Gilead&#8217;s use in Clinical Trials in the Field in the Territory.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">34</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(vi)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Liability
            for Clinical Supply Batches</font>. CGEN shall not be liable to Gilead for the failure to supply of any Permitted Subcontractors engaged by CGEN to Manufacture Clinical Supply Batches hereunder to a greater extent than such Permitted
          Subcontractors&#8217; liability is to CGEN under the applicable CGEN Development and Manufacturing Agreement, except to the extent CGEN&#8217;s actions or omissions caused any failure of such Permitted Subcontractor to perform its obligations.
          Notwithstanding Section 10.1(a) (Manufacturing Technology Transfer) and Section 10.2 (Manufacturing Costs), if CGEN is required to pay a Permitted Subcontractor any amount due to a written request by Gilead to delay, cancel, rush, or otherwise
          change any scheduled Manufacture of any Clinical Supply Batches, Gilead shall reimburse CGEN for such amount, regardless of whether CGEN has met the initial Out-Of-Pocket Costs threshold described in Section 10.1(a) (Manufacturing Technology
          Transfer).</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Commercial
            Supply</font>. Gilead shall have the sole right and control over the Manufacture, either by itself or through one or more Third Parties, of any COM503 for Commercialization activities conducted by or on behalf of Gilead in the Field in the
          Territory.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">8.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Observation by Gilead</font>. CGEN uses a CMO for the Manufacture of COM503 engaged under the CGEN CMO Manufacturing Agreement(s).
        After the Development Program Transfer Date or the No-Transfer Date, as applicable, CGEN will use Commercially Reasonable Efforts, including entering into a three-party confidentiality agreement with Gilead and such CMO (if necessary), to enable
        Gilead the opportunity to have at least two (2) representatives to observe the Manufacturing Processes for COM503 being conducted by such CMO (including reviewing assays, batch records, and release processes and procedures) for the purpose of
        enabling Gilead (or a CMO designated by Gilead) to Manufacture COM503 pursuant to Section 8.3 (Manufacturing Technology Transfer).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">8.3.&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-weight: bold;">Manufacturing Technology Transfer</font>. Within [**] after the Effective Date, CGEN and Gilead will start working together to
        commence the transfer to Gilead (or its designee) all IL-18 Know-How that is necessary or reasonably useful to enable the Manufacture of COM503, [**], and [**] (including [**]) (a &#8220;<font style="font-weight: bold;">Manufacturing Technology Transfer</font>&#8221;).
        The Manufacturing Technology Transfer shall be subject to a written plan developed and approved by the Parties through the JSC in good faith with respect to the Manufacturing Technology Transfer (the &#8220;<font style="font-weight: bold;">Manufacturing
          Transition Plan</font>&#8221;). The Parties shall perform each activity allocated to such Party under the Manufacturing Transition Plan and shall use Commercially Reasonable Efforts to implement each Manufacturing Technology Transfer to Gilead or its
        designee in accordance with the applicable Manufacturing Transition Plan. Gilead shall reimburse CGEN for the conduct of any Manufacturing Technology Transfer pursuant to Section&#160;10.1 (Reimbursable Costs).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">8.4.&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-weight: bold;">Exercise of Rights under CGEN CMO Manufacturing Agreement</font>. CGEN shall fulfill all of CGEN&#8217;s obligations under, and shall
        exercise all of CGEN&#8217;s rights under, the CGEN CMO Manufacturing Agreement(s), in each case, in order to fulfill CGEN&#8217;s obligations under this Article 8 (Manufacture and Supply). To the extent CGEN does not have rights under the CGEN CMO
        Manufacturing Agreement(s) that exist as of the Effective Date that permit CGEN to fulfill such obligations, CGEN shall use Commercially Reasonable Efforts to amend such CGEN CMO Manufacturing Agreement(s) in a manner to permit CGEN to fulfill such
        obligations.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A9"><!--Anchor--></a>9.&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; <font style="font-weight: bold; font-variant: small-caps;">Payments</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">9.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Upfront Payment</font>. In partial consideration of the rights granted by CGEN to Gilead hereunder within [**] after the Effective
        Date, Gilead shall pay to CGEN sixty million US Dollars (US$60,000,000), which shall be non-creditable and non-refundable against any other payments due under this Agreement.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">35</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">9.2.&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-weight: bold;">Research Milestone Payment</font>. Subject to the terms and conditions of this Agreement, Gilead shall pay to CGEN the one-time,
        non-creditable, non-refundable milestone payment set forth in the table below in this Section 9.2 (Research Milestone Payment) after the first achievement of the applicable milestone event by a Financial Product, whether such achievement is by or
        on behalf of CGEN or its Affiliate (such event, the &#8220;<font style="font-weight: bold;">Research Milestone Event</font>&#8221; and such payment, the &#8220;<font style="font-weight: bold;">Research Milestone Payment</font>&#8221;). For clarity, the Research Milestone
        Payment shall be payable only once, regardless of the number of times the corresponding Research Milestone Event is achieved. CGEN will promptly notify Gilead upon the achievement of the Research Milestone Event and provide an invoice to Gilead for
        the Research Milestone Payment, and Gilead will pay the Research Milestone Payment within [**] following receipt of such invoice from CGEN. </div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="3" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="za684f2d41675432b9c77803618fedc88">

          <tr>
            <td colspan="3" style="width: 100%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Research Milestone</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Number</div>
            </td>
            <td style="width: 43.96%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Research Milestone Event</div>
            </td>
            <td style="width: 43.97%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Research Milestone Payment</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">1</div>
            </td>
            <td style="width: 43.96%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">IND Clearance for the COM503 Financial Product</div>
            </td>
            <td style="width: 43.97%; vertical-align: top; border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">US$30,000,000</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">9.3.&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160;&#160; <font style="font-weight: bold;">Development Milestone Payments</font>. Subject to the terms and conditions of this Agreement (including Section 9.6 (Additional
        Milestone Payment Terms)), Gilead shall pay to CGEN the one-time, non-creditable, non-refundable milestone payments set forth in the table below in this Section 9.3 (Development Milestone Payments) after the first achievement of the applicable
        milestone events by the COM503 Financial Product and the Second Financial Product, as applicable, whether such achievement is by or on behalf of Gilead, its Affiliate or any Sublicensee of Gilead (each event, a &#8220;<font style="font-weight: bold;">Development
          Milestone Event</font>&#8221; and each payment, a &#8220;<font style="font-weight: bold;">Development Milestone Payment</font>&#8221;). Each of the Development Milestone Payments shall be payable only once with respect to each applicable Financial Product for each
        applicable Indication. Gilead will notify CGEN within [**] after the achievement by Gilead, its Affiliates, or its or their Sublicensees of each Development Milestone Event and will pay the corresponding Development Milestone Payment within [**]
        following receipt of an invoice from CGEN for such Development Milestone Payment. If Gilead or its Affiliates or Sublicensees achieve all of the Development Milestone Events with respect to all applicable Financial Products and all applicable
        Indications, then the Development Milestone Payments payable by Gilead under this Section 9.3 (Development Milestone Payments) will not exceed (i) [**] with respect to the COM503 Financial Product, and (ii) [**] with respect to the Second Financial
        Product. Notwithstanding anything to the contrary in this Agreement, Gilead shall have no obligation to pay Development Milestone Payment #1 of [**] for the [**] if [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="3" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="zfac1b7988ce542a3a72d3e4aba717d2f">

          <tr>
            <td colspan="3" style="width: 100%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Development Milestones</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.69%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Number</div>
            </td>
            <td style="width: 46.85%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Development Milestone Events</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Development Milestone Payments</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.69%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">1</div>
            </td>
            <td style="width: 46.85%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.69%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">2</div>
            </td>
            <td style="width: 46.85%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.69%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">3</div>
            </td>
            <td style="width: 46.85%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.69%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">4</div>
            </td>
            <td style="width: 46.85%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.69%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">5</div>
            </td>
            <td style="width: 46.85%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.69%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">6</div>
            </td>
            <td style="width: 46.85%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.69%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">7</div>
            </td>
            <td style="width: 46.85%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.69%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">8</div>
            </td>
            <td style="width: 46.85%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.69%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">9</div>
            </td>
            <td style="width: 46.85%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">36</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">9.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-weight: bold;">Regulatory Milestone Payments</font>.&#160;Subject to the terms and conditions of this Agreement (including Section 9.6 (Additional
        Milestone Payment Terms)), Gilead shall pay to CGEN the one-time, non-creditable, non-refundable milestone payments set forth in the table below in this Section 9.4 (Regulatory Milestone Payments) after the first achievement of the applicable
        milestone events by the COM503 Financial Product and the Second Financial Product, as applicable, whether such achievement is by or on behalf of Gilead, its Affiliate or any Sublicensee of Gilead (each event, a &#8220;<font style="font-weight: bold;">Regulatory
          Milestone Event</font>&#8221; and each payment, a &#8220;<font style="font-weight: bold;">Regulatory Milestone Payment</font>&#8221;);<font style="font-style: italic;"> provided</font>, that if the Financial Product that achieves such Regulatory Milestone Event is
        [**], then the corresponding Regulatory Milestone Payment shall be reduced by [**]. Each of the Regulatory Milestone Payments shall be payable only once with respect to each applicable Financial Product for each applicable Indication. Gilead will
        notify CGEN within [**] after the achievement by Gilead, its Affiliates, or its or their Sublicensees of each Regulatory Milestone Event and will pay the corresponding Regulatory Milestone Payment within [**] following receipt of an invoice from
        CGEN for such Regulatory Milestone Payment. If Gilead or its Affiliates or Sublicensees achieve all of the Regulatory Milestone Events with respect to all applicable Financial Products and all applicable Indications, then the Regulatory Milestone
        Payments payable by Gilead under this Section 9.4 (Regulatory Milestone Payments) will not exceed (i) [**] with respect to the COM503 Financial Product, and (ii) [**] with respect to the Second Financial Product.</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="3" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="ze82fb3a711514c40a075dc416ae15a60">

          <tr>
            <td colspan="3" style="width: 100%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Regulatory Milestones</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Number</div>
            </td>
            <td style="width: 45.47%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Regulatory Milestone Events</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Regulatory Milestone Payments</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">1</div>
            </td>
            <td style="width: 45.47%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">2</div>
            </td>
            <td style="width: 45.47%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">3</div>
            </td>
            <td style="width: 45.47%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">4</div>
            </td>
            <td style="width: 45.47%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">5</div>
            </td>
            <td style="width: 45.47%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">6</div>
            </td>
            <td style="width: 45.47%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">7</div>
            </td>
            <td style="width: 45.47%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">8</div>
            </td>
            <td style="width: 45.47%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">9</div>
            </td>
            <td style="width: 45.47%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">10</div>
            </td>
            <td style="width: 45.47%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">11</div>
            </td>
            <td style="width: 45.47%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">12</div>
            </td>
            <td style="width: 45.47%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
            <td style="width: 42.46%; vertical-align: top; border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">37</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">9.5.&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; <font style="font-weight: bold;">Commercial Milestone Payments</font>. Subject to the terms and conditions of this Agreement, Gilead shall pay to CGEN the
        one-time, non-creditable, non-refundable milestone payments set forth in the table below in this Section 9.5 (Commercial Milestone Payments) within [**] after the end of the Calendar Quarter after the first achievement of the applicable sales
        milestone event (each event, a &#8220;<font style="font-weight: bold;">Commercial Milestone Event</font>&#8221; and each payment, a &#8220;<font style="font-weight: bold;">Commercial Milestone Payment</font>&#8221;). For clarity: (a) if multiple Commercial Milestone
        Events are achieved in the same Calendar Year, then the Commercial Milestone Payments for all such Commercial Milestone Events shall be payable with respect to such Calendar Year; and (b) each of the Commercial Milestone Payments applicable to the
        COM503 Financial Product shall be payable only once with respect to the COM503 Financial Product, and each of the Commercial Milestone Payments applicable to the Second Financial Product shall be payable only once with respect to the Second
        Financial Product. If Gilead or its Affiliates or Sublicensees achieve all of the Commercial Milestone Events with respect to all applicable Financial Products, then the Commercial Milestone Payments payable by Gilead under this Section 9.5
        (Commercial Milestone Payments) will not exceed (i)&#160;[**] with respect to the COM503 Financial Product, and (ii) [**] with respect to the Second Financial Product.<font style="font-weight: bold;">&#160;</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="3" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="z82022f3532434922a4e31f53b585a999">

          <tr>
            <td colspan="3" style="width: 100%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Commercial Milestones</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Number</div>
            </td>
            <td style="width: 48.5%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Commercial Milestone Events</div>
            </td>
            <td style="width: 39.42%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Commercial Milestone Payments</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">1</div>
            </td>
            <td style="width: 48.5%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Annual Net Sales for the COM503 Financial Product first exceed [**]</div>
            </td>
            <td style="width: 39.42%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">2</div>
            </td>
            <td style="width: 48.5%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Annual Net Sales for the COM503 Financial Product first exceed [**]</div>
            </td>
            <td style="width: 39.42%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">3</div>
            </td>
            <td style="width: 48.5%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Annual Net Sales for the COM503 Financial Product first exceed [**]</div>
            </td>
            <td style="width: 39.42%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">4</div>
            </td>
            <td style="width: 48.5%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Annual Net Sales for the Second Financial Product first exceed [**]</div>
            </td>
            <td style="width: 39.42%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">5</div>
            </td>
            <td style="width: 48.5%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Annual Net Sales for the Second Financial Product first exceed [**]</div>
            </td>
            <td style="width: 39.42%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12.07%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">6</div>
            </td>
            <td style="width: 48.5%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Annual Net Sales for the Second Financial Product first exceed [**]</div>
            </td>
            <td style="width: 39.42%; vertical-align: top; border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">38</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">9.6.&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160; <font style="font-weight: bold;">Additional Milestone Payment Terms</font>.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">As used in Section 9.3 (Development
          Milestone Payments) or Section 9.4 (Regulatory Milestone Payments) above, (i) &#8220;[*]&#8221; means, [**], and (ii) &#8220;[**]&#8221; means, [**].</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">If, upon the achievement of a Development
          Milestone Event described in Section&#160;9.3 (Development Milestone Payments) for a given Financial Product [**], the achievement of an earlier Development Milestone Event described in Section 9.3 (Development Milestone Payments) other than
          Development Milestone Event #1 ([**]) for the corresponding Financial Product [**] has not occurred, such unachieved Development Milestone Event shall be deemed achieved upon achievement of the later Development Milestone Event for such Financial
          Product [**]. For illustration purposes only, if, upon achievement of Development Milestone Event number 4, Development Milestone Event number 2 (with respect to [**]) has not occurred, such Development Milestone Event number 2 shall be deemed
          achieved upon achievement of such Development Milestone Event number 4.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">If, upon the achievement of any Regulatory
          Milestone Event described in Section&#160;9.4 (Regulatory Milestone Payments) for a given Financial Product [**], the achievement of the Development Milestone Event described in Section 9.3 (Development Milestone Payments) with respect to&#160; [**] has
          not occurred, such unachieved Development Milestone Event shall be deemed achieved upon achievement of such Regulatory Milestone Event. For illustration purposes only, if, upon achievement of Regulatory Milestone Event number 1, number 3 or
          number 5 (with respect to [**]), Development Milestone Event number 4 (with respect to [**]) has not occurred, such Development Milestone Event shall be deemed achieved upon achievement of such Regulatory Milestone Event.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">9.7.&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; <font style="font-weight: bold;">Royalties on Net Sales</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Royalty
            Rate</font>. Subject to the terms and conditions of this Section 9.7 (Royalties on Net Sales), Gilead shall pay to CGEN, on a Financial Product-by-Financial Product basis, and on a country-by-country basis in the Territory, royalties on Annual
          Net Sales for each such Financial Product for each Calendar Year during the applicable Royalty Term calculated at the applicable royalty rates set forth below:</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="3" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="za78d7934c8744bc4b62a5a36c57d87bb">

          <tr>
            <td colspan="2" style="width: 100%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Royalties</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.97%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Portion of the Annual Net Sales for the Applicable Financial Product</div>
            </td>
            <td style="width: 50.03%; vertical-align: top; background-color: rgb(184, 204, 228); border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Royalty Rate</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.97%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">On the portion of Annual Net Sales for the applicable Financial Product up to (including) [**]</div>
            </td>
            <td style="width: 50.03%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.97%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">On the portion of Annual Net Sales for the applicable Financial Product greater than [**] and up to (including) [**]</div>
            </td>
            <td style="width: 50.03%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.97%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">On the portion of Annual Net Sales for the applicable Financial Product greater than [**]</div>
            </td>
            <td style="width: 50.03%; vertical-align: top; border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">[**]</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">39</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Expiration
            of the Royalty Term</font>. Upon expiration of the Royalty Term for a given Financial Product in a given country (i) no further royalties will be payable in respect of sales of such Financial Product in such country and no further Net Sales in
          such country will accrue toward the achievement of the Commercial Milestone Events by Gilead, and (ii) the IL-18 License with respect to the Exploitation of such Financial Product in such country will automatically become fully paid-up,
          perpetual, irrevocable and royalty free. For clarity, only a single royalty will be payable as a result of one or more Valid Claims claiming a Financial Product during the Royalty Term.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Royalty
            Reductions</font>.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Lack
            of Valid Claims</font>. On a Financial Product-by-Financial Product and country-by-country basis, if the Financial Product is not Covered by a Financial Patent in a given country, then the royalties payable with respect to such IL-18 Product in
          such country pursuant to Section 9.7(a) (Royalty Rate) will be reduced by [**].</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Biosimilar
            Product Market Effect</font>. On a country-by-country and Financial Product-by-Financial Product basis following the first Calendar Quarter in which a first commercial sale of one or more Biosimilar Products with respect to a Financial Product
          occurs in a country during the Royalty Term (such first Calendar Quarter, the &#8220;<font style="font-weight: bold;">Biosimilar</font>&#160;<font style="font-weight: bold;">Launch Quarter</font>&#8221;), the royalty amounts payable with respect to Annual Net
          Sales of such Financial Product shall be reduced by [**]. If the Net Sales of such Financial Product in any subsequent Calendar Quarter decline by [**] or more relative to the average Net Sales of such Financial Product occurring during the four
          consecutive Calendar Quarters immediately preceding the Biosimilar Launch Quarter (&#8220;<font style="font-weight: bold;">Percentage Decline</font>&#8221;), then, starting from such Calendar Quarter, the royalty amounts payable with respect to Annual Net
          Sales of such Financial Products shall be reduced by [**], unless and until the Net Sales of such Financial Product increase above such Percentage Decline.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Drug
            Pricing Programs</font>. If a Financial Product is selected by the Centers for Medicare and Medicaid Services for inclusion in the Medicare Maximum Fair Price Program pursuant to 42 U.S.C. &#167;1320f <font style="font-style: italic;">et seq</font>.
          and any implementing regulations or guidance promulgated thereunder (&#8220;<font style="font-weight: bold;">IRA</font>&#8221;) or similar drug pricing programs wherein Regulatory Authorities establish prescription drug prices, then the royalties payable by
          Gilead to CGEN pursuant to Section 9.7(a) (Royalty Rate) shall be reduced, on a Financial Product-by-Financial Product basis, by [**].<font style="font-weight: bold;">&#160;</font>For purposes of this Section 9.7(c)(iii), &#8220;[**]&#8221; of a Financial Product
          is [**].</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">40</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Third
            Party IP Payments</font>. Gilead and its Sublicensees shall have the right to deduct from any royalties payable by Gilead to CGEN with respect to Net Sales of a Financial Product pursuant to Section&#160;9.7(a) (Royalty Rate) up to [**] of any
          royalties paid by Gilead or its Affiliates to a Third Party in consideration for a license or other right to practice such Third Party&#8217;s Patents or other Intellectual Property Rights, that, in Gilead&#8217;s reasonable judgment is necessary or useful
          for the Exploitation of the IL-18 Molecule in such Financial Product (such amounts paid by Gilead or its Affiliates to a Third Party, &#8220;<font style="font-weight: bold;">Third Party IP Payments</font>&#8221;). For clarity, if any Third Party IP Payments
          are payable partially on the basis of a Financial Product hereunder and partially on the basis of one or more other products owned or controlled by Gilead, then the amount of offset under this Section 9.7(c)(iv) (Third Party IP Payments) shall be
          limited to a reasonable allocation of Third Party IP Payments attributable to Net Sales of Financial Products.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Royalty
            Floor</font>. In no event shall the royalty reductions available to Gilead under Section 9.7(c) (Royalty Reduction), collectively or individually, reduce the royalties payable to CGEN for a given Calendar Quarter to less than [**] of the amount
          otherwise payable under Section&#160;9.7 (Royalties on Net Sales) with respect to an applicable Financial Product. Gilead may carry forward any such reductions permitted under Section 9.7(c) (Royalty Reduction) that are incurred or accrued in a
          Calendar Quarter but are not applied against payments due to CGEN in such Calendar Quarter as a result of the foregoing floor and apply such amounts against payments due to CGEN in any subsequent Calendar Quarter (subject to the minimum floor set
          forth in this Section 9.7(d) (Royalty Floor)) until the amount of such reduction has been fully applied against payments due to CGEN.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">[**]. If any Third Party obtains a [**] in
          any country and the granted [**], then CGEN shall receive [**] of the [**] pursuant to such [**]. For clarity, Net Sales made by or on behalf of Gilead, its Affiliates, and any Sublicensees other than the [**] shall continue to bear royalties at
          the rates set forth in Section 9.7(a) (Royalty Rate), subject to any eligible reductions in Section 9.7(c) (Royalty Reductions).</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">9.8.&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; <font style="font-weight: bold;">CGEN Third Party Payments</font>.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Subject to 9.8(b) (CGEN Third Party
          Payments), CGEN shall be solely responsible for all costs and payments of any kind (including all upfront fees, annual payments, milestone payments and royalty payments) arising under any agreements between CGEN (or any of its Affiliates) and any
          Third Party, including under any Upstream License Agreement.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">On a Financial Product-by-Financial
          Product basis (as determined in accordance with Section 10.5 (Distinguishing Financial Products)), Gilead shall reimburse CGEN for any [**] that are incurred and paid by CGEN as a result of the Exploitation of any [**] under this Agreement.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A10"><!--Anchor--></a>10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold; font-variant: small-caps;">Payments; Reports; Records; Audits</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">10.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Reimbursable Costs. </font>Within [**] after the end of each Calendar Quarter during the Term, CGEN shall submit an invoice to
        Gilead detailing the FTE Costs and Out-of-Pocket Costs incurred by CGEN during such Calendar Quarter that are reimbursable under this Agreement and as further set forth in the remainder of this Section&#160;10.1 (Reimbursable Costs). Gilead shall pay
        CGEN within [**] following receipt of the applicable invoice.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><u>Manufacturing Technology Transfer</u>.
          CGEN is responsible for the first one [**] FTE hours in FTE Costs incurred by CGEN in performing the Manufacturing Technology Transfer. Thereafter Gilead shall reimburse CGEN for all additional FTE Costs incurred by CGEN to conduct the
          Manufacturing Technology Transfer. CGEN is responsible for the first [**] in Out-of-Pocket Costs incurred by or on behalf of CGEN in performing the Manufacturing Technology Transfer. Thereafter, Gilead shall reimburse CGEN for all additional
          Out-of-Pocket Costs incurred by CGEN to conduct the Manufacturing Technology Transfer.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">41</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><u>Technology Transfer</u>. CGEN is
          responsible for the first [**] FTE hours in FTE Costs incurred by CGEN in performing its obligations under Section&#160;3.5 (Technology Transfer). Thereafter Gilead shall reimburse CGEN for all additional FTE Costs incurred by CGEN to perform such
          obligations. CGEN is responsible for the first [**] in Out-of-Pocket Costs incurred by or on behalf of CGEN in performing its obligations under Section&#160;3.5 (Technology Transfer). Thereafter, Gilead shall reimburse CGEN for all additional
          Out-of-Pocket Costs incurred by CGEN to perform such obligations.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><u>All Other FTE Costs</u>. CGEN is
          responsible for the first [**] FTE hours in FTE Costs incurred by CGEN in performing the its obligations under all of (i)&#160;Section&#160;2.8(b) (IL-18 Data Package) (for clarity, excluding work in connection with a Deficiency Notice),
          (ii)&#160;Section&#160;2.8(e) (CGEN Support), (iii)&#160;Section&#160;2.8(f)(ii) (Assignment or Assistance), (iv)&#160;Section&#160;2.8(f)(iii) (Coordination and Costs), and (v) Section&#160;6.1(b) (After the Development Term) (in the aggregate, &#8220;<font style="font-weight: bold;">All
            Other FTE Cost Obligations</font>&#8221;). After CGEN has performed [**] FTE hours cumulatively for All Other FTE Cost Obligations, Gilead shall reimburse CGEN for all additional FTE Costs incurred by CGEN to conduct All Other FTE Cost Obligations.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><u>All Other Out-of-Pocket Costs</u>. CGEN
          is responsible for the first [**] in Out-of-Pocket Costs incurred by or on behalf of CGEN in performing All Other FTE Cost Obligations. Thereafter, Gilead shall reimburse CGEN for all additional Out-of-Pocket Costs incurred by CGEN to conduct All
          Other FTE Cost Obligations.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><u>Early Development Program Transfer
            Costs</u>. In the event that Gilead provides CGEN with a Development Program Transfer Notice pursuant to Section 2.8(c)(i) (Early Transfer), Gilead shall (1) pay CGEN [**] of the COM503 Transfer Price for [**]; and (2) pay or reimburse, as
          applicable, CGEN for (A) any reasonable and documented non-cancellable costs and obligations incurred by CGEN to any of its Permitted Subcontractors in connection with CGEN&#8217;s responsibilities pursuant to the Development Program other than for the
          supply of COM503 hereunder; and (B) any non-cancellable Out-of-Pocket Costs incurred by CGEN in connection with the Development Plan, up to a maximum of [**].</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">10.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Manufacturing Costs</font>. If any COM503 is supplied to Gilead by CGEN prior to execution of the Clinical Supply Agreement, as
        further described in Section 8.1(a) (Clinical Supply) (during the Clinical Supply Term), then CGEN will invoice Gilead for such COM503 at the COM503 Transfer Price and Gilead will pay CGEN the full undisputed amount of each such invoice within [**]
        after its receipt.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">10.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; [**]. If any [**] incurred by CGEN are reimbursable by Gilead pursuant to Section 9.8(b) (CGEN Third Party Payments), then CGEN will invoice Gilead for such [**]
        and Gilead will pay CGEN the full undisputed amount of each such invoice [**] after its receipt.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">42</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">10.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Royalty Payments</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">During the Term, for each Calendar
          Quarter following the First Commercial Sale of an IL-18 Product in the Territory, Gilead shall furnish to CGEN:</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">a quarterly written report for the
          Calendar Quarter showing, on a country-by-country and Financial Product-by-Financial Product basis, (1) the gross sales of all Financial Products subject to royalty payments sold by Gilead and its Related Parties in the Territory during the
          reporting period, (2) a calculation of Net Sales showing the deductions provided for in the definition of &#8220;Net Sales&#8221;, (3) a calculation of the royalties payable under this Agreement; and (4) solely for the purposes of permitting CGEN to comply
          with its obligations under the [**], a calculation of net sales showing the deductions permitted under the [**], which are set forth on <font style="font-weight: bold;">Schedule&#160;10.4(a)(i)</font>, solely to the extent that such calculation can
          be performed by Gilead under its standard internal processes for calculating net sales, or, if Gilead cannot perform such calculation under its standard internal processes, then Gilead shall use Commercially Reasonable Efforts to provide CGEN
          with the information identified by CGEN as necessary for CGEN to make such calculation (at CGEN&#8217;s request and expense); and</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">a quarterly written report for the
          Calendar Quarter showing, on a country-by-country basis, Gilead&#8217;s royalties payable to Third Parties on Net Sales made during such Calendar Quarter and any royalty adjustments taken by Gilead pursuant to Section 9.7(c) (Royalty Reduction), with
          such detail as shall reasonably allow CGEN to determine the basis for such quarterly costs.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Reports under this Section 10.4 (Royalty
          Payments) shall be due within [**] following [**].</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Royalties shown to have accrued by each
          report shall, unless otherwise specified under this Agreement, be due and payable [**] after the date such report is due.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">10.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Distinguishing Financial Products</font>. A Financial Product shall be distinct from another Financial Product for purposes of
        Milestone Payments, royalties, and [**] if a separate and distinct IND application or BLA or NDA, or their non-US equivalents, is required by a Regulatory Authority to be filed for each such Financial Product to clinically Develop in humans and
        obtain approval to Commercialize each such Financial Product.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">10.6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Payment Exchange Rate</font>. All payments to be made by Gilead to CGEN under this Agreement shall be made in US Dollars by bank
        wire transfer in immediately available funds to a bank account designated in writing by CGEN, unless otherwise specified in writing by CGEN. With respect to sales of a Financial Product that are invoiced in a currency other than US Dollars, such
        amounts and amounts payable will be converted to US Dollars using the exchange rate mechanism generally applied by Gilead or its Affiliates in preparing its financial statements for the applicable Calendar Quarter in which the applicable sales were
        made.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">43</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">10.7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Taxes</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Each Party shall be solely responsible for
          the payment of all taxes, fees, duties, levies or similar amounts imposed on its share of income arising directly or indirectly from the activities of the Parties under this Agreement. The amounts payable by one Party to the other Party pursuant
          to this Agreement shall not be reduced on account of any taxes unless required by Applicable Laws and Regulations. To the extent that a Party is required by Applicable Laws and Regulations to deduct and withhold taxes on any payment to the other
          Party, such party shall pay the amounts of such taxes to the proper governmental authority in a timely manner, shall provide the other Party the proper certificates of withholding, and in such case, such Party&#8217;s remittance of such withheld taxes,
          together with payment to the other Party of the remaining payment, will constitute such Party&#8217;s full satisfaction of payments due under this Agreement. The Parties agree to cooperate with one another and use reasonable efforts to mitigate tax
          withholding (including a reduction of rate of, or the elimination of, or recovery of, applicable withholding tax under any applicable tax treaty) or similar obligations in respect of the payments made under this Agreement, as permitted by
          Applicable Laws and Regulations. If a Party (in this Section 10.7(a), the &#8220;<font style="font-weight: bold;">Paying Party</font>&#8221;) withholds any taxes from payments while the other Party (in this Section 10.7(a), the &#8220;<font style="font-weight: bold;">Payee Party</font>&#8221;) is entitled under any applicable tax treaty to a reduction of rate of, or the elimination of, applicable withholding tax, the Paying Party shall cooperate with the Payee Party with respect to any documentation or
          information required by the appropriate governmental authority or reasonably requested by the Payee Party to secure a reduction of the rate of, or the elimination of, the applicable taxes withheld. Further, if the Paying Party withholds any taxes
          from payments while the Payee Party wishes to protest the applicability of such withholding taxes to such payments, then: (1) the Payee Party may unilaterally approach the tax authorities in order to mitigate tax withholding as aforesaid after
          providing the Paying Party with prior written notice thereof; and (2) the Paying Party shall cooperate and use reasonable efforts to assist the Payee Party to recover (whether by refund or credit) such withheld taxes, including by providing any
          documentation or information required by the appropriate governmental authority or reasonably requested by the Payee Party to obtain such recovery. Any withholding taxes recovered will be for the sole benefit of the Payee Party. Notwithstanding
          anything to the contrary herein, either Party shall be entitled to present this Agreement to the tax authorities in connection with the efforts to mitigate tax withholding, and such disclosure shall not be deemed breach of such Party&#8217;s
          confidentiality obligations pursuant to this Agreement. Each Party shall provide reasonable notice to the other Party prior to withholding any amount from such payments to allow the other Party to claim a reduction of otherwise applicable
          withholding taxes. Notwithstanding the foregoing, if Gilead assigns its rights and obligations hereunder to an Affiliate or Third Party in compliance with Section 18.3(a) (Assignment; Change of Control) and if such Affiliate or Third Party shall
          be required by Applicable Laws and Regulations to withhold any additional taxes from or in respect of any amount payable under this Agreement as a result of such assignment, then any such amount payable under this Agreement shall be increased to
          take into account the additional taxes withheld as may be necessary so that, after making all required withholdings, CGEN<font style="font-weight: bold;">&#160;</font>receives an amount equal to the sum it would have received had no such assignment
          been made.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">All payments under this Agreement are
          stated exclusive of indirect taxes (VAT, GST, sales tax and similar, collectively referred to as &#8220;<font style="font-weight: bold;">VAT</font>&#8221;) and statutory VAT is to be added, if applicable. The invoicing party is obliged to issue an invoice
          for all payable amounts under this Agreement in accordance with applicable VAT law. The invoicing party shall comply with any additional reasonable requests of invoiced party in relation to such invoices. Invoiced Party shall pay such VAT
          following the receipt of a VAT invoice. The Parties shall cooperate in any way reasonably requested, to obtain available reductions, credits or refunds of any VAT amount under this Agreement, if applicable.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">10.8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Records</font>.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Gilead
            Financial Records</font>. During the Term and for a period of [**] after expiration or termination of this Agreement, or such longer period as required by Applicable Laws and Regulations, Gilead shall, and shall cause its Related Parties to,
          keep complete and accurate records in reasonable detail to allow CGEN to determine the basis for any amounts payable to CGEN under this Article&#160;10 (Payments; Reports; Records; Audits).</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">CGEN
            Financial Records</font>. During the Term and for a period of [**] after expiration or termination of this Agreement, or such longer period as required by Applicable Laws and Regulations, CGEN shall, and shall cause its Affiliates to, keep
          complete and accurate records in sufficient detail to allow Gilead to determine the basis for the amounts payable to CGEN under this Agreement, including (i) Section 10.1 (Reimbursable Costs), (ii) Section&#160;10.2 (Manufacturing Costs), including
          for the Manufacture of COM503 during the Clinical Supply Term, (iii) Section 10.3 ([**]), (iv) the Clinical Supply Agreement, or (v) Section 2.8(f)(iii) (Coordination and Costs).</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">44</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">10.9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Audit Rights</font>. Upon the written request of a Party (&#8220;<font style="font-weight: bold;">Requesting Party</font>&#8221;) with
        reasonable advance notice and not more than [**] in each [**]&#160; (except for cause), the other Party (&#8220;<font style="font-weight: bold;">Audited Party</font>&#8221;) shall permit an Approved Auditor, at the Requesting Party&#8217;s own expense, to have access
        during normal business hours to such of the records as may be reasonably necessary to verify the relevant records required to be maintained by the Audited Party pursuant to Section 10.8 (Records) or that the correct amounts were paid by or to the
        Requesting Party under this Agreement as a result during any Calendar Year ending not more than [**] prior to the date of such request; <font style="font-style: italic;">provided</font>, that records for a particular period may only be audited
        [**]. The Approved Auditor shall disclose to the Requesting Party only whether the reports are correct or incorrect and the specific details concerning any discrepancies. No other information shall be provided to Requesting Party in connection with
        this audit right. This right to audit shall remain in effect during the Term and for a period of [**] after expiration or termination of this Agreement. If such Approved Auditor identifies a discrepancy with respect to amounts owed by the Audited
        Party to the Requesting Party under this Agreement, the Audited Party shall pay the Requesting Party the amount of such discrepancy within [**] after the date Requesting Party delivers to the Audited Party such Approved Auditor written report so
        concluding, or as otherwise agreed upon by the Parties in writing. The fees charged by such Approved Auditor shall be paid by Requesting Party unless the underpayment by the Audited Party exceeded [**] of the amount owed for such Calendar Year, in
        which case the Audited Party shall pay to Requesting Party the reasonable fees charged by such Approved Auditor.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">10.10.&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Confidentiality</font>. Each Party shall treat all information of the other Party subject to review under this Article&#160;10
        (Payments; Reports; Records; Audits) in accordance with the confidentiality and non-use provisions of this Agreement, and shall cause its Approved Auditor to enter into an acceptable confidentiality agreement with the Audited Party and any
        applicable Related Parties, obligating it or them to retain all such information in confidence pursuant to such confidentiality agreement.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A11"><!--Anchor--></a>11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold; font-variant: small-caps;">Confidentiality; Publication</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">11.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Nondisclosure Obligation</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Definition
            and Restrictions</font>. All Confidential Information disclosed by or on behalf of one Party or any of its Affiliates (the &#8220;<font style="font-weight: bold;">Disclosing Party</font>&#8221;) to the other Party or any of its Affiliates (the &#8220;<font style="font-weight: bold;">Receiving Party</font>&#8221;) at any time, including before the Effective Date (to the extent related to the subject matter of this Agreement, including pursuant to the Existing CDA), shall: (1) be maintained in confidence
          by the Receiving Party, using no less than the efforts that Receiving Party uses to maintain in confidence its own confidential or proprietary information of similar kind and value, but in any case no less than reasonable care, and (2) not be
          disclosed by the Receiving Party to any Third Party or used by the Receiving Party for any purpose except as set forth herein or in connection with the exercise of such Party&#8217;s rights and performance of its obligations under this Agreement
          without the prior written consent of the Disclosing Party, in each case ((1) and (2)), during the Term and for a period of [**] thereafter. In addition, CGEN will keep confidential, and will cause its Affiliates and its and their employees,
          consultants, licensees, Permitted Subcontractors, and professional advisors to keep confidential under customary obligations of confidentiality consistent with standards in the industry, the Know-How comprising IL-18 IP and Jointly Owned
          Foreground IP, in each case to the extent specifically related to the IL-18 Molecules or IL-18 Products on confidentiality terms at least as protective as the confidentiality provisions of this Agreement. The following shall not be Confidential
          Information for purposes of this Agreement:</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">information that is known by the
          Receiving Party at the time of its receipt without any obligation to keep it confidential or restriction on its use, and not through a prior disclosure by the Disclosing Party, as documented by the Receiving Party&#8217;s written records;</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">45</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">information that is or becomes part of
          the public domain through no wrongful act or breach of this Agreement on the part of the Receiving Party;</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">information that is subsequently
          disclosed to the Receiving Party by a Third Party who may lawfully do so and is not under an obligation of confidentiality or any restriction on use with respect to such information; and</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">information that is developed by the
          Receiving Party without any reference to, reliance upon or use of Confidential Information received from the Disclosing Party, as documented by the Receiving Party&#8217;s written records.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Combinations</font>.
          Any combination of features or disclosures shall not be deemed to fall within the exclusions set forth in Section&#160;11.1(a) (Definition and Restrictions) merely because individual features are published or available to the general public or in the
          rightful possession of the Receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the Receiving Party.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Permitted
            Disclosures</font>. Notwithstanding the restrictions set forth in Section&#160;11.1(a) (Definition and Restrictions), the Receiving Party may disclose Confidential Information of the other Party (including the existence and terms of this Agreement):</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">to any Governmental Entity in order to
          obtain Patents or to gain or maintain approval to conduct Clinical Trials or to market IL-18 Products; <font style="font-style: italic;">provided</font>, that such disclosure is only to the extent reasonably necessary to obtain such Patents or
          authorizations and reasonable steps are taken to ensure confidential treatment of such Confidential Information to the extent available. For any such disclosure that may be subject to a public disclosure law or regulation, such as the Freedom of
          Information Act (FOIA) or EU Clinical Trial Regulation, Gilead shall have the obligations as the publishing Party and CGEN shall have the rights as the reviewing Party according to the procedure set forth under Section 11.2 (Publication) for
          review of such disclosure; or</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">subject to Section 11.1(d) (Securities
          Filings; Disclosures under Applicable Law), to the extent required in the reasonable opinion of such Party&#8217;s legal counsel, in connection with complying with Applicable Laws and Regulations (including the rules and regulations promulgated by the
          United States Securities and Exchange Commission or any other national securities exchange in any jurisdiction in the Territory (each, a &#8220;<font style="font-weight: bold;">Securities Regulator</font>&#8221;));</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">to the extent the Receiving Party deems
          such disclosure necessary to be disclosed (1) to its Related Parties, or its or their respective employees, agents, representatives, consultants and Permitted Subcontractors (&#8220;<font style="font-weight: bold;">Representatives</font>&#8221;) on a
          need-to-know basis for the Development, Manufacture or Commercialization of IL-18 Molecules and IL-18 Products, (2) its attorneys, accountants and advisors, (3) in connection with a prospective or actual licensing transaction or other business
          agreement or contractual obligation related to IL-18 Molecules and IL-18 Products, (4) to existing or <font style="font-style: italic;">bona fide</font> prospective acquirers, merger partners, lenders or investors of the Receiving Party (&#8220;<font style="font-weight: bold;">Potential Partners</font>&#8221;) in connection with transactions or <font style="font-style: italic;">bona fide</font> prospective transactions with the foregoing, including loans, financings or investments, acquisitions,
          mergers, consolidations, sale of assets or similar transactions (or for such entities to determine their interest in performing such activities or to determine their rights and obligations as a result of completing such transactions) or (5) in
          order to perform its obligations or exercise its rights under this Agreement, in each case on the condition that any Third Parties, other than Regulatory Authorities, to whom such disclosures are made agree to be bound in writing or otherwise
          legally bound by confidentiality and non-use obligations substantially similar to those contained in this Agreement; <font style="font-style: italic;">provided</font>, that the term of confidentiality and non-use applicable to such Third Parties
          shall be no less than [**] (but of shorter duration if customary given the nature of such Person (i.e., investors, lenders and banking institutions)) from the date of disclosure to them; <font style="font-style: italic;">provided</font>&#160;<font style="font-style: italic;">further</font>, that with respect to Confidential Information of a Party that constitutes a trade secret, such confidentiality and non-use obligations shall apply for so long as such information constitutes a trade
          secret under Applicable Laws and Regulations. Notwithstanding the foregoing, each Receiving Party shall remain responsible and liable to the Disclosing Party for any breach by any of its Representatives or Potential Partners; or</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">46</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">if a Party is required by a valid
          judicial or administrative order to disclose Confidential Information of the other Party that is subject to the non-disclosure provisions of this Section&#160;11.1 (Nondisclosure Obligation), in which case, such Party shall provide prompt, and to the
          extent legally permissible, prior written notice to the other Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is
          disclosed pursuant to valid judicial or administrative order shall remain otherwise subject to the confidentiality and non-use provisions of this Section&#160;11.1 (Nondisclosure Obligation), and the Party disclosing Confidential Information pursuant
          to a valid order shall take all steps reasonably necessary, including obtaining an order of confidentiality, to ensure the continued confidential treatment of such Confidential Information.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Securities
            Filings; Disclosure under Applicable Law</font>. Each Party acknowledges and agrees that the other Party may submit this Agreement to, or file this Agreement with, the Securities Regulators or to other Persons as may be required by Applicable
          Laws and Regulations, and if a Party submits this Agreement to, or files this Agreement with, any Securities Regulator or other Person as may be required by Applicable Laws and Regulations, such Party agrees to consult with the other Party with
          respect to the preparation and submission of a confidential treatment request for this Agreement or other manner to redact specific information from the form of this Agreement to be filed with such Securities Regulator. Notwithstanding the
          foregoing, if a Party is required by any Securities Regulator or other Person as may be required by Applicable Laws and Regulations to make a disclosure of the terms of this Agreement in a filing or other submission as required by such Securities
          Regulator or such other Person, then such Party shall use Commercially Reasonable Efforts to: (i) provide copies of the disclosure to the other Party reasonably in advance under the circumstances of such filing or other disclosure; (ii) promptly
          notify the other Party in writing of such requirement and any respective timing constraints; and (iii) give the other Party reasonable time under the circumstances from the date of provision of copies of such disclosure to comment upon and
          request confidential treatment for such disclosure, then such Party will have the right to make such disclosure at the time and in the manner reasonably determined by its counsel to be required by the Securities Regulator or the other Person.
          Notwithstanding the foregoing, if a Party seeks to make a disclosure as required by a Securities Regulator or other Person as may be required by Applicable Law and Regulations as set forth in this Section 11.1(d) (Securities Filings; Disclosure
          under Applicable Law) and the other Party provides comments in accordance with this Section 11.1(d) (Securities Filings; Disclosure under Applicable Law), the Party seeking to make such disclosure or its counsel, as the case may be, will
          reasonably consider the incorporation of such other Party&#8217;s reasonable comments to the extent compliant with the Applicable Laws and Regulations applying to the disclosing Party governing disclosure of material agreements and material information
          that must be publicly filed.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Obligations
            Upon Termination</font>. Upon the earlier of termination or expiration of the Agreement (or in the case of Confidential Information received pursuant to an Upstream License Agreement, upon the expiration or earlier termination of such
          agreement), except to the extent the Receiving Party is otherwise required by Applicable Laws and Regulations to retain certain information, the Receiving Party shall, and shall promptly require all of its Representatives and Potential Partners,
          to securely return to the Disclosing Party or securely dispose of all Confidential Information of the Disclosing Party (at the Disclosing Party&#8217;s election), whether such Confidential Information is in written, electronic or other form of media
          and, within [**] following Disclosing Party&#8217;s written request, Receiving Party shall certify in writing the secure disposal of all such Confidential Information. Receiving Party shall not be required to return or securely dispose of the
          Disclosing Party&#8217;s Confidential Information stored on backup media, disaster recovery, or business continuity systems in the ordinary course of Receiving Party&#8217;s business, provided that Receiving Party will continue to protect such Confidential
          Information in accordance with the terms of this Agreement. Notwithstanding the foregoing, the Receiving Party may retain: (i) Confidential Information of the Disclosing Party to exercise rights and licenses which expressly survive such
          termination or expiration pursuant to this Agreement and (ii) solely for the purpose of determining the scope of its obligations under this Agreement, one (1) copy of Confidential Information received hereunder, and any such retained copies shall
          continue to be subject to the confidentiality and non-use obligations in accordance with this Agreement.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">47</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">11.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Publication</font>.&#160;Except as covered by Section 11.1(d) (Securities Filings; Disclosure under Applicable Law), any proposed
        public disclosure (whether written, electronic, oral or otherwise) by CGEN or any of its Affiliates related to activities under this Agreement or the IL-18 Molecules or the IL-18 Products will require the prior written consent of Gilead, and Gilead
        or any of its Affiliates will have the right, without any required consents from CGEN, to publish, publicly present or otherwise publicly disclose any paper, publication, oral presentation, abstract, poster, manuscript or other presentation
        relating to any activity or other matter under this Agreement, including the results of any Clinical Trial, or other activities under this Agreement. In such case, Gilead will provide CGEN with, (a) a copy of any proposed written publication at
        least [**] ([**] for an abstract) prior to submission for publication; and (b) a copy of the graphics and written outline of material to be presented for the proposed oral disclosure (to the extent not included in the graphics) at least [**] prior
        to submission. At CGEN&#8217;s request, Gilead will remove any Confidential Information of CGEN from the proposed publication and reasonably delay submission for publication for a period of [**] in order to enable CGEN to seek patent protection of CGEN&#8217;s
        patentable information disclosed therein, and request to remove any CGEN Confidential Information.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">11.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Publicity; Use of Names</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Press
            Releases</font>. On such date and time as may be agreed by the Parties immediately after the Effective Date, the Parties shall issue a joint press release announcing the execution of this Agreement in the form attached hereto as <font style="font-weight: bold;">Schedule 11.3(a)</font> (Press Release). A Party may issue any subsequent press release relating to this Agreement or activities conducted hereunder (i) pursuant to Section&#160;11.1(d) (Securities Filings; Disclosure
          under Applicable Law) or (ii) otherwise only with the prior written approval of the other Party.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">No Other
            Use of Company Names</font>. Neither Party shall use the name, Trademark, trade name or logo of the other Party, its Affiliates or its or their employees in any publicity or news release relating to this Agreement or its subject matter without
          the prior express written permission of the other Party.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Approved
            Press Releases</font>. In addition and notwithstanding anything to the contrary herein, (i) if the relevant information of a proposed press release has already previously been reviewed and approved for disclosure by the other Party then such
          text may be disclosed or republished in such proposed press release <font style="font-style: italic;">provided</font>, that the information in such press release remains true, correct and the most current information with respect to the subject
          matters set forth therein and, where practicable, the Party issuing such press release provides notice to the other Party of such press release at least [**] prior to the issuance of such press release, and (ii) if the relevant information of a
          proposed public announcement such as a corporate presentation or comments to analysts or investors has already previously been reviewed and approved for disclosure by the other Party (whether in the form of an approved press release or prior
          approved presentation materials, Q&amp;A script or the like) then such information may be included in such proposed public announcement (but not a press release) without resubmission and review by the other Party so long as the information in
          such materials remains true, correct and the most current information with respect to the subject matters set forth therein.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">48</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A12"><!--Anchor--></a>12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold; font-variant: small-caps;">Compliance</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">12.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">General</font>. Each Party shall comply with the terms of this Agreement and all Applicable Laws and Regulations relating to
        activities performed or to be performed by such Party (or its Affiliates or Sublicensee(s)) under or in relation to the Development, Manufacturing, Commercialization, or other Exploitation of IL-18 Molecules and IL-18 Products pursuant to this
        Agreement (each such Party, a &#8220;<font style="font-weight: bold;">Subject Party</font>&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">12.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Covenants, Representations and Warranties for Compliance with Laws</font>.&#160;Without limiting the generality of Section 12.1
        (General), each Subject Party agrees, on behalf of itself, its Affiliates, and its and their officers, directors, employees, agents, representatives, consultants, and Permitted Subcontractors (together with such Party, the &#8220;<font style="font-weight: bold;">Obligants</font>&#8221;) that, for the performance of its obligations hereunder:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Anticorruption
            Laws</font>.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Its Obligants shall not directly or
          indirectly pay, offer or promise to pay, or authorize the payment of any money, or give, offer or promise to give, or authorize the giving of anything else of value in violation of applicable Anti-Corruption Laws, to: (1) any Government Official
          in order to improperly influence official action; (2) any individual (whether or not a Government Official) (x) to improperly influence such individual to act in breach of a duty of good faith, impartiality or trust (&#8220;<font style="font-weight: bold;">Acting Improperly</font>&#8221;), (y) to improperly reward such individual for Acting Improperly, or (z) where it is known that such individual would be Acting Improperly by receiving the money or other thing of value; (3) any other Person
          while knowing or having reason to know that all or any portion of the money or other thing of value shall be paid, offered, promised or given to, or shall otherwise benefit, a Government Official in order to improperly influence official action
          for or against either Party in connection with the matters that are the subject of this Agreement; or (4) any Person to improperly reward that Person for Acting Improperly or to improperly induce that Person to Act Improperly.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Its Obligants shall not, directly or
          indirectly, solicit, receive or agree to accept any payment of money or anything else of value in violation of the applicable Anti-Corruption Laws.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">The Subject Party and its Obligants
          shall comply with the applicable Anti-Corruption Laws and shall not take or perform any action that is a violation of any such Anti-Corruption Laws or cause either Party (or its Affiliates) to be in violation of any such Anti-Corruption Laws. In
          furtherance of the foregoing, each acknowledges and confirms the following:</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 153pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">&#160;(1)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Each Subject Party has implemented
          policies, procedures and internal controls reasonably designed to promote compliance with applicable Anti-Corruption Laws.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 153pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">&#160;(2)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">To the best of the Subject Party&#8217;s and
          its Affiliates&#8217; knowledge upon reasonable inquiry, none of its Obligants that will participate in or support the Subject Party&#8217;s performance of its obligations hereunder has, directly or indirectly, (x) paid, offered or promised to pay, or
          authorized the payment of any money; (y) given, offered or promised to give, or authorized the giving of anything else of value; or (z) solicited, received or agreed to accept any payment of money or anything else of value, in each case ((x), (y)
          and (z)), in violation of the Anti-Corruption Laws during the [**] preceding the Effective Date in relation to the obligations under this Agreement or the Intellectual Property Rights, technology, contracts, materials, or licenses or other assets
          that are the subject of this Agreement.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">49</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 153pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">&#160;(3)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">To the best of each Subject Party&#8217;s and
          its Affiliates&#8217; knowledge upon reasonable inquiry, none of its Intellectual Property Rights, technology, contracts, materials, or licenses or other assets that are the subject of this Agreement were procured in violation of any Anti-Corruption
          Laws.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 153pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">&#160;(4)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">The Subject Party, on behalf of itself
          and its Obligants, represents and warrants to the other Party that all information provided by the Subject Party and its Obligants to the other Party in any anti-bribery and corruption due diligence checklist, similar due diligence process
          performed by the other Party or its Affiliates or inquiry by the other Party related to the Subject Party&#8217;s or its Obligants compliance with Anti-Corruption Laws is true, complete and correct in all material respects at the date it was provided
          and that any material changes in circumstances relevant to the answers provided in such exercise shall be promptly disclosed to the other Party.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 153pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">&#160;(5)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">The Subject Party shall promptly provide
          the other Party with written notice of any of the following events: (i) upon becoming aware of any actual or alleged breach or violation by the Subject Party or any of its Obligant of any representation, warranty or undertaking set forth in this
          Section 12.2 (Covenants, Representations and Warranties For Compliance with Laws); (ii) upon receiving a notification that it is the target or subject of an investigation, formal or informal inquiry or enforcement proceedings by a government
          authority for violation of any Anti-Corruption Laws in relation to the obligations under this Agreement or the Intellectual Property Rights, technology, contracts, materials, or licenses or other assets that are the subject of this Agreement;
          (iii) upon receiving any notice, request, subpoena or citation from a government authority for any violation of any Anti-Corruption Law in relation to the obligations under this Agreement or the Intellectual Property Rights, technology,
          contracts, materials, or licenses or other assets that are the subject of this Agreement; or (iv) upon receipt of information that any of the Subject Party&#8217;s Obligants is the target or subject of an investigation, formal or informal enquiry or
          enforcement proceedings by a government authority for a violation of any Anti-Corruption Law in relation to the obligations under this Agreement or the Intellectual Property Rights, technology, contracts, materials, or licenses or other assets
          that are the subject of this Agreement.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 153pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">&#160;(6)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">For the Term and for [**] following the
          expiration or earlier termination of the Agreement, the Subject Party shall for the purpose of auditing and monitoring the performance of its compliance with this Agreement and particularly this Section 12.2 (Covenants, Representations and
          Warranties For Compliance with Laws) permit the other Party and its Approved Auditors to have reasonable access, with reasonable advance notice and not more than [**] in each [**]&#160; (except for cause), to relevant premises of the Subject Party
          used in connection with this Agreement, together with a right to reasonably access personnel and records that relate to this Agreement and shall use Commercially Reasonable Efforts to provide reasonable access to relevant premises of the
          Obligants used in connection with this Agreement, together with a right to reasonably access personnel and records of Obligants that relate to this Agreement (&#8220;<font style="font-weight: bold;">Subject Party</font>&#160;<font style="font-weight: bold;">Audit</font>&#8221;).
          The Subject Party shall provide or shall use Commercially Reasonable Efforts to procure that its Obligants provide all co-operation as reasonably requested by the other Party for the purposes of the Subject Party Audit, with the understanding
          that the other Party shall be responsible for all costs and fees of any Subject Party Audit and the other Party shall procure that any auditor enters into a confidentiality agreement consistent with the confidentiality provisions elsewhere in
          this Agreement in all material respects.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">50</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 153pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">&#160;(7)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">If (A) the other Party becomes aware of,
          whether or not through a Subject Party Audit, that the Subject Party (or any of its Obligants) is in breach of any representation, warranty or undertaking in Section 12.1 (General) or of the Anti-Corruption Laws; or (B) the other Party receives
          notification that a suspected or actual violation of an Anti-Corruption Law has occurred by the Subject Party or any of its Obligants, in each case of (A)-(B), the other Party shall have the right, in addition to any other rights or remedies
          under this Agreement or to which the other Party may be entitled in law or equity, to take such steps as are reasonably necessary in order to avoid a potential violation or continuing violation by the other Party or any of its Affiliates of the
          Anti-Corruption Laws, including by requiring that the Subject Party agrees to and uses Commercially Reasonable Efforts to implement curative actions reasonably requested in good faith by the other Party. In the event that the Subject Party is in
          breach of any representation, warranty or undertaking in Section 12.1 (General) and refuses to use Commercially Reasonable Efforts to implement the curative actions reasonably requested by the other Party in good faith (and <font style="font-style: italic;">provided</font>, that the other Party has (x) provided the Subject Party with an explanation in reasonable detail as to why the other Party considers such actions necessary, (y) given the Subject Party a reasonable
          opportunity to review and comment upon the proposed actions and to provide its view as to the necessity or usefulness of these to address the event concerned, and (z) considered such comments in good faith), the other Party shall be entitled to
          terminate this Agreement in its entirety with immediate effect (subject to tolling under Section 17.2(b) for any dispute about the existence of such breach to the extent exercised by a Party thereunder). Any termination of this Agreement pursuant
          to this Section 12.2 (Covenants, Representations and Warranties For Compliance with Laws) shall be treated as a termination for breach by the Subject Party of this Agreement and the consequences of termination shall apply and additionally,
          subject to the accrued rights of the Parties prior to termination, the other Party shall have no liability to the Subject Party for any fees, reimbursements or other compensation or for any loss, cost, claim or damage resulting, directly or
          indirectly, from such termination.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Data
            Protection Laws</font>.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman',Times,serif;">From time to time during the Term,
          either Party may provide the other Party with personal information that falls under the protection of Data Protection Laws (&#8220;<font style="font-weight: bold;">Protected Personal Information</font>&#8221;). Each Party agrees to comply with all Data
          Protection Laws relating to Processing of such Protected Personal Information. The Parties agree to use good-faith efforts to agree upon and implement any security protocols and information handling guidelines that the Parties&#8217; legal advisors
          recommend in connection with each Party&#8217;s compliance with Data Protection Laws.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">CGEN agrees that it will obtain any and
          all necessary consents or authorizations to share Protected Personal Information with Gilead and that it otherwise has all necessary rights, permissions, and legal authority to share Protected Personal Information for all purposes arising out of
          this Agreement.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Information
            Security</font>.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Each Party will comply with Applicable
          Laws and Regulations in its storage, maintenance, use and dissemination of the other Party&#8217;s Confidential Information which it receives or to which it obtains access (such Confidential Information &#8220;<font style="font-weight: bold;">Secured
            Information</font>&#8221;).</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Each Party will employ commercially
          reasonable security measures to protect Secured Information in accordance with accepted applicable industry standards and such Party&#8217;s information security policy as amended from time to time. As necessary, each Party will employ additional
          security measures to protect Secured Information.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">51</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iii)</font>&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman',Times,serif;">Each Party will implement
          administrative, physical and technical safeguards to protect Secured Information that are no less rigorous than accepted industry practices and standards for information security and shall ensure that all such safeguards comply with Applicable
          Laws and Regulations.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">Each Party will notify the other Party by
          email immediately, but in no case more than [**] of (1) becoming aware of any act or omission that materially compromises the security, confidentiality, or integrity of the physical, technical, administrative, or organizational safeguards put in
          place by or on behalf of a Party, that relate to the protection of the security, confidentiality, or integrity of Secured Information or Protected Personal Information, or (2) receipt of a notification in relation to Protected Personal
          Information or the privacy and data security practices of such Party or any actual or suspected accidental or unlawful destruction, loss, alteration, disclosure of, or access to, Protected Personal Information transmitted, stored or otherwise
          Processed; (each of (1) and (2) individually and collectively a &#8220;<font style="font-weight: bold;">Security Incident</font>&#8221;).</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Other than as required by Applicable Laws
          and Regulations or a contractual obligation to a Third Party, each Party agrees that it will not inform any Third Party of an actual or potential Security Incident related to the other Party&#8217;s Confidential Information (including work product
          under the Agreement and such other Party&#8217;s Intellectual Property Rights) without first obtaining such other Party&#8217;s prior consent.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Export
            Control Laws</font>. Each Party will comply with all Applicable Laws and Regulations relating to (i) economic and trade sanctions and embargoes imposed by the Office of Foreign Assets Control of the U.S. Department of Treasury or (ii) the
          export or re-export of commodities, technologies or services (&#8220;<font style="font-weight: bold;">Export Control Laws</font>&#8221;). Each Party acknowledges and expressly notes its understanding that certain laws of the United States and other
          countries, including&#160;the Export Control Laws, the United States anti-money laundering laws, the United States anti-terrorism laws and the FCPA, and U.S. sanctions programs administered by the Office of Foreign Assets Control (&#8220;<font style="font-weight: bold;">OFAC</font>&#8221;) and the Bureau of Industry and Security, among others, may result in the imposition of sanctions on the other Party or its Affiliates in the event that, directly or indirectly, products or services are
          exported to or imported from, or payments are sent to or received from various countries or regions.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Compliance
            Event Reporting</font>. The other Party may disclose the terms of this Agreement or any action taken under this Section 12.2 (Covenants, Representations and Warranties For Compliance with Laws) to prevent a potential violation or continuing
          violation of applicable Anti-Corruption Laws, Data Protection Laws or Export Control Laws, including the identity of the Subject Party and the payment terms, to any government authority if the other Party determines, upon advice of counsel, that
          such disclosure is necessary.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A13"><!--Anchor--></a>13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold; font-variant: small-caps;">Representations and Warranties</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">13.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Mutual Representations and Warranties</font>. Each Party represents and warrants to the other Party that, as of the Effective
        Date:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">such Party is duly organized, validly
          existing and in good standing under the Applicable Laws and Regulations of the jurisdiction of its formation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof or thereof, as applicable;</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">52</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">such Party has taken all necessary
          action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder or thereunder, as applicable;</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">this Agreement has been duly executed
          and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against it in accordance with the terms hereof;</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">the execution, delivery and performance of
          this Agreement by such Party does not conflict with any agreement or any provision thereof, or any instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate any Applicable Laws and Regulations of
          any Governmental Entity having jurisdiction over such Party;</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">no government authorization, consent,
          approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any Applicable Laws and Regulations currently in effect, is
          necessary for or in connection with the transaction contemplated by this Agreement or any other agreement or instrument executed in connection herewith, or for the performance by it of its obligations under this Agreement and such other
          agreements except (i) as may be required to conduct Clinical Trials, (ii) as may be required under applicable Antitrust Laws, or (iii) to seek or obtain Regulatory Approvals or applicable regulatory materials; and</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(f)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">such Party is not debarred under the
          United States Federal Food, Drug and Cosmetic Act or comparable laws in any other country or jurisdiction, and it does not&#160;employ or use the services of any person or entity who is debarred, in connection with the Development, Manufacture or
          Commercialization of the IL-18 Products.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">13.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Representations and Warranties of CGEN</font>. CGEN represents and warrants to Gilead that, as of the Effective Date:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">it Controls the right, title and interest
          in and to the Patents set forth on <font style="font-weight: bold;">Schedule&#160;1.134 </font>(IL-18 Patents) and IL-18 Know-How, and has the right to grant to Gilead the licenses under such IL-18 Patents and IL-18 Know-How and the sublicenses
          under the Existing Upstream License Agreements that it purports to grant and may grant hereunder and has not granted any Third Party rights under such IL-18 Patents, IL-18 Know-How and Existing Upstream License Agreements that would interfere or
          be inconsistent with Gilead&#8217;s rights hereunder;</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">as of the Effective Date, <font style="font-weight: bold;">Schedule 1.134 </font>(IL-18 Patents) sets forth a complete and accurate list of all IL-18 Patents issued or pending, and all such IL-18 Patents have been prosecuted and maintained by or on behalf of CGEN in good
          faith and if issued, are in full force and effect and to CGEN&#8217;s Knowledge, are not invalid or unenforceable. All application, registration, maintenance and renewal fees due as of the Effective Date with respect to all IL-18 Patents set forth on <font style="font-weight: bold;">Schedule 1.134</font> (IL-18 Patents) have been paid and all necessary documents and certificates have been filed with the relevant patent registries for the purpose of maintaining such IL-18 Patents. Any Patents that
          claim Third Party IL-18 Inventions are set forth on <font style="font-weight: bold;">Schedule 1.134</font>. For purposes of this Section 13.2(b), &#8220;<font style="font-weight: bold;">Third Party IL-18 Inventions</font>&#8221; means Inventions conceived
          of or reduced to practice by a Third Party under contract with CGEN, wherein such Inventions are necessary or reasonably useful to Exploit IL-18 Molecules or IL-18 Products in the Field in the Territory;</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Except with respect to any IL-18 IP that
          is licensed under the Existing Upstream License Agreements, the IL-18 Patents and IL-18 Know-How are not subject to any other Third Party agreements;</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">53</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Except with respect to any IL-18 IP that
          is licensed under the Existing Upstream License Agreements, CGEN is the sole and exclusive owner of the IL-18 Patents and IL-18 Know-How,&#160;in each case, free and clear of all liens and encumbrances;</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">CGEN and its Affiliates have obtained from
          its and their employees, respectively, and any Third Party contractually engaged by CGEN who participated in any respect in the invention of any IL-18 Molecules or IL-18 Products effective assignments of all ownership rights of such employees or
          any Third Party contractually engaged by CGEN in such inventions, either pursuant to written agreement or by operation of law; and to the Knowledge of CGEN, no Person who claims to be an inventor of an Invention claimed in an IL-18 Patent is not
          identified as an inventor of such Invention in the filed patent documents for such IL-18 Patent;</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">all of CGEN and its Affiliates employees,
          officers and consultants: (1) have executed agreements or have existing obligations under Applicable Laws and Regulations requiring assignment to CGEN or its Affiliates of all Inventions made during the course of and as the result of their
          association with CGEN or its Affiliates, as applicable, and obligating the individual to assign to CGEN or its Affiliates, as applicable, all Inventions made during the course of performance under this Agreement; (2) are not subject to any
          agreement with any other Third Party that requires such officer or employee or consultant to assign any interest in any IL-18 IP to such Third Party; and (3) have executed agreements or have existing obligations under Applicable Laws and
          Regulations obligating the individual to maintain as confidential CGEN&#8217;s Confidential Information as well as confidential information of other parties (including of Gilead and its Affiliates) that such individual may receive in its performance
          under this Agreement, if any;</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">to the Knowledge of CGEN, there is no
          action, suit, inquiry, or investigation pending or ongoing by any Third Party that challenges or threatens the validity or enforceability of any of the IL-18 Patents. CGEN has not received written notice of any action, suit, inquiry,
          investigation or other proceeding by any Third Party that challenges or threatens the validity or enforceability of any of the IL-18 Patents;</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">to the Knowledge of CGEN, (a) the use of
          the IL-18 IP in the performance of the activities under the Development Plan as contemplated to be conducted under this Agreement, does not infringe, misappropriate or otherwise violate any Intellectual Property Right owned or controlled by any
          Third Party, and (b) the Manufacture or Commercialization of COM503 does not infringe, misappropriate or otherwise violate any Intellectual Property Right owned or controlled by any Third Party;</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman',Times,serif;">to the Knowledge of CGEN, there is no
          action, suit, inquiry, investigation or other proceeding threatened in writing, pending, or ongoing by any Third Party that alleges the use of the IL-18 Patents or the IL-18 Know-How or the Exploitation of any IL-18 Molecule or IL-18 Product
          would infringe, misappropriate or otherwise violate any Intellectual Property Rights of any Third Party. CGEN has not received any written notice of any action, suit, inquiry, investigation or other proceeding by any Third Party that alleges the
          use of the IL-18 Patents or the IL-18 Know-How or the Exploitation of any IL-18 Molecule or IL-18 Product would infringe, misappropriate or otherwise violate any Intellectual Property Rights of any Third Party;</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Schedule
            1.36</font> (CGEN Development and Manufacturing Agreements) sets forth a complete and accurate list of the CGEN Development and Manufacturing Agreements in effect as of the Effective Date. <font style="font-weight: bold;">Schedule 1.36(a)</font>
          (IL-18-Only Development and Manufacturing Agreements) sets forth a complete and accurate list of the IL-18-Only Development and Manufacturing Agreements in effect as of the Effective Date. CGEN has provided Gilead true, accurate and correct
          copies of each such CGEN Development and Manufacturing Agreement (in reasonably redacted form). Each such CGEN Development and Manufacturing Agreement is in full force and effect, CGEN has not received or sent any written notice of default under
          any such CGEN Development and Manufacturing Agreement, and to the Knowledge of CGEN, no party to any CGEN Development and Manufacturing Agreement is in breach of such CGEN Development and Manufacturing Agreement;</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">54</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Schedule
            1.242</font> (Existing Upstream License Agreements) sets forth a complete and accurate list of the Upstream License Agreements in effect as of the Effective Date. CGEN has provided Gilead true, correct and complete copies of each such Existing
          Upstream License Agreement (in reasonably redacted form). Each such Existing Upstream License Agreement is in full force and effect, CGEN has not received or sent any written notice of default under any such Existing Upstream License Agreement,
          and to the Knowledge of CGEN, no party to any Existing Upstream License Agreement is in breach of such Existing Upstream License Agreement. CGEN has not waived any of its rights under any such Existing Upstream License Agreement to which it is
          party;</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(l)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">CGEN has disclosed to Gilead (i) all
          material information and data related to COM503, including all safety data, and (ii) all material correspondences sent to or received from any Regulatory Authority related to COM503, in each case ((i) and (ii)), in the Control of CGEN or its
          Affiliates;</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(m)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">No government funding, facilities of a
          university, college, or other educational institution or research center was used in the development of any of the inventions claimed in the IL-18 Patents that are owned or jointly owned by CGEN; and</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(n)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">To the Knowledge of CGEN, CGEN has not
          intentionally failed to furnish Gilead with any material information specifically requested by Gilead in writing relating to the IL-18 IP.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">13.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Covenants</font>.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Each Party hereby covenants that it shall
          not, during the Development Term, employ or use the services of any person or entity who is debarred under the United States Federal Food, Drug and Cosmetic Act or comparable laws in any other country or jurisdiction, in connection with the
          Development, Manufacture or Commercialization of the IL-18 Products. If either Party becomes aware of the debarment or threatened debarment of any person or entity providing services to such Party (including the Party itself and its Affiliates
          and (Sub)licensees) during the Development Term that directly or indirectly relate to activities under this Agreement, such Party shall immediately notify the other Party in writing.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Each Party hereby covenants that it shall
          not, and shall not permit its Affiliates, (Sub)licensees or anyone acting on its or their behalf to grant or otherwise convey to any Third Party any rights that would interfere or be inconsistent with such other Party&#8217;s rights hereunder.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Neither CGEN nor its Affiliates shall
          grant any option, right or license to any Third Party relating to any of the Intellectual Property Rights it Controls (including the IL-18 IP), or otherwise with respect to any IL-18 Product that (1) conflict with any of the rights or licenses
          granted to Gilead hereunder or (2) has an adverse effect on CGEN&#8217;s ability to grant the rights or licenses granted to Gilead hereunder or to perform its obligations under this Agreement.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Except as otherwise expressly permitted
          under this Agreement, CGEN shall not, and shall cause its Affiliates not to: (1) assign, transfer, convey, encumber (through a lien, charge, security interest, mortgage or similar encumbrance) or dispose of, or enter into any agreement with any
          Third Party to assign, transfer, convey, encumber (through a lien, charge, security interest, mortgage or similar encumbrance) or dispose of, any assets related to the IL-18 IP or any IL-18 Product; or (2) license or grant to any Third Party, or
          agree to license or grant to any Third Party, any rights under the IL-18 IP the Exploitation of any IL-18 Product.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">55</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(e)</font>&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">CGEN shall: (1) maintain Control of all
          IL-18 IP licensed or sublicensed to Gilead under each Upstream License Agreement; and (2) not terminate or breach (except to the extent such breach was caused by or on behalf of Gilead) any Upstream License Agreement or CGEN Development and
          Manufacturing Agreement in a manner that would permit the counterparty thereto to terminate such Upstream License Agreement or CGEN Development and Manufacturing Agreement (as applicable) or otherwise diminish the scope or exclusivity of the
          licenses granted to Gilead under any IL-18 IP.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">&#160;CGEN shall not (1) modify, amend, or
          terminate any Upstream License Agreement, or exercise, waive, release, or assign any rights or claims thereunder, in each case in a manner that would adversely affect Gilead&#8217;s rights or CGEN&#8217;s ability to perform its obligations under this
          Agreement or (2) modify or amend any Upstream License Agreement in a manner that would impose additional obligations on Gilead as a sublicensee under such Upstream License Agreement, in each case ((1) and (2)), without first obtaining Gilead&#8217;s
          prior written consent. CGEN shall perform its obligations under the [**] in a manner that permits CGEN to exercise its option thereunder to enter into the [**]. Upon Gilead&#8217;s delivery of written notice to CGEN, CGEN shall exercise its option
          under the [**] to enter into the [**] and shall, promptly thereafter in accordance with the terms of the Selexis Services Agreement, enter into the [**] (if not already entered into at the time of delivery of such written notice).</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">If CGEN receives notice of an alleged
          default by CGEN or its Affiliates under any Upstream License Agreement, where termination of such Upstream License Agreement or any diminishment of the scope or exclusivity of the licenses granted to Gilead under the IL-18 IP is being or could be
          sought by the counterparty or result from such default, then CGEN shall provide written notice thereof to Gilead within [**] thereafter, which notice may be redacted to protect commercially sensitive information or information related to products
          that are not IL-18 Products. Within [**] after receipt of such notice (or such other time period as is reasonably necessary to allow Gilead to meaningfully cure the alleged breach) and, solely in the event CGEN determines not to contest such
          alleged default and otherwise fails to cure such alleged default within such period, CGEN hereby grants to Gilead the right (but not the obligation) to: (1) cure such alleged breach; and (2) offset any costs or expenses incurred in connection
          therewith against any payments due or that may become due under this Agreement.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Gilead and its Affiliates shall comply
          with, and will contractually require its Sublicensees and Permitted Subcontractors to comply with, all applicable terms of any Upstream License Agreement with respect to a sublicensee.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">If CGEN receives notice of an alleged
          breach by Gilead or any of its Affiliates, Sublicensees, or Permitted Subcontractors of an Upstream License Agreement, then CGEN shall notify Gilead of such breach in writing and Gilead shall use Commercially Reasonable Efforts to cooperate with
          and assist CGEN in curing such breach.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(j)</font>&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">If CGEN receives written notice of any
          action, suit, inquiry, investigation or other proceeding by any Third Party that challenges or threatens the validity or enforceability of any of the IL-18 Patents, CGEN shall notify Gilead thereof in writing.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">If CGEN receives written notice of any
          action, suit, inquiry, investigation or other proceeding by any Third Party that alleges the use of the IL-18 Patents or the IL-18 Know-How or the Exploitation of any IL-18 Molecule or IL-18 Product does or would infringe, misappropriate or
          otherwise violate any Intellectual Property Rights of any Third Party, CGEN shall notify Gilead thereof in writing.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">56</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">13.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">No Other Representations or Warranties</font><font style="font-variant: small-caps;">. EXCEPT AS </font>EXPRESSLY STATED IN THIS
        AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, IS
        MADE OR GIVEN BY OR ON BEHALF OF A PARTY. ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT
        WILL BE ABLE TO SUCCESSFULLY DEVELOP, MANUFACTURE OR COMMERCIALIZE ANY IL-18 PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR SALES LEVEL OR PROFIT (LOSS) OF SUCH IL-18 PRODUCT WILL BE ACHIEVED.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A14"><!--Anchor--></a>14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold; font-variant: small-caps;">Indemnification</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">14.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">By Gilead</font>. Gilead shall and hereby does indemnify and hold harmless CGEN, its Affiliates, and its and their directors,
        officers, employees and agents (individually and collectively, the &#8220;<font style="font-weight: bold;">CGEN Indemnitee(s)</font>&#8221;) from and against all losses, liabilities, damages and expenses (including reasonable attorneys&#8217; fees and costs)
        (individually and collectively, &#8220;<font style="font-weight: bold;">Losses</font>&#8221;) incurred in connection with any Third Party Claims to the extent arising from: (a) the Development, use, Manufacture, Commercialization, import, distribution, sale or
        other Exploitation of IL-18 Molecules or IL-18 Products, by or on behalf of Gilead or any of its Related Parties or their respective Representatives, including CGEN&#8217;s performance (i) of the Development Program (including the COM503 Phase 1 Trial)
        to the extent performed in accordance with the Development Plan and COM503 Phase 1 Trial Protocol and (ii) under the CGEN Development and Manufacturing Agreements at Gilead&#8217;s direction, (b) the negligence, illegal conduct or willful misconduct of
        Gilead or any of its Related Parties or their respective Representatives in connection with this Agreement, or (c) Gilead&#8217;s breach of Applicable Laws and Regulations, this Agreement, the Clinical Supply Agreement, or any other ancillary agreement
        hereto, except, in each case of (a)&#8211;(c), to the extent such Third Party Claims arise from any action for which CGEN has an indemnification obligation to a Gilead Indemnitee under Section 14.2 (By CGEN).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">14.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">By CGEN</font>. CGEN shall and hereby does indemnify and hold harmless Gilead, its Affiliates, and its and their directors,
        officers, employees and agents (individually and collectively, the &#8220;<font style="font-weight: bold;">Gilead Indemnitee(s)</font>&#8221;) from and against all Losses incurred in connection with any Third Party Claims to the extent arising from: (a) any
        Exploitation of any IL-18 Molecule or IL-18 Product by or on behalf of CGEN or any of its Related Parties or their respective Representatives prior to the Effective Date or after the effective date of termination of this Agreement, (b)&#160;the
        negligence, illegal conduct or willful misconduct of or any of CGEN or its Related Parties or their respective Representatives in connection with this Agreement, (c) CGEN&#8217;s breach of Applicable Laws and Regulations, this Agreement (including, for
        clarity, any failure of CGEN to adhere to the COM503 Phase 1 Trial Protocol in its performance of the COM503 Phase 1 Trial), the Clinical Supply Agreement, or any other ancillary agreement hetero, or (d) any IL-18-Only Development and Manufacturing
        Agreement that is assigned to Gilead pursuant to Section 2.8(f)(ii) (CGEN Development and Manufacturing Agreements) as a result of, or in connection with, events or occurrences prior to the date of such assignment, except, in each case of (a)&#8211;(d),
        to the extent such Third Party Claims arise from any action for which Gilead has an indemnification obligation to a CGEN Indemnitee under Section 14.1 (By Gilead).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">57</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">14.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Indemnification Procedure</font>. The Party that is seeking indemnification under Section 14.1 (By Gilead) or Section 14.2 (By
        CGEN) (the &#8220;<font style="font-weight: bold;">Indemnified Party</font>&#8221;) will inform the other Party (the &#8220;<font style="font-weight: bold;">Indemnifying Party</font>&#8221;) of the Third Party Claim giving rise to such indemnification obligations promptly
        after receiving written notice of the Third Party Claim (it being understood and agreed, <font style="font-style: italic;">however</font>, that the failure or delay by an Indemnified Party to give such notice of a Third Party Claim will not affect
        the Indemnifying Party&#8217;s indemnification obligations hereunder except to the extent the Indemnifying Party will have been actually and materially prejudiced as a result of such failure or delay to give notice). The Indemnifying Party will have the
        right, at its option, to assume the defense of any such Third Party Claim for which it is obligated to indemnify the Indemnified Party by giving written notice to the Indemnified Party within [**] after receipt of the notice of the Third Party
        Claim. The assumption of defense of a Third Party Claim will not be construed as an acknowledgement that the Indemnifying Party is liable to indemnify any Indemnified Party in respect of the Third Party Claim, nor will it constitute a waiver by the
        Indemnifying Party of any defenses it may assert against the Indemnified Party&#8217;s claim for indemnification. The Indemnified Party will cooperate with the Indemnifying Party and the Indemnifying Party&#8217;s agents and representatives (including
        insurers) as the Indemnifying Party may reasonably request, and at the Indemnifying Party&#8217;s cost and expense. The Indemnified Party will have the right to participate, at its own expense and with counsel of its choice, in the defense of any Third
        Party Claim that has been assumed by the Indemnifying Party. If the Indemnifying Party does not assume and conduct the defense of a Third Party Claim as provided above, then (a) the Indemnified Party may defend against such Third Party Claim (and
        the Indemnified Party need not consult with the Indemnifying Party in connection therewith) and (b) the Indemnified Party reserves any rights it may have under this Article 14 (Indemnification) to obtain indemnification from the Indemnifying Party
        with respect to such Third Party Claim. If the Parties cannot agree as to the application of Section 14.1 (By Gilead) or Section 14.2 (By CGEN) as to any Third Party Claim, pending resolution of the Dispute pursuant to Article 16 (Dispute
        Resolution), then the Parties may conduct separate defenses of such Third Party Claims, with each Party retaining the right to claim indemnification from the other Party in accordance with Section 14.1 (By Gilead) or Section 14.2 (By CGEN), as
        applicable, upon resolution of the underlying Third Party Claim; <font style="font-style: italic;">provided</font>, that the Parties will engage in good faith discussions regarding such Dispute before conducting separate defenses. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">14.4.&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold;">Settlement</font>. The Indemnifying Party will not settle any Third Party Claim without first obtaining the prior written
        consent of the Indemnified Party, such consent not to be unreasonably withheld, conditioned or delayed; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that the Indemnifying Party will not be
        required to obtain such consent if the settlement: (a)&#160;involves only the payment of money by the Indemnifying Party and will not result in the Indemnified Party (or other CGEN Indemnitee(s) or Gilead Indemnitee(s), as applicable) being liable to
        any payment obligation or becoming subject to injunctive or other similar type of relief; (b)&#160;does not require an admission by the Indemnified Party (or other CGEN Indemnitee(s) or Gilead Indemnitee(s), as applicable); and (c) does not adversely
        affect the rights or licenses granted to the Indemnified Party (or its Affiliates) under this Agreement.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">14.5.&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-weight: bold;">Insurance</font>. Each Party will, at its own expense, procure and maintain during the Term and for a period of [**] thereafter
        (or such longer period required pursuant to Applicable Laws and Regulations, if any), insurance policies that are consistent with normal business practices of prudent companies similarly situated and are in accordance with Applicable Laws and
        Regulations. Such insurance policies shall include, with respect to Gilead, clinical trial liability insurance covering Clinical Trials for which Gilead is a sponsor and product liability insurance if and when applicable, and with respect to CGEN,
        clinical trial liability insurance covering Clinical Trials for which CGEN is a sponsor. Such insurance will not be construed to create a limit of a Party&#8217;s liability with respect to its indemnification obligations under this Article 14
        (Indemnification). Each Party will provide the other Party with written evidence of such insurance upon request from the other Party. Notwithstanding any provision to the contrary set forth in this Agreement, Gilead may self-insure, in whole or in
        part, the insurance requirements described above. All such insurance policies: (a) shall be primary and non-contributory to any of the other Party&#8217;s insurance policies; (b) include the other Party as an additional insured (i) with respect to
        Gilead, including CGEN for clinical trial liability insurance, for as long as CGEN is obligated to supply COM503 to Gilead under this Agreement or the Clinical Supply Agreement, and (ii) with respect to CGEN, including Gilead for clinical trial
        liability insurance, for as long as CGEN is the sponsor of and is conducting the COM503 Phase 1 Trial, and (iii) with respect to Gilead including CGEN for products liability insurance, during the Term of the Agreement; and (c) include [**] notice
        to the other Party of any cancellation or material reduction in coverage thereof.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">58</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">14.6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Limitation of Liability</font>.<font style="font-weight: bold;">&#160;</font>NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY
        SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES OR FOR LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN
        THIS SECTION 14.6 (LIMITATION OF LIABILITY) IS INTENDED TO OR SHALL LIMIT OR RESTRICT (A) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER THIS ARTICLE 14 (INDEMNIFICATION), (B) DAMAGES AVAILABLE FOR CGEN&#8217;S BREACH OF ITS OBLIGATIONS
        UNDER SECTION 3.6 (EXCLUSIVITY) OR (C) DAMAGES AVAILABLE FOR A PARTY&#8217;S GROSS NEGLIGENCE, INTENTIONAL MISCONDUCT OR FRAUD OR FOR A PARTY&#8217;S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 11 (CONFIDENTIALITY; PUBLICATION).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A15"><!--Anchor--></a>15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold; font-variant: small-caps;">Intellectual Property</font>.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">15.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Ownership of Intellectual Property</font>.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Background
            IP</font>. As between the Parties, each Party will retain ownership of all Patents, Know-How and other Intellectual Property Rights that are Controlled by such Party prior to the Effective Date or are otherwise developed by such Party outside
          of this Agreement (with respect to such Party, its &#8220;<font style="font-weight: bold;">Background IP</font>&#8221;).</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Foreground
            IP</font>.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Gilead
            PD-1/PD-L1 Foreground IP</font>. As between CGEN and Gilead, Gilead shall own all Foreground IP that is related to any Gilead-Provided PD-1/PD-L1, including any Gilead-Provided PD-1/PD-L1 in combination with an IL-18 Molecule (such IP, the &#8220;<font style="font-weight: bold;">Gilead PD-1/PD-L1 Foreground IP</font>&#8221;). CGEN hereby assigns to Gilead all of CGEN&#8217;s right, title and interest in, to and under Gilead PD-1/PD-L1 Foreground IP. CGEN shall notify Gilead in writing promptly, but no
          later than [**] after, the conception or reduction to practice of any Gilead PD-1/PD-L1 Foreground IP.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Other
            Foreground IP</font>. As between the Parties, all Foreground IP that is not Gilead PD-1/PD-L1 Foreground IP and is made, created, conceived of or reduced to practice (1) solely by a Party&#8217;s or any of its Affiliates&#8217; employees, independent
          contractors or consultants, will be owned by such Party (&#8220;<font style="font-weight: bold;">Solely Owned Foreground IP</font>&#8221;), and (2) jointly by each Party&#8217;s (or any of its Affiliates&#8217;) employees, independent contractors or consultants, will be
          jointly owned by the Parties (such jointly developed Foreground IP, the &#8220;<font style="font-weight: bold;">Jointly Owned Foreground IP</font>&#8221;). All determinations of Patent inventorship under this Agreement will be made in accordance with U.S.
          patent law.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">15.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Patent Filing, Prosecution and Maintenance</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Prosecution</font>.&#160;[**]
          shall have the first right (but not the obligation), at its election, to file, prosecute and maintain the IL-18 Patents and the Jointly Owned Foreground Patents.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>[**] shall provide [**] with a reasonable opportunity to review and
          comment on its efforts to prepare, file, prosecute and maintain the IL-18 Patents and the Jointly Owned Foreground Patents, including by providing [**] with a copy of all material communications from any patent authority regarding any IL-18
          Patent or Jointly Owned Foreground Patent, and by providing drafts of any material filings or responses to be made to such patent authorities at least [**] in advance of submitting such filings or responses. [**] shall consider [**]&#8217;s comments
          regarding such communications and drafts in good faith. In the event that [**] elects not to undertake the Patent Prosecution for an IL-18 Patent or Jointly Owned Foreground Patent, [**] shall notify [**] at least [**] before any such Patents
          would become abandoned or otherwise forfeited, and [**] shall have the right (but not the obligation), to undertake the Patent Prosecution of such IL-18 Patent or Jointly Owned Foreground Patent and become the prosecuting Party therefor.
          Notwithstanding the foregoing, [**]&#8217;s right to assume Patent Prosecution of an IL-18 Patent or Jointly Owned Foreground Patent shall not apply in the event such Patent was abandoned or otherwise forfeited by [**] for strategic reasons. For
          purposes of this Section 15.2(a) (Prosecution), a &#8220;strategic reason&#8221; for which [**] desires to abandon or otherwise forfeit Patent Prosecution of a given Patent shall be the abandonment or forfeiture of such Patent on the basis that continued
          prosecution would have an adverse effect on the prosecution, validity or enforcement of another IL-18 Patent or Jointly Owned Foreground Patent. For clarity, &#8220;strategic reasons&#8221; shall not include the abandonment or forfeiting of a Patent for
          purely financial reasons (e.g., costs of Patent Prosecution therefor or decreasing the Royalty Term).</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">59</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Patent
            Invalidations</font>. If either Party desires to undertake activities intended to invalidate a pending or issued Patent owned or controlled by a Third Party and having one or more claims that Cover an IL-18 Molecule or IL-18 Product or any
          method of use thereof (except insofar as such action is a counterclaim to or defense of, or accompanies a defense of, a Third Party&#8217;s claim or assertion of infringement under Section&#160;15.5 (Defense), in which case the provisions of Section&#160;15.5
          (Defense) will govern), such Party will so notify the other Party, and the Parties will promptly confer to determine whether to bring such action, the strategy to be employed in connection with any such action, or the manner in which to settle
          such action, <font style="font-style: italic;">provided</font>, that the foregoing obligations do not apply to CGEN with respect to any Patent licensed or owned by CGEN pursuant to an Upstream License Agreement. [**] will have the first right,
          but not the obligation, to bring, at its own expense and in its sole control, any action with respect to invalidating pending or issued Third Party Patents in the Territory that Cover an IL-18 Molecule or IL-18 Product or any method of use
          thereof. If [**] decides not to bring any such action and such decision was not for strategic reasons, then [**] will notify [**] and [**] will have the right to bring, at its own expense and in its sole control, any action with respect to
          invalidating such pending or issued Third Party Patents. The Party not bringing an action under this Section&#160;15.2(b) (Patent Invalidations) will be entitled to separate representation in such proceeding by counsel of its own choice and at its own
          expense and will cooperate fully with the Party bringing such action.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Costs
            of Patent Prosecution</font>. All Out-of-Pocket Costs for Patent Prosecution of any Patent shall be solely incurred by and the sole responsibility of the prosecuting Party.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">15.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Patent Prosecution Cooperation</font>. With respect to all Patent Prosecution related to pending or issued Patents that are
        Jointly Owned Foreground Patents or IL-18 Patents, each Party shall:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">execute all further instruments to
          document and effectuate their respective ownership consistent with this Agreement as reasonably requested by the other Party;</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">make its employees, agents and consultants
          reasonably available to the other Party (or to the other Party&#8217;s authorized attorneys, agents or representatives), to the extent reasonably necessary to enable the appropriate Party hereunder to undertake its Patent Prosecution responsibilities;</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">cooperate, if necessary and appropriate,
          with the other Party in gaining Patent Term Extensions; and</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">endeavor in good faith to coordinate its
          efforts under this Agreement with the other Party to minimize or avoid interference with the Patent Prosecution of the other Party&#8217;s Patents.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">60</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">15.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Enforcement</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Notice</font>.
          Each Party shall promptly provide, but in no event later than [**] after becoming aware thereof, the other Party with written notice reasonably detailing any known or alleged infringement, misappropriation or other violation of any IL-18 Patent
          or Jointly Owned Foreground Patent (such infringement, misappropriation or other violation, &#8220;<font style="font-weight: bold;">Infringement</font>&#8221;, and cognates of the word &#8220;Infringement&#8221; shall have correlative meanings). The notifying Party will
          provide the other Party with all evidence available to it supporting its belief of such Infringement.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Enforcement
            of Patent Rights</font>. [**] shall have the first right (but not the obligation) to institute and direct any infringement, misappropriation or other appropriate suit with respect to any Infringement (&#8220;<font style="font-weight: bold;">Enforcement
            Efforts</font>&#8221;) under the IL-18 Patents and the Jointly Owned Foreground Patents. If [**] (i) does not initiate any Enforcement Effort against a Third Party alleged to be Infringing, including by commencement of a legal action under the
          applicable IL-18 Patents or Jointly Owned Foreground Patents or obtaining a settlement thereof (in accordance with this Agreement), within [**] after receiving notice of such Infringement, (ii) initiates such Enforcement Effort within such
          period, and subsequently ceases to pursue or withdraws from such Enforcement Effort, or (iii) provides written notice to [**] that it does not intend to initiate such Enforcement Effort, then in each case ((i) through (iii)) [**] shall have the
          right (but not the obligation) to take all actions reasonably necessary to abate and seek damages resulting from such Infringement, including commencement of a lawsuit against the accused Third Party if necessary; <font style="font-style: italic;">provided</font>, that if [**] notifies [**] during such period that it is electing in good faith not to institute any Enforcement Effort for strategic reasons, then [**] will not have the right to initiate and control such Enforcement
          Effort. For purposes of this Section 15.4(b) (Enforcement of Patent Rights), a &#8220;strategic reason&#8221; for which [**] desires not to institute, or desires that [**] not institute, an Enforcement Effort, shall mean the following: (1) [**] has commenced
          an Enforcement Effort in a Major Market Country and does not want to institute or have instituted such action in another country or territory in a manner that could adversely affect [**]&#8217;s existing Enforcement Effort; or (2) [**] has commenced an
          Enforcement Effort under certain, but not all, of the relevant Patents that are implicated in such Enforcement Effort.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Cooperation</font>.
          Each Party shall discuss in good faith with the other Party and shall keep the other Party updated with respect to, the progress of each Enforcement Effort being undertaken by such Party pursuant to this Section&#160;15.4 (Infringement).</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Recovery
            Allocations</font>.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">All amounts recovered by either Party
          in the Territory relating to an Enforcement Effort (&#8220;<font style="font-weight: bold;">Recovery</font>&#8221;) shall be first [**].</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">After [**], any remainder of a Recovery
          that is obtained by Gilead from an Enforcement Effort or by CGEN from an Enforcement Effort shall be retained by [**]. To the extent obtained by Gilead under this Section&#160;15.4(d)(ii) (Recovery Allocations) [**], Gilead shall pay CGEN [**]. To the
          extent obtained by CGEN under this Section&#160;15.4(d)(ii) (Recovery Allocations) [**], CGEN shall retain [**] and shall pay Gilead [**].</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Cooperation
            in Enforcement Proceedings</font>. For any action by a Party pursuant to Section 15.4(b) (Enforcement of Patent Rights), in the event that such Party is unable to initiate or prosecute such action solely in its own name, the other Party shall
          join such action voluntarily and shall execute all documents necessary for such Party to initiate, prosecute and maintain such action. If either Gilead or CGEN initiates an enforcement action pursuant to Section&#160;15.4(b) (Enforcement of Patent
          Rights), then the other Party shall cooperate to the extent reasonably necessary and at the first Party&#8217;s sole expense (except for the expenses of the non-controlling Party&#8217;s counsel, if any). Upon the reasonable request of the Party instituting
          any such action, such other Party shall join the suit and can be represented in any such legal proceedings using counsel of its own choice. Each Party shall assert and not waive the joint defense privilege with respect to all communications
          between the Parties reasonably the subject thereof.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">61</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Status;
            Settlement</font>. The Parties shall keep each other reasonably informed of the status of, and of their respective activities regarding, any enforcement action pursuant to Section&#160;15.4(b) (Enforcement of Patent Rights). In no event may the
          Party who has the right to initiate an Enforcement Effort pursuant to Section&#160;15.4(b) (Enforcement of Patent Rights) settle such Enforcement Effort in a manner that would limit the rights of the other Party or impose any obligation on the other
          Party, in each case, without the other Party&#8217;s prior written consent, which consent will not be unreasonably withheld, delayed or conditioned.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">15.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Defense</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Notice of
            Allegations</font>. Each Party shall notify the other in writing of any allegations it receives from a Third Party that the Exploitation of an IL-18 Molecule or IL-18 Product or practice of any IL-18 IP or Jointly Owned Foreground IP infringes,
          misappropriates or otherwise violates the Intellectual Property Rights of such Third Party (&#8220;<font style="font-weight: bold;">Third Party Allegation</font>&#8221;). Such notice shall be provided promptly, but in no event after more than [**], following
          receipt of such allegations.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Notice of
            Suit</font>. In the event that a Party receives notice that it or any of its Affiliates have been individually or collectively named as a defendant (or defendants) in a legal proceeding by a Third Party alleging infringement, misappropriation
          or any other violation of a Third Party&#8217;s Intellectual Property Right as a result of the Exploitation of an IL-18 Molecule or IL-18 Product or any of IL-18 IP or Jointly Owned Foreground IP (&#8220;<font style="font-weight: bold;">Third Party Suit</font>&#8221;),
          such Party shall promptly notify the other Party in writing and in no event notify such other Party later than [**] after the receipt of such notice. Such written notice shall include a copy of any summons or complaint (or the equivalent thereof)
          received regarding the foregoing. Each Party shall assert and not waive the joint defense privilege with respect to all communications between the Parties reasonably the subject thereof.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Right to
            Defend</font>. Each Party will have the first right, but not the obligation, to defend itself in any Third Party Allegation or Third Party Suit related to such IL-18 Product or the applicable IL-18 Molecule at its cost and expense. If both
          Parties are named defendants in any Third Party Suit, the Parties shall defend such Third Party Suit jointly, unless the Parties agree otherwise. In any event, the non-defending Party shall reasonably cooperate with the Party conducting the
          defense of the claim and shall have the right to participate with separate counsel at its own expense, and the defending Party shall consider comments by the non-defending Party in good faith. [**] shall bear the cost and expenses of the defense
          of any such Third Party Suit [**]. If the Parties jointly defend the claim, [**]. The non-defending Party may participate in any such claim, suit or proceeding with counsel of its choice at its own cost and expense. Without limitation of the
          foregoing, if the defending Party finds it necessary for the non-defending Party to join the defending Party as a party to any such action, then the Parties shall cooperate to execute all papers and perform such acts as shall be reasonably
          required for the non-defending Party to join such action.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Status;
            Settlement</font>. The Parties shall keep each other informed of the status of and of their respective activities regarding any litigation or settlement thereof initiated by a Third Party as contemplated under Section 15.5(c) (Right to Defend);
          <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that no settlement or consent judgment or other voluntary final disposition of a suit under this Section&#160;15.5(d) (Status; Settlement) that
          affects the other Party&#8217;s rights or interests may be undertaken by a Party without the consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">62</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">15.6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Patent Listing</font>. [**] the listing of any IL-18 Patents and Jointly Owned Foreground Patents in the then-current edition of
        the FDA&#8217;s Purple Book in connection with the Regulatory Approval of an IL-18 Product, or in equivalent patent listings in any other country within the Territory.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">15.7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Patent Term Extensions</font>. [**] all filings of requests for patent term extensions, supplementary protection certificates, or
        equivalents thereto in any country in the Territory, in each case, where applicable to an IL-18 Product, including for any IL-18 Patents, Jointly Owned Foreground Patents or Patents in Gilead&#8217;s Solely Owned Foreground IP (hereinafter &#8220;<font style="font-weight: bold;">Patent Term Extensions</font>&#8221;). All costs and expenses relating to the Patent Term Extensions will be [**]. Upon [**] request, [**] will provide support, assistance, and all necessary documents, in full, executed form
        if needed, to [**] for the purpose of supporting, filing, obtaining and maintaining Patent Term Extensions.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A16"><!--Anchor--></a>16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold; font-variant: small-caps;">Dispute Resolution</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">16.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Exclusive Dispute Resolution Mechanism</font>. The Parties agree that the procedures set forth in this Article 16 (Dispute
        Resolution) shall be the exclusive mechanism for resolving any Dispute between the Parties that may arise from time to time pursuant to this Agreement relating to either Party&#8217;s rights or obligations hereunder that is not resolved through good
        faith negotiation between the Parties. For the avoidance of doubt, this Article 16 (Dispute Resolution) shall not apply to any decision with respect to which a Party has final decision-making authority hereunder, but, for clarity, this Article 16
        (Dispute Resolution) shall apply to any dispute with respect to <font style="font-style: italic;">whether</font> a Party has final decision-making authority hereunder. Any Dispute, including Disputes that may involve the parent company,
        subsidiaries, or Affiliates under common control of any Party, shall be resolved in accordance with this Article 16 (Dispute Resolution).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">16.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Resolution by Executive Officers</font>.<font style="font-weight: bold;">&#160;</font>Except as otherwise provided in this Article 16
        (Dispute Resolution), in the event of any Dispute, the Parties will refer the Dispute to the Executive Officer of each Party for attempted resolution by good faith negotiation within [**] after such notice is received. Each Party may, in its
        discretion, seek resolution of any Disputes that are not resolved within such [**] period through litigation in accordance with the remainder of this Article 16 (Dispute Resolution). </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">16.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Jurisdiction; Venue; Service of Process</font>. Subject to Section 16.6 (Patent Disputes) and Section 16.7 (Equitable Relief),
        each Party irrevocably submits to the exclusive jurisdiction of (a) the courts of the State of New York located in New York, NY, and (b) the United States District Court for the Southern District of New York, for the purposes of any Dispute arising
        out of this Agreement. Each Party agrees to commence any Action either in the United States District Court for the Southern District of New York or if such Action may not be brought in such court for jurisdictional reasons, in the courts of the
        State of New York located in New York, NY. Each Party further agrees that service of any process, summons, notice or document by the U.S. registered mail to such Party&#8217;s respective address set forth in Section 18.5 (Notices) will be effective
        service of process for any Action in New York with respect to any matters to which it has submitted to jurisdiction in this Section 16.3 (Jurisdiction; Venue; Service of Process). Each Party irrevocably and unconditionally waives any objection to
        the laying of venue of any Action arising out of this Agreement in (x) the courts of the State of New York located in New York, NY and (y) the United States District Court for the Southern District of New York, and hereby and thereby further
        irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such Action brought in any such court has been brought in an inconvenient forum.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">16.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Governing Law</font>. This Agreement, and all claims or causes of action (whether in contract, tort, statute, or otherwise) that
        may be based upon, arise out of, or relate to this Agreement, or the negotiation, execution, or performance of this Agreement, or the breach thereof (including any claim or cause of action based upon, arising out of, or related to any
        representation or warranty made in or in connection with this Agreement or as an inducement to enter into this Agreement), will be governed by, and enforced in accordance with, the internal laws of the State of New York, including its statutes of
        limitations, without giving effect to any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The provisions of the United Nations
        Convention on Contracts for the International Sale of Goods are expressly excluded.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">63</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">16.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Waiver of Jury Trial</font>. THE PARTIES HEREBY WAIVE, AND COVENANT THAT THEY WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR
        OTHERWISE), ANY RIGHT TO TRIAL BY JURY IN ANY ACTION ARISING IN WHOLE OR IN PART UNDER OR IN CONNECTION WITH THIS AGREEMENT, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. THE PARTIES AGREE THAT ANY
        OF THEM MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY AND BARGAINED-FOR AGREEMENT AMONG THE PARTIES IRREVOCABLY TO WAIVE ITS RIGHT TO TRIAL BY JURY IN ANY PROCEEDING WHATSOEVER BETWEEN THEM RELATING
        TO THIS AGREEMENT, AND THE PARTIES WILL INSTEAD BE TRIED IN A COURT OF COMPETENT JURISDICTION BY A JUDGE SITTING WITHOUT A JURY.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">16.6.&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-weight: bold;">Patent Disputes</font>. As between the Parties, notwithstanding anything herein to the contrary, any dispute, controversy or
        claim relating to the scope, validity, enforceability or infringement of any Patent shall not be subject to such jurisdiction and venue as is set forth in Section 16.3 (Jurisdiction; Venue), but shall be submitted to a court of competent
        jurisdiction in the jurisdiction in which such Patent rights were granted or arose. With respect to any Patent issues related to the enforceability or validity of a Patent, the laws of the jurisdiction in which the applicable Patent is filed or
        granted shall govern.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">16.7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Equitable Relief</font>. Notwithstanding anything to the contrary, either Party may at any time seek to obtain preliminary
        injunctive relief or other applicable provisional relief from any court of competent jurisdiction with respect to an issue arising under this Agreement if the rights of such Party would be prejudiced absent such relief.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A17"><!--Anchor--></a>17.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold; font-variant: small-caps;">Term and Termination</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">17.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Term</font>. This Agreement shall become effective as of the Effective Date and, unless earlier terminated pursuant to this
        Article 17 (Term and Termination), shall continue in full force and effect, on an IL-18 Product-by-IL-18 Product and country-by-country basis, until the expiration of the last Royalty Term for an IL-18 Product in a country (&#8220;<font style="font-weight: bold;">Term</font>&#8221;).&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">17.2.&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold;">Termination for Material Breach</font>.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Material
            Breach</font>. Subject to Section 17.2(b) (Disagreement as to Material Breach), this Agreement may be terminated at any time during the Term upon written notice by a Party (the &#8220;<font style="font-weight: bold;">Non-Breaching Party</font>&#8221;) if
          the other Party (the &#8220;<font style="font-weight: bold;">Breaching Party</font>&#8221;) is in material breach of this Agreement and, in each case, has not cured such breach within the applicable cure period after written notice requesting cure of the
          breach, which notice will describe such material breach in reasonable detail and will state the Non-Breaching Party&#8217;s intention to terminate this Agreement, in its entirety or in part. The Breaching Party will have (i) [**] from the date of the
          breach notification to cure any payment-related breach and (ii) [**] from the date of the breach notification to cure all other breaches; <font style="font-style: italic;">provided </font>that, if such non-payment-related breach is not
          reasonably capable of being cured within such [**], then such [**] will be extended for an additional [**] so long as the Breaching Party continues to use Commercially Reasonable Efforts to cure such material breach during such extension period.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">64</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Disagreement
            as to Material Breach</font>. Notwithstanding Section 17.2(a) (Material Breach), if the Parties in good faith disagree as to whether there has been a material breach of this Agreement, then: (i)&#160;the Breaching Party may contest the allegation of
          such material breach by referring such matter, within [**] following its receipt of notice of the alleged material breach, for resolution in accordance with Article 16 (Dispute Resolution); (ii) the relevant cure period with respect to such
          alleged material breach will be tolled from the date on which the Breaching Party notifies the Non-Breaching Party of the Dispute and through the resolution of such Dispute in accordance with the applicable provisions of this Agreement; (iii)
          during the pendency of such Dispute, all of the terms and conditions of this Agreement will remain in effect and the Parties will continue to perform all of their respective obligations hereunder; and (iv) if it is ultimately determined that the
          Breaching Party committed such material breach, then the Breaching Party will have the right to cure such material breach, after such determination, within [**] for payment-related breaches or [**] for non-payment related breaches, which cure
          period will commence as of the date of such determination.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">17.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Termination for Convenience</font>. Gilead may, in its sole discretion, terminate this Agreement in its entirety upon (a) [**]
        notice to CGEN prior to the Development Program Transfer Date or the No-Transfer Date, as applicable, or (b)&#160;[**] notice to CGEN after the Development Program Transfer Date or the No-Transfer Date, as applicable.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">17.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Termination for Force Majeure</font>. This Agreement may be terminated at any time during the Term upon written notice by either
        Party in accordance with Section&#160;18.1 (Force Majeure).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">17.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Termination for Bankruptcy</font>. This Agreement may be terminated in its entirety, to the extent permitted by the Applicable
        Laws and Regulations, by a Party (the &#8220;<font style="font-weight: bold;">Non-Bankrupt Party</font>&#8221;) upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial
        portion of the assets for the benefit of creditors, in each case, of the other Party (the &#8220;<font style="font-weight: bold;">Bankrupt Party</font>&#8221;); <font style="font-style: italic;">provided, however</font>, that in the case of any involuntary
        bankruptcy, reorganization, liquidation or receivership proceeding, such right to terminate will only become effective if the Bankrupt Party consents to the involuntary bankruptcy or such proceeding is not dismissed within [**] after the filing
        thereof (such bankruptcy and related events described in this Section 17.5 (Termination for Bankruptcy), collectively, &#8220;<font style="font-weight: bold;">Bankruptcy Events</font>&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">17.6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Termination by Gilead for Safety Reasons</font>. Gilead shall have the right to terminate this Agreement on an IL-18
        Product-by-IL-18 Product basis at any time upon providing [**] prior written notice to CGEN: (a) if senior executives responsible for Gilead&#8217;s pharmacovigilance and clinical science functions determine in good faith that the IL-18 Product cannot be
        administered to patients safely; or (b) after the occurrence of serious adverse events related to the use of such IL-18 Product that causes Gilead reasonably to conclude that the continued use of the IL-18 Product by patients will result in
        patients being exposed to a product in which the risks outweigh the benefits. </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">17.7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[**]. If it is mutually agreed by the Parties or finally determined pursuant to Article 16 that [**], then [**], Gilead may, [**], exercise the following rights
        [**]:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">Gilead may [**]; except that [**] until
          such time as [**]; and</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">any [**] will be [**], and [**], <font style="font-style: italic;">provided</font>, that notwithstanding the foregoing, [**].</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">65</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For the avoidance of doubt, (x) except as set forth in this Section 17.7 ([**]), if Gilead exercises the [**] set forth above in this Section 17.7 ([**]), then [**], unless and
        until [**], and (y) CGEN shall have the right to [**].</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">17.8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Effects of Termination</font>.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">In
            General</font>. Upon any termination of this Agreement:</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">Gilead shall pay any amounts accrued
          pursuant to Section 10.1 (Reimbursable Costs), Section&#160;10.2 (Manufacturing Costs), and Section&#160;10.3 ([**]) and Article 9 (Payments) as of the effective date of termination to the extent not previously paid prior to the date of termination;</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">The licenses and sublicenses granted to
          each Party under this Agreement including pursuant to Section&#160;3.1 (License to Gilead), shall terminate and Gilead will cease any and all Exploitation of the Terminated Products as soon as is reasonably practicable under Applicable Laws and
          Regulations; <font style="font-style: italic;">provided</font>, that such licenses will continue as necessary for the Parties to complete the orderly wind-down of their activities under this Agreement in accordance with Applicable Laws and
          Regulations and as otherwise required in accordance with Section 17.8 (Effects of Termination);</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">Gilead shall cease all Development and
          Commercialization activities hereunder, including, to the extent permitted by any applicable Regulatory Authority or Applicable Laws and Regulations, halting enrollment of subjects (unless otherwise directed by CGEN in writing) into any Clinical
          Trial of Terminated Products being conducted by the Gilead and at CGEN&#8217;s direction, shall either (1) wind-down (including to cease administering the Terminated Products to Clinical Trial subjects and conducting Clinical Trial procedures on such
          Clinical Trial subjects, to the extent medically advisable and permitted by any applicable Regulatory Authority or Applicable Laws and Regulations) or (2) transition to CGEN (or its designee) any such Clinical Trial of Terminated Products being
          conducted by Gilead in accordance with Applicable Laws and Regulations;</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">All sublicenses under the rights granted
          pursuant to Section&#160;3.1 (License to Gilead) shall terminate with respect to the Terminated Products, unless converted to a direct license under Section&#160;3.2(b) (Survival of Gilead Sublicenses) subject to terms and conditions to be agreed between
          CGEN and such Sublicensee; and</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">[**] may [**] with respect to [**].
          Gilead will cooperate with CGEN and provide CGEN with reasonable assistance with the [**]. For clarity, the [**].</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Additional
            Effects of Certain Terminations</font>. If (i) CGEN terminates this Agreement pursuant to Section 17.2 (Termination for Material Breach) or Section 17.5 (Termination for Bankruptcy) or (ii) if Gilead terminates this Agreement in its entirety
          pursuant to Section 17.3 (Termination for Convenience) or with respect to an IL-18 Product or this Agreement in its entirety pursuant to Section&#160;17.6 (Termination by Gilead for Safety Reasons), then, in addition to those general effects set forth
          in Section 17.8(a) (In General):</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">upon CGEN&#8217;s written<font style="font-weight: bold;">&#160;</font>request within [**] following the effective date of such termination, for up to [**] following such request, Gilead and CGEN shall negotiate in good faith an exclusive license from Gilead to CGEN, with the
          right to grant sublicenses through multiple tiers to its Affiliates and to Third Parties (subject to Section 3.2 (Sublicenses) (applied <font style="font-style: italic;">mutatis mutandis</font> to CGEN)) under Gilead Solely Owned Foreground IP
          and Gilead PD-1/PD-L1 Foreground IP Controlled by Gilead as of the effective date of termination to Exploit the IL-18 Products that were the subject of such termination (such IL-18 Products the &#8220;<font style="font-weight: bold;">Reverted Products</font>&#8221;,
          and such license, the &#8220;<font style="font-weight: bold;">Reversion License</font>&#8221;);&#160;<font style="font-style: italic;">provided</font>, that, in no event shall such Reversion License include the right to Exploit any Other Component with respect to
          any Reverted Product that is a Combination Product, or to Exploit any other product, molecule or component Controlled by Gilead and Developed or Commercialized in combination with such Reverted Product. The terms of such Reversion License shall
          include reasonable compensation (including royalties) to Gilead for providing such Reversion License to CGEN.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">66</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">At CGEN&#8217;s request within [**] after the
          effective date of termination of this Agreement, Gilead shall assign and promptly transfer to CGEN, at no expense to CGEN, all of Gilead&#8217;s right, title and interest, if any, in and to all Regulatory Submissions for Reverted Products.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">At CGEN&#8217;s request within [**] after the
          effective date of termination of this Agreement, the Parties shall negotiate terms under which, upon reaching mutual agreement, Gilead would sell to CGEN such quantities of existing inventory of Terminated Product as CGEN requests to purchase.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">17.9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Surviving Provisions</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Accrued
            Rights; Remedies</font>. The expiration or termination of this Agreement for any reason will be without prejudice to any rights that will have accrued to the benefit of any Party prior to such expiration or termination, and any and all damages
          or remedies (whether at law or in equity) arising from any breach hereunder, each of which will survive expiration or termination of this Agreement. Such expiration or termination will not relieve any Party from obligations which are expressly
          indicated to survive expiration or termination of this Agreement. Except as otherwise expressly set forth in this Agreement, the termination provisions of this Article 17 (Term and Termination) are in addition to any other relief and remedies
          available to either Party under this Agreement, at law or in equity.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Survival</font>.
          Without limiting the provisions of Section 17.9(a) (Accrued Rights; Remedies), the following provisions, as well as any other provisions which by their nature are intended to survive termination or expiration, shall survive the termination or
          expiration of this Agreement for any reason: Article 1 (Definitions) (to the extent the definitions are used in other surviving provisions), Section&#160;2.7 (Data Ownership), Section 3.2(b) (Survival of Gilead Sublicenses), Section 5.5 (Data
          Ownership), Section 10.8 (Records) (for the period specified therein), Section 10.9 (Audit Rights) (for the period specified therein), Article 11 (Confidentiality; Publication), Article 13 (Representations and Warranties), Article 14
          (Indemnification), Article 15 (Intellectual Property), Article 17 (Term and Termination), and Article 18 (Miscellaneous).</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><a name="A18"><!--Anchor--></a>18.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold; font-variant: small-caps;">Miscellaneous</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">18.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Force Majeure</font>. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this
        Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, including embargoes, war, acts of war
        (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any governmental authority or the other Party (&#8220;<font style="font-weight: bold;">Force Majeure</font>&#8221;); <font style="font-style: italic;">provided</font>, that the affected Party (a) notify the other Party of such Force Majeure circumstances as soon as reasonably practical and (b) promptly
        undertakes all reasonable efforts necessary to cure such Force Majeure circumstances, and will continue performance in accordance with the terms of this Agreement whenever such causes are removed. For the avoidance of doubt, the inability to expend
        or access financial resources in itself shall not be a Force Majeure. In the event a Party is unable to perform its obligations under this Agreement due to Force Majeure for a period of [**], the other Party shall have the option of unilaterally
        terminating this Agreement upon delivery of [**] written notice.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">67</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">18.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Section&#160;365(n) of the Bankruptcy Code</font>.&#160;All rights and licenses granted under or pursuant to any section of this Agreement
        are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, or any similar Applicable Laws and Regulations, licenses of rights to &#8220;intellectual property&#8221; as defined under Section 101(35A) of the U.S.
        Bankruptcy Code, or any similar Applicable Laws and Regulations. The Parties shall retain and may fully exercise all of their respective rights and elections under the U.S. Bankruptcy Code, or any similar Applicable Laws and Regulations. The
        Parties agree that a Party that is a licensee of such rights under this Agreement shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code, or any similar Applicable Laws and Regulations, and that upon
        commencement of a bankruptcy proceeding by or against the licensing Party (such Party, the &#8220;<font style="font-weight: bold;">Involved Party</font>&#8221;) under the U.S. Bankruptcy Code, or any similar Applicable Laws and Regulations, the other Party
        (such Party, the &#8220;<font style="font-weight: bold;">Noninvolved Party</font>&#8221;) shall be entitled to a complete duplicate of or complete access to (as such Noninvolved Party deems appropriate), any such intellectual property and all embodiments of
        such intellectual property, provided the Noninvolved Party continues to fulfill its payment or royalty obligations as specified herein in full. Such intellectual property and all embodiments thereof shall be promptly delivered to the Noninvolved
        Party (a) upon any such commencement of a bankruptcy proceeding upon written request therefor by the Noninvolved Party, unless the Involved Party elects to continue to perform all of its obligations under this Agreement or (b) if not delivered
        under (a) above, upon the rejection of this Agreement by or on behalf of the Involved Party upon written request therefor by Noninvolved Party. Each Party hereby acknowledges that &#8220;embodiments&#8221; of such intellectual property pursuant to Section
        365(n) of the Bankruptcy Code, or any similar Applicable Laws and Regulations, includes copies of research data, laboratory samples, product samples and inventory, formulas, laboratory notes and notebooks, pre-clinical research data and results,
        tangible Know-How and rights of reference, in each case, that relate to such intellectual property. In the event of a bankruptcy proceeding by or against CGEN, the Parties agree that they intend the following rights to extend to Gilead to the
        maximum extent permitted by the Bankruptcy Code and any similar Applicable Laws and Regulations: (a) the right of access of Gilead to the IL-18 IP (including all embodiments thereof), or (b) with respect to any Third Party with whom CGEN contracts
        to perform an obligation of CGEN under this Agreement that is necessary for the Exploitation of any IL-18 Product; (i) the right of Gilead to contract directly with such Third Party to complete the contracted work and (ii) the right of Gilead to
        cure any breach of or default under such agreement with such Third Party and set off the costs thereof against amounts payable to CGEN under this Agreement. This Section 18.2 (Section 365(n) of the Bankruptcy Code) is without prejudice to, and is
        not intended to limit in any way, any rights (including election rights) the Noninvolved Party may have arising under the U.S. Bankruptcy Code or other Applicable Laws and Regulations.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">18.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Assignment; Change of Control</font>.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Neither Party may assign its rights and
          obligations under this Agreement without the prior written consent of the other Party; <font style="font-style: italic;">provided</font>, that each Party may assign its rights and obligations under this Agreement, without such consent from the
          other Party, to its Affiliate, or to any successor in interest in connection with the sale of all or substantially all of such Party&#8217;s assets or a sale of all or substantially of the business related to this Agreement, or a merger, acquisition or
          other similar transactions. For the avoidance of doubt, the terms and conditions of this Agreement shall be binding on the permitted successors and assignees of each Party.</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">68</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">If CGEN undergoes a Change of Control:</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">CGEN will notify Gilead thereof within
          [**] upon the closing of the Change of Control; <font style="font-style: italic;">provided</font>, that a public announcement within such period by or through a nationally recognized news organization recognized pharma/biotech industry news
          organization or forum of such closing shall be sufficient to provide such notification;</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">The Parties shall comply with Section
          3.6 (Exclusivity) as described therein; and</font></div>
      <div style="line-height: 1.25; text-indent: 9pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 117pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">Notwithstanding anything to the
          contrary in this Agreement, Gilead will have the right, at its sole discretion, by written notice delivered to CGEN (or its successor) at any time within [**] following the written notice contemplated by the foregoing Section&#160;18.3(b)(i), to (1)
          terminate any or all provisions of this Agreement providing for any delivery by Gilead to CGEN of Confidential Information of Gilead relating to activities contemplated by this Agreement, save only for the provisions of Article&#160;9 (Payments), (2)
          disband the JSC, and (3) require CGEN and its Acquirer to adopt reasonable procedures, to be agreed upon by the Parties in writing, to prevent disclosure of Confidential Information of Gilead to CGEN&#8217;s Acquirer. For clarity this
          Section&#160;18.3(b)(iii) does not limit any reporting obligations of Gilead that are financial in nature.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">18.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Severability</font>. If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in
        any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of
        the Parties. The Parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this
        Agreement.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">18.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Notices</font>. All notices which are required or permitted hereunder shall be in a medium that has the capability to confirm the
        exact content, the times of transmission and receipt, and the identities or each sender and recipient of each communication sent through such medium. A communication to an intended recipient Party shall be deemed to be received by the intended
        recipient Party by the existence of documentation that clearly evidences such communication was sent through a medium permitted under this Agreement to an individual who was specifically designated by the recipient Party to receive such
        communication or, if no such designation was made, an individual who has routinely received communications with similar content under this Agreement on behalf of the recipient Party.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 81pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">For notices to be communicated in writing,
          such notices shall be delivered personally, sent by facsimile or electronic mail (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by
          registered or certified mail, postage prepaid, return receipt requested, addressed as follows:</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 81pt;">
        <table cellspacing="0" cellpadding="0" border="0" style="width: 85%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z5ada184548634cc9971970279a82323b">

            <tr>
              <td style="width: 32.58%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">if to CGEN, to:</div>
              </td>
              <td style="width: 67.42%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">Compugen Ltd.</div>
                <div style="text-align: justify; line-height: 1.25;">Azrieli Center,</div>
                <div style="text-align: justify; line-height: 1.25;">26 Harokmim Street, Building D</div>
                <div style="text-align: justify; line-height: 1.25;">Holon 5885849</div>
                <div style="text-align: justify; line-height: 1.25;">Israel</div>
                <div style="text-align: justify; line-height: 1.25;">Attention: SVP Technology Innovation</div>
                <div style="text-align: justify; line-height: 1.25;">Email: [**]</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">69</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="margin-left: 81pt;">
        <table cellspacing="0" cellpadding="0" border="0" style="width: 85%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

            <tr>
              <td colspan="2" style="width: 100%; vertical-align: top;">
                <div style="line-height: 1.25;">with copy to:<br>
                  (which shall not constitute notice)</div>
              </td>
            </tr>
            <tr>
              <td style="width: 32.58%; vertical-align: top;">&#160;</td>
              <td style="width: 67.42%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">Compugen Ltd.</div>
                <div style="text-align: justify; line-height: 1.25;">Azrieli Center,</div>
                <div style="text-align: justify; line-height: 1.25;">26 Harokmim Street, Building D</div>
                <div style="text-align: justify; line-height: 1.25;">Holon 5885849</div>
                <div style="text-align: justify; line-height: 1.25;">Israel</div>
                <div style="text-align: justify; line-height: 1.25;">Attention: General Counsel</div>
                <div style="text-align: justify; line-height: 1.25;">Email: [**]</div>
                <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 32.58%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">if to Gilead, to:</div>
              </td>
              <td style="width: 67.42%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">Gilead Sciences, Inc.</div>
                <div style="text-align: justify; line-height: 1.25;">333 Lakeside Drive</div>
                <div style="text-align: justify; line-height: 1.25;">Foster City, CA 94404</div>
                <div style="text-align: justify; line-height: 1.25;">United States</div>
                <div style="text-align: justify; line-height: 1.25;">Attention: Alliance Manager</div>
                <div style="text-align: justify; line-height: 1.25;">Email: [**]</div>
                <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 32.58%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">with a copy to:</div>
              </td>
              <td style="width: 67.42%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25;">Gilead Sciences, Inc.</div>
                <div style="text-align: justify; line-height: 1.25;">333 Lakeside Drive</div>
                <div style="text-align: justify; line-height: 1.25;">Foster City, CA 94404</div>
                <div style="text-align: justify; line-height: 1.25;">United States</div>
                <div style="text-align: justify; line-height: 1.25;">Attention: General Counsel</div>
                <div style="text-align: justify; line-height: 1.25;">Email: [**]</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="text-align: justify; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; line-height: 1.25;">or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed to have been given upon
        receipt, <font style="font-style: italic;">provided</font>, that any notice sent via electronic mail is not deemed received if the sender receives a delivery failure notification.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">18.6.&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Entire Agreement; Amendments</font>. This Agreement, together with all Schedules hereto, contains the entire understanding of the
        Parties with respect to the subject matter hereof and thereof, including the licenses granted hereunder. All express or implied prior or contemporaneous agreements and understandings, either oral or written, with regard to the subject matter hereof
        and thereof, including with respect to the licenses granted hereunder (including, for clarity, the Existing CDA), are superseded by the terms of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written
        instrument duly executed by authorized representatives of both Parties hereto. Any confidential information disclosed by the Parties pursuant to the Existing CDA shall constitute Confidential Information under this Agreement.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">18.7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Headings</font>. The captions to the several Sections hereof are not a part of the Agreement but are merely for convenience to
        assist in locating and reading the several Sections and Sections of this Agreement.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">18.8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Independent Contractors</font>. It is expressly agreed that CGEN and Gilead shall be independent contractors and that the
        relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither CGEN nor Gilead shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which
        shall be binding on the other Party, without the prior written consent of the other Party.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">70</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">18.9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">No Third Party Beneficiary Rights</font>. Except as expressly set forth in this Agreement, this Agreement is not intended to and
        will not be construed to give any Third Party any interest or rights (including any Third Party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">18.10.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Performance by Affiliates</font>. Gilead will have the right to perform any or all of its obligations and exercise any or all of
        its rights under this Agreement through any Affiliate. CGEN will have the right to perform any or all of its obligations and exercise any or all of its rights under this Agreement through any wholly owned subsidiary or, with Gilead&#8217;s prior written
        consent, such consent not to be unreasonably conditioned, withheld or delayed, through any other Affiliate. Each Party shall be responsible and liable for the performance by its Affiliates of such Party&#8217;s obligations under this Agreement and will
        cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party&#8217;s Affiliate of any of such Party&#8217;s obligations under this Agreement is deemed a breach by such Party, and the other
        Party may proceed directly against such Party without any obligation to first proceed against such Party&#8217;s Affiliate.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">18.11.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Waiver</font>. The waiver by either Party of any right hereunder, or the failure of the other Party to perform, or a breach by the
        other Party, shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">18.12.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Cumulative Remedies</font>. Except as expressly otherwise stated herein, no remedy referred to in this Agreement is intended to be
        exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">18.13.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Waiver of Rule of Construction</font>. Each Party has had the opportunity to consult with counsel in connection with the review,
        drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">18.14.&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Counterparts</font>. The Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
        of which together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail, including Adobe&#8482; Portable Document Format (PDF) or any electronic signature complying with the U.S. Federal ESIGN Act of 2000, and
        any counterpart so delivered will be deemed to be original signatures, will be valid and binding upon the Parties, and, upon delivery, will constitute due execution of this Agreement.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">18.15.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Further Assurances</font>. Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further
        instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in connection with this
        Agreement or to carry out more effectively the provisions and purposes, or to better assure and confirm unto such other Party its rights and remedies under this Agreement.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">18.16.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Construction</font>. Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural
        the singular, the use of any gender shall be applicable to all genders and the word &#8220;or&#8221; is used in the inclusive sense (and/or). Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days.
        The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The words &#8220;include&#8221;, &#8220;includes,&#8221;
        &#8220;including&#8221; and &#8220;such as&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;. The word &#8220;will&#8221; will be construed to have the same meaning and effect as the word &#8220;shall&#8221;. Any reference to any person or entity will be construed to
        include the person&#8217;s or entity&#8217;s successor and assigns. The words &#8220;herein,&#8221; &#8220;hereof,&#8221; and &#8220;hereunder&#8221;, and words of similar import, will be construed to refer to this Agreement in its entirety and not any particular provision. The word &#8220;notice&#8221;
        means notice in writing (whether or not specifically stated) and will include notices, consents, approvals, and other written communications contemplated under this Agreement. Provisions that require that a Party, the Parties, or any committee
        hereunder &#8220;agree,&#8221; &#8220;consent,&#8221; &#8220;approve,&#8221; or the like will require that such agreement, consent, or approval be specific and in writing, whether by written agreement, letter, approved minutes, or otherwise (but excluding e-mail and instant
        messaging). References to &#8220;Section&#8221; or &#8220;Sections&#8221; are references to the numbered sections of this Agreement, unless expressly stated otherwise. All dollars are United States Dollars. Unless the context otherwise requires, countries shall include
        territories. References to any specific law or article, section or other division thereof, shall be deemed to include the then-current amendments or any replacement law thereto. Except as otherwise expressly set forth in this Agreement, when
        applied to Gilead, the phrases &#8220;at its own cost and expense,&#8221; &#8220;at its sole cost and expense,&#8221; &#8220;at its cost and expense,&#8221; and similar phrases used in this Agreement do not preclude the possibility that Gilead may share such costs or expenses with a
        Third Party.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">(Remainder of page intentionally left blank)</div>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">71</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">The Parties have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z77ca95199cef4a06a8a7ccc30bd845d5">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Gilead Sciences, Inc.</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Compugen Ltd.</div>
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;"> <br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">By: _____________________________________________ &#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
              </div>
              <div style="text-align: justify; line-height: 1.25;">Name: Andrew Dickinson</div>
              <div style="text-align: justify; text-indent: -30.55pt; margin-left: 30.55pt; line-height: 1.25;">Title: Executive Vice President and Chief Financial Officer</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">By: _____________________________________________</div>
              <div style="text-align: justify; line-height: 1.25;">Name: Anat Cohen Dayag</div>
              <div style="text-align: justify; line-height: 1.25;">Title: President and Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageFooter">
        <div style="text-align: center; line-height: 1.25;">[Signature Page to the License Agreement]</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: center; line-height: 1.25;"> <br>
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>Schedule </u><u>1.36</u></div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">CGEN Development and Manufacturing Agreements</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">[**]</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;"><u>Schedule </u><u>1.51</u></font></div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">COM503</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">[**]</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;"><u>Schedule </u><u>1.134</u></font></div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">IL-18 Patents</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">[**]</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;"><u>Schedule </u><u>1.137</u></font></div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">IL-18 Trial Data Package</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">[**]</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;"><u>Schedule </u><u>1.156</u></font></div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Knowledge Parties</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">[**]</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;"><u>Schedule </u><u>1.242</u></font></div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Existing Upstream License Agreements</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">[**]</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;"><u>Schedule </u><u>2.1</u></font></div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Development Plan</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">[**]</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;"><u>Schedule </u><u>2.9</u></font></div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">COM503 Study Budget</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">[**]</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;"><u>Schedule </u><u>11.3(a)</u></font></div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Press Release</div>
      <div style="line-height: 1.25">&#160;
        <table cellspacing="0" cellpadding="0" border="0" id="z09e3f9026aa6490ba7fcd1605e6d5d39" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 50.00%;">
                <div style="text-align: right;">&#160;
                  <div style="text-align: left; margin-left: 12.05pt; line-height: 1.25;"><img width="149" height="41" src="image00001.jpg"></div>
                </div>
              </td>
              <td style="width: 50%; text-align: right;"><img width="138" height="38" src="image1.jpg"></td>
            </tr>

        </table>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;"><br>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CONTACTS:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Compugen Ltd.</u></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Yvonne Naughton, Ph.D., Investors and Media </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><u>ir@cgen.com</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Gilead</u></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Investors:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Jacquie Ross </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><u>investor_relations@gilead.com</u></div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Media:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Meaghan Smith </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><u>public_affairs@gilead.com</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Clinical Immunotherapy Program</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">&#8211; <font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Gilead Will Have Exclusive Rights to Later Stage Development and Commercialization of </font></div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Anti-IL18 Binding Protein Antibodies with Potential to Treat Various Tumor Types &#8211;</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div>
        <div style="font-family: 'Times New Roman',Times,serif; font-style: italic; text-align: center;">&#8211; Gilead to Make $60 Million Upfront Payment and $30 Million in a Near Term Milestone </div>
        <div style="font-family: 'Times New Roman',Times,serif; font-style: italic; text-align: center;">Payment with a Total Deal Value of up to $848 Million &#8211;</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">FOSTER CITY, Calif. &amp; HOLON, ISRAEL </font>&#8211; December 19, 2023 &#8211; Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with
        Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively license its potential first-in-class, pre- clinical antibody
        program against IL-18 binding protein, including the COM503 drug candidate.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Compugen utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for
        developing novel cancer immunotherapies. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby releasing natural IL-18 in the tumor microenvironment and inhibiting
        cancer growth.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#8220;We are very pleased to add COM503 to our pipeline of investigational immuno-oncology therapies that have the potential to transform care for patients with cancer,&#8221; said
        Flavius Martin, M.D., Executive Vice President, Research, Gilead Sciences. &#8220;We believe that this collaboration complements our strategy of developing modalities which promote immune-mediated tumor killing and may enable new combination therapies
        with programs in our growing oncology portfolio.&#8221;</div>
      <div class="BRPFPageFooter">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#8220;We are delighted to enter into this collaboration with Gilead and believe that Gilead&#8217;s confidence in our differentiated approach to harness cytokine biology for cancer
        therapeutics speaks to the quality of our computational discovery capabilities as well as our ability to translate our novel discoveries into investigational drugs in the clinic and we look forward to working together to bring new treatment options
        to patients,&#8221; said Anat Cohen-Dayag, Ph.D., President, and CEO at Compugen. &#8220;IL-18 is one of the rare cytokines which is naturally inhibited by an endogenous binding protein, presenting a unique opportunity to use a blocking antibody to increase
        the local concentrations of IL-18 within the tumor where it can potentiate anti-tumor immune responses, thereby potentially overcoming the limitations of systemically administered cytokines.&#8221;</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Terms of the Partnership</u></div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Under the terms of the agreement, Compugen will be responsible for the ongoing pre-clinical development and the future Phase 1 study of COM503.
        Thereafter, Gilead will have the sole right to develop and commercialize COM503.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Gilead will make Compugen an upfront payment of $60 million and $30 million in a near term milestone payment subject to IND clearance of COM503 expected
        in 2024. Compugen will also be eligible to receive up to an additional $758 million in future development, regulatory and commercial milestone payments, with a total deal value of $848 million. Compugen will also be eligible to receive single-digit
        to low double-digit tiered royalties on worldwide net sales.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission (SEC), Gilead no
        longer excludes acquired IPR&amp;D expenses from its non-GAAP financial measures. This transaction with Compugen is expected to reduce Gilead&#8217;s GAAP and non-GAAP 2023 EPS by approximately $0.03 - $0.05.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">About Compugen</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new
        drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting
        TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen&#8217;s clinical stage anti-TIGIT
        antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company&#8217;s therapeutic pipeline of early-stage immuno-oncology programs consists of
        programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, is in IND enabling studies. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18
        binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen&#8217;s shares are listed on Nasdaq and the Tel Aviv Stock
        Exchange under the ticker symbol CGEN.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">About Gilead Sciences</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a
        healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide,
        with headquarters in Foster City, California.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Compugen Forward-Looking Statements</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the
        safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Forward-looking statements can be identified using terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;estimate,&#8221; &#8220;likely,&#8221;
        &#8220;should,&#8221; &#8220;confident,&#8221; and &#8220;intends,&#8221; and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Forward-looking statements include, but are not limited to, statement regarding our expectation from the collaboration, statement regarding our belief that using a blocking
        antibody to increase the local concentrations of IL-18 within the tumor where, can potentiate anti-tumor immune responses, thereby potentially overcoming the limitations of systemically administered cytokines and statement regarding the expected
        time for IND clearance of COM503. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance, or achievements of Compugen to be materially different from any future results,
        performance or achievements expressed or implied by such forward-looking statements. Among these risks: the clinical trials of any product candidates that Compugen, or any current or future collaborators, may develop may fail to satisfactorily
        demonstrate safety and efficacy to the FDA, and Compugen, or any collaborators, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these product candidates;
        Compugen&#8217;s business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model; Compugen&#8217;s
        approach to the discovery of therapeutic products is based on its proprietary computational target discovery infrastructure, which is unproven clinically; general market, political and economic conditions in the countries in which Compugen
        operates, including Israel; the effect of the evolving nature of the recent war in Gaza; and Compugen does not know whether it will be able to discover and develop additional potential product candidates or products of commercial value. These risks
        and other risks are more fully discussed in the &#8220;Risk Factors&#8221; section of Compugen&#8217;s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by
        Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen&#8217;s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not
        assume any obligation to update any forward-looking statements unless required by law.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Gilead Forward-Looking Statements</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and
        other factors, including Gilead&#8217;s ability to realize the anticipated benefits from the collaboration with Compugen; difficulties or unanticipated expenses in connection with the collaboration, and the potential effects on Gilead s earnings; the
        ability of the parties to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from trials, including those involving COM503, and additional programs that may
        become subject of the collaboration; the possibility that the parties may make a strategic decision to terminate the collaboration or discontinue development of any of the investigational agents under the collaboration, and therefore these
        investigational agents may never be successfully commercialized; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead&#8217;s Quarterly Report on Form 10-Q for the
        quarter ended September 30, 2023, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All
        statements other than statements of historical fact are statements that could be deemed forward-looking statements.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The reader is cautioned that any such forward- looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place
        undue reliance on these forward-looking statements. All forward- looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">###</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;">Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;">The Compugen name and logo are trademarks of Compugen Ltd.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;">For more information about Gilead, please visit the company&#8217;s website at <u>www.gilead.com</u>, </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;">follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;">at 1-800-GILEAD-5 or 1-650-574-3000.</div>
    </div>
    <br>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>4
<FILENAME>exhibit_8-1.htm
<DESCRIPTION>EXHIBIT 8.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div>
    <div style="line-height: 1.25; font-weight: bold; text-align: right;"><u>Exhibit 8.1</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SUBSIDIARIES</div>
    <div style="line-height: 1.25">&#160;&#160; <br>
      <table cellspacing="0" cellpadding="3" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z108f4705439046e287ba1fabf6507d57">

          <tr>
            <td style="width: 20%;"><font style="font-weight: bold;"><u>Subsidiary</u></font>&#160; <br>
            </td>
            <td style="width: 80%;"><font style="font-weight: bold;"><u>Jurisdiction</u></font></td>
          </tr>
          <tr>
            <td style="width: 20%;">
              <div>Compugen USA, Inc.&#160; <br>
              </div>
            </td>
            <td style="width: 80%;">
              <div>Delaware <br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <div style="line-height: 1.25">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>5
<FILENAME>exhibit_12-1.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 12.1</u></div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">CERTIFICATION</font>&#160;<font style="font-weight: bold;">PURSUANT TO</font></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160; RULE 13a-14(a)/RULE 15d-14(a) UNDER</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160; THE EXCHANGE ACT AND SECTION 302</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160; OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">I, Dr. Anat Cohen-Dayag, certify that:</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 20-F of Compugen Ltd.;</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
      circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
      operations and cash flows of the company as of, and for, the periods presented in this report;</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
      and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
      ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
      supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">c.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the
      effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">d.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the
      annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit
      committee of the company's board of directors (or persons performing the equivalent functions):</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
      likely to adversely affect the company's ability to record, process, summarize and report financial information; and</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over
      financial reporting.</div>
    <div style="line-height: 1.25">&#160;&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">Date: March 5, 2024</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="line-height: 1.25;"><u>/s/ Dr. Anat Cohen-Dayag</u></div>
    <div style="line-height: 1.25;">Title: President and Chief Executive Officer</div>
    <div style="line-height: 1.25">&#160;
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25">&#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>6
<FILENAME>exhibit_12-2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div>
    <div style="line-height: 1.25; font-weight: bold; text-align: right;"><u>Exhibit 12.2</u></div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160; RULE 13a-14(a)/RULE 15d-14(a) UNDER THE EXCHANGE ACT</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160; AND SECTION 302</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160; OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">I, Alberto Sessa, certify that:</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 20-F of Compugen Ltd.;</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
      circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
      operations and cash flows of the company as of, and for, the periods presented in this report;</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
      and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
      ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
      supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">c.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the
      effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">d.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the
      annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit
      committee of the company's board of directors (or persons performing the equivalent functions):</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 30.7pt; line-height: 1.25;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
      likely to adversely affect the company's ability to record, process, summarize and report financial information; and</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 30.7pt; line-height: 1.25;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over
      financial reporting.</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">Date: March 5, 2024</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><u>/s/ Alberto Sessa</u></div>
    <div style="text-align: justify; line-height: 1.25;">Title: Chief Financial Officer</div>
    <div style="line-height: 1.25">&#160;
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>7
<FILENAME>exhibit_13-1.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div>
    <div style="line-height: 1.25; font-weight: bold; text-align: right;">&#160; <u>Exhibit 13.1</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;CERTIFICATION PURSUANT TO</div>
    <div style="text-align: center; line-height: 1.25;">&#160; <font style="font-weight: bold;">RULE 13a-14(b)/RULE 15d-14(b)</font>&#160;<font style="font-weight: bold;">UNDER THE EXCHANGE ACT</font></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160; AND 18 U.S.C. SECTION 1350,</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160; AS ADOPTED PURSUANT TO</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160; SECTION 906</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160; OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">In connection with the annual report of Compugen Ltd. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof
      (the &#8220;Report&#8221;), each of the undersigned officers of the Company, certify, pursuant to Rule 13a-14(b)/Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002, that to such officer&#8217;s knowledge:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Sections 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</div>
    <div style="line-height: 1.25">&#160; <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
    <div style="line-height: 1.25">&#160;&#160; </div>
    <div style="text-align: justify; line-height: 1.25;"><u>/s/ Dr. Anat Cohen-Dayag</u></div>
    <div style="text-align: justify; line-height: 1.25;">Title:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;President and Chief Executive Officer</div>
    <div style="text-align: justify; line-height: 1.25;">Date:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;March 5, 2024</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><u>/s/ Alberto Sessa</u></div>
    Title:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chief Financial Officer
    <div style="line-height: 1.25;">Date:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;March 5, 2024</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>8
<FILENAME>exhibit_15-1.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25; text-align: right; font-weight: bold;"><u> </u>
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25; text-align: right; font-weight: bold;"><u>Exhibit 15.1</u></div>
    &#160;
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
    &#160;
    <div style="text-indent: 36pt; line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We consent to the incorporation by reference in the Registration Statement (Form S-8 Nos. 333-169239, 333-204869,
        333-223937, 333-240182, 333-251263, 333-266508) pertaining to the Employee&#8217;s share option plans of Compugen Ltd. and Registration Statement (Form F-3 333-270985)
        of our reports dated March 5, 2024, with respect to the consolidated financial statements of Compugen Ltd. and the effectiveness of internal control over financial reporting of Compugen Ltd., included in this Annual Report (Form 20-F) for the year
        ended December 31, 2023.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25">
      <table cellspacing="0" cellpadding="0" id="zb8963ab0546248348d2d19a171160f70" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50.16%; vertical-align: top;">
              <div style="line-height: 1.25;">/s/ KOST FORER GABBAY &amp; KASIERER</div>
              <div style="line-height: 1.25;">KOST FORER GABBAY &amp; KASIERER</div>
            </td>
            <td style="width: 49.84%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25;">March 5, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.16%; vertical-align: top;">
              <div style="line-height: 1.25;">A Member Firm of Ernst &amp; Young Global</div>
            </td>
            <td style="width: 49.84%; vertical-align: top;">
              <div style="text-align: right; line-height: 1.25;">Tel-Aviv, Israel</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <div style="line-height: 1.25">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>9
<FILENAME>exhibit_97-1.htm
<DESCRIPTION>EXHIBIT 97.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u> Exhibit 97.1</u><br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPUGEN LTD.<br>
      POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Compugen Ltd. (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221;) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the &#8220;<font style="font-weight: bold; font-style: italic;">Policy</font>&#8221;), effective as of October 2, 2023 ((the &#8220;<font style="font-weight: bold; font-style: italic;">Effective Date</font>&#8221;).&#160; Capitalized terms used in this Policy but not otherwise defined
      herein are defined in Section 11.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zac1bd5b073b7471db088213a8414f331">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">1.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;"><u>Persons Subject to Policy</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This Policy shall apply to and be binding and enforceable on current and former Officers. In addition, the Committee and the Board may apply this Policy to persons who are not
      Officers, and such application shall apply in the manner determined by the Committee and the Board in their sole discretion.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze845943f3fc94e31a0526528ce33ce14">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">2.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;"><u>Compensation Subject to Policy</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This Policy shall apply to Incentive-Based Compensation received on or after the Effective Date. For purposes of this Policy, the date on which Incentive-Based Compensation is
      &#8220;received&#8221; shall be determined under the Applicable Rules, which generally provide that Incentive-Based Compensation is &#8220;received&#8221; in the Company&#8217;s fiscal period during which the relevant Financial Reporting Measure is attained or satisfied, without
      regard to whether the grant, vesting or payment of the Incentive-Based Compensation occurs after the end of that period.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfa1c3dda9d104558bdd639c6681d4583">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">3.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;"><u>Recovery of Compensation</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the event that the Company is required to prepare a Restatement, the Company shall recover, reasonably promptly and in accordance with Section 4 below, the portion of any
      Incentive-Based Compensation that is Erroneously Awarded Compensation, unless the Committee and the Board have determined that recovery from the relevant current or former Officer would be Impracticable. Recovery shall be required in accordance with
      the preceding sentence regardless of whether the applicable Officer engaged in misconduct or otherwise caused or contributed to the requirement for the Restatement and regardless of whether or when restated financial statements are filed by the
      Company.&#160; For clarity, the recovery of Erroneously Awarded Compensation under this Policy will not give rise to any Officer&#8217;s right to voluntarily terminate employment for &#8220;good reason&#8221; or due to a &#8220;constructive termination&#8221; (or any similar term of
      like effect) under any plan, program or policy of or agreement with the Company or any of its affiliates.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2625fb67352840ebbde282c67b7621d6">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">4.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;"><u>Manner of Recovery; Limitation on Duplicative Recovery</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Committee and the Board shall, in its sole discretion, determine the manner of recovery of any Erroneously Awarded Compensation, which may include, without limitation,
      reduction or cancellation by the Company or an affiliate of the Company of Incentive-Based Compensation or Erroneously Awarded Compensation, reimbursement or repayment by any person subject to this Policy, and, to the extent permitted by law, an
      offset of the Erroneously Awarded Compensation against other compensation payable by the Company or an affiliate of the Company to such person. Notwithstanding the foregoing, unless otherwise prohibited by the Applicable Rules, to the extent this
      Policy provides for recovery of Erroneously Awarded Compensation already recovered by the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 or Other Recovery Arrangements, the amount of Erroneously Awarded Compensation already
      recovered by the Company from the recipient of such Erroneously Awarded Compensation may be credited to the amount of Erroneously Awarded Compensation required to be recovered pursuant to this Policy from such person.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb9b3f35de65345299767b17083d8973d">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">5.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;"><u>Administration</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This Policy shall be administered, interpreted and construed by the Committee, which is authorized to make all determinations necessary, appropriate or advisable for such purpose.
      The Board may re-vest in itself the authority to administer, interpret and construe this Policy in accordance with applicable law and the Applicable Rules, and in such event references herein to the &#8220;Committee&#8221; shall be deemed to be references to the
      Board.&#160; Subject to any permitted review by the applicable national securities exchange or association pursuant to the Applicable Rules, all determinations and decisions made by the Committee pursuant to the provisions of this Policy shall be final,
      conclusive and binding on all persons, including the Company and its affiliates, shareholders and employees. The Committee may delegate administrative duties with respect to this Policy to one or more directors or employees of the Company, as
      permitted under applicable law, including any Applicable Rules.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdabf3373b67a473e8806e093156934ce">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">6.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;"><u>Interpretation</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This Policy shall be interpreted and applied in a manner that is consistent with the requirements of the Applicable Rules, and to the extent this Policy is inconsistent with such
      Applicable Rules, it shall be deemed amended to the minimum extent necessary to ensure compliance therewith.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd103cf92ec31485b832106effe20f8bf">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">7.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;"><u>No Indemnification; No Liability</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Notwithstanding the terms of any of the Company&#8217;s organizational documents, any corporate policy or any contract, the Company shall not indemnify or insure any person against the
      loss of any Erroneously Awarded Compensation pursuant to this Policy, nor shall the Company directly or indirectly pay or reimburse any person for any premiums for third-party insurance policies that such person may elect to purchase to fund such
      person&#8217;s potential obligations under this Policy.&#160; None of the Company, an affiliate of the Company or any member of the Committee or the Board shall have any liability to any person as a result of actions taken under this Policy.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z245994b5eea24095a32887d3cc9de7dd">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">8.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;"><u>Application; Enforceability</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Except as otherwise determined by the Committee or the Board, the adoption of this Policy does not limit, and is intended to apply in addition to, any Other Recovery Arrangements.
      Without limiting the foregoing, in the event of a conflict between this Policy and the Compensation Policy, the latter shall prevail, except with respect to the recovery of any portion of Incentive-Based Compensation that is Erroneously Awarded
      Compensation that would not be recoverable under the Compensation Policy, in which case this Policy shall prevail.&#160; Subject to Section 4, the remedy specified in this Policy shall not be exclusive and shall be in addition to every other right or
      remedy at law or in equity that may be available to the Company or an affiliate of the Company or is otherwise required by applicable law and regulations.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb0a62fba945a45849b2c1cfc4d3f9d96">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">9.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;"><u>Severability</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The provisions in this Policy are intended to be applied to the fullest extent of the law; provided, however, to the extent that any provision of this Policy is found to be
      unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted, and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any
      limitations required under applicable law or the Applicable Rules.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1ef1953dda8146b3aaf6a884102f5a93">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">10.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;"><u>Amendment and Termination</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Board or the Committee may amend, modify or terminate this Policy in whole or in part at any time and from time to time in its sole discretion. This Policy will terminate
      automatically when the Company does not have a class of securities listed on a national securities exchange or association in the U.S.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zecc90af5dca5496cbce844acf0d3b702">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">11.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;"><u>Definitions</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold; font-style: italic;">Applicable Rules</font>&#8221; means Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder, the listing rules of the
      national securities exchange or association on which the Company&#8217;s securities are listed, and any applicable rules, standards or other guidance adopted by the Securities and Exchange Commission or any national securities exchange or association on
      which the Company&#8217;s securities are listed.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold; font-style: italic;">Board</font>&#8221; means the Board of Directors of the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold; font-style: italic;">Compensation Policy</font>&#8221; means the Company&#8217;s compensation policy for officers and directors, as adopted in accordance with
      the Israeli Companies Law 5759-1999 and as in effect from time to time.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold; font-style: italic;">Committee</font>&#8221; means the Compensation Committee of the Board or, in the absence of such a committee, a majority of the
      independent directors serving on the Board.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold; font-style: italic;">Erroneously Awarded Compensation</font>&#8221; means the amount of Incentive-Based Compensation received by a current or former
      Officer that exceeds the amount of Incentive-Based Compensation that would have been received by such current or former Officer based on a restated Financial Reporting Measure, as determined on a pre-tax basis in accordance with the Applicable Rules.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold; font-style: italic;">Exchange Act</font>&#8221; means the Securities Exchange Act of 1934, as amended.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold; font-style: italic;">Financial Reporting Measure</font>&#8221; means any measure determined and presented in accordance with the accounting principles
      used in preparing the Company&#8217;s financial statements, and any measures derived wholly or in part from such measures, including GAAP, IFRS and non-GAAP/IFRS financial measures, as well as share price and total shareholder return.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold; font-style: italic;">GAAP</font>&#8221; means United States generally accepted accounting principles.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold; font-style: italic;">IFRS</font>&#8221; means international financial reporting standards as adopted by the International Accounting Standards Board.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold; font-style: italic;">Impracticable</font>&#8221; means (a) the direct expense paid to third parties to assist in enforcing recovery would exceed the
      Erroneously Awarded Compensation; provided that the Company has (i) made reasonable attempt(s) to recover the Erroneously Awarded Compensation, (ii) documented such reasonable attempt(s) and (iii) provided such documentation to the relevant listing
      exchange or association, (b) the recovery would violate the Company&#8217;s home country laws adopted prior to November 28, 2022 pursuant to an opinion of home country counsel; provided that the Company has (i) obtained an opinion of home country counsel,
      acceptable to the relevant listing exchange or association, that recovery would result in such a violation and (ii) provided such opinion to the relevant listing exchange or association, or (c) recovery would likely cause an otherwise tax-qualified
      retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and the regulations thereunder.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold; font-style: italic;">Incentive-Based Compensation</font>&#8221; means, with respect to a Restatement, any compensation that is granted, earned, or vested
      based wholly or in part upon the attainment of one or more Financial Reporting Measures and received by a person: (a) after such person began service as an Officer; (b) who served as an Officer at any time during the performance period for that
      incentive-based compensation; (c) while the Company has a class of securities listed on a national securities exchange or association; and (d) during the applicable Three-Year Period.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold; font-style: italic;">Officer</font>&#8221; means each person who the Company determines serves as a Company officer, as defined in Section 16 of the
      Securities Exchange Act of 1934, as amended. The term &#8220;Officer&#8221; includes, without limitation, those officers identified by the Company in any disclosure made pursuant to the requirements of Regulation S-K Item 401(b) or Form 20-F, as applicable.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">&#8220;</font><font style="font-weight: bold; font-style: italic;">Other Recovery Arrangements</font><font style="font-style: italic;">&#8221;</font><font style="font-weight: bold; font-style: italic;">&#160;</font>means any clawback, recoupment, forfeiture or similar policies or provisions of the Company or its affiliates, including any such policies or provisions of such effect contained in any
      employment agreement, bonus plan, incentive plan, equity-based plan or award agreement thereunder or similar plan, program or agreement of the Company or an affiliate or required under applicable law (including, without limitation, the Compensation
      Policy).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold; font-style: italic;">Restatement</font>&#8221; means an accounting restatement to correct the Company&#8217;s material noncompliance with any financial
      reporting requirement under securities laws, including restatements that correct an error in previously issued financial statements (a) that is material to the previously issued financial statements or (b) that would result in a material misstatement
      if the error were corrected in the current period or left uncorrected in the current period<font style="font-style: italic;">.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold; font-style: italic;">Three-Year Period</font>&#8221; means, with respect to a Restatement, the three completed fiscal years immediately preceding the
      date that the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare such
      Restatement, or, if earlier, the date on which a court, regulator or other legally authorized body directs the Company to prepare such Restatement.&#160;The &#8220;Three-Year Period&#8221; also includes any transition period (that results from a change in the
      Company&#8217;s fiscal year) within or immediately following the three completed fiscal years identified in the preceding sentence.&#160;However, a transition period between the last day of the Company&#8217;s previous fiscal year end and the first day of its new
      fiscal year that comprises a period of nine to 12 months shall be deemed a completed fiscal year.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">ACKNOWLEDGMENT AND CONSENT TO</font><br>
      <font style="font-weight: bold;">POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The undersigned has received a copy of the Policy for Recovery of Erroneously Awarded Compensation (the &#8220;<font style="font-weight: bold;">Policy</font>&#8221;) adopted by Compugen Ltd. (the &#8220;Company&#8221;) and
      has read and understands the Policy. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Policy.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">As a condition of receiving Incentive-Based Compensation from the Company, the undersigned agrees that any Incentive-Based Compensation received on or after the Effective Date is subject to recovery
      pursuant to the terms of the Policy, as may be amended, restated, supplemented or otherwise modified from time to time. To the extent the Company&#8217;s recovery right conflicts with any other contractual rights the undersigned may have with the Company,
      the undersigned understands that the terms of the Policy shall supersede any such contractual rights. The terms of the Policy shall apply in addition to any right of recoupment against the undersigned under the Compensation Policy or applicable law
      and regulations.&#160; The undersigned also acknowledges that it would not be entitled to indemnification or advancement of expenses, in connection with any enforcement of the Policy by the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zb4ec959aadd740468ce9ea60c777c3b6">

        <tr>
          <td style="width: 27.86%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">___________________</div>
            <div style="text-align: justify; line-height: 1.25;">Date</div>
          </td>
          <td style="width: 72.14%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">________________________________________</div>
            <div style="text-align: justify; line-height: 1.25;">Signature</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 27.86%; vertical-align: top;">&#160;</td>
          <td style="width: 72.14%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">________________________________________</div>
            <div style="text-align: justify; line-height: 1.25;">Name</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 27.86%; vertical-align: top;">&#160;</td>
          <td style="width: 72.14%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">________________________________________</div>
            <div style="text-align: justify; line-height: 1.25;">Title</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="text-align: center;"> 5<br>
    </div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
    <br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>cgen-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#ConsolidatedBalanceSheets" roleURI="http://cgen.com/role/ConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-csocl" roleURI="http://cgen.com/role/cgen-csocl"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-oaraped" roleURI="http://cgen.com/role/cgen-oaraped"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#LeasesScheduleOfOperatingLeasesDetails" roleURI="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-paend" roleURI="http://cgen.com/role/cgen-paend"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-oapaaed" roleURI="http://cgen.com/role/cgen-oapaaed"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#IncomeTaxesScheduleOfLossBeforeTaxesDetails" roleURI="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails" roleURI="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"/>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="loc_cgen_SeverancePayFundNoncurrent_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_OtherShortTermInvestments_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_ReceivablesNetCurrent_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsNoncurrent_8" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_cgen_SeverancePayFundNoncurrent_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_11" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_13" xlink:to="loc_us-gaap_LiabilitiesCurrent_14" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_14" xlink:to="loc_us-gaap_AccountsPayableCurrent_14" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_14" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_15" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_14" xlink:to="loc_us-gaap_DeferredRevenueCurrent_16" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_14" xlink:to="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_17" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_14" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_18" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_13" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_20" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_20" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_20" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_20" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_21" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_20" xlink:to="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_22" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_20" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_23" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_13" xlink:to="loc_us-gaap_StockholdersEquity_25" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25" xlink:to="loc_us-gaap_CommonStockValue_25" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_26" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_27" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-csocl">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_13"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_us-gaap_OperatingIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1" xlink:to="loc_us-gaap_GrossProfit_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1" xlink:to="loc_us-gaap_Revenues_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1" xlink:to="loc_us-gaap_CostOfRevenue_2" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1" xlink:to="loc_us-gaap_OperatingExpenses_4" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4" xlink:to="loc_us-gaap_BusinessDevelopment_5" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_cgen_FinancialIncomeExpenseNet_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_13" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseDecreaseInDeferredRevenues" xlink:label="loc_cgen_IncreaseDecreaseInDeferredRevenues_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ShareBasedCompensation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_Depreciation_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_SeverancePayNet_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_5" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6" order="50" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_7" order="60" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_8" order="70" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9" order="80" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_10" order="90" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_11" order="100" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_12" order="110" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_13" order="120" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_IncreaseDecreaseInDeferredRevenues_14" order="130" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_15" order="140" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_16" order="150" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_18" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_19" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_20" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_21" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_22" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_23" order="50" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18" xlink:to="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_24" order="60" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_26" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_27" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_28" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oaraped">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_GovernmentAuthorities" xlink:label="loc_cgen_GovernmentAuthorities_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_3"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_cgen_GovernmentAuthorities_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_us-gaap_OtherAssetsCurrent_3" order="20" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paend">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oapaaed">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="loc_cgen_DeferredIncomeTaxLeaseLiabilities_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="loc_cgen_DeferredIncomeTaxRightOfUseAssets_9"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_cgen_DeferredIncomeTaxLeaseLiabilities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_9" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9" xlink:to="loc_cgen_DeferredIncomeTaxRightOfUseAssets_9" order="0" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails">
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_5"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_InterestAndDebtExpense_3" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_5" order="40" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>cgen-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-daei1" roleURI="http://cgen.com/role/cgen-daei1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#StatementsOfChangesInShareholdersEquity" roleURI="http://cgen.com/role/StatementsOfChangesInShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-sapnd" roleURI="http://cgen.com/role/cgen-sapnd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-sapsodrfpaed" roleURI="http://cgen.com/role/cgen-sapsodrfpaed"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails" roleURI="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-paend" roleURI="http://cgen.com/role/cgen-paend"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#CommitmentsAndContingenciesDetails" roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-sesopnd" roleURI="http://cgen.com/role/cgen-sesopnd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#ShareholdersEquityScheduleOfOptionActivityDetails" roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-sesosced" roleURI="http://cgen.com/role/cgen-sesosced"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#IncomeTaxesNarrativeDetails" roleURI="http://cgen.com/role/IncomeTaxesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#GeographicInformationAndMajorCustomersDetails" roleURI="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#SubsequentEventsNarrativeDetails" roleURI="http://cgen.com/role/SubsequentEventsNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#PROPERTYANDEQUIPMENTNETNarrativeDetails" roleURI="http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-daei1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_dei_OtherReportingStandardItemNumber_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_50"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1" xlink:to="loc_dei_AddressTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1" xlink:to="loc_dei_BusinessContactMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1" xlink:to="loc_dei_AddressTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentType_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentFlag_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentDescription_12" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentRegistrationStatement_13" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentAnnualReport_14" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentTransitionReport_15" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentShellCompanyReport_16" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_17" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFileNumber_18" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_ContactPersonnelName_19" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityRegistrantName_20" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_21" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine1_22" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine2_23" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine3_24" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressCityOrTown_25" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressCountry_26" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressPostalZipCode_27" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CityAreaCode_28" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_LocalPhoneNumber_29" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_ContactPersonnelFaxNumber_30" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_ContactPersonnelEmailAddress_31" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_Security12bTitle_32" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_TradingSymbol_33" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_SecurityExchangeName_34" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_35" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_36" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityVoluntaryFilers_37" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCurrentReportingStatus_38" order="330" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_39" order="340" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFilerCategory_40" order="350" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_41" order="360" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_IcfrAuditorAttestationFlag_42" order="370" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityExTransitionPeriod_43" order="380" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentAccountingStandard_44" order="390" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_OtherReportingStandardItemNumber_45" order="400" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityShellCompany_46" order="410" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AuditorName_47" order="420" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AuditorLocation_48" order="430" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AuditorFirmId_49" order="440" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_50" order="450" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/StatementsOfChangesInShareholdersEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_23"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_13" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_14" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_15" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_NumberOfWarrantsExercised_16" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_17" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_18" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_19" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_20" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_21" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_22" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_23" order="150" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapnd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MasterClinicalAgreementOneMember" xlink:label="loc_cgen_MasterClinicalAgreementOneMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MasterClinicalAgreementTwoMember" xlink:label="loc_cgen_MasterClinicalAgreementTwoMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LicenseAgreementWithGileadMember" xlink:label="loc_cgen_LicenseAgreementWithGileadMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="loc_us-gaap_ImpairmentOfInvestments_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xlink:label="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting" xlink:label="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DerivativeRelatedExpense" xlink:label="loc_cgen_DerivativeRelatedExpense_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_27"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AccruedMilestonePayments" xlink:label="loc_cgen_AccruedMilestonePayments_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xlink:label="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LicenseRevenue" xlink:label="loc_cgen_LicenseRevenue_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredRevenuesIncludedInCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredRevenuesIncludedInNonCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_34"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementOneMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementTwoMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_LicenseAgreementWithGileadMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7" xlink:to="loc_us-gaap_StockOptionMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentForAmortization_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ImpairmentOfInvestments_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DeferredRevenue_15" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_16" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_17" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SeveranceCosts1_18" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_19" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_20" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_21" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_DerivativeRelatedExpense_22" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_23" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_24" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_25" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DerivativeNotionalAmount_26" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_27" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_28" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_AccruedMilestonePayments_29" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_30" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_31" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_LicenseRevenue_32" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_33" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_34" order="230" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapsodrfpaed">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AnnualDepreciationRate" xlink:label="loc_cgen_AnnualDepreciationRate_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="loc_cgen_AnnualDepreciationRateDescription_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_cgen_AnnualDepreciationRate_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_cgen_AnnualDepreciationRateDescription_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3" order="20" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ComputerEquipmentMember_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_4" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3" xlink:to="loc_srt_RangeAxis_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MinimumMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MaximumMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="loc_cgen_EmployeeStockPurchasePlanMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5" order="40" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" xlink:to="loc_cgen_EmployeeStockPurchasePlanMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5" xlink:to="loc_srt_RangeAxis_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_10" xlink:to="loc_srt_RangeMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_10" xlink:to="loc_srt_MinimumMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_10" xlink:to="loc_srt_MaximumMember_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_10" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paend">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AntibodiesDiscoveryCollaborationAgreementMember" xlink:label="loc_cgen_AntibodiesDiscoveryCollaborationAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ExtendLease" xlink:label="loc_cgen_ExtendLease_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RoyaltyPercentage" xlink:label="loc_cgen_RoyaltyPercentage_26"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_27"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_ResearchAndDevelopmentGrantOneMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_May2012AgreementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_AntibodiesDiscoveryCollaborationAgreementMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_RangeAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7" xlink:to="loc_srt_RangeMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7" xlink:to="loc_srt_MinimumMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7" xlink:to="loc_srt_MaximumMember_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_RoyaltyExpense_16" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_RoyaltyContingentObligations_17" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_ParticipationRights_18" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_RetainerFee_19" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_20" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_AgreementStartDate_21" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_AgreementTerminationDescription_22" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_ExtendLease_23" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_ContingentFees_24" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_25" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_RoyaltyPercentage_26" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_27" order="150" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesopnd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_JmpSecuritiesLlcMember" xlink:label="loc_cgen_JmpSecuritiesLlcMember_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LeerinkPartnersLlcMember" xlink:label="loc_cgen_LeerinkPartnersLlcMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_TwoThousandTenShareOptionsPlanMember" xlink:label="loc_cgen_TwoThousandTenShareOptionsPlanMember_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EmployeesDirectorsAndNonEmployeesMember" xlink:label="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_39"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_44"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_48"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_49"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_51"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InitialOfferingPeriod" xlink:label="loc_us-gaap_InitialOfferingPeriod_52"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xlink:label="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_53"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xlink:label="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_54"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xlink:label="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_55"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_56"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_CollaborativeArrangementsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_CollaborativeArrangementsTwoMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_JmpSecuritiesLlcMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_LeerinkPartnersLlcMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_cgen_RegisteredDirectOfferingMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_us-gaap_WarrantMember_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_cgen_UnderwritersMember_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_16" xlink:to="loc_us-gaap_PlanNameDomain_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_16" xlink:to="loc_cgen_TwoThousandTenShareOptionsPlanMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_16" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_20" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20" xlink:to="loc_us-gaap_EmployeeStockMember_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_20" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24" xlink:to="loc_us-gaap_RelatedPartyDomain_24" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_24" xlink:to="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_24" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_29" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_30" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_31" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_32" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_33" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_34" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_36" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_37" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_38" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_39" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_40" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_41" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_42" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_43" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_44" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_45" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_46" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_47" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_48" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_PercentageOfClosingPrice_49" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_50" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_51" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_InitialOfferingPeriod_52" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_53" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_54" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_55" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_56" order="280" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EmployeesDirectorsAndNonEmployeesMember" xlink:label="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_24"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_15" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_17" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_18" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_20" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_20" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_21" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_23" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_24" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesosced">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7" xlink:to="loc_us-gaap_EmployeeStockMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_12" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOfCommonParentMember" xlink:label="loc_us-gaap_SubsidiaryOfCommonParentMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NetOperatingLossCarryforwardExpired" xlink:label="loc_cgen_NetOperatingLossCarryforwardExpired_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ReducedCorporateIncomeTaxRate" xlink:label="loc_cgen_ReducedCorporateIncomeTaxRate_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ReducedTaxRate" xlink:label="loc_cgen_ReducedTaxRate_20"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_DomesticCountryMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6" xlink:to="loc_us-gaap_RelatedPartyDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_us-gaap_SubsidiaryOfCommonParentMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeTaxesPaid_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_15" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_16" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_NetOperatingLossCarryforwardExpired_17" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_18" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_ReducedCorporateIncomeTaxRate_19" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_ReducedTaxRate_20" order="100" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SegmentReportingGeographicAreaAxis" xlink:label="loc_cgen_SegmentReportingGeographicAreaAxis_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SegmentReportingGeographicAreaDomain" xlink:label="loc_cgen_SegmentReportingGeographicAreaDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IL" xlink:label="loc_country_IL_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SegmentReportingGeographicAreaDomain" xlink:label="loc_cgen_SegmentReportingGeographicAreaDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CustomerOneMember" xlink:label="loc_cgen_CustomerOneMember_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CustomerTwoMember" xlink:label="loc_cgen_CustomerTwoMember_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_23"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_cgen_SegmentReportingGeographicAreaAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cgen_SegmentReportingGeographicAreaAxis_1" xlink:to="loc_cgen_SegmentReportingGeographicAreaDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_srt_EuropeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_country_IL_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_country_US_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cgen_SegmentReportingGeographicAreaAxis_1" xlink:to="loc_cgen_SegmentReportingGeographicAreaDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7" xlink:to="loc_us-gaap_SalesRevenueNetMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_11" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_11" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_11" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_srt_MajorCustomersAxis_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_15" xlink:to="loc_srt_NameOfMajorCustomerDomain_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_15" xlink:to="loc_cgen_CustomerOneMember_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_15" xlink:to="loc_cgen_CustomerTwoMember_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_15" xlink:to="loc_srt_NameOfMajorCustomerDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_Revenues_21" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_NoncurrentAssets_22" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_23" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/SubsequentEventsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_OrdinarySharesIssuedAndSoldThroughAtmMember" xlink:label="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_12" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_Depreciation_8" order="30" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>cgen-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AccruedMilestonePayments" xlink:label="loc_cgen_AccruedMilestonePayments_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AccruedMilestonePayments" xlink:label="loc_cgen_AccruedMilestonePayments_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AccruedMilestonePayments" xlink:label="loc_cgen_AccruedMilestonePayments_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_8"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xlink:label="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xlink:label="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_26"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AnnualDepreciationRate" xlink:label="loc_cgen_AnnualDepreciationRate_27"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AnnualDepreciationRate" xlink:label="loc_cgen_AnnualDepreciationRate_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="loc_cgen_AnnualDepreciationRateDescription_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="loc_cgen_AnnualDepreciationRateDescription_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="loc_cgen_AnnualDepreciationRateDescription_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AntibodiesDiscoveryCollaborationAgreementMember" xlink:label="loc_cgen_AntibodiesDiscoveryCollaborationAgreementMember_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AntibodiesDiscoveryCollaborationAgreementMember" xlink:label="loc_cgen_AntibodiesDiscoveryCollaborationAgreementMember_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:label="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_34"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:label="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_35"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_36"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_37"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_38"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_39"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_40"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_41"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_42"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_43"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_44"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_45"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CostOfSalesContractWithCustomerPolicyTextBlock" xlink:label="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_46"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CostOfSalesContractWithCustomerPolicyTextBlock" xlink:label="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_47"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CostOfSalesContractWithCustomerPolicyTextBlock" xlink:label="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_48"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CustomerOneMember" xlink:label="loc_cgen_CustomerOneMember_49"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CustomerOneMember" xlink:label="loc_cgen_CustomerOneMember_50"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CustomerOneMember" xlink:label="loc_cgen_CustomerOneMember_51"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CustomerTwoMember" xlink:label="loc_cgen_CustomerTwoMember_52"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CustomerTwoMember" xlink:label="loc_cgen_CustomerTwoMember_53"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CustomerTwoMember" xlink:label="loc_cgen_CustomerTwoMember_54"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="loc_cgen_DeferredIncomeTaxLeaseLiabilities_55"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="loc_cgen_DeferredIncomeTaxLeaseLiabilities_56"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="loc_cgen_DeferredIncomeTaxLeaseLiabilities_57"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="loc_cgen_DeferredIncomeTaxRightOfUseAssets_58"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="loc_cgen_DeferredIncomeTaxRightOfUseAssets_59"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="loc_cgen_DeferredIncomeTaxRightOfUseAssets_60"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_61"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_62"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_63"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredRevenuesIncludedInCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_64"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredRevenuesIncludedInCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_65"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredRevenuesIncludedInCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_66"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredRevenuesIncludedInNonCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_67"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredRevenuesIncludedInNonCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_68"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredRevenuesIncludedInNonCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_69"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_70"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_71"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_72"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DerivativeRelatedExpense" xlink:label="loc_cgen_DerivativeRelatedExpense_73"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DerivativeRelatedExpense" xlink:label="loc_cgen_DerivativeRelatedExpense_74"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DerivativeRelatedExpense" xlink:label="loc_cgen_DerivativeRelatedExpense_75"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_76"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_77"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_78"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EmployeesAndDirectorsMember" xlink:label="loc_cgen_EmployeesAndDirectorsMember_79"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EmployeesAndDirectorsMember" xlink:label="loc_cgen_EmployeesAndDirectorsMember_80"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EmployeesDirectorsAndNonEmployeesMember" xlink:label="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_81"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EmployeesDirectorsAndNonEmployeesMember" xlink:label="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_82"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="loc_cgen_EmployeeStockPurchasePlanMember_83"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="loc_cgen_EmployeeStockPurchasePlanMember_84"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="loc_cgen_EmployeeStockPurchasePlanMember_85"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ExtendLease" xlink:label="loc_cgen_ExtendLease_86"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ExtendLease" xlink:label="loc_cgen_ExtendLease_87"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ExtendLease" xlink:label="loc_cgen_ExtendLease_88"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_89"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_90"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_91"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_92"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_93"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_94"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_GovernmentAuthorities" xlink:label="loc_cgen_GovernmentAuthorities_95"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_GovernmentAuthorities" xlink:label="loc_cgen_GovernmentAuthorities_96"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_97"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_98"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_99"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseDecreaseInDeferredRevenues" xlink:label="loc_cgen_IncreaseDecreaseInDeferredRevenues_100"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseDecreaseInDeferredRevenues" xlink:label="loc_cgen_IncreaseDecreaseInDeferredRevenues_101"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseDecreaseInDeferredRevenues" xlink:label="loc_cgen_IncreaseDecreaseInDeferredRevenues_102"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_103"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_104"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_105"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_106"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_107"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_108"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_InterestPaidReceivedNet" xlink:label="loc_cgen_InterestPaidReceivedNet_109"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_InterestPaidReceivedNet" xlink:label="loc_cgen_InterestPaidReceivedNet_110"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_InterestPaidReceivedNet" xlink:label="loc_cgen_InterestPaidReceivedNet_111"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_112"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_113"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_114"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_115"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_116"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_117"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_JmpSecuritiesLlcMember" xlink:label="loc_cgen_JmpSecuritiesLlcMember_118"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_JmpSecuritiesLlcMember" xlink:label="loc_cgen_JmpSecuritiesLlcMember_119"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_JmpSecuritiesLlcMember" xlink:label="loc_cgen_JmpSecuritiesLlcMember_120"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_121"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_122"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LeerinkPartnersLlcMember" xlink:label="loc_cgen_LeerinkPartnersLlcMember_123"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LeerinkPartnersLlcMember" xlink:label="loc_cgen_LeerinkPartnersLlcMember_124"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LeerinkPartnersLlcMember" xlink:label="loc_cgen_LeerinkPartnersLlcMember_125"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LicenseAgreementWithGileadMember" xlink:label="loc_cgen_LicenseAgreementWithGileadMember_126"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LicenseAgreementWithGileadMember" xlink:label="loc_cgen_LicenseAgreementWithGileadMember_127"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LicenseRevenue" xlink:label="loc_cgen_LicenseRevenue_128"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LicenseRevenue" xlink:label="loc_cgen_LicenseRevenue_129"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LicenseRevenue" xlink:label="loc_cgen_LicenseRevenue_130"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_131"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_132"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_133"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_134"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_135"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MasterClinicalAgreementOneMember" xlink:label="loc_cgen_MasterClinicalAgreementOneMember_136"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MasterClinicalAgreementOneMember" xlink:label="loc_cgen_MasterClinicalAgreementOneMember_137"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MasterClinicalAgreementTwoMember" xlink:label="loc_cgen_MasterClinicalAgreementTwoMember_138"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MasterClinicalAgreementTwoMember" xlink:label="loc_cgen_MasterClinicalAgreementTwoMember_139"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_140"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_141"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_142"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_143"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_144"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_145"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_146"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_147"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_148"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_149"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MilestonePaymentReceivable" xlink:label="loc_cgen_MilestonePaymentReceivable_150"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MilestonePaymentReceivable" xlink:label="loc_cgen_MilestonePaymentReceivable_151"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MilestonePaymentReceivable" xlink:label="loc_cgen_MilestonePaymentReceivable_152"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" xlink:label="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_153"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" xlink:label="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_154"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NetOperatingLossCarryforwardExpired" xlink:label="loc_cgen_NetOperatingLossCarryforwardExpired_155"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NetOperatingLossCarryforwardExpired" xlink:label="loc_cgen_NetOperatingLossCarryforwardExpired_156"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NonRefundableUpfrontPayment" xlink:label="loc_cgen_NonRefundableUpfrontPayment_157"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NonRefundableUpfrontPayment" xlink:label="loc_cgen_NonRefundableUpfrontPayment_158"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NonRefundableUpfrontPayment" xlink:label="loc_cgen_NonRefundableUpfrontPayment_159"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xlink:label="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_160"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xlink:label="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_161"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_162"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_163"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_164"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_165"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_166"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_167"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_OrdinarySharesIssuedAndSoldThroughAtmMember" xlink:label="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_168"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_OrdinarySharesIssuedAndSoldThroughAtmMember" xlink:label="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_169"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_OrdinarySharesIssuedAndSoldThroughAtmMember" xlink:label="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_170"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_171"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_172"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_173"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_174"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_175"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_176"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_177"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_178"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_179"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_180"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_181"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_182"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_183"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xlink:label="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_184"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xlink:label="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_185"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid" xlink:label="loc_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_186"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid" xlink:label="loc_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_187"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid" xlink:label="loc_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_188"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xlink:label="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_189"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xlink:label="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_190"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xlink:label="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_191"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xlink:label="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_192"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PeriodSinceApprovalWasGranted" xlink:label="loc_cgen_PeriodSinceApprovalWasGranted_193"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PeriodSinceApprovalWasGranted" xlink:label="loc_cgen_PeriodSinceApprovalWasGranted_194"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PeriodSinceEnterpriseBeganOperating" xlink:label="loc_cgen_PeriodSinceEnterpriseBeganOperating_195"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PeriodSinceEnterpriseBeganOperating" xlink:label="loc_cgen_PeriodSinceEnterpriseBeganOperating_196"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_197"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_198"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_199"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_200"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_201"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_202"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ReducedCorporateIncomeTaxRate" xlink:label="loc_cgen_ReducedCorporateIncomeTaxRate_203"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ReducedCorporateIncomeTaxRate" xlink:label="loc_cgen_ReducedCorporateIncomeTaxRate_204"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ReducedTaxRate" xlink:label="loc_cgen_ReducedTaxRate_205"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ReducedTaxRate" xlink:label="loc_cgen_ReducedTaxRate_206"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_207"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_208"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_209"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_210"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_211"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_212"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_213"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_214"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_215"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_216"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_217"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_218"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_219"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_220"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_221"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_222"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_223"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_224"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_225"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_226"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_227"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_228"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_229"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_230"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_231"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_232"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RoyaltyPercentage" xlink:label="loc_cgen_RoyaltyPercentage_233"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RoyaltyPercentage" xlink:label="loc_cgen_RoyaltyPercentage_234"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RoyaltyPercentage" xlink:label="loc_cgen_RoyaltyPercentage_235"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_236"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_237"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_238"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SalesAgreementWithSVBSecuritiesLLCMember" xlink:label="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_239"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SalesAgreementWithSVBSecuritiesLLCMember" xlink:label="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_240"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SalesAgreementWithSVBSecuritiesLLCMember" xlink:label="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_241"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" xlink:label="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_242"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" xlink:label="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_243"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" xlink:label="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_244"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions" xlink:label="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_245"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions" xlink:label="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_246"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions" xlink:label="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_247"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" xlink:label="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_248"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" xlink:label="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_249"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" xlink:label="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_250"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SegmentReportingGeograhicAreaLineItems" xlink:label="loc_cgen_SegmentReportingGeograhicAreaLineItems_251"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SegmentReportingGeograhicAreaLineItems" xlink:label="loc_cgen_SegmentReportingGeograhicAreaLineItems_252"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SegmentReportingGeographicAreaAxis" xlink:label="loc_cgen_SegmentReportingGeographicAreaAxis_253"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SegmentReportingGeographicAreaAxis" xlink:label="loc_cgen_SegmentReportingGeographicAreaAxis_254"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SegmentReportingGeographicAreaDomain" xlink:label="loc_cgen_SegmentReportingGeographicAreaDomain_255"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SegmentReportingGeographicAreaTable" xlink:label="loc_cgen_SegmentReportingGeographicAreaTable_256"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SegmentReportingGeographicAreaTable" xlink:label="loc_cgen_SegmentReportingGeographicAreaTable_257"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ServerancePayPolicyTextBlock" xlink:label="loc_cgen_ServerancePayPolicyTextBlock_258"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ServerancePayPolicyTextBlock" xlink:label="loc_cgen_ServerancePayPolicyTextBlock_259"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ServerancePayPolicyTextBlock" xlink:label="loc_cgen_ServerancePayPolicyTextBlock_260"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="loc_cgen_SeverancePayFundNoncurrent_261"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="loc_cgen_SeverancePayFundNoncurrent_262"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="loc_cgen_SeverancePayFundNoncurrent_263"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_264"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_265"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_266"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_267"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_268"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_269"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_270"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_271"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_272"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cgen_ShortTermBankDepositsPolicyTextBlock_273"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cgen_ShortTermBankDepositsPolicyTextBlock_274"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cgen_ShortTermBankDepositsPolicyTextBlock_275"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_276"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_277"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_278"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_279"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_280"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_281"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_282"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_283"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_284"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_285"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_286"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_287"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_288"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_289"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_290"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_291"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_292"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_293"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_TaxExemptPeriod" xlink:label="loc_cgen_TaxExemptPeriod_294"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_TaxExemptPeriod" xlink:label="loc_cgen_TaxExemptPeriod_295"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_TaxRateOnDistributions" xlink:label="loc_cgen_TaxRateOnDistributions_296"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_TaxRateOnDistributions" xlink:label="loc_cgen_TaxRateOnDistributions_297"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" xlink:label="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_298"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" xlink:label="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_299"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" xlink:label="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_300"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_TwoThousandTenShareOptionsPlanMember" xlink:label="loc_cgen_TwoThousandTenShareOptionsPlanMember_301"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_TwoThousandTenShareOptionsPlanMember" xlink:label="loc_cgen_TwoThousandTenShareOptionsPlanMember_302"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_TwoThousandTenShareOptionsPlanMember" xlink:label="loc_cgen_TwoThousandTenShareOptionsPlanMember_303"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_304"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_305"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IL" xlink:label="loc_country_IL_306"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_307"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_308"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_309"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_310"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_311"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_312"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_313"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_314"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_315"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber_316"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_317"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_318"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_319"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_320"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_321"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_322"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_323"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_324"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_325"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_326"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_327"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_328"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_329"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_330"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_331"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_332"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_333"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_334"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_335"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_336"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_337"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_338"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_339"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_340"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_341"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_342"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_343"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_344"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_345"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_346"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_347"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_348"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_349"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_350"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_351"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_dei_OtherReportingStandardItemNumber_352"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_353"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_354"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_355"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_356"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_357"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_358"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_359"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_360"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_361"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_362"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_363"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_364"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_365"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_366"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_367"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_368"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_369"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_370"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_371"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_372"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_373"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_374"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_375"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_376"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_377"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_378"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_379"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_380"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_381"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_382"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_383"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_384"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_385"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_386"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_387"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_388"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_389"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_390"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_391"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_392"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_393"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_394"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_395"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_396"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_397"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_398"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_399"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_400"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_401"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_402"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_403"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_404"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_405"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_406"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_407"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_408"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_409"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_410"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_411"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_412"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_413"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_414"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_415"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_416"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_417"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_418"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_419"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_420"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_421"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_422"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_423"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_424"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_425"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_426"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_427"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_428"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_429"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_430"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_431"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_432"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_433"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_434"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_435"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_436"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_437"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_438"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_439"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_440"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_441"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_442"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_443"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_444"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_445"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_446"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_447"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_448"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_449"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_450"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_451"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_452"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_453"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_454"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_455"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_456"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_457"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_458"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_459"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_460"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_461"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_462"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_463"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_464"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_465"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting" xlink:label="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_466"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_467"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_468"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_469"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_470"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_471"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_472"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_473"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_474"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_475"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_476"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_477"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_478"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_479"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_480"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_481"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_482"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_483"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_484"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_485"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_486"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_487"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_488"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_489"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_490"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_491"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_492"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_493"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_494"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_495"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_496"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_497"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_498"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_499"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_500"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_501"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_502"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_503"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_504"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_505"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_506"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_507"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_508"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="loc_us-gaap_ImpairmentOfInvestments_509"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_510"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_511"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_512"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_513"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_514"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_515"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_516"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_517"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_518"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_519"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_520"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_521"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_522"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_523"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_524"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_525"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_526"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_527"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_528"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_529"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_530"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_531"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_532"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_533"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_534"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_535"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_536"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InitialOfferingPeriod" xlink:label="loc_us-gaap_InitialOfferingPeriod_537"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_538"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_539"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_540"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_541"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_542"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_543"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:label="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_544"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_545"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_546"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_547"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_548"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_549"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_550"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_551"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_552"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_553"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_554"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_555"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_556"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_557"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_558"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_559"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_560"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_561"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_562"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_563"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_564"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_565"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_566"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_567"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_568"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_569"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_570"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_571"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_572"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_573"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_574"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_575"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_576"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_577"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_578"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_579"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_580"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_581"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_582"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_583"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_584"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_585"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_586"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_587"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_588"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_589"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_590"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_591"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_592"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_593"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_594"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_595"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_596"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_597"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_598"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_599"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_600"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_601"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_602"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_603"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_604"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_605"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_606"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_607"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_608"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_609"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_610"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_611"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_612"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_613"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_614"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_615"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_616"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_617"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_618"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_619"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_620"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_621"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_622"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_623"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_624"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_625"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_626"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_627"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_628"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_629"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_630"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_631"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_632"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_633"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_634"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_635"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_636"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_637"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_638"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="loc_us-gaap_PaymentsForProceedsFromProductiveAssets_639"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="loc_us-gaap_PaymentsForProceedsFromProductiveAssets_640"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_641"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_642"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_643"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_644"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_645"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_646"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_647"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_648"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_649"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_650"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_651"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_652"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_653"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_654"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_655"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_656"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_657"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_658"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_659"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_660"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_661"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_662"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_663"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_664"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_665"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_666"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_667"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_668"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_669"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_670"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_671"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_672"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_673"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_674"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_675"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_676"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_677"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_678"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_679"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_680"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_681"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_682"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_683"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_685"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_686"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_687"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_688"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_689"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_690"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_691"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_692"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_693"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_694"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_695"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_696"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_697"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_698"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_699"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_700"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_701"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_702"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_703"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_704"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_705"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_706"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_707"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_708"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_709"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_710"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_711"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_712"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_713"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_714"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_715"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_716"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_717"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_718"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_719"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_720"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_721"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_722"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_723"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_724"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_725"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_726"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_727"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_728"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_729"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_730"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_731"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_732"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_733"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_734"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_735"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_736"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_737"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_738"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_739"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_740"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_741"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_742"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_743"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_744"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_745"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_746"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_747"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_748"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_749"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_750"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_751"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_752"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_753"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_755"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_756"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_757"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_758"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_759"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_760"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_761"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_762"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_763"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_764"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_765"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_766"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_767"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_768"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_769"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_770"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_771"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_772"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_773"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_774"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_775"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_776"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_777"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_778"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_779"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_780"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_781"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_782"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_783"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_784"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_785"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_786"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_787"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_788"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_789"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_790"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_791"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_792"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_793"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_794"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_795"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_796"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_797"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_798"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_799"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_800"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_801"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_802"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_803"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_804"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_805"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_806"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_807"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_808"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_809"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_810"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_811"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_812"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_813"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_814"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_815"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_816"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_817"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_818"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_819"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_820"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_821"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_822"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_823"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_824"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOfCommonParentMember" xlink:label="loc_us-gaap_SubsidiaryOfCommonParentMember_825"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOfCommonParentMember" xlink:label="loc_us-gaap_SubsidiaryOfCommonParentMember_826"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_827"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_828"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_829"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_830"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeasePayment" xlink:label="loc_us-gaap_VariableLeasePayment_831"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeasePayment" xlink:label="loc_us-gaap_VariableLeasePayment_832"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_833"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_834"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_835"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_836"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_837"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_838"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AccruedMilestonePayment_0" xml:lang="en-US">Accrued milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AccruedMilestonePayment_1" xml:lang="en-US">Accrued milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AccruedMilestonePayments_0" xml:lang="en-US">Accrued Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AccruedMilestonePayments_1" xml:lang="en-US">Amount of accrued milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AccruedMilestonePayments_2" xml:lang="en-US">Accrued milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_0" xml:lang="en-US">Adjustment For Exchange Rate Differences Loss (Gain) On Cash Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_1" xml:lang="en-US">Adjustment for Exchange rate differences loss (gain) on cash balances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_2" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_3" xml:lang="en-US">Foreign currency transaction adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_4" xml:lang="en-US">Exchange rate differences loss (gain) on cash balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_5" xml:lang="en-US">Exchange rate differences loss (gain) on cash balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_0" xml:lang="en-US">Aggregate limit of ordinary shares per calendar year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_1" xml:lang="en-US">Aggregate limit of ordinary shares per calendar year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AgreementStartDate_0" xml:lang="en-US">Agreement start date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AgreementStartDate_1" xml:lang="en-US">Agreement Start Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_AgreementStartDate_2" xml:lang="en-US">Agreement, start date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AgreementTerminationDescription_0" xml:lang="en-US">Description of termination of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AgreementTerminationDescription_1" xml:lang="en-US">Agreement Termination Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_AgreementTerminationDescription_2" xml:lang="en-US">Agreement termination description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_0" xml:lang="en-US">Amortization Of Cash Consideration Of Research And Development Funding Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_1" xml:lang="en-US">Decrease (increase) in interest receivables from short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_2" xml:lang="en-US">Amortization Of Cash Consideration Of Research And Development Funding Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_3" xml:lang="en-US">Amortization research and development component</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_0" xml:lang="en-US">Amortization Of Discount And Accrued Interest On Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_1" xml:lang="en-US">Represent the amount of Amortization of discount and accrued interest on marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_2" xml:lang="en-US">Amortization of discount and accrued interest on marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AnnualDepreciationRate_0" xml:lang="en-US">Annual Depreciation Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AnnualDepreciationRate_1" xml:lang="en-US">Annual depreciation rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AnnualDepreciationRateDescription_0" xml:lang="en-US">Annual Depreciation Rates, Description.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AnnualDepreciationRateDescription_1" xml:lang="en-US">Annual Depreciation Rate, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_AnnualDepreciationRateDescription_2" xml:lang="en-US">Annual depreciation rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AntibodiesDiscoveryCollaborationAgreementMember_0" xml:lang="en-US">Antibodies Discovery Collaboration Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AntibodiesDiscoveryCollaborationAgreementMember_1" xml:lang="en-US">Information about the Antibodies Discovery Collaboration Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_0" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_1" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_0" xml:lang="en-US">Expiration period of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_1" xml:lang="en-US">Class Of Warrant Or Rights Period From Which Warrants Or Rights Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_2" xml:lang="en-US">Expiration period of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CollaborativeArrangementsMember_0" xml:lang="en-US">Collaborative Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CollaborativeArrangementsMember_1" xml:lang="en-US">Collaborative Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CollaborativeArrangementsTwoMember_0" xml:lang="en-US">Collaborative Arrangements Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CollaborativeArrangementsTwoMember_1" xml:lang="en-US">Collaborative Arrangements Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ContingentFees_0" xml:lang="en-US">Contingent fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ContingentFees_1" xml:lang="en-US">Contingent Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ContingentFees_2" xml:lang="en-US">Contingent fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_1" xml:lang="en-US">Cost Of Sales Contract With Customer Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_2" xml:lang="en-US">Cost of revenues:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CustomerOneMember_0" xml:lang="en-US">Customer One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CustomerOneMember_1" xml:lang="en-US">Customer One Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_CustomerOneMember_2" xml:lang="en-US">Customer A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CustomerTwoMember_0" xml:lang="en-US">Customer Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CustomerTwoMember_1" xml:lang="en-US">This member stands for Customer two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_CustomerTwoMember_2" xml:lang="en-US">Customer B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredIncomeTaxLeaseLiabilities_0" xml:lang="en-US">Amount of deferred tax lease liability attributable to taxable temporary differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredIncomeTaxLeaseLiabilities_1" xml:lang="en-US">Deferred Income Tax Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredIncomeTaxLeaseLiabilities_2" xml:lang="en-US">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredIncomeTaxRightOfUseAssets_0" xml:lang="en-US">Amount of deferred tax Right of use assets attributable to taxable temporary differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredIncomeTaxRightOfUseAssets_1" xml:lang="en-US">Deferred Income Tax Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredIncomeTaxRightOfUseAssets_2" xml:lang="en-US">Right of use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_0" xml:lang="en-US">Deferred participation of BMS in R and D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_1" xml:lang="en-US">Deferred Participation Of B M S In R And D Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_2" xml:lang="en-US">Deferred participation of BMS in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredRevenuesIncludedInCurrentLiabilities_0" xml:lang="en-US">Deferred Revenues Included In Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredRevenuesIncludedInCurrentLiabilities_1" xml:lang="en-US">Amount of deferred revenues included in current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredRevenuesIncludedInCurrentLiabilities_2" xml:lang="en-US">Deferred revenues included in current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_0" xml:lang="en-US">Deferred Revenues Included In Non Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_1" xml:lang="en-US">Amount of deferred revenues included in non current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_2" xml:lang="en-US">Deferred revenues included in non current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_0" xml:lang="en-US">Deferred tax asset (liabilities) for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_1" xml:lang="en-US">Deferred Tax Assets Liabilities Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_2" xml:lang="en-US">Property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DerivativeRelatedExpense_0" xml:lang="en-US">Represents the derivative related expenses incurred during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DerivativeRelatedExpense_1" xml:lang="en-US">Derivative Related Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DerivativeRelatedExpense_2" xml:lang="en-US">Derivative related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_0" xml:lang="en-US">Percentage of domestic federal statutory tax rate applicable to pretax income (loss) for next fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_1" xml:lang="en-US">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate For Next Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_2" xml:lang="en-US">Israeli corporate tax rate for next fiscal year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_EmployeesAndDirectorsMember_0" xml:lang="en-US">Represents information pertaining to employees and directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_EmployeesAndDirectorsMember_1" xml:lang="en-US">Employees and Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_EmployeesDirectorsAndNonEmployeesMember_0" xml:lang="en-US">Employees Directors And Non Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_EmployeesDirectorsAndNonEmployeesMember_1" xml:lang="en-US">Information about the employees, directors and non-employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_EmployeeStockPurchasePlanMember_0" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_EmployeeStockPurchasePlanMember_1" xml:lang="en-US">Employee Stock Purchase Plan Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_EmployeeStockPurchasePlanMember_2" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ExtendLease_0" xml:lang="en-US">Extend Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ExtendLease_1" xml:lang="en-US">Extend Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ExtendLease_2" xml:lang="en-US">Extend lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_FinancialIncomeExpenseNet_0" xml:lang="en-US">Financial Income (Expense), Net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_FinancialIncomeExpenseNet_1" xml:lang="en-US">Financial Income Expense Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_FinancialIncomeExpenseNet_2" xml:lang="en-US">Financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cgen_FinancialIncomeExpenseNet_3" xml:lang="en-US">Financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAndOtherGrantsAxis_0" xml:lang="en-US">Government and Other Grants [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsAxis_1" xml:lang="en-US">Government and Other Grants [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAuthorities_0" xml:lang="en-US">Government Authorities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAuthorities_1" xml:lang="en-US">Government authorities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_0" xml:lang="en-US">Increase (decrease) in deferred participation in R and D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_1" xml:lang="en-US">Increase Decrease In Deferred Participation In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_2" xml:lang="en-US">Increase (decrease) in deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseDecreaseInDeferredRevenues_0" xml:lang="en-US">Increase Decrease In Deferred Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseDecreaseInDeferredRevenues_1" xml:lang="en-US">Represent the amount of deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_IncreaseDecreaseInDeferredRevenues_2" xml:lang="en-US">Increase in deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Increase (decrease) in operating lease right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_1" xml:lang="en-US">Decrease in operating lease right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_2" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating lease right of use asset increased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_1" xml:lang="en-US">Increase Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_2" xml:lang="en-US">Operating lease right of use asset increased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_InterestPaidReceivedNet_0" xml:lang="en-US">Interest payments paid (received) from bank short-term deposits and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_InterestPaidReceivedNet_1" xml:lang="en-US">Interest Paid Received Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_InterestPaidReceivedNet_2" xml:lang="en-US">Interest payments received from short-term bank deposits and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IssuanceOfSharesAndWarrantsNetShares_0" xml:lang="en-US">Issuance of shares and warrants, net, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IssuanceOfSharesAndWarrantsNetShares_1" xml:lang="en-US">Issuance of shares and warrants, net, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_IssuanceOfSharesAndWarrantsNetShares_2" xml:lang="en-US">Issuance of shares, net, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_0" xml:lang="en-US">Issuance of shares and warrants, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_1" xml:lang="en-US">Issuance Of Shares And Warrants Net Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_2" xml:lang="en-US">Issuance of shares, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_JmpSecuritiesLlcMember_0" xml:lang="en-US">Jmp Securities Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_JmpSecuritiesLlcMember_1" xml:lang="en-US">This member stands for JMP Securities LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_JmpSecuritiesLlcMember_2" xml:lang="en-US">JMP Securities LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_0" xml:lang="en-US">Laboratory Equipment And Office Furniture [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_1" xml:lang="en-US">Laboratory equipment and office furniture [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_LeerinkPartnersLlcMember_0" xml:lang="en-US">Leerink Partners Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_LeerinkPartnersLlcMember_1" xml:lang="en-US">This member stands for Leerink Partners LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_LeerinkPartnersLlcMember_2" xml:lang="en-US">Leerink Partners LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_LicenseAgreementWithGileadMember_0" xml:lang="en-US">License Agreement With Gilead [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_LicenseAgreementWithGileadMember_1" xml:lang="en-US">This member represents about license agreement with Gilead.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_LicenseRevenue_0" xml:lang="en-US">License Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_LicenseRevenue_1" xml:lang="en-US">Amount of license revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_LicenseRevenue_2" xml:lang="en-US">License revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_0" xml:lang="en-US">Long term deferred participation in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_1" xml:lang="en-US">Long Term Deferred Participation In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_2" xml:lang="en-US">Long-term deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MasterClinicalAgreementMember_0" xml:lang="en-US">Master Clinical Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MasterClinicalAgreementMember_1" xml:lang="en-US">Master Clinical Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MasterClinicalAgreementOneMember_0" xml:lang="en-US">Master Clinical Agreement One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MasterClinicalAgreementOneMember_1" xml:lang="en-US">Master Clinical Agreement One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MasterClinicalAgreementTwoMember_0" xml:lang="en-US">Master Clinical Agreement Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MasterClinicalAgreementTwoMember_1" xml:lang="en-US">Master Clinical Agreement Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Maximum Authorized Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US">Maximum Authorized Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_2" xml:lang="en-US">Aggregate offering price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_3" xml:lang="en-US">Proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_0" xml:lang="en-US">Maximum Royalty Repaid As Percentage Of Grant Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_1" xml:lang="en-US">Maximum Royalty Repaid As Percentage Of Grant Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_2" xml:lang="en-US">Maximum royalty repaid as percentage of grant received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_May2012AgreementMember_0" xml:lang="en-US">May 2012 Agreement Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_May2012AgreementMember_1" xml:lang="en-US">May 2012 Agreement Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_May2012AgreementMember_2" xml:lang="en-US">May 2012 Agreement With Advisor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MilestonePaymentReceivable_0" xml:lang="en-US">Milestone Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MilestonePaymentReceivable_1" xml:lang="en-US">Amount of milestone payment receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_MilestonePaymentReceivable_2" xml:lang="en-US">Milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_0" xml:lang="en-US">Net Income Loss After Adjustment Of Change In Fair Value Of Research And Development Funding Arrangement Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1" xml:lang="en-US">Numerator:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NetOperatingLossCarryforwardExpired_0" xml:lang="en-US">Net operating loss carryforward, Expired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NetOperatingLossCarryforwardExpired_1" xml:lang="en-US">Net operating loss carryforward, Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NonRefundableUpfrontPayment_0" xml:lang="en-US">Non Refundable Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NonRefundableUpfrontPayment_1" xml:lang="en-US">Amount of non-refundable upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_NonRefundableUpfrontPayment_2" xml:lang="en-US">Non-refundable upfront payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_0" xml:lang="en-US">Represents the number of licensed programs to achieve substantive milestones revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_1" xml:lang="en-US">Number of licensed programs to achieve substantive milestones revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NumberOfWarrantsExercised_0" xml:lang="en-US">Number of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NumberOfWarrantsExercised_1" xml:lang="en-US">Number Of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_NumberOfWarrantsExercised_2" xml:lang="en-US">Warrants exercised, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_0" xml:lang="en-US">Represents information pertaining to obsolete property and equipment and certain nonfunctional Lab equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_1" xml:lang="en-US">Obsolete property and equipment and nonfunctional Lab equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_2" xml:lang="en-US">Obsolete property and equipment and certain nonfunctional Lab equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_0" xml:lang="en-US">Ordinary Shares Issued And Sold Through Atm [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_1" xml:lang="en-US">This member stands for ordinary shares issued and sold through ATM.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_2" xml:lang="en-US">ATM [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_0" xml:lang="en-US">The entire disclosure for other accounts receivable and prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1" xml:lang="en-US">Other Accounts Receivable And Prepaid Expenses Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_2" xml:lang="en-US">OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ParticipationRights_0" xml:lang="en-US">Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to investors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ParticipationRights_1" xml:lang="en-US">Participation Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ParticipationRights_2" xml:lang="en-US">Participation Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_0" xml:lang="en-US">Amount of payments for Proceeds from Sales of equipment Investing Activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_1" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_2" xml:lang="en-US">Payments For Proceeds From Sales Of Property And Equipment Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_3" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_4" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfClosingPrice_0" xml:lang="en-US">Percentage of closing price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfClosingPrice_1" xml:lang="en-US">Percentage of closing price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_0" xml:lang="en-US">Percentage of consolidated revenues of collaborator.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_1" xml:lang="en-US">Percentage of consolidated revenues of collaborator</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_0" xml:lang="en-US">Percentage Of Expected From Upfront Payment Amount Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_1" xml:lang="en-US">Percentage of expected from upfront payment amount paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_2" xml:lang="en-US">Percentage of expected from upfront payment amount paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_0" xml:lang="en-US">Percentage of fair market value of ordinary shares at time of offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_1" xml:lang="en-US">Percentage of fair market value of ordinary shares at time of offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_0" xml:lang="en-US">Percentage of use of base salary to purchase ordinary shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_1" xml:lang="en-US">Percentage of use of base salary to purchase ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PeriodSinceApprovalWasGranted_0" xml:lang="en-US">Period since approval was granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PeriodSinceApprovalWasGranted_1" xml:lang="en-US">Period since approval was granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PeriodSinceEnterpriseBeganOperating_0" xml:lang="en-US">Period since enterprise began operating.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PeriodSinceEnterpriseBeganOperating_1" xml:lang="en-US">Period since enterprise began operating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_0" xml:lang="en-US">Purchase Of Property And Equipment As Non Cash Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_1" xml:lang="en-US">The amount of purchase property and equipment as non cash transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_2" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_3" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ReceivablesOnAccountOfShares_0" xml:lang="en-US">Receivables on account of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ReceivablesOnAccountOfShares_1" xml:lang="en-US">Receivables on account of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ReducedCorporateIncomeTaxRate_0" xml:lang="en-US">Reduced Corporate income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ReducedCorporateIncomeTaxRate_1" xml:lang="en-US">Reduced Corporate income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ReducedTaxRate_0" xml:lang="en-US">Reduced tax rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ReducedTaxRate_1" xml:lang="en-US">Reduced tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RegisteredDirectOfferingMember_0" xml:lang="en-US">Registered direct offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RegisteredDirectOfferingMember_1" xml:lang="en-US">Registered direct offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_0" xml:lang="en-US">Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_1" xml:lang="en-US">Research And Development Arrangement Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_2" xml:lang="en-US">Potential milestone compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_0" xml:lang="en-US">Potential milestone compensation company is now eligible for.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_1" xml:lang="en-US">Research And Development Arrangement Payments Receivable On Remaining Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_2" xml:lang="en-US">Potential milestone compensation company is now eligible for</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_0" xml:lang="en-US">Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_1" xml:lang="en-US">Research And Development Arrangement Preclinical Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_2" xml:lang="en-US">Preclinical milestone compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_0" xml:lang="en-US">Research and development expenses milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_1" xml:lang="en-US">Research And Development Expenses Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_2" xml:lang="en-US">Research and development expenses milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_0" xml:lang="en-US">Research and development expenses milestone payment with connection.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_1" xml:lang="en-US">Research And Development Expenses Milestone Payment With Connection</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_2" xml:lang="en-US">Research and development expenses milestone payment with connection</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_0" xml:lang="en-US">Research and Development Grant One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_1" xml:lang="en-US">Research And Development Grant One Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_2" xml:lang="en-US">IIA [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RetainerFee_0" xml:lang="en-US">Represents the retainer fee per month.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RetainerFee_1" xml:lang="en-US">Retainer Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_RetainerFee_2" xml:lang="en-US">Retainer fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RoyaltyContingentObligations_0" xml:lang="en-US">The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RoyaltyContingentObligations_1" xml:lang="en-US">Royalty Contingent Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_RoyaltyContingentObligations_2" xml:lang="en-US">Contingent royalty obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RoyaltyPercentage_0" xml:lang="en-US">Royalty percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RoyaltyPercentage_1" xml:lang="en-US">Royalty Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_RoyaltyPercentage_2" xml:lang="en-US">Royalty percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_0" xml:lang="en-US">Royalty Percentage Based On Future Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_1" xml:lang="en-US">Royalty Percentage Based On Future Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_2" xml:lang="en-US">Royalty percentage based on future revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_0" xml:lang="en-US">Sales Agreement with SVB Securities LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_1" xml:lang="en-US">Sales Agreement With S V B Securities L L C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_2" xml:lang="en-US">Sales Agreement with SVB Securities LLC. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_0" xml:lang="en-US">Tabular disclosure of the annual rates used to calculate depreciation for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_1" xml:lang="en-US">Schedule Of Property Plant And Equipment Depreciation Rates Table Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_2" xml:lang="en-US">Schedule of depreciation rates for property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_0" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of granted stock options, including, but not limited to: (a) expected term of granted share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_1" xml:lang="en-US">Schedule Of Weighted Average Assumptions For Granted Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_2" xml:lang="en-US">Schedule of weighted average assumptions for granted options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_0" xml:lang="en-US">Tabular disclosure of weighted-average remaining lease term and discount rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_1" xml:lang="en-US">Schedule Of Weighted Average Remaining Lease Term And Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_2" xml:lang="en-US">Schedule of weighted-average remaining lease term and discount rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SegmentReportingGeograhicAreaLineItems_0" xml:lang="en-US">Segment Reporting Geograhic Area [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SegmentReportingGeograhicAreaLineItems_1" xml:lang="en-US">Segment Reporting Geograhic Area [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SegmentReportingGeographicAreaAxis_0" xml:lang="en-US">Segment Reporting Geographic Area [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SegmentReportingGeographicAreaAxis_1" xml:lang="en-US">Segment Reporting Geographic Area [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SegmentReportingGeographicAreaDomain_0" xml:lang="en-US">Segment Reporting Geographic Area [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SegmentReportingGeographicAreaTable_0" xml:lang="en-US">Segment Reporting Geographic Area [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SegmentReportingGeographicAreaTable_1" xml:lang="en-US">Segment Reporting Geographic Area [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ServerancePayPolicyTextBlock_0" xml:lang="en-US">Serverance Pay [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ServerancePayPolicyTextBlock_1" xml:lang="en-US">Serverance Pay Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ServerancePayPolicyTextBlock_2" xml:lang="en-US">Severance pay:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SeverancePayFundNoncurrent_0" xml:lang="en-US">Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SeverancePayFundNoncurrent_1" xml:lang="en-US">Severance Pay Fund Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_SeverancePayFundNoncurrent_2" xml:lang="en-US">Severance pay fund</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SeverancePayNet_0" xml:lang="en-US">Severance pay, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SeverancePayNet_1" xml:lang="en-US">Severance Pay Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SeverancePayNet_2" xml:lang="en-US">Decrease in severance pay, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_2" xml:lang="en-US">Award expiration period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award Options, Remaining Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Remaining Contractual Term Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_2" xml:lang="en-US">Weighted average remaining contractual life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShortTermBankDepositsPolicyTextBlock_0" xml:lang="en-US">The entire disclosure for short-term bank deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShortTermBankDepositsPolicyTextBlock_1" xml:lang="en-US">Short Term Bank Deposits Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ShortTermBankDepositsPolicyTextBlock_2" xml:lang="en-US">Short-term bank deposits:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_0" xml:lang="en-US">The weighted average interest rate for short-term bank deposits outside of the domestic currency.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_1" xml:lang="en-US">Short Term Bank Deposits Weighted Average Rate Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_2" xml:lang="en-US">Average interest rate, short-term bank deposits in U.S. dollars</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_0" xml:lang="en-US">Short term deferred participation in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_1" xml:lang="en-US">Short Term Deferred Participation In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_2" xml:lang="en-US">Short-term deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_0" xml:lang="en-US">Stock-based compensation relating to options issued to employees and directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_1" xml:lang="en-US">Stock Based Compensation Relating To Options Issued To Employees, Directors And Non Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_2" xml:lang="en-US">Stock-based compensation issued to employees, directors and non-employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_0" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_1" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_2" xml:lang="en-US">Warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_0" xml:lang="en-US">Change In right of use asset and operating lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_1" xml:lang="en-US">Supplemental Right Of Use Asset And Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_2" xml:lang="en-US">Right-of-use asset obtained in exchange for operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_0" xml:lang="en-US">SVB Leerink LLC and Stifel, Nicolaus &amp;amp; Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_1" xml:lang="en-US">Svb Leerink Llc And Stifel Nicolaus And Company Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_2" xml:lang="en-US">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_TaxExemptPeriod_0" xml:lang="en-US">Tax exempt period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_TaxExemptPeriod_1" xml:lang="en-US">Tax exempt period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_TaxRateOnDistributions_0" xml:lang="en-US">Tax rate for dividends distributed to individuals or foreign residents from the preferred enterprise's earnings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_TaxRateOnDistributions_1" xml:lang="en-US">Tax rate on distributions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_0" xml:lang="en-US">Two Thousand and Two Thousand Ten Options Plan [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_1" xml:lang="en-US">Two Thousand And Two Thousand Ten Options Plan Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_2" xml:lang="en-US">2000 and 2010 Share Option Plans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_TwoThousandTenShareOptionsPlanMember_0" xml:lang="en-US">Two Thousand Ten Share Options Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_TwoThousandTenShareOptionsPlanMember_1" xml:lang="en-US">Information about the share option plan 2010.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_TwoThousandTenShareOptionsPlanMember_2" xml:lang="en-US">2010 Share Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_UnderwritersMember_0" xml:lang="en-US">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_UnderwritersMember_1" xml:lang="en-US">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_IL_0" xml:lang="en-US">Israel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US_0" xml:lang="en-US">Unites States [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentDescription_0" xml:lang="en-US">Amendment Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId_0" xml:lang="en-US">Auditor Firm Id</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation_0" xml:lang="en-US">Auditor Location</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName_0" xml:lang="en-US">Auditor Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember_0" xml:lang="en-US">Business Contact [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode_0" xml:lang="en-US">City Area Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelEmailAddress_0" xml:lang="en-US">Contact Personnel Email Address</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelFaxNumber_0" xml:lang="en-US">Contact Personnel Fax Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName_0" xml:lang="en-US">Contact Personnel Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAccountingStandard_0" xml:lang="en-US">Document Accounting Standard</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport_0" xml:lang="en-US">Document Annual Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag_0" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentRegistrationStatement_0" xml:lang="en-US">Document Registration Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentShellCompanyReport_0" xml:lang="en-US">Document Shell Company Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport_0" xml:lang="en-US">Document Transition Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine3_0" xml:lang="en-US">Entity Address, Address Line Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry_0" xml:lang="en-US">Entity Address Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis_0" xml:lang="en-US">Entity Addresses Address Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityAddressesAddressTypeAxis_1" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus_0" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation State Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers_0" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag_0" xml:lang="en-US">Auditor Attestation Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber_0" xml:lang="en-US">Local Phone Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_OtherReportingStandardItemNumber_0" xml:lang="en-US">Other Reporting Standard Item Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle_0" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName_0" xml:lang="en-US">Name of Exchange on which Security is Registered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_DirectorMember_0" xml:lang="en-US">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EuropeMember_0" xml:lang="en-US">Europe [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MajorCustomersAxis_0" xml:lang="en-US">Customer [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_NameOfMajorCustomerDomain_0" xml:lang="en-US">Customer [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_RangeAxis_1" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis_0" xml:lang="en-US">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0" xml:lang="en-US">OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent_0" xml:lang="en-US">Trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0" xml:lang="en-US">Accumulated depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1" xml:lang="en-US">Accumulated other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1" xml:lang="en-US">Accumulated other comprehensive income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional paid-in capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentForAmortization_0" xml:lang="en-US">Amortization in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0" xml:lang="en-US">Stock-based compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent_0" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent_1" xml:lang="en-US">Total non- current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_0" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis_0" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDevelopment_0" xml:lang="en-US">Marketing and business development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0" xml:lang="en-US">Cash equivalents:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0" xml:lang="en-US">Restricted cash:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Cash and cash equivalents and restricted cash at the end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3" xml:lang="en-US">Total cash, cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1" xml:lang="en-US">Increase (decrease) in cash, cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1" xml:lang="en-US">Increase in cash, cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0" xml:lang="en-US">Exercise price of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0" xml:lang="en-US">Warrants purchase to ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0" xml:lang="en-US">Warrants purchase to ordinary shares remain outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Ordinary shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US">Ordinary shares, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Ordinary shares, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_2" xml:lang="en-US">Ordinary shares, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Share capital: Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2021 and 2020; 86,433,432 and 83,675,856 shares issued and outstanding at December 31, 2021 and 2020, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2023 and 2022; 89,237,465 and 86,624,643 shares issued and outstanding at December 31, 2023 and 2022, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_1" xml:lang="en-US">Total comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0" xml:lang="en-US">Comprehensive income (loss):</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember_0" xml:lang="en-US">Computers, software and related equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_0" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_0" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_0" xml:lang="en-US">Concentration of credit risks:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_0" xml:lang="en-US">Sales to a single customer exceeding 10%</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_0" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_0" xml:lang="en-US">Basis of consolidation:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue_0" xml:lang="en-US">Cost of revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty_0" xml:lang="en-US">Amounts charged to research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_0" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_1" xml:lang="en-US">Deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_2" xml:lang="en-US">Deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenue_0" xml:lang="en-US">Deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueCurrent_0" xml:lang="en-US">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueCurrent_1" xml:lang="en-US">Short-term deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_0" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_1" xml:lang="en-US">Long-term deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_1" xml:lang="en-US">Deferred tax asset before valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1" xml:lang="en-US">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_1" xml:lang="en-US">Deferred tax asset after valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_0" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_1" xml:lang="en-US">Deferred tax assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0" xml:lang="en-US">Operating loss carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_0" xml:lang="en-US">Accrued social benefits and other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_0" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_1" xml:lang="en-US">Deferred tax liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeNet_0" xml:lang="en-US">Fair value of outstanding forward contracts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet_0" xml:lang="en-US">Net gain on derivative transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_0" xml:lang="en-US">Net gain on derivative recorded as financial and other income, net for the ineffective portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeNotionalAmount_0" xml:lang="en-US">Derivative, notional amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_0" xml:lang="en-US">Derivative instruments:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember_0" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract_0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Basic net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">Basic loss per ordinary share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">Diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Basic and diluted loss per share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0" xml:lang="en-US">LOSSES PER SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Israeli corporate tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0" xml:lang="en-US">U.S. income state and local taxes rate (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Effect of exchange rate changes on cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0" xml:lang="en-US">Employees and related accruals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0" xml:lang="en-US">Unrecognized share-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0" xml:lang="en-US">Unrecognized compensation cost, recognition period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockMember_0" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost_0" xml:lang="en-US">Investment amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost_1" xml:lang="en-US">Equity investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_0" xml:lang="en-US">Fair value of financial instruments:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_0" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_1" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, after Tax, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_2" xml:lang="en-US">Foreign currency transaction adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_3" xml:lang="en-US">Exchange rate differences loss (gain) on cash balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_4" xml:lang="en-US">Exchange rate differences loss (gain) on cash balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1" xml:lang="en-US">Foreign currency transaction adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2" xml:lang="en-US">Exchange rate differences loss (gain) on cash balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3" xml:lang="en-US">Exchange rate differences loss (gain) on cash balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0" xml:lang="en-US">Financial statements in U.S. dollars:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets_0" xml:lang="en-US">Gain (loss) from sales and disposals of fixed assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0" xml:lang="en-US">Loss (gain) from property and equipment sales and disposals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0" xml:lang="en-US">General and administrative expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrossProfit_0" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GrossProfit_1" xml:lang="en-US">Gross profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure_0" xml:lang="en-US">Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfInvestments_0" xml:lang="en-US">Marketable securities impairment losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0" xml:lang="en-US">Domestic (Israel)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2" xml:lang="en-US">Domestic (Israel)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xml:lang="en-US">Loss before taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xml:lang="en-US">Loss before taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0" xml:lang="en-US">Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2" xml:lang="en-US">Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_0" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_0" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">TAXES ON INCOME, NET</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid_0" xml:lang="en-US">Tax payment withheld</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2" xml:lang="en-US">Taxes on income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_0" xml:lang="en-US">Income taxes:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_0" xml:lang="en-US">Decrease (increase) in trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Increase (decrease) in trade payables and other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0" xml:lang="en-US">Decrease (increase) in other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0" xml:lang="en-US">Decrease in operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0" xml:lang="en-US">Decrease (increase) in long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InitialOfferingPeriod_0" xml:lang="en-US">Offering period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestAndDebtExpense_0" xml:lang="en-US">Bank fees and other finance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestAndDebtExpense_1" xml:lang="en-US">Interest and Debt Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember_0" xml:lang="en-US">United States [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_0" xml:lang="en-US">Investment Income, Amortization of Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_1" xml:lang="en-US">Amortization of discount on marketable securities, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest_0" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_0" xml:lang="en-US">Amount of investment in Compugen</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_0" xml:lang="en-US">Leasehold improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeDisclosureAbstract_0" xml:lang="en-US">Lessee Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeDisclosureAbstract_1" xml:lang="en-US">Lessee Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_1" xml:lang="en-US">Leases:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0" xml:lang="en-US">Schedule of Operating Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1" xml:lang="en-US">Schedule of operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xml:lang="en-US">Total operating lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1" xml:lang="en-US">2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1" xml:lang="en-US">2026</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1" xml:lang="en-US">2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1" xml:lang="en-US">2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0" xml:lang="en-US">Less: imputed interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_0" xml:lang="en-US">Period of options to extend leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_0" xml:lang="en-US">LEASES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_1" xml:lang="en-US">Total non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">NON- CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_0" xml:lang="en-US">Marketable Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_1" xml:lang="en-US">Investment in marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_0" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_1" xml:lang="en-US">Investments in marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Cash flows from financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash provided by investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Cash flows from investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Cash flows from operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_3" xml:lang="en-US">Net loss for basic and diluted loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_4" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0" xml:lang="en-US">Recently issued and recently adopted Accounting Standards:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US">Recently issued accounting pronouncement not yet adopted by the Company:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncurrentAssets_0" xml:lang="en-US">Long-lived assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfOperatingSegments_0" xml:lang="en-US">Number of operating segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfOperatingSegments_1" xml:lang="en-US">Number of operating segment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating expenses:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss_0" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability_0" xml:lang="en-US">Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_1" xml:lang="en-US">Present value of lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_2" xml:lang="en-US">Present value of lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Current maturity of operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_1" xml:lang="en-US">Lease liabilities, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0" xml:lang="en-US">Long-term operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1" xml:lang="en-US">Lease liabilities, non- current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments_0" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating lease right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0" xml:lang="en-US">Weighted average discount (annual) rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0" xml:lang="en-US">Weighted average remaining lease term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards_0" xml:lang="en-US">Net operating loss carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsExpirationDate_0" xml:lang="en-US">Year of expiration of operating loss carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0" xml:lang="en-US">GENERAL</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_1" xml:lang="en-US">Other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent_0" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsLineItems_0" xml:lang="en-US">Other Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsTable_0" xml:lang="en-US">Other Commitments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_0" xml:lang="en-US">Foreign Currency Translation income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1" xml:lang="en-US">Exchange rate income (loss) on lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1" xml:lang="en-US">Changes in other comprehensive income from marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_0" xml:lang="en-US">Net gain on derivative classified to operating expenses as effective portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1" xml:lang="en-US">Unrealized gain arising during the period from marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2" xml:lang="en-US">Changes in other comprehensive income from marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_0" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_0" xml:lang="en-US">FINANCIAL AND OTHER INCOME, NET</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilities_0" xml:lang="en-US">Trade payables and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherShortTermInvestments_0" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherShortTermInvestments_1" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_0" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForProceedsFromProductiveAssets_0" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForProceedsFromProductiveAssets_1" xml:lang="en-US">Payments for (Proceeds from) Productive Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US">Issuance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_0" xml:lang="en-US">Payments to Acquire Held-to-Maturity Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_1" xml:lang="en-US">Proceeds from maturity of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_2" xml:lang="en-US">Investment in short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_3" xml:lang="en-US">Investment in short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_0" xml:lang="en-US">Investment in short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_1" xml:lang="en-US">Payments to Acquire Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_0" xml:lang="en-US">Payments to Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_1" xml:lang="en-US">Investment in marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis_0" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_0" xml:lang="en-US">Accrued severance pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xml:lang="en-US">Other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xml:lang="en-US">Other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_0" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent_0" xml:lang="en-US">Long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds_0" xml:lang="en-US">Tax receivables refunded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0" xml:lang="en-US">Proceeds from ordinary shares in offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Proceeds from issuance of ordinary shares, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_0" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1" xml:lang="en-US">Proceeds from maturity of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2" xml:lang="en-US">Investment in short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0" xml:lang="en-US">Proceeds from maturity of short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_0" xml:lang="en-US">Proceeds from Sale of Held-to-Maturity Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_1" xml:lang="en-US">Proceeds from maturity of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_2" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_3" xml:lang="en-US">Proceeds from maturity of short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0" xml:lang="en-US">Proceeds from exercise of stock-based awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_1" xml:lang="en-US">Proceeds from warrant exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals_0" xml:lang="en-US">Costs of disposal of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals_1" xml:lang="en-US">Property, Plant and Equipment, Disposals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals_2" xml:lang="en-US">Costs of disposal of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_0" xml:lang="en-US">Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment_0" xml:lang="en-US">Impairment of long-lived assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US">Depreciated cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0" xml:lang="en-US">Property and equipment, net:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0" xml:lang="en-US">Schedule of Property And Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1" xml:lang="en-US">Schedule of property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesNetCurrent_0" xml:lang="en-US">Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReceivablesNetCurrent_1" xml:lang="en-US">Trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain_0" xml:lang="en-US">Related Party, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0" xml:lang="en-US">Related Party, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">RELATED PARTY BALANCES AND TRANSACTIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1" xml:lang="en-US">Upfront payment received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development expenses, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0" xml:lang="en-US">Research and development expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0" xml:lang="en-US">Research and development expenses, net:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_0" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_1" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Accumulated deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0" xml:lang="en-US">Revenue recognition under milestone method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0" xml:lang="en-US">Revenue recognition:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues_0" xml:lang="en-US">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Revenues_1" xml:lang="en-US">Revenue from sales to customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyExpense_0" xml:lang="en-US">Royalty expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1" xml:lang="en-US">Number of shares issued and sold in transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNetMember_0" xml:lang="en-US">Revenue [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_0" xml:lang="en-US">Schedule of Other Accounts Payable and Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0" xml:lang="en-US">Schedule of Stock-Based Compensation Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1" xml:lang="en-US">Schedule of stock-based compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0" xml:lang="en-US">Summary Of Deferred Tax Assets And Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of deferred tax assets and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0" xml:lang="en-US">Schedule of computation of basic and diluted losses per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0" xml:lang="en-US">Schedule Of Loss Before Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1" xml:lang="en-US">Schedule of loss (income) before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_0" xml:lang="en-US">Schedule Of Other Accounts Receivable And Prepaid Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1" xml:lang="en-US">Schedule of other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_0" xml:lang="en-US">Schedule of Financial and Other Income, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1" xml:lang="en-US">Schedule of financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0" xml:lang="en-US">Schedule of Related Party Balances and Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" xml:lang="en-US">Schedule of related party balances and transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_0" xml:lang="en-US">Sales To A Single Customer Exceeding 10%:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_1" xml:lang="en-US">Schedule of sales to single customer exceeding 10%</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_0" xml:lang="en-US">Total Revenues And Long-Lived Assets By Geographic Area</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_1" xml:lang="en-US">Schedule of total revenues and long-lived assets by geographic area</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_0" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0" xml:lang="en-US">Schedule Of Option Activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xml:lang="en-US">Schedule of option activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingAbstract_0" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_0" xml:lang="en-US">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember_0" xml:lang="en-US">Marketing and business development expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeveranceCosts1_0" xml:lang="en-US">Severance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0" xml:lang="en-US">Vesting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" xml:lang="en-US">Aggregate intrinsic value of exercised options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Expected life (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0" xml:lang="en-US">Volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0" xml:lang="en-US">Ordinary shares reserved for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0" xml:lang="en-US">Ordinary shares available for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0" xml:lang="en-US">Aggregate intrinsic value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0" xml:lang="en-US">Total intrinsic value of options exercised during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0" xml:lang="en-US">Options forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0" xml:lang="en-US">Options expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Weighted average fair value of stock options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xml:lang="en-US">Options outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xml:lang="en-US">Options outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US">Options outstanding at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0" xml:lang="en-US">Number of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Options outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Options outstanding at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0" xml:lang="en-US">Weighted average exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0" xml:lang="en-US">Options vested and expected to vest at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Options vested and expected to vest at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0" xml:lang="en-US">Options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0" xml:lang="en-US">Maximum percentage of total shares of common stock outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Options forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Options expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0" xml:lang="en-US">Stock-based compensation:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0" xml:lang="en-US">SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_0" xml:lang="en-US">Offering price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">Total shareholders&#8217; equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0" xml:lang="en-US">SHAREHOLDERS' EQUITY:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_0" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0" xml:lang="en-US">Exercise of options and ESPP shares, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Issuance of shares, net, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US">Issuance of shares, net, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US">Options exercised, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0" xml:lang="en-US">Exercise of options and ESPP shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Issuance of shares, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionMember_0" xml:lang="en-US">Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubleaseIncome_0" xml:lang="en-US">Sublease income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">Subsequent Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiaryOfCommonParentMember_0" xml:lang="en-US">Subsidiary of Common Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiaryOfCommonParentMember_1" xml:lang="en-US">Subsidiary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_0" xml:lang="en-US">Cash paid (received) during the year for:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_1" xml:lang="en-US">Cash received during the year for:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates_0" xml:lang="en-US">Use of estimates:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableLeasePayment_0" xml:lang="en-US">Variable Lease, Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_VariableLeasePayment_1" xml:lang="en-US">Variable payments as CPI</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember_0" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">Weighted average number of ordinary shares used in computing diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0" xml:lang="en-US">Denominator:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">Weighted average number of ordinary shares used in computing basic net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayment_1" xlink:to="lab_cgen_AccruedMilestonePayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayment_2" xlink:to="lab_cgen_AccruedMilestonePayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayments_3" xlink:to="lab_cgen_AccruedMilestonePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayments_4" xlink:to="lab_cgen_AccruedMilestonePayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayments_5" xlink:to="lab_cgen_AccruedMilestonePayments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_6" xlink:to="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_7" xlink:to="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_8" xlink:to="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_9" xlink:to="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_10" xlink:to="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_11" xlink:to="lab_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_12" xlink:to="lab_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_13" xlink:to="lab_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementStartDate_14" xlink:to="lab_cgen_AgreementStartDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementStartDate_15" xlink:to="lab_cgen_AgreementStartDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementStartDate_16" xlink:to="lab_cgen_AgreementStartDate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_17" xlink:to="lab_cgen_AgreementTerminationDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_18" xlink:to="lab_cgen_AgreementTerminationDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_19" xlink:to="lab_cgen_AgreementTerminationDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_20" xlink:to="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_21" xlink:to="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_22" xlink:to="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_23" xlink:to="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_24" xlink:to="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_25" xlink:to="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_26" xlink:to="lab_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AnnualDepreciationRate_27" xlink:to="lab_cgen_AnnualDepreciationRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AnnualDepreciationRate_28" xlink:to="lab_cgen_AnnualDepreciationRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AnnualDepreciationRateDescription_29" xlink:to="lab_cgen_AnnualDepreciationRateDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AnnualDepreciationRateDescription_30" xlink:to="lab_cgen_AnnualDepreciationRateDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AnnualDepreciationRateDescription_31" xlink:to="lab_cgen_AnnualDepreciationRateDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AntibodiesDiscoveryCollaborationAgreementMember_32" xlink:to="lab_cgen_AntibodiesDiscoveryCollaborationAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AntibodiesDiscoveryCollaborationAgreementMember_33" xlink:to="lab_cgen_AntibodiesDiscoveryCollaborationAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_34" xlink:to="lab_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_35" xlink:to="lab_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_36" xlink:to="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_37" xlink:to="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_38" xlink:to="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsMember_39" xlink:to="lab_cgen_CollaborativeArrangementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsMember_40" xlink:to="lab_cgen_CollaborativeArrangementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsTwoMember_41" xlink:to="lab_cgen_CollaborativeArrangementsTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsTwoMember_42" xlink:to="lab_cgen_CollaborativeArrangementsTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_43" xlink:to="lab_cgen_ContingentFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_44" xlink:to="lab_cgen_ContingentFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_45" xlink:to="lab_cgen_ContingentFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_46" xlink:to="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_47" xlink:to="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_48" xlink:to="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CustomerOneMember_49" xlink:to="lab_cgen_CustomerOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CustomerOneMember_50" xlink:to="lab_cgen_CustomerOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CustomerOneMember_51" xlink:to="lab_cgen_CustomerOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CustomerTwoMember_52" xlink:to="lab_cgen_CustomerTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CustomerTwoMember_53" xlink:to="lab_cgen_CustomerTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CustomerTwoMember_54" xlink:to="lab_cgen_CustomerTwoMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxLeaseLiabilities_55" xlink:to="lab_cgen_DeferredIncomeTaxLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxLeaseLiabilities_56" xlink:to="lab_cgen_DeferredIncomeTaxLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxLeaseLiabilities_57" xlink:to="lab_cgen_DeferredIncomeTaxLeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxRightOfUseAssets_58" xlink:to="lab_cgen_DeferredIncomeTaxRightOfUseAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxRightOfUseAssets_59" xlink:to="lab_cgen_DeferredIncomeTaxRightOfUseAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxRightOfUseAssets_60" xlink:to="lab_cgen_DeferredIncomeTaxRightOfUseAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_61" xlink:to="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_62" xlink:to="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_63" xlink:to="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_64" xlink:to="lab_cgen_DeferredRevenuesIncludedInCurrentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_65" xlink:to="lab_cgen_DeferredRevenuesIncludedInCurrentLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_66" xlink:to="lab_cgen_DeferredRevenuesIncludedInCurrentLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_67" xlink:to="lab_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_68" xlink:to="lab_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_69" xlink:to="lab_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_70" xlink:to="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_71" xlink:to="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_72" xlink:to="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DerivativeRelatedExpense_73" xlink:to="lab_cgen_DerivativeRelatedExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DerivativeRelatedExpense_74" xlink:to="lab_cgen_DerivativeRelatedExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DerivativeRelatedExpense_75" xlink:to="lab_cgen_DerivativeRelatedExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_76" xlink:to="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_77" xlink:to="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_78" xlink:to="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeesAndDirectorsMember_79" xlink:to="lab_cgen_EmployeesAndDirectorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeesAndDirectorsMember_80" xlink:to="lab_cgen_EmployeesAndDirectorsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_81" xlink:to="lab_cgen_EmployeesDirectorsAndNonEmployeesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_82" xlink:to="lab_cgen_EmployeesDirectorsAndNonEmployeesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeeStockPurchasePlanMember_83" xlink:to="lab_cgen_EmployeeStockPurchasePlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeeStockPurchasePlanMember_84" xlink:to="lab_cgen_EmployeeStockPurchasePlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeeStockPurchasePlanMember_85" xlink:to="lab_cgen_EmployeeStockPurchasePlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ExtendLease_86" xlink:to="lab_cgen_ExtendLease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ExtendLease_87" xlink:to="lab_cgen_ExtendLease_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ExtendLease_88" xlink:to="lab_cgen_ExtendLease_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_89" xlink:to="lab_cgen_FinancialIncomeExpenseNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_90" xlink:to="lab_cgen_FinancialIncomeExpenseNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_91" xlink:to="lab_cgen_FinancialIncomeExpenseNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_92" xlink:to="lab_cgen_FinancialIncomeExpenseNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_93" xlink:to="lab_cgen_GovernmentAndOtherGrantsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_94" xlink:to="lab_cgen_GovernmentAndOtherGrantsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAuthorities_95" xlink:to="lab_cgen_GovernmentAuthorities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAuthorities_96" xlink:to="lab_cgen_GovernmentAuthorities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_97" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_98" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_99" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredRevenues_100" xlink:to="lab_cgen_IncreaseDecreaseInDeferredRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredRevenues_101" xlink:to="lab_cgen_IncreaseDecreaseInDeferredRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredRevenues_102" xlink:to="lab_cgen_IncreaseDecreaseInDeferredRevenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_103" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_104" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_105" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_106" xlink:to="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_107" xlink:to="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_108" xlink:to="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_InterestPaidReceivedNet_109" xlink:to="lab_cgen_InterestPaidReceivedNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_InterestPaidReceivedNet_110" xlink:to="lab_cgen_InterestPaidReceivedNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_InterestPaidReceivedNet_111" xlink:to="lab_cgen_InterestPaidReceivedNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_112" xlink:to="lab_cgen_IssuanceOfSharesAndWarrantsNetShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_113" xlink:to="lab_cgen_IssuanceOfSharesAndWarrantsNetShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_114" xlink:to="lab_cgen_IssuanceOfSharesAndWarrantsNetShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_115" xlink:to="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_116" xlink:to="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_117" xlink:to="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_JmpSecuritiesLlcMember_118" xlink:to="lab_cgen_JmpSecuritiesLlcMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_JmpSecuritiesLlcMember_119" xlink:to="lab_cgen_JmpSecuritiesLlcMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_JmpSecuritiesLlcMember_120" xlink:to="lab_cgen_JmpSecuritiesLlcMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_121" xlink:to="lab_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_122" xlink:to="lab_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LeerinkPartnersLlcMember_123" xlink:to="lab_cgen_LeerinkPartnersLlcMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LeerinkPartnersLlcMember_124" xlink:to="lab_cgen_LeerinkPartnersLlcMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LeerinkPartnersLlcMember_125" xlink:to="lab_cgen_LeerinkPartnersLlcMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LicenseAgreementWithGileadMember_126" xlink:to="lab_cgen_LicenseAgreementWithGileadMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LicenseAgreementWithGileadMember_127" xlink:to="lab_cgen_LicenseAgreementWithGileadMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LicenseRevenue_128" xlink:to="lab_cgen_LicenseRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LicenseRevenue_129" xlink:to="lab_cgen_LicenseRevenue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LicenseRevenue_130" xlink:to="lab_cgen_LicenseRevenue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_131" xlink:to="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_132" xlink:to="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_133" xlink:to="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementMember_134" xlink:to="lab_cgen_MasterClinicalAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementMember_135" xlink:to="lab_cgen_MasterClinicalAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementOneMember_136" xlink:to="lab_cgen_MasterClinicalAgreementOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementOneMember_137" xlink:to="lab_cgen_MasterClinicalAgreementOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementTwoMember_138" xlink:to="lab_cgen_MasterClinicalAgreementTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementTwoMember_139" xlink:to="lab_cgen_MasterClinicalAgreementTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_140" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_141" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_142" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_143" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_144" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_145" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_146" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_147" xlink:to="lab_cgen_May2012AgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_148" xlink:to="lab_cgen_May2012AgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_149" xlink:to="lab_cgen_May2012AgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MilestonePaymentReceivable_150" xlink:to="lab_cgen_MilestonePaymentReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MilestonePaymentReceivable_151" xlink:to="lab_cgen_MilestonePaymentReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MilestonePaymentReceivable_152" xlink:to="lab_cgen_MilestonePaymentReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_153" xlink:to="lab_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_154" xlink:to="lab_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NetOperatingLossCarryforwardExpired_155" xlink:to="lab_cgen_NetOperatingLossCarryforwardExpired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NetOperatingLossCarryforwardExpired_156" xlink:to="lab_cgen_NetOperatingLossCarryforwardExpired_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NonRefundableUpfrontPayment_157" xlink:to="lab_cgen_NonRefundableUpfrontPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NonRefundableUpfrontPayment_158" xlink:to="lab_cgen_NonRefundableUpfrontPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NonRefundableUpfrontPayment_159" xlink:to="lab_cgen_NonRefundableUpfrontPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_160" xlink:to="lab_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_161" xlink:to="lab_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_162" xlink:to="lab_cgen_NumberOfWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_163" xlink:to="lab_cgen_NumberOfWarrantsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_164" xlink:to="lab_cgen_NumberOfWarrantsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_165" xlink:to="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_166" xlink:to="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_167" xlink:to="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_168" xlink:to="lab_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_169" xlink:to="lab_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_170" xlink:to="lab_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_171" xlink:to="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_172" xlink:to="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_173" xlink:to="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ParticipationRights_174" xlink:to="lab_cgen_ParticipationRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ParticipationRights_175" xlink:to="lab_cgen_ParticipationRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ParticipationRights_176" xlink:to="lab_cgen_ParticipationRights_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_177" xlink:to="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_178" xlink:to="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_179" xlink:to="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_180" xlink:to="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_181" xlink:to="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfClosingPrice_182" xlink:to="lab_cgen_PercentageOfClosingPrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfClosingPrice_183" xlink:to="lab_cgen_PercentageOfClosingPrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_184" xlink:to="lab_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_185" xlink:to="lab_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_186" xlink:to="lab_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_187" xlink:to="lab_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_188" xlink:to="lab_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_189" xlink:to="lab_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_190" xlink:to="lab_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_191" xlink:to="lab_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_192" xlink:to="lab_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PeriodSinceApprovalWasGranted_193" xlink:to="lab_cgen_PeriodSinceApprovalWasGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PeriodSinceApprovalWasGranted_194" xlink:to="lab_cgen_PeriodSinceApprovalWasGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PeriodSinceEnterpriseBeganOperating_195" xlink:to="lab_cgen_PeriodSinceEnterpriseBeganOperating_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PeriodSinceEnterpriseBeganOperating_196" xlink:to="lab_cgen_PeriodSinceEnterpriseBeganOperating_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_197" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_198" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_199" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_200" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReceivablesOnAccountOfShares_201" xlink:to="lab_cgen_ReceivablesOnAccountOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReceivablesOnAccountOfShares_202" xlink:to="lab_cgen_ReceivablesOnAccountOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReducedCorporateIncomeTaxRate_203" xlink:to="lab_cgen_ReducedCorporateIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReducedCorporateIncomeTaxRate_204" xlink:to="lab_cgen_ReducedCorporateIncomeTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReducedTaxRate_205" xlink:to="lab_cgen_ReducedTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReducedTaxRate_206" xlink:to="lab_cgen_ReducedTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RegisteredDirectOfferingMember_207" xlink:to="lab_cgen_RegisteredDirectOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RegisteredDirectOfferingMember_208" xlink:to="lab_cgen_RegisteredDirectOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_209" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_210" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_211" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_212" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_213" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_214" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_215" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_216" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_217" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_218" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_219" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_220" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_221" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_222" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_223" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_224" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_225" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_226" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_227" xlink:to="lab_cgen_RetainerFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_228" xlink:to="lab_cgen_RetainerFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_229" xlink:to="lab_cgen_RetainerFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_230" xlink:to="lab_cgen_RoyaltyContingentObligations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_231" xlink:to="lab_cgen_RoyaltyContingentObligations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_232" xlink:to="lab_cgen_RoyaltyContingentObligations_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentage_233" xlink:to="lab_cgen_RoyaltyPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentage_234" xlink:to="lab_cgen_RoyaltyPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentage_235" xlink:to="lab_cgen_RoyaltyPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_236" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_237" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_238" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_239" xlink:to="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_240" xlink:to="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_241" xlink:to="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_242" xlink:to="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_243" xlink:to="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_244" xlink:to="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_245" xlink:to="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_246" xlink:to="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_247" xlink:to="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_248" xlink:to="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_249" xlink:to="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_250" xlink:to="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeograhicAreaLineItems_251" xlink:to="lab_cgen_SegmentReportingGeograhicAreaLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeograhicAreaLineItems_252" xlink:to="lab_cgen_SegmentReportingGeograhicAreaLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeographicAreaAxis_253" xlink:to="lab_cgen_SegmentReportingGeographicAreaAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeographicAreaAxis_254" xlink:to="lab_cgen_SegmentReportingGeographicAreaAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_255" xlink:to="lab_cgen_SegmentReportingGeographicAreaDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeographicAreaTable_256" xlink:to="lab_cgen_SegmentReportingGeographicAreaTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeographicAreaTable_257" xlink:to="lab_cgen_SegmentReportingGeographicAreaTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ServerancePayPolicyTextBlock_258" xlink:to="lab_cgen_ServerancePayPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ServerancePayPolicyTextBlock_259" xlink:to="lab_cgen_ServerancePayPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ServerancePayPolicyTextBlock_260" xlink:to="lab_cgen_ServerancePayPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNoncurrent_261" xlink:to="lab_cgen_SeverancePayFundNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNoncurrent_262" xlink:to="lab_cgen_SeverancePayFundNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNoncurrent_263" xlink:to="lab_cgen_SeverancePayFundNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_264" xlink:to="lab_cgen_SeverancePayNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_265" xlink:to="lab_cgen_SeverancePayNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_266" xlink:to="lab_cgen_SeverancePayNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_267" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_268" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_269" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_270" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_271" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_272" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsPolicyTextBlock_273" xlink:to="lab_cgen_ShortTermBankDepositsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsPolicyTextBlock_274" xlink:to="lab_cgen_ShortTermBankDepositsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsPolicyTextBlock_275" xlink:to="lab_cgen_ShortTermBankDepositsPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_276" xlink:to="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_277" xlink:to="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_278" xlink:to="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_279" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_280" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_281" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_282" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_283" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_284" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_285" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_286" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_287" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_288" xlink:to="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_289" xlink:to="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_290" xlink:to="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_291" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_292" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_293" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TaxExemptPeriod_294" xlink:to="lab_cgen_TaxExemptPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TaxExemptPeriod_295" xlink:to="lab_cgen_TaxExemptPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TaxRateOnDistributions_296" xlink:to="lab_cgen_TaxRateOnDistributions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TaxRateOnDistributions_297" xlink:to="lab_cgen_TaxRateOnDistributions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_298" xlink:to="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_299" xlink:to="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_300" xlink:to="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TwoThousandTenShareOptionsPlanMember_301" xlink:to="lab_cgen_TwoThousandTenShareOptionsPlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TwoThousandTenShareOptionsPlanMember_302" xlink:to="lab_cgen_TwoThousandTenShareOptionsPlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TwoThousandTenShareOptionsPlanMember_303" xlink:to="lab_cgen_TwoThousandTenShareOptionsPlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnderwritersMember_304" xlink:to="lab_cgen_UnderwritersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnderwritersMember_305" xlink:to="lab_cgen_UnderwritersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IL_306" xlink:to="lab_country_IL_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_307" xlink:to="lab_country_US_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription_308" xlink:to="lab_dei_AmendmentDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_309" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId_310" xlink:to="lab_dei_AuditorFirmId_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation_311" xlink:to="lab_dei_AuditorLocation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName_312" xlink:to="lab_dei_AuditorName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember_313" xlink:to="lab_dei_BusinessContactMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_314" xlink:to="lab_dei_CityAreaCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelEmailAddress_315" xlink:to="lab_dei_ContactPersonnelEmailAddress_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelFaxNumber_316" xlink:to="lab_dei_ContactPersonnelFaxNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName_317" xlink:to="lab_dei_ContactPersonnelName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_318" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard_319" xlink:to="lab_dei_DocumentAccountingStandard_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_320" xlink:to="lab_dei_DocumentAnnualReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag_321" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_322" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_323" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_324" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement_325" xlink:to="lab_dei_DocumentRegistrationStatement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport_326" xlink:to="lab_dei_DocumentShellCompanyReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_327" xlink:to="lab_dei_DocumentTransitionReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_328" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_329" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_330" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine3_331" xlink:to="lab_dei_EntityAddressAddressLine3_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_332" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry_333" xlink:to="lab_dei_EntityAddressCountry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_334" xlink:to="lab_dei_EntityAddressesAddressTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_335" xlink:to="lab_dei_EntityAddressesAddressTypeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_336" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_337" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_338" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_339" xlink:to="lab_dei_EntityCurrentReportingStatus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_340" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_341" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_342" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_343" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_344" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_345" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_346" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_347" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_348" xlink:to="lab_dei_EntityVoluntaryFilers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_349" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag_350" xlink:to="lab_dei_IcfrAuditorAttestationFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_351" xlink:to="lab_dei_LocalPhoneNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_OtherReportingStandardItemNumber_352" xlink:to="lab_dei_OtherReportingStandardItemNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_353" xlink:to="lab_dei_Security12bTitle_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_354" xlink:to="lab_dei_SecurityExchangeName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_355" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember_356" xlink:to="lab_srt_DirectorMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember_357" xlink:to="lab_srt_EuropeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_358" xlink:to="lab_srt_MajorCustomersAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_359" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_360" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_361" xlink:to="lab_srt_NameOfMajorCustomerDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_362" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_363" xlink:to="lab_srt_RangeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis_364" xlink:to="lab_srt_StatementScenarioAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_365" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_366" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_367" xlink:to="lab_us-gaap_AccountsPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_368" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_369" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_370" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_371" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_372" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_373" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_374" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization_375" xlink:to="lab_us-gaap_AdjustmentForAmortization_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_376" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_377" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_378" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_379" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_380" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_381" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_382" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_383" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_384" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_385" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_386" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_387" xlink:to="lab_us-gaap_AssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_388" xlink:to="lab_us-gaap_AssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_389" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_390" xlink:to="lab_us-gaap_AwardTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDevelopment_391" xlink:to="lab_us-gaap_BusinessDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_392" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_393" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_394" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_395" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_396" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_397" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_398" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_399" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_400" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_401" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_402" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_403" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_404" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_405" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_406" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_407" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_408" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_409" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_410" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_411" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_412" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_413" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_414" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_415" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_416" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_417" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_418" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_419" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_420" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_421" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_422" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_423" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_424" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_425" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_426" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_427" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_428" xlink:to="lab_us-gaap_ComputerEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_429" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_430" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_431" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_432" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_433" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_434" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_435" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_436" xlink:to="lab_us-gaap_CostOfRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty_437" xlink:to="lab_us-gaap_CostsAndExpensesRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_438" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_439" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_440" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_441" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_442" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue_443" xlink:to="lab_us-gaap_DeferredRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_444" xlink:to="lab_us-gaap_DeferredRevenueCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_445" xlink:to="lab_us-gaap_DeferredRevenueCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_446" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_447" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_448" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_449" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_450" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_451" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_452" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_453" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_454" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_455" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_456" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_457" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_458" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_459" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_460" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_461" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_462" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_463" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNet_464" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet_465" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_466" xlink:to="lab_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount_467" xlink:to="lab_us-gaap_DerivativeNotionalAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_468" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_469" xlink:to="lab_us-gaap_DomesticCountryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_470" xlink:to="lab_us-gaap_EarningsPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_471" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_472" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_473" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_474" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_475" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_476" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_477" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_478" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_479" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_480" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_481" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_482" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_483" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_484" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_485" xlink:to="lab_us-gaap_EmployeeStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_486" xlink:to="lab_us-gaap_EmployeeStockOptionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost_487" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost_488" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_489" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_490" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_491" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_492" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_493" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_494" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossAfterTax_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_495" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_496" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_497" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_498" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_499" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_500" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherAssets_501" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_502" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_503" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_504" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_505" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_506" xlink:to="lab_us-gaap_GrossProfit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_507" xlink:to="lab_us-gaap_GrossProfit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMaximumExposure_508" xlink:to="lab_us-gaap_GuaranteeObligationsMaximumExposure_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfInvestments_509" xlink:to="lab_us-gaap_ImpairmentOfInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_510" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_511" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_512" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_513" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_514" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_515" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_516" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_517" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_518" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_519" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_520" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_521" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_522" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_523" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_524" xlink:to="lab_us-gaap_IncomeTaxesPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_525" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_526" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_527" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_528" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_529" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_530" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_531" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_532" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_533" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_534" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_535" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_536" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialOfferingPeriod_537" xlink:to="lab_us-gaap_InitialOfferingPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense_538" xlink:to="lab_us-gaap_InterestAndDebtExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense_539" xlink:to="lab_us-gaap_InterestAndDebtExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember_540" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_541" xlink:to="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_542" xlink:to="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_543" xlink:to="lab_us-gaap_InvestmentIncomeInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_544" xlink:to="lab_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_545" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_546" xlink:to="lab_us-gaap_LesseeDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_547" xlink:to="lab_us-gaap_LesseeDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_548" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_549" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_550" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_551" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_552" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_553" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_554" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_555" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_556" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_557" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_558" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_559" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_560" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_561" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_562" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_563" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_564" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_565" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_566" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_567" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_568" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_569" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_570" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_571" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_572" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_573" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent_574" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent_575" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_576" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_577" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_578" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_579" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_580" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_581" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_582" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_583" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_584" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_585" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_586" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_587" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_588" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_589" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_590" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_591" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_592" xlink:to="lab_us-gaap_NetIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_593" xlink:to="lab_us-gaap_NetIncomeLoss_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_594" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_595" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets_596" xlink:to="lab_us-gaap_NoncurrentAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_597" xlink:to="lab_us-gaap_NumberOfOperatingSegments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_598" xlink:to="lab_us-gaap_NumberOfOperatingSegments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_599" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_600" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_601" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_602" xlink:to="lab_us-gaap_OperatingIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_603" xlink:to="lab_us-gaap_OperatingIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_604" xlink:to="lab_us-gaap_OperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_605" xlink:to="lab_us-gaap_OperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_606" xlink:to="lab_us-gaap_OperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_607" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_608" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_609" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_610" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_611" xlink:to="lab_us-gaap_OperatingLeasePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_612" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_613" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_614" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_615" xlink:to="lab_us-gaap_OperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_616" xlink:to="lab_us-gaap_OperatingLossCarryforwardsExpirationDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_617" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_618" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_619" xlink:to="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_620" xlink:to="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_621" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_622" xlink:to="lab_us-gaap_OtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_623" xlink:to="lab_us-gaap_OtherCommitmentsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable_624" xlink:to="lab_us-gaap_OtherCommitmentsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_625" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_626" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_627" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_628" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_629" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_630" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_631" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_632" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_633" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_634" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities_635" xlink:to="lab_us-gaap_OtherLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments_636" xlink:to="lab_us-gaap_OtherShortTermInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments_637" xlink:to="lab_us-gaap_OtherShortTermInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_638" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromProductiveAssets_639" xlink:to="lab_us-gaap_PaymentsForProceedsFromProductiveAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromProductiveAssets_640" xlink:to="lab_us-gaap_PaymentsForProceedsFromProductiveAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_641" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_642" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_643" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_644" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_645" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_646" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments_647" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments_648" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_649" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_650" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_651" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_652" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_653" xlink:to="lab_us-gaap_PlanNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_654" xlink:to="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_655" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_656" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_657" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent_658" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIncomeTaxRefunds_659" xlink:to="lab_us-gaap_ProceedsFromIncomeTaxRefunds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_660" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_661" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_662" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_663" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_664" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_665" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_666" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_667" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_668" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_669" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_670" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_671" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_672" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_673" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_674" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_675" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_676" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_677" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_678" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals_679" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals_680" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals_681" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_682" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentImpairment_683" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentImpairment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_685" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_686" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_687" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_688" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_689" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_690" xlink:to="lab_us-gaap_ReceivablesNetCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_691" xlink:to="lab_us-gaap_ReceivablesNetCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_692" xlink:to="lab_us-gaap_RelatedPartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_693" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_694" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_695" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_696" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_697" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_698" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_699" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_700" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_701" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_702" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_703" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_704" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_705" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_706" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_707" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_708" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_709" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_710" xlink:to="lab_us-gaap_Revenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_711" xlink:to="lab_us-gaap_Revenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_712" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_713" xlink:to="lab_us-gaap_RoyaltyExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_714" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_715" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_716" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember_717" xlink:to="lab_us-gaap_SalesRevenueNetMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_718" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_719" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_720" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_721" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_722" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_723" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_724" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_725" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_726" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_727" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_728" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_729" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_730" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_731" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_732" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_733" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_734" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_735" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_736" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_737" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_738" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_739" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_740" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_741" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_742" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_743" xlink:to="lab_us-gaap_SegmentReportingAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_744" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember_745" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_746" xlink:to="lab_us-gaap_SeveranceCosts1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_747" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_748" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_749" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_750" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_751" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_752" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_753" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_755" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_756" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_757" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_758" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_759" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_760" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_761" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_762" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_763" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_764" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_765" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_766" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_767" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_768" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_769" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_770" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_771" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_772" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_773" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_774" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_775" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_776" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_777" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_778" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_779" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_780" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_781" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_782" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_783" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_784" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_785" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_786" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_787" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_788" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_789" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_790" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_791" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_792" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_793" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_794" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_795" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_796" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_797" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_798" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_799" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_800" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_801" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_802" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_803" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_804" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_805" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_806" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_807" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_808" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_809" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_810" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_811" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_812" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_813" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_814" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember_815" xlink:to="lab_us-gaap_StockOptionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome_816" xlink:to="lab_us-gaap_SubleaseIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_817" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_818" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_819" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_820" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_821" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_822" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_823" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_824" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOfCommonParentMember_825" xlink:to="lab_us-gaap_SubsidiaryOfCommonParentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOfCommonParentMember_826" xlink:to="lab_us-gaap_SubsidiaryOfCommonParentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_827" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_828" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_829" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_830" xlink:to="lab_us-gaap_UseOfEstimates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeasePayment_831" xlink:to="lab_us-gaap_VariableLeasePayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeasePayment_832" xlink:to="lab_us-gaap_VariableLeasePayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_833" xlink:to="lab_us-gaap_WarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_834" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_835" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_836" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_837" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_838" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>cgen-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-daei1" roleURI="http://cgen.com/role/cgen-daei1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#ConsolidatedBalanceSheets" roleURI="http://cgen.com/role/ConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-cbsp" roleURI="http://cgen.com/role/cgen-cbsp"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-csocl" roleURI="http://cgen.com/role/cgen-csocl"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#StatementsOfChangesInShareholdersEquity" roleURI="http://cgen.com/role/StatementsOfChangesInShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-g" roleURI="http://cgen.com/role/cgen-g"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-sap" roleURI="http://cgen.com/role/cgen-sap"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-oarape" roleURI="http://cgen.com/role/cgen-oarape"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#Leases" roleURI="http://cgen.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-paen" roleURI="http://cgen.com/role/cgen-paen"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-oapaae" roleURI="http://cgen.com/role/cgen-oapaae"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-cac1" roleURI="http://cgen.com/role/cgen-cac1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-se12" roleURI="http://cgen.com/role/cgen-se12"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-it" roleURI="http://cgen.com/role/cgen-it"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-giamc" roleURI="http://cgen.com/role/cgen-giamc"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-faoin" roleURI="http://cgen.com/role/cgen-faoin"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-rpbat" roleURI="http://cgen.com/role/cgen-rpbat"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-lps" roleURI="http://cgen.com/role/cgen-lps"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-sapp" roleURI="http://cgen.com/role/cgen-sapp"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-sapt" roleURI="http://cgen.com/role/cgen-sapt"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-oarapet" roleURI="http://cgen.com/role/cgen-oarapet"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#LeasesTables" roleURI="http://cgen.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-paent" roleURI="http://cgen.com/role/cgen-paent"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-oapaaet" roleURI="http://cgen.com/role/cgen-oapaaet"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-set1" roleURI="http://cgen.com/role/cgen-set1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-itt" roleURI="http://cgen.com/role/cgen-itt"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-giamct" roleURI="http://cgen.com/role/cgen-giamct"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-faoint" roleURI="http://cgen.com/role/cgen-faoint"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#RelatedPartyBalancesAndTransactionsTables" roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-lpst" roleURI="http://cgen.com/role/cgen-lpst"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-gd" roleURI="http://cgen.com/role/cgen-gd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-sapnd" roleURI="http://cgen.com/role/cgen-sapnd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-sapsodrfpaed" roleURI="http://cgen.com/role/cgen-sapsodrfpaed"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails" roleURI="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-oaraped" roleURI="http://cgen.com/role/cgen-oaraped"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails" roleURI="http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#LeasesScheduleOfOperatingLeasesDetails" roleURI="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-paend" roleURI="http://cgen.com/role/cgen-paend"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-oapaaed" roleURI="http://cgen.com/role/cgen-oapaaed"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#CommitmentsAndContingenciesDetails" roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-sesopnd" roleURI="http://cgen.com/role/cgen-sesopnd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#ShareholdersEquityScheduleOfOptionActivityDetails" roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#cgen-sesosced" roleURI="http://cgen.com/role/cgen-sesosced"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#IncomeTaxesNarrativeDetails" roleURI="http://cgen.com/role/IncomeTaxesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#IncomeTaxesScheduleOfLossBeforeTaxesDetails" roleURI="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#GeographicInformationAndMajorCustomersDetails" roleURI="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails" roleURI="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#RelatedPartyBalancesAndTransactionsDetails" roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails" roleURI="http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#SUBSEQUENTEVENTS" roleURI="http://cgen.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#SubsequentEventsNarrativeDetails" roleURI="http://cgen.com/role/SubsequentEventsNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#LEASESNarrative" roleURI="http://cgen.com/role/LEASESNarrative"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#PROPERTYANDEQUIPMENTNETNarrativeDetails" roleURI="http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20231231.xsd#GEOGRAPHICINFORMATIONANDMAJORCUSTOMERSNarrativeDetails" roleURI="http://cgen.com/role/GEOGRAPHICINFORMATIONANDMAJORCUSTOMERSNarrativeDetails"/>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-daei1">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_dei_OtherReportingStandardItemNumber_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_48"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1" xlink:to="loc_dei_AddressTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1" xlink:to="loc_dei_BusinessContactMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_6" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentType_8" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_AmendmentFlag_9" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_AmendmentDescription_10" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentRegistrationStatement_11" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentAnnualReport_12" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentTransitionReport_13" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentShellCompanyReport_14" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_15" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityFileNumber_16" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_ContactPersonnelName_17" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityRegistrantName_18" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_19" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressAddressLine1_20" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressAddressLine2_21" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressAddressLine3_22" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressCityOrTown_23" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressCountry_24" order="200" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressPostalZipCode_25" order="210" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_CityAreaCode_26" order="220" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_LocalPhoneNumber_27" order="230" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_ContactPersonnelFaxNumber_28" order="240" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_ContactPersonnelEmailAddress_29" order="250" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_Security12bTitle_30" order="260" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_TradingSymbol_31" order="270" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_SecurityExchangeName_32" order="280" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_33" order="290" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_34" order="300" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityVoluntaryFilers_35" order="310" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityCurrentReportingStatus_36" order="320" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityInteractiveDataCurrent_37" order="330" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityFilerCategory_38" order="340" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityEmergingGrowthCompany_39" order="350" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_IcfrAuditorAttestationFlag_40" order="360" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityExTransitionPeriod_41" order="370" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentAccountingStandard_42" order="380" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_OtherReportingStandardItemNumber_43" order="390" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityShellCompany_44" order="400" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_AuditorName_45" order="410" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_AuditorLocation_46" order="420" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_AuditorFirmId_47" order="430" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_48" order="440" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="loc_cgen_SeverancePayFundNoncurrent_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_37"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_OtherShortTermInvestments_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_ReceivablesNetCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_cgen_SeverancePayFundNoncurrent_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_11" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_12" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_us-gaap_AssetsNoncurrent_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_AccountsPayableCurrent_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_DeferredRevenueCurrent_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_20" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_21" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_LiabilitiesCurrent_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_24" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24" xlink:to="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_26" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_27" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_28" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_CommitmentsAndContingencies_30" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_StockholdersEquityAbstract_31" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_CommonStockValue_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_32" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_33" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_StockholdersEquity_35" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_37" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cbsp">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-csocl">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_Revenues_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_CostOfRevenue_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_GrossProfit_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_BusinessDevelopment_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_OperatingExpenses_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_cgen_FinancialIncomeExpenseNet_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_13" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_14" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_15" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_16" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_17" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_18" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_19" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/StatementsOfChangesInShareholdersEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_23"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_11" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_12" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cgen_NumberOfWarrantsExercised_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_15" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_17" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_19" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_20" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_NetIncomeLoss_21" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_22" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_23" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" xlink:label="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" xlink:label="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseDecreaseInDeferredRevenues" xlink:label="loc_cgen_IncreaseDecreaseInDeferredRevenues_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_38"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_39"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_42"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_InterestPaidReceivedNet" xlink:label="loc_cgen_InterestPaidReceivedNet_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_46"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_2" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_3" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_SeverancePayNet_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_10" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_11" order="90" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_12" order="100" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_13" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_14" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_IncreaseDecreaseInDeferredRevenues_15" order="130" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_16" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_25" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_26" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_29" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_30" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_31" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_32" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_34" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_35" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38" xlink:to="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_38" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38" xlink:to="loc_cgen_ReceivablesOnAccountOfShares_39" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_38" xlink:to="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_40" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_42" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_42" xlink:to="loc_cgen_InterestPaidReceivedNet_42" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_44" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_44" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_44" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_45" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_44" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_46" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-g">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sap">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oarape">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/Leases">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paen">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oapaae">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cac1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-se12">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-it">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-giamc">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-faoin">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-rpbat">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-lps">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapp">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cgen_ShortTermBankDepositsPolicyTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CostOfSalesContractWithCustomerPolicyTextBlock" xlink:label="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ServerancePayPolicyTextBlock" xlink:label="loc_cgen_ServerancePayPolicyTextBlock_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_22"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_ShortTermBankDepositsPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentImpairment_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_11" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_13" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_ServerancePayPolicyTextBlock_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_15" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_16" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_17" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_18" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_19" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_20" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_21" order="200" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_22" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapt">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" xlink:label="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions" xlink:label="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oarapet">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" xlink:label="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paent">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oapaaet">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-set1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-itt">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-giamct">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-faoint">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-lpst">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-gd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NonRefundableUpfrontPayment" xlink:label="loc_cgen_NonRefundableUpfrontPayment_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MilestonePaymentReceivable" xlink:label="loc_cgen_MilestonePaymentReceivable_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:label="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid" xlink:label="loc_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_NonRefundableUpfrontPayment_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_MilestonePaymentReceivable_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_AccruedMilestonePayment_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapnd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MasterClinicalAgreementOneMember" xlink:label="loc_cgen_MasterClinicalAgreementOneMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MasterClinicalAgreementTwoMember" xlink:label="loc_cgen_MasterClinicalAgreementTwoMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LicenseAgreementWithGileadMember" xlink:label="loc_cgen_LicenseAgreementWithGileadMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="loc_us-gaap_ImpairmentOfInvestments_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xlink:label="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting" xlink:label="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DerivativeRelatedExpense" xlink:label="loc_cgen_DerivativeRelatedExpense_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AccruedMilestonePayments" xlink:label="loc_cgen_AccruedMilestonePayments_26"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_27"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xlink:label="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LicenseRevenue" xlink:label="loc_cgen_LicenseRevenue_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredRevenuesIncludedInCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredRevenuesIncludedInNonCurrentLiabilities" xlink:label="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_31"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementOneMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementTwoMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_LicenseAgreementWithGileadMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6" xlink:to="loc_us-gaap_StockOptionMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_AdjustmentForAmortization_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_ImpairmentOfInvestments_11" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_DeferredRevenue_12" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_13" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_14" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_SeveranceCosts1_15" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_16" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_17" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_18" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_DerivativeRelatedExpense_19" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_20" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_21" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_22" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_DerivativeNotionalAmount_23" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_24" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_25" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_AccruedMilestonePayments_26" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_27" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_28" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_LicenseRevenue_29" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_DeferredRevenuesIncludedInCurrentLiabilities_30" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities_31" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapsodrfpaed">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AnnualDepreciationRate" xlink:label="loc_cgen_AnnualDepreciationRate_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="loc_cgen_AnnualDepreciationRateDescription_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_srt_RangeAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6" xlink:to="loc_srt_RangeMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MinimumMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MaximumMember_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" xlink:to="loc_cgen_AnnualDepreciationRate_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" xlink:to="loc_cgen_AnnualDepreciationRateDescription_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="loc_cgen_EmployeeStockPurchasePlanMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_cgen_EmployeeStockPurchasePlanMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5" xlink:to="loc_srt_RangeMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MinimumMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MaximumMember_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_11" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_12" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oaraped">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_GovernmentAuthorities" xlink:label="loc_cgen_GovernmentAuthorities_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_cgen_GovernmentAuthorities_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherAssetsCurrent_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paend">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oapaaed">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AntibodiesDiscoveryCollaborationAgreementMember" xlink:label="loc_cgen_AntibodiesDiscoveryCollaborationAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ExtendLease" xlink:label="loc_cgen_ExtendLease_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RoyaltyPercentage" xlink:label="loc_cgen_RoyaltyPercentage_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_24"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherCommitmentsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_ResearchAndDevelopmentGrantOneMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_May2012AgreementMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_AntibodiesDiscoveryCollaborationAgreementMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_RangeAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6" xlink:to="loc_srt_RangeMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MinimumMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MaximumMember_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_10" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_10" xlink:to="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_10" xlink:to="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_10" xlink:to="loc_us-gaap_RoyaltyExpense_13" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_10" xlink:to="loc_cgen_RoyaltyContingentObligations_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_10" xlink:to="loc_cgen_ParticipationRights_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_10" xlink:to="loc_cgen_RetainerFee_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_10" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_17" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_10" xlink:to="loc_cgen_AgreementStartDate_18" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_10" xlink:to="loc_cgen_AgreementTerminationDescription_19" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_10" xlink:to="loc_cgen_ExtendLease_20" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_10" xlink:to="loc_cgen_ContingentFees_21" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_10" xlink:to="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_22" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_10" xlink:to="loc_cgen_RoyaltyPercentage_23" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_10" xlink:to="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_24" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesopnd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_JmpSecuritiesLlcMember" xlink:label="loc_cgen_JmpSecuritiesLlcMember_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_LeerinkPartnersLlcMember" xlink:label="loc_cgen_LeerinkPartnersLlcMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_TwoThousandTenShareOptionsPlanMember" xlink:label="loc_cgen_TwoThousandTenShareOptionsPlanMember_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EmployeesDirectorsAndNonEmployeesMember" xlink:label="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_38"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_42"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_43"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InitialOfferingPeriod" xlink:label="loc_us-gaap_InitialOfferingPeriod_46"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xlink:label="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_47"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xlink:label="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_48"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xlink:label="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_50"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_CollaborativeArrangementsMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_CollaborativeArrangementsTwoMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_JmpSecuritiesLlcMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_LeerinkPartnersLlcMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_cgen_RegisteredDirectOfferingMember_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_us-gaap_WarrantMember_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_cgen_UnderwritersMember_11" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_14" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_14" xlink:to="loc_us-gaap_PlanNameDomain_14" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_14" xlink:to="loc_cgen_TwoThousandTenShareOptionsPlanMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_17" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_17" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17" xlink:to="loc_us-gaap_EmployeeStockMember_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_20" xlink:to="loc_us-gaap_RelatedPartyDomain_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_20" xlink:to="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_23" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_24" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_25" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_27" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_28" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_29" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_30" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_31" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_32" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_33" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_34" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_35" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_36" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_37" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_38" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_39" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_40" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_41" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_42" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_PercentageOfClosingPrice_43" order="200" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_44" order="210" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_45" order="220" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_InitialOfferingPeriod_46" order="230" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_47" order="240" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_48" order="250" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_49" order="260" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_50" order="270" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EmployeesDirectorsAndNonEmployeesMember" xlink:label="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_24"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cgen_EmployeesDirectorsAndNonEmployeesMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_10" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_14" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_15" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_20" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_20" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_20" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_23" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesosced">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_us-gaap_EmployeeStockMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOfCommonParentMember" xlink:label="loc_us-gaap_SubsidiaryOfCommonParentMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NetOperatingLossCarryforwardExpired" xlink:label="loc_cgen_NetOperatingLossCarryforwardExpired_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ReducedCorporateIncomeTaxRate" xlink:label="loc_cgen_ReducedCorporateIncomeTaxRate_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ReducedTaxRate" xlink:label="loc_cgen_ReducedTaxRate_17"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_DomesticCountryMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5" xlink:to="loc_us-gaap_SubsidiaryOfCommonParentMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_IncomeTaxesPaid_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_11" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_12" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_OperatingLossCarryforwards_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_cgen_NetOperatingLossCarryforwardExpired_14" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_15" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_cgen_ReducedCorporateIncomeTaxRate_16" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_cgen_ReducedTaxRate_17" order="90" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="loc_cgen_DeferredIncomeTaxLeaseLiabilities_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="loc_cgen_DeferredIncomeTaxRightOfUseAssets_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_cgen_DeferredIncomeTaxLeaseLiabilities_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_10" xlink:to="loc_cgen_DeferredIncomeTaxRightOfUseAssets_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_10" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SegmentReportingGeographicAreaAxis" xlink:label="loc_cgen_SegmentReportingGeographicAreaAxis_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_SegmentReportingGeographicAreaDomain" xlink:label="loc_cgen_SegmentReportingGeographicAreaDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IL" xlink:label="loc_country_IL_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CustomerOneMember" xlink:label="loc_cgen_CustomerOneMember_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CustomerTwoMember" xlink:label="loc_cgen_CustomerTwoMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_cgen_SegmentReportingGeographicAreaAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeographicAreaAxis_1" xlink:to="loc_cgen_SegmentReportingGeographicAreaDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_srt_EuropeMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_country_IL_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_country_US_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6" xlink:to="loc_us-gaap_SalesRevenueNetMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_srt_MajorCustomersAxis_12" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_12" xlink:to="loc_srt_NameOfMajorCustomerDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_12" xlink:to="loc_cgen_CustomerOneMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_12" xlink:to="loc_cgen_CustomerTwoMember_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_16" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_16" xlink:to="loc_us-gaap_Revenues_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_16" xlink:to="loc_us-gaap_NoncurrentAssets_17" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_16" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_18" order="20" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_InterestAndDebtExpense_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_cgen_FinancialIncomeExpenseNet_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_OtherLiabilities_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_2" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" xlink:label="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" xlink:to="loc_us-gaap_EarningsPerShareBasic_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SUBSEQUENTEVENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SubsequentEventsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_OrdinarySharesIssuedAndSoldThroughAtmMember" xlink:label="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4" xlink:to="loc_cgen_OrdinarySharesIssuedAndSoldThroughAtmMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LEASESNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_IncreaseOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeasePayment" xlink:label="loc_us-gaap_VariableLeasePayment_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:label="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasePayments_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_VariableLeasePayment_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_SubleaseIncome_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_7" order="60" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20231231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4" xlink:to="loc_us-gaap_Depreciation_6" order="20" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/GEOGRAPHICINFORMATIONANDMAJORCUSTOMERSNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_NumberOfOperatingSegments_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>cgen-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:cgen="http://cgen.com/20231231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" targetNamespace="http://cgen.com/20231231" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://cgen.com/role/cgen-daei1" id="cgen-daei1">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>0002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-cbsp" id="cgen-cbsp">
        <link:definition>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-csocl" id="cgen-csocl">
        <link:definition>0004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/StatementsOfChangesInShareholdersEquity" id="StatementsOfChangesInShareholdersEquity">
        <link:definition>0005 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-g" id="cgen-g">
        <link:definition>0007 - Disclosure - GENERAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sap" id="cgen-sap">
        <link:definition>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oarape" id="cgen-oarape">
        <link:definition>0009 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/Leases" id="Leases">
        <link:definition>0010 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-paen" id="cgen-paen">
        <link:definition>0011 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oapaae" id="cgen-oapaae">
        <link:definition>0012 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-cac1" id="cgen-cac1">
        <link:definition>0013 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-se12" id="cgen-se12">
        <link:definition>0014 - Disclosure - SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-it" id="cgen-it">
        <link:definition>0015 - Disclosure - TAXES ON INCOME, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-giamc" id="cgen-giamc">
        <link:definition>0016 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-faoin" id="cgen-faoin">
        <link:definition>0017 - Disclosure - FINANCIAL AND OTHER INCOME, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-rpbat" id="cgen-rpbat">
        <link:definition>0018 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-lps" id="cgen-lps">
        <link:definition>0019 - Disclosure - LOSSES PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SUBSEQUENTEVENTS" id="SUBSEQUENTEVENTS">
        <link:definition>0020 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sapp" id="cgen-sapp">
        <link:definition>0021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sapt" id="cgen-sapt">
        <link:definition>0022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oarapet" id="cgen-oarapet">
        <link:definition>0023 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LeasesTables" id="LeasesTables">
        <link:definition>0024 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-paent" id="cgen-paent">
        <link:definition>0025 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oapaaet" id="cgen-oapaaet">
        <link:definition>0026 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-set1" id="cgen-set1">
        <link:definition>0027 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-itt" id="cgen-itt">
        <link:definition>0028 - Disclosure - TAXES ON INCOME, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-giamct" id="cgen-giamct">
        <link:definition>0029 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-faoint" id="cgen-faoint">
        <link:definition>0030 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables" id="RelatedPartyBalancesAndTransactionsTables">
        <link:definition>0031 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-lpst" id="cgen-lpst">
        <link:definition>0032 - Disclosure - LOSSES PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-gd" id="cgen-gd">
        <link:definition>0033 - Disclosure - GENERAL (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sapnd" id="cgen-sapnd">
        <link:definition>0034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sapsodrfpaed" id="cgen-sapsodrfpaed">
        <link:definition>0035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails" id="SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails">
        <link:definition>0036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oaraped" id="cgen-oaraped">
        <link:definition>0037 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Schedule Of Other Accounts Receivable And Prepaid Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LEASESNarrative" id="LEASESNarrative">
        <link:definition>0038 - Disclosure - LEASES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails" id="LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails">
        <link:definition>0039 - Disclosure - LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails" id="LeasesScheduleOfOperatingLeasesDetails">
        <link:definition>0040 - Disclosure - LEASES (Schedule of Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" id="PROPERTYANDEQUIPMENTNETNarrativeDetails">
        <link:definition>0041 - Disclosure - PROPERTY AND EQUIPMENT, NET (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-paend" id="cgen-paend">
        <link:definition>0042 - Disclosure - PROPERTY AND EQUIPMENT, NET (Schedule of Property and Equipment, Net) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oapaaed" id="cgen-oapaaed">
        <link:definition>0043 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Schedule Of Other Accounts Payable And Accrued Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>0044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sesopnd" id="cgen-sesopnd">
        <link:definition>0045 - Disclosure - SHAREHOLDERS' EQUITY  (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails" id="ShareholdersEquityScheduleOfOptionActivityDetails">
        <link:definition>0046 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sesosced" id="cgen-sesosced">
        <link:definition>0047 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/IncomeTaxesNarrativeDetails" id="IncomeTaxesNarrativeDetails">
        <link:definition>0048 - Disclosure - TAXES ON INCOME, NET (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails" id="IncomeTaxesScheduleOfLossBeforeTaxesDetails">
        <link:definition>0049 - Disclosure - TAXES ON INCOME, NET (Schedule of Loss (Income) Before Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>0050 - Disclosure - TAXES ON INCOME, NET (Schedule of Deferred Tax Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/GEOGRAPHICINFORMATIONANDMAJORCUSTOMERSNarrativeDetails" id="GEOGRAPHICINFORMATIONANDMAJORCUSTOMERSNarrativeDetails">
        <link:definition>0051 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails" id="GeographicInformationAndMajorCustomersDetails">
        <link:definition>0052 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails" id="FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails">
        <link:definition>0053 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails" id="RelatedPartyBalancesAndTransactionsDetails">
        <link:definition>0054 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Schedule of Related Party Transactions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails" id="LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails">
        <link:definition>0055 - Disclosure - LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SubsequentEventsNarrativeDetails" id="SubsequentEventsNarrativeDetails">
        <link:definition>0056 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AccruedMilestonePayment" id="cgen_AccruedMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AccruedMilestonePayments" id="cgen_AccruedMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" id="cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AggregateLimitOfOrdinarySharesPerCalendarYear" id="cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementStartDate" id="cgen_AgreementStartDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementTerminationDescription" id="cgen_AgreementTerminationDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" id="cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" id="cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AnnualDepreciationRate" id="cgen_AnnualDepreciationRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AnnualDepreciationRateDescription" id="cgen_AnnualDepreciationRateDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AntibodiesDiscoveryCollaborationAgreementMember" id="cgen_AntibodiesDiscoveryCollaborationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" id="cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" id="cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CollaborativeArrangementsMember" id="cgen_CollaborativeArrangementsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CollaborativeArrangementsTwoMember" id="cgen_CollaborativeArrangementsTwoMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ContingentFees" id="cgen_ContingentFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CostOfSalesContractWithCustomerPolicyTextBlock" id="cgen_CostOfSalesContractWithCustomerPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CustomerOneMember" id="cgen_CustomerOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CustomerTwoMember" id="cgen_CustomerTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DeferredIncomeTaxLeaseLiabilities" id="cgen_DeferredIncomeTaxLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredIncomeTaxRightOfUseAssets" id="cgen_DeferredIncomeTaxRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredParticipationOfBMSInRAndDExpenses" id="cgen_DeferredParticipationOfBMSInRAndDExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DeferredRevenuesIncludedInCurrentLiabilities" id="cgen_DeferredRevenuesIncludedInCurrentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DeferredRevenuesIncludedInNonCurrentLiabilities" id="cgen_DeferredRevenuesIncludedInNonCurrentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" id="cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DerivativeRelatedExpense" id="cgen_DerivativeRelatedExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" id="cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeesAndDirectorsMember" id="cgen_EmployeesAndDirectorsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeesDirectorsAndNonEmployeesMember" id="cgen_EmployeesDirectorsAndNonEmployeesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeeStockPurchasePlanMember" id="cgen_EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExtendLease" id="cgen_ExtendLease" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinancialIncomeExpenseNet" id="cgen_FinancialIncomeExpenseNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="GovernmentAndOtherGrantsAxis" id="cgen_GovernmentAndOtherGrantsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="GovernmentAndOtherGrantsDomain" id="cgen_GovernmentAndOtherGrantsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentAuthorities" id="cgen_GovernmentAuthorities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseInDeferredRevenues" id="cgen_IncreaseDecreaseInDeferredRevenues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" id="cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseOperatingLeaseRightOfUseAsset" id="cgen_IncreaseOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InterestPaidReceivedNet" id="cgen_InterestPaidReceivedNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IssuanceOfSharesAndWarrantsNetShares" id="cgen_IssuanceOfSharesAndWarrantsNetShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfSharesAndWarrantsNetValue" id="cgen_IssuanceOfSharesAndWarrantsNetValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="JmpSecuritiesLlcMember" id="cgen_JmpSecuritiesLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LaboratoryEquipmentAndOfficeFurnitureMember" id="cgen_LaboratoryEquipmentAndOfficeFurnitureMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LeerinkPartnersLlcMember" id="cgen_LeerinkPartnersLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseAgreementWithGileadMember" id="cgen_LicenseAgreementWithGileadMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseRevenue" id="cgen_LicenseRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="LongTermDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MasterClinicalAgreementMember" id="cgen_MasterClinicalAgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MasterClinicalAgreementOneMember" id="cgen_MasterClinicalAgreementOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MasterClinicalAgreementTwoMember" id="cgen_MasterClinicalAgreementTwoMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MaximumAuthorizedProceedsFromIssuanceOfCommonStock" id="cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MaximumRoyaltyRepaidAsPercentageOfGrantReceived" id="cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="May2012AgreementMember" id="cgen_May2012AgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MilestonePaymentReceivable" id="cgen_MilestonePaymentReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" id="cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NetOperatingLossCarryforwardExpired" id="cgen_NetOperatingLossCarryforwardExpired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NonRefundableUpfrontPayment" id="cgen_NonRefundableUpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" id="cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsExercised" id="cgen_NumberOfWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" id="cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OrdinarySharesIssuedAndSoldThroughAtmMember" id="cgen_OrdinarySharesIssuedAndSoldThroughAtmMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherAccountsReceivableAndPrepaidExpensesTextBlock" id="cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ParticipationRights" id="cgen_ParticipationRights" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" id="cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PercentageOfClosingPrice" id="cgen_PercentageOfClosingPrice" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfConsolidatedRevenuesOfCollaborator" id="cgen_PercentageOfConsolidatedRevenuesOfCollaborator" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfExpectedFromUpfrontPaymentAmountPaid" id="cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" id="cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" id="cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PeriodSinceApprovalWasGranted" id="cgen_PeriodSinceApprovalWasGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PeriodSinceEnterpriseBeganOperating" id="cgen_PeriodSinceEnterpriseBeganOperating" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PurchaseOfPropertyAndEquipmentAsNonCashTransaction" id="cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ReceivablesOnAccountOfShares" id="cgen_ReceivablesOnAccountOfShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ReducedCorporateIncomeTaxRate" id="cgen_ReducedCorporateIncomeTaxRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ReducedTaxRate" id="cgen_ReducedTaxRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RegisteredDirectOfferingMember" id="cgen_RegisteredDirectOfferingMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ResearchAndDevelopmentArrangementPaymentsReceivable" id="cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" id="cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" id="cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentExpensesMilestonePayment" id="cgen_ResearchAndDevelopmentExpensesMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" id="cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentGrantOneMember" id="cgen_ResearchAndDevelopmentGrantOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RetainerFee" id="cgen_RetainerFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RoyaltyContingentObligations" id="cgen_RoyaltyContingentObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RoyaltyPercentage" id="cgen_RoyaltyPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltyPercentageBasedOnFutureRevenues" id="cgen_RoyaltyPercentageBasedOnFutureRevenues" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SalesAgreementWithSVBSecuritiesLLCMember" id="cgen_SalesAgreementWithSVBSecuritiesLLCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" id="cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfWeightedAverageAssumptionsForGrantedOptions" id="cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" id="cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SegmentReportingGeograhicAreaLineItems" id="cgen_SegmentReportingGeograhicAreaLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SegmentReportingGeographicAreaAxis" id="cgen_SegmentReportingGeographicAreaAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="SegmentReportingGeographicAreaDomain" id="cgen_SegmentReportingGeographicAreaDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SegmentReportingGeographicAreaTable" id="cgen_SegmentReportingGeographicAreaTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="ServerancePayPolicyTextBlock" id="cgen_ServerancePayPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeverancePayFundNoncurrent" id="cgen_SeverancePayFundNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SeverancePayNet" id="cgen_SeverancePayNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" id="cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" id="cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShortTermBankDepositsPolicyTextBlock" id="cgen_ShortTermBankDepositsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShortTermBankDepositsWeightedAverageRateForeign" id="cgen_ShortTermBankDepositsWeightedAverageRateForeign" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" id="cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueWarrantsExercised" id="cgen_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SupplementalRightOfUseAssetAndOperatingLeaseLiability" id="cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SvbLeerinkLlcAndStifelNicolausAndCompanyMember" id="cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TaxExemptPeriod" id="cgen_TaxExemptPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TaxRateOnDistributions" id="cgen_TaxRateOnDistributions" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandAndTwoThousandTenOptionsPlanMember" id="cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandTenShareOptionsPlanMember" id="cgen_TwoThousandTenShareOptionsPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnderwritersMember" id="cgen_UnderwritersMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image00001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0M!WL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M' -,20X\M4@Z4T#-.--@PI:04M(2"BBB@84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIG.P%+2"EI"04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /E.;G%>L?#_P#X\!]*\GFX
MQ7K7P\7=8CZ5GU/J\>K0.]MA\]::]*I01X-75JD?-57=BTM)2TT8A129YI:8
M!1110!&],%2,.*CQS5(PFM1_45!,^Q35CH*Q]4NA$C<]J1U4(.3L8^N:CY<3
M<UY#XDOS-,>>]=3XAU<$NNZO/KUC/)GKS64F?287#V0B'?'43+L-2Q#:,4LJ
M[JBY[%*%D.BFVK2N_F"JVTCBI8^*S.R(F-IJ0/2,,BF+UI-%SV)#ZT@YJ3;\
ME1=#2L8QN/[4F<4=LTW[U5RCF[(<S?)FK6DQ&YEQUYJC]YME=9X5TPF4$CO6
MB1Y>*JI([3P[IFU4.VO0+2+9&M9.CV@CB7BM]1A16L3Y?%5>:0'I46:D-,Q6
MB/,G>Y&>M2+3=O-. JF913N2]13=M**6HN=42"5]HKSKX@7&;)AGM7>WK;8V
M->5^-[KS(67-2V>EA*:;N>;CE]WO7>> YM]ZJ^]<(@X-=MX!0KJ(/O31Z-=6
MIGMD(_=CZ5*!4</W!]*G[4=3Y^8S/-/'2F$<T\=*#*(M%%%!84444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(3B@'- "T444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBB@ HHHH **** "BBB@ HHHH **** &/TH3I3B,T 8H 6BBB@ HHHH ****
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MV:[GP.?],4>]-&&,7NGLUMS&/I5FJMJ?W8^E6JU/F9[A11100%%%% !1110
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M,7J_6N&3[U=YX(YNUIK<X\=\)[%:C]V*M56M?]6/I5FM3YB>X4444$!1110
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M)XJQ8LUO(&S2  FEFX3BD!W^@:YLVJ6KTS2K\7"+S7SQI]W)'.O/>O6/"^J
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MUGY<"<5U&,**U6Q\CBI7D/!HIHZTK51PS0W'-2"F@4X4,B*L+1112- HHHH
M*0TM-:@"&Z.(&/M7E'CF?=$PS7J5^VVT<^U>->+Y]Y<9J)Z'JY;&\CA=WS5+
MC JK_P M/QJVW^K%9MGUE./N@AYKN?!!S>+]:X2,UW/@7_C^'UIQ/*S'2)[-
M;?ZL?2K-5H/N"K-:H^6GN%%%%,@**** "BBB@ HHHH **** "BBB@ IN>:<>
ME1?Q4T!+VJ/'S5)VI,4)@-=MJ$UQ?B;5PL#Q[JZJ_G$4+<]J\7\3ZFS7KH&X
MS0@.8UF8RS,<]ZS8P:L7),AS347BDP)%&:D)PF*1..M1RO0 T7(B/)J>&/[6
MXQSFLBY225ALKK_#&F2.4W+0!-8^'FD(.PUV>CZ$8MN4KHM(T>,(N5[5OQV$
M<?04 5M/LEC496M+R$]!2H@7I4E $?DIZ"CR5]!4E% $?DKZ"CR5]!4E% $+
M0+Z"D^SICH*GHH Q-5L5EB("]J\[UCP^9)"0E>MR1!Q@U0GTV-P25H \>LO#
MK+/]SO7I_AJS^S6P!&.*EBTF-9<[:UX(!$F * )@:?42_>J6@ HHHH ****
M"BBB@#F?&1_XE;?2O"+XYE;ZU[KXT_Y!;?2O"+W_ %K?6GT KJ:4G%1KG=3G
MH0#9?N5ZI\+O]77E<GW*]4^%OW#0!ZM1112 **** "BBB@ JCJ/^H;Z5>JCJ
M/^H;Z4 > >+O^0P_UK&!P*V/%W_(8?ZUBYXIW #US2@T8^6FKUIK<&;?AH_\
M3:+ZU]":?_QY1?[M?/'AO/\ ;$7UKZ'T[_CQB_W11("U1114@%%%% !1110
M4444 %%%% !1110 4444 %(?NFEI#T- 'AWQ/'_$P_&N%4_N@*[WXG?\?WXU
MP"_=JDP+,!PM-(^?-)&>*=UI; 6+$9O(_P#>KWOPW;H=)B) Z5X-IX_TR/\
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MTG%.J)^M $HHI%Z4M !1110 4444 %%%% !1110!'*NY,5!# N>15HC- 7%
M#/)7T%'DKZ"I** (_)7T%'DKZ"I** (_)7T%'DKZ"I** (_)7T%'DKZ"I**
M(_)7T%'DIZ"I** (6@0CH*S-1LED0@+6S4;QAQS33 \TU70S*[86N4O_  XR
MY.PU[9)81OU%96I:1&8SA>U%P/![JQ-N2"*H-)M.*] \0:0P=MJUP=_8RP,2
M1WI "_.F:KM]ZI[;_5<U"X^:@"] ?]'(]JQID*S$^]:T!_=XJK<QYY% '6>$
M=0\DHI:O:=)NQ+;ISVKYSTFX:"X09[U[7X6OO,CC&>U '<44BG(%+0 4444
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M^Y5=>&J9SA*Q9];2C[HU/O5WO@4?Z8OUK@H^37>^!3_IB_6KB>-F7PGLMO\
M<'TJ>J\!^058K5;'R<]PHHHIDA1110 4444 %%%% !1110 4444 %-QS3J*
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MF3>;"#GM6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,?0N6 Q>1_[U>_\ AG_D%1?2O ;/_C\C^M>_^&?^03%]*3=Q&U1112 ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y3E.<5Z_\
M#KBR7Z5Y!,-N*]?^'/-DOTK&"/K\U?N'I4?W*?4<?W13ZU1\C+<6BBBF(1NE
M5KD_Z.Q]JLGI56\'^C/]*"X[GE'BF?>\B9KS^8;&-=GXH?;/(?>N)D?>U<\M
MSZO+M+$&?FS4@.12;.*512>Q[U[H3/-#'%&,'-!&:ECL+GY::.:#TQ2J,4"V
M%4_-BDFXIR#YZ6=<C-4MR9#8^F:",N*BB?Y]M6PG[Q?<UHCS<0['8^%8"TT?
M%>Q:?#Y<2_2O/_".F_N8Y,5Z1;C" 5<5H?,XZKS.R)Z***H\T**** "BBB@
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MOI2:L(VZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%?/GAK_D+1?6OH/3_P#CRB_W10P+5%%%( HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%N'K368 =:Y]M8 _BI&U<%/O4 ;Z-DU+61IEX+ANM:] !1110 4444 %%%%
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M** "BBB@ HHHH **** "BBB@ HHHH **** /E*;M7KWPY'^A#Z5Y%..E>O\
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MF>.X=URS8KS289D*T[@10#Y:4#YJD5<"C%6Q$<1VWB?6O9_!\N8HQ[5XRO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT_O6^M.V@%8]*%IH.32GBF@Z"3?=KU/X6G]W7E4Y_=UZE\*S\E*P'K-%%%(
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M_K67'][-2QRD7<?UJ!GT!X9GW6$8SVKIATK@_"%SNMHUSVKNU^Z*; 6BBBD
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M_P!:OUKUGP:?W<=>3Q#,H^M>H^#Y,>6*74#U>+_5+]*?4</^I7Z5)4@%%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMV!M^&C_ ,3>+ZU]"Z=_QXQ?[HKYX\-C_B<1?6OH;3O^/&+_ '10T!;HHHI
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M[_4K]*\)\%'&I#ZU[KIIS"/I0!?HHHH **** "BBB@#F?&7_ ""V^E>$W_\
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M%% !1110 4444 %%%% !1110 4444 ?*<ZXQ7KOPX'^A+]*\DN>@KUWX;_\
M'BOTK*!]1F7P'I4?W13Z:GW:=6B/F'N(: :1J!TJ@Z"&FYI3UIAZTSG;LQVW
MFDE7,3#VJ1>E-<C&*DZ(L\T\7:?OC<XKRNYM#$YXKWKQ!:"6W;BO)=:LO*9N
M*YZBU/HL!.Z.5!PV*L*,BJS\3$5:B^[69]'2=T1-UQ1"/](3ZTC'YZEMQNNH
M_K6B1PXN6A[/X/M?]$C;':NZ ^45S?A&$#2HCCM73@<5M$^/Q$[S =*6DZ4
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MKT444 %%%% !1110 50U(_N'^E7ZSM2_U#?2@:/G[Q@/^)PY]ZR(NE;7B_\
MY"S_ %K%CX%6(<Q[4U1@T'[U.J=@-KPU_P A6+ZU]!Z?_P >47^Z*^>_#1_X
MFT7UKZ$T_P#X\HO]T4@+5%%% !1110 4444 %%%% !1110 4444 %%%% !2'
MH:6D/0T >(_$[_C^_&N#B7BN]^)O_'_^-<+']RJ0"L,FG?PT4'I36PBSI_\
MQ^1_[U>^^&5_XED7TKP'3CF\C^HKZ"\,C_B51?2E<9MT445(!1110 4444 %
M%%% !1110 4444 %%%% !12 TM !1110 'I7,^)KC;8RC/:NE;[IK@?%UX$B
MD3- 'D=Y)F^D^M5V?M3;ALW3GWJ(D[J +,3[3FH+D[VI';:M$0\Q@*=M!,A6
M(YH?(-;<.F,Z@@5'-I$F[A32#J9*-@T,W-:0TB7^Z:#I$OH:$,SB^10KX%:
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M335&TU94 K4$@Q0!:3F.J<JE235F!QMYJ.[P5XH J!]QQ6QI&G-/,..]9%K
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MW2J]C_QZ1_[HJPW2@!B')J2HU&#4E !6-XDD":3*<]JV#TKD?%MYMT^5,]J
M/#-3NC)?RC/\5.C;]Q6?=<W\A_VJNQ_ZB@".$9D-5[C_ %V*LV_WS4+C=>JO
MO0!WOP\MLW@..]>S1#8 *\T\!6GER*V*]/V]* )!TI:0=*6@ HHHH **** "
MBBB@!KG IB\T]AD4B#% &-XBA\VQ9<=J\4U^W\B5ACO7O>H1>;"17C?C:U\J
M<\570#@R?FJ9#D5"1\^*D' J@!?F?%6;>;R+N,9[BJ\8PV:;(?\ 2XS[TNH'
MT+X4G\S2XN>U=)VK@O!MWFRB3/:N\4Y45 "T444 %%%% '/^+?\ D$2?2OGZ
M^&;F3ZU] >+SC2)/I7@-Q\US)]30!65<&G$9I?X\4LGRBJ6P$1?:*Z3PQJ'D
M/UKEI?NYJSI=QY;'F@#TZ772L1.^LY?$[;R-_P"M<I-J)*[=U4A*V<YHW [O
M_A)VS]_]::_B=@/O_K7$><?6FO*Q'6E8#M#XH;'W_P!:C/BIN?G_ %KB6E;I
MFHC(WK18#H+[Q$TLN-]4)KTS+UK*\IG;=4Z@@8I[@,E3<<U$HVFK6,\4UH\5
M("))VITO*YJ,+CFG$Y&*K2P$)E*5) QG;%5Y$)?%;6B6!DF'%2!HZ3I>^5#M
M[UZOX?TT0HAVUAZ'H_"MMKOK* 11J,=* + ^7 J8=*85YIXZ4 +1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 <AXGA\RT(QVKQO5(_(O1]:]
MTUB'S("/:O%/%D?DWI^M2V>MA6=CX(N]\Z+FO5!]T5X?X!N_]/4$]Z]MB</&
M"/2JMH<V,^,?FG+40^]4JT^AYWVA]%%%(T"BBB@ -)0W2FK3'8S=;?9:,?:O
M$?%4V^<_6O9?$K[+!C[5X5K\WF7)P>]2SLPVC-3P:F=23ZU[I:KB%?I7BW@J
M!OML;8[U[? ,0K]*!8IZCP*6CM24SB;!NE>3_$Q]O2O5V^[7D/Q0)I2V.K#*
M\CRY929.M7%8XYK.A!,M:#\**Q;/HZ$;B,>:8>:">*$YJ.8[E 514\>%ZU&O
MWJ=(<#B@Z84RPS*5JBZDFE60DXJ8*"*6YT*&HV+ ZU9W@"J;':W%-,AJD6]!
MTQRW%-3K3A\PHQ@T,SE(ES\M,'6D!-(QP*0H[BL>:.HIO6GK3.E.R <4=Q0U
M-7+,,4T>?BI:'H'A"#<4.*]?M!BU0>U>9>"8,PJ2*]0A&(5%:P/D<PE>2)5I
MU-6G59YC"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %'6BB@"">
M%7C;([5Y?XFT@R3NP6O5B,C%8VIZ:LJ,V* /!KRR-LQR,5GM.OW:[?Q9IIB#
M%5KSB59%N<$'K0!H1L :E+*150DA13?--4D MQSTJ.,'O4B_.>:D"8I[@V21
M@ <U!(/GXISL10O/-#$,;.*%)%2[<U$1AJ2V&/S3#R:<W2A>E'0$(PR*%'RT
MHZT_%*P,9%\KU:\P55;Y13/,-" L3,"*@_@-(K[CS3F&5XHZ =!X&.-4'UKW
MO3CF$?2O!O!49&I X[U[MIF?)7/I2 T:*** "BBB@ HHHH YGQE_R"V^E>$W
MW^N;ZU[IXT_Y!;?2O"+T_O6^M.V@%<&ID/RU6!^:I<_+2 KR_P"LKUOX8_ZN
MO(I>M>M?"XYCIL#U6BBBD 4444 %%%% !5'4?]0WTJ]5#4/]0WTH ^?_ !B/
M^)L_UK&MSBMKQA_R%G^M8"'%.P%E^3FDW8I,Y6H<\U6P$K'(IJC!YI%.33W&
M!0@$(YI&&:4?=I%Y-(!5Z4 8-(>M*W2A@AI'-/."*0=*1>M%P%XQ2*.:#UI3
MP*$# CFFR<BG#I3.IH W?#B_Z9']:]_TC_D'Q_2O!O#H'VN/ZU[UI/\ R#X_
MI4@7J*** "D/0TM(>AH \2^)O_'_ /C7"_\ +(5W7Q-/^G_C7!@YCIH+CX>E
M.:F1\4Y^E.P7#-'%1 D4Y3S1:P#^E'%-8\TN?EH 7BCBFJ:3/S4 /XIN.:'-
M'\-'0$(PS2C&W%(O-'\5" 4#%,84]J0CY* 8V(9-=%X6'_$WB^M8, YKH/#/
M_(7C^M2![]9?\>D?^Z*LU6LO^/2/_=%6: "BBB@!'^X:\Q\9W>/,3->ERL%C
M;Z5XUXVN/],=0: /.YES<N?>K2<18J-ES(33ATQ0 V'Y7)ID'SZI&/>G.=HS
M2Z5&9-5C..] 'M_A"VV0QMCM7;]JYWPY#LLXC[5T1Z4  -+42GYJEH ****
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M/.D@P7V>G->W^$+C?:CGM2N;8J-U<ZP+S3P*%Y%.IH\JP4444#$- H- H%U
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M%<SX<M_+MUX[5U&/EK1*Q\ABIWF*M.IJC%*QQ3.1BT4BG-+0(**** "BBB@
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M5 2CI2T@Z4M2 4444 %%%% '+^-?^06WTKP2]/[YOK7O?C3_ )!;?2O [_\
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MC-,8YIV[Y:%L O6DSSBD!I,_-26X,?TI".]#'-)GY:&/H*/FI^.,5$AQ3F?
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M.*A@B"(!4]:'RU27,[A3'Z4^D(S00-CI](!BEH **** "BBB@ HHHH ****
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M>]9PT?C[M '%_8G]*3[$_I7:_P!C_P"S1_8_^S3; XK[$_I2_8G]*[3^Q_\
M9I?[(_V:$!Q7V)\=*/L3^E=K_9'^S2?V/_LT[@<7]B?TH^Q/Z5VO]C_[-']D
M?[-# XK[$_I1]B?TKM?[(_V:/[(_V: .*^Q/Z4?8G]*[3^Q_]FE_LC_9H3 X
MK[$_I2&R?TKMO[(_V::='_V:+@97AZT8749([U[KI0Q81CVKS;2-,\N9#M[U
MZ;8KMM4'M4L"QBEHHH *0]#2T'I0!XU\2+0S7F0.]>?II[JV<5[)XNL/M%QG
M&>:YC^Q<+G;5)@<'+8R'M4,5A().AKT$:+D?=IJ:)A_N4=0.'DL9,]*<MD^.
ME=Q)HO\ LTW^Q^/NT[ <5]B?TH^Q/Z5VO]D?[-']D?[-*^H'%?8G]*/L3^E=
MK_9'^S2?V/\ [-%P.+^Q/Z4?8GQTKM?[(_V:/[(_V: .*^Q/Z4?8GSTKM?['
M_P!FC^Q_]FA <5]B?TILED^SI7;_ -D?[-(='R,;:+@<%#92;N172^%[5EU6
M,X[UK#1<?P_I6KHFF>7?HVWO4@>H60Q:Q_059J*V&($'M4M !110: .4\6 F
MW./2O#]<MI'NS]:]\U^'S8B,5YGJ&D>9=?=[T <#;Z?)GH:E>PD#=*[^#0@!
M]RB71!_=H X1+!V8<5Z;X/L2D2$BLJ'1_G'RUWWAZP$4*\4 =);KMB4>U34U
M!A<4Z@ HHHH **** "BBB@ I*6BDP"BBBF 51U!-UNX]JO5#<)NC;Z4T!XGX
MFTXM<2,!WKC)+%PW2O9-9TT2.WRURTVB_-]VCH%CA8+)]_2I+G3W["NUBT;#
M?=J>31MR_=HL!PFEVTB70^M>U># PB&?2N%M](V77W>]>C>&H/)0<5# ZFBD
M'2EJ@&OTIJ4\C- &* ,'Q.F_39![5X?J%H1</QWKWS6HO,LV'M7E6IZ:?-8[
M>]- <4UN<5 86%=,VGM_=J"336_NT-6 YIH6S2")JZ!M-;'W::FFMG[IIK8#
M%\IMM,$+5O'3GSC::=_9K?W:+CV.?\ELT>4QKH&TUL?=IB::Q/W336HKF.EN
MQ%3QVQ]*W(]-;^[4XTU@1\M%P.:?2Y)#D TL>C3%NA_*O2=+T)9802M;=KX:
MC+?<'Y47$<-HNB/\NY:]$T;2$7;E:OVVAI#C"BM:WMA%C J;C$2PC4<**GC@
M5#P*EHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 AK/U6/=92#VK1JM>+OMV'J*:*B[,\!\26OE7<C8[UG:/=F.[C
M&>]=KXPTT@.^VO.H<PWJ^QJ6SUZ7O1/H/P_=^99QC/:NA4UYWX2U#='&F>U>
M@1ON4&@X<13Y9%@44T&EIG(PI:2EH$B-N*8.34KC(J-1BJ6QHGH<MXY_Y [C
MVKPJVXU%?]ZO=O&ZYTE_I7AT$?\ Q,5_WZEG10=F>^^%A_Q*(C[5N YK$\,?
M\@>,>U;:BF8RW9*O2@T#I0:1DQ&/RUY%\4#DUZXP^6O(?BAPU*6QU83XT>9H
M?EJ13BHXE^7-28KFEL?:X9>X.8]Z:#FE/2D48J;'8MA=W.*4\4W'S4YZ$7?0
M.V:;G-._AIBC!HZ@WH.S@XIP.*81S3NM-D2>@I]:;]ZG=L4T#!H,&+TXH#;*
M".]1N<TT:11)C>V:2?Y$J6!?EJ*]/RU2W,:TK(?IO[R[1?4U[7X3L?*2-\=J
M\C\-V1ENXVQWKWO1+?R[2/CM6J1\SCZFEC:7I2TE+5GAA1110 44E+0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5&S8-25$R\T &ZG#
M!6H]M2KTH K3P!QTK-GT\.I^6MS%)L% ''3:&&/W:JGPZ"?N_I7=>4OI2>2O
MH*;8'!MX<!_A_2@>'!M^[^E=YY*^@H\E?04@."7PV ?N5,OAX#^&NW\E?04>
M2OI3N!QO]@C^[5^TTD1C[M=)Y2^E C4=J0%2UMQ'VJ[@4AP*3=3L ^BBBD 4
M444 %%%% !1110 4444 5KR+S8L5AOI88GY:Z1AD4T1CTH Y@Z0,_=I/['']
MVNH\M?2CRU]*=P.5;2 /X:UM)M?('2M)X@1THB3;2 EHHHH **** "BBB@ I
MDB[E(I]% '-7FE"68MBH?[&']VNI* GI2>6OI0!R_P#8P_NT?V,/[M=1Y8]*
M/+'I0!R_]C#^[1_8X_NUU'ECTH\L>E '+_V./[M']C#^[74>6/2CRQZ4 <O_
M &./[M']C#^[74>6/2CRQZ4 <O\ V,/[M']CC^[74>6/2CRQZ4 <O_8P_NT?
MV./[M=1Y8]*/+'I0!R_]CC^[2?V,/[M=3Y8]*/+7TH YN#3A%(.*Z*!=L0%,
M:(;NE3J,"@!:*** "BBB@#"U2R\^3.*I_P!D@I]VNC= 3R*<L8QTI@<VND #
M[M(-(&?NUTWECTH\L>E%P.9;20?X:;_8X_NUU'EKZ4>6/2BX'+_V,/[M']C#
M^[74>6/2CRQZ4@.7_L<?W:/[&']VNH\L>E'ECTH Y?\ L<?W:/[&']VNH\L>
ME'ECTH Y?^QA_=H_L<?W:ZCRQZ4>6/2@#E_[&']VC^QQ_=KJ/+'I1Y8]* .7
M.CC^[3[73?*N <5TOEKZ5%Y0#YQ0!-&,(![4Z@=** "BBB@"E>0>:N,5@RZ.
M&ESMKJB :;Y:^E '.II0 ^[2/I0/\-=)L'I2>6/2@#F4T@!L[:W+*W\F/&*M
M>6/2G  4 +1110 4444 %%%% !1110 4444 %%%% !37&5(IU% &-=68D8\5
MGOI )^[72[ 32^6/2F!S"Z0!_#4ATD8^[71^6/2C8/2BX'*KHH$N[;6Y86OD
MCI5[RU]*<% J; +1113 **** *]W'YD1%<U<Z,)&)VUUA&13/+7TH XH^'P3
M]VF-X>!_AKN/*7TH\E?04V!PA\.#'W::OAL _=_2N]\E?04>2OH*0'!_\(V,
M_=IW_".#^[7=>2GH*/)7T% '"'PX,?=IJ^&P#]S]*[WR5]!1Y*^@II@<2OA\
M#^&I/[!']VNR\I?2D,:CM2 QK&P$,87%:D,(4]*E"CM3SQ0 N!2T@.:6@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %(>E+10 Q1BGT44
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *C>I*:130 O2G4@Z4M(
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@")_O5(O2D*Y-*.E  >E1C[U2TP+S0 ^BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS;M+<1H*NBHQ\HI5/--GS\G=CB*44&FCK09MZCZ***104444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS\G=A3&IQIIIHRD-%2"F8IXH8HBT444C0**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3
M-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M18NV5LJ1 8JPR5*@"C%/VYK0\*4[NXV/A:DIO2E!H,[BT444 %%%% !1110
M4444 %(:6B@!!2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44F:7M0
M W/-(_(II^_4G:@"%0<U,*C9U7K3/M*#O0!8HJ#[0OK2BX4]Z %(^:I!TI!A
MN:=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4W/-.[5$?OT 2U$1\U2#I1B@ '2DSS3JB/W
MJ )": <TQ^E*G2@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% $6/FJ7M4>X;J<6&* %SS2U%G+5(* %HHHH
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-V\TZB@
MHHIKG"YH 4L!4>Y<]:R-2U$6XZXK'_X2 9^]0!V.0U. P*P=+U,7+XS6\IR*
M %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I&.%-+4%P^V-OI0!1>Y GVYJ5[@8'-<GJ&I^3=GFJ[:Z#_ !4 =U'*
MI7.:E$J^M<&OB,*,;OUIP\2C^_0!W7FKGK3PZGO7!KXD!;[]:%MK@D_BH ZW
M<*6L.WU$22 9K:0Y4&@!U%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% #6.!55YP&ZU'?W/DJ>:Y:ZUH+*1NH [
M&&4-WJ7'.:Y73M7$A'S5TUO)YD8- $],D<*M*QP,UAZGJ'DHW- %V2Y /6K$
M,H8=:X5M<#/][O6MINJB1U7- '6CI1443;D!J6@ HHHH **** "BBHYGV1DT
M 17,H0=:I_:AZUBZMJPBR-U9"ZT"/O4 =Q;3!VQFKU<IH-_]HFQG-=1NYH ?
M132<"E4YH 6BBB@ HHHH **** "BBB@!M**04ZF2D%%%%(H*2B@T"N+1110,
M*::=330A,!2XI!3J;"(QAQ5=XE93D5:-0R4C2+..U[3EDC;"UYIJFC-ECMKV
MVYMA*I!%<YJ6C*T;G;VJ7L>E2J]#PFYC>"8@9&*U]$OY(I%RQZU8UK3'6^?"
M\9K)*M;,.,5-RYZZGL^AZVGV906[5R7Q$O%N<;37.:?K3QX7<:AUV^-V!DYI
M-Z"H4_WB9EP-A:F>0$54&0E(A9VP*#Z!/E@2>69&P*U]-TIY''!HTRQ:61<K
M7HN@Z*#M)6J1P5Z]D.T#2-@4E:[RTMUC0<5#96"Q*,"M+;M%6M#PZ]9S8\
M4 YI/X::AYH.1DF*!110386BBB@84444 %%%% !1110 4444 %%%% !1110
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M/>N]MI-\2_2O*-)NOWZ\UZ1I<^^->>U &O1110 4444 %%%% !1110 4444
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MM(*6@$%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=[V"YZ4 >A*<BG5'"<H*DH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT#1V5TW+7I6GZ<B(/E[46NC) PPHXK8BB" "JBK#Q&+]HK$8A"C@5+&*?MH
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M#0M0QM4F@#T%#E:=4-L^^%3[5-0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110>E
M &)XE;_B5R?2O%RW^E29]37L?B5O^)=(/:O%IFVW3_6@"Y9IOO%^M>I^&X=B
MJ<=J\UTA-]RA]Z]7T6/;&OTH W:*** "BBB@ HHHH *J7O,9^E6CTJG=_P"K
M/TH \B\5\:ACWK+4?(*T?%A/]I?C6;G$0H CD?G J,PECG%* 7D%;-K8EPO%
M &]X4A*HO%>CPMLMQGTKE/#]GY<8XKI+I_*M_P * .<\07NTL :\VU6Z,C,
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M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8GVJ2Q</&OTJGK[[+)C[5('EOB63S)3]:YZ!OWN*U]7D\R1OK65:Q$W JK:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNI#[US<.?.'UKK/$*9N)/K7,*FV8?6JL!Z#X7'S)7H*?<%<%X8'W*[Y/NBI
M6BBB@ HHHH *BN?^/=_I4M17/_'N_P!* /$_$?\ R&'^M4&^[Q5[Q*<:N_UJ
MG"-^!0!7>!W' I;>SDSTKI;'31,!\M;$>AA1G;0!Q8LGSTK0L=/;=]VNG_L<
M?W:OV.DC=]V@"MI&G;95)%=S!&$B'TK/M+$1D<5JJ,+B@#"\1$_V?)]*\<8_
MZ9)]:]F\1+_Q+9#[5XRW%[)]:: N:>F;Y/K7K&BQXA3Z5Y;I2YOD^M>N:6F+
M=/I2 TZ*** ,W6$!L9#[5XY?C_3)/K7LVK_\>$GTKQJ__P"/R3ZT 4K-BNJ1
M_6O;-&?-C']*\0M_^0G']:]FT)LVD8]J8%K506MW [BO*M5M3'<.Q'>O8)X?
M,0CUKA?%.G>5"S@4@/.;AL'-26%_(LF,FHYD8L>*;;1;7S5,#L+'5&!4%J[+
M3+]2%RU>3M=&&4 &MZQUAD5?FHL!ZW#*L@R#4S=*YSP_??:(@2:Z,<K2: RM
M3@$ELY]J\?U>$K?/QWKVV[3-N_TKRS6[,_:G..](#FXVV"I%OWC;@U7N08WQ
M2;,KF@#K=%U)FQN-=KIU\KD#->5V-QY(ZUT&D:J?M(7=5- >HJX8#%2J.*S-
M.F\Y <UJ#I2N!S'B,?*:\POU'VEOK7J'B/[I^E>8:B<7#4@"S7]^F/6O7_#_
M /R#T^E>1:=\TR_6O7]!&+!/I0P--_N&N(\1='KMW^X:XOQ&N(W-- >:7Y_>
M'ZUJ>&UW7J ^M9=U\TK?6M?PT/\ B8)]:-V!Z_9QA8%^E3?Q4EM_Q[I]*DQS
M0@%/W:XSQ-;[H)#BNS/2N?U^(-:N?:D!XU)%MG?ZU9T28C5XU]ZFO(@)G^M4
MM(XUR/ZT >[V?-G']!2W?_'LWTI-/YLH_P#=%278_P!';Z4 >6^)\DM7'#[]
M=OXF3[U<8RX:@#N/ W_'R/K7I_\ #7EO@4_Z5^->I#I0!P_CMRMI^%>;0G<#
MFO1_B#Q9?A7F-L_% &E;2>4^172V>I;8<;JX_P PBIH[MEXS0!T[:HVX\TG]
MJG^]7/M,VW-5WN6!H V-5N_.AQFL$8$;5(TS2C%02!@I% &YX+;_ (FWXU[*
MC#8OTKQ;P>"NI ^]>N),=@^E &G1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2X4P@9KR."4PRY]Z[31=3(0<T >DKL(SD4CO&J'D5@0:GE1\U4[_ %C8#\U
M"Z_>K'&=K54T/4=^ 6KE=8U<S C=2:'?E749[T >QVI5HP15K%86CW1DC7FM
MX=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;;#NQ57K,OUI >@>%U^Y7?I]P5PGA@<)7>+]T53 :_2FQT]^E-3K2 DHHHI
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MLE\-UJX]J\D\36C;W('>F@,*QO=LZ\]Z[VPU<>0HW=J\P2-XY,UM6EZR #-
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M3=!44Y A/TI= /-/%R;5)KAU;!KN_&+@QG%>?Y^;%(#OO S9N1]:]0'2O+/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (W2F(>:>>E-48
M- #Z*** "D I:* "F.<4^FL,T "'BD==U*HP*=0!&J8J2BB@ HHHH **** "
MBBB@ HHHH **83S3ATIV #TJ)CS4QJ(KDT(!R'-/IJC%.I %%%%  >E1Y^:I
M*9CFF@'TUNE.I&&12 8AS4E,08I] #'/-*O2D8<TY1Q3Z (PS2!:&.*<O2D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!&PYIZ]*,4M.X!1
MBBBD 4444 %%%% !1110 4444 %%%% !1110!&XIR]*4C-+0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4AZ4M% '+>+;5KBR*KGI7EL
MEDUMN# U[C=VRSQD,*\\\2:9LF.Q: .!(*R9%2_:75<9-7Y-/<'.VJ$]I(&Z
M4[@0I._F9R:G:0OWIJV;]<58CLY#VH8!:VYF< "NLTC265U)6J6A:>QN5W+Q
M7H]EIZ*JG%" O:>GEVRCVJW3478N!3J0!1110 4444 %%%% !1110 4444 %
M%%% "-TIBCFI*0"G<",CYJD'2C'-+2 **** "F.*?2$9H :G2GT@&*6@ HHH
MH **** "BBB@ HHHH **** $/2HP/FJ6DQS0 M%%% !1110 4444 %%%% !1
M110 5%CYJEI,<T +1110 4444 %%%% !1110 QQ2KTI2,THXIWT ****0!11
M10 4444 ,<<4(.*<1F@#% "T444 %(>E+10!$H^:I:3%+0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #7/%8M_
MIPNGSC-;,G2D0 T <C<Z$JIG;6'<:,-WW:]#O%'E]*Y^=1NZ4 <W%HX)QMJ]
M%H:Y'RUJ0*-_2M*)1D<4 4;32A;X?;6]:?=I)%'DT6= %RBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0K!WD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M".]8FJZGY1/S5STVOX/WZJQGS'=&XA]12?:(!W%>>GQ$<_?_ %IDGB0@??\
MUJN1CYT>C"Z@]1433PENHKSE/$Q)^_\ K4L?B(M*HW=Z7+8KF3/4;5$89%7U
MP!BN>T*[\^W!SVK:5^:EHM;%D4ZF#I3A4C04M%%3;4H****8!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4E+10!'*NY"*P+S31+(3BMUY *AW*3VIDG.?V.,_=
MJ5=* [5O':!VIF]?:GJ+0Q'TH'^&G)I@ Z5JM,H/:I$96%&I+2,?^S!GI2_V
M:,=*V=RT96GJ*R,4:8!VH.F ]JVLJ:-RBC4+*YC#31CI3#I@STK<RM-9E%"N
M*R.>N--"KTK(G@$9-=-J-TJ(>E<;J.J*&/(K6!A5T>A=A4&K&P8KGH-94?Q"
MK/\ ;*8^\*W1BV:KH*K-BJ#:NI'WA4#ZHOJ*T2,F]363 IZ@&0?6L5=47UJ>
M'4E,B\CK6<SJAL>B:./W ^E:>.:Q]#E\R $>E;-<4MSJ6J&/TI(Z5QQ21CFD
M6A["G**#2U)04444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?#R'^&D3PZJR [>]8RG<Z(1LC>\'1&.R4'TKJJRM'MUMX0OM6N,&N=O4V2N
MILE/%(PS4FJV$C-25%TJ1>:EEH=24M%%@"BBBF 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDSU@^+!_?IX\5C'W_P!:\MWW7O4BO=8[TFB7.S/3?^$L&?O_ *T[_A*A_?\
MUKRWS+K=WJ4/<X[T^70.<]-_X2H?W_UII\5@?Q_K7FF^Y]ZC=[K/>DD'.>H#
MQ4"/OTH\5#/W_P!:\Q1[G'>G*]SN[U7*2YG?ZIXC#PGYZ\]UC4#<,W-2W)N&
MC[UD_99I&Y!K6*L95-2D"Q-'FE>]:::;(1]VH9M-E[+6J9@43<DC&:9\SFK
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MSD7FNIB?<*YY'9!Z$M%%%26%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\SJ@7:*2EK,V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1124F M%)2T( HHI*+Z@+1113 **** "BBB@ HHHH
M**** "BBB@ HHHH ***2DP%HHHIH HHHH **** "BBB@ HI**F^@"T4450!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%)2; 6BBBF 4444 %%%% !1110 4444 %%%% !124M),
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M04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** $I:2EJ4 44450!1110 4444 %%%% !1110 444E)@%%+24@%HH
MI*?4!:***8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4
M44M3U ****H HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI4##YJG7I3!"T444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3:6DIDL6BDHH"XZBDH
MI#N+1110,**** "BBB@ HHHH **** "BBB@ HHHH **** $I:** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***2@!:*2
MEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **2B@!:*2EH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M124FP%HI*6A %%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3ZB1PU2"I9I$6BDS2TBPHHI,T 1..:51Q3C36<*N:+$B]Z7M5![^-&P6IO\
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M:IN+8:MZ<#GG(NWOB,H3\]9;>)R?X_UKD;^[9V.":S1,_J:WC35SGE,[:;Q
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M)J81!ZIV\96KROMKHC'0Y'+4C:W YQ4/?%66DR*@VY;-7&)+;&D<4 9IY'%
M%:6T,^8K2C!J.K,BYJ(K6;1K&6@Z(_-5Y3@5108-65;BL)1-U(V=/O/*8<UW
MNAZGDK\U>5>?Y9ZUTNB:EM9?FK&<=#JA(]TTVX#Q#FM/.17$:'J8:-1NKKK>
M7>@-<DHG7!E@#%/%(.E(3BH-$./(J!T&<U-GBH'?G%"0V[ IP:D+8%, [U4O
M;CR5/--(S;L1WUR$0\UY[K^K^6S -6AK6MB,,-U><:QJ?G.?FKHIQ.:<M1E_
MK#,Q^:L2>^,A/-5YI2[=:B .:[(Q.5RU'%N:!\U&VG*,5JD928@3FG^6-M%.
M+<55C)LC5>:>PP*:#S3F.13L3<%&:8Z<T]#0>M'*-/4:B[3FM&UO#$1S5 4C
M';S6,XG339V6GZT00-U=_H.I>:%RU>*VMR58<UZ!X:OON\UPSAJ=T):'K]HV
M],U8)K*TF??$.:U<9&:YY*QU1=Q5Y-2 4Q1S3^U2-L1AQ6'KG%E)]*UY),5A
M:])_H$A]JTBC&HU8\+\0R8U!_K6.'JSX@GSJCC/>J0Z9KK@CBJ,E\RG!\U7-
M.#8KI43FE(E,G-)OXJ(FDS2<2HRT)?,J,R?O!]:;FH\YD'UK*42E(]B\#+NM
M0?:NCO[KR5(S7,>!Y-MD/I5C7;W;NYK.,=2N8R-8U8X8;JX:^O#,[<U:U2^W
MR,,UA%]S&ME$S<F2+'N-.:(!:$;%/+Y&*T42'(SY&*OBI4;(I9(<G--C'S8H
M<04A9%R*;%(8F%6'7Y:K%>:CE*YCIM(U0HZC=7I_A_4#(J\UXG9R%)E&>]>H
M>%YOE3FLI+0WC(]6B8& $^E<KXGO!!&V#6E-?""R#9[5YSXFUH3;E#5SQB[G
M1*:L8E_JI=F^:N9O9O,8TZ>X)8\U2=]QK=1.24B$KEJE"8%/2//-2E.*WBC)
MRT(*-O%#<4JG-="CH8J6I7=BAJ[I]^4F S4#P[AFJ\2F.:LYK0VC(]9\-7^Y
MEYKU'39MZ+SVKPWPU=[9%&:]>T2YW(O/:N&JCOHR.H[4W'-"'(IU<36IUW%Q
MQ7)>+@%M&/M76$X%<=XUEVV3?2M(+4F;T/%M4D_?/]:R-]3ZC/F=^>]5HOF%
M=\(Z'FU'J)YF'J]')E*S7&'JW&?DK91,7(D=JB,Q6AVS4#"ERC4M0>4L:U=%
M_P"/M#[UEI%GFKMA)Y5TOUHY2N?4]HL+H1Z8O/:N6U[6"@;#4Z/4MNF@;NU<
M7J]]YSL,U*ICY]"K=ZFT[D$U%'&)1DU1526S5Z&38,53B9-ZD4L 4U"%YJU(
MV[FJ^<-1&)/,.,8Q529*O Y%02IFAQU+C,K02%'%=;I5^44<UR8C^:M*UEV+
MUHY33F/5/#NJ%YU7=WKU&T;= I]J\'\+W7^FKSWKVO39MULG/:N+$1U/0H2N
MC29<T@2G YI:YCH(RM<WXI;;9-]*Z1VKE?%K8L6^E:06IA59XAK=P1._/>L:
M*4DU>U8[[E_K6:@VUV*)QR9.TG-/5^*KGDU(.E:J)DY$F^CS*B-%5RD<Q.'S
M2(_[Y1[U%G%+"<W"_6HD@C+WCT3PO'ET->OZ:N+9?I7EGA2+A#7J]@,6Z_2O
M/FM3U(;%L]*P-9EVQO\ 2MUCQ7+>()=L;_2BFM1U'H>/>+KL_:&&>]<<TQ+9
MKH/%3;KIOK7/)'FNV,3BG(FBF)-6&?BJZQ%.:=G-:J)ES$JOQ4+O\]2*,"H7
M7YZ&BHLLJ_R4Q9,M0!\E1K]^L91-$]3T+P7'OD6O9--CV(*\C\ KND6O9;9=
MJ"N6J==/<M4E+25@;C7.!6#JUT(U/-:E[+Y:9K@_$.I[0WS5M3C=F%25C&UG
M4_O?-7"ZCJ!9R,U8U74]S$;JP)',K9KJC'4XYNXV5MQS42\FI=M($Q6T8G.V
M-<8I@7-3$9I-N*OET)<B+H:<>E/V9HQVJN705RUILYAE!]Z]+\.ZEE!\U>5K
M^[.:ZOP_?;0.:YIQN=,)'2^(;[*MS7FM_=$W/7O74:U>;\C-<A,A>7=4Q0I2
M+:S'RJ@:;)H(VQU77EJUC$PE(D+$TY6P*-G%,)P:T<1*1)OJ.1L"GJ,C-13#
MY:PFC:#U.T\!OONU'O7NEFF(E^E>%?#T9O%^M>]VJXB7Z5R3.ZF65I)/NTHI
M'Y%8G2MBJK_O*LD_+4&S#9J&[N/*3K0E<5[$=Y,$4\UQFLZIY>[#5:U;5P@;
MYJ\\UK5][,-U=$(Z&%20FI:VQ8C=7.W6H&3/-5KFX,C$YJF2371%'*Y#V?>:
M84IRC%28S6Z1SS8(G%+LYIP.!2%N:TY3%L/+%*L0-)OIR/BFHB<KB- /2HS"
M *G9ZB+Y.*4HZ%19!O,;<5J:=J;1..35%H-PS4(4Q-FN643HA(]7\.ZP7*@M
M7I.F7 D0<UX%H.H>4Z_-7KOAR_\ -1>:Y*D=3KIR.TQFEID+[EJ2N=HZ^@N:
M#]TTE#?=-- <7XG?"O7C>O3_ .D'GO7KOBIL*]>):]+_ *41[UO31R57J5/.
M)I'/%1Q#(S4Y3(KMBCCDQ]IS3;KAJ=#\E07+Y>M+$\Q:B/[NJTK$-5FW&8J@
MFCYJ;%J1)92?.*]9\#MG;7D=H,25ZEX,FV!:RG&Z+A+4]$U"Y$=LW/:O&O%.
MLLMVRAN]=MXBUD11LN[M7D.MSFYN2V<\U,(6*G,1[TSGDU T(;FJ\>5JTCYX
MK=1U,I3(?)Q4;L5.*N$<54E3)K91,W*XB_-2R+M7-+&,5(Z[EQ3FM C+4BL[
MLQR=>]=YX>U,Y7YJ\]>,QG-;6BWGENO/>O/DM3L@SW_0KGS(QS71IR*X#PK>
M;XEYKO+=MR5SU%8Z:>I+0*1N*13S69JMR2BBBD6%%%% !1110 4444 )2T44
MD@"H).E39IC &F)F5=H2AKF+^U+$\5VDL6X5G36(8]*8FCB8].R_W:M?V8/[
MM=*FG 'I4_V$>E4F0XZG)C3>?NU)_9HV_=KI_L(STIWV(8Z57,)P.0.FC/W:
M:=-_V:ZXV(STI#8#TI\Q+@<C_9W^S4;:?S]VNQ_L\>E,;3AZ52F1[,Y9;' Z
M4Y;50>1703V@1#Q6/*0CFK3N9/0KR6RXZ5!Y"9Z5::0$=:J2RA3UK2*T,&R>
M.TC;M4ZV$/H*@AG&WK3A> -C-:*.A/,3M8Q8Z5";*,'I4WVD%>M1M./6FMA7
M!;6+'(IK64;'I5>2\VGK5BVG\QA4N1487#^S%/1:DBTI<_=K<M8/,0'%7DLP
M.<5G*I8V5%LS[#3ECQQ6_;PA0*CAAV]JN(,"N:I.YU4H6%QB@FANE0[_ )JA
M*YHW8EJ*:=8E.33]W%<WK]_]G1N:(Q$YV,GQ%J@57PU>0:[J,C7!PW>M_7M:
M+NPW5R5R//RU=5.F<E2H4FN&?J:6-,GFH]F'Q5R-, 5VTX'%4F."A14;M4C'
M%0GDUT*-CGN )S4HZ4T+\N::&^;%9ME<MT244'[M1[JI.Z(Y1Y&:C*\U(IS3
MRGRYH!.S(,4Y>*3^+%.88%921M%E2Y8YXJYIMRR.O-577>:='^[-9RB=*D>F
M^'M1.Y5W5ZGI<F^%37@6@7V+Q%SWKW/0)-]HA]JYJD;([*;N=$O2HWJ1?NBF
ML*XF=8T?=JHY/F5<Q\M5I5P<U<3.;'&4*O)KF=?U!4C;!J_J%WY49YKSGQ)J
M_##=6T:>IS2J7.;\0ZHQ9L-7*/<-*>34FHW9F<\U6A7-=M.D<LYC@"34H7BI
MEBXIKC%=<:=D<DJFI'2XIN>:FC&14M60)W(^E--2N,&HP,FLU(IQ$ -+@U,B
M9HD3:*TB[F;1!12@9H[U38NHY1S39ONU*!QFHY!D8K)JYO!V*D;%7KL= NBK
M+S7(LN#6SI<_EXYK&=/0WC4/;-!OU,:@M77P,'C!KQK1=6*S(NZO6-(F\VU4
MY[5Q5H6.RC4N:5)FD8\4BG-<YON5IR17->(+@"QD&>U=3<I^[)]J\\\3W>U'
M3-;0U,*BL>,:T2VK,?>E7_5BIM2CW7C/[U$O3%=\(61PU)#<4A&*L!*:R5M$
MYY;$-)WI3P:=MXJG$CF(VZ5&H_>#ZU*:15^85E*!M%GIGA.X$=GU[54\07N2
MP!K-T:\\FWQGM5#4[SS92,UE;4HP+N1FF-1)G-7)8<_-4"KAJW2T(DQ>: W-
M2A>*@?Y7JXK0RO<N;08LU45<2U:C;,>*C*X;-/E&F.<96H?+S4PYXJ58^*SE
M$T3,]<K.OUKT/PU<A%3FO/IEVS ^]=#I-[Y07FLG TC(](UG4=NF\-VKRG4+
MYY9W&>]='J.I^9:;=W:N.;YY6/O4* ^8A=CFFJ"34SI4B1?)FM%$CF%CQBI&
M'%5?,VRXJX?]7FM4K&<BG,*CCZU.PW&F;<&M$9I6+:*#'6?*N).*O(WR55D&
M6I26A47J:NASF.8<]Z]>\,W7F!!FO$[23RG!KU+P-=><ZC->?55CT:+/5X?N
MBI34<0PHJ6N%[G>MB)S@5PGCF7_0F^E=Q<'"&O._&\F;5A[5M36IA4=CQ"]<
MFX?ZU/:#Y>:BG7=<-]:G@&U:]&G&Z/-J2LR.8?O*F7[E1OS)5@+^[K?EL<[E
M=D!/--I6ZTE'*5<M0@;*K[BMR"/6@2[>* ,MNI. 7-\WI^Q;<]JYV61GF.:N
M";*;<U"\7.:AZ%)W$C6HY6*GBI5XJ&09:D.Q*ARM1MUJ1!A*81EJN*,F*AYI
M[#-- Q3@<U:B"9&5% )%.:F8I2C8M2N;WARXV7BDGO7MNA7@DA0 ]J\ TZ;R
M9P<]Z]6\(:CYS(N:X*Z.^A+H>GIT%/[4R+_5J?:GUP,] KRG%<CXNE'V%AGM
M777/$9->?^++C-NXSVK>EJSFK:'CU\=UT_UJFZ^E6KP_Z2Y]ZA W5Z,(7//G
M,C44ZI-N!3.];<AAS:B$4@J1A\M,09-'*)RU$846I_TI![U*R<5!;<7\8]ZQ
MJ*R+AK(]E\(P9A0X[5Z3:C$(%<7X-MLV*-CL*[F)<(!7EU'J>Q27NB/TKBO$
M\NQ7KMV'RFO.?&DWEAZJEK(FHK(\D\0/ON3]:H0)D5)JLN^X_&G6X_=YKTZ<
M#S:D[,250$JJ@YJY)R,5!MP:TDC)3NQW:HR/FI^>*9GYJGE-%+4DQ\E1!<M5
MD#Y*2%-TE9SCH;0>IZ-\/(SYJY]:]DC&$%>3^ HMKK7K2?<%>;5^(]&DO='4
MUVVC-/JEJ$OE0$UDMS5[&3K5ZJ1'GM7E'B/4"2^&KI?$&K$;ANKS35KSS6;F
MNVE#0X:TS$NYW>3\:DM_N\T)#YG-+CRVQ79"F<;F3 <TKK@4J<C-$G2M>0Q<
MKD:T,.:9G!IXY%*Q-]11C%- RU-+8.*ECYYI,9%<#"\5<TB<H>M5YURM):GR
MS63C<VA(T+^<NW6J2@'K4DIW\U6WX;%2XV&Y$LH^6JT8P]6\;DJNXVFM8HQ;
M)Q@BJLOWJEB?--D&6K3ET(3U)(Q\E1S+D5-']RC;N;%<U1'32U.P^'L9^V+]
M:]XMQ^Y7Z5XMX"AVW*GWKVN+B%?I7GU=STJ*T'$X- YJ"1\-4T9RM9&XR4A%
MS7,ZW?*B-@UMZI-Y4!.:\S\0:KRPW5K3C<QJNS,;6]2)+8:N$U"Z=Y.M:M_>
M>:3S6),NYLUTQB<DYD:L6ZU(HI$3!J?;A<UO&)@YC:>E1YYJ5.E:QT1SRE=C
M6XJ,FGOUIE:)B:T&C.:?DBG*E#+@52U)0W=48)WBE-.5><TIZ(<7J:,04Q53
MO %&14J2X&*BNSE*Y^4VC(AL)V608/>O5/"5_M"!C7D]DN9*['2+[[/(@SWK
M"I3.FE/4]YTZ82Q@@UH5S7ABY\^V4Y[5TM<$U9GHPU0VD8_*:5J83\IJ4#?0
M\^\7S!0XS7B.MMONR1ZUZOX\NO+=QFO)KK][+NKKHHXZSLPMA\HJUCBJ\/'%
M6"<+79%'#)W8QN.E4I02]7A\U,:++5K;0E;D]J,1U'-BID&V.J<S\U+0G(DM
MA^\KO/#ER(%&3VK@[+YGK>CO/LJ]<5"149%KQ7J+/(0K5R63)R:T+Z?[6V<Y
MJH$VBJY33<@88%+$3FGD9-)MV\U<48R9..14;K3XCFED'%6MS-2*_0U+&,FH
M"?GQ5J(<9IRV+B];D%Y'\G%5K)V24?6K\PWC%5DBVN/K7)*.IU4YW/5_!UU\
MB FO5+!]T(->*>%9]A09KV+1WW6H/M7%61W47=FBYIL?6@G)IZK6#.A$E%%%
M(H**** "BBB@ HHHH 0G J"2;;WJ21L+6/?7.P'F@ENS+INQZT?:QZUS+ZA@
M]:0:CSUJT@N=/]I&.M1M<K[5@_V@-O6JSZC@_>J;"N=*+E?:GBX4URBZES]Z
MK$>H#^]18'(Z,W"CTI/M*^U<X^H\_>IG]H\?>HL+F.F%RI/:G>>M<NFH_-]Z
MK'V\8ZU5A<QNM<J/2FFY7;GBN:FU'!^]49U+]T?FIJ)+F:.I:BB1MR*XR[UE
M1*?F%0:WJQ"MAJ\^O-6?SFY-=,8V..;U._76%/\ $*BFU(,>M<##JKYZFK:Z
M@S=S6T48-G;QZD G6JYU0>9]ZN4_M!@O6J[:@V[K6A)WBZL OWJ8^L+_ 'JX
M=M28+U-57U1\]34/0N,=3N6U#S&X-;NE2;V6O.].N7E9>37?Z$I)6L),ZJ<=
M3T+35!B6M;8-O2L[3%_="M4#BN:;.R*&*N*=G%+BHV/-8-ZEI#CR*K'AJL#D
M5#+P,UM QJ%>YN1$G6O/?%>H[E8 UTVNW?DQ'GM7E>NZCYK,,UTPIG%4J'*Z
MG,TDW4]:;$_[GFF3?.V:AW[>*[(PL<TI ?\ 6YJRIXJL/6I4;FNJ$3FFQ[#-
M0,=IJXJY%4+L[6JY;"B6%?*XJ/&&S44)+$"KQ@;R\XKDDSIBB+=N&*C?Y:E@
MA<OC!HO(C'VIP>I,HV0V,YJ8L-M5H3Q2L_:M&<[W 'YZD?D5"/6I%YJ>6YHG
M8:B4V48%60M0RCBGRFD9ZC]'F*:BG/>O>_#%V&M(QGM7SW8DI>J?>O8?"=[E
M47-<=9'?0E<]5B;*"E8U!:MF)3[5)(:\V1WIZ#QR*JW;[(R:L*?EK*U><);M
MSVJZ:,:KLCD=?U((K#->6:W?&9F -=!XHU(AG&ZO/S<F:8Y/>O0A$X+C/++G
M-68H]E6K> $9Q1,FRNVFCDJ2%5QC%1R#(J 2?/BK/5:Z[:'+)V95QS4J/M%#
M"JLSE37+4V.BF3O)DTBMS5926J=4;'2N*^ITVT+2.!397R*@)*TS?FMZ;,)H
MF2FG[U.3I36ZUIN9+<F!^6HSUIH:E;I3BC2Y%)5BV?;55C3XVQ5..@7LSH=)
MN#]M3GO7N7AR;-BG/:O =*?_ $M/K7MOAF?_ $5!GM7!B(:'70GJ=<Q^6EBZ
MTP'*4Z/K7ERW/3@+<_ZAOI7D?BV4B=AGO7K=U_Q[M]*\:\8/BX?ZUO0>IE7>
MAP=X09#55>M/N'S(:B%>Q&-XGD2>I95J1FJ'=BC=FE#>PI;#6'S4\<C%)CBA
M#EL5T6.>^H;*3&#5DI\M0/Q6-30V@R[!<[(\9JI-*6ESFJK3%3BG9)7-<_4Z
M.A<\P%,5#CFJR2G?BK1^[FM8ZF$AR]*JS??JPAJO-R]:F:+$)^6E9Q3$X2HM
MQ+52!/4E#8-6HI 16=(2HIT$IJ)+4U3'W/+YJ6"4IWJ.3FHMVVLV5$T)KDM'
MC-44?YJC:0GBF@G-38399=QFK,3 Q&LIY#FKUN^8ZI";*SC_ $C-:'_+(54*
M_O,U9!^2K);(P.::]/:HC0@8X-Q33UI,T5I):$+<0G%>D?#IB9E^M>;&O2/A
MU_KE^M>;7V/0H/4]LC^X/I3ZCC^X/I3Z\\]-,K7IVQ$UY?XRFS"XS7IFIMMM
MF/M7D/BR?<'&:Z**N<]?0\UD_P!>WUJ5.E1/_K6^M2ITKU:4=#R*K&'[]6O^
M6553]^K#']U6[6ASW*I.6IX7-0J<R5=C7BI6YHV5VB.:E5<)5L1@BH9<#BB0
M)W*H;$E6'D&RJK]<TQG-<\C:*)0V33]F>:@3.:O1 ;:BY;V(N@Q4?>GRG#5'
M71!&#'D\4+Q3%.:5N*V2,K]!6.:;0.:0U,UH:1%5MIS7H'@*<FY49[UYZU=O
MX"?%VOUKSZRT.JG.S/>8&S$OTJ2JMJV8E^E6A7ERW/5A+F17O3BW8UY?XKE^
M1Q7IVH'%LU>2>*Y?OC-;T-S/$;'FUT<SM]:2,TR8YG;ZT XKVJ4=#Q9O4G/2
MHOXZ>IRM1?QULT9IDSCY*BC^]4[_ .KJO%]ZHD"=V3N<+4%HN[48_P#>I\K5
M-ID>Z^C/O7+5>AT4OB/?O!: :8GT%=8.E<SX07;IR?05TXKR)[GM4MA&^Z:\
MJ\?/@O7JCG"FO(_B"_S-6E#XB:[]T\FN_FFS[U9A;$>*@F&7S[TJ-@8KVJ:T
M/#JN[)B>::QI,TW-$D33$SBF_P 5*U-'6FE<W1;!_=U-9+NF_&JV?EJYI@W3
MCZUE65D:PW/5/!*89*].7[HKSKP?'MVUZ*/NBO'J?$>I2^$&.%S6!KEV%MF&
M>U;<[;8B:X3Q!>X5AFI@KL=25D>?^(+HF1^:XFYD+.:Z+6I]SMS7,,=SFO4I
M1N>74E<NVA 2H)_]92Q-M%-DY.:[8JQR29-&_P M$C<575B#3I&XJFB15&XU
M.$P*;9KN-6I0!7/)V*1GNOS5-&>*&7/-,7AL5G<NQ+(>*A4\T^7[M0Q]:UBK
MA>Q:!^6J;G]Y5G/%5G^]2<=1ON7(CE<5%<CBB%N:?<CY*(K4SDR"W/-2/UJ.
MWZT^7K6S6A'4E4_+3[?YI<56W?+5G3?GN />N2LCLH'IG@B';,IQWKUR/_5#
MZ5YGX/AVLAKTU/N#Z5Y53<]:EI$K2K\U/#[(\FI&7/-4+Z7RX&YJ4KCD[&-X
M@U "!AGM7D.O7I+OS77^(-2^\NZO--6N=SMS792AH<56I<I&0N>M%00'<:F/
M6NJ,#DG+0<HYJ1_NTU:)#\M5L8MD:#+5(QV46X^:FW?'2BY*CU(VDS0IYJ%4
M=NQJ>.!\]#33-+:$P.!3&;-/EC94Z&JJ$[JTBR+#SUJ13\M,(H!IS=R;:BC.
M^G7',="BB;[M1%!S6(K+AZTXYBLZ8/>LN#Y6JTC_ +Y?K2G'0Z:3U/<?!5S_
M *(H)[5W<;;ES7E?@VYVPH,]J].LVW0@UY5:-F>K2>A,U1,<(?I4IJ"8X0_2
ML1S=G<\9^(K'SF^M><#FO1/B$<S-]:\Z%=E%'GUI7'KP:F9LBH!3@<UZ$8Z'
M'?4<K[:E#@U3F;;1%(35-#-#=\N*I2H2<U.C9J5HP5S4M:&,GJ16(VO4FI2D
M+P:;#\KU#J#;A4(TAN1V\N1S4S.*SHF*U8#DBJ1T;$P/S4Z3[M0*W-3=15V.
M6H[,6$XJ5^15<G;4R'<M49W*C?ZRKB?<JJX_>U9!_=TFKFJT0H.337X:FJ>:
M'/(K.:+INS.K\.OB5/K7M>@G-DOTKP[P^W[Y/K7M_AX_Z$OTKSJZ/5PYK#[U
M3CI4(^]4W:N:1U1%HHHJ44%%%% !1110 4444 4[J3:F:Y+5;W&[FNFO\^4<
M5PVKI(=V*JQBV8]SJFQC\U0+J_/WJR[^&;<< U26&?T-4F-'3C5OE^]4,FJ?
M[58BPSXZ4CP38Z&A(3-F/4\G[U3?VMM_BKGXH)L]#1/#..QHL2V;IU;=_%2?
MVKQ]ZL!(9R.AI_D3^E(5S=75<'[U6%U;(^]7,^1/Z5+'%-Z&FA&W+J.>]5WU
M3"$;JHM!-CH:I3039Z&M8F;&7]P9\C-<_-8L[DXK?CLY7?D5HKI1*<K6Z,9:
MG&I8LIZ5+Y)6NJ?2B/X:J2Z8W]VM$S%HY\H::(236U_9KY^[4J:8_P#=IN0U
M$PFMB5Z4Q;!G;I73C36(^[5JUT@EA\M1)FD$5=%THDK\M>D:+II4*<50T?2P
MNW*UW.G6BH@XKFG+0ZZ2U+-G%LC JZ.E-50HI0:YV[G2A343#FI2:8:SEN,%
MZ56NVVQDU9S@5G:I)L@)K:F857H<)XLOMD3<]J\GO+SS96Y[UVOC&]RC@&O-
M$D9IFSZUZ,%H>9,N@9%5W7YZLQ_=J)A\];Q,9/0 ORTW.#5C;\E5)#@UTQV,
M'N:%L=PJA?C]YBKE@V1S5>^7=./K4S9<(ZEG3;0R$<5U=MHQEC VU5\/66]5
M.*](TC3%*KE:XJDK';3C=G'P>&B#G9^E8?B'3#;@_+7N2Z5&(_N]J\Y\<6:Q
MAL"L:56\BL1"R/+%&WBEVY-/E7#&ECQ7HK5'G,/+XIGW:M<;:JS>U6D*Y+&V
MZED3(J*V..M62036BAH)2U*L46V4-7?^$;G_ $A%SWKC"H"9K>\'RG^TE&>]
M<&(CH>AAY:GOUCS;H?:IW&:AT_\ X](_I5DBO(EN>LMB)CLB)KB_$6H[(V7-
M=?>R!+9_I7D/BC4<3NNZMJ,;LY\1L<9XAN?-D?FN7M_]:3[UK:A(96)K.B3#
MYKNCH>>Y&W:GY:ANFYI('PM17#9-=E,Y)E=1F2KW1*JQCYJLL<)70WH8M79"
MQJ!H][4\G)JW:VYD8<5RU6==-#[/3R^.*U?[)(CSMK9TC3-RCY:Z)]+'V;[O
M:N)O4ZK:'E]U:%,\5G;<&NRU>P,>XXKE)DPYKHI['/4"/D4U^M.CZ4C]:V1A
MU& 4_&12"GJ*J)97=<4BU/,*A44[Z$LNZ>^VY7ZUZ_X7N\QHN:\8MVVSJ?>O
M2_"EU\Z+FN.OL=-!:GKT/S0@U,@J"R^:V4^U6A7D2W/7AL0W?_'L_P!*\.\9
MRXNW'O7M]ZV+5_I7@?C:3_3V^M;T%J95]CD93E\T(,TTG-2P]:]J'PGC/XB.
M4;:6(;A2W7%.M?NU$5J$W8:_%-C^_3IOO4R/K71T,$BX3\M5)6J9GPM57RQX
MKGJ,W@B+;N:KHA_<YIUK9M(1Q6U_9SBW/R]JYD]3I2T.3 Q/5\<J*9/:LDYX
MIZ\"NF".>8TG;3-NXT3&I(.16ADAP7Y:8L?S5/BG(!FG$95N(\+4$(P:T+E1
MMJDG6E(N)8VY6J4K8?%:*X\LUGNA:? K"3-$A\<>ZK(MCCI5NRL6<#BM8:<P
M3[M3S!8Y&YCV&K-IRE3:M;F-NE0VG"U29+6A(5^:G]!2GK3'.!6B,F'6F.,4
MZ(Y-+**M(KH18XIH/S8J4?=J ?ZRGNB%N2.N%S7HGPY/[]?K7G\@_=UWWPX_
MX^%^M>=B-CT<.M3VY/N#Z4\4Q?N+]*>*\X]%;F;K3;;-C[5XEXGN,R.,U[1X
MB;;8.?:O _$4^ZYD&>]=.',,1L<ZOS2'ZU8 P*@@'SFK+<5ZM-Z'D5$0D?-3
MW/[NDILGW*Z#EZD$0S)5[.T53M_]95N;[O%9[,T8X3X'6JLD^6J%F85$H9Y
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MT8^Y^E=[]G3T%!MT]!0F-HX%/#H!^Y22>' ?X*[W[.@["@P(>PIW(LC@5\.
M?P?I3O\ A'!_<KO/LZ>@I/)3T% 61P?_  C@_NTJ^'@/X:[OR$]!2-"@'04"
M:1PK:"!_#4+^'U/.VNONG2//2LF?4XHP02*T5S#2YA)H2J_W:O#25"=*0ZU%
MOZBI3K$>SJ*UNS![E9M)4]JC.B*W\-6AJ\9/45.NJ18ZBJ;=B4M3).A+N^[4
MO]AJ$SMJU)K$0;J*D76(G&,BI<F:12,Z/1P7QMK2@T0#!VU;L94EDSQ710Q*
M5' I5)6-*<3*M+ 1XXK;MUVK2^6!VJ11Q6#=SHBK,'.!42/EJD<<5"B_-2-4
M3,>*1>10XXH0<5GU&,=L5A>()]EFQSVK9N#M!-<=XIO +-QGM7331Q5I'E'B
M*\\Z9USWKED3#DUHZA*9+Q^>]0+'7H01Y\F"G IN<O0_RTB<M6R1E(M,/W6:
MS)C\QK5;F/%9DZ$$UM%D%BQ?%3.GF7"_6JMKP:U+6+?<)]:RJ/4V@M3OO"UC
MNB4XKTC3[7RT!Q7,>$[7_1U..U=W#&%CKS:T]3T*4=!X'RXKS3Q\G#5Z:!7G
M'CU<AJSHOWRJL;PU/(IH^35,OM;%:DZXS6--_K*]6+T/)DM2UYGRTT?.:B!^
M6IH.M;19G)6$;]W0DF33[A<BJZ@J:V3T)2ZEUF_=5L^#3_Q-5^M8!;]W6]X,
M'_$T7ZUP8C8[L/N?1&G?\><?TJRW2JVG?\><?TJQ)PA->,]SV5L8>LW/EVTG
M/:O"?$U^6U!ESWKU?Q1?B..1<UX=K;&74"V>]=5%''7EH-(\P9J/R]M2PGY!
M2OTKM43SKD/F;:3.XTQUR:<@Q71#<SDB9%YITQPE(II)3E<5K)Z&:6I!%\SU
MU&CVGF,O%<Y:QDO7H/AJTWE>*XJDCKI1.LT32_W8^6MY]/'E8Q5K2+8)$..U
M:C1#;TKSY3U.[DT/+O$NG>7"QQVKS"Z3$K#WKV_Q?"!:,<=J\6OAB=_K791E
M='%5C8H9Q36-./-,-=D=CF$4\U/T%5U^]5CJM6-L8W-,QBGXQ2&AAT&)Q(#7
M:>$[G_3$7/>N+QBNB\)R'^TD'O7%6V.BAN?0VG'-FA]JN"J.E\V$?TJ\*\E[
MGKHH:D^+9_I7@/C1\W[?6O=M7?%O)]*\!\8MF_;ZUU4%J<V(D<ZK59BJJ@JP
MG%>O'X3R9;B7/-.MSA:9+S3HN%H@M12V&R]:8O6GORU+Y?&:U,R.9\+4EDGG
M.!5:XZ5M>'K0S2+QWKCJLZ8'4:+I'FA3MKIWT,"U/R]JO>']/"HN5KJ)+1?L
MQ&.U<DIV9U*/NGB6L:9Y3L=M<U(-KD5ZAXHLPB.V*\NN6_?L/>NNE*Z.216E
M.:D@;BHY!2Q\5T&2+9/RU'')^\Q3S_JZJ*V)*<09=N&RE4E/-6'.Y:KD8IS+
M@64;C%26MOYMP.*JHWS 5T.C6WF3KQ7')ZFZ1TFCZ1O13MK=FT8+%]WM6MHE
M@!"IVUN7-H#%T[5@Y^\7R.QX?XEL_*8\5SL/R\5WOC2W\MFXK@NC5T1=S"2L
M3YXJ"1JD!^6H9!6RW,F+$W-3GYA52+K5M>E:,+Z$;' J%?OU-(*B4?-2D[(A
M;EAN4KT'X=+BX7ZUP &17HWP^3$R_6O-Q#T/1PU[GLB?<'TIPIJ?<'TIU<!Z
M9A>*&VZ:_P!*^>=:EW7T@]Z^@/%C_P#$L?Z&OG75#G49/K75AT<V)9'",&GR
M-2)TIDIP:].D>14W$#<TZ3[E,09-2N/DKH,;$%O_ *RK[KN6J$ _>5H9^6LV
MRBF\53V-IYEPHQWIKL-V*W-$M_,N$.*PJ2T-Z*U.PT31 T2G;72IH8*#Y:OZ
M#: 6R<=JZ-(%V]*X*L]3T*<#SZ^T0*I^6O+O$]EY,QX[U]":A;*8VXKQ3QO&
M$G;CO6]"5T8UE9G%P\+4HIB#BG5Z$-CAEJQ2<BD'%+BDIMBL*32@\4VEQ1N&
MPV3I70>%GQ<+]:YY^E;GAKBX'UKDK(VAN>Y^'GS&OTKI^U<CX:.46NM_AKRJ
MFY[-'X3(U]L:?)]*^??$4O\ I\GUKWOQ')C3Y/I7SSK[YU%_K6M!:G/79G Y
M-(QI%XH;FO:I;'E3W+,/*5 Y_>58AX2J[C]Y6C9E'<L#[E0L:D!^2HGXK"3T
M+L0D_O!]:[SPK#O9#BN!ZRCZUZ=X-ARJ'%<=1G331ZSHB[;51[5JUGZ8NV 5
MH5YTMSUH;&/K,FR-OI7B7C2?=*W/>O8O$4FR)OI7B'BM_,E;ZUU8<RK;&!;G
M*4$_/26_"48^>O4CL>-66I-C"U"3DU.?N5!C!H:(ICT.*:W)H%!Z52-B-SQB
MNC\&INOE^M<T>377^"8_].7ZUC6^$Z*1[CI,>V!/I6LW"FJ6GKBW3Z5<E.(F
M/M7C3W/4I_"<QX@NMELXSVKPOQ%<[[U^>]>J^*K[8KKFO&-6<R7;'WKII1.2
MJRH.3FK42U7B&35U%P*]"DM#@F]2&5MIIRM\N:CN/O4J'Y*Z$82W$WY;%/(X
MJ ?ZRK>WY:ALI(IN<&M;2K3SW7C-9,RX:NU\*6?FE#BN6;-XQ.ETC0@\(.WM
M6LOAX9^Y^E='HUFJ0 8[5L"V7T%<,YZG53@>7ZWHX@A)V]J\XU*/:[5[IXGM
M@;<X':O&=<AV2-]:[,,[HPKJTC#B.*D897-0*>:L#F.NAF)5!_>5;4\53QB2
MK2'BK@8R$<9IG2I&J/K5R(CN1OTK=\)#=J*CWK#8<8KHO!T?_$S4^]<5?8[J
M+U/>](BVVL9]JUNU4M-7%G']*NG[M>7)ZGJ1V,^_FV0M]*\J\3WGS.,UZ%K5
MSY<3C/:O'_$=UNG89[UI36IS5I=#D[U]\S57C7FI)?FD)H05ZL(Z'E3D3QCB
MHY7P:D!P*K3<FM$A1=T*K?-4Y/RU50<U/_#431O FM[?SG'%>C>%-)SM.VN,
MT.#S91QWKV+PM9A$7(KDJNR.VG&YOZ?!Y" 8K3S\M0%=IXJ4?=KB?<W6FAC:
MS%YD1&.U>0^*X/)W'%>UWL>Y#7D_CN#:C<5T4WH<E169YO$^YC4I-5(3M8U:
MZBNJ#N<53<CW8-2*^1BH'ZT^(\UUQ1D.EX%0+RPJQ-R*A0<TIG32W.G\/3;;
MF,>]>[^'VS8*?:OG[1&Q>1_6O?O#9SIR?2O)Q&YZE'8V<US'B6;RXVYKIAUK
MC?&#[8VK".Y4_@9Y)XCE\R5JYFMK5Y-TA^M8^,UZ-!'DU-Q!4J-DU&1Q3H^M
M=J1@WJ6::W2@G II;BE(96D?#4W.122C+4(,G%9,31HZ9!YT@&*[K2]'W ?+
M7.>&[7?,O'>O5])L J+Q6$I'1")C'008R=O:N6UFP\G<,5[%]D7R3QVK@?$U
MGC>0*SISO(VE&T3R:==DYJ1&R,4[4$VW#"H8>M=D6<M5#+@8HA/%/N5S3(A@
M5JCGZ$I:H\TXBF421K%Z#U.:4G#"FJ,4CGYQ7/,N"U.N\.INE0^]>V>'UQ9J
M/:O'O"D6XH:]GT5=ML![5YU<]7#&D%YI]%%<S.T2EI*6DMP"BBBF 4444 %%
M%% %8W"^HIOVE/45Q#^(0!]ZJ<WB<)_'^M48-GH?VI/44HNT]17E[>+@/X_U
MIG_"8#_GI^M%AQD>J?:D]11]J3U%>7#Q>,??_6GIXN!/W_UHL5S'IK72>HIH
MND]17F[^*QC[_P"M,7Q6/[_ZTTM#-SU/3#=)CJ*B-VF>HKSD^*Q_?_6F_P#"
M4C^_^M-(F4CTM;I/45'/=*%ZBO.T\4C/W_UIMQXH&W[_ .M"6HN?0W-9U((&
MPU>=ZQKS([88TNJ>(/-W?-7&ZA<F=B<UT06IS3D7_P#A(G,WWS5[^WW\O[QK
MC0K>9FK98B.MN4SO<ZB'7V+?>-6SKS!?O5PWGE#UIWVPD=:30T=-<>(7W?>-
M3:=KKR3A=QKCF<R-6[H-JSW2\=ZSL:I'KN@7#2!2<UW=H<H*Y#P_8E84.*[*
MW3:HK&;N;TXNY.:<*8YI@?FLCH2U)B,BFA<&E!XH!YI%"D<4 <4M%3U&4KX[
M86->7>++WY'7->FZHVVU<^U>)>*[O,SKFNJBKL\_$'$2/ONV^M78U!6LS=^_
M)]ZOQ2\5Z44>>RO=?*U)%2W/S-38^!5HDMJ<C%17$?&:6-N:?-RM6B.I4@&#
M70Z5#OF3CO7.@[7KM/#<'FNAQ7/59T4UJ>K^%[?;:+QVKJ5&!BL;08O+M1]*
MUPW->5.6IZL%9$F.*\Y\=8PU>C$_+7F/CZ;:'ITOBN%9>Y8\PN2/FK%F_P!9
M5ZXGR36<QW25Z<9'DRAJ2KTJ6,X-,QA*B:7;6JFB7"YH@!Q5:8!326\^13+B
M3FM>?0SY!=W&*Z;P6O\ Q,E/O7(+)EL5VG@Q?].0^]<>(=T=>'5F?0&G_P#'
MG']*FF.(F^E5=/;_ $1/I2W<NV%OI7F<NIZG.K'DGC>_*3LN>]><W \U]]=7
MX[GS>MSWKDT.8Z[J$3SL1+4B#8XIQ;-1OP::K9-=ECC3+")NI&7!IT9P*5AF
MJ0R+.*4'=3&X-*IP:J4M"4M30LXLL*]0\(VNX+Q7F^F+O=:]<\(PX1:X*TCM
MHQU.TM8MB"K!I%&%IF_YL5P/5GH6T.7\7K_H;?2O#M3XG?ZU[GXP_P"/%OI7
MA>IG,[_6N[#;'#B8ZE!.::XI4.*#S7H+8\]Z,8!4B'-,-*#BK$2.,"HZ5FS3
M,TF]!K<5AQ6SX4;_ (FJ?6L8_=K7\*?\A5/K7%7>AV45J?1ND?\ (/C^E7C5
M'2/^0?']*O,>*\M[GJ=# UM\0/\ 2O _%K9OV^M>W>(9]D;C/:O#?$IWWK'W
MKJH+4XJ[,J,?+3^E1QGC%.8\5ZT5[IYLMP;FI$X%1IR:D/RBG%:DRV&=9*NF
M/]SFJ*G]X*OLW[BAD(RYAEJ[GP39B5UXKAG.9/QKTWX>Q;BO%<=65CMHQN>F
MZ;:"-!Q6JT8\O%01_NP!5@O\E<$KMG<DDK'"^,H MF[8[&O#;A_],<>]>[>-
MG_T!_H:\#F;_ $^3ZUVT-C@FM2=ER*11@U,B[A367:U=B.=CS_JZI-P]7?X*
MJ.OS5<$2V31'=1,N*;#P:F==PJ:I<-RK$?WH'O7?>&;;?(AQ7GZ<72CWKU?P
MA;;D1L5Q5'H=4%J>D:7:A+93CM5]H@R$4RV^2U'TIZ29S7!=[G<HH\H\?Q;&
M:O,&^]7JGQ$/+5Y-(_SUW47>)Q5U[Q.IHE7Y:;$<U,XRM=<#DD58A\U6JK@;
M34RMFM&9L&'%1 ?-4K&HN^:F:T'!79<A7=BO2_ <>V5:\XT\>9(!7J_@N#8R
MG%>=7V/3PVYZ6OW12D_+2#[HILIQ&:X4=YR_BR3_ (E[CVKY^U+G4)/K7N'B
MRX_T5QGM7A][\U\Y]Z[:*.&O+41.E03'FIC\HJO)R:]"&YYTWJ30C(I[CY:C
MB.!4C'Y:W9D11C#U89L"JZ'YJD<\5DRHD!?,H'O7=^&+?>R'%<&B[IU^M>J>
M$+7,:'%<=>5CLI+4])TB+;;+]*UUZ53L4V0"K8->=)W9Z5.-D5[M<QM]*\.\
M?KMN6^M>Z7'^K;Z5X?\ $$?Z2WUKIPSU./$;G#1#Y:4#YJ;&<#%/[YKU8['G
MO<5AQ48IY.1311<:%Q3L<4V@MQ3CN*8QNM;WA\8F'UK!/6N@\.C,R_6N>N:4
MMSV7PQ]U:ZX_<KDO#2X1:ZN0XB/TKR*FY[-+X3F/$TN+&0>U?/VLMNU)_K7N
M'BBXQ;R+FO#-4YOV/O7301S5V5CP*%YIQ'RTBC%>K#1'F/<L)PM1/]ZI%Z5"
MY^:J;(6Y(AI)N!2+Q22'<*REL6D01#,R_6O7/!468D->30K^^7ZU[-X'BS O
MTKAJ,[**/1[%<1"K=06PPE3UP2W/3AL<EXL?9"WTKQ37&\R1J]B\:OMA;Z5X
MKJ<FZ1OK79ACFQ#,U.*>!S48IP:O3B>35W)>U,<8I0::QS39$1JTIZ4W.*=U
M6FC1$:\O7=>"8O\ 2U/O7"P?-/BO2O!D&)T..]<]=^Z=5'<]BM!BW3Z5)<'$
M#'VIMOQ OTJ*\?;;O]*\>UV>DG9'COC6]*W+KGO7G-R?,D)KK/',_P#I[#/>
MN0!W"O0IQT1QU'J/MQ\U77&%JG%\IJP[Y%=D%H>?4>I7EY-(.E#'FG!>*VZ&
M2&J/FS5Q>E5.AJ02XK"HS:"U&7"_,*]-\"6F^-3BO-U7S7%>P> K?$*\=JXJ
MDCLIQNSO;.+RT JYCBF(N!3\\5Q2=V=<58P=>3?"?I7C7BB+8S<5[3K7^J/T
MKQ_Q6,EZ]+";'!7W.$SAJN1\I5%SB2KL/,==,CG(F7YJ>AIKGFD!Q5Q(D/D-
M"<BD/S4H.T5<MC..XTCYL5U?@^+_ $]#[URJ?-)7;>$(O]+0^]<-?8[J"U/;
M]/\ ^/2/Z5:;[AJM8\6J?2II#B-OI7EL]1:'"^*+KRPXS7C^LW&^Y//>O1?&
M=ULD<9KRR]??,3[UT4D<59ZLAQGFE44*>*7I7J4UH>1/<1CBF$9IQYIM:-%1
M8!>:D/2D I&/%1(WIR.I\)H'F7/K7M&BJL<:].E>(>&;CR90:].L=8"H/FKB
MKQNCNHRLSM9)5SUIR3KCK7(R:T/[U0G7PO\ %7)R.QMSJYV,\B%>HKS+QX%,
M38K5G\1@+]_]:XGQ/K NE8;LU=.+N8UFC@G^60_6KD/,=5<;WS5R(8CKL@K,
MX*A5D^]3H^M-F^]1$?FKJCL8D[\BF**<_ I$.:F>QT4=S5T8XOH_K7O_ (9_
MY!R?2OGW2#_I\?UKZ!\,?\@U/I7EXC<]6CL;E<'XW?;$U=V37G/CZ7;&U8TU
M[PZK]P\CU%]TA^M5$&14EPV^0_6FIP*]6BK'CS8TBE4<TK4P'FNI(Y];CI#@
M5#NI\AIBKFAHH<5R*2%<R8J7&%IMM_KZYI%Q.\\(VP:9>*]<LK8)&O':O,O!
MR?O5KU>,[8E^E<-5N]COHQ)2@\LBN,\26X,+G%=@9/D-<MXA.;=ZFE=,WJI<
MIXAK"[;MA[U2A/-7]=.+M_K67 ^6KN@SS:J+4HR*C48J20\4P5U+8Y;,<1Q4
M8'S4XFD'K1+8TB.(P*KD_O!]:F9N*@_Y:K]:Y9F\#TSP;%N5#BO7M+7; *\P
M\#0[HD->J6:[8P*\^L>GAM"W24A/%(IYKE>YVCZ***8!1110 4444 %%%% '
MS_+)/M[UDWDES@XS7H;Z%D?=JJ_AP2'[E:V..]SR^1KOWJ M=Y[UZF?"0/\
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M!7(:#>-*BY-=C;G,8K*2L;K5$F,"E6EQ2@5)26HM-[T[M43'FD62"EI%Z4M
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M3EYI&X-=43D8I&3FG+SQ0/NT1??HGL$=R*X&P9K>\,P_:)%X[UA:CQ'Q76>
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M?-6",&NA5#GY=2R@^2JT@P]68S\E59&^>I<M1I!GBDQ1VIR<U$I6*4;L2/\
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MCI6L9<IE*%]3R6_T8\X6N9N]%;?]VO:;K2%;/RUB7.AJ3]VNB$[G/*-CR?\
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M\?=->M_\(\G]P4?V O\ =%4ZER?969XY)X?<G[IK4TK0GCE4[3UKTX^'4/\
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MHJ@$HI:*!6&T4IHIBL-Q2@4M+0"04444B@HHHH **** "BBB@ HHHH ****
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ME"W!['@.KQ;)G^M48$#"MSQ%#LD<X[UST,VWBNRCN<5782==IXJMWJX_S\U
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M1[.:EI#5B$ Q3'/-.!IK#)I, 49%+LYI5'%.I)@ Z4M%%5< HHHH *2EI*3
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M*EHIA2T44T2%)2T4, I*6BBP"&BEI*0!2TE+30!1113 **** "BBB@ HHHH
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M6D%+0(**** "DI:2@38M%%% PHHHH 3%+110 E%%%2 4444 %+1130!1113
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M110 4444 %)114L I:2EIH HHHI@%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%%*P"4M%%%@"DH-(*8KZBT
MM-I10">HM%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@!*2E- IDO<**6DI#L+1110,*2EHI,!*6BBDE8 HHHJ@
M"BBB@ HHHH 2@4M% K!1110,*2EHH8!1110 4444 %%%% !1110 4444 %%%
M% !110>E*P$;-@T!J8_6D7K5I$WU.8\:MBP;Z5\_ZJ^ZX?ZU[_XU0M8-CTKP
M>]LI&N7X[UK2,JVQD1\&KJ_ZO-*-/DS]VKZ6#^5]VNV+/+J1,*1\28J6-\5)
M-82>;]VI%L),?=K12,U B=MPJ+I5^.PD/:B33I,_=J)2U-%'0KVXS(*[OPJG
M^DI]:Y6TL'WCY:[SPS9LLR$BN>H;4UJ>L:?Q:)]*NJ<U3LQBU4>U6DKE9Z,"
M6BBBH- HHHH **** "BBB@ HHHH *2EI*!,*6FTZ@$%%%% PHHHH 2EHHI6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***0T (:!113("BEI*!CJ***104444 %%
M%% !1110 4444 (:*#13$]PHH-% =0HI.]+0 4M(*6D""DI:;WH!CJ***!A1
M110 4AI:0T Q**44&F2%%%)WH =1112*"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (F6A5YIY
MIN>::(ZF)XBM_/M2,=J\UFT'=,QV]Z]<OH_,BQBL$V +GY:T@R*BN>?CP^,_
M=_2K:Z"-F-M=N+!?[M2BR7'W:Z8R1PU('F\GAT%\[*</#HQ]S]*]"-@I/W13
MOL"_W:TYT*--G Q>'1_<_2G/X=!_@KT!+)?2GM9+C[HK-S+Y-#SN+00L@^6N
MKTC2A$5.VM'[$OF?=K7M8 JCBL9R*A'4L0IMB J51B@<"E!K"YW)#J***104
M444 %%%% !1110 4444 %)2TV@3%I:** 04444#"BBB@ HHHH **** "BBB@
M HHHH 2FTIHID,44M(*6D4@HHHH&%(12T4 -%.[4E+4]0(R.:,8I^.:#33!B
M"F2#*D4\4C4TR'L<]J.G"?/%<I>^&A(Q.S]*])* ]14+VR'L*TC.QE*":/(+
MOPT(LG9^E8T^G>7GY:]BU*Q5D.%%<??:5DG"UV4ZNAR2IMGG4UN0>E5S9$\X
MKLIM%8M]VD&BG9]VMU6,G29Q'V8@XQ4JVI]*ZEM#;?\ =-2KHC?W:<JJ!4G<
MYA;(MVJQ%I6X_=KJ8=&(_AK1@TC!'RUA*H="A8YFUT'<1\M;UOX;#*/DKI++
M30I&5KH;6R4 ?**Q<S=0..M/#8C8'9^E=#9:8(\?+70"U0#H*41A>U9<[&X:
MD=M%L%6#TI.E.ZBLV[EI$8/S5*#Q4./FJ4=*SN5L.I12"G4T4@HHHIC"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@!**6B@+!24M% !1110 4444 %%%% !1110 4444 %)2T
M4 %%%% "4M%% !1110 4E+10 4444 %%%% !1110 4444 %)2T4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% #6Z5#GYJF-1;>:9/4<Z[UJO]G&>E6A0V!0AM%7R!Z4>
M2*LCFHG.#5ILQG%$0A&:<81CI3E;FI7^[1S,48JQ72*I#%2*>:F'-#DR^56*
MI@^;I4Z+@4[%. I-DJ.HUCQ21G)IS#-(BX-2:HEHHHI%!1110 4444 %%%%
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M $HHHJ.HQ:***L04444 %%%% !1112N 4444P"BBB@ HHHH **2EI %%%%,
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M** "BBB@ HI,TFX4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH 2EHHI6 ****+ %)2T46 ****8!1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MED\-N.=GZ52*3T(+77) !EC78>&M6,TZ@MWKA[G3FME)QC%7/#M[Y-X 3T-
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M5UVGVVP!L4F5%&L/NBG"D'2EI&B%HHHI#"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$ATC*UR78C5Y#KP\V_4_[5>I>)I-J-7EM\=]XI]ZTAL8U7J>E^#8\:>OTKI
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA33-#TYB0<&M+4=*<QDX/2M;F33.2^T&2Y"9ZFN^\-Z&'VR[:\Z:(P:HH/\
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "HKC_4M]*EJ&Y_X]W^E 'C7C";%^1GO2^'(=TZ-69XTGQJV/]JN@\)Q[U1J
MV6QS27O'IVGC%JH]JMU!:#%NOTJ>LRQ10W"T"FS'$9-(M'+^+)A_9[C/:O)]
M!&_7&_WJ] \777^C.N>U>>^%COUP_P"]5)F4E=GMVF1[8$^E:$W^H;Z5#8IB
MV3Z58F'[IOI0W<:5CR7Q9!FY9L=ZQM D"ZDJ^]=7XJA^^V*X/1[C;K@7_:JN
MAG;6Y[]IIS9)]*YOQ4I,;8K?TALZ?']*S]=M_-C;CM4QW-I/0\&UDE+]<_WJ
M]=\!S#[ HSVKRKQ7#Y-^./XJ[[P-=[;5!GM52,([GIXY&:4#FHK>0-&#FI20
M.]1<VY>I%<2A$->;>*K_  [*#79ZO=B)&YKR3Q)?E[K&>]58B6Y5LX#/J"OC
MO7LOA^'99)QVKSCPU8^<R/BO5M-B\NW4>U($BAK\@C@/TKR+7CY\YQZUZ=XN
MG\NV;GM7EF[[3<'OS51V">IZ#X"CV6Z_2NPU49LV^E<[X0B\N%?I73:@N;5A
M[5+W+6QXYK,>R[9O>L^*^\LXS6WXEC\MW:N FO2LQ&>]7<S6YU>3>N.]>A>%
MK/RXEXK@O"L?VMESS7K.D6ODQCBANR':[+=Y\EHWTKRWQ'*'=US7I^KMLL7/
MM7CFJ7/FWS+GO2B5-:&GX,BQ>YQWKU^/_5+]*\R\(P;9E;%>G)_JQ4RW+AL%
M+32:45(7!NE>>^/(C) WTKT(UR/BNV\V%N.U4F*1XM; PW(^M>Q>$+@&U&3V
MKRK4(/L]QT[UW/A*\VQ*,U;U1G%V9Z*&W/5I>%JE:,'4-FK4L@5.M9LW0R>8
M+WIL<@>,_2LF]N\$\U-IT_F1GGM2L*YR'BU<K(:\PL&*Z^O^]7J_BE-R/7E"
M+Y>M ^]-&;>I] :#,#IT8SVK8%<;X;O0;:-<]J["-@4'-(M:BLV*S]2N52U?
MGM4MU,%!YKE=;U'; XSVH)<K,X'Q#>F6\9 >]6O"=CF\#D=37.W,QN-5Q[UZ
M-X7LMNQL51">IWUM&$MU^E<=XJFV!QFNV3B ?2O.O&4NUV%*.YI/X3SUE,FK
M*?\ :KVOPPNW34'M7D5E")+Y6]Z]CT !+%1[5<C.*-6H9YEC4\TZ60*.M<[K
M&H>4K<U)6R.7\5ZCAF :N'AC-Q>JW7FKGB"_,TY&>]6= M?.D1L5:V)1Z%X;
MMMD"<=JZ.\;9;_A531K;9;KQVJ36'\N _2I>K+2LCRSQF1(Y^M=%\/4"PK7)
M^)I=\I^M==X!($2T-$+0]%J-^E.##UH."*DJUR./.ZK(Z5"@&:GI,T@K(***
M*184444 -D^X?I7E_B^4"5AFO3Y?]4WTKQGQQ=;+PC/>FB9;&;IB[K]#[U[-
MHPQ8I]*\=\/+YMPC5[-I2XLU^E6S-(O"LW4Q^Z?Z5IBJ&H+F)OI26Y70\&\6
MQG^U@?\ :KT7P3<JMDBY["N(\808OMV.AJ_X7U+RG2/-60D>S(VZ+(H4<U7T
M^42VBG/:K0P*R-;#)G"1GZ5YQXJOL%P#7::K="-&YKRGQ)>>9,PSWJHDR9S4
M:&?5 >O->M^&K3;"AQ7FND6QDO5..]>R:);;+5..U/8E*YL=(P*6.G[>*55Q
M4%6U'5G:R,V;?2M*L_51FU8>U"'L>+^((\3N?>M'P3(JW Y[U4\4KL9S5#PC
M>[+K&>]:F3/=X'#H,5-TK)TFY$L:\UJR, A.:AE15T-:55')IJ7"LV :Q[Z]
M\O/-5-/U#S;C&>]*Q:.FE^X:\H\;KF8_6O6#\T/X5Y=XVC_>M0B)HYO1#BX0
M>]>Q:-S9+]*\8TIMMVGUKV70F!L5^E,F!I*,FH[AQ&AJ<8S6/K-R(HSS1?4T
MMH<)XLOL2, :Y73K<SWR/C/-3>)KTR7.,]36MX8L_."OBKN8MGIOA]=EBH]J
ML:FVV(_2FZ8OEP*M1:T^V _2HZFL7>)Y!XW?>Y^M='\-UQ"M<KXL??*?K77_
M  Z7$*U;9CUL>D5B>)AG3V^E;H%8WB1<V#?2IN4HGBTIV7[GWKT3P;*&VUYM
MJC>7=N?>NW\ S^8ZC-5+8<5J>H/]S-<QXCG LI!GM732\0Y]J\]\57FV)US4
M1"HCS_3?F\1Y_P!JO=M*7_08_I7@>B/OU\'_ &J]^THC[#'SVILF"+3TJ=*5
ML4*1BE?0V2&'[U3+TIF,FI!TJ2T+1112&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M';%(C9H >WW:SI7(>M%NE49(LOF@!T39JP5R*AC3%6,X% F-5<4I% .:=3)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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H#I49ZU(.E(IBT444R0HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" RG"P,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***JRZC;1#_6!SZ)S_P#6K&OB*-"/-5DHKS948RD[)%JD
M9E12SL%4=23@5BRZQ,XQ$BQ^_4U1DEDF??(Y9O4U\WB^*\-3TH1<W]R_S_ Z
M8823^+0VY]5@B&(\RMGH.!^=9\VJW$F0I$:\_='/YU1HKYG%Y_CL3IS<J[1T
M_'?\3JAAZ<>ESHM.):PC))))8DGOR:*33/\ D'Q?C_,T5^AY:[X*BW_+'\D>
M;5^-^I;HHHKM("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"0?%^/\S17Z[EO^Y4?\,?R1XU7XWZENBBBNT@**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%%%%<984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% '0Z9_R#XOQ_F:*-,_Y!\7X_S-%?KN6_[E1_
MPQ_)'C5?C?J6Z***[2 HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(2%!)( '))[52FU
M6WCR%)D;G[HX_.N;$8RAAH\U::CZ_P"1482E\*+U,DE2%-\CA5]36+/JL\IQ
M'B)?0<G\ZHLS.Q9V+,>I)R:^;Q?%E&%XX>+D^[T7^?Y'5#"2?Q.QM2ZQ"AQ$
MC2<]>@K.EU&YE/\ K"@ST3C_ .O56BOF<7GF.Q6DIV79:?\ !?S9U0H4X;(*
M***\@V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#H=,_Y!\7X_S-%&F?\@^+
M\?YFBOUW+?\ <J/^&/Y(\:K\;]2W1117:0%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445
M%+<0P#][(J]\9Y_*HJ5(4X\TVDO,:3;LB6BLJ761C$,1^K_X#_&L^>\GN"=\
MAVG^$<#\J^?Q?$^#HZ4KS?EHOO?Z)G1#"SEOH;D]_;P#YG#,#C:O)K/FUB0Y
M$,84<\MR?\_G6917S.+XEQM?2F^1>6_W_P"5CJAA81WU'RS2S',CLW/&3TIE
M%%>!.<IRYI.[.A)+1!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** .ATS_ )!\7X_S-%&F?\@^+\?YFBOUW+?]RH_X8_DCQJOQOU+=%%%=
MI 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#H=,_Y!\7X_S-%&F?\@^+\?YFBOUW
M+?\ <J/^&/Y(\:K\;]2W1117:0%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%12W$, _>R*O?&>?RK/GU@ D01[O1FZ?E7!B\
MTPF$_C32?;=_<C2%*<]D:M5YKZW@R&D!89^5>3QV]JPY[V>X&))#MS]T<"J]
M?,XOBWIAH?.7^2_S.J&#_F9IS:Q(<B&,*.>6Y/\ G\ZH33RSMNE<L>V>@J.B
MOF,5F6+Q>E:;:[;+[EH=4*4(?"@HHHKA- HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#H=,_Y!\7X_
MS-%&F?\ (/B_'^9HK]=RW_<J/^&/Y(\:K\;]2W1117:0%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%(2%!)( '))[54EU.VB.-Y<YZ(,_KTK"OBJ
M&'7-6FH^K*C"4MD7*:\B1C+NJC.,L<5BRZO.Y_=A8QGTR?UJB\CR'+NS'IEC
MFOF\7Q7AX:8>+D^[T7^?Y'3#"2?Q.QM2ZO @_=AI#],"L^74[F48WA!Z(,?K
MUJG17S&+SW'8G1SY5VCI_P '\3JAAZ<>@I)8DDDDG))[TE%%>0W?5FP4444A
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 =#IG_ "#XOQ_F:*-,_P"0?%^/\S17Z[EO
M^Y4?\,?R1XU7XWZENBBBNT@**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** .ATS_D'Q?C_,T4:9_R#XOQ_F:*_7<M_P!RH_X8
M_DCQJOQOU+=%%%=I 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%,EFBA&9'5?3)ZUGS:P@R(8RQYY;@?Y_*N'%YEA<)_&FD
M^V[^Y:FD*4Y_"C3J">\@MP=\@W#^$<G\JPY[^XG/S.54\;5X%5J^9Q?%JUCA
MH?-_Y+_,Z88/^9FK+K)SB&(=>K_X#_&L^6XFG/[V1FYSC/'Y5%17S.+S3%XO
M2M-M=ME]R.J%*$-D%%%%>>:A1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 =#IG_(/B_'^9HHTS_D'Q?C
M_,T5^NY;_N5'_#'\D>-5^-^I;HHHKM("BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHJK+J-M$/]8'/HG/\ ]:L:^(HT(\U62BO-E1C*3LD6J1F5
M%+.P51U).!6++K$SC$2+'[]35&2629]\CEF]37S>+XKPU/2A%S?W+_/\#IAA
M)/XM#:GU:",E4!D8>G _.L^?5+B884B-<_P]?SJE17S&+S['8FZ<N5/HM/QW
M_$ZH8>G'H*26)))))R2>])117CMWU9L%%%%(84444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 =#IG_(/B_'^9HHTS_D'Q?C_,T5^NY;_N5'_#'\D>-5^-^I;HHHKM("BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHIDLT4(S(ZKZ9/6IG.,(\TG9#2;T0^BLR?6(U.
M(4+_ .T>!5"?4+B<$,^U3_"O KP<7Q)@J%U!\[\MOOV^ZYO##3EOH;DMW! <
M22J#GIU/Y5G2ZR<XAB'7J_\ @/\ &LJBOF<7Q/C*VE*T%Y:O[W^B1U0PL([Z
MDLUU-<8\V0L!VZ#\JBHHKY^I5G5ES5&V^[U.E))604445F,**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** .ATS_D'Q?C_,T4:9_P @^+\?YFBOUW+?
M]RH_X8_DCQJOQOU+=%%%=I 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !15674;:(?ZP.?1.?\ ZU9\
M^L2L2(5"+V)Y/^%>3B\[P6%^*=WV6K_R^]FT*%2>R-EF5%+.P51U).!5*;5;
M>/(4F1N?NCC\ZQ)9I9CF1V;GC)Z4ROF<7Q96EIAH**[O5_Y?F=4,)%?$R]-J
MMQ)D*1&O/W1S^=4F9G8L[%F/4DY-)17S6(QF(Q+O6FY>O^6QTQA&/PH****Y
MBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Z
M'3/^0?%^/\S11IG_ "#XOQ_F:*_7<M_W*C_AC^2/&J_&_4MT445VD!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH Z'3/^0?%^/\S11IG_ "#XOQ_F:*_7<M_W*C_AC^2/&J_&_4MT
M445VD!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#H=,_Y!\7X_P S11IG_(/B
M_'^9HK]=RW_<J/\ AC^2/&J_&_4MT445VD!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%->1(QEW51G&6.*4I**NW9 .HK.EUB%#B)&DYZ]!6?-J5S-CY]@'9.*\+
M%\1X&AI&7._+_/;[KG1##5);Z&Y+<0P#][(J]\9Y_*L^761C$,1^K_X#_&LB
MBOF,7Q1BZVE%*"^]_>_\CJAA8+?4GGO)[@G?(=I_A' _*H***^>JUJE:7/4D
MV_,Z$DE9!1116904444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!T.F?\
M@^+\?YFBC3/^0?%^/\S17Z[EO^Y4?\,?R1XU7XWZENBBBNT@**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH Z'3/^0?%^/\S11IG_ "#XOQ_F:*_7<M_W
M*C_AC^2/&J_&_4MT445VD!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !137D2,9=U49QECBJ$VKPI@1*9#^0KDQ6/PV%5Z
MTTOS^[<N-.4_A1HU%+<0P#][(J]\9Y_*L274[F48WA!Z(,?KUJG7S.+XMA'3
M#0OYO3\%_FCJA@W]IFO/K !(@CW>C-T_*J$][/<#$DAVY^Z.!5>BOF<7F^,Q
M=U4F[/HM%_P?G<ZH480V04445YAJ%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 =#IG_(/B_'^9HHTS_D'Q
M?C_,T5^NY;_N5'_#'\D>-5^-^I;HHHKM("BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% '0Z9_P @^+\?YFBC3/\
MD'Q?C_,T5^NY;_N5'_#'\D>-5^-^I;HHHKM("BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%* 6( !))P .]-*^B$)15A
M+&ZDSM@88_O?+_.IUTBY9028U/H3S^E=M++,95UA2E]S(=6"W90HK8314!^>
M9F'HJX_QJ=-*M5&"K/SU9O\ "O3I<,9A/XDH^K_RN9/%4T8%/2*27/EQL^.N
MT9Q721VT$1!2)%*\ A>?SJ6O3I<(/>K5^Y?JW^AD\9V1SL>G74@!\HJ">K'&
M/PZU931I2?GE11ZKD_X5LT5Z5'A; P^.\O5_Y6,GBZCVT,Q-&B ^>5V.>JX'
M^-65TZT1@PA&1ZDD?K5JBO3HY1@:/P4E\U?\[F3K5'NQB11Q9\N-4SUVC&:?
M117?&,8JT59&;=PHHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ&6[@@.))5!STZG\JSJ5
M:=*/-4DDO-V&DV[(FHK(EUDYQ#$.O5_\!_C6?-=37&/-D+ =N@_*OGL7Q1@Z
M.E*\W]R^]_HF=,,+-[Z&Y-J5M#CY]Y/9.:SY=8F<8B18_?J:SJ*^8Q?$>.KZ
M1ER+R_SW^ZQU0PU..^HYY'D.7=F/3+'--HHKPI2<G=N[-PHHHI#"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **>D4DN?+C9\==HSBI
MUTZ[=0PA.#ZD _K712PM>M_#@Y>B;)<XK=E6BM--&E)^>5%'JN3_ (5,FC1
M?/*['/5<#_&O3I</9C4_Y=V]6O\ AS)XFFNIC45T4>G6L9!$08CNQSG\.E3I
M%'%GRXU3/7:,9KTJ7".(?\6HEZ7?^1D\9'HCFUM;A]NV&0ANAVG'YU832KIC
M@JJ>[-_A6_17ITN$\+'6I.3^Y?Y_F9/&3Z(R%T5BHWS@-W 7(JPND6RL"3(P
M]">/TJ_17ITLAR^EM33];O\ /0R>(J/J0)96T8P($/.?F&?YU, %    '  [
M4M%>E2H4J2M3BEZ*QDY-[L****U$%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\[6Q%6O+GJR<GYG3&*BK)!1116)04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDOFK_G<S=:H]V,2*.+/EQJF>NT8S3Z**[XQC%6BK(R;N%%%%4 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(2%
M!)( '))[52FU6WCR%)D;G[HX_.N;$8RAAH\U::CZ_P"1482E\*+U,DE2%-\C
MA5]36+/JL\IQ'B)?0<G\ZHLS.Q9V+,>I)R:^;Q?%E&%XX>+D^[T7^?Y'5#"2
M?Q.QLSZQ$H(A4NW8G@?XUGRZC<RG_6%!GHG'_P!>JM%?,8O.\;BOBG9=EHO\
M_O9U0H4X;(****\DV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(2%!)(
M '))[4-VU8"T52GU2WA.%)D;_9Z?G6?/JT\@*H!&I].3^=>-B\^P.&NG+F:Z
M+7\=OQ-X8>I+H;;R)&,NZJ,XRQQ5"76(4.(D:3GKT%8K,SL6=BS'J2<FDKYC
M%\5XBIIAXJ"[[O\ R_!G5#"17Q:EN;4KF;'S[ .R<54HHKYROB:V(ES5I.3\
MSIC&,59(****P*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***4 L0 "23@ =Z
M:5]$(2BK"65S(<"!QW^88_G4Z:3<L,G8G/1F_P *[*66XRK\%*3^3_,AU8+=
ME"BM==%4,-\Y*]P%P:G32;5,[@SY_O-T_*O3I<,YA/XDH^K_ ,KF3Q5-&#3D
MC>0X1&8]<*,UTJVMNFW;#&"O0[1G\ZEKTZ7"$O\ E[5^Y?\ !_0R>,71'.KI
MUVZAA"<'U(!_6K"Z-,6&^2,+W(R36U17ITN%L##X[R]7_E8R>+J/8S$T:(#Y
MY78YZK@?XU873;1=O[K)'<D\U;HKTJ63X"E\-)?-7_.YFZU1[L8D4<6?+C5,
M]=HQFGT45Z$8QBK15D9-W"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=L,8*]#M&?SJ6BO2HY?A:/\ #II?)?F9.I.6["BBBNP@**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **IRZG;1'&\N<]$&?UZ50FU>9\"
M)1&/S->/B\]P.&TE/F?9:_\  ^]FT,/4ET-IF5%+.P51U).!5"75X$'[L-(?
MI@5BO(\AR[LQZ98YIM?,XOBNO/3#Q45W>K_R_,ZH82*^)W+DNIW,HQO"#T08
M_7K50DL22223DD]Z2BOFZ^*KXA\U:;EZLZHPC'9!1117.4%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%.2-Y#A$9CUPHS4Z6%U(,B%ASCYN/YUO2PU>M_#@Y
M>B;)<HK=E:BM)=&F+#?)&%[D9)J=-&C&?,F9O3:,?XUZ=+A_,:G_ "[MZM+]
M;F3Q%-=3&HKH5TVT7;^ZR1W)/-6$ABC.4B13TRJ@5Z5+A+$/^)42]+O_ ",G
MC(]$<TMO,ZADAD93T(4D5872[MF *!1ZEAC]*Z"BO3I<)8:/\2;?I9?YF3QD
MNB,=-%<CYYE4YZ*N?\*G71[<;2SR,1UY !K1HKTZ609=3VIW]6W_ , R>(J/
MJ5TL;6/.V!3G^]\W\ZG5510J*%4= !@4M%>E2P]&C_#@H^B2,W*3W84445L2
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHJ1;>9U#)#(RGH0I(JX0E-V@KB;2W(Z*N+I
M=VS % H]2PQ^E6$T5R/GF53GHJY_PKT:62YA5^&D_GI^=C-UZ:W9ET5MKH]N
M-I9Y&(Z\@ U92QM8\[8%.?[WS?SKTJ/"N-G\;4?G?\O\S)XN"V.;JPEE<R'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1152;4K:''S[R>R<UA7Q-'#QYJTE%>948RD[)%ND9E12SL%4=23@5
MBRZQ,XQ$BQ^_4U0>1Y#EW9CTRQS7SF+XKP]/3#Q<WWV7^?X(Z8823^+0VY]6
M@C)5 9&'IP/SK/GU2XF&%(C7/\/7\ZI45\QB\^QV)NG+E3Z+3\=_Q.J&'IQZ
M"DEB2222<DGO2445X[=]6;!1112&%%%% !1110 4444 %%%% !1110 4444
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MP%+X:2^>OYW,G6J/=C$ABC.4B13TRJ@4^BBO0C",%:*LC-MO<****H04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 444R6:*$9D=5],GK4SG&$>:3LAI-Z(?169/K$:G$*
M%_\ :/ JA/J%Q."&?:I_A7@5X.+XDP5"Z@^=^6WW[?=<WAAIRWT-N>\@MP=\
M@W#^$<G\JSY=9.<0Q#KU?_ ?XUE45\QB^)\96TI6@O+5_>_T2.J&%A'?4EEN
M)IS^]D9N<XSQ^51445\_4J3J2YIMM^9TI)*R"BBBH&%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%.2-Y#A$9CUPHS4Z6%U(,B%ASCYN/YUO2
MPU>M_#@Y>B;)<HK=E:BM&/1YV(WNB@]<<D5831HQGS)F;TVC'^->E2X?S&K_
M ,N[+S:7_!_ R>(IKJ8U%="NFVB[?W62.Y)YJPD,49RD2*>F54"O3I<)8A_Q
M*B7I=_Y&3QD>B.:6WF=0R0R,IZ$*2*L+I=VS % H]2PQ^E=!17ITN$L-'^)-
MOTLO\S)XR71&.FBN1\\RJ<]%7/\ A4ZZ/;C:6>1B.O( -:-%>G2R#+J>U._J
MV_\ @&3Q%1]2NEC:QYVP*<_WOF_G4ZJJ*%10JCH ,"EHKTJ6'HT?X<%'T21F
MY2>["BBBMB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **JR
MZC;1#_6!SZ)S_P#6K.EUB9QB)%C]^IKR<7GF!PNDIW?9:_\  7S9M"A4GLC:
M9E12SL%4=23@52GU6"(8CS*V>@X'YUB22R3/OD<LWJ:97S&+XLK3O'#Q45W>
MK_R_,ZH82*^)W+TVJW$F0I$:\_='/YU2)+$DDDDY)/>DHKYO$8ROB9<U:;EZ
M_P"1TQA&/PH****YBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ***JSZA;P$AGW,/X5Y-8UL12H1YZLE%>948N3LD6J0D*"20 .23V
MK'GUB1AB% G/WCR:SY9I9CF1V;GC)Z5\[B^*L+2]V@G-_<O\_P #HAA)OXM#
M;FU6WCR%)D;G[HX_.L^;5;B3(4B->?NCG\ZHT5\QB^(,=B=.;E7:.GX[_B=<
M,/3CTN*S,[%G8LQZDG)I***\5MMW9L%%%%(84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%->1(QEW51G&6.*H3:O"F!$ID/Y"N3%8_#857K32_/[MRXTY
M3^%&C44MQ# /WLBKWQGG\JQ)=3N91C>$'H@Q^O6J=?,XOBV$=,-"_F]/P7^:
M.J&#?VF:\NLC&(8C]7_P'^-9\]Y/<$[Y#M/\(X'Y5!17S&+S?&8O2K-V[+1?
MA^IU0HPAL@HHHKS34**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **FCM+B0C9"YW<@D8'YU832;I\[@J8_O-U_*NREE^+K?PZ<G\G;[]C-
MU(1W91HK671?NEY_J O]:L)I-LIR=[^S-_A7ITN&LPGO%1]6OTN9/%4T8-*J
ML[!44LQZ #)KI%L[9%"B"/ ]5R?UJ>O3I<(3?\6JEZ*_YV_(S>,71'.)874@
MR(6'./FX_G5A='N#M+/&H/7DDBMNBO2I<*X*'QN4OG;\E^ID\7-[&8FC1C/F
M3,WIM&/\:G72[15 *%CZECG]*N45Z=+)L!2^&DOGK^=S)UZCZC$ABC.4B13T
MRJ@4^BBO1C",%:*LC-MO<****H04444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDP'/(5?Z_P#UJUZ*]*EPSE]/XDY>K_RL9/%5&44TFV4Y.]_9F_PJ=+*VC&!
MAYS\PS_.IZ*].EEN#I?!2BODOS,G5F]V%%%%=I 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 444C,J*6=@JCJ2<"DVDKL!:*HSZK!$,1YE;/0<#\ZSYM5N),A
M2(UY^Z.?SKQ<7Q!@<-IS<S[1U_';\3>&'J2Z6-N6:*$9D=5],GK6?-K"#(AC
M+'GEN!_G\JQR2Q)))).23WI*^8Q?%.*JZ4$H+[W_ )?@=4,)!?%J69[^XG/S
M.54\;5X%5J**^=K5ZM>7/5DY/S.F,5%604445B4%%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45#+=P0'$D
MJ@YZ=3^59TNLG.(8AUZO_@/\:\[%YM@\)I5FK]EJ_N6WS-849SV1KU5EU&VB
M'^L#GT3G_P"M6%-=37&/-D+ =N@_*HJ^8Q?%LGIAH6\W_DO\V=4,&OM,T9=8
MF<8B18_?J:HR2R3/OD<LWJ:917S.*S#%8K^--O\ +[EH=,*<(?"@HHHKC- H
MHHH **** "BBB@ HHHH ***>D4DN?+C9\==HSBJC&4G:*NQ-V&45;73;MMO[
MK /<D<5831I2?GE11ZKD_P"%>A2R?'U?AI/YJWYV,W6IK=F916TNC0A1ODD+
M=R, 5873K1&#"$9'J21^M>G2X6QT_CM'U?\ E<R>+IK8YVI5M;A]NV&0ANAV
MG'YUTJ1I&,(BJ,YPHQ3J]*EPA'_E[5^Y?\']#)XQ]$8*:3=/G<%3']YNOY5.
MNBL5&^<!NX"Y%:]%>G2X9R^'Q)R]7_E8R>*J,HII-LIR=[^S-_A4Z65M&,"!
M#SGYAG^=3T5Z=++<'2^"E%?)?F9.K-[L0 *    . !VI:**[4K:(@**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "@   #@ =J].CPC4?\ %JI>BO\ G8R>,71'.)8W4F=L##'][Y?YU8CTBX8
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M=3_Y=W]6W_P#)XBH^I573K1&#"$9'J21^M6$C2,81%49SA1BG45Z=+"T*/\
M"@H^B2,G.4MV%%%%;DA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M3'9EP%C+D^X 'U_R:KR1WLS$>;'"F/X/F/ZX_2N>MB'3TC!R?9+]79?B5&-]
MW8L22I"F^1PJ^IJC+K$*'$2-)SUZ"C^R8W^:6:5W/5L]:G73K1&#"$9'J21^
MM>76>;U]*2C37F^9_E;^MS5>QCO=F/+J-S*?]84&>B<?_7J);6X?;MAD(;H=
MIQ^==*D:1C"(JC.<*,4ZO.?#-2O+GQ5=R?\ 7=O\C7ZTHZ0C8P4TFZ?.X*F/
M[S=?RJ==%8J-\X#=P%R*UZ*[:7#.7P^).7J_\K&;Q51E%-)ME.3O?V9O\*G2
MRMHQ@0(><_,,_P ZGHKTZ66X.E\%**^2_,R=6;W8@ 4    < #M2T45VI6T1
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45CWOBG
M1M.O)+2[O/+GCQN7RG.,@$<@8Z$57_X3;P[_ -!#_P @R?\ Q- '045S_P#P
MFWAW_H(?^09/_B:/^$V\._\ 00_\@R?_ !- '045S_\ PFWAW_H(?^09/_B:
M/^$V\._]!#_R#)_\30!T%%<__P )MX=_Z"'_ )!D_P#B:/\ A-O#O_00_P#(
M,G_Q- '045S_ /PFWAW_ *"'_D&3_P")H_X3;P[_ -!#_P @R?\ Q- '045S
M_P#PFWAW_H(?^09/_B:/^$V\._\ 00_\@R?_ !- '045S_\ PFWAW_H(?^09
M/_B:/^$V\._]!#_R#)_\30!T%%<__P )MX=_Z"'_ )!D_P#B:/\ A-O#O_00
M_P#(,G_Q- '045S_ /PFWAW_ *"'_D&3_P")H_X3;P[_ -!#_P @R?\ Q- '
M045S_P#PFWAW_H(?^09/_B:/^$V\._\ 00_\@R?_ !- '045S_\ PFWAW_H(
M?^09/_B:/^$V\._]!#_R#)_\30!T%%<__P )MX=_Z"'_ )!D_P#B:/\ A-O#
MO_00_P#(,G_Q- '045S_ /PFWAW_ *"'_D&3_P")H_X3;P[_ -!#_P @R?\
MQ- '045S_P#PFWAW_H(?^09/_B:/^$V\._\ 00_\@R?_ !- '045S_\ PFWA
MW_H(?^09/_B:/^$V\._]!#_R#)_\30!T%%<__P )MX=_Z"'_ )!D_P#B:/\
MA-O#O_00_P#(,G_Q- '045S_ /PFWAW_ *"'_D&3_P")H_X3;P[_ -!#_P @
MR?\ Q- '045S_P#PFWAW_H(?^09/_B:/^$V\._\ 00_\@R?_ !- '045S_\
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M -!#_P @R?\ Q- '045S_P#PFWAW_H(?^09/_B:/^$V\._\ 00_\@R?_ !-
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M-'_";>'?^@A_Y!D_^)H Z"BN?_X3;P[_ -!#_P @R?\ Q-'_  FWAW_H(?\
MD&3_ .)H Z"BN?\ ^$V\._\ 00_\@R?_ !-'_";>'?\ H(?^09/_ (F@#H**
MY_\ X3;P[_T$/_(,G_Q-'_";>'?^@A_Y!D_^)H Z"BN?_P"$V\._]!#_ ,@R
M?_$T?\)MX=_Z"'_D&3_XF@#H**Y__A-O#O\ T$/_ "#)_P#$T?\ ";>'?^@A
M_P"09/\ XF@#H**Y_P#X3;P[_P!!#_R#)_\ $T?\)MX=_P"@A_Y!D_\ B: .
M@HKG_P#A-O#O_00_\@R?_$T?\)MX=_Z"'_D&3_XF@#H**Y__ (3;P[_T$/\
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M (F@#H**Y_\ X3;P[_T$/_(,G_Q-;5K=07UK'<VTJRPR#*NO?_/I0!-1110
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M^)H Z"BN?_X3;P[_ -!#_P @R?\ Q-'_  FWAW_H(?\ D&3_ .)H Z"BN?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!Y!XV_Y&^^_[9_^BUKGZZ#QM_R-]]_V
MS_\ 1:US] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 58L;R;3KZ&\MVQ+"X9>3@^QQV/0^QJO10![KIVH0:II\-[;%
MC%*,C<,$8."#]""*M5YIX UU;.\;2ISB*Y?=$Q( 63'0_P"]@#Z@<<UZ70 4
M444 %%%% !1110 4444 %9/B/1AKNCR6@94E!#Q.V<*P]<>H)'?KG%:U% '@
M4D;Q2-'(C(Z$JRL,$$=013:[;X@Z(EK=1:I;QJD=P=DP48_><G/7N,]!_#GJ
M:XF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *] ^'>L_ZW2)G]
M9;?)_P"^E&3^( ']XUY_5BQO)M.OH;RW;$L+AEY.#[''8]#[&@#W>BJ]C>0Z
MC8PWENV8ID#+R,CV..XZ'W%6* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KRCQUJ_]HZX;:,Y@L\QCCJ_\9Z9Z@#_@.1UKO_$^K_V+H<URAQ.W
M[N'C^,]#T(X&3SUQCO7C% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 445I:#I3ZUK$%FNX(QW2L/X4'4YP<>@SW(H [3X>Z(B6KZO/&IDD)2W)
M&=JCAB.>YR.F>/0UW--CC2*-8XT5$0!551@ #H *=0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!Y!XV_Y&^^_P"V?_HM:Y^N@\;?\C???]L__1:US] !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 .CD>*1
M9(W9'0AE93@@CH0:]G\.:R-=T>.[*JDH)25%SA6'IGU!![]<9KQ:NB\':X='
MUA4D95M+DA)B0/EZ[6R<8P3S[$^U 'KM%%% !1110 4444 %%%% !1110!7O
MK.'4;&:SN%S%,A5N!D>XSW'4>XKQ"^LYM.OIK.X7$L+E6X.#[C/8]1[&O=ZX
MGX@Z(]U:Q:I;QL\EN-DP49_=\G/7L<]!_%GH* /-J*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#N/AWJ_DWDNE2'Y)\R1<?Q@<CIW49Y/\/O
M7H]>"03R6UQ%<0MMEB<.C8S@@Y!YKV_2M0CU72[>^B&%F3)7^Z>A'09P01GV
MH N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 445S_ (PUG^R-#D\M]MU<
M?NHL'!&>K=0>!W'0D4 <-XVUM-6U@16\BO:VHV(RG(9C]X@X]@.X^7(ZUS-%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ZWX,T)M&TGS)ABZ
MNMLD@P04&/E4@]QDYXZG':N(\&:$NLZMYDPS:VNV208!#G/RJ0>QP<\=!CO7
MK= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!Y!XV_Y&^^_[9_\ HM:Y^N@\;?\
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M0=536='@O%VAV&V51_"XZC&3CU&>Q%:5 !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %>0>,-9_M?7)/+?=:V_[J+!R#CJW4CD]QU %=_XPUG^R-#D\M]MU<?NH
ML'!&>K=0>!W'0D5Y!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%.CC>618XT9W<A551DDGH *;7<> -!\^X;5;J#,,7%OO7AGSRPY_AQCIU/J*
M .S\/Z/'H>DQVB<R'YYFW9#2$#)'MQ@<=!ZUJ444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'D'C;_ )&^^_[9_P#HM:Y^N@\;?\C???\ ;/\ ]%K7/T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>B?#[75>$Z+,<.FZ2!B0 1U*^N<DGOQGIBO.ZL6-Y-IU]#>6[8EA
M<,O)P?8X['H?8T >[T53TK4(]5TNWOHAA9DR5_NGH1T&<$$9]JN4 %%%% !1
M110 4444 %%%% !7DWC;1$TG6!+;QJEK=#>BJ,!6'W@!GW![#YL#I7K-9NO:
M4FM://9MM#L-T3'^%QT.<''H<=B: /$J*DG@DMKB6WF7;+$Y1USG!!P1Q4=
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!V'@#6?L6J-I\SX@NON
M9/"R#IU.!D<>I.VO3Z\"CD>*19(W9'0AE93@@CH0:]KT'54UG1X+Q=H=AME4
M?PN.HQDX]1GL10!I4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<OXZU?\ L[0S;1G$
M]YF,<=$_C/3'0@?\"R.E ' >)]7_ +:UR:Y0Y@7]W#Q_ .AZ \G)YZ9QVK'H
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +6G:?/JFH0V5L%,L
MIP-QP!@9)/T )KVVQLX=.L8;.W7$4*!5X&3[G'<]3[FN3\ :$UG9MJLXQ+<I
MMB4@@K'GJ?\ >P#] .>:[2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(
M/&W_ "-]]_VS_P#1:US]=!XV_P"1OOO^V?\ Z+6N?H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#R#QM_R-]]_VS_]%K7/UT'C;_D;[[_MG_Z+6N?H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M
M[PGK@T/6%>9F%I,-DP )QZ-CV/UX)Q6#10![_17)^!==74=+%A*<7-F@49(^
M>/H"![< _ASS764 %%%% !1110 4444 %%%% !7&^/M#%YI_]J0HQN+8 . 2
M=T63V]B<YXXSGM7944 > 45M>)]$?1-8EB6-A:R$O;MC@KZ9R>F<<\]#WK%H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .H\"ZO_9VN"VD.(+S$
M9XZ/_ >F>I(_X%D]*]7KP"O9_#&K_P!M:'#<N<SK^[FX_C'4] .1@\=,X[4
M;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4V21(HVDD=41 69F.  .I)IU<?X_UG[%I:Z?"^)[K[^#
MRL8Z]#D9/'H1NH X+7M5?6=8GO&W!&.V)3_"@Z#&3CU..Y-9M%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !114D$$ES<16\*[I97"(N<9). .: .H\
M"Z$VHZH+^48MK-PPR#\\G4 'VX)_#CFO4ZS]%TF'1-+BLH3OVY+R%0"['J3C
M\OH *T* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(/&W_(WWW_;
M/_T6M<_70>-O^1OOO^V?_HM:Y^@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D'C;_ )&^
M^_[9_P#HM:Y^N@\;?\C???\ ;/\ ]%K7/T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@CBHZ] ^(FC?ZK5X4](KC _[Y8X'X$D_W17G] !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!T'@_6?[(UR/S'VVMQ^ZER< 9Z-U X/<] 37K]> 5
MZSX)UM]6T<Q7$C/=6IV.S')93]TDX]B.Y^7)ZT =-1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<\\=M;RW$S;8HD
M+NV,X &2>*DKA/B#KJI"-%A.7?;).P(( ZA?7.0#VXQUS0!P^JZA)JNJ7%]*
M,-,^0O\ ='0#H,X  S[53HHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ***W/"VA-KNK+&XQ:PXDG)!P1G[N1T)^O3)[4 =KX#T,Z?IK7\Z+Y]V 4Y!
MVQ8R/IGJ1GLO<5UU%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!Y!XV_Y&^^_[9_\ HM:Y^N@\;?\ (WWW_;/_ -%K7/T %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 >G^ -9^VZ6VGS/F>U^YD\M&>G4Y.#QZ ;:["O#-*U"32M4M[Z(9:
M%\E?[PZ$=#C()&?>O:[&\AU&QAO+=LQ3(&7D9'L<=QT/N* +%%%% !1110 4
M444 %%%% !1110!X]XLT,:'K#)"C"TF&^$DDX]5S['Z\$9K!KV7Q/HB:WH\L
M2QJ;J,%[=L<AO3.1UQCGCH>U>.21O%(T<B,CH2K*PP01U!% #:*** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R#QM_P C
M???]L_\ T6M<_70>-O\ D;[[_MG_ .BUKGZ "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% %S2M0DTK5+>^B&6A?)7^\.A'0XR"1GWKV^
M">.YMXKB%MT4J!T;&,@C(/->"5Z1\.]7\ZSETJ0_/!F2+C^ GD=.S'/)_B]J
M .WHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LW7M531M'GO&VE
MU&V)3_$YZ#&1GU..P-:5>8>/]9^VZHNGPOF"U^_@\-(>O0X.!QZ@[J .1DD>
M61I)'9W<EF9CDDGJ2:;110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MT7@[0SK&L*\B*UI:D/,"1\W7:N#G.2.?8'VKGXXWED6.-&=W(5549))Z "O:
M?#^CQZ'I,=HG,A^>9MV0TA R1[<8''0>M &I1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!Y!XV_Y&^^_[9_\ HM:Y^N@\
M;?\ (WWW_;/_ -%K7/T %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MK>'-9.A:Q'=E6>(@I*BXRRGTSZ$ ]NF,UDT4 >^QR)+&LD;JZ. RLIR"#T(-
M.KB_ &NM>6;:5.<RVR;HF))+1YZ'_=R!]"..*[2@ HHHH **** "BBB@ HHH
MH *YGQMHCZMHXEMXV>ZM3O15&2RG[P S[ ]S\N!UKIJ* / **Z+QCH9T?6&>
M-%6TNB7A (^7IN7 QC!/'L1[USM !1110 4444 %%%% !1110 4444 %%%%
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MPH Z[X?:(EU=2ZI<1J\=N=D(89_><'/7L,=1_%GJ*])JO8V<.G6,-G;KB*%
MJ\#)]SCN>I]S5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH \@\;?\ (WWW_;/_ -%K7/UT'C;_ )&^^_[9_P#HM:Y^
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'D'C;_D;[[_MG_Z+6N?KH/&W_(WWW_;/_P!%K7/T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5-:6SWEY!:QE0\TBQJ6Z DX&?SJ&M#0O^1ATS_K[B_\
M0Q0!T'_"N-8_Y^;'_OM__B:/^%<:Q_S\V/\ WV__ ,37I]% 'F'_  KC6/\
MGYL?^^W_ /B:/^%<:Q_S\V/_ 'V__P 37I]% 'F'_"N-8_Y^;'_OM_\ XFC_
M (5QK'_/S8_]]O\ _$UZ?10!YA_PKC6/^?FQ_P"^W_\ B:/^%<:Q_P _-C_W
MV_\ \37I]% 'F'_"N-8_Y^;'_OM__B:/^%<:Q_S\V/\ WV__ ,37I]% 'F'_
M  KC6/\ GYL?^^W_ /B:/^%<:Q_S\V/_ 'V__P 37I]% 'F'_"N-8_Y^;'_O
MM_\ XFC_ (5QK'_/S8_]]O\ _$UZ?10!YA_PKC6/^?FQ_P"^W_\ B:/^%<:Q
M_P _-C_WV_\ \37I]% 'F'_"N-8_Y^;'_OM__B:/^%<:Q_S\V/\ WV__ ,37
MI]% 'F'_  KC6/\ GYL?^^W_ /B:/^%<:Q_S\V/_ 'V__P 37I]% 'F'_"N-
M8_Y^;'_OM_\ XFC_ (5QK'_/S8_]]O\ _$UZ?10!YA_PKC6/^?FQ_P"^W_\
MB:/^%<:Q_P _-C_WV_\ \37I]% 'F'_"N-8_Y^;'_OM__B:/^%<:Q_S\V/\
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M;*H!)://4?[N2?H3SQ7FE !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5
MBQO)M.OH;RW;$L+AEY.#[''8]#[&J]% 'N>E:A'JNEV]]$,+,F2O]T]".@S@
M@C/M5RO./AWJ_DWDNE2'Y)\R1<?Q@<CIW49Y/\/O7H] !1110 4444 %%%%
M!1110 4444 8/BS7#H>CL\+*+N8[(00#CU;'L/KR1FO'JZ#QAK/]KZY)Y;[K
M6W_=18.0<=6ZD<GN.H KGZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBNJ\#:(^H:PE[+&WV6T._=CAI!]T9SV^]WZ 'K0!V?@[0QH^CJ\B,MW= /,
M"3\O7:N#C& >?<GVKHJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH \@\;?\ (WWW_;/_ -%K7/UT'C;_ )&^
M^_[9_P#HM:Y^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M#0O^1ATS_K[B_]
M#%9]:&A?\C#IG_7W%_Z&* /;Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW'0D5T%>.>*==;7=6:1#BUAS'  3@C/WL'H3].F!VH PZ*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** )(()+FXBMX5W2RN$1<XR2< <U[3H.E)HNCP
M6:[2ZC=*P_B<]3G SZ#/8"N0^'NAAF?69T;*$I;<D=L,WOUP.?[WH*]!H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH \@\;?\C???]L__ $6M<_70>-O^1OOO^V?_ *+6N?H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ K0T+_ )&'3/\ K[B_]#%9]:&A?\C#IG_7W%_Z
M&* /;Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RCQK
MH/\ 96J?:;:#98W'*[5PJ/W7K[9'3K@=*Y>O;=>TI-:T>>S;:'8;HF/\+CH<
MX./0X[$UXM/!);7$MO,NV6)RCKG."#@CB@".BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "G1R/%(LD;LCH0RLIP01T(--HH ]MT'54UG1X+Q=H=AME4?PN
M.HQDX]1GL16E7F'@#6?L6J-I\SX@NON9/"R#IU.!D<>I.VO3Z "BBB@ HHHH
M **** .7\=:O_9VAFVC.)[S,8XZ)_&>F.A _X%D=*\HK8\3ZO_;6N37*',"_
MNX>/X!T/0'DY//3..U8] !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5S
M2M/DU75+>QB.&F?!;^Z.I/49P 3CVJG7J/@/0SI^FM?SHOGW8!3D';%C(^F>
MI&>R]Q0!U%K:P6-K';6T2Q0QC"HO;_/K4U%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D'C;_D;[[_
M +9_^BUKGZZ#QM_R-]]_VS_]%K7/T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5H:%_R,.F?]?<7_ *&*SZT-"_Y&'3/^ON+_ -#% 'M]%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5YY\0="9)AK4(RC[8YU )(/0-Z
M8P .W..N:]#JO?6<.HV,UG<+F*9"K<#(]QGN.H]Q0!X115S5=/DTK5+BQE.6
MA? ;^\.H/4XR"#CWJG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 Z.1X
MI%DC=D="&5E."".A!KVO0=536='@O%VAV&V51_"XZC&3CU&>Q%>)5U7@;6WT
M_6$LI9&^RW9V;<\+(?NG&._W>W4$]* /5:*** "BBB@ KD_'6NKIVEFPB.;F
M\0J<$?)'T)(]^0/QYXKJI)$BC:21U1$!9F8X  ZDFO%->U5]9UB>\;<$8[8E
M/\*#H,9./4X[DT 9M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &YX
M6T)M=U98W&+6'$DY(.",_=R.A/UZ9/:O8ZP_"VA+H6DK&XS=38DG) R#C[N1
MU ^O7)[UN4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'D'C;_D;[[_MG_Z+6N?KH/&W_(WWW_;/
M_P!%K7/T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5H:%_P C#IG_ %]Q?^AB
ML^M#0O\ D8=,_P"ON+_T,4 >WT444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!Q_C_1OMNEKJ$*9GM?OX'+1GKT&3@\^@&ZO,*]_K
MQKQ/HCZ)K$L2QL+60E[=L<%?3.3TSCGGH>] &+1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110![/X8U?^VM#AN7.9U_=S<?QCJ>@'(P>.F<=JV*\H\"
MZO\ V=K@MI#B"\Q&>.C_ ,!Z9ZDC_@63TKU>@ HHJ.>>.VMY;B9ML42%W;&<
M #)/% ')^/\ 6?L6EKI\+XGNOOX/*QCKT.1D\>A&ZO,*TM>U5]9UB>\;<$8[
M8E/\*#H,9./4X[DUFT %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %==X#
MT,:AJ37\Z-Y%H04Y(W2YR/KCJ1GNO8UR]K:SWUU';6T32S2'"HO?_/K7MNE:
M?'I6EV]C$<K"F"W]X]2>IQDDG'O0!<HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(/?#-[=,#G^]ZBN]J."".VMXK>%=L42!$7.< # '-24 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!Y!XV_Y&^^_P"V?_HM:Y^N@\;?\C???]L__1:US] !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %:&A?\C#IG_7W%_P"ABL^M#0O^1ATS_K[B_P#0Q0![
M?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!1U?2X-8TV:SG5<./D<C/EMCAA]/UZ=Z\2G@DMKB6WF7;+$Y1USG!!P1Q7O
M=<%\0M#+*FLP(N$ 2YY [X5O?K@\_P!WT- 'GM%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '5:KXL?4/"=IIQ9C<D[;EC_$J8VG)SG/!)R#E3V-<K
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5ZKX&T1-/T=+V6-?M5V-
M^['*QG[HSGO][MU /2N,\':&=8UA7D16M+4AY@2/FZ[5P<YR1S[ ^U>NT %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 >0>-O^1OOO^V?_ *+6N?KH/&W_ "-]]_VS
M_P#1:US] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %:&A?\C#IG_7W%_Z&*SZ
MT-"_Y&'3/^ON+_T,4 >WT444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %1SP1W-O+;S+NBE0HZYQD$8(XJ2B@#Q#6M)FT35
M);*8[]N"D@4@.IZ$9_+Z@BL^O4_'6A+J.EF_B&+FS0L< ?/'U()]N2/QXYKR
MR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ IT<;RR+'&C.[D*JJ,DD] !3:[3P!H2WEXVJSC,5L^V)2
M0TF.I_W<@_4CGB@#M?#FC#0M'CM"RO*27E=<X9CZ9]  .W3.*UJ** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** /(/&W_ "-]]_VS_P#1:US]=!XV_P"1OOO^V?\
MZ+6N?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K0T+_D8=,_Z^XO_0Q6?6AH
M7_(PZ9_U]Q?^AB@#V^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\>\6:&-#UADA1A:3#?"22<>JY]C]>",U[#6
M/XGTC^VM#FMD&9U_>0\_QCH.H'(R.>F<]J /&**=)&\4C1R(R.A*LK#!!'4$
M4V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** +%C9S:C?0V=NN99G"KP<#W..PZGV%>WV-G#IUC#9VZXBA0*O R
M?<X[GJ?<UR/P^T1[6UEU2XC9)+@;(0PQ^[X.>O<XZC^'/0UVU !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!Y!XV_P"1OOO^V?\ Z+6N?KH/&W_(WWW_ &S_
M /1:US] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %:&A?\C#IG_7W%_Z&*SZT
M-"_Y&'3/^ON+_P!#% 'M]%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >9>/M#-GJ']J0HHM[D@. 0-LN#V]
MP,YYYSGM7&U[GJNGQZKI=Q8RG"S)@-_=/4'J,X(!Q[5XI?6<VG7TUG<+B6%R
MK<'!]QGL>H]C0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *U/#^CR:YJT=HG$8^>9MV"L8(R1[\X''4^E9=>N^#M#&
MCZ.KR(RW=T \P)/R]=JX.,8!Y]R?:@#H(XTBC6.-%1$ 5548  Z "G444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'D'C;_D;[[_MG_P"BUKGZZ#QM_P C
M???]L_\ T6M<_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6AH7_(PZ9_U]Q?
M^ABL^IK2Y>SO(+J,*7AD610W0D'(S^5 'O-%>8?\+'UC_GVL?^^'_P#BJ/\
MA8^L?\^UC_WP_P#\50!Z?17F'_"Q]8_Y]K'_ +X?_P"*H_X6/K'_ #[6/_?#
M_P#Q5 'I]%>8?\+'UC_GVL?^^'_^*H_X6/K'_/M8_P#?#_\ Q5 'I]%>8?\
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MU[2GT76)[-MQ13NB8_Q(>AS@9]#CN#6;0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !114D$$ES<16\*[I97"(N<9). .: .B\$Z(F
MK:P9;B-7M;4;W5AD,Q^Z",^Q/<?+@]:]9K-T'2DT71X+-=I=1NE8?Q.>IS@9
M]!GL!6E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D'C;_D;[[_MG
M_P"BUKGZZ#QM_P C???]L_\ T6M<_0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %>G_  X_Y%ZX_P"OMO\ T!*\PKT_X<?\B]<?]?;?^@)0!V%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!S/C;1'U;1Q+;QL]U:G>BJ,EE/W@!GV![GY<#K7DU>_UY)XST)=&U;S(
M1BUNMTD8P $.?F4 =AD8XZ'':@#FZ*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KO/A]H3/,=:F&$3=' I!!)Z%O3&"1WYSTQ7'Z5I\F
MJZI;V,1PTSX+?W1U)ZC. "<>U>UV-G#IUC#9VZXBA0*O R?<X[GJ?<T 6***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \@\;?\ (WWW_;/_ -%K
M7/UT'C;_ )&^^_[9_P#HM:Y^@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \@\;?\ (WWW_;/_ -%K7/UT'C;_ )&^^_[9
M_P#HM:Y^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!Y!XV_Y&^^_[9_^BUKGZZ#QM_R-]]_VS_\ 1:US] !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5Z?\./\ D7KC_K[;_P! 2O,*]/\ AQ_R+UQ_
MU]M_Z E '84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4V2-)8VCD171P596&00>H(IU% 'BWB
M/1CH6L26@9GB(#Q.V,LI]<>A!';IG%9->O\ C#1O[7T.3RTW75O^]BP,DXZK
MT)Y'8=2!7D% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5)!!)<W$5O"NZ65PB+
MG&23@#FHZ]"^'NAE5?69T7#@I;<@]\,WMTP.?[WJ* .OTC2X-'TV&S@5<(/G
M<#'F-CEC]?TZ=JO444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'D'C;_D;[[_MG_Z+6N?KH/&W_(WWW_;/_P!%K7/T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7I_PX_P"1>N/^OMO_ $!*\PKT_P"''_(O7'_7
MVW_H"4 =A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5Y5XYT1]/UA[V*-OLMV=^['"R'
M[PSGO][MU('2O5:S=>TI-:T>>S;:'8;HF/\ "XZ'.#CT..Q- 'B5%23P26UQ
M+;S+MEB<HZYS@@X(XJ.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#0T729M;U2*RA.S=
MDO(5)"*.I./R^I KVN"".VMXK>%=L42!$7.< # '-<OX%T)=.TL7\HS<WB!A
MD#Y(^H /OP3^''%=90 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'D'C;_D;[[_ +9_^BUKGZZ#QM_R-]]_VS_]%K7/T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7I_PX_Y%ZX_Z^V_] 2O,*]/^''_(O7'_
M %]M_P"@)0!V%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y]\0M#"LFLP(V7(2Y
MY)[85O;I@\_W?4UP->\W5K!?6LEM<Q++#(,,C=_\^M>):KI\FE:I<6,IRT+X
M#?WAU!ZG&00<>] %.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *Z#P?HW]KZY'YB;K6W_>RY&0<
M=%Z$<GL>H!K!CC>618XT9W<A551DDGH *]E\,:1_8NAPVSC$[?O)N?XSU'4C
M@8''7&>] &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'D'C;_ )&^^_[9_P#HM:Y^N@\;?\C???\ ;/\ ]%K7/T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7I_PX_Y%ZX_Z^V_] 2O,*]/^''_ "+U
MQ_U]M_Z E '84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'^/]&^VZ6NH0IF>U
M^_@<M&>O09.#SZ ;J["B@#P"BMSQ3H3:%JS1H,VLV9(" < 9^[D]2/KTP>]8
M= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !115BQLYM1OH;.W7,LSA5X.![G'8=3["@#K/ &A+>7C:K.,Q6S
M[8E(!#28ZG_=R#]2.>*]+JKIVGP:7I\-E;!A%$,#<<DY.23]22:M4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >0>-O^
M1OOO^V?_ *+6N?KH/&W_ "-]]_VS_P#1:US] !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5Z?\ #C_D7KC_ *^V_P#0$KS"O3_AQ_R+UQ_U]M_Z E '8444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!A^*="77=):-!BZAS) 0!DG'W<GH
M#]>N#VKQRO?Z\N\>:&-/U);^!&\B[)+\D[9<Y/TSU SV;L* .1HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KT
MCP!H/D6[:K=08FEXM]Z\JF.6'/\ %G'3H/0UQ?A_1Y-<U:.T3B,?/,V[!6,$
M9(]^<#CJ?2O:8XTBC6.-%1$ 5548  Z "@!U%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D'C;_D;[[_MG_Z+6N?K
MH/&W_(WWW_;/_P!%K7/T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7I_PX
M_P"1>N/^OMO_ $!*\PKT_P"''_(O7'_7VW_H"4 =A1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!Y!XV_P"1OOO^V?\ Z+6N?KH/&W_(WWW_ &S_
M /1:US] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z?\./^1>N/^OMO_0$
MKS"O3_AQ_P B]<?]?;?^@)0!V%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% $<\$=S;RV\R[HI4*.N<9!&".*\4UK29M$U26RF._;@I(%(#J>A&?R^
MH(KV^N3\=:$NHZ6;^(8N;-"QP!\\?4@GVY(_'CF@#RRBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!T<;RR+'&C.[D*JJ,DD]
M!7M>@Z4FBZ/!9KM+J-TK#^)SU.<#/H,]@*XSX>Z([W3ZO/&PCC!2W)&-S'AB
M.>PR.F.?45Z+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'D'C;_D;[[_MG_Z+6N?KH/&W_(WWW_;/_P!%
MK7/T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7I_PX_P"1>N/^OMO_ $!*
M\PKT_P"''_(O7'_7VW_H"4 =A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \@\;?\C???\ ;/\ ]%K7/UT'C;_D
M;[[_ +9_^BUKGZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KT_X<?\B]<?
M]?;?^@)7F%>G_#C_ )%ZX_Z^V_\ 0$H ["BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *\R\?:&;/4/[4A11;W) < @;9<'M[@9SSSG/:O3:
MJZCI\&J:?-97(8Q2C!VG!&#D$?0@&@#PJBK%]9S:=?36=PN)87*MP<'W&>QZ
MCV-5Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#:\,:(^MZQ%$T
M;&UC(>X;' 7TSD=<8XYZGM7L<<:11K'&BHB *JJ,  = !6'X3T,Z'HZI,BB[
MF.^8@@X]%S[#Z\DXK>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^(O^@?\ ^1H__BJ/^$)\1?\ 0/\ _(T?_P 50!S]%=!_PA/B+_H'_P#D:/\
M^*H_X0GQ%_T#_P#R-'_\50!S]>G_  X_Y%ZX_P"OMO\ T!*Y#_A"?$7_ $#_
M /R-'_\ %5W?@K2[W2-&FM[Z'RI6N&<+N#<;5&>"?0T =)1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M $6M<_70>-O^1OOO^V?_ *+6N?H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M0T+_ )&'3/\ K[B_]#%9]:&A?\C#IG_7W%_Z&* /;Z*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR#QM_R-]]_VS_\ 1:UZ_7D'
MC;_D;[[_ +9_^BUH Y^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -#0O\
MD8=,_P"ON+_T,5[?7B&A?\C#IG_7W%_Z&*]OH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M(/&W_(WWW_;/_P!%K7/UT'C;_D;[[_MG_P"BUKGZ "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *T-"_P"1ATS_ *^XO_0Q6?6AH7_(PZ9_U]Q?^AB@#V^BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\@\;?\C???
M]L__ $6M>OUY!XV_Y&^^_P"V?_HM: .?HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#0T+_ )&'3/\ K[B_]#%>WUXAH7_(PZ9_U]Q?^ABO;Z "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#R#QM_R-]]_VS_\ 1:US]=!XV_Y&^^_[9_\ HM:Y^@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "M#0O\ D8=,_P"ON+_T,5GUH:%_R,.F?]?<
M7_H8H ]OHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O(/&W_(WWW_;/_P!%K7K]>0>-O^1OOO\ MG_Z+6@#GZ*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH T-"_P"1ATS_ *^XO_0Q7M]>(:%_R,.F?]?<7_H8
MKV^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH \@\;?\C???]L__ $6M<_70>-O^1OOO^V?_
M *+6N?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K0T+_ )&'3/\ K[B_]#%9
M]:&A?\C#IG_7W%_Z&* /;Z*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KR#QM_R-]]_VS_\ 1:UZ_7D'C;_D;[[_ +9_^BUH Y^B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** -#0O\ D8=,_P"ON+_T,5[?7B&A
M?\C#IG_7W%_Z&*]OH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /(/&W_(WWW_;/_P!%K7/U
MT'C;_D;[[_MG_P"BUKGZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *T-"_P"1
MATS_ *^XO_0Q6?6AH7_(PZ9_U]Q?^AB@#V^BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *\@\;?\C???]L__ $6M>OUY!XV_Y&^^
M_P"V?_HM: .?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#0T+_ )&'3/\
MK[B_]#%>WUXAH7_(PZ9_U]Q?^ABO;Z "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R#QM_R-
M]]_VS_\ 1:US]=!XV_Y&^^_[9_\ HM:Y^@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "M#0O\ D8=,_P"ON+_T,5GUH:%_R,.F?]?<7_H8H ]OHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O(/&W_(WWW_;/_P!%
MK7K]>0>-O^1OOO\ MG_Z+6@#GZ*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M T-"_P"1ATS_ *^XO_0Q7M]>(:%_R,.F?]?<7_H8KV^@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH \@\;?\C???]L__ $6M<_70>-O^1OOO^V?_ *+6N?H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K0T+_ )&'3/\ K[B_]#%9]:&A?\C#IG_7W%_Z&* /
M;Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR#Q
MM_R-]]_VS_\ 1:UZ_7D'C;_D;[[_ +9_^BUH Y^BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** -#0O\ D8=,_P"ON+_T,5[?7B&A?\C#IG_7W%_Z&*]OH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /(/&W_(WWW_;/_P!%K7/UT'C;_D;[[_MG_P"BUKGZ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *T-"_P"1ATS_ *^XO_0Q6?6AH7_(
MPZ9_U]Q?^AB@#V^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *\@\;?\C???]L__ $6M>OUY!XV_Y&^^_P"V?_HM: .?HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#0T+_ )&'3/\ K[B_]#%>WUXAH7_(PZ9_
MU]Q?^ABO;Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#R#QM_R-]]_VS_\ 1:US]=!XV_Y&
M^^_[9_\ HM:Y^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M#0O\ D8=,_P"O
MN+_T,5GUH:%_R,.F?]?<7_H8H ]OHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "O(/&W_(WWW_;/_P!%K7K]>0>-O^1OOO\ MG_Z
M+6@#GZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH T-"_P"1ATS_ *^XO_0Q
M7M]>(:%_R,.F?]?<7_H8KV^@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \@\;?\C???]L__
M $6M<_70>-O^1OOO^V?_ *+6N?H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M0T+_ )&'3/\ K[B_]#%9]:&A?\C#IG_7W%_Z&* /;Z*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR#QM_R-]]_VS_\ 1:UZ_7D'
MC;_D;[[_ +9_^BUH Y^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -#0O\
MD8=,_P"ON+_T,5[?7B&A?\C#IG_7W%_Z&*]OH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M(/&W_(WWW_;/_P!%K7/UT'C;_D;[[_MG_P"BUKGZ "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *L6%U]BU&VN]F_R)5DVYQNVD'&?PJO10!Z!_PLW_ *A'_DS_
M /84?\+-_P"H1_Y,_P#V%>?T4 >@?\+-_P"H1_Y,_P#V%'_"S?\ J$?^3/\
M]A7G]% 'H'_"S?\ J$?^3/\ ]A1_PLW_ *A'_DS_ /85Y_10!Z!_PLW_ *A'
M_DS_ /84?\+-_P"H1_Y,_P#V%>?T4 >@?\+-_P"H1_Y,_P#V%'_"S?\ J$?^
M3/\ ]A7G]% 'H'_"S?\ J$?^3/\ ]A1_PLW_ *A'_DS_ /85Y_10!Z!_PLW_
M *A'_DS_ /84?\+-_P"H1_Y,_P#V%>?T4 >@?\+-_P"H1_Y,_P#V%'_"S?\
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M4 >@?\+-_P"H1_Y,_P#V%'_"S?\ J$?^3/\ ]A7G]% 'H'_"S?\ J$?^3/\
M]A1_PLW_ *A'_DS_ /85Y_10!Z!_PLW_ *A'_DS_ /84?\+-_P"H1_Y,_P#V
M%>?T4 >GZ)XY_MC5X+#^SO)\W=\_G[L84GIM'I785Y!X)_Y&^Q_[:?\ HMJ]
M?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *\@\;?\C???\ ;/\ ]%K7K]>0>-O^1OOO^V?_ *+6@#GZ*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH T-"_Y&'3/^ON+_P!#%>WUXAH7_(PZ9_U]
MQ?\ H8KV^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \@\;?\C???\ ;/\ ]%K7/UT'C;_D
M;[[_ +9_^BUKGZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#H/!/_(WV/\ VT_]%M7K]>0>
M"?\ D;['_MI_Z+:O7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "O(/&W_(WWW_;/_T6M>OUY!XV_P"1OOO^V?\
MZ+6@#GZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH T-"_Y&'3/^ON+_ -#%
M>WUXAH7_ ",.F?\ 7W%_Z&*]OH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(/&W_(WWW_;
M/_T6M<_70>-O^1OOO^V?_HM:Y^@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Z#P3_R-]C_V
MT_\ 1;5Z_7D'@G_D;['_ +:?^BVKU^@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR#QM_R-]]_VS_\ 1:UZ_7D'
MC;_D;[[_ +9_^BUH Y^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -#0O\
MD8=,_P"ON+_T,5[?7B&A?\C#IG_7W%_Z&*]OH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M(/&W_(WWW_;/_P!%K7/UT'C;_D;[[_MG_P"BUKGZ "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#H/!/_ "-]C_VT_P#1;5Z_7D'@G_D;['_MI_Z+:O7Z "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O(/&W_ "-]
M]_VS_P#1:UZ_7D'C;_D;[[_MG_Z+6@#GZ*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH T-"_Y&'3/^ON+_T,5[?7B&A?\C#IG_7W%_Z&*]OH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /(/&W_ "-]]_VS_P#1:US]=!XV_P"1OOO^V?\ Z+6N?H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .@\$_P#(WV/_ &T_]%M7K]>0>"?^1OL?^VG_ *+:O7Z
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O(/&W_(WWW_ &S_ /1:UZ_7D'C;_D;[[_MG_P"BUH Y^BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** -#0O^1ATS_K[B_\ 0Q7M]>(:%_R,.F?]?<7_
M *&*]OH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /(/&W_(WWW_ &S_ /1:US]=!XV_Y&^^
M_P"V?_HM:Y^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH Z#P3_R-]C_ -M/_1;5Z_7D'@G_
M )&^Q_[:?^BVKU^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KR#QM_R-]]_VS_]%K7K]>0>-O\ D;[[_MG_ .BU
MH Y^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** -#0O^1ATS_K[B_P#0Q7M]
M>(:%_P C#IG_ %]Q?^ABO;Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R#QM_R-]]_VS_]
M%K7/UT'C;_D;[[_MG_Z+6N?H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .@\$_\C?8_]M/_
M $6U>OUY!X)_Y&^Q_P"VG_HMJ]?H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *\@\;?\C???]L__ $6M>OUY!XV_
MY&^^_P"V?_HM: .?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#0T+_ )&'
M3/\ K[B_]#%>WUXAH7_(PZ9_U]Q?^ABO;Z "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R#Q
MM_R-]]_VS_\ 1:US]=!XV_Y&^^_[9_\ HM:Y^@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MZ#P3_P C?8_]M/\ T6U>OUY!X)_Y&^Q_[:?^BVKU^@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR#QM_P C???]
ML_\ T6M>OUY!XV_Y&^^_[9_^BUH Y^BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** -#0O^1ATS_K[B_]#%>WUXAH7_(PZ9_U]Q?^ABO;Z "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#R#QM_P C???]L_\ T6M<_70>-O\ D;[[_MG_ .BUKGZ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#H/!/\ R-]C_P!M/_1;5Z_7D'@G_D;['_MI_P"BVKU^@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KR#QM_R-]]_P!L_P#T6M>OUY!XV_Y&^^_[9_\ HM: .?HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#0T+_D8=,_Z^XO_ $,5[?7B&A?\C#IG_7W%_P"A
MBO;Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#R#QM_R-]]_P!L_P#T6M<_70>-O^1OOO\
MMG_Z+6N?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** .@\$_\C?8_P#;3_T6U>OUY!X)_P"1
MOL?^VG_HMJ]?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *\@\;?\C???]L__1:UZ_7D'C;_ )&^^_[9_P#HM: .
M?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#0T+_D8=,_Z^XO\ T,5[?7B&
MA?\ (PZ9_P!?<7_H8KV^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \@\;?\C???]L__1:U
MS]=!XV_Y&^^_[9_^BUKGZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#H/!/_(WV/_;3_P!%
MM7K]>0>"?^1OL?\ MI_Z+:O7Z "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O(/&W_(WWW_;/_P!%K7K]>0>-O^1O
MOO\ MG_Z+6@#GZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH T-"_P"1ATS_
M *^XO_0Q7M]>(:%_R,.F?]?<7_H8KV^@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \@\;?\
MC???]L__ $6M<_70>-O^1OOO^V?_ *+6N?H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .@\
M$_\ (WV/_;3_ -%M7K]>0>"?^1OL?^VG_HMJ]?H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\@\;?\ (WWW_;/_
M -%K7K]>0>-O^1OOO^V?_HM: .?HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#0T+_D8=,_Z^XO_0Q7M]>(:%_R,.F?]?<7_H8KV^@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \@\;?\ (WWW_;/_ -%K7/UT'C;_ )&^^_[9_P#HM:Y^@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH Z#P3_ ,C?8_\ ;3_T6U>OUY!X)_Y&^Q_[:?\ HMJ]?H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M\@\;?\C???\ ;/\ ]%K7K]>0>-O^1OOO^V?_ *+6@#GZ*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH T-"_Y&'3/^ON+_P!#%>WUXAH7_(PZ9_U]Q?\ H8KV
M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH \@\;?\C???\ ;/\ ]%K7/UT'C;_D;[[_ +9_
M^BUKGZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#H/!/_(WV/\ VT_]%M7K]>0>"?\ D;['
M_MI_Z+:O7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "O(/&W_(WWW_;/_T6M>OUY!XV_P"1OOO^V?\ Z+6@#GZ*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH T-"_Y&'3/^ON+_ -#%>WUXAH7_
M ",.F?\ 7W%_Z&*]OH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1_\ GYOO^^T_^)H_X5QH_P#S\WW_ 'VG_P 30!YA17I__"N-'_Y^;[_OM/\
MXFC_ (5QH_\ S\WW_?:?_$T >845Z?\ \*XT?_GYOO\ OM/_ (FC_A7&C_\
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M_P 30!YA17I__"N-'_Y^;[_OM/\ XFC_ (5QH_\ S\WW_?:?_$T >845Z?\
M\*XT?_GYOO\ OM/_ (FC_A7&C_\ /S??]]I_\30!YA17I_\ PKC1_P#GYOO^
M^T_^)H_X5QH__/S??]]I_P#$T >845Z?_P *XT?_ )^;[_OM/_B:/^%<:/\
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M%%>G_P#"N-'_ .?F^_[[3_XFC_A7&C_\_-]_WVG_ ,30!YA17I__  KC1_\
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MQH__ #\WW_?:?_$T >845Z?_ ,*XT?\ Y^;[_OM/_B:/^%<:/_S\WW_?:?\
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M%>G_ /"N-'_Y^;[_ +[3_P")H_X5QH__ #\WW_?:?_$T >845Z?_ ,*XT?\
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M_GYOO^^T_P#B:/\ A7&C_P#/S??]]I_\30!YA17I_P#PKC1_^?F^_P"^T_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%8^K^)]
M+T7*7,^^<?\ +"+YG[=1T'!SR1GM6Q0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%-21)%W(ZL 2I*G/(."/P((H =111
M0 4444 %%%% !1110 4444 %%%% !1110 44V21(HVDD=41 69F.  .I)HCD
M26-9(W5T<!E93D$'H0: '4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!Y9XOU;4K;Q3>0V^H7<42[-J1S,JCY%/0&L/^W=8
M_P"@K??^!#_XUH>-O^1OOO\ MG_Z+6N?H T/[=UC_H*WW_@0_P#C1_;NL?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16/J_B
M?2]%RES/OG'_ "PB^9^W4=!P<\D9[5P&K^.M4U',=L?L,![1-\YZ=7Z]1VQU
MP<T =_J_B?2]%RES/OG'_+"+YG[=1T'!SR1GM7 :OXZU34<QVQ^PP'M$WSGI
MU?KU';'7!S7+T4 %>_UX!7O] !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%<_K/C#2](WQ^9]INER/)A.<'G[S=!R,'N,]* .@KG]9\8
M:7I&^/S/M-TN1Y,)S@\_>;H.1@]QGI7 :SXPU35]\?F?9K5LCR83C(Y^\W4\
M'![''2N?H Z#6?&&J:OOC\S[-:MD>3"<9'/WFZG@X/8XZ5W_ ()_Y%"Q_P"V
MG_HQJ\@KU_P3_P BA8_]M/\ T8U '04444 %%%% !1110 4444 %%%% !139
M)$BC:21U1$!9F8X  ZDFN1UGQ_8V6^'3U^V3C(W](U/(Z]6Y Z<$'K0!UTDB
M11M)(ZHB LS,<  =237(ZSX_L;+?#IZ_;)QD;^D:GD=>K<@=."#UK@M5U[4=
M9DW7EPS(#E8EX1>N,#VR1DY/O6;0!I:KKVHZS)NO+AF0'*Q+PB]<8'MDC)R?
M>O7="_Y%[3/^O2+_ - %>(5[?H7_ "+VF?\ 7I%_Z * -"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M4444 %%%% !7H'PR_P"8I_VR_P#9Z\_KT#X9?\Q3_ME_[/0!W]%%% !1110!
MYA\1_P#D8;?_ *]%_P#0WKCZ[#XC_P#(PV__ %Z+_P"AO7'T %%%% !1110!
M[_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<!\3?\ F%_]M?\
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M *!__D:3_P"*H \@HKU__A"?#O\ T#__ "-)_P#%4?\ "$^'?^@?_P"1I/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5P'Q-_P"87_VU_P#9*[^N ^)O_,+_ .VO_LE 'G]%%% !
M1110 5[_ %X!7O\ 0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<_XV_P"10OO^V?\ Z,6N@KG_ !M_R*%]_P!L_P#T8M 'D%%%% !1110 5Z_X
M)_Y%"Q_[:?\ HQJ\@KU_P3_R*%C_ -M/_1C4 =!1110 4444 %%%% !1110
M5Q_Q'_Y%ZW_Z^U_] >NPKC_B/_R+UO\ ]?:_^@/0!YA1110 4444 %>WZ%_R
M+VF?]>D7_H KQ"O;]"_Y%[3/^O2+_P! % &A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'D'C;_D;[[_MG_P"BUKGZZ#QM
M_P C???]L_\ T6M<_0 4444 %:&A?\C#IG_7W%_Z&*SZT-"_Y&'3/^ON+_T,
M4 >WT444 %%%% !1110 4444 %-DC26-HY$5T<%65AD$'J"*=10!XYXIT)M"
MU9HT&;6;,D! . ,_=R>I'UZ8/>L.O6?'ELD_A6:1BP,$B2+CN2=O/X,:\FH
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MS&[RI VW/3./H:L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4455N=2L+.01W5[;0.1N"RRJI(]<$^U %JBL_P#MW1_^@K8_^!"?XU>CD26-
M9(W5T<!E93D$'H0: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 45#<W=M9QB2ZN(H$)VAI7"
M@GTR?I57^W='_P"@K8_^!"?XT :%%9_]NZ/_ -!6Q_\  A/\:M6UW;7D9DM;
MB*= =I:)PP!],CZT 34444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO:9_UZ1?^@"O$*]OT+_D7M,_Z](O_0!0!H4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%-DD2*-I)'5$0%F9C@ #J2: '45G_V[H_\ T%;'_P "$_QJ
MQ:W]G>[OLEW!<;,;O*D#;<],X^AH L4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%4Y]6TVVF:&XU"TBE7[R23*K#OT)H N45G_
M -NZ/_T%;'_P(3_&KT<B2QK)&ZNC@,K*<@@]"#0 ZBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(/&W_(WWW_;
M/_T6M<_70>-O^1OOO^V?_HM:Y^@ HHHH *T-"_Y&'3/^ON+_ -#%9]:&A?\
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M>0?05S?_  FWB+_H(?\ D&/_ .)K0^(__(PV_P#UZ+_Z&]<?0!T'_";>(O\
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MS@<=3Z4 >C^"-,73_#L,K1[9[K]\Y."2#]WD=MN#@]"372444 %%%% !7/\
MC;_D4+[_ +9_^C%KH*Y_QM_R*%]_VS_]&+0!Y!1110 4444 %>O^"?\ D4+'
M_MI_Z,:O(*]?\$_\BA8_]M/_ $8U '04444 %%%% !1110 5P'Q-_P"87_VU
M_P#9*[^N ^)O_,+_ .VO_LE 'G]%%% !1110 5[_ %X!7O\ 0 4444 %%%%
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M 4444 %%%% !1110!Y!XV_Y&^^_[9_\ HM:Y^N@\;?\ (WWW_;/_ -%K7/T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445>TO2+W6+I8+.%G
M.0&?!V1Y[L>W0_7'&: *]K:SWUU';6T32S2'"HO?_/K7L/AO0H]!TM8,1M<O
M\T\JC[Y[#GL.@_/ R:A\/^%;+0H]V%N+LDDW#H 1U&%'.W@^O/Y ;U !1110
M 4444 %<_P"-O^10OO\ MG_Z,6N@KG_&W_(H7W_;/_T8M 'D%%%% !1110 5
MZ_X)_P"10L?^VG_HQJ\@KU_P3_R*%C_VT_\ 1C4 =!1110 4444 %%%% !7
M?$W_ )A?_;7_ -DKOZX#XF_\PO\ [:_^R4 >?T444 %%%% !7O\ 7@%>_P!
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M0/AE_P Q3_ME_P"ST =_1110 4444 >8?$?_ )&&W_Z]%_\ 0WKCZ[#XC_\
M(PV__7HO_H;UQ] !1110 4444 %%%;6@>&;W7Y&,.V*WC(#S.#CZ#U..<?F1
MD4 8M20037,RPV\4DLK?=2-2S'OT%>NZ?X.T33U&+-;A\$%[GY\\YZ?=_$"M
MZ@#PJYTV_LXQ)=65S A.T-+$R@GTR1[55KW^J=YI6GZCDWEE!,Q39O= 6 ]
MW4=3TH \,HKNO$'@%X%>ZT<M)&H+-;L<N.>B<<\=CSQW)KA: "BBB@ HHHH
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M -=_I?AO2M'97M;5?.  \Z0[GZ8R">F<G.,4 >.6UI<WDACM;>6=P-Q6)"Q
M]<#ZTV>":VF:&XBDBE7[R2*58=^AKWNFR1I+&T<B*Z."K*PR"#U!% '@5%>K
MZOX%TO4<R6P^PSGO$OR'IU3IT';'7)S7FFIZ9=:1?/:7<>V1>01]UQV8'N/\
M]: *=%%% !1110 5ZOX%U?\ M'0Q;2',]GB,\=4_@/3'0$?\!R>M>45T7@G4
M!8>)H Y4)<@P,2">N"N,>K!1^- 'KM%%% !1110 5YAX[U_[???V;;MFVM7_
M 'F4P6E&0>?0=.W.>O%=OXGU?^Q=#FN4.)V_=P\?QGH>A' R>>N,=Z\8H **
M** "BBB@ J:VM+F\D,=K;RSN!N*Q(6('K@?6MKPUX6N->F$K'RK%'*R2@C=D
M8.T#UY')X^O2O5=/TZTTNU%M90+#$"6P"3DGN2>3^- 'FEM\/M;GC+2"VMR#
MC9++DGW^4$?K4W_"N-8_Y^;'_OM__B:]/HH \BU#P3K=@I<6ZW*  EK9MW4X
MQMX8_@*Y^2-XI&CD1D="596&"".H(KWVL?7?#=CKT)\]-ERJ%8YU^\G?D?Q#
MV/J<8SF@#QBBKFIZ9=:1?/:7<>V1>01]UQV8'N/\]:IT %%%% !7L/A/7#KF
MCJ\S*;N$[)@ !GT;'N/IR#BO'JZ;P-J@T_Q D4C,(KL>21DX#$_*<#KSQ[;C
M0!ZS1110!YA\1_\ D8;?_KT7_P!#>N/KU?Q'X/\ ^$@U&.[^W?9]D0CV^3NS
M@DYSN'K61_PK+_J+_P#DM_\ 9T >?T5Z!_PK+_J+_P#DM_\ 9UGZWX&_L;2)
M[_\ M'SO*V_)Y&W.6 Z[CZT <?1110 4444 %%%=AHG@;^V=(@O_ .T?)\W=
M\GD;L88CKN'I0!Q]%>@?\*R_ZB__ )+?_9T?\*R_ZB__ )+?_9T >?T5Z!_P
MK+_J+_\ DM_]G1_PK+_J+_\ DM_]G0!W]%%% 'B&N_\ (PZG_P!?<O\ Z&:S
MZ](O_AY]MU&YN_[4V>?*TFW[/G;N).,[O>J__"LO^HO_ .2W_P!G0!Y_17H'
M_"LO^HO_ .2W_P!G6/XC\'_\(_IT=W]N^T;Y1'M\G;C()SG<?2@#EZ*** "B
MBB@ HHKN+#X>?;=.MKO^U-GGQ+)M^SYV[@#C.[WH X>BO0/^%9?]1?\ \EO_
M +.C_A67_47_ /);_P"SH \_HKT#_A67_47_ /);_P"SH_X5E_U%_P#R6_\
MLZ .OT+_ )%[3/\ KTB_] %:%5["V^Q:=;6F_?Y$2Q[L8W;0!G'X58H ***;
M)(D4;22.J(@+,S'  '4DT <CX[U_[!8_V;;MBYND_>93(6(Y!Y]3T[\9Z<5Y
MA5S5=0DU75+B^E&&F?(7^Z.@'09P !GVJG0 4444 %%%7-,TRZU>^2TM(]TC
M<DG[J#NQ/8?YZT 58XWED6.-&=W(5549))Z "N@T_P $ZW?J'-NMLA!(:Y;;
MT.,;>6'XBO0]$\,:=HD:-%$LMT!\UPXRQ/.<?W>I'';KFMJ@#S#_ (5QK'_/
MS8_]]O\ _$U#<_#[6X(PT8MK@DXV12X(]_F 'ZUZK10!X-<VES9R".ZMY8'(
MW!94*DCUP?I4->[WEC:ZC;FWO((YHC_"XS@XQD>AY/(YKR[Q7X4.@-'<6\C2
MV4A" N1O1L9P?7."01]/J <S1110 4444 >A?#W7"ROHT[+A 7MN .^67WZY
M''][T%=[7A6FWKZ;J5M>)N)AD#D*VW< >1GW&1^->XP3QW-O%<0MNBE0.C8Q
MD$9!YH DHHHH *X_XC_\B];_ /7VO_H#UV%<?\1_^1>M_P#K[7_T!Z /,***
M* "BBB@ HHHH ***ZS3/ &J7JI+=-'9Q-V?YI,8R#M'Y8)!'/% ')T5Z7!\-
M]-6%1<7EW)+_ !-'M13^!!Q^=2?\*XT?_GYOO^^T_P#B: /,**[R\^&LPRUC
MJ$;Y?A)T*X7_ 'AG)Z=A7)ZEH>IZ1M-]:21*W1^&7//&X9&>#QUH SZ]+^'%
MGY6DW5XRR!IY=HW#Y2JC@C\68?A7FE>U^'+/[!X=L+<K(K"(,ZR##*S?,P_
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M "*%C_VT_P#1C5Y!7K_@G_D4+'_MI_Z,:@#H**** "BBB@ HHHH *X#XF_\
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M* //Z*** "BBB@"2">2VN(KB%MLL3AT;&<$'(/->]UX!7O\ 0 4444 %%%%
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M>UM8+&UCMK:)8H8QA47M_GUJ:BB@ HHHH **** ,'Q9H9US1V2%%-W"=\))
MSZKGW'TY S7CU>_UXQXILX;#Q-?6]NNV(.&5< !=RAL#'89X]J ,>BBB@ IT
M<CQ2+)&[(Z$,K*<$$="#3:* /<='U :IH]I>@J3+&"^T$ ,.& SZ$$5>KD?A
MY=&;P_) TJL8)V"IQE5(!'YDMR??TKKJ "BBB@ KG_&W_(H7W_;/_P!&+705
MS_C;_D4+[_MG_P"C%H \@HHHH **** "O7_!/_(H6/\ VT_]&-7D%>O^"?\
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M*U2XL93EH7P&_O#J#U.,@@X]ZIUZ!\2K+_CQOUC_ +T,C[OQ48_[[_SBO/Z
M"BBB@ KU/P!J;7NAM:RR;I;1]@SG/EGE<D_\"''0 5Y979?#FZ,6MW%L955)
MH,A#CYF4C&._ +<#^E 'IM%%% !7'_$?_D7K?_K[7_T!Z["N/^(__(O6_P#U
M]K_Z ] 'F%%%% !1110 445TW@;2QJ'B!)9%8Q6@\XG!P6!^49'3GGWVF@#K
M?!_A:/2K>._NEW7TJ9 9<>2".F#_ !>I_#USUE%% !1110 4V2-)8VCD171P
M596&00>H(IU% ')ZCX#TVYNXKBU3R,2JTL.X^6Z;LL!W4X/&..,8'6NLHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#R#QM_R-]]_P!L_P#T6M<_70>-O^1OOO\ MG_Z+6N?H **** "I(()+FXB
MMX5W2RN$1<XR2< <U'6AH7_(PZ9_U]Q?^AB@#0_X0GQ%_P! _P#\C1__ !5'
M_"$^(O\ H'_^1H__ (JO7Z* /(/^$)\1?] __P C1_\ Q5'_  A/B+_H'_\
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M!VSS^*H9%*@01O(V>X(V\?BPKF:[SX:01M<:C<%?WJ)&BMGH&+$C_P ='Y4
M>AT444 %%%% !1110 5P'Q-_YA?_ &U_]DKOZX#XF_\ ,+_[:_\ LE 'G]%%
M% !1110 5[_7@%>_T %%%% !6?KO_(O:G_UZ2_\ H!K0K/UW_D7M3_Z])?\
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M&PLUPJ.,=1AFQ^:C\JZRN$^)<\BV^G6X;]T[R.RXZE0H!_\ 'C^= 'G=%%%
M!1110 5ZK\/K9X/#/F,5(GG>1<=@,+S^*FO*J]K\.01V_AK34B7:IMT<C.>6
M&XG\R: -2BBB@ HHHH **** "O$-=_Y&'4_^ON7_ -#->WUXAKO_ ",.I_\
M7W+_ .AF@#/HHHH **** .P^''_(PW'_ %Z-_P"AI7I]>8?#C_D8;C_KT;_T
M-*]/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BL77_$UEH$:B;=+<
M2 E(4(S]3Z#/&?R!P:\RU?Q/JFM92YGV0'_EA%\J=NHZGD9Y)QVH ]%U#QMH
ME@Q07#7+@@%;9=W49SNX4_@:Y34/B+J-PI6RMXK0$#YB?,<'/8D =..0:XVB
M@#6N?$^MW4@>34[E2!C$3^6/R7 _&LN21Y9&DD=G=R69F.22>I)IM% !1110
M!:MM2O[.,QVM[<P(3N*Q2LH)]< ^U;5GXYUVTP&N([E%3:%G0'\<C!)^I[US
M=% 'I&G?$>UDVIJ-I)"WR@R1'>N>Y(Z@>PW'^N;X_P!2LM2CTM[.ZBG $A(1
M@2N=F,CJ/H:XFB@ HHHH **** "O?Z\ KW^@ HHHH **** "BBB@ HHHH **
M** "BBB@ K@/B;_S"_\ MK_[)7?UP'Q-_P"87_VU_P#9* //Z*** "BBB@ K
MW^O *]_H **** "BBB@ HHHH Y_QI9?;?"]UMCWR08F3YL;=I^8_]\EO_P!=
M>05[S=VR7EG/:R%@DT;1L5Z@$8./SKP:@ HHHH **** .^^&MT!)J%FTK98)
M*D?..,ACZ#JOZ>E>@UYA\./^1AN/^O1O_0TKT^@ K'\577V3POJ$FS?NB,>,
MX^^=N?PW9_"MBN/^(_\ R+UO_P!?:_\ H#T >84444 %%%% !7L/@R-X_"5@
MKHRDAV 88X+L0?Q!!KQZKT>M:K%&L<>IWB(@"JJSL  .@ S0![C17B']NZQ_
MT%;[_P "'_QH_MW6/^@K??\ @0_^- 'M]%>(?V[K'_05OO\ P(?_ !H_MW6/
M^@K??^!#_P"- 'M]%>(?V[K'_05OO_ A_P#&C^W=8_Z"M]_X$/\ XT >WUYI
M\2()%UFTN"O[I[?8K9ZE6)(_\>'YUS?]NZQ_T%;[_P "'_QJO=7]Y>[?M=W/
M<;,[?-D+;<]<9^@H KT444 %%%% '<?#6ZV:C?6FS/FQ+)NSTVG&,>^_]*]'
MKR+P/(Z>+;-5=E#B16 .-PV$X/KR ?PKUV@ HHHH *Y_QM_R*%]_VS_]&+70
M5S_C;_D4+[_MG_Z,6@#R"BBB@ HHHH *]?\ !/\ R*%C_P!M/_1C5Y!7K_@G
M_D4+'_MI_P"C&H Z"BBB@ HHHH **** "BBB@ KC_B/_ ,B];_\ 7VO_ * ]
M=A7'_$?_ )%ZW_Z^U_\ 0'H \PHHHH **** "O;]"_Y%[3/^O2+_ - %>(5[
M?H7_ "+VF?\ 7I%_Z * -"BBB@ HHHH **** "O"+^Z^VZC<W>S9Y\K2;<YV
M[B3C/XU[/KO_ "+VI_\ 7I+_ .@&O$* "BBB@ HHHH [[X9QH9-3D**741J&
MQR =V1GWP/R%>@UX1:W]Y9;OLEW/;[\;O*D*[L=,X^IJQ_;NL?\ 05OO_ A_
M\: /;Z*\0_MW6/\ H*WW_@0_^-']NZQ_T%;[_P "'_QH ]OHKQ#^W=8_Z"M]
M_P"!#_XT?V[K'_05OO\ P(?_ !H ]OHKQ#^W=8_Z"M]_X$/_ (T?V[K'_05O
MO_ A_P#&@#T?Q];>?X7>3?M^SRI)C&=V3MQ[?>S^%>45<GU;4KF%H;C4+N6)
MOO)),S*>_0FJ= !1110 5L>%;K[)XHT^39OW2B/&<??&W/X;L_A6/3HY'BD6
M2-V1T(964X((Z$&@#WVBBB@ KC_B/_R+UO\ ]?:_^@/785Q_Q'_Y%ZW_ .OM
M?_0'H \PHHHH **** "O2_AO!&NC7=P%_>O<;&;/4*H('_CQ_.O-*]?\$_\
M(H6/_;3_ -&-0!T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 >0>-O^1OOO^V?_HM:Y^N@
M\;?\C???]L__ $6M<_0 4444 %:&A?\ (PZ9_P!?<7_H8K/K0T+_ )&'3/\
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MO_9Z ._HHHH **** /,/B/\ \C#;_P#7HO\ Z&]<?78?$?\ Y&&W_P"O1?\
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MAM_^O1?_ $-ZX^NP^(__ ",-O_UZ+_Z&]<?0 4444 %%%% 'O]%%% !1110
M4444 %%%% 'D'C;_ )&^^_[9_P#HM:Y^N@\;?\C???\ ;/\ ]%K7/T %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >0>-O\
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M"=WXYKS"NR^'6H"WUB>R8J!=1Y7@Y+)D@>W!8\^@H ]-HHHH **** "BBB@
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M@ HHHH **** "BBB@ KC_B/_ ,B];_\ 7VO_ * ]=A7'_$?_ )%ZW_Z^U_\
M0'H \PHHHH **** "O;]"_Y%[3/^O2+_ - %>(5[?H7_ "+VF?\ 7I%_Z *
M-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /(/&W_(WWW_ &S_ /1:US]=!XV_Y&^^_P"V
M?_HM:Y^@ HHHH *T-"_Y&'3/^ON+_P!#%9]6+"Z^Q:C;7>S?Y$JR;<XW;2#C
M/X4 >[T5P'_"S?\ J$?^3/\ ]A1_PLW_ *A'_DS_ /84 =_17 ?\+-_ZA'_D
MS_\ 84?\+-_ZA'_DS_\ 84 =_17 ?\+-_P"H1_Y,_P#V%'_"S?\ J$?^3/\
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M0 4444 >8?$?_D8;?_KT7_T-ZX^NP^(__(PV_P#UZ+_Z&]<?0 4444 %%%%
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M5 MK<$X$B@^4W(QW)7KWXXSGM0!V5%0VUW;7D9DM;B*= =I:)PP!],CZU-0
M45FW7B#2+)9#/J-LIC.UT60,X.<8VC)Z^U<1K?Q!GNHWM]+B:WC88,SG]YVZ
M8X7N,\^HP: -OQGXG33;5]/LY6%_(!N:,_ZE3ZGU(Z=QG/'&?+J** "BBB@
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M2(UM8W!WR)EI<=>#T4_GQU'2N9U77M1UF3=>7#,@.5B7A%ZXP/;)&3D^]9M
M'M>A:[:Z]8BXMSMD7 EA)^:,_P!1Z'O]<@:E>&:9J=UI%\EW:2;9%X(/W7'=
M2.X_SUKU_0M=M=>L1<6YVR+@2PD_-&?ZCT/?ZY  -2BBB@ HHHH *X_XC_\
M(O6__7VO_H#UV%<?\1_^1>M_^OM?_0'H \PHHHH **** "O;]"_Y%[3/^O2+
M_P! %>(5[?H7_(O:9_UZ1?\ H H T**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \@\;?\
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M%% '@%%%% !1110 5Z!\,O\ F*?]LO\ V>O/Z] ^&7_,4_[9?^ST =_1110
M4444 >8?$?\ Y&&W_P"O1?\ T-ZX^NP^(_\ R,-O_P!>B_\ H;UQ] !1110
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MTS_KTB_] % &A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 5[_ $ %%%% !1110 4444 %%%% !1110 4444 %<!\3?^87_P!M?_9*[^N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .$\1>"M2U?7;F^MY[18I=NT2.P;A
M0.RGTK+_ .%<:Q_S\V/_ 'V__P 37I]% 'F'_"N-8_Y^;'_OM_\ XFC_ (5Q
MK'_/S8_]]O\ _$UZ?10!YA_PKC6/^?FQ_P"^W_\ B:/^%<:Q_P _-C_WV_\
M\37I]% 'F'_"N-8_Y^;'_OM__B:/^%<:Q_S\V/\ WV__ ,37I]% 'F'_  KC
M6/\ GYL?^^W_ /B:/^%<:Q_S\V/_ 'V__P 37I]% 'F'_"N-8_Y^;'_OM_\
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M;_\ Q->GT4 >8?\ "N-8_P"?FQ_[[?\ ^)H_X5QK'_/S8_\ ?;__ !->GT4
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M^,/#EYX@^Q?9)($\C?N\UB,[MN,8!]#7444 >8?\*XUC_GYL?^^W_P#B:/\
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M31_PKC6/^?FQ_P"^W_\ B:]/HH \P_X5QK'_ #\V/_?;_P#Q->GT44 %%%%
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MQVPQ@YX^9ASQ[#_'O:* *NGZ=::7:BVLH%AB!+8!)R3W)/)_&K5%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !115/4]3M=(L7N[N3;&O  ^\Y[*!W/\ GI0!D^--533?#\T?RF:[!A13
MZ$?,<9SP._J17D5;'B379->U1I\R+;)\L$3'[@[GCN>I_+)P*QZ "BBB@ HH
MJ:TMGO+R"UC*AYI%C4MT!)P,_G0!ZWX-M3:>%;(/$J/(#*V,?-N)*DX_V=O\
MJWJC@@CMK>*WA7;%$@1%SG  P!S4E !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4457OC=+8S-9"-KI4)C6095B.W4=
M>F<\9H L45YA_P +'UC_ )]K'_OA_P#XJFR?$767C95ALT+ @.L;97W&6(_,
M4 >HU'//#;0M-<2QQ1+]YY&"J.W4UY!/XPU^XA:)]2D"MU,:*C?FH!%8\\\U
MS,TUQ+)+*WWGD8LQ[=30!ZCJGCW2K%66U+7LP)&V/Y4&#W8CZX(!Z5YUJVM7
MVMW FO9MVW.Q%&%0$YP!_4\\#FL^B@ HHHH **** "NX^'>D>=>2ZK(/D@S'
M%S_&1R>O93CD?Q>U<;:VL]]=1VUM$TLTAPJ+W_SZU[3HNDPZ)I<5E"=^W)>0
MJ 78]2<?E] !0!H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!Y!XPT;^R-<D\M-MK<?O8L# &>J] .#V'0
M$5S]>K^.M(_M'0S<QC,]GF0<]4_C'7'0 _\  <#K7E% !1110 4444 %%%%
M!14UK:SWUU';6T32S2'"HO?_ #ZUZ7X8\&0:;'%>:A&LM^"'5<Y6'T'H3[]C
MC'3) '>"O#?]E6?V^Y21;ZX3!1N/+3.<8]3@$YZ=..<]9110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 445FZKKVG:-'NO+A5<C*Q+R[=<8'O@C)P/>@#2K-U77M.T:/=>7"JY&
M5B7EVZXP/?!&3@>]<%K/C^^O=\.GK]C@.1OZR,.1UZ+P1TY!'6N1DD>61I)'
M9W<EF9CDDGJ2: .NUGQ_?7N^'3U^QP'(W]9&'(Z]%X(Z<@CK7H.BR/+H6GR2
M.SN]M&S,QR22HR2:\.KV_0O^1>TS_KTB_P#0!0!H4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% '-ZIXUTW2-2EL;B"[:6+&XQHI7D ]V'K5/_A8^
MC_\ /M??]\)_\57(>-O^1OOO^V?_ *+6N?H ]/\ ^%CZ/_S[7W_?"?\ Q5'_
M  L?1_\ GVOO^^$_^*KS"B@#T_\ X6/H_P#S[7W_ 'PG_P 55S2_&NFZOJ45
MC;P7:RRYVF1%"\ GLQ]*\DKH/!/_ "-]C_VT_P#1;4 >OT444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %>):]I3Z+K$]FVXHIW1,?XD/0YP,^AQW!K
MVVN1\;^';K6([6>PA62XB)1U^52RGD'<2.A'3_:- 'EU%=%'X'\0/(JM9*@8
M@%VF3"^YP2?R%7O^%<:Q_P _-C_WV_\ \30!Q]%=Q:_#6\?=]KU""+&-OE(9
M,^N<[<=O6M^U\ :%!N\R.>YW8QYLI&WZ;<?KZ4 >51QO+(L<:,[N0JJHR23T
M %==HW@"^O=DVH-]C@.#LZR,.#TZ+P3UY!'2O1[6PL[+=]DM(+??C=Y487=C
MIG'U-6* ,W2M!T[18]MG;JKD8:5N7;IG)]\ X&![5I444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%-DD2*-I)'5$0%F9C@ #J2: '4V2
M1(HVDD=41 69F.  .I)KD=9\?V-EOAT]?MDXR-_2-3R.O5N0.G!!ZUP6JZ]J
M.LR;KRX9D!RL2\(O7&![9(R<GWH [W6?']C9;X=/7[9.,C?TC4\CKU;D#IP0
M>M'@C6K[6[C4YKV;=M\O8BC"H"7. /ZGG@<UYA7H'PR_YBG_ &R_]GH [^BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN7U?QUI>G9CM
MC]NG':)OD'3J_3H>V>F#B@#J*Y?5_'6EZ=F.V/VZ<=HF^0=.K].A[9Z8.*X#
M5_$^J:UE+F?9 ?\ EA%\J=NHZGD9Y)QVK'H ]&\(^(]1UWQ',+N51$MLS+#&
M,(IW(,^I_$GJ<5W->8?#C_D8;C_KT;_T-*]/H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZKJUIHUG
M]JO'94)VJ%4DLV"0!]<'K@5>KC_B/_R+UO\ ]?:_^@/0!@:SX_OKW?#IZ_8X
M#D;^LC#D=>B\$=.01UKD9)'ED:21V=W)9F8Y))ZDFFT4 %%%% !7M^A?\B]I
MG_7I%_Z *\0KV_0O^1>TS_KTB_\ 0!0!H4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% 'D'C;_D;[[_MG_P"BUKGZZ#QM_P C???]L_\ T6M<_0 4
M444 %=!X)_Y&^Q_[:?\ HMJY^N@\$_\ (WV/_;3_ -%M0!Z_1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% ''ZSX_L;+?#IZ_;)QD;^D
M:GD=>K<@=."#UK@M5U[4=9DW7EPS(#E8EX1>N,#VR1DY/O6;10 4444 %>@?
M#+_F*?\ ;+_V>O/Z] ^&7_,4_P"V7_L] '?T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7,ZWXVT[29'MX@UW=(=K1H<*IXR"WXGIGD8.*Z:O$-
M=_Y&'4_^ON7_ -#- %C5_$^J:UE+F?9 ?^6$7RIVZCJ>1GDG':L>BB@ HHHH
M [#X<?\ (PW'_7HW_H:5Z?7F'PX_Y&&X_P"O1O\ T-*]/H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** / **** "BBB
M@ KT#X9?\Q3_ +9?^SUY_7H'PR_YBG_;+_V>@#OZ*** "BBB@ HHHH ****
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MM]YY(59CVZD5'_86C_\ 0*L?_ =/\*T** ,_^PM'_P"@58_^ Z?X4?V%H_\
MT"K'_P !T_PK0HH S_["T?\ Z!5C_P" Z?X5)!I.FVTRS6^GVD4J_=>.%58=
MNH%7** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M **** "BBB@ KT#X9?\ ,4_[9?\ L]>?UZ!\,O\ F*?]LO\ V>@#OZ*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ#7?^1AU/\ Z^Y?_0S7M]>(
M:[_R,.I_]?<O_H9H SZ*** "BBB@#L/AQ_R,-Q_UZ-_Z&E>GUYA\./\ D8;C
M_KT;_P!#2O3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 2$RJQ.2S#L1Z5A?\+'UC_GVL?\ OA__ (J@#T^BO,/^%CZQ_P ^UC_WP_\
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MWSR9*)_LC!&3Z^G3KG !V5%>8?\ "Q]8_P"?:Q_[X?\ ^*H_X6/K'_/M8_\
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M =I138Y$EC62-U=' 964Y!!Z$&N/\6>++_0=5BM;6&V='@$A,JL3DLP[$>E
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M#_\ Q5:WAOQM?ZMKD-C=6]L$E#8:(,I4A2W<G/3'XT =S1110 4444 %%%%
M!17)^+O%5QH-Q:V]FL$DLB%Y%E1C@9PI&".N&_*N<_X6/K'_ #[6/_?#_P#Q
M5 'I]%>8?\+'UC_GVL?^^'_^*H_X6/K'_/M8_P#?#_\ Q5 'I]%>8?\ "Q]8
M_P"?:Q_[X?\ ^*JQ8>/=8O=1MK3R;%//E6/=Y3G;N(&<;_>@#T>BBB@ HHHH
M **** "BFR2)%&TDCJB("S,QP !U)-<GJ'Q"TJV4BS26\? ((&Q.O()//3GH
M: .NHKRC4?'FL7NY('CM(CN&(ERQ!Z98]QZC%8-SJ5_>1B.ZO;F= =P665F
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M !1110!X!1110 4444 %>@?#+_F*?]LO_9Z\_KT#X9?\Q3_ME_[/0!W]%%%
M!1110 4444 %%%% !17.ZUXRTS1Y#!EKJX ;*0D$*PXPQSQS]2/3IGD-0^(6
MJW+$6:16:9!! WOTY!)XZ\]!0!ZC39)$BC:21U1$!9F8X  ZDFO#+G4K^\C$
M=U>W,Z [@LLK, ?7!/O56@#W6VU*PO)#':WMM.X&XK%*K$#UP#[U:KP"I()Y
MK:99K>62*5?NO&Q5AVZB@#WNBO*-.\>:Q9;4G>.[B&T8E7# #KAAW/J<UV^C
M>,-+U?9'YGV:Z; \F8XR>/NMT/)P.YQTH Z"O$-=_P"1AU/_ *^Y?_0S7M]>
M(:[_ ,C#J?\ U]R_^AF@#/HHHH **** .P^''_(PW'_7HW_H:5Z?7F'PX_Y&
M&X_Z]&_]#2O3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#_M8[#L/Q],<O0!)//-<S--<2R2RM]YY&+,>W4U'110 4444 %%%% !1110
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MVO\ Z ]=A7'_ !'_ .1>M_\ K[7_ - >@#S"BBB@ HHHH *]OT+_ )%[3/\
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MD:2QM'(BNC@JRL,@@]017A%W;/9WD]K(5+PR-&Q7H2#@X_*@"&BBB@ HHHH
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M *,6O(*]?\;?\BA??]L__1BUY!0 4444 %%%% 'J?AS4[72/ 5I=W<FV-?,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1RKYC;<X0\-Q_NDU[?7@%>WZ'>_VCH=E=F3S'DB7S&VXRXX;C_>!H T****
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MZ&E>GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\.2\?F:M<LA8<0VY&5Z=6((]1@#\:Z/PSX9@T"UR=LM[(/WLN.G^ROM_/KZ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLSYL2R;L]-IQC'OO_2@#T>BBB@#S#XB7OGZY%:+)N2VB&Y=N-KMR>>_R[/\
M.:X^M#7+W^T=<O;L2>8DDK>6VW&4'"\?[H%9] !1110 5VGPXL_-U:ZO&6,K
M!%M&X?,&8\$?@K#\:XNO6? ED]GX9C=]P-S(TP5EQM!PH^N0H.?>@#IJ***
M"O)/'-Y]K\43J&C9+=%A4H<]!DY]PS$?A7K,DB11M)(ZHB LS,<  =237A%W
M<O>7D]U(%#S2-(P7H"3DX_.@"&BBB@ HHHH *]G\,:1_8NAPVSC$[?O)N?XS
MU'4C@8''7&>]>;>#M/.H>)K48;9 ?/<J0,;>1U_VMH_&O8: "BBB@ HHHH *
M*** . ^(FC?ZK5X4](KC _[Y8X'X$D_W17G]>XZQIXU31[NR(4F6,A-Q( 8<
MJ3CT(!KPZ@ HHHH **** /2_AQ>>;I-U9LTA:"7<-Q^4*PX _%6/XUVE>5>
M+U[?Q(ML-Q2ZC9"-V "!N!QWZ$?\"->JT %%%% 'F'Q'_P"1AM_^O1?_ $-Z
MX^NP^(__ ",-O_UZ+_Z&]<?0 4444 %%%% 'HWPYTL1VMQJCJP>0^3'D$?*,
M$D=CDX'MM^M=S67X<@CM_#6FI$NU3;HY&<\L-Q/YDUJ4 %%%% !1110 4444
M %%%% !7'_$?_D7K?_K[7_T!Z["N/^(__(O6_P#U]K_Z ] 'F%%%% !1110
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M* "O,/B/_P C#;_]>B_^AO7I]>8?$?\ Y&&W_P"O1?\ T-Z ./HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC=M(.,_A7N] !1110!YA\1_^1AM_^O1?_0WKCZ[#XC_\C#;_ /7HO_H;UQ]
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M_D4+'_MI_P"C&H Z"BBB@#G_ !M_R*%]_P!L_P#T8M>05Z_XV_Y%"^_[9_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N?\:67VWPO=;8]\D&)D^;&W:?F/\ WR6_
M_7704V2-)8VCD171P596&00>H(H \"HJ:[MGL[R>UD*EX9&C8KT)!P<?E4-
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M]2O4TW3;F\?:1#&7 9MNX@<#/N<#\:\,DD>61I)'9W<EF9CDDGJ2: &T444
M%%%% &AH7_(PZ9_U]Q?^ABO;Z\H\ VWG^*$DW[?L\3R8QG=D;<>WWL_A7J]
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M/F+*>2?P91^%<70 4444 %=!XBU+[;INA0HN(H;(8)'S%LE&[]/W?'UKGZ*
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M(-OH_P P_0BO::\L^(-G]G\1"X59-MS$K%F'R[A\I _ +^= ')T444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'E7C^R>W\2-<G<4NHU<';@ @;2,]^@/_ A
M7*UZ7\1[/S=)M;Q5D+02[3M'RA6')/XJH_&O-* "BBB@ HHHH **** "O=["
MV^Q:=;6F_?Y$2Q[L8W;0!G'X5Y!X5MOM?BC3X]^S;*),XS]P;L?CMQ^->ST
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MR;4;Z:\N&S+,Y9N3@>PSV'0>PJO0 4444 %%%.CC>618XT9W<A551DDGH *
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MHHH **** . ^)O\ S"_^VO\ [)7G]>@?$W_F%_\ ;7_V2O/Z "BBB@ HHHH
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M?]>C?^AI7I]>8?#C_D8;C_KT;_T-*]/H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S]<LO[1T.]M
M!'YCR1-Y:[L9<<KS_O 5XA7O]>*>([/[!XBO[<+&JB4LBQC"JK?,H_ $4 9=
M%%% !1110 4444 =Y\-;/-Q?7S+(-J+"AQ\IR<M^(VK^?O7H=<[X)T\V'AF
MN&#W),[ D'K@+C'JH4_C714 %%%% !7B6OZ>-+UZ\LU"A$DR@4DX4_,HR>>
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M^BVH ]?HHHH **** .?\;?\ (H7W_;/_ -&+7D%>O^-O^10OO^V?_HQ:\@H
M**** "BBB@#U_P $_P#(H6/_ &T_]&-705S_ ()_Y%"Q_P"VG_HQJZ"@ HHH
MH **** "BBB@#@/B;_S"_P#MK_[)7G]>@?$W_F%_]M?_ &2O/Z "BBB@ HHH
MH ]_HHHH **** .=\;:>;_PS.4#%[8B=0"!TR&SGT4L?PKR*O?9(TEC:.1%=
M'!5E89!!Z@BO%->TI]%UB>S;<44[HF/\2'H<X&?0X[@T 9M%%% !1110 5WG
MA_Q_Y$,=IJZR2!?E%TO+8XQN'?'/(YX'!/-<'10![O:W]G>[OLEW!<;,;O*D
M#;<],X^AJQ7@%7/[6U+[/]G_ +0N_(V;/+\YMNW&,8SC&.U 'M\\\-M"TUQ+
M'%$OWGD8*H[=37)ZSX_L;+?#IZ_;)QD;^D:GD=>K<@=."#UKS"B@"UJ&HW>J
M71N;V=II2 N2 , =@!P/PJK110 4444 %%%% !7O]> 5[_0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7D'C2R^Q>*+K;'LCGQ,GS9W;A\Q_[
MZ#?_ *J]?KA/B59YM[&^58QM=H7./F.1E?P&UOS]Z /.Z*** "BBB@ HHHH
MN:59_P!HZM:6960K-*JOY8^8+GYC^ R?PKW.O+OA[IYN=>>\(;9:1D@@C[S?
M* 1UZ;NGI7J- !1110 5P7Q)T\>79ZDH4$$P.<G)SEEXZ<8;\Q^'>UA^+[/[
M;X7O5"QEXD\Y2X^[M.3CWV@C\: /'**** "BBB@ HHHH *]OT.R_L[0[*T,?
MEO'$OF+NSASRW/\ O$UY)X<L_M_B*PMRL;*90SK(,JRK\S#\0#7M= !1110
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M "BBB@ HHHH \ HHHH **** "O0/AE_S%/\ ME_[/7G]>@?#+_F*?]LO_9Z
M._HHHH **** /,OB+IXM]8@O5"@74>&Y.2R8!/MP5''H:XVO9_$^D?VUH<UL
M@S.O[R'G^,=!U Y&1STSGM7C% !1110 4444 36MU/8W4=S;2M%-&<JZ]O\
M/I7I^B>.=.U"-(KUUL[K'S;^(V/.<-VZ=\=<<UY510![['(DL:R1NKHX#*RG
M((/0@TZO!()YK:99K>62*5?NO&Q5AVZBI+J_O+W;]KNY[C9G;YLA;;GKC/T%
M 'M.H:SIVEJ3>WD4) #;"V7()QD*.3SZ"N*\0>/_ #X9+32%DC#?*;IN&QSG
M:.V>.3SR> >:X.B@ HHHH **** "BBB@#L/AQ_R,-Q_UZ-_Z&E>GUYA\./\
MD8;C_KT;_P!#2O3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?^VG_HMJ /7Z*** "BBB@#G_ !M_R*%]_P!L_P#T8M>05Z_XV_Y%"^_[9_\
MHQ:\@H **** "BBB@#U_P3_R*%C_ -M/_1C5T%<_X)_Y%"Q_[:?^C&KH* "B
MBB@ HHHH **** . ^)O_ #"_^VO_ +)7G]>@?$W_ )A?_;7_ -DKS^@ HHHH
M **** /?Z*** "BBB@ KF_&>A-K.D^9",W5KNDC&"2XQ\R@#N<#''48[UTE%
M '@%%=QXP\'_ &3S-3TR/_1_O30*/]7ZLH_N^H[?3IP] !1110 4444 %%%%
M !1110 4444 %%%% !1110 5[_7@%>_T %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#D:/\ ^*H_X0GQ%_T#_P#R-'_\50!S]%=!_P (3XB_Z!__ )&C_P#BJ/\
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MC(+ $<5[G7B&A?\ (PZ9_P!?<7_H8KV^@ HHHH **** "BBB@ HHHH ****
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MXB_Z!_\ Y&C_ /BJ/^$)\1?] _\ \C1__%4 <_170?\ "$^(O^@?_P"1H_\
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MW5=(UF:XOK7RHFMV0-YBMSN4XX)]#7=T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 53GTG3;F9IKC3[265OO/)"K,>W4BKE% &/=>%="N
M]OF:9 NW./*!CZ^NW&?QJ2#PYHMO"L2:7:%5Z&2(.WYMDFM2B@"&VM+:SC,=
MK;Q0(3N*Q(%!/K@?2IJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O=6%G>
M[?M=I!<;,[?-C#;<]<9^@JG/X<T6XA:)]+M K=3'$$;\UP16I10!CVOA70K3
M=Y>F0-NQGS09.GINSC\*T+6PL[+=]DM(+??C=Y487=CIG'U-6** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@ K-U[2DUK1Y[-MH=ANB8_P +CH<X./0X[$T44 >9?\(3XB_Z!_\
MY&C_ /BJFMO >O3R%9((K< 9WRR@@^WRY/Z444 7(_AOJID427=FJ$C<59B0
M.^!M&?S%;-G\.-/BPUY=SW#!\X0"-2/0CD^O((HHH WK+PSHNGR>9;:?$'R&
M#/ERI'0@L3C\*UJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957551018624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001119774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Compugen Ltd<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Azrieli Center<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">26 Harokmim Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Building D<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Holon<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">5885849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, par value NIS 0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CGEN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of Exchange on which Security is Registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">89,237,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KOST FORER GABBAY & KASIERER<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv, Israel<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm Id</a></td>
<td class="text">1281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Alberto Sessa<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Azrieli Center<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">26 Harokmim Str<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Building D<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Holon<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">5885849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">3-765-8585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelFaxNumber', window );">Contact Personnel Fax Number</a></td>
<td class="text">972-3-765-8555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelFaxNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fax Number of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelFaxNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957551562192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,890<span></span>
</td>
<td class="nump">$ 11,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term bank deposits</a></td>
<td class="nump">25,053<span></span>
</td>
<td class="nump">72,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="nump">11,742<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables</a></td>
<td class="nump">61,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other accounts receivable and prepaid expenses</a></td>
<td class="nump">2,529<span></span>
</td>
<td class="nump">2,417<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">114,579<span></span>
</td>
<td class="nump">86,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long-term prepaid expenses</a></td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SeverancePayFundNoncurrent', window );">Severance pay fund</a></td>
<td class="nump">2,977<span></span>
</td>
<td class="nump">2,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="nump">1,329<span></span>
</td>
<td class="nump">1,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non- current assets</a></td>
<td class="nump">6,755<span></span>
</td>
<td class="nump">8,051<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">121,334<span></span>
</td>
<td class="nump">94,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade payables</a></td>
<td class="nump">3,502<span></span>
</td>
<td class="nump">1,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses', window );">Short-term deferred participation in R&amp;D expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Short-term deferred revenues</a></td>
<td class="nump">11,149<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturity of operating lease liability</a></td>
<td class="nump">632<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other accounts payable and accrued expenses</a></td>
<td class="nump">10,983<span></span>
</td>
<td class="nump">9,208<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">26,266<span></span>
</td>
<td class="nump">11,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON- CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term deferred revenues</a></td>
<td class="nump">25,392<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">1,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent', window );">Accrued severance pay</a></td>
<td class="nump">3,398<span></span>
</td>
<td class="nump">3,265<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">29,509<span></span>
</td>
<td class="nump">4,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2023 and 2022; 89,237,465 and 86,624,643 shares issued and outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">539,837<span></span>
</td>
<td class="nump">533,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(474,527)<span></span>
</td>
<td class="num">(455,773)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">65,559<span></span>
</td>
<td class="nump">77,680<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 121,334<span></span>
</td>
<td class="nump">$ 94,176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SeverancePayFundNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SeverancePayFundNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term deferred participation in R&amp;amp;D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481179/712-10-25-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481179/712-10-25-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957551380480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value</a></td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">89,237,465<span></span>
</td>
<td class="nump">86,624,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">89,237,465<span></span>
</td>
<td class="nump">86,624,643<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957551396768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 33,459<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">2,004<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="nump">680<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">31,455<span></span>
</td>
<td class="nump">6,525<span></span>
</td>
<td class="nump">5,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses, net</a></td>
<td class="nump">34,472<span></span>
</td>
<td class="nump">30,648<span></span>
</td>
<td class="nump">28,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDevelopment', window );">Marketing and business development expenses</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">932<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">9,731<span></span>
</td>
<td class="nump">10,319<span></span>
</td>
<td class="nump">10,858<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">44,447<span></span>
</td>
<td class="nump">41,899<span></span>
</td>
<td class="nump">40,394<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(12,992)<span></span>
</td>
<td class="num">(35,374)<span></span>
</td>
<td class="num">(35,074)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_FinancialIncomeExpenseNet', window );">Financial and other income, net</a></td>
<td class="nump">3,208<span></span>
</td>
<td class="nump">1,738<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income</a></td>
<td class="num">(9,784)<span></span>
</td>
<td class="num">(33,636)<span></span>
</td>
<td class="num">(34,203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income, net</a></td>
<td class="nump">8,970<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,754)<span></span>
</td>
<td class="num">$ (33,694)<span></span>
</td>
<td class="num">$ (34,203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain arising during the period from marketable securities</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (18,752)<span></span>
</td>
<td class="num">$ (33,694)<span></span>
</td>
<td class="num">$ (34,203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares used in computing basic net loss per share</a></td>
<td class="nump">87,633,298<span></span>
</td>
<td class="nump">86,555,628<span></span>
</td>
<td class="nump">84,203,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares used in computing diluted net loss per share</a></td>
<td class="nump">87,633,298<span></span>
</td>
<td class="nump">86,555,628<span></span>
</td>
<td class="nump">84,203,971<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_FinancialIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Income (Expense), Net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_FinancialIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957551035792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Additional paid-in capital [Member]</div></th>
<th class="th"><div>Accumulated other comprehensive income [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 507,427<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (387,876)<span></span>
</td>
<td class="nump">$ 119,782<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">83,675,856<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Exercise of options and ESPP shares</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Exercise of options and ESPP shares, shares</a></td>
<td class="nump">335,204<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_NumberOfWarrantsExercised', window );">Warrants exercised, shares</a></td>
<td class="nump">89,557<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IssuanceOfSharesAndWarrantsNetValue', window );">Issuance of shares, net</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IssuanceOfSharesAndWarrantsNetShares', window );">Issuance of shares, net, shares</a></td>
<td class="nump">2,332,815<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees', window );">Stock-based compensation issued to employees, directors and non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,203)<span></span>
</td>
<td class="num">(34,203)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 239<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">528,533<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(422,079)<span></span>
</td>
<td class="nump">106,693<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">86,433,432<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Exercise of options and ESPP shares</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Exercise of options and ESPP shares, shares</a></td>
<td class="nump">191,211<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees', window );">Stock-based compensation issued to employees, directors and non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,694)<span></span>
</td>
<td class="num">(33,694)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">533,213<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(455,773)<span></span>
</td>
<td class="nump">$ 77,680<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">86,624,643<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,624,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IssuanceOfSharesAndWarrantsNetValue', window );">Issuance of shares, net</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IssuanceOfSharesAndWarrantsNetShares', window );">Issuance of shares, net, shares</a></td>
<td class="nump">2,612,822<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees', window );">Stock-based compensation issued to employees, directors and non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Changes in other comprehensive income from marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,754)<span></span>
</td>
<td class="num">(18,754)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 539,837<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">$ (474,527)<span></span>
</td>
<td class="nump">$ 65,559<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">89,237,465<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,237,465<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Representing amount lower than $ 1.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IssuanceOfSharesAndWarrantsNetShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants, net, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IssuanceOfSharesAndWarrantsNetShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IssuanceOfSharesAndWarrantsNetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IssuanceOfSharesAndWarrantsNetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation relating to options issued to employees and directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957551065696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,754)<span></span>
</td>
<td class="num">$ (33,694)<span></span>
</td>
<td class="num">$ (34,203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,550<span></span>
</td>
<td class="nump">4,328<span></span>
</td>
<td class="nump">4,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">482<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SeverancePayNet', window );">Decrease in severance pay, net</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss (gain) from property and equipment sales and disposals</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances', window );">Exchange rate differences loss (gain) on cash balances</a></td>
<td class="num">(129)<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement', window );">Decrease (increase) in interest receivables from short-term bank deposits</a></td>
<td class="nump">92<span></span>
</td>
<td class="num">(584)<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities', window );">Amortization of discount and accrued interest on marketable securities</a></td>
<td class="num">(280)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Decrease (increase) in trade receivables</a></td>
<td class="num">(61,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in other accounts receivable and prepaid expenses</a></td>
<td class="num">(112)<span></span>
</td>
<td class="nump">3,043<span></span>
</td>
<td class="num">(2,802)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease (increase) in long-term prepaid expenses</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Decrease in operating lease right of use asset</a></td>
<td class="nump">568<span></span>
</td>
<td class="nump">658<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in trade payables and other accounts payable and accrued expenses</a></td>
<td class="nump">3,509<span></span>
</td>
<td class="num">(1,601)<span></span>
</td>
<td class="nump">3,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses', window );">Increase (decrease) in deferred participation in R&amp;D expenses</a></td>
<td class="num">(325)<span></span>
</td>
<td class="num">(6,019)<span></span>
</td>
<td class="nump">3,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IncreaseDecreaseInDeferredRevenues', window );">Increase in deferred revenues</a></td>
<td class="nump">36,541<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Decrease in operating lease liability</a></td>
<td class="num">(645)<span></span>
</td>
<td class="num">(1,062)<span></span>
</td>
<td class="num">(416)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(35,886)<span></span>
</td>
<td class="num">(34,113)<span></span>
</td>
<td class="num">(22,691)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities', window );">Proceeds from maturity of short-term bank deposits</a></td>
<td class="nump">79,242<span></span>
</td>
<td class="nump">114,445<span></span>
</td>
<td class="nump">136,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Investment in short-term bank deposits</a></td>
<td class="num">(32,100)<span></span>
</td>
<td class="num">(76,900)<span></span>
</td>
<td class="num">(129,945)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturity of marketable securities</a></td>
<td class="nump">10,145<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Investment in marketable securities</a></td>
<td class="num">(21,605)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(172)<span></span>
</td>
<td class="num">(477)<span></span>
</td>
<td class="num">(292)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Costs of disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">35,510<span></span>
</td>
<td class="nump">37,060<span></span>
</td>
<td class="nump">6,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net</a></td>
<td class="nump">3,081<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock-based awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="nump">1,455<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">3,081<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="nump">16,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">129<span></span>
</td>
<td class="num">(393)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">2,834<span></span>
</td>
<td class="nump">2,907<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the year</a></td>
<td class="nump">11,421<span></span>
</td>
<td class="nump">8,514<span></span>
</td>
<td class="nump">7,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at the end of the year</a></td>
<td class="nump">14,255<span></span>
</td>
<td class="nump">11,421<span></span>
</td>
<td class="nump">8,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction', window );">Purchase of property and equipment</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash received during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_InterestPaidReceivedNet', window );">Interest payments received from short-term bank deposits and cash equivalents</a></td>
<td class="nump">3,052<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="nump">1,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">13,890<span></span>
</td>
<td class="nump">11,059<span></span>
</td>
<td class="nump">7,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 14,255<span></span>
</td>
<td class="nump">$ 11,421<span></span>
</td>
<td class="nump">$ 8,514<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment for Exchange rate differences loss (gain) on cash balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Cash Consideration Of Research And Development Funding Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of Amortization of discount and accrued interest on marketable securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deferred participation in R and D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseDecreaseInDeferredRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of deferred revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseDecreaseInDeferredRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_InterestPaidReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest payments paid (received) from bank short-term deposits and cash equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_InterestPaidReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payments for Proceeds from Sales of equipment Investing Activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchase property and equipment as non cash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SeverancePayNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance pay, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SeverancePayNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In right of use asset and operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957551017008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text">
        <div>
          <div>
            <div style="text-align:justify;line-height:1.25">
              <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">

                  <tr>
                    <td style="font-size:10pt;vertical-align:top;width:56.7pt">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">NOTE 1:-</span></p>
                    </td>
                    <td style="font-size:10pt;width:auto"><span style="fonfamily:Times New Roman,Times,serif"><span style="font-weight:bold">GENERAL</span></span></td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compugen Ltd. (the &#8220;Company&#8221;) is a clinical-stage therapeutic discovery and development company utilizing our broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. The Company&#8217;s innovative immuno-oncology pipeline consists of three clinical stage programs, COM701, COM902 and rilvegostomig, targeting immune checkpoints the Company discovered computationally. Two programs that are pursued internally, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. Based on the data from the Phase 1 trials and as part of our focus on two specific tumor types for the further clinical evaluation of COM701 and COM902, the Company initiated in 2023 two clinical trials evaluating the triple combination treatment of COM701, COM902 and pembrolizumab, one in metastatic microsatellite stable colorectal cancer patients and one in platinum resistant ovarian cancer patients. Rilvegostomig, a novel anti PD-1/TIGIT bispecific antibody with a TIGIT-specific component that is derived from the Company&#8217;s COM902 antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between the Company and AstraZeneca and is being evaluated in multiple clinical trials, including in Phase 3 clinical trial in patients with biliary tract cancer who will be randomized to receive rilvegostomig or placebo with investigator choice chemotherapy as adjuvant treatment after resection with curative intent. The Company&#8217;s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. The Company&#8217;s most advanced early-stage program, COM503, is in IND enabling studies and was licensed to Gilead in December 2023. COM503 is a potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. The Company&#8217;s business model is to selectively enter into collaborations for our novel targets and drug product candidates at various stages of research and development under various revenue-sharing arrangements.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is headquartered in Holon, Israel. Its clinical development activities are headed from its United States subsidiary, Compugen USA, Inc, located in San Francisco, CA.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has incurred losses in the amount of $ 18,754 during the year ended December 31, 2023, has an accumulated deficit of $ 474,527 as of December 31, 2023 and has an accumulated negative cash flow from operating activities in the amount of $ 35,886 for the year ended December 31, 2023. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures at least twelve months from the reporting date.</span></span></div>
                  </td>
                </tr>

            </table>
            <div>
              <p style="margin:0pt">&#160;</p>
              <div></div>
            </div>
          </div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (&#8220;Bayer Agreement&#8221;) with Bayer Pharma AG (&#8220;Bayer&#8221;) for the research, development, and commercialization of antibody-based therapeutics against two novel, Compugen-discovered immune checkpoint regulators.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the terms of the Bayer Agreement, the Company received an upfront payment of $ 10,000, and, following the return of the CGEN 15022 program in 2017, the Company was eligible to receive an aggregate amount of over $ 250,000 in potential milestone payments for Bapotulimab (formerly known as BAY1905254), not including aggregate milestone payments of $ 23,200 received to date. Additionally, the Company was eligible to receive mid to high single digit royalties on global net sales of any approved products under the collaboration.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the terms of Bayer Agreement, Bapotulimab program was transferred to Bayer&#8217;s full control for further preclinical and clinical development activities, and worldwide commercialization under milestone and royalty bearing license from Compugen.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 29, 2022, Bayer notified the Company that it has resolved to terminate,&#160;</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">effective as of February 27, 2023, the Bayer Agreement.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#8220;AstraZeneca&#8221;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and will be solely responsible for all research, development, and commercial activities under the agreement. In connection with such license agreement, AstraZeneca developed rilvegostomig, a novel PD-/TIGIT bi-specific antibody with a TIGIT component that is derived from our COM902 and entered the clinic in September 2021 and initiated Phase 3 with first patient dosing in Phase 3 in December 2023. Compugen received a $10,000 upfront payment, and received or accrued $ 25,500 milestone payments out of up to $ 200,000 it is eligible to receive in development, regulatory and commercial milestones for the first product in addition to tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Agreement&#8221;) with Bristol-Myers Squibb Company (&#8220;Bristol-Myers Squibb&#8221;) to evaluate the safety and tolerability of Compugen&#8217;s COM701 in combination with Bristol-Myers Squibbs&#8217; PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors.</span></span></div>
                    <div>&#160;</div>
                  </td>
                </tr>

            </table>
            <div></div>
            <div style="text-align:justify;margin-left:85.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the Agreement, Compugen was responsible for and sponsored the ongoing two-part Phase 1 trial, which included the evaluation of the combination of COM701 and Opdivo&#174;. The collaboration was also designed to address potential future combinations, including trials sponsored by Bristol-Myers Squibb to investigate combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT. Bristol-Myers Squibb and Compugen each supplied the other company with its own compound for the other party&#8217;s study, and otherwise each party was responsible for all costs associated with the study that it is conducting.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In conjunction with the signing of the Agreement in October 2018, Bristol-Myers Squibb made a $ 12,000 investment in Compugen, see Note 8b.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On February 14, 2020, the Agreement was amended to include a triple combination clinical trial to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo&#174; (nivolumab), and Bristol-Myers Squibb&#8217;s investigational antibody targeting TIGIT known as BMS-986207, in patients with advanced solid tumors, instead of the planned expansion of the combined therapy study designed to evaluate the dual combination of COM701 and Opdivo&#174;.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the Agreement, as amended, the Company sponsored the two-part Phase 1/2 trial, which evaluates the triple combination of COM701, Opdivo&#174; and BMS-986207, in patients with advanced solid tumors where Bristol-Myers Squibb provided Opdivo&#174; and BMS-986207 at no cost to the Company.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As part of the amended Agreement, it was agreed that the Company will complete the dose escalation arm of the dual combination of COM701 with Opdivo<sup style="vertical-align:text-top;line-height:1;font-size:smaller">&#174;</sup> under the ongoing Phase 1 study and will not continue the expansion cohorts of the dual combination. However, on February 19, 2021, the Agreement was further amended to include an expansion of the Phase 1 combination study designed to evaluate the dual combination of COM701 and Opdivo&#174; in patients with advanced solid tumors, where the Company is responsible for and sponsored the expansion cohort and Bristol Myers Squibb provided Opdivo&#174; at no cost to the Company for this study.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 10, 2021, the Agreement was further amended to establish a joint steering committee (alongside the existing joint development committee which acts at an operational level) to facilitate strategic oversight and guidance for the programs run under the collaboration.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In conjunction with the signing of the amendment to the Agreement in November 2021, Bristol-Myers Squibb made a $ 20,000 investment in Compugen, see Note 8b.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 3, 2022, the Company and Bristol-Myers Squibb entered into a letter agreement pursuant to which the Agreement, as amended thereafter, was terminated as of such date.</span></span></div>
            <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25">&#160;</div>
            <div></div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt">&#160;</td>
                  <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 18, 2023, the Company entered into an exclusive license agreement (the &#160;&#8220;License Agreement&#8221;) with Gilead Sciences, Inc. (&#8220;Gilead&#8221;), pursuant to which the Company granted Gilead an exclusive license under the Company&#8217;s pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products, including the Company&#8217;s COM503 product candidate (&#8220;COM503 License&#8221;), and additional products that may be so developed by Gilead (together with COM503, the &#8220;Licensed Products&#8221;).</span></span></div>
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<br/>Pursuant to the License Agreement, Gilead paid the Company a one-time, upfront payment of $60 million in January 2024. The Company has continued to develop COM503 during the initial development term, which included conducting activities defined within the agreement to advance COM503 through the clearance of an investigational new drug application (&#8220;IND&#8221;). The Company is eligible to receive from Gilead $30 million in the form of a milestone payment upon clearance of the IND for COM503. The Company is also eligible to receive up to approximately $758 million in additional milestone payments upon the achievement of certain development, regulatory and commercial milestones. The Company is further eligible to receive single-digit to low double-digit tiered royalties on worldwide net sales of Licensed Products.<br/>&#160;<br/>The Company will be responsible for conducting a Phase 1 clinical trial for COM503, including handling the regulatory matters in connection therewith, and will bear the costs of such trial (including the COM503 drug supply), with Gilead providing at no cost an anti-PD-1/PD-L1 antibody for such trial. In certain circumstances, Gilead may assume the role of conducting the Phase 1 clinical trial.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="text-align:justify;margin-left:84.3pt;line-height:1.25">
              <p style="margin:0pt">&#160;</p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Upon completion of the Phase 1 clinical trial for COM503, the Company will initiate the transfer of development activities related to COM503 to Gilead, following which, Gilead will have sole responsibility to develop and commercialize the Licensed Products.<br/>&#160;<br/>During the term of the License Agreement, the Company is prohibited from researching, developing, making, and commercializing any compounds, molecules, products or treatment methods that are directed to IL-18 or any companion diagnostics for an IL-18 product.<br/>&#160;<br/>Unless terminated early by a party pursuant to its terms, the License Agreement will continue in effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the last royalty term in such country.<br/>&#160;<br/>Gilead withheld at source 15% from the upfront payment amount paid to the Company in January 2024 and is expected to continue and withhold at source all taxes required by law from all payments payable to the Company under the License Agreement.<br/>&#160;<br/>The License Agreement contains customary representations, warranties, covenants, and terms governing the prosecution and enforcement of certain intellectual property and issues related to technology transfer, manufacturing transfer, provisions with respect to establishment of joint steering committee and its governance covenants with respect change of control and others.</span></span></span></span>
            </div>
          </div>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957641918352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">
    <div>
      <div style="margin-top:0pt;margin-bottom:0pt">
        <div style="margin-top:0pt;margin-bottom:0pt">
          <div style="margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
              <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">

                  <tr>
                    <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:56.7pt">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold">NOTE 2:-</span></span></span></p>
                    </td>
                    <td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="fonfamily:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">SIGNIFICANT ACCOUNTING POLICIES</span></span></span></span></td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
            <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</span></span></span></span></div>
            <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
          </div>
        </div>

          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">a.<span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt">Use of estimates:</span></span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company&#8217;s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></span></span></span></p>

        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>

          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">b.<span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt">Financial statements in U.S. dollars:</span></span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The reporting and functional currency of the Company is the U.S. dollar, as the Company&#8217;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.</span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No. 830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate.</span></span></span></span></p>

        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>

          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">c.<span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt">Basis of consolidation:</span></span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation.</span></span></span></span></p>

        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>

          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">d.<span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt">Cash equivalents:</span></span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.</span></span></span></span></p>

        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>

          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">e.<span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt">Restricted cash:</span></span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Restricted cash is held in interest bearing saving accounts which are used as a security for the Company&#8217;s Israeli facility leasehold&#160;and leased cars fueling bank guarantees and credit card security for Compugen USA, Inc.</span></span></span></span></p>

        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
        <div style="margin-top:0pt;margin-bottom:0pt"></div>
      </div>

        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">f.<span style="padding-left:22.17pt;margin-top:0pt;margin-bottom:0pt">Short-term bank deposits:</span></span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values.</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The short-term bank deposits as of December 31, 2023&#160;and 2022&#160;are in U.S. dollars and bear an annual weighted average interest rate of 6.20% and 4.84%, respectively.</span></span></span></span></p>

      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
      <div style="margin-top:0pt;margin-bottom:0pt">
        <div style="margin-top:0pt;margin-bottom:0pt">

            <div style="margin-top:0pt;margin-bottom:0pt">
              <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">g.&#160; &#160; &#160; &#160; &#160;Investments in marketable securities:</span></span></span></span></div>
              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company accounts for investments in marketable securities in accordance with ASC No. 320, &#8220;Investments - Debt Securities&#8221;.</span></span></span></span></div>
              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation at each balance sheet date. The Company classifies all of its debt securities as available-for-sale (&#8220;AFS&#8221;). The Company classifies its marketable securities as either short-term or long-term based on each instrument&#8217;s underlying contractual maturity date. Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders&#8217; equity. Realized gains and losses on sale of investments are included in financial income, net.</span></span></span></span></div>
              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.</span></span></span></span></div>
              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">At each reporting period, the Company evaluates whether declines in fair value below amortized cost are due to expected credit losses, as well as the Company&#8217;s ability and intent to hold the investment until a forecasted recovery occurs in accordance with ASC 326, Financial Instrument- Credit losses. Allowance for credit losses on AFS debt securities are recognized in the Company&#8217;s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in shareholders&#8217; equity. No credit loss impairment was identified in the year ended December 31, 2023.</span></span></span></span></div>
            </div>

        </div>
      </div>
      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>

        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">h.<span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt">Property and equipment, net:</span></span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:</span></span></span></span></p>
        <div style="margin-top:0pt;margin-bottom:0pt">

            <div style="margin-top:0pt;margin-bottom:0pt">
              <div style="margin-top:0pt;margin-bottom:0pt">
                <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                <div style="margin-left:90pt;margin-top:0pt;margin-bottom:0pt">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">

                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="padding-bottom:2px;width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td colspan="1" style="padding-bottom:2px;width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="border-bottom:2px solid rgb(0, 0, 0);width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">%</span></span></span></div>
                        </td>
                        <td colspan="1" style="padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>
                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>
                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="width:80%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Computers, software and related equipment</span></span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td rowspan="1" style="width:18%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="line-height:1.25;font-family:Times New Roman, Times, serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">33</span></span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>
                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Laboratory equipment and office furniture</span></span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:center;line-height:1.25;text-indent:2pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">6 - 20 (mainly 20)</span></span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>
                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="background-color:rgb(204, 238, 255);width:80%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Leasehold improvements</span></span></span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="background-color:rgb(204, 238, 255);width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:center;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Shorter of the term of the lease or useful life</p>
                          </div>
                        </td>
                        <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>

        </div>

      <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>

        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">i.<span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt">Impairment of long-lived assets:</span></span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The long-lived assets of the Company. are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant, and Equipment&#8221; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset (assets group) with the future undiscounted cash flows expected to be generated by the asset (assets group). If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets group exceeds the fair value of the assets group. During the years 2023, 2022 and 2021, no impairment losses have been identified.</span></span></span></span></p>

      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
      <div style="margin-top:0pt;margin-bottom:0pt">
        <div style="margin-top:0pt;margin-bottom:0pt">
          <div style="margin-top:0pt;margin-bottom:0pt">

              <div style="margin-top:0pt;margin-bottom:0pt">
                <div style="margin-top:0pt;margin-bottom:0pt">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">j.<span style="padding-left:22.72pt;margin-top:0pt;margin-bottom:0pt">Leases:</span></span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company accounts for its leases according to ASC 842 - Leases (&#8220;ASC 842&#8221;). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#8220;ROU&#8221;) asset for leases with a term of twelve months or less. The Company elected to combine its lease and non-lease components.</span></span></span></span></p>
                  <p style="margin:0pt">&#160;</p>
                  <div style="margin-top:0pt;margin-bottom:0pt"></div>
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured based on the discounted present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The implicit rate within the operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (&#8220;IBR&#8221;) based on the information available at commencement date in determining the present value of lease payments. The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located.</span></span></p>
                  <p style="margin:0pt">&#160;</p>
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate the lease is considered unless it is reasonably certain that the Company will not exercise the option.</span></span></p>
                </div>
              </div>

          </div>
        </div>
      </div>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify">&#160;</p>
      <div style="margin-top:0pt;margin-bottom:0pt">
        <div style="margin-top:0pt;margin-bottom:0pt">
          <div style="margin-top:0pt;margin-bottom:0pt">
            <div style="margin-top:0pt;margin-bottom:0pt">

                <div style="margin-top:0pt;margin-bottom:0pt">
                  <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:76pt;text-indent:-20pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">k.<span style="padding-left:23.06pt;margin-top:0pt;margin-bottom:0pt">Revenue recognition:</span></span></span></p>
                  <p style="margin:0pt">&#160;</p>
                  <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:85.05pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements.</span></span></p>
                  <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:85.05pt;text-align:justify">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company recognizes revenue in accordance with ASC 606 &#8211; &#8220;Revenue from Contracts with Customers&#8221;.</span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">As such, the Company analyzes its contracts to assess whether they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:</span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
                  <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">

                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">&#8226;</span></span></span></p>
                        </td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-style:italic">Identification of the contract, or contracts, with a customer</span></span></span></p>
                        </td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">&#160;</td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">&#8226;</span></span></span></p>
                        </td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt;font-style:italic">Identification of the performance obligations in the contract</span>&#160;</span></span></span></p>
                        </td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">&#160;</td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">&#8226;</span></span></span></p>
                        </td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt;font-style:italic">Determination of the transaction price</span>&#160;</span></span></span></p>
                        </td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">&#160;</td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">&#8226;</span></span></span></p>
                        </td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt;font-style:italic">Allocation of the transaction price to the performance obligations in the contract</span>&#160;</span></span></span></p>
                        </td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">&#160;</td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">&#8226;</span></span></span></p>
                        </td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt;font-style:italic">Recognition of revenue when, or as, the Company satisfies a performance obligation</span>&#160;</span></span></span></p>
                        </td>
                      </tr>

                  </table>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt">&#160;</p>
                  <div style="margin-top:0pt;margin-bottom:0pt"></div>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:85pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">At the contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></span></span></span></p>
                  <p style="margin:0pt">&#160;</p>
                  <div style="margin-top:0pt;margin-bottom:0pt">
                    <div style="margin-left:85.05pt;text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property (</span></span></span></span>&#8220;<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">IP&#8221;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $&#160;10,000 upfront payment and is eligible to receive up to $&#160;200,000 for development, regulatory and commercial milestones for the first product, of which $&#160;25,500 was received or accrued&#160;as well as tiered royalties on future product sales.</span></span></span></span></div>
                    <div style="margin-left:85.05pt;text-align:justify;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                  </div>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer.</span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#8220;probable&#8221; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone.</span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Sales&#160;or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales&#160;or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties.</span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">On December 18, 2020 the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 2,000 in accordance with the criteria prescribed under ASC 606.</span></span></span></span></p>
                  <p style="margin:0pt">&#160;</p>
                  <div style="margin-top:0pt;margin-bottom:0pt"></div>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On&#160;September 29, 2021 the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 6,000 in accordance with the criteria prescribed under ASC 606.</span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">On November 11, 2022, the third milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 7,500 in accordance with the criteria prescribed under ASC 606.</span></span></span></span><br/>&#160;</p>
                  <div style="margin-top:0pt;margin-bottom:0pt">
                    <div style="margin-top:0pt;margin-bottom:0pt">
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">On December 27, 2023, the fourth milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 10,000 in accordance with the criteria prescribed under ASC 606.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">On December 18, 2023, the Company entered into an exclusive License Agreement with Gilead. Under the terms of the agreement, the Company granted Gilead an exclusive license under the Company&#8217;s pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products derived from a Compugen pipeline program. Compugen received an upfront payment of $60,000 and is also eligible to receive up to approximately $ 788,000 additional milestone payments subject to and upon the achievement of certain development, regulatory and commercial milestones and as detailed in the agreement.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Gilead may terminate the Gilead Collaboration Agreement for convenience by giving a certain prior written notice to the Company at any time after the effective date of the agreement.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company concluded that Gilead is a customer and therefore revenue recognition should be accounted for in accordance with ASC 606, because the Company granted to Gilead licenses to its intellectual property and will provide research and development services, all of which are outputs of the Company&#8217;s ongoing activities, in exchange for consideration.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company assessed the promises under the License Agreement and concluded that (i) the delivery of the COM503 License; (ii) the preclinical research and development activities towards IND approval of COM503 (the &#8220;IND research and development activities&#8221;) and (iii) the contingent promise to additional research and development activities for Phase 1 clinical (the &#8220;Phase 1 research and development activities&#8221;), are capable of being distinct and are distinct within the context of the License Agreement. The Company considered that the license has standalone functionality, considered to be functional intellectual property, and is capable of being distinct. The Company also determined that the IND research and development activities and Phase 1 research and development activities could be provided by resources otherwise available to Gilead and thus are capable of being distinct. Also, the Company concluded that the Company&#8217;s contingent promise to additional research and development activities for Phase 1 clinical represents a material right.</span></span></span></span></div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">As a result, the Company concluded that its promise to deliver the COM503 License, the promise to perform IND research and development activities and Phase 1 research and development activities represented separate performance obligations in the License Agreement.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="margin-top:0pt;margin-bottom:0pt"></div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company also evaluated as a possible variable consideration all milestones and royalties. With respect to clinical development and regulatory milestones, based upon the high degree of uncertainty and risk associated with these potential payments, the Company concluded that all such amounts should be fully constrained and are not included in the initial transaction price as the Company cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Accordingly, the Company did not include any potential clinical development, regulatory and sales milestones and royalties in the initial transaction price.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company allocated the transaction price to each performance obligation on a relative estimated standalone selling price basis. The Company developed the estimated standalone selling price for the COM503 License based on the present value of expected future cash flows associated with the license and related clinical development and regulatory milestones. In developing such estimate, the Company applied judgement in determining the timing needed to develop the Licensed Product, the probability of success, and the discount rate. The Company developed the estimated standalone selling price for the IND research and development activities using a &#8220;cost plus&#8221; reasonable margin approach. To determine the estimated standalone selling price of the material right for the Phase 1 research and development activities obligation, the Company estimated the standalone selling price of the underlying performance obligations included in the material right and estimated the probability of the Company&#8217;s performance of such obligations.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company determined that the COM503 License was a functional license since the underlying intellectual property (the &#8220;IP&#8221;) has significant standalone functionality. In addition, the Company determined that December 18, 2023 represents (i) the date at which the Company made available the IP to Gilead and (ii) the beginning of the period during which Gilead is able to use and benefit from its right to use the IP. Based upon these considerations, the Company recognized the entirety of the initial transaction price allocated to the COM503 License performance obligation during the year ended December 31, 2023.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Further, the IND research and development activities and Phase 1 research and development activities performance obligations are recognized over time when, or as, the Company performs the required services to Gilead. The Company determined that the input method under ASC 606 is the best measure of progress towards satisfying the performance obligation and reflects a faithful depiction of the transfer of goods and services. The method of measuring progress towards delivery of the services incorporates actual internal and external costs incurred, relative to total internal and external costs expected to be incurred to satisfy the performance obligation. The period over which total costs were estimated reflected the Company&#8217;s best estimate of the period over which it would perform the activities to achieve clearance of an IND application for COM503 and the phase 1 clinical trial.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">During the year ended December 31, 2023, the Company recognized $ 23,459 of license revenue. The Company included deferred revenues of $ 11,149 in current liabilities and $ 25,392 in non-current liabilities.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">For additional information regarding revenues, please refer to Note 10 below.</span></span></span></span></div>
                      <p style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                      <div style="margin-top:0pt;margin-bottom:0pt"></div>
                    </div>
                  </div>
                </div>

            </div>

              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">l.<span style="padding-left:22.72pt;margin-top:0pt;margin-bottom:0pt">Cost of revenues:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Cost of revenues consist of certain royalties and milestones paid or accrued.</span></span></span></span></p>

            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt">&#160;</p>

              <div style="margin-top:0pt;margin-bottom:0pt">
                <div style="margin-top:0pt;margin-bottom:0pt">
                  <div style="margin:0pt 0px 0pt 58pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">m.&#160; &#160; &#160; &#160;Research and development expenses, net:</span></span></span></span></div>
                  <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                  <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received.</span></span></span></span></div>
                  <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                  <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span></span></span></span></div>
                  <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                  <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The portion of the Bristol-Myers Squibb $ 12,000 investment in 2018 over the fair market value of the shares issued in the amount of $ 4,121 and the portion of the $ 20,000 investment in 2021 over the fair market value of the shares issued in the amount of $ 5,000 were considered as deferred participation of Bristol-Myers Squibb in R&amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;D, see Note 1f and Note 8b.</span></span></span></span></div>
                  <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                  <div style="text-align:justify;margin-left:85.5pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Amortization of participation in R&amp;D expenses for the years ended December 31, 2023, 2022 and 2021 were $ 325, $ 6,019 and $ 1,291, respectively.</span></span></span></span></div>
                </div>
              </div>

            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
            <div style="margin-top:0pt;margin-bottom:0pt"></div>

              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">n.<span style="padding-left:22.72pt;margin-top:0pt;margin-bottom:0pt">Severance pay:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company&#8217;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date, and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset on the Company&#8217;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#8217;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#8217;s monthly salary for each year of service, no additional calculations are conducted between the parties regarding the matter of severance pay and no additional payments are made by the Company to the employee.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Severance expenses for the years ended December 31, 2023, 2022 and 2021 amounted to approximately $&#160;432, $&#160;468 and $&#160;383, respectively.</span></span></span></span></p>

            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>

              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">o.<span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt">Stock-based compensation:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company accounts for stock-based compensation to employees and non-employees in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company selected the Black-Scholes-Merton (&#8220;Black-Scholes&#8221;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></span></span></span></p>
              <p style="margin:0pt">&#160;</p>
              <div style="margin-top:0pt;margin-bottom:0pt"></div>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company used the following assumptions for options granted to employees, directors and non-employees and ESPP:</span></span></span></span></p>
              <p style="margin:0pt">&#160;</p>
              <div style="margin-left:90pt;margin-top:0pt;margin-bottom:0pt">

                  <div style="margin-top:0pt;margin-bottom:0pt">
                    <div style="margin-top:0pt;margin-bottom:0pt">
                      <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">

                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="5" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Year ended December 31,</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2023</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2022</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2021</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="background-color:rgb(204, 238, 255);width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Employee stock options</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Volatility</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">75.93%-80.95%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                            </td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">69.44%-74.61%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">66.02%-69.05%</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Risk-free interest rate</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">3.37%-4.81%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                            </td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">1.54%-4.39%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0.51%-1.14%</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Dividend yield</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                            </td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0%</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Expected life (years)</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">4.02-5.06</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">5.05-5.4</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">5.04-5.31</span></span></span></span></div>
                            </td>
                          </tr>

                      </table>
                      <p style="margin:0pt">&#160;</p>
                    </div>
                  </div>

              </div>
              <div style="margin-left:90pt;margin-top:0pt;margin-bottom:0pt">
                <div style="margin-top:0pt;margin-bottom:0pt">

                    <div style="margin-top:0pt;margin-bottom:0pt">
                      <div style="margin-top:0pt;margin-bottom:0pt">
                        <div style="margin-top:0pt;margin-bottom:0pt">
                          <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">

                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="5" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Year ended December 31,</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2023</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2022</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2021</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="background-color:rgb(204, 238, 255);width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">ESPP</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Volatility</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">-</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">69.74%</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                                </td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">64.68%-69.68%</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Risk-free interest rate</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">-</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">1.63%</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                                </td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0.04%-0.10%</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Dividend yield</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">-</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0%</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                                </td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0%</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Expected life (years)</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt">-</div>
                                </td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0.50</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0.42-0.50</span></span></span></span></div>
                                </td>
                              </tr>

                          </table>
                        </div>
                      </div>
                    </div>

                </div>
              </div>

            <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>

              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">p.<span style="padding-left:21.5pt;margin-top:0pt;margin-bottom:0pt">Concentration of credit risks:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits and investment in marketable securities.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Cash, cash equivalents, restricted cash and short-term bank deposits are invested in major banks in Israel and in the United States. Generally, these deposits may be redeemed upon demand and bear minimal risk.</span></span></span></span></p>

            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>

              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">q.<span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt">Basic and diluted loss per share:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#8220;Earnings per Share</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#8221;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">All outstanding share options and warrants for the years ended December 31, 2023, 2022 and 2021 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2023, 2022 and 2021 the average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 7,921,020, 8,405,615 and 6,758,300, respectively.</span></span></span></span></p>

            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
            <div style="margin-top:0pt;margin-bottom:0pt"></div>

              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">r.<span style="padding-left:24.5pt;margin-top:0pt;margin-bottom:0pt">Income taxes:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company accounts for income taxes in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2023 and 2022, a full valuation allowance was provided by the Company.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10.</span></span></span></span></p>

            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>

              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">s.<span style="padding-left:23.5pt;margin-top:0pt;margin-bottom:0pt">Fair value of financial instruments:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company applies ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.</span></span></span></span></p>
              <p style="margin:0pt">&#160;</p>
              <div style="margin-top:0pt;margin-bottom:0pt"></div>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The hierarchy is broken down into three levels based on the inputs as follows:</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;margin-top:0pt;margin-bottom:0pt">

                  <tr style="margin-top:0pt;margin-bottom:0pt">
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Level 1&#160;</span><span style="margin-top:0pt;margin-bottom:0pt">-</span></span></span></p>
                    </td>
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can </span>access at the measurement date.</span></span></span></td>
                  </tr>
                  <tr>
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                  </tr>

              </table>
              <div style="margin-top:0pt;margin-bottom:0pt">
                <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;margin-top:0pt;margin-bottom:0pt">

                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt">
                        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Level 2&#160;-</span></span></span></p>
                      </td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Valuations based on one or more quoted prices in markets that are not active or for which all </span>significant inputs are observable, either directly or indirectly.</span></span></span></td>
                    </tr>
                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="width:85.5pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      <td style="width:56.7pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      <td style="text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                    </tr>
                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt">
                        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Level 3&#160;-</span></span></span></p>
                      </td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></span></span></span></td>
                    </tr>

                </table>
              </div>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, other accounts receivable and prepaid expenses, trade payable and other accounts payable and accrued expenses approximate their fair values due to the short-term maturities of such instruments.</span></span></span></span></p>

            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>

              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">t.<span style="padding-left:23.06pt;margin-top:0pt;margin-bottom:0pt">Recently issued accounting pronouncement not yet adopted by the Company:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">In&#160;December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.</span></span></span></span></p>

          </div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957555289680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock', window );">OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</a></td>
<td class="text">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;color:rgb(0, 0, 0)">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span>NOTE 3:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</span></span></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <div>
          <div style="line-height:1.25">&#160;</div>
          <div style="margin-left:63pt">

              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid expenses</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,211</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,100</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Government authorities</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">92</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">85</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-indent:-4.25pt;margin-left:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">226</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">232</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="width:76%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,529</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,417</span></span></div>
                    </td>
                  </tr>

              </table>

          </div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other accounts receivable and prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957550885584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;color:rgb(0, 0, 0)">

        <tr>
          <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span>NOTE 4:-</span></span></td>
          <td style="width:auto;vertical-align:top;text-align:justify">
            <div style="font-weight:bold"><span style="font-size:10pt"><span>LEASES</span></span></div>
          </td>
        </tr>

    </table>
    <div>
      <div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company leases all its real estate, storage area and cars under various operating lease agreements that expire on various dates.</span></span></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s operating leases have original lease periods expiring between 2021 and 2026. The offices in Israel lease include two options to renew, one of which was exercised in 2020. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably certain.</span></span></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease payments included in the measurement of the lease liability comprise the following: the fixed non-cancelable lease payments and payments for optional renewal periods where it is reasonably certain the renewal period will be exercised.</span></span></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under ASC 842, all leases, including non-cancelable operating leases, are now recognized on the balance sheet. The aggregated present value of lease payments is recorded as a long-term asset titled Operating lease right of use asset. The corresponding lease liabilities are split between current maturity of operating lease liability within current liabilities and long-term operating lease liability within long-term liabilities. The Company&#8217;s leases do not provide an implicit rate, therefore the Company uses its incremental borrowing rate based on information available on the commencement date to determine the present value of lease payments.</span></span></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table represents the weighted-average remaining lease term and discount rate:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">

            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;width:89.79%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.03%;vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:top;width:9.18%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;width:89.79%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1.03%;vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);width:9.18%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:89.79%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.03%;vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:top;width:9.18%;vertical-align:bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:89.79%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining lease term</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.03%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td rowspan="1" style="vertical-align:bottom;width:9.18%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-align:center">2.19</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:89.79%;vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average discount (annual) rate</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.03%;vertical-align:bottom">&#160;</td>
                    <td rowspan="1" style="vertical-align:bottom;width:9.18%;vertical-align:bottom">
                      <div style="text-align:center">5.32%</div>
                    </td>
                  </tr>

              </table>
            </div>

        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease expenses were approximately $ 800, $ 884 and $ 956 in the years ended December 31, 2023, 2022 and 2021, respectively.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Variable payments as CPI, included in the lease expenses, were approximately $ 61, $ 37 and $ 14 in the years ended December 31, 2023, 2022 and 2021, respectively.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash paid for amounts included in the measurement of lease liabilities was approximately $ 852, $ 959 and $ 914 in the years ended December 31, 2023, 2022 and 2021, respectively.</span></span></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
        <div></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Maturities of operating lease liabilities were as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,&#160;2023</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">690</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">631</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">115</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total operating lease payments</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,436</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less: imputed interest</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">85</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,351</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, current</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">632</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, non- current</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">719</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom">
                      <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,351</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>

        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The above annual minimum future rental commitments include the period covered by the first exercised option with respect to the leased facility of Compugen Ltd. through March 2026 and exclude the second option to extend the lease of the Company facility for additional five-year period following expiration of the current lease period.</span></span></div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957555133664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;color:rgb(0, 0, 0)">

        <tr>
          <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span>NOTE 5:-</span></span></td>
          <td style="width:auto;vertical-align:top;text-align:justify">
            <div style="font-weight:bold"><span style="font-size:10pt"><span>PROPERTY AND EQUIPMENT, NET</span></span></div>
          </td>
        </tr>

    </table>
    <div>
      <div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">

            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers, software and related equipment</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">739</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,617</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment and office furniture</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,519</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,831</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,314</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,314</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,572</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,762</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated depreciation:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers, software and related equipment</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">609</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,435</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment and office furniture</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,909</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,190</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,838</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,605</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,356</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,230</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciated cost</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,216</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,532</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>

        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During 2023 and 2022 total cost of $ 1,357 and $ 99, respectively and total accumulated depreciation of $ 1,350 and $ 95, respectively were disposed from the consolidated balance sheets.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the years ended December 31, 2023, 2022 and 2021, depreciation expenses were approximately $ 476, $ 482 and $ 461, respectively.</span></span></div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957552322752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</a></td>
<td class="text">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NOTE 6:-</span></span></span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></span></span></span></div>
              </td>
            </tr>

        </table>

          <div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December 31,</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Employees and related accruals</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,125</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,812</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued expenses</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7,858</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6,396</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>10,983</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>9,208</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>

      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957555058992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 7:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMMITMENTS AND CONTINGENCIES</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company provided bank guarantees in the amount of $ 296 related to its offices in Israel, leased cars fueling in Israel and credit card security for its U.S. subsidiary.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the Office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly known as the Office of the Chief Scientist (the &#8220;IIA&#8221;), the Company is not obligated to repay any amounts received from the IIA if it does not generate any income from the results of the funded research program(s). If income is generated from a funded research program, the Company is committed to pay royalties at a rate of between 3% to 5% of future revenue arising from such research program(s), and up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum to be repaid is 100% plus interest at LIBOR until December 31, 2023, and from January 1, 2024, the 12 months Term SOFR interest). For the years ended December 31, 2023, 2022 and 2021, the Company had an aggregate of paid or accrued royalties to the IIA, recorded as cost of revenue in the consolidated statements of comprehensive loss in the amount of $ 1,004, $ 225 and $ 180, respectively.</span></span></div>
                <div>&#160;</div>
                <div style="font-family:'Times New Roman',Times,serif">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, the Company&#8217;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled approximately to $ 8,970.</span></span></div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 25, 2012 the Company entered into an Antibodies Discovery Collaboration Agreement (the &#8220;Antibodies Discovery Agreement&#8221;) with a U.S. antibody technology company (&#8220;mAb Technology Company&#8221;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company will be entitled to certain royalties that could be eliminated, upon payment of certain one-time fees (all payments referred together as &#8220;Contingent Fees&#8221;). For the years ended December 31, 2023, 2022 and 2021, the Company incurred such Contingent Fees in the amounts of $ 1,000, $ 750 and $ 500.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 9, 2012, the Company entered into agreement (the &#8220;May 2012 Agreement&#8221;) with a U.S. Business Development Strategic Advisor (&#8220;Advisor&#8221;) for the purpose of entering into transactions with Pharma companies related to selected Pipeline Program Candidates.</span></span></div>
                <div>&#160;</div>
                <div style="font-family:'Times New Roman',Times,serif">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the agreement the Advisor was entitled to 4% of the cash considerations that may be received under such transactions. In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Bayer Agreement was terminated effective February 27, 2023 and no further payments are expected under the May 2012 Agreement.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the years ended December 31, 2023, 2022 and 2021, the Company has not paid and did not accrue payments under this agreement.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                </div>
              </td>
            </tr>

        </table>
        <div></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (CLA) with a European cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and 1% royalties on annual net sales with respect to each commercialized product manufactured using the company&#8217;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the years ended December 31, 2023, 2022 and 2021, the Company did not incur any amount in the research and development expenses in connection with such milestone payment.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the years ended December 31, 2023, 2022 and 2021, the Company incurred in the research and development expenses such milestone payment in the amounts of $ 500, $ 0 and $ 250.</span></span></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957555133664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">SHAREHOLDERS' EQUITY</a></td>
<td class="text">
      <div>
        <div style="text-align:justify;line-height:1.25">
          <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">

              <tr>
                <td style="font-size:10pt;vertical-align:top;width:56.7pt">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">NOTE 8:-</span></p>
                </td>
                <td style="font-size:10pt;width:auto"><span style="fonfamily:Times New Roman,Times,serif"><span style="font-weight:bold">SHAREHOLDERS</span>&#8217;<span style="font-weight:bold"> EQUITY</span></span></td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary shares:</span></span></div>
                <div>&#160;</div>
                <div style="font-family:'Times New Roman',Times,serif">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The ordinary shares confer upon their holders the right to attend and vote at general meetings of the shareholders. Subject to the rights of holders of shares with limited or preferred rights which may be issued in the future, the ordinary shares of the Company confer upon the holders thereof equal rights to receive dividends, and to participate in the distribution of the assets of the Company upon its winding-up, in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the nominal value, if any.</span></span></div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25">
          <div></div>
        </div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares:</span></span></div>
                <div>&#160;</div>
                <div style="font-family:'Times New Roman',Times,serif">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 14, 2018, the Company entered into securities purchase agreement with certain institutional investors and a placement agency agreement with JMP Securities LLC in connection with a registered direct offering (the &#8220;Offering&#8221;) of an aggregate of 5,316,457 ordinary shares (the &#8220;RD Shares&#8221;) of the Company at a purchase price of $ 3.95 per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to 4,253,165 additional ordinary shares. The Warrants were exercisable at a price of $ 4.74 per ordinary share and had a term of five years from the date of issuance. The Offering was made pursuant to the Company&#8217;s Registration Statement. Proceeds from the Offering were $ 19,767 (net of $ 1,233 issuance expenses).</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the years ended December 31, 2021 and 2020, warrants to purchase an aggregate of 3,955,696 ordinary shares were exercised with proceeds of approximately $ 18,750 and as of December 31, 2023 and 2022, warrants to purchase 0 and up to 297,469 ordinary shares, respectively, remain outstanding. The warrants expired in June 2023.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Master Clinical Agreement&#8221;) with Bristol-Myers Squibb to evaluate the safety and tolerability of the Company&#8217;s COM701 in combination with Bristol-Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol-Myers Squibb made a $ 12,000 equity investment in the Company.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the terms of the securities purchase agreement, Bristol-Myers Squibb purchased 2,424,243 ordinary shares of the Company at a purchase price of $ 4.95 per share. The share price represented a 33% premium over the average closing price of Compugen&#8217;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The premium over the fair market value in the amount of $ 4,121 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D) and $ 7,788 (net of $ 91 issuance expenses) were considered equity investment.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $ 20,000 investment in the Company, purchasing 2,332,815 ordinary shares of the Company at a purchase price of $ 8.57333 per share. The share price represented a 33% premium over the closing price of Company&#8217;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The premium over the fair market value in the amount of $ 5,000 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D) and $ 14,958 (net of $ 42 issuance expenses) were considered equity investment.</span></span></div>
                </div>
              </td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
        <div></div>
        <div style="margin-left:85.05pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On January 31, 2023, the Company entered into a Sales Agreement with Leerink Partners LLC (previously known as SVB Securities LLC) (&#8220;Leerink Partners&#8221;), as sales agent, pursuant to which the Company may offer and sell, from time to time through Leerink Partners, its ordinary shares through an &#8220;at the market offering&#8221; (ATM). The offer and sale of our ordinary shares, if any, will be made pursuant to the Company&#8217;s shelf registration statement on Form F-3, as supplemented by a prospectus supplement filed on January 31, 2023. Pursuant to the applicable prospectus supplement, the Company may offer and sell up to $50,000 of its ordinary shares. As of December 31, 2023, 2,612,822 ordinary shares were issued and sold through the ATM, with proceeds of approximately $3,081 (net of $513 issuance expenses).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share option plan:</span></span></div>
                <div>&#160;</div>
                <div style="font-family:'Times New Roman',Times,serif">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the Company&#8217;s 2010 Share Option Plan, as amended (the &#8220;Plan&#8221;), options may be granted to employees, directors and non-employees of the Company and Compugen USA, Inc.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the 2010 Share Option Plan the Company reserved for issuance up to an aggregate of 13,895,152 ordinary shares. The Company&#8217;s Board of Directors last amended the Plan in August 2023, to decrease the number of shares available under the 2010 Plan. As of December 31, 2023, an aggregate of 1,202,301 options under the 2010 Share Option Plan of the Company were still available for future grants.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In general, options granted under the Plan vest over a four-year period and expire 10 years from the date of grant and are granted at an exercise price of not less than the fair market value of the Company&#8217;s ordinary shares on the date of grant, unless otherwise determined by the Company&#8217;s board of directors. The exercise price of the options granted under the Plan may not be less than the nominal value of the shares into which such options are exercisable, and the expiration date may not be later than 10 years from the date of grant. If a grantee leaves his or her employment or other relationship with the Company, or if his or her relationship with the Company is terminated without cause (and other than by reason of death or disability, as defined in the Plan), the term of his or her unexercised options will generally expire in 90 days, unless determined otherwise by the Company.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Any options that are cancelled, forfeited or expired become available for future grants.</span></span></div>
                </div>
              </td>
            </tr>

        </table>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <div style="width:100%">&#160;</div>
        </div>
        <div></div>
        <div style="font-family:'Times New Roman',Times,serif">
          <div style="line-height:1.25;margin-left:85.05pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Transactions related to the grant of options to employees, directors and non-employees under the above Plan during the year ended December 31, 2023, were as follows:</span></span></div>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:90pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of options</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">price</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining contractual</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">life</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Aggregate</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">intrinsic</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">value</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Years</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options outstanding at beginning of year</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,157,749</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.43</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6.32</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options granted</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,576,500</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.20</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options forfeited</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,086,404</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.49</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="width:52%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options expired</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(274,100</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.92</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options outstanding at end of year</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,373,745</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.65</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6.61</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,912</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercisable at end of year</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,017,329</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.71</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.15</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">117</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average fair value of options granted to employees, directors and non-employees during the years 2023, 2022 and 2021 was $ 0.70, $ 1.51 and $ 3.81 per share, respectively.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Aggregate intrinsic value of exercised options by employees, directors and non-employees during the years 2023, 2022 and 2021 was $ 0, $ 19 and $ 759, respectively. The aggregate intrinsic value of the exercised options represents the total intrinsic value (the difference between the sale price of the Company&#8217;s share at the date of exercise, and the exercise price) multiplied by the number of options exercised.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company&#8217;s closing share price on the last trading day of calendar 2023 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2023. This amount is impacted by the changes in the fair market value of the Company&#8217;s shares.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, the total unrecognized estimated compensation cost related to non-vested share options granted prior to that date was $ 5,370 which is expected to be recognized over a weighted average period of approximately 2.06 years.</span></span></div>
        <div style="text-align:justify;margin-left:85.5pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;line-height:1.25">
          <div></div>
        </div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:58.5pt">&#160;</td>
              <td style="width:26.5pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee Stock Purchase Plan:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company adopted an ESPP in November 2020, with the first offering period starting on January 1, 2021. In connection with its adoption, a total of 600,000 ordinary shares were reserved for issuance under this plan.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:0.5pt;margin-left:85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The ESPP is implemented through six-month offering periods (except for the first offering period that was five months). According to the ESPP, eligible employees and non-employees may use up to 15% of their base salaries to purchase ordinary shares up to an aggregate limit of $ 40 per participant for every calendar year. The price of an ordinary share purchased under the ESPP is equal to 85% of the lower of the fair market value of the ordinary share on the first day of each offering period or on the last day of such period.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:0.5pt;margin-left:85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In the years ended December 31, 2023, 2022 and 2021, 0, 158,025 and 117,829 ordinary shares, respectively, had been purchased under the ESPP and as of December 31, 2023, 114,146 ordinary shares were available for issuance under the ESPP.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.3pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The stock-based compensation expenses related to stock options and ESPP are included as follows in the expense categories:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:90pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,933</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,158</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,971</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing and business development expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(41</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">269</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">215</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,658</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,901</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,090</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,550</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,328</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,276</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957552322752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME, NET</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

        <tr>
          <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 9:-</span></td>
          <td style="width:auto;vertical-align:top;text-align:justify">
            <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">TAXES ON INCOME, NET</span></div>
          </td>
        </tr>

    </table>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Israeli taxation:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax rates applicable to the income of the Company.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxable income of the Company is subject to a corporate tax rate of 23% in 2021, 2022 and 2023.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Measurement of taxable income in U.S. dollars:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has elected to measure its taxable income and file its tax return under the Israeli Income Tax Regulations (Principles Regarding the Management of Books of Account of Foreign Invested Companies and Certain Partnerships and the Determination of Their Taxable Income), 1986. Accordingly, results for tax purposes are measured in terms of earnings in dollars.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax benefits under the Israeli Law for the Encouragement of Capital Investments, 1959 (the &#8220;Investment Law&#8221;):</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 1, 2005, an amendment to the Investment Law came into effect (the &#8220;Amendment 60&#8221;) that significantly changed the provisions of the Investment Law. The Amendment 60 limits the scope of enterprises that may be approved by the Investment Center by setting criteria for the approval of a facility as a &#8220;Beneficiary Enterprise&#8221; including a provision generally requiring that at least 25% of the Beneficiary Enterprise&#8217;s income will be derived from export.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Another condition for receiving the benefits under the alternative track in respect of expansion programs pursuant to Amendment 60 is a minimum qualifying investment. The Company was eligible under the terms of minimum qualifying investment and elected 2012 as its &#8220;year of election&#8221;.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additionally, Amendment 60 enacted major changes in the manner in which tax benefits are awarded under the Investment Law so that companies no longer require Investment Center approval in order to qualify for tax benefits. However, the Investment Law provides that terms and benefits included in any certificate of approval already granted will remain subject to the provisions of the Investment Law as they were on the date of such approval.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, there was no taxable income attributable to the Beneficiary Enterprise.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In January 2011, another amendment to the Investment Law came into effect (the &#8220;2011 Amendment&#8221;). According to the 2011 Amendment, the benefit tracks in the Investment Law were modified and a flat tax rate applies to the Company&#8217;s entire income subject to this amendment (the &#8220;Preferred Income&#8221;).</span></span></div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25">&#160;</div>
        <div></div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Once an election is made, the Company&#8217;s income will be subject to the amended tax rate of 16% from 2015 and thereafter (or 9% for a preferred enterprise located in development area A).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commencing 2011 tax year, the Company can elect (without possibility of reversal) to apply the Amendment in a certain tax year and from that year and thereafter, it will be subject to the amended tax rates.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company does not currently intend to adopt the 2011 Amendment and intends to continue to comply with the Investment Law as in effect prior to enactment of the 2011 Amendment. Accordingly, the Company did not adjust its deferred tax balances as of December 31, 2023. The Company&#8217;s position may change in the future.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2016 and 2017 Budget Years), 2016, which includes Amendment 73 to the Law (the &#8220;Amendment 73&#8221;) was published. According to Amendment 73, a preferred enterprise located in development area A will be subject to a tax rate of 7.5% instead of 9% effective from January 1, 2016 and thereafter (the tax rate applicable to preferred enterprises located in other areas remains at 16%).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amendment 73 also prescribes special tax tracks for technological enterprises, which are subject to rules that were issued by the Minister of Finance in May 2017. The new tax tracks under the Amendment are as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preferred Technological Enterprise (&#8220;PTE&#8221;) - an enterprise for which total consolidated revenues of its parent company and all subsidiaries are less than NIS 10 billion in a tax year. A PTE, as defined in the Law, which is located in the center of Israel will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development area A - a tax rate of 7.5%).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The above changes in the tax rates relating to PTE tax track were not taken into account in the computation of deferred taxes as of December 31, 2023 and 2022, since the Company estimates that it will not implement the PTE tax track.</span></span></div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25">&#160;</div>
        <div></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax benefits under the law for the Encouragement of Industry (Taxes), 1969 (the &#8220;Encouragement Law&#8221;):</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Encouragement Law provides several tax benefits for industrial companies. An industrial company is defined as a company resident in Israel, at least 90% of the income of which in a given tax year exclusive of income from specified Government loans, capital gains, interest and dividends, is derived from an industrial enterprise owned by it. An industrial enterprise is defined as an enterprise whose major activity in a given tax year is industrial production activity.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Management believes that the Company is currently qualified as an &#8220;industrial company&#8220; under the Encouragement Law and, as such, is entitled to tax benefits, including: (1) deduction of purchase of know-how and patents and/or right to use a patent over an eight-year period; (2) the right to elect, under specified conditions, to file a consolidated tax return with additional related Israeli industrial companies and an industrial holding company; (3) accelerated depreciation rates on equipment and buildings; and (4) expenses related to a public offering on the Tel-Aviv Stock exchange and on recognized stock markets outside of Israel, are deductible in equal amounts over three years.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Eligibility for benefits under the Encouragement Law is not subject to receipt of prior approval from any Governmental authority. No assurance can be given that the Israeli tax authorities will agree that the Company qualifies, or, that the Company will continue to qualify as an industrial company or that the benefits described above will be available to the Company in the future.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:85.05pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net operating losses carryforward and capital loss:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, Compugen Ltd. &#8217;s net operating losses carryforward for tax purposes in Israel amounted to approximately $ 401,100. These net operating losses may be carried forward indefinitely and may be offset against future taxable income.</span></span></div>
        <div style="text-align:justify;margin-left:113.4pt;line-height:1.25">&#160;</div>
        <div></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-Israeli subsidiary, Compugen USA, Inc.:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the &#8220;U.S. Tax Reform&#8221; or &#8220;TCJA&#8221;); a comprehensive tax legislation that includes significant changes to the taxation of business entities. These changes include several key tax provisions that might impact the Company, among others: (i) a permanent reduction to the statutory federal corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017; (ii) a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain new rules designed to prevent erosion of the U.S. income tax base - &#8220;BEAT&#8221;); (iii) establishing immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits; and (iv) providing a permanent deduction to corporations generating revenues from non-US markets (known as a deduction for foreign derived intangible income - &#8220;FDII&#8221;) .</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, Compugen USA, Inc. has net operating loss carryforwards for federal income tax purposes of approximately $ 3,050. Approximately $1,950 of these losses are available to offset any future U.S. taxable income of our U.S. subsidiary and will expire in the years 2024 to 2032. Utilization of the U.S. net operating losses may be subject to substantial annual limitation due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Neither Israeli income taxes, foreign withholding taxes nor deferred income taxes were provided in relation to undistributed earnings of the Company&#8217;s foreign subsidiary. This is because the Company has the intent and ability to reinvest these earnings indefinitely in the foreign subsidiary and therefore those earnings are continually redeployed in those jurisdictions.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss (income) before taxes is comprised as follows:</span></span></div>
              </td>
            </tr>

        </table>

          <div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:90pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Domestic (Israel)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,164</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">34,096</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">34,619</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:64%;padding-bottom:2px;vertical-align:baseline">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(380</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(460</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(416</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,784</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,636</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">34,203</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>

        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxes on income for the years ended December 31, 2023 and 2022, represent state income taxes in the United States.</span></span></div>
              </td>
            </tr>

        </table>
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
        <div></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred taxes:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company and Compugen USA, Inc.&#8217;s deferred tax assets are comprised of operating loss carryforward and other temporary differences. Significant components of the Company and Compugen USA, Inc. deferred tax assets are as follows:</span></span></div>

          <div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:90pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax assets:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating loss carryforward</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">92,885</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">91,704</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,109</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,083</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued social benefits and other</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,072</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,123</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">312</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">444</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax asset before valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">108,380</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">107,356</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(108,073</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(106,941</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax asset after valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">307</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">415</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax liabilities:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:76%;padding-bottom:2px;vertical-align:baseline">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right of use assets</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(307</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(415</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:76%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:76%;padding-bottom:2px;vertical-align:baseline">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(307</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(415</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax assets</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>

        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has provided full valuation allowances in respect of deferred tax assets resulting from operating loss carryforward and other temporary differences. Management currently believes that since the Company has a history of losses, it is more likely than not that the deferred tax regarding the operating loss carryforward and other temporary differences will not be realized in the foreseeable future.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Reconciliation of the theoretical tax expense (benefit) to the actual tax expense (benefit):</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits from accumulated net operating loss carryforward among the Company and<span style="font-weight:bold">&#160;</span>Compugen USA, Inc. due to the uncertainty of the realization of such tax benefits&#160;and withholding taxes on the upfront payment pursuant to the Gilead license agreement.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt">&#160;</td>
              <td style="width:28.35pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax assessments:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has tax assessments through 2018 that are deemed to be final.</span></span></div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957556088496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</a></td>
<td class="text">
    <div>
      <div>
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 10:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s business is currently comprised of one operating segment, the research, development and commercialization of therapeutic and product candidates. The nature of the products and services provided by the Company and the type of customers for these products and services are similar. Operations in Israel and the United States include research and development, clinical operations, marketing and business development. The Company follows ASC 280, &#8220;Segment Reporting&#8221;. Total revenues are attributed to geographic areas based on the location of the end customer.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div>
            <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following represents the total revenue for the years ended December 31, 2023, 2022 and 2021 and long-lived assets as of December 31, 2023 and 2022:</span></span></div>

              <div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
                <div style="margin-left:63pt">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue from sales to customers:</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Europe</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,000</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,500</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,000</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">United States</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23,459</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total revenue</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,459</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,500</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,000</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
                <div style="line-height:1.25">&#160;</div>
                <div style="margin-left:63pt">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-lived assets:</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Israel</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,468</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,239</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                          <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">United States</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">77</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">119</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                          <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total long-lived assets</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,545</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,358</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
              </div>

            <div style="margin-left:63pt">&#160;</div>
          </div>
          <div style="margin-left:63pt">

              <div>
                <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sales to a single customer exceeding 10%:</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer A</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">30</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">100</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">100</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                        <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer B</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">70</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>

                </table>
              </div>

          </div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957641679520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">FINANCIAL AND OTHER INCOME, NET</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

        <tr>
          <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 11:-</span></td>
          <td style="width:auto;vertical-align:top;text-align:justify">
            <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">FINANCIAL AND OTHER INCOME, NET</span></div>
          </td>
        </tr>

    </table>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
    <div>
      <div>
        <div style="margin-left:63pt">

            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,960</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,437</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">894</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of discount on marketable securities, net</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">281</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank fees and other finance expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(31</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(27</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(25</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign currency transaction adjustments</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">340</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gain (loss) from sales and disposals of fixed assets</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(7</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:1.5px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:1.5px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,208</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,738</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">871</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>

        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 610<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//610/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 720<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//720/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957555227632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY BALANCES AND TRANSACTIONS</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

        <tr>
          <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 12:-</span></td>
          <td style="width:auto;vertical-align:top;text-align:justify">
            <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">RELATED PARTY BALANCES AND TRANSACTIONS</span></div>
          </td>
        </tr>

    </table>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
    <div>
      <div>

          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables and accrued expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">53</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">83</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts charged to:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">147</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">194</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">240</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>

        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the years ended December 31, 2023, 2022 and 2021 the Company received research and development services related with cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies. The transaction was at arm&#8217;s length.</span></span></div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957552667744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSSES PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSSES PER SHARE</a></td>
<td class="text">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 13:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">LOSSES PER SHARE</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin:0px 0px 0px 85.5pt;line-height:1.25;text-align:justify;text-indent:-28.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the computation of basic and diluted losses per share:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:63pt">

            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Numerator:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:64%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for basic and diluted loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(18,754</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(33,694</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(34,203</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Denominator:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares</span></span></div>
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">used in computing basic and diluted net loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">87,633,298</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">86,555,628</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">84,203,971</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted loss per ordinary share</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.21</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:3px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.39</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:3px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.41</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:3px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>

        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957552227024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
    <div>
      <div>
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 14:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SUBSEQUENT EVENTS</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
          <div style="margin:0px 0px 0px 85.5pt;line-height:1.25;text-align:justify;text-indent:-28.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In January 2024, 292,728 ordinary shares were issued and sold through the ATM, with proceeds of approximately $562 (net of $17 issuance expenses).</span></span></div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957550095344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates:</a></td>
<td class="text">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">a.<span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt">Use of estimates:</span></span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company&#8217;s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></span></span></span></p>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Financial statements in U.S. dollars:</a></td>
<td class="text">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">b.<span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt">Financial statements in U.S. dollars:</span></span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The reporting and functional currency of the Company is the U.S. dollar, as the Company&#8217;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.</span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No. 830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate.</span></span></span></span></p>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of consolidation:</a></td>
<td class="text">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">c.<span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt">Basis of consolidation:</span></span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation.</span></span></span></span></p>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents:</a></td>
<td class="text">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">d.<span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt">Cash equivalents:</span></span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.</span></span></span></span></p>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash:</a></td>
<td class="text">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">e.<span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt">Restricted cash:</span></span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Restricted cash is held in interest bearing saving accounts which are used as a security for the Company&#8217;s Israeli facility leasehold&#160;and leased cars fueling bank guarantees and credit card security for Compugen USA, Inc.</span></span></span></span></p>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ShortTermBankDepositsPolicyTextBlock', window );">Short-term bank deposits:</a></td>
<td class="text">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">f.<span style="padding-left:22.17pt;margin-top:0pt;margin-bottom:0pt">Short-term bank deposits:</span></span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values.</span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The short-term bank deposits as of December 31, 2023&#160;and 2022&#160;are in U.S. dollars and bear an annual weighted average interest rate of 6.20% and 4.84%, respectively.</span></span></span></span></p>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in marketable securities</a></td>
<td class="text">
            <div style="margin-top:0pt;margin-bottom:0pt">
              <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">g.&#160; &#160; &#160; &#160; &#160;Investments in marketable securities:</span></span></span></span></div>
              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company accounts for investments in marketable securities in accordance with ASC No. 320, &#8220;Investments - Debt Securities&#8221;.</span></span></span></span></div>
              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation at each balance sheet date. The Company classifies all of its debt securities as available-for-sale (&#8220;AFS&#8221;). The Company classifies its marketable securities as either short-term or long-term based on each instrument&#8217;s underlying contractual maturity date. Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders&#8217; equity. Realized gains and losses on sale of investments are included in financial income, net.</span></span></span></span></div>
              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.</span></span></span></span></div>
              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
              <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">At each reporting period, the Company evaluates whether declines in fair value below amortized cost are due to expected credit losses, as well as the Company&#8217;s ability and intent to hold the investment until a forecasted recovery occurs in accordance with ASC 326, Financial Instrument- Credit losses. Allowance for credit losses on AFS debt securities are recognized in the Company&#8217;s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in shareholders&#8217; equity. No credit loss impairment was identified in the year ended December 31, 2023.</span></span></span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net:</a></td>
<td class="text">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">h.<span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt">Property and equipment, net:</span></span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:</span></span></span></span></p>
        <div style="margin-top:0pt;margin-bottom:0pt">

            <div style="margin-top:0pt;margin-bottom:0pt">
              <div style="margin-top:0pt;margin-bottom:0pt">
                <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                <div style="margin-left:90pt;margin-top:0pt;margin-bottom:0pt">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">

                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="padding-bottom:2px;width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td colspan="1" style="padding-bottom:2px;width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="border-bottom:2px solid rgb(0, 0, 0);width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">%</span></span></span></div>
                        </td>
                        <td colspan="1" style="padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>
                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>
                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="width:80%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Computers, software and related equipment</span></span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td rowspan="1" style="width:18%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="line-height:1.25;font-family:Times New Roman, Times, serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">33</span></span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>
                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Laboratory equipment and office furniture</span></span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:center;line-height:1.25;text-indent:2pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">6 - 20 (mainly 20)</span></span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>
                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="background-color:rgb(204, 238, 255);width:80%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Leasehold improvements</span></span></span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="background-color:rgb(204, 238, 255);width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:center;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Shorter of the term of the lease or useful life</p>
                          </div>
                        </td>
                        <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>

        </div>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Impairment of long-lived assets:</a></td>
<td class="text">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">i.<span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt">Impairment of long-lived assets:</span></span></span></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The long-lived assets of the Company. are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant, and Equipment&#8221; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset (assets group) with the future undiscounted cash flows expected to be generated by the asset (assets group). If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets group exceeds the fair value of the assets group. During the years 2023, 2022 and 2021, no impairment losses have been identified.</span></span></span></span></p>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases:</a></td>
<td class="text">
              <div style="margin-top:0pt;margin-bottom:0pt">
                <div style="margin-top:0pt;margin-bottom:0pt">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">j.<span style="padding-left:22.72pt;margin-top:0pt;margin-bottom:0pt">Leases:</span></span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company accounts for its leases according to ASC 842 - Leases (&#8220;ASC 842&#8221;). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#8220;ROU&#8221;) asset for leases with a term of twelve months or less. The Company elected to combine its lease and non-lease components.</span></span></span></span></p>
                  <p style="margin:0pt">&#160;</p>
                  <div style="margin-top:0pt;margin-bottom:0pt"></div>
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured based on the discounted present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The implicit rate within the operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (&#8220;IBR&#8221;) based on the information available at commencement date in determining the present value of lease payments. The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located.</span></span></p>
                  <p style="margin:0pt">&#160;</p>
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate the lease is considered unless it is reasonably certain that the Company will not exercise the option.</span></span></p>
                </div>
              </div>
            <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition:</a></td>
<td class="text">
                <div style="margin-top:0pt;margin-bottom:0pt">
                  <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:76pt;text-indent:-20pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">k.<span style="padding-left:23.06pt;margin-top:0pt;margin-bottom:0pt">Revenue recognition:</span></span></span></p>
                  <p style="margin:0pt">&#160;</p>
                  <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:85.05pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements.</span></span></p>
                  <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:85.05pt;text-align:justify">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company recognizes revenue in accordance with ASC 606 &#8211; &#8220;Revenue from Contracts with Customers&#8221;.</span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">As such, the Company analyzes its contracts to assess whether they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:</span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
                  <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">

                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">&#8226;</span></span></span></p>
                        </td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt;font-style:italic">Identification of the contract, or contracts, with a customer</span></span></span></p>
                        </td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">&#160;</td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">&#8226;</span></span></span></p>
                        </td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt;font-style:italic">Identification of the performance obligations in the contract</span>&#160;</span></span></span></p>
                        </td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">&#160;</td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">&#8226;</span></span></span></p>
                        </td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt;font-style:italic">Determination of the transaction price</span>&#160;</span></span></span></p>
                        </td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">&#160;</td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">&#8226;</span></span></span></p>
                        </td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt;font-style:italic">Allocation of the transaction price to the performance obligations in the contract</span>&#160;</span></span></span></p>
                        </td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">&#160;</td>
                      </tr>
                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt">&#160;</td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">&#8226;</span></span></span></p>
                        </td>
                        <td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto">
                          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt;font-style:italic">Recognition of revenue when, or as, the Company satisfies a performance obligation</span>&#160;</span></span></span></p>
                        </td>
                      </tr>

                  </table>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt">&#160;</p>
                  <div style="margin-top:0pt;margin-bottom:0pt"></div>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:85pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">At the contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></span></span></span></p>
                  <p style="margin:0pt">&#160;</p>
                  <div style="margin-top:0pt;margin-bottom:0pt">
                    <div style="margin-left:85.05pt;text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property (</span></span></span></span>&#8220;<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">IP&#8221;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $&#160;10,000 upfront payment and is eligible to receive up to $&#160;200,000 for development, regulatory and commercial milestones for the first product, of which $&#160;25,500 was received or accrued&#160;as well as tiered royalties on future product sales.</span></span></span></span></div>
                    <div style="margin-left:85.05pt;text-align:justify;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                  </div>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer.</span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#8220;probable&#8221; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone.</span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Sales&#160;or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales&#160;or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties.</span></span></span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">On December 18, 2020 the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 2,000 in accordance with the criteria prescribed under ASC 606.</span></span></span></span></p>
                  <p style="margin:0pt">&#160;</p>
                  <div style="margin-top:0pt;margin-bottom:0pt"></div>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On&#160;September 29, 2021 the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 6,000 in accordance with the criteria prescribed under ASC 606.</span></span></p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt">&#160;</p>
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">On November 11, 2022, the third milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 7,500 in accordance with the criteria prescribed under ASC 606.</span></span></span></span><br/>&#160;</p>
                  <div style="margin-top:0pt;margin-bottom:0pt">
                    <div style="margin-top:0pt;margin-bottom:0pt">
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">On December 27, 2023, the fourth milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 10,000 in accordance with the criteria prescribed under ASC 606.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">On December 18, 2023, the Company entered into an exclusive License Agreement with Gilead. Under the terms of the agreement, the Company granted Gilead an exclusive license under the Company&#8217;s pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products derived from a Compugen pipeline program. Compugen received an upfront payment of $60,000 and is also eligible to receive up to approximately $ 788,000 additional milestone payments subject to and upon the achievement of certain development, regulatory and commercial milestones and as detailed in the agreement.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Gilead may terminate the Gilead Collaboration Agreement for convenience by giving a certain prior written notice to the Company at any time after the effective date of the agreement.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company concluded that Gilead is a customer and therefore revenue recognition should be accounted for in accordance with ASC 606, because the Company granted to Gilead licenses to its intellectual property and will provide research and development services, all of which are outputs of the Company&#8217;s ongoing activities, in exchange for consideration.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company assessed the promises under the License Agreement and concluded that (i) the delivery of the COM503 License; (ii) the preclinical research and development activities towards IND approval of COM503 (the &#8220;IND research and development activities&#8221;) and (iii) the contingent promise to additional research and development activities for Phase 1 clinical (the &#8220;Phase 1 research and development activities&#8221;), are capable of being distinct and are distinct within the context of the License Agreement. The Company considered that the license has standalone functionality, considered to be functional intellectual property, and is capable of being distinct. The Company also determined that the IND research and development activities and Phase 1 research and development activities could be provided by resources otherwise available to Gilead and thus are capable of being distinct. Also, the Company concluded that the Company&#8217;s contingent promise to additional research and development activities for Phase 1 clinical represents a material right.</span></span></span></span></div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">As a result, the Company concluded that its promise to deliver the COM503 License, the promise to perform IND research and development activities and Phase 1 research and development activities represented separate performance obligations in the License Agreement.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="margin-top:0pt;margin-bottom:0pt"></div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company also evaluated as a possible variable consideration all milestones and royalties. With respect to clinical development and regulatory milestones, based upon the high degree of uncertainty and risk associated with these potential payments, the Company concluded that all such amounts should be fully constrained and are not included in the initial transaction price as the Company cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Accordingly, the Company did not include any potential clinical development, regulatory and sales milestones and royalties in the initial transaction price.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company allocated the transaction price to each performance obligation on a relative estimated standalone selling price basis. The Company developed the estimated standalone selling price for the COM503 License based on the present value of expected future cash flows associated with the license and related clinical development and regulatory milestones. In developing such estimate, the Company applied judgement in determining the timing needed to develop the Licensed Product, the probability of success, and the discount rate. The Company developed the estimated standalone selling price for the IND research and development activities using a &#8220;cost plus&#8221; reasonable margin approach. To determine the estimated standalone selling price of the material right for the Phase 1 research and development activities obligation, the Company estimated the standalone selling price of the underlying performance obligations included in the material right and estimated the probability of the Company&#8217;s performance of such obligations.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company determined that the COM503 License was a functional license since the underlying intellectual property (the &#8220;IP&#8221;) has significant standalone functionality. In addition, the Company determined that December 18, 2023 represents (i) the date at which the Company made available the IP to Gilead and (ii) the beginning of the period during which Gilead is able to use and benefit from its right to use the IP. Based upon these considerations, the Company recognized the entirety of the initial transaction price allocated to the COM503 License performance obligation during the year ended December 31, 2023.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Further, the IND research and development activities and Phase 1 research and development activities performance obligations are recognized over time when, or as, the Company performs the required services to Gilead. The Company determined that the input method under ASC 606 is the best measure of progress towards satisfying the performance obligation and reflects a faithful depiction of the transfer of goods and services. The method of measuring progress towards delivery of the services incorporates actual internal and external costs incurred, relative to total internal and external costs expected to be incurred to satisfy the performance obligation. The period over which total costs were estimated reflected the Company&#8217;s best estimate of the period over which it would perform the activities to achieve clearance of an IND application for COM503 and the phase 1 clinical trial.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">During the year ended December 31, 2023, the Company recognized $ 23,459 of license revenue. The Company included deferred revenues of $ 11,149 in current liabilities and $ 25,392 in non-current liabilities.</span></span></span></span></div>
                      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                      <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">For additional information regarding revenues, please refer to Note 10 below.</span></span></span></span></div>
                      <p style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                      <div style="margin-top:0pt;margin-bottom:0pt"></div>
                    </div>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_CostOfSalesContractWithCustomerPolicyTextBlock', window );">Cost of revenues:</a></td>
<td class="text">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">l.<span style="padding-left:22.72pt;margin-top:0pt;margin-bottom:0pt">Cost of revenues:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Cost of revenues consist of certain royalties and milestones paid or accrued.</span></span></span></span></p>
            <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses, net:</a></td>
<td class="text">
              <div style="margin-top:0pt;margin-bottom:0pt">
                <div style="margin-top:0pt;margin-bottom:0pt">
                  <div style="margin:0pt 0px 0pt 58pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">m.&#160; &#160; &#160; &#160;Research and development expenses, net:</span></span></span></span></div>
                  <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                  <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received.</span></span></span></span></div>
                  <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                  <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span></span></span></span></div>
                  <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                  <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The portion of the Bristol-Myers Squibb $ 12,000 investment in 2018 over the fair market value of the shares issued in the amount of $ 4,121 and the portion of the $ 20,000 investment in 2021 over the fair market value of the shares issued in the amount of $ 5,000 were considered as deferred participation of Bristol-Myers Squibb in R&amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;D, see Note 1f and Note 8b.</span></span></span></span></div>
                  <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                  <div style="text-align:justify;margin-left:85.5pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Amortization of participation in R&amp;D expenses for the years ended December 31, 2023, 2022 and 2021 were $ 325, $ 6,019 and $ 1,291, respectively.</span></span></span></span></div>
                </div>
              </div>
            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ServerancePayPolicyTextBlock', window );">Severance pay:</a></td>
<td class="text">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">n.<span style="padding-left:22.72pt;margin-top:0pt;margin-bottom:0pt">Severance pay:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company&#8217;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date, and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset on the Company&#8217;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#8217;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#8217;s monthly salary for each year of service, no additional calculations are conducted between the parties regarding the matter of severance pay and no additional payments are made by the Company to the employee.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Severance expenses for the years ended December 31, 2023, 2022 and 2021 amounted to approximately $&#160;432, $&#160;468 and $&#160;383, respectively.</span></span></span></span></p>
            <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation:</a></td>
<td class="text">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">o.<span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt">Stock-based compensation:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company accounts for stock-based compensation to employees and non-employees in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company selected the Black-Scholes-Merton (&#8220;Black-Scholes&#8221;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></span></span></span></p>
              <p style="margin:0pt">&#160;</p>
              <div style="margin-top:0pt;margin-bottom:0pt"></div>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company used the following assumptions for options granted to employees, directors and non-employees and ESPP:</span></span></span></span></p>
              <p style="margin:0pt">&#160;</p>
              <div style="margin-left:90pt;margin-top:0pt;margin-bottom:0pt">

                  <div style="margin-top:0pt;margin-bottom:0pt">
                    <div style="margin-top:0pt;margin-bottom:0pt">
                      <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">

                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="5" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Year ended December 31,</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2023</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2022</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2021</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="background-color:rgb(204, 238, 255);width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Employee stock options</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Volatility</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">75.93%-80.95%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                            </td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">69.44%-74.61%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">66.02%-69.05%</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Risk-free interest rate</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">3.37%-4.81%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                            </td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">1.54%-4.39%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0.51%-1.14%</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Dividend yield</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                            </td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0%</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Expected life (years)</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">4.02-5.06</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">5.05-5.4</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">5.04-5.31</span></span></span></span></div>
                            </td>
                          </tr>

                      </table>
                      <p style="margin:0pt">&#160;</p>
                    </div>
                  </div>

              </div>
              <div style="margin-left:90pt;margin-top:0pt;margin-bottom:0pt">
                <div style="margin-top:0pt;margin-bottom:0pt">

                    <div style="margin-top:0pt;margin-bottom:0pt">
                      <div style="margin-top:0pt;margin-bottom:0pt">
                        <div style="margin-top:0pt;margin-bottom:0pt">
                          <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">

                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="5" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Year ended December 31,</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2023</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2022</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2021</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="background-color:rgb(204, 238, 255);width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">ESPP</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Volatility</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">-</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">69.74%</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                                </td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">64.68%-69.68%</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Risk-free interest rate</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">-</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">1.63%</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                                </td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0.04%-0.10%</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Dividend yield</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">-</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0%</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                                </td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0%</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Expected life (years)</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt">-</div>
                                </td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0.50</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0.42-0.50</span></span></span></span></div>
                                </td>
                              </tr>

                          </table>
                        </div>
                      </div>
                    </div>

                </div>
              </div>
            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks:</a></td>
<td class="text">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">p.<span style="padding-left:21.5pt;margin-top:0pt;margin-bottom:0pt">Concentration of credit risks:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits and investment in marketable securities.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Cash, cash equivalents, restricted cash and short-term bank deposits are invested in major banks in Israel and in the United States. Generally, these deposits may be redeemed upon demand and bear minimal risk.</span></span></span></span></p>
            <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted loss per share:</a></td>
<td class="text">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">q.<span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt">Basic and diluted loss per share:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#8220;Earnings per Share</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#8221;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">All outstanding share options and warrants for the years ended December 31, 2023, 2022 and 2021 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2023, 2022 and 2021 the average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 7,921,020, 8,405,615 and 6,758,300, respectively.</span></span></span></span></p>
            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes:</a></td>
<td class="text">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">r.<span style="padding-left:24.5pt;margin-top:0pt;margin-bottom:0pt">Income taxes:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company accounts for income taxes in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2023 and 2022, a full valuation allowance was provided by the Company.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10.</span></span></span></span></p>
            <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments:</a></td>
<td class="text">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">s.<span style="padding-left:23.5pt;margin-top:0pt;margin-bottom:0pt">Fair value of financial instruments:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The Company applies ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.</span></span></span></span></p>
              <p style="margin:0pt">&#160;</p>
              <div style="margin-top:0pt;margin-bottom:0pt"></div>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The hierarchy is broken down into three levels based on the inputs as follows:</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;margin-top:0pt;margin-bottom:0pt">

                  <tr style="margin-top:0pt;margin-bottom:0pt">
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Level 1&#160;</span><span style="margin-top:0pt;margin-bottom:0pt">-</span></span></span></p>
                    </td>
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can </span>access at the measurement date.</span></span></span></td>
                  </tr>
                  <tr>
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                    <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                  </tr>

              </table>
              <div style="margin-top:0pt;margin-bottom:0pt">
                <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;margin-top:0pt;margin-bottom:0pt">

                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt">
                        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Level 2&#160;-</span></span></span></p>
                      </td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Valuations based on one or more quoted prices in markets that are not active or for which all </span>significant inputs are observable, either directly or indirectly.</span></span></span></td>
                    </tr>
                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="width:85.5pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      <td style="width:56.7pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      <td style="text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                    </tr>
                    <tr style="margin-top:0pt;margin-bottom:0pt">
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt">
                        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Level 3&#160;-</span></span></span></p>
                      </td>
                      <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></span></span></span></td>
                    </tr>

                </table>
              </div>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, other accounts receivable and prepaid expenses, trade payable and other accounts payable and accrued expenses approximate their fair values due to the short-term maturities of such instruments.</span></span></span></span></p>
            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncement not yet adopted by the Company:</a></td>
<td class="text">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">t.<span style="padding-left:23.06pt;margin-top:0pt;margin-bottom:0pt">Recently issued accounting pronouncement not yet adopted by the Company:</span></span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.</span></span></span></span></p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">In&#160;December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.</span></span></span></span></p>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_CostOfSalesContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_CostOfSalesContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ServerancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Serverance Pay [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ServerancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShortTermBankDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term bank deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShortTermBankDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957555135584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock', window );">Schedule of depreciation rates for property and equipment</a></td>
<td class="text">
            <div style="margin-top:0pt;margin-bottom:0pt">
              <div style="margin-top:0pt;margin-bottom:0pt">
                <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                <div style="margin-left:90pt;margin-top:0pt;margin-bottom:0pt">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">

                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="padding-bottom:2px;width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td colspan="1" style="padding-bottom:2px;width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="border-bottom:2px solid rgb(0, 0, 0);width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">%</span></span></span></div>
                        </td>
                        <td colspan="1" style="padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>
                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>
                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="width:80%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Computers, software and related equipment</span></span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td rowspan="1" style="width:18%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="line-height:1.25;font-family:Times New Roman, Times, serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">33</span></span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>
                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Laboratory equipment and office furniture</span></span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:center;line-height:1.25;text-indent:2pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">6 - 20 (mainly 20)</span></span></span></div>
                        </td>
                        <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>
                      <tr style="margin-top:0pt;margin-bottom:0pt">
                        <td style="background-color:rgb(204, 238, 255);width:80%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt">Leasehold improvements</span></span></span></div>
                        </td>
                        <td colspan="1" style="background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                        <td style="background-color:rgb(204, 238, 255);width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                          <div style="text-align:center;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
                            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Shorter of the term of the lease or useful life</p>
                          </div>
                        </td>
                        <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions', window );">Schedule of weighted average assumptions for granted options</a></td>
<td class="text">
                  <div style="margin-top:0pt;margin-bottom:0pt">
                    <div style="margin-top:0pt;margin-bottom:0pt">
                      <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">

                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="5" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Year ended December 31,</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2023</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2022</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2021</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="background-color:rgb(204, 238, 255);width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Employee stock options</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Volatility</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">75.93%-80.95%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                            </td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">69.44%-74.61%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">66.02%-69.05%</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Risk-free interest rate</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">3.37%-4.81%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                            </td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">1.54%-4.39%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0.51%-1.14%</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Dividend yield</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                            </td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0%</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0%</span></span></span></span></div>
                            </td>
                          </tr>
                          <tr style="margin-top:0pt;margin-bottom:0pt">
                            <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Expected life (years)</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">4.02-5.06</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">5.05-5.4</span></span></span></span></div>
                            </td>
                            <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                            <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                              <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">5.04-5.31</span></span></span></span></div>
                            </td>
                          </tr>

                      </table>
                      <p style="margin:0pt">&#160;</p>
                    </div>
                  </div>

                    <div style="margin-top:0pt;margin-bottom:0pt">
                      <div style="margin-top:0pt;margin-bottom:0pt">
                        <div style="margin-top:0pt;margin-bottom:0pt">
                          <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">

                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="5" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Year ended December 31,</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2023</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2022</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2021</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="background-color:rgb(204, 238, 255);width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">ESPP</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Volatility</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">-</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">69.74%</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                                </td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">64.68%-69.68%</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Risk-free interest rate</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">-</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">1.63%</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                                </td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0.04%-0.10%</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Dividend yield</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">-</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0%</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</div>
                                </td>
                                <td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0%</span></span></span></span></div>
                                </td>
                              </tr>
                              <tr style="margin-top:0pt;margin-bottom:0pt">
                                <td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Expected life (years)</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt">-</div>
                                </td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0.50</span></span></span></span></div>
                                </td>
                                <td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                                <td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
                                  <div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">0.42-0.50</span></span></span></span></div>
                                </td>
                              </tr>

                          </table>
                        </div>
                      </div>
                    </div>
                  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the annual rates used to calculate depreciation for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of granted stock options, including, but not limited to: (a) expected term of granted share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957552189648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of other accounts receivable and prepaid expenses</a></td>
<td class="text">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid expenses</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,211</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,100</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Government authorities</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">92</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">85</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="text-indent:-4.25pt;margin-left:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">226</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">232</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="width:76%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,529</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,417</span></span></div>
                    </td>
                  </tr>

              </table>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957641693040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate', window );">Schedule of weighted-average remaining lease term and discount rate</a></td>
<td class="text">
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;width:89.79%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.03%;vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:top;width:9.18%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;width:89.79%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1.03%;vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);width:9.18%;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:89.79%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1.03%;vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:top;width:9.18%;vertical-align:bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:89.79%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining lease term</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.03%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td rowspan="1" style="vertical-align:bottom;width:9.18%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-align:center">2.19</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:89.79%;vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average discount (annual) rate</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1.03%;vertical-align:bottom">&#160;</td>
                    <td rowspan="1" style="vertical-align:bottom;width:9.18%;vertical-align:bottom">
                      <div style="text-align:center">5.32%</div>
                    </td>
                  </tr>

              </table>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of operating leases</a></td>
<td class="text">
          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,&#160;2023</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">690</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">631</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">115</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total operating lease payments</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,436</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less: imputed interest</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">85</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,351</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, current</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">632</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, non- current</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">719</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom">
                      <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,351</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of weighted-average remaining lease term and discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957552230864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text">
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers, software and related equipment</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">739</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,617</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment and office furniture</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,519</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,831</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,314</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,314</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,572</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,762</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated depreciation:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers, software and related equipment</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">609</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,435</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment and office furniture</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,909</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,190</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,838</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,605</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,356</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,230</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciated cost</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,216</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,532</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957552236784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of other accounts payable and accrued expenses</a></td>
<td class="text">
          <div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December 31,</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Employees and related accruals</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,125</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,812</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued expenses</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7,858</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6,396</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>10,983</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>9,208</span></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957555094032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of stock-based compensation expenses</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of options</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">price</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining contractual</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">life</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Aggregate</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">intrinsic</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">value</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Years</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options outstanding at beginning of year</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,157,749</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.43</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6.32</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options granted</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,576,500</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.20</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options forfeited</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,086,404</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.49</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="width:52%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options expired</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(274,100</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.92</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options outstanding at end of year</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,373,745</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.65</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6.61</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,912</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercisable at end of year</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,017,329</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.71</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.15</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">117</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,933</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,158</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,971</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing and business development expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(41</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">269</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">215</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,658</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,901</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,090</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,550</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,328</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,276</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957552249120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of loss (income) before taxes</a></td>
<td class="text">
          <div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:90pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Domestic (Israel)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,164</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">34,096</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">34,619</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:64%;padding-bottom:2px;vertical-align:baseline">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(380</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(460</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(416</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,784</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,636</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">34,203</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text">
          <div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:90pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax assets:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating loss carryforward</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">92,885</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">91,704</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,109</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,083</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued social benefits and other</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,072</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,123</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">312</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">444</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax asset before valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">108,380</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">107,356</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(108,073</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(106,941</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax asset after valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">307</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">415</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax liabilities:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:76%;padding-bottom:2px;vertical-align:baseline">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right of use assets</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(307</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(415</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:76%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:76%;padding-bottom:2px;vertical-align:baseline">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(307</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(415</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax assets</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957556006896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of total revenues and long-lived assets by geographic area</a></td>
<td class="text">
              <div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
                <div style="margin-left:63pt">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue from sales to customers:</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Europe</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,000</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,500</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,000</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">United States</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23,459</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                          <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total revenue</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,459</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,500</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,000</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
                <div style="line-height:1.25">&#160;</div>
                <div style="margin-left:63pt">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-lived assets:</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Israel</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,468</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,239</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                          <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">United States</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">77</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">119</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                          <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total long-lived assets</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,545</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,358</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
              </div>
            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of sales to single customer exceeding 10%</a></td>
<td class="text">
              <div>
                <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sales to a single customer exceeding 10%:</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer A</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">30</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">100</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">100</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                        <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer B</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">70</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>

                </table>
              </div>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957555304240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of financial and other income, net</a></td>
<td class="text">
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,960</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,437</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">894</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of discount on marketable securities, net</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">281</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank fees and other finance expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(31</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(27</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(25</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign currency transaction adjustments</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">340</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gain (loss) from sales and disposals of fixed assets</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(7</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:1.5px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:1.5px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,208</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,738</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">871</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957552271744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related party balances and transactions</a></td>
<td class="text">
          <div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables and accrued expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">53</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">83</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:63pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts charged to:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">147</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">194</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">240</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957552230336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSSES PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted losses per share</a></td>
<td class="text">
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Numerator:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:64%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for basic and diluted loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(18,754</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(33,694</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(34,203</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Denominator:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares</span></span></div>
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">used in computing basic and diluted net loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">87,633,298</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">86,555,628</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">84,203,971</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted loss per ordinary share</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.21</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:3px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.39</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:3px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.41</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:3px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957548033808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 05, 2013</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 18, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18,754)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (33,694)<span></span>
</td>
<td class="num">$ (34,203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(474,527)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(455,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (34,113)<span></span>
</td>
<td class="num">$ (22,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_NonRefundableUpfrontPayment', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MilestonePaymentReceivable', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram', window );">Potential milestone compensation company is now eligible for</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 758,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable', window );">Preclinical milestone compensation</a></td>
<td class="nump">$ 23,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue', window );">Amount of investment in Compugen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Upfront payment received</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AccruedMilestonePayment', window );">Accrued milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable', window );">Potential milestone compensation</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid', window );">Percentage of expected from upfront payment amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AccruedMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AccruedMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_NonRefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-refundable upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_NonRefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of expected from upfront payment amount paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone compensation company is now eligible for.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount on the investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 10<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480679/815-10-10-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 10<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480769/815-20-10-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957547007344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 18, 2023</div></th>
<th class="th"><div>Nov. 11, 2022</div></th>
<th class="th"><div>Aug. 05, 2013</div></th>
<th class="th"><div>Dec. 27, 2023</div></th>
<th class="th"><div>Sep. 29, 2021</div></th>
<th class="th"><div>Dec. 18, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ShortTermBankDepositsWeightedAverageRateForeign', window );">Average interest rate, short-term bank deposits in U.S. dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">4.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization in R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">$ 6,019<span></span>
</td>
<td class="nump">$ 1,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognition under milestone method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">$ 383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable', window );">Research And Development Arrangement Payments Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AccruedMilestonePayments', window );">Accrued milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_LicenseRevenue', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredRevenuesIncludedInCurrentLiabilities', window );">Deferred revenues included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities', window );">Deferred revenues included in non current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,921,020<span></span>
</td>
<td class="nump">8,405,615<span></span>
</td>
<td class="nump">6,758,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementOneMember', window );">Master Clinical Agreement One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredParticipationOfBMSInRAndDExpenses', window );">Deferred participation of BMS in R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementTwoMember', window );">Master Clinical Agreement Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredParticipationOfBMSInRAndDExpenses', window );">Deferred participation of BMS in R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_LicenseAgreementWithGileadMember', window );">License Agreement With Gilead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable', window );">Research And Development Arrangement Payments Receivable</a></td>
<td class="nump">$ 788,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AccruedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AccruedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredParticipationOfBMSInRAndDExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred participation of BMS in R and D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredParticipationOfBMSInRAndDExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredRevenuesIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenues included in current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredRevenuesIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredRevenuesIncludedInNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenues included in non current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredRevenuesIncludedInNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_LicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of license revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_LicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShortTermBankDepositsWeightedAverageRateForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average interest rate for short-term bank deposits outside of the domestic currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShortTermBankDepositsWeightedAverageRateForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_MasterClinicalAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_MasterClinicalAgreementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_LicenseAgreementWithGileadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_LicenseAgreementWithGileadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957550769312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers, software and related equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory equipment and office furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory equipment and office furniture [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory equipment and office furniture [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AnnualDepreciationRateDescription', window );">Annual depreciation rate</a></td>
<td class="text">Shorter of the term of the lease or useful life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AnnualDepreciationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Depreciation Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AnnualDepreciationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AnnualDepreciationRateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Depreciation Rates, Description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AnnualDepreciationRateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957546906000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">75.93%<span></span>
</td>
<td class="nump">69.44%<span></span>
</td>
<td class="nump">66.02%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.37%<span></span>
</td>
<td class="nump">1.54%<span></span>
</td>
<td class="nump">0.51%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">4 years 7 days<span></span>
</td>
<td class="text">5 years 18 days<span></span>
</td>
<td class="text">5 years 14 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">80.95%<span></span>
</td>
<td class="nump">74.61%<span></span>
</td>
<td class="nump">69.05%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.81%<span></span>
</td>
<td class="nump">4.39%<span></span>
</td>
<td class="nump">1.14%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 21 days<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">69.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.68%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.68%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957550981632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Schedule Of Other Accounts Receivable And Prepaid Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 2,211<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other accounts receivable and prepaid expenses</a></td>
<td class="nump">$ 2,529<span></span>
</td>
<td class="nump">$ 2,417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Authorities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957550981920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 884<span></span>
</td>
<td class="nump">$ 956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeasePayment', window );">Variable payments as CPI</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities', window );">Cash paid for amounts included in measurement of lease liabilities</a></td>
<td class="nump">$ 852<span></span>
</td>
<td class="nump">$ 959<span></span>
</td>
<td class="nump">$ 914<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for variable lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957551002528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">2 years 2 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount (annual) rate</a></td>
<td class="nump">5.32%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957546945136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Schedule of Operating Leases) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">$ 690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">1,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">1,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current</a></td>
<td class="nump">632<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, non- current</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">$ 1,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 1,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957549985024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 6,572<span></span>
</td>
<td class="nump">$ 7,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">5,356<span></span>
</td>
<td class="nump">6,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">482<span></span>
</td>
<td class="nump">$ 461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember', window );">Obsolete property and equipment and certain nonfunctional Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">1,357<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 1,350<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957547977408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Schedule of Property and Equipment, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 6,572<span></span>
</td>
<td class="nump">$ 7,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">5,356<span></span>
</td>
<td class="nump">6,230<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Depreciated cost</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers, software and related equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">739<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">609<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory equipment and office furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">3,519<span></span>
</td>
<td class="nump">3,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">2,909<span></span>
</td>
<td class="nump">3,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">2,314<span></span>
</td>
<td class="nump">2,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 1,838<span></span>
</td>
<td class="nump">$ 1,605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957556135952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Schedule Of Other Accounts Payable And Accrued Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees and related accruals</a></td>
<td class="nump">$ 3,125<span></span>
</td>
<td class="nump">$ 2,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">7,858<span></span>
</td>
<td class="nump">6,396<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other accounts payable and accrued expenses</a></td>
<td class="nump">$ 10,983<span></span>
</td>
<td class="nump">$ 9,208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957551092144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security</a></td>
<td class="nump">$ 296,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentExpensesMilestonePayment', window );">Research and development expenses milestone payment</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember', window );">IIA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived', window );">Maximum royalty repaid as percentage of grant received</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 1,004,000<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyContingentObligations', window );">Contingent royalty obligations</a></td>
<td class="nump">$ 8,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember', window );">IIA [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyPercentageBasedOnFutureRevenues', window );">Royalty percentage based on future revenues</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember', window );">IIA [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyPercentageBasedOnFutureRevenues', window );">Royalty percentage based on future revenues</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember', window );">May 2012 Agreement Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AgreementStartDate', window );">Agreement, start date</a></td>
<td class="text">May  09,  2012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AgreementTerminationDescription', window );">Agreement termination description</a></td>
<td class="text">In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember', window );">May 2012 Agreement Member | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ParticipationRights', window );">Participation Rights</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_AntibodiesDiscoveryCollaborationAgreementMember', window );">Antibodies Discovery Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ContingentFees', window );">Contingent fees</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AgreementStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement start date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AgreementStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ContingentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ContingentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Royalty Repaid As Percentage Of Grant Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ParticipationRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ParticipationRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentExpensesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentExpensesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyContingentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyContingentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyPercentageBasedOnFutureRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Percentage Based On Future Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyPercentageBasedOnFutureRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsAxis=cgen_AntibodiesDiscoveryCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsAxis=cgen_AntibodiesDiscoveryCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957550381824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY  (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 10, 2018</div></th>
<th class="th"><div>Jun. 14, 2018</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cgen_EmployeesDirectorsAndNonEmployeesMember', window );">Employees Directors And Non Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="nump">$ 3.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value of exercised options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Ordinary shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ordinary shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InitialOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">five months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares', window );">Percentage of use of base salary to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear', window );">Aggregate limit of ordinary shares per calendar year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering', window );">Percentage of fair market value of ordinary shares at time of offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">158,025<span></span>
</td>
<td class="nump">117,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cgen_TwoThousandTenShareOptionsPlanMember', window );">2010 Share Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Ordinary shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,895,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ordinary shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,202,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants purchase to ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,955,696<span></span>
</td>
<td class="nump">3,955,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants purchase to ordinary shares remain outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,469<span></span>
</td>
<td class="nump">297,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,750<span></span>
</td>
<td class="nump">$ 18,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementMember', window );">Master Clinical Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share</a></td>
<td class="nump">$ 4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.57333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Maximum Authorized Proceeds From Issuance Of Common Stock</a></td>
<td class="nump">$ 2,424,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,332,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity investment</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PercentageOfClosingPrice', window );">Percentage of closing price</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_CollaborativeArrangementsMember', window );">Collaborative Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Maximum Authorized Proceeds From Issuance Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredParticipationOfBMSInRAndDExpenses', window );">Deferred Participation Of B M S In R And D Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_CollaborativeArrangementsTwoMember', window );">Collaborative Arrangements Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Maximum Authorized Proceeds From Issuance Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredParticipationOfBMSInRAndDExpenses', window );">Deferred Participation Of B M S In R And D Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_JmpSecuritiesLlcMember', window );">JMP Securities LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants purchase to ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,253,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable', window );">Expiration period of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,316,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from ordinary shares in offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_LeerinkPartnersLlcMember', window );">Leerink Partners LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,612,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from ordinary shares in offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate limit of ordinary shares per calendar year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AggregateLimitOfOrdinarySharesPerCalendarYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration period of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredParticipationOfBMSInRAndDExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred participation of BMS in R and D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredParticipationOfBMSInRAndDExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Authorized Proceeds From Issuance Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfClosingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of closing price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfClosingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair market value of ordinary shares at time of offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of use of base salary to purchase ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the time period when the company made its initial offering of a class of securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cgen_EmployeesDirectorsAndNonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cgen_EmployeesDirectorsAndNonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cgen_TwoThousandTenShareOptionsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cgen_TwoThousandTenShareOptionsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_MasterClinicalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_CollaborativeArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_CollaborativeArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_CollaborativeArrangementsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_CollaborativeArrangementsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_JmpSecuritiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_JmpSecuritiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_LeerinkPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_LeerinkPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957550927424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details) - Employees Directors And Non Employees [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of year</a></td>
<td class="nump">8,157,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">1,576,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options forfeited</a></td>
<td class="num">(1,086,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options expired</a></td>
<td class="num">(274,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at end of year</a></td>
<td class="nump">8,373,745<span></span>
</td>
<td class="nump">8,157,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year</a></td>
<td class="nump">5,017,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of year</a></td>
<td class="nump">$ 5.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options forfeited</a></td>
<td class="nump">5.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options expired</a></td>
<td class="nump">4.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at end of year</a></td>
<td class="nump">4.65<span></span>
</td>
<td class="nump">$ 5.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year</a></td>
<td class="nump">$ 5.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract', window );"><strong>Weighted average remaining contractual life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options outstanding</a></td>
<td class="text">6 years 7 months 9 days<span></span>
</td>
<td class="text">6 years 3 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable at end of year</a></td>
<td class="text">5 years 1 month 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at end of year</a></td>
<td class="nump">$ 1,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at end of year</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award Options, Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cgen_EmployeesDirectorsAndNonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cgen_EmployeesDirectorsAndNonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957551416416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details) - Employee Stock Purchase Plan [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">$ 3,550<span></span>
</td>
<td class="nump">$ 4,328<span></span>
</td>
<td class="nump">$ 4,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">1,933<span></span>
</td>
<td class="nump">2,158<span></span>
</td>
<td class="nump">1,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Marketing and business development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="num">(41)<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">$ 1,658<span></span>
</td>
<td class="nump">$ 1,901<span></span>
</td>
<td class="nump">$ 2,090<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957549924048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME, NET (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Israeli corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ReducedTaxRate', window );">Reduced tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_NetOperatingLossCarryforwardExpired', window );">Net operating loss carryforward, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">United States [Member] | Subsidiary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_NetOperatingLossCarryforwardExpired', window );">Net operating loss carryforward, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 401,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_NetOperatingLossCarryforwardExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforward, Expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_NetOperatingLossCarryforwardExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ReducedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduced tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ReducedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_SubsidiaryOfCommonParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_SubsidiaryOfCommonParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957555945168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME, NET (Schedule of Loss (Income) Before Taxes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic (Israel)</a></td>
<td class="nump">$ 10,164<span></span>
</td>
<td class="nump">$ 34,096<span></span>
</td>
<td class="nump">$ 34,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(380)<span></span>
</td>
<td class="num">(460)<span></span>
</td>
<td class="num">(416)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income</a></td>
<td class="num">$ (9,784)<span></span>
</td>
<td class="num">$ (33,636)<span></span>
</td>
<td class="num">$ (34,203)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957549914144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>TAXES ON INCOME, NET (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">$ 92,885<span></span>
</td>
<td class="nump">$ 91,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development</a></td>
<td class="nump">12,109<span></span>
</td>
<td class="nump">12,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Accrued social benefits and other</a></td>
<td class="nump">3,072<span></span>
</td>
<td class="nump">3,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredIncomeTaxLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">312<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax asset before valuation allowance</a></td>
<td class="nump">108,380<span></span>
</td>
<td class="nump">107,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(108,073)<span></span>
</td>
<td class="num">(106,941)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax asset after valuation allowance</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredIncomeTaxRightOfUseAssets', window );">Right of use assets</a></td>
<td class="num">(307)<span></span>
</td>
<td class="num">(415)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(307)<span></span>
</td>
<td class="num">(415)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredIncomeTaxLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax lease liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredIncomeTaxLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredIncomeTaxRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax Right of use assets attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredIncomeTaxRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset (liabilities) for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957555266704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>Item</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957546986016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from sales to customers</a></td>
<td class="nump">$ 33,459<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 2,545<span></span>
</td>
<td class="nump">$ 3,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue [Member] | Customer Concentration Risk [Member] | Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Sales to a single customer exceeding 10%</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue [Member] | Customer Concentration Risk [Member] | Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Sales to a single customer exceeding 10%</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SegmentReportingGeographicAreaAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from sales to customers</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SegmentReportingGeographicAreaAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">2,468<span></span>
</td>
<td class="nump">3,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SegmentReportingGeographicAreaAxis=country_US', window );">Unites States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from sales to customers</a></td>
<td class="nump">23,459<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cgen_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cgen_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cgen_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cgen_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SegmentReportingGeographicAreaAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SegmentReportingGeographicAreaAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SegmentReportingGeographicAreaAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SegmentReportingGeographicAreaAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SegmentReportingGeographicAreaAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SegmentReportingGeographicAreaAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957548076480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 2,960<span></span>
</td>
<td class="nump">$ 1,437<span></span>
</td>
<td class="nump">$ 894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfDiscount', window );">Amortization of discount on marketable securities, net</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Bank fees and other finance expenses</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction adjustments</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain (loss) from sales and disposals of fixed assets</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_FinancialIncomeExpenseNet', window );">Financial and other income, net</a></td>
<td class="nump">$ 3,208<span></span>
</td>
<td class="nump">$ 1,738<span></span>
</td>
<td class="nump">$ 871<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_FinancialIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Income (Expense), Net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_FinancialIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 835<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion of purchase discount on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957549903152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Schedule of Related Party Transactions) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Trade payables and accrued expenses</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Amounts charged to research and development expenses</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957550883856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for basic and diluted loss per share</a></td>
<td class="num">$ (18,754)<span></span>
</td>
<td class="num">$ (33,694)<span></span>
</td>
<td class="num">$ (34,203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares used in computing basic net loss per share</a></td>
<td class="nump">87,633,298<span></span>
</td>
<td class="nump">86,555,628<span></span>
</td>
<td class="nump">84,203,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares used in computing diluted net loss per share</a></td>
<td class="nump">87,633,298<span></span>
</td>
<td class="nump">86,555,628<span></span>
</td>
<td class="nump">84,203,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per ordinary share</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139957550868992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Narrative) (Details) - Subsequent Event [Member] - ATM [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued and sold in transaction | shares</a></td>
<td class="nump">292,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Authorized Proceeds From Issuance Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cgen_OrdinarySharesIssuedAndSoldThroughAtmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cgen_OrdinarySharesIssuedAndSoldThroughAtmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>75
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M#8#W"\[5RXW^P/[L>/PO4$L#!!0    ( ,B 95@BJ^S?\08  "HM   8
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MP@0LT&,'9MMX_A.C]2.EB4-K\!MF][D#U=GX43PV#K;@T&HZNL0)>G>3YU#
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MH$\("S#1JH6!L. RJSXFZQ8T/4 D6B4'EM,-CBNZ:PX<_FJ:W(93H-D*D,:
M%CBTU_%'QG$7M5O@4<?\$9*7;<-8II^ U9*]$JD@=$I(M",+ T@M(&_L9R:=
M)A,IEALX!D$WLM0G5D$ :?T16!KHK55B>HS/2+L!0UMMER#.G+%-V(0_%@)Z
M3YXB=]"^0*!5%2K(>W*"$"Z@4% [@4Y(I,,:9]/%["D]>C(]/WF:HDY%+0"B
MH]Q/C];(CH'V84G>!HE_.4OM3#S/UX[H\(SU(QY_2 0?+X((CD&9 'J637+K
M)_%R^&W0L(5"Y(+!S;HT$G%)7H)-HU<Z]R:I)@C#"K%!!C_OVCK? ,$3LH"X
M\"#I8"T21Z$L* >QZ9I$9?!=5Y87)%AC/#D0D$U =P@(!6XKP@VRJC,2)X#1
MB06)Y4WPRQ]N@_$],CG..HQWF%MITI@1*:)(,M7:T26R.&R*=@0*K:E;1(^7
M$2UXE76Y1]Y'JP%]MC:(O+UL^_)P!P?[!)(&$5%K9J-5!K8 ,4O*!(%GT58@
M=$O]3QC2UZYI AJ4Q&OV*0UF)E-6NVU+XD\V#[H:4O3A,YSG.<L!@ 6EG&AW
MV">IBF:/0GED?<01[0N/,::BGI#IZV&"FX\.#!Y0(S@YR1"8J(\CD/A9\5MK
M2>W".<D3GH1A5UO=;L4MR$'PNE_0LF>F)!>)#T<$6V>6QJP5(8F0[N4%[JX#
MQR/V="E\T+??TXX5$!CI?L,K%RHOB6=Q:D\&:"Z#J]Y#$J*W8$.5S5?E]8VC
M"R#R>P7\-6*0LS?#U@ANE[U(4G(X/)QE@@XS3$,F,"A@7 K^,"!:P2H'(ANW
M)8\79VGD?UQ[-IHD5S&P9$2:>WH8S[>S$SP#8/=!QD$XUA6A1>S#_C:'[47+
MY,J'1D0#)P)$!,2-YQ7QVR&7$6Y[U/V7\MH[$R,@T; A7=-)W,-9:G "&A1P
M?LNDU!5&N0Y5)_@[T^2F1F=&SAI7V>%LM*>+D1\'E+O'0;Q94-UP!EI,SC?1
M)V26/"MS&=A:Y]9B@ O5\P2)/=D"[1M VIVJ.Y$&?$*MVA),T;O@9#M_O!&?
M#*F&_572^S7%78Z>'I&%A5Y*FEBS:NYQ-ZR_&!J_SZ/CXZ.?LJ6!)PV0<[1_
M&&U6H"?1W:LKC1[?T1FHW\4L>89T A;P8O;\Z"=O&L(YU; -(J\C,N9@2P(W
M*QC^F\Q'U#9^@RL@$# XPCG#2%)%N/="-LVVQL'7/>=B*FQQI]6]",N(?L;8
M]"S8&HX<TN0&M'C#W/&]0XOH7!19E<(CPQ!&0^8\& G5FH57KFN@$* ><EAT
M5:"UH8*[C^J.-">[ND13%>\'9/0^J0P:]$[(H/I$!20?6&J%> X(+1A+#@&"
M2F8^D)[W>9= V<2-X"#8* CW  S/9.IU;=K=\Z"&V>]'U2]:Q7DD*R!#&P0Q
M@\11Q89!\,3;FQR.?<66E"/MFMU,8//:3\5'J$2#1 ?*/\=2L+OSAM4K;A ^
MA1C)P.XC]B+08#NY4@4KCT@=#0P%Q@]1*Y1&EF1/*C8[&^\@D"H3PR[2/?BS
M0;)-CWZ;)L19#YK8\"\QDQ6J)A ,D?3YR0)XE:<(1B/_,&PX1C:S9EJH:Z1H
M9AST&YEQ743OT) F^I9!R&L82L:?G"UYD3R;/_?:7H(99#FBMC7EG9CK+0>2
M,S1>P'S GX/,)[RGR;-%=R:W"[-LR$"C< M*642(;9?(C(WF&#?&:^)(VA((
M=87(]($:@2 0+;B5IEUO3,L,[.P9Q,6SXV%(-N1K>Q@*H%\)SO9G[YZ#*CT3
MH1SPM.T/P 5B66/)$A.SFN"\[JC?__S!';-L844A!Z('3@4$H0QFTET_,C$*
M%(B2)2HN3WT$1F6J"7]"40.N-D7P (I."+D#_X -0YIV"Q27BQ^'8M.[(AP6
MI<!AX,5@M/#LNVPO!H[3J/P];K8+$)DP6HC""PT,R'  ,A5Y42M9E*DJDGT'
MP(3E1L!(DUW96K*V9&U'&&AAD'6-8<:"L=\_;S*_#R#NX.<AZ+X,53]0< B6
M! =X9Q#TF+J=B$;K%(#Q4_DHV4I_DO"R$RP'V0Z.6?K3YCV#@,1<H$0JD%+%
MRN-XM(>>G)&0N$)6B1<B:&NUXL!0@+NU(F2NJYS#L' $KTU=LQWU'A=U/'3]
M^KWGH0Z21Q,YA\0+P#NPG((X.)?N:0QGIP 6W'"P#H$3HS"3@!4'><B/P!!1
M@R@B]EKZ?9($L'JK,4J.X#&#^F-DIV@PV4#^FF!5(H$L8 "\TJ"A@XD:4 @[
M\2M!D8)W540$IFVLXCG95TEY $'61YEGVP$QLB=C#,013NL3;T"A8,5E1#M"
M<XX$[C4H /5)U;FV8I0QK#VPA9@:-0IY6U%T\0N71E*-EE=N]:./:.5Q2DQD
M8HB\NQF<465=]@Q#/&2,D_+2E!6#0R>+'CTO3MWE&.]/LG6M5$1D?@KRID&G
MH5D=3]?NX!\T560"1Q\4+@0[!\TVXO [\-'9;\"\N\Y=!#AD$CUI.1<$XQ$:
M\-=@7#;+-Y@2.V2 H!W\CL>L^+/9&1GQ<[#/G1:4)V@S5V)LB/Z[HJ*.3B*'
M8WI=09=56;G_IT33<C\%LA^:;S;6_9R[C606R.(=L;C AU'5 ^*.HY/!''6;
M/;!PN^$,L,G+%5 5PV>6I5YGDHS& !T'8B3"&(Z_NT40K"C/;,^GM(W:@3-)
MZ#G[^NA:;+"\G\LGC*3D CGTI,[$R 7)GYE%(*#SC/<0<EXTKY_EC9/T\21Q
M#@[0F2L_'(,K^<-CB>'_ "3O Z/&IX8BB5"2]7!M83[+H=^1M3!\UK.-Q9"&
M"7%H]T<;#'?G+3U @#W:)@H6A;@VIB#KSW,PD.56HWR7"8F6_,JQ:J<IC).F
ME. =P:/4+?"RCG5H8K\: A+!05L41Z K&AJ4^Y%\R(*(B/R^\1-'6#7%X%EM
M.1H(J9"Q(R*-\XR.]_D#9(.SNP,'GZYC4).NEHPT.%O@;()A2(G;OK 6"8=A
MH_\&Z9]CJ0WQM@NLA.B0>R0-*3:,R6@,C443"'<.K0K0H!E1HKV/$:6=BXX]
M2ZY]N0^[' =Y79=.C-4!#%GJ">(3F9Z.?]N63>>K1B]-L<>EBC:G3 AK(I;:
M/[]]-5M,PX;@P!7'?Y*ODODLG<UF7D^)DF'SQ6*">.W2L_(8#,5/7X%'SH\B
MT!' J-G6&++#:!BK,##I:@K?>G5E_597N@9[2R!/<;?L,\#\I^DI3']/1"D0
M(\'D>=VR%/?!:4V44)M]5G)"LW*1%IF8$@S6'?L@*\="8-,Y3C)V;T0T9'%5
M"WZ+/(">*F:Q2"RC"@=?N<A*U,MA-$5F8PH&_+)_2M581;]\Q+8[C/ZG#KFX
M>30MQ#!2(V1&;+I2=2W.@[>82)TU6./%<1!@3W8A<5T*O4EP=1AV1ZO7-[0+
M]@S2$5Q1M,,''T9XFR49QZZ\96)[WBS)!J,Y]"@E7N0G@! UI7<9!0(L_8GV
M+P Y'0HN&5-%,)N"O=Z-FMUE8$X@X;OO(I QKMTN?Y.*'UQ@9#1^PE U /],
M3]64SZ)KC)!"@H&2"6"12E)5+# XV"7.[0*GK" ZY(;(JX'"O4G!P75D5F^@
M1DNV7O9Y5>2)A+(QE#X2_J$XC65YS8E$L<V;?6R(/H %.E*+P:GB>8=TQ X;
M.0R$QNT]#69!9KM!'?)^1-\PUP U#4P)&@LECHD-9<17=_PTN45!P;'U;*TF
M[+4&R>*-299'FC0 ,P^%AY@.2; #&QP&9XA8,XGKLQ*<LP+$$!M( O( *!LJ
M(+@$&7S&D-T#NA)@8]EII4I)<N,T^_BV.-!&\=.@R&.]"\2+"MLP4/#W+JN;
MYV3M!\20R9+MHXK-((2O@@8@]-+1%VI%PE:$6:1Y>1.%+B**S!ZLDJ1(04^<
MR^-1](]\(6$'THP>^FGR<Q4R7_-SBCO/(OT4"(H4?T1O88R<?1&466"TV'3X
M263593!/,-#)9%GXZ/"!^U8$Z!%GIO&5?H@:T)>DC0=<.^+T6@/1Z8QB)_!A
MZ>6 =ZP !;=8NDPX6+PB',R9>#"*4?Q;(.'LSR/A':;@B XX [I@P@(#OO[W
MP,%+LIO^, Z.8EY8O$PE$\.N;5LWFW\+)(A=^Z<HH2\1CGOU%Z,>R,"F<.4?
M 6]9\1CG(UYF316!A3P]['0$W/;#GK#!"1:%@*50=CP%F'8+2V*NITFN?YK,
MS\'/J J^V& :I<7:*<L10U-<&-1;9.BM.6"LP<L&?+16A1B7MV%3K.)N5UCJ
M)/GTX!V@C![V8++(&=,[15E_V<&@6U,=N#-($F=,$>+99*4U#[@W462XW"-/
MG9_STT6AQ?@?,#(BLY RR3L)=_=L#A?=_'*O24QF\%4R^/)0>4X=E6 2O!M^
ME1^N0FP3(R6>0#G870%+:8R_8[)WK;D2UL/+-M0]\$X#^ ;M&H5]?$2D(45+
MEGJV:EQ-!EVL0/064C[9 SOVBWK6L !.+H6SY)U<D/Q$?1CTQ;H\O-NP]%74
MKIAA-/:9PN \:ZT:9#_8IT#BC3QT]2GE-,0>WO>2^,'G [ZI,]A"R;%IFUU[
M$"?PS&VJM>%B9>?,I0<F:<<8[R):PDB%)%4H>F0C67(HQB0D'1_/,_U<8A98
M5%*'&QX_OSV=';LYOH9Q,A +?)Q &L5)QSV]SVIP0:[?O6&VO&-/1Q9XAG.Z
M?!,,><24(:^+V6?M (MC[8P,8N3 \8^!%E%^0]6N\\1O,X;1_?@%<*92XKDC
MZQH#0@I/W?O7SBOU7T3Q2]R4^N2#> ='>L!ZOF[$I5Z<CJ$@QTAP(#VL.(G"
M)(,,DCI)/+JO'K&BP.X$:02^1QXZ_?0%R)>[44L5 H#+/7FR;9V[^S+W2"0A
M@1ED!,NGUCY\<EBU:,U!7CAFKR&V_]<1:I2IS[#8%6VDDC4]^7N9W!Q[$&3=
MV!@N$0P#0B&-!0\.%<?V7W:D?GM8R<FW*C^;L/@,Q[ =(96X<CUD9ZPELV(L
MBE0>*/7(%?U'SZ;VA]/9%)4B>HLAS);&]R41?KR/ X\B]$B <?R&)M'V(RH"
M@T67DJG YS!7:;"F%PD@9"T?.';<E96J:*JP"AIXU99\W8?#86+7NRA/7 ;+
M<4VNZSA,./0R=WE6X?,.CCAXYB)'#X;+G/7DW8;#P%GL<'2#9'B74DK&ROUP
M[,%=Y:(4H4?FT'D>F'\<KQDCDL]BJD^C/C\SEKGC!-)P7 DIEF-]B)A00!$I
M POR7:Y$YQ3_T;9?&T=[%1 >,8>_6=61&)\I9?+UDQ)XBDHK!T@\)(JBNMXO
MXS9)1]-(RO@B_;O=]5*%NUV)P32\@:Q<+6T_D]W@?;QU4BE5L")UL?]($A58
M<,TNM8C/9533"A" =HKN#;MZ)JII^8L.Y;'RF4NV,V?ZT+T#+-]RL>SHEO<V
MJ]=HFJ.!![0(@$;:_K'PB9'355P>ZB_1%('\>SY_*!_JYDH& 8FN^(QKF:[P
MZ\%.)?6=-7OG/>CSQVM)B#M:<Z1J-38XNDQ'$9G8H'.,8[5+IT<['<E^QF9Z
MR(,^/G,&C.8LG <2=["!@ZA-;-5X;X5J19J!2]_8." VZ7SR+[+LO"^S5$"T
MQ+VA#D.;PMW!Y]DC!U:,Q%:$CM3-ALHC7^SJO%#,MKWN*'3;LR9Z2CG25\0T
MH'-J%4CE =W:3^+WB&!$.13=NNWQ6R0_8.A0U>F_U&8?+9KH)F*X7!-#%*-E
M)IV2'I^B]94=GAX^STRZ A?>W5+I!!E=IX(EEAQ*-2I?1C-@KMG@^G(J9N_K
M'\?SJ7+;G?@U SV'UT,*M=/Y0>W.BG-07+1")H?LC7?D;M6L!#")"W;AZOO\
M'CUX6ZG>&:ZSDXN-5%Q)[0FH8X)\Z%;MIL'.0"JDJ.Y#S_4N3+AI*!'(.'L
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MU1&X]T^QQJHEWV*IFGLE]9;$[&1H.)M6HD120]C=,%\DC9?I:#J*;0BQ^SL
MIK.MGJ/NE%V_;'?KVLD1+3'C+=4F*U=]//&Q=$-0/O0O_2&$R#I$U>\#2+?C
M  F820"H^-Z<OV_<+8,,E.3O>PBD(^HWEF5_3HKR_*I_O9"*2$Z.%RA:3\[.
M1; >GQ_WQ:H!4!J3?Y02333E 9JH@]S@178[\D@7&>Z:<21HAXLA7F+H3()U
M5_%T$P8NB;]TP=SXCCQ,$)+7[A*P-!WE!G7BZ'IOV:O]$,RG9B:R*7\O@0,/
M[JZN^-GL4DBTV=U G&!<"[_9FD*5TW'DP?]7BMIS6*&YO4OQQ,]$]V0Z*#Z@
M%[\#$K(,L*LBZ6BIA_N8$,*0N?P]GF!DN$MI9/[0"EU8K8K"%*]!_'V<W.98
MP6LG;\'LA_7=:75^]&'9(0SZ>FWJ'A1=N8N.3?;@-#N9:Q,C'58%%=0.Q D'
M)J<;UR$,.X9XT+Z_O8GZX^+V!L'RA)5%"CSJ[!I=*O'@QR'G3*[B^E@202U1
MT3N#(MKW"NB,<Q==Z;+W]^[;Z GT<2,[QI^]!,0V:'?69"?&2VY="Q@F!>DR
MX.Y:A<Z+7G+[&)AT(W"T9N)FO0>CW*FXT=H& "/(\+F:2\+8Q>U<Y8_,7G\U
MHS\Q[JP7IS-M0X%^.$2Y1ZOMQ\D*4]3=*]@Q4"2*-79I(:E/'?R:FH*3^V1I
MT"3RM[(B)-'IQ+R!*8>P0;GY3HY4H=%U<[;5AJX:=-JV@B%1D=A"7>M'=Z=O
M74%5U%LH:C.,K-''4"RD4VEG8.HA>4V\ VQQ<?1?PS&\(]1)^)\%_F=^Y!F-
M-(1;^>A73Z1'+T^GKXZ?3LYGTU>G3X_.7DU/3IY.7IY,S^;PZ6PZ6SR=P)<S
M^.W]\"$='4^/7SZ=G$S/X8GY]/0$_SY^]?1H-CV=/YW,I_.3IT=O!%E\@D>S
MI_(_SS;4P^@9J=KG1R>P[.1T.CL[@O^<PE\G^,<)_'$\?_3. 4WQ/B>XMY<
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MA4. D)MRH-RX^^8+OGWBA!Z0 I>@.0*1G!E&%>GC.,YXI%%\N1K5#^47I%4
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MT/D$^.T*46:$5XT43V#<E$.]*!SV;>+%(^J,O%%"G66:ME7;$<D +R/ES&2
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MR7J.U1LM2CL[ED+3)+)B2J,?I3&@\Y40>K<Q ?8_D_$?4$L#!!0    ( ,B
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M?#5-YIS8YF*J>Q11E97I]P7 L%?U;,V*W=2B7$>YW/&G&@>^G=U8 P;"FTL
M3DJ*4NZ#]$MB,CH-?S4N;#;WCRI<7!$7M3X$N06R!M0]W[Q([DF*NULHA44
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M[AP)$"7X*.ES^S(-ON7L;:XIR3+XF'(]"690\D";,*7ULMT[1$YGS^Q>2-\
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M(^HQ3WHV4B>MO*M!G<?,EI)<EG<PMUII&\60EN)]2^R77P-M7O+CRPY'L);
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M8>\4:Z2:0=HLC*S<\)I+@Z/0B2M\>T!9!3Q?2&EV"^N@?<VROU!+ P04
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M1@#O-P*[VN%@# R#?OXW4$L#!!0    ( ,B 95BD0J_$B@,   \(   9
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MIFDI,T]5$EEJE0KNA;[?\0J6E^ZP;_?NY; OMIKG)=Y+4-NB8/+'&+G8#=S
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M-[F1I>A!$$E8V9S@*[2D#+.$X@P]JI-$9>)2HG]NGV0I5"K]US"ANV8 (_,
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MEAB(]RM*^>M-TD!Q"FWR'U!+ P04    " #(@&58Q?0NV^4"  !K!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6RM5=MNFT 0_941C:I4<L/%-KG4
M1B*8-I':V+*3M%+5AS6,PRK TMW%3OOUW05,'8>D>>@+[&7.V3.'87:T8?Q>
M)(@2'K(T%V,CD;(X,TT1)9@1<<0*S-7.BO&,2#7E=Z8H.)*X F6IZ5B6:V:$
MYH8WJM9FW!NQ4J8TQQD'4689X;_.,66;L6$;VX4YO4ND7C"]44'N<('RIIAQ
M-3-;EIAFF O*<N"X&AN^?1:X.KX*N*6X$3MCT)DL&;O7D\MX;%A:$*882<U
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M7%SJ.HAJ4E4;Q8NR=T^YTI.@7*9ZN*,P!OI^QKE:;XR#YN]"^!=02P,$%
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MKN37"C!E()\O*!6/"^6@_OX)?@-02P,$%     @ R(!E6)EATS_, P  7Q
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MGFA##?D0D"P2#W3[&Q0)V8K/HQ'//]&VB#4TY&5<T+@ 2P5QF.R^R??"B H
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M000+D98%BL^729*_O"DK>$K2K]7N7/X/4$L#!!0    ( ,B 95A52>!%FP0
M '85   9    >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;+68:V_B.!2&_XJ5
M'>VVT@R)G81 %Y HL.I(VVFG3&>T6NT'0PY@31*SMH'VWZ]S:0(AI)2E7R"W
M\_H\OIR\<6?#Q4^Y %#H*0PBV3462BVO3%-.%Q!2V>!+B/2=&1<A5?I4S$VY
M%$#])"@,3&)933.D+#)ZG>3:O>AU^$H%+()[@>0J#*EXOH: ;[H&-EXN/+#Y
M0L47S%YG2><P!O6XO!?ZS,Q5?!9")!F/D(!9U^CCJP$A<4#RQ'<&&[EUC&*4
M"><_XY//?M>PXHP@@*F*):C^6\, @B!6TGG\FXD:>9MQX/;QB_H?";R&F5 )
M Q[\8+Y:=(V6@7R8T56@'OCF!C(@-]:;\D FOVB3/6L9:+J2BH=9L,X@9%'Z
M3Y^RCM@*(,Z! )(%D'* >R# S@+L!#3-+,$:4D5['<$W2,1/:[7X(.F;)%K3
ML"@>QK$2^B[3<:HWOND_C&[N_AR.'L:_H='7Q\_?_D(78SU;_%4 Z&Z&[I9)
M?_?C_F;J^1)=#$%1%LA+] F-PF7 GP$D&C*A1X8+B?J1C[[HB.+>W[<03D#\
MHP,>QT-T\>$2?4 FD@LJ]%T6H<>(*?E17]3'WQ9\)6GDRXZI-&"<ICG-8*Y3
M&'( !A-TRR.UD&@4^>#O"IBZ9_+N(2_=<TUJ%8<P;2 ;?T3$(G9%0H/CPTE-
M.G8^6G:BYQ[0^[**^Q'Q&>+)J%3V42IA5TO$9>%*+ND4NH9>]Q+$&HS>K[_@
MIO5[%=^9Q'9HG9S6J5/OI3-/(EU]I-(S@D5S1!6:P)Q%47RB^^$9J*CJA%39
M293C4K;NM;#K>4Z[8ZZW^6HS.)'/S?G<H_CF@D:J/%U3#'</0U,T7<LJ8=0V
M=")&,\=H'H6AWRDS8 = FGL@G[#5:CJ64R*I;>M$$B\G\8XB@:>EKF:5'-X^
M!_$<O#<@M0V=B-'*,5JGK!O0=;EFQ;3V5XSMV9[CEL@JGBNMK)VDVWG2[=JD
M1T\@IDS2B7[KO)YL>R\)U\*>3<K+N[;-$X<!6\6[U:HMUS\2$P$^HFL0VA3I
MB95  EH*-H7*%YQUSNI]+K5=_BUO@=^M@&?2K>TA;CAV:7SK$S@5D!2 Y/]6
M\$P!V]LUO$'*'+7MG,I1V I<^QX_KH1G&MC9'9+RDJMOZE24PC/@XTQ#30W/
M%'9 G$9[;TS>PQO@PAS@X]S!VZIX)EIB:Y:+>/;8P=6UFW/A!'"]%7A;$<_$
M=I/P<#G5]W $N+ $V'M;#1<0?QW'HS'5WQI"?X>N:( "-JNNYV<R EE?O(>M
MP(6OP&\V%I7,]2K-9$)(Y*$P_5AK(Y\^5WW*#(Y4LE^4B%LAM0M;^!%\3D/R
MBIB;98K33!%Q#C._AV<AA6<A]9ZE/Y\+F%,%^EM<"19)-D5K&JPJ9S<YJULY
ME]HN>>%6R$ENY96!ST2;VZ_W-BZ_2^J;/A6M\"FDWJ>\;2YG8CM(V"L3G=6Q
MF%L[6"&(>;*Q)W6%744JW:W)K^:;A_UDRZQT_1I?#=(MP$(FW9&\I4+;3HD"
MF&E)J^'I%2#23;[T1/%ELD\VX4KQ,#E< /5!Q _H^S/.U<M)W$"^U=K[#U!+
M P04    " #(@&58+M'-XN4#   0$@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970T-RYX;6S%6&%OHS@0_2L6M[IKI;9@2$C32R*E(7>MM-5FD^V=3JO]X, D
MH +F;"=I[]>O;0@-*47M":E?$MO,/,\\SP/;@QUE#SP$$.@QB5,^-$(ALBO3
MY'X(">$7-(-4/EE1EA ANVQM\HP!";13$INV9;EF0J+4& WTV(R-!G0CXBB%
M&4-\DR2$/5U#3'=# QO[@7FT#H4:,$>#C*QA >(^FS'9,TN4($H@Y1%-$8/5
MT!CC*P\[RD%;_!7!CA^TD4IE2>F#ZMP&0\-2$4$,OE 01/YM80)QK)!D'/\6
MH$8YIW(\;._1_]#)RV26A,.$QG]'@0B'QJ6! EB132SF='<#14)=A>?3F.M?
MM"ML+0/Y&RYH4CC+")(HS?_)8T'$@0-V7W&P"P?[V*'SBH-3.#AO=>@4#AW-
M3)Z*YL$C@HP&C.X04]82334TF=I;IA^E:MT7@LFGD?03H\7->#Z]^?+9F\X7
MOZ'IU_O;;_^@DX4LKV 3 _JR0@M!_0<TH8DL-4[T8DT?51M.T8D'@D0Q/T7G
M:)ID,7T"*!QF&^:'<D'0+"8I^GX'R1+8#VEWO_#0R:=3] E%*?H6T@TG:< '
MII#9J)A,OXC\.H_<?B5R;*,[FHJ0HVD:0% %,"4-)1?VGHMKNQ'1 _\".?@,
MV9;MU 0T>;N[7>/NO=T=-V3CE"OK:+SN:RL;$@;G2A,!FI$GJ56!QHR1= VJ
M?;9?Q0!)_M&$9)$@<?0?!&=HG-"-M/[^64*B6P$)_U&W/OG\3OW\ZH5UQ3/B
MP]"0;R0.; O&Z-=?L&O]7L=MFV!>2V 5WCLE[YTF])$N_X)W_U UD/-=6^HY
MI*LAU:MZ.W*Z76M@;@\I>FG4<>S+JI%78V3WW-*HDE*W3*G;F-)<DD2DG'6E
M!+"57XM,U],^I5+?=;DU8K^W3-H$\UH"JW#JEIRZ'RQ/MTW>VP3S6@*K\-XK
M>>^U+\\<LG,@*MQWG"-YOC2R<?=8GG5(/5POS\LRI<O&E.X(>P 1I6M=*LL-
ME\\Y?[]0&V=Y;\&T">:U!%9AMU^RV_]@H?;;Y+U-,*\EL KOV'K>FEKM2[7
M/%38>0<?2;7&R';[1U*M,\+=>JGB@_TV;DSJ3TB!D5@7"PGDCC[B@A%U^'F;
M2)OAWULMK:)Y;:%5J;6?J;4_6*E% &V1WR::UQ9:E?SGTP9NW%3_3[$Z+W:K
MV#W^9D[JK/H6/I;K2RO;ZEM'>C4/CLH)L+6^<N R8KG\^4FQ'"VO-<;Z,'\T
M?JVN._01_!DFORN1G^-UE'(4PTI"6A<]6:\LOW[(.X)F^D"^I$(>[W4S!!(
M4P;R^8I2L>^H"<I+H-%/4$L#!!0    ( ,B 95CY Z8L4@,  +\-   9
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;+5776_:,!3]*U=9-;521S[X:.D
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M6[;\C"M!3<WGL5!D3UCF?5NJLY<*R:(56(T@HG'^)H\K(]8 =FL/P%D!G&U
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M#-0-"[GNH+[/&)//%1V@N+/U?@-02P,$%     @ R(!E6#UA+4OO @  /0@
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M< U0[^>,R<U$;]#\8XC^ 5!+ P04    " #(@&58-7IDX9X#  #(#   &0
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M0N,<8Q\W.)J"- !\GPBA/Q;F ^6P._X/4$L#!!0    ( ,B 95C_$<]?VP(
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MI7,W@4K$NXZRFTC6Z![KE4GHV/2P@":<< 6 _35C<C]1#QC:^OA?4$L#!!0
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MR$:V$(RIINXV9"$;V4)PU=N+)F0A&]E"<-7;PX0L9"-;Z'75JZ9TCHH)?@N
M;:'3Y?1^%J]B0A:R6PL-CU_\K/E&Y'SMR[^H9/LJS59A29I-]Z;2LIMW")M#
MECFR+<B](ET?/R Z?OST^5]02P,$%     @ R(!E6 P_D/SE 0  ?R$  !H
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M"[(M!&X+PBT$<@O2+01V"^(M!'HKZJT$>BOJK01ZZ^AAFT!O1;V50&]%O95
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M;W!S+V%P<"YX;6Q02P$"% ,4    " #(@&58UB1(O.X    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #(@&58
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( ,B 95AK8^:FY08  '(@   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #(@&58
M]5^QE^8&  !G'0  &               @($H#P  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ R(!E6"A,'<&9 @  /0<  !@
M     ("!1!8  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M ,B 95@?/8OZB04  $<6   8              " @1,9  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " #(@&58(JOLW_$&   J+0  &
M            @('2'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ R(!E6#+;;7F6"0  LC   !@              ("!^24  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ,B 95B_'ED2-@\  .8I
M   8              " @<4O  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " #(@&58''Y<&D E   B>@  &               @($Q/P
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ R(!E6+#G\!.5
M @  H04  !@              ("!IV0  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( ,B 95@7L"T^% 8   H/   9              "
M@7)G  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ R(!E
M6!O@@I)I P  GP<  !D              ("!O6T  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " #(@&58:JHS"'L"  "#!0  &0
M        @(%=<0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( ,B 95@UL!+@[0@  .L6   9              " @0]T  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ R(!E6'1QS<[A#@  O"H
M !D              ("!,WT  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " #(@&5860.*?5D1  !.+@  &0              @(%+C
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( ,B 95AONHF(
M*P0  )4)   9              " @=N=  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ R(!E6)FR,7T' P  7P8  !D
M ("!/:(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #(
M@&58XJX911$#  "T!@  &0              @(%[I0  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ,B 95C15A IY (  %@&   9
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M970R,RYX;6Q02P$"% ,4    " #(@&58[A905]8"  #9!@  &0
M    @('\VP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M ,B 95B%H[G;ZP(  &4&   9              " @0G?  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ R(!E6&P2[[Z. @  8P4  !D
M             ("!*^(  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " #(@&58WRKA5:0#  #T!P  &0              @('PY   >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( ,B 95BD0J_$B@,
M  \(   9              " @<OH  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ R(!E6%[^FWP? P  60<  !D              ("!
MC.P  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #(@&58
M<5]#/0<#  !*!@  &0              @('B[P  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( ,B 95C+<74DH (  * %   9
M      " @2#S  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ R(!E6$)K7,[0 @  '08  !D              ("!]_4  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #(@&58+@>' 7P%   Y)
M&0              @('^^   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( ,B 95B9M(E]YP<  -U%   9              " @;'^  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ R(!E6$E6'O]V
M P   0X  !D              ("!SP8! 'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " #(@&58I6:8<*8%  "1)@  &0
M@(%\"@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( ,B
M95C%]"[;Y0(  &L'   9              " @5D0 0!X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ R(!E6 S]S^[J @  .@@  !D
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M=#0R+GAM;%!+ 0(4 Q0    ( ,B 95AMN]XGKP(  +,&   9
M  " @04D 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
MR(!E6/=C9$#X!0  1R,  !D              ("!ZR8! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " #(@&58.=L4$9H-   VI0  &0
M            @($:+0$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( ,B 95A52>!%FP0  '85   9              " @>LZ 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ R(!E6"[1S>+E P
M$!(  !D              ("!O3\! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " #(@&58^0.F+%(#  "_#0  &0              @('9
M0P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( ,B 95@]
M82U+[P(  #T(   9              " @6)' 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ R(!E6#5Z9.&> P  R P  !D
M     ("!B$H! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,B 95C>4Y3'= ,  .(+   9              "
M@9-< 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ R(!E
M6%W8Q,2G @  # 8  !D              ("!/F ! 'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    " #(@&58SWR]HFT#  #2%0  #0
M        @ $<8P$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,B 95B7BKL<
MP    !,"   +              "  ;1F 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( ,B 95B^*H:(K 0  ( E   /              "  9UG 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " #(@&58##^0_.4!  !_(0  &@
M    @ %V; $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" #(@&58C^&W:=,!   V(0  $P              @ &3;@$ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     0 !  '<1  "7< $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>148</ContextCount>
  <ElementCount>307</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-daei1</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-cbsp</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-csocl</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/StatementsOfChangesInShareholdersEquity</Role>
      <ShortName>STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - GENERAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-g</Role>
      <ShortName>GENERAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sap</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oarape</Role>
      <ShortName>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-paen</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oapaae</Role>
      <ShortName>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-cac1</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-se12</Role>
      <ShortName>SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - TAXES ON INCOME, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-it</Role>
      <ShortName>TAXES ON INCOME, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-giamc</Role>
      <ShortName>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - FINANCIAL AND OTHER INCOME, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-faoin</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-rpbat</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - LOSSES PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-lps</Role>
      <ShortName>LOSSES PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sapp</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sapt</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-sap</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0023 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oarapet</Role>
      <ShortName>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-oarape</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0024 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0025 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-paent</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-paen</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0026 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oapaaet</Role>
      <ShortName>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-oapaae</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0027 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-set1</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-se12</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0028 - Disclosure - TAXES ON INCOME, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-itt</Role>
      <ShortName>TAXES ON INCOME, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-it</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0029 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-giamct</Role>
      <ShortName>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-giamc</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0030 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-faoint</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-faoin</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0031 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-rpbat</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0032 - Disclosure - LOSSES PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-lpst</Role>
      <ShortName>LOSSES PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-lps</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0033 - Disclosure - GENERAL (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-gd</Role>
      <ShortName>GENERAL (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-g</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sapnd</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-sapt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sapsodrfpaed</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-sapt</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-sapt</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0037 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Schedule Of Other Accounts Receivable And Prepaid Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oaraped</Role>
      <ShortName>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Schedule Of Other Accounts Receivable And Prepaid Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-oarapet</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0038 - Disclosure - LEASES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LEASESNarrative</Role>
      <ShortName>LEASES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/LeasesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0039 - Disclosure - LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails</Role>
      <ShortName>LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/LeasesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0040 - Disclosure - LEASES (Schedule of Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails</Role>
      <ShortName>LEASES (Schedule of Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/LeasesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0041 - Disclosure - PROPERTY AND EQUIPMENT, NET (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-paent</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0042 - Disclosure - PROPERTY AND EQUIPMENT, NET (Schedule of Property and Equipment, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-paend</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Schedule of Property and Equipment, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-paent</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0043 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Schedule Of Other Accounts Payable And Accrued Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oapaaed</Role>
      <ShortName>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Schedule Of Other Accounts Payable And Accrued Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-oapaaet</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-cac1</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0045 - Disclosure - SHAREHOLDERS' EQUITY  (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sesopnd</Role>
      <ShortName>SHAREHOLDERS' EQUITY  (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set1</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0046 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set1</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0047 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sesosced</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set1</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0048 - Disclosure - TAXES ON INCOME, NET (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>TAXES ON INCOME, NET (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-itt</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0049 - Disclosure - TAXES ON INCOME, NET (Schedule of Loss (Income) Before Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails</Role>
      <ShortName>TAXES ON INCOME, NET (Schedule of Loss (Income) Before Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-itt</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0050 - Disclosure - TAXES ON INCOME, NET (Schedule of Deferred Tax Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>TAXES ON INCOME, NET (Schedule of Deferred Tax Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-itt</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0051 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/GEOGRAPHICINFORMATIONANDMAJORCUSTOMERSNarrativeDetails</Role>
      <ShortName>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-giamct</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0052 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/GeographicInformationAndMajorCustomersDetails</Role>
      <ShortName>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-giamct</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0053 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-faoint</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0054 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Schedule of Related Party Transactions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Schedule of Related Party Transactions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0055 - Disclosure - LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails</Role>
      <ShortName>LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-lpst</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="zk2431047.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0056 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SubsequentEventsNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cgen-20231231.xsd</File>
    <File>cgen-20231231_cal.xml</File>
    <File>cgen-20231231_def.xml</File>
    <File>cgen-20231231_lab.xml</File>
    <File>cgen-20231231_pre.xml</File>
    <File doctype="20-F" isDefinitelyFs="true" isUsgaap="true" original="zk2431047.htm">zk2431047.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="551">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="47">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>81
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "zk2431047.htm": {
   "nsprefix": "cgen",
   "nsuri": "http://cgen.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "cgen-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cgen-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cgen-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cgen-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cgen-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "zk2431047.htm"
     ]
    }
   },
   "keyStandard": 243,
   "keyCustom": 64,
   "axisStandard": 16,
   "axisCustom": 2,
   "memberStandard": 25,
   "memberCustom": 19,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2023": 3,
    "http://cgen.com/20231231": 1
   },
   "contextCount": 148,
   "entityCount": 1,
   "segmentCount": 44,
   "elementCount": 485,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 551,
    "http://xbrl.sec.gov/dei/2023": 47
   },
   "report": {
    "R1": {
     "role": "http://cgen.com/role/cgen-daei1",
     "longName": "0001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "dei:CurrentFiscalYearEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "dei:DocumentPeriodEndDate",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "dei:CurrentFiscalYearEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "dei:DocumentPeriodEndDate",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cgen.com/role/ConsolidatedBalanceSheets",
     "longName": "0002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://cgen.com/role/cgen-cbsp",
     "longName": "0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "NIS_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "NIS_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://cgen.com/role/cgen-csocl",
     "longName": "0004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
     "longName": "0005 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "shortName": "STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://cgen.com/role/cgen-g",
     "longName": "0007 - Disclosure - GENERAL",
     "shortName": "GENERAL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://cgen.com/role/cgen-sap",
     "longName": "0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://cgen.com/role/cgen-oarape",
     "longName": "0009 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES",
     "shortName": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cgen.com/role/Leases",
     "longName": "0010 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cgen.com/role/cgen-paen",
     "longName": "0011 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cgen.com/role/cgen-oapaae",
     "longName": "0012 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "shortName": "OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cgen.com/role/cgen-cac1",
     "longName": "0013 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cgen.com/role/cgen-se12",
     "longName": "0014 - Disclosure - SHAREHOLDERS' EQUITY",
     "shortName": "SHAREHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cgen.com/role/cgen-it",
     "longName": "0015 - Disclosure - TAXES ON INCOME, NET",
     "shortName": "TAXES ON INCOME, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cgen.com/role/cgen-giamc",
     "longName": "0016 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS",
     "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cgen.com/role/cgen-faoin",
     "longName": "0017 - Disclosure - FINANCIAL AND OTHER INCOME, NET",
     "shortName": "FINANCIAL AND OTHER INCOME, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cgen.com/role/cgen-rpbat",
     "longName": "0018 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cgen.com/role/cgen-lps",
     "longName": "0019 - Disclosure - LOSSES PER SHARE",
     "shortName": "LOSSES PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cgen.com/role/SUBSEQUENTEVENTS",
     "longName": "0020 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cgen.com/role/cgen-sapp",
     "longName": "0021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://cgen.com/role/cgen-sapt",
     "longName": "0022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://cgen.com/role/cgen-oarapet",
     "longName": "0023 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)",
     "shortName": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://cgen.com/role/LeasesTables",
     "longName": "0024 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://cgen.com/role/cgen-paent",
     "longName": "0025 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://cgen.com/role/cgen-oapaaet",
     "longName": "0026 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "shortName": "OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://cgen.com/role/cgen-set1",
     "longName": "0027 - Disclosure - SHAREHOLDERS' EQUITY (Tables)",
     "shortName": "SHAREHOLDERS' EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://cgen.com/role/cgen-itt",
     "longName": "0028 - Disclosure - TAXES ON INCOME, NET (Tables)",
     "shortName": "TAXES ON INCOME, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://cgen.com/role/cgen-giamct",
     "longName": "0029 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)",
     "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://cgen.com/role/cgen-faoint",
     "longName": "0030 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)",
     "shortName": "FINANCIAL AND OTHER INCOME, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables",
     "longName": "0031 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://cgen.com/role/cgen-lpst",
     "longName": "0032 - Disclosure - LOSSES PER SHARE (Tables)",
     "shortName": "LOSSES PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://cgen.com/role/cgen-gd",
     "longName": "0033 - Disclosure - GENERAL (Narrative) (Details)",
     "shortName": "GENERAL (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231218",
      "name": "cgen:NonRefundableUpfrontPayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://cgen.com/role/cgen-sapnd",
     "longName": "0034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cgen:ShortTermBankDepositsWeightedAverageRateForeign",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "p",
       "cgen:ShortTermBankDepositsPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cgen:ShortTermBankDepositsWeightedAverageRateForeign",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "p",
       "cgen:ShortTermBankDepositsPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://cgen.com/role/cgen-sapsodrfpaed",
     "longName": "0035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "name": "cgen:AnnualDepreciationRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "name": "cgen:AnnualDepreciationRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
     "longName": "0036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "cgen:ScheduleOfWeightedAverageAssumptionsForGrantedOptions",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "cgen:ScheduleOfWeightedAverageAssumptionsForGrantedOptions",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://cgen.com/role/cgen-oaraped",
     "longName": "0037 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Schedule Of Other Accounts Receivable And Prepaid Expenses) (Details)",
     "shortName": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Schedule Of Other Accounts Receivable And Prepaid Expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://cgen.com/role/LEASESNarrative",
     "longName": "0038 - Disclosure - LEASES (Narrative) (Details)",
     "shortName": "LEASES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails",
     "longName": "0039 - Disclosure - LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)",
     "shortName": "LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails",
     "longName": "0040 - Disclosure - LEASES (Schedule of Operating Leases) (Details)",
     "shortName": "LEASES (Schedule of Operating Leases) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
     "longName": "0041 - Disclosure - PROPERTY AND EQUIPMENT, NET (Narrative) (Details)",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://cgen.com/role/cgen-paend",
     "longName": "0042 - Disclosure - PROPERTY AND EQUIPMENT, NET (Schedule of Property and Equipment, Net) (Details)",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Schedule of Property and Equipment, Net) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://cgen.com/role/cgen-oapaaed",
     "longName": "0043 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Schedule Of Other Accounts Payable And Accrued Expenses) (Details)",
     "shortName": "OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Schedule Of Other Accounts Payable And Accrued Expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://cgen.com/role/CommitmentsAndContingenciesDetails",
     "longName": "0044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://cgen.com/role/cgen-sesopnd",
     "longName": "0045 - Disclosure - SHAREHOLDERS' EQUITY  (Narrative) (Details)",
     "shortName": "SHAREHOLDERS' EQUITY  (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "USD_per_share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
     "longName": "0046 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)",
     "shortName": "SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://cgen.com/role/cgen-sesosced",
     "longName": "0047 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)",
     "shortName": "SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://cgen.com/role/IncomeTaxesNarrativeDetails",
     "longName": "0048 - Disclosure - TAXES ON INCOME, NET (Narrative) (Details)",
     "shortName": "TAXES ON INCOME, NET (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails",
     "longName": "0049 - Disclosure - TAXES ON INCOME, NET (Schedule of Loss (Income) Before Taxes) (Details)",
     "shortName": "TAXES ON INCOME, NET (Schedule of Loss (Income) Before Taxes) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "0050 - Disclosure - TAXES ON INCOME, NET (Schedule of Deferred Tax Assets and Liabilities) (Details)",
     "shortName": "TAXES ON INCOME, NET (Schedule of Deferred Tax Assets and Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://cgen.com/role/GEOGRAPHICINFORMATIONANDMAJORCUSTOMERSNarrativeDetails",
     "longName": "0051 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Narrative) (Details)",
     "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Item",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Item",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails",
     "longName": "0052 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details)",
     "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails",
     "longName": "0053 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)",
     "shortName": "FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails",
     "longName": "0054 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Schedule of Related Party Transactions) (Details)",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS (Schedule of Related Party Transactions) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:OtherLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:OtherLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
     "longName": "0055 - Disclosure - LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)",
     "shortName": "LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://cgen.com/role/SubsequentEventsNarrativeDetails",
     "longName": "0056 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)",
     "shortName": "SUBSEQUENT EVENTS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_20240101to20240131_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240131_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431047.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-oapaae"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r518"
     ]
    },
    "cgen_AccruedMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "AccruedMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued milestone payment.",
        "label": "Accrued milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AccruedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "AccruedMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Milestone Payments",
        "documentation": "Amount of accrued milestone payments.",
        "terseLabel": "Accrued milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-paend": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r142",
      "r412"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r88",
      "r144",
      "r408",
      "r424",
      "r425"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "Accumulated other comprehensive income [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14",
      "r29",
      "r336",
      "r339",
      "r373",
      "r420",
      "r421",
      "r553",
      "r554",
      "r555",
      "r560",
      "r561",
      "r562"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r437",
      "r560",
      "r561",
      "r562",
      "r609",
      "r626"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentForAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentForAmortization",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization in R&amp;D expenses",
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r47"
     ]
    },
    "cgen_AdjustmentForExchangeRateDifferencesLossGainOnCashBalances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "AdjustmentForExchangeRateDifferencesLossGainOnCashBalances",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment For Exchange Rate Differences Loss (Gain) On Cash Balances",
        "documentation": "Adjustment for Exchange rate differences loss (gain) on cash balances.",
        "totalLabel": "Gain (Loss), Foreign Currency Transaction, before Tax, Total",
        "terseLabel": "Foreign currency transaction adjustments",
        "verboseLabel": "Exchange rate differences loss (gain) on cash balances",
        "negatedLabel": "Exchange rate differences loss (gain) on cash balances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AggregateLimitOfOrdinarySharesPerCalendarYear": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "AggregateLimitOfOrdinarySharesPerCalendarYear",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate limit of ordinary shares per calendar year.",
        "label": "Aggregate limit of ordinary shares per calendar year"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AgreementStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "AgreementStartDate",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement start date.",
        "label": "Agreement Start Date",
        "verboseLabel": "Agreement, start date"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AgreementTerminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "AgreementTerminationDescription",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of termination of agreement.",
        "label": "Agreement Termination Description",
        "verboseLabel": "Agreement termination description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expenses",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r304"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of Cash Consideration Of Research And Development Funding Arrangement",
        "negatedLabel": "Decrease (increase) in interest receivables from short-term bank deposits",
        "label": "Amortization Of Cash Consideration Of Research And Development Funding Arrangement",
        "terseLabel": "Amortization research and development component"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization Of Discount And Accrued Interest On Marketable Securities",
        "documentation": "Represent the amount of Amortization of discount and accrued interest on marketable securities",
        "negatedLabel": "Amortization of discount and accrued interest on marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AnnualDepreciationRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "AnnualDepreciationRate",
     "presentation": [
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Depreciation Rate",
        "label": "Annual depreciation rate"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AnnualDepreciationRateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "AnnualDepreciationRateDescription",
     "presentation": [
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Depreciation Rates, Description.",
        "label": "Annual Depreciation Rate, Description",
        "verboseLabel": "Annual depreciation rate"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AntibodiesDiscoveryCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "AntibodiesDiscoveryCollaborationAgreementMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antibodies Discovery Collaboration Agreement [Member]",
        "documentation": "Information about the Antibodies Discovery Collaboration Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r143",
      "r165",
      "r200",
      "r208",
      "r213",
      "r224",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r331",
      "r333",
      "r345",
      "r404",
      "r460",
      "r518",
      "r530",
      "r570",
      "r571",
      "r613"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r147",
      "r165",
      "r224",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r331",
      "r333",
      "r345",
      "r518",
      "r570",
      "r571",
      "r613"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non- current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r224",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r331",
      "r333",
      "r345",
      "r570",
      "r571",
      "r613"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm Id",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r535",
      "r536",
      "r537"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r535",
      "r536",
      "r537"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r535",
      "r536",
      "r537"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r536",
      "r537"
     ]
    },
    "us-gaap_BusinessDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing and business development expenses",
        "documentation": "Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r140",
      "r506"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents:",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash:",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r118"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents and restricted cash at the end of the year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the year",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "verboseLabel": "Total cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r102",
      "r163"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of cash, cash equivalents and restricted cash:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r102"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash paid for amounts included in measurement of lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants purchase to ordinary shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants purchase to ordinary shares remain outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration period of warrants.",
        "label": "Class Of Warrant Or Rights Period From Which Warrants Or Rights Exercisable",
        "terseLabel": "Expiration period of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CollaborativeArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "CollaborativeArrangementsMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements [Member]",
        "label": "Collaborative Arrangements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CollaborativeArrangementsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "CollaborativeArrangementsTwoMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements Two [Member]",
        "label": "Collaborative Arrangements Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENT LIABILITIES",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r69",
      "r405",
      "r447"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-cac1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r231",
      "r232",
      "r502",
      "r569"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r521",
      "r522",
      "r524",
      "r525",
      "r526",
      "r527",
      "r560",
      "r561",
      "r609",
      "r624",
      "r626"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Ordinary shares, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r448"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-cbsp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "label": "Ordinary shares, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r82",
      "r448",
      "r466",
      "r626",
      "r627"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share capital: Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2021 and 2020; 86,433,432 and 83,675,856 shares issued and outstanding at December 31, 2021 and 2020, respectively",
        "terseLabel": "Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2023 and 2022; 89,237,465 and 86,624,643 shares issued and outstanding at December 31, 2023 and 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r407",
      "r518"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r152",
      "r154",
      "r160",
      "r398",
      "r416"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income (loss):",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computers, software and related equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r42",
      "r66",
      "r67",
      "r221",
      "r501"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r42",
      "r66",
      "r67",
      "r221",
      "r426",
      "r501"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r42",
      "r66",
      "r67",
      "r221",
      "r501",
      "r546"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of credit risks:",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r128"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales to a single customer exceeding 10%",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r42",
      "r66",
      "r67",
      "r221"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r42",
      "r66",
      "r67",
      "r221",
      "r501"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of consolidation:",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r508"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ContingentFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ContingentFees",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent fees.",
        "label": "Contingent Fees",
        "verboseLabel": "Contingent fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r165",
      "r224",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r345",
      "r570"
     ]
    },
    "cgen_CostOfSalesContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "CostOfSalesContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.",
        "label": "Cost Of Sales Contract With Customer Policy Text Block",
        "terseLabel": "Cost of revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amounts charged to research and development expenses",
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r221"
     ]
    },
    "cgen_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer One [Member]",
        "label": "Customer One Member",
        "terseLabel": "Customer A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Two [Member]",
        "documentation": "This member stands for Customer two",
        "verboseLabel": "Customer B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_DeferredIncomeTaxLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "DeferredIncomeTaxLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax lease liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Deferred tax liabilities",
        "negatedTotalLabel": "Deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r120",
      "r316"
     ]
    },
    "cgen_DeferredIncomeTaxRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "DeferredIncomeTaxRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax Right of use assets attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Right Of Use Assets",
        "terseLabel": "Right of use assets"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_DeferredParticipationOfBMSInRAndDExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "DeferredParticipationOfBMSInRAndDExpenses",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred participation of BMS in R and D expenses.",
        "label": "Deferred Participation Of B M S In R And D Expenses",
        "terseLabel": "Deferred participation of BMS in R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenues",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Current",
        "terseLabel": "Short-term deferred revenues",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Long-term deferred revenues",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "cgen_DeferredRevenuesIncludedInCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "DeferredRevenuesIncludedInCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenues Included In Current Liabilities",
        "documentation": "Amount of deferred revenues included in current liabilities.",
        "terseLabel": "Deferred revenues included in current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_DeferredRevenuesIncludedInNonCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "DeferredRevenuesIncludedInNonCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenues Included In Non Current Liabilities",
        "documentation": "Amount of deferred revenues included in non current liabilities.",
        "terseLabel": "Deferred revenues included in non current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax asset before valuation allowance",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax asset (liabilities) for property, plant and equipment.",
        "label": "Deferred Tax Assets Liabilities Property Plant And Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax asset after valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r604"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r604"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued social benefits and other",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r604"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "verboseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r48"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFairValueOfDerivativeNet",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of outstanding forward contracts",
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net gain on derivative transactions",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net gain on derivative recorded as financial and other income, net for the ineffective portion",
        "documentation": "The portion of gains on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r64"
     ]
    },
    "us-gaap_DerivativeNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeNotionalAmount",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, notional amount",
        "documentation": "Nominal or face amount used to calculate payment on derivative."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r607"
     ]
    },
    "cgen_DerivativeRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "DerivativeRelatedExpense",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the derivative related expenses incurred during the reporting period.",
        "label": "Derivative Related Expense",
        "terseLabel": "Derivative related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative instruments:",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r58",
      "r59",
      "r60",
      "r62",
      "r168"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r536",
      "r537"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r536",
      "r537",
      "r539"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic net loss per share",
        "terseLabel": "Basic loss per ordinary share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r184",
      "r186",
      "r188",
      "r189",
      "r190",
      "r194",
      "r342",
      "r343",
      "r399",
      "r417",
      "r509"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r186",
      "r188",
      "r189",
      "r190",
      "r194",
      "r342",
      "r343",
      "r399",
      "r417",
      "r509"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted loss per share:",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-lps"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LOSSES PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r191",
      "r192",
      "r193"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Effect of exchange rate changes on cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israeli corporate tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r312",
      "r327"
     ]
    },
    "cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss) for next fiscal year.",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate For Next Fiscal Year",
        "terseLabel": "Israeli corporate tax rate for next fiscal year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. income state and local taxes rate (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r605"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-oapaaed": {
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-oapaaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees and related accruals",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized share-based compensation expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost, recognition period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd",
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan Member",
        "verboseLabel": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_EmployeesDirectorsAndNonEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "EmployeesDirectorsAndNonEmployeesMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees Directors And Non Employees [Member]",
        "documentation": "Information about the employees, directors and non-employees."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses Address Type [Axis]",
        "verboseLabel": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r136",
      "r156",
      "r157",
      "r158",
      "r169",
      "r170",
      "r171",
      "r173",
      "r179",
      "r181",
      "r195",
      "r225",
      "r226",
      "r248",
      "r297",
      "r298",
      "r299",
      "r322",
      "r323",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r373",
      "r420",
      "r421",
      "r422",
      "r437",
      "r489"
     ]
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentAggregateCost",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment amount",
        "verboseLabel": "Equity investment",
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EuropeMember",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r629",
      "r630",
      "r631"
     ]
    },
    "cgen_ExtendLease": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ExtendLease",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extend Lease",
        "label": "Extend Lease",
        "verboseLabel": "Extend lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of financial instruments:",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r20"
     ]
    },
    "cgen_FinancialIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "FinancialIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 10.0
      },
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Income (Expense), Net.",
        "label": "Financial Income Expense Net",
        "terseLabel": "Financial and other income, net",
        "totalLabel": "Financial and other income, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "terseLabel": "Foreign currency transaction adjustments",
        "verboseLabel": "Exchange rate differences loss (gain) on cash balances",
        "negatedLabel": "Exchange rate differences loss (gain) on cash balances",
        "totalLabel": "Gain (Loss), Foreign Currency Transaction, before Tax, Total",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r351",
      "r486"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial statements in U.S. dollars:",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (loss) from sales and disposals of fixed assets",
        "documentation": "Amount of gain (loss) on sale or disposal of other assets."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss (gain) from property and equipment sales and disposals",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r470"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "cgen_GovernmentAndOtherGrantsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "GovernmentAndOtherGrantsAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and Other Grants [Axis]",
        "label": "Government and Other Grants [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_GovernmentAndOtherGrantsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "GovernmentAndOtherGrantsDomain",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "auth_ref": []
    },
    "cgen_GovernmentAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "GovernmentAuthorities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-oaraped": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-oaraped"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Authorities",
        "label": "Government authorities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r165",
      "r200",
      "r207",
      "r212",
      "r215",
      "r224",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r345",
      "r510",
      "r570"
     ]
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsMaximumExposure",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security",
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "IL",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r535",
      "r536",
      "r537"
     ]
    },
    "us-gaap_ImpairmentOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfInvestments",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities impairment losses",
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Domestic (Israel)",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "verboseLabel": "Domestic (Israel)",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r326"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Loss before taxes on income",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before taxes on income",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r90",
      "r122",
      "r200",
      "r207",
      "r212",
      "r215",
      "r400",
      "r414",
      "r510"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r326"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r473"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r473"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-it"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TAXES ON INCOME, NET",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r308",
      "r313",
      "r314",
      "r320",
      "r324",
      "r328",
      "r329",
      "r330",
      "r433"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Taxes on income",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Taxes on income, net",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r134",
      "r180",
      "r181",
      "r204",
      "r311",
      "r325",
      "r418"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes:",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r309",
      "r310",
      "r314",
      "r315",
      "r319",
      "r321",
      "r430"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax payment withheld",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r37"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 150.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in trade receivables",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 100.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in trade payables and other accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 80.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in other accounts receivable and prepaid expenses",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 110.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in deferred participation in R and D expenses.",
        "label": "Increase Decrease In Deferred Participation In Research And Development Expenses",
        "terseLabel": "Increase (decrease) in deferred participation in R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_IncreaseDecreaseInDeferredRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "IncreaseDecreaseInDeferredRevenues",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 130.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Deferred Revenues",
        "documentation": "Represent the amount of deferred revenues",
        "negatedLabel": "Increase in deferred revenues"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 120.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease right of use asset.",
        "negatedLabel": "Decrease in operating lease right of use asset",
        "label": "Increase Decrease In Operating Lease Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 140.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in operating lease liability",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 90.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in long-term prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "cgen_IncreaseOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "IncreaseOperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease right of use asset increased.",
        "label": "Increase Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right of use asset increased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InitialOfferingPeriod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InitialOfferingPeriod",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering period",
        "documentation": "A description of the time period when the company made its initial offering of a class of securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestAndDebtExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestAndDebtExpense",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Bank fees and other finance expenses",
        "label": "Interest and Debt Expense",
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "cgen_InterestPaidReceivedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "InterestPaidReceivedNet",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest payments paid (received) from bank short-term deposits and cash equivalents",
        "label": "Interest Paid Received Net",
        "terseLabel": "Interest payments received from short-term bank deposits and cash equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States [Member]",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeAmortizationOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeAmortizationOfDiscount",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Amortization of Discount",
        "verboseLabel": "Amortization of discount on marketable securities, net",
        "documentation": "Amount of accretion of purchase discount on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r203"
     ]
    },
    "us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentOwnedUnderlyingFaceAmountAtMarketValue",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of investment in Compugen",
        "documentation": "Nominal or face amount on the investment owned."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r63"
     ]
    },
    "cgen_IssuanceOfSharesAndWarrantsNetShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "IssuanceOfSharesAndWarrantsNetShares",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares and warrants, net, shares.",
        "label": "Issuance of shares and warrants, net, shares",
        "terseLabel": "Issuance of shares, net, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_IssuanceOfSharesAndWarrantsNetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "IssuanceOfSharesAndWarrantsNetValue",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares and warrants, net.",
        "label": "Issuance Of Shares And Warrants Net Value",
        "terseLabel": "Issuance of shares, net"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_JmpSecuritiesLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "JmpSecuritiesLlcMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jmp Securities Llc [Member]",
        "documentation": "This member stands for JMP Securities LLC.",
        "verboseLabel": "JMP Securities LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_LaboratoryEquipmentAndOfficeFurnitureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "LaboratoryEquipmentAndOfficeFurnitureMember",
     "presentation": [
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment And Office Furniture [Member]",
        "label": "Laboratory equipment and office furniture [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "cgen_LeerinkPartnersLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "LeerinkPartnersLlcMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leerink Partners Llc [Member]",
        "documentation": "This member stands for Leerink Partners LLC.",
        "verboseLabel": "Leerink Partners LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]",
        "verboseLabel": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases:",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cgen.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Leases",
        "terseLabel": "Schedule of operating leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period of options to extend leases",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://cgen.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r121",
      "r410",
      "r518",
      "r558",
      "r567",
      "r610"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r139",
      "r165",
      "r224",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r332",
      "r333",
      "r334",
      "r345",
      "r518",
      "r570",
      "r613",
      "r614"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r75",
      "r76",
      "r77",
      "r78",
      "r165",
      "r224",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r332",
      "r333",
      "r334",
      "r345",
      "r570",
      "r613",
      "r614"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON- CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_LicenseAgreementWithGileadMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "LicenseAgreementWithGileadMember",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement With Gilead [Member]",
        "documentation": "This member represents about license agreement with Gilead."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_LicenseRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "LicenseRevenue",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Revenue",
        "documentation": "Amount of license revenue.",
        "terseLabel": "License revenue"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "LongTermDeferredParticipationInResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term deferred participation in R&amp;amp;D expenses.",
        "label": "Long Term Deferred Participation In Research And Development Expenses",
        "terseLabel": "Long-term deferred participation in R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r221",
      "r513",
      "r573",
      "r622",
      "r623"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Current",
        "terseLabel": "Investment in marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "verboseLabel": "Investments in marketable securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "cgen_MasterClinicalAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "MasterClinicalAgreementMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Clinical Agreement [Member]",
        "label": "Master Clinical Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_MasterClinicalAgreementOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "MasterClinicalAgreementOneMember",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Clinical Agreement One [Member]",
        "label": "Master Clinical Agreement One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_MasterClinicalAgreementTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "MasterClinicalAgreementTwoMember",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Clinical Agreement Two [Member]",
        "label": "Master Clinical Agreement Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "MaximumAuthorizedProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Authorized Proceeds From Issuance Of Common Stock",
        "label": "Maximum Authorized Proceeds From Issuance Of Common Stock",
        "terseLabel": "Aggregate offering price",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r236",
      "r261",
      "r384",
      "r419",
      "r439",
      "r440",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r503",
      "r504",
      "r511",
      "r512",
      "r514",
      "r519",
      "r572",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620"
     ]
    },
    "cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "MaximumRoyaltyRepaidAsPercentageOfGrantReceived",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Royalty Repaid As Percentage Of Grant Received",
        "label": "Maximum Royalty Repaid As Percentage Of Grant Received",
        "verboseLabel": "Maximum royalty repaid as percentage of grant received"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_May2012AgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "May2012AgreementMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "May 2012 Agreement Member",
        "label": "May 2012 Agreement Member",
        "terseLabel": "May 2012 Agreement With Advisor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_MilestonePaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "MilestonePaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payment Receivable",
        "documentation": "Amount of milestone payment receivables.",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r236",
      "r261",
      "r384",
      "r419",
      "r439",
      "r440",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r503",
      "r504",
      "r511",
      "r512",
      "r514",
      "r519",
      "r572",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r221",
      "r513",
      "r573",
      "r622",
      "r623"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-csocl",
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss",
        "label": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss for basic and diluted loss per share",
        "terseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r104",
      "r123",
      "r137",
      "r151",
      "r153",
      "r158",
      "r165",
      "r172",
      "r174",
      "r175",
      "r176",
      "r177",
      "r180",
      "r181",
      "r187",
      "r200",
      "r207",
      "r212",
      "r215",
      "r224",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r343",
      "r345",
      "r415",
      "r468",
      "r487",
      "r488",
      "r510",
      "r528",
      "r570"
     ]
    },
    "cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss After Adjustment Of Change In Fair Value Of Research And Development Funding Arrangement Abstract",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_NetOperatingLossCarryforwardExpired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "NetOperatingLossCarryforwardExpired",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryforward, Expired.",
        "label": "Net operating loss carryforward, Expired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently issued and recently adopted Accounting Standards:",
        "verboseLabel": "Recently issued accounting pronouncement not yet adopted by the Company:",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_NonRefundableUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "NonRefundableUpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Refundable Upfront Payment",
        "documentation": "Amount of non-refundable upfront payment.",
        "verboseLabel": "Non-refundable upfront payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-lived assets",
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues": {
     "xbrltype": "integerItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of licensed programs to achieve substantive milestones revenues.",
        "label": "Number of licensed programs to achieve substantive milestones revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://cgen.com/role/GEOGRAPHICINFORMATIONANDMAJORCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "cgen_NumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "NumberOfWarrantsExercised",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised.",
        "label": "Number Of Warrants Exercised",
        "terseLabel": "Warrants exercised, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to obsolete property and equipment and certain nonfunctional Lab equipment.",
        "label": "Obsolete property and equipment and nonfunctional Lab equipment [Member]",
        "terseLabel": "Obsolete property and equipment and certain nonfunctional Lab equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r207",
      "r212",
      "r215",
      "r510"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liability",
        "terseLabel": "Present value of lease liabilities",
        "verboseLabel": "Present value of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current maturity of operating lease liability",
        "verboseLabel": "Lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term operating lease liability",
        "verboseLabel": "Lease liabilities, non- current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r369"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right of use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount (annual) rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r517"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r517"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforward",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year of expiration of operating loss carryforward",
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "cgen_OrdinarySharesIssuedAndSoldThroughAtmMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "OrdinarySharesIssuedAndSoldThroughAtmMember",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares Issued And Sold Through Atm [Member]",
        "documentation": "This member stands for ordinary shares issued and sold through ATM.",
        "verboseLabel": "ATM [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-g"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GENERAL",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r117",
      "r427",
      "r428"
     ]
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      },
      "http://cgen.com/role/cgen-oapaaed": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/cgen-oapaaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accounts payable and accrued expenses",
        "totalLabel": "Other accounts payable and accrued expenses",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "OtherAccountsReceivableAndPrepaidExpensesTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-oarape"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other accounts receivable and prepaid expenses.",
        "label": "Other Accounts Receivable And Prepaid Expenses Text Block",
        "terseLabel": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-oapaaed": {
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-oapaaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-oaraped": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-oaraped"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r518"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Translation income",
        "verboseLabel": "Exchange rate income (loss) on lease liabilities",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r5",
      "r350",
      "r358"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "verboseLabel": "Changes in other comprehensive income from marketable securities",
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r88",
      "r150",
      "r223"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net gain on derivative classified to operating expenses as effective portion",
        "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r65",
      "r88"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain arising during the period from marketable securities",
        "verboseLabel": "Changes in other comprehensive income from marketable securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r223"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-faoin"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCIAL AND OTHER INCOME, NET",
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r115"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables and accrued expenses",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r402",
      "r443",
      "r444",
      "r530",
      "r625"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_OtherShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term bank deposits",
        "verboseLabel": "Short-term bank deposits",
        "documentation": "Amount of short-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r403",
      "r551"
     ]
    },
    "cgen_ParticipationRights": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ParticipationRights",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to investors.",
        "label": "Participation Rights",
        "verboseLabel": "Participation Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payments for Proceeds from Sales of equipment Investing Activities.",
        "negatedLabel": "Proceeds from sale of property and equipment",
        "label": "Payments For Proceeds From Sales Of Property And Equipment Investing Activities",
        "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total",
        "verboseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/SubsequentEventsNarrativeDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Issuance expenses",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireHeldToMaturitySecurities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Held-to-Maturity Securities",
        "terseLabel": "Proceeds from maturity of marketable securities",
        "positiveTerseLabel": "Investment in short-term bank deposits",
        "negatedLabel": "Investment in short-term bank deposits",
        "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r222"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Investment in marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "cgen_PercentageOfClosingPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "PercentageOfClosingPrice",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of closing price.",
        "label": "Percentage of closing price"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_PercentageOfConsolidatedRevenuesOfCollaborator": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "PercentageOfConsolidatedRevenuesOfCollaborator",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of consolidated revenues of collaborator.",
        "label": "Percentage of consolidated revenues of collaborator"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_PercentageOfExpectedFromUpfrontPaymentAmountPaid": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "PercentageOfExpectedFromUpfrontPaymentAmountPaid",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Expected From Upfront Payment Amount Paid",
        "documentation": "Percentage of expected from upfront payment amount paid.",
        "terseLabel": "Percentage of expected from upfront payment amount paid"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair market value of ordinary shares at time of offering.",
        "label": "Percentage of fair market value of ordinary shares at time of offering"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of use of base salary to purchase ordinary shares.",
        "label": "Percentage of use of base salary to purchase ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ]
    },
    "us-gaap_PostemploymentBenefitsLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PostemploymentBenefitsLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued severance pay",
        "documentation": "For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 50.0
      },
      "http://cgen.com/role/cgen-oaraped": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/cgen-oaraped"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accounts receivable and prepaid expenses",
        "totalLabel": "Other accounts receivable and prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-oaraped": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-oaraped"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r227",
      "r228",
      "r507"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term prepaid expenses",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIncomeTaxRefunds",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax receivables refunded",
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r103"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from ordinary shares in offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of ordinary shares, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturity of marketable securities",
        "positiveTerseLabel": "Investment in short-term bank deposits",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfHeldToMaturitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Held-to-Maturity Securities",
        "terseLabel": "Proceeds from maturity of marketable securities",
        "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total",
        "positiveLabel": "Proceeds from maturity of short-term bank deposits",
        "documentation": "The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r222"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of stock-based awards",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r19"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "verboseLabel": "Proceeds from warrant exercised",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Axis]",
        "verboseLabel": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-paen"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT, NET",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r129",
      "r132",
      "r133"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisposals",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Costs of disposal of property and equipment",
        "label": "Property, Plant and Equipment, Disposals",
        "verboseLabel": "Costs of disposal of property and equipment",
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-paend": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r141",
      "r413"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentImpairment",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets:",
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 20.0
      },
      "http://cgen.com/role/cgen-paend": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/cgen-paend"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Depreciated cost",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r401",
      "r413",
      "r518"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net:",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r129",
      "r132",
      "r411"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-paent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property And Equipment, Net",
        "terseLabel": "Schedule of property and equipment, net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "PurchaseOfPropertyAndEquipmentAsNonCashTransaction",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Of Property And Equipment As Non Cash Transaction",
        "documentation": "The amount of purchase property and equipment as non cash transaction.",
        "negatedLabel": "Purchase of property and equipment",
        "terseLabel": "Purchase of property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "verboseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r236",
      "r259",
      "r261",
      "r291",
      "r292",
      "r293",
      "r383",
      "r384",
      "r419",
      "r439",
      "r440",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r503",
      "r504",
      "r511",
      "r512",
      "r514",
      "r519",
      "r522",
      "r568",
      "r572",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r236",
      "r259",
      "r261",
      "r291",
      "r292",
      "r293",
      "r383",
      "r384",
      "r419",
      "r439",
      "r440",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r503",
      "r504",
      "r511",
      "r512",
      "r514",
      "r519",
      "r522",
      "r568",
      "r572",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "cgen_ReceivablesOnAccountOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ReceivablesOnAccountOfShares",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables on account of shares.",
        "label": "Receivables on account of shares"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ReducedCorporateIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ReducedCorporateIncomeTaxRate",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduced Corporate income tax rate",
        "label": "Reduced Corporate income tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ReducedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ReducedTaxRate",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduced tax rate.",
        "label": "Reduced tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered direct offering [Member]",
        "label": "Registered direct offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r377",
      "r378",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r465",
      "r467",
      "r494"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r377",
      "r378",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r465",
      "r467",
      "r494",
      "r612"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-rpbat"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY BALANCES AND TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r434",
      "r435",
      "r436",
      "r471",
      "r472",
      "r473",
      "r492",
      "r493"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-gd",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Upfront payment received",
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "cgen_ResearchAndDevelopmentArrangementPaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ResearchAndDevelopmentArrangementPaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.",
        "label": "Research And Development Arrangement Payments Receivable",
        "terseLabel": "Potential milestone compensation"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone compensation company is now eligible for.",
        "label": "Research And Development Arrangement Payments Receivable On Remaining Program",
        "terseLabel": "Potential milestone compensation company is now eligible for"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.",
        "label": "Research And Development Arrangement Preclinical Payments Receivable",
        "terseLabel": "Preclinical milestone compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses, net",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r306",
      "r621"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses, net:",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "cgen_ResearchAndDevelopmentExpensesMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ResearchAndDevelopmentExpensesMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses milestone payment.",
        "label": "Research And Development Expenses Milestone Payment",
        "verboseLabel": "Research and development expenses milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ResearchAndDevelopmentExpensesMilestonePaymentWithConnection",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses milestone payment with connection.",
        "label": "Research And Development Expenses Milestone Payment With Connection",
        "verboseLabel": "Research and development expenses milestone payment with connection"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ResearchAndDevelopmentGrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ResearchAndDevelopmentGrantOneMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Grant One [Member]",
        "label": "Research And Development Grant One Member",
        "terseLabel": "IIA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Restricted cash",
        "label": "Restricted Cash and Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r118",
      "r140",
      "r163",
      "r406"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r140",
      "r163"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/cgen-gd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r111",
      "r409",
      "r423",
      "r425",
      "r432",
      "r449",
      "r518"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r169",
      "r170",
      "r171",
      "r173",
      "r179",
      "r181",
      "r225",
      "r226",
      "r297",
      "r298",
      "r299",
      "r322",
      "r323",
      "r335",
      "r337",
      "r338",
      "r340",
      "r341",
      "r420",
      "r422",
      "r437",
      "r626"
     ]
    },
    "cgen_RetainerFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "RetainerFee",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the retainer fee per month.",
        "label": "Retainer Fee",
        "verboseLabel": "Retainer fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue recognition under milestone method",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r206",
      "r210",
      "r211",
      "r217",
      "r219",
      "r221",
      "r257",
      "r258",
      "r385"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue recognition:",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r505"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "verboseLabel": "Revenue from sales to customers",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r165",
      "r201",
      "r202",
      "r206",
      "r210",
      "r211",
      "r217",
      "r219",
      "r221",
      "r224",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r345",
      "r400",
      "r570"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_RoyaltyContingentObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "RoyaltyContingentObligations",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.",
        "label": "Royalty Contingent Obligations",
        "verboseLabel": "Contingent royalty obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "cgen_RoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "RoyaltyPercentage",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty percentage.",
        "label": "Royalty Percentage",
        "verboseLabel": "Royalty percentage"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_RoyaltyPercentageBasedOnFutureRevenues": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "RoyaltyPercentageBasedOnFutureRevenues",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Percentage Based On Future Revenues",
        "label": "Royalty Percentage Based On Future Revenues",
        "verboseLabel": "Royalty percentage based on future revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails",
      "http://cgen.com/role/cgen-sesopnd",
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "verboseLabel": "Number of shares issued and sold in transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r545"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "auth_ref": [
      "r182",
      "r262",
      "r543",
      "r563"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-oapaaet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Accounts Payable and Accrued Expenses",
        "terseLabel": "Schedule of other accounts payable and accrued expenses",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-set1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-Based Compensation Expenses",
        "terseLabel": "Schedule of stock-based compensation expenses",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-itt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Deferred Tax Assets And Liabilities",
        "terseLabel": "Schedule of deferred tax assets and liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-lpst"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of computation of basic and diluted losses per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-itt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Loss Before Taxes",
        "terseLabel": "Schedule of loss (income) before taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-oarapet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Other Accounts Receivable And Prepaid Expenses",
        "terseLabel": "Schedule of other accounts receivable and prepaid expenses",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-faoint"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial and Other Income, Net",
        "terseLabel": "Schedule of financial and other income, net",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the annual rates used to calculate depreciation for property, plant and equipment.",
        "label": "Schedule Of Property Plant And Equipment Depreciation Rates Table Text Block",
        "verboseLabel": "Schedule of depreciation rates for property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Balances and Transactions",
        "terseLabel": "Schedule of related party balances and transactions",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-giamct"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales To A Single Customer Exceeding 10%:",
        "terseLabel": "Schedule of sales to single customer exceeding 10%",
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-giamct"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Revenues And Long-Lived Assets By Geographic Area",
        "terseLabel": "Schedule of total revenues and long-lived assets by geographic area",
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r94"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r89"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-set1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Option Activity",
        "terseLabel": "Schedule of option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r52"
     ]
    },
    "cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ScheduleOfWeightedAverageAssumptionsForGrantedOptions",
     "presentation": [
      "http://cgen.com/role/cgen-sapt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of granted stock options, including, but not limited to: (a) expected term of granted share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Weighted Average Assumptions For Granted Options",
        "verboseLabel": "Schedule of weighted average assumptions for granted options"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate",
     "presentation": [
      "http://cgen.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of weighted-average remaining lease term and discount rate.",
        "label": "Schedule Of Weighted Average Remaining Lease Term And Discount Rate",
        "terseLabel": "Schedule of weighted-average remaining lease term and discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Exchange on which Security is Registered",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-giamc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r205",
      "r209",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r221"
     ]
    },
    "cgen_SegmentReportingGeographicAreaAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "SegmentReportingGeographicAreaAxis",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Reporting Geographic Area [Axis]",
        "label": "Segment Reporting Geographic Area [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_SegmentReportingGeographicAreaDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "SegmentReportingGeographicAreaDomain",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Geographic Area [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing and business development expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling and marketing expense."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "cgen_ServerancePayPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ServerancePayPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Serverance Pay [Policy Text Block]",
        "label": "Serverance Pay Policy Text Block",
        "terseLabel": "Severance pay:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance expenses",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "cgen_SeverancePayFundNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "SeverancePayFundNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.",
        "label": "Severance Pay Fund Noncurrent",
        "verboseLabel": "Severance pay fund"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_SeverancePayNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "SeverancePayNet",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance pay, net.",
        "label": "Severance Pay Net",
        "terseLabel": "Decrease in severance pay, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period",
        "verboseLabel": "Award expiration period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares reserved for issuance",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares available for issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable at end of year",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total intrinsic value of options exercised during the period",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options forfeited",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options expired",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value of stock options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding at end of year",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options outstanding at end of year",
        "periodStartLabel": "Options outstanding at beginning of year",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options outstanding at end of year",
        "periodStartLabel": "Options outstanding at beginning of year",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award Options, Remaining Contractual Term [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Remaining Contractual Term Abstract",
        "verboseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable at end of year",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options vested and expected to vest at end of year",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Options vested and expected to vest at end of year",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum percentage of total shares of common stock outstanding",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation:",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r269",
      "r288",
      "r289",
      "r290",
      "r291",
      "r294",
      "r300",
      "r301",
      "r302",
      "r303"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value of exercised options",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Exercisable at end of year",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Exercisable at end of year",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-se12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r113"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ShortTermBankDepositsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ShortTermBankDepositsPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for short-term bank deposits.",
        "label": "Short Term Bank Deposits Policy Text Block",
        "verboseLabel": "Short-term bank deposits:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ShortTermBankDepositsWeightedAverageRateForeign": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ShortTermBankDepositsWeightedAverageRateForeign",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average interest rate for short-term bank deposits outside of the domestic currency.",
        "label": "Short Term Bank Deposits Weighted Average Rate Foreign",
        "terseLabel": "Average interest rate, short-term bank deposits in U.S. dollars"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "ShortTermDeferredParticipationInResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term deferred participation in R&amp;amp;D expenses.",
        "label": "Short Term Deferred Participation In Research And Development Expenses",
        "terseLabel": "Short-term deferred participation in R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sap"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r164"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r27",
      "r136",
      "r156",
      "r157",
      "r158",
      "r169",
      "r170",
      "r171",
      "r173",
      "r179",
      "r181",
      "r195",
      "r225",
      "r226",
      "r248",
      "r297",
      "r298",
      "r299",
      "r322",
      "r323",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r373",
      "r420",
      "r421",
      "r422",
      "r437",
      "r489"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-daei1",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r195",
      "r385",
      "r429",
      "r438",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r448",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r467",
      "r469",
      "r470",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r489",
      "r523"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r182",
      "r262",
      "r543",
      "r544",
      "r563"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-daei1",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r195",
      "r385",
      "r429",
      "r438",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r448",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r467",
      "r469",
      "r470",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r489",
      "r523"
     ]
    },
    "cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation relating to options issued to employees and directors.",
        "label": "Stock Based Compensation Relating To Options Issued To Employees, Directors And Non Employees",
        "terseLabel": "Stock-based compensation issued to employees, directors and non-employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of options and ESPP shares, shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r81",
      "r82",
      "r111"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares, net, shares",
        "verboseLabel": "Issuance of shares, net, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r81",
      "r82",
      "r111",
      "r431",
      "r489",
      "r500"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options exercised",
        "label": "Options exercised, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r81",
      "r82",
      "r111",
      "r275"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of options and ESPP shares",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r81",
      "r82",
      "r111"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares, net",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r81",
      "r82",
      "r111",
      "r437",
      "r489",
      "r500",
      "r529"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r27",
      "r111"
     ]
    },
    "cgen_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r85",
      "r86",
      "r106",
      "r450",
      "r466",
      "r490",
      "r491",
      "r518",
      "r530",
      "r558",
      "r567",
      "r610",
      "r626"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublease income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r517"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r381"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r381"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r381"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r381"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r381"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r382"
     ]
    },
    "us-gaap_SubsidiaryOfCommonParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOfCommonParentMember",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary of Common Parent [Member]",
        "terseLabel": "Subsidiary [Member]",
        "documentation": "Refers to an entity under the control of the same parent as another entity (that is, a sister company)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails",
      "http://cgen.com/role/cgen-sesopnd",
      "http://cgen.com/role/cgen-sesosced"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid (received) during the year for:",
        "terseLabel": "Cash received during the year for:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "SupplementalRightOfUseAssetAndOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In right of use asset and operating lease liability.",
        "label": "Supplemental Right Of Use Asset And Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "SvbLeerinkLlcAndStifelNicolausAndCompanyMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SVB Leerink LLC and Stifel, Nicolaus &amp;amp; Company [Member]",
        "label": "Svb Leerink Llc And Stifel Nicolaus And Company Member",
        "terseLabel": "SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_TwoThousandTenShareOptionsPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "TwoThousandTenShareOptionsPlanMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Ten Share Options Plan [Member]",
        "documentation": "Information about the share option plan 2010.",
        "verboseLabel": "2010 Share Option Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unites States [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_UnderwritersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20231231",
     "localname": "UnderwritersMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters [Member]",
        "label": "Underwriters [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of estimates:",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45",
      "r126",
      "r127",
      "r130",
      "r131"
     ]
    },
    "us-gaap_VariableLeasePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeasePayment",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Payment",
        "verboseLabel": "Variable payments as CPI",
        "documentation": "Amount of cash outflow for variable lease payment excluded from lease liability."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of ordinary shares used in computing diluted net loss per share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r190"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of ordinary shares used in computing basic net loss per share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r190"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "835",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.12)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "10",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480679/815-10-10-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "20",
   "Section": "10",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480769/815-20-10-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "25",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480901/815-30-45-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "610",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//610/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "720",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//720/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-8A"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-21"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "712",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481179/712-10-25-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "712",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481179/712-10-25-5"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>82
<FILENAME>0001178913-24-000818-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-24-000818-xbrl.zip
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MZM@>2U['"V4_S$NXS;9+I*J1^-G,;<U9G W',LIQ9PO++PGAQFOC8F9/YO9
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M.M!<_[:AW4R24\^:AFO,K&3L<6N&'4P>A+%B@1D*2@)O$0']\+C%E.->CL7
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M<J?>)>+$D1N-?@1LS=?);V ]6W/F8:)%I?0D1W4\*-V+1XE LG,I4;!B'"Q
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M8BY"OC0E]&33']]5A];P-6AQ@=PEHM_ ! \X";E!.38"[Z"2+,.[:&;&M];
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MW&@)T#1Z6+D0K.+0QW-G\D<:)"\B1++-M(6;?4'N)O*E>)27U-4IBGVXV+A
MNN]MA=;#%"RC8!%X;I2,/2].HP0OXKLX#+P (++0_#0$L\6O(%BN$N"?N'C9
MNTLP1BA=;\CR0=<Q_ QQ=>#/\@]7('&#$ E'MKN>M8P+9J_D9,A+MNWT,EZO
M@R2;ZN/(OXPS?N!M%7-#DJ,2+>B9L0#%T@NE*-MZGAXL^>T4R4=_["7!$_XN
M._V4&]3&.^3)KO2R<-NNI_AT7H.Y^PS0K0LA/O>>@"2?>%7;POH,XB5T-ZO
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MR30Q9I4W;Y>X17*-#^A,_3];J*]U5N5V&8=[N*;E\Z:["UG>?KO\QLU]X;Z
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M-B_80T[:*WP.'W+27O6G]"%G\6WX C_D[+Z,A_TA)_9M9!$PY%R_3>T(1/F
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M_B]%GA&\6N8']%>7,%,<FF2GG'(D: 8+OV+1&W[#NQ?>+OAL.RSIC*Q+?#*
MN=]3 ) "A"@L4:V8LJVQ-I#B0"M[VXD>:SHL \U7<8K<R)^#*!O8(BN7.(."
M3-WA,+2?.?J0/J+ #USX\N!FUSZBUA9,6&8=98/F]O"W  @K9XLYWB>0F^G#
MQ%N-L+)Y@G9BG*JE-BFO.\<V!OTLC'N0^;$3L?ZEA@F?/O5?!"M%OA%ENV^M
M! J'Z;"P+D/U<@JC7#",(;EBWL91]5TNBXZ@^O#8V]-QT%0M>IL2-A=J0S1.
MDU4,@S^ISF*=]>6<F78*TD7"DQN$1&M:IB8UP+7]+IUSZR[57$'_%X"RS*_X
M&AG[PJQ_FKIQSO7< -MAFCQO@MPL.8?%U.1I[<4YM^[FR<)?W )R*^9I@;_,
M"#S.$P)G/Q++ABI72!=SJ!D2Y]QT#,Y*D 3P*?  G5Y\K#[AY0#R^8'F<>*&
M]=^)%<QMG/P&B,U=O(P$^W]G?3KGI@_[SDC))PS>HXM/I!QOLS,+Q#FW+F<F
M:R'6S4)G:8(2-_+QOIY?G')#TB[6OT2WSGDOF1Z;I%4B$:N2EVF$$ICF9G#$
M\F&^<J-BGQLOEQ L\58VC1(81"CPLOVL1KF(R3W!<LZUQ/TP>+A-GO'4"A"H
M3I5L&>\2V.&))M.]<VXZ5'$NVQ*K3 P:X@T08\N^B3A!J^.<*UXG^.$UMO>4
M.QA[ /CH&L;KTH)TMB &1'&4[0SL1WC5EIP+TU+]9>@B-%L4#R<SF-DV5W>/
MZM7VT@U#X']Z*<JAHB!/F=*R9>?">"1\&F"YO5!4U;DP+8Q3$96[0+9NJA\K
MEO,DE4;M.1<]!*>O5E@!I]KZ>+I]3C7G0H_FC,I!5 AJI-]5X*WV65B@8)B!
M:6G7N3 N%9:V^,"_2F%U7<]W]EOP+?N)^Z(AU8!S8?PMJ8.@,Q>F)9U<//L"
M\*'E3[.;1R9,E#(90<6[T8AK.Q=Z0A#5A?7+,$9D'I"-B+506.6="SV"PQ58
M  ASM7#E*S1;?/KR,(WNB?%P:3+, BC=@//!M)A DURFY%KIAG?I8QAXI86(
MY";+;</Y8/KH+V"4 )AZ.FYYYX,>T\7Z//V*\'^(4/_@ABY\F<=E'L49Q'(%
M>=+-]CR9*2_9E/-!CW5CM>1O@G60X.OT3B\8&!;\0.2[\#?@LH.,JC3B?-!S
M4->91G1\7USX.TCR*^@>@G$R#\@K*&?VMVW2^3 8I0U5>VI,3>M\V![W;ZF@
M#\S[CRZBDU;F[/*?YX!@7?0G+E@*71QW!?L">W#1[A(GY?<P? K%[A.6!<C0
M2F3=!\.RN!A-Z%1VWK L(D83FIG>()9%Q&A"&\>YQ'@@#+F(0UI.CD&$'.M0
M7BB[.'![L2]>&1LJ0P3MR+?%KH.X<VHI>X78Q^95\ZCL[L"EQS+QIH^I0_<S
MLC#$I16[S=OIM.O 4CHN]3A?1#E*]Y'R"=JZ.-FY8U)P4A:UK'M4?PH(8?[)
M1L/VMCPEW+2,W_NDURH?-H-4*4\N.Q>S)'8ZX0P','N7=$>C^[;FFSB<&5>0
M2&\"BG2(F;%U6K-S%V!@I1SK"AYO]FX#78VOY4&L.WW;Z\*=[HV/6AWL+'MA
ML)J=#/<[RQXLNF1A1TY\ECV+6#T)F_OO61JGO$LN=^K09VED]$'RD^G,9VF@
M=BNW!DG7/DLCPG?.TAX=^2R-4V_E+%9TY[,U,'[GO&4Y"-H:4K\S>;29#Z*M
M\?F[G#<:_!5M#>=OG&U[KH^V9@(PSA<9ATE1\H!C9);(_[+BR2NX3FASZJR8
M]IJN!]*>H15W7I&D+W(TK7CRBD1Q28?5K2KX^%DC]):MF/%:I&@ES]R*.Z](
M>%;R[:T8](K$9*;'<,6,5R ;M_%)KOCT"L3B9K[/%8=>BY#<TJNZXM=KDH^U
MNUQ77&3(T1WFNLN0KN(0]X]R,6YKLI7C'7M)\(2_7Y$$MR%Z2XCWEA!/WF;O
MN /8]TE?DP#K>B(Y&PI?/S3F#BQZ?7$8U;3,]W$87L>0_-C%ILGM4$_FN'[X
MEK]OF&%9WM?@N+4K\GR&,>KD7&;WY@POUFUIQ68B"A"E-Z>70+8M:, [R0($
M20J!"8Y1>G,&DXJCH.&7W(@J(B:3^"0&_CPFGTQN;;(0+,Q_*6=>0N3@SKEX
MT)=RVL;>V54;\3U;TYWW7B(R+$S**))@G)'I*+V&:.R?RQ:REGGME;&=UL9>
M?2B<D>GL(:V)HT@L??%9$8HSLBX8I8A"BK#3%[,5H9C/A=J]1-33=MT.F#,:
MV@V,06]-UK)K("2!.2,]D</;4G$/B-8,SYK+.$J@ZR6I&\X!7(\?4?9/EOJP
MZWY[2";;U'>@Z<)DL4"84M *D+8,4/$H6AF%9P&E,INPG&02H@7MWA<(KVK+
MM&"-).%GRJ-C'*%S-K1KY]CW@_RE]2I )'HS$2PX6Y"1?ITSZVX\\E<Y8^FX
MF'WVQ+X6FV-MQ>V2TN6.S.ZTGCGZ+0K\P9OV6Q1X'G/H_%=Z5+<N/'PS*L2<
ML#1H/!\JQ8A,_DG_*,+SJ(SM6W0>_98"Q\9+(;V=\[<R*[!S(QH:9^D&"&_3
MMD-;A6,+,]43<^EF#<<6@*HGYJH8.QQ;Q*K>-@N*9<0KC%/5CT7$\6_**LSH
M=63JP_$V&LU'0Z_1Q?&+A!8,20/[C+>-R\"X-##E.'Y!M/\#I;V=Q_'+KM:.
MDH(1R"N2@HT9CEBV/YFCFS/)K3$:L4O\M7-L>C$9.38IV,!]7&@_<J1GL)CN
MSF_9A\8F=FTL5K"Z,[L4P5[18:2,S X6 10C#Y<W:E\D%15]'&:=!R2HUG[<
M\RPZW8U$2 S-/?48'T,/)?*Q,C3V9SSTP33"LQQ4::QO"HR"0!F<6K90((SC
MP*W70P@*!/ NOR+1\, 3".,- 57$Q6-&U5"H;9RB!Q#BYI884AY8"O\M2XZH
MJG-FF);/(,*R;(@!C?TU/E#(29@$3T"6(*GZCFG;U6Y63D_!4%B9%GG3C)F=
MT;C#DC#G(X\,<<)(T_10$G7*2!ZUM)['-@+]K(I"Z  ^728IMA\.97(-D/3I
M/5B-ZY=86?>:CD2](S8GU\PH^KCPQ5!K;<D%L)5HM=R.7(B:3JR</'M4)$O(
MO)8J2QL2+"L3&W^0EW<<Z& A#RRUMY%MGB>G&U\3TKL\%S6#4!E)WLY=3PXZ
MG6RZ_&^OOU W(VNYNY Q85O^RM'?@T"^A\_=9X!N218A<F[U$R2[.D9D@EX?
M%#:OI"\A"+7K.P5[4BKC 2[>PX6AH^D5+, MJ<T[K-(#]@1 O'KOL<0?I>5&
M,[U_$"J0!#6-4X(92#*Y>Y=Q&B7P18B?6MZXDEOGW.E'W64Z"+SI &-MXY0;
M#XA6"4IEBE2,!N_IX@<@;L7!\;V?U3!9+ !)X &J57J/@1&Q+/*",,@%MN0:
M^.0:3L[;%&-XV2G,4]JW;UTY5"TK*T%[*-<QO,7RWW6 /#<D&8$HE'?65UU]
M;GBK!^C.#7CQ=/=*FH_(NI,:K6(C6*21S]O%>=7,QSR5F369Q#N.?*(0"FML
M;[D&6<V:CT4ZVP!R4XJ6-S%"E_C:]%+8RO-(9%=2CN_)V#UN0<+L)/,? K3U
M(5O5?/!+-L>VWE!7_+U=M@E= 27O@9]ZY)H/-S%N'8C.('$E9Z08D9^/3 Y*
MV7<M2J')&%JTVSU+';5_NSZ^E\@#"GG:>,J]W?+70QIB60H'\69(!\PB473_
M/Q9*69J"'I]!Y![)-,S783R-2>X[2EH&>Q^YU,@0LZ)25-BY8.E01:^6#!V&
MO0]<'8VJY2]<*@*4)NW'@#G1J3;$UB ,"C.$HCBQS$6X"54BM8JMOH>:ES9/
MJ6*K<[T""_A*EY) V_*DRVY:DEJ;DDS;TIMK&<=#/4Y)+B,/N<WDRJF#2@)_
M'#:!-2735GHP;@#S&<1+Z&Y6@3>-\)Q:YR<]L5W];PPO4Y1@WD/4BTE,H03(
MCJC)<ZX8J!!E>S9>#WA[]\<( 3G7V*9-]N@#JPA9WMFU2<.:LH\_Y.K%>X!7
M.-G5MI-P#('+>-:7K&D$(O/M6+JN'E,6!)/:;,+_VLXD_ ]GDL)XPW9JW"_2
M"A,"WG?+^.G4RQ5:.:SB'UM4Q0=G>D-C7O5C*Y,9-21?'SA(OCZH^G+V-9WZ
ML4RXQ*(TB))< +D/T.^?7CZ!R%NM72CRV115->XX> BHA".T%!%5[<4)$A4;
M/):2Q68ZM/)'-0+6K(\Y[DY]:92US">%/@!#H*B/Q[96#R044LT!*.&Z$-0\
MAM'0N# $TLCNE8*Q!N@%-=FX" #F#AT[O3-9RRVO#)<A-92MSB*V$$<OJ!O!
M_%LLAZ JJ"EKK[$AZ\O0.;^$2=Q9S2=FO,7;1@K)4U=^!>2 W"_JG)FVA#S8
MX^X )!_<)3<#'Z]:/0FA0?N?%DH*U@MFVTO_\5D5M>8(1;$GI9RPSAQ) ;HR
MS98:*"DAWR6:HC,Y&MIV]"^6O6AK("M3YE@8A,#  AR&Q97F/5E!TV2O798,
M>%FR#Y12=NU<*L 9<@Y#C66O@5:'P_NVYMDJM!Y/ ?7UO@-<DMQ===M UOD>
M: :I8I7<H)9[R]%]E:N<K20T;IDG7-@<K(=$<36*=JUB,5R*L$K54QX173O:
M3PM=.31-1LOMO_4KT.HZV%=#-$VG:ZD]MW[B17IAP4'3H<4><4<!?Z0DC.83
MR=#7<]RJ730W,M&K&%7,&]GM A&:SE&*FP_&OP=";$W J&$#<G$\;E:=OM%+
M!;XY*-\WZI8\/X:$ *9C970=CE[/,_\,^D%$N)6ECILBE&8I^Q[BT)^O8)PN
M5^-DS3< 4&CBZ :AIX51 Y82ON)_U)@_C6I )>D3->.,%,]HQGS[XCX'ZW2]
MS5&XXXZ&^W6Q]%5ZVV;06--.O27S1EM%@C14<+E$E<51Y0P,KUI/B1HXHAM+
M)4\7FH[/H(!!IQQ7MC*9=>8!$I"E:;34'$ *L121O=D$J,6\UC2.P] ]*R],
MEN!H[R,Q%S7[J50H6EJZ3*6@4[2T:B*JW4M8_W!;KM1M('HH"K:#)[R%0&RI
M7E=]T$5"<W]ZV[O[V=WD?O[;^/9J\N^OT[LOD]OY[63>K_KVCE@RPN2%Y(1/
M\%XX^2,--K)I",25>_2;9H*3]Y#F-V%<F<>$(^54)E';'HJD%)42M34Y@\\>
M$5[!"2A[K'>&_[Z-HT4:>?D^<N,^5K\)-&:M6CW"P>I'C<9$]AG&J-&*RBH:
MCVT_]KQTG6:QVJ[ !@(OCW"$_\:3+,B">HS7Q$;XS^P[$SV'8EU=&/<LKJ/E
MT%<OYOS0AX)-ZDAER;OR!]?QJ=\4:&<(CE+GH[7J.4GXBK0/0&DGB9VF#FA[
M_MJK(>A\-EBN+&BSC0J/]2.D6>/!;JDFH0UW]L0"917"SZ>DV4<7@;__/U!+
M P04    " #(@&58^BT7S"NK  "J>0@ %0   &-G96XM,C R,S$R,S%?;&%B
M+GAM;.R]?7/C.)(G_/]]"CYS<;O5$:[NKJI^G=V]"_FM1[LNRX^LZMZYB2<<
M- G9G*9('4C9UGSZ)Q,O)"6#("B! -U[<;?3+AL ?S\@@4P B<Q__5\OJS1X
M(K1(\NS?_O3AZV__%) LRN,D>_BW/VW*Y?N?_O2__N=_^]<TR7Z_#PL20/&L
M^+<_/9;E^L_??//\_/SURSU-O\[IPS<?O_WVTS>RX)]XR3^_%,E.Z>=/LNR'
M;_[S\]5M]$A6X?LD*\HPB^I:V(RJWH>??_[Y&_97*%HD?RY8_:L\"DM&H!-7
MT%H"__5>%GN/OWK_X>/[3Q^^?BGB/_W/_Q8$__K_O'\?3*\7%[],_S.XWP87
M_WC_GZ?SJ^#]>_97FJ=D3I8!0_?G<KLF__:G(EFM4V3%?O=(R5(-,:7T&ZS_
M348>PI+$^/F?\?,??L#/_W?QZZOPGJ1_"K#DE_FTE>W/.VWQ2M^XPGA#:)+'
M%]EA8/=J.T9]6X:T/ )WH[XSY(N\#-.#,#=J.D-[30[KWZJ>NWZ%-9$<UJ]U
M3:MHR]=(>W?F3B^F^/,5?'\'&7DI21:36&+#FIJ%E37,%F1L$UO-HYWV4ER<
M<[I+-7H@&=#Y^.G#1[["_G?\S=TDBNB&Q)^3E!1EGI&;<+LB62GK,L"LQ3M=
M\;L/G. XP'P<$DS1$TUQ]VE<<+X;%YSO[<")_[XI2FSQ,J<7+]%CF#V0.:P-
MY\ER22@86*2XRHOBES#)9ME96#R>ABG:/^V #V[Q[H<_'J4?_WB4?OKC4?KY
MCT?IP[=_0$Z6M.7# V7VSU6R2LK9<D9A#QG2[>UC2$D!]O%9F()=$=*_DI"V
MTNC3R-T'2ZK5 W)+6AB^27#0V<;C'+[>#F^_Y-T'2ZKW* R6].U1&"PI2-DR
MF/\K&'H\CS@G1423-?[8"4A=[>Z#)5TW$#I+:FL@=)8TT"JG9?(/UOQLB6OG
M69X524RH^-6<%#"IH\=)%I^3)Y+F:[80;S(\19M0BFNQ=N=@ZP-W'RWIIS?$
MV)+V>D.,+6F]-\38DK;< 72>%%&^R4KXNM@-3K,2+*6BG&6?0_H[*</[E-R2
M:$.3,M%87D>U>O?1DA8>)3=+VGV4W"Q9#5FV"=-SLJ8D2AB6N<YZ49:^^VC)
M1K""Q9)%H&S=Q";HJGCWT9)5,!S"3Y:T^( (+6G=K$SN\QCF$YM_3X1NS_(4
MX.1<1U0&WF>RNB?M>Z]^S=Q]LJ1!/:&WHPU1(=^$27R94U@*8>DKIEF4;F)<
M^3Z3L-A0]M'9\@K^ ;O:\#Y)M0OJP0W>?;*C \?$R([F.TO#HI@M?PO1&"IG
M=)X\/)8%OVN\I/GJM\<D>A1_+>2?+UX(C9("]54KL2/;O?MD1_N-EY\=C3I>
M?G:T=&.=>B(-B[W0KW@=U>X^V='0 Z'[SHYV;OW,XCD_$&!5\^X[._IY6(QV
MM#!L*DO8+^+.D6B6\IU2=]]9TJ$'?=N2MCOHVY;T4@[[HN5MF)("/T##J/PM
M*1_/-D69KPB]R=,DVB[(2WD*K?[>CJU/*W??6=(Y7K!;TB=>L%O2%:+Y648Z
MEH[]@G??6=('AR/XWM*:?P0"2RNZ:+A[ =\O>/>]I?7Z" 265NTC$-A9N\_)
MDE"*VX@(VE^$+Z8[DLZ*=]_;6>&'1&AG'1\2H9W5^M6'F!T^6WXIR*0H2+MW
M4F?%N^_MK,E#(K2S9@^(\ <[:[K\T$U(RR1*UN) ^?3S[32;X]7&Q<N:9$6W
M/'8V</>#'1W@$K$=G>$2L1T=(S\X)T\DVY#&P='9!GZ?E3T6*I,V[GZPJYG<
MX;:KK]SAMJO%7G_S.K<"7=G,W0]V-9QK]':UGVOT=C4CJ#:NT!K?N*'YFM!R
M>Y.&[$KSXO]LDK7NKOZ@QNY^M*M!?3*QJUE],K&E<6GRQ [OYB3%1RU"0;:#
M59>_^]&6/K6%QY:>M(7'COZ[6"Y)A,W7]BY\94ZB/(M 9OA%8GE)T/LFO2W#
M<@,M;W<*7^;TFKR4ETD1A:G.U76(;]W]:$>?OOU^L*.9WWX_V-'Q%ZMUFF\)
M*=#(3RC@S&G'_8^FRMV/=G2W950_V='#U2>J]N%;8,-4OS=$J*]^]Y,=7>L*
MK1U]*IN]+?/H]YL-C1[#@J#V-D/94NWN)SO:=2AT=G3M4.@L:5[V7):=(;8B
MJ8O<_61)S_7\JB6MTO.K=M;PRR0+09.$*5<9PG*Z)JV6<VN%NY_LK-\6$?UL
M9^VVB<C.^FP3D9TU^!?TK<MPEP1+_:Q\)/07YB S>4E:-_>Z.G<_VUE][>.R
ML^XVOK$I'W.].[6R\-W/=M98&TCLK+L@FQ37MG/"_SO-E$?+TTS]N*'KG-I2
M\W<_VUGOWPI;.WKFK;"UH\/:X<B#S/Y$9,V[#]_:46L#@[2CZ08&:4?YO?[4
M;,U>8F4/S%C;NQXU1ZQM!N#;T9'>X-M1I=[@V]&_\KM'@>Z":E=!#PK5KG8=
M%*HMU<@?P^%KB#F)2/+$0G*U@U,6!SBV=)<=.);">5B#8TD?%<4&0WO,ECSX
M!-@1\BT ?(;_KA6;05T :DDG#0_4DO89'J@E/:/]V*]ANFD]N#&H"C MZ9.A
M85K2)4/#M*-'_GVUKA\F7Z61_EA471K V-$4EL#8T1-VP%@*JG'%W\/D=%O=
MUN/9S7*91.1R0[.DW- .M_ >30!L.]K$.6P[NN6*$ J%<&N=$=H]^&WE 9 =
M'6(1D!U=81&0':UP!>*0@>4JWSOCHY1?DI2$<0>PCGH T(X^&!"@'4T@/B0.
M#SK@B%+P<3LK_X$?M[/2'_9Q2X$6KO+L 4-063TN/*I1H&9I]1\C-4L:8HS4
M[.B:SV$!6\PS*)A$86H8AT);":#9T3J#0+.C?UJ^TOE8KZL> +2C?P8$:$?_
MM'RH\Z%=5ST :$='#0C0CA[['+XDJ\U*W%S^ Q80FD>$Q 6&=:@WE6?Y:I5G
MS+.E'7+?ENX^6 IMX)F$'<WGF80='>>9A"UMQCX]S[=A6F[G9!TF\02CG8 Q
M5X8/\%7F^R"/4CL8F#8#\&UI/$_P;6E%3_!MZ<SMQV\_?#0V-%2E 8PM_6@%
MC"U=: 6,);VWEXF!RX$N!E)[C;L/EL(U6 9E22_9!65'SUR3DGOM88SYR1)L
MI3H@/2@%%HU^FEV&"65'W^:Q7R?W!0M0TL9M\ ]#%]G18G_H+K*C*0%I?9T-
M8,]"2K?+G#Z'%-]+);1=O1A4!9AV-.+@,.UHONL\FY,EC!K.]"_K)<VSLB.%
MD:8*P+*C ZW#LJ,-K<.RHQ>O-ZAF9TMQ<HE6]P,-5\4BGT2/"<S.V\T]ID[$
MYU?5.E]T^9T=U^K=!TNA,T9*SHZ>EC#DM:\(OZA9&]HJ "1+6MHF)$M:T28D
M.UIH=E_D*2F)?&/=?%[-WXC!G(_P/)=E3ZS^IK>?CVL5R-G172,E9T?CC92<
M';VYFU (3UQ(#)^_S=-X\4CSS</CI%QU,#%O F#;T:O.8=O1NZYA6PJEP5X"
M32*6RJ"H]WGPV1O*CESD55-GD,C^+0$).YK3,PD[NM8S"3O:>>?VDD>1;D.I
M* HP[&CDHV'8T9U'P["CY62NTLN<-L_@63S7V5*EI:;9$UBYN'G', W:QW-6
M&@>J=G3>FZ!J1T^^":IV=.M;H&HII,:;H&I':S>O<L[2O("OW%#8@K>B;RD/
M@.QH8(N +&G3Y@?R#'8528RAH.31 _Y61LW/6\W*?JT >$LZV ]X2YJ[\5FT
MEB+X)$Z5W4,[GN,%7^68P#=I!PA8TOG^"%C2Y/X(6-+/C0_C70E/"B=N3':W
M>I-RD:SPMYAY&581$RX]FP1:EG3QR&A9"H?2Q/"E@/\Y#0L"BA&^O,AE+*!=
M+"9T#)L"&O9UJA<:UC1QDL>W21:1R7I-\Z<P_2TLF+]'^T&OMA) LZ:3[4.S
MIG'E5R[PQ>B:)@4Y)0]A_>C; &!;58!I3;<."].2!I4BKC2,)P7&Z@V+QP4,
M8A%&NNR(_5L"$I:TJ%\2EC2I7Q*6]*9/$A\M15>I#Q.+629.&.6#U3:XNCH
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M6"@I%M4P*7X_!2OZ<172WUN?QII6!3;NM?,^I&T%JL/%J*OJW7='Q0&TQ,;
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M80NM;NBN#9R<VY8..+FV%!M'S"*8!=JNU8%D9Q@\H_K R[4U!ZL.21XR;DK
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M,0,R3QX>R]GR2T&8Z6Y,8*\>\/"FG1F>WP@"(O'D"7[[0.0+2TPE>$-HU$?
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MU;G[R7W>,<OXG6OS72R=IRR*XH#:N2[>@P&?ZCHE5=< [,[U[6LDW:E7V^H
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MKV&G'VP*?###YS#B X'XPIN9!8K..61>Z(1DQ',&%%[*PX[84"4LY7W5(CJ
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M\<+>NM0E/,B;KIN4 BA"GM4U@D85;R*IHZ&2T09\&<0M'Y9&'ZFMG8K4:Y=
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M#Z8SHZ<L^)L@Y '+S,DZI[A8_T+00>8QB2:4A%=)1J8E6:G5IJ@:5'6#JG*
MM8._8?V ->#^!L20F%*N?1,[8N36@N'D)>DW:NN:'=8=RX#M\.DS6"/G<Y[C
MLG#H"/':8Y6]1:MKF0$U5GELH[5H]>3RRLAPK"BJHBS"^_R;/$VBK?Y4H:Z
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MJZEZ^R!*!%@DF#IULVL O,JCL'VD!419R!/&ZW"E?C@B\6$!U]A.-T62D:)
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MU+:AQAE%0G]IFI+N'W#7N"^3E&B.OP1>+.7IT*N&2<]@G_.0Z]4K*QC(DG[
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M0-S)$%Q=>8:Z^EVY(M+6QH%)]+E(Q#S"+7>Z2N\ 7GVJ"_P26008Q^FW )P
M:'<R8C#W'9VN#]S'W(^^:IM@-!VPKB+L;NQ'NY'(7"@+8<S:9HWT)X"P\)96
M.=:6D-%K@,I-UT$DU3:%Z;SYI6)?NE!Q#VLOL'T*H@0'YFFR"\U"8+J,O4!V
MDT#.JQM(,XP3M? 6":X0WR3% MT-C$%X1 +*WJ-88"5$NT[RML37554(%3">
MBE,&4#T6 O1#(O"BCN_20CZR5(@[I96/21LO<&CG[T]I-6.+%2<62"=(C%EY
MB5;UU8A6(38;,"+05 ?K 8\6%29M/,)Q'F31#$"0?,1LX"$"DG>8#1BYQFY
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M;;\T^HRQTV1&+^U'?I71-!E%JVM;K/QHA]9E?.]I?6VS@8<(:+Y@-/ CGYJ
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MKIH=U09NTV1Q&[V*L#C-T'P7.*,EIO?VR=E>Z2:(\TTU&SFCM:5W2C+&7.J
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M?*3O2+18>97_=VDN6G@LP[75DAM3P?PNU[)6YRD88:V?CX7NUW+V GQ731,
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M73. )CE'/T<C0DRRD7Z.RMS^/_^FPKL%A__^W^ _X%_<^/;O_P]02P,$%
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M)XB?K;)(++)FND#W'(&=4D(#-;U_!@\'>CBHCJ$J,^(J:)4-[@CJPUJPSYI
M?;9D><A[#U]Z#$."C@;'L%@TY>=@<EN]#=$)--^$5)O?9 5H?$H1>3Q>US\J
MTSOO%=7X#?:M07J,WV<.7-936BYHGU7NE+_>M!^\_]M.8X3)GI;/^&Y,[;]
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M(8S'Q#2*0U 8I7\.\0_7^-]>7*$K3P93X9(_DG$SJ8Z^_'=9B'TEL#]87<$
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MRG7]>,R83-/[\Q="WC.(X%__#U!+ P04    " #(@&582K7?I$X'  !4'0
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MCXH4<6("P/M*VIBZ4[<$6YVV.]V'T@9*V\(()P)&JQ*%S.A A&BV[!GB'@J
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M3B,&[0C7_6WV3$T!L>P?,/''#1/?V;.D+B4>?V7),WN.CLK=<QM?36+2X79
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M=F>)\<-/>N"FE_W XCH"'YE!\ A^W^CM3$3R%GG[4=;"I'E%VS:X*\I@-6A
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MY\TOQ]]7A4'799$-#+I\?OS__<M?_M^:(U>7(Y?074^V^@+MG]IVNGOK=KK
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M;.*\EY$<!%X@DHESC0]]>7:M;7QUV%FSS]%V9V?I^.=*)@/,TXP\B9E%O<$
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MY--0/+"?(L^DY7G2$<P-3*XF;V'!/\3L>.UO>1*D?L"RIEK !Z\+[C%2EIE
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M:KB[CAHN3$"]3HSC^.1Z9C^:3@9U=0ZUR;$#K6O+EQDY+%$><>:$<2#H&QE
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M-!44C"K5KM14,^HFI]^JX:+9073K89TJIDQW\#@JB!(@;@ WXF+N^*F8/P9
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M,X$Q0=-S6$$5)0'Z)[FADVX$4'>%!IBT0#CT.FQ84#ZZ?33Z2TQH6&-(J+X
MY=['U/4*H9FLC3IS[VI^H-7 FKVA+_[,[QRF4WI:$!EZ<U,1?F.0\A;16.K5
MK=DN:32/-\FI,: *_;5M7LS.SFR>ECGV+.:Z6.BUV-AEQ@R-ZD9VK>P9W27*
M0@K7V[U UV-CJMBUURIJK<$"*0W$@IDB/PT8"BQW$P6#,R[A-Y3?%5B'@\(R
MJNNT@CCU?71I$YQ74<9K7VM W\A95/LJ^US9=FI)JVK4<'(J*&LU[X Y5"1C
M;$V?2M_2&0"V^G&$'?U\O8ZP&%@-SF!H?ASI:FT--C^6"54G1XQT4:V9BY5_
M3('LF[A13>O*ITKHR_7"I;67WT"%Q IJA8XV9I\Y'^"D8!)<*F9L<7\1&!*R
M@;K.AN^+!!8AC^&=>-[K"V@*W.ZN_,NF-NIA P9#ZX=V;?QYW&UU0NV1XN*W
MVP=P_+9KNO-XQ6:7=M3[Z$+\)L$XFDT=/\)BFM)]+2/4;/ZS>4@DV?!VSJZ:
M%3B#@*SAQ= @10_[DSAC"GRD(G04G)U&&[!D8C]4)FW*/G44IJQV(\P)]Q2I
M;='">8&(N]*,-<96MPQ*.!P:2'/#@O%)W>=04-U;B=S0P PD&K^E@)%^QFOT
MS=4(4;MLCJ?<D<[S.;6> (T6-FP:8V*7^+V5QG5G,7ZH*I>N)NT6X]NY/:V5
MC&2'W<4(Y(4XYG'R%<$08I6(29">CD^)T#8J@.KN!Q?-V"#,QK;G/N4*UMUJ
M^_IOD'7\4 FZ7SR1K#$-\C#<HK1X<@QR]Z/'$'0K" ):3;H/_)SZ3T6J>Q^B
M#!&H+1K:%AW&V'$3P:=\4!W_)>&?C3(D%>A:6PEA(JE&I@K:S-9.,9W?3N.W
M "1FR></!>CAOBCPU%DQMT>U6>#)@N:+2>>91H<8T,&E6\ ZL/;L<C(#)T?3
MMO.9>@2.> "T]MA07LJO\!8X/>X(:762&CRC,/@J&>P;<1?Z"B%.^@7 [B@/
MLV!,Q8L;9/E\(SW>6GY\WQ8\<$ML,3Q] OI]CNHW_H( Q0\BX==%%&+ 2?#"
MF(Z_A'T*[&GFS8$;F&:QNG'$?$ @F?>Q0O^!9^';P.Z+8ILKN,,4-]M*F1V)
M+9 _\;D#I6]/@/#MDA:+<6/"E+$K^NQ6-;.\6Z #<H5#_0YUS7I=X^(9IC%&
M+*]\R<J$J]-2=[Q'@&\+ ,.(L1<'%>A"G^43HR?2R-\]%P5Z"CR;=Z7>('=8
MU^&7.,J3AITTG0T^<_&%W: Y!$W5GVB@$P,!8Y#+%4P+DP?MW+&8D$5;V^QV
M';"<+V#9V5E'+!<GOQ;CUE>BI=X8=!*%-4Z'/A[W>/W4L>_J\U+!T3><[ T'
MNN4FFO=DWW;>V\__*^A4V/"@XSK=G>ZNAATOOM>=0JB?-^@I*!/*"HR2=_@^
MK$.LR-\@M1NTB"C"$U'XN)JZT$7-'7<8M[I$XSDU@M9&H;XZLW4][.>I7TUM
M'4U*6?D>E8)[(CU)A_YN1U\W0G$("BB\.F2W6BAQ24HS!&7FMC2E2+DL418_
MB*&"X$H%:H64^ZM43%C*"&P&-);[<91CHZ)$8/=)ULDR]OZ-"KAW$K1*(S;R
MUIQ+0512="-E@RC]",=GP FKWH2B\7:C9\ X8E%SH1' ].(:*$N<M6K*PP>Q
ME1)T+\VX715'-RU676!'C))@2-WS\K&(%'JE+Q'5C&/V]FRG)HFG6$&"Y\^W
M78Z SG/",T]+J1R!_-_G(-_19BW;3K.K7QS\<HLF5*J1M:QVOX7')M(/E*F&
MI8P(W5NL%BZ/2V:>UL4H#QM>H8(?=<40Y&Q48<J?6*+& ^J6CDJ-E8JJ6QJ;
M=MTW>=^RZ%@F?<ZSK7BP=15[V&\5:8#*3% ,9DK5,TV!&YY;QZ3X)IKFI)QU
MK@C)MA(<ZUNZ?8 *S&NH:^SFM96/W^F"Z9J)4GLD5 +M1ER;]7. )]/2_J3"
MO%++%P]%'^R51#P4;>+LL $(X2'Y_6B3IVF,6Q3M,;"28*245X\/23<QZ09!
M(W7#\U#T95@"-JQ]P3U^ 3>'A-F,\5K5/IHFJ;55?G_=V@UTR"O,!'DD[94I
MY"EC^48@=I64P'=/X?FI)2LDQZ9J%U%#,M2NR:& IDBJ$7(Y\X?2BRSUNI!$
M)=(JO,74 .B.XBB @5.1$$Y,\PNW<T ?+<,5$\7I4(9'C(WTAKG@<S0<Y$9P
MCR9\,!X7]VR41;B?FZM5BO9 3C4(VBSWH5$\Q'R+[Z#+$]T%FJR(/$GL?:_W
M5LU.X0;<YEYUW!2-YRRVIS@<463;.8O0OJ;AL#GTI*A+#8PC]?,9H2F>FK$"
M):1^)2BL:>I$<AABY,LC_Q&:[X,\=$8( 6IL/IR46^V>40W@6K':;8(\-W85
M+>$, S=NF((Z)$&X/7:UB_K'7N]*\^%4>W7B7M7U&U\PCF&1)[S898G,^\8$
M.'7/%>Z%E:DO9!5-DV93S/W1:1D_CUX8,T"EF)&LU^DA[7**S%/;,?-QC2M7
M:U 0*+U2MT@^8:\@#@N;A03">@%&M-M%J.=$:)\FU/NKF\;T:HT4_[[ OC =
M@V[@D "-WJ>D@:(%&\BE;L<YWOZP?;U-.]4YZ.RXE:9+A4!L%X47$A1F?>S1
M\$<;B[T[G7DJ)^:D!G6\&&%=A-Q(-V<+#>UA(>][EJHMBP+-4PDQ+Z6N3K8Z
M/\(_YQWGL=CY2U02[F]W=+EG%;:P:13M6HCN0D*93(NM*]WNL*!%8_Y"#TZ2
M?NQ/3+]+"Y_(IB4=R]RDMJ8[+-O:4Q W7<0';A[49EWF%#6=(85/89=W%$:]
M1FUMUSHN)*RJJ/H]B)#%UF@GZ$FGNY 0T\?SJK@I.F _?3,6O%$?(<YTO%*9
M.O6=<DCM:+K#+12-8CLHM^93N8&T$X>89#P5;XKB:,MT 0B+]ZJ& -.P^X^I
M._M')@1KA:&YLZ_=EH2ZWK(/J!CY;Z#4I[Z"J2)CD-P?8H3EPA.R6[B2S7($
M(203!891QX+_UD!9O )NQ9\HQ-19AY@6)[]F"S'-(7QPPY-;A[!>X,BK%3O4
MN)L: ?-%+O^%S8IT](&;:J-O'9L/L7.>6Y16TU906H&LP&/8.K;UHQU/C(6G
M,[WQ_RROHZM[*%&;+=<9<($KMR^1+FL)$8^0#%9N4DHMJH(Q/'Q83!B^MS[Y
MIM&;JXJ*W:)=*@X]M0N0^>N">O#D4]!ILLD[TUI[1@)9OCNX23(H7$"=!T6Y
M(;%R]H7:^UP,_AUUBYKCI71M_>A]?A!Z:]C3/M9I">H/O4PX(I#DU+^8$8W,
M+3P*=BG+39U3D:JF);,N/=Y67JZ:$5N+9%TKU6\%.?FZ9"@BW3^%078H1PN.
MM/MV&9?=A01I:NC7I*)SU$/WLYO>:'ISH9<0OC4;C,H:X*U1[<+0[BC6?6B/
M!R[_=R[2H/2E,&4?BFEA1.B?W2B#'.H-VX]%XN-_?/R ?O([^"]U:Z2VU:,@
MY6V,P_<"&*V][377E$90;/T@2K,DYZ^9\XC-+5%H24>+T]S*_K,2R-*\7SP?
M2*CZGIJ-9/VN"5 ,KAAPE;5]F7I)T&<=G0+S:)/&Y)L/!18ST^IRQ*=H30=$
M2:RN\Y1\!HN_R>*%^F-Z#%MI^AR2; VSP'Q165)K4-BE"M:%1(R=4) %+%[(
M'E3YY3!2FA7]&K*+7J>>\Q%@4-9<U!V#E)%:7-AKOEJ"<IS8M5I&N>R+1K@9
M#&*(A$F8B6_$3P7+X5(\J'[OS;R7] ,@"9>QE&/3 U5Y3=[W.+'J;ZP<PKB\
M/Y2\Y)INY&*,?,DTG19FG":EZ(>'A,O=;6.N?X6_D;7=FJ.CD8ULIC6ON&+1
M/1M3N<Q2P#!<V0G'B48;]0WB[+M2:\*-0>V1TRYYO! O_*>;:X3@:#3T/@$=
MMFX\T/FWKF-@N)@<)R"$TLPY&Z&NHVPETP[S\,#9Z.SS,-"5?[Q-:?V':F2=
MHY;5&747XK0_._[42-.SDOQ"M#W5[AI8'.B-<=&4?FT7G1;B>J=JQZW/407R
M%L^#<A3-I+(\"O[T7("VW0-+&&CH!8P-SCJH5M8^=!<2'Z E:\;>QV[%&$&/
MO-AJA\N945S;BK$]UU9^U34#.![B!T+GBP+T>JK$Y9^<OW?V,+C6JB2F[D)"
M"D2A]_6!T=G(^_[J&03^_';_[=NC5C'O[D(B!<R!#76-))PMI)"B5(._U45F
M[:+34Y[X>:OJRG-M#* 4Y8M%TU7\_J^@CV%JZ6=R&M24Z&T:O\)Q22?4R5SL
M1+"\Q^6,$V%27BM9PGAK1G>3K[62I&M>&DFL+L=,7W)+F&0<4!\QYP64887(
M6 %T2:<075*MAA*BD_X +TL"<DY7TH]H?G7T:)=<VUU(?(()IQ!-9PKH[&(F
MI(9 -4F3;2/60O+MRXSWJ#=4A3$#9D\=U-SJBY3*9#3KZEHOSHDT_KP7W8!D
M;4VEQG-NG@;7L8.LZK2R8S<J_LFH/+KM'KEN;5.#*AQ].-D\'3B**]8@4H?2
MJ)Y:_G7\I#9^TEW'3Q8G,F;SJ\XI+&IQ!JS3VB :S'A8J^LWBRK1QV0%BHAB
M>5_JL,:WMN:TU@3ARI@2T:V4]R=H-!-I<-HAIK+.C>(%O*4!?S9*(P0AFF4"
M+W08I?;Y]9DXF8$(0I6B+*P$)$;7XUP9-8%XC@G,UZKPT=FJOAB/<5^5XTR=
M*;DP8:UD.' I9.AQ1;3(' L-A#3)."O%D$H@@TAGR@[:9CZ@_%^$*S),++%C
M0IQD='[E8PIBO=!J4])2[5&,1Z7X6AH%+-28Q@":5IYP8K+ OG="HQK'@Y9I
M70MQA9:D1:,@'6ND,PH@3@S$#)99,*+62">TN(X?IU@LYZJB+]5W&)07F:KM
M9" ,78,Y: 4ET87NQ<D8TUTLE$,CY>#!H<)\H&J# BN44LKPIXW.IH&$T$B(
M!F56)5C3QBC*F=J55+V[&/\LTO'Z.]PLUW-X6?33&-@,ET?Y78JE_COLYL.6
M.6 6Y_!5F8TG")YQ18543;7%#PE6H6%-)17LJ#VB#VDEW8.(2B$K@<=YSAX2
MIX>.&L1&TR#;Y=[=78Q[]_*D0?@1YE>J\:6!-)?R02&ZV_T"+:1 ZWNN..NK
M\#=G5VCP1<0>4;E^M,.LHE^=\Q?8KTX=T*(T3HI^;J;JJ$0]9B-78YF269-R
M6TKXT\@6=4]HU]+/YGR>9]&=8[2QD#BSPI0X<!?7F<*-!%*C2U6QOCP89ZI$
ME;N3E>M,<?FQM#1D!T\Y#4EO>ERP0&]LRJ)L6%P3*+82-57,F,&=*X"6F*D)
MO.=)J5.X&<X3J*"]#O+;.$B$AOVI5-@_B(#KD!B_@!_Q5'HK@X\^W 7PIIH!
M%=.O'UFK^&]O,<YY+CFAP[2F9>V+A/KV,#7?O,@SR.H>G -M0W;<6TB2O9[\
MI*$S<'-USQ)1;C%.;+8&8=Z-X&_MHL)<WND9-A21Z2P:H&%)1Z8FP(NUB>8F
M1=@=FFL_6L96\^1$_ISF8_U>0H8#>:_?3:_,XG'U3=HA&_PN?W+2$>BXY-X%
M^L+#?IV=3^%X:N33ND[KY?-( =U5H+W)J: QKLLWM&N1%N,=> 1"MM&,+$Q!
MQ!)2K0<5F@ B7ZA><*'/:I/RW^A&!^,)8]NZJHVK#?OHHU5"7@7X Z,]&@>7
M(0:&IF&5 K,H%'%&D; OT4X>3K(L@'U=TKJY7XQOVH"FG(";DPI67%!Z9X&>
M,J8ID5(4H\L_*KXH+C)3M:XK?U="@-*WT859'<0P)Y'K .L[5NKDIH;'@-5+
M HE9EYIJW&?/@)(;-*DBHF1#66!S''3'#-%=@Q7]A4 TX)6T#OQP^$0>  ,B
M20FL8,YHZ.'9%,@2?A]:OZ52I)8)RL4X;32W/>:=\RA3U3"FJYJUN)6V+JJ;
MB^L@KK['K0I&5J='XGC,4.7,W$$0J>HRD5F1T?1)M.MV+<MB7#K1?1S>SZ*S
MVZ#J76?#A/H/]C>B3;WIWHOH:Y*/,V_B',?^BVD ?Z+P[>XZ?+NX+;00IUMC
M'+::J3:?4MW8!Y11!+!6^C,=B<4;K7#6U9,]U]O;7[VSMY#TS">3VYY.EU.!
MYT=6O%W!MOV%N'J>2#QX(H]A^8BX$$\.3=^YR:140%,C<H.;KC^@D3S]C)OC
MF4[L/9 9:)9?$* H JVU2^/<7XC'!Z@#9-TZOA-!PO6C+^^2;#UEGY/C.-U,
MC9/Z[L0]!>^<<2@8N517ESFJ'5^[YO[<1G(SA!YE<H^(&4412:,;X4*D&<',
M5.]PN98.$92S!^Q>1JDF&D3.1>> U'\7/98IE&*5_UG(%-B+QD 7&WUA=WMW
M8[#9,JY\X39X3Q[@MM<@]0*.^E.?7K#L[W24T@2BL=H3<3I3XZ71-9S99"R=
M![ CTUC>HP7*F236@HAH&/1U":7YA(^NW*==$MH)E+K&[DRUX8N9)C3 ?^?D
MN^%>(P;EN)RPHCZ!^?L5Z!%*?ZC^W+K#SD3IUR ,74(L!E(0L'$F"8 ;IF>Y
M2!12KH:D<[F=<( Q8^].CM!1A'6E!K/.[F>"O],]\'/Q(8N_!>9Y#/BH/9!F
M!%1'+,))9J[1D*6Z!S)>1>XK!4&J/^>^!@8=ZWB&2MH9E>J]E'M!I?,4E6&/
MKGN[MLU"'#-_T\PRJ[]9Q80YU8Q<JH;?V V &#X<P4UU+J'INJBZ5,R9WK%_
M8++ES'!U5\66517L+\1-<QZGZ12D4V.LKT-(?KKHHE74>>%^=Q>]7D/R$0)3
MR\RJR%<X G9:"W="H?28RY.>Z[P_[Q7I"'5Y,*F47_&1UL-5'DPI\8\3(W26
MK>-CF@U"%"B9648I=NV$F$JN0E,V3-$5U0RWP"<H^99=E;1@SR)("TAGSOCE
M6:A.0J;E*1AG/%'*TY%AJ+K$U+=,+5' '@(#@#.6,>@PG*V3<2YSR[AS(7Z'
M"_$;4.0TQ[@3]K%F<C6W(&LECO#!0CP)3)H+9K*G"&/0D^H)VBYR+<1G8$&,
MUTL]3*MD['4\>P/MVU<>E[(^9*M\2C6RU2*K89VM9UIX4]8%]?#R50T.E;W*
MFTG_8UVW_';$>8^V3$@HD2$U6:'.)48%5 ]TL>N A0*_22(UW.*V#J@CQHD8
M2OT4NJ/< H AY55 -=;H^D4)GM(NJ13%P@8$+JQB#!0-H]6!LPU?#2/&6Q_H
MH+&OE]Q:4;V47,P MC:"*"8<W(2_<85AN%48\_E9!QY2U2-TAYBK$E'.55\$
M5H9CF98@T,O=#NTRF@H!+$9IUQ9=B-.IC#%QQ?S[6*HZ;3S=4ZG20Z"H7B^5
M1EFE[KH\2C5?(S> G8U9?B@.Z1;M2=1#)@9CM=0N)YK8W3.,Y_NQLM,9J[.-
M#5 :D&NZ# ZHOT ))ZCHK++K;#PYCTW5^\/:H7G" 'S,K"8O<S$-=OY$4<J]
M=91R<8)I(77I3^Z>F8S+&3=BNP3]0L 0*T3 F7-ZRE4H%A!H>)3PQ<9IZ0HL
M)*OO LQF4.TBZ9S>-X8=P81.03+@J5.^W"UI,%,_6I;WU&]T"FHMIZ!]Y;IV
MN:4.%N([+*9\)29U %^%JE.S#OJ>IJ4H?J]=#?VS99(HQ)]B=6HN;]FZS.8N
MG'E%+D^:'&*FX*MGN8(JKJ</)SU2TZ;]6W5IQ=H>!Z4.%3_;"BCEK,;)E&M>
MD#,)+E+%6_2=[1T2F89DMX9HN:%+&9ZENC6L4@([237M>M271L@K>98&OE&W
M$?70K:EPF_*)N;H/&9FDZ!RK*2=G.C'L0(:5ZK \RL!3#2SA&@RN#%7":##J
MYTG*V:@]-8"6F4W/R:&JCRBW:UXO7)5W*3/G1H3U?1BFPRKD#OY '4>#H@^4
M:[5YXT9PY-0)O%(C$]5$\5IRWWL5%]%&9<&4J>"XI 8E3^V46C']=@YN.B(9
MF<ZEH8R&*"M0S1">]I<(NW6<LZ%+U?'>TJ@FFZJ0SL=<6^.ZB:C,6MX'<9Z2
M!8@_JE W>\3+4W?+^?D_O;9 /^HT\=$T5PP$2*7)3\Y_WX)IGI(0OHY'(OIO
ME[YP4YD$ [AS0Q1]FF;=7=/_/O_]Y'FN,B5^^0?E!RZ$QOT_GL:VKV75R.NU
M@;PZUL1"B-BZ\#?;'@;=&!0OV5RE9?#;L QE+G\!KJ]0KG-$SK&6+H'\XY>
MRZ**]K2K)FP&+2#Q1IFK%7:3I?_8\H;E#,JG%5J%80M6P>#-$8L_&QQ-623M
M*H;@[M$2_4F,0D;9C%3VEE-RBM*,*\UHT&XV:C0%5T@;QW(W E,1H9>KHDEC
MI[3'&KNAM!S5]]JTE/8E6M#D1#6&03^.O^JR6>S(2#'69JMHXH+Q'A *$;NU
MJWT<.46-4M>,R6.Y$'I%%V/3GW?;J3;SU$$G@?$E*F<T8^=JXF)VB*RB9HCP
M<OPD\V9X2K1%7;^)H?F%EBN%DQPI>$YN8/N4G>E1\IL';#&4#D*4V4\R 4DR
M]$(#I:*:\SC\)&]")B4F&L A\^7&.0&33"0E$#17)Q]0!W1XA(4;@QFM2 SM
MN2E-I>@)'IJNW]O./V&5L/@ZA%LRC9"G^DVK-C\5SQ")")P._6&X2;E?%"^9
M34#12-IHK+;D48CQV>=*%CL0J_ 77]#Q\2>*-^ZOXXV+D;7(CJT1_&>V\+:0
M5ZN>+72WIK4>*U'^^AC+QB-*44$/U[$%LFC[N$PVY12PK **/,8VHR RG;_G
M, 3,F$"!6O"/D1^%@-%G+'OJ6)H@?O<#)CX6B7Y4R-DN9^@9$X&5#I1;+N9K
M&R)M]2=;FEY] 3+:114EQ49H>(KPB:#D<.U*\-)R[:KY>B/=U*E%?#+7+A9J
M>2/8F27GIU727\,K"DE53*TA=[O"W%@&1:GC#5C/.%3^1G$O,8O,6NLQ/ 2[
MKM%%M8I*NQ;V,LY0RZ'C7^7Z9'<*.$/U[(7S7F^#H%2K5,R:3D<=O=!:FO%*
MXTD[M2U3W3:,V'Z<)VDN(E5-T"X2=;8[APO)= 439CZ,9-P9,@LH]P_(.$S$
MZ,6S"O[O_RGVSN[V@:DK[Y&3_CB,,5<2]S*E>1VSKH@?.0>L74D&APM)N;V,
MHRT-:K$P7+O#[7UGXY:$A@K+PBXJH#1:1N>%Y$T2G1.,@LV$;/=L0G>Y7!>.
M" ++XE>VC, +R?\" @=+@?7R0D1<2-+79;RE,ZP(C'XF&G:WCS8\)5F5TM+.
M-*W#A:1I?09[?RB>Z/U7,%P7&>XX!N53J-2?HOFM1D3[ITB @";(C4=E&!1>
M' 3@:AEE%Y)]]?E#;S;\!R0J@JIMG'ZCE!5U?K>14 NIGJS8&K/1;/M@IV@G
M.6T<M+)IY.$+EU=^SK.M>+!U%7M<H)76)_A-I[-XW*K8JOTHFFH@/!MVDJ)2
M] @;_W(9<8B>[<"W@*>5#[=04JT6+/"2(NE$5X"; GE\F':*:Q!"M"_1;^G;
MF.7LC;5*F?IYYA1]=G2K+@^G7C)0R;R]/76NJ7N6[G7%UXF,FE\S_"&\#-5G
MXXKMD\I!;4SD0.1AIFH2A.E':OFB2U,LZ+"A+#9@##2IJ9E)Y9TX&JSRE"EW
MW>+VXZJ?M/93ZL$5]C0W7^8L2F[H90X\S%0K+#Z]5.I$4P\R79O):V)/FRG3
M5'=:/*C&*V^L%3U]/%$'>*+BD7H<P\5Z<W()5EIJ?H3426/SKG9MV(54G-;7
M<=7FA8Z38$0=S%.)6T(5[V0(>8M_E\OD0ET11MXT70>\P3UW"E 'VR539$Y:
MS[)/]$V.->A*/IVCEJMB/_2IZ.(_W<^F30MXM!!O09V"#D29Y_;@";B *Q!#
M(Y 5[:+F;#;\'(0@^0A'-K!WWH@^6H=QD9';B[M,I&,,1JFB4V17S-:;RP(%
MCA\+*G>SXH24J(RH+VIT5 R'E:;H(&.T6@OH-QZXY;3J#04EBY@TZ:8-L9%Q
MUCP>2CK>:2*/>F;D?/;FG,9(1%H:H)=0(U6KPXRZ?>*@? QU\L#OI6Z)0$G9
M&JO7"HQ5^S\&$6WX>_00,N"P1G#@ [J(<1(4+T7#)3[Y/I /A+><!/<:$R>1
M6_*;T'X5A-B!PV%KB-9#<0=<%*0I(>S$8YT3JQ+5RU@0]E0VBDQ:-77[URI+
ME6@/QW1!@$+90#I89/30H2RC(2L[=O\RBG*0#QY$:RB"D<K4+8$9%Z-9H[#.
M'6\\6,<;%R?DGW(@SBG>ZVN.2',/0R5"5 F_VCZV%%41/A71<DGFZHY'8Y 3
MNE]2"='$:F];+"HIU2E=39D-?:!,ENMN<@'_IGK%!5&N)5+I(PX'!1J.0\ND
M1$;R@9Y9P6FW6^S0KV511\:!>F=1:T-:78%HCH8:0XK)HF-Z&'S%CL #7=US
M9Z@8:U3X^E*?=BD3"_&C*A%,?2=/#847X*O>WSYT-NK?UBZGP]%"7*U7)UN=
MY[7XPSOG:/"GVODY?^_L=SH'[:+L0ARR0)_SYY/V_%FT?7OY/W\_;!=M%^*2
MO<(@'G6SN\G['$_WLOC1VOKGB8==K <OO:-M4N&%"UNOZA!\37=#[/!P'_@Y
MPDVF<2@-XF=,H+PN':J15!\H>U#Z]5^&@887LG^V/1K<TY7 U:9OPDX5<&RZ
M!39NE@#U7.<W GQ.L]C[6ERD?LLCJU>L;P!8Z!5\'R;C$"I,%9X.-Z'JHI<,
M1:1 =TJ0+LX0>V%$"JH'3" 8*#EJ0$?1>@G:33A??1%HL9C?6>X273RG7:RV
M$%C_JSN12KZG4VF9U%!AS3*RP#;%2UT-V%/8M'&BTVE)M=*7U=17*R>UM)*+
MR^IJ?<):Q7WJ?3R^8F^H2I0-)]H!7" /@2))W7 R?C7!!&)6+\TIK1T=N]0S
MAB6&2TW>DY.*@:1D:YD)H&:0CEC]5LBR7^$:8$#:H[)PWAO"60BT$TVFAM)J
MUI>S0"NG=U*$V=W$N8]#M(YA\ZH%@-D_Q'FH#/J'(,519D$ZF-1V$GVJ'Z1Q
MME@+8263U7&":CC#"^H:[,DN,-?VA^WK;0=Y[5!QZ2Z&[!!:W"VU-VKJL)IQ
M)TKS>,T7< [3692A>N].U>MKT$C31PI>@?UR5)8WTN0>L^9:UE7ZZ(5+M:V=
MWOUC=KK;L-4-:S][VV/QB ASS,RD@-%@(*EE.)U,)8@QO:,(^\"N,2DZ)^(,
MBT]I:80&0\*'O46Y_@E-B@O,53O4+/<GNI5](2XX]W TLD,\Z1T0;XLP$PB>
M@0>N:CV"%*L^"I0R\^X*43&7GY 9R(,6]SDDB>$'/+<C-(7MR3$U**,3'9HB
MP&)TZ@)/EO>(6EES_&HQ4J6*W+98X=*O$RZO*5/*2(;"H7WH= H:5#H;,J)'
MA'%C088P# [9A)JT:3YDZ! I&6-6P<F-#1!)=:'P\)E:*C73PB=MY?9B SDS
MUJJX:)68?#M;:.HY8G+W43$Y9TSAF3+5DA4S"]<7D:G:2Z:QXN&5"F,YD26%
M:"BX#LQG(5CN,8"%>IAJ4!+(E,- RI,%JBC5XVQ!;I58W9-*!\P9@4F9;:%P
M5-L:6!Y,EWHIKX2PT@,)YL.'+8"/IZ1^.@;&=Y,T !D;F<@O0]DP\U>9@#/#
M89/D*=DP*&F#^SA#0X,$/\X!P5M!(;PC3[:>*PX&" &/\HS"5QTO/JX8F664
M*-!N0M:Q>\EK/"/%013^!Y,09UC?AWQ0TNB>)^$?%;C>"PC<1S"77EN9^Q.%
M@P[7X:#%'5,+R=NW#JN]5SJLK)W+*$<,>Z=%C97%]ABFFEV/IL'[IU4\"F^Q
MD0OJ4S@IR?+'SIL:T6JA&*!H+;0K[GU+UQ29/PFJQ*#=@THU4LZF34I.P7@8
MQ>XI6X)ST'0&FE.64T9F<B+1+.*X79K50DH@KC[=.#WOT>S49X:2MKN')I45
MCLM6IJZ^G2U:-SLUE>KQB!FO+ E4KVIZJ&LWE,PSE=5F-3TR&P,U!&X 3@N%
MK;Y)_2C8W9=@V%+45AJ5PB2\6C\JTZ7(J\/J0]"/M';$:B)M44R.8TNVUDJG
MGT ^16ARYZA7!9++[4J^ *TYHL:XI=3'6LUQ_"R=L:" %A[<&SU(2TJR?MH4
M:8R+TIJ"41*I:95"ZD<+D%V816[B1:]7^.CT^!\4> !>C&HU:Y((>%Y(S#(C
MI.]TGA1+8K<"M Y4+W*@E,#23RCF?\NF"4P<,YZ]3*>_:NL&M ,Z+\S4^]*+
M$>:$,2X,:4W'"] (X86VV+1.E-*4X:ZZRU3 CM3C\AW5WC38F<QW5!/Y/*7P
M<^%O,699G0C?+BA0,O0WOFT: WK*AM@0A;SC!NO$,:PTP6UJ^Y=VMZOW-:W5
M9+/1/'>UBV'J>Q-6J1D.FY<R&:5DX55'A]_%$8)4U [.R'%*UK/#2,HWIMQP
M6LZSOXP*G66[PBQO9XOSSRZAGT0^K:\UJ%;LLX[4 .^JFS^A,TT5<)./RGJ=
ME9&)>"4&^A6X/Y+#. N4Y"X<EF,U<KJ^^9@P+4-4MCL#QZ)ZB&8^UHS;0_&K
M#964]69J*6S'1=E23:0G@W&&*8D$J&EGV8_$5ZG\@78?+-="]DWLPRJSRE#-
MJ0.S)-@6E;&M94;S$RL/PFUD0& 8U[=EVL=B,BVXO4=3[CTA7.AV/=QCBS1B
MJX4/_(4:/#:N *W:X3:V(E0]*>D.DA^E']!LD"3-8K0J+0;'TIH<K&WRFJOM
MI'W%'C;U\'0;1(^**@A9V8XJ<PV):MQA^NH(7XPS,PL19E+'QQ,)M@MJ'0SH
MDX>9^B''PP7/E#"F1FEX(F&AR2A(53@:_I"&@4J>6V!IDAOW(@C1F0X#P(77
MH6NO*-9R;:L#QJY[HL'X4A5-]Z6IBRFWZM'"W*SAS UZ6L78BTESX01"+"76
MC'=6F)JSUR0BX,"FLW&"W'Q5)"6VKR[Q[4+J$J]1;M\OLN"]H_I3GUBJ!1VW
M9C.TC= +R>4 0N/I/V/-^_[VWH;/G*EO='IA&*NP9\L(MI *LFL$#R2D@ EK
M9%3U-QOY#K</@>>VGYKWJY.JN_-40&P.\A3*IJD=G;5_[A"C/5.A:JIS,T^U
MZF:+KEI%#-M6V72%SZ/VX)2/D=&99.A/Q;VLU#%V;!2U2^KU6FFW:XMP_-8
M;C 2HZQ%*\IMC\U*HBF-[IW)KL><@#PBK5/WZ4/WOO#*%40S6:,:*V#Z?>ON
M7W.'0X[6X9#%":FGPB'.=\BJ1^WJ:4EEN1=G[S=,#C4[PH$16DL1OSRQFBR3
MG\ZT>7BB\7$A"776HE5=7+2LP5U.5<2/.W&;^AC/,,4B8/*T#X/E:YQ*V_6#
M+])IC_:C4P4/J WX-FD:W9V%1#WJ5KK16K8XQ,IIML]-PRSF5 CE$%:A^ $X
M6]V@,\\HIF9E5 RF8O)3[3GI-#0LYTYW/77+/B;N@42\0FEIQ40:4E:L%KG*
M4:L;&Q295@4)2A,$RY2K??N(])=QTR)\2BI&V&4S8F.W5:SUPL&?@JGF ]T[
MQ5K<%#6O"5JV0>S/*"KKHKAV;6!3DA&[^,?T*FYCC%4!"K-2!7]GD(Q4T)QR
M1,:$,E3O]J+8SW6LSCRJLLS^E>(O6%2(L8B("Y-3=&U,]_3E$9<'.@-H"_QD
MXS^S$X6!3/2[$EP0=ES2\$U[K7H]MB2Y=4L/88L$::TI/WQ#;@^WT;G[0)$T
M D<QP3/K\E+CZ_(/<3)&(OK83ZWTPUCZ,%78Z94"[^+&JB C5YYU3:O,R^[.
M0HK[FKLKSF1BOMW>0]/\D9Z FZWRPG5W%N)>?HP"*TK'V;R9SZ%@8;$V:A\:
ML,.J>.;.@^96/AA06V  IEIA;8YV2RDN15+2(I1"(I.L&TQ"Q0!D0)BL1F>V
MD.X+E>'L\@2> 6HW_ OJMH*RJ+/!BVZ,Y,K&U!U8!D]E[QOSVYJ9>?.CL=]2
M[OTHB'+E5$>B8'(V.LIM='QXUO@.&8^/'TF3C9-G1)VK >RGCNIV2=L%N9FM
M%ABSVGZJ7P8".UD'N,I]#A)],1[9]I'>+G(NR)E<X%?=/X&R5'+$>QJRK*@2
M/C$1L':YE;L["W(K4SK@3!&/@G8[VV^=C1Z(-MCQ^+B6D:JS$ BPIK[5S20K
M3O4NGNJ-[99;1KV%I/\V3W]&Q6BI2+@@Q\R]3.C84%DLLT9_CG18MU?8HJ>J
M? _!XU4ZBX5WWC(ML[,0X)CK>")"4/]PWO6','79F&J>@/TV:AJ=8,%T8T,.
MDZ*H[/2^' 81Q6GL&DN. 6'=M]4P_<:X3NO[ 1MCF])2OXV#A!_+OC94$K*B
M"Y/& _'Q>XXFT=!@#>Z<C<[.SVD^UC1#;D.?FUXX6J\L'E>720<E@M_E3TXZ
M0HPT#'%D=S__"$_[%4&9(CB7$W(4JY'XE,(U:)XMN1%J)US.M,*P5*G\BBA0
MJA\-18KCWJ)?[!8HRN."V-:)@>.K?6?%Y6/>KG-1V6/RQ(LMY7C:K57$PIZ<
M]+I::-[PV-MU>&QQLGDA_J@;JD/\L7?J7 C0RY/9SKH#A:K>\U'<*/T, >NQ
M1A73W3^&<9^$#%4Y8I83IE.W3'E8B&OJAM"$IX5+(^P4XX],"R-=!NL':#9@
MM1(EB)L.2\UPT6@W[!>[9N.$GC#,@Y1:C$PW*=K<+)P;"OMZZJ+M%SRQ],+B
MJ=4JCGA.RB"V<7ITM_#E;[</,#>H5=-=B,\%9IUC!O:,:9'/3._#'$KT*K2,
MH@MQNQ!%.9''J#8+RICD;BWMHNE"_#&*I@B#XA&>WP)Y]+Y=!.TNQ&MS(X>)
M'$YW!FJ.&Y]^XW/)J6GX1K@&\J'N)Y>JW_3;Z,PZ_38.XX 3[*W(0I%):&,/
MD(;_['=7,AC,L6D/H>G-['V_B$/@O5"YE$L>^;12P$@Q<(%=+E1U@U75[ +G
MHM;%41,[+?(,='LJ:,CY]$:DL8GR'_)XN#YFAN%@,9:@I(L S3&K G-JSMJ4
M?"G*LK^=BPX1721%*J !&8JQ,=2>6G@[-"2CE&/V1>$J-S?629=MZ\<(V^<[
MU1%6,FE>3PWU#YC=<WQW#;-KU;R>XT.;GA=NL/;-[3DVZ++,;3'F((C7<.)\
M?D!-X@.&K,F+X)Q=+00XNV,ZF7+GK^*-UOEPU3)]9"&%6C=Y_S?4->:(MG6W
M.\[&1T8*;1F)%F.IV21R*,PX>P&;X)#NQD'+*+48"ZR(\S?@8A;MRBC/]N$.
M]$(K+=!JZ6[E%.CD1<RC4<]7>)'<B\#C)G%T605;0S5%P<?K.\IMJP65T*I@
M.U?LNU;'%4Q\*7>1,UW#4A99#8#>[<ISZ#['.%P")6)W(3;:K?3N(@87+GK;
MA>+E_3/\W2XW=YYZ9[LDQNY"PO UL<[&L'&'6V"WC"P+":WKT'<17&]N80,B
MLYST7/4AZ"QQ6_ AE;/B)=103# $D$7Q7<L[7NT^?ARC71U@(MXFI6T7MQV4
MKRY:-^)]*M9Q+46*I;*NL2N5M2SO%>R7#0^A 5"L\7-+0;3L$X(21TE=-LO7
M<<DYXY+=G75<<G&"8B$Y(Z9.I%[?HK1=NY:,FU<98.^'. G;54.V^US3V9DE
M7RF0#_5E.\O=F+V[.Y=1/H.N0F2UE/5&?#S57*0H&\(S2=&*"K*GTX-1V%-/
MX>G?VT74A1C<M@74"['V<$&AO_WM?4+VN(PS;,N,Z/+F=2W+3]Q=B-UN4_H8
MFV!6DC:> ^RJ,9#NP?13E<RJ/,)^FR]'\#4VX*/7VF4<7J;[[069*JXH]0S5
MP$Q>0@T(J"#9"^Z#D*O0'&UA8G@'NP#:N$<M6]07;C5O$QA3-:B9^52$MRC&
M*;D:T&@')==#=+^TVL\"@U-*9'%IXB,5B79-BOB*_H @XW[JT^6'O+R^'JM,
MZTH4N=4] _1Z0.5X1#UIL,N\'R.Z1YPY)Z 4A_'8M>J+96GE2P68LL8FH('H
MQQ'B&UZ3CV'NZ 49Z01FUTDX"Y6Z#B-</.AHULN*V8\5\ L,>V;:V>>$OE]7
MZNO5(=#,<GAM0"AX6++?+@9?2,3=9MN;_'%7XW><#/W2R8 O:I?TV%N,9R<1
M*)N3KXWJ<H97.)$@=-4P'L;41A5;SSBA>."?\0&J%8-,[I&$](U;_#KU8[DS
MJW4>X.EA=YM5%<H:A;9]"OK>0OQ I18&S^]K_V7[9KLQ@[#2)@'T(1"90'BC
MAV;*F%+&DB7KXC25J>J46P9>.";>>*"N8OC,JUPF(!*O R\V?4!P5,X_ K1>
MG;,T1-6@74LZFP]K]E48 Z=+,7+.E;/>N&T:#VNMUG!G0>WDX7X^I9/<]E2Q
M8XM,B2#:,G$ W=Z^6+^_1?'#UJ?XH4!N>33Y0\,<<'MFW1CE[(KAJ_,$V$&F
MTSXIFS7HH&^F0TI(GO X9)JGQ;ASX]U)/P<]@U9+4='9,$DDU3=9V KFE9N.
MU)<+XP X-;#A)Y@EM(%UL:BVS+S6C4-H6O26'3,+\<I\N7%.P% 04VGBS/!E
M0:2N=%6)QL,@#T$13!+=7I,DR$V[J+:0'/M_P(!\MM0:HH=D3@%-?E*>;X<Z
MH+.C(8^XK,77933U*-"I",P5H&Z2/MR7U+CM/OZ*2.:6CGN'\'?P8$PG\R25
MVI 5=D\C1:Q<4,:\0/?"H-<E62%ERO@[IF&J1WE=.((R:E0>@2H )XE^D?ZL
M&M@I!SF5;0DLG-( ]701&QNE*8D^? 5*O:^ =(%X-$%'^$47I+XT$[*G7IZU
MQDU1/>>MYR4E.\3T^1#.6$8D";D;O*WDL'S%D=(HP5I@K]LPQK(CP3W<_.(J
M,Q\/4_A!:ON<)^DGX@&H-D S&>RG1/[&B+,X03WS::+H<2'E1G$BV1HA#R(:
M@N7B-RF2,,""M7$2,#8#%HK5>="4+SV E0X\8&;5G$#[&1D[AP%\%!M[DFQ1
M7@+A6-R/G)50?*0HE#.-YO(^W([9A=2>#W[4Q5AT)T,/BR'63TX]MA1A(<W3
MZE50[J&JGI;W4RS(CM ^I95OF>+RG%RDA8:U_T3!HLXZ6#0G8]=Q\<^"C,U?
MWO2Z\.$_MK9ZD7<7)UM;\"KQZYS!Y=E]_+RF]R()!.XRJCG:\L08UT!YFT@#
M5VG':JG;EA[;W9X="W.>^$>) F"OO2/L\1BX01/".=%)TM*QK\:X-VMR.E^(
M);+"$"07@WT]2N$2:&!M7K[VD<V0BEZ7Y50RFH3SD.#A'X'J4HQC'&+H!M\Q
MJ[96I5%%92,'"#4.**;QS,?;,J',C\:DH*:3A%\NRO3%D5&?),O<>GK]C;F%
MJ8[J71O5QVXJP&$T^=3DL&U"4AW"U!+;)$'X12\8BT(9LUMS@#$6P),* JBJ
M0]VDAEO08)E **O HQ9RI=8BRG<+=3N.K_Q+7_6J54D:H %RKU/_GFHH=;O0
MRQ/=48GR0>@1=;RO()I8XT">U,TW]8)56NJ,U5[3;/_$].?BVMHG5#9WP54Z
M\]/*BN&0,)C>H!E.G!I1642(779-,!'0&2@=U>6$&N"AWERW+IKXR-)_O3E6
M]R<4O+9\&HJJ*L9@.L_H^!%R#S>I49Y^WS0'A='Z[(10ZS"U892X>918CQ76
M[E&"-0&DX$R#/K ),D0]21NOIJF54N7P4G_3KME5YM?6!;7\ )H3LA?[BJP^
M'(0*AIR@.HJA"\>&PGQ!HL"FB]3,#"#9&'G#:JA>QS=:R..:$P0M+7AI]YAE
M+B@PO=[;3B^:Z#GZ+S8SU;L7^XY9S>:HKQ5UGB$+"@>)?]B"B$^DFF6<7CT]
M0CC]+9L1#- 6P;]TM^=1RJ;_?5)$:?\9T +EQ__/WKLWMXUD>X+_;\1^!VS/
MQ ZY >M:EI_MF(Y0V:X>WZF';[EJ.B8V]@^(!"6T28 7 "6K/_V>5V:>3"1
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MRMF>7Q4R)OR;PKNHY9N]-/_H;&WO*=!8@NCA-"?2 B8',MBW>2^E&[>\5B]
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MW\B(=A/_UM;T:=#K!5.J\+Z>1;7E@A5*#6)+!Q%@E'Y7U 4EP\&KX2M\"N@
M>'YX-G3RM9B-O#.\ N(S@GUZ)A$\^33GAHASI76]E7H.?J<-W1ZIS'%-4V^L
M,H-8[=ODERKYB 8__,J/WATAQ9;'@Q6)=PC/-&HL*=P5%FT*KGKAB[\F&+OT
M$F!6'5N<6L!S@TV#:#LUH&:YK&9FPZ,\XF'DLPM#W];T-4V0S,VS&#S86\TF
MA?K=?$R\U<,8&LHSU^S%4O(P-I ;OO3EL7W[,?;U(/:"_5F\&9E%_\UU,#S5
M.,$N$'P10?:!Y1PMH#8QZY?4E"N96#8,MP)A<YOI$69Z,"D #\V_HBM08#S
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M50/HBS"$.92-H:)$JC%:< NNM'<(4NI%&"MK5< HV@YNPU1E=8!>"=NKFC_
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M99C<N*>F=Q'?(@^)/!Q<,!PL6[7-YOP\)U@VJ.*6"QO=.Y=%1C#,ZV[!;*4
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MB?HZBA?&+"C=?+K ? ;H ?T98S,Z'$5H[T6-O  4-&AH&+HTFIFD-KG[B7V
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M\$07TI\Q0@OY&HS+#/L;@]5(AK<&&GE<&R+373Y]BVT^1#=(,5SR-1G/1<<
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M]C9YQ_$NQ*I7Q/[*]$R%['3O>VB; C3"CHZ']39HJUQAC+)6&*"B##6UJT-
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M0 "IQO9Q][E:PWF6U%LW[;3,S[,E<8*#)9;&<E=<MDE=8_'';97K@1:L*8_
M(L9]",[Q:K,\S]JHD_9'24"9SRVE?MQ2T6,LE2BRK!9BU4F&F)0QFY9()NF^
M:(DK)<'X3_A#,Q??O=-?8H+A(.R/,#:WK(9HR6>#!//T$"FZR[L5]H/HFG'H
M:GF7*U0RGM)D'F0)*!%13A4K_DL-G:EE))9@#Z:Z7$8RR<Z%!CD7LA)JV(LE
MORX_2:>YMR_C#O4#WBM"7 /:O7H52M"'3]KJ"69I@I(IU2,Q]:N2:H_2V!K
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M>NR<V2O<S>8#C2?43Z_]0U0]%4&96),P!Q9L+]ID&]Q%MXL3N4E3*7WU]D.
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MJSL]<R865$!9Y\7J#&FT^63;*"B&KO*RL:K.?&M9-51=B9%^L.R+%?YQGJW
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M1S03ABCRY]MO-D:;:#6L"Q^(E746YI]ALD-YB*EN <6I&!#9^2 \*'($J!;
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M0E,P>"#P3;8PM@QC4QGYU0RMH? 3$3,1_@CN22(-?$;4@G9%5<DA?7_C(K^
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M/ ^@F,'7$4(ZZ9OI2NVBPMLNRE&:H64'RZ%>'=3]M^N=599"*BW67 L239H
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M&A:#N07MHS +=/_!@?(Q'%V=7-AI&.0 $X_4D/NT7*)3F:_O'DU]TH_HG$[
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M<H.UE1C<@?!%DI/ZYR(=IIN7YU$0TQ4!&_FN*&+44@B\77=FA!LL'[('GW%
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MK[UEPNSY4\+LW@+D]\S9R0F40ZK]]MNVX*"-N2B\H2N2;OVE33ULAX!AL86
M2.9UZ5 TD-ME^-+!?L<UO<_+J7$AWA?%UR;L/O@Z4[5#96$'0C?&3?>1E,E/
MB4GG:$]>F!MH=M:_\&OJN<_'*V'\WBF$A;+Q^KO(1@!2X<L(PO0(FOI("CP(
M,8L7&: ;J4H%?Q\3_S5>(G OF7V;\<9"DP!1KP/:BP87=EM7T76.N40B9N;=
M"G>JEGN#GVE?E6I0 TEQ#40C#K$%4$^K-+$IT:<B(BO4[:POT0:,S]S1&-U:
M-5:W<(M\7A1"7_;\,5V..W.H%,'3+,8>.598UX-[SYL=J^8BZ0'FCMX86:X
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M@,$)-I2X&]'(2X>V/4(O0-TFF'" N>E0*.R"=@/0AMD6V@NQ+MF507+=AW_
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MQ<S?'F#O&:7E1V^?;3^'+'4^'R6#&<6)Y8L*]\-^>9=U'_Y1S/RW !J"B25
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M@0#^A?4>2:Y =,76P"X$.:!D*<?V.O":["3E@/:39V))J\$$BN01;"YC+-*
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M/L;FR;?W6PE$D5#LEK4-R@^$E?88*X#N-5!5KRB)(B29KMX9Y0CY'@5->A[
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M!)',KKO-@+/MY9(::@(A!B-X$'/IP6:6Y]7.B@?U*"E7'!1<(=S+5%LZV]F
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MQT\[+\R*TM__XZ<7.V9UR\%__)1-C"Z ==G9_GUZ44_RV1%]"Z3OR["B25;
M&]_N&S<^^&\W/CNV!\5K;2[?7 W"]5YNN:/SSM[YV<]WJ@3O8:!&_05548M2
MK=\V@)]^^>T*>O^BHV1NG@"X:2>7V_O;4$AVE5863.Y3.LR2>]LOG'-6_N?
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M/-JQ5",L6?-><+LT"+\@[Q?Y14%"GFY9QV@8A)80Q')./::7 ,NV8Z8&=22
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MFD>)X59"J^8<$&AE\C;RXHJ(I61L:"S!16WC"UC7,<Y&Z18,%. >X*?&TH*
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MR8\S,HB:M!K,*\4AQP;/J?ER=( *Q7&/":?-J'ZN,)K("]7)<]#SIRD4=X
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MR?9OX$?7\W^^@:&3J+7YP^I#J#?-Y_PO4$L#!!0    ( ,B 95A\EW5#91@
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M-![/@BB:#.?A9#+K1Z/Q;+@7L3C<NUCTK0U_HWSE O&M85]QC7Q!>]OC9N1
M)?Y=2$7N(Y 78HVHA .SZAP$&7)3I_:$$4G*$*L#'SC@&9@H"9O5.H</B#G0
MR C#3$7 _(+8N;0R1B#0DNS&-$LB ;DQ9I[;ZE;&I4G P.\R"3L@*D$JZEL1
MT9)?UZ0K-:[<5HAA2G5QYN A")LZ.F0W69$0N'R[6BL>YD8R'U56;"G,2XIO
M$\D1@$B#DIA@JD9W!-YBY"!-"@CFRT)>Z0(W()$N^,+TL@)AG:51$=+ *^LP
MY&1%PC7X.5<2[$>S$<R<:9@D4-$<QVO>MB!"M@\(;H:/J%3I;@#2I1(H']<$
M?]'OZ%"KF[O=:<[R184+TDK)W"I8]1"W@-.6%2JXD; *:"0O4*DK) ,9!AM'
MN%+%&:\G_'B=)46:PQ 02-!.01TO5NLDVY3DL>ISD661Y0JG0>''J#"]N+N
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M3SWNY O8,TB2ULWQ:TJ5+)>X--H["0(67A"L:-T!7S]!<'NT$H02_DI3H-I
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MX?O3\+ Y #P& C89G>)!A"BS3<"PZ/Z[ "[$1)HJXR5WYWF8DR),:,YXO *
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M?6Q*UHM24+++[C_96Y +)&,#DJ]O,$UCT.N^,3,JM]:7L9&V=U!SN[BM9LV
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MI82[]OQ'] ;2!_OB[/\'4$L#!!0    ( ,B 95A'E=^O6"0! (&> P *
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M:5=F4.EF>Z&1+.N51[P51K)>A@+HF?V#KCG*[O%,O+L^]=]C(?,(I]AE?Y&
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MXEMPCQEJZ/YUJ '2V#1!=\V *=2AAMG0L3,*P5;KP=+(<UTA30U9M6O9B_8
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M4G;0J1F<LGLEH!Q,;L&,ZU%M=(4^7+-I/(,'^C63J3IG8DWQYCZQ$-P'$J.
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M(VR6VJZCJV(I,!;,LV\DM,O#72QNI%J:T[1S.,U1HQ;B0[?TSH^B2QG6SC"
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M>XLJJMU+L8P3\RX(<FPDG>;/UI^DACX[/-2B_?QF?__4EM!MTTK50=!%T-2
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MR[RNAGC7!.2$%P'HB2, -_P3D%5I_BN3!&!9$W!V9>AGGTR>]5^<6]T%QDX
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MQC_3:2JVJI.F0MHA>.(J 1ZVAC%[$:NAQL/-K4F<-S:@0#QMO5G#KA7 F7]
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M0BYK K98N"P!H%2[F3](_(W Z)\V=%_G*3; TA& TIKWN[6K:O0HEG=+<Q*
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M0J05VQWWIC^(RO0^^M@@)VB_%AC'[)>+TJM.1(SLL+02*<WB/TY1P82/KG?
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M"JGBK=V%7OO^@; FN>L7@[*^A*VG$*S:3OKV\,4+:WGW9/$AQHDQR_YF</@
MZFG!G-)+%D(\G?GZF=MX<A.D][Y4N;(=DK4TIRSB+%#58#EG'GP#,.(F#,.S
M,V>33P-?2</;!D@2C ;*G)'.H&;R05P&>][L5#\1%4F5$7::Q) V;$*<F@:3
M\JT4/#%Y/*R@^$FG)J* ;XAB)7#YCB/30G.1H7+S:-/2Z;11I0],056(Y_G]
MWLC%\<[BRIUA.JQ2^&(K[<#34L;@(D/%N,A0?.DZ'O1  ])U"-R*/:/-6IN
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M_4;#Z'PPU;&D5W>JG3E2VRTI!KFMDF'LS-8Y.N\-^KA=_*)D)L7HL7(&J^_
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M=>[6A'#R.Q.96&%/QN==W, %A$GH2/ATH35,B^Z)9PYOE>\A%Q7$DEAB:0L
MH%!2%"%?$C[?GW6F7C5?@+%<U%MBDJ/X*Z2_R8Y=[MC62;>\6V%E]67!0G?.
M71A[+]<OSAB7H+H-T#/@"]/5)B6Y"AN&/,T1TUZ-C*E,_^)G\0=8922NN@_[
MJTC:B/29F5''/-=9&HTQ?I<?OH3].OW>SG7Z:#63@MS-214:=@;EER(!Y<G[
MBCR^G6[E=RYGKM_GS2K2O2X!!,8^)QOL;75A]7/_J.PNS?J>I9HN4^C0AP]F
M$@Q$O)WZ,8?TX/YGEV3"!WBICQS?''7)[R\DF9NPT,=OUD\K!%&,K:Q2K?OM
M?[',(6QT7\Q=G6 )>A6[G)DS(M)Q[3H:#[@(E=NK_(N?KE-J!#6[\7*"E-K2
MK*Z9\TZB;/7NG:H1Q!? 7X\6I$<RI&"DSC,]BT=Q4]'7F1$JPR0)()>#70_T
M3^]-^L:29:(&J&)Y/44_<*I<>)LKSOUD@BX9!"87%4#$?<=: R95[Z&9XUG?
MWT8V;A0/*GXB"NK4<AUM:70CO_OJ);S 8[U-.,) 246'1AF\#1AM?OU-\&4Z
MR1D] ].T:EN4G2%E1DW$<&V*0Q\DIDJ<J/=W-CTP':9N3W%,H)I#G+X1Z/75
M?C>>1=\^].#(>.;%>WVFCW7ZN#V#(.:]FT%3&M=E">;5-21Q<69V,G^_/L]
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M=BM, W@]36#Y_@TTU+92R/&!9;4YO*/UPKODVVR'" '#$H/I@C!EK#<<\[A
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MG"\X2<R:*!*D43<2FF30P1^F\.[ELJG5<=E%TL9%4<XN[$X O"H>&6GNG+_
M\+%((5;8XX.[FU@>2"WUC]!!E!9$QW,>W<WU%7BE51"4I,BP?@ P=^TL^>U6
MIRR#NR(^)VVJLXC,(S&( $2Q-:UM^9-DOI(X6WK.^1#ZRX[:>>RQ8H-F6R40
M28#V."-U\Z*&:#;=*--\C]:+C451() >+WHIXP<Y!L\!\@,=AAG3[U#='D1Y
M5PBB/4D$NLN6!A> #?#SA(9J-BW+IG!65\IT+6 T4:6C=:4@/1+VV;*LJTN
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M;]BMJ2<RCF*$-OE56I8>#SD>#'TN93:X7V:QS\V527M<_%C2WAV:5DKQ0,&
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M#$U['.M(4]>9$IC[Y%.D$DE(:@2<#E6<UK^<GG9!,!.A^P<N?OC\9FVO"$X
M8'QTUK-Y'$-[4E!83BHWY9D;GSY 5A@?N,N:WI*B%7R/GCA)'J]4:!(3[O:^
MY79$VQE>;CZX"'(6#/VE]Z]K\_V-:"EEJ/*2#(?3V5ATG;R;O03:O10/]^BD
MU&_>%>7&U<PHF;UX=351^('ET&3WZWT55TP*, /=_T*C\G+Q.+R_?N0!G6C,
MZ6 )182>NZ@(_=4+"@-A;4\T;GN?F,+MA/N;]],ZCUTRGENYG_G<]))]I[,M
MV$>8,7!;O>'? R;W+C8%QE<31D\&KUZ.+)N1>_MB?8I-B48DEV;*' 7G;1K1
M]/&:M^EQD/Q<ZB>#WHGR??3^&'MKH*)U@U"937S"L VJ?UF*]DH\>EV]\*X5
M/3M_/<'YTBUK*5H'9$HZUX:&P2K%+J#>"MM2O,6*[[D+\,4IO%M03-0N8&[V
MPOJG5P,QKAW"&9X$'[V6-.FKCME-\8&S90'.S&AE"SX9&S)<H UA5DL36Q&P
MD\G"ML,YTD][W%=DVWQ63"7=:(?%;;7+DTC##Y\OE>4%&S'8?ZSDNOG85I0D
MLG4*2Q0BMTB!,'S>G*OP]*D"U#F<GE0*CW)@<P7)C]?]%>3^;V*2Z,4'N2GN
M54T2&>]535Z$AUSC"YSL&O8*CG5&B@XRPAG;<N"QO6[K!-)45(,]*RNT#W8!
M:NRUG+],Z/F.%;$;5KJ0O5I+^7A?-D_E%>2.>T6/7?\*0QP)\:W.G,U5Y>LT
M['??:=\D1'IR\RIN 91=.9\E5;XQM=&^[H2JAYSRU ]1L]ETQYG41_]E%Y'_
MUD[$^/&+^9@ BJ^MO>6N08Z['!Y07O?CK]^G6QB7%07W]5W!O3TY1?GF:HH9
M''-MI,!>C#RL4ZB3D4_,D'WH;NV]K;#X/P$/IH9(+2R^Q&LX%#E2GI73OB4R
M&W<221^[M9J1U:B<U6G8:VQ&!O \*0O($WVP"KJMD9)P[,/@=)[.7ZY<U^['
M *0X$R);]>@39]B^D.%5FD%)[SH/NE_L$P'4Y=M%6L80B@?OV-7/L;>,!8V&
M)891T9W4T*!D#$X(6.]#NMF-5)5FNZMU7Z90#>JD1;K=M76OPVK3HEGQFPZR
MN>P=6-J9<WJF3A<X>?,R3@EECR&34U@DL5\F(K^X218JB"N/?[QO[(74<V0B
M;AU^YREQX.F0.-7T>7U$-XT0 0LO'6?$AU_.CE<_#:)>8ILMN_B(<!*LQ*UK
ME'3WC-1V\_(Y4G"TRY8FTW=;1W*T>599FR3##B+(K-\]4G>)H\&CA-32)2#Z
MDR0#M_Q.IGU@EL(I1"+KR$U)*-B%),8X1:"_[;CK;[H^?L$]V*E\40O?/>H7
MNVD_\>NW_EI>T^$2L^%?L'2(YI?\[\M:=@'+-6K:8O:6"O.0UA']O:90<(WL
MG@%%"[OSLOS&IX,0F*TN 93+O*\93"O:U2M/MC[@KJ1)ZRI]8CF<P'E\-:;/
M8:7;B<C_GFUZ1<4ZU9Q+B*$4^=0_@V4!:3NVC=OR,J4Y9S=#F)7',^:,:ME;
MMS]I^.[A31K)3^>P%:/LV]:9'_R5+M5P?TA?9L7@D3__EA4.J6Q,%/(;\WJK
MP7VSXG;@A] 3F'I+E?*W$ ?'>!(N\72=F>97W-G5!98@'B-QO T^AL^>$IQ[
M&U:R/7HSP:U10D )@!=;0TABF]H*YAYZ@9$@+#&K?@YS'S6;M/@D>]'W3I[U
M^7%D)_/Y$!= ]2$:KDW[*MX'D[7G">]Y:XA0!(#*)_B2C\^"Z<#QZ/GUUK;Q
M'%,AB9SD1ZB:+DMY"2SN8.*<])ZO.BCT;_'54LM?;"_XK/B27K^2#9]EE"8G
M*O!!1+ASPHF#;[L@2=T[,;JU&26=>X%,>//F3=U%&LWE=9A,!K3"T> ^NC1C
M:DU1\B$T6BR?X2]<H' 1NN/0ML>3 V\MT8G6F#4^J5)]_7#LP?;I=0E@80*I
MY,:S#R=73_#W]&9:"C7P6FM[?JK]N(!M7\^XDA0'X;2\7/ R7XG]N6,-KV*]
M^!W[;P9>5'A0^X)P>VR_K_JM<,4I0 )0F@#.QR&XJ,B1OJXFP%%;+JW?'8D>
M*_%XF&Y;IV5#7$@%CM7REI #8,P2T:U/[K9=LW5L=&7<F2N8QC9L0R7+/*U4
M"25@OO;LRH/@E_B6-6YM#Z:GBX4Q;*;BH$1%&B93C;O<C)%>=Y:GI.JV CIP
MX0"=S,A\I&U2;TF>E2< Z.(P%@J9KKVE=R%S9$=&)MJH7SL0:=X^5E.UUB**
M=A9?G ;#57]IG"Y%3RQKZ1Q=F>7LL:D*>FDF^">G2K-7(.Y!Y25(I[CW13A5
MQV)VNB@R=]3R"A5^:'J^-3 LWB9LXXL.*_[@+QZ<P&4;*,FJ0+S2\YL0D*OE
M>/M-X#RBL[#2&+1P"O5O:MDW 2M<A,XW@+G*M]7\C7A]QBHNN;UVL;SK,IEO
M;M=_%_]EI_CEM$<?PF4MQJ5V+L>@] P9D>^!P5*7BEBQ5(5!?[[ZD!HJ=-R'
MD7Y#[ GT(MA'%F#-@$XKG^':!80/[<3>+MFP29&-RB[V'KEN3'+:7"6!-N2F
M(OFTO2K0[Q&U9.+;3(H\V\]X1"49JN%\GI4^M:\_""QDR877M-<%3 VGLI_V
M)E65M=F:]+3@(G_7T=#7?SZ"YORX$(N$/[BT $FY($4-)LK:IO!%.<EG*2[S
M87H'"C#)V$VB7<!LAO??->+YMQ#GHQ0.$_P6R4LSWN[7B04%S76#E@)C+MSE
MYID3VP7DN,_ZIU+ (QX)=8+U!(U>-@JQX/<8?YR2\-7\%J1>;:]9JLNL"9P?
M8_L0&*XB=1R@T\G?F [>O':-:8#)5G$[12Q3PF]S%OP\R9E"J3/S<MVV/;(D
M=8FD]'RRS) $+X\./4U;8IM]KL_9W$9,9T/B0EQE7&4"!LUK=M^3R?N$Q6LM
MB]%@UN?S28_(Y3V\DW!GN;8$G??,U?*>A>2)[/9A:9JK-7QAJU.V$JD!7[ ,
MX#Z.SIX;^:H)_4R,_BXK^(EWW?EZ--]];?3EHO(,P_C\5N-[TX_Y?<M%6J&+
MC)/,I]WG8S<K9E0D+7X $H<+=V#<ATOM_A;X^__"A3="L39TO\O20FAAZ;+)
M7M8BG"_D<RI<>Y&P=0Y[B>)4ED6AOU8VZ7/K304&3X.60M%OX)\D]> NH';5
M1W&G-U&YW(<6IR09)@4F5]N<.=?GP*RXT+!N$A<:3CJ.X$+#*=Q9^; _8XKD
M_*CZQ+4Y<_5$L=AW-O$O[MZ#XA>6<SU:+IH2-W5=&R+3MXAPL[Y/MFF3;[+I
MM[.BNPOX\@T))+O3W=WJP"[G*ZTU*%/<3I:Y@_<MJ0O310M,]F&XCD6%Q0WT
M7>"T:QLS[&''V] ,U[1!=\\^3'0WS98T5[HRM])G$^BZL,.*WSZU'R(\+_,H
M)']37WCM#<US2\%B6\C"TMPN0"1#,D>@<0A%9[LVISC!')X?A;#YBY:+8=Y+
M>W^W-4W1HZW-7S)@5(;L!+IR(\N$AA4,WA\Q9L]@VNC+$;T;#X7</_77=1XW
MJFFS3IP-39@<]!3]2H5?4J$==(=5GT\QZ;W6?D_-3X+PIGLE#X.O2]-1@/:L
MD^WZ\X@!!3+Q#OY B@3F,>3R3\YQ+X8G"7I_RAHA7(7:KB_$\G4Y,'EYU>H9
MET+R?7*64YQ?==W+DW);9Y.J&90W6,L+J2E]<@C.$29]^DIH*QU,MA* Q,=N
M&GIMG%-9EX7LN 9G)@?=EB_.NJ@8Q7O>AI&0]KWP"B,U>N9[L+12[D<19QGA
M\+#YHLGE?B&&O]A) !CU$*3^6XBF)Q=XJ.J9N1!945!H4 _ JX#6:4H><P*^
M#_P"7[CM@=A/AK"EN(A(Q@4Y^_'P\)#O\# PT4VDH\HQGSHQ%1BZR3-V=BGP
MG+QAA!<J?U:_V6C#]@0*(_ N22E7N4B$JI5#Z/QFA,Y?O\CW/PYN<J:?JVIM
MJ-5,3*@'4,Z-<J 0XPR3Y*-?.LSBF+<M@Y)--4(8O8F<JR83PCX'2U@G,;S?
MPI<B<Y/.4,F841'+AIQ0\.;ER;2;GG&NQWIJ*/^$*:=O@*3\%#N0!0Y!"YSG
M[>K2:(^+^ZH)U_#$.$C45=M'UF% 7\#;\N$M^DUK#]@RYX-B$T50WI(O,HI^
MP=_$?6J&EH2&]K*=%W);X8?&">V;V R?"M"24,\N *&R<^$+[I;A^$V:.2@J
M&?OL$6!UZ]]& $6M\$T-51>/*5W*#&B#5 T/?P2QUDVW2FXKNS3;@(C3P^Q3
M&Q-TW2*>UJ%\5>6Q3Z W4(<8#_B5N4'BTR[5 V&G"=3.1#]E?C^N6)O"^(5Z
M5O)B!2WXLJ9LI;)EQJ3$36V[359,:L2^#<DMX;%=*[O2F225E#-+-3"U"[BZ
M<S+M5>Z[_K=QJ<8.C/=#6\*YP4F$!,BE!%*'_;^"01W6KHE.+#S<!5RZ$F%I
M4VS"0H5AQ:\ID;:W<I.&BD0:$8L1.-2<\O&M$44#!:(/"%+I@O6KUV[T-0OA
M\WN=5!_(.5]?^[$>PY;N,$1Z[8]!QG!'_Q?2^.0>UFD*^,O'"R2Q?^%-?_R%
MZ17^LW=[>!K.7AWV8=#!4WCK'P+Y7T&,$'\-A  -3>GF\GV3->2[SIC)(>BT
MGH3+4+ Y%CX"Z>$(7)O/9I6.\P-*5FC%?RX)WU^Z"ST^V2,N>\]:1^ 6JR8N
MN%0OTP!Y7LF:VAO#\WY:,[Y/5/GMB$FC\KGL3>-QXI 7'D F=.I?>"KJ)=B6
M#LL%?#EJRI<13:"KYFZ)B\(,0<Y&+M JI2$FF8#V!WWKO$&-^6)A$/&US3QH
M#/S%00V)0'-V7T-FH9H.?ZC%BL-IT'768]1[#S,KR0!VCZ^2&WBEG,_#ZWM[
M:9Z!FP5-O EGT>#@+*M.0>C/#8W=R+)H$;)@1()\ :ZE.*.+,RA!7![5(Z[I
M6>;A;M?C.9TL07M,01GHUFP=SOS\#LPGG]S7SG>ZHUHAD.-I1C+-EVK>%AV[
M20@5?5($ VA+U/I?&+,\:48C(F9[DLF$"M45OW$R@?1V,'^ 0##_G3_PU._<
M!8@"KG;A#/\>]8O++8B$73;"K+]!B+-_7G9L&3'1B[73]X7XX3X&2 _W,?JC
MVHD;\VGT"\77-QVA,6U A@,46W^R$G4RSC#]3V[_(F$R[Y,21"Z&!,&8R7?L
M/K@0:&7Q[=1:E!0KCQP^BMF[-HI),BGB,#.Z<9$PA+XPJ=X$HR#IK.MXK ZO
M0K)_>+%M"_[LR* 4\H7<,;!@9[6??S(KV>6Z\RD$<87$,5L?#3?:@&('BNA?
MI)_1"BSA?:/L3W7-,X7MS8T):'V:74O.U]I9D5==*[JJ*BK($RHG/>')_.]X
MW?BZE2Y:W0*S9IH:W)-N!028Q' 246.O>)>U5\NM3T+EX-1!%0:#;^0">J<H
M,YEV 70,D2YTAS#@@^L?4YD--S[,SL51=#'WEMO+B1LSN*%:1XI!ON::-(O4
M4[)O=!$GM<&F2ZK&$^I $50%>^V&*O#E=PN@/4S,8^504Q0ET:YS93'&L$F<
M4WH7X$4O>H8] J:^X6Z.=C9NNI^D(E97,$=($5^M#'"X\S,Q9)1Z 1,H&K_C
MWK@+>/UJ;>M(^P;C]O_Q28>],XO3$5P@F0"48?]:1U!S,<VM G&G?1VA63B3
M!\4IG8$76HW*Y]D@/CBE\Q<6"$3#3N]K_21OR+6,2P6^>8WG_>1JK*7KQ+MP
M$519[24EZGJ:U$3/A@;;$Q(G^'LG@_L&=?VCS6]==#(W!IR.J#;:T)A%>5!T
MCO5FFU\7-P99HUJ1^: @S<6W"STE7 YYRN$J3V^/MZ!J)QC6Z_9(:P (\W*]
MG<VUJN8B;;WB/)[PFXJCB0=%^V7TIM,.[\%ZRK1JLF3TVMH4XH5S/%.4#+!2
MV_S?.,JE#",#S\->-SJVHUQ?WNP>B*TK(1%S0^Q1UEXLKN:'C?I%>"SD_!%N
M2(GPRJ??!3B!@@"V>U$7^?N1QM:/S@&?AW,>O5'-Z*!E2W5+@P*4C=KWB@+4
M'=B?9W? .!-/@2GI98G;0I,"L7=,\[D@;[7W_,$V9IP_>%E:&#,+K(6#Y7T'
M):++VMGD8Y"6)'/;._T>_'CC9-\S.N?T^F7W!HYKGG@6\R#"4P3FD).G)"9\
MS9!#C;);X%J7)S??IN9?OY\I#R[^NJ]4AX;:+OXKPJ8[NKN+2H"HQC_K]25%
MD5H1#@E2V1T)LS:SD+V@Z=)J[8Y[/M8SLN=P]AU\;=35.'=1,)$F\G*R*>&0
M_*;?E*RK,H0BF,E^T0+)R^MW-BN<I\ <GPD>*C\B18OZ)G#4U!2X4V>\XUZ-
M.W4!:UOH9T2PS$>"<%>AS7-IT79!" 7AUA'PPGX6\O!<NHPCPW:_"?'O3 =@
M_=7_;BN0(Y>@.$_J+N#^;&A_817Q=F$!%K]KA<7'IU;/L-15POFXRX+WZIVN
M$M!I*.NKMA/Z\@D,5VOLZA9FB 'V=XYH1\CAEB 9AWS$;P3#GQN"I,8?<A*[
M\&8/TM]VV#W,^_H^YET-8X09'%;UW_\2I_-Q"ZKN+\B3FI !Q2W(JO5U0<HO
M;8<Y%3_-J/V:\/TQV4TS_H>S7[ZG'C6LGC(K8$3>\Q6E"':P<MC4JP$PBL=R
M4@^9' #DASE@J51@UG67&X;-QR)ES5?9*,-V 2&D+27SI:"16LPS.,/JVM#6
M,57@O4.B=D@,.F>;CO!X #;?^0"'!TC^-GJF1<O;65TK:<29R<0,FU"Y$Z,E
MEYR9\PJB!HT0'#=OP44J@ 0VX'6P(C(:E.7\QI&(^NUGCH8SABD5K85&+(L)
M))8'O+';&^Z0M1"2:$>3==T;#>0JS3F83_%5^>/Z1I#:2MWT5T&K[YHV,SFB
MLSM-:W@6RE=@\GN3%_U=)V?#=#BBP_LN%CHBS?)9XG8!G*W+KY"S,GJEV'8X
MEV55W'U%=HA%/I7TYT7L%/F^@3FOHRLQ/G9A;X3+L[T1+L)4F-FT#;_DMQEO
MC6U.V\B3?83<,]2S]2NH?:TJ&?<E>KB8*V\#YSNX(GWX0,U!Q?(-T(4W.-]A
M#LO8NY-8^69$0Z*[(_7"O64+T%7\1?9-56#4P1>:\SA3LFWE._<BQVA4Y;(W
M0W'.L/&0"7 QO6&DC+J_6'OF0A)GW9@BWD(4 <,.P".WOPT8X;PT/KEXI_VC
M*F,0DYX3@>7DHJ%>L]9OYH (@+]U=!GRTX'DMT^6WOTTH.@[=O?# WQ4_;W6
M!!COOW2UV&O$U1W6RLD>G3/OS;M-SQ=?(#BYB(BO*8T[4D@D174@%*;.'EV#
M&]Z?\<XU4#MP!@62 Z_%K [3LR/,ZDI(:<J?F??>>L$8]L(K-O$>E61,*(AZ
M]? 4.W;OC<A'?[JXCU85J"V*QQC'D-,G)WJ4Y0["F18O"$%)_F@(K.!4W_N]
MV>GXFPH,>XT&#P3>%>1K608?<9=4CA:L8JJQ6R?IQXK9;< #<0$<"RZ ^TJ1
M2J3>3\'_\RA/XN?3HGE/#U8Y:^Q3*6E(?@DR*%M[E[L$RV;VX7^_-4<&_J@5
MYO,N  7#UNOO0":K"I%F0:+]0@NWF!WU[$_?P=\%!,<W> J+?J>UQ9_6O0Q[
M8C_5EDE\K,[)I;P)JF96G?JO.J7].CWF4,^/-D+W_PL@/8!FD'-6_9R;LEM0
M@?\#/G;R&AE,O\MP.!\*W B&++*U4EP0:LBBJVLKK&W@MBWW[Q]ZG@NP/JAR
M=U&I-/O+@FVIBW"(=O2ZZ[V_\'"VC:$CU>U&*4Z[TAR/V.Y4B(8>QXD7SNBT
ML,570L;T'\[W"\W'#;ERBD;>Q=U>&S*I7294) 1F*Z1_5!?JZR^('/]43^O"
M8S5^8+HUGO@9[21F:.M08JK"U9<I''E]HB9WVDSPX2MB7',HDH:VVO$2&ZX7
MQ=E^XOF@A?-ZM56I%EL.08,8B%J.JPW<NL4.E;V:,9B)4;=8*R>:.;O0F\=T
MQ2:^P,EP$1%2XRE^_T!$-='$\/@1^Y"'0]D-BY,B Q'%DD.N#+Z&;C>*")4E
MFXW,4R!@29N68_$R[>4&.GXCZ=W-<EN=#]UZHI1[IW.0E.M#6QH&P5:2\%'_
M+G[SJ*F/[V7B?%@D1UZ$?/84.>#J29P?28^[M@![:2@6>T\FY,5=HW+\0BC7
MH_E9EDI!E>0-RYH^9425:P\OBDTKBC'$'(E.?_15'4RZ61M@S[(W?T@Z3S^J
M2TE3>U-DDCZ^;9/\[P.K+@\Z@EW 8UO]M*KHJ/Y32."CE<DXGND=%7T]*$ZH
M*3) LZCR%8*,SX>]CJ-T"' \SBB]'WM>[<2*BO0]>\8PH8^&(9JAY<=+[>$3
M9DK&)27>W;RO)\(,U0;P6/!!L:[-^X['/QN03/[Z-;2N\AT4WF^P19FVU=96
M/G:O$S0[S[5S6A68W_X[Z?V'H-W^]<A$A[R[U.T:JJ8'3JC]=-.0H6N+9!?P
M9RC><UF]+_:;_.EJHS6WHWS1--N5*1(W>4\(KW_83[]I*@];J)IB&162'I[5
M#V$.C"%D&1>F@R 1-AD/ P#K6^PLE2ZOOZS0F"4;\1D^*&#$5'K?%#7V"7'I
M/JP#&0\-\EYM.](,]ZO23T"K8(+60&N=N'MR]^[YB=&Z#XM_380?*F<@GSWB
MD/WX2P/<<@$7OBXG)V!/WOJS]O]>H+)_#4M>V04T<6'[=@%SD9.K4S\-VEW^
M 3VM?\6D)C&X[;SDN\^">*9__.Y&BU#$9\V9ITU2<A?EG$F2XC\=,\&O_9[P
M[\320NM*<8K3 />[A,L07Q>K2LB9*4T>/[596ZT,".##,'((N,2/UWMH?X]@
MP'LA\&'1D:)U_V[R=IQQU[]NHUB%4<B"V".4JOME2WPIC[?@>]5+%*J"AM41
M&@9/Y[!#(XAMZRP^RF>7:GB;&I=9,0ID>*,'A#=+Y^O+<V#6K/L=!)&8J!,>
M:R->\195#)]+57#N4TO; LY]TJT]CW.?A.UP[M,B^>BO-;(K0T^=Y!A(:X\U
M?#".E6&A,@)$;)XI";'2 2S-'*@'_)'TYQBH00YTX(G0P,;'VIU%K)U^7*KQ
M3F+20*]O8$X[;_(+2=6>395A:^BI1K3^<USD:E8D$:[R,GX"%[F.@];K#'"1
MJ_W7S'Z^?UJ$RN+EU1Q7QY-"*>I]9-RG ?2]M2/:_%\=KBYGPMFZQ>ORV4Y]
MEYR78RP^#<1#BT-J2BFJ**XW5JXOO]2Y])%;7F^,AU+/,)G9#BQPSV'MFES?
M5^A4?0\Z-0528=@[L(R#[O&5;P9T)."\'R(-ERT8>)@6B3;;?GAVN @6E+\1
M\+D_S?R=:DO6Z50V3!/H#+&K/@1>:<9BUMBX7'!)[B(#UVE%@F54C@VV#2:[
M+\(EIXYP-6'N_]1.,Z,YEF1'BQ_(?6X*#N;ILK@6TBP_#LX_C$0<CF0RO M!
M3^WJ*9Y$GOV8K<<F7'OKB;G'(Q ;8*GA0-&M,OBIB6W8JAL_/&G;D!"#HKDS
M[&*KB#%K3(5CSN\=B7W*3Y 4W?%OR.3/JID=?NC<@*6_/PE]^7#\)AG''@ ?
M^&B*/?[0L?U]0/'/\[;D1Y'E4LD"4O_R92+<3>7;EP&0[_7]KL$!$\I$*HZG
MB'3E%-1/B=QJ(P&V:?H=HG2QXE__V;G[O[Z0?C^? JV),K! EW;WK-<37E&)
MIG&,?[$+&+I<ON/0=OM!T.6@Q##R]@H-#2H"^H0  )J-S:S8.+LDKOOZVY&P
MQ/NE)X% ADB9KWM  SY7J&1 ;KHD?)]:A<-BU?J.1Y*&_D#C(%C%@5%U6:&#
M&^P9$1'2\OJ;1,Z5T9F.(K7B5KW#S.@I(D);0TG+\?PDWQ3TK8+\NJ'&Z.D"
MHQ"'IK2*O]P0\@UX&!D/^Z]\/KP1G<B(Z:+(YNCY*U2GCC7F6P-]0FQ\-K[H
MS$KB0K7XJNLC&LKY/.P7[BW-,US%1Q-MPEG^_@$]WMH^?Y4^WG7/6UFL[G61
MIU98?,OKW^!T^[D4%(.*Z+M,TP?X9SD\)3OP3HG<YYO"$Y KYO+3<2[H9BF]
MFZ13ZSLVQC>&O_#I7FM* JGR@4LC5'4V*8ZV*[)=B\B4DI!J["HCE@ ??!F\
M+GZV']%HQ3L?<(=U-N;!66]AV(FXD]<R+N>_=&P\_Y=#B[5T!:TJP7?7%5BI
MB#L13)8=NX!6(85&: FEUR[ ;6R'O1QV"7TS@4-<&6#[FE/:RY]@M4+/\(LW
M3BLZ'FGO:76^OQ3NGTM%R\HN)B>XQ=( DF*'K[)W==HCHFO[_N!YCA=M.0K$
MEYS$7X2=/MJ0'R_GVY.8F!@L<4_'KZY38)^P(V8;Q/$M)C=>,P_ESRV*OZAQ
M>F!1FS_8.@*&_7-@ZM"*DCG\7)N4]JU;V[@82(8,#_6[5L-'T:@Y]I"]U-2E
MU?(==QC6<P5OXN>[E<W,)%:['+O;^;,5K%-PKGYKNBOGWY2+EYU!U[>E@UUC
MWZU9"P'PEIYO)^P")/M)_XQ[Y2EL];1/*[Q[Z([L_<7X*W\>\[@=?G*.VU9B
MW9V]Q6Q@(6VDR_QA=H%>-2^Y):%\0:M-EVO (M&L2,[L=-H\Q;G/X[H^/O-\
M/:OT-9[LWR%S9WSM[0LI?6ZM3SG+)E2(&*>[AA_8S-SL6]E"LXXY)VDS.<I?
MI]*^>8+I-6%I[8TNIB_VQ:Y33RX\J#>8CWML3U5!8-SGR?FSDAT[0N\L.M)G
M=_^3'Z)W[MWT<Y]=52#LX/G^85'J+'9ON>M?EZO!&:5=P-YZK_?7,]24/HRD
M ZN&-GUW 0B#G?"]7,>/T!D,_6%><-XD+NC5/H3.MJ5,>HM%0RPF]-MO^-+9
M!7ISR^.LRH&_0S[HQA\G4-!ET>BQVB&D7JOZU@NT@<;,^F1$?(+'/UC\XY2.
M@-)C$ZW"VEMA(;8-0*04??Y_##W[^EE&J<>?KSD6NIHP+76(Z#;J]WZFUXQ?
M5TC;0DDR]6[JY*:/IMTS?F;:)WF_ <*"-F+PM?GFODN/7E-"%5GZGN*\]*3N
M;MCRA7JYA<YU-W>S^&]G^55'[P(78VY@"B1)JRM?2O%3ZZ0J7''8#)2[\8:0
MG>9R$7\3K7'"I]J"AT T+D[\#9,*]XD=%J_4=R^U8"Q9%U^H-'X.5:3=GA>'
M9IGYPG07F^/[,%QBQ\/B!KJ-3O"U#4_VL)_?T S_EOYC\1=@M;(W(*VDKJ.F
MD2GX2"G^&!FOA4!?*BP*5QR+O"AOGG8UDU"4N#IS,Q,S=6P?]OCM'+89[,G.
M9K\G=SDI)>KY/C+3%Q %NJ3<WH#+WJH@<.Q>U/U<?-__V*5)8<!=DD<W]EWS
MZA(5\[6R*UV&MDDY*$;$U"Z >^<$S!3&L>%CO 8]2^2K+=A?E:;MUUC@ED3Z
MB6M2BC;V %(?I"QT-3AOVL&HIN,0.+\"_0O[&)X#]]0LFLY__]XT#^Z?<S*1
MY'H>*BE8SCU8?D3JPL])2_8G&Y&VL\;)?9[%S&%C+&5W * 5OBU-.[ RLKBK
M9)'_:;1"7M ]CO38*J.0SN-/:W,!=OP' C-7=B[/U>#4]&*AF@Z(VV+%5LOC
ML6;PT3F3\VM1]<;&Q]., F2H:]X6A1(20MD K_Y#T=/!]<][1Q^*MX;@3(LD
M7<TC&Y-:D8'GWQLCV9+.0'DUO5#34O3ZWX]4[?#F6 'ZK4\#X@43HW#MJ6HI
MC">,%J:X86$;]!:LXXE QBBHF/-Z@E;PMU2!%O\_WO4[-3(.!F6Y0L\)U/>K
MS0A8.PX?(^S@&TH H2_JI;O\3=DCC/\PH%DZ^!DQI^.0^VX'^X<2_9RA8QNA
MS89FJ+,& N7!VHD<RC9_\R<29&U9B\QG"'*5^"JT-N5G[9=M$BM<7OOG1A#7
M?=+\Q#(4FAAR&VP$'LK0AII,.>5Y@WC&_$MR!P(+QB&[ .=3BX=%C/V+&]Z#
M*"R-;EA.:5?@&*H"0)=@7'X=.BQ7DG6$'@QS^C5SITK0=7!^QNCYL[8I CCS
M:K-$%GG=>@<*W&JQ6\2[@!F800;3Z)6P2>WJ#S62SCRT);L /''ZTA=(+PRX
M"V_B0&4?K;&!F;4YW.FV=^:B,'&D,;J%X10-?(#L,LXD'U4O'3$X(^G[W@VA
MG#2N82TO17J:IY5*W GS%+!&?36S+KPF2VYF:GBO9P#I=6+1;_Y56JF3?FZ;
MN7)UQ0#3 ]D3('Z_+=+;B%E/*9'6IZ_*(XPO1%)M3E:%+V( :%&G>W&DZ&UX
M])=GL_6Y--,P3AK>IO'H"*\YOAY[^L^I!ZFC*23D@192SLF67%U.D27AF*<$
MS4AZ7K/HUH*'6Z^&1,%TCK'(^M"6II7V%GWT3MB;OIZH_G:6%KNP@G!=6A+>
MFQ*IU_>Y54><+OTCZ-;^&_R,7FFX_^R2L?YH.75H<P^Y7*L]A["M*?RF[_>5
MH86>,#0IW]^ZW!N(D$.&NRIBJ59;*0G0 J@M"IQU-]YQP<5X":< ;5_1=N$-
M_R2(4-BCS)!P-WDN4 T0"'.@'(:2EKI(W.KF7_Q@LN[XQU7>FNN6S(#*2!;Z
MQ_A2]'2RHD?'N[<=\%2"E-7,TGD5>28\MLB% 6&5KA%!R?0!9CZI%X0B3.%M
M@[IYEWTKN5B /<C,*?<@@&LI.?';!K!VA0/EW0BY+%;+A+.XP.#=_T1(;$\T
M=*O66LU&+>2$V)1N=A"7A2R3M@749S2.<L9=6WW*=8>5XM9(H0C'"X)MZSLV
M4V9!_XK.\#<V5".U11P/!J$@?JNO\M1H8LC5&A9WQP:CW0I.[((GMOV-]U4,
M=T#H$U;UZ]%U"/ZAZK.L $U8E2@K -;FTEUWOZWZ:FWL?=3MB)R[IT\#)#WQ
MI,B_4T?_B[J2@ZCLY>) Q*#S0WGE*H1"-KEZRS!O\K1GU61?R:O2B?E>+H[)
MW-"/BHDF/3#5$Q6UD^"SS%9D0;1/ZZ9N9'VL(' @4,4W^?DD=$A2(\P[81GK
MD\V1AHC@:#F[>)S#_192Z@KRM2BK'W&7E-A>_X.YA6>]9<Z#)G-#E; :9[?.
M#" NC\>L95TXR6]!0SZ#1RF,F?V<[*UDYH]S<+.JQNGL8LY8RY,O./R]\DL@
M\?A9RQ=9'=.^/.F?Z-0GFV/!K:$WSW1*\@4'B7OJ2YC2AHWQN*F09F 689Q^
MHO7FC93AD.H7'GL]7@^P2XI%^M;F#@LK\@?7"(IOMB_YWJL'!:1@S'(^N&3$
MTZ>^[==JL,Z^@@^U7P6FM)P TG?AC?QU.^E(097%-X GGC3WB_/-9SR5[Z89
M[TL1.+#/QH2[+L:]@(F]3[=,SBP*GNC3"#!I48?G;ZXDD$+>9*U<<X2#,RDN
M3)H_\^)@QK3'STB00C.DN@ZX]UD*87(="C-//;/Y: % -67 [2^K"OSN@F;U
MO=8^8]=M)@2%;ZWNB*[!SOU2DZ(I.[H+.$_L.,V8U\^1P&+*'")07B*_M%"_
M^FGB>^,L?+O/%Z 6B[+AD:%)*I,\TNN.@8';E@ /@3F'RG]!U_W/T0N^$P@\
MO^_0SYG'V=;9-DDJ:--M;"]T;@5O:"]BTU#Q1X7/5HH&6FH=]TJB<;\]P9!"
MGKY',R,W4\MR%U(KS':OJKPHI>TX#T#;S'-#J5._A8-_4Y,L]K5E:LN&2I5I
MANDL[1)L[3'3>FI0\1/GNR".+?I/9_7)_XXFML) M1'+C]#LG!N_!V6D><6'
M?:OR?I4IV29FL<;M!P'X?S+$MB=5(+TL;'O;@@6!AV']>8A9,95-PS(633Z*
M"R%'XYBRMX%/8:C/-1\N<SRC_/PAORD13:!*J/]3L+S7,$*\W\" MT[PS6<_
MAJOUC1Y,C[ >JU,.+1LL*H+T5)X%=]>96SZ%N@QS\LR\5D%^VQ'R41UL''^I
MRU+S]<>*O%Z*PK>76>LG/65=+2#).)>170/G,@9R+%J(R3=IJS!C3R>B$T@X
M?V['X%/A:( [#AE3Z[6$#Z'1-(XA>[5BLM =]=G5SVX"V=6EJ\L<QG9IK#;+
MIT_G#SMQC:/T!WX( _% %EB[U>PBSHBV9X(3SOJ$M+S#V9M+6RT6HEMF8KY5
M'PLUAH>W ]<DY#,_K$X-2J(WXT"H9W<>AG-?&"&79^-;WEIL6T72 6 BWY^)
M>(%TX\/Z]0BK9AL3:<*!?D_1F/>35BR=\74A,IT8PS>/3O$XYRUXW]##O)BD
M\U@8)G9>)<-;..JQR=LY61A3AL^,LIZ)??W6.B'^S_BWS@)D>#.BY2$YLP*O
MV,_ -4]Q9P#G?8QI8\:V%BM65Y;356X7?5F(FY]7[A "D!;Y9'GU0.-R;_YD
M E+0G&$[B1E$+PGO9E?YQ<$P^!DNWM!A80FS:.^3G):7\GV=E-@?R[;P*GZB
MA6=MV,E17PBA>VT$4>1BS[!N<N>; M 5&9/AI1\<^G]63*!SB"/6FDY,A)6C
MX\.6X?1=6S7 U9WL-US&7]H^%O_"]@) ?+_CZX?[[91</](9\L?498A3%?%5
M#H>G"Y?ZWCL3\0:W%/3;!&\"9U^-F?5B5)*@%B9VNHQ-L]MU$"Q/FP-^6%CK
MGY.YSM4_=*-\9:E!2_;S&Z$8]$.% NPQ")T83RO+1FEJ/NQ,VRK77-"C[HV,
M<7^L36!LTIF>,3MOFP4P@M:?PXS9,B,8G_UJ'>,*8QO^0<3^WSI?:O)(%@1<
M?J@?SW<Q6#T*?.D=4?B'6YX<@K[ 7C_3R7YX?] #51*[F!=GA>$3D:I&/8V5
M8K2O,Y]L5V+X7!)0NJ;0H=4G<E:?EMSH7JCTS D8&3PGN=W!?PYA(ROVQA"C
MX$([;-R&+.#'B_[!X/;#0,=DZ-YE9"E0C%,H-1H&6M(MMC+% 0F6]>C(\.;7
M\M><BLOJG8[7-%DN)1'G2_"%O$XE'R:WV]95VP;A#%T.)R8H6KQ<) ]5PQ.(
MI$1)T0^)HQ'7._64:&]Q#4(HV8('E&U=6D/FS/,KDV$(%BJ:+;GD,'BJ+?#F
M"0FS)M8$(ITGB4X?]&FB>_M,%8C" 9_H/&E)/W_XJ27?/\39OA;/-LZ!68L0
M]'635?7+QHXCRPS;4T)[Q;,>!2K^&I#\S#+U0 M'WQ9)P[!(#&$W9F<*O^7G
MJ*;PK?8NP&2F.\KH 3O_!]AXR M.#\.-T_&?2UM*BD?FXRP=)DLNYNG(*3"&
ME RQ$CA,%R>_=0G:?\H*-\7.VN?&[UE5I;E%ZNM;M)VG:VB6&?Q<M3RXLK>M
M?!?N<!B-JH@HA13GC"&'3)@6$TAI?[83,*NVN?+L'#%V&8:HQ:JR^_,MM$O]
MNX 290B+'P=V:)2=R#8SZZ6,:!UO6NHR-T9* &5_&!\8.L.?E-G-5/+LT=MA
MC@8Q4:1-C=@80X99&,SL;XGV0?HZK88.EW.;E,G:8WB%K)9GI<X<H+YF*EV6
M*\6O[8S$9%B/VP)$@)E GPWXZVF#,SG;3]=F%+K#O1I3.(,ZWXG03@;2QYHU
MI220.N669Y<.K"D5< H:.D4R6A1.Q[@3*Q]M^>YU2XJ^,L6Y]H_.KHE%2P;
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M,Z5J^P,0Z'E\%81GGO\+4$L#!!0    ( ,B 95BD!E>"6E0$ !A_)0 -
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M/GU*-0U"SIL<Y0W\:LP]CD25)]JF0 'C;4*B XS!(('C+5*GWUXE_FP>H%Q
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M&:@Y@EY>-_Q7[^F132;@US>5G]N@%S!9;[.I>_4>_RQ,WMJ6WY3&NQ-;\^D
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MM'U>NI<$NQO5U]V!W:.JKC7LKK.=U=1N=V&W1<:Z&V%74[L:=L]@(ZZIW<[
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MR!^K_'A!,S('6S@'#R/4FH-'$&JW<K[*4F ^\H?"C)5AQL)#>5LX!P7,6'?
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MKH0?O?A8S0EW%K&?^O!T3+XC'G,7S<*@IME<OS9?Q,D"78VDP E[LCC("3L
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M33G27EPHN:+P779!M#@+C*6PV 0O*6K#/8^3M324:6]\HMRPTB$+2,2(H\#
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M]/%(*,^'1Y_&)__]]0B4H1>ZF9]ULE=\4N8N.J5HF""I'IWI&O/GT\/Q\?B
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MR.Q.:EZ5?2:!X9#IR*LD WIO,L.8O1"F4S2:T$:B/=4LTJ&W=UNXS2H$4EG
MH<=:;K_5[;J]@35@]H!WNMQL=;K]GCEPS>$K91PXG'PY_N0GZ3FVO4FQP%*P
MTV;E I5F?U.LVH *\^8!;M<\MS:\%]:N=VU\+UNDT0914W(_E +',K<^LKP$
MT$+4!8A8P@7)!3HBO =D- \=V"72)*P]A/0P!/*:V8,I#@0^B ;Q>1QYL,EL
M/_#3Y7YNX:J*W'I$"%FVQUO]SG!H=TT+D&.W6X.^VQL.N.79W4&_AM ]("0
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M(:XVR7.51;@::"K<^^X[WU%(;\(&90M7!.W9BP0VN =]Y A+?Z;W%3JX)*X
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M5M+AAN:\'"$"(!_]@#.W=!"13A_+0Y_/QGJ'K.\,/=-C?69U!][ M!SNXLF
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M'C2DXIH*<YM5ZCBCPZIGA4*BQH<L*D6O#9J[L(\5*P&,<3?9MBI.MREZT'B
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MT"@M  W1HCL5D:DT8,Q](5?@N7-5%U5)3M#SA,SAQ-SFJ8JQ706UP'HBZA6
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MVUL);422*(Y.94="LSLVE+M."RY_#\GM&C=>E8_M.I^K<A%F92;H<[D?'=I
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MHV^RRD).7%I)%D*0C!Q!:$06)) ?03[EHOZZ)ER2AD[D0P:I!$MI/\S*=#:
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MR-KGPWEFTV6S:*HBTR;:G#?+M-"S>CK/F[+*BBH_R<6C4Q5=R':C*_@)4F\
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MT_#UO)7PUL")QAW\D7.6QN61V0%(@7G3^T\!OX]JV<6CNLU-Q]9L%%T_,G'
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MV A9+K[:YA\>96/>":*\\.4"_$_2>,16Y](UD;AI83U_@(L=R"T?^!\]<LU
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MA=VB))LP8=.;51JK:ZY-3V=N!WCL(3<$6/7V&C@_*)8W[T=0Z/2PWMX@!G/
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MY0?80PU+P^ASFB[>TSAQ.Q$O-*30:H-"XZI:,1+,0:.)@E$J])!,1H$W#$F
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M0]%@3VEA%GQS= ECV8<1";JPUT9*I;[6P(-)0_3YY,6&!_OP[O=40/#WBFY
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M,^5\7(;Q#+OM>TI1V;<GXXC=AI$]DM'$D-EDJLSSR.FP0$#@Q-)78:Z(%.'
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MM38;J$%MM_V:&5GQE_Y1(QDR9ON&9B0-QLMQ)(Y?\P_U85%=WV)%:04>@H4
M>^\"H8\^<0)N@L+!AVX#_&+;<+_ BZ>42C#69_(CH$\_**BQPKF.*D583,K,
M"=H2A<W6)M"1,1?$UFB_>]H(B?07V?0R#47H)S^]_2]+7V=^SJ?+=#;/)M]
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MM\]Z(\MH2/W>W<D/=ZR9&S-&E@,&4IX"J;BQ!=&7>((F=-M!LHY_W_91B#[
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M%1IY68ZK_/.Q;WRQ-EKD^>XV#P3 1"$LW*-B"7H@@[H]SI/MN !GV[$/:-[
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M\=TA&([>DG>:_!SCD<1)'YC5EX.1OC([RX*&F!-+?-AP2UW_L8<)$WA(J '
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MONMS?X<YABA%<D<3HL&6+;-L_O>[OJWVNV[TV^$#L#?R-[H,7@K>PQH<\,/
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M6E?L!PO9$XYK\\<1P<!.XU-0$X$7'T,D B$W:?( UN]X82G-+$/'[ Z=3WZ
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M-'QH[N'5-VUDN-0FS"[I,>F"N"ASE%YFAK?X\3;>:Q+(0K!#HL9 WC*V(4&
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M!Y8/!_LU9L04+SH0+;!\80\:J38;R!+>!"SGG#V3?AI"61R*MKH2,0UH0!]
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MO].H=0>[#1_A/BT9LXMW/JXO[#[C^/:_Z!DX1L@Y4E#7U?J&2&Y;J^@=%_6
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MI[#MB^FEGX['EZ.KZ<7QQ5EYZ?WY=#8^*?YDYV'?]OL:CP0[I1V:4]2?-8+
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MC^3'=0-B(:GSJME'('Z?ZA7?_,?IU5.]XFM7?'GW<,M!SI\:CG4B1"D_CD
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MC,S&+DA]6_U'U\]3)0BW/\IC?%C/S+N!4HEUGHWXY;#_Y3#9HA[8T/F70I)
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M?**]F]D"KF/_C=I"-VR]E*LT>,?D.J@%)FT;N5CKI86M1;U[";#$'+1DKWA
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M#7G$HITE/C$#:%DVH5YFJB""B2Z<G<YU 5^\:)-,FIP,F ^<KYB*@)ES[/Y
M]YDMANUZ!^3II5,F'%K)FY#_1\G=IOZPM1D(>S7;Y BX/.9W> W2I[S -H4Z
M+&=LGU^'L>+*QM(-"6OW<AS2K>"753V\[Y9$35>R-*%#,E_2;S8::_8U%V&A
M9MMN=D:%$CME;Q#$7JT5[=-S85)VAF1=G;H!;TG998FZ@JQ4A\,(OH,A5Z82
MI3=E>31Z'4ZY.UE#M2JFBZP!>PB4CL;M=$EA8- I2X$<O#\IG!.0BS0#-3[=
M;,-;K<52?.1=J&BS0H:B@M8*X,I&VCA(WB$GPY<STQ_5]IX4F?&QK8BE@N!;
M-;%*\CL8ZOA4DY@H9BNQ-4?3,!RK&#09?5$V^$72),*#<L)S&$5"'ZWT]5=F
M[+S;R5!J9B%_P)NY/FJW,ZU)2ZJ5]Q0FP';_=] BZ!KLFOKA->Y,?<:,LQPT
M&D0^G>'(_IRG_:#$==*1=]UB%TQ!;>0D:0C$,]=U78:30XQN)7?0A36I%P \
M7A3+);U../_-E%J2,7L2YX 5'>4WMN N>K!BB(4:@1I'DVW&W"P 9T(V DS*
M3#;ZA=K@9YYE+HYA?3I01R3_IA#Q:%3D4EKHWF:/R'^FPLE5S !Z-J%+7.XE
M[32,[;>F&Z^PG%YXIX@?.AOZ)!<<//<A.R:UR0U 9&9[&Y>E;3]0 ),G -@V
M!?B@I66;/)BN.,I>I#^'>^X&?6R9,=DVR0+!U4Q(*)ID[O#M+V_GSBD$KH_%
MOF3G-IVM?'=3.P#P\EM4T!0+W)I"KTG[ MP$KE]0[T"X_J?<GY@\3Y4HPK[P
M0LN\6M7 =A:;"P3?"#\6F$RQ9 *KC$>6-)N&S^+Q8E)$&E4/]10W;N\L9DC!
M437H><JY80DWUI;E\XRDJ]I(6?J9O#/W?DRYOE.U3!DQBP]6.6_;AJ<\IJG7
MU[85<6:%D:&UU9@!OBPL>?#C7/I-E-JH%IC%L+G@I.U#[*@I0C#*J2*B<\_@
MXC[#GS4NF"SDU"Z0+@R0_44? \EWMRM(;<^%.A#S.]VV?[[KC*E]7 1-ZB+\
M$OR:-OLE2A/"&_XL;2%OJ;OQ7\#52>4;9(N!%7:,Q&/N^CGGPW"O%:Q!2[DR
MB5[$D 7+&&*SQ2;XHG-D,,@F51EEF?_7Z.CX&"XG6N*41B<BA) ,SO/7NHZ,
M-&<"8C./!-!I8XXJGQC/&1Q]U@L1@K(PH^_]%\X@_#PT>M3BD83GNYB<%,&&
MGW#@#)4+OW?\^[?HT=-OLQ]_?*F-"+)@G#%MD3J66Z ["]W/T4:CBMS0L$EB
M*]R,>2AHZ(XZXQA0SD4:SN-+H!'N-O0,R HE7U>)(J>)-V$$AFMAC2VS."K9
M;?U=YG27\1S]O,Q^#K'()/SX=)2S\-.=Z?4HLKNF"O[%4MCIU#^4A/#_#=&G
M">B^]7"ORUTD\PL?GFV1)H8FSPWMSAG%QXB1)O'/O6]#S)9)>'5Z3/ (#I<U
M0U(66\R[VP(,]V%('EORY[VOBR6=L&#_N0EWV.@D)[&L9Z1S-(2,EVVSXR#J
M--+7NN_G]40WL&!$!W?W07>!<&YY_K.Y1P+B3UFEN$AN$TLV-P4F=(B/>8 H
MQI8"=LS=%^_E#/XLK!/*+/\];)H%[G=:PP?,IOM]LRE;?G@??-R6=[][RS]@
MO72O%\L-#'6,,S5.9LK]$?LN^[1]YP;>(UI*$<]\/!PL"H<RR@_2:9(4N._X
M[+) CG'#Z@_W!;4CR2B]/Z;5\$J@]RF(- L23OM-JEX0%&1CFACV*&"+\8*3
MSPY=BSE]&8V3M0_Z8XWY9/6O:*$?:%Y<=[L"]1<\,&FK&'@<13P\RS+^$!9B
M]HGX7C&.42]K'W^L(3(47L+8M,?>!=_X24K7%&IB32=Z>7AU@.XWXNR6,Z:C
M0;5%KLWF*(@ @FN%2+NXS\% ]6>KO)X^55[_9U1>OR,R NW]L?>LBU1DIG)(
M)0E2(L+Z"GG@RA$^=%,38=JJP5[%U-P^HGJ?%"(E^DR2 DUF\@-D;+B?R,_G
MN=1&IT3F3J2.TFE*?V%(.;1S:X<#R[:*(7$4,>;B"1-+U+Y E.Q>Z:?PDIAG
M<4B<MK+]Q@OVAEE3H)4UAJ5 EB0QT) %C)I9#QH )N+XVU_@6WX;7!LP+8XC
MH=-<_) B_/6:\I>75_G)Z44^/C_K/=$4JQ^Q\B!=B)CJ0M-HV+-,]VM!B3JJ
M1L"$G!R/CBDQD[U6E->;>;',7:09Q4V#?XF_T?P!:J*_$NY6>LH; 1G2GX*P
MXMLW;[ >9F8WB[-[E9]?'>>CJY/^XJ Z42SOF_>PD #9WE1E]\VMM*Z308"*
M'-[^G9>&\>&;P/B((S_<^->5G'[$12;[V\G^C@/)-<7/N7(Y%U &+*D<K&R1
M P7<6%T(3D5P)4AR#1YX6\\W"T])S\(J0 +TRHW&XYU*%5C7IX-B4Y$#690V
MV F1L2'9'#Q]W*M-QVVK;AK]]?",?.*)_S+48QU!A0<N"]H;!>[FI-[%Q9<=
MCXB8$&*>E0_#B6*J!\"N@]7%B4-P95SEX M,S@Y'0_ADY<UPJTV#6>?P1T1
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M,MO?I):>A5D7-382XF]YZ-$",_9;YAW;KS87&*W1=F?D;C3<ZX#8Q%!;OAJ
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M/II/P-68)HNBF$\FR:R8# D8/\B^4<_CCW#OWZK2N95@>N0:UCP6%":SPWK
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M_ERB%:"[+\MMC2CM=2Y]&1VEK;I7=D,..X9CXU8=7XF];U;5KC$G>5TU#8'
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M8@,RQN +CL<@6E?K$^J&QQD+-"<L.XX:$TIS\/@T?N[*VUDZR+GCQ^-*,L]
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MM).HE6PJ,[(P-_QI\$L\U+0RG7IR(-.#D8(=L]]04T0GN2AHY\0*'PAZXSV
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M5[AL-N<F/&<4Z=*4MJ>V-A*,M=$&"Y^(M 8[&,85L6%^(%^=(MP]F_Z5*1S
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MDN'D),&8IX#%G5+L+\6Z;3B@@1:URU=.#)*I(43B2\N9%M:)\QYK$<"7;ES
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M'Q<XR_F^8FB115\MYM0Q5)0M#$[]E0->5 D*DE@?GHNBR1DWRA'8$^3R$=E
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M1A@^B[S@3RXYK9")0TR]M?C;C2(?L]4\S^8(PI\JEX5X>LC<Z= "X *:#JL
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MM5JO$BX6,BLBKR?1E#(3>CWN&*NG%*M=682PP0&U#/TIM%SFV1W:B2TW\ZQ
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M@?ENC-<( E<S>TJHXT-WBRAV4@[#.&8K$44[7!HXQ$EAE2ISW9@[K:FO06A
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M> >9-CYFD^0/>X&^21,25KQ(2XJ!HDL#!Y]<)7+R:2#,F*AWWR\8XS7F1=2
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MV/"GW%1(D@JC0;[VI7]1B8]N+!;P@> Y+WV?Q[M[X$KA=7L5N02"*$65EK.
M%IIE#H<YU@BMSY;%@K&8,C.+"@.V,..KN#07-9<X-0,/KEOC68F<' R4K+%=
M>3;LA?],D3_95*>%3E'>>59]"M_$5,T'QC'^LX*+QQS^#V[!CQZ&C?N87761
M* CV:QK<Z9&9.B\1*-FDSKBP&W,-FQ>=45):T"31X,\JC%M#Z@*6__+\^/0H
M/#E]\^'\_<'ER8?3=2:U4/4N<N7]A.LYP57E, )2N54%_S)),8]*&A@+X^(Q
M!R+@J@*5D&IM@Y=*\O+S7&]!%)RHE2)4C!E7!\*AK$R&0/;],>/ *P$]EA(U
M2EUB;1A:8')=DTT38'J3E 4&W)1WCF-W\FC0NMDG]'K@]91)B^U#I>)0<O Y
M\5/B,9L:CM7"%JG!&A#A+?N2+(;$C3>.%U4:6.7GU(KB2W$IP'""\PMV_)2,
M^PPLXS$'@62!I6+ FH!\!5+=)/W>/-UX ;T0[A<,B;JV34!7PQ148"W%JGA4
M,C *L(X9Y,58.[R@]H#RVN3.FF!XL!(AL.3AL7N9B/O%!8 A9:/)!J:[MD3U
M,Q'U8RTFODWNT6(;3?WUY>?\1\M3[#SG*3Y/=7]Q.N/!;SK@^B!0$@?6['N#
M5:AKNRHNF-_S-J4B7*K%P>)A+YDB>@_U@-&,D5M4K'?R&)\EFC 5G9HF/L-X
M5F&FFWG#T28 )6O+E?W !G\)'W,7+3G&&D:U1\DLEP+X'YBH$7)>JRYQI'&.
M>OEJ$:/1DMHI:(1';\YB1-K2$IJOF@NE!-BLXX)Y]^4!68+FLJ/L4Z]3PAZU
MR9\O>1_S27P#/@N.YNVT&&');!D>@;:GD.E9@75)8_[I,5PYQ0Q^>F@"4)W'
M\,OE4U1L*8]8T5A#U1@\YI2&9O/KE11@@6"D5.0(SX>;:HQ1BIL"#%^JLHL"
M+<],=6II?I.5!3N&>!OZ"7M.^Z1H$8%Q@$?6KAXQ>'#E'SB),7@J1.8!X@9C
M3C&;4$D=UE51)&SE:L(O"L!6F,I%G:3FKR1;,ZKTEP+3&FR'R<2*=C@#:5J8
MN";&XVHLX<6P)'/"4[Y)XG0<;ZR(=KTJP(RHM?9 2O?XH >8 \/)4IYU:E>G
M@EL^*6XI.U22*4.) _0QV?C2#^IM[T00J!JA=]'3!)C)G'&_ GV6K8M;M7_2
M@!0)%BK"9-!VB\4H\;L4:  MBXEKZW+Y-S[>1D2=+]-Z],(/>?@F'964ZMK7
M5-=[V*DE.5*[KZO@A&K<<5H7O&\D#MYG, )]FU_A\K%@O>V(,^B'41A H/,-
MYC$?<T'QM,#^,/,C5"VP2#PWW-#@8,"NU4%?&R[@&6AM@<&KYE2>7I%9*<82
MR@4&,<":GQ;%)S\>@B:>F7I_V#GWYK2D_230877,#8U:*G"%DX M*WR]#67L
MR&E_G=&QP5"1>;S)/*@9FLUF,'04:C!HP((MJ35H-H^M;1KG 065<7"VP]#(
M(CCAY6+.4[6W2FR.=B(22(.8@+Q'+;'-,SPH%S45B!:E)[R_%2K"@2?!;*]+
MH6JE$AWQW6A<#U^FG>K?]NU+72DLU?2(R:*4(30>19T33JR@QA=?+2/K2TR:
MIZ?+K?BNJIT3FU'72=>9V7K($<:YG65@\;"59'(H+K@6&6455+P>C5O*<+%8
MGV.P)J9_?OQ4QEAD"^LQ@<NS=LR&!ST29.%M_ <]BYR@:\Q!TN;&9-AJF$5?
MK5U.=PS!4;3>M6?U;<1K0HXH:(90U8"L2" I&%$#)@K;N$1)Q.@B259<G%Q)
M:,X5SM]*D.CSAI)I+5K0O6B<ZUU@V<HUYE/">8'YHHS35N*X7]'H2O51)]Q4
M*'7>=!'*!]WA<R?+.+6GF[IAX=16-1IO[3%V[&OD^<AR,3F^<FTJ5;.0;EA0
M(6:7*'1I+*HI,F./XSE5@5.%TJ)D;;QP0KVTEQ%&UC&%1IN/-8]7522Z)TFQ
MO,<K^CL]N>B)/6^MT<H*$GCA-9JW<*ZP]5L"\"2IA>GE=#3/&*/ZI5C497K%
M 5VU\RF0(2>.ZI2]%@W*EU05GE<1,P[O7>FC=4AZ$.!:X=F8HJVF9)DTGEP#
M\*&EW99V(T7,WE6KP4\;.I]8Q/!82S7/0<;7YO\=^&<%*QEL2Y/MG<.4.PIS
MKK488JB0<(ATQIP*X^(SSG)J)4=62;:U*+W4=E[D&V0<&KNGI" U[K3YG:EA
MI3@_-053"1,K?17\\-@M=:T"- %!0D5Y<<M%C._&4T]Z13Z.2HP-,G=2\16F
MPFJWG(ZEWB:_\4PD"VFDD9D:.TB7CEP-C2QR(8>17E9>I8HL!L/EIB9C26P:
M#)O2WWA),;N&<^?2*4<+O&I4_[DS@ 4*,$T][/5_CL#8ZPU^YJJP86_X\ZL5
MK9&1TY&&I15O2%_$L_DTC<P=0B5R;(-U5>MA5S";7?W-GUV=%=PY6-(R'%VE
MPVU=.K\ (?,CMQUU-/W>EJVCN273TQ]4X"WH0T?E^)@Q3.L1P^G;RAO1U;ZW
M83P\J__$P9ED6+.JYI\QG;^%OX')TJP2B9<[M6%4Z*UGBDQQYEAR[BJ*:]!L
ME(#KQ)]PDF->G3I'CN>$$Q(T4U[]?B_\;^R5H @W#.< )@,_F.J_C[)J/"W8
M.3X8887.>[;S*9RLZ;$3S2NBMJ5?/=5,THE;S/DT[@5JOV<_VP<L0$7/+>%\
M2WB8!0%' +IQ"LC"3^/2)GSAT\LLG4JY"M<3J=!Y!:[>5>,XHC8?0ZDL]PX*
MG#O(>Q:)7B_TUKP*&W=)M/HRH6B#_]T[;HW@WD&[MX=G66O6WQ[&.S<FPHGA
M0?-')ZFL-)@CNA<;];1(Q<2Q>&^Q:,58L_Q&+U3KF,1V/)HW$^LMTM+<L=$6
MV-4I6T\U'%P_&&@H5E/&W%])_9H^"(5U$._5+^U-%OW22JDW]4OP=/3+CY;!
MVGW.8#WU#-8E9I'#2VGW_B7C#M/UI:_,&\.7X"D7<#!S<35'F:2IT?^NLU&1
M4'[IX.@0_IOF?RQGHGKFZ=622V+ 4JM3,/A>!0;_ A23Z:"9Q'"M85M?R8UZ
M57K%]5'BL%+C=0:*JJK+):I/@EQ8S,$>IH*Y-T<'MDXTH4IU,;SY!L/GUM?\
M-C2^4- ##(8D6*^*8!T,')#3^:+*11O\*!2*!1Z9I[>ABV$1ODQ[5[T(EF3#
MK(FW6G9Y9EAWM]&U<H'\'4OE8IYX%%Z&B.LG:"-E]4KNJUN>9SR^3@5BB/KZ
M?Y]/BXRM:1O=\:;;$3S">B!:R!3!DN+Q4GHSQX1'IE73Q80&4E.;>R8(=EQ#
ME,:U033 >$]I,:4.#\XW+NV7(@X]8>TI7%Y8D)' @N!':QJMC;0PV$"@FRV>
MV4V<31UGCM[2V@L#^F)6!^9;8J#":]S'R]?+WYAK3SP5>DY-D%@H'?  !6K(
MBYM4EX([_BW,P5=(.G[ML$<O/#P_N3PY/'@7'AP>?OAX>GER^C8\OK@\>7]P
MN48THTLR3U)TR#U;]YX6_<H)SW;6 *&#F1)\!4L/R/I!GB^H-TP0!*1%@?%,
M#-@>54Y^ LL+QCPS:!Z_+1)1.USKQ"%(Z0* QZ&'3.6X['Y6%=E>T\Q@342!
MZ4[$YUF$(P<"ARH8V<AA/6/PW?B![$':9S*X"SOW7,8*ZY=O<&B;@(4D%&GF
M$@58:SSUBI')'MS@HEXMQJ:\*)?CVW8@.8GWHL9$VHB)^J( =Z8V[32K*]KD
MN^M%D"'7 "-N9J_%HG<##6PG:SN(@[@6-E#> J\"+G4*>,=9.5[,./!=L=IR
MLT/>"%""Z4N\@0HE8B74N"U6)F,RB+G\O"P1M22@ ($CC$W9L35[7"H>)U@E
M!X<F)B.?NV;I>$D=2B\\8!A '3GJ2E:/IOC4%36>?F#]!G?E*(6@90U/#@#C
M D]$^ N=B#,Y$6NM(AU3#H#;K^MB_$E.)QH><$K,26RVO!Q<'(:[_;U(/:M#
MY_/!1GB!CPK='XIO1/ZH^3(G58UZ]*P=W5VQS#*GVYFKBGP]$L:2L1-3#8L,
MM 0]7%3BQ#+@[ 8ZJ?B369%@LJBQ#O#_DS2KR?_C+K@E@TKR<?*:KN&:WX#K
M)'8#*%0AA*.QX=$@+YS'1B$AL)'"^H/C**V+R%P_:@:6Z36L)27?*=!<42TG
MZS(JZ+!E_556IUJ"(J%E.%,?Y[ U=A#2L\7?SQS B:K@ ^O\SAFKFEU=\Y6#
M3F<73CA'B=:J9@WF&8[IERGX:AL7X^MBFE8;[].ROBYR@UCLBH V.\Z*2DQ.
M^#5*T"R%[_"D11ZUT-^72!/L$*%D8735+WX/*U*XDDP+XQ"9)Z>@ R^@O];>
M'@?W[G%#]J2-!;1CM3")%-P3:DB1A,.OJ7VA?^A;HB5?#>1E?*;$@(]Q'S8(
M&4R6C,' L(9ELA1]K5:+MB_=:W>9[A^I3 'S0.TF[K[EU6#S0O$1Q4I:X_5.
M@(HL1VHAL3@5<@7!/F:,F<<G#1&9KJ:IP;R&PY0A+C!G2A=5@$N3)5A=P@AD
M5-A$NS+-)BEX>_I3K#-\Q6*6Y7.XF+E>0+O2S;@HU$_I\-J<8(%W-,^B1XL(
M\=O6N82XP3B;+/?R-*R_J1?>.7&XB&06<U.1;S^[0+4V/A@WO.II^KN+&X1'
M$.TNM*9:W;?><OM+)%%/\PFGE,)5"X&$1?4L>4^DT.VGC0FV1S1BRVJ_,XYC
MAMV=N>H5G,6B-JO5-83,.4,@#" 96* 0K!BDZJONP3CK*I%V# 43R!%'\3G3
M5*-IQWXR][OY-5;HK8/3L0S_2.'FA#L7+R5*356V9P0=!UI[7&[3V>RM&PEK
MQW:01E-)DGO@#@GO7A]KDD<^'BU=?%;74C,A%8;*PTA:47&[YTJA+&L\?LGW
MP*6^<&ZF3AWOW#GL28B%9CN?740+@W,;!3]M69@-$E;O!VX*N5J=0[XK)_VU
MENKS+?1S<3#/K8.Y-K7(R,7JRY<6:@A+B,BY)G?(@<.^2<7[(E1Y!T-3FY8#
M^Z/(?W:]G*/TPT.U?]Y]QV(.?V"B4,UM*E<T40/36NUX^R &6%:;HW5]C5XK
M#^1[(-QKF8H1],H$#E8X-SN;.^&&>C<J [02AX)37W&7_"&\NIBEG]G ]#50
MY[4QSZE2@>V)I\L_!)GB(?+AE'/=7E-[;D".#X$+6S2^:ES,28?*&I%8J;Y5
M%>E8T$YKNRXXZT/?S'6'/EE,)Z! >.A.BW/ JHEPFQ % P,-CBR[CP =C;$-
MH2RQP'LX??!)Y@*%)2US M&D-X/R$$02.N#-5F2]8"S[_9H1E[J?(0/@UA$?
M9<%]!3T#'M)I^E!S;#PVWDJ*G[YYA>@-Q=@KL6E]TL!*/G085"H$SW:B:.Z6
M@43DM!PQEP?B]5&!71^[;W"PE)[!!A^< MW[85*@W\QQ4&\IE@. .,D"U&)$
M7(U+/;V:?J&*V$GVNPVJ1X'Z >8GU!P$B]0+_Z6_\M])A;%%KKV_]%0#T]$^
MG7B<G#9J?1999SEYTV"Z]H)?L9D^]</ A35NQ?=&Z(4I7K)5"E87NO9:@4&:
MLEL%&+5EAZDK119TC2,412.8-(0#TJEI[GJ/Y\*KGY:L''9US[AI46S (K;7
M.-T[YJY9H14%A4@G9@!2'&#^%?.@+6NH5!<\#I[*2C%[;,3K:U@ A.=G1!V#
M2G.;7VVO T69^+)'N:^QM[Y<JF<#=CKE3!9S"<W@-4C%3Y7)JV*K_'2AUX1I
MV9<F_5YX )>P+9A:.8K61JRXL+2_H8J5QH)B8W7'G->^^&#_&)\&.<LT+(S
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M']-ZQ<#<CJN<O+M,+V)_HG ,WCK&]@I6FHS"#_6K@5[2^.F]9IN)],FYD:@
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MQ,OPR\G/ZJ%(@$RGV)V(NK95"*U&>&."4A;&W"@.WWK#OY(=[W4Z YP__/?
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M/ PJ@;O:<"MFL##@6^4,K; $Y,K<%."]T0($B^5V0,JJZ7"I%WJC>YU7AY2
MAWKIYU1*5- 0JGWL2XJ!/:S$F"WRX@KY"[W??;4=Z/18](:(IQ3Y*"H-F'0A
M_)'W73%)S(G-14E DPL-=S-WWKPRG>8T)NU:I0?75914*C0ISN;9'ZPR\1ZJ
M5%S,CA530KGRUYC7O^G#::F^1F=BZ^\X%JA+,W(7Y 5!=F$K"M96D@"9?T8N
M;9R.;+.?9&4/O7QY76)S;I^YA+R%V \)P\ @:?[^4^<G^GF!EHS\S'R(_IDE
M?__IC[A[,.E/>J.]9!H/XFEZ$$\'DU&:C'JCX2A.1G:W)?K"3[8+D!EZHZL/
M_X**7K.IK]U.G859S.ZG!^DI)DO6<J=G=0L:[-^B4YR73YG@[F?0^LO$1*K:
MV=13=1>[;N7=&UOU#6[\K@@R-3SVI.I$(?YO&[_%.:3>4UF_697C:O;> $=(
MW]0-CC6'=<60(WNH#P,#&E</V*F\=_=.Y8_1\NRV-"-S;6W_=T<:J75@N^\]
M_4@A;70*@E&#4+/H6F1W] ,>9?=9F\[?Z[;W?GJ@ _.IZ;<ZN#7:P_E=56@\
MG<8YFDY;?]F^>^= [W7Q\9#'8;MWI KO1WVS_H$H0GE;X.)?(QX>^K,(;L&0
MNNAT DI\. ;3?S!9L2'R/PF1GRZ+R=>=U^2\==05H+SP 4EOL"&]#>FYI/>%
MG)OWDK4O4F6]2YM>4% ?NDVOKPG-;<383_\P632"0.7O_?<\+:\?H=\U(GB^
MU+D]7B_N;N?!26^P=Q#U^H,7TGW[$4YC0\<_!AV/NE%WV-G0\8:.OVLZ'O8&
M46>TX<<;.OZ^Z;@;#4:#:##8_]XI^9%,B-L9!PZ SNTL@_;*5R^^SC-9",]S
M1U_,[;N%GM,;8CK52[E5S\7Y-_2R+A_N=T&?V-O0RX9>UJ*7WEXW&G9Z&WK9
MT,M:]++?VXN&HX,722_?B^O7KJ&\G7)7K]AO*:'<N'TWYEF-S7>!S?>Z+^7:
M;MP,+V=NWQ<=PRN#_HL1/QLZ?CES^Z[HN-OK1(/!BS'K-W3\<N;V7='Q< _H
M^.6XI[YKIZ]!"'L C^^U:%X;I^_+-K*[!\-HM+=QXFWH94UZP62(_HNQ[C;T
M\M+I9;\?[?>'&WK9T,MZ6MZ@$XT&_1=)+]^+T]?N=7 W_>ZDI=O!$Y>>;LRR
MEV^6=??WH]'+40@V[H67,[?OBXY'>U&O\V(,H0T=OYRY?5]TO#>*!KW1AHXW
M=/Q=T_&PWXMZWW^V.DU9F0U_)<";VV)&W8Q M1Y2#\/S))UI?]#9FQP<C ?3
M_>[^<&]TT-_O[,?C9#2>'.@-?7MZ\OY#5BV_W!&CQX$;NPFPIQ6C1XVRCRAO
M"J;()H7F<RU0,0BKT?YBO%H6+;::!T6I1L7_0" J/U2/ ]6J4*D(AV^ZRO.=
M)6R9@8P5I%<!IPH3QDYD$$&"Z"(\3L*.X=8=O?YNW;YS[=1U"<X/UW<+LDKC
MP6#4'>V/AKUDD.ZE^]-^=SA,DO&D/SGH[?UYR:KWB&3U)J[.7; WA7:64,ND
M>2RDA4(GG4\0J8V10JE!->&<%SFBFA+%38HYSH1>61;RITJ@+]-ODW/$30X1
M"QT)[>/1J9Y-?W>T?[#W=T3!['14^SS!5F-(.H6<R=^@-DPT$,(=,:*EP*=]
M3A>(CCWG+CSA9WAHU^;QST"[H^G!?N=@F/2&>\/!:#\YF(['!\ 7TX.]=&\\
MZOUI:;?_F"S1B\N'F/Y%OIK-%:JO ;.EA@@&\\3NH[(\+RIJG9(0P8^O5/,O
M/.(\OMP-3Q'%L&TH/;%9?*6^&REL/NH-MK0'E#]8J*U>UAZ!CC!?53C314QP
MAO O;.%59F-IPP?S^"OB$>=YH?JNPGW0TZGB"X(DGX)*@:,(1G%H811?Q!-I
M63F!6PQCX7]PO$O^NVI+F\VK%;U22?<E!6)<9M57\]=P*]T]VXU *$WAY02Q
M;ZD7>:3G%$\F%-/=AOF<%PB\CS<ZSM-J0FU\8*EFO72["=@XATE/T.N(?0_B
M;]A,O:IV5@OSJ$$Q;CLF_!*V\X+']70(&-+7_VA1P'%A4X)GYAV#[BB-]Y).
M.NCW!OO]Z?C@8-0_&/3'W>F@UTOZ?UK>,7A&WE$J&2(WF&"T"<>S3/CINZ!X
M&O1EE_PL7%(OTO*J;* MUS!9_:HAHC]7J]E"\XKP:WI%W:F01*IP56F]44\(
M-G.RRC6*+8&W*IT (:T13W15R8L?"Q# O4+- I=&=ZR@1KB(TNK;(812AUV"
MA:=YE7)S%K7_?"#KZ9R/ ^GK@!.=(!.X>FI(\U\)^[:)CRL-)4J%@8NH_ E0
M3!C7,/QIUDJ+@NVN M[OB8_'(;B[C0BZ5#"Z;#40W:0:4=?ZPSE3F2U'[6E$
M(<X3FYQ0BVE+Z@1-5ATA(CI3*K=,R3.1'-P7"'9D-M?=Q44<>Q8-]Z-88:OB
M^&O*2BC(&Z3>B/M=:.T5Y6(4</^EXH+;>G)WNP7U T*$(@+'1SW6 3%7QE1D
MMRS -JD@"'7;\XF"_Z7FK_R&U0W0R' 8/\"6I>D%[U^Y*%@_'O_.NH%T_=/]
MX*@' .V8:G@WQ4Z5,G_K<RC,U<R?')7_$[ #+TU:;<%KMRQB?&AL'<BT/8YS
M4BG&Z?(R3>=T6-D,^0/]&E:KCBG[ S?&)4L< ;8,NW!3UPK@04OL'R1J 0XV
M3^42582/3 CV5H-B=P&S%%\%-A?4-84<Z&J'K&?I\Y1-\)N$N*L:$QI&: Z6
M.@;X=D+!-#,XLS,+;,B0+9>IW"'X\[B VX6;8:B4A$J<P/5#2IH!W:Q*H2,P
MJ+YE<K%0#8TSD.HA;9,THG%VT6E@:?4(F7Q%4XP:\D:!?;%F,;I.L0W4/#Q+
ML:75XIPT-K@;D31!XX8?ZFIC1WF>T&YX7)0I;G[41B-((M@^E,0JS']6P$[2
M=8%S:9X_7RS3_ID) %Z%[5CE2VI;H5KFX/,(:+Z38^F1::QAGZ3X6/# B4UR
ML\8"VWC,@<N ?8K=$L#0Q1X=\%W2C8$5P6_-89/CI8PO0?XNT."&J\'=:)>@
M!)/& 60(ZQ1T]0I;?"VEW0-PEYR:8!%35JVH84%GW 9XX;1 "ZPNQ!)HUQT[
M")C\,J7.;=2L@8[/:ABV Z/#AU"15VV=K7X?+%JXW5R*OLQSVHIL[C3QEA;;
M]0NC" /N28Q<S=V;<9KCH4E'B6S)G2JH+]AL19W;$/C<(4@261%/ XX15?]:
M>Q/@LOA;<T=H\+@4J/ME1F:8-@:<T:D-!HHP?@DN4*4;BUL[@N\2Y'JVE$%3
ML5\( )\.M]ITM[AM=XOAIKO%=6#Z=QL"6X5-T)@AME:S@47=1 5#FOID8(P
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MK1M39)]30*X6G'CN;L'6C5E_V6ZJBKDBO2@\#'N^VU%@E"G#(M5J"= KYAV
M%6$*DOP$NE]6D>OC#,^-RR:L'&#.;;'RA$@[P<74UP)[NH7HM<"Q5H2D1BG4
MJQ*+=3!+X<9RR[%MQ[!=J(Z4'?=$2CX.:%\+6Y;(D=,!!<X!*;Z*TRF)N9,N
ML"R67-\T,J01J<QMICZ>BGJ?IH23[SF_EF/:?G+=[,NYA8CH)B*AN(1_1NB
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M];>M4DBYRV[Q:R#%KQXX'.O3KGRTH5=*H65_26UMU"=7UH\Q?PB>"_\G+ID
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M/ J2"_?$P'?:O%EZ R (W"3-+D0I9C_612KRVRK6=HMK/ S*#3E1RYS24FY
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MMG(!I@]=/"W-N0J]5,@J3&^TXI7KY(%O-M3Z02]*'UM'S;GCO-,$9AA-T[O
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M-[ <FSP!_XWGIF>-O"=+PWH")?$<&22R%9[D@QL8^-CE7NUA%IMVY#,U"F6
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M;\#JXT21'K.E?Q+ZK]4V\D5H7YXVM'IRF&;[$>*X$^SO[@?;N]6=.9__M+_
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M9&R II9[B(?@50T!^@[;W83Q>ZBTI]%\S@GSN&(G([V3\),,DVH& +Y+H.1
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M94AIJ\G0=%3+1? X890XL>$G,8T/N8NAI]N!S_&LA&@NSMU<@E3"@.25K?S
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M4[:ESC92)5LXA[OL1.[]@P/TM4RW/)SZ U+@6:Y.FU9CKQWAH%O/,Q$OY#_
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M.D+1%TW>$TV^5OHAA%VR/<JF/&!4K5[!ZBY3IS@G(T_7'2%$=#)%,B)=LT-
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M-W]<VS7Y^OSGBT[_TN_US/K"+WJ]ZN5]!>,E@6@7!:)=+Q GG4^GETKY"Z+
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MXY1"OTJ(Q^@G2HFEW/1,"*$Y?*A?-$4V-? KT%<G'F<K-V"Q<NA71$K81^0
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M45R,C+JV/?)J?*HZ +L$HJ?8_L3TKK+.,G=ED5L$F=3SU7>WP5?XB;UIKBK
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MS'9Y9QB?*HO!(-Y&YO$3HI2![MSDC*+"82_[ P;RDBT'R-?H^77;>:8<9I-
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M/JBRTD#3X/(?&?10"/7/G0<C'D-'#B6$WRAB\@/M:&[]=TX$<FK0I_.M*M:
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MW4B:9"_ID+U$D>5>3_YSN\'V;8$@R[;5%W.'=KC+-ZNJ2)UF_=WK"NJ+"&L
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MY!67C]4)9\8ZE$8+^FYM:U)$6D12&^6US )E 65)I2RQ!J$[*$N&C>2E;D^
M4GE1[:X:]MD:8;)@S9I@--/>T90\&D1\REX,>%"U8:50B\E%KJJSQ2Z:2DP>
ML76^ +X[[?V:/'A!YJ@J]3H5.50"NBO08HY;=]OR_KJ;Y8&P3J]Y/+H+D<O/
MPQFF=?W6(S*QYF+$5 _94S0G+U@IOQB^4=Y]*;+!#^$:3#3%X!Z$@2 ,Y.]S
M2JR[>H! -Q2 [ND:A]/O+F:EH3D'3ALBM$T C0&-V:0QZJ$:DVGT5&W70V-J
M=3BT4)/QSK&) 'KOK/D9'>$^HT,,)&258"N6='IE+Q.S4.D0WC)M55I6X' 6
M',ZJ6P0JH:T9!_H[4[.\OJ5?!5A_F[MAKBH"F!D &  8 !CK 2.AG]E.@)&E
M7])JE#>"1@3 @+.=(MP(:E:!C\!'<6Y4$S[6*E8E?",S8D*<0C>S2JX/NIF!
MKPF^9AU]S35MQPJJ:6Q+G=9Q]PX28<D $@ 2&T%B37NQ@HHGNY+<4HX:)" (
M)<*-:N+TBDI>X"/P\1CY6$ 0J@E!J" ()4;<Z4"&Y.Y.B+*^U'$G41:<"T'+
M<2F%(VG4'R/+0[H]I\-BZ^20_;TH:$KK]XI YX0?'%2567*O_W:LOPWWI_.M
M_5(5J='8\Q B*J')/T#FX>L33Y4!,BM+YW38%FM'M!;;LHL0]IJ2TA&OL+5(
M!(M[D7^+?*@1:0Q_OEEZ@ONL4"S\HY R_&?N>L;TO1BO[^$)(VTRL9_)C]_I
M^6K+]LBW-8>\3622R-BCHYEHICGLN+5'ODXDCT7N-0_K:&I8FC4QR%=<C[Q!
MJRC=LZBD1,CXZRSJYYZSM0<$FJW[<O1A/VUZ/,2?#_%3(KXW[=DS_DO_M2]2
M#?).JG,D.SO0B=SQ_W^-3E'L7$GTC]GG-<*Q6.*3$WSJBPB-H'.=^(EC1UQ9
M@@]BU_L4#CIH<\\.WF# S-_AH$P1 2=<8*8]XM.Q@[4?I]J4O'&NF:_:NQNF
M?YS\C#2_Q*%DHZ9LL6=W5"HN2J_\C;%MZK'-X==DG$N^#=_(4MPD!U6^&'Z[
M^_[UZA;=/%R>H?[M)1H\C-#H^Y?1X'+0O_\C!7XGO)GTUL$D7@.(65PZ%\+>
MCH8W@\O^P]4E^M*_Z=]>7*'1[U=7#Z,-2$<>1C =#>EB*Z:++::*FUE_Z Y6
M#+N^GXW.B,%HFIKCDAV,[%GVW-4LW44?\-L$SSSD/O']34<S[/BOR':F?=RB
M(OOM\LQ80!-LFKY!\]N)?,)>4VLD>)WPE'%/.[JWK6R*(090&5D1--^JDN5_
MG*PU;/AR]XF5IYU[GJ%7EL,MU2VW%.61\G7'<R!L>\LMHPZ?+[)^?<B&^V]Q
MX^((6 X@7>()?AX3I&DH4E%.5$ZBE%UV[3@0H]Z"?4M\Q8H+-(A0N2)$@_(@
M0B!"AXF06G$1RFY;+:B13Z>PD36#_I?!S>!A<#5B(8W1[_W[J]^'-Y=7]Z-_
M_M15E<XG=/6_WP</:<(;F8A 08U[2E]#;G3(%UZ!/< > =8@"GNRVUGRIDC5
M@S<E*!.0#$AV!-9FD570P=3ED-U9V.AEV!O!=!%@#< >8(\(EN4N\8@B&PL_
M.)K.IK31O&YA9U_ <"F<9'M>7X3BTO**> 4F2KJ*VUZLXG8R(6CJN7=<XR\*
M:.31D%IR>8TB055!5:N@JAUY;U7-LJ=KIU/>6&NQ#+D:3I$8/=F.=^IAYYD(
MQ103>=)9,;PQ,68:%TT+W?]3>YY]ND28SX@NS"8$E^?H/=(JK"&V\1S#R:V.
M$IV427'D@<#(I8\B=V$0&5CWV,6:,WGJ6_HE?L&FS1J2^T/G,SW*.C7>L'[Z
M%W;LD\^GI6U<H+)"K^$X55;-5V6S,SH;:GEM'B&^6(+)Z1 !L^80;8001G&0
M7S4X?QL[)H79)D':#D':+@&E9N?/]899$#4(\/V>*UD1 3Y%D91F>4-=03U
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M8K<E$\LS-A(QP:1=PN20HN1%&"0'#"-O;->]Q=YP^J"]Y1L)+7^#!C6OV&)
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M<>6'FFD?(S5J9OL079:9DWJ=I!$5QXV:\=#<WR(?TJXYX<\WZU)PGQ6B%:Z
M#T\8:1,:\M*L=QKSLFR/?)M(#B)7,XBP/3J:B6::X]&8&6T81$30M4U#UVA
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M91]'.4!@"CFN)X:Z9;$8$;2K[ :7QX)/L6[O##K\C#O'F9Q1Z8!!NHVD0W,
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M+K?S-#7 1%A9#]3T'BS:5#I9ZU![ZI?P2LC"A4T5$"JA(=1BCBN[$CMCW(H
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MR-5;:;9S=5?@,%NR,(ODHH1E%]E36@8X(<_LL9I ;3)QYJP)J^^PD.^0E?[
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MO-IM&*$%NB6X;J4(6>^I6]!D$52KIJJ5;M!#JZ6T.G)N^I5+XT4!6K2#QY!
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MF=YM:U@YI@P%+P"("\05A+A[07VKQ2Z<-=2O7#9GB=CW;OM)1%[/EEHB@+A
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MKAT:LR,6//ER'[05M#6M;$]JK:W$U*3&Y]RAFFK:KHL7SKOV;,^YS_%WE*Z
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M3\Q(5)#/>DT@F*(E,;(5TU+#H,2KB;-41*[KZC+$+8E2Y8!///SUHG >Y1)
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M X;<\^>8-("3R&TW&G+?I=0R\!I^B _H=='U$3+?MQ)/'LT&99 NNR]VJ3G
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MP3!HRW=PEN\3^F,)=-YVN4B@]/KLR:0P=*SE+6,.BR19!W1I8/'\ZL'JV^W
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MN)>@U@YNW$>MT^%9J]\I$G9X&)YQ05.<Q1L+ ZQ5,A&%4]CS%7[(A@YH-]^
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M!TMMP> Q<@O62MEXOA^;)E(,:ROL"&@I$ROP'(P@$\N4%SD67V,GS/[.W9V
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M.K]>7U_07]U??V[QBX5]M /#]<#^<=/%#8;/YB82"BZ$=0S@FPFSOZOT:O!
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MC67@B,P  8H A"AJ"D5V>+(J=UB]ZM9:G:OMSYOXO ;\:\;Z1B^?C)LF(9:
M$JC[M2"\$S@\Z&GJ@P]F6)ZE-'*4)'_5T(%)KF%QZ"HG0QNKD_/T.T]^<T7'
MSD\VV'J6<?EU@<ET@_]X^M,3*TO"U"U4-EGVF3:A[L+/GS.HK3WI1F2"7-*
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M-8V,5 GNH<4;_?E#9MC2 C[ASQ^]J^:R]<!M 3_7;5J=W.%X9_X@N%SM!:?
MZ&PJ*)#/5R2YE]#F)/53+V%Q4WV^+,T(BP)01YI$K['V\S@-AN\.&RX:#(,9
M:1Y0_8*-=V4W94_SA+J8YO"$SC'5X%)PCS&2AC4,8'KSF$[85OM9E[@E[VIA
M!36;,;1<FV<NVQ8%)&>.51]5C44 !'"YJP8KI PY+,)72V:+<]AIGCI]V+>
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MP3W]/?(;L*Y90;;.F>U&\6W!C7Z44I#M/@Q+^_"5UWE<Y8Y^>)WJ+KU$(:(
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MH!R&66O^E4!A=^FSA<:1X$Z_J&)WU4C$:+*\ S%W%T"FTNHUU;1&,)K2L<>
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MN7C5465WR=QR'/V)ATEA-VQT\SN:\8[EPL[G!H_"+@,:Z,-G'GSTR@=WX3E
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MX0A.3 FH$E"%H&Y.0$UE>FT"U!+*ZY: VFS6.I66VDE %9V8$E EH I!W9R
MVMX64$LHV(L :JNF-JILFB\!=7MBEMD+J=+RZ9.[V6K8._RC5EBZ?_B'E?MZ
MK*26^RI2!'!Y,)R1 _^&FM9,-P^2EK*T0@2)8 NWH#6FA2 KW)]D%6+ZZ1!-
M\IGDLR-<D.0S:>0>U<U.3&D6F=1R7^6^RGU-W%UV@B_)[OT_=GTZ)AH\D/9,
MB>FQREEK0BP;Z*+9"YZTEK\EO,!/ZSGPI+KIMQG +@3I7#TS2.6K(%]O@_C(
M=J@5*M[G$J/,%Z+L)$.4 5#T.4[<,YAXF+"V%<Z#YSHN"!$P*VMAL562';]$
M-'9Y=_]YTY#O;JW3;-;4JYYL.BK0LB7(2)#9 F2Z18/,ZL2SG4"F4VNWV[6.
M*D%&I&5+D)$@LP7(I$;E[ LRJY.Q=@(9EGU5N^HJ$F26CR/=P$+>[,3<2B*3
M6NZKW%>YKXF[%U*I?$;>W4^K*Y'CWMT*DKUE=8>L[CANZF97=T1Z_BHMI=GN
MM)5N8V-S=+_#[U:.TN^#FW^#Z/Z;2>Q65L:RV".?S92:KY?9J+CRQ3?J:I:5
M=/#"E6;A!I(H+%]%): \&.3!<-S4S7<P=)6FFO9&Y3\85CNW*SL8>JE>]GD/
MAG(7WZ@WK^3!( \&>3#(@T$DZN8\&)I*HYV*A>8_&%8')*H[&)1=#X9R%]^H
MMZ3%<&0'0[:7[Y?4AW)-SUTU+E>\4:H[#F136HUVL]ML7K52/H>!]^30_WC4
M=&]?X(=3XD"V)-V%'M"69J8LACOV,6VM/&/:,AYSKT%M<<"IY&EQ_.KM_WZ_
MO1^2VW_A.,]< )1%C#3PQ* D!3@[3!<C&1WXA9_;=F>2?VJFA\$"P <XG]9J
M-2TP\7H@<BU%;333L\\TG'LV< &%XHD7=X[CT?&=.5P.QLZ J58(4_"OIO)O
MS\&K)H!NN)C3_D_=R7[W*QL-%7E/'^OP:)&%L>^.GJGYX,=(HBOLF^,!L/)P
M"B?W\[3OSOCU]LP"4:_46C<CSRR9A$]>J4V)SE;"XCH.K(6X?#%L@EY_^+7&
MYYG/;6M$Z=AAH\GG\-=/N)=+C07Y:[X-;*IJ*]3KD![OOVIP#6_6]]RI90-;
MC;_Y]_AL6S.D#XY"?YA<6[.993):'ND>[MQ6Z6.[HZ9W\0*+"F ;\A*^TVZE
M'$7?M 4.KW?\!PRH?6TY;E;+J-.FLM)-$UGW*4+HSSDU'>J\JZ\?#BF$#IB>
M>QB?UKM<UCP/<.<=L1@?-IW]%,V2IK!__MM?>FI#^7#I_VZE9I;-EPIGPI)"
M36]D4,U&6VB:'%H?[N9R)+?O:V"?J'?;.,R9C5 *)E9&KAN-TF=,I$S>[-?U
M=VON<:O@VA%6C YMSOCY9(T7\&OJSHR/_Q]02P$"% ,4    " #(@&58[9+.
M.1P5  !.U@  $0              @ $     8V=E;BTR,#(S,3(S,2YX<V10
M2P$"% ,4    " #(@&58>\^\@%\.  #ERP  %0              @ %+%0
M8V=E;BTR,#(S,3(S,5]C86PN>&UL4$L! A0#%     @ R(!E6%8>>:JC)@
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M:&EB:71?,3(M,2YH=&U02P$"% ,4    " #(@&58<,CUU2<'  #I'   $
M            @ 'W0P$ 97AH:6)I=%\Q,BTR+FAT;5!+ 0(4 Q0    ( ,B
M95BO9>K0?00  (L/   0              "  4Q+ 0!E>&AI8FET7S$S+3$N
M:'1M4$L! A0#%     @ R(!E6&7/T&$0!   ; P  !               ( !
M]T\! &5X:&EB:71?,34M,2YH=&U02P$"% ,4    " #(@&58C Q">\ @   :
MC@  #P              @ $U5 $ 97AH:6)I=%\R+3$N:'1M4$L! A0#%
M  @ R(!E6)]HMBWQ90$ L]\) !               ( !(G4! &5X:&EB:71?
M-"TQ,2YH=&U02P$"% ,4    " #(@&58X[84(XT"  #7!P  #P
M    @ %!VP( 97AH:6)I=%\X+3$N:'1M4$L! A0#%     @ R(!E6'R7=4-E
M&   07L  !               ( !^]T" &5X:&EB:71?.3<M,2YH=&U02P$"
M% ,4    " #(@&581Y7?KU@D 0"!G@, "@              @ &.]@( :6UA
M9V4P+FIP9U!+ 0(4 Q0    ( ,B 95BD!E>"6E0$ !A_)0 -
K  "  0X;! !Z:S(T,S$P-#<N:'1M4$L%!@     /  \ K ,  )-O"     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>zk2431047_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cgen="http://cgen.com/20231231"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cgen-20231231.xsd" xlink:type="simple"/>
    <context id="C_20230101to20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:AntibodiesDiscoveryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:AntibodiesDiscoveryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:AntibodiesDiscoveryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20221101to20221111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-11</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210901to20210929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-29</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20231201to20231227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-27</endDate>
        </period>
    </context>
    <context id="C_20231210to20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:LicenseAgreementWithGileadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-10</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="C_20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:LicenseAgreementWithGileadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="C_20201201to20201218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-18</endDate>
        </period>
    </context>
    <context id="C_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240131_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cgen:OrdinarySharesIssuedAndSoldThroughAtmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-10</instant>
        </period>
    </context>
    <context id="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-10</endDate>
        </period>
    </context>
    <context id="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-02</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:TwoThousandTenShareOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:TwoThousandTenShareOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cgen:EmployeesDirectorsAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20201231_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20180601to20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:JmpSecuritiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-14</endDate>
        </period>
    </context>
    <context id="C_20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:JmpSecuritiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-14</instant>
        </period>
    </context>
    <context id="C_20230101to20230131_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:LeerinkPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:LeerinkPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_cgenSegmentReportingGeographicAreaAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_cgenSegmentReportingGeographicAreaAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_cgenSegmentReportingGeographicAreaAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_cgenSegmentReportingGeographicAreaAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_cgenSegmentReportingGeographicAreaAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_cgenSegmentReportingGeographicAreaAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapSubsidiaryOfCommonParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:SubsidiaryOfCommonParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20130801to20130805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2013-08-01</startDate>
            <endDate>2013-08-05</endDate>
        </period>
    </context>
    <context id="C_20130805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2013-08-05</instant>
        </period>
    </context>
    <context id="C_20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_20230101to20231218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="C_20231218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="C_20240101to20240131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <unit id="Item">
        <measure>cgen:Item</measure>
    </unit>
    <unit id="NIS_Per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USD_per_share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_20230101to20231231" id="FFact_0000000000684">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_20230101to20231231" id="FFact_0000000000685">0001119774</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus contextRef="C_20230101to20231231" id="FFact_0000000000686">FY</dei:DocumentFiscalPeriodFocus>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20230214013608017"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="C_20230101to20231231" id="F20240228054805245_0">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="C_20230101to20231231" id="F20240228054805246_1">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="C_20230101to20231231" id="F20240228054805246_2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_20230101to20231231" id="F20240228054805246_3">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="C_20230101to20231231" id="F20240228054805247_4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_20230101to20231231" id="F20240228054805247_5">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_20230101to20231231" id="F20240228054805247_6">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="C_20230101to20231231" id="F20240228054805247_7">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="C_20230101to20231231" id="F20240228054805248_8">000-30902</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_20230101to20231231" id="F20240228054805248_9">Compugen Ltd</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_20230101to20231231"
      id="F20240228054805254_38">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="C_20230101to20231231"
      id="F20240228054805248_10">Azrieli Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_20230101to20231231"
      id="F20240228054805248_11">26 Harokmim Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="C_20230101to20231231"
      id="F20240228054805248_12">Building D</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="C_20230101to20231231"
      id="F20240228054805249_13">Holon</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20230101to20231231"
      id="F20240228054805249_14">5885849</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="C_20230101to20231231"
      id="F20240228054805249_15">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName
      contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20240228054805249_16">Alberto Sessa</dei:ContactPersonnelName>
    <dei:CityAreaCode
      contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20240228054805250_17">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20240228131713468">3-765-8585</dei:LocalPhoneNumber>
    <dei:ContactPersonnelFaxNumber
      contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20240228054805250_19">972-3-765-8555</dei:ContactPersonnelFaxNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20240228054805250_20">Azrieli Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20240228054805250_21">26 Harokmim Str</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20240228054805251_22">Building D</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20240228054805251_23">Holon</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20240228054805251_24">5885849</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="F20240228054805251_25">IL</dei:EntityAddressCountry>
    <dei:Security12bTitle
      contextRef="C_20230101to20231231"
      id="F20240228054805251_26">Ordinary shares, par value NIS 0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_20230101to20231231"
      id="F20240228054805252_27">CGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_20230101to20231231"
      id="F20240228054805252_28">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_20231231"
      decimals="INF"
      id="F20240228054805252_29"
      unitRef="Shares">89237465</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_20230101to20231231"
      id="F20240228054805252_30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_20230101to20231231"
      id="F20240228054805252_31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_20230101to20231231"
      id="F20240228054805253_32">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_20230101to20231231"
      id="F20240228054805253_33">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240305013307112">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_20230101to20231231"
      id="F20240228054805254_39">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_20230101to20231231"
      id="F20240228054805253_35">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_20230101to20231231"
      id="F20240228054805254_40">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard
      contextRef="C_20230101to20231231"
      id="F20240228054805253_36">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany
      contextRef="C_20230101to20231231"
      id="F20240228054805254_37">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="C_20230101to20231231" id="FFact_0000000000042">1281</dei:AuditorFirmId>
    <dei:AuditorName contextRef="C_20230101to20231231" id="FFact_0000000000043">KOST FORER GABBAY &amp; KASIERER</dei:AuditorName>
    <dei:AuditorLocation contextRef="C_20230101to20231231" id="FFact_0000000000044">Tel-Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000045"
      unitRef="usd">13890000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000046"
      unitRef="usd">11059000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000047"
      unitRef="usd">365000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000048"
      unitRef="usd">362000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000049"
      unitRef="usd">25053000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000050"
      unitRef="usd">72287000</us-gaap:OtherShortTermInvestments>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240227231100990_Fact_0000000000049"
      unitRef="usd">11742000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240227231100990_Fact_0000000000050"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240227231059015_Fact_0000000000049"
      unitRef="usd">61000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240227231059015_Fact_0000000000050"
      unitRef="usd">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000053"
      unitRef="usd">2529000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000054"
      unitRef="usd">2417000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000055"
      unitRef="usd">114579000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000056"
      unitRef="usd">86125000</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000057"
      unitRef="usd">1233000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000058"
      unitRef="usd">1899000</us-gaap:PrepaidExpenseNoncurrent>
    <cgen:SeverancePayFundNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000059"
      unitRef="usd">2977000</cgen:SeverancePayFundNoncurrent>
    <cgen:SeverancePayFundNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000060"
      unitRef="usd">2794000</cgen:SeverancePayFundNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000061"
      unitRef="usd">1329000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000062"
      unitRef="usd">1826000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000063"
      unitRef="usd">1216000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000064"
      unitRef="usd">1532000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000065"
      unitRef="usd">6755000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000066"
      unitRef="usd">8051000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000067"
      unitRef="usd">121334000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000068"
      unitRef="usd">94176000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000069"
      unitRef="usd">3502000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000070"
      unitRef="usd">1773000</us-gaap:AccountsPayableCurrent>
    <cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000071"
      unitRef="usd">0</cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000072"
      unitRef="usd">325000</cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240227231820447_Fact_0000000000071"
      unitRef="usd">11149000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240227231820447_Fact_0000000000072"
      unitRef="usd">0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000073"
      unitRef="usd">632000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000074"
      unitRef="usd">613000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000075"
      unitRef="usd">10983000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000076"
      unitRef="usd">9208000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000077"
      unitRef="usd">26266000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000078"
      unitRef="usd">11919000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240227232504678_Fact_0000000000081"
      unitRef="usd">25392000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240227232504678_Fact_0000000000082"
      unitRef="usd">0</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000081"
      unitRef="usd">719000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000082"
      unitRef="usd">1312000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000083"
      unitRef="usd">3398000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000084"
      unitRef="usd">3265000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000085"
      unitRef="usd">29509000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000086"
      unitRef="usd">4577000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20231231"
      id="Fxbrl_20240301101027819"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20221231"
      id="Fxbrl_20240301101033339"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20230214011115128"
      unitRef="NIS_Per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20230214011053357"
      unitRef="NIS_Per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_s_20230214011030882"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20230214011030883"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20230214101530012"
      unitRef="Shares">89237465</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20231231"
      decimals="INF"
      id="FFact_0000000000092"
      unitRef="Shares">89237465</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20230214011437479"
      unitRef="Shares">86624643</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20221231"
      decimals="INF"
      id="FFact_0000000000094"
      unitRef="Shares">86624643</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000095"
      unitRef="usd">247000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000096"
      unitRef="usd">240000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000097"
      unitRef="usd">539837000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000098"
      unitRef="usd">533213000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240227232850023_Fact_0000000000097"
      unitRef="usd">2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240227232850023_Fact_0000000000098"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000099"
      unitRef="usd">-474527000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000100"
      unitRef="usd">-455773000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000101"
      unitRef="usd">65559000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000102"
      unitRef="usd">77680000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000103"
      unitRef="usd">121334000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000104"
      unitRef="usd">94176000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000105"
      unitRef="usd">33459000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000106"
      unitRef="usd">7500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214012425376"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000108"
      unitRef="usd">2004000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000109"
      unitRef="usd">975000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214012430928"
      unitRef="usd">680000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000111"
      unitRef="usd">31455000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000112"
      unitRef="usd">6525000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214012436309"
      unitRef="usd">5320000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230222115443735_Fact_0000000000117"
      unitRef="usd">34472000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230222115443735_Fact_0000000000118"
      unitRef="usd">30648000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230222115443735_Fact_0000000000119"
      unitRef="usd">28694000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:BusinessDevelopment
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000117"
      unitRef="usd">244000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000118"
      unitRef="usd">932000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000119"
      unitRef="usd">842000</us-gaap:BusinessDevelopment>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230222115622478_Fact_0000000000117"
      unitRef="usd">9731000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230222115622478_Fact_0000000000118"
      unitRef="usd">10319000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230222115622478_Fact_0000000000119"
      unitRef="usd">10858000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230222115529913"
      unitRef="usd">44447000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000124"
      unitRef="usd">41899000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000125"
      unitRef="usd">40394000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000126"
      unitRef="usd">-12992000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000127"
      unitRef="usd">-35374000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000128"
      unitRef="usd">-35074000</us-gaap:OperatingIncomeLoss>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000129"
      unitRef="usd">3208000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000130"
      unitRef="usd">1738000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000131"
      unitRef="usd">871000</cgen:FinancialIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000132"
      unitRef="usd">-9784000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000133"
      unitRef="usd">-33636000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000134"
      unitRef="usd">-34203000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230214012403897"
      unitRef="usd">8970000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214012406780"
      unitRef="usd">58000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000137"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000138"
      unitRef="usd">-18754000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000139"
      unitRef="usd">-33694000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000140"
      unitRef="usd">-34203000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="FFact_0000000000141"
      unitRef="USD_per_share">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000142"
      unitRef="USD_per_share">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000143"
      unitRef="USD_per_share">-0.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228001617126_Fact_0000000000129"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240228001617126_Fact_0000000000130"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240228001617126_Fact_0000000000131"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000147"
      unitRef="usd">-18752000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000148"
      unitRef="usd">-33694000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000149"
      unitRef="usd">-34203000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20240228001903510"
      unitRef="Shares">87633298</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="FFact_0000000000153"
      unitRef="Shares">87633298</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20240228001918048"
      unitRef="Shares">86555628</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000154"
      unitRef="Shares">86555628</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20240228001929235"
      unitRef="Shares">84203971</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000155"
      unitRef="Shares">84203971</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="FFact_0000000000156"
      unitRef="Shares">83675856</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="FFact_0000000000157"
      unitRef="usd">231000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000158"
      unitRef="usd">507427000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240228010706277"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="FFact_0000000000159"
      unitRef="usd">-387876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231"
      decimals="-3"
      id="FFact_0000000000160"
      unitRef="usd">119782000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230214013709298"
      unitRef="Shares">335204</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230214013718917"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230214013728837"
      unitRef="usd">1454000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214013739149"
      unitRef="usd">1455000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <cgen:NumberOfWarrantsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230214013524660"
      unitRef="Shares">89557</cgen:NumberOfWarrantsExercised>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230214013559422"
      unitRef="usd">425000</cgen:StockIssuedDuringPeriodValueWarrantsExercised>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214013636006"
      unitRef="usd">425000</cgen:StockIssuedDuringPeriodValueWarrantsExercised>
    <cgen:IssuanceOfSharesAndWarrantsNetShares
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="FFact_0000000000165"
      unitRef="Shares">2332815</cgen:IssuanceOfSharesAndWarrantsNetShares>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="FFact_0000000000166"
      unitRef="usd">7000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000167"
      unitRef="usd">14951000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000168"
      unitRef="usd">14958000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000190"
      unitRef="usd">4276000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000191"
      unitRef="usd">4276000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="FFact_0000000000171"
      unitRef="usd">-34203000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000172"
      unitRef="usd">-34203000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="FFact_0000000000173"
      unitRef="Shares">86433432</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="FFact_0000000000174"
      unitRef="usd">239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000175"
      unitRef="usd">528533000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240228010711681"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="FFact_0000000000176"
      unitRef="usd">-422079000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000177"
      unitRef="usd">106693000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="FFact_0000000000199"
      unitRef="Shares">191211</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="FFact_0000000000200"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000201"
      unitRef="usd">352000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000202"
      unitRef="usd">353000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000211"
      unitRef="usd">4328000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000212"
      unitRef="usd">4328000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="FFact_0000000000213"
      unitRef="usd">-33694000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000214"
      unitRef="usd">-33694000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="FFact_0000000000215"
      unitRef="Shares">86624643</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="FFact_0000000000216"
      unitRef="usd">240000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000217"
      unitRef="usd">533213000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240228010718949"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="FFact_0000000000218"
      unitRef="usd">-455773000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000219"
      unitRef="usd">77680000</us-gaap:StockholdersEquity>
    <cgen:IssuanceOfSharesAndWarrantsNetShares
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240228004702895_Fact_0000000000165"
      unitRef="Shares">2612822</cgen:IssuanceOfSharesAndWarrantsNetShares>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240228004702895_Fact_0000000000166"
      unitRef="usd">7000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240228004702895_Fact_0000000000167"
      unitRef="usd">3074000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228004702895_Fact_0000000000168"
      unitRef="usd">3081000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240228004651156_Fact_0000000000211"
      unitRef="usd">3550000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228004651156_Fact_0000000000212"
      unitRef="usd">3550000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240228005606782"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228005611158"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240228004710783_Fact_0000000000213"
      unitRef="usd">-18754000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228004710783_Fact_0000000000214"
      unitRef="usd">-18754000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240228003430903_Fact_0000000000215"
      unitRef="Shares">89237465</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240228003430903_Fact_0000000000216"
      unitRef="usd">247000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240228003430903_Fact_0000000000217"
      unitRef="usd">539837000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20240228010218091"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240228003430903_Fact_0000000000218"
      unitRef="usd">-474527000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240228005626619"
      unitRef="usd">65559000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000220"
      unitRef="usd">-18754000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000221"
      unitRef="usd">-33694000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000222"
      unitRef="usd">-34203000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000223"
      unitRef="usd">3550000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000224"
      unitRef="usd">4328000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000225"
      unitRef="usd">4276000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000226"
      unitRef="usd">476000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000227"
      unitRef="usd">482000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000228"
      unitRef="usd">461000</us-gaap:Depreciation>
    <cgen:SeverancePayNet
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000229"
      unitRef="usd">-50000</cgen:SeverancePayNet>
    <cgen:SeverancePayNet
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214015430934"
      unitRef="usd">-81000</cgen:SeverancePayNet>
    <cgen:SeverancePayNet
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000231"
      unitRef="usd">-101000</cgen:SeverancePayNet>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000232"
      unitRef="usd">-7000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000233"
      unitRef="usd">-12000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000234"
      unitRef="usd">3000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240301111210380"
      unitRef="usd">129000</cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances>
    <cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240301111218731"
      unitRef="usd">-393000</cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances>
    <cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240301111232004"
      unitRef="usd">-59000</cgen:AdjustmentForExchangeRateDifferencesLossGainOnCashBalances>
    <cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230214015508662"
      unitRef="usd">-92000</cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement>
    <cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000236"
      unitRef="usd">584000</cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement>
    <cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214015458380"
      unitRef="usd">-469000</cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement>
    <cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228013916179_xbrl_20230214015610319"
      unitRef="usd">280000</cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities>
    <cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240228013916179_Fact_0000000000251"
      unitRef="usd">0</cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities>
    <cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240228013916179_Fact_0000000000252"
      unitRef="usd">0</cgen:AmortizationOfDiscountAndAccruedInterestOnMarketableSecurities>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000238"
      unitRef="usd">61000000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000239"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214015520285"
      unitRef="usd">-2000000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000241"
      unitRef="usd">112000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000242"
      unitRef="usd">-3043000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000243"
      unitRef="usd">2802000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000244"
      unitRef="usd">-666000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000245"
      unitRef="usd">-12000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214015551570"
      unitRef="usd">31000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000247"
      unitRef="usd">-568000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000248"
      unitRef="usd">-658000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000249"
      unitRef="usd">-525000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230214015610319"
      unitRef="usd">3509000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000251"
      unitRef="usd">-1601000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000252"
      unitRef="usd">3367000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230214015629815"
      unitRef="usd">-325000</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000254"
      unitRef="usd">-6019000</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000255"
      unitRef="usd">3708000</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:IncreaseDecreaseInDeferredRevenues
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228013913681_xbrl_20230214015610319"
      unitRef="usd">-36541000</cgen:IncreaseDecreaseInDeferredRevenues>
    <cgen:IncreaseDecreaseInDeferredRevenues
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240228013913681_Fact_0000000000251"
      unitRef="usd">0</cgen:IncreaseDecreaseInDeferredRevenues>
    <cgen:IncreaseDecreaseInDeferredRevenues
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240228013913681_Fact_0000000000252"
      unitRef="usd">0</cgen:IncreaseDecreaseInDeferredRevenues>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000256"
      unitRef="usd">-645000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000257"
      unitRef="usd">-1062000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000258"
      unitRef="usd">-416000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000259"
      unitRef="usd">-35886000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000260"
      unitRef="usd">-34113000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000261"
      unitRef="usd">-22691000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000262"
      unitRef="usd">79242000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000263"
      unitRef="usd">114445000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000264"
      unitRef="usd">136850000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000265"
      unitRef="usd">32100000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000266"
      unitRef="usd">76900000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000267"
      unitRef="usd">129945000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228013918979_xbrl_20230214015610319"
      unitRef="usd">10145000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240228013918979_Fact_0000000000251"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240228013918979_Fact_0000000000252"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228013920658_xbrl_20230214015610319"
      unitRef="usd">21605000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240228013920658_Fact_0000000000251"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240228013920658_Fact_0000000000252"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000268"
      unitRef="usd">172000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000269"
      unitRef="usd">477000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000270"
      unitRef="usd">292000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230222115924752_Fact_0000000000268"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230222115924752_Fact_0000000000269"
      unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230222115924752_Fact_0000000000270"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentDisposals>
    <cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230222112447073"
      unitRef="usd">0</cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities>
    <cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000272"
      unitRef="usd">-2000</cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities>
    <cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000273"
      unitRef="usd">-3000</cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000274"
      unitRef="usd">35510000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000275"
      unitRef="usd">37060000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214015724492"
      unitRef="usd">6616000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000277"
      unitRef="usd">3081000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000278"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000279"
      unitRef="usd">14958000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000280"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000281"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214015741861"
      unitRef="usd">425000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000283"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000284"
      unitRef="usd">353000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000285"
      unitRef="usd">1455000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000286"
      unitRef="usd">3081000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000287"
      unitRef="usd">353000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000288"
      unitRef="usd">16838000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240301111348803"
      unitRef="usd">129000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240301111408147"
      unitRef="usd">-393000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240301111411299"
      unitRef="usd">-59000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000289"
      unitRef="usd">2834000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000290"
      unitRef="usd">2907000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214015801453"
      unitRef="usd">704000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000292"
      unitRef="usd">11421000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000293"
      unitRef="usd">8514000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20201231"
      decimals="-3"
      id="FFact_0000000000294"
      unitRef="usd">7810000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000295"
      unitRef="usd">14255000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000296"
      unitRef="usd">11421000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000297"
      unitRef="usd">8514000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000298"
      unitRef="usd">-5000</cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction>
    <cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000299"
      unitRef="usd">117000</cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction>
    <cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000300"
      unitRef="usd">116000</cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction>
    <cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230214015821971"
      unitRef="usd">71000</cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability>
    <cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000305"
      unitRef="usd">237000</cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability>
    <cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214015838501"
      unitRef="usd">0</cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability>
    <cgen:InterestPaidReceivedNet
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000307"
      unitRef="usd">3052000</cgen:InterestPaidReceivedNet>
    <cgen:InterestPaidReceivedNet
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000308"
      unitRef="usd">852000</cgen:InterestPaidReceivedNet>
    <cgen:InterestPaidReceivedNet
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000309"
      unitRef="usd">1364000</cgen:InterestPaidReceivedNet>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000310"
      unitRef="usd">13890000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000311"
      unitRef="usd">11059000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000312"
      unitRef="usd">7801000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000313"
      unitRef="usd">365000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000314"
      unitRef="usd">362000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000315"
      unitRef="usd">713000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000316"
      unitRef="usd">14255000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000317"
      unitRef="usd">11421000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000318"
      unitRef="usd">8514000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240228025141975">
        &lt;div&gt;
          &lt;div&gt;
            &lt;div style="text-align:justify;line-height:1.25"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%"&gt;

                  &lt;tr&gt;
                    &lt;td style="font-size:10pt;vertical-align:top;width:56.7pt"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;NOTE 1:-&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="font-size:10pt;width:auto"&gt;&lt;span style="fonfamily:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;GENERAL&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Compugen Ltd. (the &#x201c;Company&#x201d;) is a clinical-stage therapeutic discovery and development company utilizing our broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. The Company&#x2019;s innovative immuno-oncology pipeline consists of three clinical stage programs, COM701, COM902 and rilvegostomig, targeting immune checkpoints the Company discovered computationally. Two programs that are pursued internally, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. Based on the data from the Phase 1 trials and as part of our focus on two specific tumor types for the further clinical evaluation of COM701 and COM902, the Company initiated in 2023 two clinical trials evaluating the triple combination treatment of COM701, COM902 and pembrolizumab, one in metastatic microsatellite stable colorectal cancer patients and one in platinum resistant ovarian cancer patients. Rilvegostomig, a novel anti PD-1/TIGIT bispecific antibody with a TIGIT-specific component that is derived from the Company&#x2019;s COM902 antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between the Company and AstraZeneca and is being evaluated in multiple clinical trials, including in Phase 3 clinical trial in patients with biliary tract cancer who will be randomized to receive rilvegostomig or placebo with investigator choice chemotherapy as adjuvant treatment after resection with curative intent. The Company&#x2019;s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. The Company&#x2019;s most advanced early-stage program, COM503, is in IND enabling studies and was licensed to Gilead in December 2023. COM503 is a potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. The Company&#x2019;s business model is to selectively enter into collaborations for our novel targets and drug product candidates at various stages of research and development under various revenue-sharing arrangements.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company is headquartered in Holon, Israel. Its clinical development activities are headed from its United States subsidiary, Compugen USA, Inc, located in San Francisco, CA.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has incurred losses in the amount of $ 18,754 during the year ended December 31, 2023, has an accumulated deficit of $ 474,527 as of December 31, 2023 and has an accumulated negative cash flow from operating activities in the amount of $ 35,886 for the year ended December 31, 2023. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures at least twelve months from the reporting date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div&gt;
              &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
              &lt;div&gt;&lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (&#x201c;Bayer Agreement&#x201d;) with Bayer Pharma AG (&#x201c;Bayer&#x201d;) for the research, development, and commercialization of antibody-based therapeutics against two novel, Compugen-discovered immune checkpoint regulators.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the terms of the Bayer Agreement, the Company received an upfront payment of $ 10,000, and, following the return of the CGEN 15022 program in 2017, the Company was eligible to receive an aggregate amount of over $ 250,000 in potential milestone payments for Bapotulimab (formerly known as BAY1905254), not including aggregate milestone payments of $ 23,200 received to date. Additionally, the Company was eligible to receive mid to high single digit royalties on global net sales of any approved products under the collaboration.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pursuant to the terms of Bayer Agreement, Bapotulimab program was transferred to Bayer&#x2019;s full control for further preclinical and clinical development activities, and worldwide commercialization under milestone and royalty bearing license from Compugen.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On November 29, 2022, Bayer notified the Company that it has resolved to terminate,&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;effective as of February 27, 2023, the Bayer Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#x201c;AstraZeneca&#x201d;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and will be solely responsible for all research, development, and commercial activities under the agreement. In connection with such license agreement, AstraZeneca developed rilvegostomig, a novel PD-/TIGIT bi-specific antibody with a TIGIT component that is derived from our COM902 and entered the clinic in September 2021 and initiated Phase 3 with first patient dosing in Phase 3 in December 2023. Compugen received a $10,000 upfront payment, and received or accrued $ 25,500 milestone payments out of up to $ 200,000 it is eligible to receive in development, regulatory and commercial milestones for the first product in addition to tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#x201c;Agreement&#x201d;) with Bristol-Myers Squibb Company (&#x201c;Bristol-Myers Squibb&#x201d;) to evaluate the safety and tolerability of Compugen&#x2019;s COM701 in combination with Bristol-Myers Squibbs&#x2019; PD-1 immune checkpoint inhibitor Opdivo&#xae; (nivolumab), in patients with advanced solid tumors.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div&gt;&#160;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pursuant to the Agreement, Compugen was responsible for and sponsored the ongoing two-part Phase 1 trial, which included the evaluation of the combination of COM701 and Opdivo&#xae;. The collaboration was also designed to address potential future combinations, including trials sponsored by Bristol-Myers Squibb to investigate combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT. Bristol-Myers Squibb and Compugen each supplied the other company with its own compound for the other party&#x2019;s study, and otherwise each party was responsible for all costs associated with the study that it is conducting.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In conjunction with the signing of the Agreement in October 2018, Bristol-Myers Squibb made a $ 12,000 investment in Compugen, see Note 8b.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On February 14, 2020, the Agreement was amended to include a triple combination clinical trial to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo&#xae; (nivolumab), and Bristol-Myers Squibb&#x2019;s investigational antibody targeting TIGIT known as BMS-986207, in patients with advanced solid tumors, instead of the planned expansion of the combined therapy study designed to evaluate the dual combination of COM701 and Opdivo&#xae;.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:85.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pursuant to the Agreement, as amended, the Company sponsored the two-part Phase 1/2 trial, which evaluates the triple combination of COM701, Opdivo&#xae; and BMS-986207, in patients with advanced solid tumors where Bristol-Myers Squibb provided Opdivo&#xae; and BMS-986207 at no cost to the Company.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As part of the amended Agreement, it was agreed that the Company will complete the dose escalation arm of the dual combination of COM701 with Opdivo&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;&#xae;&lt;/sup&gt; under the ongoing Phase 1 study and will not continue the expansion cohorts of the dual combination. However, on February 19, 2021, the Agreement was further amended to include an expansion of the Phase 1 combination study designed to evaluate the dual combination of COM701 and Opdivo&#xae; in patients with advanced solid tumors, where the Company is responsible for and sponsored the expansion cohort and Bristol Myers Squibb provided Opdivo&#xae; at no cost to the Company for this study.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On November 10, 2021, the Agreement was further amended to establish a joint steering committee (alongside the existing joint development committee which acts at an operational level) to facilitate strategic oversight and guidance for the programs run under the collaboration.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In conjunction with the signing of the amendment to the Agreement in November 2021, Bristol-Myers Squibb made a $ 20,000 investment in Compugen, see Note 8b.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On August 3, 2022, the Company and Bristol-Myers Squibb entered into a letter agreement pursuant to which the Agreement, as amended thereafter, was terminated as of such date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div&gt;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;g.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 18, 2023, the Company entered into an exclusive license agreement (the &#160;&#x201c;License Agreement&#x201d;) with Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;), pursuant to which the Company granted Gilead an exclusive license under the Company&#x2019;s pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products, including the Company&#x2019;s COM503 product candidate (&#x201c;COM503 License&#x201d;), and additional products that may be so developed by Gilead (together with COM503, the &#x201c;Licensed Products&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&lt;br/&gt;Pursuant to the License Agreement, Gilead paid the Company a one-time, upfront payment of $60 million in January 2024. The Company has continued to develop COM503 during the initial development term, which included conducting activities defined within the agreement to advance COM503 through the clearance of an investigational new drug application (&#x201c;IND&#x201d;). The Company is eligible to receive from Gilead $30 million in the form of a milestone payment upon clearance of the IND for COM503. The Company is also eligible to receive up to approximately $758 million in additional milestone payments upon the achievement of certain development, regulatory and commercial milestones. The Company is further eligible to receive single-digit to low double-digit tiered royalties on worldwide net sales of Licensed Products.&lt;br/&gt;&#160;&lt;br/&gt;The Company will be responsible for conducting a Phase 1 clinical trial for COM503, including handling the regulatory matters in connection therewith, and will bear the costs of such trial (including the COM503 drug supply), with Gilead providing at no cost an anti-PD-1/PD-L1 antibody for such trial. In certain circumstances, Gilead may assume the role of conducting the Phase 1 clinical trial.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="text-align:justify;margin-left:84.3pt;line-height:1.25"&gt;
              &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Upon completion of the Phase 1 clinical trial for COM503, the Company will initiate the transfer of development activities related to COM503 to Gilead, following which, Gilead will have sole responsibility to develop and commercialize the Licensed Products.&lt;br/&gt;&#160;&lt;br/&gt;During the term of the License Agreement, the Company is prohibited from researching, developing, making, and commercializing any compounds, molecules, products or treatment methods that are directed to IL-18 or any companion diagnostics for an IL-18 product.&lt;br/&gt;&#160;&lt;br/&gt;Unless terminated early by a party pursuant to its terms, the License Agreement will continue in effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the last royalty term in such country.&lt;br/&gt;&#160;&lt;br/&gt;Gilead withheld at source 15% from the upfront payment amount paid to the Company in January 2024 and is expected to continue and withhold at source all taxes required by law from all payments payable to the Company under the License Agreement.&lt;br/&gt;&#160;&lt;br/&gt;The License Agreement contains customary representations, warranties, covenants, and terms governing the prosecution and enforcement of certain intellectual property and issues related to technology transfer, manufacturing transfer, provisions with respect to establishment of joint steering committee and its governance covenants with respect change of control and others.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000319"
      unitRef="usd">-18754000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000320"
      unitRef="usd">-474527000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000321"
      unitRef="usd">-35886000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20130801to20130805"
      decimals="-3"
      id="FFact_0000000000323"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="C_20130805"
      decimals="-3"
      id="FFact_0000000000324"
      unitRef="usd">250000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable
      contextRef="C_20130805"
      decimals="-3"
      id="FFact_0000000000325"
      unitRef="usd">23200000</cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000326"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:AccruedMilestonePayment
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000327"
      unitRef="usd">25500000</cgen:AccruedMilestonePayment>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240228095106065"
      unitRef="usd">200000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000329"
      unitRef="usd">12000000</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue
      contextRef="C_20211130"
      decimals="-3"
      id="FFact_0000000000330"
      unitRef="usd">20000000</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <cgen:NonRefundableUpfrontPayment
      contextRef="C_20230101to20231218"
      decimals="-6"
      id="Fxbrl_20240228025953345"
      unitRef="usd">60000000</cgen:NonRefundableUpfrontPayment>
    <cgen:MilestonePaymentReceivable
      contextRef="C_20230101to20231218"
      decimals="-6"
      id="Fxbrl_20240228031257594"
      unitRef="usd">30000000</cgen:MilestonePaymentReceivable>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram
      contextRef="C_20231218"
      decimals="-6"
      id="Fxbrl_20240228030428945"
      unitRef="usd">758000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram>
    <cgen:PercentageOfExpectedFromUpfrontPaymentAmountPaid
      contextRef="C_20240101to20240131"
      decimals="2"
      id="Fxbrl_20240228030716817"
      unitRef="Pure">0.15</cgen:PercentageOfExpectedFromUpfrontPaymentAmountPaid>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240228140455566">
    &lt;div&gt;
      &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
        &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
          &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
            &lt;div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%"&gt;

                  &lt;tr&gt;
                    &lt;td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:56.7pt"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt;font-weight:bold"&gt;NOTE 2:-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="fonfamily:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;

          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;a.&lt;span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt"&gt;Use of estimates:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company&#x2019;s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;b.&lt;span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt"&gt;Financial statements in U.S. dollars:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The reporting and functional currency of the Company is the U.S. dollar, as the Company&#x2019;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No. 830, &#x201c;Foreign Currency Matters&#x201d;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;c.&lt;span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt"&gt;Basis of consolidation:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;d.&lt;span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt"&gt;Cash equivalents:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;e.&lt;span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt"&gt;Restricted cash:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Restricted cash is held in interest bearing saving accounts which are used as a security for the Company&#x2019;s Israeli facility leasehold&#160;and leased cars fueling bank guarantees and credit card security for Compugen USA, Inc.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
        &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
      &lt;/div&gt;

        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;f.&lt;span style="padding-left:22.17pt;margin-top:0pt;margin-bottom:0pt"&gt;Short-term bank deposits:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The short-term bank deposits as of December 31, 2023&#160;and 2022&#160;are in U.S. dollars and bear an annual weighted average interest rate of 6.20% and 4.84%, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
      &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
        &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;

            &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
              &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;g.&#160; &#160; &#160; &#160; &#160;Investments in marketable securities:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company accounts for investments in marketable securities in accordance with ASC No. 320, &#x201c;Investments - Debt Securities&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation at each balance sheet date. The Company classifies all of its debt securities as available-for-sale (&#x201c;AFS&#x201d;). The Company classifies its marketable securities as either short-term or long-term based on each instrument&#x2019;s underlying contractual maturity date. Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders&#x2019; equity. Realized gains and losses on sale of investments are included in financial income, net.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;At each reporting period, the Company evaluates whether declines in fair value below amortized cost are due to expected credit losses, as well as the Company&#x2019;s ability and intent to hold the investment until a forecasted recovery occurs in accordance with ASC 326, Financial Instrument- Credit losses. Allowance for credit losses on AFS debt securities are recognized in the Company&#x2019;s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in shareholders&#x2019; equity. No credit loss impairment was identified in the year ended December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;

        &lt;/div&gt;
      &lt;/div&gt;
      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;

        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;h.&lt;span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt"&gt;Property and equipment, net:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;

            &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
              &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                &lt;div style="margin-left:90pt;margin-top:0pt;margin-bottom:0pt"&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;

                      &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;td style="padding-bottom:2px;width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="padding-bottom:2px;width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;td style="width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;td style="width:80%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Computers, software and related equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td rowspan="1" style="width:18%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="line-height:1.25;font-family:Times New Roman, Times, serif;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;td style="width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:center;line-height:1.25;text-indent:2pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;6 - 20 (mainly 20)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;td style="background-color:rgb(204, 238, 255);width:80%;vertical-align:top;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="background-color:rgb(204, 238, 255);width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:center;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Shorter of the term of the lease or useful life&lt;/p&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;

        &lt;/div&gt;

      &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left"&gt;&#160;&lt;/p&gt;

        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;i.&lt;span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt"&gt;Impairment of long-lived assets:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The long-lived assets of the Company. are reviewed for impairment in accordance with ASC 360, &#x201c;Property, Plant, and Equipment&#x201d; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset (assets group) with the future undiscounted cash flows expected to be generated by the asset (assets group). If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets group exceeds the fair value of the assets group. During the years 2023, 2022 and 2021, no impairment losses have been identified.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
      &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
        &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
          &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;

              &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;j.&lt;span style="padding-left:22.72pt;margin-top:0pt;margin-bottom:0pt"&gt;Leases:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company accounts for its leases according to ASC 842 - Leases (&#x201c;ASC 842&#x201d;). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#x201c;ROU&#x201d;) asset for leases with a term of twelve months or less. The Company elected to combine its lease and non-lease components.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
                  &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured based on the discounted present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The implicit rate within the operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (&#x201c;IBR&#x201d;) based on the information available at commencement date in determining the present value of lease payments. The Company&#x2019;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate the lease is considered unless it is reasonably certain that the Company will not exercise the option.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/div&gt;
              &lt;/div&gt;

          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"&gt;&#160;&lt;/p&gt;
      &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
        &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
          &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
            &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;

                &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                  &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:76pt;text-indent:-20pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;k.&lt;span style="padding-left:23.06pt;margin-top:0pt;margin-bottom:0pt"&gt;Revenue recognition:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:85.05pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:85.05pt;text-align:justify"&gt;&#160;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company recognizes revenue in accordance with ASC 606 &#x2013; &#x201c;Revenue from Contracts with Customers&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;As such, the Company analyzes its contracts to assess whether they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%"&gt;

                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt;font-style:italic"&gt;Identification of the contract, or contracts, with a customer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt;font-style:italic"&gt;Identification of the performance obligations in the contract&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt;font-style:italic"&gt;Determination of the transaction price&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt;font-style:italic"&gt;Allocation of the transaction price to the performance obligations in the contract&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt;font-style:italic"&gt;Recognition of revenue when, or as, the Company satisfies a performance obligation&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:85pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;At the contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                    &lt;div style="margin-left:85.05pt;text-align:justify;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property (&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&#x201c;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;IP&#x201d;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $&#160;10,000 upfront payment and is eligible to receive up to $&#160;200,000 for development, regulatory and commercial milestones for the first product, of which $&#160;25,500 was received or accrued&#160;as well as tiered royalties on future product sales.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="margin-left:85.05pt;text-align:justify;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                  &lt;/div&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#x201c;probable&#x201d; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Sales&#160;or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales&#160;or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;On December 18, 2020 the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 2,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On&#160;September 29, 2021 the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 6,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;On November 11, 2022, the third milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 7,500 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/p&gt;
                  &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                    &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;On December 27, 2023, the fourth milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 10,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;On December 18, 2023, the Company entered into an exclusive License Agreement with Gilead. Under the terms of the agreement, the Company granted Gilead an exclusive license under the Company&#x2019;s pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products derived from a Compugen pipeline program. Compugen received an upfront payment of $60,000 and is also eligible to receive up to approximately $ 788,000 additional milestone payments subject to and upon the achievement of certain development, regulatory and commercial milestones and as detailed in the agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Gilead may terminate the Gilead Collaboration Agreement for convenience by giving a certain prior written notice to the Company at any time after the effective date of the agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company concluded that Gilead is a customer and therefore revenue recognition should be accounted for in accordance with ASC 606, because the Company granted to Gilead licenses to its intellectual property and will provide research and development services, all of which are outputs of the Company&#x2019;s ongoing activities, in exchange for consideration.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company assessed the promises under the License Agreement and concluded that (i) the delivery of the COM503 License; (ii) the preclinical research and development activities towards IND approval of COM503 (the &#x201c;IND research and development activities&#x201d;) and (iii) the contingent promise to additional research and development activities for Phase 1 clinical (the &#x201c;Phase 1 research and development activities&#x201d;), are capable of being distinct and are distinct within the context of the License Agreement. The Company considered that the license has standalone functionality, considered to be functional intellectual property, and is capable of being distinct. The Company also determined that the IND research and development activities and Phase 1 research and development activities could be provided by resources otherwise available to Gilead and thus are capable of being distinct. Also, the Company concluded that the Company&#x2019;s contingent promise to additional research and development activities for Phase 1 clinical represents a material right.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;As a result, the Company concluded that its promise to deliver the COM503 License, the promise to perform IND research and development activities and Phase 1 research and development activities represented separate performance obligations in the License Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company also evaluated as a possible variable consideration all milestones and royalties. With respect to clinical development and regulatory milestones, based upon the high degree of uncertainty and risk associated with these potential payments, the Company concluded that all such amounts should be fully constrained and are not included in the initial transaction price as the Company cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Accordingly, the Company did not include any potential clinical development, regulatory and sales milestones and royalties in the initial transaction price.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company allocated the transaction price to each performance obligation on a relative estimated standalone selling price basis. The Company developed the estimated standalone selling price for the COM503 License based on the present value of expected future cash flows associated with the license and related clinical development and regulatory milestones. In developing such estimate, the Company applied judgement in determining the timing needed to develop the Licensed Product, the probability of success, and the discount rate. The Company developed the estimated standalone selling price for the IND research and development activities using a &#x201c;cost plus&#x201d; reasonable margin approach. To determine the estimated standalone selling price of the material right for the Phase 1 research and development activities obligation, the Company estimated the standalone selling price of the underlying performance obligations included in the material right and estimated the probability of the Company&#x2019;s performance of such obligations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company determined that the COM503 License was a functional license since the underlying intellectual property (the &#x201c;IP&#x201d;) has significant standalone functionality. In addition, the Company determined that December 18, 2023 represents (i) the date at which the Company made available the IP to Gilead and (ii) the beginning of the period during which Gilead is able to use and benefit from its right to use the IP. Based upon these considerations, the Company recognized the entirety of the initial transaction price allocated to the COM503 License performance obligation during the year ended December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Further, the IND research and development activities and Phase 1 research and development activities performance obligations are recognized over time when, or as, the Company performs the required services to Gilead. The Company determined that the input method under ASC 606 is the best measure of progress towards satisfying the performance obligation and reflects a faithful depiction of the transfer of goods and services. The method of measuring progress towards delivery of the services incorporates actual internal and external costs incurred, relative to total internal and external costs expected to be incurred to satisfy the performance obligation. The period over which total costs were estimated reflected the Company&#x2019;s best estimate of the period over which it would perform the activities to achieve clearance of an IND application for COM503 and the phase 1 clinical trial.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;During the year ended December 31, 2023, the Company recognized $ 23,459 of license revenue. The Company included deferred revenues of $ 11,149 in current liabilities and $ 25,392 in non-current liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;For additional information regarding revenues, please refer to Note 10 below.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;p style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                      &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;

              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;l.&lt;span style="padding-left:22.72pt;margin-top:0pt;margin-bottom:0pt"&gt;Cost of revenues:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Cost of revenues consist of certain royalties and milestones paid or accrued.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

            &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

              &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                  &lt;div style="margin:0pt 0px 0pt 58pt;line-height:1.25;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;m.&#160; &#160; &#160; &#160;Research and development expenses, net:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                  &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                  &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                  &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The portion of the Bristol-Myers Squibb $ 12,000 investment in 2018 over the fair market value of the shares issued in the amount of $ 4,121 and the portion of the $ 20,000 investment in 2021 over the fair market value of the shares issued in the amount of $ 5,000 were considered as deferred participation of Bristol-Myers Squibb in R&amp;amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;amp;D, see Note 1f and Note 8b.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                  &lt;div style="text-align:justify;margin-left:85.5pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Amortization of participation in R&amp;amp;D expenses for the years ended December 31, 2023, 2022 and 2021 were $ 325, $ 6,019 and $ 1,291, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/div&gt;

            &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
            &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;

              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;n.&lt;span style="padding-left:22.72pt;margin-top:0pt;margin-bottom:0pt"&gt;Severance pay:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company&#x2019;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date, and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset on the Company&#x2019;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#x2019;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#x2019;s monthly salary for each year of service, no additional calculations are conducted between the parties regarding the matter of severance pay and no additional payments are made by the Company to the employee.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Severance expenses for the years ended December 31, 2023, 2022 and 2021 amounted to approximately $&#160;432, $&#160;468 and $&#160;383, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

            &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;o.&lt;span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt"&gt;Stock-based compensation:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company accounts for stock-based compensation to employees and non-employees in accordance with ASC 718, &#x201c;Compensation - Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company selected the Black-Scholes-Merton (&#x201c;Black-Scholes&#x201d;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
              &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company used the following assumptions for options granted to employees, directors and non-employees and ESPP:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
              &lt;div style="margin-left:90pt;margin-top:0pt;margin-bottom:0pt"&gt;

                  &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                    &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;

                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="5" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="background-color:rgb(204, 238, 255);width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Employee stock options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;75.93%-80.95%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;69.44%-74.61%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;66.02%-69.05%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;3.37%-4.81%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;1.54%-4.39%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0.51%-1.14%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;4.02-5.06&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;5.05-5.4&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;5.04-5.31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;

                      &lt;/table&gt;
                      &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;

              &lt;/div&gt;
              &lt;div style="margin-left:90pt;margin-top:0pt;margin-bottom:0pt"&gt;
                &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;

                    &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;

                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="5" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="background-color:rgb(204, 238, 255);width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;ESPP&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;69.74%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;64.68%-69.68%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;1.63%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0.04%-0.10%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0.42-0.50&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;

                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/div&gt;

                &lt;/div&gt;
              &lt;/div&gt;

            &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left"&gt;&#160;&lt;/p&gt;

              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;p.&lt;span style="padding-left:21.5pt;margin-top:0pt;margin-bottom:0pt"&gt;Concentration of credit risks:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits and investment in marketable securities.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Cash, cash equivalents, restricted cash and short-term bank deposits are invested in major banks in Israel and in the United States. Generally, these deposits may be redeemed upon demand and bear minimal risk.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

            &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;q.&lt;span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt"&gt;Basic and diluted loss per share:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#x201c;Earnings per Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&#x201d;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;All outstanding share options and warrants for the years ended December 31, 2023, 2022 and 2021 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2023, 2022 and 2021 the average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 7,921,020, 8,405,615 and 6,758,300, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

            &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
            &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;

              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;r.&lt;span style="padding-left:24.5pt;margin-top:0pt;margin-bottom:0pt"&gt;Income taxes:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company accounts for income taxes in accordance with ASC No. 740, &#x201c;Income Taxes&#x201d;, (&#x201c;ASC 740&#x201d;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2023 and 2022, a full valuation allowance was provided by the Company.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

            &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;s.&lt;span style="padding-left:23.5pt;margin-top:0pt;margin-bottom:0pt"&gt;Fair value of financial instruments:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company applies ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market participants at the measurement date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
              &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The hierarchy is broken down into three levels based on the inputs as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;margin-top:0pt;margin-bottom:0pt"&gt;

                  &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                    &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Level 1&#160;&lt;/span&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can &lt;/span&gt;access at the measurement date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                &lt;table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;margin-top:0pt;margin-bottom:0pt"&gt;

                    &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Level 2&#160;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Valuations based on one or more quoted prices in markets that are not active or for which all &lt;/span&gt;significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;td style="width:85.5pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="width:56.7pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Level 3&#160;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, other accounts receivable and prepaid expenses, trade payable and other accounts payable and accrued expenses approximate their fair values due to the short-term maturities of such instruments.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

            &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;t.&lt;span style="padding-left:23.06pt;margin-top:0pt;margin-bottom:0pt"&gt;Recently issued accounting pronouncement not yet adopted by the Company:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;In&#160;December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_20230101to20231231" id="F20240228054857421_1">
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;a.&lt;span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt"&gt;Use of estimates:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company&#x2019;s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        </us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="C_20230101to20231231" id="F20240228054857421_2">
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;b.&lt;span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt"&gt;Financial statements in U.S. dollars:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The reporting and functional currency of the Company is the U.S. dollar, as the Company&#x2019;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No. 830, &#x201c;Foreign Currency Matters&#x201d;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        </us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_20230101to20231231" id="F20240228054857422_3">
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;c.&lt;span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt"&gt;Basis of consolidation:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        </us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_20230101to20231231" id="F20240228054857422_4">
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;d.&lt;span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt"&gt;Cash equivalents:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        </us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_20230101to20231231" id="F20240228054857423_5">
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;e.&lt;span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt"&gt;Restricted cash:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Restricted cash is held in interest bearing saving accounts which are used as a security for the Company&#x2019;s Israeli facility leasehold&#160;and leased cars fueling bank guarantees and credit card security for Compugen USA, Inc.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        </us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <cgen:ShortTermBankDepositsPolicyTextBlock contextRef="C_20230101to20231231" id="F20240228054857423_6">
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;f.&lt;span style="padding-left:22.17pt;margin-top:0pt;margin-bottom:0pt"&gt;Short-term bank deposits:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The short-term bank deposits as of December 31, 2023&#160;and 2022&#160;are in U.S. dollars and bear an annual weighted average interest rate of 6.20% and 4.84%, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      </cgen:ShortTermBankDepositsPolicyTextBlock>
    <cgen:ShortTermBankDepositsWeightedAverageRateForeign
      contextRef="C_20230101to20231231"
      decimals="4"
      id="F20240228054857424_7"
      unitRef="Pure">0.062</cgen:ShortTermBankDepositsWeightedAverageRateForeign>
    <cgen:ShortTermBankDepositsWeightedAverageRateForeign
      contextRef="C_20220101to20221231"
      decimals="4"
      id="F20240228054857424_8"
      unitRef="Pure">0.0484</cgen:ShortTermBankDepositsWeightedAverageRateForeign>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_20230101to20231231"
      id="F20240228054857466_78">
            &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
              &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;g.&#160; &#160; &#160; &#160; &#160;Investments in marketable securities:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company accounts for investments in marketable securities in accordance with ASC No. 320, &#x201c;Investments - Debt Securities&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation at each balance sheet date. The Company classifies all of its debt securities as available-for-sale (&#x201c;AFS&#x201d;). The Company classifies its marketable securities as either short-term or long-term based on each instrument&#x2019;s underlying contractual maturity date. Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders&#x2019; equity. Realized gains and losses on sale of investments are included in financial income, net.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;At each reporting period, the Company evaluates whether declines in fair value below amortized cost are due to expected credit losses, as well as the Company&#x2019;s ability and intent to hold the investment until a forecasted recovery occurs in accordance with ASC 326, Financial Instrument- Credit losses. Allowance for credit losses on AFS debt securities are recognized in the Company&#x2019;s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in shareholders&#x2019; equity. No credit loss impairment was identified in the year ended December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_20230101to20231231" id="F20240228054857425_9">
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;h.&lt;span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt"&gt;Property and equipment, net:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;

            &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
              &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                &lt;div style="margin-left:90pt;margin-top:0pt;margin-bottom:0pt"&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;

                      &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;td style="padding-bottom:2px;width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="padding-bottom:2px;width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;td style="width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;td style="width:80%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Computers, software and related equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td rowspan="1" style="width:18%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="line-height:1.25;font-family:Times New Roman, Times, serif;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;td style="width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:center;line-height:1.25;text-indent:2pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;6 - 20 (mainly 20)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;td style="background-color:rgb(204, 238, 255);width:80%;vertical-align:top;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="background-color:rgb(204, 238, 255);width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:center;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Shorter of the term of the lease or useful life&lt;/p&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;

        &lt;/div&gt;
      </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock
      contextRef="C_20230101to20231231"
      id="F20240228054857451_53">
            &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
              &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                &lt;div style="margin-left:90pt;margin-top:0pt;margin-bottom:0pt"&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;

                      &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;td style="padding-bottom:2px;width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="padding-bottom:2px;width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;td style="width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;td style="width:80%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Computers, software and related equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td rowspan="1" style="width:18%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="line-height:1.25;font-family:Times New Roman, Times, serif;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;td style="width:80%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:center;line-height:1.25;text-indent:2pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;6 - 20 (mainly 20)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;td style="background-color:rgb(204, 238, 255);width:80%;vertical-align:top;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:justify;margin-left:2.85pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:1%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="background-color:rgb(204, 238, 255);width:18%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;div style="text-align:center;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Shorter of the term of the lease or useful life&lt;/p&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          </cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock>
    <cgen:AnnualDepreciationRate
      contextRef="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="2"
      id="F20240228054857425_10"
      unitRef="Pure">0.33</cgen:AnnualDepreciationRate>
    <cgen:AnnualDepreciationRate
      contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="2"
      id="F20240228054857426_11"
      unitRef="Pure">0.06</cgen:AnnualDepreciationRate>
    <cgen:AnnualDepreciationRate
      contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="2"
      id="F20240228054857426_12"
      unitRef="Pure">0.20</cgen:AnnualDepreciationRate>
    <cgen:AnnualDepreciationRate
      contextRef="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="2"
      id="F20240228054857431_13"
      unitRef="Pure">0.20</cgen:AnnualDepreciationRate>
    <cgen:AnnualDepreciationRateDescription
      contextRef="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      id="Fxbrl_20240228113754899">Shorter of the term of the lease or useful life</cgen:AnnualDepreciationRateDescription>
    <us-gaap:PropertyPlantAndEquipmentImpairment
      contextRef="C_20230101to20231231"
      id="F20240228054857432_15">
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;i.&lt;span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt"&gt;Impairment of long-lived assets:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The long-lived assets of the Company. are reviewed for impairment in accordance with ASC 360, &#x201c;Property, Plant, and Equipment&#x201d; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset (assets group) with the future undiscounted cash flows expected to be generated by the asset (assets group). If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets group exceeds the fair value of the assets group. During the years 2023, 2022 and 2021, no impairment losses have been identified.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      </us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20240228054857465_76">
              &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;j.&lt;span style="padding-left:22.72pt;margin-top:0pt;margin-bottom:0pt"&gt;Leases:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company accounts for its leases according to ASC 842 - Leases (&#x201c;ASC 842&#x201d;). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#x201c;ROU&#x201d;) asset for leases with a term of twelve months or less. The Company elected to combine its lease and non-lease components.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
                  &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured based on the discounted present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The implicit rate within the operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (&#x201c;IBR&#x201d;) based on the information available at commencement date in determining the present value of lease payments. The Company&#x2019;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate the lease is considered unless it is reasonably certain that the Company will not exercise the option.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20240228054857465_77">
                &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                  &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:76pt;text-indent:-20pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;k.&lt;span style="padding-left:23.06pt;margin-top:0pt;margin-bottom:0pt"&gt;Revenue recognition:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:85.05pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:85.05pt;text-align:justify"&gt;&#160;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company recognizes revenue in accordance with ASC 606 &#x2013; &#x201c;Revenue from Contracts with Customers&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;As such, the Company analyzes its contracts to assess whether they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%"&gt;

                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt;font-style:italic"&gt;Identification of the contract, or contracts, with a customer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt;font-style:italic"&gt;Identification of the performance obligations in the contract&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt;font-style:italic"&gt;Determination of the transaction price&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt;font-style:italic"&gt;Allocation of the transaction price to the performance obligations in the contract&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:85.05pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;vertical-align:top;width:27pt"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:auto"&gt;
                          &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt;font-style:italic"&gt;Recognition of revenue when, or as, the Company satisfies a performance obligation&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:85pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;At the contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                    &lt;div style="margin-left:85.05pt;text-align:justify;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property (&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&#x201c;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;IP&#x201d;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $&#160;10,000 upfront payment and is eligible to receive up to $&#160;200,000 for development, regulatory and commercial milestones for the first product, of which $&#160;25,500 was received or accrued&#160;as well as tiered royalties on future product sales.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="margin-left:85.05pt;text-align:justify;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                  &lt;/div&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#x201c;probable&#x201d; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Sales&#160;or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales&#160;or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;On December 18, 2020 the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 2,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On&#160;September 29, 2021 the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 6,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;On November 11, 2022, the third milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 7,500 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/p&gt;
                  &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                    &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;On December 27, 2023, the fourth milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 10,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;On December 18, 2023, the Company entered into an exclusive License Agreement with Gilead. Under the terms of the agreement, the Company granted Gilead an exclusive license under the Company&#x2019;s pre-clinical antibody program against IL-18 binding protein and all intellectual property rights subsisting therein, to use, research, develop, manufacture and commercialize products derived from a Compugen pipeline program. Compugen received an upfront payment of $60,000 and is also eligible to receive up to approximately $ 788,000 additional milestone payments subject to and upon the achievement of certain development, regulatory and commercial milestones and as detailed in the agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Gilead may terminate the Gilead Collaboration Agreement for convenience by giving a certain prior written notice to the Company at any time after the effective date of the agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company concluded that Gilead is a customer and therefore revenue recognition should be accounted for in accordance with ASC 606, because the Company granted to Gilead licenses to its intellectual property and will provide research and development services, all of which are outputs of the Company&#x2019;s ongoing activities, in exchange for consideration.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company assessed the promises under the License Agreement and concluded that (i) the delivery of the COM503 License; (ii) the preclinical research and development activities towards IND approval of COM503 (the &#x201c;IND research and development activities&#x201d;) and (iii) the contingent promise to additional research and development activities for Phase 1 clinical (the &#x201c;Phase 1 research and development activities&#x201d;), are capable of being distinct and are distinct within the context of the License Agreement. The Company considered that the license has standalone functionality, considered to be functional intellectual property, and is capable of being distinct. The Company also determined that the IND research and development activities and Phase 1 research and development activities could be provided by resources otherwise available to Gilead and thus are capable of being distinct. Also, the Company concluded that the Company&#x2019;s contingent promise to additional research and development activities for Phase 1 clinical represents a material right.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;As a result, the Company concluded that its promise to deliver the COM503 License, the promise to perform IND research and development activities and Phase 1 research and development activities represented separate performance obligations in the License Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company also evaluated as a possible variable consideration all milestones and royalties. With respect to clinical development and regulatory milestones, based upon the high degree of uncertainty and risk associated with these potential payments, the Company concluded that all such amounts should be fully constrained and are not included in the initial transaction price as the Company cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Accordingly, the Company did not include any potential clinical development, regulatory and sales milestones and royalties in the initial transaction price.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company allocated the transaction price to each performance obligation on a relative estimated standalone selling price basis. The Company developed the estimated standalone selling price for the COM503 License based on the present value of expected future cash flows associated with the license and related clinical development and regulatory milestones. In developing such estimate, the Company applied judgement in determining the timing needed to develop the Licensed Product, the probability of success, and the discount rate. The Company developed the estimated standalone selling price for the IND research and development activities using a &#x201c;cost plus&#x201d; reasonable margin approach. To determine the estimated standalone selling price of the material right for the Phase 1 research and development activities obligation, the Company estimated the standalone selling price of the underlying performance obligations included in the material right and estimated the probability of the Company&#x2019;s performance of such obligations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company determined that the COM503 License was a functional license since the underlying intellectual property (the &#x201c;IP&#x201d;) has significant standalone functionality. In addition, the Company determined that December 18, 2023 represents (i) the date at which the Company made available the IP to Gilead and (ii) the beginning of the period during which Gilead is able to use and benefit from its right to use the IP. Based upon these considerations, the Company recognized the entirety of the initial transaction price allocated to the COM503 License performance obligation during the year ended December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Further, the IND research and development activities and Phase 1 research and development activities performance obligations are recognized over time when, or as, the Company performs the required services to Gilead. The Company determined that the input method under ASC 606 is the best measure of progress towards satisfying the performance obligation and reflects a faithful depiction of the transfer of goods and services. The method of measuring progress towards delivery of the services incorporates actual internal and external costs incurred, relative to total internal and external costs expected to be incurred to satisfy the performance obligation. The period over which total costs were estimated reflected the Company&#x2019;s best estimate of the period over which it would perform the activities to achieve clearance of an IND application for COM503 and the phase 1 clinical trial.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;During the year ended December 31, 2023, the Company recognized $ 23,459 of license revenue. The Company included deferred revenues of $ 11,149 in current liabilities and $ 25,392 in non-current liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;For additional information regarding revenues, please refer to Note 10 below.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;p style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                      &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240228054857433_16"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="C_20231231"
      decimals="-3"
      id="F20240228054857433_17"
      unitRef="usd">200000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <cgen:AccruedMilestonePayments
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240228054857434_18"
      unitRef="usd">25500000</cgen:AccruedMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_20201201to20201218"
      decimals="-3"
      id="Fxbrl_20240301103700585"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_20210901to20210929"
      decimals="-3"
      id="F20240228054857467_79"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_20221101to20221111"
      decimals="-3"
      id="F20240228054857446_43"
      unitRef="usd">7500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_20231201to20231227"
      decimals="-3"
      id="Fxbrl_20240228115609016"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20231210to20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember"
      decimals="-3"
      id="Fxbrl_20240228120200198"
      unitRef="usd">60000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="C_20231218_srtStatementScenarioAxis_cgenLicenseAgreementWithGileadMember"
      decimals="-3"
      id="Fxbrl_20240228120212438"
      unitRef="usd">788000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <cgen:LicenseRevenue
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228121336624"
      unitRef="usd">23459000</cgen:LicenseRevenue>
    <cgen:DeferredRevenuesIncludedInCurrentLiabilities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228121352406"
      unitRef="usd">11149000</cgen:DeferredRevenuesIncludedInCurrentLiabilities>
    <cgen:DeferredRevenuesIncludedInNonCurrentLiabilities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228121407737"
      unitRef="usd">25392000</cgen:DeferredRevenuesIncludedInNonCurrentLiabilities>
    <cgen:CostOfSalesContractWithCustomerPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20240228054857434_19">
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;l.&lt;span style="padding-left:22.72pt;margin-top:0pt;margin-bottom:0pt"&gt;Cost of revenues:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Cost of revenues consist of certain royalties and milestones paid or accrued.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
            </cgen:CostOfSalesContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_20230101to20231231"
      id="F20240228054857434_20">
              &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                  &lt;div style="margin:0pt 0px 0pt 58pt;line-height:1.25;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;m.&#160; &#160; &#160; &#160;Research and development expenses, net:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                  &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                  &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                  &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The portion of the Bristol-Myers Squibb $ 12,000 investment in 2018 over the fair market value of the shares issued in the amount of $ 4,121 and the portion of the $ 20,000 investment in 2021 over the fair market value of the shares issued in the amount of $ 5,000 were considered as deferred participation of Bristol-Myers Squibb in R&amp;amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;amp;D, see Note 1f and Note 8b.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                  &lt;div style="text-align:justify;margin-left:85.5pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Amortization of participation in R&amp;amp;D expenses for the years ended December 31, 2023, 2022 and 2021 were $ 325, $ 6,019 and $ 1,291, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20231231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember"
      decimals="-3"
      id="F20240228054857451_54"
      unitRef="usd">12000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <cgen:DeferredParticipationOfBMSInRAndDExpenses
      contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember"
      decimals="-3"
      id="F20240228054857452_55"
      unitRef="usd">4121000</cgen:DeferredParticipationOfBMSInRAndDExpenses>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20231231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember"
      decimals="-3"
      id="F20240228054857453_56"
      unitRef="usd">20000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <cgen:DeferredParticipationOfBMSInRAndDExpenses
      contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember"
      decimals="-3"
      id="F20240228054857453_57"
      unitRef="usd">5000000</cgen:DeferredParticipationOfBMSInRAndDExpenses>
    <us-gaap:AdjustmentForAmortization
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240228054857435_21"
      unitRef="usd">325000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240228054857435_22"
      unitRef="usd">6019000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="F20240228054857436_23"
      unitRef="usd">1291000</us-gaap:AdjustmentForAmortization>
    <cgen:ServerancePayPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20240228054857436_24">
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;n.&lt;span style="padding-left:22.72pt;margin-top:0pt;margin-bottom:0pt"&gt;Severance pay:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company&#x2019;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date, and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset on the Company&#x2019;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#x2019;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#x2019;s monthly salary for each year of service, no additional calculations are conducted between the parties regarding the matter of severance pay and no additional payments are made by the Company to the employee.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Severance expenses for the years ended December 31, 2023, 2022 and 2021 amounted to approximately $&#160;432, $&#160;468 and $&#160;383, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
            </cgen:ServerancePayPolicyTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="F20240228054857437_25"
      unitRef="usd">432000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20240228054857437_26"
      unitRef="usd">468000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="F20240228054857438_27"
      unitRef="usd">383000</us-gaap:SeveranceCosts1>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_20230101to20231231"
      id="F20240228054857438_28">
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;o.&lt;span style="padding-left:22.06pt;margin-top:0pt;margin-bottom:0pt"&gt;Stock-based compensation:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company accounts for stock-based compensation to employees and non-employees in accordance with ASC 718, &#x201c;Compensation - Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company selected the Black-Scholes-Merton (&#x201c;Black-Scholes&#x201d;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
              &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company used the following assumptions for options granted to employees, directors and non-employees and ESPP:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
              &lt;div style="margin-left:90pt;margin-top:0pt;margin-bottom:0pt"&gt;

                  &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                    &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;

                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="5" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="background-color:rgb(204, 238, 255);width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Employee stock options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;75.93%-80.95%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;69.44%-74.61%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;66.02%-69.05%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;3.37%-4.81%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;1.54%-4.39%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0.51%-1.14%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;4.02-5.06&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;5.05-5.4&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;5.04-5.31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;

                      &lt;/table&gt;
                      &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;

              &lt;/div&gt;
              &lt;div style="margin-left:90pt;margin-top:0pt;margin-bottom:0pt"&gt;
                &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;

                    &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;

                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="5" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="background-color:rgb(204, 238, 255);width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;ESPP&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;69.74%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;64.68%-69.68%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;1.63%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0.04%-0.10%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0.42-0.50&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;

                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/div&gt;

                &lt;/div&gt;
              &lt;/div&gt;
            </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <cgen:ScheduleOfWeightedAverageAssumptionsForGrantedOptions
      contextRef="C_20230101to20231231"
      id="F20240228054857450_52">
                  &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                    &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;

                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="5" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="background-color:rgb(204, 238, 255);width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Employee stock options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="background-color:rgb(204, 238, 255);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;75.93%-80.95%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;69.44%-74.61%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;66.02%-69.05%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;3.37%-4.81%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;1.54%-4.39%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0.51%-1.14%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;
                          &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                            &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;4.02-5.06&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;5.05-5.4&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                            &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                            &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                              &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;5.04-5.31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;
                          &lt;/tr&gt;

                      &lt;/table&gt;
                      &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;

                    &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;

                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="5" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="padding-bottom:2px;width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="padding-bottom:2px;width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="border-bottom:2px solid rgb(0, 0, 0);width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="background-color:rgb(204, 238, 255);width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;ESPP&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="background-color:rgb(204, 238, 255);width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="background-color:rgb(204, 238, 255);width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td style="width:12%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;69.74%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;64.68%-69.68%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;1.63%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0.04%-0.10%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="width:61%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;background-color:rgb(204, 238, 255);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                                &lt;td style="width:61%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="width:0.97%;text-align:center;vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                                &lt;td rowspan="1" style="width:12%;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt"&gt;
                                  &lt;div style="line-height:1.25;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;0.42-0.50&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                              &lt;/tr&gt;

                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/div&gt;
                  </cgen:ScheduleOfWeightedAverageAssumptionsForGrantedOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857454_58"
      unitRef="Pure">0.7593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857454_59"
      unitRef="Pure">0.8095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857455_60"
      unitRef="Pure">0.6944</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857455_61"
      unitRef="Pure">0.7461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857456_62"
      unitRef="Pure">0.6602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857456_63"
      unitRef="Pure">0.6905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857457_64"
      unitRef="Pure">0.0337</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857458_65"
      unitRef="Pure">0.0481</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857459_66"
      unitRef="Pure">0.0154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857460_67"
      unitRef="Pure">0.0439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857460_68"
      unitRef="Pure">0.0051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="F20240228054857461_69"
      unitRef="Pure">0.0114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20230101to20231231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="2"
      id="F20240228054857439_29"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="2"
      id="F20240228054857439_30"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20210101to20211231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="2"
      id="Fxbrl_20240228114441654"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="F20240228054857461_70">P4Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="F20240228054857462_71">P5Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="F20240228054857463_72">P5Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="F20240228054857463_73">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="F20240228054857464_74">P5Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="F20240228054857464_75">P5Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20230101to20231231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="2"
      id="F20240228054857440_31"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="4"
      id="F20240228054857447_44"
      unitRef="Pure">0.6974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="4"
      id="F20240228054857467_80"
      unitRef="Pure">0.6468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="4"
      id="F20240228054857447_45"
      unitRef="Pure">0.6968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20230101to20231231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="2"
      id="F20240228054857440_32"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="4"
      id="F20240228054857448_46"
      unitRef="Pure">0.0163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="4"
      id="F20240228054857468_81"
      unitRef="Pure">0.0004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="4"
      id="F20240228054857448_47"
      unitRef="Pure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20230101to20231231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="2"
      id="F20240228054857440_33"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="2"
      id="F20240228054857449_48"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20210101to20211231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="2"
      id="F20240228054857450_51"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      id="F20240228054857449_49">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      id="F20240228054857468_82">P0Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      id="F20240228054857449_50">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_20230101to20231231"
      id="F20240228054857441_35">
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;p.&lt;span style="padding-left:21.5pt;margin-top:0pt;margin-bottom:0pt"&gt;Concentration of credit risks:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits and investment in marketable securities.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Cash, cash equivalents, restricted cash and short-term bank deposits are invested in major banks in Israel and in the United States. Generally, these deposits may be redeemed upon demand and bear minimal risk.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
            </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20240228054857442_36">
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;q.&lt;span style="padding-left:22.5pt;margin-top:0pt;margin-bottom:0pt"&gt;Basic and diluted loss per share:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#x201c;Earnings per Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&#x201d;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;All outstanding share options and warrants for the years ended December 31, 2023, 2022 and 2021 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2023, 2022 and 2021 the average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 7,921,020, 8,405,615 and 6,758,300, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
            </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"
      decimals="INF"
      id="F20240228054857442_37"
      unitRef="Shares">7921020</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"
      decimals="INF"
      id="F20240228054857443_38"
      unitRef="Shares">8405615</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"
      decimals="INF"
      id="F20240228054857445_39"
      unitRef="Shares">6758300</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20240228054857445_40">
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;r.&lt;span style="padding-left:24.5pt;margin-top:0pt;margin-bottom:0pt"&gt;Income taxes:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company accounts for income taxes in accordance with ASC No. 740, &#x201c;Income Taxes&#x201d;, (&#x201c;ASC 740&#x201d;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2023 and 2022, a full valuation allowance was provided by the Company.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
            </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_20230101to20231231"
      id="F20240228054857446_41">
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;s.&lt;span style="padding-left:23.5pt;margin-top:0pt;margin-bottom:0pt"&gt;Fair value of financial instruments:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The Company applies ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market participants at the measurement date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
              &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The hierarchy is broken down into three levels based on the inputs as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;margin-top:0pt;margin-bottom:0pt"&gt;

                  &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                    &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Level 1&#160;&lt;/span&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can &lt;/span&gt;access at the measurement date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
                &lt;table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;margin-top:0pt;margin-bottom:0pt"&gt;

                    &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Level 2&#160;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Valuations based on one or more quoted prices in markets that are not active or for which all &lt;/span&gt;significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;td style="width:85.5pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="width:56.7pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt;margin-top:0pt;margin-bottom:0pt"&gt;
                        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Level 3&#160;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                      &lt;/td&gt;
                      &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, other accounts receivable and prepaid expenses, trade payable and other accounts payable and accrued expenses approximate their fair values due to the short-term maturities of such instruments.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
            </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="F20240228054857446_42">
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;t.&lt;span style="padding-left:23.06pt;margin-top:0pt;margin-bottom:0pt"&gt;Recently issued accounting pronouncement not yet adopted by the Company:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;In&#160;December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
            </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20230222132226340">
    &lt;div&gt;
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;color:rgb(0, 0, 0)"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;NOTE 3:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="margin-left:63pt"&gt;

              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                    &lt;td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Prepaid expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                    &lt;td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Government authorities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                    &lt;td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="text-indent:-4.25pt;margin-left:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;232&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                    &lt;td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                    &lt;td style="width:76%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;

          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240228020440395">
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                    &lt;td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Prepaid expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                    &lt;td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Government authorities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                    &lt;td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="text-indent:-4.25pt;margin-left:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;232&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                    &lt;td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                    &lt;td style="width:76%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            </us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000406"
      unitRef="usd">2211000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000407"
      unitRef="usd">2100000</us-gaap:PrepaidExpenseCurrent>
    <cgen:GovernmentAuthorities
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000408"
      unitRef="usd">92000</cgen:GovernmentAuthorities>
    <cgen:GovernmentAuthorities
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000409"
      unitRef="usd">85000</cgen:GovernmentAuthorities>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000410"
      unitRef="usd">226000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000411"
      unitRef="usd">232000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000412"
      unitRef="usd">2529000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000413"
      unitRef="usd">2417000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000441">
    &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;color:rgb(0, 0, 0)"&gt;

        &lt;tr&gt;
          &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;NOTE 4:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
          &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
            &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;LEASES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;

    &lt;/table&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company leases all its real estate, storage area and cars under various operating lease agreements that expire on various dates.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s operating leases have original lease periods expiring between 2021 and 2026. The offices in Israel lease include two options to renew, one of which was exercised in 2020. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably certain.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease payments included in the measurement of the lease liability comprise the following: the fixed non-cancelable lease payments and payments for optional renewal periods where it is reasonably certain the renewal period will be exercised.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under ASC 842, all leases, including non-cancelable operating leases, are now recognized on the balance sheet. The aggregated present value of lease payments is recorded as a long-term asset titled Operating lease right of use asset. The corresponding lease liabilities are split between current maturity of operating lease liability within current liabilities and long-term operating lease liability within long-term liabilities. The Company&#x2019;s leases do not provide an implicit rate, therefore the Company uses its incremental borrowing rate based on information available on the commencement date to determine the present value of lease payments.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table represents the weighted-average remaining lease term and discount rate:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:63pt"&gt;

            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:89.79%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.03%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:9.18%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;width:89.79%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1.03%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);width:9.18%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:89.79%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.03%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:9.18%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:89.79%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.03%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td rowspan="1" style="vertical-align:bottom;width:9.18%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-align:center"&gt;2.19&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:89.79%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average discount (annual) rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.03%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td rowspan="1" style="vertical-align:bottom;width:9.18%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center"&gt;5.32%&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating lease expenses were approximately $ 800, $ 884 and $ 956 in the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Variable payments as CPI, included in the lease expenses, were approximately $ 61, $ 37 and $ 14 in the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash paid for amounts included in the measurement of lease liabilities was approximately $ 852, $ 959 and $ 914 in the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Maturities of operating lease liabilities were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&#160;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;631&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total operating lease payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,436&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less: imputed interest&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities, current&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;632&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities, non- current&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The above annual minimum future rental commitments include the period covered by the first exercised option with respect to the leased facility of Compugen Ltd. through March 2026 and exclude the second option to extend the lease of the Company facility for additional five-year period following expiration of the current lease period.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:LesseeOperatingLeasesTextBlock>
    <cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate
      contextRef="C_20230101to20231231"
      id="Fxbrl_20230222013426728">
            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:89.79%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.03%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:9.18%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;width:89.79%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1.03%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);width:9.18%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:89.79%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.03%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:9.18%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:89.79%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.03%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td rowspan="1" style="vertical-align:bottom;width:9.18%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-align:center"&gt;2.19&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:89.79%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average discount (annual) rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1.03%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td rowspan="1" style="vertical-align:bottom;width:9.18%;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center"&gt;5.32%&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          </cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_20231231" id="FFact_0000000000421">P2Y2M8D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_20231231"
      decimals="4"
      id="FFact_0000000000422"
      unitRef="Pure">0.0532</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000424"
      unitRef="usd">800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000425"
      unitRef="usd">884000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000426"
      unitRef="usd">956000</us-gaap:OperatingLeasePayments>
    <us-gaap:VariableLeasePayment
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240301102821130"
      unitRef="usd">61000</us-gaap:VariableLeasePayment>
    <us-gaap:VariableLeasePayment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240301102854023"
      unitRef="usd">37000</us-gaap:VariableLeasePayment>
    <us-gaap:VariableLeasePayment
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240301102901175"
      unitRef="usd">14000</us-gaap:VariableLeasePayment>
    <cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000427"
      unitRef="usd">852000</cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000428"
      unitRef="usd">959000</cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000429"
      unitRef="usd">914000</cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20230222013609784">
          &lt;div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&#160;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;631&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total operating lease payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,436&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less: imputed interest&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities, current&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;632&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities, non- current&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000431"
      unitRef="usd">690000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000432"
      unitRef="usd">631000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000433"
      unitRef="usd">115000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000435"
      unitRef="usd">1436000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000436"
      unitRef="usd">85000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000437"
      unitRef="usd">1351000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000438"
      unitRef="usd">632000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000439"
      unitRef="usd">719000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230214024012785"
      unitRef="usd">1351000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000468">
    &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;color:rgb(0, 0, 0)"&gt;

        &lt;tr&gt;
          &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;NOTE 5:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
          &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
            &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;

    &lt;/table&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:63pt"&gt;

            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cost:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers, software and related equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;739&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,617&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,519&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,831&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accumulated depreciation:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers, software and related equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;609&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,435&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Depreciated cost&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During 2023 and 2022 total cost of $ 1,357 and $ 99, respectively and total accumulated depreciation of $ 1,350 and $ 95, respectively were disposed from the consolidated balance sheets.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the years ended December 31, 2023, 2022 and 2021, depreciation expenses were approximately $ 476, $ 482 and $ 461, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000460">
            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cost:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers, software and related equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;739&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,617&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,519&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,831&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accumulated depreciation:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers, software and related equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;609&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,435&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Depreciated cost&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000442"
      unitRef="usd">739000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000443"
      unitRef="usd">1617000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="-3"
      id="FFact_0000000000444"
      unitRef="usd">3519000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="-3"
      id="FFact_0000000000445"
      unitRef="usd">3831000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000446"
      unitRef="usd">2314000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000447"
      unitRef="usd">2314000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000448"
      unitRef="usd">6572000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000449"
      unitRef="usd">7762000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000450"
      unitRef="usd">609000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000451"
      unitRef="usd">1435000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="-3"
      id="FFact_0000000000452"
      unitRef="usd">2909000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="-3"
      id="FFact_0000000000453"
      unitRef="usd">3190000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000454"
      unitRef="usd">1838000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000455"
      unitRef="usd">1605000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000456"
      unitRef="usd">5356000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000457"
      unitRef="usd">6230000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000458"
      unitRef="usd">1216000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000459"
      unitRef="usd">1532000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"
      decimals="-3"
      id="FFact_0000000000461"
      unitRef="usd">1357000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"
      decimals="-3"
      id="FFact_0000000000462"
      unitRef="usd">99000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"
      decimals="-3"
      id="FFact_0000000000463"
      unitRef="usd">1350000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"
      decimals="-3"
      id="FFact_0000000000464"
      unitRef="usd">95000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000465"
      unitRef="usd">476000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000466"
      unitRef="usd">482000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000467"
      unitRef="usd">461000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000476">
    &lt;div&gt;
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;NOTE 6:-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

          &lt;div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Employees and related accruals&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,125&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,812&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7,858&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;6,396&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;10,983&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;9,208&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;

      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20230222132609363">
          &lt;div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Employees and related accruals&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3,125&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,812&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;7,858&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;6,396&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;10,983&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;9,208&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000469"
      unitRef="usd">3125000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000470"
      unitRef="usd">2812000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000471"
      unitRef="usd">7858000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000472"
      unitRef="usd">6396000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000473"
      unitRef="usd">10983000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000474"
      unitRef="usd">9208000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000498">
    &lt;div&gt;
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 7:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company provided bank guarantees in the amount of $ 296 related to its offices in Israel, leased cars fueling in Israel and credit card security for its U.S. subsidiary.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the Office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly known as the Office of the Chief Scientist (the &#x201c;IIA&#x201d;), the Company is not obligated to repay any amounts received from the IIA if it does not generate any income from the results of the funded research program(s). If income is generated from a funded research program, the Company is committed to pay royalties at a rate of between 3% to 5% of future revenue arising from such research program(s), and up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum to be repaid is 100% plus interest at LIBOR until December 31, 2023, and from January 1, 2024, the 12 months Term SOFR interest). For the years ended December 31, 2023, 2022 and 2021, the Company had an aggregate of paid or accrued royalties to the IIA, recorded as cost of revenue in the consolidated statements of comprehensive loss in the amount of $ 1,004, $ 225 and $ 180, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
                &lt;div style="font-family:'Times New Roman',Times,serif"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2023, the Company&#x2019;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled approximately to $ 8,970.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On June 25, 2012 the Company entered into an Antibodies Discovery Collaboration Agreement (the &#x201c;Antibodies Discovery Agreement&#x201d;) with a U.S. antibody technology company (&#x201c;mAb Technology Company&#x201d;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company will be entitled to certain royalties that could be eliminated, upon payment of certain one-time fees (all payments referred together as &#x201c;Contingent Fees&#x201d;). For the years ended December 31, 2023, 2022 and 2021, the Company incurred such Contingent Fees in the amounts of $ 1,000, $ 750 and $ 500.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On May 9, 2012, the Company entered into agreement (the &#x201c;May 2012 Agreement&#x201d;) with a U.S. Business Development Strategic Advisor (&#x201c;Advisor&#x201d;) for the purpose of entering into transactions with Pharma companies related to selected Pipeline Program Candidates.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
                &lt;div style="font-family:'Times New Roman',Times,serif"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the agreement the Advisor was entitled to 4% of the cash considerations that may be received under such transactions. In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Bayer Agreement was terminated effective February 27, 2023 and no further payments are expected under the May 2012 Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the years ended December 31, 2023, 2022 and 2021, the Company has not paid and did not accrue payments under this agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (CLA) with a European cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and 1% royalties on annual net sales with respect to each commercialized product manufactured using the company&#x2019;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the years ended December 31, 2023, 2022 and 2021, the Company did not incur any amount in the research and development expenses in connection with such milestone payment.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the years ended December 31, 2023, 2022 and 2021, the Company incurred in the research and development expenses such milestone payment in the amounts of $ 500, $ 0 and $ 250.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000477"
      unitRef="usd">296000</us-gaap:GuaranteeObligationsMaximumExposure>
    <cgen:RoyaltyPercentageBasedOnFutureRevenues
      contextRef="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMinimumMember"
      decimals="2"
      id="FFact_0000000000478"
      unitRef="Pure">0.03</cgen:RoyaltyPercentageBasedOnFutureRevenues>
    <cgen:RoyaltyPercentageBasedOnFutureRevenues
      contextRef="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMaximumMember"
      decimals="2"
      id="FFact_0000000000479"
      unitRef="Pure">0.05</cgen:RoyaltyPercentageBasedOnFutureRevenues>
    <cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived
      contextRef="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"
      decimals="2"
      id="FFact_0000000000480"
      unitRef="Pure">1</cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived>
    <us-gaap:RoyaltyExpense
      contextRef="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"
      decimals="-3"
      id="FFact_0000000000481"
      unitRef="usd">1004000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"
      decimals="-3"
      id="FFact_0000000000482"
      unitRef="usd">225000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_20210101to20211231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"
      decimals="-3"
      id="FFact_0000000000483"
      unitRef="usd">180000</us-gaap:RoyaltyExpense>
    <cgen:RoyaltyContingentObligations
      contextRef="C_20231231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"
      decimals="-3"
      id="FFact_0000000000484"
      unitRef="usd">8970000</cgen:RoyaltyContingentObligations>
    <cgen:ContingentFees
      contextRef="C_20231231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember"
      decimals="-3"
      id="FFact_0000000000485"
      unitRef="usd">1000000</cgen:ContingentFees>
    <cgen:ContingentFees
      contextRef="C_20221231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember"
      decimals="-3"
      id="FFact_0000000000486"
      unitRef="usd">750000</cgen:ContingentFees>
    <cgen:ContingentFees
      contextRef="C_20211231_cgenGovernmentAndOtherGrantsAxis_cgenAntibodiesDiscoveryCollaborationAgreementMember"
      decimals="-3"
      id="FFact_0000000000487"
      unitRef="usd">500000</cgen:ContingentFees>
    <cgen:AgreementStartDate
      contextRef="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"
      id="FFact_0000000000488">2012-05-09</cgen:AgreementStartDate>
    <cgen:ParticipationRights
      contextRef="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember_srtRangeAxis_srtMinimumMember"
      decimals="2"
      id="FFact_0000000000489"
      unitRef="Pure">0.04</cgen:ParticipationRights>
    <cgen:AgreementTerminationDescription
      contextRef="C_20230101to20231231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"
      id="FFact_0000000000490">In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.</cgen:AgreementTerminationDescription>
    <cgen:RoyaltyPercentage
      contextRef="C_20230101to20231231"
      decimals="2"
      id="FFact_0000000000491"
      unitRef="Pure">0.01</cgen:RoyaltyPercentage>
    <cgen:ResearchAndDevelopmentExpensesMilestonePayment
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000495"
      unitRef="usd">500000</cgen:ResearchAndDevelopmentExpensesMilestonePayment>
    <cgen:ResearchAndDevelopmentExpensesMilestonePayment
      contextRef="C_20220101to20221231"
      decimals="0"
      id="FFact_0000000000496"
      unitRef="usd">0</cgen:ResearchAndDevelopmentExpensesMilestonePayment>
    <cgen:ResearchAndDevelopmentExpensesMilestonePayment
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000497"
      unitRef="usd">250000</cgen:ResearchAndDevelopmentExpensesMilestonePayment>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240228135111319">
      &lt;div&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%"&gt;

              &lt;tr&gt;
                &lt;td style="font-size:10pt;vertical-align:top;width:56.7pt"&gt;
                  &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;NOTE 8:-&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="font-size:10pt;width:auto"&gt;&lt;span style="fonfamily:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;SHAREHOLDERS&lt;/span&gt;&#x2019;&lt;span style="font-weight:bold"&gt; EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Ordinary shares:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
                &lt;div style="font-family:'Times New Roman',Times,serif"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The ordinary shares confer upon their holders the right to attend and vote at general meetings of the shareholders. Subject to the rights of holders of shares with limited or preferred rights which may be issued in the future, the ordinary shares of the Company confer upon the holders thereof equal rights to receive dividends, and to participate in the distribution of the assets of the Company upon its winding-up, in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the nominal value, if any.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;
          &lt;div&gt;&lt;/div&gt;
        &lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Issuance of shares:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
                &lt;div style="font-family:'Times New Roman',Times,serif"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On June 14, 2018, the Company entered into securities purchase agreement with certain institutional investors and a placement agency agreement with JMP Securities LLC in connection with a registered direct offering (the &#x201c;Offering&#x201d;) of an aggregate of 5,316,457 ordinary shares (the &#x201c;RD Shares&#x201d;) of the Company at a purchase price of $ 3.95 per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to 4,253,165 additional ordinary shares. The Warrants were exercisable at a price of $ 4.74 per ordinary share and had a term of five years from the date of issuance. The Offering was made pursuant to the Company&#x2019;s Registration Statement. Proceeds from the Offering were $ 19,767 (net of $ 1,233 issuance expenses).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the years ended December 31, 2021 and 2020, warrants to purchase an aggregate of 3,955,696 ordinary shares were exercised with proceeds of approximately $ 18,750 and as of December 31, 2023 and 2022, warrants to purchase 0 and up to 297,469 ordinary shares, respectively, remain outstanding. The warrants expired in June 2023.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#x201c;Master Clinical Agreement&#x201d;) with Bristol-Myers Squibb to evaluate the safety and tolerability of the Company&#x2019;s COM701 in combination with Bristol-Myers Squibb&#x2019;s PD-1 immune checkpoint inhibitor Opdivo&#xae; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol-Myers Squibb made a $ 12,000 equity investment in the Company.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the terms of the securities purchase agreement, Bristol-Myers Squibb purchased 2,424,243 ordinary shares of the Company at a purchase price of $ 4.95 per share. The share price represented a 33% premium over the average closing price of Compugen&#x2019;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The premium over the fair market value in the amount of $ 4,121 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;amp;D) and $ 7,788 (net of $ 91 issuance expenses) were considered equity investment.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $ 20,000 investment in the Company, purchasing 2,332,815 ordinary shares of the Company at a purchase price of $ 8.57333 per share. The share price represented a 33% premium over the closing price of Company&#x2019;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The premium over the fair market value in the amount of $ 5,000 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;amp;D) and $ 14,958 (net of $ 42 issuance expenses) were considered equity investment.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left"&gt;&#160;&lt;/p&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="margin-left:85.05pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On January 31, 2023, the Company entered into a Sales Agreement with Leerink Partners LLC (previously known as SVB Securities LLC) (&#x201c;Leerink Partners&#x201d;), as sales agent, pursuant to which the Company may offer and sell, from time to time through Leerink Partners, its ordinary shares through an &#x201c;at the market offering&#x201d; (ATM). The offer and sale of our ordinary shares, if any, will be made pursuant to the Company&#x2019;s shelf registration statement on Form F-3, as supplemented by a prospectus supplement filed on January 31, 2023. Pursuant to the applicable prospectus supplement, the Company may offer and sell up to $50,000 of its ordinary shares. As of December 31, 2023, 2,612,822 ordinary shares were issued and sold through the ATM, with proceeds of approximately $3,081 (net of $513 issuance expenses).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share option plan:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
                &lt;div style="font-family:'Times New Roman',Times,serif"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the Company&#x2019;s 2010 Share Option Plan, as amended (the &#x201c;Plan&#x201d;), options may be granted to employees, directors and non-employees of the Company and Compugen USA, Inc.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the 2010 Share Option Plan the Company reserved for issuance up to an aggregate of 13,895,152 ordinary shares. The Company&#x2019;s Board of Directors last amended the Plan in August 2023, to decrease the number of shares available under the 2010 Plan. As of December 31, 2023, an aggregate of 1,202,301 options under the 2010 Share Option Plan of the Company were still available for future grants.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In general, options granted under the Plan vest over a four-year period and expire 10 years from the date of grant and are granted at an exercise price of not less than the fair market value of the Company&#x2019;s ordinary shares on the date of grant, unless otherwise determined by the Company&#x2019;s board of directors. The exercise price of the options granted under the Plan may not be less than the nominal value of the shares into which such options are exercisable, and the expiration date may not be later than 10 years from the date of grant. If a grantee leaves his or her employment or other relationship with the Company, or if his or her relationship with the Company is terminated without cause (and other than by reason of death or disability, as defined in the Plan), the term of his or her unexercised options will generally expire in 90 days, unless determined otherwise by the Company.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Any options that are cancelled, forfeited or expired become available for future grants.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="clear:both;margin-top:0pt;margin-bottom:0pt"&gt;
          &lt;div style="width:100%"&gt;&#160;&lt;/div&gt;
        &lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="font-family:'Times New Roman',Times,serif"&gt;
          &lt;div style="line-height:1.25;margin-left:85.05pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Transactions related to the grant of options to employees, directors and non-employees under the above Plan during the year ended December 31, 2023, were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:90pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;exercise&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;remaining contractual&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;life&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Aggregate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;intrinsic&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options outstanding at beginning of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,157,749&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options granted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,576,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options forfeited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,086,404&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="width:52%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options expired&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(274,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options outstanding at end of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,373,745&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6.61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercisable at end of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,017,329&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average fair value of options granted to employees, directors and non-employees during the years 2023, 2022 and 2021 was $ 0.70, $ 1.51 and $ 3.81 per share, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Aggregate intrinsic value of exercised options by employees, directors and non-employees during the years 2023, 2022 and 2021 was $ 0, $ 19 and $ 759, respectively. The aggregate intrinsic value of the exercised options represents the total intrinsic value (the difference between the sale price of the Company&#x2019;s share at the date of exercise, and the exercise price) multiplied by the number of options exercised.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company&#x2019;s closing share price on the last trading day of calendar 2023 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2023. This amount is impacted by the changes in the fair market value of the Company&#x2019;s shares.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2023, the total unrecognized estimated compensation cost related to non-vested share options granted prior to that date was $ 5,370 which is expected to be recognized over a weighted average period of approximately 2.06 years.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.5pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;
          &lt;div&gt;&lt;/div&gt;
        &lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:58.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:26.5pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Employee Stock Purchase Plan:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company adopted an ESPP in November 2020, with the first offering period starting on January 1, 2021. In connection with its adoption, a total of 600,000 ordinary shares were reserved for issuance under this plan.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:0.5pt;margin-left:85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The ESPP is implemented through six-month offering periods (except for the first offering period that was five months). According to the ESPP, eligible employees and non-employees may use up to 15% of their base salaries to purchase ordinary shares up to an aggregate limit of $ 40 per participant for every calendar year. The price of an ordinary share purchased under the ESPP is equal to 85% of the lower of the fair market value of the ordinary share on the first day of each offering period or on the last day of such period.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:0.5pt;margin-left:85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In the years ended December 31, 2023, 2022 and 2021, 0, 158,025 and 117,829 ordinary shares, respectively, had been purchased under the ESPP and as of December 31, 2023, 114,146 ordinary shares were available for issuance under the ESPP.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.3pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The stock-based compensation expenses related to stock options and ESPP are included as follows in the expense categories:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:90pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,971&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Marketing and business development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;General and administrative expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,658&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,901&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,090&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,328&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20180601to20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember"
      decimals="INF"
      id="Fxbrl_20240227235014159"
      unitRef="Shares">5316457</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember"
      decimals="INF"
      id="Fxbrl_20240227235028063"
      unitRef="USD_per_share">3.95</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember"
      decimals="INF"
      id="Fxbrl_20240227235036671"
      unitRef="Shares">4253165</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember"
      decimals="2"
      id="Fxbrl_20240227235043689"
      unitRef="USD_per_share">4.74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cgen:ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable
      contextRef="C_20180601to20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember"
      id="Fxbrl_20240227235050367">P5Y</cgen:ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_20180601to20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember"
      decimals="-3"
      id="Fxbrl_20240227235102743"
      unitRef="usd">19767000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20180601to20180614_srtStatementScenarioAxis_cgenJmpSecuritiesLlcMember"
      decimals="-3"
      id="Fxbrl_20240227235108404"
      unitRef="usd">1233000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20201231_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20240228112711109"
      unitRef="Shares">3955696</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20211231_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20230214032847386"
      unitRef="Shares">3955696</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="-3"
      id="Fxbrl_20230214033059280"
      unitRef="usd">18750000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20210101to20211231_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="-3"
      id="Fxbrl_20230214032855904"
      unitRef="usd">18750000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20221231_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_s_20240228112751966"
      unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20231231_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20240228112751966"
      unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20221231_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20240228112829453"
      unitRef="Shares">297469</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20231231_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20230214032904124"
      unitRef="Shares">297469</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="-3"
      id="FFact_0000000000516"
      unitRef="usd">12000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="-3"
      id="FFact_0000000000517"
      unitRef="usd">2424243000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="INF"
      id="FFact_0000000000518"
      unitRef="USD_per_share">4.95</us-gaap:SharesIssuedPricePerShare>
    <cgen:PercentageOfClosingPrice
      contextRef="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="2"
      id="FFact_0000000000519"
      unitRef="Pure">0.33</cgen:PercentageOfClosingPrice>
    <cgen:DeferredParticipationOfBMSInRAndDExpenses
      contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="Fxbrl_20230221120705140"
      unitRef="usd">4121000</cgen:DeferredParticipationOfBMSInRAndDExpenses>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="Fxbrl_20230221120728895"
      unitRef="usd">7788000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="Fxbrl_20230221120826639"
      unitRef="usd">91000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="-3"
      id="FFact_0000000000523"
      unitRef="usd">20000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="-3"
      id="FFact_0000000000524"
      unitRef="usd">2332815000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="INF"
      id="FFact_0000000000525"
      unitRef="USD_per_share">8.57333</us-gaap:SharesIssuedPricePerShare>
    <cgen:PercentageOfClosingPrice
      contextRef="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="2"
      id="FFact_0000000000526"
      unitRef="Pure">0.33</cgen:PercentageOfClosingPrice>
    <cgen:DeferredParticipationOfBMSInRAndDExpenses
      contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20230221122449076"
      unitRef="usd">5000000</cgen:DeferredParticipationOfBMSInRAndDExpenses>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20230221122456788"
      unitRef="usd">14958000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20230221122504540"
      unitRef="usd">42000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_20230101to20230131_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember"
      decimals="-3"
      id="Fxbrl_20240228000020266"
      unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember"
      decimals="INF"
      id="Fxbrl_20240228001142902"
      unitRef="Shares">2612822</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember"
      decimals="-3"
      id="Fxbrl_20240228000338462"
      unitRef="usd">3081000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20230101to20231231_srtStatementScenarioAxis_cgenLeerinkPartnersLlcMember"
      decimals="-3"
      id="Fxbrl_20240228000400555"
      unitRef="usd">513000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_20231231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember"
      decimals="INF"
      id="FFact_0000000000537"
      unitRef="Shares">13895152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_20231231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember"
      decimals="INF"
      id="FFact_0000000000538"
      unitRef="Shares">1202301</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember"
      id="FFact_0000000000539">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cgen:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember"
      id="FFact_0000000000540">P10Y</cgen:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240228135136508">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;exercise&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;remaining contractual&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;life&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Aggregate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;intrinsic&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options outstanding at beginning of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,157,749&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options granted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,576,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options forfeited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,086,404&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="width:52%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options expired&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(274,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options outstanding at end of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,373,745&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6.61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercisable at end of year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,017,329&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000541"
      unitRef="Shares">8157749</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000542"
      unitRef="USD_per_share">5.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      id="FFact_0000000000543">P6Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000545"
      unitRef="Shares">1576500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000546"
      unitRef="USD_per_share">1.2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000549"
      unitRef="Shares">1086404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000550"
      unitRef="USD_per_share">5.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000551"
      unitRef="Shares">274100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000552"
      unitRef="USD_per_share">4.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000553"
      unitRef="Shares">8373745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000554"
      unitRef="USD_per_share">4.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      id="FFact_0000000000555">P6Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="FFact_0000000000556"
      unitRef="usd">1912000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000557"
      unitRef="Shares">5017329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000558"
      unitRef="USD_per_share">5.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      id="FFact_0000000000559">P5Y1M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="FFact_0000000000560"
      unitRef="usd">117000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000562"
      unitRef="USD_per_share">0.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000563"
      unitRef="USD_per_share">1.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20210101to20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="INF"
      id="FFact_0000000000564"
      unitRef="USD_per_share">3.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="FFact_0000000000565"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="FFact_0000000000566"
      unitRef="usd">19000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cgenEmployeesDirectorsAndNonEmployeesMember"
      decimals="-3"
      id="FFact_0000000000567"
      unitRef="usd">759000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_20231231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember"
      decimals="-3"
      id="FFact_0000000000568"
      unitRef="usd">5370000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cgenTwoThousandTenShareOptionsPlanMember"
      id="FFact_0000000000569">P2Y21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="Fxbrl_20240228002524767"
      unitRef="Shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:InitialOfferingPeriod
      contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      id="FFact_0000000000571">five months</us-gaap:InitialOfferingPeriod>
    <cgen:PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares
      contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="FFact_0000000000572"
      unitRef="Pure">0.15</cgen:PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares>
    <cgen:AggregateLimitOfOrdinarySharesPerCalendarYear
      contextRef="C_20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="FFact_0000000000573"
      unitRef="USD_per_share">40</cgen:AggregateLimitOfOrdinarySharesPerCalendarYear>
    <cgen:PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering
      contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="FFact_0000000000574"
      unitRef="Pure">0.85</cgen:PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="Fxbrl_20240301101934967"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="Fxbrl_20240301101942293"
      unitRef="Shares">158025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_20210101to20211231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="Fxbrl_20240301101953685"
      unitRef="Shares">117829</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="Fxbrl_20240301102135569"
      unitRef="Shares">114146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240228135148323">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,971&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Marketing and business development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;General and administrative expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,658&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,901&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,090&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,328&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000577"
      unitRef="usd">1933000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000578"
      unitRef="usd">2158000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000579"
      unitRef="usd">1971000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000580"
      unitRef="usd">-41000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000581"
      unitRef="usd">269000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000582"
      unitRef="usd">215000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000583"
      unitRef="usd">1658000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000584"
      unitRef="usd">1901000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000585"
      unitRef="usd">2090000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000586"
      unitRef="usd">3550000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000587"
      unitRef="usd">4328000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_0000000000588"
      unitRef="usd">4276000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000629">
    &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;

        &lt;tr&gt;
          &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;NOTE 9:-&lt;/span&gt;&lt;/td&gt;
          &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
            &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold"&gt;TAXES ON INCOME, NET&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;

    &lt;/table&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Israeli taxation:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax rates applicable to the income of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Taxable income of the Company is subject to a corporate tax rate of 23% in 2021, 2022 and 2023.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Measurement of taxable income in U.S. dollars:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has elected to measure its taxable income and file its tax return under the Israeli Income Tax Regulations (Principles Regarding the Management of Books of Account of Foreign Invested Companies and Certain Partnerships and the Determination of Their Taxable Income), 1986. Accordingly, results for tax purposes are measured in terms of earnings in dollars.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax benefits under the Israeli Law for the Encouragement of Capital Investments, 1959 (the &#x201c;Investment Law&#x201d;):&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On April 1, 2005, an amendment to the Investment Law came into effect (the &#x201c;Amendment 60&#x201d;) that significantly changed the provisions of the Investment Law. The Amendment 60 limits the scope of enterprises that may be approved by the Investment Center by setting criteria for the approval of a facility as a &#x201c;Beneficiary Enterprise&#x201d; including a provision generally requiring that at least 25% of the Beneficiary Enterprise&#x2019;s income will be derived from export.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Another condition for receiving the benefits under the alternative track in respect of expansion programs pursuant to Amendment 60 is a minimum qualifying investment. The Company was eligible under the terms of minimum qualifying investment and elected 2012 as its &#x201c;year of election&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additionally, Amendment 60 enacted major changes in the manner in which tax benefits are awarded under the Investment Law so that companies no longer require Investment Center approval in order to qualify for tax benefits. However, the Investment Law provides that terms and benefits included in any certificate of approval already granted will remain subject to the provisions of the Investment Law as they were on the date of such approval.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2023, there was no taxable income attributable to the Beneficiary Enterprise.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In January 2011, another amendment to the Investment Law came into effect (the &#x201c;2011 Amendment&#x201d;). According to the 2011 Amendment, the benefit tracks in the Investment Law were modified and a flat tax rate applies to the Company&#x2019;s entire income subject to this amendment (the &#x201c;Preferred Income&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Once an election is made, the Company&#x2019;s income will be subject to the amended tax rate of 16% from 2015 and thereafter (or 9% for a preferred enterprise located in development area A).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Commencing 2011 tax year, the Company can elect (without possibility of reversal) to apply the Amendment in a certain tax year and from that year and thereafter, it will be subject to the amended tax rates.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company does not currently intend to adopt the 2011 Amendment and intends to continue to comply with the Investment Law as in effect prior to enactment of the 2011 Amendment. Accordingly, the Company did not adjust its deferred tax balances as of December 31, 2023. The Company&#x2019;s position may change in the future.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2016 and 2017 Budget Years), 2016, which includes Amendment 73 to the Law (the &#x201c;Amendment 73&#x201d;) was published. According to Amendment 73, a preferred enterprise located in development area A will be subject to a tax rate of 7.5% instead of 9% effective from January 1, 2016 and thereafter (the tax rate applicable to preferred enterprises located in other areas remains at 16%).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amendment 73 also prescribes special tax tracks for technological enterprises, which are subject to rules that were issued by the Minister of Finance in May 2017. The new tax tracks under the Amendment are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Preferred Technological Enterprise (&#x201c;PTE&#x201d;) - an enterprise for which total consolidated revenues of its parent company and all subsidiaries are less than NIS 10 billion in a tax year. A PTE, as defined in the Law, which is located in the center of Israel will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development area A - a tax rate of 7.5%).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The above changes in the tax rates relating to PTE tax track were not taken into account in the computation of deferred taxes as of December 31, 2023 and 2022, since the Company estimates that it will not implement the PTE tax track.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax benefits under the law for the Encouragement of Industry (Taxes), 1969 (the &#x201c;Encouragement Law&#x201d;):&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Encouragement Law provides several tax benefits for industrial companies. An industrial company is defined as a company resident in Israel, at least 90% of the income of which in a given tax year exclusive of income from specified Government loans, capital gains, interest and dividends, is derived from an industrial enterprise owned by it. An industrial enterprise is defined as an enterprise whose major activity in a given tax year is industrial production activity.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Management believes that the Company is currently qualified as an &#x201c;industrial company&#x201c; under the Encouragement Law and, as such, is entitled to tax benefits, including: (1) deduction of purchase of know-how and patents and/or right to use a patent over an eight-year period; (2) the right to elect, under specified conditions, to file a consolidated tax return with additional related Israeli industrial companies and an industrial holding company; (3) accelerated depreciation rates on equipment and buildings; and (4) expenses related to a public offering on the Tel-Aviv Stock exchange and on recognized stock markets outside of Israel, are deductible in equal amounts over three years.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Eligibility for benefits under the Encouragement Law is not subject to receipt of prior approval from any Governmental authority. No assurance can be given that the Israeli tax authorities will agree that the Company qualifies, or, that the Company will continue to qualify as an industrial company or that the benefits described above will be available to the Company in the future.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:85.05pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net operating losses carryforward and capital loss:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2023, Compugen Ltd. &#x2019;s net operating losses carryforward for tax purposes in Israel amounted to approximately $ 401,100. These net operating losses may be carried forward indefinitely and may be offset against future taxable income.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:113.4pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-Israeli subsidiary, Compugen USA, Inc.:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.5pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the &#x201c;U.S. Tax Reform&#x201d; or &#x201c;TCJA&#x201d;); a comprehensive tax legislation that includes significant changes to the taxation of business entities. These changes include several key tax provisions that might impact the Company, among others: (i) a permanent reduction to the statutory federal corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017; (ii) a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain new rules designed to prevent erosion of the U.S. income tax base - &#x201c;BEAT&#x201d;); (iii) establishing immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits; and (iv) providing a permanent deduction to corporations generating revenues from non-US markets (known as a deduction for foreign derived intangible income - &#x201c;FDII&#x201d;) .&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2023, Compugen USA, Inc. has net operating loss carryforwards for federal income tax purposes of approximately $ 3,050. Approximately $1,950 of these losses are available to offset any future U.S. taxable income of our U.S. subsidiary and will expire in the years 2024 to 2032. Utilization of the U.S. net operating losses may be subject to substantial annual limitation due to the &#x201c;change in ownership&#x201d; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Neither Israeli income taxes, foreign withholding taxes nor deferred income taxes were provided in relation to undistributed earnings of the Company&#x2019;s foreign subsidiary. This is because the Company has the intent and ability to reinvest these earnings indefinitely in the foreign subsidiary and therefore those earnings are continually redeployed in those jurisdictions.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss (income) before taxes is comprised as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

          &lt;div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:90pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Domestic (Israel)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;34,096&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;34,619&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:64%;padding-bottom:2px;vertical-align:baseline"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Foreign&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(460&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(416&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,784&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;34,203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Taxes on income for the years ended December 31, 2023 and 2022, represent state income taxes in the United States.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred taxes:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company and Compugen USA, Inc.&#x2019;s deferred tax assets are comprised of operating loss carryforward and other temporary differences. Significant components of the Company and Compugen USA, Inc. deferred tax assets are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:90pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax assets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating loss carryforward&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;92,885&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;91,704&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,083&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accrued social benefits and other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,072&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;444&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax asset before valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;108,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;107,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(108,073&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(106,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax asset after valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:76%;padding-bottom:2px;vertical-align:baseline"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:76%;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:76%;padding-bottom:2px;vertical-align:baseline"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has provided full valuation allowances in respect of deferred tax assets resulting from operating loss carryforward and other temporary differences. Management currently believes that since the Company has a history of losses, it is more likely than not that the deferred tax regarding the operating loss carryforward and other temporary differences will not be realized in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Reconciliation of the theoretical tax expense (benefit) to the actual tax expense (benefit):&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits from accumulated net operating loss carryforward among the Company and&lt;span style="font-weight:bold"&gt;&#160;&lt;/span&gt;Compugen USA, Inc. due to the uncertainty of the realization of such tax benefits&#160;and withholding taxes on the upfront payment pursuant to the Gilead license agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;g.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax assessments:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has tax assessments through 2018 that are deemed to be final.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20210101to20211231"
      decimals="2"
      id="Fxbrl_20230214114856319"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20220101to20221231"
      decimals="2"
      id="Fxbrl_20230214114847978"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20230101to20231231"
      decimals="2"
      id="Fxbrl_20230214114839776"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <cgen:ReducedTaxRate
      contextRef="C_20230101to20231231"
      decimals="2"
      id="FFact_0000000000594"
      unitRef="Pure">0.25</cgen:ReducedTaxRate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_20231231_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember"
      decimals="-3"
      id="FFact_0000000000595"
      unitRef="usd">401100000</us-gaap:OperatingLossCarryforwards>
    <cgen:NetOperatingLossCarryforwardExpired
      contextRef="C_20211231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember"
      decimals="-3"
      id="FFact_0000000000597"
      unitRef="usd">3050000</cgen:NetOperatingLossCarryforwardExpired>
    <cgen:NetOperatingLossCarryforwardExpired
      contextRef="C_20211231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapSubsidiaryOfCommonParentMember"
      decimals="-3"
      id="Fxbrl_20240228003646758"
      unitRef="usd">1950000</cgen:NetOperatingLossCarryforwardExpired>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20230214044607742">
          &lt;div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:90pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Domestic (Israel)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;34,096&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;34,619&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:64%;padding-bottom:2px;vertical-align:baseline"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Foreign&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(460&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(416&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,784&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;34,203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000600"
      unitRef="usd">-10164000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000601"
      unitRef="usd">-34096000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000602"
      unitRef="usd">-34619000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000603"
      unitRef="usd">380000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000604"
      unitRef="usd">460000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000605"
      unitRef="usd">416000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000606"
      unitRef="usd">-9784000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000607"
      unitRef="usd">-33636000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000608"
      unitRef="usd">-34203000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20230214044633836">
          &lt;div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:90pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax assets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating loss carryforward&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;92,885&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;91,704&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,083&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accrued social benefits and other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,072&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;444&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax asset before valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;108,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;107,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(108,073&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(106,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax asset after valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:76%;padding-bottom:2px;vertical-align:baseline"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:76%;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:76%;padding-bottom:2px;vertical-align:baseline"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000610"
      unitRef="usd">92885000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000611"
      unitRef="usd">91704000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000612"
      unitRef="usd">12109000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000613"
      unitRef="usd">12083000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000614"
      unitRef="usd">3072000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000615"
      unitRef="usd">3123000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <cgen:DeferredIncomeTaxLeaseLiabilities
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000618"
      unitRef="usd">312000</cgen:DeferredIncomeTaxLeaseLiabilities>
    <cgen:DeferredIncomeTaxLeaseLiabilities
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000619"
      unitRef="usd">444000</cgen:DeferredIncomeTaxLeaseLiabilities>
    <cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000620"
      unitRef="usd">2000</cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment>
    <cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000621"
      unitRef="usd">2000</cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000622"
      unitRef="usd">108380000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000623"
      unitRef="usd">107356000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000624"
      unitRef="usd">108073000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000625"
      unitRef="usd">106941000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240228010347732_Fact_0000000000622"
      unitRef="usd">307000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240228010347732_Fact_0000000000623"
      unitRef="usd">415000</us-gaap:DeferredTaxAssetsNet>
    <cgen:DeferredIncomeTaxRightOfUseAssets
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000616"
      unitRef="usd">-307000</cgen:DeferredIncomeTaxRightOfUseAssets>
    <cgen:DeferredIncomeTaxRightOfUseAssets
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000617"
      unitRef="usd">-415000</cgen:DeferredIncomeTaxRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240228010350775_Fact_0000000000622"
      unitRef="usd">307000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240228010350775_Fact_0000000000623"
      unitRef="usd">415000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240228010353797_Fact_0000000000622"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240228010353797_Fact_0000000000623"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20230222123726446">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 10:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                  &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s business is currently comprised of one operating segment, the research, development and commercialization of therapeutic and product candidates. The nature of the products and services provided by the Company and the type of customers for these products and services are similar. Operations in Israel and the United States include research and development, clinical operations, marketing and business development. The Company follows ASC 280, &#x201c;Segment Reporting&#x201d;. Total revenues are attributed to geographic areas based on the location of the end customer.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following represents the total revenue for the years ended December 31, 2023, 2022 and 2021 and long-lived assets as of December 31, 2023 and 2022:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

              &lt;div&gt;
                &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="margin-left:63pt"&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Revenue from sales to customers:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Europe&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23,459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total revenue&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33,459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="margin-left:63pt"&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Long-lived assets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Israel&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,468&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total long-lived assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,545&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              &lt;/div&gt;

            &lt;div style="margin-left:63pt"&gt;&#160;&lt;/div&gt;
          &lt;/div&gt;
          &lt;div style="margin-left:63pt"&gt;

              &lt;div&gt;
                &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sales to a single customer exceeding 10%:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Customer A&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                        &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Customer B&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;

          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="FFact_0000000000630"
      unitRef="Item">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240228125735648">
              &lt;div&gt;
                &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="margin-left:63pt"&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Revenue from sales to customers:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Europe&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23,459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total revenue&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33,459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="margin-left:63pt"&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Long-lived assets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Israel&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,468&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;United States&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;
                          &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total long-lived assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,545&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            </us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"
      decimals="-3"
      id="FFact_0000000000631"
      unitRef="usd">10000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"
      decimals="-3"
      id="FFact_0000000000632"
      unitRef="usd">7500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20210101to20211231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"
      decimals="-3"
      id="Fxbrl_20230214023238881"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231_cgenSegmentReportingGeographicAreaAxis_countryUS"
      decimals="-3"
      id="Fxbrl_20240228002914108_Fact_0000000000631"
      unitRef="usd">23459000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_countryUS"
      decimals="-3"
      id="Fxbrl_20240228002914108_Fact_0000000000632"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20210101to20211231_cgenSegmentReportingGeographicAreaAxis_countryUS"
      decimals="-3"
      id="Fxbrl_20240228002914108_xbrl_20230214023238881"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000634"
      unitRef="usd">33459000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000635"
      unitRef="usd">7500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214023305010"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:NoncurrentAssets
      contextRef="C_20231231_cgenSegmentReportingGeographicAreaAxis_countryIL"
      decimals="-3"
      id="FFact_0000000000637"
      unitRef="usd">2468000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_20221231_cgenSegmentReportingGeographicAreaAxis_countryIL"
      decimals="-3"
      id="FFact_0000000000638"
      unitRef="usd">3239000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_20231231_cgenSegmentReportingGeographicAreaAxis_countryUS"
      decimals="-3"
      id="FFact_0000000000639"
      unitRef="usd">77000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_20221231_cgenSegmentReportingGeographicAreaAxis_countryUS"
      decimals="-3"
      id="FFact_0000000000640"
      unitRef="usd">119000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000641"
      unitRef="usd">2545000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000642"
      unitRef="usd">3358000</us-gaap:NoncurrentAssets>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000647">
              &lt;div&gt;
                &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sales to a single customer exceeding 10%:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Customer A&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                        &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Customer B&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
            </us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20230101to20231231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"
      decimals="2"
      id="FFact_0000000000644"
      unitRef="Pure">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"
      decimals="2"
      id="FFact_0000000000645"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20210101to20211231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"
      decimals="2"
      id="Fxbrl_20230214023433284"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20230101to20231231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"
      decimals="2"
      id="Fxbrl_20240228002946105_Fact_0000000000644"
      unitRef="Pure">0.70</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"
      decimals="2"
      id="Fxbrl_20240228002946105_Fact_0000000000645"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20210101to20211231_srtMajorCustomersAxis_cgenCustomerTwoMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"
      decimals="2"
      id="Fxbrl_20240228002946105_xbrl_20230214023433284"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000665">
    &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;

        &lt;tr&gt;
          &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;NOTE 11:-&lt;/span&gt;&lt;/td&gt;
          &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
            &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold"&gt;FINANCIAL AND OTHER INCOME, NET&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;

    &lt;/table&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="margin-left:63pt"&gt;

            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,437&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;894&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortization of discount on marketable securities, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Bank fees and other finance expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Foreign currency transaction adjustments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gain (loss) from sales and disposals of fixed assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:1.5px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:1.5px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial and other income, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;871&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000664">
            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,437&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;894&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortization of discount on marketable securities, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Bank fees and other finance expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Foreign currency transaction adjustments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gain (loss) from sales and disposals of fixed assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:1.5px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:1.5px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial and other income, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;871&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          </us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000649"
      unitRef="usd">2960000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000650"
      unitRef="usd">1437000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000651"
      unitRef="usd">894000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240228002028020_Fact_0000000000649"
      unitRef="usd">281000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240228002028020_Fact_0000000000650"
      unitRef="usd">0</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240228002028020_Fact_0000000000651"
      unitRef="usd">0</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:InterestAndDebtExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000652"
      unitRef="usd">31000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000653"
      unitRef="usd">27000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000654"
      unitRef="usd">25000</us-gaap:InterestAndDebtExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000655"
      unitRef="usd">5000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214022140608"
      unitRef="usd">340000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000657"
      unitRef="usd">-1000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230214022153855"
      unitRef="usd">-7000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000659"
      unitRef="usd">-12000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000660"
      unitRef="usd">3000</us-gaap:GainLossOnSaleOfOtherAssets>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000661"
      unitRef="usd">3208000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000662"
      unitRef="usd">1738000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000663"
      unitRef="usd">871000</cgen:FinancialIncomeExpenseNet>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000672">
    &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;

        &lt;tr&gt;
          &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;NOTE 12:-&lt;/span&gt;&lt;/td&gt;
          &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
            &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold"&gt;RELATED PARTY BALANCES AND TRANSACTIONS&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;

    &lt;/table&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;

          &lt;div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade payables and accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amounts charged to:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the years ended December 31, 2023, 2022 and 2021 the Company received research and development services related with cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies. The transaction was at arm&#x2019;s length.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000671">
          &lt;div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade payables and accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:63pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amounts charged to:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OtherLiabilities
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000666"
      unitRef="usd">53000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000667"
      unitRef="usd">83000</us-gaap:OtherLiabilities>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000668"
      unitRef="usd">147000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000669"
      unitRef="usd">194000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000670"
      unitRef="usd">240000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20230222124735774">
    &lt;div&gt;
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 13:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;LOSSES PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin:0px 0px 0px 85.5pt;line-height:1.25;text-align:justify;text-indent:-28.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table sets forth the computation of basic and diluted losses per share:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:63pt"&gt;

            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:64%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss for basic and diluted loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(18,754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(33,694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(34,203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Denominator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average number of ordinary shares&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;used in computing basic and diluted net loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;87,633,298&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;86,555,628&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;84,203,971&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic and diluted loss per ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:3px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:3px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:3px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20230222124750140">
            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:80%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:64%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss for basic and diluted loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(18,754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(33,694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(34,203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2pt;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Denominator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average number of ordinary shares&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;used in computing basic and diluted net loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;87,633,298&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;86,555,628&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;84,203,971&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic and diluted loss per ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:3px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:3px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:3px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000673"
      unitRef="usd">-18754000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000674"
      unitRef="usd">-33694000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000675"
      unitRef="usd">-34203000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="FFact_0000000000676"
      unitRef="Shares">87633298</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000677"
      unitRef="Shares">86555628</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000678"
      unitRef="Shares">84203971</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20230214135651704"
      unitRef="USD_per_share">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="FFact_0000000000679"
      unitRef="USD_per_share">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20230214135713278"
      unitRef="USD_per_share">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000680"
      unitRef="USD_per_share">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230214135731057"
      unitRef="USD_per_share">-0.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000681"
      unitRef="USD_per_share">-0.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20230214053733944">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 14:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                  &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="margin:0px 0px 0px 85.5pt;line-height:1.25;text-align:justify;text-indent:-28.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In January 2024, 292,728 ordinary shares were issued and sold through the ATM, with proceeds of approximately $562 (net of $17 issuance expenses).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_20240101to20240131_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember"
      decimals="INF"
      id="Fxbrl_20240228000412030"
      unitRef="Shares">292728</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="C_20240101to20240131_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember"
      decimals="-3"
      id="Fxbrl_20240228000432241"
      unitRef="usd">562000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20240101to20240131_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapSubsidiarySaleOfStockAxis_cgenOrdinarySharesIssuedAndSoldThroughAtmMember"
      decimals="-3"
      id="Fxbrl_20240228000436548"
      unitRef="usd">17000</us-gaap:PaymentsOfStockIssuanceCosts>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fxbrl_20230214013608017"
          xlink:label="Fxbrl_20230214013608017"
          xlink:type="locator"/>
        <link:footnote id="FN20240228010307168" xlink:label="FN20240228010307168" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Representing amount lower than $ 1.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230214013608017"
          xlink:to="FN20240228010307168"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
